PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Bombardier, CH; Fann, JR; Temkin, N; Esselman, PC; Pelzer, E; Keough, M; Dikmen, S				Bombardier, Charles H.; Fann, Jesse R.; Temkin, Nancy; Esselman, Peter C.; Pelzer, Erika; Keough, Meghan; Dikmen, Sureyya			Posttraumatic stress disorder symptoms during the first six months after traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	51st Annual Meeting of the Academy-of-Psychosomatic-Medicine	NOV, 2004	Ft Myers, FL	Acad Psychosomat Med			PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; PTSD CHECKLIST; HEAD-INJURY; PRIME-MD; DEPRESSION; VALIDITY; CLASSIFICATION; AMNESIA; COCAINE	Controversy exists regarding the rate and risk factors for posttraumatic stress disorder (PTSD) following traumatic brain injury (TBI) The authors determined the rate and phenomenology of PTSD symptoms in the 6 months after TBI by conducting a prospective cohort study of 124 subjects who completed the PTSD Checklist-Civilian Version. The cumulative incidence of meeting PTSD symptom criteria at 6 months was 11% and full criteria 5.6%. Prevalence peaked at I month (10%). Eighty-six percent had another psychiatric disorder and 29% a history of PTSD. Symptoms were associated with not completing high school, assault, recalling being terrified or helpless, and positive toxicology. PTSD after TBI is rare and the relation to risk factors and comorbidities must be examined.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA		Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R0-1 HD39415] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER		Acierno R, 1999, J ANXIETY DISORD, V13, P541, DOI 10.1016/S0887-6185(99)00030-4; American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, VIV; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOROWSKI TB, 1994, PHARMACOL BIOCHEM BE, V49, P935, DOI 10.1016/0091-3057(94)90246-1; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Epstein RS, 1998, AM J PSYCHIAT, V155, P934, DOI 10.1176/ajp.155.7.934; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KORNBLITH AB, 2003, CANCER, V98, P697; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Post R M, 1999, Semin Clin Neuropsychiatry, V4, P282; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Semple WE, 2000, PSYCHIATRY, V63, P65, DOI 10.1080/00332747.2000.11024895; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Solomon SD, 2002, J CLIN PSYCHOL, V58, P947, DOI 10.1002/jclp.10069; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weather FW, 1991, PTSD CHECKLIST CIVIL; Weathers F., 1993, INT SOC TRAUM STRESS; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	45	61	62	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2006	18	4					501	508		10.1176/appi.neuropsych.18.4.501			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychiatry	103BX	WOS:000241861800005	17135375				2022-02-06	
J	Browne, GJ; Lam, LT				Browne, GJ; Lam, LT			Concussive head injury in children and adolescents related to sports and other leisure physical activities	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; INTRACRANIAL INJURY; MANAGEMENT; OUTCOMES; SCHOOL	Objective: To compare the characteristics of children and adolescents with concussive head injury (CHI) sustained during organised sports or other leisure physical activity. Methods: This was a case series study reviewing the medical records retrospectively over a four year period of children 6 - 16 years presenting to the emergency department with a CHI after participating in sport and/or recreation activity. Results: There were 592 cases of sport and recreation related concussion over the study period ( 2000 2003). Most of the patients (n = 424, 71.6%) were male, with half ( n = 304, 51.4%) being older than 10 years of age. A total of 152 ( 25.7%) cases of CHI were related to playing sports. Most cases (71.2%) were mild concussion. The cause of injury was a fall ( n = 322, 54.4%) or a collision. Nearly a quarter of the children ( n = 143, 24.2%) were admitted to hospital, with imaging performed in 134 ( 22.7%). Most children were treated appropriately and no adverse events were reported. Conclusions: A severe CHI in a child is six times more likely to have resulted from organised sport than from other leisure physical activities. Outcomes for CHI in children is excellent, although their management places a considerable burden on emergency services. The need for activity restriction and the benefits of this in reducing long term cognitive effects of CHI are uncertain.	Childrens Hosp Westmead, CHISM, Sydney, NSW 2145, Australia; Royal Alexandra Hosp Children, Sydney, NSW, Australia		Browne, GJ (corresponding author), Childrens Hosp Westmead, CHISM, Sydney, NSW 2145, Australia.	garyb@chw.edu.au		Lam, Lawrence T./0000-0001-6183-6854			Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bergman DA, 1999, PEDIATRICS, V104, P1407; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; BIJUR PE, 1990, PEDIATRICS, V86, P337; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; CANTU RC, 1995, CLIN SPORT MED, V14, P517; Cassell EP, 2003, BRIT J SPORT MED, V37, P405, DOI 10.1136/bjsm.37.5.405; CEDILLA RK, 2002, ANN EMERG MED, V40, P446; DUNNING J, 2004, EMERG MED AUSTRAL S1, V16, pA93; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gotsch K, 2002, JAMA-J AM MED ASSOC, V288, P1977; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LECHER S, 2001, SPORTS MED, V31, P629; Ni H, 2002, INJURY PREV, V8, P60, DOI 10.1136/ip.8.1.60; O' Rourke KP, 2004, MED SCI SPORT EXER, V36, pS312; OSMOND MH, 2004, ACAD EMERG MED, V11, P449; Poirier MP, 2000, PEDIATR EMERG CARE, V16, P278, DOI 10.1097/00006565-200008000-00018; Poirier MP, 2003, CLIN PEDIATR EMERG M, V4, P179, DOI DOI 10.1016/S1522-8401(03)00061-2; Posner Jill C, 2004, Pediatr Crit Care Med, V5, P293, DOI 10.1097/01.PCC.0000124018.18536.0B; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; SWAINE B, 2000, ARCH PHYS MED REHAB, V81, P1617; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; 1999, P 3 WRLD C BRAIN INJ, P230	34	61	62	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2006	40	2					163	168		10.1136/bjsm.2005.021220			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	005NP	WOS:000234831400016	16432005	Green Published			2022-02-06	
J	Perlstein, WM; Larson, MJ; Dotson, VM; Kelly, KG				Perlstein, WM; Larson, MJ; Dotson, VM; Kelly, KG			Temporal dissociation of components of cognitive control dysfunction in severe TBI: ERPs and the cued-Stroop task	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		traumatic brain injury; cognitive control; event-related potentials; Stroop task; working memory capacity	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY LOAD; ANTERIOR CINGULATE; PREFRONTAL CORTEX; HEAD-INJURY; CONFLICT; DEFICITS; ATTENTION; CONTEXT; SCHIZOPHRENIA	Cognitive control comprises two essential interactive component processes: a regulative component supporting the activation and implementation of control and an evaluative component that monitors the need for regulative control and signals when adjustments in control are necessary. Survivors of severe traumatic brain injury (TBI) experience cognitive control impairments, but the specific nature of these impairments is poorly characterized. Using event-related potentials (ERPs) acquired in the context of a trial-by-trial task-switching version of the Stroop task we temporally dissociated the regulative and evaluative processes in order to shed light on the potential roles of these components in TBI-related cognitive control impairment. Behaviorally, TBI patients showed a specific performance deficit suggestive of a failure to implement cognitive control in the service of processing conflict information. ERP findings showed that TBI patients were impaired in both the implementation of control and subsequent detection and processing of conflict. TBI patients were also impaired on a measure of, working memory capacity, a measure that correlated with the ability to implement regulative control and overcome conflict. These findings suggest that patients with predominantly chronic severe TBI patients are impaired on both regulative and evaluative components of cognitive control, and may have implications for the design and evaluation of behavioral and pharmacological remediation strategies. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA		Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@grove.ufl.edu	Dotson, Vonetta/K-6090-2015; Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065; Dotson, Vonetta/0000-0002-3043-3320	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barch DM, 1999, SCHIZOPHRENIA BULL, V25, P749, DOI 10.1093/oxfordjournals.schbul.a033416; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; BRAVER TS, 1999, PDPCNS991 CARN MELL; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Clark J, 1924, AM J PHYSL OPTICS; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Curtin JJ, 2003, J ABNORM PSYCHOL, V112, P424, DOI 10.1037/0021-843X.112.3.424; DANEMAN M, 1980, J CLIN EXP NEUROPSYC, V21, P200; Dias EC, 2003, CEREB CORTEX, V13, P701, DOI 10.1093/cercor/13.7.701; ERSKINE A, 1990, PAIN, V41, P255, DOI 10.1016/0304-3959(90)90002-U; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; Golden CJ, 1978, STROOP COLOR WORD TE; Ille N, 2002, J CLIN NEUROPHYSIOL, V19, P113, DOI 10.1097/00004691-200203000-00002; Ille N., 1997, BIOMED TECHNOL, V42, P80; JONIDES J, 1984, PSYCHOL BULL, V96, P29, DOI 10.1037/0033-2909.96.1.29; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LARSON MJ, 2004, 32 ANN M INT NEUR SO; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McNeely HE, 2003, J ABNORM PSYCHOL, V112, P679, DOI 10.1037/0021-843X.112.4.679; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Neter J., 1985, APPL LINEAR STAT MOD; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Rebai M, 1997, INT J NEUROSCI, V91, P85, DOI 10.3109/00207459708986367; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; ROCKSTROH B, 1985, SLOW CORTICAL POTENT; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Schwarz N, 1999, AM PSYCHOL, V54, P93, DOI 10.1037/0003-066X.54.2.93; SEIGNOUREL PJ, IN PRESS NEUROPSYCHO; Speilberger C, 1983, MANUAL STATE TRAIT A; Stone AA, 2002, ANN BEHAV MED, V24, P236, DOI 10.1207/S15324796ABM2403_09; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; West R, 1999, J GERONTOL B-PSYCHOL, V54, pP34, DOI 10.1093/geronb/54B.1.P34; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2004, J COGNITIVE NEUROSCI, V16, P103, DOI 10.1162/089892904322755593; West R, 2000, PSYCHOPHYSIOLOGY, V37, P179, DOI 10.1111/1469-8986.3720179; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; West R, 2000, CEREB CORTEX, V10, P748, DOI 10.1093/cercor/10.8.748; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	90	61	63	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	2					260	274		10.1016/j.neuropsychologia.2005.05.009			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Behavioral Sciences; Neurosciences & Neurology; Psychology	011HS	WOS:000235259500011	15979655				2022-02-06	
J	Piland, SG; Motl, RW; Guskiewicz, KM; McCrea, M; Ferrara, MS				Piland, SG; Motl, RW; Guskiewicz, KM; McCrea, M; Ferrara, MS			Structural validity of a self-report concussion-related symptom scale	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						confirmatory factor analysis; factorial validity; self-report symptoms (SRS); measurement	COLLEGIATE FOOTBALL PLAYERS; VALIDATION; RECOVERY; RETURN; FIT	Purpose: This Study evaluated the factorial validity of a self-report measure of concussion-related symptom severity among a large sample of male, high-school athletes. Methods: Participants (N = 1089) were nonconcussed, male, high-school football players. All participants completed a single baseline self-report measure of concussion-related symptom severity, namely the graded symptom checklist (GSC). We tested the factorial validity of the, measure with confirmatory factor analysis using LISREL 8.50. Results: The, analysis indicated that a theoretically derived, three-factor model provided a good, but not excellent, fit for the 16-item GSC. Excellent model-data fit was demonstrated for the three-factor model for a 9-item version of the GSC. In both instances, the three factors were best described by a single second-order factor, namely concussion symptomatology. Conclusions: This Study provides additional evidence for the factorial validity of a summative self-reported measure of concussion-related symptoms. The factor structure represents a cohesive group of nine symptoms that can be explained by three underlying latent variables, namely somatic symptoms, neurobehavioral symptoms, and "cognitive" symptoms, subsumed under a single higher-order factor, namely concussion symptoms.	Univ So Mississippi, Sch Human Performance & Recreat, Hattiesburg, MS 39406 USA; Univ Illinois, Dept Kinesiol, Champaign, IL USA; Univ Carolina, Dept Excercise & Sport Sci, Chapel Hill, NC USA; Waukesha Mem Hosp, Neurosci Ctr, Waukesha, WI USA; Univ Georgia, St Marys Athlet Training Educ & Res Lab, Dept Exercise Sci, Athens, GA USA		Piland, SG (corresponding author), Univ So Mississippi, Sch Human Performance & Recreat, 118 Coll Dr 5142, Hattiesburg, MS 39406 USA.	scott.piland@usm.edu	, scott/ABB-2057-2021	Guskiewicz, Kevin/0000-0002-8682-2130			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTLER H, 2003, PSYCHOL BULL, V88, P588; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; BOLLEN KA, 1993, TESTING STRUCTURAL E, P10; BROWNE MW, 2002, TESTING STRUCTURAL E, P136; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CUDECK R, 1983, MULTIVAR BEHAV RES, V18, P147, DOI 10.1207/s15327906mbr1802_2; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 2001, J ATHL TRAINING, V36, P198; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JORESKOG K, 1996, LISREL 8 USERS REFER, P271; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104	26	61	61	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2006	38	1					27	32		10.1249/01.mss.0000183186.98212.d5			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	000LS	WOS:000234464100006	16394950				2022-02-06	
J	Bennett, PC; Ong, B; Ponsford, J				Bennett, PC; Ong, B; Ponsford, J			Assessment of executive dysfunction following traumatic brain injury: Comparison of the BADS with other clinical neuropsychological measures	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						neuropsychological assessment; dysexecutive syndrome; behavioral assessment ofthe dysexecutive syndrome; ED; BADS; cognitive impairment	DYSEXECUTIVE SYNDROME; FRONTAL LOBES; BEHAVIORAL-ASSESSMENT; VALIDITY; TESTS	Traditional neuropsychological measures of executive dysfunction (ED) are widely believed to lack adequate sensitivity and selectivity. This may indicate that existing measures are poorly designed and Constructed, although an alternative explanation is that executive cognition is multifactorial. such that its assessment necessarily requires administration of multiple measures. This possibility led to the development of it test battery, the Behavioural Assessment of the Dysexecutive Syndrome (BADS). To investigate the sensitivity of the BADS to ED, it and various other measures of ED were administered to 64 persons who had sustained traumatic brain injury. The treating clinical neuropsychologist and occupational therapist for each participant also completed a behavioural rating scale, the Dysexecutive Questionnaire (DEX). Four factors were found to underlie scores on the neuropsychological measures, but few tests were sufficiently powerful to make a significant unique contribution to predicting scores on the DEX. This confirms that multiple tests, drawn from both the BADS and other sources, may be necessary to detect ED in a clinical population.	Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Caulfield, Vic 3145, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic, Australia		Bennett, PC (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, POB 197, Caulfield, Vic 3145, Australia.	p.bennett@med.monash.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			ALDERMAN N, 1993, J CLIN EXP NEUROPSYC, V15, P69; Ardila A, 2000, ARCH CLIN NEUROPSYCH, V15, P31, DOI 10.1016/S0887-6177(98)00159-0; AXELROD BN, 1994, ASSESSMENT, V0001, P00269, DOI DOI 10.1177/107319119400100307; Banich M.T., 1997, NEUROPSYCHOLOGY NEUR; BENNETT PC, 2005, J INT NEUROPSYCH SOC, V11, P1; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Crawford JR, 2000, AGING NEUROPSYCHOL C, V7, P9, DOI 10.1076/anec.7.1.9.806; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Heaton R.K., 1981, WISCONSIN CARD SORTI; Kafer K L, 1997, J Int Neuropsychol Soc, V3, P108; Knight RT., 2002, PRINCIPLES FRONTAL L, P261, DOI [10.1093/acprof:oso/9780195134971.003.0017, DOI 10.1093/ACPROF:OSO/9780195134971.003.0017]; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Obonsawin MC, 2002, NEUROPSYCHOLOGIA, V40, P970, DOI 10.1016/S0028-3932(01)00171-3; Porteus S.D., 1965, PORTEUS MAZE TEST 50; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570	25	61	63	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2005	11	5					606	613		10.1017/S1355617705050721			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	968TJ	WOS:000232185000012	16212688				2022-02-06	
J	Vagnozzi, R; Signoretti, S; Tavazzi, B; Cimatti, M; Amorini, AM; Donzelli, S; Delfini, R; Lazzarino, G				Vagnozzi, R; Signoretti, S; Tavazzi, B; Cimatti, M; Amorini, AM; Donzelli, S; Delfini, R; Lazzarino, G			Hypothesis of the postconcussive vulnerable brain: Experimental evidence of its metabolic occurrence	NEUROSURGERY			English	Article						brain concussion; energetic metabolism; high-performance liquid chromatography; N-acetylaspartate; second impact; sports-related injury	MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL ASPARTATE; MITOCHONDRIAL DYSFUNCTION; CEREBRAL CONCUSSION; HEAD-INJURY; CYCLOSPORINE-A; AXONAL INJURY; NEURONAL LOSS; 2ND IMPACT; ACETYLASPARTATE	OBJECTIVE: We evaluated the effects of two consecutive concussive injuries on brain energy metabolism and N-acetylaspartate (NAA) to investigate how the temporal interval between traumatic events influences overall injury severity. METHODS: Rats were injured to induce diffuse traumatic brain injury (TBI) (mild, 450 g/1 m; severe, 450 g/2 m). In two groups, two mild TBIs were delivered in 3- or 5-day intervals. Three additional animal groups were used: single mild TBI, single severe TBI, and sham. All animals were killed 48 hours postinjury. Adenosine 5'-triphosphate (ATP), adenosine diphosphate, and NAA concentrations were analyzed with high-performance liquid chromatography on deproteinized whole brain extracts. RESULTS: In control animals, the NAA concentration was 9.17 +/- 0.38 mu mol/g wet weight, the ATP concentration was 2.25 +/- 0.21 mu mol/g wet weight, and the ATP-to-adenosine diphosphate ratio was 9.38 +/- 1.23. These concentrations decreased to 6.68 +/- 1.12 mu mol/g wet weight, 1.68 +/- 0.24 mu mol/g wet weight, and 6.10 +/- 1.21 mu mol/g wet weight, respectively, in rats that received two mild TBIs at a 5-day interval (P < 0.01; not different from results in rats with single mild TBI). When a second TBI was delivered after 3 days, the NAA concentration was 3.86 +/- 0.53 mu mol/g wet weight, the ATP concentration was 1.11 +/- 0.18 mu mol/g wet weight, and the ATP-to-adenosine diphosphate ratio was 2.64 +/- 0.43 (P < 0.001 versus both controls and 3-day interval; not different from rats receiving a single severe TBI). CONCLUSION: The biochemical modification severity in double TBI is dependent on the interval between traumatic events, which demonstrates the metabolic state of the vulnerable brain after mild TBI. These data support the hypothesis of the application of proton magnetic resonance spectroscopy to measure NAA as a possible tool to monitor the full recovery of brain metabolic functions in the clinical setting, particularly in sports medicine.	Univ Catania, Dept Chem Sci, Biochem Lab, I-95125 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy; Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy		Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BAILES JE, 2001, NEUROLOGICAL SPORTS, P1; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2004, NEUROSURGERY, V54, P1078; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GERBERDING JL, 2003, C MILD TRAUM BRAIN I, P31; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V7, P469; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MOFFETT JR, 1993, J HISTOCHEM CYTOCHEM, V41, P559, DOI 10.1177/41.4.8450195; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Powell JW, 2001, J ATHL TRAINING, V36, P307; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164, DOI 10.1097/00004647-199902000-00008; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; 1997, MMWR MORB MORTAL WKL, V46, P224	63	61	62	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2005	57	1					164	171		10.1227/01.NEU.0000163413.90259.85			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	942ZQ	WOS:000230321800044	15987552				2022-02-06	
J	Eilander, HJ; Wijnen, VJM; Scheirs, JGM; De Kort, PLM; Prevo, AJH				Eilander, HJ; Wijnen, VJM; Scheirs, JGM; De Kort, PLM; Prevo, AJH			Children and young adults in a prolonged unconscious state due to severe brain injury: Outcome after an early intensive neurorehabilitation programme	BRAIN INJURY			English	Article						severe brain injury; children; young adults; outcome; early intensive neurorehabilitation; vegetative state; minimally consciousness	CLOSED HEAD-INJURY; VEGETATIVE STATE; SENSORY STIMULATION; COMA AROUSAL; MANAGEMENT; CHILDHOOD; RECOVERY	Primary objective. The Rehabilitation Centre Leijpark in the Netherlands provides an Early Intensive Neurorehabilitation Programme (EINP) to children and young adults in a prolonged unconscious state after severe brain injury. In an extensive research project the effects of EINP were studied. This part of the project focused on the outcome in terms of level of consciousness (LOC) in relation to the specific characteristics of a retrospectively studied cohort. Research design. This study was executed according to a one-group archived pre-test-post-test design. Subjects. Subjects were all consecutively admitted patients (n = 145, 72% male) between December 1987-January 2001. Inclusion criteria were: age 0-25 years, within 6 months after injury, LOC at admission vegetative state (VS) or minimally conscious state (MCS). One hundred and four patients (72%) suffered a traumatic injury and 41 patients (28%) a non-traumatic injury. Methods and procedures. All patients had received EINP until they reached consciousness or until it was concluded that no progress was achieved during 3 months after the start of EINP. Medical files were investigated to collect the patients' characteristics and injury data, to determine the LOC at admission and at discharge and to determine the discharge destination. Results. Almost two-thirds of the patients reached full consciousness. LOC at admission, aetiology and interval since injury were found to be significant prognostic factors. Traumatic patients had a much better outcome than non-traumatic patients. A comparison with earlier outcome studies showed a more favourable outcome than expected. It is argued that a multi-centre study is needed to confirm possible effects of EINP.	Rehabil Ctr Leijpk, Div Res, Project VLB NAH, NL-5004 EA Tilburg, Netherlands; Tilburg Univ, Fac Social Sci, Dept Psychol & Hlth, NL-5000 LE Tilburg, Netherlands; St Elizabeth Hosp, Div Neurol, Tilburg, Netherlands; UMC Utrecht, Rudolf Magnus Inst Neurosci, Rehabil Ctr De Hoogstraat, Utrecht, Netherlands		Eilander, HJ (corresponding author), Rehabil Ctr Leijpk, Div Res, Project VLB NAH, POB 5022, NL-5004 EA Tilburg, Netherlands.	h.j.eilander@hccnet.nl	Wijnen, Viona/G-1328-2016; Eilander, Henk/D-9643-2016; Wijnen, Viona/AAX-3041-2021	Wijnen, Viona/0000-0001-7797-1882; 			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bach-y-Rita P, 2003, ARCH PHYS MED REHAB, V84, P1100, DOI 10.1016/S0003-9993(03)00312-5; Bach-y-Rita P., 1980, RECOVERY FUNCTION TH; BACHYRITA P, 2000, CEREBRAL REORGANIZAT, P357; BARIN JJ, 1985, HEAD INJURY REHABILI, P101; BARKER RA, 1999, NEUROPSY REHABIL MOD, P1; BONTKE CF, 1992, J HEAD TRAUMA REHAB, V7, P115; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; CUMMINS RA, 1992, AUST PSYCHOL, V27, P71, DOI 10.1080/00050069208257582; DeYoung S, 1987, Rehabil Nurs, V12, P121; DOMAN RJ, 1960, JAMA-J AM MED ASSOC, V174, P257, DOI 10.1001/jama.1960.03030030037007; EILANDER HJ, 2003, KINDERREVALIDATIE, P302; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; Grafman J, 2000, J COMMUN DISORD, V33, P345, DOI 10.1016/S0021-9924(00)00030-7; JAFFE MB, 1985, HEAD INJURY REHABILI, P167; KOLB B, 1996, RECOVERY TRAUMATIC B, P199; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; Kriel RL, 1995, J NEUROL REHABIL, V9, P145; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; Rosenzweig M.R., 1987, ENRICHED IMPOVERISHE; Schwartz CE, 1997, PSYCHOSOM MED, V59, P362, DOI 10.1097/00006842-199707000-00005; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SMITH GJ, 1985, HEAD INJURY REHABILI, P275; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; SZEKERES SF, 1985, HEAD INJURY REHABILI, P219; TEASDALE G, 1974, LANCET, V2, P81; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; WEBER PL, 1984, ARCH PHYS MED REHAB, V65, P457; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson SL, 1996, BRAIN INJURY, V10, P807, DOI 10.1080/026990596123927; Ylvisaker M., 1985, HEAD INJURY REHABILI; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; ZASLER ND, 1996, RECOVERY TRAUMATIC B, P185; [No title captured]; [No title captured]	63	61	62	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2005	19	6					425	436		10.1080/02699050400025299			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	932JI	WOS:000229549600004	16101265				2022-02-06	
J	Boake, C; McCauley, SR; Pedroza, C; Levin, HS; Brown, SA; Brundage, SI				Boake, C; McCauley, SR; Pedroza, C; Levin, HS; Brown, SA; Brundage, SI			Lost productive work time after mild to moderate traumatic brain injury with and without hospitalization	NEUROSURGERY			English	Article						craniocerebral trauma; economic costs; employment; head injuries; minor head injury; prognosis; traumatic brain injury	HEAD-INJURY; MODEL SYSTEMS; RETURN; DISABILITY; METAANALYSIS	OBJECTIVE: Lost productivity after mild traumatic brain injury (TBI) is a large component of the economic costs of brain trauma in the United States. This is the first prospective study of employment after mild TBI to include patients not admitted to a hospital. METHODS: Concurrent inception cohorts of 210 working-age adults with mild to moderate TBI and 122 patients who sustained general trauma not involving the brain were recruited at a trauma center and followed up to 6 months later. Outcomes were time from injury until first day worked and problems reported after resuming work. RESULTS: Most patients who worked after their injury remained employed 6 months later in a similar capacity as before the injury. No consistent differences were demonstrated between employment outcomes of patients with mild TBI and those with general trauma. The majority of nonhospitalized patients with mild TBI did not work for at least 1 month and did not begin working until 1 to 3 months after injury. Most patients with moderate TBI remained unemployed at 6 months postinjury. Patients with lower preinjury occupational status tended to have longer work absences. CONCLUSION: Lost productive work time after nonhospitalized TBI may cause significant economic costs because these injuries are frequent. Contrary to the theory that brain injury is more disabling to patients in cognitively demanding occupations, patients with higher job status tended to begin work earlier. A technique is needed to screen patients with mild TBI for risk of employment problems. Rehabilitation after moderate TBI may help to minimize lost productivity.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Stanford Univ, Dept Surg, Med Ctr, Stanford, CA 94305 USA		Boake, C (corresponding author), TIRR,1333 Moursund, Houston, TX 77030 USA.	corwin.boake@uth.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282	ODCDC CDC HHS [R49/CCR612707, R49/CCR612707-01] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Centers for Disease Control and Prevention, REP C MILD TRAUM BRA; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; COX DR, 1972, J R STAT SOC B, V34, P187; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2001, HEAD TRAUMA, P327; *US CENS BUR, 2000, QTP3; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006	29	61	63	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2005	56	5					994	1002		10.1227/01.NEU.0000158319.38230.C3			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	925LJ	WOS:000229054300039	15854247				2022-02-06	
J	Ewert, T; Grill, E; Bartholomeyczik, S; Finger, M; Mokrusch, T; Kostanjsek, N; Stucki, G				Ewert, T; Grill, E; Bartholomeyczik, S; Finger, M; Mokrusch, T; Kostanjsek, N; Stucki, G			ICF Core Set for patients with neurological conditions in the acute hospital	DISABILITY AND REHABILITATION			English	Article						rehabilitation; consensus development conference; nervous system diseases; acute rehabilitation; ICF; ICF core set	TRAUMATIC BRAIN-INJURY; STROKE UNIT; REHABILITATION; DEPRESSION; IDENTIFICATION; IMPAIRMENT; DISABILITY; CATEGORIES; PRINCIPLES; MANAGEMENT	Purpose: The aim of this consensus process was to decide on a first version of the ICF Core Set for patients with neurological conditions in the acute hospital. Methods: The ICF Core Set development involved a formal decision-making and consensus process, integrating evidence gathered from preliminary studies including focus groups of health professionals, a systematic review of the literature and empiric data collection from patients. Results: Twenty-one experts selected a total of 85 second-level categories. The largest number of categories was selected from the ICF component Body Functions ( 41 categories or 48%). Five (6%) of the categories were selected from the component Body Structures, 18 (21%) from Activities and Participation and 21 (25%) from Environmental Factors. Conclusions: The Acute ICF Core Set for patients with neurological conditions provides all professionals with a clinical framework to comprehensively assess patients in the acute hospital. This first ICF Core Set will be further tested through empiric studies in German-speaking countries and internationally.	Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany; Univ Munich, IMBK, WHO FIC Collaborating Ctr, ICF Res Branch, Munich, Germany; Univ Witten Herdecke, Inst Nursing Sci, Witten, Germany; Rehabil Clin Bellikon, Bellikon, Switzerland; Hedon Clin, Lingen, Germany; WHO, Classificat Assessment Surveys & Terminol Team, CH-1211 Geneva, Switzerland		Stucki, G (corresponding author), Univ Munich, Dept Phys Med & Rehabil, Marchioninistr 15, D-81377 Munich, Germany.	gerold.stucki@med.uni-muenchen.de	Grill, Eva/AAF-8104-2020; Grill, Eva/D-1875-2010	Grill, Eva/0000-0002-0273-7984; Grill, Eva/0000-0002-0273-7984			Adams HP, 1997, DRUGS, V54, P60, DOI 10.2165/00003495-199700543-00010; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Barnes MP, 2003, J NEUROL NEUROSUR PS, V74, P3; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; *DEP HLTH, HOSP EP STAT ENGL FI, P7; Dombovy ML, 1998, BRAIN INJURY, V12, P443, DOI 10.1080/026990598122412; Donchin Yoel, 2002, Curr Opin Crit Care, V8, P316, DOI 10.1097/00075198-200208000-00008; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Grill E, 2005, DISABIL REHABIL, V27, P447, DOI 10.1080/09638280400014048; Grill E, 2005, DISABIL REHABIL, V27, P437, DOI 10.1080/09638280400014030; Grill E, 2005, DISABIL REHABIL, V27, P361, DOI 10.1080/09638280400013974; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howard RS, 2003, J NEUROL NEUROSUR PS, V74, pIII10, DOI 10.1136/jnnp.74.suppl_3.iii10; Howard RS, 2003, J NEUROL NEUROSUR PS, V74, piii2; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kase CS, 1998, STROKE, V29, P805, DOI 10.1161/01.STR.29.4.805; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Launois R, 2004, STROKE, V35, P770, DOI 10.1161/01.STR.0000117574.19517.80; MAHONEY F I, 1965, Md State Med J, V14, P61; McKinney Aidin A, 2002, Intensive Crit Care Nurs, V18, P320, DOI 10.1016/S0964-3397(02)00069-1; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Payne KA, 2002, PHARMACOECONOMICS, V20, P813, DOI 10.2165/00019053-200220120-00002; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Robinson RG, 1997, ANNU REV MED, V48, P217; Scheuringer M, 2005, DISABIL REHABIL, V27, P419, DOI 10.1080/09638280400014089; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Srikanth VK, 2003, STROKE, V34, P1136, DOI 10.1161/01.STR.0000069161.35736.39; Stier-Jarmer M, 2005, DISABIL REHABIL, V27, P389, DOI 10.1080/09638280400014022; Stucki G, 2005, DISABIL REHABIL, V27, P353, DOI 10.1080/09638280400014105; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; TEASDALE G, 1974, LANCET, V2, P81; WADE DT, 1993, CURR OPIN NEUROL NEU, V6, P78; Wade DT, 2003, AM J PHYS MED REHAB, V82, pS26, DOI 10.1097/01.PHM.0000086996.89383.A1; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Weir CJ, 2003, QJM-INT J MED, V96, P67, DOI 10.1093/qjmed/hcg008; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; World Health Organization, 2007, INT CLASS FUNCT DIS	43	61	75	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	APR	2005	27	7-8					367	373		10.1080/09638280400014014			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	920CN	WOS:000228666600004	16040538				2022-02-06	
J	Parizel, PM; Van Goethem, JW; Ozsarlak, O; Maes, M; Phillips, CD				Parizel, PM; Van Goethem, JW; Ozsarlak, O; Maes, M; Phillips, CD			New developments in the neuroradiological diagnosis of craniocerebral trauma	EUROPEAN RADIOLOGY			English	Article						head trauma; diffusion-weighted imaging; multi-detector CT	DIFFUSE AXONAL INJURY; CHRONIC SUBDURAL-HEMATOMA; HEAD-INJURY; WEIGHTED MRI; BRAIN-INJURY; INTRACRANIAL HEMORRHAGE; IMAGING FINDINGS; CT; FEATURES	Accurate radiographic diagnosis is a cornerstone of the clinical management and outcome prediction of the head-injured patient. New technological advances, such as multi-detector computed tomography (MDCT) scanning and diffusion-weighted magnetic resonance imaging (MRI) have influenced imaging strategy. In this article we review the impact of these developments on the neuroradiological diagnosis of acute head injury. In the acute phase, multi-detector CT has supplanted plain X-ray films of the skull as the initial imaging study of choice. MRI, including fluid-attenuated inversion recovery, gradient echo T2* and diffusion-weighted sequences, is useful in determining the severity of acute brain tissue injury and may help to predict outcome. The role of MRI in showing diffuse axonal injuries is emphasized. We review the different patterns of primary and secondary extra-axial and intra-axial traumatic brain lesions and integrate new insights. Assessment of intracranial hypertension and cerebral herniation are of major clinical importance in patient management. We discuss the issue of pediatric brain trauma and stress the importance of MRI in non-accidental injury. In summary, new developments in imaging technology have advanced our understanding of the pathophysiology of brain trauma and contribute to improving the survival of patients with craniocerebral injuries.	Univ Antwerp, Dept Radiol, B-2020 Antwerp, Belgium; Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA		Parizel, PM (corresponding author), Univ Antwerp, Dept Radiol, B-2020 Antwerp, Belgium.	paul.parizel@uza.be		Van Goethem, Johan/0000-0003-3993-4583; Parizel, Paul M./0000-0002-0221-2854			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bakshi R, 1999, AM J NEURORADIOL, V20, P629; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Blumenthal I, 2002, POSTGRAD MED J, V78, P732, DOI 10.1136/pmj.78.926.732; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Campbell B G, 1998, Top Magn Reson Imaging, V9, P208; Demaerel P, 2002, EUR RADIOL, V12, P849, DOI 10.1007/s00330-001-1145-9; Gean A D, 1995, New Horiz, V3, P549; Gean AD, 1994, IMAGING HEAD TRAUMA; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 2002, MAGNETIC RESONANCE I, P1059; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; HASHIMOTO N, 1992, J NEUROSURG, V77, P310, DOI 10.3171/jns.1992.77.2.0310; Heidemann RM, 2003, EUR RADIOL, V13, P2323, DOI 10.1007/s00330-003-1992-7; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IPLIKCIOGLU AC, 1991, J TRAUMA, V31, P272; Lin DDM, 2001, AM J NEURORADIOL, V22, P1275; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mirvis S E, 1994, J Intensive Care Med, V9, P305; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; PARIZEL G, 1973, ANGIOLOGY, V24, P17, DOI 10.1177/000331977302400103; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2004, DISEASES OF THE BRAIN, HEAD AND NECK, SPINE, P60; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; Parizel PM, 2002, INTENS CARE MED, V28, P85, DOI 10.1007/s00134-001-1160-y; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Parizel PM, 2001, STROKE, V32, P2942, DOI 10.1161/str.32.12.2942; Poussaint TY, 2002, NEUROIMAG CLIN N AM, V12, P271, DOI 10.1016/S1052-5149(02)00005-9; Schaefer PW, 2001, J NEUROL SCI, V186, pS25, DOI 10.1016/S0022-510X(01)00488-9; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Server A, 2001, ACTA RADIOL, V42, P254; Sklar EM, 2000, AM J NEURORADIOL, V21, P808; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; WILMS G, 1992, NEURORADIOLOGY, V34, P497, DOI 10.1007/BF00598959; YORK JE, 1999, CURR PRACT MED, V2, P773; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	45	61	65	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					569	581		10.1007/s00330-004-2558-z			13	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500018	15696294				2022-02-06	
J	Goverover, Y; Chiaravalloti, N; DeLuca, J				Goverover, Y; Chiaravalloti, N; DeLuca, J			The relationship between self-awareness of neurobehavioral symptoms, cognitive functioning, and emotional symptoms in multiple sclerosis	MULTIPLE SCLEROSIS JOURNAL			English	Article						affect measures; concordance; multiple sclerosis; neuropsychological measures; neurobehavioral symptoms; rehabilitation; self-awareness	TRAUMATIC BRAIN-INJURY; IMPAIRED AWARENESS; REHABILITATION; METAMEMORY; DEPRESSION; INVENTORY; DEFICITS; BEHAVIOR; PATIENT; CORTEX	Objective: To examine self-awareness of neurobehavioral symptoms in multiple sclerosis (MS) across three domains of function (apathy, disinhibition, and executive control), and examine the relationship between self-awareness and cognitive functioning. Methods: Twenty-six individuals with MS completed neuropsychological testing, measures of emotional functioning, and self-ratings of neurobehavioral symptoms using the Frontal Systems Behavior Scale (FrSBe), a 46-item questionnaire with subscales assessing frequency of symptoms in executive dysfunction, disinhibition, and apathy. Informants' ratings of the FrSBe were also obtained. Decreasing differences between patient and informant reports on each subscale of the FrSBe (concordance) indicate higher levels of self-awareness. Results: Results showed significant positive correlations between cognitive abilities and self-awareness of executive dysfunction and disinhibition. In contrast, affect symptomatology (measures of anxiety and depression) were negatively correlated with self-awareness of executive dysfunction. Conclusions: Level of self-awareness of neurobehavioral symptoms in MS is related to level of cognitive impairment. In addition, symptoms of depression and anxiety reduced the accuracy of self-reporting. Thus, a clinician who relies on self-reports in creating an evaluation and treatment plan should consider the patient's cognitive and emotional states.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA		Chiaravalloti, N (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	nchiaravalloti@kmrrec.org		Chiaravalloti, Nancy/0000-0003-2943-7567			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/0013164402062004005; BEATTY WW, 1991, J CLIN EXP NEUROPSYC, V13, P309, DOI 10.1080/01688639108401046; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beck AT, 1987, BECK DEPRESSION INVE; Benedict RHB, 2002, J NEUROPSYCH CLIN N, V14, P44, DOI 10.1176/appi.neuropsych.14.1.44; Benedict RHB, 2001, J NEUROPSYCH CLIN N, V13, P70, DOI 10.1176/appi.neuropsych.13.1.70; Benson D.F., 1986, FRONTAL LOBES; Bisiach E., 1991, AWARENESS DEFICIT BR, P17; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BROWNELL B, 1962, J NEUROL NEUROSUR PS, V25, P315, DOI 10.1136/jnnp.25.4.315; Burgess P, 1996, BEHAV ASSESSMENT DYS; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FONG J, 1997, BRAIN, V120, P15; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Groth-Marnat G., 1990, HDB PSYCHOL ASSESSME, V2nd ed.; Halper June, 2003, J Neurosci Nurs, V35, P70; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEINZE L, 2004, 32 ANN CONV INT NEUR; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; JARMAN RF, 1995, GENET SOC GEN PSYCH, V121, P153; Johnson SK., 2001, J CHRONIC FATIGUE SY, V8, P41, DOI [10.1300/J092v08n03_05, DOI 10.1300/J092V08N03_05]; Kaplan E, 1983, BOSTON NAMING TEST; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Maor Y, 2001, MULT SCLER, V7, P131, DOI 10.1191/135245801678227658; McDonnell GV, 2003, MULT SCLER J, V9, P204, DOI 10.1191/1352458503ms890cr; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Nelson T. O., 1992, METACOGNITION CORE R; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1991, AWARENESS DEFICIT TR; Randolph JJ, 2004, ARCH CLIN NEUROPSYCH, V19, P259, DOI 10.1016/S0887-6177(03)00026-X; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shimamura AP, 1995, ANN NY ACAD SCI, V769, P151, DOI 10.1111/j.1749-6632.1995.tb38136.x; Souchay C, 2002, NEUROPSYCHOLOGIA, V40, P2386, DOI 10.1016/S0028-3932(02)00075-1; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O, 1991, COMPENDIUM NEUROPSYC; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wechsler D., 1987, WECHSLER ADULT INTEL	59	61	61	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1352-4585			MULT SCLER J	Mult. Scler. J.		2005	11	2					203	212		10.1191/1352458505ms1153oa			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	907KW	WOS:000227717400014	15794396				2022-02-06	
J	Hudak, AM; Trivedi, K; Harper, CR; Booker, K; Caesar, RR; Agostini, M; Van Ness, PC; Diaz-Arrastia, R				Hudak, AM; Trivedi, K; Harper, CR; Booker, K; Caesar, RR; Agostini, M; Van Ness, PC; Diaz-Arrastia, R			Evaluation of seizure-like episodes in survivors of moderate and severe traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						nonepileptic seizures; posttraumatic epilepsy; video-EEG monitoring	TEMPORAL-LOBE EPILEPSY; LATE POSTTRAUMATIC SEIZURES; NONEPILEPTIC SEIZURES; HEAD-INJURY; FEATURES; DIAGNOSIS; ADULTS; RISK	Background: Transient paroxysmal alterations of consciousness or behavior are common sequelae of moderate and severe traumatic brain injury (TBI). Clinicians caring for patients with such episodes often diagnose them as epileptic seizures, a frequent and well-studied complication of TBI. As it is difficult to confirm this diagnosis, antiepileptic drugs are often used empirically. However, as such therapy is frequently ineffective, we studied the usefulness of prolonged video electroencephalogram (VEEG) monitoring in the clinical management of paroxysmal behaviors in TBI survivors. Methods: Records of patients referred evaluation in an epilepsy monitoring unit for management of medically intractable epilepsy were retrospectively reviewed. Patients with a documented history of moderate-to-severe brain injury preceding the onset of epilepsy were identified. These patients were studied by simultaneous videotape and scalp electroencephalographic recordings, and the majority also underwent magnetic resonance imaging and neuropsychologic studies. Results: Of the 1858 consecutive admissions over a 66-month period, 127 (7%) fulfilled enrollment criteria. VEEG monitoring was conducted for an average of 4.6 days. Monitoring was successful in establishing a diagnosis in 82% of the cases referred: 62% had focal seizures, 6% had generalized seizures, and 33% had psychogenic nonepileptic seizures. Of those with temporal lobe epilepsy, 53% had mesial temporal sclerosis, as shown by magnetic resonance imaging. Conclusions: VEEG is a useful procedure in the evaluation of TBI survivors with spells. The yield of diagnoses that may alter treatment is substantial. Additionally, mesial temporal sclerosis is associated with TBI. Given the variety of seizure types found in survivors of moderate-to-severe TBI, obtaining specific diagnosis of seizure type by VEEG monitoring impacts treatment options.	Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA		Hudak, AM (corresponding author), Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Anne.Hudak@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; BENBADIS SR, 2000, COMPREHENSIVE CLIN N, P468; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; ELOVIC E, 1996, MED REHABILITATION T, P1; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; Krumholz A, 1999, NEUROLOGY, V53, pS76; KUZNIECKY R, 1995, MAGNETIC RESONANCE I; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MEIERKORD H, 1991, NEUROLOGY, V41, P1643, DOI 10.1212/WNL.41.10.1643; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	24	61	61	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2004	19	4					290	295		10.1097/00001199-200407000-00003			6	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	839CB	WOS:000222759800003	15263856				2022-02-06	
J	Wurm, G; Tomancok, B; Nussbaumer, K; Adelwohrer, C; Holl, K				Wurm, G; Tomancok, B; Nussbaumer, K; Adelwohrer, C; Holl, K			Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						subarachnoid hemorrhage; low-molecular-weight heparin; cerebral vasospasm	MOLECULAR-WEIGHT HEPARIN; TRAUMATIC BRAIN INJURY; VENOUS THROMBOEMBOLISM; CEREBRAL VASOSPASM; PREVENTION; MANAGEMENT; SURGERY; PROLIFERATION; COMPLICATIONS; PROPHYLAXIS	Background: Cerebral vasospasm, including its ischemic sequelae, remains a leading cause of death and disability following subarachnoid hemorrhage (SAH). This study was designed to evaluate whether the low-molecular-weight heparin (LMWH) enoxaparin reduces the occurrence of cerebral vasospasm and ischemia following spontaneous SAH. Methods: A prospective, double-blind, randomized study was conducted in 120 consecutive patients with SAH (Hunt Hess Scale (HHS) I-III). Patients received one subcutaneous injection per day of either 20 mg enoxaparin or placebo for 3 weeks following SAH. Efficacy endpoints were the occurrence of cerebral vasospasm, delayed ischemic deficit (DID), cerebral infarction, and overall outcome at I year following SAH. Results: At 1-year follow-up, enoxaparin significantly reduced DID and cerebral infarction. Delayed ischemic deficit occurred in 8.8% of the enoxaparin group versus 66.7% of the placebo group (P < 0.001), while 3.5% of vasospasm-related cerebral infarctions occurred in enoxaparin-treated patients and 28.3% in placebo-treated patients (P < 0.001). Severe shunt-dependent hydrocephalus was significantly lower in the enoxaparin group (1.8% versus 16.7%; P = 0.019). Compared with the placebo group, the enoxaparin group had fewer intracranial bleeding events and better overall outcomes at 1-year follow-up. Although there was potential bias as a result of patients in the placebo group being more severely affected (in terms of HHS), treatment with enoxaparin for 3 weeks improved long-term outcome following SAH. Conclusions: Enoxaparin is safe and effective in reducing cerebral vasospasm and ischemia following SAH (Hunt Hess grades I-III), resulting in a better long-term outcome for the patient. (C) 2004 Elsevier B.V. All rights reserved.	Landesnervenklin Wagner Jauregg, Dept Neurosurg, A-4020 Linz, Austria; Landesnervenklin Wagner Jauregg, Dept Neuroradiol, A-4020 Linz, Austria; Landesnervenklin Wagner Jauregg, Dept Neurol, A-4020 Linz, Austria		Nussbaumer, K (corresponding author), Landesnervenklin Wagner Jauregg, Dept Neurosurg, Wagner Jauregg Weg 15, A-4020 Linz, Austria.	gabriele.wurm@gespag.at					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Agnelli G, 1999, THROMB HAEMOSTASIS, V82, P925; BAZZONI G, 1993, J LAB CLIN MED, V121, P268; BLASBERG R, 1981, NEUROSURGERY, V9, P686, DOI 10.1227/00006123-198112000-00012; Charpentier C, 1999, STROKE, V30, P1402, DOI 10.1161/01.STR.30.7.1402; CHIMOWITZ MI, 1987, STROKE, V18, P1169, DOI 10.1161/01.STR.18.6.1169; CLOWES AW, 1985, LAB INVEST, V52, P611; Cupitt JM, 2001, ANAESTHESIA, V56, P780; Fareed J, 2000, SEMIN THROMB HEMOST, V26, P5, DOI 10.1055/s-2000-9498; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FRIM DM, 1992, NEUROSURGERY, V30, P830, DOI 10.1227/00006123-199206000-00002; Gikakis N, 1996, CIRCULATION, V94, P341; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Hutter BO, 1999, ACT NEUR S, V72, P157; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; JENNETT B, 1975, LANCET, V1, P480; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Juvela S, 2000, J NEUROSURG, V92, P390, DOI 10.3171/jns.2000.92.3.0390; KAPP JP, 1982, SURG NEUROL, V18, P40, DOI 10.1016/0090-3019(82)90011-8; KARNOFSKY DA, 1951, ARCH INTERN MED, V87, P477, DOI 10.1001/archinte.1951.03810040002001; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Libersan D, 1998, CARDIOVASC RES, V37, P656, DOI 10.1016/S0008-6363(97)00292-7; MACDONALD RL, 1994, J NEUROSURG, V80, P433, DOI 10.3171/jns.1994.80.3.0433; Macdonald RL, 1999, NEUROSURGERY, V45, P245, DOI 10.1097/00006123-199908000-00008; MAHONEY F I, 1965, Md State Med J, V14, P61; Mary V, 2001, STROKE, V32, P993, DOI 10.1161/01.STR.32.4.993; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; NAGY Z, 1995, STROKE, V26, P265, DOI 10.1161/01.STR.26.2.265; Okada Y, 1999, NEUROSURGERY, V45, P443, DOI 10.1097/00006123-199909000-00005; Persson L, 1999, ACT NEUR S, V72, P73; Pratt J, 1998, HAEMOSTASIS, V28, P78; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; TEKKOK IH, 1994, ACTA NEUROCHIR, V127, P112, DOI 10.1007/BF01808557; Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Weir B, 1999, ACT NEUR S, V72, P27; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; YAMAMOTO Y, 1992, NEUROSURGERY, V30, P337, DOI 10.1227/00006123-199203000-00005	41	61	63	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAR	2004	106	2					97	103		10.1016/j.clineuro.2004.01.006			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	805BI	WOS:000220341400005	15003298				2022-02-06	
J	Sohlberg, MM; Avery, J; Kennedy, M; Ylvisaker, M; Coelho, C; Turkstra, L; Yorkston, K				Sohlberg, MM; Avery, J; Kennedy, M; Ylvisaker, M; Coelho, C; Turkstra, L; Yorkston, K			Practice guidelines for direct attention training	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							DEFICITS; REHABILITATION; REMEDIATION	This article is part of a series of reports from a committee charged with developing evidence-based practice (EBP) guidelines for rehabilitation of cognitive-communication deficits following traumatic brain injury (TBI). We examine the literature for evidence of the effectiveness of direct attention training to treat attention impairments following TBI. Evidence is gleaned from the outcomes of nine Class I and Class II studies that span intervention from acute to outpatient rehabilitation. Results and discussion are organized using five key questions as a mechanism to review the research to determine if the approach, outcomes, and associated recommendations warrant a change in clinical practice. The key questions are: Who are the participants who received the intervention? What comprises the attention training? What are the outcomes of the intervention? Are there methodological concerns? Are there clinically applicable trends across different attention remediation studies? The complexities and difficulties inherent in implementing clinical trials with the heterogeneous TBI population are discussed. The article concludes with treatment guidelines and options supported by the research review. Future research needs are highlighted.	Univ Oregon, Eugene, OR 97403 USA; Univ Minnesota, Dept Commun Disorders, Minneapolis, MN 55455 USA; Coll St Rose, Dept Commun Disorders, Albany, NY USA; Univ Connecticut, Dept Commun Sci, Storrs, CT USA; Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Sohlberg, MM (corresponding author), Univ Oregon, 5281, Eugene, OR 97403 USA.	mckay@oregon.uoregon.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GODFREY HPD, 1985, J CONSULT CLIN PSYCH, V53, P555, DOI 10.1037/0022-006X.53.4.555; Golper L., 2001, EVIDENCE BASED PRACT; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; KENNEDY MR, 2002, J MED SPEECH-LANG PA, V10, P9; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Lucyshyn JM, 1997, J CONSULT CLIN PSYCH, V65, P241, DOI 10.1037/0022-006X.65.2.241; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; MOFFAT N, 1992, CLIN MANAGEMENT MEMO, P83; Montgomery EB, 2003, J MED SPEECH-LANG PA, V11, pIX; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBEY R, 2001, ASHA SPECIAL INTERES, V11, P10; SimmonsMackie NN, 1996, DISABIL REHABIL, V18, P540, DOI 10.3109/09638289609166315; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; STRACHE W, 1987, INT J REHABIL RES S5, V10, pS141; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M., 1998, COLLABORATIVE BRAIN	28	61	62	0	15	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	2003	11	3					XIX	XLII					21	Audiology & Speech-Language Pathology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Neurosciences & Neurology	722PH	WOS:000185384900003					2022-02-06	
J	Amorini, AM; Lazzarino, G; Galvano, F; Fazzina, G; Tavazzi, B; Galvano, G				Amorini, AM; Lazzarino, G; Galvano, F; Fazzina, G; Tavazzi, B; Galvano, G			Cyanidin-3-O-beta-glucopyranoside protects myocardium and erythrocytes from oxygen radical-mediated damages	FREE RADICAL RESEARCH			English	Article						anthocyanin; cyanidin-3-O-beta-glucopyranoside; nutritional antioxidants; reactive oxygen species; oxidative stress; myocardial ischemia and reperfusion	BLOOD ORANGE JUICES; PERFORMANCE LIQUID-CHROMATOGRAPHY; TRAUMATIC BRAIN INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS; DNA-DAMAGE; REPERFUSION INJURY; ANTHOCYANINS; ANTIOXIDANT; ISCHEMIA	The cyanidin-3-O-beta-glucopyranoside (C-3-G) antioxidant capacity towards reactive oxygen species (ROS)-mediated damages was assessed in tissue and cells submitted to increased oxidative stress. In the isolated ischemic and reperfused rat heart, 10 or 30 muM C-3-G protected from both lipid peroxidation (66.7 and 94% inhibition of malondialdehyde (MDA) generation in 10 and 30 muM C-3-G-reperfused hearts, respectively, in comparison with control reperfused hearts) and energy metabolism impairment (higher ATP concentration in 10 and 30 muM C-3-G-reperfused hearts than in control reperfused hearts). These effects were associated to C-3-G permeation within myocardial cells, as indicated by results obtained in the isolated rat heart perfused for 30 min in the recirculating Langendorff mode under normoxia with 10 and 30 muM C-3-G. Protective effects were exerted, in a dose-dependent manner, by C-3-G also in 2 mM hydrogen peroxide-treated human erythrocytes. With respect to MDA formation, an apparent IC50 of 5.12 muM was calculated for C-3-G (the polyphenol resveratrol used for comparison showed an apparent IC50 of 38.43 muM). The general indications are that C-3-G (largely diffused in dietary plants and fruits, such as pigmented oranges very common in the Mediterranean diet) represents a powerful natural antioxidant with beneficial effects in case of increased oxidative stress, and at pharmacological concentrations it is able to decrease tissue damages occurring in myocardial ischemia and reperfusion.	Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy; Univ Reggio Calabria, Dept Agroforestry & Environm Sci & Technol, I-89061 Reggio Di Calabria, Italy; Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, I-00167 Rome, Italy; Univ Catania, Dept Agron Agrochem & Anim Prod Sci, I-95125 Catania, Italy		Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, Catania, Italy.		TAVAZZI, BARBARA/AAB-9830-2019; Galvano, Fabio/F-8122-2010; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Galvano, Fabio/0000-0003-0644-0755; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279			AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Amorini AM, 2001, FREE RADICAL RES, V35, P953, DOI 10.1080/10715760100301451; Berenshtein E, 1997, J MOL CELL CARDIOL, V29, P3025, DOI 10.1006/jmcc.1997.0535; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Dhalla NS, 2000, CARDIOVASC RES, V47, P446, DOI 10.1016/S0008-6363(00)00078-X; ESTERBAUER H, 1984, METHOD ENZYMOL, V105, P319; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRANCIS FJ, 1989, CRIT REV FOOD SCI, V28, P273, DOI 10.1080/10408398909527503; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Iqbal K, 2002, AM J CARDIOL, V89, P334, DOI 10.1016/S0002-9149(01)02237-8; ISLAM N, 1995, NEUROSCI LETT, V188, P159, DOI 10.1016/0304-3940(95)11419-W; Landrault N, 2001, J AGR FOOD CHEM, V49, P3341, DOI 10.1021/jf010128f; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Leighton F, 1999, DRUG EXP CLIN RES, V25, P133; Meiers S, 2001, J AGR FOOD CHEM, V49, P958, DOI 10.1021/jf0009100; Milbury PE, 2002, MECH AGEING DEV, V123, P997, DOI 10.1016/S0047-6374(01)00383-9; Miyazawa T, 1999, J AGR FOOD CHEM, V47, P1083, DOI 10.1021/jf9809582; Mondello L, 2000, J PHARMACEUT BIOMED, V23, P191, DOI 10.1016/S0731-7085(00)00269-7; Ramirez-Tortosa C, 2001, FREE RADICAL BIO MED, V31, P1033, DOI 10.1016/S0891-5849(01)00618-9; RAPISARDA P, 1994, AGROCHIMICA, V38, P157; Rapisarda P, 1998, J AGR FOOD CHEM, V46, P464, DOI 10.1021/jf9603700; Rapisarda P., 1992, P INT SOC CITRIC, V3, P1130; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; SatueGracia MT, 1997, J AGR FOOD CHEM, V45, P3362, DOI 10.1021/jf970234a; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; Tavazzi B, 2001, J BIOL CHEM, V276, P48083, DOI 10.1074/jbc.M101715200; TERAHARA N, 1994, BIOSCI BIOTECH BIOCH, V58, P1324, DOI 10.1271/bbb.58.1324; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; Treitinger A, 2000, EUR J CLIN INVEST, V30, P454; Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014-5793(99)00407-X; Uesugi N, 2001, AM J KIDNEY DIS, V38, P1016, DOI 10.1053/ajkd.2001.28591; Wang HB, 1999, J NAT PROD, V62, P294, DOI 10.1021/np980501m; WHITEHEAD TP, 1995, CLIN CHEM, V41, P32	38	61	63	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1071-5762			FREE RADICAL RES	Free Radic. Res.		2003	37	4					453	460		10.1080/1071576021000055253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643AD	WOS:000180839000013	12747740				2022-02-06	
J	Andersson, S; Bergedalen, AM				Andersson, S; Bergedalen, AM			Cognitive correlates of apathy in traumatic brain injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						apathy; cognitive function; frontal lobe dysfunction; traumatic brain injury	ANTERIOR CINGULATE CORTEX; FRONTAL-SUBCORTICAL CIRCUITS; ALZHEIMERS-DISEASE; HIV-1 INFECTION; DEPRESSION; PERFORMANCE; RELIABILITY; INTERFACE; DEFICITS; VALIDITY	Objective: To investigate the relation between apathy and cognitive deficits in patients with severe traumatic brain injury (TBI). Background: Apathy defined as reduced goal-directed behavior due to lack of motivation constitutes a major neuropsychiatric symptom following TBI. According to definition, apathy should not be associated with global cognitive reduction, but rather with specific areas of cognitive dysfunction. Methods: Results from the Apathy Evaluation Scale (AES) and a comprehensive neuropsychologic assessment were collected in up to 53 patients With severe TBI. Neuropsychologic tests were organized in the following seven areas of cognitive function: acquisition and memory, attention span, executive function, psychomotor speed, verbal skills, nonverbal skills, and motor speed. Results: Apathy score was significantly correlated with reduced performance on acquisition and memory, psychomotor speed, and executive functions. A principal component analysis showed that these specific areas of cognitive functions clustered together with the cognitive dimension of apathy, not with behavioral or emotional aspects of apathy, Conclusions: Apathy is associated with specific cognitive deficits related to frontal lobe dysfunction. The results are in accordance with the definition of apathy and confirm apathy-cognitive function relationships reported in other neurologic populations.	Sunnaas Rehabil Hosp, Oslo, Norway		Andersson, S (corresponding author), Sunnaas Rehab Hosp, Neuropsychol Lab, N-1450 Nesoddtangen, Norway.						Allman JM, 2001, ANN NY ACAD SCI, V935, P107, DOI 10.1111/j.1749-6632.2001.tb03476.x; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Andersson S., 1992, J NORWEGIAN MED ASS, V112, P2070; Andreasen N.C., 1990, SCHIZOPHRENIA POSITI; Arthur G, 1947, POINT SCALE PERFORMA; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Carter CS, 2001, AM J PSYCHIAT, V158, P1423, DOI 10.1176/appi.ajp.158.9.1423; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; Castellon SA, 1998, J NEUROPSYCH CLIN N, V10, P320, DOI 10.1176/jnp.10.3.320; Castellon SA, 2000, J INT NEUROPSYCH SOC, V6, P336, DOI 10.1017/S1355617700633088; Cummings JL, 1995, ANN NY ACAD SCI, V769, P1, DOI 10.1111/j.1749-6632.1995.tb38127.x; DELIS D, 1987, CALIFORNIA VERBAL LE; Finset A, 2000, BRAIN INJURY, V14, P887; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Galynker I, 1997, J NERV MENT DIS, V185, P616, DOI 10.1097/00005053-199710000-00004; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heaton RK, 1991, COMPREHENSIVE NORMS; HEATON RK, 1993, WISCONSIN CARD SORTI, V2; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Kuzis G, 1999, NEUROLOGY, V52, P1403, DOI 10.1212/WNL.52.7.1403; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Litvan I, 1996, NEUROLOGY, V47, P1184, DOI 10.1212/WNL.47.5.1184; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1997, REV PSYCHIAT, V15, P205; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Rabkin JG, 2000, J NEUROPSYCH CLIN N, V12, P451, DOI 10.1176/appi.neuropsych.12.4.451; Spreen O, 1991, COMPENDIUM NEUROPSYC; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Wechsler D, 1955, WAIS MANUAL WECHSLER; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; Wolfson, 1993, HALSTEAD REITAN NEUR	44	61	62	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	SEP	2002	15	3					184	191		10.1097/01.WNN.0000026596.88167.8E			8	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	592CL	WOS:000177919100003	12218711				2022-02-06	
J	Kunz, T; Marklund, N; Hillered, L; Oliw, EH				Kunz, T; Marklund, N; Hillered, L; Oliw, EH			Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H-2 metabolism in traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical contusion injury; cyclopentenone prostaglandins; fluid percussion injury; nonenzymatic transformation; prostaglandin metabolism; TUNEL staining	ACTIVATED RECEPTOR-GAMMA; MOLECULAR-BIOLOGY; FEBRILE RESPONSE; CELL-DEATH; MICE; IDENTIFICATION; EXPRESSION; NEURONS; ACIDS; LEUKOTRIENES	Inflammatory mediators are important in traumatic brain injury (TBI). The objective of the present study was to investigate the expression of cyclooxygenase-2 (COX-2), prostaglandin E (PGE) and PGD synthases, and PGH(2) metabolism in two rat models of TBI. Fluid percussion injury (FPI) resulted in bilateral induction of COX-2 mRNA in the dentate gyri and the cortex, whereas controlled cortical contusion injury (CCC) induced COX-2 mRNA in the ipsilateral dentate gyrus and intensely in the cortex as judged by in situ hybridization. The induction subsided within 24 h. COX-2 immunoreactivity was detectable in these areas and persisted in the ipsilateral cortex for at least 72 h after CCC. Regions with COX-2 induction co-localized with TUNEL staining, suggesting a link between COX-2 expression and cell damage. COX-2 forms PGH(2), which can be isomerized to PGD(2), PGE(2), and PGF(2alpha) by enzymatic and non-enzymatic mechanisms. In situ hybridization showed that mRNA of PGD synthase and microsomal PGE synthase were present in the choroid plexus. The microsomal PGE synthase was induced bilaterally after FPI and unilaterally after CCC. Liquid chromatography-mass spectrometry showed that low speed supernatant of normal and traumatized cortex and hippocampus transformed PGH(2) to PGD(2) as main product. PGD(2) was dehydrated in brain homogenates to biological active compounds, for example, 15-deoxy-Delta(12,14)-PGJ(2). Thus COX-2 increases in certain neurons following TBI without neuronal induction of PGD and microsomal PGE synthases, suggesting that PGH(2) may decompose to PGD(2) and its dehydration products by nonenzymatic mechanisms or to PGD(2) by low constitutive levels of PGD synthase.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden		Kunz, T (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, POB 591, SE-75124 Uppsala, Sweden.	Tina.Kunz@farmbio.uu.se		Oliw, Ernst/0000-0002-7986-8130; Marklund, Niklas/0000-0002-9797-5626			ABDELHALIM MS, 1977, PROSTAGLANDINS, V14, P633, DOI 10.1016/0090-6980(77)90190-3; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1976, BIOCHIM BIOPHYS ACTA, V431, P189, DOI 10.1016/0005-2760(76)90273-3; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li LY, 2001, J BIOL CHEM, V276, P38152; Li S, 1999, BRAIN RES, V825, P86, DOI 10.1016/S0006-8993(99)01225-1; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medhora M, 2001, TRENDS CARDIOVAS MED, V11, P38, DOI 10.1016/S1050-1738(01)00082-2; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Oliw EH, 2001, BIOCHEM PHARMACOL, V62, P407, DOI 10.1016/S0006-2952(01)00683-9; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paxinos G, 1996, RAT BRAIN STEREOTAXI; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	48	61	63	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1051	1064		10.1089/089771502760341965			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900006	12482118				2022-02-06	
J	Yount, R; Raschke, KA; Biru, M; Tate, DF; Miller, MJ; Abildskov, T; Gandhi, P; Ryser, D; Hopkins, RO; Bigler, ED				Yount, R; Raschke, KA; Biru, M; Tate, DF; Miller, MJ; Abildskov, T; Gandhi, P; Ryser, D; Hopkins, RO; Bigler, ED			Traumatic brain injury and atrophy of the cingulate gyrus	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ANTERIOR CINGULATE; AXONAL INJURY; CORTEX; MR; DEFICITS; ANATOMY; REGIONS; DAMAGE	The medial surface areas of the cingulate gyrus (CG) and other midline structures (corpus cal-losum, thalamus, lateral ventricle) were examined in 27 traumatically brain injured (TBI) and 12 age- and gender-matched control subjects from an established TBI data base. Significant atrophy, primarily in the posterior CG, was found in TBI patients. Degree of atrophy was related to severity of injury. TBI subjects also had significantly reduced corpus callosum and thalamic cross-sectional surface areas with associated increased lateral ventricular volume, as well as reduced brain volume and increased ventricle-to-brain ratio. Despite significant atrophy of the posterior CG, neuropsychological performance was not related to changes in CG cross-sectional surface area in the TBI subjects. This apparent discrepancy is discussed.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; LDS Hosp, Dept Phys Med & Rehabil, Salt Lake City, UT USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Tate, David/G-5166-2011	Tate, David/0000-0003-0213-1920			Abernathy, 1990, ATLAS CEREBRAL SULCI; Beck AT, 1990, BECK ANXIETY INVENTO; Beck AT, 1987, BECK DEPRESSION INVE; Berman KF, 1999, NEUROBIOLOGY MENTAL, P246; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Carter CS, 1997, AM J PSYCHIAT, V154, P1670, DOI 10.1176/ajp.154.12.1670; CLARK DL, 2000, BRAIN BEHAV INTRO BE; CONNOR PD, 1995, THESIS BRIGHAM YOUNG; CUMMINGS JL, 2000, TXB GERIATRIC NEUROP, P81; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEN AD, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GLUHBEGOVIC N, 1980, HUMANBRAIN PHOTOGRAP; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Hinnant D.W., 1999, TRAUMATIC BRAIN INJU, P187; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; LONG CJ, 1978, J NEUROSURG, V49, P264, DOI 10.3171/jns.1978.49.2.0264; MALAMUD N, 1967, ARCH NEUROL-CHICAGO, V17, P113, DOI 10.1001/archneur.1967.00470260003001; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Mesulam M.-M., 2000, PRINC BEHAV COGN NEU, V2, P1, DOI [DOI 10.1017/9781108164320.002, 10.1017/9781108164320.002]; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RASBAND W, 1994, NIH IMAGE 155; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A, 1958, LEXAMEN CLINIQUE PSY; Roberts M, 1970, ATLAS HUMAN BRAIN SE; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; SUTHERLAND RJ, 1993, NEUROBIOLOGY CINGULA, P461; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; VOGT BA, 1993, NEUROBIOLOGY CINGULA, P19, DOI [10.1007/978-1-4899-6704-6_2, DOI 10.1007/978-1-4899-6704-6_2]; Wechsler D, 1987, MEMORY SCALE REVISED; Wu J, 1999, AM J PSYCHIAT, V156, P1149	48	61	62	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2002	14	4					416	423		10.1176/appi.neuropsych.14.4.416			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	611ZB	WOS:000179047300004	12426409				2022-02-06	
J	Sandstrom, NJ; Loy, R; Williams, CL				Sandstrom, NJ; Loy, R; Williams, CL			Prenatal choline supplementation increases NGF levels in the hippocampus and frontal cortex of young and adult rats	BRAIN RESEARCH			English	Article						nutrition; development; aging; learning; memory	NERVE GROWTH-FACTOR; BASAL FOREBRAIN NEURONS; ENHANCED VISUOSPATIAL MEMORY; FIMBRIA-FORNIX TRANSECTION; P75 NEUROTROPHIN RECEPTOR; RADIAL MAZE PERFORMANCE; IMPROVES SPATIAL MEMORY; LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; AGED RATS	Female Sprague-Dawley rats received similar to300 mg/kg per day of choline chloride through their drinking water on days 11 of pregnancy through birth and the level of nerve growth factor (NGF) in the hippocampus and frontal cortex of their male offspring was measured at 20 and 90 days of age. Prenatal choline supplementation caused significant increases in hippocampal NGF levels at 20 and 90 days of age, while levels of NGF in the frontal cortex were elevated in choline-supplemented rats at 20 days of age, but not 90 days of age. These results suggest that increases in NGF levels during development or adulthood may be one mechanism underlying improvements in spatial and temporal memory of adult rats exposed to elevated levels of choline chloride perinatally. (C) 2002 Elsevier Science B.V. All rights reserved.	Williams Coll, Bronfman Sci Ctr, Dept Psychol, Williamstown, MA 01267 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14620 USA; Duke Univ, Dept Psychol & Brain Sci, Durham, NC 27708 USA		Sandstrom, NJ (corresponding author), Williams Coll, Bronfman Sci Ctr, Dept Psychol, 18 Hoxsey St, Williamstown, MA 01267 USA.	noah.sandstrom@williams.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09525] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009525] Funding Source: NIH RePORTER		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bergado JA, 1997, BRAIN RES, V770, P1, DOI 10.1016/S0006-8993(97)00610-0; Bergado JA, 1998, EUR J PHARMACOL, V345, P181, DOI 10.1016/S0014-2999(98)00092-2; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Brandner C, 2000, NEUROBIOL LEARN MEM, V73, P49, DOI 10.1006/nlme.1999.3917; Brandner C, 2000, BEHAV BRAIN RES, V111, P165, DOI 10.1016/S0166-4328(00)00153-4; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brooks AI, 1999, NEUROREPORT, V10, P337, DOI 10.1097/00001756-199902050-00024; Brooks AI, 2000, P NATL ACAD SCI USA, V97, P13378, DOI 10.1073/pnas.230169397; Brooks AI, 2000, HUM GENE THER, V11, P2341, DOI 10.1089/104303400750038453; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Cassel JC, 1998, NEUROBIOL LEARN MEM, V69, P22, DOI 10.1006/nlme.1997.3807; CASSEL JC, 1989, PHYSIOL BEHAV, V46, P347, DOI 10.1016/0031-9384(89)90002-4; CAVICCHIOLI L, 1991, MOL BRAIN RES, V9, P319, DOI 10.1016/0169-328X(91)90079-D; Cermak JM, 1999, DEV NEUROSCI-BASEL, V21, P94, DOI 10.1159/000017371; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; Chen KS, 1997, J NEUROSCI, V17, P7288; CRUTCHER KA, 1993, J NEUROSCI, V13, P2540, DOI 10.1523/JNEUROSCI.13-06-02540.1993; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Eagle KS, 1995, J COMP NEUROL, V363, P377, DOI 10.1002/cne.903630304; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FISCHER W, 1991, EXP NEUROL, V113, P93, DOI 10.1016/0014-4886(91)90167-B; FISCHER W, 1992, NEUROBIOL AGING, V13, P9, DOI 10.1016/0197-4580(92)90003-G; FISCHER W, 1991, J NEUROSCI, V11, P1889; FISCHER W, 1994, P NATL ACAD SCI USA, V91, P8607, DOI 10.1073/pnas.91.18.8607; FUSCO M, 1989, NEUROSCIENCE, V33, P47, DOI 10.1016/0306-4522(89)90309-6; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; Gustilo MC, 1999, J COMP NEUROL, V405, P491, DOI 10.1002/(SICI)1096-9861(19990322)405:4<491::AID-CNE4>3.0.CO;2-N; HEFTI F, 1986, J NEUROSCI, V6, P2155; HELLWEG R, 1990, BRAIN RES, V537, P123, DOI 10.1016/0006-8993(90)90348-F; Holler T, 1996, FASEB J, V10, P1653, DOI 10.1096/fasebj.10.14.9002559; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; Janis LS, 1997, PHYSIOL BEHAV, V62, P69, DOI 10.1016/S0031-9384(97)00143-1; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; Kelly A, 1998, NEUROPHARMACOLOGY, V37, P561, DOI 10.1016/S0028-3908(98)00048-3; KOH S, 1989, BRAIN RES, V498, P397, DOI 10.1016/0006-8993(89)91125-6; KOH SY, 1989, J NEUROSCI, V9, P2999; KOH SY, 1988, BRAIN RES, V440, P396, DOI 10.1016/0006-8993(88)91015-3; KORNACK DR, 1991, BRAIN RES, V542, P171, DOI 10.1016/0006-8993(91)91015-S; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LARKFORS L, 1988, PROG BRAIN RES, V78, P27; LARKFORS L, 1987, J NEUROSCI RES, V18, P525, DOI 10.1002/jnr.490180404; LI YW, 1995, J NEUROSCI, V15, P2888; LOY R, 1991, ADV EXP MED BIOL, V295, P373; LOY R, 1987, DEV BRAIN RES, V34, P156, DOI 10.1016/0165-3806(87)90205-7; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; Markowska AL, 1996, J NEUROSCI, V16, P3541; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; MOBLEY WC, 1986, MOL BRAIN RES, V1, P53, DOI 10.1016/0169-328X(86)90020-3; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; Montoya DAC, 2000, DEV BRAIN RES, V123, P25, DOI 10.1016/S0165-3806(00)00075-4; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; Schenk F, 1995, PSYCHOBIOLOGY, V23, P302; SENUT MC, 1990, INT J DEV NEUROSCI, V8, P65, DOI 10.1016/0736-5748(90)90024-V; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SKJEI K, 1995, SOC NEUR ABSTR, V25, P161; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; Tees RC, 1999, DEV PSYCHOBIOL, V35, P328, DOI 10.1002/(SICI)1098-2302(199912)35:4&lt;328::AID-DEV7&gt;3.0.CO;2-4; Tees RC, 1999, DEV PSYCHOBIOL, V35, P226, DOI 10.1002/(SICI)1098-2302(199911)35:3&lt;226::AID-DEV7&gt;3.0.CO;2-H; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Thomas JD, 2000, NEUROTOXICOL TERATOL, V22, P703, DOI 10.1016/S0892-0362(00)00097-0; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; VANTINI G, 1989, NEURON, V3, P267, DOI 10.1016/0896-6273(89)90251-1; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WILL B, 1985, BEHAV BRAIN RES, V17, P17, DOI 10.1016/0166-4328(85)90004-X; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WOOLF NJ, 1986, NEUROSCI LETT, V66, P281, DOI 10.1016/0304-3940(86)90032-7; WOOLF NJ, 1983, NEUROSCI LETT, V40, P93, DOI 10.1016/0304-3940(83)90285-9; WOOLF NJ, 1984, BRAIN RES BULL, V13, P751, DOI 10.1016/0361-9230(84)90236-3; Yang YL, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0006.2000; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	91	61	61	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 23	2002	947	1					9	16	PII S0006-8993(02)02900-1	10.1016/S0006-8993(02)02900-1			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	589PR	WOS:000177769400002	12144847				2022-02-06	
J	Grossmann, R; Stence, N; Carr, J; Fuller, L; Waite, M; Dailey, ME				Grossmann, R; Stence, N; Carr, J; Fuller, L; Waite, M; Dailey, ME			Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development	GLIA			English	Article						microglial activation; brain slice; blood vessel; time-lapse imaging; cell motility	HIPPOCAMPAL SLICE CULTURES; PERIVASCULAR CELLS; NERVOUS-SYSTEM; T-LYMPHOCYTES; RAT-BRAIN; LECTIN; MACROPHAGES; NUCLEUS; IMMUNOREACTIVITY; DEGENERATION	Some parenchymal microglia in mammalian brain tissues, termed ''juxtavascular microglia,'' directly contact the basal lamina of blood vessels; however, the functional consequences of this unique structural relationship are unknown. Here we used a rat brain slice model of traumatic brain injury to investigate the dynamic behavior of juxtavascular microglia following activation. Juxtavascular microglia were identified by confocal 3D reconstruction in tissue slices stained with a fluorescent lectin (FITC-IB4) that labels both microglia and blood vessel endothelial cells. Immunolabeling confirmed that juxtavascular cells were true parenchymal microglia (OX42(+), ED2(-)) and not perivascular cells or pericytes. Time-lapse imaging in live tissue slices revealed that activating juxtavascular microglia withdraw most extant branches but often maintain contact with blood vessels, usually moving to the surface of a vessel within 1-4 h. Subsequently, some microglia migrate along the parenchymal surface of vessels, moving at rates up to 40 mum/h. Activated juxtavascular microglia sometimes repeatedly extend veil-like protrusions into the surrounding tissue, consistent with a role in tissue surveillance. Juxtavascular cells were twice as likely as nonjuxtavascular cells to be locomotory by 10 h in vitro, suggesting an enhanced activation response. Moreover, 38% of all juxtavascular cells migrated along a vessel, whereas this was never observed for a nonjuxtavascular cell. These observations identify a mobile subpopulation (10%-30%) of parenchymal microglia that activate rapidly and are preferentially recruited to the surfaces of blood vessels following brain tissue injury. The dynamic and sustained interaction of microglia with brain microvessels may facilitate signaling between injured brain parenchyma and components of the blood-brain barrier or circulating immune cells of the blood in vivo. (C) 2002 Wiley-Liss, Inc.	Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA		Dailey, ME (corresponding author), Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA.			Grossmann, Ruth/0000-0001-6725-2008	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043468] Funding Source: Medline		BOYA J, 1991, J ANAT, V175, P229; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Calvo CF, 1996, EUR J NEUROSCI, V8, P1725, DOI 10.1111/j.1460-9568.1996.tb01316.x; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; COYLE P, 1978, EXP NEUROL, V58, P549, DOI 10.1016/0014-4886(78)90108-5; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; DAILEY ME, 1999, IMAGING LIVING CELLS; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.0.CO;2-N; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; KIDA SY, 1993, ACTA NEUROPATHOL, V85, P646, DOI 10.1007/BF00334675; Kulla A, 2000, MODERN PATHOL, V13, P56, DOI 10.1038/modpathol.3880010; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; Mato M, 1996, P NATL ACAD SCI USA, V93, P3269, DOI 10.1073/pnas.93.8.3269; MATO M, 1986, ACTA NEUROPATHOL, V72, P117, DOI 10.1007/BF00685972; MATSUMOTO Y, 1987, J NEUROL SCI, V77, P35, DOI 10.1016/0022-510X(87)90204-8; Medana IM, 1997, GLIA, V19, P91, DOI 10.1002/(SICI)1098-1136(199702)19:2<91::AID-GLIA1>3.0.CO;2-C; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Persidsky Y, 1999, AM J PATHOL, V155, P1599, DOI 10.1016/S0002-9440(10)65476-4; Raivich G, 1998, J NEUROSCI, V18, P5804; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Skibo GG, 2000, NEUROSCIENCE, V96, P427, DOI 10.1016/S0306-4522(99)00562-X; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STREIT WJ, 1993, GLIA, V7, P68, DOI 10.1002/glia.440070112; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Thomas WE, 1999, BRAIN RES REV, V31, P42, DOI 10.1016/S0165-0173(99)00024-7; Watanabe T, 1998, J NEUROIMMUNOL, V81, P90, DOI 10.1016/S0165-5728(97)00163-X; WHITELAND JL, 1995, J HISTOCHEM CYTOCHEM, V43, P313, DOI 10.1177/43.3.7868861; Wu CH, 1997, NEUROSCI RES, V27, P133, DOI 10.1016/S0168-0102(96)01140-6	43	61	66	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	MAR 1	2002	37	3					229	240		10.1002/glia.10031			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	533FH	WOS:000174518400004	11857681				2022-02-06	
J	Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA				Greve, KW; Bianchini, KJ; Mathias, CW; Houston, RJ; Crouch, JA			Detecting malingered performance with the Wisconsin Card Sorting Test: A preliminary investigation in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY	The present study examined the classification accuracy of four potential Wisconsin Card Sorting Test malingering indicators (Bernard and Suhr formulas and two types of Unique responses). Participants were 89 traumatic brain-injury (TBI) patients assigned to malingering and nonmalingering groups on the basis of the Slick, Sherman, and Iversion (1999) criteria. Individual Sensitivities were greater than .33 with acceptable Specificity. Combined Sensitivity for two of the indicators was greater than .60. Overall, this study demonstrated three distinct approaches to the WCST used by probable malingerers. The clinical relevance of these findings and directions for future research are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA; Inst Living, Hartford, CT USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			Allen LM, 2001, ARCH CLIN NEUROPSYCH, V16, P846; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DONDERS J, 1999, J FORENSIC NEUROPSYC, V1, P35; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; GREVE KW, IN PRESS ARCH CLIN N; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HEATON SK, 1993, WISCONSIN CORD SORTI; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; KNIGHT JA, 1986, 94 M AM PSYCH ASS WA; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; Reynolds CR, 2001, ARCH CLIN NEUROPSYCH, V16, P199; Reynolds CR, 1998, CRIT ISS NE, P261; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	36	61	63	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2002	16	2					179	191		10.1076/clin.16.2.179.13241			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	588KH	WOS:000177700300006	12221480				2022-02-06	
J	Orihara, Y; Ikematsu, K; Tsuda, R; Nakasono, I				Orihara, Y; Ikematsu, K; Tsuda, R; Nakasono, I			Induction of nitric oxide synthase by traumatic brain injury	FORENSIC SCIENCE INTERNATIONAL			English	Article						inducible nitric oxide synthase; cerebrovascular smooth muscle cell; neutrophil; microglia; traumatic brain injury	SMOOTH-MUSCLE CELLS; CEREBRAL BLOOD-FLOW; HEAD-INJURY; HUMAN-NEUTROPHILS; L-ARGININE; RATS; EXPRESSION; IMMATURE	We investigated the dynamic induction/expression of inducible nitric oxide synthase (iNOS) using human brains made available through death by traumatic brain injury (TBI). Astrocytes. micro.-lia. and neutrophils were identified in tissue using immunohistochemical staining with antibodies against glial fibrillary acidic protein (GFAP). MHC class II antigen, and neutrophil elastase. respectively. The localization of iNOS protein in each of these cell types was evaluated using immunohistochemistry. Within 2 days of injury, iNOS immunoreactivity was not detected. However, after 2 days, immunoreactivity was detected in the traumatized brain. The iNOS immunoreactivity was localized on neutrophils and microglia/macrophages in the areas around the tissue necrosis in the traumatized cortical hemisphere, in the deep part of the cortex and the dentate gyri of the hippocampi adjacent to the hemorrhage, and within the cytoplasm of vascular smooth muscle cell of a small artery or arteriole surrounding the injured region. This reactivity was absent after 8 days post-injury, These observations confirmed the prolonged induction of iNOS within various cells in the injured brain. These responses suggest that iNOS plays a crucial role in cerebrovascular damage and/or secondary brain damage subsequent to traumatic brain injury. Furthermore. the dense nitric oxide (NO) generated by iNOS may play a role in neuronal cell death after injury. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Nagasaki Univ, Sch Med, Dept Legal Med, Nagasaki 8528523, Japan		Orihara, Y (corresponding author), Nagasaki Univ, Sch Med, Dept Legal Med, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.						Akaike T, 1996, METHOD ENZYMOL, V268, P211; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CHAO CC, 1992, J IMMUNOL, V149, P2736; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; DING AH, 1988, J IMMUNOL, V141, P2407; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; THOMAS WE, 1992, BRAIN RES REV, V17, P116; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; YAN L, 1994, J IMMUNOL, V153, P1825	32	61	66	1	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	DEC 1	2001	123	2-3					142	149		10.1016/S0379-0738(01)00537-0			8	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	504ZW	WOS:000172887100009	11728740				2022-02-06	
J	Clausen, T; Zauner, A; Levasseur, JE; Rice, AC; Bullock, R				Clausen, T; Zauner, A; Levasseur, JE; Rice, AC; Bullock, R			Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events	BRAIN RESEARCH			English	Article						mitochondrial failure; cerebral metabolism; traumatic brain injury; microdialysis; cyanide	EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; SUBARACHNOID HEMORRHAGE; MULTIPARAMETER SENSORS; ENDOPLASMIC-RETICULUM; SUBSTRATE DELIVERY; CYANIDE PERFUSION; RELEASE; MICRODIALYSIS; CALCIUM	Objective: Recently, evidence has become available implicating mitochondrial failure as a crucial factor in the pathogenesis of acute brain damage following severe traumatic brain injury (TBI). However, it remains unclear how mitochondrial dysfunction affects cerebral metabolism. Therefore the aim of the study was to evaluate the impact of `isolated' mitochondrial failure on local cerebral metabolism. Methods: Cerebral mitochondrial metabolism was blocked by local microdialysis perfusion with cyanide in seven cats. Local brain tissue oxygen tension (p(tiO2)), carbon dioxide tension (p(tiCO2)) and pH, as well as extracellular cerebral fluid, glucose, lactate, pyruvate and glutamate were monitored, using a Neurotrend sensor-and microdialysis, respectively. Tissue oxygen consumption was measured in a microrespirometric system, and ultrastructural changes evaluated via electron microscopy. Results: Brain tissue oxygen tension increased from a baseline of 31 +/-9 mmHg to 84 +/- 30 mmHg after 60 min of cyanide perfusion (P <0.05), concomitant a decrease in oxygen consumption from 14.45 +/-3.91 mul/h/mg to 10.83 +/-1.74 mul/h/mg (P <0.05). Brain tissue pH was decreased after 60 min of cyanide perfusion (6.83 +/-0.16) compared to baseline (7.07 +/-0.39) (P <0.05), whereas p(tiCO2), did not show significant changes. Lactate massively increased from a baseline of 599 +/- 270 mu mol/l to 2609 +/- 1188 mu mol/l immediately after cyanide perfusion (P <0.05). The lactate:glucose ratio increased from 0.79 +/-0.15 before cyanide perfusion to 6.40 +/-1.44 at 40 min after cyanide perfusion (P <0.05), while no significant changes in the lactate:pyruvate ratio could be observed. Glutamate increased from a baseline of 11.6 +/-7.2 mu mol/l to 61.4 +/- 44.7 mu mol/l after cyanide perfusion (P <0.05). Conclusion: The results of this study show that `isolated' cerebral mitochondrial failure initiates changes in cerebral substrates and biochemistry, which are very similar to most of the changes seen after severe human head injury, except for the early fall in p(tiO2), further indicating a crucial involvement of mitochondrial impairment in the development of brain damage after TBI. (C) 2001 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle, Germany		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	robullock@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		ALBAUM HG, 1946, J BIOL CHEM, V164, P45; Alessandri B, 1999, ACT NEUR S, V75, P21; ALIUKHIN S, 1974, FIZIOL ZH SSSR IM IM, V60, P1376; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOROWITZ JL, 1994, TOXICOL APPL PHARM, V129, P80, DOI 10.1006/taap.1994.1230; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CAMERINO PW, 1966, J BIOL CHEM, V241, P970; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALLANTYNE B, 1972, BRIT J PHARMACOL, V44, pP382; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; JOHNSON JD, 1986, TOXICOL APPL PHARM, V84, P464, DOI 10.1016/0041-008X(86)90251-6; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X; Kanchukh A A, 1971, Nauchnye Doki Vyss Shkoly Biol Nauki, V12, P37; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIUCHI Y, 1992, NEUROSCI LETT, V147, P193, DOI 10.1016/0304-3940(92)90593-V; Koester J., 1991, PRINCIPLES NEURAL SC, V3, P81; KOOLMAN J, 1998, TASCHENATLAS BIOCH, P140; Koura SS, 1998, ACT NEUR S, V71, P244; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; MACMILLAN VH, 1989, J CEREBR BLOOD F MET, V9, P156, DOI 10.1038/jcbfm.1989.23; MATSUMOTO M, 1993, NEUROPHARMACOLOGY, V32, P681, DOI 10.1016/0028-3908(93)90081-D; Miller RJ, 1998, TRENDS NEUROSCI, V21, P95, DOI 10.1016/S0166-2236(97)01206-X; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V275, P279, DOI 10.1016/0005-2728(72)90208-3; NIEMI M, 1965, HISTOCHEMISTRY, V4, P451, DOI 10.1007/BF00306255; PATEL MN, 1991, NEUROSCI LETT, V131, P42, DOI 10.1016/0304-3940(91)90332-N; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PIANTADOSI CA, 1983, J CLIN INVEST, V72, P1224, DOI 10.1172/JCI111078; PIANTADOSI CA, 1984, TOXICOLOGY, V33, P67, DOI 10.1016/0300-483X(84)90017-9; PITT BR, 1979, ARCH ENVIRON HEALTH, V34, P354, DOI 10.1080/00039896.1979.10667431; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SANCHEZPRIETO J, 1988, J NEUROCHEM, V50, P1322, DOI 10.1111/j.1471-4159.1988.tb10611.x; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sarrafzadeh AS, 1998, ZBL NEUROCHIR, V59, P269; Siesjo BK, 1999, J CEREBR BLOOD F MET, V19, P19, DOI 10.1097/00004647-199901000-00002; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Solomanson LP, 1981, CYANIDE BIOL, P11; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZAUNER A, 2000, UNPUB CEREBRAL METAB	54	61	61	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 20	2001	908	1					35	48		10.1016/S0006-8993(01)02566-5			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	456RB	WOS:000170095100004	11457429				2022-02-06	
J	Ballard, JC				Ballard, JC			Assessing attention: Comparison of response-inhibition and traditional continuous performance tests	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	106th Annual Convention of the American-Psychological-Association	AUG 14-18, 1998	SAN FRANCISCO, CALIFORNIA	Amer Psychol Assoc			CLOSED-HEAD INJURY; SUSTAINED ATTENTION; EVENT RATE; COMPUTERIZED ASSESSMENT; VIGILANCE; CHILDREN; NOISE; ANXIETY; ALCOHOL	The purpose of this study was to compare a recently developed response-inhibition task (Conners, 1995) to slow- and fast-event-rate versions of the traditional A-X Continuous Performance Test (CPT). Among 146 normal adults, results revealed significant differences between tasks in omission and commission error rates, reaction time, reaction time variability, and responses to critical signals. Effects of environmental noise and participant anxiety also differed for the three tasks. Traditional CPTs produced time-related performance decrements, but the response-inhibition task produced improvement across initial blocks of trials. The response-inhibition task may measure "executive control" rather than sustained attention, and therefore may represent functions of different brain systems.	SUNY Geneseo, Dept Psychol, Coll Geneseo, Geneseo, NY 14454 USA		Ballard, JC (corresponding author), SUNY Geneseo, Dept Psychol, Coll Geneseo, Geneseo, NY 14454 USA.						BAKER CH, 1959, BRIT J PSYCHOL, V50, P30, DOI 10.1111/j.2044-8295.1959.tb00678.x; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P864, DOI 10.1080/01688639608408308; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BEALE IL, 1987, J ABNORM CHILD PSYCH, V15, P229, DOI 10.1007/BF00916351; BERCH DB, 1984, SUSTAINED ATTENTION, P143; BROADBENT DE, 1965, HUM FACTORS, V7, P155, DOI 10.1177/001872086500700207; CAMPBELL JW, 1991, J SCHOOL PSYCHOL, V29, P143; CHEE P, 1989, J ABNORM CHILD PSYCH, V17, P371, DOI 10.1007/BF00915033; Conners CK., 1995, CONNERS CONTINUOUS P; COONS HW, 1987, PSYCHOPHYSIOLOGY, V24, P572; Davies D. R., 1984, VARIETIES ATTENTION, P395; DAVIES DR, 1966, BRIT J PSYCHOL, V57, P381, DOI 10.1111/j.2044-8295.1966.tb01039.x; Deaton J. E., 1993, HUM PERFORM, V6, P71, DOI DOI 10.1207/S15327043HUP0601_; EARLEBOYER EA, 1991, PSYCHIAT RES, V37, P47, DOI 10.1016/0165-1781(91)90105-X; GIAMBRA LM, 1988, PSYCHOL AGING, V3, P75, DOI 10.1037/0882-7974.3.1.75; GOETSCH VL, 1990, J PSYCHOPATHOL BEHAV, V12, P329, DOI 10.1007/BF00965987; GOLOMBOK S, 1988, PSYCHOL MED, V18, P365, DOI 10.1017/S0033291700007911; HOCKEY R, 1984, VARIETIES ATTENTION, P395; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KNOPF IJ, 1975, MERRILL PALMER QUART, V21, P195; KOELEGA HS, 1986, HUM FACTORS, V28, P465, DOI 10.1177/001872088602800408; KRUEGER GP, 1989, WORK STRESS, V3, P129, DOI 10.1080/02678378908256939; LEVY F, 1980, J CHILD PSYCHOL PSYC, V21, P72; LINNOILA M, 1978, J STUD ALCOHOL, V39, P745, DOI 10.15288/jsa.1978.39.745; Loeb M, 1984, SUSTAINED ATTENTION, P179; Loeb M., 1986, NOISE HUMAN EFFICIEN; MACKWORTH NH, 1950, MED RES COUNCIL SPEC, V268, P174; McGrath J. J., 1968, STUDIES HUMAN VIGILA, P1; MCGRATH JJ, 1968, STUDIES HUMAN VIGILA, P295; MCGRATH JJ, 1968, STUDIES HUMAN VIGILA, P235; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1992, J PSYCHIAT RES, V26, P383, DOI 10.1016/0022-3956(92)90042-M; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; PARASURAMAN R, 1991, PSYCHOL AGING, V6, P155, DOI 10.1037/0882-7974.6.2.155; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; Parasuraman R, 1998, ATTENTIVE BRAIN, P3; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARASURAMAN R, 1987, PERCEPT PSYCHOPHYS, V41, P17, DOI 10.3758/BF03208208; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R., 1984, SUSTAINED ATTENTION, P61; Parasuraman R., 1993, NEUROPSYCHOLOGY, V7, P242, DOI [10.1037/0894-4105.7.3.242, DOI 10.1037/0894-4105.7.3.242]; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Posner MI, 1998, ATTENTIVE BRAIN, P401; Posner MI., 1994, IMAGES MIND; RAPPORT MD, 1993, J AM ACAD CHILD PSY, V32, P333, DOI 10.1097/00004583-199303000-00014; ROHRBAUGH JW, 1988, PSYCHOPHARMACOLOGY, V96, P442, DOI 10.1007/BF02180021; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHIFF AR, 1985, CHILD DEV, V56, P621; SEIDEL WT, 1991, CLIN NEUROPSYCHOL, V5, P53; SMITH A, 1989, SCAND J PSYCHOL, V30, P185, DOI 10.1111/j.1467-9450.1989.tb01082.x; SMITH AP, 1992, NEUROPSYCHOBIOLOGY, V26, P198, DOI 10.1159/000118920; Spielberger C.D., 1980, STRESS ANXIETY, V7, P95; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TARVER SG, 1974, J LEARN DISABIL, V7, P560, DOI 10.1177/002221947400700906; Warm J.S., 1984, SUSTAINED ATTENTION, P15; Warm J.S., 1984, SUSTAINED ATTENTION, P103, DOI DOI 10.1016/8978-032302588-1.50009-9; WARNER HD, 1972, HUM FACTORS, V14, P181, DOI 10.1177/001872087201400208; [No title captured]; [No title captured]	61	61	64	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2001	23	3					331	350		10.1076/jcen.23.3.331.1188			20	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	439JG	WOS:000169112900008	11404811	Green Submitted			2022-02-06	
J	Chistyakov, AV; Soustiel, JF; Hafner, H; Trubnik, M; Levy, G; Feinsod, M				Chistyakov, AV; Soustiel, JF; Hafner, H; Trubnik, M; Levy, G; Feinsod, M			Excitatory and inhibitory corticospinal responses to transcranial magnetic stimulation in patients with minor to moderate head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; silent period; motor evoked potential; transcranial magnetic stimulation	MOTOR CORTEX EXCITABILITY; SILENT PERIOD; BRAIN-STIMULATION; PARKINSONS-DISEASE; CORTICAL STIMULATION; DISSOCIATION; STROKE; HUMANS; FACILITATION; POTENTIALS	Objectives-The changes in excitatory and inhibitory responses to transcranial magnetic stimulation (TMS), as attested by motor evoked potential (MEP) and silent period (SP) parameters, were compared in patients who sustained minor to moderate head injury. Methods-A total of 38 patients with brain concussion, and diffuse, focal, and combined brain injury and 20 healthy volunteers were examined. The MEPs and SPs were recorded from the abductor pollicis brevis muscle after single pulse TMS 2 weeks after head trauma. The parameters assessed were the MEP resting threshold, the MEP/M wave amplitude ratio, the central motor conduction time (CMCT), the SP threshold, the interthreshold difference (ITD), and the SP duration (SPD). Results-The main finding was an increase in the ITD in patients with mild and moderate head injury due to the relatively greater augmentation of the MEP threshold. This was associated with a reduction of the MEP/M wave amplitude ratio. The degree of MEP and SP changes depended on severity of head injury and was not related to the type of brain lesions. The SPD did not differ significantly in brain concussion, or diffuse, focal and combined brain injury groups compared with the control group. The CMCT was prolonged in patients with diffuse and combined brain lesions. Among subjective complaints only fatigue was significantly related to ITD, MEP, and SP threshold abnormalities. Conclusions-The results suggest that mechanisms involved in MEP and SP generation are differently affected in head injury, the first being impaired more severely. The increase of the ITD accompanied by reduction of the MEP/M wave amplitude ratio may reflect a dissociated impairment of inhibitory and excitatory components of central motor control in head trauma.	Rambam Maimonides Med Ctr, Dept Neurosurg, Ctr Treatment & Appl Res Head Injury, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel		Chistyakov, AV (corresponding author), Rambam Maimonides Med Ctr, Dept Neurosurg, Ctr Treatment & Appl Res Head Injury, POB 9602, IL-31096 Haifa, Israel.						Ashby P, 1999, CLIN NEUROPHYSIOL, V110, P550, DOI 10.1016/S1388-2457(98)00082-0; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P29, DOI 10.1016/S0924-980X(96)96515-7; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P290, DOI 10.1016/S0924-980X(97)00021-0; Chen R, 1997, NEUROLOGY, V49, P881, DOI 10.1212/WNL.49.3.881; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; CHIAPPA KH, 1991, NEUROLOGY, V41, P1154, DOI 10.1212/WNL.41.7.1154; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; CHISTYAKOV AV, 1995, SPINE, V20, P2135, DOI 10.1097/00007632-199510000-00012; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; CLAUS D, 1991, ELECTROENCEPHALOGR C, V81, P342; DAVEY NJ, 1994, J PHYSIOL-LONDON, V477, P223, DOI 10.1113/jphysiol.1994.sp020186; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; George MS, 1999, ARCH GEN PSYCHIAT, V56, P300, DOI 10.1001/archpsyc.56.4.300; Inghilleri M, 1996, EXP BRAIN RES, V109, P467; Lewko JP, 1996, BRAIN TOPOGR, V8, P397, DOI 10.1007/BF01186915; Liepert J, 2000, CLIN NEUROPHYSIOL, V111, P671, DOI 10.1016/S1388-2457(99)00312-0; MAVROUDAKIS N, 1994, ELECTROEN CLIN NEURO, V93, P428, DOI 10.1016/0168-5597(94)90149-X; PRIORI A, 1994, MOVEMENT DISORD, V9, P178, DOI 10.1002/mds.870090209; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; SchulzeBonhage A, 1996, ELECTROEN CLIN NEURO, V99, P267; VALLSSOLE J, 1994, NEUROLOGY, V44, P735, DOI 10.1212/WNL.44.4.735; VALZANIA F, 1996, ELECTROENCEPHALOGR C, V105, P37; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WASSERMANN EM, 1993, ELECTROEN CLIN NEURO, V89, P424, DOI 10.1016/0168-5597(93)90116-7; Young MS, 1997, NEUROLOGY, V49, P1278, DOI 10.1212/WNL.49.5.1278; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	28	61	62	2	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2001	70	5					580	587		10.1136/jnnp.70.5.580			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	426AE	WOS:000168326200003	11309450	Green Published, Bronze			2022-02-06	
J	Lyeth, BG; Gong, QZ; Shields, S; Muizelaar, JP; Berman, RF				Lyeth, BG; Gong, QZ; Shields, S; Muizelaar, JP; Berman, RF			Group I metabotropic glutamate antagonist reduces acute neuronal degeneration and behavioral deficits after traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						metabotropic glutamate receptor; fluid percussion; traumatic brain injury; rat; AIDA	SIGNAL-TRANSDUCTION PATHWAY; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; PHENYLGLYCINE DERIVATIVES; SPATIAL DISCRIMINATION; RECEPTOR SUBTYPES; NMDA-RECEPTORS; FLUORO-JADE; DEATH	Recent studies indicate that acute activation of Group I mGluRs following traumatic brain injury (TBI) contributes to the ensuing pathophysiology. The present study examined the effects of post-TBI administration of the selective mGluR1 antagonist (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA) on acute neuronal degeneration in the hippocampus and longterm sensorimotor and learning/memory outcome. In Experiment 1, 26 rats received 0.4, 2.0, or 10.0 nmol AIDA or artificial CSF vehicle infusion into the hippocampus starting 5 min postinjury. At 24 h after TBI characteristic pyramidal cell degeneration was observed in Fluoro-Jade-stained coronal sections of the CA2/3 sectors of the dorsal hippocampus. The mean (+/- SERI) number of Fluoro-Jade-positive neurons in the 10 nmol AIDA group (184 +/- 32) was significantly less (P < 0.05) than the vehicle group (310 <plus/minus> 47). In Experiment 2, 20 rats were trained on sensorimotor and memory tasks prior to parasagittal fluid percussion TBI. Rats were administered 10 nmol AIDA or vehicle as in Experiment 1. Rats were assessed on beam walking and radial arm maze (RAM) performance weekly for 6 weeks after TBI. Acquisition of a Morris water maze (MWM) task was assessed on days 11-15 after TBI. The AIDA-treated group had significantly reduced deficits in beam walk, MWM, and RAM performance compared to the vehicle-treated group. These data indicate that injury-induced acute activation of mGluR1 receptors contributes to both the cellular pathology and the behavioral morbidity associated with TBI. (C) 2001 Academic Press.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474; Shields, Shannon/0000-0002-8006-7103	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER		CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jiang ZW, 2000, BRAIN RES, V852, P37, DOI 10.1016/S0006-8993(99)02230-1; Johnson MP, 1999, BRAIN RES, V821, P539, DOI 10.1016/S0006-8993(99)01065-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KESNER RP, 1982, SCIENCE, V218, P173, DOI 10.1126/science.7123228; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; OPITZ T, 1995, NEUROSCIENCE, V68, P989, DOI 10.1016/0306-4522(95)00195-O; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; ROBERTS PJ, 1995, NEUROPHARMACOLOGY, V34, P813, DOI 10.1016/0028-3908(95)00094-M; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715	43	61	67	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2001	169	1					191	199		10.1006/exnr.2001.7643			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	431KD	WOS:000168629600020	11312571				2022-02-06	
J	Dennis, M				Dennis, M			Developmental plasticity in children: The role of biological risk development, time, and reserve	JOURNAL OF COMMUNICATION DISORDERS			English	Article						plasticity; biological risk; neurobehavioral outcome; development; reserve	CLOSED-HEAD-INJURY; BRAIN-TUMORS; HYDROCEPHALUS; DISEASE; AGE; ADOLESCENTS; MENINGITIS; CHILDHOOD; SEQUELAE	Older views of the functional developmental plasticity of the developing central nervous system (CNS) focused on the protective effect of a young age at the time of insult. In these views, a younger rather than an older age at onset was thought to produce fewer and/or less severe symptoms and a more rapid recovery. More recently, neurobehavioral outcome has been studied in a variety of medical conditions that affect the developing CNS; at the same time, new investigative techniques, such as brain imaging, have elucidated the biological basis of structural and functional brain plasticity. In consequence of a better understanding of the structural and functional consequences of developmental CNS insults, a body of research has emerged that is shaping a new view of functional developmental plasticity, in which neurobehavioral outcome is set by the biological risk associated with a medical condition and moderated by age and development, the time since onset of the condition, and the reserve available within the child, family, school, and community. (C) 2000 by Elsevier Science Inc.	Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD35946] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS21889-16] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD035946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; ANDEREGG F, 1995, AIP CONF PROC, P1; Anderson RH, 1997, CARDIOL YOUNG, V7, P2, DOI 10.1017/S1047951100005795; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BARNES MA, 1999, J INT NEUROPSYCH SOC, V5, P149; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; BROWN RT, 1993, J CLIN CHILD PSYCHOL, V22, P207, DOI 10.1207/s15374424jccp2202_7; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; CARLSONGREEN B, 1995, J PEDIATR PSYCHOL, V20, P769, DOI 10.1093/jpepsy/20.6.769; DENNIS M, 1994, J DEV BEHAV PEDIATR, V15, P124; Dennis M, 1999, CHANGING NERVOUS SYSTEM, P172; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 1999, DEV COGN NEUROSCI, P505; DENNIS M, 1998, J INT NEUROPSYCHOLOI, V4, P3; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; Dennis M., 1988, MASTER LECT SERIES, V7, P85; Dennis M, 1994, HDB PERCEPTION COGNI, P219; DUFFNER PK, 1983, CANCER, V51, P233, DOI 10.1002/1097-0142(19830115)51:2<233::AID-CNCR2820510211>3.0.CO;2-8; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; GREENOUGH WT, 1993, AT-RISK INFANTS, P173; Hetherington R, 1999, DEV NEUROPSYCHOL, V15, P25, DOI 10.1080/87565649909540738; HOLMES CS, 1985, J DEV BEHAV PEDIATR, V6, P323; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KUN LE, 1983, J NEUROSURG, V58, P1, DOI 10.3171/jns.1983.58.1.0001; Maria BL, 1997, J CHILD NEUROL, V12, P423, DOI 10.1177/088307389701200703; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; RAIMONDI AJ, 1981, J NEUROSURG, V55, P174, DOI 10.3171/jns.1981.55.2.0174; Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; STOVRING J, 1980, J PEDIATR-US, V96, P820, DOI 10.1016/S0022-3476(80)80549-X; TAKEUCHI T, 1968, MINAMATA DIS, P144; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TAYLOR HG, 1999, UNPUB LONGITUDINAL O; TEYLER TJ, 1995, BRAIN SLICES BASIC C, P1; WEBSTER MJ, 1991, J NEUROSCI, V11, P1095; WHITTON CW, 1993, PROGR ANESTHESIOLOGY, V7, P46; WRIGHT M, 1994, ARCH DIS CHILD, V71, P64, DOI 10.1136/adc.71.1.64; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; [No title captured]	47	61	61	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2000	33	4					321	332		10.1016/S0021-9924(00)00028-9			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	354AQ	WOS:000089308000005	11001159				2022-02-06	
J	Fichtenberg, NL; Millis, SR; Mann, NR; Zafonte, RD; Millard, AE				Fichtenberg, NL; Millis, SR; Mann, NR; Zafonte, RD; Millard, AE			Factors associated with insomnia among post-acute traumatic brain injury survivors	BRAIN INJURY			English	Article							HEAD-INJURY; SLEEP; DISTURBANCES; COMPLAINTS; DISORDERS; QUALITY	This study investigated the relationships between insomnia and select demographic, injury and psychosocial variables in post-acute, traumatic brain injury. Clinical assessment of sleep and mood was undertaken via objective measures and a diagnostic interview among 91 consecutive brain injury admissions to an outpatient neurorehabilitation clinic. No associations between insomnia and gender, education, age, and time since injury were found. A logistic regression model of insomnia prediction based upon the Beck Depression Inventory (BDI), sell-reported pain disturbance, litigation and Glasgow Coma Score (GCS) correctly classified 87% of the sample with respect to the presence or absence of insomnia; however, depression and injury severity were the only variables that made a significant unique contribution to the prediction of insomnia. It is concluded that among post-acute traumatic brain injury patients, insomnia is linked with both the presence of depression and a history of milder brain injuries. This suggests that the determinants of insomnia may differ from the acute to the post-acute phase, with neurological factors playing a primary role early in the recovery process and psychosocial factors ascending later. Therefore, assessment and treatment of insomnia must give careful attention to the larger psychosocial context in which the sleep disorder emerges, particularly to role of emotional disturbance.	Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; Univ Michigan Hosp, Ann Arbor, MI 48109 USA		Fichtenberg, NL (corresponding author), DMC Rehab Ctr Novi, 42005 W 12 Mile Rd, Novi, MI 48337 USA.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Beck AT, 1987, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGSTROM J, 1974, CLIN NEPHROL, V2, P24; BUYSSE DJ, 1994, SLEEP, V17, P630, DOI 10.1093/sleep/17.7.630; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CRAGG JG, 1970, CAN J ECONOMICS, V3, P386, DOI 10.2307/133656; ESTRELLA A, IN PRESS NEW MEASURE; FICHTENBERG NL, 1998, AM J PHYSICAL MED RE, V77, P181; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Hagen C, 1979, REHABILITATION HEAD; HYYPPA MT, 1989, J CLIN EPIDEMIOL, V42, P633, DOI 10.1016/0895-4356(89)90006-1; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; LESSARD CS, 1974, AEROSPACE MED, V45, P664; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; PASSOUANT P, 1965, ELECTROEN CLIN NEURO, V18, P726; Ravesloot C, 1997, REHABIL PSYCHOL, V42, P3, DOI 10.1037/0090-5550.42.1.3; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304	24	61	61	0	7	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2000	14	7					659	667					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600006	10914647				2022-02-06	
J	Sandhu, RS; Pasquale, MD; Miller, K; Wasser, TE				Sandhu, RS; Pasquale, MD; Miller, K; Wasser, TE			Measurement of endotracheal tube cuff leak to predict postextubation stridor and need for reintubation	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRACHEAL EXTUBATION; LARYNGEAL EDEMA; DOUBLE-BLIND; RISK-FACTORS; PREVENTION; DEXAMETHASONE; COMPLICATIONS; INTUBATION; ADULTS	Background: The purpose of this study was to determine the predictive value of an endotracheal tube cuff leak for the development of postextubation strider and the need for reintubation. Study Design: Consecutive trauma patients who required intubation at a level I trauma center from July 1997 to July 1998 were studied prospectively. Pediatric patients and those who did not meet the standard weaning protocol criteria established by the Division of Trauma and Surgical Critical Care were excluded. Injury Severity Score, endotracheal tube size, reason for intubation, and the number of days intubated before the initial extubation attempt were recorded. At the time of extubation, the difference in exhaled tidal volume from before to after endotracheal tube cuff deflation was calculated. This number was then divided by the exhaled tidal volume before cuff deflation and was recorded as the percent cuff leak. Patients were followed for 24 hours after extubation for the development of strider or need for reintubation. Statistical analysis to compare subgroups of patients was performed using ANOVA with Scheffe post hoc analysis. Results: Among the 110 patients analyzed, the most common reason for intubation was closed-head injury. Seven patients (6.4%) developed strider alone and had a mean cuff leak of 58 mL (8.4% of tidal volume before cuff deflation). Six patients (5.5%) experienced strider that required reintubation and had a mean cuff leak of 68 mL (9.2% of tidal volume before cuff deflation). Patients who developed strider or needed reintubation had been intubated for a significantly greater length of time than those not developing strider or requiring reintubation (2.6 versus 3.0 days, p < 0.001). There were no differences in Injury Severity Score, endotracheal tube size, or reason for intubation between these groups. Conclusions: A cuff leak of less than 10% of tidal volume before cuff deflation is useful in identifying patients at risk for strider or reintubation (96% specificity). It appears that the amount of cuff leak decreases after intubation for more than 3 days, increasing the risk of strider and need for reintubation. This information may be helpful in identifying those patients who need treatment for laryngotracheal edema, ie, use of steroids or anesthesia during extubation, the efficacy of which remains to be determined. (J Am Coll Surg 2000;190:682-687, (C) 2000 by the American College of Surgeons).	Lehigh Valley Hosp, Dept Surg, Allentown, PA 18105 USA; Lehigh Valley Hosp, Div Trauma & Surg Crit Care, Allentown, PA 18105 USA; Lehigh Valley Hosp, Dept Resp Care, Allentown, PA 18105 USA; Lehigh Valley Hosp, Dept Hlth Studies, Allentown, PA 18105 USA		Sandhu, RS (corresponding author), Lehigh Valley Hosp, Dept Surg, Cedar Crest & I-78,POB 689, Allentown, PA 18105 USA.						ADDERLEY RJ, 1987, CAN J ANAESTH, V34, P304, DOI 10.1007/BF03015171; Anene O, 1996, CRIT CARE MED, V24, P1666, DOI 10.1097/00003246-199610000-00011; Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; Daley BJ, 1996, CHEST, V110, P1577, DOI 10.1378/chest.110.6.1577; DARMON JY, 1992, ANESTHESIOLOGY, V77, P245, DOI 10.1097/00000542-199208000-00004; DEMLING RH, 1988, CRIT CARE MED, V16, P573, DOI 10.1097/00003246-198806000-00001; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; FISHER MM, 1992, ANAESTHESIA, V47, P10, DOI 10.1111/j.1365-2044.1992.tb01943.x; Ho LI, 1996, INTENS CARE MED, V22, P933; KASTANOS N, 1983, CRIT CARE MED, V11, P362, DOI 10.1097/00003246-198305000-00009; MARIK PE, 1996, RESP CARE, V41, P509; Miller RL, 1996, CHEST, V110, P1035, DOI 10.1378/chest.110.4.1035; Mort TC, 1998, ANESTH ANALG, V86, P1171, DOI 10.1097/00000539-199806000-00006; TELLEZ DW, 1991, J PEDIATR-US, V118, P289, DOI 10.1016/S0022-3476(05)80505-0	15	61	66	0	1	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2000	190	6					682	687		10.1016/S1072-7515(00)00269-6			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	321TN	WOS:000087470900010	10873003				2022-02-06	
S	Emmerling, MR; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Raby, CA		Kalaria, RN; Ince, P		Emmerling, MR; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Raby, CA			Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta(42) in human CSF - A possible role for nerve cell injury	VASCULAR FACTORS IN ALZHEIMER'S DISEASE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Vascular Factors in Alzheimers Disease	MAY 25-28, 1999	NEWCASTLE TYNE, ENGLAND	Bayer AG, Eisai Ltd, GJ Livanos Trust, Alzheimers Report, Hoechst Marrion Roussel, Janssen Pharmaceut, Novartis Pharma AG, Parke Davis, Pfizer Inc, SmithKline Beecham Pharmaceut, Zeneca, Med Res Council, Inst Brain & Blood Vessels, Akita, Inst Hlth Elderly, Univ Newcastle Upon Tyne			CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; PRECURSOR PROTEIN; TAU-PROTEINS; HEAD-INJURY; DISEASE; PROGRESSION; SERUM	The increased risk for Alzheimer's Disease (AD) associated with traumatic brain injury (TBI) suggests that environmental insults may influence the development of this age-related dementia, Recently, we have shown that the levels of the beta-amyloid peptide (A beta(1-42)) increase in the cerebrospinal fluid (CSF) of patients after severe brain injury and remain elevated for some time after the initial event, The relationships of elevated A beta with markers of blood-brain barrier (BBB) disruption, inflammation, and nerve cell or axonal injury were evaluated in CSF samples taken daily from TBI patients, This analysis reveals that the rise in A beta(1-42) is best correlated with possible markers of neuronal or axonal injury, the cytoskeletal protein tan, neuron-specific enolase (NSE), and apolipoprotein E (ApoE), Similar or better correlations were observed between A beta(1-40) and the three aforementioned markers, These results imply that the degree of brain injury may play a decisive role in determining the levels of A beta(1-42) and A beta(1-40) in the CSP of TBI patients, inflammation and alterations in BBB may play lesser, but nonetheless significant, roles In determining the A beta level in CSF after brain injury.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Thepeut, Ann Arbor, MI 48106 USA; Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; Sun Hlth Res Inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ 85372 USA		Emmerling, MR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Thepeut, 2800 Plymouth Rd, Ann Arbor, MI 48106 USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; EMMERLING MR, 1999, UNIFYING HYPOTHESIS, P33; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LEHTIMAKI T, 1995, HUM GENET, V95, P39; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Pirttila T, 1996, BRAIN RES, V722, P71, DOI 10.1016/0006-8993(96)00183-7; PIRTTILA T, 1994, NEUROBIOL AGING, V15, P313, DOI 10.1016/0197-4580(94)90026-4; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Smith AD, 1996, BRIT MED BULL, V52, P575; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	18	61	61	0	7	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-251-7	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	903						118	122		10.1111/j.1749-6632.2000.tb06357.x			5	Multidisciplinary Sciences; Clinical Neurology; Peripheral Vascular Disease	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology; Cardiovascular System & Cardiology	BQ26Z	WOS:000087756800016	10818496				2022-02-06	
J	Steinsapir, KD; Goldberg, RA; Sinha, S; Hovda, DA				Steinsapir, KD; Goldberg, RA; Sinha, S; Hovda, DA			Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						corticosteroids; methylprednisolone; optic nerve injury; traumatic optic neuropathy; TON	RETINAL GANGLION-CELLS; SPINAL-CORD INJURY; ADULT-RATS; LIPID-PEROXIDATION; CONTROLLED TRIAL; BRAIN INJURY; NEUROPATHY; METABOLISM; RECOVERY; SURVIVAL	Purpose: This study investigates the clinical dogma that very high doses of methylprednisolone helpful in spinal cord injury are also helpful in optic nerve trauma. Methods: The right optic nerve of 29 male rats received a 5 second traumatic crush followed 30 minutes later by one of five intravenous treatments (methylprednisolone 30 mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg, or saline). Treatment was continued for three additional administrations at 6 hour intervals. Untreated sham controls (n = 7) were also prepared. 'Six weeks after injury, animals were sacrificed, perfused and optic nerves systematically counted. Results: Axon counts (means +/- s.e.m.) were as follows: Saline = 16,670 +/- 8,900 (n = 5); Methylprednisolone: 30 mg/kg = 8,098 +/- 4,741 (n = 5); 60 mg/kg = 6,925 +/- 6,517 (n = 4); 90 mg/kg = 2,663 +/- 2,653 (n = 4); 120 mg/kg = 6,149 +/- 3,487 (n = 6). Consequently, the data revealed that saline treated animals retained more axons than those that were administered methylprednisolone (p < 0.02). Conclusions: We conclude that methylprednisolone exacerbates axonal loss following crush injury in the rat optic nerve. Based on the results of this study, clinical studies of traumatic optic neuropathy in the future should also examine the possibility that corticosteroid treatment may have an adverse effect on visual outcome following optic nerve trauma.	Jules Stein Eye Inst, Orbital & Ophthalm Plast Surg Div, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA		Steinsapir, KD (corresponding author), 537 Newport Ctr Dr,Suite 371, Newport Beach, CA 92660 USA.		Goldberg, Robert/AAE-3046-2019				ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; BRAY GM, 1991, ANN NY ACAD SCI, V633, P214; CHO EYP, 1989, EXP BRAIN RES, V78, P567; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; DEJUAN J, 1978, ACTA ANAT, V102, P294; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FADEN AI, 1984, J NEUROSURG, V60, P712, DOI 10.3171/jns.1984.60.4.0712; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FORRESTER J, 1967, NATURE, V214, P245, DOI 10.1038/214245a0; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GRAHAM LT, 1967, J NEUROCHEM, V14, P465, DOI 10.1111/j.1471-4159.1967.tb09545.x; GROSS CE, 1981, J NEUROSURG, V55, P963, DOI 10.3171/jns.1981.55.6.0963; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HARMAN K, 1991, J NEUROSCI METH, V38, P107, DOI 10.1016/0165-0270(91)90160-2; HUBEL DAVID H., 1963, SCI AMER, V209, P54; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744; MATHESON D F, 1970, Brain Research, V24, P257, DOI 10.1016/0006-8993(70)90105-8; MAURIELLO JA, 1992, BRIT J OPHTHALMOL, V76, P349, DOI 10.1136/bjo.76.6.349; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RANSOM BR, 1990, NEUROLOGY, V40, P1399, DOI 10.1212/WNL.40.9.1399; Riesen A, 1950, SCI AM, V183, P16; RusselakisCarneiro M, 1996, J NEUROCYTOL, V25, P393, DOI 10.1007/BF02284810; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; SABEL BA, 1995, EXP BRAIN RES, V106, P93; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SEIFF SR, 1990, OPHTHALMIC SURG LAS, V21, P389; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; STEINSAPIR KD, 1994, INVEST OPHTH VIS SCI, V35, P1544; STEINSAPIR KD, 1993, J CEREBR BLOOD FLOW, V13, pS570; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9	63	61	63	1	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2000	17	4					157	163					7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	456FF	WOS:000170071900001	11490087				2022-02-06	
J	Yamamoto, M; Marmarou, CR; Stiefel, MF; Beaumont, A; Marmarou, A				Yamamoto, M; Marmarou, CR; Stiefel, MF; Beaumont, A; Marmarou, A			Neuroprotective effect of hypothermia on neuronal injury in diffuse traumatic brain injury coupled with hypoxia and hypotension	JOURNAL OF NEUROTRAUMA			English	Article						neuronal damage; rat; secondary insult; selective vulnerability; traumatic brain injury	ENERGY PHOSPHATE-METABOLISM; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; COMA DATA-BANK; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA; FLUID-PERCUSSION; RAT-BRAIN	It is well established in mechanical head trauma that posttraumatic secondary insults, such as hypoxia and hypotension exacerbate neuronal injury and lead to worse outcome. In this study, the neuroprotective effect of hypothermia on the reduction of supraventricular subcortical neuronal damage was evaluated using an impact-acceleration model of diffuse traumatic brain injury coupled with both moderate and severe periods of hypoxia and hypotension. A total of 135 adult male Sprague-Dawley rats (340-375 g) were divided into three experimental studies: (I) physiological evaluation (n = 36); (II) quantitative analysis of the effect of trauma coupled with moderate and severe hypotension on neuronal damage assessed at 4 (n = 39) and 24 h (n = 24); and (III) the neuroprotective effect of hypothermia following moderate secondary insult (n = 36). Induction of hypothermia occurred at 15 min postinjury, to a level of 30 degrees C for 60 min. At the designated time points (4 and 24 h), the animals were sacrificed via standard transcardial perfusion techniques for histological processing. Quantitative assessment of neuronal damage using routine H&E staining at 4 hours showed neuronal damage which correlated with the severity of secondary insult. Animals exposed to trauma alone had a mean number of damaged neurons of 7.61 +/- 3.08/high powered field (hpf) compared with a mean of 1.21 +/- 0.30/hpf in the sham operated group (p = 0.015). Animals exposed to trauma,vith 10 min of hypoxia and hypotension (THH-10) showed a statistically significant number of damaged neurons compared to the sham-operated animals (7.50 +/- 2.15 damaged neurons/hpf, p = 0.013), whereas, neuronal damage in animals undergoing trauma with a 30-min secondary insult of hypoxia and hypotension (THH-30) was markedly increased (100 +/- 30.20/hpf, p = 0.002). Statistical analysis showed no significant difference in neuronal damage in animals subjected to secondary insult alone. At 24 h, the evolution of neuronal damage in the trauma alone group (5.08 +/- 1.63/hpf) was relatively static; however, there was a remarkable increase in the neuronal damage of the THH-10 group (29.88 50 +/- 8.20/hpf). However, hypothermia provided nearly complete protection against secondary insults, and neuronal damage was equal to that of the trauma alone group (p = 0.42). The results of this study confirm that hypothermia provides remarkable protection against the adverse effects of neuronal damage exacerbated by secondary injury. This study also presents a new model of secondary insult, which can be used experimentally to further define the mechanism of increased vulnerability of the injured brain.	Virginia Commonwealth Univ Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Marmarou, A (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Div Neurosurg, POB 508,MCV Stn,Sanger Hall,Rm 8004,1101 E Marsha, Richmond, VA 23298 USA.	marmarou@abic.vcu.edu	Beaumont, Andrew/AAJ-7457-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS12587, R01 NS19235] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRIERLEY JB, 1973, ARCH NEUROL-CHICAGO, V29, P367, DOI 10.1001/archneur.1973.00490300029003; BROWN AW, 1973, ACTA NEUROPATHOL, V23, P9, DOI 10.1007/BF00689000; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chappell JE, 1996, J TRAUMA, V41, P781, DOI 10.1097/00005373-199611000-00003; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KATAYAMA Y, 1989, NEUROTRAUMA SOC, V6, P200; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KITA H, 1994, ACTA NEUROCHIR, P452; KLEMPT M, 1993, MOL BRAIN RES, V17, P347, DOI 10.1016/0169-328X(93)90021-G; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Yamamoto T, 1997, ACT NEUR S, V70, P71; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	69	61	69	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					487	500		10.1089/neu.1999.16.487			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800005	10391365				2022-02-06	
J	Brown, JIM; Baker, AJ; Konasiewicz, SJ; Moulton, RJ				Brown, JIM; Baker, AJ; Konasiewicz, SJ; Moulton, RJ			Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; clinical outcome; glutamate; temporal pattern; traumatic brain injury	EXCITATORY AMINO-ACIDS; SEVERE HEAD-INJURY; IN-VIVO MICRODIALYSIS; CEREBROSPINAL-FLUID; RELEASE; ISCHEMIA; ASPARTATE; ANTAGONISTS; RECEPTORS; GLYCINE	Glutamate excitotoxicity is a putative mechanism of secondary damage after traumatic brain injury (TBI), No relationship between glutamate release and clinical status has been shown in humans, however, We hypothesize a dose-response relationship between CSF glutamate concentrations and severity of injury, electrophysiological deterioration as measured by somatosensory evoked potential amplitudes, and clinical outcome, From August 1991 to March 1996, intensive monitoring of 55 patients with severe TBI (GCS less than or equal to 8 after resuscitation) included twice daily CSF glutamate levels and hourly somatosensory evoked potentials (SSEPs) for an average of 5 days, Clinical outcomes were survival/nonsurvival and Glasgow outcome score (GOS) at 3 months or more post-injury, Glutamate levels were not associated with severity of injury, electrophysiological deterioration, or clinical outcome. Neither peak nor mean glutamate levels significantly improved a simple logistic regression model which used only age and presence of bilaterally unreactive pupils to predict survival, Using this methodology CSF glutamate concentrations did not display a dose-response relationship to severity of injury, electrophysiological deterioration, or predict clinical outcomes following TBI in a group of 55 patients, An early effect of glutamate, an effect dependent on time of exposure to glutamate or other modulating effects cannot be ruled out.	Univ Toronto, St Michaels Hosp, Dept Anaesthesia, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada		Brown, JIM (corresponding author), Univ Toronto, St Michaels Hosp, Dept Anaesthesia, 30 Bond St, Toronto, ON M5B 1W8, Canada.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; CHOI DW, 1987, J NEUROSCI, V7, P357; DAVSON H, 1967, PHYSL CEREBROSPINAL; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARESE C, 1993, ANN NEUROL, V33, P316, DOI 10.1002/ana.410330316; GENNARELLI TA, 1993, HEAD INJURY, P1; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1976, LANCET, V1, P1031; Kanthan R, 1996, NEUROSCI LETT, V209, P207, DOI 10.1016/0304-3940(96)12642-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P219; KONASIEWICZ SJ, 1994, J TRAUMA, V37, P370, DOI 10.1097/00005373-199409000-00006; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; SHEDDEN P M, 1990, Pediatric Neurosurgery, V16, P203, DOI 10.1159/000120527; Shuaib A, 1996, ACT NEUR S, V67, P53; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zauner A, 1996, ACT NEUR S, V67, P40; ZORNOW MH, 1995, J NEUROSURG ANESTH, V7, P148, DOI 10.1097/00008506-199504000-00022	41	61	61	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1998	15	4					253	263		10.1089/neu.1998.15.253			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZF401	WOS:000072893800003	9555971				2022-02-06	
J	Ewing-Cobbs, L; Brookshire, B; Scott, MA; Fletcher, JM				Ewing-Cobbs, L; Brookshire, B; Scott, MA; Fletcher, JM			Children's narratives following traumatic brain injury: Linguistic structure, cohesion, and thematic recall	BRAIN AND LANGUAGE			English	Article							CLOSED-HEAD-INJURY; ADOLESCENTS; DISCOURSE; PERFORMANCE; CHILDHOOD; SEQUELAE; ADULTS	Narrative discourse and intellectual functioning were examined 3 years following traumatic brain injury (TBI) in children 1 to 8 years of age at the time of injury. The language-impaired TBI group (n = 9) had language deficits during the subacute stage of recovery; their performance was contrasted with that of a TBI comparison group equated on neurologic and demographic variables that did not show subacute language impairment (n = 8) and a sibling comparison group (n = 9). The language-impaired TBI group had lower Verbal and Full-Scale IQ scores and produced fewer words and utterances than the sibling group on a story retelling task; their stories were characterized by fewer complete referential and lexical ties and more referential errors, indicating difficulty conjoining meaning across sentences. The language impaired TBI group recalled approximately one-third of the propositions needed to maintain the story theme and made more errors sequencing the propositions than either the TBI or the sibling comparison groups. Group differences were not obtained on the Performance IQ scores or on measures of rate or fluency of speech production, mazes, use of conjunctives, or naming errors. The discourse deficiencies of children with TBI and acute language impairment were most pronounced at the level of cognitive organization of the text reflecting text macrostructure and were least apparent at the level of lexical and sentential organization reflecting text microstructure. Results are discussed in terms of the vulnerability of developing language abilities to disruption by brain injury. (C) 1998 Academic Press.	Univ Texas, Hlth Sci Ctr, Dept Pediat MSB 3 222, Div Dev Pediat, Houston, TX 77030 USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat MSB 3 222, Div Dev Pediat, 6431 Fannin, Houston, TX 77030 USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27597, NS 29462] Funding Source: Medline		BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BENSON DF, 1979, STUDIES NEUROLINGUIS, P00293; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1909, DISCOURSE ABILITY BR, P199; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOLDBERG E, 1981, BRAIN LANG, V14, P144, DOI 10.1016/0093-934X(81)90072-9; Halliday M. K., 1976, COHESION ENGLISH; HEDRICK DL, 1974, SEQUENCED INVENTORY; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; JORDAN FM, 1988, BRAIN INJURY, V2, P175; JORDAN FM, 1909, BRIN INJURY, V4, P147; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Lee L. L.., 1974, DEV SENTENCE ANAL GR; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; LOVETT MW, 1986, BRAIN LANG, V29, P224, DOI 10.1016/0093-934X(86)90046-5; McCarthy, 1972, MCCARTHY SCALES CHIL; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILLER J, 1992, SALT SYSTEMATIC ANAL; Miller J, 1981, ASSESSING LANGUAGE P; Opie, 1974, CLASSIC FAIRY TALES; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; SPREEN O, 1966, NEUROSENSORY CTR COM; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; VANDIJK TA, 1985, HDB DISCOURSE ANAL; Wechsler D., 1974, WECHSLER INTELLIGENC; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOOD BS, 1976, CHILDREN COMMUNICATI; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	47	61	61	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	FEB 15	1998	61	3					395	419		10.1006/brln.1997.1884			25	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	ZK818	WOS:000073366800005	9570871				2022-02-06	
J	Clark, RSB; Carcillo, JA; Kochanek, PM; Obrist, WD; Jackson, EK; Mi, ZC; Wisneiwski, SR; Bell, MJ; Marion, DW				Clark, RSB; Carcillo, JA; Kochanek, PM; Obrist, WD; Jackson, EK; Mi, ZC; Wisneiwski, SR; Bell, MJ; Marion, DW			Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans	NEUROSURGERY			English	Article; Proceedings Paper	10th International Symposium on Brain Edema	OCT 20-23, 1996	SAN DIEGO, CA			adenosine; cerebral blood flow; cerebral metabolism; cerebrospinal fluid; head injury; oxidative metabolism	INTRACRANIAL HYPERTENSION; GLUCOSE-UTILIZATION; AUTO-REGULATION; BRAIN TRAUMA; RAT-BRAIN; RECEPTORS; ISCHEMIA; CHILDREN; PRESSURE; HYPOXIA	OBJECTIVE: Uncoupling of cerebral blood flow (CBF) and oxidative metabolism is observed after severe head injury in comatose patients; however, the mechanism(s) involved remain undefined. Adenosine can produce cerebral vasodilation and reduce neuronal activity and is a possible mediator of uncoupling. We hypothesized that cerebrospinal fluid (CSF) adenosine concentrations would be increased during uncoupling of CBF and oxidative metabolism, defined as a narrow arterio-jugular venous oxygen difference [D(a-v)O-2 4 vol%] after head injury. METHODS: Adenosine concentrations were measured using fluorescent-based high-pressure liquid chromatography in 67 CSF samples obtained from 13 comatose (Glasgow Coma Scale score 7) adult patients who sustained a severe closed head injury. At the time each sample was obtained, CBF was measured by the xenon-133 method, and blood samples were obtained for determination of D(a-v)O-2. RESULTS: CSF adenosine concentration was negatively associated with D(a-v)O-2 (P < 0.05, generalized multivariate linear regression model), In addition, CSF adenosine concentration was increased when D(a-v)O-2 was 4 versus >4 vol% (38.5 [3.2-306.3] versus 14.0 [2.7-795.5] nmol/L, respectively, median [range]; P < 0.025) and in patients who died versus survivors (40.1 [6.9-306.3] versus 12.9 [2.7-795.5] nmol/L, respectively, median [range]; P < 0.001). CONCLUSION: The association between increased CSF adenosine concentration and a reduction in global cross-brain extraction of oxygen supports a regulatory role for adenosine in the complex balance between CBF and oxidative and nonoxidative metabolism after severe head injury in humans.	UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT PEDIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT NEUROSURG,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT PHARMACOL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA 15260				Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BERNINI JC, 1995, LANCET, V345, P544, DOI 10.1016/S0140-6736(95)90464-6; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAUN JS, 1994, J NEUROCYTOL, V23, P193, DOI 10.1007/BF01181560; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; CRONSTEIN BN, 1994, J APPL PHYSIOL, V176, P5; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIRNAGL U, 1994, AM J PHYSIOL, V267, pH296, DOI 10.1152/ajpheart.1994.267.1.H296; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P325; FLEISCHER AS, 1977, J NEUROSURG, V47, P517, DOI 10.3171/jns.1977.47.4.0517; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; GINSBERG MD, 1987, NEUROLOGY, V37, P11, DOI 10.1212/WNL.37.1.11; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; JACKSON EK, 1997, J PHARMACOL EXP THER, V279, P1250; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; JENNETT B, 1985, LANCET, V1, P480; KO KR, 1990, AM J PHYSIOL, V259, pH1703, DOI 10.1152/ajpheart.1990.259.6.H1703; Lam JMK, 1996, BRIT J NEUROSURG, V10, P357; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LAUDIGNON N, 1991, J CEREBR BLOOD F MET, V11, P424, DOI 10.1038/jcbfm.1991.83; LEE KS, 1986, BRAIN RES, V380, P155, DOI 10.1016/0006-8993(86)91440-X; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1997, P 10 INT S BRAIN ED, P90; MASS AIR, 1977, CEREBROSPINAL FLUID, P17; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MILLER LP, 1992, J NEUROTRAUM, V9, pS563; MORII S, 1987, AM J PHYSIOL, V253, pH165, DOI 10.1152/ajpheart.1987.253.1.H165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; ONODERA H, 1987, BRAIN RES, V415, P309, DOI 10.1016/0006-8993(87)90213-7; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1984, J CEREBR BLOOD F MET, V4, P586, DOI 10.1038/jcbfm.1984.83; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; RUBIO R, 1975, AM J PHYSIOL, V228, P1896, DOI 10.1152/ajplegacy.1975.228.6.1896; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUTH VJ, 1993, AM J PHYSIOL, V265, pH1762; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SCHRODER ML, 1994, XENON CT CBF CLIN DE, P275; SHALMON E, 1996, J NEUROSURG, V84, pA344; SOLLEVI A, 1986, PROG NEUROBIOL, V27, P319, DOI 10.1016/0301-0082(86)90005-5; STEFANOVICH V, 1988, ROLE ADENOSINE CEREB, P2; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; VILLRINGER A, 1995, CEREBROVAS BRAIN MET, V7, P240; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; WINN HR, 1980, AM J PHYSIOL, V239, pH636, DOI 10.1152/ajpheart.1980.239.5.H636; WINN HR, 1981, J CEREBR BLOOD F MET, V1, P239, DOI 10.1038/jcbfm.1981.29; WINN HR, 1985, ANN BIOMED ENG, V13, P321, DOI 10.1007/BF02584250; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	64	61	64	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1997	41	6					1284	1292		10.1097/00006123-199712000-00010			9	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	YH863	WOS:A1997YH86300034	9402580				2022-02-06	
J	Hall, ED; Andrus, PK; Smith, SL; Fleck, TJ; Scherch, HM; Lutzke, BS; Sawada, GA; Althaus, JS; Vonvoigtlander, PF; Padbury, GE; Larson, PG; Palmer, JR; Bundy, GL				Hall, ED; Andrus, PK; Smith, SL; Fleck, TJ; Scherch, HM; Lutzke, BS; Sawada, GA; Althaus, JS; Vonvoigtlander, PF; Padbury, GE; Larson, PG; Palmer, JR; Bundy, GL			Pyrrolopyrimidines: Novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NERVOUS-SYSTEM TRAUMA; CEREBRAL-ARTERY OCCLUSION; LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; PARKINSONS-DISEASE; TRANSIENT; U74006F; RATS; 21-AMINOSTEROIDS; PROTECTION	A novel group of antioxidant compounds, the pyrrolopyrimidines, has been discovered recently. Many of these possess significantly improved oral bioavailability (56-70% in rats), increased efficacy and potency in protecting cultured neurons against iron-induced lipid peroxidative injury and as much as a 5-fold increase in brain uptake compared with the 21-aminosteroid antioxidant compound, tirilazad mesylate (U-74006F), described earlier. They appear to quench lipid peroxidation reactions by electron-donating and/or radical-trapping mechanisms. Several compounds in the series, such as U-101033E and U-104067F, demonstrate greater ability than tirilazad to protect the hippocampal CA1 region in the gerbil transient (5-min) forebrain ischemia model. Delaying treatment until 4 hr after the ischemic insult still results in significant CA1 neuronal protection. U-101033E is still effective in salvaging a portion of the CA1 neuronal population when the ischemic duration is extended to 10 min. In addition, U-101033E has been found to be protective in the context of focal cerebral ischemia, reducing infarct size in the mouse permanent middle cerebral artery occlusion model, in contrast to tirilazad which is minimally effective. These results suggest that antioxidant compounds with improved brain parenchymal penetration are better able to limit certain types of ischemic brain damage than those which are localized in the cerebral microvasculature. However, the activity of U-101033E in improving early post-traumatic recovery in mice subjected to severe concussive head injury is similar to that of tirilazad. Last, the oral bioavailability of many pyrrolopyrimidines suggests that they may be useful for certain chronic neurodegenerative disorders in which lipid peroxidation plays a role.	PHARMACIA & UPJOHN INC,DRUG DELIVERY SYST RES,KALAMAZOO,MI 49001; PHARMACIA & UPJOHN INC,DRUG METAB RES,KALAMAZOO,MI 49001; PHARMACIA & UPJOHN INC,MED CHEM RES,KALAMAZOO,MI 49001		Hall, ED (corresponding author), PHARMACIA & UPJOHN INC,CNS DIS RES,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUCHAN AM, 1992, J CEREBR BLOOD F MET, V12, P250, DOI 10.1038/jcbfm.1992.35; BUNDY GL, 1995, J MED CHEM, V38, P4161, DOI 10.1021/jm00021a004; BUXSER S, 1981, INFECT IMMUN, V31, P929, DOI 10.1128/IAI.31.3.929-934.1981; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; COHEN G, 1986, ADV NEUROL, V45, P119; FICI GJ, 1996, FREE RADIC BIOL MED, V22, P223; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1993, STROKE, V24, P711, DOI 10.1161/01.STR.24.5.711; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P1008, DOI 10.1161/01.STR.19.8.1008; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALL ED, 1995, ACTA NEUROCHIR S, V66, P107; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; PARK CK, 1994, BRAIN RES, V645, P157; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; PREHN JHM, 1992, J CEREBR BLOOD F MET, V12, P78, DOI 10.1038/jcbfm.1992.10; Raub TJ, 1993, J DRUG TARGET, V1, P269, DOI 10.3109/10611869308996085; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sawada G. A., 1995, Pharmaceutical Research (New York), V12, pS311; Sawada G. A., 1995, Pharmaceutical Research (New York), V12, pS300; SCHMIDELSAESSER R, 1996, CEREBROVASC DIS, V6, P43; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SMITH MA, 1994, ANN NY ACAD SCI, V738, P447; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; SUTHERLAND G, 1993, NEUROSCI LETT, V149, P123, DOI 10.1016/0304-3940(93)90751-6; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YOUDIM MBH, 1993, MOVEMENT DISORD, V8, P1, DOI 10.1002/mds.870080102; Zhang JR, 1996, J NEUROCHEM, V66, P355; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	39	61	62	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAY	1997	281	2					895	904					10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WX658	WOS:A1997WX65800037	9152399				2022-02-06	
J	Max, JE; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Lindgren, SD; Robin, DA; Stierwalt, JAG				Max, JE; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Lindgren, SD; Robin, DA; Stierwalt, JAG			Traumatic brain injury in children and adolescents: Psychiatric disorders in the first three months	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children; adolescents; psychiatric disorder	HEAD-INJURY; FAMILY; RELIABILITY; SEVERITY; SCALE	Objective: To assess predictive factors of psychiatric outcome in the first 3 months after traumatic brain injury (TBI) in children and adolescents. Method: Subjects were children aged 6 to 14 years at the time they were hospitalized after TBI. The study used a prospective follow-up design. Assessments of preinjury psychiatric, behavioral, adaptive functioning, family functioning, and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales and neuroimaging was analyzed. The outcome measure was the development of a psychiatric disorder, never before present (''novel'') in a subject during the first 3 months after the TBI. Results: Fifty subjects enrolled, and the analyses focused on 37 subjects followed up at 3 months. Increasing severity of injury, presence of a lifetime psychiatric disorder, family psychiatric history, family dysfunction, and lower socioeconomic class/preinjury intellectual function predicted the development of a ''novel'' psychiatric disorder in the first 3 months of follow-up. Conclusions: These data suggest that there are children, identifiable through clinical assessment, at increased risk for development of psychiatric disorders in the first 3 months after TBI.	UNIV MONTANA,MISSOULA,MT 59812; CEDAR CTR,PSYCHIAT GRP,CEDAR RAPIDS,IA; UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT SPEECH PATHOL & AUDIOL,IOWA CITY,IA 52242				Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Ciccetti D., 1984, VINELAND ADAPTIVE BE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Garmezy N, 1994, CHILD ADOLESCENT PSY, P191; GERSON AC, 1993, P ANN M AM AC CHILD; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max J. E., 1992, NEUROPSYCHIATRIC RAT; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; *SPSS, 1993, SPSS WIND PROF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81	28	61	61	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1997	36	1					94	102		10.1097/00004583-199701000-00022			9	Psychology, Developmental; Pediatrics; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	WA553	WOS:A1997WA55300023	9000786				2022-02-06	
J	Vilkki, J; Virtanen, S; SurmaAho, O; Servo, A				Vilkki, J; Virtanen, S; SurmaAho, O; Servo, A			Dual task performance after focal cerebral lesions and closed head injuries	NEUROPSYCHOLOGIA			English	Article						attention; diffuse brain injury; executive function; frontal lobe; supervisory control	DIGIT SPAN; ATTENTION; NEGLECT; MEMORY	The aim of this study was to demonstrate that focal frontal lobe lesions and closed head injuries cause a deficit in the deliberate minimizing of dual task decrements that follow when two separate tasks should be done concurrently. In single tasks, subjects counted backwards and cancelled visual targets as quickly and accurately as possible on separate 1 min trials. In the dual task, they were required to do both tasks simultaneously, taking care that performance on neither task would be notably more impaired than on the other, as only the performance showing a larger percentage decrement from the corresponding single task performance was taken into account as the result of the test. Patients with acute closed head injury displayed more pronounced dual task decrement than the controls. This deficit was not secondary to inefficiency on the single tasks but was related to the depth of coma at admission, the acuteness of injury and age. Contrary to expectation, patients with focal frontal lobe lesions or patients with subacute closed head injury did not demonstrate abnormal dual task decrement. Copyright (C) 1996 Elsevier Science Ltd.			Vilkki, J (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT NEUROSURG,TOPELIUKSENKATU 5,FIN-00260 HELSINKI,FINLAND.						BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; Baddeley A.D., 1986, WORKING MEMORY; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Mayes A., 1988, HUMAN ORGANIC MEMORY; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; NORMAN DA, 1980, 99 CHIP U CAL SAN DI; RAPPORT LJ, 1994, NEUROPSYCHOLOGIA, V32, P517, DOI 10.1016/0028-3932(94)90141-4; ROBERTSON IH, 1990, NEUROPSYCHOLOGIA, V28, P217, DOI 10.1016/0028-3932(90)90103-U; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Shallice T., 1988, NEUROPSYCHOLOGY MENT; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; TEASDALE G, 1974, LANCET, V2, P81; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; VELTMAN JC, IN PRESS J CLIN EXPT; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WEINBERG J, 1972, J CLIN PSYCHOL, V28, P361, DOI 10.1002/1097-4679(197207)28:3+<361::AID-JCLP2270280315>3.0.CO;2-5; [No title captured]	19	61	61	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	NOV	1996	34	11					1051	1056		10.1016/0028-3932(96)00028-0			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	VP114	WOS:A1996VP11400002	8904742				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration	BRAIN RESEARCH			English	Article						nuclear magnetic resonance; trauma; brain injury	RAT; DEFICIENCY; METABOLISM; MECHANISMS; ISCHEMIA; NEURONS; DAMAGE; MG-2+	Decline in brain intracellular free magnesium concentration following experimental traumatic brain injury has been widely reported in a number of studies. However, to date, these studies have been confined to focal models of brain injury and temporally limited to the immediate 8-h period post-trauma. Recently, a new model of impact-acceleration brain injury has been developed which produces nonfocal diffuse axonal injury more typical of severe clinical trauma. The present study has used phosphorus magnetic resonance spectroscopy and the rotarod motor test to characterise magnesium homeostasis and neurologic outcome over a period of 8 days after induction of severe impact-acceleration injury in rats. Severe impact-acceleration induced injury resulted in a highly significant and sustained decline in intracellular free magnesium concentration that was apparent for 4 days post-trauma with recovery to preinjury levels by day six. There were no significant changes in pH or ATP concentration at any time point post-injury. All animals demonstrated a significant neurologic deficit over the assessment period. The extended period of magnesium decline after severe diffuse brain trauma suggests that repeated administration may be required for pharmacotherapies targeted at restoring magnesium homeostasis.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA				Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.physiol.53.1.299; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; Bara M., 1984, MAGNESIUM, V3, P212; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARFINKEL L, 1985, Magnesium, V4, P60; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALLAK M, 1994, J SOC GYNECOL INVEST, V1, P25, DOI 10.1177/107155769400100106; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1988, J BIOL CHEM, V263, P757; WELCH KMA, 1993, NEUROLOGY, V43, P21; WILLIAMS GD, 1995, MAGNET RESON MED, V33, P853, DOI 10.1002/mrm.1910330618	26	61	66	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 28	1996	738	1					150	153		10.1016/0006-8993(96)00957-2			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VT492	WOS:A1996VT49200020	8949939				2022-02-06	
J	KINSELLA, G; PRIOR, M; SAWYER, M; MURTAGH, D; EISENMAJER, R; ANDERSON, V; BRYAN, D; KLUG, G				KINSELLA, G; PRIOR, M; SAWYER, M; MURTAGH, D; EISENMAJER, R; ANDERSON, V; BRYAN, D; KLUG, G			NEUROPSYCHOLOGICAL DEFICIT AND ACADEMIC-PERFORMANCE IN CHILDREN AND ADOLESCENTS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL TESTING; NEUROPSYCHOLOGICAL DEFICIT; NEUROPSYCHOLOGICAL ASSESSMENT; SPECIAL EDUCATION; FOLLOW-UP; ACADEMIC PERFORMANCE	CLOSED-HEAD-INJURY; SEQUELAE; MEMORY; SEVERITY; RECOVERY; COMA	Evaluated the utility of neuropsychological testing in predicting academic outcome in children 1 year following traumatic brain injury (TBI). Fifty-one schoolage children who were admitted to hospital after TBI were assessed with a battery of neuropsychological measures at 3 months postinjury, Academic achievement was assessed at 3 and 12 months postinjury, The neuropsychological battery included intelligence resting and measures of memory, learning, and speed of information processing. Academic outcome was assessed in terms of post-TBI changes in reading, spelling, and arithmetic; changes in teacher ratings of school performance; and change in school placement. According to logistic regression analysis, change in placement from regular to special education at 1-year post-TBI was predicted by injury severity and by neuropsychological performance cat 3 months post-TBI. Findings suggest that neuropsychological resting is useful in identifying children with special educational needs subsequent to TBI.	ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,ADELAIDE,SA 5006,AUSTRALIA		KINSELLA, G (corresponding author), LA TROBE UNIV,DEPT PSYCHOL,BUNDOORA,VIC 3083,AUSTRALIA.		Murtagh, Donal/F-8694-2011; Kinsella, Glynda/O-6347-2017	Murtagh, Donal/0000-0003-1539-3559; Kinsella, Glynda/0000-0002-5859-0934			ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENTON AL, 1978, MANUAL MULTILINGUAL; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CLARREN SB, 1993, DEV NEUROPSYCHOL, V9, P161, DOI 10.1080/87565649309540550; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DANIEL A, 1983, POWER PRIVILEDGE PRE; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Edelbrock C., 1986, MANUAL TEACHERS REPO; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1985, INJURED CHILD, P30; Forrester G., 1991, CLIN NEUROPSYCHOL, V5, P345, DOI [10.1080/13854049108404102, DOI 10.1080/13854049108404102]; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P1996; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, NEUROBEHAVIOURAL REC; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Rey A., 1964, EXAMEN CLIN PSYCHOL; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; Smith, 1973, SYMBOL DIGIT MODALIT; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TUCKER A, 1987, AUST PSYCHOL, V22, P353, DOI 10.1080/00050068708259536; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	44	61	61	0	5	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	DEC	1995	20	6					753	767		10.1093/jpepsy/20.6.753			15	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	TK236	WOS:A1995TK23600005	8558376				2022-02-06	
J	MEJIA, RE; POLLACK, MM				MEJIA, RE; POLLACK, MM			VARIABILITY IN BRAIN-DEATH DETERMINATION PRACTICES IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES	Objective.-To investigate variability in practices for determining brain death and organ procurement results in pediatric intensive care units (PICUs). Design.-Prospective cohort study. Setting.-Pediatric ICUs. Patients.-Children undergoing brain death evaluations selected from 5415 consecutive PICU admissions. Main Outcome Measures.-Data from children undergoing brain death evaluations including number of coma examinations, number and duration of apnea tests, Pco(2) measurements at the end of the apnea test, ancillary tests used to confirm brain death, organ procurement, and reasons for nonprocurement. Results.-A total of 93 (37%) of 248 deaths were brain deaths. Compared with the other deaths, children who were classified as brain dead were sicker on admission (mean Pediatric Risk of Mortality [PRISM] score+/-SD: 31+/-11 vs 23+/-12, P<,001; pre-ICU cardiopulmonary resuscitation, 72% vs 40%, P<.001), and had more traumatic injuries (42% vs 12%, P<.001). Variability in apnea testing included lack of apnea testing in 23 patients (25%) and controversial apnea testing practices in 20 patients (22%). Three patients (3%) had brain death evaluations within hours of discontinuing barbiturate infusions, and four of 30 patients younger than 1 year did not have a confirmatory test, Solid organ procurement was successful in 32%, Reasons for nonprocurement included parental refusal (12%), disease state (12%), and medical examiner's case (22%). Conclusions.-Substantial variability exists in the criteria used by clinicians for the diagnosis of brain death. Some practices are contradictory to the Guidelines for the Determination of Brain Death in Children and to recommendations for apnea testing. Organ procurement could be improved by increased medical examiner cooperation.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CHILRENS RES INST,CTR HLTH SERV & CLIN RES,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH-110584] Funding Source: Medline		ALJUMAH M, 1992, CRIT CARE MED, V20, P1564; ASHWAL S, 1993, J HEART LUNG TRANSPL, V12, pS176; Ashwal S, 1991, Adv Pediatr, V38, P181; DRAKE B, 1986, PEDIATRICS, V78, P107; EDMONDS JF, 1989, PEDIAT BRAIN DEATH O, P89; FACKLER JC, 1988, AM J DIS CHILD, V142, P999, DOI 10.1001/archpedi.1988.02150090097034; FREEMAN JM, 1988, PEDIATRICS, V81, P301; GONNELLA JS, 1986, DISEASE STAGING CLIN; Hauser J E, 1969, J Forensic Sci, V14, P501; KAUFMAN HH, 1989, NEUROSURGERY, V25, P275, DOI 10.1227/00006123-198908000-00019; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; LEVETOWN M, 1994, JAMA-J AM MED ASSOC, V272, P1271, DOI 10.1001/jama.272.16.1271; NARKEWICZ RM, 1989, PEDIATRICS, V83, P629; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POWNER DJ, 1976, JAMA-J AM MED ASSOC, V236, P1123, DOI 10.1001/jama.236.10.1123; RIVIELLO JJ, 1988, PEDIATR NEUROL, V4, P213, DOI 10.1016/0887-8994(88)90033-1; SCHAFER JA, 1984, CRIT CARE MED, V12, P357; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; SHERIDAN F, 1993, J HEART LUNG TRANSPL, V12, pS179; SHEWMON DA, 1988, ANN NEUROL, V24, P789; SHEWMON DA, 1988, NEUROLOGY, V38, P1813, DOI 10.1212/WNL.38.11.1813-b; SQUIRES S, 1993, WASHINGTON POST 1118; SQUIRES S, 1994, WASHINGTON POST 0729; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; 1984, PEDIATRICS, V74, P505; 1981, JAMA-J AM MED ASSOC, V246, P2184	28	61	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					550	553		10.1001/jama.274.7.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	WOS:A1995RN46600025	7629983				2022-02-06	
J	JOYCE, BM; ROCKWOOD, KJ; MATEKOLE, CC				JOYCE, BM; ROCKWOOD, KJ; MATEKOLE, CC			USE OF GOAL ATTAINMENT SCALING IN BRAIN INJURY IN A REHABILITATION-HOSPITAL	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						BRAIN INJURY; FUNCTIONAL OUTCOME; REHABILITATION; GOAL ATTAINMENT SCALING		We report a study of the measurement properties of goal attainment (GA) scaling when used in the rehabilitation of brain injury patients. GA scaling is an individualized measurement technique with mathematical properties allowing for calculation of summary scores with a normal distribution. The present study examined 16 inpatients, 13 of whom had suffered a traumatic brain injury. In addition to GA scaling, standardized measures were employed to address issues such as content validity and construct validity. GA scaling change scores correlated highly (r = 0.81) with clinical judgment of efficacy and modestly with standard performance measures. A high level of inter-rater reliability was found between admission (r = 0.92) and discharge (r = 0.94) scores. GA scaling seems to be a feasible method of evaluating rehabilitation in brain injury patients, with promising measurement properties. The goals set are extremely meaningful to the patient and rehabilitation team, providing valuable feedback throughout the rehabilitation course.	DALHOUSIE UNIV, DIV PHYS MED & REHABIL, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DIV GERIATR MED, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DEPT PSYCHOL, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DEPT PSYCHIAT, HALIFAX B3H 4H2, NS, CANADA				Rockwood, Kenneth/AAD-8951-2019				HAFFEY WJ, 1989, REHABIL PSYCHOL, V34, P147, DOI 10.1037//0090-5550.34.2.147; JENNINGS B, 1983, ETHICS SOCIAL SCI PO, P3; JOHNSTON MV, 1991, AM J PHYS MED REHAB, V70, P40, DOI 10.1097/00002060-199102000-00008; Kirusek T. J., 1968, COMMUNITY MENTAL HLT, V4, P443; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; Leonardelli C. A., 1988, MILWAUKEE EVALUATION; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MCGOURTY LK, 1988, MENTAL HLTH ASSESSME; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spilker, 1990, QUALITY LIFE ASSESSM, P115; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STOLEE P, 1992, J AM GERIATR SOC, P40; Streiner D.L., 1989, HLTH MEASUREMENT SCA	16	61	61	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	1994	73	1					10	14		10.1097/00002060-199473010-00003			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	MX590	WOS:A1994MX59000003	8305175				2022-02-06	
J	HARIRI, RJ; FIRLICK, AD; SHEPARD, SR; COHEN, DS; BARIE, PS; EMERY, JM; GHAJAR, JBG				HARIRI, RJ; FIRLICK, AD; SHEPARD, SR; COHEN, DS; BARIE, PS; EMERY, JM; GHAJAR, JBG			TRAUMATIC BRAIN INJURY, HEMORRHAGIC-SHOCK, AND FLUID RESUSCITATION - EFFECTS ON INTRACRANIAL-PRESSURE AND BRAIN COMPLIANCE	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; HYPOTENSION; INTRACRANIAL HYPERTENSION; RESUSCITATION; BRAIN COMPLIANCE; INTRACRANIAL PRESSURE	HEAD-INJURY; HYPERTONIC SALINE; SYSTEM; EPIDEMIOLOGY; DEATHS; MODEL	Intracranial hypertension following traumatic brain injury is associated with considerable morbidity and mortality. Hemorrhagic hypovolemia commonly coexists with head injury in this population of patients. Therapy directed at correcting hypovolemic shock includes vigorous volume expansion with crystalloid' solutions. It is hypothesized that, following traumatic brain injury, cerebrovascular dysfunction results in rapid loss of brain compliance, resulting in increased sensitivity to cerebrovascular venous pressure. Increased central venous pressure (CVP) occurring with vigorous crystalloid resuscitation may therefore contribute to the loss of brain compliance and the development of intracranial hypertension. The authors tested this hypothesis in miniature swine subjected to traumatic brain injury, hemorrhage, and resuscitation. Elevated CVP following resuscitation from hemorrhage to a high CVP significantly worsened intracranial hypertension in animals with concurrent traumatic brain injury, as compared to animals subjected to traumatic brain injury alone (mean +/- standard error of the mean: 33.0 +/- 2.0 vs. 20.0 +/- 2.0 mm Hg, p < 0.05) or to animals subjected to the combination of traumatic brain injury, hemorrhage, and resuscitation to a low CVP (33.0 +/- 2.0 vs. 24.0 +/- 2.0 mm Hg, p < 0.05). These data support the hypothesis that reduction in brain compliance can occur secondary to elevation of CVP following resuscitation from hemorrhagic shock. This may worsen intracranial hypertension in patients with traumatic brain injury and hemorrhagic shock.			HARIRI, RJ (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,AITKEN NEUROSURG LAB,1300 YORK AVE,NEW YORK,NY 10021, USA.		Barie, Philip/AAN-8811-2020				ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; CRENSHAW C A, 1962, Surg Forum, V13, P6; CROCKARD A, 1979, NEURAL TRAUMA, P19; EISENBERG HM, 1985, CENTRAL NERVOUS SYST, P271; FUJITA K, 1984, BRAIN EDEMA, P228; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; GUNNAR W, 1988, SURGERY, V103, P398; HARIRI RJ, 1989, ANESTH ANALG, V68, pS115; Huizenga KA, 1943, J PHARMACOL EXP THER, V78, P139; JOHNSTON I, 1975, INTRACRANIAL PRESSUR, V2, P50; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KING AS, 1989, JAMA-J AM MED ASSOC, V262, P2195, DOI 10.1001/jama.262.16.2195; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARSHALL LF, 1982, CLIN NEUR, V29, P312; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; SATO S, 1984, BRAIN EDEMA, P235; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHIRES GT, 1972, ANN SURG, V176, P288, DOI 10.1097/00000658-197209000-00004; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TODD MM, 1984, ANESTSIOLOGY, V61, P122; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	34	61	62	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1993	79	3					421	427		10.3171/jns.1993.79.3.0421			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LU690	WOS:A1993LU69000017	8360740				2022-02-06	
J	ANDREWS, K				ANDREWS, K			RECOVERY OF PATIENTS AFTER 4 MONTHS OR MORE IN THE PERSISTENT VEGETATIVE STATE	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; TRAUMATIC COMA; PROGNOSIS	A retrospective review was made of the case notes of 43 consecutive patients admitted to a unit specialising in the rehabilitation of people in the persistent vegetative state. Eleven of these patients regained awareness four months or more after suffering brain damage. The time to the first reported incidence of eye tracking was between four months and three years, and the time to the first response to command was between four and 12 months. Only one patient was eventually unable to communicate, six could use non-verbal methods of indicating at least a yes or no response, and four were able to speak. Six patients remained totally dependent while two became independent in daily activities. Four patients became independent in feeding, three required help, and four remained on gastrostomy feeding. Thus some patients can regain awareness after more than four months in a vegetative state, and, although few reach full independence, most can achieve an improved quality of life within the limitations of their disabilities. The recovery period is prolonged and may continue for several years. Even patients with profound brain damage should be offered the opportunity of a specialist rehabilitation programme.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.						ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; CRAIG CW, 1986, J NEUROSURG, V65, P9; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Levy D E, 1978, Ann N Y Acad Sci, V315, P293, DOI 10.1111/j.1749-6632.1978.tb50347.x; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; ROSIN AJ, 1978, SCAND J REHABIL MED, V10, P33; SAZBON L, 1992, BRAIN INJURY, V4, P359; STEINBOCK B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562294; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; [No title captured]; [No title captured]; 1993, BMA NEWS REV, V19, P9	30	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1597	1600		10.1136/bmj.306.6892.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	WOS:A1993LH12800027	8329926	Green Published, Bronze			2022-02-06	
J	YOSHINO, A; HOVDA, DA; KATAYAMA, Y; KAWAMATA, T; BECKER, DP				YOSHINO, A; HOVDA, DA; KATAYAMA, Y; KAWAMATA, T; BECKER, DP			HIPPOCAMPAL CA3 LESION PREVENTS POSTCONCUSSIVE METABOLIC DYSFUNCTION IN CA1	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CEREBRAL CONCUSSION; 2-DEOXY-DEUTERIUM-GLUCOSE AUTORADIOGRAPHY; EXCITATORY AMINO ACIDS; GLUCOSE METABOLISM; GLUTAMATE; HIPPOCAMPUS	CEREBRAL GLUCOSE-UTILIZATION; TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; RAT-BRAIN; BLOOD-FLOW; EXTRACELLULAR POTASSIUM; PYRAMIDAL CELLS; AMINO-ACIDS; HEAD-INJURY; ISCHEMIA	Immediately following fluid-percussion (F-P) brain injury, the hippocampus exhibits a marked increase in its local CMR(glc) (LCMR(glc); mumol/100 g/min) as determined using [C-14]2-deoxy-D-glucose autoradiography This injury-induced increase in metabolism is followed in 6 h by a subsequent decrease in LCMR(glc). These two postinjury metabolic states may be the result of ionic disruptions following trauma via stimulation of glutamategated ion channels. To determine if endogenous glutamate innervation to the CA, region of the hippocampus can provide an anatomical basis for this proposed mechanism, it was removed by kainic-acid-induced destruction of CA3, and the effect on CA, metabolism following concussive injury was studied. Five days before a lateral F-P injury (3.5-4.5 atm), kainic acid (0.5 mug) or vehicle was stereotaxically injected into the left ventricle of 65 rats. Histological inspection indicated that kainic acid produced severe cell loss primarily in the CA1 region of the hippocampus ipsilateral to the injection. The metabolic results indicated that immediately following injury, animals with an intact hippocampus exhibited an increase in LCMR(glc) to 84.6 +/- 5 within the CA1 region, representing a 81.5% increase over controls. However, in the CA3-lesioned animals, CA1 showed no evidence of an injury-induced hypermetabolism, with LCMR(glc) remaining at control levels (51.4 +/- 3.9). At 6 h postinjury, the intact hippocampus exhibited a reduction of LCMR(glc) to rates of 40.7 +/- 4.7 within the CA1 region, representing a 17.9% reduction compared with controls. In contrast, CA3-lesioned animals exhibited less of an injury-induced decrease in LCMR(glc) within the CA1 region, exhibiting a mean rate of 43.4 +/- 4.5, representing only a 12.5% reduction compared with controls. These results indicate that the removal of the CA3 projection to CA1 protects the CA1 cells from the metabolic dysfunction typically seen following injury. This supports our previous work indicating the important role glutamate plays in the ionic flux and subsequent metabolic changes that follow traumatic brain injury.	UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, 74-140 CHS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, LOS ANGELES, CA 90024 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27544, NS30308] Funding Source: Medline		ANDERSEN BJ, 1989, J CEREB BLOOD FLOW M, V9, pS386; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; GINSBERG M D, 1979, Acta Neurologica Scandinavica Supplementum, V60, P226; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1991, J CEREB BLOOD FLO S2, V11, pS315; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JORGENSEN MB, 1990, J CEREBR BLOOD F MET, V10, P243, DOI 10.1038/jcbfm.1990.41; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KUSHNER M, 1984, ANN NEUROL, V15, P425, DOI 10.1002/ana.410150505; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NADLER JV, 1976, NATURE, V260, P538, DOI 10.1038/260538a0; NAKAI H, 1988, NEUROL MED CHIR TOKY, V528, P11; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ONODERA H, 1988, NEUROSCI LETT, V89, P90, DOI 10.1016/0304-3940(88)90486-7; ONODERA H, 1986, NEUROSCI LETT, V68, P169, DOI 10.1016/0304-3940(86)90136-9; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PAPPIUS HM, 1982, ANN NEUROL, V12, P157, DOI 10.1002/ana.410120205; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; THOMAS S, 1991, Society for Neuroscience Abstracts, V17, P166; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	49	61	61	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1992	12	6					996	1006		10.1038/jcbfm.1992.137			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	JT803	WOS:A1992JT80300012	1356995	Bronze			2022-02-06	
J	MCDONALD, S				MCDONALD, S			DIFFERENTIAL PRAGMATIC LANGUAGE LOSS AFTER CLOSED HEAD-INJURY - ABILITY TO COMPREHEND CONVERSATIONAL IMPLICATURE	APPLIED PSYCHOLINGUISTICS			English	Article							BRAIN-DAMAGED PATIENTS; REQUESTS; APPRECIATION	Two experiments in which 2 closed-head-injured (CHI) subjects and 12 non-brain-damaged control subjects took part investigated the capacity to comprehend indirect speech acts. In the first experiment. the subjects were required to interpret conventional indirect speech acts. One CHI subject, but not the other, had trouble rejecting the literal meaning. In the second experiment, the subjects were required to interpret the meaning behind two literally conflicting sentences. While the control subjects interpreted these as representing a sarcastic exchange, the CHI subjects were unable to provide an adequate explanation. The results were interpreted in terms of common cognitive deficits after closed head injury.			MCDONALD, S (corresponding author), LIDCOMBE HOSP,DEPT NEUROPSYCHOL,JOSEPH ST,LIDCOMBE,NSW 2141,AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; CLARK HH, 1975, J VERB LEARN VERB BE, V14, P56, DOI 10.1016/S0022-5371(75)80006-5; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; EDINGTON ES, 1980, RANDOPMISATION TESTS, V31; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; GIBBS R, 1982, TEXT, V2, P9; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Gordon D., 1975, SYNTAX SEMANTICS; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Hagan C., 1982, COGNITIVE REHABILITA, P131; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; HOLLAND AL, 1984, CLIN APHASIOLOGY, V14, P345; JORGENSON J, 1984, J EXPT PSYCHOL GENER, V13, P112; KERTESZ A, 1981, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVINSONSC, 1983, PRAGMETICS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Searle John, 1975, SYNTAX SEMANTICS, V3; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Slugoski B. R., 1988, J LANG SOCIAL PSYCHO, V7, P102, DOI DOI 10.1177/0261927X8800700202; SNOW P, 1987, BRAIN IMPAIRMENT; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; Sperber D., 1981, RADICAL PRAGMATICS; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; WALK KW, 1985, UNDERSTANDING BRAIN; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Wilson D., 1986, RELEVANCE COMMUNICAT	33	61	64	1	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0142-7164			APPL PSYCHOLINGUIST	Appl. Psycholinguist.	SEP	1992	13	3					295	312		10.1017/S0142716400005658			18	Linguistics; Psychology, Experimental	Social Science Citation Index (SSCI)	Linguistics; Psychology	KB875	WOS:A1992KB87500003					2022-02-06	
J	BROUWER, WH; PONDS, RWHM; VANWOLFFELAAR, PC; VANZOMEREN, AH				BROUWER, WH; PONDS, RWHM; VANWOLFFELAAR, PC; VANZOMEREN, AH			DIVIDED ATTENTION 5 TO 10 YEARS AFTER SEVERE CLOSED HEAD-INJURY	CORTEX			English	Article									STATE UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; TRAFF RES CTR,HAREN,NETHERLANDS		BROUWER, WH (corresponding author), ACAD HOSP,NEUROPSYCHOL UNIT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.			ponds, rudolf/0000-0002-9748-4659			BROUWER WH, 1985, THESIS U GRONINGEN; DENCKER SJ, 1958, ACTA PSYCHIATRI S122, V33; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P335; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; Luteijn F., 1983, HANDLEIDING GRONINGE; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Miller E, 1970, Cortex, V6, P121; Ponds R. W. H. M., 1988, J GERONTOL, V43, P151; REITAN RM, 1958, PERCEPT MOTOR SKILL, V8, P272; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SOMBERG BL, 1982, J EXP PSYCHOL HUMAN, V8, P651, DOI 10.1037/0096-1523.8.5.651; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANWOLFFELAAR PC, 1988, TRACKING TASK DRIVIN; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; WICKENS C. D., 1984, VARIETIES ATTENTION, P63; [No title captured]	24	61	61	0	6	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1989	25	2					219	230		10.1016/S0010-9452(89)80038-3			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	AD216	WOS:A1989AD21600004	2758848	Bronze			2022-02-06	
J	CULLUM, CM; BIGLER, ED				CULLUM, CM; BIGLER, ED			VENTRICLE SIZE, CORTICAL ATROPHY AND THE RELATIONSHIP WITH NEUROPSYCHOLOGICAL STATUS IN CLOSED HEAD-INJURY - A QUANTITATIVE-ANALYSIS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									AUSTIN NEUROLOG CLIN,CTR MED SCI,BLDG F,711 W 38TH ST,AUSTIN,TX 78705; UNIV TEXAS,AUSTIN,TX 78712				Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BIGLER ED, 1985, J NERV MENT DIS, V173, P347, DOI 10.1097/00005053-198506000-00004; BIGLER ED, 1984, INT J NEUROSCI, V24, P295, DOI 10.3109/00207458409089820; BIRD JM, 1982, PROG NEUROBIOL, V19, P91, DOI 10.1016/0301-0082(82)90022-3; Blinkov SM., 1968, HUMAN BRAIN FIGURES; BOLLER FC, 1972, J NEUROL NEUROSUR PS, V35, P463, DOI 10.1136/jnnp.35.4.463; BRASSOW F, 1978, NEURORADIOLOGY, V16, P187, DOI 10.1007/BF00395246; BRINKMAN SD, 1981, RADIOLOGY, V138, P89, DOI 10.1148/radiology.138.1.7455102; BULL JW, 1961, NEUROLOGY, V11, P1; CULLUM CM, 1985, INT J NEUROSCI, V28, P279, DOI 10.3109/00207458508985395; DAMASIO H, 1983, ARCH NEUROL-CHICAGO, V40, P715, DOI 10.1001/archneur.1983.04050110033004; DELEON MJ, 1983, DEMENTIAS, P103; EARNEST MP, 1979, NEUROLOGY, V29, P1138, DOI 10.1212/WNL.29.8.1138; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; HUCKMAN MS, 1975, NEURORADIOLOGY, V166, P85; JACOBY RJ, 1980, BRIT J PSYCHIAT, V136, P249, DOI 10.1192/bjp.136.3.249; Jennett B, 1981, MANAGEMENT HEAD INJU; JERNIGAN TL, 1979, RADIOLOGY, V132, P463, DOI 10.1148/132.2.463; KASZNIAK AW, 1979, NEUROLOGY, V29, P1273, DOI 10.1212/WNL.29.9_Part_1.1273; KERTESZ A, 1983, LOCALIZATION NEUROPS; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOHLMEYER K, 1981, NEURORADIOLOGY, V20, P271; LAST RJ, 1953, BRIT J SURG, V40, P525, DOI 10.1002/bjs.18004016403; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LITTMAN EB, 1984, 12TH ANN M INT NEUR; MEESE W, 1980, NEURORADIOLOGY, V19, P131, DOI 10.1007/BF00342387; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; ROBERTS MA, 1976, J NEUROL NEUROSUR PS, V39, P986, DOI 10.1136/jnnp.39.10.986; Rosenzweig M. R., 1982, PHYSL PSYCHOL; Russell E. W., 1970, ASSESSMENT BRAIN DAM; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; TURKHEIMER E, 1984, J NEUROL NEUROSUR PS, V47, P1314, DOI 10.1136/jnnp.47.12.1314; TURKHEIMER E, 1983, BEHAV RES METH INSTR, V15, P471, DOI 10.3758/BF03203689; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WU S, 1981, NEUROLOGY, V31, P1180, DOI 10.1212/WNL.31.9.1180; YEO RA, 1984, INT J NEUROSCI, V24, P299, DOI 10.3109/00207458409089821; YEO RA, 1983, CLIN NEUROPSYCHOLOGY, V5, P45	45	61	61	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1986	8	4					437	452		10.1080/01688638608401333			16	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	D6021	WOS:A1986D602100010	3745416				2022-02-06	
J	LEVIN, HS; HIGH, WM; EISENBERG, HM				LEVIN, HS; HIGH, WM; EISENBERG, HM			IMPAIRMENT OF OLFACTORY RECOGNITION AFTER CLOSED HEAD-INJURY	BRAIN			English	Article											LEVIN, HS (corresponding author), UNIV TEXAS, MED BRANCH, DIV NEUROSURG E-17, GALVESTON, TX 77550 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889, NS 07377] Funding Source: Medline		ABRAHAM A, 1983, NEUROPSYCHOLOGIA, V21, P277, DOI 10.1016/0028-3932(83)90045-3; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; [Anonymous], 1942, Proc R Soc Med, V35, P601; Benton A., 1978, MULTILINGUAL APHASIA; Brodal A., 1981, NEUROLOGICAL ANATOMY; Cain W S, 1979, Neurol Res, V1, P1; CAIN WS, 1979, SCIENCE, V203, P467, DOI 10.1126/science.760202; EICHENBAUM H, 1983, BRAIN, V106, P459, DOI 10.1093/brain/106.2.459; ESKENAZI B, 1983, NEUROPSYCHOLOGIA, V21, P365, DOI 10.1016/0028-3932(83)90023-4; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JONES BP, 1978, NEUROPSYCHOLOGIA, V16, P323, DOI 10.1016/0028-3932(78)90026-X; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; PINCHING AJ, 1977, BRAIN, V100, P377, DOI 10.1093/brain/100.2.377; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; RAUSCH R, 1977, CORTEX, V13, P445, DOI 10.1016/S0010-9452(77)80024-5; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1960, INJURIES BRAIN SPINA, P118; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SUMNER D, 1962, LANCET, V2, P895; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284, DOI 10.1152/jn.1975.38.5.1284; TEASDALE G, 1974, LANCET, V2, P81; VENSTROM D, 1968, J FOOD SCI, V33, P264, DOI 10.1111/j.1365-2621.1968.tb01364.x	28	61	62	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain		1985	108	SEP					579	591		10.1093/brain/108.3.579			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AQV77	WOS:A1985AQV7700002	4041775				2022-02-06	
J	GRIFFITHS, MV				GRIFFITHS, MV			INCIDENCE OF AUDITORY AND VESTIBULAR CONCUSSION FOLLOWING MINOR HEAD-INJURY	JOURNAL OF LARYNGOLOGY AND OTOLOGY			English	Article																	BARBER H O, 1964, Laryngoscope, V74, P891; BARR JB, 1964, LANCET, V2, P519; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HOUGH JVD, 1969, ANN OTO RHINOL LARYN, V78, P210, DOI 10.1177/000348946907800202; JENNETT B, 1975, BRIT MED J, V3, P267, DOI 10.1136/bmj.3.5978.267; KERR TA, 1971, BRIT J PREV SOC MED, V25, P179; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LEWIN W, 1970, P ROY SOC MED, V63, P8; MAWSON SR, 1967, DISEASES EAR, P431; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MORRISON AW, 1975, MANAGEMENT SENSORI N, P210; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109	14	61	64	1	1	HEADLEY BROTHERS LTD	ASHFORD	INVICTA PRESS, ASHFORD, KENT, ENGLAND TN24 8HH	0022-2151			J LARYNGOL OTOL	J. Laryngol. Otol.		1979	93	3					253	265		10.1017/S0022215100086990			13	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Otorhinolaryngology	GM951	WOS:A1979GM95100003	429902				2022-02-06	
J	GROAT, RA; WINDLE, WF; MAGOUN, HW				GROAT, RA; WINDLE, WF; MAGOUN, HW			FUNCTIONAL AND STRUCTURAL CHANGES IN THE MONKEYS BRAIN DURING AND AFTER CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article																	Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Groat RA, 1944, AM J PHYSIOL, V141, P0117, DOI 10.1152/ajplegacy.1944.141.1.117; JAKOB A, 1913, HISTOLOGISCHE HISTOP, V5, P182; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; SHELDEN CH, 1944, 70TH PROGR AM NEUR A, P40; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	7	61	61	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1945	2	1					26	35		10.3171/jns.1945.2.1.0026			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UN052	WOS:A1945UN05200004					2022-02-06	
J	Thelin, E; Al Nimer, F; Frostell, A; Zetterberg, H; Blennow, K; Nystrom, H; Svensson, M; Bellander, BM; Piehl, F; Nelson, DW				Thelin, Eric; Al Nimer, Faiez; Frostell, Arvid; Zetterberg, Henrik; Blennow, Kaj; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael; Piehl, Fredrik; Nelson, David W.			A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional outcome; injury severity assessment; neuroradiology; protein biomarkers; serum analysis; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; NEURON-SPECIFIC ENOLASE; NEUROFILAMENT LIGHT PROTEIN; S-100B PROTEIN; PROGNOSTIC ANALYSIS; PLASMA-LEVELS; TAU PROTEINS; S100B; BLOOD	Brain-enriched protein biomarkers of tissue fate are being introduced clinically to aid in traumatic brain injury (TBI) management. The aim of this study was to determine how concentrations of six different protein biomarkers, measured in samples collected during the first weeks after TBI, relate to injury severity and outcome. We included neurocritical care TBI patients that were prospectively enrolled from 2007 to 2013, all having one to three blood samples drawn during the first 2 weeks. The biomarkers analyzed were S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), tau, and neurofilament-light (NF-L). Glasgow Outcome Score (GOS) was assessed at 12 months. In total, 172 patients were included. All serum markers were associated with injury severity as classified on computed tomography scans at admission. Almost all biomarkers outperformed other known outcome predictors with higher levels the first 5 days, correlating with unfavorable outcomes, and UCH-L1 (0.260, pseduo-R-2) displaying the best discrimination in univariate analyses. After adjusting for acknowledged TBI outcome predictors, GFAP and NF-L added most independent information to predict favorable/unfavorable GOS, improving the model from 0.38 to 0.51 pseudo-R-2. A correlation matrix indicated substantial covariance, with the strongest correlation between UCH-L1, GFAP, and tau (r = 0.827-0.880). Additionally, the principal component analysis exhibited clustering of UCH-L1 and tau, as well as GFAP, S100B, and NSE, which was separate from NF-L. In summary, a panel of several different protein biomarkers, all associated with injury severity, with different cellular origin and temporal trajectories, improve outcome prediction models.	[Thelin, Eric; Al Nimer, Faiez; Frostell, Arvid; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael; Piehl, Fredrik] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Thelin, Eric; Al Nimer, Faiez; Piehl, Fredrik] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden; [Thelin, Eric] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Nystrom, Harriet] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Nelson, David W.] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden		Thelin, E (corresponding author), Karolinska Univ Sjukhuset Solna, BioClin J5 20, Tema Neuro, Forskargrp Svensson, S-17176 Stockholm, Sweden.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012; Svensson, Mikael/F-8662-2012; Nimer, Faiez Al/ABB-9465-2020; Frostell, Arvid/ABG-5167-2021	Thelin, Eric Peter/0000-0002-2338-4364; Svensson, Mikael/0000-0003-1179-7003; Al Nimer, Faiez/0000-0003-0937-5995; Nelson, David/0000-0003-2530-8207			Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Blennow K, 2018, J INTERN MED, V284, P643, DOI 10.1111/joim.12816; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Dadas A, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0045-y; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Korfias S, 2006, BRAIN INJURY, V20, P867, DOI 10.1080/02699050600832395; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Lumpkins KM, 2008, J TRAUMA, V65, P782; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pandey S, 2017, BRIT J NEUROSURG, V31, P356, DOI 10.1080/02688697.2017.1297378; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; R Core Team, 2008, R LANG ENV STAT COMP; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rodriguez-Rodriguez A, 2016, NEUROL RES, V38, P130, DOI 10.1080/01616412.2016.1144410; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sjostedt E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130028; Soderstrom CA, 1997, J TRAUMA, V43, P925; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002368; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; Thelin EP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1450-y; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	85	60	62	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2019	36	20					2850	2862		10.1089/neu.2019.6375		JUN 2019	13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	JC0JD	WOS:000472064000001	31072225	Green Published, hybrid, Green Submitted			2022-02-06	
J	Tao, L; Li, D; Liu, HX; Jiang, F; Xu, YT; Cao, Y; Gao, R; Chen, G				Tao, Li; Li, Di; Liu, Huixiang; Jiang, Feng; Xu, Yitian; Cao, Ying; Gao, Rong; Chen, Gang			Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-kappa B and MAPK signaling pathway	BRAIN RESEARCH BULLETIN			English	Article						Metformin; Traumatic brain injury; Inflammation; Microglia activation	OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; POSSIBLE INVOLVEMENT; CEREBRAL-ISCHEMIA; ACTIVATION; MICROGLIA; RESPONSES; MODULATION; DISEASE; OXYGEN	Traumatic brain injury (TBI) triggers a complex sequence of inflammatory responses that contribute to secondary injury. Metformin, a first-line drug used to treat type 2 diabetes, is reported to exhibit potent anti-inflammatory activity on diseases associated with the central nervous system (CNS). The aim of this study is to investigate the potential neuroprotective effects of metformin on acute brain injury after TBI and explore the underlying mechanisms. Male Sprague-Dawley (SD) rats were divided into four groups: sham group, TBI group, TBI + saline (NS) group and TBI + metformin group. A weight-dropping model was employed to induce TBI in rats. Modified neurological severity scores (mNSS) were employed to assess the short-term neurological deficits, neuronal degeneration and apoptosis in the brain tissues were assayed with Fluoro-Jade B and TUNEL staining, immunofluorescence was designed to investigate microglial activation. The mRNA and protein expression levels of pro-inflammatory cytokines such as necrosis factor-alpha (TNF-alpha), interleukin-beta (IL-1 beta) and nterleukin-6 (IL-6) were evaluated by real-time quantitative reverse transcriptase polymerase chain reaction (QPCR) and enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was engaged to examine the expression of NF-kappa B p65 and phosphorylation of ERK1/2 and p38 MAPK. Our results showed that metformin significantly ameliorated neurological deficit, cerebral edema and neuronal apoptosis in rats following TBI. Moreover, metformin administration inhibited microglial activation and decreased the production of pro-inflammatory cytokines including TNF-alpha, IL-beta and IL-6. In addition, metformin inhibited the translocation of NF-kappa B p65 from cytoplasm into the nucleus, as well as the phosphorylation of ERK1/2 and p38 MAPK. This study suggests that metformin administration inhibits microglia activation-mediated inflammation via NF-kappa B and MAPK signaling pathway to improve neurobehavioral function following TBI, which provide a potential therapeutic benefit in treating brain injury.	[Tao, Li; Cao, Ying] Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Pharm, Suzhou, Peoples R China; [Tao, Li; Li, Di] Soochow Univ, Peoples Hosp Zhangjiagang 1, Translat Med Ctr, Suzhou, Peoples R China; [Li, Di; Liu, Huixiang; Jiang, Feng; Gao, Rong] Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Neurosurg, Suzhou, Peoples R China; [Xu, Yitian] Nanjing Med Univ, Sch Basic Med Sci, Nanjing 211166, Jiangsu, Peoples R China; [Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China		Cao, Y (corresponding author), Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Pharm, Suzhou, Peoples R China.; Gao, R (corresponding author), Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Neurosurg, Suzhou, Peoples R China.	caoyaoshi@126.com; lidi715@163.com	Xu, Yitian/AAH-9794-2019				Abd-Elsameea AA, 2014, EUR REV MED PHARMACO, V18, P2387; Asghari A, 2016, J PEDIATR UROL, V12, DOI 10.1016/j.jpurol.2016.06.017; Asghari A, 2016, ACTA CIR BRAS, V31, P411, DOI 10.1590/S0102-865020160060000008; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cahova M, 2015, AM J PHYSIOL-GASTR L, V309, pG100, DOI 10.1152/ajpgi.00329.2014; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3]; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Furuyashiki T, 2012, J PHARMACOL SCI, V120, P63, DOI 10.1254/jphs.12R09CP; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Harada S, 2010, BRAIN RES, V1351, P254, DOI 10.1016/j.brainres.2010.06.052; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jiang T, 2014, BRIT J PHARMACOL, V171, P3146, DOI 10.1111/bph.12655; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Qi BX, 2017, NEUROCHEM RES, V42, P2912, DOI 10.1007/s11064-017-2322-9; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Schulte Joann M, 2014, N Engl J Med, V370, pe2, DOI 10.1056/NEJMclde1314028; Selvin E, 2008, ATHEROSCLEROSIS, V201, P425, DOI 10.1016/j.atherosclerosis.2008.02.002; Soraya H, 2012, PHARMACOL REP, V64, P1476, DOI 10.1016/S1734-1140(12)70945-3; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun XB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-157; Tao L, 2014, J PHARMACOL SCI, V125, P364, DOI 10.1254/jphs.14025FP; Wang Z, 2015, PROCEEDINGS OF THE 2014 INTERNATIONAL CONFERENCE ON MATERIALS SCIENCE AND ENERGY ENGINEERING (CMSEE 2014), P53; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu XC, 2015, MOL NEUROBIOL, V52, P375, DOI 10.1007/s12035-014-8866-7	41	60	65	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JUN	2018	140						154	161		10.1016/j.brainresbull.2018.04.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GO0ZR	WOS:000439675700020	29698747				2022-02-06	
J	Page, D; Ablordeppey, E; Wessman, BT; Mohr, NM; Trzeciak, S; Kollef, MH; Roberts, BW; Fuller, BM				Page, David; Ablordeppey, Enyo; Wessman, Brian T.; Mohr, Nicholas M.; Trzeciak, Stephen; Kollef, Marin H.; Roberts, Brian W.; Fuller, Brian M.			Emergency department hyperoxia is associated with increased mortality in mechanically ventilated patients: a cohort study	CRITICAL CARE			English	Article						Hyperoxia; Mechanical ventilation; Emergency department	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; ARTERIAL HYPEROXIA; OXYGEN-THERAPY; CARDIAC-ARREST; OBSERVATIONAL COHORT; MULTICENTER COHORT; LUNG INJURY; TRIAL; RESUSCITATION	Background: Providing supplemental oxygen is fundamental in the management of mechanically ventilated patients. Increasing amounts of data show worse clinical outcomes associated with hyperoxia. However, these previous data in the critically ill have not focused on outcomes associated with brief hyperoxia exposure immediately after endotracheal intubation. Therefore, the objectives of this study were to evaluate the impact of isolated early hyperoxia exposure in the emergency department (ED) on clinical outcomes among mechanically ventilated patients with subsequent normoxia in the intensive care unit (ICU). Methods: This was an observational cohort study conducted in the ED and ICUs of an academic center in the USA. Mechanically ventilated normoxic (partial pressure of arterial oxygen (PaO2) 60-120 mm Hg) ICU patients with mechanical ventilation initiated in the ED were studied. The cohort was categorized into three oxygen exposure groups based on PaO2 values obtained after ED intubation: hypoxia, normoxia, and hyperoxia (defined as PaO2 < 60 mmHg, PaO2 60-120 mm Hg, and PaO2 > 120 mm Hg, respectively, based on previous literature). Results: A total of 688 patients were included. ED normoxia occurred in 350 (50.9%) patients, and 300 (43.6%) had exposure to ED hyperoxia. The ED hyperoxia group had a median (IQR) ED PaO2 of 189 mm Hg (146-249), compared toan ED PaO2 of 88 mm Hg (76-101) in the normoxia group, P < 0.001. Patients with ED hyperoxia had greater hospitalmortality (29.7%), when compared to those with normoxia (19.4%) and hypoxia (13.2%). After multivariable logistic regression analysis, ED hyperoxia was an independent predictor of hospital mortality (adjusted OR 1.95 (1.34-2.85)). Conclusions: ED exposure to hyperoxia is common and associated with increased mortality in mechanically ventilated patients achieving normoxia after admission. This suggests that hyperoxia in the immediate post-intubation period could be particularly injurious, and targeting normoxia from initiation of mechanical ventilation may improve outcome.	[Ablordeppey, Enyo; Wessman, Brian T.; Fuller, Brian M.] Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63110 USA; [Ablordeppey, Enyo; Wessman, Brian T.; Fuller, Brian M.] Washington Univ, Sch Med St Louis, Div Crit Care Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Page, David; Kollef, Marin H.] Washington Univ, Dept Med, Sch Med St Louis, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Mohr, Nicholas M.] Univ Iowa, Dept Emergency Med, Roy J & Lucille A Carver Coll Med, 200 Hawkins Dr,1008 RCP, Iowa City, IA 52242 USA; [Mohr, Nicholas M.] Univ Iowa, Dept Anesthesiol, Roy J & Lucille A Carver Coll Med, Div Crit Care Med, 200 Hawkins Dr,1008 RCP, Iowa City, IA 52242 USA; [Trzeciak, Stephen] Cooper Univ Hosp, Div Crit Care Med, Dept Med, One Cooper Plaza,K152, Camden, NJ 08103 USA; [Trzeciak, Stephen; Roberts, Brian W.] Cooper Univ Hosp, Dept Emergency Med, One Cooper Plaza,K152, Camden, NJ 08103 USA		Fuller, BM (corresponding author), Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63110 USA.; Fuller, BM (corresponding author), Washington Univ, Sch Med St Louis, Div Crit Care Med, Dept Anesthesiol, St Louis, MO 63110 USA.	fullerb@wustl.edu	Wessman, Brian/ABF-3081-2020; Mohr, Nicholas/N-1112-2017	Wessman, Brian/0000-0002-8020-2678; Mohr, Nicholas/0000-0003-0497-5828; Ablordeppey, Enyo/0000-0003-4351-6720	KL2 Career Development Award; Washington University Institute of Clinical and Translational Sciences from National Center for Advancing Translational Sciences (NCATS) [UL1 TR000448, KL2 TR000450]; Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Washington University School of Medicine Faculty Scholars grant; Foundation for Barnes-Jewish Hospital; Barnes-Jewish Hospital Foundation; National Institutes of Health/National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL126979]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002345, KL2TR002346, UL1TR000448, KL2TR000450] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL126979] Funding Source: NIH RePORTER	BMF was funded by the KL2 Career Development Award, and this research was supported by the Washington University Institute of Clinical and Translational Sciences (Grants UL1 TR000448 and KL2 TR000450) from the National Center for Advancing Translational Sciences (NCATS). NMM was supported by grant funds from the Health Resources and Services Administration. EA was supported by the Washington University School of Medicine Faculty Scholars grant and the Foundation for Barnes-Jewish Hospital. MHK was supported by the Barnes-Jewish Hospital Foundation. BWR was supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL126979). Funders played no role in the design and conduct of the study, nor in the collection, management, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.	Andrade PV, 2014, INFLAMMATION, V37, P486, DOI 10.1007/s10753-013-9762-4; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Cavassani SS, 2011, ACTA CIR BRAS, V26, P107, DOI 10.1590/S0102-86502011000200006; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; Damiani E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0711-x; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Fuller BM, 2017, ANN EMERG MED, V70, P406, DOI 10.1016/j.annemergmed.2017.01.013; Fuller BM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010991; Fuller BM, 2015, CHEST, V148, P365, DOI 10.1378/chest.14-2476; Fuller BM, 2013, ACAD EMERG MED, V20, P659, DOI 10.1111/acem.12167; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Helmerhorst HJF, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0142-5; Helmerhorst HJF, 2017, CRIT CARE MED, V45, P187, DOI 10.1097/CCM.0000000000002084; Helmerhorst HJF, 2015, CRIT CARE MED, V43, P1508, DOI 10.1097/CCM.0000000000000998; Helmerhorst HJF, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0023-y; Iscoe S, 2005, CHEST, V128, P430, DOI 10.1378/chest.128.1.430; Janz DR, 2012, CRIT CARE MED, V40, P3135, DOI 10.1097/CCM.0b013e3182656976; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc5704; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Panwar R, 2013, ANAESTH INTENS CARE, V41, P505, DOI 10.1177/0310057X1304100412; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Rose L, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-30; Stolmeijer R, 2014, EUR J EMERG MED, V21, P233, DOI 10.1097/MEJ.0b013e328361c6c7; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010	33	60	64	1	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	JAN 18	2018	22								9	10.1186/s13054-017-1926-4			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS9JL	WOS:000422734100002	29347982	gold, Green Published			2022-02-06	
J	del-Pino-Casado, R; Frias-Osuna, A; Palomino-Moral, PA; Ruzafa-Martinez, M; Ramos-Morcillo, AJ				del-Pino-Casado, Rafael; Frias-Osuna, Antonio; Palomino-Moral, Pedro A.; Ruzafa-Martinez, Maria; Ramos-Morcillo, Antonio J.			Social support and subjective burden in caregivers of adults and older adults: A meta-analysis	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; PUBLICATION BIAS; ALZHEIMERS-DISEASE; PERCEIVED BURDEN; MENTAL-HEALTH; NURSING-HOME; DEMENTIA	Background & para;& para;Despite the generally accepted belief that social support improves caregiver adjustment in general and subjective burden in particular, the literature shows mixed findings, and a recent review concluded that the predictive strength of caregiver social support in determining caregiver burden is less evident, due to the conceptual diversity of this determinant.& para;& para;Objective & para;& para;The purpose of this review is to analyse the relationship of perceived and received social support with subjective burden among informal caregivers of an adult or older adult.& para;& para;Methods & para;& para;A systematic search was carried out up to September 2017 in the following databases: MEDLINE (PubMed), CINAHL, EMBASE, PsycINFO), Scopus and ISI Proceedings, and a meta-analysis was performed with the results of the selected and included studies.& para;& para;Results & para;& para;Fifty-six studies were included in the meta-analysis, which provided 46 independent comparisons for perceived support and 16 for received support. Most of these studies were cross-sectional. There was a moderate, negative association of perceived social support on subjective burden (r =-0.36; CI 95%=-0.40,-0.32) and a very small, negative association of received support on subjective burden (r =-0.05; CI 95%=-0.095,-0.001). & para;& para;Conclusions & para;& para;1) perceived and received support are not redundant constructs, 2) the relationships between social support and subjective burden depend on whether the social support is measured as perceived or received, 3) the relationship of perceived social support with subjective burden has a bigger effect size than that of received social support, the relation between received support and subjective burden being clinically irrelevant, 4) perceived social support may be a good predictor of subjective burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.	[del-Pino-Casado, Rafael; Frias-Osuna, Antonio; Palomino-Moral, Pedro A.] Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain; [Ruzafa-Martinez, Maria; Ramos-Morcillo, Antonio J.] Univ Murcia, Fac Nursing, Dept Nursing, Murcia, Spain		del-Pino-Casado, R (corresponding author), Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain.	rdelpino@ujaen.es	del-Pino-Casado, Rafael/L-3733-2018; Ruzafa-Martinez, Maria/AAB-5248-2019; Ramos-Morcillo, Antonio Jesus/J-2195-2016	del-Pino-Casado, Rafael/0000-0003-2263-2415; Ruzafa-Martinez, Maria/0000-0001-6570-738X; Ramos-Morcillo, Antonio Jesus/0000-0002-3490-3326			Adriaansen JJE, 2011, PATIENT EDUC COUNS, V85, pE48, DOI 10.1016/j.pec.2010.12.011; Alonso SL., 2005, ENFERM COMUNITARIA, V1, P12; Alvarez-Ude F, 2004, J NEPHROL, V17, P841; Aneshensel C. S., 1995, PROFILES CAREGIVING; Annisa F, 2015, THAI PHARM HLTH SCI, V10, P87; Artaso B., 2003, Revista Espanola de Geriatria y Gerontologia, V38, P212; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bainbridge D, 2009, AGING MENT HEALTH, V13, P537, DOI 10.1080/13607860802607322; Barrera M, 1983, CONNECTIONS, V3, P8; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Blake H, 2000, CLIN REHABIL, V14, P307, DOI 10.1191/026921500667530134; Boyle M.H., 1998, EVID-BASED MENT HEAL, V1, P37, DOI DOI 10.1136/EBMH.1.2.37; Burton Allison M, 2008, Palliat Support Care, V6, P149, DOI 10.1017/S1478951508000230; Carretero S, 2009, ARCH GERONTOL GERIAT, V49, P74, DOI 10.1016/j.archger.2008.05.004; Cassidy T, 2013, PSYCHOL HEALTH, V28, P250, DOI 10.1080/08870446.2012.717623; Chang BL, 2001, WOMEN HEALTH, V33, P39, DOI 10.1300/J013v33n01_04; Cheng ST, 2013, GERONTOLOGIST, V53, P998, DOI 10.1093/geront/gns195; Chiou CJ, 2009, ARCH GERONTOL GERIAT, V48, P419, DOI 10.1016/j.archger.2008.04.001; CLAIR JM, 1995, SOCIOL PERSPECT, V38, P195, DOI 10.2307/1389290; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676; Cooper C, 2007, INT PSYCHOGERIATR, V19, P175, DOI 10.1017/S1041610206004297; COOPER H. M., 2009, HDB RES SYNTHESIS ME, V2nd; Vérez Cotelo Natalia, 2015, Pharmacy Pract (Granada), V13, DOI 10.18549/PharmPract.2015.02.521; Dam AEH, 2016, MATURITAS, V85, P117, DOI 10.1016/j.maturitas.2015.12.008; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; del-Pino-Casado R, 2014, J NURS SCHOLARSHIP, V46, P176, DOI 10.1111/jnu.12070; del-Pino-Casado R, 2011, J ADV NURS, V67, P2311, DOI 10.1111/j.1365-2648.2011.05725.x; Dorfman LT, 1996, FAM RELAT, V45, P46, DOI 10.2307/584769; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edwards Nancy E, 2002, J Neurosci Nurs, V34, P184; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elvish R, 2013, PSYCHOL INTERVENTION; FOLKMAN S, 1994, J CONSULT CLIN PSYCH, V62, P746, DOI 10.1037/0022-006X.62.4.746; Folkman S., 1984, STRESS; Gallart A, 2013, J ADV NURS, V69, P642, DOI 10.1111/j.1365-2648.2012.06049.x; Gold DP, 1995, INT J AGING HUM DEV, V41, P183, DOI 10.2190/RGYJ-5KA2-7THX-7BQ5; Goldsworthy B, 2008, J GERONTOL B-PSYCHOL, V63, pP372, DOI 10.1093/geronb/63.6.P372; Goris S, 2016, HOLIST NURS PRACT, V30, P227, DOI 10.1097/HNP.0000000000000153; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; Greenberger H, 2003, J ADV NURS, V41, P332, DOI 10.1046/j.1365-2648.2003.02531.x; Greene MC, 2013, AIDS BEHAV, V17, P1775, DOI 10.1007/s10461-012-0396-6; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Kahriman Fatma, 2015, Asian Pac J Cancer Prev, V16, P3313; Kaur N, 2014, DELHI PSYCHIAT J, V17, P337; Kim H, 2012, J ADV NURS, V68, P846, DOI 10.1111/j.1365-2648.2011.05787.x; Kruithof WJ, 2016, PATIENT EDUC COUNS, V99, P1632, DOI 10.1016/j.pec.2016.04.007; LECHNER VM, 1993, SOC WORK, V38, P461; Leibach G, 2013, EXAMINING RELATIONS; Liu Y, 2012, NURS RES, V61, P39, DOI 10.1097/NNR.0b013e31823bc451; Losada A, 2010, AGING MENT HEALTH, V14, P193, DOI 10.1080/13607860903167838; Losada A, 2010, ARCH GERONTOL GERIAT, V50, P347, DOI 10.1016/j.archger.2009.06.001; Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503; Majerovitz SD, 2007, AGING MENT HEALTH, V11, P323, DOI 10.1080/13607860600963380; Manso Martínez Mª Esperanza, 2013, Clínica y Salud, V24, P37, DOI 10.5093/cl2013a5; Marwit SJ, 2002, GERONTOLOGIST, V42, P751, DOI 10.1093/geront/42.6.751; Meader N, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-82; Meiland FJM, 2001, SCAND J PUBLIC HEALT, V29, P113, DOI 10.1177/14034948010290020801; Melrose KL, 2015, PERS INDIV DIFFER, V77, P97, DOI 10.1016/j.paid.2014.12.047; Moller-Leimkuhler AM, 2012, EUR ARCH PSY CLIN N, V262, P157, DOI 10.1007/s00406-011-0215-5; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Molina Linde JM, 2005, PSICOLOGIA SALUD, V15, P33; Moral Serrano M S, 2003, Aten Primaria, V32, P77, DOI 10.1157/13049173; Bermejo LM, 2015, REV ROL ENFERM, V38, P852; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Prati G, 2010, J COMMUNITY PSYCHOL, V38, P403, DOI 10.1002/jcop.20371; REIS MF, 1994, INT J AGING HUM DEV, V39, P257, DOI 10.2190/6LYN-YFWQ-P87D-MKWX; Riemsma RP, 1999, PSYCHOL HEALTH, V14, P773, DOI 10.1080/08870449908407347; Rodakowski J, 2012, ARCH PHYS MED REHAB, V93, P2229, DOI 10.1016/j.apmr.2012.07.004; Roe B, 2007, REVIEWING RESEARCH EVIDENCE FOR NURSING PRACTICE: SYSTEMATIC REVIEWS, P9, DOI 10.1002/9780470692127.ch2; Rothman K.J., 2008, Modern epidemiology, V3rd; Ryan KA, 2012, DEMENT GERIATR COGN, V34, P206, DOI 10.1159/000339955; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Schoenmakers B, 2010, MATURITAS, V66, P191, DOI 10.1016/j.maturitas.2010.02.009; Shieh SC, 2012, J NURS SCHOLARSHIP, V44, P223, DOI 10.1111/j.1547-5069.2012.01453.x; Smerglia VL, 2007, AGING MENT HEALTH, V11, P205, DOI 10.1080/13607860600844515; Son Gwi-Ryung, 2003, J Gerontol Nurs, V29, P19; Spaid W.M, 1994, J GERONTOL SOC WORK, V21, P197, DOI 10.1300/J083V21N03_13; Stevens LF, 2013, AM J PHYS MED REHABI; STOMMEL M, 1990, J AGING HEALTH, V2, P81, DOI DOI 10.1177/089826439000200106; Tang Y, 2006, OBLIGATION FILIAL PI; Teixeira RJ, 2013, PSYCHO-ONCOLOGY, V22, P1587, DOI 10.1002/pon.3173; THOMPSON EH, 1993, J GERONTOL, V48, pS245, DOI 10.1093/geronj/48.5.S245; Uchino BN, 2012, SOC SCI MED, V74, P949, DOI 10.1016/j.socscimed.2011.11.023; van der Lee J, 2014, AGEING RES REV, V15, P76, DOI 10.1016/j.arr.2014.03.003; Verbakel E, 2016, CAREGIVING OLDER ADU; Viswanathan M., 2013, AHRQ METHODS EFFECTI; Vrabec N J, 1997, Image J Nurs Sch, V29, P383, DOI 10.1111/j.1547-5069.1997.tb01062.x; Wang Hsiu-Hung, 2003, Kaohsiung Journal of Medical Sciences, V19, P345, DOI 10.1016/S1607-551X(09)70436-X; Wang Li-Chieh, 2011, Hu Li Za Zhi, V58, P54; Wittenberg-Lyles E, 2014, HEALTH COMMUN, V29, P901, DOI 10.1080/10410236.2013.815111; Yuksel MM, 2013, WELL BEING SIBLINGS; Yurtsever S, 2013, J NURS EDUC, V3, P1, DOI [10.5430/jnep.v3n9p1, DOI 10.5430/JNEP.V3N9P1]; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; Zegwaard MI, 2011, J CLIN NURS, V20, P2233, DOI 10.1111/j.1365-2702.2010.03524.x	101	60	61	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0189874	10.1371/journal.pone.0189874			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FR5JA	WOS:000419101600038	29293522	Green Submitted, gold, Green Published			2022-02-06	
J	Chang, CF; Wan, JR; Li, Q; Renfroe, SC; Heller, NM; Wang, J				Chang, Che-Feng; Wan, Jieru; Li, Qiang; Renfroe, Stephen C.; Heller, Nicola M.; Wang, Jian			Alternative activation-skewed microglia/macrophages promote hematoma resolution in experimental intracerebral hemorrhage	NEUROBIOLOGY OF DISEASE			English	Article						Intracerebral hemorrhage; Hematoma resolution; Microglia/macrophage polarization; Phagocytosis; Interleukin-10	GAMMA AGONIST ROSIGLITAZONE; HIPPOCAMPAL SLICE CULTURES; TRAUMATIC BRAIN-INJURY; TUFTSIN FRAGMENT 1-3; RECEPTOR-GAMMA; PPAR-GAMMA; MACROPHAGE ACTIVATION; HEME OXYGENASE-1; SPINAL-CORD; NEUROLOGICAL DEFICITS	Microglia/macrophages (MM Phi) are highly plastic phagocytes that can promote both injury and repair in diseased brain through the distinct function of classically activated and alternatively activated subsets. The role of MM Phi polarization in intracerebral hemorrhage (ICH) is unknown. Herein, we comprehensively characterized MM Phi dynamics after ICH in mice and evaluated the relevance of MM Phi polarity to hematoma resolution. MM Phi accumulated within the hematoma territory until at least 14 days after ICH induction. Microglia rapidly reacted to the hemorrhagic insult as early as 1-1.5 h after ICH and specifically presented a "protective" alternatively activated phenotype. Substantial numbers of activated microglia and newly recruited monocytes also assumed an early alternatively activated phenotype, but the phenotype gradually shifted to a mixed spectrum over time. Ultimately, markers of MM Phi classic activation dominated at the chronic stage of ICH. We enhanced MM Phi alternative activation by administering intraperitoneal injections of rosiglitazone, and subsequently observed elevations in CD206 expression on brain-isolated CD11b(+) cells and increases in IL-10 levels in serum and perihematomal tissue. Enhancement of MM Phi alternative activation correlated with hematoma volume reduction and improvement in neurologic deficits. Intraventricular injection of alternative activation signature cytokine IL-10 accelerated hematoma resolution, whereas microglial phagocytic ability was abolished by IL-10 receptor neutralization. Our results suggest that MM Phi respond dynamically to brain hemorrhage by exhibiting diverse phenotypic changes at different stages of ICH. Alternative activation-skewed MM Phi aid in hematoma resolution, and IL-10 signaling might contribute to regulation of MM Phi phagocytosis and hematoma clearance in ICH. (C) 2017 Elsevier Inc. All rights reserved.	[Chang, Che-Feng; Wan, Jieru; Li, Qiang; Heller, Nicola M.; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 367, Baltimore, MD 21205 USA; [Heller, Nicola M.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA; [Chang, Che-Feng; Renfroe, Stephen C.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06511 USA		Heller, NM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 367, Baltimore, MD 21205 USA.	nheller@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Heller, Nicola/0000-0001-7247-2021; Chang, Che-Feng/0000-0002-3211-1739	AHAAmerican Heart Association [13GRNT15730001, R01NS078026, R01AT007317]; MOST/raiwan Grant [105-2917-1-564-082];  [R01 HL124477]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL124477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This work was supported by AHA 13GRNT15730001, R01NS078026, and R01AT007317 OW). NMH was supported by R01 HL124477. CFC was supported by MOST/raiwan Grant 105-2917-1-564-082. We thank Claire Levine, MS, ELS, for editing the manuscript and Dr. Raymond Koehler for insightful input. We thank Dr. Lauren H Sansing for providing laboratory resources for the revision experiments.	Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Allahtavakoli M, 2006, CLIN EXP PHARMACOL P, V33, P1052, DOI 10.1111/j.1440-1681.2006.04486.x; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Avdic S, 2013, J VIROL, V87, P10273, DOI 10.1128/JVI.00912-13; Ballesteros I, 2014, J LEUKOCYTE BIOL, V95, P587, DOI 10.1189/jlb.0613326; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Chang CF, 2015, TRANSL STROKE RES, V6, P384, DOI 10.1007/s12975-015-0399-5; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; De Simoni A, 2006, NAT PROTOC, V1, P1439, DOI 10.1038/nprot.2006.228; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Egashira Y, 2015, BRAIN RES, V1623, P97, DOI 10.1016/j.brainres.2015.04.003; Fang H, 2014, J IMMUNOL, V192, P5984, DOI 10.4049/jimmunol.1400054; Flores JJ, 2016, NEUROBIOL DIS, V87, P124, DOI 10.1016/j.nbd.2015.12.015; Foerch C, 2008, STROKE, V39, P3397, DOI 10.1161/STROKEAHA.108.517482; Garcia J.A., 2014, CURR PROTOC IMMUNOL, V104; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Gogolla N, 2006, NAT PROTOC, V1, P1165, DOI 10.1038/nprot.2006.168; Gonzales NR, 2013, INT J STROKE, V8, P388, DOI 10.1111/j.1747-4949.2011.00761.x; Hammond MD, 2014, STROKE, V45, P2485, DOI 10.1161/STROKEAHA.114.005551; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Hammond MD, 2012, TRANSL STROKE RES, V3, pS125, DOI 10.1007/s12975-012-0174-9; Hasegawa-Moriyama M, 2012, BIOCHEM BIOPH RES CO, V426, P76, DOI 10.1016/j.bbrc.2012.08.039; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Katsuki H, 2010, J PHARMACOL SCI, V114, P366, DOI 10.1254/jphs.10R05CR; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kellner CP, 2010, STROKE, V41, pS99, DOI 10.1161/STROKEAHA.110.597476; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Koscso B, 2013, J LEUKOCYTE BIOL, V94, P1309, DOI 10.1189/jlb.0113043; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; LoPresti MA, 2014, J NEUROL SCI, V345, P3, DOI 10.1016/j.jns.2014.06.057; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Mietto BS, 2015, J NEUROSCI, V35, P16431, DOI 10.1523/JNEUROSCI.2119-15.2015; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801; Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Papatriantafyllou M, 2011, NAT REV IMMUNOL, V11, P158, DOI 10.1038/nri2947; Pelidou SH, 1999, EUR J NEUROL, V6, P437, DOI 10.1046/j.1468-1331.1999.640437.x; Pisanu A, 2014, NEUROBIOL DIS, V71, P280, DOI 10.1016/j.nbd.2014.08.011; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Regnier-Vigouroux A, 2003, INT REV CYTOL, V226, P321, DOI 10.1016/S0074-7696(03)01006-4; Schallner N, 2015, J CLIN INVEST, V125, P2609, DOI 10.1172/JCI78443; Shimada K, 2015, STROKE, V46, P1664, DOI 10.1161/STROKEAHA.114.007722; Shouval DS, 2014, IMMUNITY, V40, P706, DOI 10.1016/j.immuni.2014.03.011; Sonni Shruti, 2014, Curr Treat Options Cardiovasc Med, V16, P277, DOI 10.1007/s11936-013-0277-y; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Toyoda K, 2015, NEUROLOGY, V84, P444, DOI 10.1212/WNL.0000000000001221; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Wan S, 2016, TRANSL STROKE RES, V7, P478, DOI 10.1007/s12975-016-0472-8; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Wu GF, 2016, NEUROL RES, V38, P261, DOI 10.1080/01616412.2015.1105627; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2010, BRAIN RES, V1342, P111, DOI 10.1016/j.brainres.2010.04.033; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Zhang Z., 2016, MOL NEUROBIOL; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2015, J NEUROCHEM, V133, P144, DOI 10.1111/jnc.12974; Zhao XR, 2014, TRANSL STROKE RES, V5, P554, DOI 10.1007/s12975-014-0341-2; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158; Zhou K., 2016, J CEREB BLOOD FLOW M; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423; Ziai WC, 2013, STROKE, V44, pS74, DOI 10.1161/STROKEAHA.111.000662	94	60	64	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUL	2017	103						54	69		10.1016/j.nbd.2017.03.016			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EV3TY	WOS:000401683200006	28365213	Green Accepted			2022-02-06	
J	Di Virgilio, TG; Hunter, A; Wilson, L; Stewart, W; Goodall, S; Howatson, G; Donaldson, DI; Ietswaart, M				Di Virgilio, Thomas G.; Hunter, Angus; Wilson, Lindsay; Stewart, William; Goodall, Stuart; Howatson, Glyn; Donaldson, David I.; Ietswaart, Magdalena			Evidence for Acute Electrophysiological and Cognitive Changes Following Routine Soccer Heading	EBIOMEDICINE			English	Article						Sports concussion; Transcranial magnetic stimulation; Sub-concussion; Traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; MOTOR CORTEX; SPORTS CONCUSSION; POSTURAL CONTROL; LONG-TERM; INHIBITION; ABNORMALITIES	Introduction: There is growing concern around the effects of concussion and sub-concussive impacts in sport. Routine game-play in soccer involves intentional and repeated head impacts through ball heading. Although heading is frequently cited as a risk to brain health, little data exist regarding the consequences of this activity. This study aims to assess the immediate outcomes of routine football heading using direct and sensitive measures of brain function. Methods: Nineteen amateur football players (5 females; age 22 +/- 3 y) headed machine-projected soccer balls at standardized speeds, modelling routine soccer practice. The primary outcome measure of corticomotor inhibition measured using transcranial magnetic stimulation, was assessed prior to heading and repeated immediately, 24 h, 48 h and 2 weeks post-heading. Secondary outcome measures were cortical excitability, postural control, and cognitive function. Results: Immediately following heading an increase in corticomotor inhibition was detected; further to these electrophysiological alterations, measurable reduction memory function were also found. These acute changes appear transient, with values normalizing 24 h post-heading. Discussion: Sub-concussive head impacts routine in soccer heading are associated with immediate, measurable electrophysiological and cognitive impairments. Although these changes in brain function were transient, these effects may signal direct consequences of routine soccer heading on (long-term) brain health which requires further study. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Di Virgilio, Thomas G.; Hunter, Angus] Univ Stirling, Physiol Exercise & Nutr Res Grp, Stirling FK9 4LA, Scotland; [Wilson, Lindsay; Donaldson, David I.; Ietswaart, Magdalena] Univ Stirling, Psychol, Stirling FK9 4LA, Scotland; [Stewart, William] Univ Glasgow, Queen Elizabeth Univ Hosp, Glasgow & Inst Neurosci & Psychol, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland; [Goodall, Stuart; Howatson, Glyn] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Howatson, Glyn] North West Univ, Water Res Grp, Unit Environm Sci & Management, Potchefstroom, South Africa		Ietswaart, M (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	magdalena.ietswaart@stir.ac.uk	Howatson, Glyn/AAE-9508-2021; Wilson, Lindsay/A-3659-2009; Donaldson, David I/A-5249-2009; Goodall, Stuart/AAE-7871-2020; Wilson, Lindsay/O-8883-2019	Howatson, Glyn/0000-0001-8494-2043; Wilson, Lindsay/0000-0003-4113-2328; Donaldson, David I/0000-0002-8036-3455; Goodall, Stuart/0000-0001-9029-2171; Wilson, Lindsay/0000-0003-4113-2328; Stewart, William/0000-0003-2199-2582; Ietswaart, Magdalena/0000-0003-4576-9393; Hunter, Angus/0000-0001-7562-6145			Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Cantu R., 2012, CONCUSSIONS OUR KIDS; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goodall S, 2009, EXP PHYSIOL, V94, P995, DOI 10.1113/expphysiol.2009.047902; Goodall S, 2014, EUR J SPORT SCI, V14, pS332, DOI 10.1080/17461391.2012.704079; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Patlak M., 2002, SUMM IOM WORKSH NEUR; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Peugh JL, 2005, EDUC PSYCHOL MEAS, V65, P811, DOI 10.1177/0013164405278558; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; WILSON SA, 1995, ELECTROMYOGR MOTOR C, V97, P246, DOI 10.1016/0924-980X(95)80001-8	32	60	60	0	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	NOV	2016	13						66	71		10.1016/j.ebiom.2016.10.029			6	Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Research & Experimental Medicine	EG0EU	WOS:000390704800022	27789273	Green Published, Green Accepted, gold			2022-02-06	
J	Daverey, A; Agrawal, SK				Daverey, Amita; Agrawal, Sandeep K.			CURCUMIN ALLEVIATES OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION IN ASTROCYTES	NEUROSCIENCE			English	Article						oxidative stress; curcumin; astrocytes; GFAP; neurodegenerative diseases	TRAUMATIC BRAIN-INJURY; PEROXIREDOXIN 6; EXPRESSION; NEURONS; GFAP; AGE	Oxidative stress plays a critical role in various neurodegenerative diseases, thus alleviating oxidative stress is a potential strategy for therapeutic intervention and/or prevention of neurodegenerative diseases. In the present study, alleviation of oxidative stress through curcumin is investigated in A172 (human glioblastoma cell line) and HA-sp (human astrocytes cell line derived from the spinal cord) astrocytes. H2O2 was used to induce oxidative stress in astrocytes (A172 and HA-sp). Data show that H2O2 induces activation of astrocytes in dose-and time-dependent manner as evident by increased expression of GFAP in A172 and HA-sp cells after 24 and 12 h respectively. An upregulation of Prdx6 was also observed in A172 and HA-sp cells after 24 h of H2O2 treatment as compared to untreated control. Our data also showed that curcumin inhibits oxidative stress-induced cytoskeleton disarrangement, and impedes the activation of astrocytes by inhibiting upregulation of GFAP, vimentin and Prdx6. In addition, we observed an inhibition of oxidative stress-induced inflammation, apoptosis and mitochondria fragmentation after curcumin treatment. Therefore, our results suggest that curcumin not only protects astrocytes from H2O2-induced oxidative stress but also reverses the mitochondrial damage and dysfunction induced by oxidative stress. This study also provides evidence for protective role of curcumin on astrocytes by showing its effects on attenuating reactive astrogliosis and inhibiting apoptosis. Published by Elsevier Ltd on behalf of IBRO.	[Daverey, Amita; Agrawal, Sandeep K.] Univ Nebraska Med Ctr, Div Neurosurg, Dept Surg, Omaha, NE USA		Agrawal, SK (corresponding author), Univ Nebraska Med Ctr, Div Neurosurg, Dept Surg, Omaha, NE 68198 USA.	agrawals@unmc.edu	Daverey, Amita/S-1718-2019		Division of Neurosurgery	The authors would like to acknowledge James R. Talaska and Janice Taylor for providing training to use the confocal microscope available at UNMC's core facility. Authors are thankful to the Division of Neurosurgery for providing funding for this study.	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; Bachetti T, 2012, EXP CELL RES, V318, P1844, DOI 10.1016/j.yexcr.2012.06.008; Bae MK, 2006, BBA-MOL CELL RES, V1763, P282, DOI 10.1016/j.bbamcr.2006.01.005; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; Bisht K, 2010, TOXICOLOGY, V278, P88, DOI 10.1016/j.tox.2009.11.008; Buonora JE, 2015, J NEUROTRAUM, V32, P1805, DOI 10.1089/neu.2014.3736; Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098; Chen XP, 2012, NEURAL REGEN RES, V7, P376, DOI 10.3969/j.issn.1673-5374.2012.05.009; Cole GM, 2007, ADV EXP MED BIOL, V595, P197; Dinkova-Kostova AT, 2008, MOL NUTR FOOD RES, V52, pS128, DOI 10.1002/mnfr.200700195; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Gonzalez-Reyes S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/801418; Gurd BJ, 2011, APPL PHYSIOL NUTR ME, V36, P589, DOI [10.1139/h11-070, 10.1139/H11-070]; Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325; Kim SY, 2011, CELL DEATH DIFFER, V18, P1573, DOI 10.1038/cdd.2011.21; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; Kumar A, 2011, J ASIAN NAT PROD RES, V13, P42, DOI 10.1080/10286020.2010.544253; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lin MS, 2011, J SURG RES, V166, P280, DOI 10.1016/j.jss.2009.07.001; Liu L, 2014, NEUROCHEM RES, V39, P1322, DOI 10.1007/s11064-014-1315-1; Lone J, 2016, J NUTR BIOCHEM, V27, P193, DOI 10.1016/j.jnutbio.2015.09.006; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Metzler M, 2013, BIOFACTORS, V39, P14, DOI 10.1002/biof.1042; Monroy A, 2013, BIOFACTORS, V39, P122, DOI 10.1002/biof.1063; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Nishinaka T, 2007, TOXICOL LETT, V170, P238, DOI 10.1016/j.toxlet.2007.03.011; Park SJ, 2012, J IMMUNOL, V188, P5132, DOI 10.4049/jimmunol.1101600; Phatnani H., 2015, COLD SPRING HARB PER, V7; Rastogi M, 2014, BIOGERONTOLOGY, V15, P21, DOI 10.1007/s10522-013-9466-z; Raza H, 2008, TOXICOL APPL PHARM, V226, P161, DOI 10.1016/j.taap.2007.09.002; Rodriguez-Arellano JJ, 2016, NEUROSCIENCE, V323, P170, DOI 10.1016/j.neuroscience.2015.01.007; Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Seyedzadeh MH, 2014, INT IMMUNOPHARMACOL, V22, P230, DOI 10.1016/j.intimp.2014.06.035; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; Wu JX, 2015, NEURAL REGEN RES, V10, P481, DOI 10.4103/1673-5374.153700; Yang YS, 2014, PHYTOTHER RES, V28, P1770, DOI 10.1002/ptr.5197; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507	44	60	63	2	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 1	2016	333						92	103		10.1016/j.neuroscience.2016.07.012			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DU1BU	WOS:000381942000009	27423629				2022-02-06	
J	Egawa, J; Pearn, ML; Lemkuil, BP; Patel, PM; Head, BP				Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.			Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function	JOURNAL OF PHYSIOLOGY-LONDON			English	Article; Proceedings Paper	Symposium on Membrane/Lipid Rafts - Age-Associated Changes in Membrane Biology and Function	APR 10-11, 2015	Edinburgh, SCOTLAND				TRAUMATIC BRAIN-INJURY; DENSITY-LIPOPROTEIN RECEPTOR; SYNAPTIC PLASMA-MEMBRANES; LONG-TERM POTENTIATION; GROWTH CONE MOTILITY; CHOLESTEROL 24-HYDROXYLASE; ALZHEIMERS-DISEASE; KINASE-I; GM1 GANGLIOSIDE; SNARE PROTEINS	A better understanding of the cellular physiological role that plasma membrane lipids, fatty acids and sterols play in various cellular systems may yield more insight into how cellular and whole organ function is altered during the ageing process. Membrane lipid rafts (MLRs) within the plasma membrane of most cells serve as key organizers of intracellular signalling and tethering points of cytoskeletal components. MLRs are plasmalemmal microdomains enriched in sphingolipids, cholesterol and scaffolding proteins; they serve as a platform for signal transduction, cytoskeletal organization and vesicular trafficking. Within MLRs are the scaffolding and cholesterol binding proteins named caveolin (Cav). Cavs not only organize a multitude of receptors including neurotransmitter receptors (NMDA and AMPA receptors), signalling proteins that regulate the production of cAMP (G protein-coupled receptors, adenylyl cyclases, phosphodiesterases (PDEs)), and receptor tyrosine kinases involved in growth (Trk), but also interact with components that modulate actin and tubulin cytoskeletal dynamics (e.g. RhoGTPases and actin binding proteins). MLRs are essential for the regulation of the physiology of organs such as the brain, and age-related loss of cholesterol from the plasma membrane leads to loss of MLRs, decreased presynaptic vesicle fusion, and changes in neurotransmitter release, all of which contribute to different forms of neurodegeneration. Thus, MLRs provide an active membrane domain that tethers and reorganizes the cytoskeletal machinery necessary for membrane and cellular repair, and genetic interventions that restore MLRs to normal cellular levels maybe exploited as potential therapeutic means to reverse the ageing and neurodegenerative processes.	[Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.] Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Egawa, Junji; Pearn, Matthew L.; Lemkuil, Brian P.; Patel, Piyush M.; Head, Brian P.] Univ Calif San Diego, Sch Med, Dept Anesthesiol, La Jolla, CA 92093 USA		Head, BP (corresponding author), Univ Calif San Diego, Dept Anesthesiol, VASDHS 9125,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	bhead@ucsd.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS073653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073653] Funding Source: NIH RePORTER		Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2013, NEUROSCI LETT, V532, P1, DOI 10.1016/j.neulet.2012.10.019; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Aziz R, 2013, PSYCHIAT CLIN N AM, V36, P497, DOI 10.1016/j.psc.2013.08.001; BARNES CA, 1980, J PHYSIOL-LONDON, V309, P473, DOI 10.1113/jphysiol.1980.sp013521; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bassani Silvia, 2012, Bioarchitecture, V2, P95; Begley DJ, 2003, PROG DRUG RES, V61, P39; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P2209, DOI 10.1161/01.ATV.0000148704.72481.28; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 2010, J LIPID RES, V51, P2489, DOI 10.1194/jlr.R006338; Breceda EY, 2013, CURR OPIN NEUROL, V26, P595, DOI 10.1097/WCO.0000000000000024; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bulloj A, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-22; BURGER M, 1958, Z Alternsforsch, V12, P52; Calabrese F, 2013, NEUROBIOL AGING, V34, P2768, DOI 10.1016/j.neurobiolaging.2013.06.014; CARTER HE, 1947, J BIOL CHEM, V169, P77; Cecchi C, 2008, J CELL MOL MED, V12, P1990, DOI 10.1111/j.1582-4934.2008.00216.x; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Churchward MA, 2005, J CELL SCI, V118, P4833, DOI 10.1242/jcs.02601; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Cole AA, 2010, BIOCHEM J, V427, P535, DOI 10.1042/BJ20091344; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Crutcher KA, 2002, AUTON NEUROSCI-BASIC, V96, P25, DOI 10.1016/S1566-0702(01)00373-3; de Chaves EP, 2010, FEBS LETT, V584, P1748, DOI 10.1016/j.febslet.2009.12.010; Denisova NA, 2001, FREE RADICAL BIO MED, V30, P671, DOI 10.1016/S0891-5849(00)00513-X; Dent EW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a001800; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Ledesma MD, 2012, PROG LIPID RES, V51, P23, DOI 10.1016/j.plipres.2011.11.004; Egawa J, 2014, J NEUROSURG ANESTHES, V26, P478; Fantini J, 2009, BBA-BIOMEMBRANES, V1788, P2345, DOI 10.1016/j.bbamem.2009.08.016; Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Frank C, 2008, EXP NEUROL, V212, P407, DOI 10.1016/j.expneurol.2008.04.019; Frank C, 2004, FEBS LETT, V566, P25, DOI 10.1016/j.febslet.2004.03.113; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gao Y, 2003, J NEUROSCI, V23, P11770; Garg S, 2011, BIOPHYS J, V101, P370, DOI 10.1016/j.bpj.2011.06.014; Garmy N, 2005, J LIPID RES, V46, P36, DOI 10.1194/jlr.M400199-JLR200; Gil C, 2006, BIOCHEM BIOPH RES CO, V348, P1334, DOI 10.1016/j.bbrc.2006.07.201; GORIO A, 1986, CRC CR REV CL NEUROB, V2, P241; Gresack JE, 2010, BEHAV BRAIN RES, V209, P80, DOI 10.1016/j.bbr.2010.01.018; Hall A, 2010, COLD SPRING HARB PER, V2; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Head BP, 2011, J BIOL CHEM, V286, P33310, DOI 10.1074/jbc.M111.255976; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Henley Jeremy M, 1800, Dialogues Clin Neurosci, V15, P11; Hering H, 2003, J NEUROSCI, V23, P3262; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Heverin M, 2015, BEHAV BRAIN RES, V278, P356, DOI 10.1016/j.bbr.2014.10.018; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Jiang L, 2010, NEUROBIOL AGING, V31, P2146, DOI 10.1016/j.neurobiolaging.2008.11.005; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Kalaitzakis ME, 2008, J NEUROPATH EXP NEUR, V67, P155, DOI 10.1097/NEN.0b013e31816362aa; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kao PF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013337; Kelly A, 2000, NEUROSCIENCE, V95, P359; Kong MMC, 2007, MOL PHARMACOL, V72, P1157, DOI 10.1124/mol.107.034769; Kudinov A. R., 2006, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P61; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Leal SL, 2013, AGEING RES REV, V12, P823, DOI 10.1016/j.arr.2013.01.006; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; LESKAWA KC, 1979, NEUROCHEM RES, V4, P483, DOI 10.1007/BF00964643; Linetti A, 2010, J CELL SCI, V123, P595, DOI 10.1242/jcs.060681; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; Lowery LA, 2009, NAT REV MOL CELL BIO, V10, P332, DOI 10.1038/nrm2679; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MacDonald E, 2007, NEUROREHAB NEURAL RE, V21, P486, DOI 10.1177/1545968307305521; Mailman T, 2011, J NEUROCHEM, V119, P1002, DOI 10.1111/j.1471-4159.2011.07474.x; Maioli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068534; Mandal PK, 2006, NEUROCHEM RES, V31, P1153, DOI 10.1007/s11064-006-9140-9; Martin M, 2010, BBA-MOL CELL BIOL L, V1801, P934, DOI 10.1016/j.bbalip.2010.03.011; Martin MG, 2008, MOL BIOL CELL, V19, P2101, DOI 10.1091/mbc.E07-09-0897; Martin MG, 2014, EMBO REP, V15, P1036, DOI 10.15252/embr.201439225; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mishra M, 2011, J CELL MOL MED, V15, P1713, DOI 10.1111/j.1582-4934.2010.01134.x; Morrison JH, 2014, JAMA PSYCHIAT, V71, P835, DOI 10.1001/jamapsychiatry.2014.380; Murray AJ, 2009, J NEUROSCI, V29, P15434, DOI 10.1523/JNEUROSCI.3071-09.2009; Neumann Aaron K, 2010, F1000 Biol Rep, V2, P31, DOI 10.3410/B2-31; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Paila YD, 2009, BBA-BIOMEMBRANES, V1788, P295, DOI 10.1016/j.bbamem.2008.11.020; Paul G, 2015, J CLIN INVEST, V125, P1339, DOI 10.1172/JCI79635; Peri A, 2008, J MOL ENDOCRINOL, V41, P251, DOI 10.1677/JME-08-0071; Phillips C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00170; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; Remy F, 2004, NEUROSCI LETT, V358, P25, DOI 10.1016/j.neulet.2003.12.122; Renner M, 2009, J NEUROSCI, V29, P2926, DOI 10.1523/JNEUROSCI.4445-08.2009; ROMAN F, 1987, BRAIN RES, V418, P221, DOI 10.1016/0006-8993(87)90089-8; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; RUNQUIST M, 1995, J NEUROCHEM, V65, P2299; Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859; Sacket SJ, 2009, ACTA PHARMACOL SIN, V30, P1454, DOI 10.1038/aps.2009.136; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Schilling JM, 2014, BEHAV BRAIN RES, V267, P6, DOI 10.1016/j.bbr.2014.03.014; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; Shafaati M, 2011, J LIPID RES, V52, P1004, DOI 10.1194/jlr.M014548; SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x; Sodero AO, 2011, J NEUROCHEM, V116, P747, DOI 10.1111/j.1471-4159.2010.07079.x; Steck TL, 2012, BIOPHYS J, V102, P945, DOI 10.1016/j.bpj.2011.10.059; Stiess M, 2011, DEV NEUROBIOL, V71, P430, DOI 10.1002/dneu.20849; Suzuki T, 2002, NEUROSCI RES, V44, P1, DOI 10.1016/S0168-0102(02)00080-9; SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802; Thelen KM, 2006, NEUROSCI LETT, V403, P15, DOI 10.1016/j.neulet.2006.04.034; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Thudichum JLW, 1884, TREATISE CHEM CONSTI; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tong J, 2011, NEUROBIOL DIS, V41, P458, DOI 10.1016/j.nbd.2010.10.017; Trovo L, 2011, J CELL SCI, V124, P1308, DOI 10.1242/jcs.078766; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Vance JE, 2010, BBA-MOL CELL BIOL L, V1801, P806, DOI 10.1016/j.bbalip.2010.02.007; Vanmierlo T, 2010, J ALZHEIMERS DIS, V19, P117, DOI 10.3233/JAD-2010-1209; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Wasser CR, 2009, NEUROSCIENCE, V158, P177, DOI 10.1016/j.neuroscience.2008.03.028; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Wayman GA, 2006, NEURON, V50, P897, DOI 10.1016/j.neuron.2006.05.008; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Wood WG, 2011, J NEUROCHEM, V116, P684, DOI 10.1111/j.1471-4159.2010.07017.x; Wu GS, 1997, MOL BRAIN RES, V44, P341, DOI 10.1016/S0169-328X(96)00281-1; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Yamamoto N, 2008, BBA-BIOMEMBRANES, V1778, P2717, DOI 10.1016/j.bbamem.2008.07.028	137	60	60	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	AUG 15	2016	594	16					4565	4579		10.1113/JP270590			15	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Physiology	DV5GV	WOS:000382956100009	26332795	Bronze, Green Published			2022-02-06	
J	Burger, N; Lambert, MI; Viljoen, W; Brown, JC; Readhead, C; Hendricks, S				Burger, Nicholas; Lambert, Michael I.; Viljoen, Wayne; Brown, James C.; Readhead, Clint; Hendricks, Sharief			Tackle technique and tackle-related injuries in high-level South African Rugby Union under-18 players: real-match video analysis	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INCIDENT ANALYSIS; MECHANISMS; FOOTBALL; PERFORMANCE; LEAGUE; EPIDEMIOLOGY; CONCUSSIONS; STRATEGIES; CONTACT; SCHOOLS	Background The high injury rate associated with rugby union is primarily due to the tackle, and poor contact technique has been identified as a risk factor for injury. We aimed to determine whether the tackle technique proficiency scores were different in injurious tackles versus tackles that did not result in injury using real-match scenarios in high-level youth rugby union. Methods Injury surveillance was conducted at the under-18 Craven Week tournaments ( 2011-2013). Tackle-related injury information was used to identify injury events in the match video footage and non-injury events were identified for the injured player cohort. Injury and non-injury events were scored for technique proficiency and Cohen's effect sizes were calculated and the Student t test ( p< 0.05) was performed to compare injury versus non-injury scores. Results The overall mean score for front-on ball-carrier proficiency was 7.17+/-1.90 and 9.02+/-2.15 for injury and non-injury tackle events, respectively ( effect size=moderate; p< 0.05). The overall mean score for side/behind ball-carrier proficiency was 4.09+/-2.12 and 7.68+/-1.72 for injury and non-injury tackle events, respectively ( effect size=large; p< 0.01). The overall mean score for front-on tackler proficiency was 7.00 +/- 1.95 and 9.35+/-2.56 for injury and non-injury tackle events, respectively ( effect size=moderate; p< 0.05). The overall mean score for side/behind tackler proficiency was 5.47+/-1.60 and 8.14+/-1.75 for injury and non-injury tackle events, respectively ( effect size=large; p< 0.01). Summary Higher overall mean and criterion-specific tackle-related technique scores were associated with a non-injury outcome. The ability to perform well during tackle events may decrease the risk of injury and may manifest in superior performance.	[Burger, Nicholas; Lambert, Michael I.; Viljoen, Wayne; Brown, James C.; Readhead, Clint; Hendricks, Sharief] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Private Bag X5, ZA-7725 Cape Town, Western Cape, South Africa; [Viljoen, Wayne; Readhead, Clint] South African Rugby Union SARU, SARU House, Cape Town, Western Cape, South Africa		Burger, N (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Private Bag X5, ZA-7725 Cape Town, Western Cape, South Africa.	burgernick@vodamail.co.za	Brown, James Craig/H-7637-2019; Hendricks, Sharief/U-3278-2019	Brown, James Craig/0000-0002-7778-7783; Hendricks, Sharief/0000-0002-3416-6266; Viljoen, Wayne/0000-0002-9432-6153	National Research Foundation	Funding for NB was provided by the National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship).	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Brown JC, 2012, S AFR J SPORTS MED, V24, P49; Burger N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005556; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gabbett T, 2007, INT J SPORTS SCI COA, V2, P467, DOI [10.1260/174795407783359731, DOI 10.1260/174795407783359731]; Gabbett T, 2009, INT J SPORTS SCI COA, V4, P521, DOI 10.1260/174795409790291402; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; HENDRICKS S, 2012, S AFR J SPORTS MED, V24, P122, DOI DOI 10.7196/SAJSM.357; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2012, SAFETY SCI, V50, P266, DOI 10.1016/j.ssci.2011.08.061; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King D, 2012, RES SPORTS MED, V20, P86, DOI 10.1080/15438627.2012.660824; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Patricios JS, 2014, CURR SPORT MED REP, V13, P326, DOI 10.1249/JSR.0000000000000086; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Viljoen W, 2009, SA RUGBY BOKSMART SA; Wheeler KW, 2010, EUR J SPORT SCI, V10, P237, DOI 10.1080/17461391.2010.482595	34	60	61	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2016	50	15					932	+		10.1136/bjsports-2015-095295			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DS7AR	WOS:000380935300011	26781294				2022-02-06	
J	Ryan, NP; van Bijnen, L; Catroppa, C; Beauchamp, MH; Crossley, L; Hearps, S; Anderson, V				Ryan, Nicholas P.; van Bijnen, Loeka; Catroppa, Cathy; Beauchamp, Miriam H.; Crossley, Louise; Hearps, Stephen; Anderson, Vicki			Longitudinal outcome and recovery of social problems after pediatric traumatic brain injury (TBI): Contribution of brain insult and family environment	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Social problems; Pediatrics; Brain injuries; Magnetic resonance imaging; Neurobiology	PROBLEM-SOLVING SKILLS; LONG-TERM OUTCOMES; SELF-REGULATION; HEAD-INJURY; CHILDREN; CHILDHOOD; AGE; COMPETENCE; PREDICTORS; SEVERITY	Pediatric traumatic brain injury (TBI) can result in a range of social impairments, however longitudinal recovery is not well characterized, and clinicians are poorly equipped to identify children at risk for persisting difficulties. Using a longitudinal prospective design, this study aimed to evaluate the contribution of injury and non-injury related risk and resilience factors to longitudinal outcome and recovery of social problems from 12- to 24-months post-TBI. 78 children with TBI (injury age: 5.0-15.0 years) and 40 age and gender-matched typically developing (TD) children underwent magnetic resonance imaging including a susceptibility-weighted imaging (SWI) sequence 2-8 weeks post-injury (M = 39.25, SD = 27.64 days). At 12 and 24-months post-injury, parents completed questionnaires rating their child's social functioning, and environmental factors including socioeconomic status, caregiver mental health and family functioning. Results revealed that longitudinal recovery profiles differed as a function of injury severity, such that among children with severe TBI, social problems significantly increased from 12- to 24-months post injury, and were found to be significantly worse than TD controls and children with mild and moderate TBI. In contrast, children with mild and moderate injuries showed few problems at 12-months post-injury and little change over time. Pre-injury environment and SWI did not significantly contribute to outcome at 24-months, however concurrent caregiver mental health and family functioning explained a large and significant proportion of variance in these outcomes. Overall, this study shows that longitudinal recovery profiles differ as a function of injury severity, with evidence for late-emerging social problems among children with severe TBI. Poorer long-term social outcomes were associated with family dysfunction and poorer caregiver mental health at 24-months post injury, suggesting that efforts to optimize the child's environment and bolster family coping resources may enhance recovery of social problems following pediatric TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Ryan, Nicholas P.; van Bijnen, Loeka; Catroppa, Cathy; Beauchamp, Miriam H.; Crossley, Louise; Hearps, Stephen; Anderson, Vicki] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada		Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Hearps, Stephen/L-6853-2016; Ryan, Nicholas/K-5445-2019	Catroppa, Cathy/0000-0002-9750-0436; Ryan, Nicholas/0000-0002-0878-8889; Hearps, Stephen/0000-0003-2984-1172	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Victoria Neurotrauma Initiative, Australia; Victorian Government Operational Infrastructure Support Program	All phases of this study were supported in part by a National Health and Medical Research Council Moving Ahead Seed Grant (Nicholas Ryan, awarded 2014); a National Health and Medical Research Council Senior Practitioner Fellowship (Vicki Anderson; awarded 2014); a grant from the Victoria Neurotrauma Initiative, Australia; and the Victorian Government Operational Infrastructure Support Program. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Achenbach TM, 2001, ASEBA SCH AGE FORMS; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2012, DEV SOCIAL NEUROSCIE; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coffey CE, 1991, PSYCHOPATHOL BRAIN, P243; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Greenough WT, 1999, CHANGING NERVOUS SYSTEM, P51; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kosty JA, 2013, NEUROL RES, V35, P277, DOI 10.1179/1743132813Y.0000000168; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Levan A, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000040; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Schroeder J., 2011, J DEV DISABIL, V17; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D, 2011, WASI 2 WECHSLER ABBR; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]; Woods D., 2014, SOCIAL CARE NEURODIS, V5, P51, DOI [10.1108/SCN-01-2013-0002, DOI 10.1108/SCN-01-2013-0002]; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	58	60	60	0	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	2016	49						23	30		10.1016/j.ijdevneu.2015.12.004			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	DG3AG	WOS:000371941300004	26739435				2022-02-06	
J	Perrone, D; Aelterman, J; Pizurica, A; Jeurissen, B; Philips, W; Leemans, A				Perrone, Daniele; Aelterman, Jan; Pizurica, Aleksandra; Jeurissen, Ben; Philips, Wilfried; Leemans, Alexander			The effect of Gibbs ringing artifacts on measures derived from diffusion MRI	NEUROIMAGE			English	Article						Gibbs ringing artifact; Diffusion MRI; Diffusion tensor imaging; Diffusion kurtosis imaging; Data quality; Fractional anisotropy; Mean diffusivity	TRAUMATIC BRAIN-INJURY; INTRAVOXEL INCOHERENT MOTIONS; AMYOTROPHIC-LATERAL-SCLEROSIS; WHITE-MATTER ABNORMALITIES; EDDY-CURRENT ARTIFACTS; LINEAR LEAST-SQUARES; ECHO-PLANAR IMAGES; TENSOR MRI; CORPUS-CALLOSUM; WATER DIFFUSION	Diffusion-weighted (DW) magnetic resonance imaging (MRI) is a unique method to investigate microstructural tissue properties noninvasively and is one of the most popular methods for studying the brain white matter in vivo. To obtain reliable statistical inferences with diffusion MRI, however, there are still many challenges, such as acquiring high-quality DW-MRI data (e.g., high SNR and high resolution), careful data preprocessing (e.g., correcting for subject motion and eddy current induced geometric distortions), choosing the appropriate diffusion approach (e.g., diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), or diffusion spectrum MRI), and applying a robust analysis strategy (e.g., tractography based or voxel based analysis). Notwithstanding the numerous efforts to optimize many steps in this complex and lengthy diffusion analysis pipeline, to date, a well-known artifact in MRI -i.e., Gibbs ringing (GR)-has largely gone unnoticed or deemed insignificant as a potential confound in quantitative DW-MRI analysis. Considering the recent explosion of diffusion MRI applications in biomedical and clinical applications, a systematic and comprehensive investigation is necessary to understand the influence of GR on the estimation of diffusion measures. In this work, we demonstrate with simulations and experimental DW-MRI data that diffusion estimates are significantly affected by GR artifacts and we show that an off-the-shelf GR correction procedure based on total variation already can alleviate this issue substantially. (C) 2015 Elsevier Inc. All rights reserved.	[Perrone, Daniele; Aelterman, Jan; Pizurica, Aleksandra; Philips, Wilfried] Univ Ghent, iMinds IPI, B-9000 Ghent, Belgium; [Jeurissen, Ben] Univ Antwerp, Dept Phys, iMinds Vis Lab, Antwerp, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands		Perrone, D (corresponding author), Univ Ghent, iMinds IPI, Sint Pietersnieuwstr 41, B-9000 Ghent, Belgium.	daniele.perrone@telin.ugent.be	Pizurica, Aleksandra/AAG-4687-2021; Pizurica, Aleksandra/K-6866-2015; Jeurissen, Ben/C-3246-2011; Leemans, Alexander/A-1784-2011	Pizurica, Aleksandra/0000-0002-9322-4999; Jeurissen, Ben/0000-0002-3488-9819; Leemans, Alexander/0000-0002-9306-6126; Aelterman, Jan/0000-0002-5543-2631	Fund for Scientific Research - Flanders (FWO)FWO [G.0.690.10.N.10]; Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [639.072.411]; Interuniversity Attraction Poles Program (IUAP)Belgian Federal Science Policy Office [P7/11]	This work was financially supported by the Fund for Scientific Research - Flanders (FWO, Grant G.0.690.10.N.10). The research of A.L. is supported by VIDI Grant 639.072.411 from the Netherlands Organization for Scientific Research (NWO). B.J. also acknowledges the Interuniversity Attraction Poles Program (IUAP); Grant number: P7/11.	Alexander AL, 1997, MAGN RESON MED, V38, P1016, DOI 10.1002/mrm.1910380623; Alexander DC, 2005, ANN NY ACAD SCI, V1064, P113, DOI 10.1196/annals.1340.018; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Archibald R, 2002, IEEE T MED IMAGING, V21, P305, DOI 10.1109/TMI.2002.1000255; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Bakir T, 2000, IEEE T MED IMAGING, V19, P585, DOI 10.1109/42.870664; Barker G, 2001, P 9 M INT SOC MAGN R, P1546; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Ben-Amitay S, 2012, MAGN RESON MED, V67, P1694, DOI 10.1002/mrm.23186; Blain CRV, 2011, J NEUROL NEUROSUR PS, V82, P843, DOI 10.1136/jnnp.2010.236018; Block KT, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/184123; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carballedo A, 2012, AM J MED GENET B, V159B, P537, DOI 10.1002/ajmg.b.32060; Chambolle A, 2004, J MATH IMAGING VIS, V20, P89; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; Colby JB, 2012, NEUROIMAGE, V59, P3227, DOI 10.1016/j.neuroimage.2011.11.004; Collier Q, 2015, MAGN RESON MED, V73, P2174, DOI 10.1002/mrm.25351; De Bondt T, 2013, EUR RADIOL, V23, P57, DOI 10.1007/s00330-012-2572-5; De Groof G, 2006, NEUROIMAGE, V29, P754, DOI 10.1016/j.neuroimage.2005.09.022; De Groof G, 2009, J NEUROSCI, V29, P13557, DOI 10.1523/JNEUROSCI.1788-09.2009; Dell'Acqua F, 2010, NEUROIMAGE, V49, P1446, DOI 10.1016/j.neuroimage.2009.09.033; den Dekker AJ, 2014, PHYS MEDICA, V30, P725, DOI 10.1016/j.ejmp.2014.05.002; Descoteaux M, 2011, MED IMAGE ANAL, V15, P603, DOI 10.1016/j.media.2010.07.001; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Di Paola M, 2010, J ALZHEIMERS DIS, V20, P67, DOI 10.3233/JAD-2010-1370; Gallichan D, 2010, HUM BRAIN MAPP, V31, P193, DOI 10.1002/hbm.20856; Gooijers J, 2013, HUM BRAIN MAPP, V34, P241, DOI 10.1002/hbm.21429; Hemels MA, 2012, PEDIATR CRIT CARE ME, V13, P678, DOI 10.1097/PCC.0b013e3182455778; Hsu JL, 2008, NEUROIMAGE, V39, P566, DOI 10.1016/j.neuroimage.2007.09.017; Hsu JL, 2012, NEUROIMAGE, V59, P1098, DOI 10.1016/j.neuroimage.2011.09.041; Hsu JL, 2010, NEUROIMAGE, V49, P32, DOI 10.1016/j.neuroimage.2009.08.031; Huang X, 2005, P ANN INT IEEE EMBS, P1367; Huppi PS, 2006, SEMIN FETAL NEONAT M, V11, P489, DOI 10.1016/j.siny.2006.07.006; Irfanoglu MO, 2012, NEUROIMAGE, V61, P275, DOI 10.1016/j.neuroimage.2012.02.054; Jambawalikar S, 2010, SKELETAL RADIOL, V39, P1073, DOI 10.1007/s00256-010-0974-5; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jeurissen B, 2014, NEUROIMAGE, V103, P411, DOI 10.1016/j.neuroimage.2014.07.061; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jezzard P, 1998, MAGNET RESON MED, V39, P801, DOI 10.1002/mrm.1910390518; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Jones DK, 2004, MAGN RESON MED, V52, P979, DOI 10.1002/mrm.20283; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Knoll F, 2011, MAGN RESON MED, V65, P480, DOI 10.1002/mrm.22595; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Kodl CT, 2008, DIABETES, V57, P3083, DOI 10.2337/db08-0724; Kwan RKS, 1996, LECT NOTES COMPUT SC, V1131, P135; Landman BA, 2009, MAGN RESON IMAGING, V27, P741, DOI 10.1016/j.mri.2009.01.001; Langen M, 2012, CORTEX, V48, P183, DOI 10.1016/j.cortex.2011.05.018; Latt J, 2013, J MAGN RESON IMAGING, V37, P610, DOI 10.1002/jmri.23857; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1989, MAGNET RESON MED, V10, P324; Leemans A, 2005, MAGN RESON MED, V53, P944, DOI 10.1002/mrm.20418; Leemans A., 2009, P 17 SCI M INT SOC M, V17, P3537; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liang Z.P., 2000, IEEE PRESS SERIES BI; MERBOLDT KD, 1989, MAGNET RESON MED, V9, P423, DOI 10.1002/mrm.1910090316; Metzler-Baddeley C, 2012, NEUROLOGY, V79, P2233, DOI 10.1212/WNL.0b013e31827689e8; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; O'Sullivan M, 2010, STROKE, V41, pS154, DOI 10.1161/STROKEAHA.110.595314; Ooi MB, 2013, MAGN RESON MED, V69, P803, DOI 10.1002/mrm.24285; Panagiotaki E, 2012, NEUROIMAGE, V59, P2241, DOI 10.1016/j.neuroimage.2011.09.081; Perrone D., 2011, 10 BELG DAY BIOM ENG; Perrone D, 2012, 4 ANN M ISMRM BEN CH, P99; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Poot DHJ, 2010, IEEE T MED IMAGING, V29, P819, DOI 10.1109/TMI.2009.2037915; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Reijmer YD, 2013, DIABETES CARE, V36, P137, DOI 10.2337/dc12-0493; Reijmer YD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044074; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rovaris M, 2007, J NEUROIMAGING, V17, p27S, DOI 10.1111/j.1552-6569.2007.00133.x; RUDIN LI, 1992, PHYSICA D, V60, P259, DOI 10.1016/0167-2789(92)90242-F; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Sarra SA, 2006, NUMER ALGORITHMS, V41, P17, DOI 10.1007/s11075-005-9003-5; Setsompop K, 2013, NEUROIMAGE, V80, P220, DOI 10.1016/j.neuroimage.2013.05.078; Sexton CE, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.05.019; Sisti HM, 2012, LEARN MEMORY, V19, P351, DOI 10.1101/lm.026534.112; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sullivan EV, 2006, NEUROSCI BIOBEHAV R, V30, P749, DOI 10.1016/j.neubiorev.2006.06.002; Surova Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066022; Szczepankiewicz F, 2013, NEUROIMAGE, V76, P145, DOI 10.1016/j.neuroimage.2013.02.078; Tax CMW, 2015, MAGN RESON MED, V73, P794, DOI 10.1002/mrm.25165; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Ugurbil K, 2013, NEUROIMAGE, V80, P80, DOI 10.1016/j.neuroimage.2013.05.012; Van Camp N, 2009, NMR BIOMED, V22, P697, DOI 10.1002/nbm.1381; van der Aa NE, 2011, STROKE, V42, P3410, DOI 10.1161/STROKEAHA.111.624858; van der Jagt PKN, 2012, NEUROIMAGE, V62, P1792, DOI 10.1016/j.neuroimage.2012.06.001; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Van Hecke W, 2010, J MAGN RESON IMAGING, V31, P1492, DOI 10.1002/jmri.22198; Van Hecke W, 2009, J MAGN RESON IMAGING, V30, P25, DOI 10.1002/jmri.21817; Van Hecke W, 2008, J MAGN RESON IMAGING, V27, P978, DOI 10.1002/jmri.21338; Veraart J, 2013, NEUROIMAGE, V81, P335, DOI 10.1016/j.neuroimage.2013.05.028; Veraart J, 2013, MAGN RESON MED, V70, P972, DOI 10.1002/mrm.24529; Veraart J, 2011, MAGN RESON MED, V66, P678, DOI 10.1002/mrm.22835; Verhoeven JS, 2012, CEREB CORTEX, V22, P2263, DOI 10.1093/cercor/bhr292; Verhoeven JS, 2010, HUM BRAIN MAPP, V31, P470, DOI 10.1002/hbm.20880; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Walker L, 2011, NEUROIMAGE, V54, P1168, DOI 10.1016/j.neuroimage.2010.08.048; Wang HC, 2012, ARCH NEUROL-CHICAGO, V69, P1340, DOI 10.1001/archneurol.2012.633; Wang SM, 2005, ANN NY ACAD SCI, V1064, P61, DOI 10.1196/annals.1340.013; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	128	60	61	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 15	2015	120						441	455		10.1016/j.neuroimage.2015.06.068			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CS4DK	WOS:000362025000039	26142273				2022-02-06	
J	Gao, WW; Zhao, ZL; Yu, GJ; Zhou, ZW; Zhou, Y; Hu, TT; Jiang, RC; Zhang, JN				Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Hu, Tingting; Jiang, Rongcai; Zhang, Jianning			VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-kappa B signaling pathway in experimental traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Nuclear factor-kappa B (NF-kappa B); Inflammatory cytokine; Blood brain barrier	TOLL-LIKE RECEPTORS; RAT MODEL; NEURONAL APOPTOSIS; IMMUNE-SYSTEM; LESION SIZE; MOUSE MODEL; CNS; EXPRESSION; GROWTH; CELLS	Acute traumatic brain injury (TBI) tends to cause the over-activation of inflammatory response and disruption of blood brain barrier (BBB), associating with long-term cognitive and behavioral dysfunction. Vascular endothelial growth inhibitor (VEGI), as a suppressor in the angiogenesis specifically by inducing apoptosis in proliferating endothelial cells, has been applied to different diseases, especially the tumors. But rare study had been done in the field of brain injury. So in this study, we investigated the effects and mechanisms associated with VEGI-induced neuroprotection following CNS injury in mice TBI models. We demonstrated that the VEGI treatment reduced the contusion brain tissue loss, the permeation of inflammatory cells (MPO+) and the activation of microglia (Iba-1(+)). The treatment upregulated the tight junction proteins (CLN5, ZO-1 and OCLN), which are vital importance for the integrity of the blood brain barrier (BBB), the B-cell lymphoma 2 (Bcl-2) cell survival factors, while down-regulated the expression of TLR4, NF-kappa B and inflammatory cytokines (IL-1 beta, TNF-alpha, iNOS). The treatment also decreased the expression of reactive astrocytes (GFAP(+)), as well as the VEGF, and lowered the permeability of Evens Blue (EB). These findings suggested that the VEGI-treatment could alleviate the post-traumatic excessive inflammatory response, and maintain the stability of blood vessels, remitting the secondary brain damage. (C) 2015 Published by Elsevier B.V.	[Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Minist Educ & Tianjin City, Key Lab Postneurotrauma Neurorepair & Regenerat C, Tianjin 300052, Peoples R China; [Hu, Tingting] Tianjin Med Univ, Gen Hosp, Dept Nursing, Tianjin 300052, Peoples R China		Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Minist Educ, 154 Anshan Rd, Tianjin 300052, Peoples R China.	hongw1980@hotmail.com; ZilongZ@psbc.org; yugongjie@hotmail.com; 1985zhouziwei@163.com; zy963000@126.com; tingtinghu91@hotmail.com; jianghope@gmail.com; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81330029]	We acknowledge Wei-yun Cui, Li Liu and Lei Zhou for their excellent technical support. The work is supported by the National Natural Science Foundation of China (Grants 81271361 and 81330029).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Barclay L.A., 2015, MOL CELL; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Cao GD, 2002, J NEUROSCI, V22, P5423; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Conway Kevin P, 2007, Int Wound J, V4, P55, DOI 10.1111/j.1742-481X.2006.00295.x; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Li YN, 2014, J NEUROCHEM, V129, P120, DOI 10.1111/jnc.12611; Liu B, 2015, INT J BIOL SCI, V11, P353, DOI 10.7150/ijbs.9813; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Ryu JK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-18; Smith CC, 2015, ALCOHOL CLIN EXP RES, V39, P36, DOI 10.1111/acer.12606; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xu LX, 2014, INT J BIOCHEM CELL B, V55, P109, DOI 10.1016/j.biocel.2014.08.015; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yuksel H, 2013, NEUROL SCI, V34, P1941, DOI 10.1007/s10072-013-1411-z; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073	40	60	62	1	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 5	2015	1622						230	239		10.1016/j.brainres.2015.04.035			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CS4OC	WOS:000362054100022	26080076				2022-02-06	
J	Bernick, C; Banks, SJ; Shin, W; Obuchowski, N; Butler, S; Noback, M; Phillips, M; Lowe, M; Jones, S; Modic, M				Bernick, Charles; Banks, Sarah J.; Shin, Wanyong; Obuchowski, Nancy; Butler, Sam; Noback, Michael; Phillips, Michael; Lowe, Mark; Jones, Stephen; Modic, Michael			Repeated head trauma is associated with smaller thalamic volumes and slower processing speed: the Professional Fighters' Brain Health Study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							ENCEPHALOPATHY; CONCUSSION; SPORTS; CONSEQUENCES; CONNECTIONS; INJURY	Objectives Cumulative head trauma may alter brain structure and function. We explored the relationship between exposure variables, cognition and MRI brain structural measures in a cohort of professional combatants. Methods 224 fighters (131 mixed martial arts fighters and 93 boxers) participating in the Professional Fighters Brain Health Study, a longitudinal cohort study of licensed professional combatants, were recruited, as were 22 controls. Each participant underwent computerised cognitive testing and volumetric brain MRI. Fighting history including years of fighting and fights per year was obtained from self-report and published records. Statistical analyses of the baseline evaluations were applied cross-sectionally to determine the relationship between fight exposure variables and volumes of the hippocampus, amygdala, thalamus, caudate, putamen. Moreover, the relationship between exposure and brain volumes with cognitive function was assessed. Results Increasing exposure to repetitive head trauma measured by number of professional fights, years of fighting, or a Fight Exposure Score (FES) was associated with lower brain volumes, particularly the thalamus and caudate. In addition, speed of processing decreased with decreased thalamic volumes and with increasing fight exposure. Higher scores on a FES used to reflect exposure to repetitive head trauma were associated with greater likelihood of having cognitive impairment. Conclusions Greater exposure to repetitive head trauma is associated with lower brain volumes and lower processing speed in active professional fighters.	[Bernick, Charles; Banks, Sarah J.; Noback, Michael] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA; [Shin, Wanyong; Phillips, Michael; Lowe, Mark; Jones, Stephen; Modic, Michael] Cleveland Clin, Dept Radiol, Cleveland, OH 44106 USA; [Obuchowski, Nancy; Butler, Sam] Cleveland Clin, Dept Qualitat Hlth Sci, Cleveland, OH 44106 USA		Banks, SJ (corresponding author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA.	bankss2@ccf.org		Banks, Sarah/0000-0001-7536-2370			Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Minagar A, 2013, NEUROLOGY, V80, P210, DOI 10.1212/WNL.0b013e31827b910b; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001	24	60	60	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2015	49	15					1007	U74		10.1136/bjsports-2014-093877			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CM9IR	WOS:000358022600013	25633832	hybrid, Green Published			2022-02-06	
J	Sullivan, S; Eucker, SA; Gabrieli, D; Bradfield, C; Coats, B; Maltese, MR; Lee, J; Smith, C; Margulies, SS				Sullivan, Sarah; Eucker, Stephanie A.; Gabrieli, David; Bradfield, Connor; Coats, Brittany; Maltese, Matthew R.; Lee, Jongho; Smith, Colin; Margulies, Susan S.			White matter tract-oriented deformation predicts traumatic axonal brain injury and reveals rotational direction-specific vulnerabilities	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Finite element modeling; Porcine; Pediatric; Sports-related head injury; Diffusion tensor imaging	CENTRAL-NERVOUS-SYSTEM; FINITE-ELEMENT MODEL; HEAD-INJURY; MECHANICAL CHARACTERIZATION; PROFESSIONAL FOOTBALL; IN-VITRO; STRAIN; TISSUE; IMPACTS; BIOMECHANICS	A systematic correlation between finite element models (FEMs) and histopathology is needed to define deformation thresholds associated with traumatic brain injury (TBI). In this study, a FEM of a transected piglet brain was used to reverse engineer the range of optimal shear moduli for infant (5 days old, 553-658 Pa) and 4-week-old toddler piglet brain (692-811 Pa) from comparisons with measured in situ tissue strains. The more mature brain modulus was found to have significant strain and strain rate dependencies not observed with the infant brain. Age-appropriate FEMs were then used to simulate experimental TBI in infant () and preadolescent () piglets undergoing a range of rotational head loads. The experimental animals were evaluated for the presence of clinically significant traumatic axonal injury (TAI), which was then correlated with FEM-calculated measures of overall and white matter tract-oriented tissue deformations, and used to identify the metric with the highest sensitivity and specificity for detecting TAI. The best predictors of TAI were the tract-oriented strain (6-7 %), strain rate (38-40 s, and strain times strain rate (1.3-1.8 s values exceeded by 90 % of the brain. These tract-oriented strain and strain rate thresholds for TAI were comparable to those found in isolated axonal stretch studies. Furthermore, we proposed that the higher degree of agreement between tissue distortion aligned with white matter tracts and TAI may be the underlying mechanism responsible for more severe TAI after horizontal and sagittal head rotations in our porcine model of nonimpact TAI than coronal plane rotations.	[Sullivan, Sarah; Gabrieli, David; Bradfield, Connor; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Eucker, Stephanie A.] Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC 27710 USA; [Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; [Maltese, Matthew R.] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Lee, Jongho] Seoul Natl Univ, Dept Elect & Comp Engn, Seoul, South Korea; [Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Acad Dept Neuropathol, Edinburgh, Midlothian, Scotland		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Coats, Brittany/A-4523-2009; Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773; Smith, Colin/0000-0002-4507-5132	Department of Transportation-National Highway Transportation and Safety Administration [DTNH 22-07-H-00088]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; American Heart AssociationAmerican Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, U01NS069545] Funding Source: NIH RePORTER	We gratefully acknowledge support from the Department of Transportation-National Highway Transportation and Safety Administration (DTNH 22-07-H-00088), the National Institutes of Health (R01 NS39679), and the American Heart Association. We also acknowledge the work of Sohaib Hashmi, Nicole Ibrahim, and Jesse Jiang in the development of the finite element models and DTI image processing.	Anderson Andrew E., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P171, DOI 10.1080/10255840601160484; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chatelin S, 2012, J MECH BEHAV BIOMED, V6, P166, DOI 10.1016/j.jmbbm.2011.09.013; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Eucker S A, 2009, THESIS U PENNSYLVANI; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Fung Y C, 1994, 1 COURSE CONTINUUM M; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Maltese MR, 2012, TRAUMATIC BRAIN INJU; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Ogden, 1984, NONLINEAR ELASTIC DE; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Patton DA, 2013, J APPL BIOMECH, V29, P721, DOI 10.1123/jab.29.6.721; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prabhu R, 2011, J MECH BEHAV BIOMED, V4, P1067, DOI 10.1016/j.jmbbm.2011.03.015; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Sahoo D, 2013, COMPUT METHOD BIOMEC, V16, P198, DOI 10.1080/10255842.2013.815908; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Traumatic brain injury in the United States, 2010, EM DEP VIS HOSP DEAT; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang L, 2001, Stapp Car Crash J, V45, P369	62	60	60	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2015	14	4					877	896		10.1007/s10237-014-0643-z			20	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	CL9ZZ	WOS:000357339300014	25547650	Green Accepted			2022-02-06	
J	Cuthbert, JP; Harrison-Felix, C; Corrigan, JD; Bell, JM; Haarbauer-Krupa, JK; Miller, AC				Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Corrigan, John D.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet K.; Miller, A. Cate			Unemployment in the United States After Traumatic Brain Injury for Working-Age Individuals: Prevalence and Associated Factors 2 Years Postinjury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						injury outcomes; prevalence; TBI; traumatic brain injury; unemployment	EMPLOYMENT OUTCOME 2; GALVESTON ORIENTATION; RACIAL-DIFFERENCES; AMNESIA TEST; RETURN; REPRESENTATIVENESS; REHABILITATION; PREDICTORS; DISABILITY; MODERATE	Objective: To estimate the prevalence of unemployment and part-time employment in the United States for working-age individuals completing rehabilitation for a primary diagnosis of traumatic brain injury (TBI) between 2001 and 2010. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 to 60 years at injury who completed inpatient rehabilitation for TBI between 2001 and 2010. Main Outcome Measures: Unemployment; Part-time employment. Results: The prevalence of unemployment for persons in the selected cohort was 60.4% at 2-year postinjury. Prevalence of unemployment at 2-year postinjury was significantly associated with the majority of categories of age group, race, gender, marital status, primary inpatient rehabilitation payment source, education, preinjury vocational status, length of stay, and Disability Rating Scale. The direction of association for the majority of these variables complement previous research in this area, with only Hispanic ethnicity and the FIM Cognitive subscale demonstrating disparate findings. For those employed at 2-year postinjury, the prevalence of part-time employment was 35.0%. The model of prevalence for part-time employment at 2-year postinjury was less robust, with significant relationships with some categorical components of age group, gender, marital status, primary payment source, preinjury vocational status, and Disability Rating Scale. Conclusions: The prevalence of unemployment for patients completing inpatient rehabilitation for TBI was substantial (60.4%). The majority of factors found to associate with 2 years' unemployment were complementary of previously published research; however, these were often smaller in magnitude than previous reports. The prevalence of part-time employment was also an issue for this cohort and included 35.0% of all employed individuals. In regard to the determination of factors associated with part-time employment, additional analyses that include more fine-grained factors associated with employment, including physical and psychosocial functioning, are recommended.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Jeneita M.; Haarbauer-Krupa, Juliet K.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA		Cuthbert, JP (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@craighospital.org			Intramural CDC HHS [CC999999] Funding Source: Medline		American Medical Rehabilitation Providers Association, EREHABDATA; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bureau of Labor Statistics, 2016, BLS INF GLOSS; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, TECHNICAL REPORT PRO; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Izrael D, 2000, P 25 ANN SAS US GROU; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JOHNSON RW, 2001, RETIRING TOGETHER WO; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, WHAT AR POT EFF TBI; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; National Institute of Neurological Disorders and Stroke, NINDS TRAUM BRAIN IN; Office of Special Education and Rehabilitative Services Department of Education, 1998, FIN PRIOR, P26030; Office of Special Education and Rehabilitative Services Department of Education, 2013, FIN PRIOR, P27038; Shigaki CL, 2009, DISABIL REHABIL, V31, P484, DOI 10.1080/09638280802240449; Sugerman D., 2012, BRAIN INJURY MED, P45; The Traumatic Brain Injury Model Systems National Data and Statistical Center, TBI MOD SYST PRES; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; UDS, 2014, UN DAT SYST MED REH; US Department of Labor Bureau of Labor Statistics, UN RAT LEV; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Viera AJ, 2008, SOUTH MED J, V101, P730, DOI 10.1097/SMJ.0b013e31817a7ee4; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	48	60	60	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					160	174		10.1097/HTR.0000000000000090			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100129	25955703	Green Accepted			2022-02-06	
J	Rosenberg, H; McDonald, S; Dethier, M; Kessels, RPC; Westbrook, RF				Rosenberg, Hannah; McDonald, Skye; Dethier, Marie; Kessels, Roy P. C.; Westbrook, R. Frederick			Facial Emotion Recognition Deficits following Moderate-Severe Traumatic Brain Injury (TBI): Re-examining the Valence Effect and the Role of Emotion Intensity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Emotion recognition; Facial affect; Valence; Positive emotion; Negative emotion	ANXIETY STRESS SCALES; CLOSED-HEAD-INJURY; PERCEPTION DEFICITS; SOCIAL-PERCEPTION; STROKE PATIENTS; EXPRESSIONS; COMMUNICATION; DEPRESSION; DAMAGE; SCHIZOPHRENIA	Many individuals who sustain moderate-severe traumatic brain injuries (TBI) are poor at recognizing emotional expressions, with a greater impairment in recognizing negative (e.g., fear, disgust, sadness, and anger) than positive emotions (e.g., happiness and surprise). It has been questioned whether this "valence effect" might be an artifact of the wide use of static facial emotion stimuli (usually full-blown expressions) which differ in difficulty rather than a real consequence of brain impairment. This study aimed to investigate the valence effect in TBI, while examining emotion recognition across different intensities (low, medium, and high). Method: Twenty-seven individuals with TBI and 28 matched control participants were tested on the Emotion Recognition Task (ERT). The TBI group was more impaired in overall emotion recognition, and less accurate recognizing negative emotions. However, examining the performance across the different intensities indicated that this difference was driven by some emotions (e.g., happiness) being much easier to recognize than others (e.g., fear and surprise). Our findings indicate that individuals with TBI have an overall deficit in facial emotion recognition, and that both people with TBI and control participants found some emotions more difficult than others. These results suggest that conventional measures of facial affect recognition that do not examine variance in the difficulty of emotions may produce erroneous conclusions about differential impairment. They also cast doubt on the notion that dissociable neural pathways underlie the recognition of positive and negative emotions, which are differentially affected by TBI and potentially other neurological or psychiatric disorders.	[Rosenberg, Hannah; McDonald, Skye; Westbrook, R. Frederick] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Dethier, Marie] Univ Liege, Dept Psychol Cognit & Behav, Liege, Belgium; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6525 ED Nijmegen, Netherlands; [Kessels, Roy P. C.] Korsakoff Clin, Vincent van Gogh Inst Psychiat, Venray, Netherlands		Rosenberg, H (corresponding author), Univ New S Wales, Sch Psychol, Mathews Bldg, Sydney, NSW 2052, Australia.	hannah.rosenberg@unsw.edu.au	McDonald, Skye/G-4118-2014; Kessels, Roy P.C./D-1902-2010	McDonald, Skye/0000-0003-0723-6094; Kessels, Roy P.C./0000-0001-9500-9793; Westbrook, Fred/0000-0002-6880-9274	Australian Research Council (ARC)Australian Research Council [DP0988689]; NHMRCNational Health and Medical Research Council of Australia	This research was funded by the Australian Research Council (ARC) Discovery Project grant DP0988689 and the NHMRC. The authors have no conflict of interest affecting this manuscript. The authors wish to thank the individuals who participated in this study. The authors are also grateful to Jacob Rosenberg for assistance with data processing and Marios Panayi for statistical advice.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Ammerlaan EJG, 2008, ACTA NEUROBIOL EXP, V68, P214; Anderson AK, 2000, PSYCHOL SCI, V11, P106, DOI 10.1111/1467-9280.00224; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bird KD, 2011, PSYCHOL METHODS, V16, P432, DOI 10.1037/a0024447; Bornhofen C., 2010, READING SMILES OTHER; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Braun M, 2005, BRAIN COGNITION, V58, P193, DOI 10.1016/j.bandc.2004.11.003; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Demaree Heath A, 2005, Behav Cogn Neurosci Rev, V4, P3, DOI 10.1177/1534582305276837; Dethier M., 2013, J INT NEUROPSYCH SOC, V19, P1; Dethier M, 2012, J CLIN EXP NEUROPSYC, V34, P936, DOI 10.1080/13803395.2012.702734; Ekman P., 1976, PICTURES FACIAL AFFE; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fernandez-Duque D, 2005, NEUROPSYCHOLOGIA, V43, P1673, DOI 10.1016/j.neuropsychologia.2005.01.005; Frigerio E, 2002, PSYCHIAT RES, V113, P161, DOI 10.1016/S0165-1781(02)00244-5; Gray John, 2006, Cogn Neuropsychiatry, V11, P505, DOI 10.1080/13546800544000028; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hennenlotter A, 2006, PROG BRAIN RES, V156, P443, DOI 10.1016/S0079-6123(06)56024-8; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessels RPC, 2007, BEHAV NEUROL, V18, P31, DOI 10.1155/2007/868431; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kohler CG, 2005, AM J GERIAT PSYCHIAT, V13, P926, DOI 10.1176/appi.ajgp.13.11.926; Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.psych.46.1.209; LOVIBOND PF, 1995, MANUAL DEPRESSION AN; Mallery P., 2003, SPSS WINDOWS STEP ST, V4th; Mandal MK, 1998, SCHIZOPHRENIA BULL, V24, P399, DOI 10.1093/oxfordjournals.schbul.a033335; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Montagne B, 2008, EUR PSYCHIAT, V23, P26, DOI 10.1016/j.eurpsy.2007.07.007; Montagne B, 2007, ACTA NEUROPSYCHIATR, V19, P279, DOI 10.1111/j.1601-5215.2007.00235.x; Montagne B, 2007, BRIT J PSYCHOL, V98, P517, DOI 10.1348/000712606X160669; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Montagne Barbara, 2006, Cogn Neuropsychiatry, V11, P389, DOI 10.1080/13546800444000254; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Rosenberg H., 2014, EMOTION PERCEP UNPUB; RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037/0033-2909.115.1.102; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Smith MJL, 2010, NEUROPSYCHOLOGIA, V48, P2777, DOI 10.1016/j.neuropsychologia.2010.03.008; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Vuilleumier P, 2002, CURR OPIN PSYCHIATR, V15, P291, DOI 10.1097/00001504-200205000-00011; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Zupan B, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829dded6	62	60	61	0	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2014	20	10					994	1003		10.1017/S1355617714000940			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AW3FN	WOS:000346171700005	25396693				2022-02-06	
J	Liu, Y; Zhang, R; Yan, K; Chen, FF; Huang, WY; Lv, BK; Sun, CM; Xu, LM; Li, F; Jiang, XD				Liu, Yi; Zhang, Run; Yan, Ke; Chen, Fanfan; Huang, Weiyi; Lv, Bingke; Sun, Chengmei; Xu, Limin; Li, Feng; Jiang, Xiaodan			Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6	JOURNAL OF NEUROINFLAMMATION			English	Article							ANTIINFLAMMATORY PROTEIN TSG-6; MARROW STROMAL CELLS; IMMUNE-RESPONSES; NITRIC-OXIDE; BRAIN; SYSTEM; INJURY; TRANSPLANTATION; DIFFERENTIATION; MACROPHAGES	Microglia are the primary immunocompetent cells in brain tissue and microglia-mediated inflammation is associated with the pathogenesis of various neuronal disorders. Recently, many studies have shown that mesenchymal stem cells (MSCs) display a remarkable ability to modulate inflammatory and immune responses through the release of a variety of bioactive molecules, thereby protecting the central nervous system. Previously, we reported that MSCs have the ability to modulate inflammatory responses in a traumatic brain injury model and that the potential mechanisms may be partially attributed to upregulated TNF-alpha stimulated gene/protein 6 (TSG-6) expression. However, whether TSG-6 exerts an anti-inflammatory effect by affecting microglia is not fully understood. In this study, we investigated the anti-inflammatory effects of MSCs and TSG-6 in an in vitro lipopolysaccharide (LPS)-induced BV2 microglial activation model. We found that MSCs and TSG-6 significantly inhibited the expression of pro-inflammatory mediators in activated microglia. However, MSC effects on microglia were attenuated when TSG-6 expression was silenced. In addition, we found that the activation of nuclear factor (NF)-kappa B and mitogen-activated protein kinase (MAPK) pathways in LPS-stimulated BV2 microglial cells was significantly inhibited by TSG-6. Furthermore, we found that the presence of CD44 in BV2 microglial cells was essential for MSC- and TSG-6-mediated inhibition of pro-inflammatory gene expression and of NF-kappa B and MAPK activation in BV2 microglial cells. The results of this study suggest that MSCs can modulate microglia activation through TSG-6 and that TSG-6 attenuates the inflammatory cascade in activated microglia. Our study indicates that novel mechanisms are responsible for the immunomodulatory effect of MSCs on microglia and that MSCs, as well as TSG-6, might be promising therapeutic agents for the treatment of neurotraumatic injuries or neuroinflammatory diseases associated with microglial activation.	[Liu, Yi; Zhang, Run; Yan, Ke; Chen, Fanfan; Huang, Weiyi; Lv, Bingke; Sun, Chengmei; Xu, Limin; Li, Feng; Jiang, Xiaodan] Southern Med Univ, Zhujiang Hosp,Natl Key Clin Specialty, Neurosurg Inst Guandong Prov,Dept Neurosurg, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China		Jiang, XD (corresponding author), Southern Med Univ, Zhujiang Hosp,Natl Key Clin Specialty, Neurosurg Inst Guandong Prov,Dept Neurosurg, Guangdong Prov Key Lab Brain Funct Repair & Regen, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.	jiangxiao_dan@163.com		li, feng/0000-0002-2010-8081	funds for National Key Clinic Department; Funds for Key Natural Science Foundation of Guangdong [S2013020012754]; Educational Commission of Guangdong [2013CXZDA008]; Key Project of Health Collaborative Innovation of Guangzhou [201400000003-2]; Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81171179, 81272439]	This work was supported by grants from the funds for National Key Clinic Department, the Natural Science Fund of China (number: 81171179, number: 81272439), the Funds for Key Natural Science Foundation of Guangdong (number:. S2013020012754), the Educational Commission of Guangdong (number: 2013CXZDA008), and the Key Project of Health Collaborative Innovation of Guangzhou (number: 201400000003-2) to Professor Xiaodan Jiang.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Ahn JO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074897; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Baranova NS, 2011, J BIOL CHEM, V286, P25675, DOI 10.1074/jbc.M111.247395; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Chen ML, 2013, BRAIN RES, V1532, P63, DOI 10.1016/j.brainres.2013.07.037; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Kawana H, 2008, J IMMUNOL, V180, P4235, DOI 10.4049/jimmunol.180.6.4235; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; Kumar A, 2014, FREE RADICAL BIO MED, V73, P51, DOI 10.1016/j.freeradbiomed.2014.04.014; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee KW, 2013, J ETHNOPHARMACOL, V147, P286, DOI 10.1016/j.jep.2013.02.033; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Muto J, 2009, MOL IMMUNOL, V47, P449, DOI 10.1016/j.molimm.2009.08.026; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Park S, 2014, LIFE SCI, V103, P59, DOI 10.1016/j.lfs.2014.04.003; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416; Rahmat Z, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt160; Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roubelakis MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054747; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Nguyen TTN, 2013, J BIOL CHEM, V288, P5645, DOI 10.1074/jbc.M112.410126; Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	48	60	62	0	19	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 4	2014	11								135	10.1186/1742-2094-11-135			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AN5UQ	WOS:000340657200001	25088370	gold, Green Published			2022-02-06	
J	Lange, S; Rocha-Ferreira, E; Thei, L; Mawjee, P; Bennett, K; Thompson, PR; Subramanian, V; Nicholas, AP; Peebles, D; Hristova, M; Raivich, G				Lange, Sigrun; Rocha-Ferreira, Eridan; Thei, Laura; Mawjee, Priyanka; Bennett, Kate; Thompson, Paul R.; Subramanian, Venkataraman; Nicholas, Anthony P.; Peebles, Donald; Hristova, Mariya; Raivich, Gennadij			Peptidylariginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates	JOURNAL OF NEUROCHEMISTRY			English	Article						hypoxic ischaemic encephalopathy; lipopolysaccharide; microglia; neonatal; peptidylarginine deiminases; protein deimination/citrullination	WHITE-MATTER INJURY; PEPTIDYLARGININE DEIMINASE; POSTTRANSLATIONAL MODIFICATION; CELL-DEATH; BRAIN; CITRULLINATION; EXPRESSION; ASPHYXIA; ENZYMES; MODELS	Neonatal hypoxic ischaemic (HI) injury frequently causes neural impairment in surviving infants. Our knowledge of the underlying molecular mechanisms is still limited. Protein deimination is a post-translational modification caused by Ca+2-regulated peptidylarginine deiminases (PADs), a group of five isozymes that display tissue-specific expression and different preference for target proteins. Protein deimination results in altered protein conformation and function of target proteins, and is associated with neurodegenerative diseases, gene regulation and autoimmunity. In this study, we used the neonatal HI and HI/infection [lipopolysaccharide (LPS) stimulation] murine models to investigate changes in protein deimination. Brains showed increases in deiminated proteins, cell death, activated microglia and neuronal loss in affected brain areas at 48 h after hypoxic ischaemic insult. Upon treatment with the pan-PAD inhibitor Cl-amidine, a significant reduction was seen in microglial activation, cell death and infarct size compared with control saline or LPS-treated animals. Deimination of histone 3, a target protein of the PAD4 isozyme, was increased in hippocampus and cortex specifically upon LPS stimulation and markedly reduced following Cl-amidine treatment. Here, we demonstrate a novel role for PAD enzymes in neural impairment in neonatal HI Encephalopathy, highlighting their role as promising new candidates for drug-directed intervention in neurotrauma.	[Lange, Sigrun; Rocha-Ferreira, Eridan; Thei, Laura; Mawjee, Priyanka; Hristova, Mariya; Raivich, Gennadij] UCL Inst Womens Hlth Maternal & Fetal Med, Perinatal Brain Repair Grp, London WC1E 6HX, England; [Lange, Sigrun] UCL Sch Pharm, London, England; [Bennett, Kate] UCL Inst Womens Hlth, London, England; [Thompson, Paul R.; Subramanian, Venkataraman] Scripps Res Inst, Dept Chem, Jupiter, FL USA; [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; [Nicholas, Anthony P.] Birmingham VA, Med Ctr, Birmingham, AL 35294 USA; [Peebles, Donald] UCL Med Sch, London, England		Lange, S (corresponding author), UCL Inst Womens Hlth Maternal & Fetal Med, Perinatal Brain Repair Grp, London WC1E 6HX, England.	sigrun.lange@ucl.ac.uk	Raivich, Gennadij/AAL-7229-2021	Rocha Ferreira, Eridan/0000-0002-9342-4691	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM079357] Funding Source: NIH RePORTER; Wellbeing of WomenWellbeing of Women (WoW) [RG1266] Funding Source: researchfish; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM079357] Funding Source: Medline		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Gyorgy B, 2006, INT J BIOCHEM CELL B, V38, P1662, DOI 10.1016/j.biocel.2006.03.008; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; Horibata S, 2012, J REPROD DEVELOP, V58, P274, DOI 10.1262/jrd.2011-040; Hristova M, 2010, GLIA, V58, P11, DOI 10.1002/glia.20896; Keilhoff G, 2008, DEV NEUROBIOL, V68, P101, DOI 10.1002/dneu.20578; Kendall GS, 2011, DEV NEUROSCI-BASEL, V33, P505, DOI 10.1159/000333850; Kendall GS, 2011, LAB INVEST, V91, P328, DOI 10.1038/labinvest.2010.192; Kendall GS, 2006, PEDIATR RES, V59, P227, DOI 10.1203/01.pdr.0000196805.68082.22; Kumral A, 2013, EARLY HUM DEV, V89, P165, DOI 10.1016/j.earlhumdev.2012.09.016; Lange S, 2011, DEV BIOL, V355, P205, DOI 10.1016/j.ydbio.2011.04.015; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Loos T, 2008, BLOOD, V112, P2648, DOI 10.1182/blood-2008-04-149039; Loos T, 2009, METHOD ENZYMOL, V461, P3, DOI 10.1016/S0076-6879(09)05401-9; Luo Y, 2006, BIOCHEMISTRY-US, V45, P11727, DOI 10.1021/bi061180d; Mallard C, 2003, NEUROCHEM RES, V28, P215, DOI 10.1023/A:1022368915400; Mastronardi FG, 2006, J NEUROSCI, V26, P11387, DOI 10.1523/JNEUROSCI.3349-06.2006; Moelants EAV, 2013, CYTOKINE, V61, P161, DOI 10.1016/j.cyto.2012.09.011; Moelants EAV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028976; Moller JC, 1996, GLIA, V17, P121; Nicholas AP, 2002, GLIA, V37, P328, DOI 10.1002/glia.10039; Perlman JM, 2006, CLIN THER, V28, P1353, DOI 10.1016/j.clinthera.2006.09.005; Pirianov G, 2007, J CEREBR BLOOD F MET, V27, P1022, DOI 10.1038/sj.jcbfm.9600413; Proost P, 2008, J EXP MED, V205, P2085, DOI 10.1084/jem.20080305; Robertson NJ, 2013, BRAIN, V136, P90, DOI 10.1093/brain/aws285; Robertson NJ, 2004, NEUROPEDIATRICS, V35, P20, DOI 10.1055/s-2004-815787; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Wu Y. W, 2000, JAMA-J AM MED ASSOC, V28, P2996; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019	38	60	60	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2014	130	4					555	562		10.1111/jnc.12744			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN3ZN	WOS:000340527500009	24762056	Green Accepted, Green Published, hybrid			2022-02-06	
J	Zweckberger, K; Hackenberg, K; Jung, CS; Hertle, DN; Kiening, KL; Unterberg, AW; Sakowitz, OW				Zweckberger, K.; Hackenberg, K.; Jung, C. S.; Hertle, D. N.; Kiening, K. L.; Unterberg, A. W.; Sakowitz, O. W.			GLIBENCLAMIDE REDUCES SECONDARY BRAIN DAMAGE AFTER EXPERIMENTAL TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; glibenclamide; secondary brain damage; brain edema; cerebral metabolism; epileptic seizures	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; SULFONYLUREA RECEPTOR 1; ISCHEMIC-STROKE; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; ANEURYSM SURGERY; CEREBRAL EDEMA; MICRODIALYSIS; MODEL	Following traumatic brain injury (TBI) SUR1-regulated NCCa-ATP (SUR1/TRPM4) channels are transcriptionally up-regulated in ischemic astrocytes, neurons, and capillaries. ATP depletion results in depolarization and opening of the channel leading to cytotoxic edema. Glibenclamide is an inhibitor of SUR-1 and, thus, might prevent cytotoxic edema and secondary brain damage following TBI. Anesthetized adult Sprague Dawley rats underwent parietal craniotomy and were subjected to controlled cortical impact injury (CCI). Glibenclamide was administered as a bolus injection 15 min after CCI injury and continuously via osmotic pumps throughout 7 days. In an acute trial (180 min) mean arterial blood pressure, heart rate, intracranial pressure, encephalographic activity, and cerebral metabolism were monitored. Brain water content was assessed gravimetrically 24 h after CCI injury and contusion volumes were measured by MRI scanning technique at 8 h, 24 h, 72 h, and 7 d post injury. Throughout the entire time of observation neurological function was quantified using the "beam-walking" test. Glibenclamide-treated animals showed a significant reduction in the development of brain tissue water content(80.47% +/- 0.37% (glibenclamide) vs. 80.83% +/- 0.44% (control); p < 0.05; n = 14). Contusion sizes increased continuously within 72 h following CCI injury, but glibenclamide-treated animals had significantly smaller volumes at any time-points, like 172.53 +/- 38.74 mm(3) (gliben-clamide) vs. 299.20 +/- 64.02 mm(3) (control) (p < 0.01; n = 10; 24h) or 211.10 +/- 41.03 mm(3) (glibenclamide) vs. 309.76 +/- 19.45 mm(3) (control) (p < 0.05; n = 10; 72 h), respectively. An effect on acute parameters, however, could not be detected, most likely because of the up-regulation of the channel within 3-6 h after injury. Furthermore, there was no significant effect on motor function assessed by the beam-walking test throughout 7 days. In accordance to these results and the available literature, glibenclamide seems to have promising potency in the treatment of TBI. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Zweckberger, K.; Hackenberg, K.; Jung, C. S.; Hertle, D. N.; Kiening, K. L.; Unterberg, A. W.; Sakowitz, O. W.] Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany		Zweckberger, K (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	klaus.zweckberger@med.uni-heidelberg.de		Sakowitz, Oliver/0000-0003-3248-6335			Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BTF-Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, P1; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cremer CM, 2009, NEUROSCIENCE, V163, P490, DOI 10.1016/j.neuroscience.2009.03.068; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201, DOI 10.1093/neurosurgery/46.1.201; Kang N, 2005, J NEUROPHYSIOL, V94, P4121, DOI 10.1152/jn.00448.2005; Kett-White R, 2002, ACT NEUR S, V81, P363; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Sakowitz OW, 2002, ACT NEUR S, V81, P221; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Vazquez-Lopez A, 2005, NEUROSCI LETT, V388, P81, DOI 10.1016/j.neulet.2005.06.063; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	36	60	61	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 11	2014	272						199	206		10.1016/j.neuroscience.2014.04.040			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AJ0IY	WOS:000337335400019	24792709				2022-02-06	
J	Alvarez, Z; Castano, O; Castells, AA; Mateos-Timoneda, MA; Planell, JA; Engel, E; Alcantara, S				Alvarez, Zaida; Castano, Oscar; Castells, Alba A.; Mateos-Timoneda, Miguel A.; Planell, Josep A.; Engel, Elisabeth; Alcantara, Soledad			Neurogenesis and vascularization of the damaged brain using a lactate-releasing biomimetic scaffold	BIOMATERIALS			English	Article						Nanofibers; Lactate; Regeneration; Neural stem cells; Vascularization; Neurogenesis	NEURAL STEM-CELLS; RADIAL GLIA; EXTRACELLULAR-MATRIX; MIGRATING NEURONS; SPINAL-CORD; ASTROCYTES; SYSTEM; ANGIOGENESIS; REGENERATION; PROGENITORS	Regenerative medicine strategies to promote recovery following traumatic brain injuries are currently focused on the use of biomaterials as delivery systems for cells or bioactive molecules. This study shows that cell-free biomimetic scaffolds consisting of radially aligned electrospun poly-L/DL. lactic acid (PLA70/30) nanofibers release L-lactate and reproduce the 3D organization and supportive function of radial glia embryonic neural stem cells. The topology of PLA nanofibers supports neuronal migration while L-lactate released during PLA degradation acts as an alternative fuel for neurons and is required for progenitor maintenance. Radial scaffolds implanted into cavities made in the postnatal mouse brain fostered complete implant vascularization, sustained neurogenesis, and allowed the long-term survival and integration of the newly generated neurons. Our results suggest that the endogenous central nervous system is capable of regeneration through the in vivo dedifferentiation induced by biophysical and metabolic cues, with no need for exogenous cells, growth factors, or genetic manipulation. (C) 2014 Elsevier Ltd. All rights reserved.	[Alvarez, Zaida; Castano, Oscar; Mateos-Timoneda, Miguel A.; Planell, Josep A.; Engel, Elisabeth] Inst Bioengn Catalonia IBEC, Barcelona, Spain; [Alvarez, Zaida; Castells, Alba A.; Alcantara, Soledad] Univ Barcelona, Dpt Pathol & Expt Therapeut, Sch Med, Barcelona, Spain; [Castano, Oscar; Engel, Elisabeth] Tech Univ Catalonia UPC, Dpt Mat Sci & Met Engn, Barcelona, Spain; [Alvarez, Zaida; Castano, Oscar; Mateos-Timoneda, Miguel A.; Engel, Elisabeth] CIBER BBN, Barcelona, Spain		Alcantara, S (corresponding author), Univ Barcelona, Cell Biol Unit, Dept Expt Pathol & Therapeut, Sch Med, Bellvitge Campus, Barcelona 08907, Spain.	salcantara@ub.edu	Castells, Alba Aina/AAB-2200-2020; alvarez, zaida/AAA-3132-2020; Alcantara, Soledad/K-3648-2014; Castano, Oscar/F-6725-2012; Engel, Elisabeth/D-4365-2014; Timoneda, Miguel Angel Mateos/D-4666-2014; Engel, Elisabeth/AAU-6657-2021	Castells, Alba Aina/0000-0002-3508-8562; Alcantara, Soledad/0000-0003-3313-2715; Castano, Oscar/0000-0001-9212-784X; Engel, Elisabeth/0000-0003-4855-8874; Timoneda, Miguel Angel Mateos/0000-0001-7657-1414; Engel, Elisabeth/0000-0003-4855-8874; Alvarez, Zaida/0000-0001-5104-1388	Spain's Ministerio de Economia y Competitividad (MINECO) [MAT2011-29778-C02-02, MAT2011-29778-C02-01]; European Regional Development FundEuropean Commission; fellowship IBEC [10-2009-01]; Spanish MINECO for the Ramon y Cajal contract;  [SGR 719]	This study was supported by grants from Spain's Ministerio de Economia y Competitividad (MINECO) [MAT2011-29778-C02-02] and [MAT2011-29778-C02-01], co-financed by the European Regional Development Fund, to S.A. and O.C., respectively; from 2009 SGR 719 to S.A.; and from fellowship IBEC 10-2009-01 to Z.A. O.C. acknowledges the Spanish MINECO for the Ramon y Cajal contract. We are grateful to Wendy Ran for editorial assistance, to P. Hyrossova for helping with lactate degradation studies, to J.C. Perales and J. Domingo for critical reading of the manuscript, to J.A. Ortega for the drawing in Figure 6, to B. Torrejon from the UB's Scientific-Technical Services (Bellvitge Campus) for technical support in confocal microscopy, to X. Ramis for DSC measurements and technical support, to the Experimental 7T MRI Unit (IDIBAPS) and to F. Artigas and M.P. Celada for electrophysiological studies.	Alvarez Z, 2013, BIOMATERIALS, V34, P2221, DOI 10.1016/j.biomaterials.2012.12.001; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Anton ES, 1997, DEVELOPMENT, V124, P3501; Baud O, 2003, J COMP NEUROL, V465, P445, DOI 10.1002/cne.10853; Belvindrah R, 2007, J NEUROSCI, V27, P13854, DOI 10.1523/JNEUROSCI.4494-07.2007; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bible E, 2009, BIOMATERIALS, V30, P2985, DOI 10.1016/j.biomaterials.2009.02.012; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Christensen K, 2008, J NEURO-ONCOL, V90, P157, DOI 10.1007/s11060-008-9648-8; Conte WL, 2009, NAT PROTOC, V4, P1157, DOI 10.1038/nprot.2009.93; Covey MV, 2010, DEV NEUROSCI-BASEL, V32, P488, DOI 10.1159/000321607; Englund C, 2005, J NEUROSCI, V25, P247, DOI 10.1523/JNEUROSCI.2899-04.2005; Fame RM, 2011, TRENDS NEUROSCI, V34, P41, DOI 10.1016/j.tins.2010.10.002; Fan HJ, 2007, NANO LETT, V7, P993, DOI 10.1021/nl070026p; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Frontczak-Baniewicz M, 2011, FOLIA NEUROPATHOL, V49, P204; Hisaoka T, 2010, NEUROSCIENCE, V166, P551, DOI 10.1016/j.neuroscience.2009.12.055; Hsieh J, 2012, GENE DEV, V26, P1010, DOI 10.1101/gad.187336.112; Hurtado A, 2011, BIOMATERIALS, V32, P6068, DOI 10.1016/j.biomaterials.2011.05.006; Kazanis I, 2010, J NEUROSCI, V30, P9771, DOI 10.1523/JNEUROSCI.0700-10.2010; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lathia JD, 2007, DEV DYNAM, V236, P3267, DOI 10.1002/dvdy.21319; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Loulier K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000176; Ma S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001469; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mattotti M, 2012, BIOMATERIALS, V33, P1759, DOI 10.1016/j.biomaterials.2011.10.086; Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Ovens MJ, BIOCH J; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Rakic P, 2003, CEREB CORTEX, V13, P541, DOI 10.1093/cercor/13.6.541; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Saha B, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00014; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Simon-Assmann P, 2011, INT J DEV BIOL, V55, P455, DOI 10.1387/ijdb.103223ps; Speder P, 2011, CURR OPIN CELL BIOL, V23, P724, DOI 10.1016/j.ceb.2011.08.004; Stubbs D, 2009, CEREB CORTEX, V19, pI32, DOI 10.1093/cercor/bhp040; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Tam SJ, 2010, ANNU REV NEUROSCI, V33, P379, DOI 10.1146/annurev-neuro-060909-152829; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Volpato FZ, 2013, BIOMATERIALS, V34, P4945, DOI 10.1016/j.biomaterials.2013.03.057; Weissman T, 2003, CEREB CORTEX, V13, P550, DOI 10.1093/cercor/13.6.550	50	60	61	1	84	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JUN	2014	35	17					4769	4781		10.1016/j.biomaterials.2014.02.051			13	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	AG4ZT	WOS:000335429600005	24636215				2022-02-06	
J	Aarabi, B; Tofighi, B; Kufera, JA; Hadley, J; Ahn, ES; Cooper, C; Malik, JM; Naff, NJ; Chang, L; Radley, M; Kheder, A; Uscinski, RH				Aarabi, Bizhan; Tofighi, Babak; Kufera, Joseph A.; Hadley, Jeffrey; Ahn, Edward S.; Cooper, Carnell; Malik, Jacek M.; Naff, Neal J.; Chang, Louis; Radley, Michael; Kheder, Ashker; Uscinski, Ronald H.			Predictors of outcome in civilian gunshot wounds to the head	JOURNAL OF NEUROSURGERY			English	Article						trauma; gunshot wound; traumatic brain injury; penetrating brain injury; Glasgow Outcome Scale; decompressive craniectomy	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; PROGNOSTIC-FACTORS; ENDOVASCULAR MANAGEMENT; INTRACRANIAL ANEURYSMS; MULTIVARIATE-ANALYSIS; MISSILE INJURIES; WARTIME; EXPERIENCE; MORTALITY	Object. Civilian gunshot wounds to the head (GSWH) are often deadly, but some patients with open cranial wounds need medical and surgical management and are potentially good candidates for acceptable functional recovery. The authors analyzed predictors of favorable clinical outcome (Glasgow Outcome Scale scores of 4 and 5) after GSWH over a 24-month period. Methods. The authors posited 2 questions: First, what percentage of civilians with GSWH died in the state of Maryland in a given period of time? Second, what were the predictors of favorable outcome after GSWH? The authors examined demographic, clinical, imaging, and acute care data for 786 civilians who sustained GSWH. Univariate and logistic regression analyses were used to analyze the data. Results. Of the 786 patients in this series, 712(91%) died and 74(9%) completed acute care in 9 trauma centers. Of the 69 patients admitted to one Maryland center, 46 (67%) eventually died. In 48 patients who were resuscitated, the Injury Severity Score was 26.2, Glasgow Coma Scale (GCS) score was 7.8, and an abnormal pupillary response (APR) to light was present in 41% of patients. Computed tomography indicated midline shift in 17%, obliteration of basal cisterns in 41.3%, intracranial hematomas in 34.8%, and intraventricular hemorrhage in 49% of cases. When analyzed for trajectory, 57.5% of bullet slugs crossed midcoronal, midsagittal, or both planes. Two subsets of admissions were studied: 27 patients (65%) who had poor outcome (25 patients who died and 2 who had severe disability) and 15 patients (35%) who had a favorable outcome when followed for a mean period of 40.6 months. Six patients were lost to follow-up. Univariate analysis indicated that admission GCS score (p < 0.001), missile trajectory (p <0.001), surgery (p < 0.001), APR to light (p = 0.002), patency of basal cisterns (p = 0.01), age (p = 0.01), and intraventricular bleed (p = 0.03) had a significant relationship to outcome. Multivariable logistic regression analysis indicated that GCS score and patency of the basal cistern were significant determinants of outcome. Exclusion of GCS score from the regression models indicated missile trajectory and APR to light were significant in determining outcome. Conclusions. Admission GCS score, trajectory of the missile track, APR to light, and patency of basal cisterns were significant determinants of outcome in civilian GSWH.	[Aarabi, Bizhan; Kufera, Joseph A.; Cooper, Carnell] Dept Neurosurg, Baltimore, MD USA; [Tofighi, Babak] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Tofighi, Babak; Hadley, Jeffrey] Johns Hopkins Univ, 0ff Chief Med Examiner State Maryland, Baltimore, MD USA; [Ahn, Edward S.; Naff, Neal J.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA; [Malik, Jacek M.] Peninsula Neurosurg Associates, Salisbury, PA USA; [Chang, Louis] Cent Maryland Neurosurg Associates, Baltimore, MD USA; [Radley, Michael] Pkwy Neurosci & Spine Inst, Div Neurosurg, Hagerstown, MD USA; [Kheder, Ashker] Western Maryland Hlth, Cumberland, MD USA; [Uscinski, Ronald H.] Georgetown Univ, Dept Neurosurg, Washington, DC USA		Aarabi, B (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Ste S-12-D, Baltimore, MD 21201 USA.	baarabi@smail.umaryland.edu	Chang, Louis/AAZ-2488-2020	Tofighi, Babak/0000-0001-7393-7564			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Allison PD, 2008, SAS GLOB FOR SAN ANT; Ambrosi PB, 2012, NEUROSURG REV, V35, P429, DOI 10.1007/s10143-012-0377-2; Amirjamshidi A, 2003, SURG NEUROL, V60, P105, DOI 10.1016/S0090-3019(03)00358-6; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1025; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; Carey ME, 2004, YOUMANS NEUROLOGICAL, V4, P5223; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cosar A, 2005, MINIM INVAS NEUROSUR, V48, P113, DOI 10.1055/s-2004-830222; Frankowski RF, 1999, MISSILE WOUNDS HEAD, V1, P17; Glapa M, 2009, AM SURGEON, V75, P223; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; Hofbauer M, 2010, J TRAUMA, V69, P770, DOI 10.1097/TA.0b013e3181c81d7d; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Kaufman H H, 1991, Neurosurg Clin N Am, V2, P387; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; KAUFMAN HH, 1991, NEUROSURGERY, V29, P479; Kim KA, 2005, NEUROSURGERY, V57, P737, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; KRIEGER MD, 1995, NEUROSURG CLIN N AM, V6, P605; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; Levi L, 1999, MISSILE WOUNDS HEAD, V1, P411; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Lin DJ., 2012, SURG NEUROL INT, V3, P98, DOI [DOI 10.4103/2152-7806, 10.4103/2152-7806.100187, DOI 10.4103/2152-7806.100187]; Mao ZQ, 2012, ACTA NEUROCHIR, V154, P2187, DOI 10.1007/s00701-012-1487-x; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Murano T, 2005, AM SURGEON, V71, P1009; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pai BS, 2008, NEUROL INDIA, V56, P488, DOI 10.4103/0028-3886.44821; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Petridis AK, 2011, CENT EUR NEUROSURG, V72, P5, DOI 10.1055/s-0029-1241850; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rosenfeld JV, 2010, INJURY, V41, P899, DOI 10.1016/j.injury.2010.06.010; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	58	60	62	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2014	120	5					1138	1146		10.3171/2014.1.JNS131869			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AF7OD	WOS:000334903500017	24506239				2022-02-06	
J	Baym, CL; Khan, NA; Monti, JM; Raine, LB; Drollette, ES; Moore, RD; Scudder, MR; Kramer, AF; Hillman, CH; Cohen, NJ				Baym, Carol L.; Khan, Naiman A.; Monti, Jim M.; Raine, Lauren B.; Drollette, Eric S.; Moore, R. Davis; Scudder, Mark R.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.			Dietary lipids are differentially associated with hippocampal-dependent relational memory in prepubescent children	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Article							HIGH-FAT DIET; TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; PREADOLESCENT CHILDREN; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; AEROBIC FITNESS; COGNITIVE PERFORMANCE; INDUCED OBESITY; MALE RATS	Background: Studies in rodents and older humans have shown that the hippocampus a brain structure critical to relational/associative memory has remarkable plasticity as a result of lifestyle factors (eg, exercise). However, the effect of dietary intake on hippocampal-dependent memory during childhood has remained unexamined. Objective: We investigated the cross-sectional relation of dietary components characteristic of the Western diet, including saturated fatty acids (SFAs), omega-3 (n-3) fatty acids, and refined sugar, with hippocampal-dependent relational memory in prepubescent children. Design: Participants aged 7-9 y (n = 52) reported their dietary intake by using the Youth-Adolescent Food-Frequency Questionnaire and completed memory tasks designed to assess relational (hippocampal-dependent) and item (hippocampal-independent) memory. Performance on the memory tasks was assessed with both direct (accuracy) and indirect (eye movement) measures. Results: Partial correlations adjusted for body mass index showed a positive relation between relational memory accuracy and intake of omega-3 fatty acids and a negative relation of both relational and item memory accuracy with intake of SFAs. Potential confounding factors of age, sex, intelligence quotient, socioeconomic status, pubertal timing, and aerobic fitness (maximal oxygen volume) were not significantly related to any of the dietary intake measures. Eye movement measures of relational memory (preferential viewing to the target stimulus) showed a negative relation with intake of added sugar. Conclusions: SFA intake was negatively associated with both forms of memory, whereas omega-3 fatty acid intake was selectively positively. associated with hippocampal-dependent relational memory. These findings are among the first to show a link between habitual dietary intake and cognitive health as pertaining to hippocampal function in childhood. The Fitness Improves Thinking Kids (FITKids) and FITKids2 trials were registered at www.clinicaltrials.gov as NCT01334359 and NCT01619826, respectively.	[Baym, Carol L.; Monti, Jim M.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Dept Psychol, Urbana, IL 61801 USA; [Baym, Carol L.; Monti, Jim M.; Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Khan, Naiman A.; Raine, Lauren B.; Drollette, Eric S.; Moore, R. Davis; Scudder, Mark R.; Kramer, Arthur F.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Ctr Nutr Learning & Memory, Urbana, IL 61801 USA; [Kramer, Arthur F.; Hillman, Charles H.; Cohen, Neal J.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA		Cohen, NJ (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, 405 North Mathews Ave, Urbana, IL 61801 USA.	cbaym@illinois.edu; njc@illinois.edu	Meijer, Anna/K-5118-2016; Hillman, Charles/AAD-4828-2019; Kramer, Arthur/AAB-2937-2019	Kramer, Arthur/0000-0001-5870-2724; Khan, Naiman/0000-0002-6135-9389; Hillman, Charles/0000-0002-3722-5612	Eunice Kennedy Shriver National Institute of Child Health and Human Development grant [HD055352]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055352] Funding Source: NIH RePORTER	Supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development grant HD055352 (CHH).	Aberg MA, 2009, ACTA PAEDIATR, V98, P555, DOI 10.1111/j.1651-2227.2008.01103.x; Agrawal R, 2012, J PHYSIOL-LONDON, V590, P2485, DOI 10.1113/jphysiol.2012.230078; Alsaif MA, 2004, NUTR RES, V24, P417, DOI 10.1016/j.nutres.2003.11.011; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Benton D, 2007, PHYSIOL BEHAV, V92, P717, DOI 10.1016/j.physbeh.2007.05.065; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Birnbaum AS, 2002, AM J HEALTH BEHAV, V26, P284, DOI 10.5993/AJHB.26.4.5; Block G, 2002, AM J EPIDEMIOL, V156, P274, DOI 10.1093/aje/kwf029; Boitard C, 2012, HIPPOCAMPUS, V22, P2095, DOI 10.1002/hipo.22032; Boucher O, 2011, AM J CLIN NUTR, V93, P1025, DOI 10.3945/ajcn.110.000323; Chaddock L, 2010, BRAIN RES, V1358, P172, DOI 10.1016/j.brainres.2010.08.049; Cohen, 2001, CONDITIONING CONSCIO; Dalton A, 2009, PROSTAG LEUKOTR ESS, V80, P143, DOI 10.1016/j.plefa.2008.12.006; Davachi L, 2002, J NEUROPHYSIOL, V88, P982, DOI 10.1152/jn.2002.88.2.982; Davachi L, 2006, CURR OPIN NEUROBIOL, V16, P693, DOI 10.1016/j.conb.2006.10.012; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Eskelinen MH, 2008, INT J GERIATR PSYCH, V23, P741, DOI 10.1002/gps.1969; Ghys A, 2002, EARLY HUM DEV, V69, P83, DOI 10.1016/S0378-3782(02)00067-1; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; Jurdak N, 2008, NUTR NEUROSCI, V11, P48, DOI 10.1179/147683008X301333; Jurdak N, 2009, PHYSIOL BEHAV, V96, P1, DOI 10.1016/j.physbeh.2008.07.023; Kamijo K, 2011, DEVELOPMENTAL SCI, V14, P1046, DOI 10.1111/j.1467-7687.2011.01054.x; Kanoski SE, 2007, BEHAV BRAIN RES, V182, P57, DOI 10.1016/j.bbr.2007.05.004; Kanoski SE, 2011, PHYSIOL BEHAV, V103, P59, DOI 10.1016/j.physbeh.2010.12.003; Kanoski SE, 2010, J EXP PSYCHOL-ANIM B, V36, P313, DOI 10.1037/a0017228; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kaufman A, 1990, TEST KBI; Kirby A, 2010, BRIT EDUC RES J, V36, P699, DOI 10.1080/01411920903111557; Kosari S, 2012, BEHAV BRAIN RES, V235, P98, DOI 10.1016/j.bbr.2012.07.017; Kuczmarski RJ., 2002, ADV DATA, V11, P1, DOI DOI 10.1016/J.BBRC.2015.06.114; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McGrew KS, 2001, WOODCOCKJOHNSON 3; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Monti JM, 2012, HIPPOCAMPUS, V22, P1876, DOI 10.1002/hipo.22023; Muthayya S, 2009, AM J CLIN NUTR, V89, P1766, DOI 10.3945/ajcn.2008.26993; NEMO Study Grp, 2007, AM J CLIN NUTR, V86, P1082; Okereke OI, 2012, ANN NEUROL, V72, P124, DOI 10.1002/ana.23593; Park HR, 2010, NEUROSCI LETT, V482, P235, DOI 10.1016/j.neulet.2010.07.046; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Radecki DT, 2005, HIPPOCAMPUS, V15, P246, DOI 10.1002/hipo.20048; Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200; Stockhorst U, 2004, PHYSIOL BEHAV, V83, P47, DOI 10.1016/j.physbeh.2004.07.022; Taylor SJC, 2001, PAEDIATR PERINAT EP, V15, P88; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Voss MW, 2011, NEUROSCIENCE, V199, P166, DOI 10.1016/j.neuroscience.2011.10.009; Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; Zhang J, 2005, J NUTR, V135, P1967, DOI 10.1093/jn/135.8.1967	57	60	60	2	40	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9165	1938-3207		AM J CLIN NUTR	Am. J. Clin. Nutr.	MAY	2014	99	5					1026	1033		10.3945/ajcn.113.079624			8	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	AF7LD	WOS:000334895700010	24522447	Bronze, Green Published			2022-02-06	
J	Wisco, BE; Marx, BP; Holowka, DW; Vasterling, JJ; Han, SC; Chen, MS; Gradus, JL; Nock, MK; Rosen, RC; Keane, TM				Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Han, Sohyun C.; Chen, May S.; Gradus, Jaimie L.; Nock, Matthew K.; Rosen, Raymond C.; Keane, Terence M.			Traumatic Brain Injury, PTSD, and Current Suicidal Ideation Among Iraq and Afghanistan U.S. Veterans	JOURNAL OF TRAUMATIC STRESS			English	Article							MILITARY PERSONNEL; RISK; DEPLOYMENT; INTERVIEW; PROJECT; HISTORY	Suicide is a prevalent problem among veterans deployed to Iraq and Afghanistan. Traumatic brain injury (TBI) and psychiatric conditions, such as posttraumatic stress disorder (PTSD), are potentially important risk factors for suicide in this population, but the literature is limited by a dearth of research on female veterans and imprecise assessment of TBI and suicidal behavior. This study examined 824 male and 825 female U.S. veterans who were enrolled in the baseline assessment of the Veterans After-Discharge Longitudinal Registry (Project VALOR), an observational registry of veterans with and without PTSD who deployed in support of the wars in Iraq and Afghanistan and were enrolled in the Veterans Affairs healthcare system. Results indicated that current depressive symptoms, PTSD, and history of prior TBI were all significantly associated with current suicidal ideation (Cohen's d = 0.91, Cramers' Vs = .19 and .08, respectively). After adding a number of variables to the model, including psychiatric comorbidity, TBI history was associated with increased risk of current suicidal ideation among male veterans only (RR = 1.55). TBI is an important variable to consider in future research on suicide among veterans of the wars in Iraq and Afghanistan, particularly among male veterans.	[Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Han, Sohyun C.; Chen, May S.; Gradus, Jaimie L.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Gradus, Jaimie L.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; [Rosen, Raymond C.] New England Res Inst, Watertown, MA 02172 USA		Marx, BP (corresponding author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 South Huntington Ave,116B-4, Boston, MA 02130 USA.	brian.marx@va.gov	Marx, Brian/AAK-5072-2020; Nock, Matthew/AAE-8330-2019; Keane, Terence/I-8253-2014	Keane, Terence/0000-0002-0482-3149; Gradus, Jaimie/0000-0003-1459-5327	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: NIH RePORTER		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Rosen RC, 2012, INT J METH PSYCH RES, V21, P5, DOI 10.1002/mpr.355; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wells TS, 2013, J AFFECT DISORDERS, V148, P77, DOI 10.1016/j.jad.2012.11.052	14	60	60	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	APR	2014	27	2					244	248		10.1002/jts.21900			5	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	AF2II	WOS:000334535400017	24639101				2022-02-06	
J	Leong, DF; Balcer, LJ; Galetta, SL; Liu, Z; Master, CL				Leong, D. F.; Balcer, L. J.; Galetta, S. L.; Liu, Z.; Master, C. L.			The King-Devick test as a concussion screening tool administered by sports parents	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						Eye movements; Sports; Boxing	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; ON-FIELD; RECURRENT CONCUSSION; EARLY ADULTHOOD; EPIDEMIOLOGY; RISK; ENCEPHALOPATHY; SYMPTOMS	Background. Sports-related concussion has received increasing awareness due to short- and long-term neurologic seguelae seen among athletes. The King-Devick (K-D) test captures impairment of eye movements and other correlates of suboptimal brain function. We investigated the K-D test as a screening for concussion when administered by layperson sports parents in a cohort of amateur boxers. Methods. The K-D test was administered pre-fight and post-fight by laypersons masked to the head trauma status of each athlete. Matches were watched over by a ringside physician and boxing trainer. Athletes with suspected head trauma received testing with the Military Acute Concussion Evaluation (MACE) by the ringside physician to determine concussion status. Athletes sustaining concussion were compared to the athletes screened using the K-D test. Results. Post-fight K-D scores were lower (better) than the best baseline score (41 vs. 39.3 s, P=0.34, Wilcoxon signe-drank test), in the absence of concussion. One boxer sustained a concussion as determined by the ringside physician. This boxer was accurately identified by the layperson K-D testers due to a worsening in K-D test compared to baseline (3.2 seconds) and an increased number of errors. High levels of test-retest reliability were observed (intraclass correlation coefficient 0.90 [95% CI 0.84-0.97]). Additionally, 6 boxers who participated in multiple bouts showed no worsening of their K-D times further supporting that scores are not affected by the fatigue associated with sparring. Conclusion. The K-D test is a rapid sideline screening tool for concussion that can be effectively administered by nonmedically trained laypersons.	[Leong, D. F.] King Devick Test LLC, Oak Brook Terrace, IL 60181 USA; [Balcer, L. J.] NYU, Langone Med Ctr, New York, NY 10003 USA; [Galetta, S. L.] Beverly Hosp, Dept Internal Med, Danvers, MA USA; [Liu, Z.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Master, C. L.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Sports Med, Philadelphia, PA 19104 USA		Leong, DF (corresponding author), King Devick Test LLC, 2 Mid America Pl Ste 110, Oak Brook Terrace, IL 60181 USA.	dleong@kingdevicktest.com		Master, Christina/0000-0002-6717-4270	NIH/NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); National MS SocietyNational Multiple Sclerosis Society	Dr. Leong is employed at King-Devick Test, LLC as a Director of Research; Dr. Balcer has served as a consultant for Biogen Idec, Questcor, and Novartis; and has received research support from the NIH/NEI and the National MS Society; Dr. Galetta has served as a consultant for Biogen Idec, Questcor, and Teva Pharmaceutical Industries Ltd.	Alla S, 2009, BR J SPORTS MED S1, V43, pi13; Bay E, 2011, ADV EMERG NURS J, V33, P71, DOI 10.1097/TME.0b013e318207e851; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Defense and Veterans Brain Injury Center, MIL AC CONC EV; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2011, PHYS MED REH CLIN N, V22, P603, DOI 10.1016/j.pmr.2011.08.003; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Krumholtz I, 2000, OPTOMETRY, V71, P489; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Reilly R., 2011, COMMUNICATION; Ridgway GR, 2012, NEUROLOGY, V79, P80, DOI 10.1212/WNL.0b013e31825dce28; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Talavage TM, 2010, J NEUROTRAUMA; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230; Zazryn TR, 2009, CLIN J SPORT MED, V19, P20, DOI 10.1097/JSM.0b013e31818f1582	47	60	60	0	18	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707	1827-1928		J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	FEB	2014	54	1					70	77					8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	AB8PG	WOS:000332051900010	24445547				2022-02-06	
J	Wali, B; Ishrat, T; Won, S; Stein, DG; Sayeed, I				Wali, Bushra; Ishrat, Tauheed; Won, Soonmi; Stein, Donald G.; Sayeed, Iqbal			Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study	BRAIN			English	Article						dose response; functional recovery; progesterone; stroke; therapeutic time window	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; VITAMIN-D HORMONE; COMBINATION TREATMENT; ISCHEMIC-STROKE; FOCAL ISCHEMIA; INFARCT VOLUME; HEART-DISEASE; ALLOPREGNANOLONE; NEUROPROTECTION	Currently, the only approved treatment for ischaemic stroke is tissue plasminogen activator, a clot-buster. This treatment can have dangerous consequences if not given within the first 4 h after stroke. Our group and others have shown progesterone to be beneficial in preclinical studies of stroke, but a progesterone dose-response and time-window study is lacking. We tested male Sprague-Dawley rats (12 months old) with permanent middle cerebral artery occlusion or sham operations on multiple measures of sensory, motor and cognitive performance. For the dose-response study, animals received intraperitoneal injections of progesterone (8, 16 or 32 mg/kg) at 1 h post-occlusion, and subcutaneous injections at 6 h and then once every 24 h for 7 days. For the time-window study, the optimal dose of progesterone was given starting at 3, 6 or 24 h post-stroke. Behavioural recovery was evaluated at repeated intervals. Rats were killed at 22 days post-stroke and brains extracted for evaluation of infarct volume. Both 8 and 16 mg/kg doses of progesterone produced attenuation of infarct volume compared with the placebo, and improved functional outcomes up to 3 weeks after stroke on locomotor activity, grip strength, sensory neglect, gait impairment, motor coordination and spatial navigation tests. In the time-window study, the progesterone group exhibited substantial neuroprotection as late as 6 h after stroke onset. Compared with placebo, progesterone showed a significant reduction in infarct size with 3- and 6-h delays. Moderate doses (8 and 16 mg/kg) of progesterone reduced infarct size and improved functional deficits in our clinically relevant model of stroke. The 8 mg/kg dose was optimal in improving motor, sensory and memory function, and this effect was observed over a large therapeutic time window. Progesterone shows promise as a potential therapeutic agent and should be examined for safety and efficacy in a clinical trial for ischaemic stroke.	[Wali, Bushra; Ishrat, Tauheed; Won, Soonmi; Stein, Donald G.; Sayeed, Iqbal] Emory Univ, Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA		Sayeed, I (corresponding author), Emory Univ, Brain Res Lab, Dept Emergency Med, 1365B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	isayeed@emory.edu	Stein, Donald/AAJ-5139-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS062676]; American Heart AssociationAmerican Heart Association [11SDG5430002]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS062676] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants UO1 NS062676 to D.G.S. and American Heart Association grant 11SDG5430002 to I.S.	Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bitran D, 1996, PSYCHOPHARMACOLOGY, V125, P65, DOI 10.1007/BF02247394; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; BIXO M, 1990, PSYCHONEUROENDOCRINO, V15, P159, DOI 10.1016/0306-4530(90)90025-5; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DELCKER A, 1993, EUR ARCH PSY CLIN N, V242, P179, DOI 10.1007/BF02189960; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hankey GJ, 1999, ARCH NEUROL-CHICAGO, V56, P748, DOI 10.1001/archneur.56.6.748; Hetze S, 2012, J NEUROSCI METH, V206, P7, DOI 10.1016/j.jneumeth.2012.02.001; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Muntner P, 2006, AM J EPIDEMIOL, V163, P913, DOI 10.1093/aje/kwj124; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Parkkinen S, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/410972; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Savitz SI, 2011, STROKE, V42, P825, DOI 10.1161/STROKEAHA.110.601914; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Won S, 2013, STROKE, V44; Wong R, 2013, J NEUROENDO IN PRESS; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yousuf S, 2013, NEUROSCIENCE, V239, P92, DOI 10.1016/j.neuroscience.2012.10.017	73	60	61	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2014	137		2				486	502		10.1093/brain/awt319			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AA7QB	WOS:000331290900017	24374329	Bronze, Green Published			2022-02-06	
J	Defrin, R				Defrin, Ruth			Chronic post-traumatic headache: clinical findings and possible mechanisms	JOURNAL OF MANUAL & MANIPULATIVE THERAPY			English	Article						Chronic pain; Traumatic brain injury; Headache; Mechanisms	TRAUMATIC BRAIN-INJURY; TENSION-TYPE HEADACHE; NECROSIS-FACTOR-ALPHA; SPINAL-CORD; NEUROPATHIC PAIN; STRESS-DISORDER; CENTRAL SENSITIZATION; TRIGEMINAL NEURALGIA; MODEL; WHIPLASH	Chronic post-traumatic headache (CPTHA), the most frequent complaint after traumatic brain injury (TBI), dramatically affects quality of life and function. Despite its high prevalence and persistence, the mechanism of CPTHA is poorly understood. This literature review aimed to analyze the results of studies assessing the characteristics and sensory profile of CPTHA in order to shed light on its possible underlying mechanisms. The search for English language articles published between 1960 and 2013 was conducted in MEDLINE, CINAHL, and PubMed. Studies assessing clinical features of headache after TBI as well as studies conducting quantitative somatosensory testing (QST) in individuals with CPTHA and in individuals suffering from other types of pain were included. Studies on animal models of pain following damage to peripheral tissues and to the peripheral and central nervous system were also included. The clinical features of CPTHA resembled those of primary headache, especially tension-type and migraine headache. Positive and negative signs were prevalent among individuals with CPTHA, in both the head and in other body regions, suggesting the presence of local (cranial) mechanical hypersensitivity, together with generalized thermal hypoesthesia and hypoalgesia. Evidence of dysfunctional pain modulation was also observed. Chronic post-traumatic headache can result from damage to intra-and pericranial tissues that caused chronic sensitization of these tissues. Alternatively, although not mutually exclusive, CPTHA might possibly be a form of central pain due to damage to brain structures involved in pain processing. These, other possibilities, as well as risk factors for CPTHA are discussed at length.	[Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Sch Allied Hlth Profess, Dept Phys Therapy, Tel Aviv, Israel		Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel.	rutidef@post.tau.ac.il					Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; Basbaum A.I., 2000, PRINCIPLES NEURAL SC, P472; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; Bettucci D, 1998, ITAL J NEUROL SCI, V19, P20, DOI 10.1007/BF03028807; Bezov D, 2011, HEADACHE, V51, P262, DOI 10.1111/j.1526-4610.2010.01768.x; Boroujerdi A, 2011, PAIN, V152, P649, DOI 10.1016/j.pain.2010.12.014; BRING G, 1991, Scandinavian Journal of Primary Health Care, V9, P135, DOI 10.3109/02813439109026597; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Buchgreitz L, 2006, PAIN, V123, P19, DOI 10.1016/j.pain.2006.01.040; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Cao Y, 2013, J PAIN, V14, P193, DOI 10.1016/j.jpain.2012.11.005; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; COOPER PR, 1993, HEAD INJURY, P1; Defrin R, 2011, EUR J PAIN S, V5, P138, DOI DOI 10.1016/S1754-3207(11)70471-0; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Devor M, 2006, J PAIN, V7, pS3, DOI 10.1016/j.jpain.2005.09.006; Devor M, 2002, J NEUROSURG, V96, P532, DOI 10.3171/jns.2002.96.3.0532; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Fernandez-de-las-Penas C, 2011, HEADACHE, V51, P384, DOI 10.1111/j.1526-4610.2010.01791.x; Fields HL, 2006, WALL MELZACKS TXB PA, P125; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Haas DC, 2002, HEADACHE, V42, P162, DOI 10.1046/j.1526-4610.2002.02039.x; Hains BC, 2007, PROG BRAIN RES, V161, P195, DOI 10.1016/S0079-6123(06)61013-3; Hansson P, 2004, EUR J NEUROL, V11, P22, DOI 10.1111/j.1471-0552.2004.00793.x; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Jensen R, 1999, CEPHALALGIA, V19, P602, DOI 10.1046/j.1468-2982.1999.019006602.x; Keidel M, 2001, PAIN, V92, P319, DOI 10.1016/S0304-3959(01)00272-X; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Krause T, 2012, J NEUROL NEUROSUR PS, V83, P776, DOI 10.1136/jnnp-2011-301936; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Le Bars D, 2002, BRAIN RES REV, V40, P29, DOI 10.1016/S0165-0173(02)00186-8; LENZ FA, 1987, PAIN, V31, P225, DOI 10.1016/0304-3959(87)90038-8; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lucas S, 2013, CEPHALALGIA; Luo DS, 2012, PAIN PHYSICIAN, V15, P187; Main A, 1997, HEADACHE, V37, P492, DOI 10.1046/j.1526-4610.1997.3708492.x; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Masri R, 2009, J NEUROPHYSIOL, V102, P181, DOI 10.1152/jn.00152.2009; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Nakagawa K, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-9; Nampiaparampil DE, 2000, JAMA-J AM MED ASSOC, V300, P711; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Obelieniene D, 1998, CEPHALALGIA, V18, P559, DOI 10.1046/j.1468-2982.1998.1808559.x; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Packard Russell C, 2002, Curr Pain Headache Rep, V6, P301, DOI 10.1007/s11916-002-0051-4; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Pearce JMS, 2001, SPINAL CORD, V39, P228, DOI 10.1038/sj.sc.3101128; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Peyron R, 2004, NEUROLOGY, V63, P1838, DOI 10.1212/01.WNL.0000144177.61125.85; Pielsticker A, 2005, PAIN, V118, P215, DOI 10.1016/j.pain.2005.08.019; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; Ruff RL, 2012, J REHABIL RES DEV, V49, P1305, DOI 10.1682/JRRD.2011.12.0251; Sandhir R, 2011, NEUROCHEM RES, V36, P856, DOI 10.1007/s11064-011-0414-5; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; Sandrini G, 2002, NEUROSCI LETT, V317, P135, DOI 10.1016/S0304-3940(01)02447-8; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Wu G, 2002, J NEUROSCI, V22, P7746; Yarnitsky D, 2010, EUR J PAIN, V14, P339, DOI 10.1016/j.ejpain.2010.02.004; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zeilig G, 2012, BRAIN, V135, P418, DOI 10.1093/brain/awr270	90	60	60	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1066-9817	2042-6186		J MAN MANIP THER	J. Man. Manip. Ther.		2014	22	1					36	43		10.1179/2042618613Y.0000000053			8	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V70KE	WOS:000211504700005	24976746	Green Published			2022-02-06	
J	Bayen, E; Pradat-Diehl, P; Jourdan, C; Ghout, I; Bosserelle, V; Azerad, S; Weiss, JJ; Joel, ME; Aegerter, P; Azouvi, P				Bayen, Eleonore; Pradat-Diehl, Pascale; Jourdan, Claire; Ghout, Idir; Bosserelle, Vanessa; Azerad, Sylvie; Weiss, Jean-Jacques; Joel, Marie-Eve; Aegerter, Philippe; Azouvi, Philippe		Steering Comm PariS-TBI Study	Predictors of Informal Care Burden 1 Year After a Severe Traumatic Brain Injury: Results From the PariS-TBI study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dysexecutive syndrome; GOS-E; informal care; SF-36; traumatic brain injury; Zarit Burden Inventory	FAMILY CAREGIVERS; LIFE SATISFACTION; HEAD-INJURY; EXECUTIVE DYSFUNCTION; COGNITIVE DEFICITS; HEALTH SURVEY; FOLLOW-UP; COMMUNITY; PROGRAM; DISABILITY	Objective: To investigate predictors of informal care burden 1 year after a severe traumatic brain injury (TBI). Participants: Patients (N = 66) aged 15 years or older with severe TBI (Glasgow Coma Scale score of 8 or less) and their primary informal caregivers. Setting: Multicenter inception cohort study over 22 months in Paris and the surrounding area (PariS-TBI study). Main measures: Patients' preinjury characteristics; injury severity data; outcome measures at discharge from intensive care and 1 year after the injury; Dysexecutive Questionnaire; Medical Outcome Study Short Form-36; Zarit Burden Inventory. Results: Among the 257 survivors at discharge from acute care, 66 patient-caregiver couples were included. Primary informal caregivers were predominantly women (73%), of middle age (age, 50 years), supporting male patients (79%), of mean age of 38 years. The majority (56%) of caregivers experienced significant burden, and 44% were at risk of depression. Caregivers' impaired health status and perceived burden significantly correlated with patients' global disability (as assessed with the Glasgow Outcome Scale-Extended) and impairments of executive functions (as assessed with the Dysexecutive Questionnaire). A focused principal component analysis suggested that disability and executive dysfunctions were independent predictors of perceived burden, whereas demographics, injury severity, and Glasgow Outcome Scale at discharge from acute care did not significantly correlate with caregiver's burden. Conclusion: Global handicap and impairments of executive functions are independent significant predictors of caregiver burden 1 year after TBI.	[Bayen, Eleonore; Pradat-Diehl, Pascale] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Bayen, Eleonore; Joel, Marie-Eve] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Univ Paris 06, UFR Med, Paris, France; [Pradat-Diehl, Pascale; Jourdan, Claire; Azouvi, Philippe] Univ Paris 06, Unite ER 6, Paris, France; [Jourdan, Claire; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, Garches, France; [Jourdan, Claire; Azouvi, Philippe] Univ Versailles St Quentin, UFR Med, EA 4497, Guyancourt, France; [Ghout, Idir; Bosserelle, Vanessa; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, AP HP, Unite Rech Clin Paris Ouest, Boulogne, France; [Bosserelle, Vanessa; Azerad, Sylvie; Weiss, Jean-Jacques] Ctr Ressources Francilien Traumatisme Cranien, Paris, France; [Aegerter, Philippe] Univ Versailles St Quentin, UPRES EA 2506, Guyancourt, France		Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr	AEGERTER, Philippe/AAY-6003-2021	AEGERTER, Philippe/0000-0002-9156-5028; tazarourte, karim/0000-0002-3376-1258	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM-04-084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Fondation Garches and the French Society of Physical Medicine and Rehabilitation (SOFMER)	PariS-TBI study has been funded by a grant of French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM-04-084), supported by AP-HP (Departement de la Recherche Clinique et du Developpement). The authors thank all patients and family participants who took the time to share their experience and all members of the CRFTC Steering Committee (Centre Ressource Francilien des Traumatises Craniens) for their valuable help.; The authors also thank Prof Pernot, Dr Dulou, Prof Tadie, Prof Truelle, Dr Carli, and Dr Welschbillig for their participation in the study. The first author thanks the Fondation Garches and the French Society of Physical Medicine and Rehabilitation (SOFMER) for their grant support.	Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Andrieu S, 2003, REV MED INTERNE, V24, p351S, DOI 10.1016/S0248-8663(03)80695-1; [Anonymous], 1999, JAMA, V282, P974; Azouvi Philippe, 2009, Rev Prat, V59, P1087; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bachner YG, 2007, AGING MENT HEALTH, V11, P678, DOI 10.1080/13607860701529965; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brehaut JC, 2004, PEDIATRICS, V114, P182; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Centre Ressources Francilien du Traumatisme Cranien, 2012, FORM SEM 2012; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Davin B, 2005, REV EPIDEMIOL SANTE, V53, P509, DOI 10.1016/S0398-7620(05)84728-5; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Falissard B, 2011, ANALYSIS OF QUESTIONNAIRE DATA WITH R; Falissard B, 1999, J COMPUT GRAPH STAT, V8, P906, DOI 10.2307/1390833; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Haute Autorite de Sante, 2004, SORT MOND HOSP RET D; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Higginson IJ, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-42; Institut national de la statistique et des etudes economiques, ENQ HAND SANT 2008 V; Institut national de la statistique et des etudes economiques, 2012, NOM PROF CAT SOC; Institut national de la statistique et des etudes economiques, ENQ HAND SANT 2008 A; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Joel Marie-Eve, 2003, Psychol Neuropsychiatr Vieil, V1, P259; Joel ME, 2003, REV EPIDEMIOL SANTE, V51, P574; Jourdan C, NEUROREHABI IN PRESS; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Leplege A, 1998, J CLIN EPIDEMIOL, V51, P1013, DOI 10.1016/S0895-4356(98)00093-6; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; RANKIN ED, 1994, GERONTOLOGIST, V34, P828, DOI 10.1093/geront/34.6.828; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Roche V, 2009, AM J MED SCI, V337, P199, DOI 10.1097/MAJ.0b013e31818b114d; Rosenberg PB, 2005, AM J GERIAT PSYCHIAT, V13, P822, DOI 10.1176/appi.ajgp.13.9.822; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Schreiner AS, 2006, AGING MENT HEALTH, V10, P107, DOI 10.1080/13607860500312142; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SF 36 HLTH SURV MAN; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	65	60	60	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					408	418		10.1097/HTR.0b013e31825413cf			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200004	22691963				2022-02-06	
J	Katzenberger, RJ; Loewen, CA; Wassarman, DR; Petersen, AJ; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Loewen, Carin A.; Wassarman, Douglas R.; Petersen, Andrew J.; Ganetzky, Barry; Wassarman, David A.			A Drosophila model of closed head traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						concussion; insect; chronic traumatic encephalopathy	APOLIPOPROTEIN-E; IMMUNE-RESPONSE; TNF-ALPHA; AGE; NEURODEGENERATION; ENCEPHALOPATHY; ORGANIZATION; RESVERATROL; ACTIVATION; GENETICS	Traumatic brain injury (TBI) is a substantial health issue worldwide, yet the mechanisms responsible for its complex spectrum of pathologies remains largely unknown. To investigate the mechanisms underlying TBI pathologies, we developed a model of TBI in Drosophila melanogaster. The model allows us to take advantage of the wealth of experimental tools available in flies. Closed head TBI was inflicted with a mechanical device that subjects flies to rapid acceleration and deceleration. Similar to humans with TBI, flies with TBI exhibited temporary incapacitation, ataxia, activation of the innate immune response, neurodegeneration, and death. Our data indicate that TBI results in death shortly after a primary injury only if the injury exceeds a certain threshold and that age and genetic background, but not sex, substantially affect this threshold. Furthermore, this threshold also appears to be dependent on the same cellular and molecular mechanisms that control normal longevity. This study demonstrates the potential of flies for providing key insights into human TBI that may ultimately provide unique opportunities for therapeutic intervention.	[Katzenberger, Rebeccah J.; Wassarman, Douglas R.; Petersen, Andrew J.; Wassarman, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53706 USA; [Loewen, Carin A.; Ganetzky, Barry] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA		Ganetzky, B (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	ganetzky@wisc.edu; dawassarman@wisc.edu		Wassarman, Douglas/0000-0002-6922-9378	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS059001, R01 AG033620]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033620] Funding Source: NIH RePORTER	We thank Nicole Bertram, Grace Boekhoff- Falk, members of the D.A.W. and B.G. laboratories, and Ron Kalil for their insights that greatly improved this research; Russell Little for help in determining the impact velocity; and Satoshi Kinoshita for performing the histology. This work was supported by National Institutes of Health Grants R01 NS059001 (to D.A.W.) and R01 AG033620 (to B.G.).	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Boyan GS, 2011, TRENDS NEUROSCI, V34, P247, DOI 10.1016/j.tins.2011.02.002; Bushey D, 2011, INT REV NEUROBIOL, V99, P213, DOI 10.1016/B978-0-12-387003-2.00009-4; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Desalvo MK, 2011, GLIA, V59, P1322, DOI 10.1002/glia.21147; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Faul M, 2010, TRAUMATIC BRAIN INJU; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kahsai L, 2011, INT REV NEUROBIOL, V99, P139, DOI 10.1016/B978-0-12-387003-2.00006-9; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lessing D, 2009, NAT REV GENET, V10, P359, DOI 10.1038/nrg2563; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Petersen AJ, 2013, GENETICS, V194, P133, DOI 10.1534/genetics.113.150854; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Piyankarage SC, 2012, ANAL CHEM, V84, P4460, DOI 10.1021/ac3002319; Ramsden S, 2008, AGING CELL, V7, P225, DOI 10.1111/j.1474-9726.2008.00370.x; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Reichert H, 2005, BRAIN RES BULL, V66, P491, DOI 10.1016/j.brainresbull.2004.11.028; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Stork Tobias, 2012, Cold Spring Harb Protoc, V2012, P1, DOI 10.1101/pdb.top067587; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tanzi R.E, 2012, COLD SPRING HARB PER, V2, P10, DOI DOI 10.1101/CSHPERSPECT.A006296; Timmers S, 2012, AGING-US, V4, P146, DOI 10.18632/aging.100445; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	42	60	60	2	34	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	OCT 29	2013	110	44					E4152	E4159		10.1073/pnas.1316895110			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242LJ	WOS:000326243100010	24127584	Bronze, Green Published			2022-02-06	
J	Valdeolivas, S; Pazos, MR; Bisogno, T; Piscitelli, F; Iannotti, FA; Allara, M; Sagredo, O; Di Marzo, V; Fernandez-Ruiz, J				Valdeolivas, S.; Pazos, M. R.; Bisogno, T.; Piscitelli, F.; Iannotti, F. A.; Allara, M.; Sagredo, O.; Di Marzo, V.; Fernandez-Ruiz, J.			The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG	CELL DEATH & DISEASE			English	Article						endocannabinoids; CB1 and CB2 receptors; diacyl-glycerol lipase; monoacyl-glycerol lipase; cyclooxygenase-2; Huntington's disease; malonate; neuroprotection	TRAUMATIC BRAIN-INJURY; HUNTINGTONS-DISEASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; CANNABINOID RECEPTORS; ALZHEIMERS-DISEASE; BASAL GANGLIA; IN-VIVO; MODEL; COX-2; NEURODEGENERATION	The cannabinoid CB2 receptor, which is activated by the endocannabinoid 2-arachidonoyl-glycerol (2-AG), protects striatal neurons from apoptotic death caused by the local administration of malonate, a rat model of Huntington's disease (HD). In the present study, we investigated whether endocannabinoids provide tonic neuroprotection in this HD model, by examining the effect of O-3841, an inhibitor of diacylglycerol lipases, the enzymes that catalyse 2-AG biosynthesis, and JZL184 or OMDM169, two inhibitors of 2-AG inactivation by monoacylglycerol lipase (MAGL). The inhibitors were injected in rats with the striatum lesioned with malonate, and several biochemical and morphological parameters were measured in this brain area. Similar experiments were also conducted in vitro in cultured M-213 cells, which have the phenotypic characteristics of striatal neurons. O-3841 produced a significant reduction in the striatal levels of 2-AG in animals lesioned with malonate. However, surprisingly, the inhibitor attenuated malonate-induced GABA and BDNF deficiencies and the reduction in Nissl staining, as well as the increase in GFAP immunostaining. In contrast, JZL184 exacerbated malonate-induced striatal damage. Cyclooxygenase-2 (COX-2) was induced in the striatum 24 h after the lesion simultaneously with other pro-inflammatory responses. The COX-2-derived 2-AG metabolite, prostaglandin E-2 glyceryl ester (PGE(2)-G), exacerbated neurotoxicity, and this effect was antagonized by the blockade of PGE(2)-G action with AGN220675. In M-213 cells exposed to malonate, in which COX-2 was also upregulated, JZL184 worsened neurotoxicity, and this effect was attenuated by the COX-2 inhibitor celecoxib or AGN220675. OMDM169 also worsened neurotoxicity and produced measurable levels of PGE(2)-G. In conclusion, the inhibition of 2-AG biosynthesis is neuroprotective in rats lesioned with malonate, possibly through the counteraction of the formation of pro-neuroinflammatory PGE(2)-G, formed from COX-2-mediated oxygenation of 2-AG. Accordingly, MAGL inhibition or the administration of PGE(2)-G aggravates the malonate toxicity.	[Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, IUIN, E-28040 Madrid, Spain; [Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] IRYCIS, Madrid, Spain; [Bisogno, T.; Piscitelli, F.; Iannotti, F. A.; Allara, M.; Di Marzo, V.] CNR, Endocannabinoid Res Grp, Inst Biomol Chem, I-80078 Naples, Italy		Sagredo, O (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol, Fac Med, E-28040 Madrid, Spain.	onintza@med.ucm.es; vdimarzo@icmib.na.cnr.it; jjfr@med.ucm.es	Di Marzo, Vincenzo/AAD-7742-2019; SAGREDO, ONINTZA/I-9094-2016; Bisogno, Tiziana/B-7891-2015; Piscitelli, Fabiana/A-7100-2014; Pazos, Ruth/D-6797-2019; Valdeolivas Rojas, Sara/I-9361-2016; iannotti, fabio a/K-5704-2016; FERNANDEZ RUIZ, JOSE JAVIER/S-3875-2018	Di Marzo, Vincenzo/0000-0002-1490-3070; SAGREDO, ONINTZA/0000-0003-0452-3223; Pazos, Ruth/0000-0001-7613-795X; Valdeolivas Rojas, Sara/0000-0003-1379-6602; iannotti, fabio a/0000-0003-4480-8370; Piscitelli, Fabiana/0000-0001-9343-4622; FERNANDEZ RUIZ, JOSE JAVIER/0000-0002-4490-0604	CIBERNEDInstituto de Salud Carlos III [CB06/05/0089]; MICINNSpanish GovernmentEuropean Commission [SAF2009/11847]; CAM [S2011/BMD-2308]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA009789]; 'Programa FPI-Ministerio de Ciencia e Innovacion'; Complutense University-Predoctoral Program; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This work was supported by grants from CIBERNED (CB06/05/0089), MICINN (SAF2009/11847) and CAM (S2011/BMD-2308) to SV, MRP, OS and JFR, and by NIH (grant nr. DA009789) to VDM. MRP was a predoctoral fellow supported by the 'Programa FPI-Ministerio de Ciencia e Innovacion' and SV was supported by the Complutense University-Predoctoral Program. We are indebted to Yolanda Garcia Movellan and Davide Castelluccio for technical and administrative assistance.	Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Bisogno T, 2006, BBA-MOL CELL BIOL L, V1761, P205, DOI 10.1016/j.bbalip.2005.12.009; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; Bisogno T, 2008, NEUROCHEM INT, V52, P307, DOI 10.1016/j.neuint.2007.06.031; Bisogno T, 2007, PHARMACOL RES, V56, P428, DOI 10.1016/j.phrs.2007.09.002; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blazquez C, 2011, BRAIN, V134, P119, DOI 10.1093/brain/awq278; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Burgunder JM, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-2; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; De Yebenes J., 201002422724 EUDRACT; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Du H, 2001, BRIT J PHARMACOL, V163, P1533; Fernandez-Ruiz J, 2011, BRIT J PHARMACOL, V163, P1365, DOI 10.1111/j.1476-5381.2011.01365.x; Gatta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031111; GIORDANO M, 1993, EXP NEUROL, V124, P395, DOI 10.1006/exnr.1993.1213; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hoozemans JJM, 2008, CURR PHARM DESIGN, V14, P1419, DOI 10.2174/138161208784480171; Hu SSJ, 2008, BRIT J PHARMACOL, V153, P1538, DOI 10.1038/bjp.2008.33; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; Kreutz S, 2009, GLIA, V57, P286, DOI 10.1002/glia.20756; Lastres-Becker I, 2003, J NEUROCHEM, V84, P1097, DOI 10.1046/j.1471-4159.2003.01595.x; Lastres-Becker I, 2001, NEUROREPORT, V12, P2125, DOI 10.1097/00001756-200107200-00017; Lastres-Becker I, 2004, NEUROREPORT, V15, P2375, DOI 10.1097/00001756-200410250-00015; Lastres-Becker I, 2003, NEUROREPORT, V14, P813, DOI 10.1097/00001756-200305060-00007; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; McMurray CT, 2001, TRENDS NEUROSCI, V24, pS32, DOI 10.1016/S0166-2236(00)01997-4; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Minghetti L, 2007, J NEUROPATH EXP NEUR, V66, P363, DOI 10.1097/nen.0b013e3180517477; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; O'Sullivan SE, 2010, IMMUNOBIOLOGY, V215, P611, DOI 10.1016/j.imbio.2009.09.007; Ortar G, 2008, J MED CHEM, V51, P6970, DOI 10.1021/jm800978m; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Palkovits M., 1988, MAPS GUIDE MICRODISS; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pazos MR, 2008, CURR PHARM DESIGN, V14, P2317, DOI 10.2174/138161208785740108; Pintor A, 2006, NEUROPHARMACOLOGY, V51, P1004, DOI 10.1016/j.neuropharm.2006.06.013; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Sagredo O, 2007, EUR J NEUROSCI, V26, P843, DOI 10.1111/j.1460-9568.2007.05717.x; Sagredo Onintza, 2012, Recent Pat CNS Drug Discov, V7, P41; Sagredo O, 2011, J NEUROSCI RES, V89, P1509, DOI 10.1002/jnr.22682; Sagredo O, 2009, GLIA, V57, P1154, DOI 10.1002/glia.20838; Sang N, 2007, J NEUROCHEM, V102, P1966, DOI 10.1111/j.1471-4159.2007.04668.x; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Sun Y, 2007, PPAR RES, V2007, DOI 10.1155/2007/23513; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Toulmond S, 2004, BRIT J PHARMACOL, V141, P689, DOI 10.1038/sj.bjp.0705662; Tzeng Shun-Fen, 2005, Current Drug Targets - Inflammation and Allergy, V4, P335, DOI 10.2174/1568010054022051; Valdeolivas S, 2012, ACS CHEM NEUROSCI, V3, P400, DOI 10.1021/cn200114w; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Woodward DF, 2008, PHARMACOL THERAPEUT, V120, P71, DOI 10.1016/j.pharmthera.2008.08.001; Wright BLC, 2007, CURR MOL MED, V7, P579, DOI 10.2174/156652407781695738; Yang HW, 2008, CURR PHARM DESIGN, V14, P1443, DOI 10.2174/138161208784480144; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200	59	60	60	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	OCT	2013	4								e862	10.1038/cddis.2013.387			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	251XK	WOS:000326967100048	24136226	Green Published, gold			2022-02-06	
J	Niyonkuru, C; Wagner, AK; Ozawa, H; Amin, K; Goyal, A; Fabio, A				Niyonkuru, Christian; Wagner, Amy K.; Ozawa, Haishin; Amin, Krutika; Goyal, Akash; Fabio, Anthony			Group-Based Trajectory Analysis Applications for Prognostic Biomarker Model Development in Severe TBI: A Practical Example	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; prognosis; S100b; trajectory analysis; traumatic brain injury	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; SERUM S-100B PROTEIN; CEREBROSPINAL-FLUID; HEAD-INJURY; OUTCOME PREDICTION; MARKER; DAMAGE; S100B; REHABILOMICS	Over the last decade, biomarker research has identified potential biomarkers for the diagnosis, prognosis, and management of traumatic brain injury (TBI). Several cerebrospinal fluid (CSF) and serum biomarkers have shown promise in predicting long-term outcome after severe TBI. Despite this increased focus on identifying biomarkers for outcome prognostication after a severe TBI, several challenges still exist in effectively modeling the significant heterogeneity observed in TBI-related pathology, as well as the biomarker-outcome relationships. Biomarker data collected over time are usually summarized into single-point estimates (e.g., average or peak biomarker levels), which are, in turn, used to examine the relationships between biomarker levels and outcomes. Further, many biomarker studies to date have focused on the prediction power of biomarkers without controlling for potential clinical and demographic confounders that have been previously shown to affect long-term outcome. In this article, we demonstrate the application of a practical approach to delineate and describe distinct subpopulations having similar longitudinal biomarker profiles and to model the relationships between these biomarker profiles and outcomes while taking into account potential confounding factors. As an example, we demonstrate a group-based modeling technique to identify temporal S100 calcium-binding protein B (S100b) profiles, measured from CSF over the first week post-injury, in a sample of adult subjects with TBI, and we use multivariate logistic regression to show that the prediction power of S100b biomarker profiles can be superior to the prediction power of single-point estimates.	[Niyonkuru, Christian; Wagner, Amy K.; Ozawa, Haishin; Amin, Krutika; Goyal, Akash] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Epidemiol Data Ctr, Dept Epidemiol, Pittsburgh, PA 15213 USA		Fabio, A (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Dept Epidemiol, 130 DeSoto St,127 Parran Hall, Pittsburgh, PA 15213 USA.	afabio@pitt.edu		Fabio, Anthony/0000-0002-6808-4939	 [DODW81XWH-071-0701];  [R49 CCR 323155-03]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	This study was supported by DODW81XWH-071-0701 (to A. F., A. K. W., C.N., H.O., K. A., and A. G.) and R49 CCR 323155-03 (to A. F. and A. K. W.).	Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Demidenko E., 2004, MIXED MODELS THEORY; Duncan TE, 2004, BEHAV THER, V35, P333, DOI 10.1016/S0005-7894(04)80042-X; Goyal A, 2012, J NEUROTRAUMA; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; JENNETT B, 1975, LANCET, V1, P480; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Kotz S., 2000, WILEY SER PROB STAT; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; MEREDITH W, 1990, PSYCHOMETRIKA, V55, P107, DOI 10.1007/BF02294746; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nagin D.S., 2005, GROUP BASED MODELING; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, PM&R, V3, pS28, DOI 10.1016/j.pmrj.2011.04.013; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	35	60	64	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					938	945		10.1089/neu.2012.2578			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300004	23421760	Green Submitted			2022-02-06	
J	Hussmann, B; Lefering, R; Waydhas, C; Touma, A; Kauther, MD; Ruchholtz, S; Lendemans, S				Hussmann, Bjoern; Lefering, Rolf; Waydhas, Christian; Touma, Alexander; Kauther, Max D.; Ruchholtz, Steffen; Lendemans, Sven		German Soc Trauma Surg	Does increased prehospital replacement volume lead to a poor clinical course and an increased mortality? A matched-pair analysis of 1896 patients of the Trauma Registry of the German Society for Trauma Surgery who were managed by an emergency doctor at the accident site	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Prehospital replacement volume; Mortality; Trauma Registry; Haemorrhagic shock; Emergency medicine	RESUSCITATION; IMPACT	Introduction: Severe bleeding after trauma frequently leads to a poor outcome. Prehospital fluid replacement therapy is regarded as an important primary treatment option. Our study aimed to assess the influence of prehospital fluid replacement therapy on the post-traumatic course of severely injured patients in a retrospective analysis of matched pairs. Patients and methods: The data of 51,425 patients of the Trauma Registry of the German Society for Trauma Surgery were analysed. The following patients were included: Injury Severity Score >= 16 points, primary admission, age >= 16 years, no isolated brain injury, transfusion of at least one unit of packed red blood cells (pRBC), systolic blood pressure >= 60 mm Hg at the accident site. The patients were divided into two groups according to the following matched-pair criteria (low-volume: 0-1500 ml prehospital volume replaced; high-volume: >= 1501 ml prehospital volume): intubation at the accident site (yes/no), time from injury to hospital +/- 10 min., means of rescue (emergency helicopter, MICU), Abbreviated Injury Scale (body regions), injury year, systolic blood pressure and age (years). All patients were managed by an emergency doctor at the accident site. Results: A total of 948 patients in each group met the inclusion criteria. Increasing replacement volume was associated with an increased need for transfusion (pRBCs: low-volume: 7 units, high-volume: 8.3 units; p < 0.001) and a reduced ability to coagulate (prothrombin ratio (PR): low-volume: 68%, high-volume: 61.5%; p < 0.001). Patients in shock (systolic BP < 90 mm Hg) upon admission to the hospital were equally in both groups (25.6%; p = 0.98). Significantly higher lethality was observed in cases of increasing volume (low-volume: 22.7%, high-volume: 27.6%; p < 0.01). Conclusions: Excessive prehospital fluid replacement leads to an increased mortality rate. The results of this study support the concept of restrained volume replacement in the prehospital treatment of patients with severe trauma. (C) 2012 Elsevier Ltd. All rights reserved.	[Hussmann, Bjoern; Waydhas, Christian; Touma, Alexander; Kauther, Max D.; Lendemans, Sven] Univ Hosp Essen, Dept Trauma Surg, D-45122 Essen, Germany; [Lefering, Rolf] Witten Herdecke Univ GmbH, Inst Res Operat Med IFOM, Fac Med, Cologne Merheim Med Ctr, Witten, Germany; [Ruchholtz, Steffen] Univ Hosp Marburg, Trauma Dept, Hand & Reconstruct Surg Unit, Marburg, Germany		Hussmann, B (corresponding author), Univ Hosp Essen, Dept Trauma Surg, Hufelandstr 55, D-45122 Essen, Germany.	bjoern.hussmann@uk-essen.de	Kauther, Max/A-1505-2016	Kauther, Max/0000-0003-3795-6068			Malvestio MAA, 2010, REV ESC ENFERM USP, V44, P350; Bernhard M, 2004, ANAESTHESIST, V53, P887, DOI 10.1007/s00101-004-0732-y; Bickell W H, 1998, Curr Opin Anaesthesiol, V11, P177, DOI 10.1097/00001503-199804000-00010; BICKELL WH, 1993, ANN EMERG MED, V22, P225, DOI 10.1016/S0196-0644(05)80208-2; BICKELL WH, 1994, AM J EMERG MED, V12, P36, DOI 10.1016/0735-6757(94)90194-5; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; Butler F, 2011, J TRAUMA, V70, pS11, DOI 10.1097/TA.0b013e31821a4b90; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Geeraedts LMG, 2009, INJURY, V40, P11, DOI 10.1016/j.injury.2008.10.007; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Holcomb JB, 2004, CRIT CARE, V8, pS57, DOI 10.1186/cc2407; Hubetamann Bjorn, 2011, J Emerg Trauma Shock, V4, P465, DOI 10.4103/0974-2700.86630; Hussmann B, 2011, UNFALLCHIRURG, V114, P705, DOI 10.1007/s00113-010-1842-4; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; Kreimeier U, 1997, ANAESTHESIST, V46, P309, DOI 10.1007/s001010050406; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Kreimeier U, 2003, NOTFALL RETTUNGSMED, V6, P77; Lefering R, 2009, EUR J TRAUMA EMERG S, V35, P437, DOI 10.1007/s00068-009-9122-0; NASTKOLB D, 1993, CHIRURG, V64, P552; Oestern HJ, 1999, UNFALLCHIRURG, V102, P80, DOI 10.1007/s001130050378; Raum M, 2006, NOTFALL RETTUNGSMED, V9, P485; Sapsford W, 2008, SCAND J SURG, V97, P4, DOI 10.1177/145749690809700102; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Trunkey D D, 2001, Emerg Med Serv, V30, P93; Trunkey DD., 2001, EMERG MED SERV, V30, P98; Trunkey DD, 2001, EMERG MED SERV, V30, P93; Turner J, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/hta4310; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; White CE, 2009, INJURY, V40, P1023, DOI 10.1016/j.injury.2008.11.023; Williams J G, 2007, J R Army Med Corps, V153 Suppl 1, P70; Yaghoubian A, 2007, AM SURGEON, V73, P1027; Ziegenfuss T, 1996, ZBL CHIR, V121, P924	33	60	61	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2013	44	5					611	617		10.1016/j.injury.2012.02.004			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	122VE	WOS:000317345400008	22377276				2022-02-06	
J	Wei, J; Pan, XD; Pei, Z; Wang, WM; Qiu, WS; Shi, ZH; Xiao, GM				Wei, Jing; Pan, Xiangdong; Pei, Zhong; Wang, Weimin; Qiu, Wusi; Shi, Zhenghua; Xiao, Guomin			The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Ceftriaxone; neuroprotection; traumatic brain injury; rats	INCREASES GLUTAMATE UPTAKE; TRANSPORTERS; EXPRESSION; OPPORTUNITIES; MECHANISMS; CHALLENGES; PROTEINS; EAAT2	BACKGROUND: The beta-lactam antibiotic, ceftriaxone (CTX), has been reported to induce neuroprotection in animal models of diverse neurologic diseases. Currently, no data have explored the potential for CTX to provide neuroprotection in the animal models of traumatic brain injury (TBI). The aim of this study was to investigate the neuroprotective effect by CTX on TBI and to determine the underlying mechanisms. METHODS: Rats were immediately subjected to a lateral cortical impact injury caused by a free-falling object and divided randomly into three groups: sham-operated, trauma, and trauma + CTX treatment group. The CTX treatment group was given CTX (200 mg/kg of body weight, intravenously) immediately after injury. The cognitive function was assessed by Y-maze testing and cerebral edema was evaluated. Inflammatory cytokines expression was measured using enzyme-linked immunosorbent assay array. The expression of glutamate transporter-1 protein was identified by Western blot analysis. RESULTS: This study shows that the CTX causes attenuation of TBI-induced cerebral edema and cognitive function deficits. CTX treatment significantly reduced levels of the proinflammatory cytokines interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha and upregulated glutamate transporter-1 expression after TBI. CONCLUSION: Our results provide in vivo evidence that CTX could exert neuroprotective effect against TBI by improving cognitive function and alleviating brain edema via reducing excitotoxicity and inflammation after TBI. (J Trauma Acute Care Surg. 2012; 73: 654-660. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Wang, Weimin; Qiu, Wusi; Shi, Zhenghua; Xiao, Guomin] Hangzhou Normal Univ, Affiliated Hosp, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China; [Wei, Jing] Hangzhou Normal Univ, Affiliated Hosp, Med Ctr, Hangzhou 310015, Zhejiang, Peoples R China; [Pan, Xiangdong] Tradit Chinese Med Hosp Linan, Dept Neurosurg, Linan, Peoples R China; [Pei, Zhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol Lab, Guangzhou 510275, Guangdong, Peoples R China		Xiao, GM (corresponding author), Hangzhou Normal Univ, Affiliated Hosp, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China.	gxiao@hznu.edu.cn			Health Department of Hangzhou; Science and Technology Department of Lin'an, Zhejiang province, China	Supported by grants from the Health Department of Hangzhou and the Science and Technology Department of Lin'an, Zhejiang province, China.	Anderson CM, 2000, GLIA, V32, P1; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gardoni F, 2010, PROG BRAIN RES, V183, P169, DOI 10.1016/S0079-6123(10)83009-2; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hedlund E, 2011, EXP NEUROL, V231, P14, DOI 10.1016/j.expneurol.2011.06.002; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li DQ, 2004, NEUROSCI RES, V50, P169, DOI 10.1016/j.neures.2004.06.009; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1996, LAB INVEST, V74, P315; Miller BR, 2008, NEUROSCIENCE, V153, P329, DOI 10.1016/j.neuroscience.2008.02.004; Nizzardo M, 2011, EXP NEUROL, V229, P214, DOI 10.1016/j.expneurol.2011.01.017; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Thone-Reineke C, 2008, J HYPERTENS, V26, P2426, DOI 10.1097/HJH.0b013e328313e403; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	37	60	63	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					654	660		10.1097/TA.0b013e31825133c0			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	009TK	WOS:000309047900018	22710775				2022-02-06	
J	Yu, FS; Zhang, YM; Chuang, DM				Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw			Lithium Reduces BACE1 Overexpression, Beta Amyloid Accumulation, and Spatial Learning Deficits in Mice with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						beta amyloid; beta-APP-cleaving enzyme-1; learning and memory; lithium; traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEUROTROPHIC FACTOR; CEREBROSPINAL-FLUID; MOUSE MODEL; PHOSPHORYLATION; INHIBITION; EXPRESSION; INCREASES	Traumatic brain injury (TBI) leads to both acute injury and long-term neurodegeneration, and is a major risk factor for developing Alzheimer's disease (AD). Beta amyloid (A beta) peptide deposits in the brain are one of the pathological hallmarks of AD. A beta levels increase after TBI in animal models and in patients with head trauma, and reducing A beta levels after TBI has beneficial effects. Lithium is known to be neuroprotective in various models of neurodegenerative disease, and can reduce A beta generation by modulating glycogen synthase kinase-3 (GSK-3) activity. In this study we explored whether lithium would reduce A beta load after TBI, and improve learning and memory in a mouse TBI model. Lithium chloride (1.5 mEq/kg, IP) was administered 15 min after TBI, and once daily thereafter for up to 3 weeks. At 3 days after injury, lithium attenuated TBI-induced A beta load increases, amyloid precursor protein (APP) accumulation, and beta-APP-cleaving enzyme-1 (BACE1) overexpression in the corpus callosum and hippocampus. Increased Tau protein phosphorylation in the thalamus was also attenuated after lithium treatment following TBI at the same time point. Notably, lithium treatment significantly improved spatial learning and memory in the Y-maze test conducted 10 days after TBI, and in the Morris water maze test performed 17-20 days post-TBI, in association with increased hippocampal preservation. Thus post-insult treatment with lithium appears to alleviate the TBI-induced A beta load and consequently improves spatial memory. Our findings suggest that lithium is a potentially useful agent for managing memory impairments after TBI or other head trauma.	[Yu, Fengshan; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC-1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov		Yu, Fengshan/0000-0001-8620-3084	Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM); Blast Lethality Injury and Research Program; Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM), the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH). We are grateful to Drs. Oz Malkesman and Amanda Fu, and to Ms. Laura Tucker from the CNRM for assistance with the behavioral tests and CCI surgery. We would like to thank Drs. Chi-Tso Chiu and Zhifei Wang of the NIMH, and Dr. Flaubert Tchantchou from the Uniformed Services University of the Health Sciences, for their helpful discussions. The authors also wish to gratefully acknowledge the editorial assistance of Peter Leeds and Ioline Henter of the NIMH.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; Barry AE, 2011, J NEUROSCI, V31, P7259, DOI 10.1523/JNEUROSCI.6500-10.2011; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Carter MD, 2010, CLIN PHARMACOL THER, V88, P475, DOI 10.1038/clpt.2010.165; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Giuffrida ML, 2010, REV NEUROSCIENCE, V21, P83; Hashimoto R, 2002, NEUROPHARMACOLOGY, V43, P1173, DOI 10.1016/S0028-3908(02)00217-4; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jacobsen JPR, 2004, BRAIN RES, V1024, P183, DOI 10.1016/j.brainres.2004.07.065; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Liu H., 2012, J COMPUTATIONAL OPTI, V4, P135, DOI 10.1016/j.jecm.2012.04.001.; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Roggo Silvio, 2002, Current Topics in Medicinal Chemistry, V2, P359, DOI 10.2174/1568026024607490; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Weiler J, 2011, J COGNITIVE NEUROSCI, V23, P3037, DOI 10.1162/jocn.2011.21633; Yau JLW, 2007, J NEUROSCI, V27, P10487, DOI 10.1523/JNEUROSCI.2190-07.2007; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	49	60	63	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2342	2351		10.1089/neu.2012.2449			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900010	22583494	Green Published			2022-02-06	
J	Wise, EK; Hoffman, JM; Powell, JM; Bombardier, CH; Bell, KR				Wise, Elizabeth K.; Hoffman, Jeanne M.; Powell, Janet M.; Bombardier, Charles H.; Bell, Kathleen R.			Benefits of Exercise Maintenance After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Exercise; Rehabilitation; Treatment outcome	RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY INTERVENTIONS; REHABILITATION OUTCOMES; VIRTUAL-REALITY; DEPRESSION; METAANALYSIS; EFFICACY; PROGRAM; QUALITY; BEHAVIORS	Wise EK, Hoffman JM, Powell JM, Bombardier CH, Bell KR. Benefits of exercise maintenance after traumatic brain injury. Arch Phys Med Rehabil 2012;93: 1319-23. Objective: To examine the effect of exercise intervention on exercise maintenance, depression, quality of life, and mental health at 6 months for people with traumatic brain injury (TBI) with at least mild depression. Design: Treatment group participants were assessed at baseline, after a 10-week exercise intervention, and 6 months after completion of the intervention. Setting: Community. Participants: Participants (N = 40) with self-reported TBI from 6 months to 5 years prior to study enrollment and a score of 5 or greater on the Patient Health Questionnaire-9. Interventions: Ten-week exercise intervention program consisting of supervised weekly 60-minute sessions and unsupervised 30 minutes of aerobic exercises 4 times each week. Telephone follow-up was conducted every 2 weeks for an additional 6 months to promote exercise maintenance for individuals randomized to the intervention group. Main Outcome Measure: Beck Depression Inventory (BD!) comparing participant outcomes over time. Post hoc analyses included comparison among those who exercised more or less than 90 minutes per week. Results: Participants reduced their scores on the BDI from baseline to 10 weeks and maintained improvement over time. Many participants (48%) demonstrated increased physical activity at 6 months compared with baseline. Those who exercised more than 90 minutes had lower scores on the BDI at the 10-week and 6-month assessments and reported higher perceived quality of life and mental health. Conclusions: Exercise may contribute to improvement in mood and quality of life for people with TBI and should be considered as part of the approach to depression treatment.	[Wise, Elizabeth K.] Harborview Med Ctr, Seattle, WA 98104 USA; [Hoffman, Jeanne M.; Powell, Janet M.; Bombardier, Charles H.; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Wise, EK (corresponding author), Harborview Med Ctr, Box 359818,325 9th Ave, Seattle, WA 98104 USA.	bwise@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research [H133A070032]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A070032) funds for the Traumatic Brain Injury Model Systems.	*AM COLL SPORTS ME, 2009, GUID EX TEST PRESCR; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Baillet A, 2010, ARTHRIT CARE RES, V62, P984, DOI 10.1002/acr.20146; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blake H, 2009, CLIN REHABIL, V23, P589, DOI 10.1177/0269215508101736; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bopp Melissa, 2007, Prev Chronic Dis, V4, pA87; Borg G., 1998, BORGS PERCEIVED EXER; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Conn VS, 2010, NURS RES, V59, P224, DOI 10.1097/NNR.0b013e3181dbb2f8; Conn VS, 2010, ANN BEHAV MED, V39, P128, DOI 10.1007/s12160-010-9172-x; Conn VS, 2009, NURS RES, V58, P175, DOI 10.1097/NNR.0b013e318199b53a; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hassett LM, 2011, BRAIN INJURY, V25, P698, DOI 10.3109/02699052.2011.579934; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Jensen MP, 2001, HDB PAIN ASSESSMENT, P15; Kosinski M., 1995, SF 12 SCORE SF 12 PH; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Pinto BM, 2011, AM J PREV MED, V41, P274, DOI 10.1016/j.amepre.2011.04.015; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Randolph C., 1998, REPEATABLE BATTERY A; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rush AJ, 2004, CONTROL CLIN TRIALS, V25, P119, DOI 10.1016/S0197-2456(03)00112-0; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Sofi F, 2011, J INTERN MED, V269, P107, DOI 10.1111/j.1365-2796.2010.02281.x; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wycherley TP, 2012, DIABETIC MED, V29, P632, DOI 10.1111/j.1464-5491.2011.03451.x	39	60	62	0	38	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1319	1323		10.1016/j.apmr.2012.05.009			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700004	22840829				2022-02-06	
J	Huang, MX; Nichols, S; Robb, A; Angeles, A; Drake, A; Holland, M; Asmussen, S; D'Andrea, J; Chun, W; Levy, M; Cui, L; Song, T; Baker, DG; Hammer, P; McLay, R; Theilmann, RJ; Coimbra, R; Diwakar, M; Boyd, C; Neff, J; Liu, TT; Webb-Murphy, J; Farinpour, R; Cheung, C; Harrington, DL; Heister, D; Lee, RR				Huang, Ming-Xiong; Nichols, Sharon; Robb, Ashley; Angeles, Annemarie; Drake, Angela; Holland, Martin; Asmussen, Sarah; D'Andrea, John; Chun, Won; Levy, Michael; Cui, Li; Song, Tao; Baker, Dewleen G.; Hammer, Paul; McLay, Robert; Theilmann, Rebecca J.; Coimbra, Raul; Diwakar, Mithun; Boyd, Cynthia; Neff, John; Liu, Thomas T.; Webb-Murphy, Jennifer; Farinpour, Roxanna; Cheung, Catherine; Harrington, Deborah L.; Heister, David; Lee, Roland R.			An automatic MEG low-frequency source imaging approach for detecting injuries in mild and moderate TBI patients with blast and non-blast causes	NEUROIMAGE			English	Article						Magnetoencephalography; Traumatic brain injury; Slow-wave; Blast; Motor vehicle accident; Sport injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; SIGNAL SPACE SEPARATION; WHITE-MATTER INJURY; SLOW-WAVE ACTIVITY; MINOR HEAD-INJURY; DELTA WAVES; POSTCONCUSSIVE SYNDROME; SCHIZOPHRENIC-PATIENTS; CLINICAL MANAGEMENT	Traumatic brain injury (TBI) is a leading cause of sustained impairment in military and civilian populations. However, mild (and some moderate) TBI can be difficult to diagnose because the injuries are often not detectable on conventional MRI or CT. Injured brain tissues in TBI patients generate abnormal low-frequency magnetic activity (ALFMA, peaked at 1-4 Hz) that can be measured and localized by magnetoencephalography (MEG). We developed a new automated MEG low-frequency source imaging method and applied this method in 45 mild TB! (23 from combat-related blasts, and 22 from non-blast causes) and 10 moderate TBI patients (non-blast causes). Seventeen of the patients with mild TBI from blasts had tertiary injuries resulting from the blast. The results show our method detected abnormalities at the rates of 87% for the mild TBI group (blast-induced plus non-blast causes) and 100% for the moderate group. Among the mild TBI patients, the rates of abnormalities were 96% and 77% for the blast and non-blast TBI groups, respectively. The spatial characteristics of abnormal slow-wave generation measured by Z scores in the mild blast TBI group significantly correlated with those in non-blast mild TBI group. Among 96 cortical regions, the likelihood of abnormal slow-wave generation was less in the mild TBI patients with blast than in the mild non-blast TBI patients, suggesting possible protective effects due to the military helmet and armor. Finally, the number of cortical regions that generated abnormal slow-waves correlated significantly with the total post-concussive symptom scores in TBI patients. This study provides a foundation for using MEG low-frequency source imaging to support the clinical diagnosis of TBI. Published by Elsevier Inc.	[Huang, Ming-Xiong] Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, San Diego, CA 92121 USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Rehab Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Chun, Won; Baker, Dewleen G.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Nichols, Sharon] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; [Drake, Angela; Holland, Martin; Asmussen, Sarah; McLay, Robert; Boyd, Cynthia; Neff, John; Farinpour, Roxanna; Cheung, Catherine] USN, San Diego Med Ctr, San Diego, CA 92152 USA; [Levy, Michael] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92121 USA; [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA; [Hammer, Paul] Def Ctr Excellence Psychol Hlth, Arlington, VA USA; [Hammer, Paul] Def Ctr Traumat Brain Injury, Arlington, VA USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92121 USA; [Webb-Murphy, Jennifer] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92152 USA		Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Baker, Dewleen/O-4957-2019; Coimbra, Raul/AAP-3019-2020; Levy, Michael/AAL-4647-2020	Baker, Dewleen/0000-0002-1736-9838; Coimbra, Raul/0000-0002-3759-6851; Liu, Thomas/0000-0002-1978-7486	Department of Veterans AffairsUS Department of Veterans Affairs; National Football League; McDonnell Foundation via the Brain Trauma Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS082083] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000146] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Grants from the Department of Veterans Affairs (two for M.X. Huang, one R.R. Lee), National Football League (M.X. Huang and R.R. Lee), and McDonnell Foundation via the Brain Trauma Foundation (PI: J. Ghajar, site PIs: R.R. Lee and M.X. Huang). We would like to thank Angelica Dilay, Susan Yoder, Richard Daugherty, and Terry Curry (RN) for their efforts in recruiting TBI patients, and Dr. J. Chris Edgar for helpful suggestions to the manuscript. We would also like to thank the anonymous reviewers' constructive suggestions that substantially strengthen the present study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Brang D, 2010, NEUROIMAGE, V53, P268, DOI 10.1016/j.neuroimage.2010.06.008; Canive JM, 1998, PSYCHOPHARMACOL BULL, V34, P101; Canive JM, 1996, PSYCHOPHARMACOL BULL, V32, P741; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen D, 2002, P 13 INT C BIOM, P919; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Eiselt H. A., 1987, CONTINUOUS OPTIMIZAT; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Faul M, 2010, TRAUMATIC BRAIN INJU; Fehr T, 2003, SCHIZOPHR RES, V63, P63, DOI 10.1016/S0920-9964(02)00213-X; Fehr T, 2001, BIOL PSYCHIAT, V50, P108, DOI 10.1016/S0006-3223(01)01122-2; Fernandez A, 2002, BIOL PSYCHIAT, V52, P764, DOI 10.1016/S0006-3223(02)01366-5; FISCH BJ, 1999, FISCH SPEHLMANNS EEG; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2010, BRAIN TOPOGR, V23, P82, DOI 10.1007/s10548-009-0122-5; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2000, HUM BRAIN MAPP, V11, P59, DOI 10.1002/1097-0193(200010)11:2<59::AID-HBM10>3.0.CO;2-5; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ioannides A. A., 1993, Brain Topography, V6, P27; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Matsuura K, 1997, IEEE T BIO-MED ENG, V44, P720, DOI 10.1109/10.605428; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; Niedermeyer E., 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rockstroh BS, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-44; Rowan A.J., 2003, PRIMER EEG MINIATLAS; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S, 2004, Neurol Clin Neurophysiol, V2004, P35; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uutela K, 1999, NEUROIMAGE, V10, P173, DOI 10.1006/nimg.1999.0454; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	89	60	60	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUL 16	2012	61	4					1067	1082		10.1016/j.neuroimage.2012.04.029			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	967PP	WOS:000305920600034	22542638				2022-02-06	
J	Giacino, J; Fins, JJ; Machado, A; Schiff, ND				Giacino, Joseph; Fins, Joseph J.; Machado, Andre; Schiff, Nicholas D.			Central Thalamic Deep Brain Stimulation to Promote Recovery from Chronic Posttraumatic Minimally Conscious State: Challenges and Opportunities	NEUROMODULATION			English	Article						Deep brain stimulation (DBS); minimally conscious state (MCS); neuromodulation; neurostimulation; thalamus	THRESHOLD CALCIUM CURRENTS; INTRATHECAL BACLOFEN; VISUOMOTOR FUNCTIONS; RETICULAR-FORMATION; VEGETATIVE STATE; SPIKE-BURSTS; COMA; ACTIVATION; MECHANISMS; DISORDERS	Background: Central thalamic deep brain stimulation (CT-DBS) may have therapeutic potential to improve behavioral functioning in patients with severe traumatic brain injury (TBI), but its use remains experimental. Current research suggests that the central thalamus plays a critical role in modulating arousal during tasks requiring sustained attention, working memory, and motor function. The aim of the current article is to review the methodology used in the CT-DBS protocol developed by our group, outline the challenges we encountered and offer suggestions for future DBS trials in this population. Rational for CT-DBS in TBI: CT-DBS may therefore be able to stimulate these functions by eliciting action potentials that excite thalamocortical and thalamostriatal pathways. Because patients in chronic minimally conscious state (MCS) have a very low probability of regaining functional independence, yet often have significant sparing of cortical connectivity, they may represent a particularly appropriate target group for CT-DBS. Pilot Study Results: We have conducted a series of single-subject studies of CT-DBS in patients with chronic posttraumatic MCS, with 24-month follow-up. Outcomes were measured using the Coma Recovery Scale-Revised as well as a battery of secondary outcome measures to capture more granular changes. Findings from our index case suggest that CT-DBS can significantly increase functional communication, motor performance, feeding, and object naming in the DBS on state, with performance in some domains remaining above baseline even after DBS was turned off. Conclusions: The use of CT-DBS in patients in MCS, however, presents challenges at almost every step, including during surgical planning, outcome measurement, and postoperative care. Additionally, given the difficulties of obtaining informed consent from patients in MCS and the experimental nature of the treatment, a robust, scientifically rooted ethical framework is resented for pursuing this line of work.	[Giacino, Joseph] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Giacino, Joseph] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Fins, Joseph J.] Weill Cornell Med Coll, Div Med Eth, New York, NY USA; [Machado, Andre] Cleveland Clin Fdn, Neurol Inst, Ctr Neurol Restorat, Cleveland, OH 44195 USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA		Giacino, J (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	jgiacino@partners.org	Machado, Andre GG/B-7572-2014; Giacino, Joseph/AAF-1952-2021	Machado, Andre GG/0000-0002-8132-5610; Giacino, Joseph/0000-0002-7916-9698; Fins, Joseph/0000-0002-7221-0053			APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Bell E, 2010, J CLIN ETHIC, V21, P101; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bosk CL, 2003, FORGIVE REMEMBER MAN; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; COHADON F, 1985, NEUROSTIMULATION OVE, P247; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; DELIAC P, 1993, NEUROCHIRURGIE, V39, P293; Fins J J, 2000, CNS Spectr, V5, P32; Fins JJ, 2003, NEUROSURG CLIN N AM, V14, P303, DOI 10.1016/S1042-3680(02)00118-3; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2000, NEUROL RES, V22, P273; Fins JJ, 2011, PRES BIOETH COMM NEW; Fins JJ, 2006, PALLIATIVE ETHIC CAR; Fins JJ, RIGHTS COME MI UNPUB; Fins JJ, 2008, AM J BIOETHICS, V8, P46, DOI 10.1080/15265160802334490; Fins Joseph J, 2006, Palliat Support Care, V4, P169; Fins JJ, 2010, HASTINGS CENT REP, V40, P21, DOI 10.1353/hcr.0.0257; Fins Joseph J, 2008, Cleve Clin J Med, V75 Suppl 6, pS7; Giacino JT, 2007, CURR OPIN NEUROL, V20, P614, DOI 10.1097/WCO.0b013e3282f189ef; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 2005, REHABILITATION TRAUM, P305; GLENN LL, 1982, J NEUROSCI, V2, P1387; Gold L, 2002, P NATL ACAD SCI USA, V99, P7699, DOI 10.1073/pnas.112012499; Grillner S, 2005, TRENDS NEUROSCI, V28, P364, DOI 10.1016/j.tins.2005.05.004; HASSLER R, 1969, ELECTROEN CLIN NEURO, V27, P306, DOI 10.1016/0013-4694(69)90060-1; Hosobuchi Y, 1993, Adv Neurol, V63, P247; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.ph.58.030196.001553; Isope P, 2005, J PHYSIOL-LONDON, V562, P257, DOI 10.1113/jphysiol.2004.074211; Jeanmonod D, 1996, BRAIN, V119, P363, DOI 10.1093/brain/119.2.363; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jones EG, 2001, TRENDS NEUROSCI, V24, P595, DOI 10.1016/S0166-2236(00)01922-6; Jones EG, 2007, THALAMUS; Kahneman D., 1973, ATTENTION EFFORT; Kaplan E, 1983, BOSTON NAMING TEST; Kelley AS, 2009, AM HEART J, V157; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S., 2003, European Journal of Neurology, V10, P224; Llinas RR, 2002, P NATL ACAD SCI USA, V99, P449, DOI 10.1073/pnas.012604899; Lujan JL, 2009, STEREOT FUNCT NEUROS, V87, P229, DOI 10.1159/000225976; Machado A, 2006, MOVEMENT DISORD, V21, pS247, DOI 10.1002/mds.20959; Mair RG, 2008, J NEUROSCI, V28, P14293, DOI 10.1523/JNEUROSCI.3301-08.2008; McLardy T, 1968, Trans Am Neurol Assoc, V93, P25; Medtronic, 2010, MRI GUID MEDTR DEEP; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Nagai Y, 2004, NEUROIMAGE, V21, P1232, DOI 10.1016/j.neuroimage.2003.10.036; Nakase-Thompson R, 2005, BRAIN INJURY, V19, P685, DOI 10.1080/02699050400025331; NAT'L BIOETHICS ADVISORY COMM'N, 1998, RES INV PERS MENT DI; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; Parasuraman R, 1999, ATTENTIVE BRAIN, P1; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Posner, 1978, CHRONOMETRIC EXPLORA; Purpura KP, 1997, NEUROSCIENTIST, V3, P8, DOI 10.1177/107385849700300110; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIZZOLATTI G, 1987, NEUROPSYCHOLOGIA, V25, P31, DOI 10.1016/0028-3932(87)90041-8; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff N.D., 1997, Patent No. [#5,938,688, 5938688]; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schiff ND, 2009, ARCH NEUROL-CHICAGO, V66, P697, DOI 10.1001/archneurol.2009.79; Schiff Nicholas D., 2002, Thalamus & Related Systems, V2, P55, DOI 10.1016/S1472-9288(02)00028-6; SCHLAG J, 1984, J NEUROPHYSIOL, V51, P1175, DOI 10.1152/jn.1984.51.6.1175; SCHLAGREY M, 1984, J NEUROPHYSIOL, V51, P1149, DOI 10.1152/jn.1984.51.6.1149; Shah SA, 2010, EUR J NEUROSCI, V32, P1135, DOI 10.1111/j.1460-9568.2010.07420.x; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Shirvalkar P, 2006, P NATL ACAD SCI USA, V103, P17007, DOI 10.1073/pnas.0604811103; Smith AC, 2009, J NEUROSCI METH, V183, P267, DOI 10.1016/j.jneumeth.2009.06.028; Smith Y, 2009, BRAIN RES BULL, V78, P60, DOI 10.1016/j.brainresbull.2008.08.015; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; Steriade M, 1997, THALAMUS; STURM V, 1979, ACTA NEUROCHIR, V47, P235, DOI 10.1007/BF01406406; Tsubokawa T, 1990, Brain Inj, V4, P315; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	86	60	75	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					339	349		10.1111/j.1525-1403.2012.00458.x			11	Medicine, Research & Experimental; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900009	22624587				2022-02-06	
J	Villamar, MF; Portilla, AS; Fregni, F; Zafonte, R				Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross			Noninvasive Brain Stimulation to Modulate Neuroplasticity in Traumatic Brain Injury	NEUROMODULATION			English	Article						Diffuse axonal injury; neuroplasticity; transcranial direct current stimulation; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; LONG-TERM POTENTIATION; THETA-BURST-STIMULATION; LOW-FREQUENCY RTMS; ADULT HUMAN BRAIN; SYNAPTIC PLASTICITY; STROKE PATIENTS; WORKING-MEMORY; CORTICAL EXCITABILITY	Objective: To review the use of noninvasive brain stimulation (NBS) as a therapeutic tool to enhance neuroplasticity following traumatic brain injury (TBI). Materials and Methods: Based on a literature search, we describe the pathophysiological events following TBI and the rationale for the use of transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) in this setting. Results: The pathophysiological mechanisms occurring after TBI vary across time and therefore require differential interventions. Theoretically, given the neurophysiological effects of both TMS and tDCS, these tools may: 1) decrease cortical hyperexcitability acutely after TBI; 2) modulate long-term synaptic plasticity as to avoid maladaptive consequences; and 3) combined with physical and behavioral therapy, facilitate cortical reorganization and consolidation of learning in specific neural networks. All of these interventions may help decrease the burden of disabling sequelae after brain injury. Conclusions: Evidence from animal and human studies reveals the potential benefit of NBS in decreasing the extent of injury and enhancing plastic changes to facilitate learning and recovery of function in lesioned neural tissue. However, this evidence is mainly theoretical at this point. Given safety constraints, studies in TBI patients are necessary to address the role of NBS in this condition as well as to further elucidate its therapeutic effects and define optimal stimulation parameters.	[Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross] Harvard Univ, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Lab Neuromodulat,Med Sch, Boston, MA 02114 USA; [Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA		Zafonte, R (corresponding author), Harvard Univ, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Lab Neuromodulat,Med Sch, 125 Nashua St 706, Boston, MA 02114 USA.	rzafonte@partners.org	Villamar, Mauricio F./AAU-9130-2021	Villamar, Mauricio F./0000-0003-4503-8152; Edwards, Dylan/0000-0001-7346-3100; Fregni, Felipe/0000-0001-9359-8643			Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; [Anonymous], 1999, JAMA, V282, P974; [Anonymous], 2011, PLASTICITY INFLAMMAT; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; ARONIADOU VA, 1995, CEREB CORTEX, V5, P353, DOI 10.1093/cercor/5.4.353; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Bae EH, 2007, EPILEPSY BEHAV, V10, P521, DOI 10.1016/j.yebeh.2007.03.004; BARKER AT, 1985, LANCET, V1, P1106; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Black JE, 2004, AM J PSYCHIAT, V161, P742, DOI 10.1176/appi.ajp.161.4.742; Bliss TVP, 2011, CLINICS, V66, P3, DOI 10.1590/S1807-59322011001300002; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Blitz DM, 2004, NAT REV NEUROSCI, V5, P630, DOI 10.1038/nrn1475; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bolognini N, 2011, NEUROREHAB NEURAL RE, V25, P819, DOI 10.1177/1545968311411056; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Bortolomasi M, 2007, PSYCHIAT RES, V150, P181, DOI 10.1016/j.psychres.2006.04.010; Braunewell KH, 2001, REV NEUROSCIENCE, V12, P121; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Bueno VF, 2011, NEUROCASE, V17, P318, DOI 10.1080/13554794.2010.509319; Buki A, 2000, J NEUROSCI, V20, P2825; BURNS BD, 1954, J PHYSIOL-LONDON, V125, P427, DOI 10.1113/jphysiol.1954.sp005170; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; Cao Y, 1999, STROKE, V30, P2331, DOI 10.1161/01.STR.30.11.2331; Carey JR, 2006, RESTOR NEUROL NEUROS, V24, P191; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CHOI DW, 1987, J NEUROSCI, V7, P369; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Collingridge GL, 2003, PHILOS T R SOC B, V358, P635, DOI 10.1098/rstb.2002.1241; Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CREUTZFELDT O, 1962, EXP NEUROL, V5, P436, DOI 10.1016/0014-4886(62)90056-0; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Deng ZD, 2010, IEEE ENG MED BIO, P6821, DOI 10.1109/IEMBS.2010.5625958; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Destexhe A, 2004, NATURE, V431, P789, DOI 10.1038/nature03011; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P715, DOI 10.1016/j.clinph.2007.11.049; Ding YC, 2002, NEUROL RES, V24, P829, DOI 10.1179/016164102101200816; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Fregni F, 2006, CLIN NEUROPHYSIOL, V117, P1217, DOI 10.1016/j.clinph.2006.02.015; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GENTRY LR, 1994, RADIOLOGY, V191, P1; George MS, 2010, EXPERT REV NEUROTHER, V10, P1761, DOI [10.1586/ern.10.95, 10.1586/ERN.10.95]; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; Gilio F, 2003, J PHYSIOL-LONDON, V551, P563, DOI 10.1113/jphysiol.2003.044313; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GOLDRING S, 1951, J NEUROPHYSIOL, V14, P275, DOI 10.1152/jn.1951.14.4.275; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gulledge AT, 2005, J NEUROBIOL, V64, P75, DOI 10.1002/neu.20144; Hallett M, 2005, J REHABIL RES DEV, V42, pXVII, DOI 10.1682/JRRD.2005.07.0126; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hasan A, 2011, BEHAV BRAIN RES, V224, P15, DOI 10.1016/j.bbr.2011.05.017; Hausmann A, 2000, MOL BRAIN RES, V76, P355, DOI 10.1016/S0169-328X(00)00024-3; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; Heiss WD, 1999, ANN NEUROL, V45, P430, DOI 10.1002/1531-8249(199904)45:4<430::AID-ANA3>3.0.CO;2-P; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hesse S, 2011, NEUROREHAB NEURAL RE, V25, P838, DOI 10.1177/1545968311413906; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holderbach R, 2007, BIOL PSYCHIAT, V62, P92, DOI 10.1016/j.biopsych.2006.07.007; Holscher C, 1999, J NEUROSCI RES, V58, P62; Hua Y, 2007, STROKE, V38, P759, DOI 10.1161/01.STR.0000247868.97078.10; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; Hummel F, 2005, NEUROREHAB NEURAL RE, V19, P14, DOI 10.1177/1545968304272698; Iyer MB, 2003, J NEUROSCI, V23, P10867; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kim YH, 2004, NEUROSCI LETT, V367, P181, DOI 10.1016/j.neulet.2004.05.113; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kohler S, 2004, J COGNITIVE NEUROSCI, V16, P178, DOI 10.1162/089892904322984490; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; Laurer H.L., 2002, ENCY HUMAN BRAIN, P93; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2006, EPILEPSIA, V47, P1216, DOI 10.1111/j.1528-1167.2006.00539.x; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Linden DJ, 1999, NEURON, V22, P661, DOI 10.1016/S0896-6273(00)80726-6; Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luber B, 2007, BRAIN RES, V1128, P120, DOI 10.1016/j.brainres.2006.10.011; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Miniussi C, 2008, BRAIN STIMUL, V1, P326, DOI 10.1016/j.brs.2008.07.002; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; NICHOLLS DG, 1985, PROG BRAIN RES, V63, P97; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2004, CEREB CORTEX, V14, P1240, DOI 10.1093/cercor/bhh085; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Callaghan RM, 2007, BEHAV BRAIN RES, V176, P362, DOI 10.1016/j.bbr.2006.10.018; Oliveri M, 2001, NEUROLOGY, V57, P1338, DOI 10.1212/WNL.57.7.1338; Pannasch U, 2011, P NATL ACAD SCI USA, V108, P8467, DOI 10.1073/pnas.1016650108; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Paulus W, 2003, SUPPL CLIN NEUROPHYS, V56, P249; de la Ossa NP, 2010, STROKE, V41, P810, DOI 10.1161/STROKEAHA.109.570168; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Preston G, 2010, J COGNITIVE NEUROSCI, V22, P447, DOI 10.1162/jocn.2009.21209; PRINCE DA, 1984, ANN NEUROL, V16, pS59, DOI 10.1002/ana.410160710; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; Quartarone A, 2008, CURR OPIN NEUROL, V21, P484, DOI 10.1097/WCO.0b013e328307bf07; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Reis J, 2008, BRAIN STIMUL, V1, P363, DOI 10.1016/j.brs.2008.08.001; Reithler J, 2011, PROG NEUROBIOL, V94, P149, DOI 10.1016/j.pneurobio.2011.04.004; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Romero JR, 2002, CLIN NEUROPHYSIOL, V113, P101, DOI 10.1016/S1388-2457(01)00693-9; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rotenberg A, 2007, CLIN NEUROPHYSIOL, V118, P2536, DOI 10.1016/j.clinph.2007.08.003; Rotenberg A, 2009, CLIN NEUROPHYSIOL, V120, P1417, DOI 10.1016/j.clinph.2009.05.004; Rothwell JC, 2010, FOLIA PHONIATR LOGO, V62, P153, DOI 10.1159/000314030; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Schambra HM, 2003, CLIN NEUROPHYSIOL, V114, P130, DOI 10.1016/S1388-2457(02)00342-5; Schatz DS, 2000, SYNAPSE, V36, P75, DOI 10.1002/(SICI)1098-2396(200004)36:1<75::AID-SYN8>3.0.CO;2-I; Sczesny-Kaiser M, 2009, NEUROSCI LETT, V457, P71, DOI 10.1016/j.neulet.2009.04.015; Shindo K, 2006, J REHABIL MED, V38, P65, DOI 10.1080/16501970500441807; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P597, DOI 10.1017/S0140525X97001593; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Speer AM, 2000, BIOL PSYCHIAT, V48, P1133, DOI 10.1016/S0006-3223(00)01065-9; Stagg CJ, 2009, J NEUROPHYSIOL, V101, P2872, DOI 10.1152/jn.91060.2008; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.0.CO;2-6; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Takeuchi N, 2005, STROKE, V36, P2681, DOI 10.1161/01.STR.0000189658.51972.34; Takeuchi N, 2008, J REHABIL MED, V40, P298, DOI 10.2340/16501977-0181; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Tasset I, 2010, NEUROCHEM RES, V35, P1182, DOI 10.1007/s11064-010-0172-9; Teo F, 2011, FRONT PSYCHIATRY, V2, P1; Teyler TJ, 2001, INT REV NEUROBIOL, V45, P253; Thickbroom GW, 2007, EXP BRAIN RES, V180, P583, DOI 10.1007/s00221-007-0991-3; Thickbroom GW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vines BW, 2006, NEUROREPORT, V17, P671, DOI 10.1097/00001756-200604240-00023; Wagner T, 2006, NEUROIMAGE, V30, P857, DOI 10.1016/j.neuroimage.2005.04.046; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Ward NS, 2005, PROG BRAIN RES, V150, P527, DOI 10.1016/S0079-6123(05)50036-0; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yablon SA, 2007, BRAIN INJURY MED PRI, V1, P452; Yamashima T, 2003, HIPPOCAMPUS, V13, P791, DOI 10.1002/hipo.10127; Yue L, 2009, BRAIN RES, V1260, P94, DOI 10.1016/j.brainres.2009.01.009; Zago S, 2008, NEUROSCIENTIST, V14, P521, DOI 10.1177/1073858407311101; Zhang XQ, 2007, J HUAZHONG U SCI-MED, V27, P415, DOI 10.1007/s11596-007-0416-3; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	209	60	62	2	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					326	338		10.1111/j.1525-1403.2012.00474.x			13	Medicine, Research & Experimental; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900008	22882244				2022-02-06	
J	Messe, A; Caplain, S; Pelegrini-Issac, M; Blancho, S; Montreuil, M; Levy, R; Lehericy, S; Benali, H				Messe, Arnaud; Caplain, Sophie; Pelegrini-Issac, Melanie; Blancho, Sophie; Montreuil, Michele; Levy, Richard; Lehericy, Stephane; Benali, Habib			Structural integrity and postconcussion syndrome in mild traumatic brain injury patients	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild TBI; Postconcussion syndrome; Structural integrity; Diffuse axonal injury	DIFFUSE AXONAL INJURY; POST-CONCUSSION SYMPTOMS; TENSOR IMAGING DETECTS; MINOR HEAD-INJURY; FOLLOW-UP; QUESTIONNAIRE; EPIDEMIOLOGY; DIAGNOSIS; RELIABILITY; IMPAIRMENT	The presence of a postconcussion syndrome (PCS) induces substantial socio-professional troubles in mild traumatic brain injury (mTBI) patients. Although the exact origin of these disorders is not known, they may be the consequence of diffuse axonal injury (DAI) impacting structural integrity. In the present study, we compared structural integrity at the subacute and late stages after mTBI and in case of PCS, using diffusion-weighted imaging (DWI). Fifty-three mTBI patients were investigated and compared with 40 healthy controls. All patients underwent a DWI examination at the subacute (8-21 days) and late (6 months) phases after injury. MTBI patients with PCS were detected at the subacute phase using the ICD-10 classification. Groupwise differences in structural integrity were investigated using Tract-Based Spatial Statistics (TBSS). A loss of structural integrity was found in mTBI patients at the subacute phase but partially resolved over time. Moreover, we observed that mTBI patients with PCS had greater and wider structural impairment than patients without PCS. These damages persisted over time for PCS patients, while mTBI patients without PCS partly recovered. In conclusion, our results strengthen the relationship between structural integrity and PCS.	[Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib] Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonct, F-75634 Paris, France; [Messe, Arnaud; Pelegrini-Issac, Melanie; Lehericy, Stephane; Benali, Habib] Univ Paris 11, DSV I2BM NeuroSpin, F-91191 Gif Sur Yvette, France; [Caplain, Sophie; Montreuil, Michele] Univ Paris 08, EA 2027, F-93526 St Denis, France; [Blancho, Sophie] Inst Rech Moelle Epiniere & Encephale, F-75015 Paris, France; [Levy, Richard; Lehericy, Stephane] Univ Paris 06, CNRS, UMRS 975,CRICM, Grp Hosp Pitie Salpetriere,UMR 7225, F-75634 Paris, France; [Levy, Richard] Hop St Antoine, Assistance Publ Hop Paris, F-75012 Paris, France; [Lehericy, Stephane] Univ Paris 06, CENIR, Ctr Neuroimaging Res, CHU Pitie Salpetriere, F-75013 Paris, France; [Benali, Habib] Univ Montreal, MIC UNF, Montreal, PQ H3W 1W5, Canada		Messe, A (corresponding author), Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonct, F-75634 Paris, France.	Arnaud.Messe@imed.jussieu.fr	Levy, Richard/D-8411-2011; Messe, Arnaud/I-1738-2019	Messe, Arnaud/0000-0001-9081-3088; Pelegrini-Issac, Melanie/0000-0003-3260-5795	GMF (Garantie Mutuelle des Fonctionnaires)	This study was initiated by the IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale) and supported by a grant from the GMF (Garantie Mutuelle des Fonctionnaires).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Azouvi P, 2001, REV NEUROPSYCHOL, V11, P383; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2010, J HEAD TRAUMA REHAB, V25, P225, DOI 10.1097/HTR.0b013e3181e7f784; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Concha L, 2010, J NEUROSCI, V30, P996, DOI 10.1523/JNEUROSCI.1619-09.2010; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M., 2008, MILD TRAUMATIC BRAIN; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2005, MRI ATLAS HUMAN WHIT; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild KRH, 2008, ACT NEUR S, V101, P55; *WHO, 1993, INT CLASS DIS HLTH R; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	54	60	60	1	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		283	292		10.1007/s11682-012-9159-2			10	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900009	22477019				2022-02-06	
J	Max, JE; Keatley, E; Wilde, EA; Bigler, ED; Schachar, RJ; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Yang, TT; Levin, HS				Max, Jeffrey E.; Keatley, Eva; Wilde, Elisabeth A.; Bigler, Erin D.; Schachar, Russell J.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Yang, Tony T.; Levin, Harvey S.			Depression in children and adolescents in the first 6 months after traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Depression; Anxiety; Traumatic brain injury; Children; Adolescents; Frontal lobe	PSYCHIATRIC-DISORDERS; PERSONALITY-CHANGE; HEAD-INJURY; RELIABILITY; VALIDITY; PREDICTORS; SCHEDULE; SEQUELAE	The objective was to assess the nature, rate, predictive factors, and neuroimaging correlates of novel (new-onset) depressive disorders, both definite and subclinical, after traumatic brain injury (TBI). Children with TBI from consecutive admissions were enrolled and studied with psychiatric interviews soon after injury (baseline), and again 6 months post-injury. Novel definite/subclinical depressive disorders at 6-month follow up occurred in 11% (n = 15) of the children and subsets of children with non-anxious depression (n = 9) and anxious depression (n = 6) were identified. Novel definite/subclinical depressive disorder was significantly associated with older age at the time of injury, family history of anxiety disorder, left inferior frontal gyrus (IFG) lesions, and right frontal white matter lesions. Non-anxious depressions were associated with older age at injury, left IFG and left temporal pole lesions. Anxious depressions were associated with family history of anxiety disorder, Personality Change due to TBI, right frontal white matter lesions, and left parietal lesions. These findings, which are similar to those reported after adult TBI, identify both similarities and differences in non-anxious and anxious depression following childhood TBI with respect to lesion laterality, genetic factors (in the form of family psychiatric history of anxiety disorder), age at injury, and more generalized affective dysregulation. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Max, Jeffrey E.; Yang, Tony T.] Rady Childrens Hosp, San Diego, CA 92123 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Ctr Neurosci, Provo, UT 84602 USA; [Schachar, Russell J.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Saunders, Ann E.] Univ Texas Houston, UT Harris Cty Psychiat Ctr, Dept Psychiat, Houston, TX 77021 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75235 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Max, Jeffrey E.; Yang, Tony T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92123 USA		Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu; ekeatley@gmail.com; ewilde@bcm.edu; erinb@cortex.byu.edu; russell.schachar@sickkids.ca; Ann.E.Saunders@uth.tmc.edu; Linda.Ewing-Cobbs@uth.tmc.edu; schapman@utdallas.edu; maureen.dennis@sickkids.ca; tyang@ucsd.edu; hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800, R01MH085734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Beesdo K, 2009, ARCH GEN PSYCHIAT, V66, P275, DOI 10.1001/archgenpsychiatry.2008.545; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-00011; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Capizzano AA, 2010, J NEUROPSYCH CLIN N, V22, P370, DOI 10.1176/appi.neuropsych.22.4.370; Ciccetti D., 1984, VINELAND ADAPTIVE BE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Klein DN, 2009, J AM ACAD CHILD PSY, V48, P703, DOI 10.1097/CHI.0b013e3181a56606; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Max J.E., 2011, TXB TRAUMATIC BRAIN, P438; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI 10.1001/archpsyc.64.6.651; Pine D S, 2001, CNS Spectr, V6, P27; Shankman SA, 2009, J CHILD PSYCHOL PSYC, V50, P1485, DOI 10.1111/j.1469-7610.2009.02117.x; TEASDALE G, 1974, LANCET, V2, P81	34	60	60	2	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		239	245		10.1016/j.ijdevneu.2011.12.005			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800010	22197971	Green Accepted			2022-02-06	
J	Lobo, D; Beane, WS; Levin, M				Lobo, Daniel; Beane, Wendy S.; Levin, Michael			Modeling Planarian Regeneration: A Primer for Reverse-Engineering the Worm	PLOS COMPUTATIONAL BIOLOGY			English	Article							GAP-JUNCTIONAL COMMUNICATION; ANTERIOR-POSTERIOR POLARITY; CENTRAL-NERVOUS-SYSTEM; FRESH-WATER PLANARIAN; LEFT-RIGHT ASYMMETRY; STEM-CELLS; INTERCALARY REGENERATION; BETA-CATENIN; TRANSCRIPTION FACTOR; BLASTEMA POLARITY	A mechanistic understanding of robust self-assembly and repair capabilities of complex systems would have enormous implications for basic evolutionary developmental biology as well as for transformative applications in regenerative biomedicine and the engineering of highly fault-tolerant cybernetic systems. Molecular biologists are working to identify the pathways underlying the remarkable regenerative abilities of model species that perfectly regenerate limbs, brains, and other complex body parts. However, a profound disconnect remains between the deluge of high-resolution genetic and protein data on pathways required for regeneration, and the desired spatial, algorithmic models that show how self-monitoring and growth control arise from the synthesis of cellular activities. This barrier to progress in the understanding of morphogenetic controls may be breached by powerful techniques from the computational sciences-using non-traditional modeling approaches to reverse-engineer systems such as planaria: flatworms with a complex bodyplan and nervous system that are able to regenerate any body part after traumatic injury. Currently, the involvement of experts from outside of molecular genetics is hampered by the specialist literature of molecular developmental biology: impactful collaborations across such different fields require that review literature be available that presents the key functional capabilities of important biological model systems while abstracting away from the often irrelevant and confusing details of specific genes and proteins. To facilitate modeling efforts by computer scientists, physicists, engineers, and mathematicians, we present a different kind of review of planarian regeneration. Focusing on the main patterning properties of this system, we review what is known about the signal exchanges that occur during regenerative repair in planaria and the cellular mechanisms that are thought to underlie them. By establishing an engineering-like style for reviews of the molecular developmental biology of biomedically important model systems, significant fresh insights and quantitative computational models will be developed by new collaborations between biology and the information sciences.	[Lobo, Daniel] Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA; Tufts Univ, Dept Biol, Medford, MA 02155 USA		Lobo, D (corresponding author), Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA.	michael.levin@tufts.edu	Levin, Michael/A-5918-2011	Levin, Michael/0000-0001-7292-8084; Lobo, Daniel/0000-0003-4666-6118	Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-10-2-0058]; G. Harold and Leila Y. Mathers Charitable Foundation; NSF CDINational Science Foundation (NSF) [EF-1124651]; NIH Kirschstein-NRSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32 GM08354]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [F32GM083547] Funding Source: NIH RePORTER	This work was supported by the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) through award W81XWH-10-2-0058. ML is also grateful for the support of the G. Harold and Leila Y. Mathers Charitable Foundation, and NSF CDI grant - EF-1124651. WSB gratefully acknowledges the support of the NIH Kirschstein-NRSA grant F32 GM08354. The funders had no role in the preparation of the manuscript.	Aboobaker AA, 2011, TRENDS CELL BIOL, V21, P304, DOI 10.1016/j.tcb.2011.01.005; Adams DS, 2008, TISSUE ENG PT A, V14, P1461, DOI 10.1089/ten.tea.2008.0080; Adell T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000505; Adell T, 2009, DEVELOPMENT, V136, P905, DOI 10.1242/dev.033761; Agata K, 2003, CURR OPIN GENET DEV, V13, P492, DOI 10.1016/j.gde.2003.08.009; Agata K, 2003, DEV DYNAM, V226, P308, DOI 10.1002/dvdy.10249; Allen MT, 2005, NEW PHYTOL, V166, P869, DOI 10.1111/j.1469-8137.2005.01348.x; Almuedo-Castillo M, 2011, P NATL ACAD SCI USA, V108, P2813, DOI 10.1073/pnas.1012090108; Andersen T, 2009, ARTIF LIFE, V15, P161, DOI 10.1162/artl.2009.15.2.15201; Aoki R, 2009, NEUROSCIENCE, V159, P908, DOI 10.1016/j.neuroscience.2008.11.011; BAGUNA J, 1981, HYDROBIOLOGIA, V84, P181, DOI 10.1007/BF00026179; BAGUNA J, 1989, DEVELOPMENT, V107, P77; Ball P., 1999, SELF MADE TAPESTRY P; Basanta D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000030; Beane WS, 2011, CHEM BIOL, V18, P77, DOI 10.1016/j.chembiol.2010.11.012; Bongard J, 2006, SCIENCE, V314, P1118, DOI 10.1126/science.1133687; Brondsted H., 1969, PLANARIAN REGENERATI; BRONDSTED HV, 1955, BIOL REV, V30, P65, DOI 10.1111/j.1469-185X.1955.tb00649.x; BROWN F A JR, 1975, International Journal of Chronobiology, V3, P57; BROWN FA, 1975, PHYSIOL ZOOL, V48, P168, DOI 10.1086/physzool.48.2.30155650; BROWN FA, 1966, NATURE, V209, P533, DOI 10.1038/209533b0; BROWN FA, 1964, NATURE, V202, P469, DOI 10.1038/202469a0; Brown FD, 2008, GENESIS, V46, P605, DOI 10.1002/dvg.20471; BROWN HM, 1968, J GEN PHYSIOL, V51, P237, DOI 10.1085/jgp.51.2.237; BROWN HM, 1968, J GEN PHYSIOL, V51, P255, DOI 10.1085/jgp.51.2.255; Cebria F, 2005, DEVELOPMENT, V132, P3691, DOI 10.1242/dev.01941; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; Cebria F, 2008, NEUROSCI RES, V61, P375, DOI 10.1016/j.neures.2008.04.005; Cebria F, 2007, DEV GENES EVOL, V217, P733, DOI 10.1007/s00427-007-0188-6; Cebria F, 2007, DEV BIOL, V307, P394, DOI 10.1016/j.ydbio.2007.05.006; Cebria F, 2007, DEVELOPMENT, V134, P833, DOI 10.1242/dev.02794; CHANDEBOIS R, 1979, DEV GROWTH DIFFER, V21, P195; de Garis H, 1992, DYNAMIC GENETIC CHAO; Devert A, 2007, GECCO 2007: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P982; DIMMITT J, 1952, J CELL COMPAR PHYSL, V40, P11, DOI 10.1002/jcp.1030400103; Molina MD, 2011, CURR BIOL, V21, P300, DOI 10.1016/j.cub.2011.01.016; Eisenhoffer GT, 2008, CELL STEM CELL, V3, P327, DOI 10.1016/j.stem.2008.07.002; Ellner SP, 2006, DYNAMIC MODELS BIOL; Esser AT, 2006, DEV DYNAM, V235, P2144, DOI 10.1002/dvdy.20870; Fernandez-Blanco E, 2007, LECT NOTES ARTIF INT, V4648, P825; Fisher J, 2007, NAT BIOTECHNOL, V25, P1239, DOI 10.1038/nbt1356; Forsthoefel DJ, 2011, DEV BIOL, V356, P445, DOI 10.1016/j.ydbio.2011.05.669; Fraguas S, 2011, DEV BIOL, V354, P87, DOI 10.1016/j.ydbio.2011.03.023; Gautier H, 2000, ANN BOT-LONDON, V85, P359, DOI 10.1006/anbo.1999.1069; Gavino MA, 2011, CURR BIOL, V21, P294, DOI 10.1016/j.cub.2011.01.017; Gentile L, 2011, DIS MODEL MECH, V4, P12, DOI 10.1242/dmm.006692; GLAZIER JA, 1993, PHYS REV E, V47, P2128, DOI 10.1103/PhysRevE.47.2128; Gonzalez-Estevez C, 2007, AUTOPHAGY, V3, P640, DOI 10.4161/auto.4934; Gordon R, 2003, INT J DEV BIOL, V47, P183; Gurley KA, 2008, SCIENCE, V319, P323, DOI 10.1126/science.1150029; Gurley KA, 2010, DEV BIOL, V347, P24, DOI 10.1016/j.ydbio.2010.08.007; Haddow PC, 2007, GECCO 2007: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P1013; Handberg-Thorsager M, 2008, FRONT BIOSCI-LANDMRK, V13, P6374, DOI 10.2741/3160; Harrison LG, KINETIC THEORY LIVIN; Hogeweg P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002021; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iglesias M, 2008, DEVELOPMENT, V135, P1215, DOI 10.1242/dev.020289; Iglesias M, 2011, DEV BIOL, V358, P68, DOI 10.1016/j.ydbio.2011.07.013; Jaeger J, 2009, MOL BIOSYST, V5, P1549, DOI 10.1039/b904722k; Jenkins MM, 1963, BIPOLAR PLANARIANS S, P142; KANATANI HARUO, 1958, JOUR FAC SCI TOKYO UNIV SECT IV ZOOL, V8, P253; Kato K, 1999, DEVELOPMENT, V126, P1031; Kennaway R, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002071; Kobayashi C, 1999, MECH DEVELOP, V89, P25, DOI 10.1016/S0925-4773(99)00192-6; LANGE CS, 1978, DIFFERENTIATION, V11, P1, DOI 10.1111/j.1432-0436.1978.tb00965.x; Larson DE, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000841; Levin M, 2007, PROG BIOPHYS MOL BIO, V94, P186, DOI 10.1016/j.pbiomolbio.2007.03.005; Levin M, 2007, TRENDS CELL BIOL, V17, P261, DOI 10.1016/j.tcb.2007.04.007; Levin M, 2006, DEV NEUROSCI-BASEL, V28, P171, DOI 10.1159/000091915; Levin M, 2009, SEMIN CELL DEV BIOL, V20, P543, DOI 10.1016/j.semcdb.2009.04.013; LINDENMAYER A, 1968, J THEOR BIOL, V18, P280, DOI 10.1016/0022-5193(68)90079-9; Lobo D, 2011, THEOR COMPUT SCI, V412, P6101, DOI 10.1016/j.tcs.2011.07.004; Lobo D, 2010, BIOSYSTEMS, V102, P112, DOI 10.1016/j.biosystems.2010.08.003; Lowe CJ, 2006, PLOS BIOL, V4, P1603, DOI 10.1371/journal.pbio.0040291; Maclachlan J. C., 1999, GROWTH FORM SPATIOTE; MARSH G, 1952, J CELL COMPAR PHYSL, V39, P191, DOI 10.1002/jcp.1030390203; MASON PR, 1975, ANIM BEHAV, V23, P460, DOI 10.1016/0003-3472(75)90095-0; MCWHINNIE MA, 1955, BIOL BULL, V108, P54, DOI 10.2307/1538397; MEINHARDT H, 1978, J THEOR BIOL, V74, P307, DOI 10.1016/0022-5193(78)90078-4; Meinhardt H., 2009, COLD SPRING HARB PER, V1; Meinhardt H., 1982, MODELS BIOL PATTERN; Meinhardt H, 2009, BIOESSAYS, V31, P5, DOI 10.1002/bies.080193; Miller JF, 2004, LECT NOTES COMPUT SC, V3102, P129; MITTENTHAL JE, 1988, DEV BIOL, V126, P315, DOI 10.1016/0012-1606(88)90141-8; MIYAMOTO S, 1985, ZOOL SCI, V2, P389; Molina MD, 2007, DEV BIOL, V311, P79, DOI 10.1016/j.ydbio.2007.08.019; Molina Ma Dolores, 2011, Communicative & Integrative Biology, V4, P498, DOI 10.4161/cib.4.4.15753; MONTGOMERY JR, 1974, T AM MICROSC SOC, V93, P386, DOI 10.2307/3225439; Morgan T. H., 1898, Archiv fuer Entwicklungsmechanik, Vvii, P364; Morgan TH, 1901, ARCH ENTWICKLUNG ORG, V13, P179, DOI 10.1007/BF02161982; Murray JD, 2002, MATH BIOL I INTRO IN; Newmark P, 2001, REGENERATION PLANARI; Newmark PA, 2005, DEV CELL, V8, P623, DOI 10.1016/j.devcel.2005.04.007; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Newmark PA, 1999, PLANARIAN REGENERATI; Nishimura K, 2008, NEUROSCIENCE, V153, P1103, DOI 10.1016/j.neuroscience.2008.03.026; Nishimura K, 2010, NEUROSCIENCE, V168, P18, DOI 10.1016/j.neuroscience.2010.03.038; Nishimura K, 2007, DEV NEUROBIOL, V67, P1059, DOI 10.1002/dneu.20377; Nogi T, 2005, DEV BIOL, V287, P314, DOI 10.1016/j.ydbio.2005.09.002; Nogi T, 2005, LATERALITY, V10, P193, DOI 10.1080/1357650054200001440; Nogi T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000464; Orii H, 2007, DEV GROWTH DIFFER, V49, P345, DOI 10.1111/j.1440-169x.2007.00931.x; Oviedo N, 2008, DIS MOD MECH, V1; Oviedo NJ, 2007, DEVELOPMENT, V134, P3121, DOI 10.1242/dev.006635; Oviedo NJ, 2010, DEV BIOL, V339, P188, DOI 10.1016/j.ydbio.2009.12.012; Oviedo NJ, 2003, DEV DYNAM, V226, P326, DOI 10.1002/dvdy.10228; Palakodeti D, 2008, RNA, V14, P1174, DOI 10.1261/rna.1085008; PASCOLINI R, 1984, CELL TISSUE RES, V236, P345; Pellettieri J, 2007, ANNU REV GENET, V41, P83, DOI 10.1146/annurev.genet.41.110306.130244; Pellettieri J, 2010, DEV BIOL, V338, P76, DOI 10.1016/j.ydbio.2009.09.015; Perkins TJ, 2006, PLOS COMPUT BIOL, V2, P417, DOI 10.1371/journal.pcbi.0020051; Petersen CP, 2008, SCIENCE, V319, P327, DOI 10.1126/science.1149943; Petersen CP, 2011, SCIENCE, V332, P852, DOI 10.1126/science.1202143; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Priami C, 2009, COMMUN ACM, V52, P80, DOI 10.1145/1506409.1506427; Prusinkiewicz P, 2007, SCIENCE, V316, P1452, DOI 10.1126/science.1140429; Reddien PW, 2007, DEVELOPMENT, V134, P4043, DOI 10.1242/dev.007138; Reddien PW, 2011, TRENDS GENET, V27, P277, DOI 10.1016/j.tig.2011.04.004; Reddien PW, 2005, SCIENCE, V310, P1327, DOI 10.1126/science.1116110; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Rink JC, 2009, SCIENCE, V326, P1406, DOI 10.1126/science.1178712; Romero R, 2001, INT J DEV BIOL, V45, P669; Rossi L, 2006, DEV GENES EVOL, V216, P335, DOI 10.1007/s00427-006-0060-0; Rubenstein M, 2009, INT J DEV BIOL, V53, P869, DOI 10.1387/ijdb.092937mr; Salo E, 2006, BIOESSAYS, V28, P546, DOI 10.1002/bies.20416; SALO E, 1984, J EMBRYOL EXP MORPH, V83, P63; SALO E, 1985, ROUX ARCH DEV BIOL, V194, P364; Salo E, 2009, INT J DEV BIOL, V53, P1317, DOI 10.1387/ijdb.072414es; Santos FV, 1929, BIOL BULL-US, V57, P188, DOI 10.2307/1536781; SARNAT HB, 1985, CAN J NEUROL SCI, V12, P296, DOI 10.1017/S031716710003537X; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Savill NJ, 1997, J THEOR BIOL, V184, P229, DOI 10.1006/jtbi.1996.0237; Schnell S, 2007, MULTISCALE MODELING; SLACK JMW, 1980, J THEOR BIOL, V82, P105, DOI 10.1016/0022-5193(80)90092-2; Szallasi Z., 2006, SYST MOD CELL BIOL, DOI 10.7551/mitpress/9780262195485.001.0001.; Takeda H, 2009, ZOOL SCI, V26, P805, DOI 10.2108/zsj.26.805; Tasaki J, 2011, DEVELOPMENT, V138, P2417, DOI 10.1242/dev.060764; Tasaki J, 2011, DEV GROWTH DIFFER, V53, P389, DOI 10.1111/j.1440-169X.2011.01254.x; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; WADDINGTON CH, 1968, NATURE, V218, P525, DOI 10.1038/218525a0; Wagner DE, 2011, SCIENCE, V332, P811, DOI 10.1126/science.1203983; Wenemoser D, 2010, DEV BIOL, V344, P979, DOI 10.1016/j.ydbio.2010.06.017; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Yang SJ, 2004, EUR J NEUROSCI, V19, P1153, DOI 10.1111/j.1460-9568.2004.03250.x; Yazawa S, 2009, P NATL ACAD SCI USA, V106, P22329, DOI 10.1073/pnas.0907464106; Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925	146	60	60	3	99	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-734X	1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	APR	2012	8	4							e1002481	10.1371/journal.pcbi.1002481			12	Biochemical Research Methods; Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Mathematical & Computational Biology	934JM	WOS:000303440400033	22570595	Green Submitted, Green Published, gold			2022-02-06	
J	Andelic, N; Stevens, LF; Sigurdardottir, S; Arango-Lasprilla, JC; Roe, C				Andelic, Nada; Stevens, Lillian Flores; Sigurdardottir, Solrun; Arango-Lasprilla, Juan Carlos; Roe, Cecilie			Associations between disability and employment 1 year after traumatic brain injury in a working age population	BRAIN INJURY			English	Article						Traumatic brain injury; ICF; disability; employment; outcome	PREDICTING RETURN; MULTIPLE INJURIES; HEALTH; ICF; OUTCOMES; CLASSIFICATION; MODEL	Objective: To investigate associations between disability and employment 1 year after traumatic brain injury (TBI) using the International Classification of Functioning, Disability and Health (ICF) as a conceptual model. Design and methods: A prospective study including 93 patients with moderate-to-severe TBI (aged 16-55 year). Disability components of the ICF model (impairments, activity limitations and participation restrictions) and personal factors (age, gender, pre-injury employment status) were used as independent variables. The outcome measure was employment at 1 year post-injury categorized into unemployed and employed groups. Results: Personal factors, impairments (brain injury severity, overall trauma severity and number of impaired body functions) and activity limitations (motor and cognitive abilities) accounted for 57% of the variance in employment outcome. Multivariate analyses showed that the probabilities of being employed 1 year post-injury were 95% lower for patients who were unemployed pre-injury (OR = 0.05), 74% lower for those with more severe brain injury (OR = 0.26) and 82% lower for those with more cognitive limitations (OR = 0.18). Conclusion: Rehabilitation professionals should take into account the importance of the ICF model when planning vocational rehabilitation interventions for individuals with TBI and focus on targeting modifiable aspects related to employment outcome, such as the individual's cognitive ability.	[Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Stevens, Lillian Flores; Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway		Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	nadand@ous-hf.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority	The authors would like to thank all the patients for their participation. Special thanks are given to Tone Jerstad (Neuroradiologist, Oslo University Hospital, Ulleval) for the CT assessments and Morten Hestnes (Trauma Register, Oslo University Hospital, Ulleval) for the extraction of trauma scores. This study was supported by grants from the Norwegian Health South-East Authority.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL 1990; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johansson U, 2001, DISABIL REHABIL, V23, P474; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; O'Donovan MA, 2009, DISABIL REHABIL, V31, P2073, DOI 10.3109/09638280902918738; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Pistarini C, 2011, FUNCTIONING DISABILI; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Ptyushkin P, 2010, BRAIN INJURY, V24, P1519, DOI 10.3109/02699052.2010.523054; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skaga NO, 2006, J TRAUMA, V60, P538, DOI 10.1097/01.ta.0000205613.52586.d1; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2007, INT CLASS FUNCT DIS	42	60	61	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					261	269		10.3109/02699052.2012.654589			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100006	22372413				2022-02-06	
J	Crowe, LM; Catroppa, C; Babl, FE; Anderson, V				Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Anderson, Vicki			Intellectual, Behavioral, and Social Outcomes of Accidental Traumatic Brain Injury in Early Childhood	PEDIATRICS			English	Article						traumatic brain injury; children; infants; intellectual functioning	YOUNG-CHILDREN; FUNCTIONAL RECOVERY; HEAD-INJURIES; FOLLOW-UP; INFANTS; ADOLESCENTS; PREDICTORS; AGE	OBJECTIVE: The intellectual, behavioral, and social function of children who sustained traumatic brain injury (TBI) before 3 years of age were compared with a group of uninjured children. The role of injury and environmental factors in recovery was examined. METHODS: A group of 53 children who sustained a TBI before 3 years of age (20 mild and 33 moderate/severe) and 27 uninjured children (control group) were assessed on an IQ measure and parent measures of behavior and social skills. Children were aged 4 to 6 years and were an average of 40 months since sustaining their injury. RESULTS: There were no demographic differences between the groups. Although all group scores were in the average range, children with moderate/severe TBI performed significantly below uninjured children on an IQ measure. No significant differences were found on parent behavior ratings, although effect sizes between groups were medium to large. No differences were found for social skills. All outcomes were significantly influenced by environmental but not injury factors. CONCLUSIONS: Moderate/severe TBI at an early age appears to be associated with lowered intellectual function and possibly behavior problems. A child's environment influences cognitive and behavior function after TBI. Pediatrics 2012;129:e262-e268	[Babl, Franz E.; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crowe, Louise M.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia		Crowe, LM (corresponding author), Royal Childrens Hosp, Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436; Crowe, Louise/0000-0003-4619-9708	Foundation for Children; Victorian Government	This work was supported by a grant from the Foundation for Children and by the Victorian Government's Operational Infrastructure Support Program.	Achenbach TM., 2000, CHILD BEHAV CHECKLIS; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Case ME, 2008, BRAIN PATHOL, V18, P562, DOI 10.1111/j.1750-3639.2008.00202.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cohen J., 2013, STAT POWER ANAL BEHA; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ennis Elaine, 2004, Pediatr Rehabil, V7, P205, DOI 10.1080/13638490410001703316; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Falk AC, 2007, DEV NEUROREHABIL, V10, P267; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gresham FM, 1995, SOCIAL SKILLS RATING; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Lalloo R, 2003, INJURY, V34, P261, DOI 10.1016/S0020-1383(02)00277-2; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Noller P., 1988, ICPS FAMILY FUNCTION; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; Spady DW, 2004, PEDIATRICS, V113, P522, DOI 10.1542/peds.113.3.522; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Trewin D, 2009, AUSTR NZ STANDARD CL; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wechsler D., 2002, WECHSLER PRESCHOOL P; Wetherington CE, 2010, J PEDIATR PSYCHOL, V35, P662, DOI 10.1093/jpepsy/jsp081; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	45	60	60	0	24	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2012	129	2					E262	E268		10.1542/peds.2011-0438			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	893YZ	WOS:000300395100002	22271692	Bronze			2022-02-06	
J	Tran, HT; Sanchez, L; Brody, DL				Tran, Hien T.; Sanchez, Laura; Brody, David L.			Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury-Induced Tauopathy in Transgenic Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						c-Jun N-terminal kinase; Controlled cortical impact; D-JNKil; Kinase; Phosphorylation; Tau; Traumatic brain injury	DEPENDENT PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; PHOSPHORYLATES TAU-PROTEIN; ALZHEIMER-DISEASE BRAIN; REPETITIVE HEAD-INJURY; DIFFUSE AXONAL INJURY; BETA-AMYLOID PROTEIN; IN-VIVO; NEUROFIBRILLARY TANGLES; MOUSE MODEL	Traumatic brain injury (TBI) is a major environmental risk factor for subsequent development of Alzheimer disease (AD). Pathological features that are common to AD and many tauopathies are neurofibrillary tangles (NFTs) and neuropil threads composed of hyperphosphorylated tau. Axonal accumulations of total and phospho-tau have been observed within hours to weeks, and intracytoplasmic NFTs have been documented years after severe TBI in humans. We previously reported that controlled cortical impact TBI accelerated tau pathology in young 3xTg-AD mice. Here, we used this TBI mouse model to investigate mechanisms responsible for increased tau phosphorylation and accumulation after brain trauma. We found that TBI resulted in abnormal axonal accumulation of several kinases that phosphorylate tau. Notably, c-Jun N-terminal kinase (JNK) was markedly activated in injured axons and colocalized with phospho-tau. We found that moderate reduction of JNK activity (40%) by a peptide inhibitor, D-JNKil, was sufficient to reduce total and phospho-tau accumulations in axons of these mice with TBI. Longer-term studies will be required to determine whether reducing acute tau pathology proves beneficial in brain trauma.	[Tran, Hien T.; Sanchez, Laura; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069, K08 NS049237]; Wellcome Career Award in the Biomedical Sciences; Thrasher Research Fund; NIH Neuroscience Blueprint Interdisciplinary Center [P30 NS057105]; Office of Undergraduate Research Award at Washington University; Alafi Neuroimaging facility; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057105, R01NS065069, K08NS049237] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS065069 (David L. Brody), NIH K08 NS049237 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (David L. Brody), the Thrasher Research Fund (Brody), the Alafi Neuroimaging facility and the NIH Neuroscience Blueprint Interdisciplinary Center Core Grant P30 NS057105 to Washington University, and the Office of Undergraduate Research Award at Washington University (Laura Sanchez).	ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Anderton BH, 1998, PROG NEUROBIOL, V55, P595, DOI 10.1016/S0301-0082(98)00022-7; Arendt T, 1998, NEUROBIOL AGING, V19, P3, DOI 10.1016/S0197-4580(98)00003-7; Averill S, 2001, MOL CELL NEUROSCI, V18, P183, DOI 10.1006/mcne.2001.1015; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Ballatore C, 2010, J MED CHEM, V53, P3739, DOI 10.1021/jm100138f; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Brunden KR, 2009, NAT REV DRUG DISCOV, V8, P783, DOI 10.1038/nrd2959; Buee-Scherrer V, 2002, FEBS LETT, V515, P151, DOI 10.1016/S0014-5793(02)02460-2; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cohen TJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1255; Colombo A, 2007, CELL DEATH DIFFER, V14, P1845, DOI 10.1038/sj.cdd.4402202; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerdts J, 2011, J BIOL CHEM, V286, P28011, DOI 10.1074/jbc.M111.250472; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2011, BRAIN PATHOL, P12; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kim J, 2009, NEURON, V64, P632, DOI 10.1016/j.neuron.2009.11.013; Kins S, 2001, J BIOL CHEM, V276, P38193; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merrick SE, 1997, J NEUROSCI, V17, P5726; Middlemas A, 2003, BRAIN, V126, P1671, DOI 10.1093/brain/awg150; Miller BR, 2009, NAT NEUROSCI, V12, P387, DOI 10.1038/nn.2290; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Reynolds AJ, 2001, NEUROSCIENCE, V105, P761, DOI 10.1016/S0306-4522(01)00235-4; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTSON J, 1993, DEMENTIA, V4, P256, DOI 10.1159/000107331; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Silva RM, 2005, MOVEMENT DISORD, V20, P653, DOI 10.1002/mds.20390; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tseng HC, 2002, FEBS LETT, V523, P58, DOI 10.1016/S0014-5793(02)02934-4; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Virdee K, 2007, FEBS LETT, V581, P2657, DOI 10.1016/j.febslet.2007.05.009; Vogel J, 2009, NEUROPHARMACOLOGY, V57, P539, DOI 10.1016/j.neuropharm.2009.07.021; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; Yoshida H, 2004, J NEUROCHEM, V90, P352, DOI 10.1111/j.1471-4159.2004.02479.x; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	97	60	65	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2012	71	2					116	129		10.1097/NEN.0b013e3182456aed			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	879IQ	WOS:000299323300003	22249463	Bronze, Green Accepted			2022-02-06	
J	Baguley, IJ; Nott, MT; Howie, AA; Simpson, GK; Browne, S; King, AC; Cotter, RE; Hodgkinson, A				Baguley, Ian J.; Nott, Melissa T.; Howie, Alison A.; Simpson, Grahame K.; Browne, Stuart; King, A. Clayton; Cotter, Rachel E.; Hodgkinson, Adeline			Late mortality after severe traumatic brain injury in New South Wales: a multicentre study	MEDICAL JOURNAL OF AUSTRALIA			English	Article							LONG-TERM SURVIVAL; REHABILITATION; POPULATION; OUTCOMES; TRENDS; DEATH; CARE	Objectives: To determine the long-term mortality pattern of adults with severe traumatic brain injury (TBI), and to identify the risk factors associated with death in this group. Design, patients and setting: Inception cohort study of 2545 adults consecutively discharged from one of three metropolitan tertiary, post-acute inpatient rehabilitation services of the New South Wales Brain Injury Rehabilitation Program from 1 January 1990 to 1 October 2007 after inpatient rehabilitation for primary TBI. Main outcome measure: Survival status at 1 October 2009. Results: 258 deaths were recorded in this sample, yielding a standardised mortality ratio of 3.19 (95% Cl, 2.80-3.60). Risk of death remained elevated above societal norms for at least 8 years after discharge from rehabilitation. Mortality risk was increased by: functional dependence at discharge; age at injury; pre-injury drug and alcohol misuse; pre-injury epilepsy; and discharge to an aged care facility. The risk of death from external causes, and respiratory system and nervous system disorders was six to seven times higher, and the risk of death from disorders of the digestive system, and mental and behavioural disorders was five times higher in adults with severe TBI than in the general population. Conclusions: People who survive to discharge from inpatient rehabilitation following a severe TBI were found to have a sustained increase in risk of death for eight years post discharge. Various demographic and injury-related variables selectively increase mortality risk and may be modifiable in order to reduce the observed increase in mortality.	[Baguley, Ian J.; Nott, Melissa T.; Howie, Alison A.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Simpson, Grahame K.; Cotter, Rachel E.; Hodgkinson, Adeline] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Browne, Stuart; King, A. Clayton] Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, Sydney, NSW, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia.	Ian.Baguley@swahs.health.nsw.gov.au	Baguley, Ian J/K-6878-2013; Simpson, Grahame K/W-1074-2019; Baguley, Ian/AAM-5828-2021; Nott, Melissa T/M-6778-2018	Baguley, Ian J/0000-0001-5650-3705; Simpson, Grahame K/0000-0001-8156-9060; Nott, Melissa T/0000-0001-7088-5826	New South Wales Government [08157, 10588]	We gratefully acknowledge the statistical advice provided by Karen Byth of Westmead Hospital, and the financial support provided by the New South Wales Government Lifetime Care and Support Authority to complete this study (research grants 08157 and 10588).	Australian Bureau of Statistics, 2008, DEATHS AUSTR; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Economics A., 2009, EC COST SPINAL CORD, P31; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NSW Health, NSW BRAIN INJ REH PR; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; *UN DAT SYST MED R, 1997, GUID UN DAT SET MED; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	25	60	62	0	5	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X	1326-5377		MED J AUSTRALIA	Med. J. Aust.	JAN 16	2012	196	1					40	45		10.5694/mja11.10090			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881QH	WOS:000299500700024	22256933	Bronze			2022-02-06	
J	Gallun, FJ; Diedesch, AC; Kubli, LR; Walden, TC; Folmer, RL; Lewis, MS; McDermott, DJ; Fausti, SA; Leek, MR				Gallun, Frederick J.; Diedesch, Anna C.; Kubli, Lina R.; Walden, Therese C.; Folmer, Robert L.; Lewis, M. Samantha; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.			Performance on tests of central auditory processing by individuals exposed to high-intensity blasts	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						audiometric evaluation; auditory dysfunction; auditory processing disorder; blast; central auditory processing; evoked potential; hearing loss; rehabilitation; traumatic brain injury; Veterans	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; HEARING-LOSS; DYSFUNCTION; COCHLEAR; WAR	Thirty-six blast-exposed patients and twenty-nine non-blast-exposed control subjects were tested on a battery of behavioral and electrophysiological tests that have been shown to be sensitive to central auditory processing deficits. Abnormal performance among the blast-exposed patients was assessed with reference to normative values established as the mean performance on each test by the control subjects plus or minus two standard deviations. Blast-exposed patients performed abnormally at rates significantly above that which would occur by chance on three of the behavioral tests of central auditory processing: the Gaps-In-Noise, Masking Level Difference, and Staggered Spondaic Words tests. The proportion of blast-exposed patients performing abnormally on a speech-in-noise test (Quick Speech-In-Noise) was also significantly above that expected by chance. These results suggest that, for some patients, blast exposure may lead to difficulties with hearing in complex auditory environments, even when peripheral hearing sensitivity is near normal limits	[Gallun, Frederick J.; Diedesch, Anna C.; Folmer, Robert L.; Lewis, M. Samantha; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.] Portland Dept Vet Affairs Med Ctr, NCRAR, Portland, OR USA; [Gallun, Frederick J.; Folmer, Robert L.; Lewis, M. Samantha; Fausti, Stephen A.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kubli, Lina R.; Walden, Therese C.] Walter Reed Natl Mil Med Ctr, Audiol & Speech Ctr, Sci & Clin Studies Sect, Bethesda, MD USA		Gallun, FJ (corresponding author), VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Frederick.Gallun@va.gov	Gallun, Frederick J./G-3792-2012; Folmer, Robert L/E-3105-2010	Gallun, Frederick J./0000-0002-4145-2199; 	VA Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B5067R, C7755I]; Senior Research Career Scientist award [C4042L]; VA Career Development II awards [C4963W, C7067W]; VA Rehabilitation Research and Development NCRAR (Center of Excellence) [C4844C]; Veterans AffairsUS Department of Veterans Affairs [I01RX000536] Funding Source: NIH RePORTER	This material was based on work supported by the VA Rehabilitation Research and Development Service (Merit Review awards B5067R [PIs: Leek, Fausti] and C7755I [PIs: Gallun, Leek]), a Senior Research Career Scientist award (grant C4042L [PI: Leek]), VA Career Development II awards (grants C4963W [PI: Gallun] and C7067W [PI: Lewis]), and the VA Rehabilitation Research and Development NCRAR (Center of Excellence award C4844C).	Alberti A, 2001, HEADACHE, V41, P579, DOI 10.1046/j.1526-4610.2001.041006579.x; ARNST DJ, 1983, EAR HEARING, V4, P243, DOI 10.1097/00003446-198309000-00004; Bamiou DE, 2006, NEUROLOGY, V67, P614, DOI 10.1212/01.wnl.0000230197.40410.db; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chandler CDW, 2006, ASHA LEAD, V11, P8, DOI DOI 10.1044/LEADER.FTR4.11092006.8; Chermak GD., 1997, CENTRAL AUDITORY PRO; Department of Veterans Affairs, 1991, SPEECH REC ID MAT CO; Department of Veterans Affairs Office of Patient Care Services Office of Rehabilitation Services, 2011, TBI COMPR EV SUMM RE; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1059, DOI 10.1682/JRRD.2010.09.0166; Hall J, 2006, HDB CENTRAL AUDITORY, V1, P287; Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); HENDLER T, 1990, EAR HEARING, V11, P403, DOI 10.1097/00003446-199012000-00002; Humes L E, 1996, J Am Acad Audiol, V7, P419; JERGER J, 1984, ARCH OTOLARYNGOL, V110, P290; Katz J., 1998, SSW TEST MANUAL, Vfifth; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; MUELLER H G, 1987, Seminars in Hearing, V8, P267, DOI 10.1055/s-0028-1091377; Musiek F E, 1992, J Am Acad Audiol, V3, P5; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1989, AM J OTOL, V10, P343; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2004, AM J FOREN MED PATH, V25, P270, DOI 10.1097/01.paf.0000136642.17300.8b; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; RAPPAPORT JM, 1994, J OTOLARYNGOL, V23, P307; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Turner L, 1966, THESIS U KANSAS LAWR; Wilson Richard H, 2003, J Am Acad Audiol, V14, P1, DOI 10.3766/jaaa.14.1.2	33	60	61	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1005	1024		10.1682/JRRD.2012.03.0038			20	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EZ	WOS:000319303100006	23341276	Bronze			2022-02-06	
J	Zlotnik, A; Sinelnikov, I; Gruenbaum, BF; Gruenbaum, SE; Dubilet, M; Dubilet, E; Leibowitz, A; Ohayon, S; Regev, A; Boyko, M; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Sinelnikov, Igor; Gruenbaum, Benjamin F.; Gruenbaum, Shaun E.; Dubilet, Michael; Dubilet, Elena; Leibowitz, Akiva; Ohayon, Sharon; Regev, Adi; Boyko, Matthew; Shapira, Yoram; Teichberg, Vivian I.			Effect of Glutamate and Blood Glutamate Scavengers Oxaloacetate and Pyruvate on Neurological Outcome and Pathohistology of the Hippocampus after Traumatic Brain Injury in Rats	ANESTHESIOLOGY			English	Article							CLOSED-HEAD-INJURY; CORTICAL CONTUSION INJURY; EXCITATORY AMINO-ACIDS; LONG-TERM OUTCOMES; CEREBROSPINAL-FLUID; EXPERIMENTAL-MODELS; COGNITIVE DEFICITS; ISCHEMIC-STROKE; NEURONAL LOSS; RELEASE	Background: Decreasing blood glutamate concentrations after traumatic brain injury accelerates brain-to-blood glutamate efflux, leading to improved neurologic outcomes. The authors hypothesize that treatment with blood glutamate scavengers should reduce neuronal cell loss, whereas administration of glutamate should worsen outcomes. The authors performed histologic studies of neuronal survival in the rat hippocampus after traumatic brain injury and treatment with blood glutamate scavengers. Methods: Traumatic brain injury was induced on anesthetized male Sprague-Dawley rats by a standardized weight drop. Intravenous treatment groups included saline (control), oxaloacetate, pyruvate, and glutamate. Neurologic outcome was assessed using a Neurological Severity Score at 1 h, and 1, 2, 7, 14, 21, 28 days. Blood glutamate was determined at baseline and 90 min. Four weeks after traumatic brain injury, a histologic analysis of surviving neurons was performed. Results: Oxaloacetate and pyruvate treatment groups demonstrated increased neuronal survival (oxaloacetate 2,200 +/- 37, pyruvate 2,108 +/- 137 vs. control 1,978 +/- 46, P < 0.001, mean +/- SD). Glutamate treatment revealed decreased neuronal survival (1,715 +/- 48, P < 0.001). Treatment groups demonstrated favorable neurologic outcomes at 24 and 48 h (Neurological Severity Score at 24 and 48 h: 5.5 (1-8.25), 5 (1.75-7.25), P = 0.02 and 3(1-6.5), 4 (1.75-4.5), P = 0.027, median +/- corresponding interquartile range). Blood glutamate concentrations were decreased in the oxaloacetate and pyruvate treatment groups. Administration of oxaloacetate and pyruvate was not shown to have any adverse effects. Conclusions: The authors demonstrate that the blood glutamate scavengers oxaloacetate and pyruvate provide neuro-protection after traumatic brain injury, expressed both by reduced neuronal loss in the hippocampus and improved neurologic outcomes. The findings of this study may bring about new therapeutic possibilities in a variety of clinical settings.	[Zlotnik, Alexander] Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Zlotnik, Alexander; Gruenbaum, Benjamin F.; Dubilet, Michael; Leibowitz, Akiva; Ohayon, Sharon; Regev, Adi; Boyko, Matthew; Shapira, Yoram] Soroka Univ Med Ctr, Dept Anesthesiol & Crit Care, Beer Sheva, Israel; [Sinelnikov, Igor; Dubilet, Elena] Soroka Univ Med Ctr, Dept Pathol, Beer Sheva, Israel; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA		Zlotnik, A (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel.	zlotnika@bgu.ac.il	Leibowitz, Akiva/F-1397-2012	Leibowitz, Akiva/0000-0003-4244-1915; Boyko, Matthew/0000-0003-3116-1643	Ben-Gurion University of the Negev, Beer-Sheva, Israel; Nella and Leon Benoziyo Center for Neurological Diseases, Weizmann Institute of Science, Rehovot, Israel; Carl and Micaela Einhorn-Dominic Institute for Brain Research, Weizmann Institute of Science; Irwin Green Alzheimer's Research Fund, Detroit, Michigan; Nursing, Critical Care Unit, Soroka Medical Center, Beer Sheva, Israel	Received from the Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel. Submitted for publication August 18, 2010. Accepted for publication September 26, 2011. Supported by Ben-Gurion University of the Negev, Beer-Sheva, Israel; Nella and Leon Benoziyo Center for Neurological Diseases, Weizmann Institute of Science, Rehovot, Israel; Carl and Micaela Einhorn-Dominic Institute for Brain Research, Weizmann Institute of Science; and Irwin Green Alzheimer's Research Fund, Detroit, Michigan. Dr. Teichberg was the incumbent of the Louis and Florence Katz Cohen Professorial Chair of Neuropharmacology, Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel. The data obtained are part of Matthew Boyko's doctoral thesis. Drs. Zlotnik and Sinelnikov contributed equally to the article.; The authors gratefully acknowledge the help of Shira Ovadia, D.V.M., Director of the Animal Resources Unit, Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel. The authors also thank Adina Elir, R.N., M.A., Director of Nursing, Critical Care Unit, Soroka Medical Center, Beer Sheva, Israel, for her support and helpful discussions.	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Cosar M, 2009, SURG NEUROL, V71, P54, DOI 10.1016/j.surneu.2007.08.020; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Klin Y, 2010, BIOCHEM BIOPH RES CO, V399, P694, DOI 10.1016/j.bbrc.2010.07.144; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Koura SS, 1998, ACT NEUR S, V71, P244; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prieto R, 2009, NEUROCIRUGIA, V20, P225; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	51	60	61	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JAN	2012	116	1					73	83		10.1097/ALN.0b013e31823d7731			11	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	869OU	WOS:000298608400012	22129535	Bronze			2022-02-06	
J	Elkin, BS; Ilankovan, AI; Morrison, B				Elkin, Benjamin S.; Ilankovan, Ashok I.; Morrison, Barclay, III			A Detailed Viscoelastic Characterization of the P17 and Adult Rat Brain	JOURNAL OF NEUROTRAUMA			English	Article						age-dependence; constitutive modeling; heterogeneous mechanical properties; indentation; neurosurgery; rat brain; traumatic brain injury; viscoelasticity	TISSUE; INJURY; DEFORMATION; INDENTATION; STRESS; MODELS; TESTS	Brain is a morphologically and mechanically heterogeneous organ. Although rat brain is commonly used as an experimental neurophysiological model for various in vivo biomechanical studies, little is known about its regional viscoelastic properties. To address this issue, we have generated viscoelastic mechanical property data for specific anatomical regions of the P17 and adult rat brain. These ages are commonly used in rat experimental models. We measured mechanical properties of both white and gray matter regions in coronal slices with a custom-designed microindentation device performing stress-relaxation indentations to 10% effective strain. Shear moduli calculated for short (100 ms), intermediate (1 sec), and long (20 sec) time points, ranged from similar to 1 kPa for short term moduli to similar to 0.4 kPa for long term moduli. Both age and anatomic region were significant factors affecting the time-dependent shear modulus. White matter regions and regions of the cerebellum were much more compliant than those of the hippocampus, cortex, and thalamus. Linear viscoelastic models (Prony series, continuous phase lag, and a power law model) were fit to the time-dependent shear modulus data. All models fit the data equally with no significant differences between them (F-test; p > 0.05). The F-test was also used to statistically determine that a Prony series with three time-dependent parameters accurately fit the data with no added benefit from additional terms. The age-and region-dependent rat brain viscoelastic properties presented here will help inform future biomechanical models of the rat brain with specific and accurate regional mechanical property data.	[Elkin, Benjamin S.; Ilankovan, Ashok I.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,1210 Amsterdam Ave,MC 8904, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); National Highway Traffic Safety Administration	The authors thank Chris Puleo for help performing indentation tests and Dr. Ed X. Guo for use of laboratory space and equipment. This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) postgraduate scholarship (BSE) and the National Highway Traffic Safety Administration.	Allen M. P., 1997, UNDERSTANDING REGRES, P113; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bonferroni, 1935, STUDI ONORE PROFESSO, P13; Cheng L, 2000, J POLYM SCI POL PHYS, V38, P10, DOI 10.1002/(SICI)1099-0488(20000101)38:1<10::AID-POLB2>3.0.CO;2-6; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Dong X Neil, 2005, Mech Chem Biosyst, V2, P63; Dutta-Roy T, 2008, J BIOMECH, V41, P2263, DOI 10.1016/j.jbiomech.2008.04.014; Elkin B.S., 2010, J BIOMECH ENG, V121; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Gao CP, 2008, ACTA NEUROCHIR SUPPL, V102, P279, DOI 10.1007/978-3-211-85578-2_52; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; HARDING JW, 1945, P CAMB PHILOS SOC, V41, P16, DOI 10.1017/S0305004100022325; HILDEBRANDT J, 1969, B MATH BIOPHYS, V31, P651, DOI 10.1007/BF02477779; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Kalidindi SR, 2008, ACTA MATER, V56, P3523, DOI 10.1016/j.actamat.2008.03.036; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; NEUBERT HKP, 1963, AERONAUT QUART, V14, P187, DOI 10.1017/S0001925900002754; Papazoglou S, 2009, PHYS MED BIOL, V54, P2229, DOI 10.1088/0031-9155/54/7/025; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Schiessel H, 1995, J PHYS A-MATH GEN, V28, P6567, DOI 10.1088/0305-4470/28/23/012; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tripathy S., 2009, J BIOMECH ENG, V131; Zamir EA, 2004, J BIOMECH ENG-T ASME, V126, P276, DOI 10.1115/1.1695573	31	60	60	0	27	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2235	2244		10.1089/neu.2010.1604			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600004	21341982				2022-02-06	
J	Brooks, BL; Holdnack, JA; Iverson, GL				Brooks, Brian L.; Holdnack, James A.; Iverson, Grant L.			Advanced Clinical Interpretation of the WAIS-IV and WMS-IV: Prevalence of Low Scores Varies by Level of Intelligence and Years of Education	ASSESSMENT			English	Article						base rates; misdiagnosis; assessment; memory; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEALTHY OLDER-ADULTS; NEUROPSYCHOLOGICAL TEST BATTERIES; BASE RATES; DISCREPANCY SCORES; MEMORY SCORES; PERFORMANCE; IMPAIRMENT; CRITERIA; INDEX	Clinicians can use the base rates of low scores in healthy people to reduce the likelihood of misdiagnosing cognitive impairment. In the present study, base rates were developed for the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) and Wechsler Memory Scale-Fourth Edition (WMS-IV) using 900 healthy adults and validated on 28 patients with moderate or severe traumatic brain injuries (TBIs). Results indicated that healthy people obtain some low scores on the WAIS-IV/WMS-IV, with prevalence rates increasing with fewer years of education and lower predicted intelligence. When applying the base rates information to the clinical sample, the TBI patients were 13 times more likely to be identified as having a low cognitive profile compared with the controls. Using the base rates information is a psychometrically advanced method for establishing criteria to determine low cognitive abilities on the WAIS-IV/WMS-IV.	[Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB, Canada; [Holdnack, James A.] Pearson Assessment, San Antonio, TX USA; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca		Iverson, Grant/0000-0001-7348-9570			Axelrod BN, 2002, INT J NEUROSCI, V112, P1479, DOI 10.1080/00207450290158377; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Brooks BL, 2009, ARCH CLIN NEUROPSYCH, V24, P647, DOI 10.1093/arclin/acp061; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Brooks BL, 2009, J INT NEUROPSYCH SOC, V15, P613, DOI 10.1017/S1355617709090651; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Ferri J, 2004, NEUROLOGIA, V19, P285; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Heaton R. K., 2004, REVISED COMPREHENSIV; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2008, NEUROPSYCHOLOGY HDB, P279; Iverson GL, 2008, NEUROPSYCHOLOGY COUR, P243; IVERSON GL, BLACK BOOK IN PRESS; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Pearson Assessment, 2009, ADV CLIN SOL WAIS 4; Reitan R.M., 1993, HALSTEADREITAN NEURO; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL	26	60	60	1	37	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	JUN	2011	18	2					156	167		10.1177/1073191110385316			12	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	762XA	WOS:000290514300004	20947705				2022-02-06	
J	Cook, KF; Bombardier, CH; Bamer, AM; Choi, SW; Kroenke, K; Fann, JR				Cook, Karon F.; Bombardier, Charles H.; Bamer, Alyssa M.; Choi, Seung W.; Kroenke, Kurt; Fann, Jesse R.			Do Somatic and Cognitive Symptoms of Traumatic Brain Injury Confound Depression Screening?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Diagnosis; Psychometrics; Rehabilitation	ORDINAL LOGISTIC-REGRESSION; 1ST YEAR; DSM-IV; VALIDITY; SERTRALINE; CRITERIA; IMPACT; ADULTS; PHQ-9	Objective: To evaluate whether items of the Patient Health Questionnaire 9 (PHQ-9) function differently in persons with traumatic brain injury (TBI) than in persons from a primary care sample. Design: This study was a retrospective analysis of responses to the PHQ-9 collected in 2 previous studies. Responses to the PHQ-9 were modeled using item response theory, and the presence of DIF was evaluated using ordinal logistic regression. Setting: Eight primary care sites and a single trauma center in Washington state. Participants: Participants (N=3365) were persons from 8 primary care sites (n=3000) and a consecutive sample of persons with complicated mild to severe TBI from a trauma center who were 1 year postinjury (n=365). Interventions: Not applicable. Main Outcome Measure: PHQ-9. Results: No PHQ-9 item demonstrated statistically significant or meaningful DIF attributable to TBI. A sensitivity analysis failed to show that the cumulative effects of nonsignificant DIF resulted in a systematic inflation of PHQ-9 total scores. Therefore, the results also do not support the hypothesis that cumulative DIF for PHQ-9 items spuriously inflates the numbers of persons with TBI screened as potentially having major depressive disorder. Conclusions: The PHQ-9 is a valid screener of major depressive disorder in people with complicated mild to severe TB!, and all symptoms can be counted toward the diagnosis of major depressive disorder without special concern about over-diagnosis or unnecessary treatment.	[Cook, Karon F.] Univ Washington, Rehabil Res Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98105 USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98105 USA; [Choi, Seung W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Kroenke, Kurt] Indiana Univ Sch Med, VA Ctr Excellence Implementing Evidence Based Pra, Indianapolis, IN USA; [Kroenke, Kurt] Regenstrief Inst Hlth Care, Indianapolis, IN USA		Cook, KF (corresponding author), Univ Washington, Rehabil Res Ctr, Sch Med, Dept Rehabil Med, 4907 25th Ave NE, Seattle, WA 98105 USA.	karonc2@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Kroenke, Kurt/0000-0002-0114-4669	Department of Education (National Institute on Disability and Rehabilitation Research) [H133B080024]; National Center for Medical Rehabilitation Research; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD39415]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	Supported by the Department of Education (National Institute on Disability and Rehabilitation Research) (grant no. H133B080024, and by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health (grant no. R01 HD39415).	Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Cohen J., 2013, STAT POWER ANAL BEHA; Crane PK, 2007, QUAL LIFE RES, V16, P69, DOI 10.1007/s11136-007-9185-5; Crane PK, 2006, MED CARE, V44, pS115, DOI 10.1097/01.mlr.0000245183.28384.ed; Crane PK, 2004, STAT MED, V23, P241, DOI 10.1002/sim.1713; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faul M, 2010, TRAUMATIC BRAIN INJU; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Hambleton RK., 1991, FUNDAMENTALS ITEM RE; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koenig HG, 1997, AM J PSYCHIAT, V154, P1376; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Samejima F., 1969, PSYCHOMETRIC MONOGRA; Simon GE, 2006, PSYCHOL MED, V36, P27, DOI 10.1017/S0033291705006136; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Zumbo B., 1999, HDB THEORY METHODS D	32	60	61	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2011	92	5					818	823		10.1016/j.apmr.2010.12.008			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	759YO	WOS:000290288000019	21530731	Green Accepted, Green Published			2022-02-06	
J	Lingsma, HF; Roozenbeek, B; Li, BYE; Lu, JA; Weir, J; Butcher, I; Marmarou, A; Murray, GD; Maas, AIR; Steyerberg, EW				Lingsma, Hester F.; Roozenbeek, Bob; Li, Bayoue; Lu, Juan; Weir, James; Butcher, Isabella; Marmarou, Anthony; Murray, Gordon D.; Maas, Andrew I. R.; Steyerberg, Ewout W.			Large Between-Center Differences in Outcome After Moderate and Severe Traumatic Brain Injury in the International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury (IMPACT) Study	NEUROSURGERY			English	Article						Center effects; Quality of care; Outcome; Randomized controlled trial; Traumatic brain injury	ACUTE MYOCARDIAL-INFARCTION; ADJUSTMENT METHODS; RISK-ADJUSTMENT; PRACTICAL SCALE; HEAD-INJURY; CARE; QUALITY; EXPERIENCE; MANAGEMENT; MORTALITY	BACKGROUND: Differences between centers in patient outcome after traumatic brain injury are of importance for multicenter studies and have seldom been studied. OBJECTIVE: To quantify the differences in centers enrolling patients in randomized clinical trials (RCTs) and surveys. METHODS: We analyzed individual patient data from 9578 patients with moderate and severe traumatic brain injury enrolled in 10 RCTs and 3 observational studies. We used random-effects logistic regression models to estimate the between-center differences in unfavorable outcome (dead, vegetative state, or severe disability measured with the Glasgow Outcome Scale) at 6 months adjusted for differences in patient characteristics. We calculated the difference in odds of unfavorable outcome between the centers at the higher end vs those at the lower end of the outcome distribution. We analyzed the total database, Europe and the United States separately, and 4 larger RCTs. RESULTS: The 9578 patients were enrolled at 265 centers, and 4629 (48%) had an unfavorable outcome. After adjustment for patient characteristics, there was a 3.3-fold difference in the odds of unfavorable outcome between the centers at the lower end of the outcome distribution (2.5th percentile) vs those at the higher end of the outcome distribution (97.5th percentile; P < .001). In the 4 larger RCTs, the differences between centers were similar. However, differences were smaller between centers in the United States (2.4-fold) than between centers in Europe (3.8-fold). CONCLUSION: Outcome after traumatic brain injury differs substantially between centers, particularly in Europe. Further research is needed to study explanations for these differences to suggest where quality of care might be improved.	[Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Li, Bayoue] Erasmus MC, Dept Biostat, NL-3000 CA Rotterdam, Netherlands; [Roozenbeek, Bob; Murray, Gordon D.; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA; [Weir, James; Butcher, Isabella] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland		Lingsma, HF (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-01923521]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	Grant support was provided by National Institute of Health (NS-01923521). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Biau DJ, 2008, ANN SURG, V247, P892, DOI 10.1097/SLA.0b013e31816ffa99; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; DeLong ER, 1997, STAT MED, V16, P2645, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2645::AID-SIM696>3.0.CO;2-D; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Kelly A, 2008, STROKE, V39, P3367, DOI 10.1161/STROKEAHA.108.518738; Krumholz HM, 2008, CIRCULATION, V118, P1885, DOI 10.1161/CIRCULATIONAHA.108.190500; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Steyerberg EW, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.07.008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Timbie JW, 2008, MED DECIS MAKING, V28, P419, DOI 10.1177/0272989X07312476; Wright J, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b569	22	60	62	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2011	68	3					601	607		10.1227/NEU.0b013e318209333b			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	719WN	WOS:000287242300022	21311293				2022-02-06	
J	Newcombe, VFJ; Outtrim, JG; Chatfield, DA; Manktelow, A; Hutchinson, PJ; Coles, JP; Williams, GB; Sahakian, BJ; Menon, DK				Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Hutchinson, Peter J.; Coles, Jonathan P.; Williams, Guy B.; Sahakian, Barbara J.; Menon, David K.			Parcellating the neuroanatomical basis of impaired decision-making in traumatic brain injury	BRAIN			English	Article						traumatic brain injury; diffusion tensor imaging; decision-making	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PREFRONTAL CORTEX LESIONS; DIFFUSE AXONAL INJURY; HEAD-INJURY; PERSONALITY-CHANGE; NORMAL VOLUNTEERS; DAMAGE; AMANTADINE; SURVIVORS; COGNITION	Cognitive dysfunction is a devastating consequence of traumatic brain injury that affects the majority of those who survive with moderate-to-severe injury, and many patients with mild head injury. Disruption of key monoaminergic neurotransmitter systems, such as the dopaminergic system, may play a key role in the widespread cognitive dysfunction seen after traumatic axonal injury. Manifestations of injury to this system may include impaired decision-making and impulsivity. We used the Cambridge Gambling Task to characterize decision-making and risk-taking behaviour, outside of a learning context, in a cohort of 44 patients at least six months post-traumatic brain injury. These patients were found to have broadly intact processing of risk adjustment and probability judgement, and to bet similar amounts to controls. However, a patient preference for consistently early bets indicated a higher level of impulsiveness. These behavioural measures were compared with imaging findings on diffusion tensor magnetic resonance imaging. Performance in specific domains of the Cambridge Gambling Task correlated inversely and specifically with the severity of diffusion tensor imaging abnormalities in regions that have been implicated in these cognitive processes. Thus, impulsivity was associated with increased apparent diffusion coefficient bilaterally in the orbitofrontal gyrus, insula and caudate; abnormal risk adjustment with increased apparent diffusion coefficient in the right thalamus and dorsal striatum and left caudate; and impaired performance on rational choice with increased apparent diffusion coefficient in the bilateral dorsolateral prefrontal cortices, and the superior frontal gyri, right ventrolateral prefrontal cortex, the dorsal and ventral striatum, and left hippocampus. Importantly, performance in specific cognitive domains of the task did not correlate with diffusion tensor imaging abnormalities in areas not implicated in their performance. The ability to dissociate the location and extent of damage with performance on the various task components using diffusion tensor imaging allows important insights into the neuroanatomical basis of impulsivity following traumatic brain injury. The ability to detect such damage in vivo may have important implications for patient management, patient selection for trials, and to help understand complex neurocognitive pathways.	[Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Coles, Jonathan P.; Williams, Guy B.; Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris A.; Manktelow, Anne; Hutchinson, Peter J.; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Sahakian, Barbara J.] Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England; [Sahakian, Barbara J.] Univ Cambridge, MRC Wellcome Trust Behav, Cambridge CB2 3EB, England; [Sahakian, Barbara J.] Univ Cambridge, Clin Neurosci Inst, Cambridge CB2 3EB, England		Newcombe, VFJ (corresponding author), Addenbrookes Hosp, Univ Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 2QQ, England.	vfjn2@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Newcombe, Virginia/0000-0001-6044-9035; Outtrim, Joanne/0000-0001-8118-6430; Coles, Jonathan/0000-0003-4013-679X	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institutes of Health Research Biomedical Research Centre at Cambridge; UK Department of Health, Technology; Gates Cambridge Trust; Overseas Research Studentship; National Institute for Health ResearchNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Academy of Medical Sciences/Health Foundation; Clinician Scientist Award; Wellcome TrustWellcome TrustEuropean Commission [089589/Z/09/Z]; BOC Professorship of the Royal College of Anaesthetists; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001354, G0001237, G9439390, G1000183B, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0508-10327] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI	Medical Research Council (UK) Program Grant [Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)]; UK National Institutes of Health Research Biomedical Research Centre at Cambridge; UK Department of Health, Technology Platform funding. Gates Cambridge Trust (to V.F.J.N.); Overseas Research Studentship (to V.F.J.N.); National Institute for Health Research Academic Clinical Fellow (to V.F.J.N.); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship (to P.J.H.); Academy of Medical Sciences/Health Foundation, Clinician Scientist Award (to J.P.C.); Wellcome Trust Programme Grant (No 089589/Z/09/Z to B.J.S.); BOC Professorship of the Royal College of Anaesthetists (to D.K.M.); Evelyn Trust (to D.K.M.).	Bazanis E, 2002, PSYCHOL MED, V32, P1395, DOI 10.1017/S0033291702006657; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; Brennan AR, 2008, ANN NY ACAD SCI, V1129, P236, DOI 10.1196/annals.1417.007; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Correia MM, 2009, MAGN RESON IMAGING, V27, P163, DOI 10.1016/j.mri.2008.06.011; Deakin J, 2004, J INT NEUROPSYCH SOC, V10, P590, DOI 10.1017/S1355617704104104; Debette S, 2002, J NEUROL, V249, P1678, DOI 10.1007/s00415-002-0903-1; DeVito EE, 2008, BIOL PSYCHIAT, V64, P636, DOI 10.1016/j.biopsych.2008.04.017; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7; Franzen M D, 2000, Crit Care Nurs Q, V23, P58; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garcia-Molina A, 2007, NEUROLOGIA, V22, P206; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Hanten G, 2006, NEUROCASE, V12, P247, DOI 10.1080/13554790600910490; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Johansen-Berg H, 2007, CURR BIOL, V17, pR141, DOI 10.1016/j.cub.2006.12.022; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langevin R, 2006, BRAIN COGNITION, V60, P206; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; MacPherson SE, 2009, CLIN NEUROPSYCHOL, V23, P510, DOI 10.1080/13854040802396586; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rubinsztein JS, 2001, BRAIN, V124, P2550, DOI 10.1093/brain/124.12.2550; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Shiga T, 2006, EUR J NUCL MED MOL I, V33, P817, DOI 10.1007/s00259-005-0033-y; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Volkow ND, 2007, ARCH GEN PSYCHIAT, V64, P932, DOI 10.1001/archpsyc.64.8.932; Watkins LHA, 2000, NEUROPSYCHOLOGIA, V38, P1112, DOI 10.1016/S0028-3932(00)00028-2; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Xue G, 2010, NEUROIMAGE, V50, P709, DOI 10.1016/j.neuroimage.2009.12.097; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	60	60	62	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2011	134		3				759	768		10.1093/brain/awq388			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	726RZ	WOS:000287745100012	21310727	Bronze, Green Published			2022-02-06	
J	Czlonkowska, A; Kurkowska-Jastrzebska, I				Czlonkowska, Anna; Kurkowska-Jastrzebska, Iwona			Inflammation and gliosis in neurological diseases - clinical implications	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Neurodegeneration; Multiple sclerosis; Parkinson's disease; Alzheimer's disease; Stroke	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; APPEARING WHITE-MATTER; AMYLOID-BETA PEPTIDE; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; MOUSE MODEL; MICROGLIAL ACTIVATION; T-CELLS; DOPAMINERGIC-NEURONS; ALZHEIMER-DISEASE	The inflammatory reaction accompany all acute processes in the central nervous system (CNS), (as stroke or traumatic brain injury) and chronic neurodegenerative processes (as Parkinson's or Alzheimer's disease), and through the stage of cleaning of damage tissue, contribute to recovery and regeneration and eventually to restoration of the function. However many studies showed that inflammation in the CNS may be harmful because of an excessive vulnerability of the nervous tissue or impaired regulation. Manipulation of the inflammation is now one of the approaches in the treatment of the various diseases of the CNS. (C) 2010 Elsevier B.V. All rights reserved.	[Czlonkowska, Anna; Kurkowska-Jastrzebska, Iwona] Inst Psychiat & Neurol, Dept Neurol 2, Warsaw, Poland; [Czlonkowska, Anna] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland		Czlonkowska, A (corresponding author), Sobieskiego 9, PL-02957 Warsaw, Poland.	czlonkow@ipin.edu.pl		Kurkowska-Jastrzebska, Iwona/0000-0001-6553-9080; Czlonkowska, Anna/0000-0002-1956-1866			Aharoni R, 2010, J NEUROIMMUNOL, V225, P100, DOI 10.1016/j.jneuroim.2010.04.022; Aisen PS, 2008, CURR ALZHEIMER RES, V5, P73, DOI 10.2174/156720508783884602; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Aktas O, 2010, NAT REV NEUROL, V6, P373, DOI 10.1038/nrneurol.2010.76; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Barouch R, 2002, FASEB J, V16, P1304, DOI 10.1096/fj.01-0467fje; Bartels AL, 2007, MOVEMENT DISORD, V22, P1852, DOI 10.1002/mds.21552; Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Carvey PM, 2001, EXP NEUROL, V171, P98, DOI 10.1006/exnr.2001.7735; Castellani ML, 2007, INT J IMMUNOPATH PH, V20, P447, DOI 10.1177/039463200702000303; Chen HL, 2005, ANN NEUROL, V58, P963, DOI 10.1002/ana.20682; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Ciesielska A, 2003, ACTA NEUROBIOL EXP, V63, P117; Compston A, 1996, Mult Scler, V1, P388; Danilov AI, 2006, EUR J NEUROSCI, V23, P394, DOI 10.1111/j.1460-9568.2005.04563.x; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dodel R, 2002, ANN NEUROL, V52, P253, DOI 10.1002/ana.10253; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/S1074-7613(01)00143-1; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Gimsa U, 2000, BRAIN PATHOL, V10, P365; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Gromadzka G, 2007, J NEUROL NEUROSUR PS, V78, P183, DOI 10.1136/jnnp.2006.093104; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Hernan MA, 2006, NEUROLOGY, V66, P1097, DOI 10.1212/01.wnl.0000204446.82823.28; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Johansson S, 2002, J COMP NEUROL, V443, P237, DOI 10.1002/cne.10119; Joniec I, 2009, BRAIN RES, V1261, P7, DOI 10.1016/j.brainres.2008.12.081; Kokjohn TA, 2009, CNS NEUROL DISORD-DR, V8, P88, DOI 10.2174/187152709787847315; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Kurkowska-Jastrzebska I, 2007, PARKINSONISM RELAT D, V13, pS141, DOI 10.1016/S1353-8020(08)70772-7; Kurkowska-Jastrzebska I, 2006, ANN NEUROL, V59, P988, DOI 10.1002/ana.20860; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; Kurkowska-Jastrzebska I, 2005, NEUROSCIENCE, V131, P247, DOI 10.1016/j.neuroscience.2004.10.027; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; Kurkowska-Jastrzebska I, 2002, INT IMMUNOPHARMACOL, V2, P1213, DOI 10.1016/S1567-5769(02)00078-4; Kurkowska-Jastrzebska I, 2009, INT IMMUNOPHARMACOL, V9, P781, DOI 10.1016/j.intimp.2009.03.003; Kurkowska-Jastrzebska I, 2007, NEUROREPORT, V18, P425, DOI 10.1097/WNR.0b013e3280586777; Kurkowska-Jastrzebska I, 2008, J NEUROIMMUNOL, V203, P233; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Lisak RP, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-30; Lisak RP, 2006, MULT SCLER J, V12, P149, DOI 10.1191/135248506ms1251oa; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lyketsos CG, 2007, NEUROLOGY, V68, P1800; McCombe PA, 2008, INT J STROKE, V3, P254, DOI 10.1111/j.1747-4949.2008.00222.x; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Naismith RT, 2010, NEUROLOGY, V74, P1860, DOI 10.1212/WNL.0b013e3181e24373; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Noto ATW, 2006, THROMB HAEMOSTASIS, V96, P53, DOI 10.1160/TH05-11-0772; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Przybylkowski A, 2004, BRAIN RES, V1019, P144, DOI 10.1016/j.brainres.2004.05.095; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; Relkin NR, 2009, NEUROBIOL AGING, V30, P1728, DOI 10.1016/j.neurobiolaging.2007.12.021; Samii A, 2009, DRUG AGING, V26, P769, DOI 10.2165/11316780-000000000-00000; Sawada M, 2008, NEURODEGENER DIS, V5, P254, DOI 10.1159/000113717; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Schwartz M, 2005, J NEUROL SCI, V233, P163, DOI 10.1016/j.jns.2005.03.014; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Schwartz M, 2006, J NEUROIMMUNE PHARM, V1, P4, DOI 10.1007/s11481-005-9010-2; Schwartz M, 2008, TRENDS PHARMACOL SCI, V29, P287, DOI 10.1016/j.tips.2008.03.006; Serrano-Pozo A, 2010, BRAIN, V133, P1312, DOI 10.1093/brain/awq056; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; STRIJBOS PJLM, 1995, J NEUROSCI, V15, P3468; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tsutsui S, 2009, ANN NEUROL, V66, P711, DOI 10.1002/ana.21845; Um JY, 2003, MOL BRAIN RES, V115, P50, DOI 10.1016/S0169-328X(03)00179-7; Van der Walt A, 2010, PHARMACOL THERAPEUT, V126, P82, DOI 10.1016/j.pharmthera.2010.01.006; Villoslada P, 2008, CLIN IMMUNOL, V128, P294, DOI 10.1016/j.clim.2008.04.003; Wang XJ, 2007, NEUROCHEM INT, V50, P39, DOI 10.1016/j.neuint.2006.07.014; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Willenborg DO, 1999, J NEUROIMMUNOL, V100, P21, DOI 10.1016/S0165-5728(99)00212-X; Worrall BB, 2007, STROKE, V38, P1189, DOI 10.1161/01.STR.0000260099.42744.b0; Zhang SC, 2003, GLIA, V41, P191, DOI 10.1002/glia.10172	93	60	61	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	FEB	2011	231	1-2			SI		78	85		10.1016/j.jneuroim.2010.09.020			8	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	744YT	WOS:000289131800012	20943275				2022-02-06	
J	Beauchamp, M; Catroppa, C; Godfrey, C; Morse, S; Rosenfeld, JV; Anderson, V				Beauchamp, Miriam; Catroppa, Cathy; Godfrey, Celia; Morse, Sue; Rosenfeld, Jeffrey V.; Anderson, Vicki			Selective Changes in Executive Functioning Ten Years After Severe Childhood Traumatic Brain Injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LATENT VARIABLE ANALYSIS; PROBLEM-SOLVING SKILLS; ATTENTIONAL SKILLS; PRESCHOOL-CHILDREN; MEMORY FUNCTION; YOUNG-CHILDREN; FOLLOW-UP; RECOVERY; TBI; PERFORMANCE	Pediatric traumatic brain injury (TBI) impacts on children's executive functions, but little is known of how such deficits evolve in the long term. Forty adolescents with TBI were assessed ten years post-injury and compared to 19 typically developing participants on a range of executive measures (attentional control, cognitive flexibility, goal setting, information processing). Children with mild or moderate TBI performed within age expectations on all tests; however, those with severe injuries had poorer performance on goal setting and processing speed tasks. Childhood TBI may result in subtle lasting changes in complex executive skills, which could require ongoing support into adulthood.	[Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Catroppa, Cathy; Godfrey, Celia; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Morse, Sue] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia		Beauchamp, M (corresponding author), CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 			Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P., 2008, EXECUTIVE FUNCTIONS, P4; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Benson D.F., 1986, FRONTAL LOBES; Best JR, 2009, DEV REV, V29, P180, DOI 10.1016/j.dr.2009.05.002; Bull R, 2008, DEV NEUROPSYCHOL, V33, P205, DOI 10.1080/87565640801982312; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G. A., 2004, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberg E, 2005, PSYCHIAT CLIN N AM, V28, P567, DOI 10.1016/j.psc.2005.05.005; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; HOLM S, 1979, SCAND J STAT, V6, P65; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luria A.R., 1966, HIGHER CORTICAL FUNC; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MUSCARA F, 2008, NEUROPSYCHOL REHABIL, V19, P541; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; PARKER DM, 1992, HDB NEUROPSYCHOLOGIC, P267; Prigatano GP, 2008, CLIN NEUROPSYCHOL, V22, P603, DOI 10.1080/13854040701440501; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Spreen O., 1985, DEV NEUROPSYCHOLOGY; TEASDALE G, 1974, LANCET, V2, P81; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; WALSH KW, 1998, NEUROPSYCHOLOGY CLIN; Wechsler D., 1997, WECHSLER ADULTS INTE; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; [No title captured]	82	60	60	1	16	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2011	36	5					578	595	PII 938567966	10.1080/87565641.2011.555572			18	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	776NK	WOS:000291542000004	21667362				2022-02-06	
J	Bellander, BM; Olafsson, IH; Ghatan, PH; Skejo, HPB; Hansson, LO; Wanecek, M; Svensson, MA				Bellander, Bo-Michael; Olafsson, Ingvar Hakon; Ghatan, Per Hamid; Skejo, Hanne Pernille Bro; Hansson, Lars-Olof; Wanecek, Mikael; Svensson, Mikael A.			Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Complement; C5b9; S-100B; NSE; Human; Secondary insults	SEVERE HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; NEUROLOGICAL DISORDERS; BARRIER DYSFUNCTION; INTENSIVE-CARE; IGG ANALYSES; ADULT-RAT; SERUM; CYTOKINES; IMPACT	Complement activation has been suggested to play a role in the development of secondary injuries following traumatic brain injury (TBI). The present study was initiated in order to analyze complement activation in relation to the primary brain injury and to secondary insults, frequently occurring following TBI. Twenty patients suffering from severe TBI (Glasgow coma score a parts per thousand currency sign8) were included in the study. The "membrane attack complex," C5b9, which is the cytolytic end product of the complement system was analyzed in cerebrospinal fluid (CSF). The degree of brain tissue damage was assessed using the release of S100B and neuron-specific enolase (NSE) to the CSF and blood. The blood-brain barrier was assessed using the CSF/serum quotient of albumin (Q (A)). Following impact, initial peaks (0-48 h) of C5b9, S100B, and NSE with a concomitant loss of integrity of the blood-brain barrier were observed. Secondary insults at the intensive care unit were monitored. Severe secondary insults were paralleled by a more pronounced complement activation (C5b9 in CSF) as well as increased levels of S100B (measured in CSF), but not with NSE. This human study indicates that complement activation in the brain is triggered not only by the impact of trauma per se but also by the amount of secondary insults that frequently occur at the scene of accident as well as during treatment in the neurointensive care unit. Complement activation and in particular the end product C5b9 may in turn contribute to additional secondary brain injuries by its membrane destructive properties.	[Bellander, Bo-Michael; Olafsson, Ingvar Hakon; Svensson, Mikael A.] Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Ghatan, Per Hamid] Karolinska Univ Hosp Solna, Sect Cognit Neurophysiol, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Skejo, Hanne Pernille Bro] Karolinska Univ Hosp Solna, Neuroradiol Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Wanecek, Mikael] Karolinska Univ Hosp Solna, Sect Anesthesiol & Intens Care Med, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Hansson, Lars-Olof] Karolinska Univ Hosp Solna, Karolinska Univ Lab, S-17176 Stockholm, Sweden		Bellander, BM (corresponding author), Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden.	bo-michael.bellander@karolinska.se	Svensson, Mikael/F-8662-2012; Wanecek, Michael/AAE-7998-2021	Svensson, Mikael/0000-0003-1179-7003; 	Stockholm countyStockholm County Council; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission	The study was approved by the local ethical committee (01-297; 03-540). The staff at NICU, especially Pia Svensson, R.N., and Birgitta Ohlgren, R.N., are gratefully acknowledged for their everlasting enthusiasm and help concerning the present project. Mrs. Rumjana Dijlai-Merzoug is greatly acknowledged for excellent laboratory technical assistance. Magnus Backheden and Margaretha Krook are acknowledged for their help and guidance concerning the statistical analysis. This study was funded by the Stockholm county and the Swedish Medical Research Council.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; BARNUM SR, 1993, GLIA, V7, P225, DOI 10.1002/glia.440070306; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; Edwards P, 2005, LANCET, V365, P1957; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; GRAHAM DI, 1993, HEAD INJURY, P91; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MILLER JD, 1995, NEUROTRAUMA, P61; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Olney J W, 1986, Adv Exp Med Biol, V203, P631; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; RUS HG, 1992, J IMMUNOL, V148, P928; Sandelin M, 2004, J COMP NEUROL, V473, P233, DOI 10.1002/cne.20115; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; TODD NV, 1990, ACT NEUR S, V51, P296; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91	46	60	65	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2011	153	1					90	100		10.1007/s00701-010-0737-z			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	700YD	WOS:000285780600015	20686797	hybrid, Green Published			2022-02-06	
J	Covassin, T; Elbin, RJ				Covassin, Tracey; Elbin, R. J.			The Female Athlete: The Role of Gender in the Assessment and Management of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Gender differences; Females; Symptoms	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; SEX-DIFFERENCES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; AGREEMENT STATEMENT; SYMPTOMS; MIGRAINE	Concussions remain a serious public health concern, with approximately 1.6 million to 3 million sport and recreational traumatic and brain injuries occurring every year in the United States. Most research on concussions has been conducted on male athletes, specifically, football players. However, female sport participation has steadily increased over the past decade. Recent studies suggest that the incidence of and recovery from sport-related concussion varies between male and female athletes, with women having a higher risk of sustaining a concussion and taking a longer time to recover than men. As a result, this article addresses the role of gender in the assessment and management of sport-related concussion.	[Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Elbin, R. J.] E Tennessee State Univ, Dept Kinesiol Leisure & Sport Sci, Johnson City, TN 37614 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 2001, J ATHL TRAINING, V36, P253; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; DEHAAS DM, 2009, 198182200708 NCAA; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRANITO VJ, 2000, DISS ABSTR INT B, V61, P530; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kreighbaum E, 1996, BIOMECHANICS QUALITA; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Launer LJ, 1999, NEUROLOGY, V53, P537, DOI 10.1212/WNL.53.3.537; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Mansell J, 2005, J ATHL TRAINING, V40, P310; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; *NFHSA, 2008, PART HIGH SCH SPORTS; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SILBERSTEIN SD, 2007, TXB CLIN NEUROLOGY, P1247; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X	43	60	60	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					125	+		10.1016/j.csm.2010.08.001			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	691XR	WOS:000285114800012	21074087				2022-02-06	
J	Douglas-Escobar, M; Yang, C; Bennett, J; Shuster, J; Theriaque, D; Leibovici, A; Kays, D; Zheng, T; Rossignol, C; Shaw, G; Weiss, MD				Douglas-Escobar, Martha; Yang, Cui; Bennett, Jeffrey; Shuster, Jonathan; Theriaque, Douglas; Leibovici, Avital; Kays, David; Zheng, Tong; Rossignol, Candace; Shaw, Gerry; Weiss, Michael D.			A Pilot Study of Novel Biomarkers in Neonates With Hypoxic-Ischemic Encephalopathy	PEDIATRIC RESEARCH			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; NF-H; TERMINAL HYDROLASE; PNF-H; MARKER; BLOOD; EXPRESSION; PROTEINS; SERUM	Severe hypoxic-ischemic encephalopathy (HIE) is a devastating condition that can lead to mortality and long-term disabilities in term newborns. No rapid and reliable laboratory test exists to assess the degree of neuronal injury in these patients. We propose two possible biomarkers: 1) phosphorylated axonal neurofilament heavy chain (pNF-H) protein, one of the major subunits of neuro-filaments, found only in axonal cytoskeleton of neurons and 2) Ubiquitin C-terminal hydrolase 1 (UCHL1 protein) that is heavily and specifically concentrated in neuronal perikarya and dendrites. High-serum pNF-H and UCHL1 levels are reported in subarachnoid hemorrhage and traumatic brain injury, suggesting that they are released into blood following neuronal injury. We hypothesized that serum pNF-H and UCHL1 were higher in neonates with moderate-to-severe HIE than in healthy neonates. A time-limited enrollment of 14 consecutive patients with HIE and 14 healthy controls was performed. UCHL1 and pNF-H were correlated with clinical data and brain MRI. UCHL1 and pNF-H serum levels were higher in HIE versus controls. UCHL1 showed correlation with the 10-min Apgar score, and pNF-H showed correlation with abnormal brain MRI. Our findings suggest that serum UCHL1 and pNF-H could be explored as diagnostic and prognostic tools in neonatal HIE. (Pediatr Res 68: 531-536, 2010)	[Douglas-Escobar, Martha] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Yang, Cui; Zheng, Tong; Shaw, Gerry] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Bennett, Jeffrey] Univ Florida, Dept Neuroradiol, Gainesville, FL 32611 USA; [Shuster, Jonathan] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL 32611 USA; [Leibovici, Avital; Rossignol, Candace; Weiss, Michael D.] Univ Florida, Dept Pediat, Gainesville, FL 32611 USA; [Kays, David] Univ Florida, Dept Pediat Surg, Gainesville, FL 32611 USA; [Shuster, Jonathan; Theriaque, Douglas] Univ Florida, Clin & Translat Sci Inst, Gainesville, FL 32610 USA		Douglas-Escobar, M (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin MC WT 6-145, Houston, TX 77030 USA.	douglase@bcm.edu	, Gerry/X-2377-2019; Shuster, Jonathan/ABB-5773-2021	Shuster, Jonathan/0000-0001-9499-5616	National Institute of Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00082, U54RR025208]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA;  [NS02198]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002198] Funding Source: NIH RePORTER	Supported, in part, by Grants M01RR00082 and U54RR025208 from the National Institute of Research Resources and National Institutes of Health and by Grant NS02198 [M.D.W.].	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Guy J, 2008, MOL VIS, V14, P2443; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shaw, 1998, NEUROFILAMENTS; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, pA61; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	19	60	63	0	11	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	DEC	2010	68	6					531	536		10.1203/PDR.0b013e3181f85a03			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	683YY	WOS:000284515400014	20736881	Green Accepted, Bronze			2022-02-06	
J	Gean, AD; Fischbein, NJ				Gean, Alisa D.; Fischbein, Nancy J.			Head Trauma	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Scalp; Skull; Vascular; Hemorrhage	DIFFUSE AXONAL INJURY; PROTON MR SPECTROSCOPY; PHOTON EMISSION CT; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; PERFUSION-CT; DECOMPRESSIVE CRANIECTOMY; CORPUS-CALLOSUM; MIXED-DENSITY	Worldwide, an estimated 10 million people are affected annually by traumatic brain injury (TBI). More than 5 million Americans currently live with long-term disability as a result of TBI and more than 1.5 million individuals sustain a new TBI each year. It has been predicted that TBI will become the third leading cause of death and disability in the world by the year 2020. This article outlines the classification of TBI, details the types of lesions encountered, and discusses the various imaging modalities available for the evaluation of TBI.	[Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Fischbein, Nancy J.] Stanford Univ, Sch Med, Dept Radiol NF, Stanford, CA 94305 USA		Gean, AD (corresponding author), Univ Calif San Francisco, Dept Radiol, San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	agean@sfghrad.ucsf.edu					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Chang MC, 2010, NEUROREHABILITATION, V26, P339, DOI 10.3233/NRE-2010-0571; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Davis PC, 2007, AM J NEURORADIOL, V28, P1619; Enterline DS, 2006, TECH VASC INTERV RAD, V9, P192, DOI 10.1053/j.tvir.2007.03.003; Field AS, 2005, AM J NEURORADIOL, V26, P2168; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GEAN AD, RADIOLOGY IN PRESS; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Given CA, 2003, AM J NEURORADIOL, V24, P254; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krings T, 2008, EUR RADIOL, V18, P1531, DOI 10.1007/s00330-008-0915-z; Kunze E, 1998, ACT NEUR S, V71, P16; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Little SC, 2006, ARCH OTOLARYNGOL, V132, P1300, DOI 10.1001/archotol.132.12.1300; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Marion Donald W, 2006, Prog Neurol Surg, V19, P171, DOI 10.1159/000095191; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; NANASSIS K, 1989, Neurosurgical Review, V12, P243, DOI 10.1007/BF01790657; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Provenzale J, 2007, EMERG RADIOL, V14, P1, DOI 10.1007/s10140-007-0587-z; PROVENZALE JM, 1995, AM J ROENTGENOL, V165, P1099, DOI 10.2214/ajr.165.5.7572483; Pruthi N, 2009, SURG NEUROL, V71, P202, DOI 10.1016/j.surneu.2007.10.032; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmiedeskamp H, 2010, MAGN RESON MED, V63, P959, DOI 10.1002/mrm.22222; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; Su TM, 2008, J TRAUMA, V65, P1298, DOI 10.1097/TA.0b013e31815885d9; Subramanian SK, 2002, NEUROL RES, V24, P125, DOI 10.1179/016164102101199657; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Woodcock RJ, 2001, AM J NEURORADIOL, V22, P1698; WU Z, J MAGN RESON IMAGING; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; York G, 2005, AM J ROENTGENOL, V184, P1672, DOI 10.2214/ajr.184.5.01841672; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	95	60	61	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	NOV	2010	20	4					527	+		10.1016/j.nic.2010.08.001			32	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	683VE	WOS:000284504300007	20974375				2022-02-06	
J	Kahraman, S; Dutton, RP; Hu, P; Xiao, Y; Aarabi, B; Stein, DM; Scalea, TM				Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Xiao, Yan; Aarabi, Bizhan; Stein, Deborah M.; Scalea, Thomas M.			Automated Measurement of "Pressure Times Time Dose" of Intracranial Hypertension Best Predicts Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Outcome; Automated recording; Pressure time dose; ICP; CPP; TBI; PTD	CEREBRAL PERFUSION-PRESSURE; THRESHOLDS; REACTIVITY; AGREEMENT; INSULTS; IMPACT	Background: Earlier, more accurate assessment of secondary brain injury is essential in management of patients with traumatic brain injury (TBI). We assessed the accuracy and utility of high-resolution automated intracranial pressure (ICP) and cerebral perfusion pressure (CPP) recording and their analysis in patients with severe TBI. Methods: ICP and CPP data for 30 severe TBI patients were collected automatically at 6-second intervals. The degree and duration of ICP and CPP above and below treatment thresholds were calculated as "pressure times time dose" (PTD; mm Hg . h) using automated recordings (PTDa) or manual recordings (PTDm) for early stage (trauma resuscitation unit [TRU]) and total monitoring time (TRU and intensive care unit). Results: Bland-Altman plots showed lack of agreement between PTDa and PTDm. For ICP >20 mm Hg and CPP <60 mm Hg, PTDa, but not PTD m, was significantly higher in patients with unfavorable outcome (Extended Glasgow Outcome Scale score <= 4) than in patients with favorable outcome (Extended Glasgow Outcome Scale score >4). Total PTD a for ICP >20 mm Hg and CPP <60 mm Hg had high predictive power for functional outcome (area under the receiver operating characteristics curve: 0.92 +/- 0.05 and 0.82 +/- 0.08, respectively) and inhospital mortality (0.76 +/- 0.15 and 0.79 +/- 0.14, respectively) and were strongly correlated with length of intensive care unit stay (p = 0.009 and 0.007), length of hospital stay (p = 0.009 and 0.005), and discharge Glasgow Coma Scale scores (p = 0.008 and p = 0.038). PTD a of CPP > 100 mm Hg during TRU monitoring and during the first 24 hours showed highest predictive power for mortality (area under the receiver operating characteristics curve: 0.72 +/- 0.18 and 0.85 +/- 0.13, respectively). PTD a was better than PTD m and the duration of episodes alone in predicting outcome. Conclusions: PTD calculation of high resolution ICP and CPP recording is a reliable and feasible way of monitoring severe TBI patients.	[Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Xiao, Yan] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Dutton, Richard P.] Univ Maryland Med Syst, Div Trauma Anesthesiol, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Dutton, RP (corresponding author), Univ Maryland Med Syst, Div Trauma Anesthesiol, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	RDutton@umaryland.edu	Xiao, Yan/A-7506-2009	Xiao, Yan/0000-0003-2805-0619; Stein, Deborah/0000-0003-3683-3963			[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; O'Sullivan Cormac T, 2007, AANA J, V75, P43; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	22	60	60	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2010	69	1					110	118		10.1097/TA.0b013e3181c99853			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	627AQ	WOS:000280010600017	20038855				2022-02-06	
J	Vaishnav, RA; Singh, IN; Miller, DM; Hall, ED				Vaishnav, Radhika A.; Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.			Lipid Peroxidation-Derived Reactive Aldehydes Directly and Differentially Impair Spinal Cord and Brain Mitochondrial Function	JOURNAL OF NEUROTRAUMA			English	Article						acrolein; 4-hydroxy 2-nonenal; oxidative stress; spinal cord injury; traumatic brain injury	INDUCED OXIDATIVE DAMAGE; HYDROGEN-PEROXIDE; ALZHEIMERS-DISEASE; FREE-RADICALS; PEROXYNITRITE SCAVENGERS; MOUSE MODEL; CELL-DEATH; INJURY; ACROLEIN; STRESS	Mitochondrial bioenergetic dysfunction in traumatic spinal cord and brain injury is associated with post-traumatic free radical-mediated oxidative damage to proteins and lipids. Lipid peroxidation by-products, such as 4-hydroxy-2-nonenal and acrolein, can form adducts with proteins and exacerbate the effects of direct free radical-induced protein oxidation. The aim of the present investigation was to determine and compare the direct contribution of 4-hydroxy-2-nonenal and acrolein to spinal cord and brain mitochondrial dysfunction. Ficoll gradient-isolated mitochondria from normal rat spinal cords and brains were treated with carefully selected doses of 4-hydroxy-2-nonenal or acrolein, followed by measurement of complex I- and complex II-driven respiratory rates. Both compounds were potent inhibitors of mitochondrial respiration in a dose-dependent manner. 4-Hydroxy-2-nonenal significantly compromised spinal cord mitochondrial respiration at a 0.1-mu M concentration, whereas 10-fold greater concentrations produced a similar effect in brain. Acrolein was more potent than 4-hydroxy-2-nonenal, significantly decreasing spinal cord and brain mitochondrial respiration at 0.01 mu M and 0.1 mu M concentrations, respectively. The results of this study show that 4-hydroxy-2-nonenal and acrolein can directly and differentially impair spinal cord and brain mitochondrial function, and that the targets for the toxic effects of aldehydes appear to include pyruvate dehydrogenase and complex I-associated proteins. Furthermore, they suggest that protein modification by these lipid peroxidation products may directly contribute to post-traumatic mitochondrial damage, with spinal cord mitochondria showing a greater sensitivity than those in brain.	[Vaishnav, Radhika A.; Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.] Univ Kentucky, Coll Med, SCoBIRC, Lexington, KY 40536 USA; [Singh, Indrapal N.; Miller, Darren M.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, SCoBIRC, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Vaishnav, Radhika/AAN-4556-2021; Hall, Edward D/F-8930-2013		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-NINDS 1F32NS063744-01, NIH-NIDA 1T32DA022738-01, NIH-NINDS 1P30NS051220-01]; Kentucky Spinal Cord and Head Injury Research Trust [6-5]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS063744, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by funding from the National Institutes of Health: NIH-NINDS 1F32NS063744-01 (R.A.V.); NIH-NIDA 1T32DA022738-01 (E.D.H.); NIH-NINDS 1P30NS051220-01 (E.D.H.); and the Kentucky Spinal Cord and Head Injury Research Trust Grant #6-5 (E.D.H.). We thank Dr. Malhar Jhaveri and Dr. Manan Jhaveri for assistance with the statistical analyses. Also we thank Drs. Bradford Hill and Daniel Conklin for sharing their valuable suggestions on storage and handling of acrolein.	Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI 10.1089/neu.2008-0870; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Ellis EM, 2007, PHARMACOL THERAPEUT, V115, P13, DOI 10.1016/j.pharmthera.2007.03.015; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hill BG, 2009, BIOCHEM J, V417, P513, DOI 10.1042/BJ20081615; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jenner P, 2006, NEUROLOGY, V66, pS24, DOI 10.1212/WNL.66.10_suppl_4.S24; Jia ZQ, 2009, NEUROCHEM RES, V34, P1924, DOI 10.1007/s11064-009-9978-8; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kruman I, 1997, J NEUROSCI, V17, P5089; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nunomura A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P411, DOI 10.2174/187152707783399201; PARKER WD, 1984, NEUROLOGY, V34, P1477, DOI 10.1212/WNL.34.11.1477; Perez-Pinzon MA, 2005, ANTIOXID REDOX SIGN, V7, P1150, DOI 10.1089/ars.2005.7.1150; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j; Sims NR, 2000, MOL BRAIN RES, V77, P176, DOI 10.1016/S0169-328X(00)00049-8; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, FREE RADICAL RES, V43, P604, DOI 10.1080/10715760902977432; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	60	60	60	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1311	1320		10.1089/neu.2009.1172			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100015	20392143	Green Published			2022-02-06	
J	Walker, PA; Harting, MT; Jimenez, F; Shah, SK; Pati, S; Dash, PK; Cox, CS				Walker, Peter A.; Harting, Matthew T.; Jimenez, Fernando; Shah, Shinil K.; Pati, Shibani; Dash, Pramod K.; Cox, Charles S., Jr.			Direct Intrathecal Implantation of Mesenchymal Stromal Cells Leads to Enhanced Neuroprotection via an NF kappa B-Mediated Increase in Interleukin-6 Production	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; INFLAMMATORY RESPONSE; ISCHEMIC BRAIN; RAT; TRANSPLANTATION	Mesenchymal stromal cell (MSC) therapy has shown promise for the treatment of traumatic brain injury (TBI). Although the mechanism(s) by which MSCs offer protection is unclear, initial in vivo work has suggested that modulation of the locoregional inflammatory response could explain the observed benefit. We hypothesize that the direct implantation of MSCs into the injured brain activates resident neuronal stem cell (NSC) niches altering the intracerebral milieu. To test our hypothesis, we conducted initial in vivo studies, followed by a sequence of in vitro studies. In vivo: Sprague-Dawley rats received a controlled cortical impact (CCI) injury with implantation of 1 million MSCs 6 h after injury. Brain tissue supernatant was harvested for analysis of the proinflammatory cytokine profile. In vitro: NSCs were transfected with a firefly luciferase reporter for NF kappa B and placed in contact culture and transwell culture. Additionally, multiplex, quantitative PCR, caspase 3, and EDU assays were completed to evaluate NSC cytokine production, apoptosis, and proliferation, respectively. In vivo: Brain supernatant analysis showed an increase in the proinflammatory cytokines IL-1 alpha, IL-1 beta, and IL-6. In vitro: NSC N kappa B activity increased only when in contact culture with MSCs. When in contact with MSCs, NSCs show an increase in IL-6 production as well as a decrease in apoptosis. Direct implantation of MSCs enhances neuroprotection via activation of resident NSC NF kappa B activity (independent of PI3 kinase/AKT pathway) leading to an increase in IL-6 production and decrease in apoptosis. In addition, the observed NF kappa B activity depends on direct cell contact.	[Walker, Peter A.; Harting, Matthew T.; Jimenez, Fernando; Shah, Shinil K.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Harting, Matthew T.; Shah, Shinil K.; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparit Cardiovasc Sci &, College Stn, TX USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311; Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH T32 GM 08 79201, M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148, M01RR002558] Funding Source: NIH RePORTER	This work was supported by grants NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating	Adams SD, 2008, J TRAUMA, V65, P170, DOI 10.1097/TA.0b013e31805824ca; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Harting MT, 2008, CYTOTHERAPY, V10, P243, DOI 10.1080/14653240801950000; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 2007, J VET SCI, V8, P275, DOI 10.4142/jvs.2007.8.3.275; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nijboer CH, 2008, STROKE, V39, P2578, DOI 10.1161/STROKEAHA.108.516401; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; Penolazzi L, 2008, CELL BIOL INT, V32, P320, DOI 10.1016/j.cellbi.2007.08.030; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	27	60	65	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUN	2010	19	6					867	876		10.1089/scd.2009.0188			10	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	614CX	WOS:000279033900011	19775197	Green Accepted, Green Published			2022-02-06	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Taymans, T; Linden, CV; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; Geurts, M.; Taymans, T.; Linden, C. Vander; Smits-Engelsman, B. C. M.; Sunaert, S.; Swinnen, S. P.			Brain-behavior relationships in young traumatic brain injury patients: Fractional anisotropy measures are highly correlated with dynamic visuomotor tracking performance	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Diffusion tensor imaging; Children; Manual pursuit; Eye-hand coordination; Motor control	MOVEMENT ASSESSMENT BATTERY; DIFFUSION TENSOR IMAGES; WHITE-MATTER INJURY; PERIVENTRICULAR LEUKOMALACIA; CEREBRAL-PALSY; MOTOR DEFICITS; AXONAL INJURY; CHILDREN; RELIABILITY; MODERATE	Traumatic brain injury (TBI) patients have a high incidence of eye-hand coordination deficits. Diffuse axonal injury is common in TBI and is presumed to contribute to persistent motor problems. Using Diffusion Tensor Imaging (DTI), this study sought to identify changes in (sensori)motor white matter (WM) pathways/regions in a TBI group during the chronic recovery stage. A secondary objective was to examine the relationship between WM integrity and upper-limb visuomotor tracking performance. A young TBI (n = 17) and control (n = 14) group performed a dynamic tracking task, characterized by increasing information processing speed and predictive movement control. DTI scans were administered along with standard anatomical scans. The TBI group was found to perform inferior to the control group on the tracking task. Decreased fractional anisotropy was found in the TBI group in dedicated pathways involved in transmission of afferent and efferent information, i.e., corticospinal tract, posterior thalamic radiation, and optic radiation, due to increased diffusivity parallel and perpendicular to axonal fibre direction. This decrease in WM integrity was associated with inferior visuomotor tracking performance. Moreover, discriminant function analysis demonstrated that the model, based on the combined application of DTI and behavioral measures, was the most effective in distinguishing between TBI patients and controls. This study shows that specific eye-hand coordination deficits in a young TBI group are related to microstructural abnormalities in task-specific cerebral WM structures. Measures of white matter integrity are potentially important biomarkers for TBI that may support prognosis of motor deficits. (C) 2010 Elsevier Ltd. All rights reserved.	[Swinnen, S. P.] Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, B-3001 Heverlee, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Dept Radiol, Image Sci Inst, Utrecht, Netherlands; [Leemans, A.] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff, S Glam, Wales; [Linden, C. Vander] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Smits-Engelsman, B. C. M.] Univ Profess, Avans, Breda, Netherlands; [Sunaert, S.] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium		Swinnen, SP (corresponding author), Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be; Stephan.Swinnen@faber.kuleuven.be	Sunaert, Stefan/E-8031-2011; Leemans, Alexander/A-1784-2011	Sunaert, Stefan/0000-0002-1177-4680; Leemans, Alexander/0000-0002-9306-6126; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation-Flanders (FWO)FWO [7.0004.05]; Belgian federal government [P6/29]	Support for this study was provided through a grant from the Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05), as well as Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a PhD fellowship of the Research Foundation-Flanders (FWO).	Aralasmak A, 2006, J COMPUT ASSIST TOMO, V30, P695, DOI 10.1097/01.rct.0000226397.43235.8b; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Bookheimer SY, 2000, MENT RETARD DEV D R, V6, P161, DOI 10.1002/1098-2779(2000)6:3<161::AID-MRDD2>3.0.CO;2-W; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Caeyenberghs K, 2009, J HEAD TRAUMA REHAB, V24, P363, DOI 10.1097/HTR.0b013e3181af0810; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Croce RV, 2001, PERCEPT MOTOR SKILL, V93, P275, DOI 10.2466/pms.2001.93.1.275; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; DeJong WP, 1996, HANDWRITING AND DRAWING RESEARCH, P429; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Foulder-Hughes L., 2003, BRIT J OCCUPATIONAL, V66, P9; Gaillard WD, 2001, NEUROIMAGE, V13, P239, DOI 10.1006/nimg.2000.0681; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Galea MP, 1997, J COMP NEUROL, V381, P307; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Hoon AH, 2002, NEUROLOGY, V59, P752, DOI 10.1212/WNL.59.5.752; Hoon AH, 2009, DEV MED CHILD NEUROL, V51, P697, DOI 10.1111/j.1469-8749.2009.03306.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2004, MAGN RESON MED, V52, P979, DOI 10.1002/mrm.20283; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; KAMALI A, 2001, EUROPEAN RADIOLOGY, V19, P1480; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, 17 ANN M INT SOC MAG, DOI DOI 10.1093/OCCMED/KQR069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lemon RN, 1997, NEUROSCIENTIST, V3, P389, DOI 10.1177/107385849700300612; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Miall RC, 2001, NAT NEUROSCI, V4, P638, DOI 10.1038/88465; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nagae LM, 2007, AM J NEURORADIOL, V28, P1213, DOI 10.3174/ajnr.A0534; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rivkin MJ, 2000, MENT RETARD DEV D R, V6, P68, DOI 10.1002/(SICI)1098-2779(2000)6:1<68::AID-MRDD9>3.0.CO;2-9; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schneider KA, 2004, J NEUROSCI, V24, P8975, DOI 10.1523/JNEUROSCI.2413-04.2004; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Smits-Engelsman BCM, 1998, HUM MOVEMENT SCI, V17, P699, DOI 10.1016/S0167-9457(98)00019-0; Smits-Engelsman BCM, 2008, PHYS THER, V88, P286, DOI 10.2522/ptj.20070068; Stamatakis EA, 2002, J NUCL MED, V43, P476; Sugden, 1992, MOVEMENT ASSESSMENT; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; van Hartingsveldt Margo J, 2005, Occup Ther Int, V12, P1, DOI 10.1002/oti.11; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; van Roon D, 2008, CHILD DEV, V79, P852, DOI 10.1111/j.1467-8624.2008.01163.x; Van Waelvelde H, 2007, CLIN REHABIL, V21, P465, DOI 10.1177/0269215507074052; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilke M, 2003, NEUROPEDIATRICS, V34, P225; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	77	60	61	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	APR	2010	48	5					1472	1482		10.1016/j.neuropsychologia.2010.01.017			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	584RR	WOS:000276770800032	20117121				2022-02-06	
J	Lee, C; Agoston, DV				Lee, Cheol; Agoston, Denes V.			Vascular Endothelial Growth Factor Is Involved in Mediating Increased De Novo Hippocampal Neurogenesis in Response to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						dentate gyrus; neurogenesis; traumatic brain injury; VEGF	CENTRAL-NERVOUS-SYSTEM; TRANSIENT FOREBRAIN ISCHEMIA; RECEPTOR TYROSINE KINASE; FOCAL CEREBRAL-ISCHEMIA; DENTATE GYRUS; ADULT-RAT; CELL-PROLIFERATION; NEUROTROPHIC FACTOR; COGNITIVE RECOVERY; FACTOR VEGF	Stimulating the endogenous repair process after traumatic brain injury (TBI) can be an important approach in neuroregenerative medicine. Vascular endothelial growth factor (VEGF) is one of the molecules that can increase de novo hippocampal neurogenesis. Here, we tested whether VEGF signaling through Flk1 (VEGF receptor 2) is involved in the neurogenic process after experimental TBI. We found that Flk1 is expressed both by neuroblasts in the subgranular layer (SGL) and by maturing granule neurons in the adult dentate gyrus (DG) of the hippocampus. After lateral fluid percussion TBI (LFP-TBI) in the rat, we detected elevated VEGF levels and also increased numbers of de novo neurons in the ipsilateral DG. To test the involvement of VEGF and Flk1 in the neurogenic process directly, we delivered recombinant VEGF or SU5416, an inhibitor to Flk1, into the ipsilateral cerebral ventricle of injured animals. We found that VEGF infusion significantly increased the number of BrdU+/Prox1+ new neurons, decreased the number of TUNEL+ cells, but did not change the number of BrdU+ newborn cells per se. Infusion with SU5416 caused no significant changes. Our results suggest that (a) VEGF is a part of the molecular signaling network that mediates de novo hippocampal neurogenesis after TBI; (b) VEGF predominantly mediates survival of de novo granule neurons rather than proliferation of neuroblasts in the injured brain; and (c) additional VEGF receptor(s) and/or other molecular mechanism(s) are also involved in mediating increased neurogenesis following injury.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, APG, Neurosci Program,Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, APG, Neurosci Program,Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Department of DefenseUnited States Department of Defense	We thank Drs. S. Juliano, S. Young, G. Ling, and T. Darling for their help with the project. We also thank Ms. E. Lee for her technical assistance; Dr. C. Olsen, USUHS Biostatistics Consulting Center, for statistical consultation; and Ms. A. Thorburn for her editorial assistance. C. L. was supported by the Translational Research Program of Defense Brain & Spinal Cord Injury Program of the Department of Defense. The views and statements expressed herein are the private opinions of the authors and do not reflect the official policy or position of the USUHS, the Department of Defense, or the United States Government.	Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi JS, 2007, J NEUROTRAUM, V24, P521, DOI 10.1089/neu.2006.0139; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dobi A, 2000, J NEUROSCI, V20, P1073, DOI 10.1523/JNEUROSCI.20-03-01073.2000; Dombrowski SM, 2008, NEUROSCIENCE, V152, P346, DOI 10.1016/j.neuroscience.2007.11.049; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Hashimoto T, 2006, DEVELOPMENT, V133, P2201, DOI 10.1242/dev.02385; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kawai T, 2006, NEUROSCIENCE, V141, P1209, DOI 10.1016/j.neuroscience.2006.04.064; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Okragly AJ, 1997, EXP NEUROL, V145, P592, DOI 10.1006/exnr.1997.6500; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Rosenstein JM, 2003, J NEUROSCI, V23, P11036; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170, DOI 10.1097/01.wcb.0000037988.07114.98; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618	61	60	63	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					541	553		10.1089/neu.2009.0905			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100008	20001687				2022-02-06	
J	Seel, RT; Macciocchi, S; Kreutzer, JS				Seel, Ronald T.; Macciocchi, Stephen; Kreutzer, Jeffrey S.			Clinical Considerations for the Diagnosis of Major Depression After Moderate to Severe TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; diagnosis; rehabilitation; traumatic brain injury; validity	TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL FUNCTIONING INVENTORY; SELF-REPORTED ANXIETY; PSYCHIATRIC-DISORDERS; TRIPARTITE MODEL; SLEEP DISORDERS; RISK-FACTORS; PREVALENCE; PATIENT; APATHY	Major depression (MD) is the most common psychiatric disorder after traumatic brain injury (TBI). Yet, diagnosing MD is often challenging because of cognitive, emotional, and somatic symptoms that overlap with TBI and other psychiatric disorders. Best current evidence suggests that depressed mood is characterized more by irritability, anger, and aggression than by sadness and tearfulness in persons with TBI. Rumination, self-criticism, and guilt may best differentiate depressed persons from nondepressed persons. Anxiety, aggression, sleep problems, alcohol use, lower-income levels, and poor social functioning appear to be primary associated factors to MD. Objective levels of injury severity, impairment, and functioning do not appear to be related to developing MD. The presence of "organic" TBI sequelae that overlap with the Diagnostic and Statistical Manual of Mental Disorders-Version IV MD criteria does not appear to lead to false-positive MD diagnoses, and anosognosia does not appear to lead to false-negative MD diagnoses. Only the Patient Health Questionnaire-9 and Neurobehavioral Functioning Inventory-Depression demonstrated evidence of acceptably ruling out MD in persons with TBI; the Patient Health Questionnaire-9 had the best ability to rule in the presence of MD following TBI. Apathy, anxiety, dysregulation, and emotional lability require careful clinical consideration when making a differential diagnosis of MD in persons with TBI. Lastly, recommendations are provided on how clinicians can improve diagnostic accuracy and what future research is required to improve our understanding of MD in persons with TBI.	[Seel, Ronald T.; Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA 30309 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Richmond, VA USA		Seel, RT (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	ron_seel@shepherd.org					ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Barnhart W Jason, 2004, J Psychiatr Pract, V10, P196, DOI 10.1097/00131746-200405000-00010; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Beck A.T, 1976, COGNITIVE THERAPY EM; Benca RM, 2008, SLEEP MED, V9, pS3, DOI 10.1016/S1389-9457(08)70010-8; Bessell AL, 2008, J INT NEUROPSYCH SOC, V14, P63, DOI 10.1017/S1355617708080065; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Caracciolo B, 2002, J REHABIL MED, V34, P221, DOI 10.1080/165019702760279215; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CLARK DA, 1990, J ABNORM PSYCHOL, V99, P148, DOI 10.1037/0021-843X.99.2.148; CLARK DA, 1994, J ABNORM PSYCHOL, V103, P645, DOI 10.1037/0021-843X.103.4.645; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Deb S, 1999, AM J PSYCHIAT, V156, P374; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; DICESARE A, 1990, J COG REHABIL    MAR, P14; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Dow BM, 1996, BIOL PSYCHIAT, V39, P42, DOI 10.1016/0006-3223(95)00103-4; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Finset A, 2000, BRAIN INJURY, V14, P887; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Franklin G., 2004, CLIN PRACTICE GUIDEL; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Goodyer IM, 2003, PSYCHOL MED, V33, P601, DOI 10.1017/S0033291702007286; Goodyer IM, 1998, PSYCHOL MED, V28, P265, DOI 10.1017/S0033291797006314; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Just N, 1997, J ABNORM PSYCHOL, V106, P221, DOI 10.1037/0021-843X.106.2.221; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KREUTZER JS, 2001, BRAIN INJURY, V15, P543; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MCALLISTER TW, 2007, BRAIN INJURY MED PRI, P835; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Michael A, 2000, BIOL PSYCHIAT, V48, P989, DOI 10.1016/S0006-3223(00)00955-0; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nolen-Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Posener JA, 2004, PSYCHONEUROENDOCRINO, V29, P1129, DOI 10.1016/j.psyneuen.2004.01.004; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Riemann D, 2007, SLEEP MED, V8, pS15, DOI 10.1016/S1389-9457(08)70004-2; Roberts JE, 1998, COGNITIVE THER RES, V22, P401, DOI 10.1023/A:1018713313894; ROSENBERGARSKA M, 1989, PHAGOCYTES DISEASE, P43; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; STEER RA, 1995, J ABNORM PSYCHOL, V104, P542, DOI 10.1037/0021-843X.104.3.542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Watkins E, 2001, J ABNORM PSYCHOL, V110, P353, DOI 10.1037/0021-843X.110.2.333; Watkins E, 2004, J AFFECT DISORDERS, V82, P1, DOI 10.1016/j.jad.2003.10.006; WATSON D, 1995, J ABNORM PSYCHOL, V104, P3, DOI 10.1037/0021-843X.104.1.3; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Young AH, 2002, AM J PSYCHIAT, V159, P1237, DOI 10.1176/appi.ajp.159.7.1237	118	60	62	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					99	112		10.1097/HTR.0b013e3181ce3966			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000005	20134332				2022-02-06	
J	Talving, P; Plurad, D; Barmparas, G; DuBose, J; Inaba, K; Lam, L; Chan, L; Demetriades, D				Talving, Peep; Plurad, David; Barmparas, Galinos; DuBose, Joseph; Inaba, Kenji; Lam, Lydia; Chan, Linda; Demetriades, Demetrios			Isolated Severe Traumatic Brain Injuries: Association of Blood Alcohol Levels With the Severity of Injuries and Outcomes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Injury; Traumatic brain injury; Alcohol; Intoxication; Complications; Outcomes	753 CONSECUTIVE DEATHS; BETA-BLOCKER EXPOSURE; SEVERE HEAD-INJURY; IMPROVED SURVIVAL; ACUTE ETHANOLISM; HOSPITAL COURSE; UNITED-STATES; INTOXICATION; PREVALENCE; ABUSE	Background: Traumatic brain injury is a common cause of death after traumatic insults. Alcohol intoxication is a recognized contributor to the occurrence of these injuries. The specific effects of alcohol exposure on injury severity and subsequent outcomes,. however, remain controversial. The ann of this study was to investigate the relationship between blood alcohol levels (BAL) and Outcomes in patients with isolated severe traumatic brain injuries (sTBI). Methods: During the calendar year 2003, as part of a pilot project, the Los Angeles County Department of Health Services obtained routine BAL on all patients transported to any of its 13 trauma centers. This Study analyzes the effect of BAL on outcomes in patients with isolated sTBI (head Abbreviated Injury Scale (AIS) score >= 3; extracranial AIS score <3). The Low/No ethanol (ETOH) group included patients with negative or low (<0.08 mg/dL) BAL. Patients with BAL >= 0.08 mg/dL constituted the high ETOH group. Logistic regression was performed to determine whether alcohol levels had an independent association with outcomes. Results: There were 815 patients with isolated severe head injuries. Overall, 468 patients (57%) constituted the Low/No ETCH group, and 347 (43%) the high ETCH group. Alcohol levels were not significantly associated with severity of injury. hypotension at admission. Glasgow Coma Scale score, incidence of major complications, and intensive care unit or hospital length of stay. However, adjusted mortality was significantly lower in the high ETOH group when compared with the Low/No ETCH (8.9%.vs. 17.1%; adjusted odds ratio: 0.60, 95% confidence interval: 0.37-0.96, p = 0.037). In the subgroup of patients with Injury Severity Score > 15 the relative risk for mortality in the high ETOH group was significantly lower than in patients with Low/No ETOH. There was also an increased Survival with high ETOH in patients with Injury Severity Score >25, but this was not statistically significant. Conclusions: Among patients with isolated sTBL BAL do not seem to be associated with overall injury severity, head injury severity, or the occurrence of major morbidities. Similarly, hospital and intensive care unit lengths are not affected by high admission BAL level. The adjusted overall in hospital mortality, however, is significantly lower in patients presenting with the high BAL (>= 0.08 g/dL) after isolated sTBI.	[Talving, Peep; Plurad, David; Barmparas, Galinos; DuBose, Joseph; Inaba, Kenji; Lam, Lydia; Chan, Linda; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA		Demetriades, D (corresponding author), LAC USC, Med Ctr, IPT C4E100,1200 N State St, Los Angeles, CA 90033 USA.	demetria@usc.edu	Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013; Barmparas, Galinos/L-6530-2019; INABA, KENJI/AAC-8532-2020	Talving, Peep/0000-0002-9741-2073; 			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Chen SC, 1999, J TRAUMA, V47, P881, DOI 10.1097/00005373-199911000-00011; Christensen M A, 2001, J Neurosci Nurs, V33, P184; Cornwell EE, 1998, AM SURGEON, V64, P461; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Enderson BL, 2007, J TRAUMA, V62, P33; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; Flaherty S, 2003, J TRAUMA, V54, P70; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HERVE C, 1986, J TRAUMA, V26, P1123, DOI 10.1097/00005373-198612000-00013; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis GC, 1998, ALCOHOL CLIN EXP RES, V22, P2055, DOI 10.1111/j.1530-0277.1998.tb05916.x; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Madan AK, 1999, J TRAUMA, V47, P568, DOI 10.1097/00005373-199909000-00026; *NAT HIGHW TRAFF S, 1985, DOTHS806569 US DEP T; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; *NIH, 2001, ALC TRANSP SAF; *NIH, 1999, ALC WORKSPL; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Plurad D, 2006, J AM COLL SURGEONS, V202, P919, DOI 10.1016/j.jamcollsurg.2006.02.024; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Pryor JP, 2007, J TRAUMA, V62, P61; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Soderstrom C A, 1988, Md Med J, V37, P541; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tate PS, 1999, BRAIN INJURY, V13, P767; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x	51	60	61	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2010	68	2					357	362		10.1097/TA.0b013e3181bb80bf			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	555FC	WOS:000274492600027	20154549				2022-02-06	
J	Goodrich-Hunsaker, NJ; Livingstone, SA; Skelton, RW; Hopkins, RO				Goodrich-Hunsaker, Naomi J.; Livingstone, Sharon A.; Skelton, Ronald W.; Hopkins, Ramona O.			Spatial Deficits in a Virtual Water Maze in Amnesic Participants with Hippocampal Damage	HIPPOCAMPUS			English	Article						hippocampus; amnesia; spatial navigation	TRAUMATIC BRAIN-INJURY; MEDIAL TEMPORAL-LOBE; HUMAN NAVIGATION; CAUDATE-NUCLEUS; TOPOGRAPHICAL DISORIENTATION; PLACE NAVIGATION; NEURAL-NETWORKS; MEMORY; HUMANS; PERFORMANCE	The Morris water maze is a standard paradigm for the testing of hippocampal function in laboratory animals. Virtual versions of the Morris water maze are now available and can be used to assess spatial learning and memory ability in both healthy and brain injured participants. To evaluate the importance of the hippocampus in spatial learning and memory, we tested five amnesic participants with selective hippocampal damage using a virtual water maze called the Arena Maze. The amnesic participants with hippocampal damage were impaired on the invisible platform (place) task that required them to use distal cues, but were able to navigate almost as well as comparison participants when the invisible platform was marked by a single proximal cue. These results not only confirm that the hippocampus plays a necessary role in human navigation in large-scale environments but also provides a new link between the mnemonic and navigational roles of the hippocampus. (C) 2009 Wiley-Liss, Inc.	[Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dept Physiol & Dev Biol, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Livingstone, Sharon A.; Skelton, Ronald W.] Univ Victoria, Dept Psychol, Victoria, BC, Canada; [Hopkins, Ramona O.] Latter Day St Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT 84143 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Div Pulm & Crit Care, Dept Med, Murray, UT USA		Goodrich-Hunsaker, NJ (corresponding author), Brigham Young Univ, Dept Psychol, 1082 SWKT, Provo, UT 84602 USA.		Skelton, Ronald/E-5605-2012				Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Dolleman-van der Weel MJ, 2009, BRAIN STRUCT FUNCT, V213, P329, DOI 10.1007/s00429-008-0200-6; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Etchamendy N, 2007, HIPPOCAMPUS, V17, P595, DOI 10.1002/hipo.20303; Gron G, 2000, NAT NEUROSCI, V3, P404, DOI 10.1038/73980; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P1877, DOI 10.1016/j.neuropsychologia.2004.05.008; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; King JA, 2004, NEUROPSYCHOLOGY, V18, P405, DOI 10.1037/0894-4105.18.3.405; Kumaran D, 2005, J NEUROSCI, V25, P7254, DOI 10.1523/JNEUROSCI.1103-05.2005; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; Mellet E, 2000, NEUROIMAGE, V12, P588, DOI 10.1006/nimg.2000.0648; Meyers JE., 1995, REY COMPLEX FIGURE T; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Nadel L, 2004, NEUROPSYCHOLOGY, V18, P473, DOI 10.1037/0894-4105.18.3.473; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Parron C, 2004, BEHAV BRAIN RES, V154, P345, DOI 10.1016/j.bbr.2004.03.006; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Rauchs G, 2008, HIPPOCAMPUS, V18, P503, DOI 10.1002/hipo.20411; Rosenbaum RS, 2004, HIPPOCAMPUS, V14, P826, DOI 10.1002/hipo.10218; ROSS ED, 1980, ARCH NEUROL-CHICAGO, V37, P193, DOI 10.1001/archneur.1980.00500530031001; Rowland LM, 2005, NEUROPSYCHOPHARMACOL, V30, P633, DOI 10.1038/sj.npp.1300642; Save E, 2000, BEHAV BRAIN RES, V109, P195, DOI 10.1016/S0166-4328(99)00173-4; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Squire LR, 1997, PHILOS T R SOC B, V352, P1663, DOI 10.1098/rstb.1997.0148; TOLMAN EC, 1948, PSYCHOL REV, V55, P1, DOI 10.1037/h0058521; Voermans NC, 2004, NEURON, V43, P427, DOI 10.1016/j.neuron.2004.07.009; Wais PE, 2006, NEURON, V49, P459, DOI 10.1016/j.neuron.2005.12.020; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL	54	60	61	0	15	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1050-9631			HIPPOCAMPUS	Hippocampus		2010	20	4					481	491		10.1002/hipo.20651			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	585FZ	WOS:000276811300004	19554566				2022-02-06	
S	Maruta, J; Lee, SW; Jacobs, EF; Ghajar, J		Barchas, JD; Difede, J		Maruta, Jun; Lee, Stephanie W.; Jacobs, Emily F.; Ghajar, Jamshid			A unified science of concussion	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	smooth pursuit; attention; prefrontal cortex; diffuse axonal injury (DAI); blast injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; WORKING-MEMORY; HEAD TRAUMA; COGNITIVE SEQUELAE; PREFRONTAL CORTEX; EYE-MOVEMENTS; REACTION-TIME; ABNORMALITIES	The etiology, imaging, and behavioral assessment of mild traumatic brain injury (mTBI) are daunting fields, given the lack of a cohesive neurobiological explanation for the observed cognitive deficits seen following mTBI. Although subjective patient self-report is the leading method of diagnosing mTBI, current scientific evidence suggests that quantitative measures of predictive timing, such as visual tracking, could be a useful adjunct to guide the assessment of attention and to screen for advanced brain imaging. Magnetic resonance diffusion tensor imaging (DTI) has demonstrated that mTBI is associated with widespread microstructural changes that include those in the frontal white matter tracts. Deficits observed during predictive visual tracking correlate with DTI findings that show lesions localized in neural pathways subserving the cognitive functions often disrupted in mTBI. Unifying the anatomical and behavioral approaches, the emerging evidence supports an explanation for mTBI that the observed cognitive impairments are a result of predictive timing deficits caused by shearing injuries in the frontal white matter tracts.	[Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA		Ghajar, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 250 Greenwich St,34th Floor, New York, NY 10007 USA.	ghajar@braintrauma.org	Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	Department of DefenseUnited States Department of Defense [W81XWH-08-1-0646, W81XWH-08-2-0177]; James S. McDonnell Foundation; Attention Dynamics Consortium in Traumatic Brain Injury	The work is supported by the Department of Defense Grants W81XWH-08-1-0646, and W81XWH-08-2-0177; James S. McDonnell Foundation grants for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury and the Attention Dynamics Consortium in Traumatic Brain Injury. Ownership Interest: Sync-Think, Inc. (J.G.).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BARBAS H, 1984, EXP BRAIN RES, V55, P187; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chen Y, 2002, PROG BRAIN RES, V140, P255; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; *DEF VET BRAIN INJ, 2008, CLIN PRACT GUID; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MARUTA J, 2010, J HEAD TRAU IN PRESS; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NIOGI SN, 2010, J HEAD TRAU IN PRESS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; TANELIAN T, 2008, INVISIBLE WOUNDS MEN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Umile EM, 1998, BRAIN INJURY, V12, P577; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178	96	60	61	0	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						58	66		10.1111/j.1749-6632.2010.05695.x			9	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000008	20955326	Green Published, Bronze			2022-02-06	
J	Rockswold, GL; Solid, CA; Paredes-Andrade, E; Rockswold, SB; Jancik, JT; Quickel, RR				Rockswold, Gaylan L.; Solid, Craig A.; Paredes-Andrade, Eduardo; Rockswold, Sarah B.; Jancik, Jon T.; Quickel, Robert R.			HYPERTONIC SALINE AND ITS EFFECT ON INTRACRANIAL PRESSURE, CEREBRAL PERFUSION PRESSURE, AND BRAIN TISSUE OXYGEN	NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral perfusion pressure; Hypertonic saline; Intracranial pressure; Mean arterial pressure	HEAD-INJURED PATIENTS; CRITICAL-CARE MANAGEMENT; BLOOD-FLOW; 7.5-PERCENT SALINE; MANNITOL SOLUTION; SODIUM-CHLORIDE; HYPERTENSION; RESUSCITATION; DEXTRAN; EDEMA	OBJECTIVE: Hypertonic saline is emerging as a potentially effective single osmotic agent for control of acute elevations in intracranial pressure (ICP) caused by severe traumatic brain injury. This study examines its effect on ICP, cerebral perfusion pressure (CPP) and brain tissue oxygen tension (PbtO(2)). METHODS: Twenty-five consecutive patients with severe traumatic brain injury who were treated with 23.4% NaCl for elevated ICP were evaluated. Bolt catheter probes were placed in the noninjured hemisphere, and hourly ICP, mean arterial pressure, CPP, and PbtO(2) values were recorded. Thirty milliliters of 23.40% NaCl was infused over 15 minutes for intracranial hypertension, defined as ICP greater than 20 mm Hg. Twenty-one male patients and 4 female patients aged 16 to 64 years were included. The mean presenting Glasgow Coma Scale score was 5.7. RESULTS: Mean pretreatment values included an ICP level of 25.9 mm Hg and a PbtO(2) value of 32 mm Hg. The posttreatment ICP level was decreased by a mean of 8.3 mm Hg (P < 0.0001), and there was an improvement in PbtO(2) of 3.1 mm Hg (P < 0,01). ICP of more than 31 mm Hg decreased by 14.2 mm Hg. Pretreatment CPP values of less than 70 mm Hg increased by a mean of 6 mm Hg (P < 0.0001). No complications occurred from this treatment, with the exception of electrolyte and chemistry abnormalities. At 6 months postinjury, the mortality rate was 28%, with 48% of patients achieving a favorable outcome by the dichotomized Glasgow Outcome Scale. CONCLUSION: Hypertonic saline as a single osmotic agent decreased ICP while improving CPP and PbtO(2) in patients with severe traumatic brain injury. Patients with higher baseline ICP and lower CPP levels responded to hypertonic saline more significantly.	[Rockswold, Gaylan L.; Paredes-Andrade, Eduardo; Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, Minneapolis, MN 55415 USA; [Rockswold, Gaylan L.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; [Solid, Craig A.] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Analyt Serv, Minneapolis, MN USA; [Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Phys Med & Rehabil, Minneapolis, MN 55415 USA; [Jancik, Jon T.] Hennepin Cty Med Ctr, Dept Pharm, Minneapolis, MN 55415 USA		Rockswold, GL (corresponding author), Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@hcmed.org					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUBICK MA, 1995, SHOCK, V3, P137, DOI 10.1097/00024382-199502000-00009; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FISHMAN RA, 1992, CEREBROSPINAL FLUID, P43; Gasco J, 2005, ACTA NEUROCHIR SUPPL, V95, P73; Georgiadis Alexandros L, 2003, Curr Neurol Neurosci Rep, V3, P524, DOI 10.1007/s11910-003-0058-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hartl R, 1997, ACT NEUR S, V70, P40; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Mayer SA, 2002, J INTENSIVE CARE MED, V17, P55, DOI 10.1046/j.1525-1489.2002.17201.x; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Pascual JL, 2008, AM SURGEON, V74, P253; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RAMIRES JAF, 1992, CIRC SHOCK, V37, P220; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; SCHMALL LM, 1990, EQUINE VET J, V22, P273, DOI 10.1111/j.2042-3306.1990.tb04266.x; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Swanson PD, 1976, HDB CLIN NEUROLOGY, V28, P443; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WALSH JC, 1991, CIRC SHOCK, V34, P336; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; Zornow M H, 1995, New Horiz, V3, P488	53	60	64	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2009	65	6					1035	1041		10.1227/01.NEU.0000359533.16214.04			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	522SQ	WOS:000272019400014	19934962				2022-02-06	
J	Statler, KD; Scheerlinck, P; Pouliot, W; Hamilton, M; White, HS; Dudek, FE				Statler, K. D.; Scheerlinck, P.; Pouliot, W.; Hamilton, M.; White, H. S.; Dudek, F. E.			A potential model of pediatric posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Head injury; Controlled cortical impact; Seizures; Immaturity; Development	HEAD-INJURY	Preclinical models of pediatric posttraumatic epilepsy (PTE) are tacking. We hypothesized that traumatic brain injury (TBI), induced by controlled cortical impact, in immature rats would cause etectroencephatographic (EEG) epileptiform activity and behavioral seizures. TBI or sham craniotomy was performed on postnatal day 17. Using video-EEG monitoring 4-11 months post-TBI, most TBI rats (87.5%) showed EEG spiking and one had spontaneous, recurrent seizures. Controls showed neither EEG spikes nor electrographic/behavioral seizures. Late seizures were rare after TBI, but EEG spiking was common and may represent a surrogate for PTE. (C) 2009 Elsevier B.V. All rights reserved.	[Statler, K. D.] Univ Utah, Div Pediat Crit Care, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; [Scheerlinck, P.; Pouliot, W.; Dudek, F. E.] Univ Utah, Sch Med, Dept Physiol, Salt Lake City, UT 84158 USA; [Scheerlinck, P.; Pouliot, W.; Hamilton, M.; White, H. S.; Dudek, F. E.] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA; [Statler, K. D.; Hamilton, M.; White, H. S.] Univ Utah, Dept Pharmacol & Toxicol, Sch Med, Salt Lake City, UT 84112 USA		Statler, KD (corresponding author), Univ Utah, Div Pediat Crit Care, Sch Med, Dept Pediat, POB 581289,295 Chipeta Way, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-HD01410-01, NS045144]; Primary Children's Medical Center Foundation; University of Utah Children's Health Research Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045144] Funding Source: NIH RePORTER	National Institutes of Health (K12-HD01410-01 & NS045144), Primary Children's Medical Center Foundation, and University of Utah Children's Health Research Center. Dr. Statter is a CHRCDA awardee, PCMC Foundation Scholar, and University of Utah PCAT Scholar.	Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0	7	60	60	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	OCT	2009	86	2-3					221	223		10.1016/j.eplepsyres.2009.05.006			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	511FZ	WOS:000271150600014	19520549	Green Accepted			2022-02-06	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, Armin; Pech, Katrin; Kakulas, Byron A.; Martin, Didier; Schoenen, Jean; Noth, Johannes; Brook, Gary A.			NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury	BMC NEUROLOGY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; CELL-ADHESION MOLECULES; PROTEIN-TYROSINE-PHOSPHATASE; PDGF ALPHA-RECEPTOR; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; NEURITE OUTGROWTH; CNS INJURY; GLIAL SCAR; RAT-BRAIN	Background: A major class of axon growth-repulsive molecules associated with CNS scar tissue is the family of chondroitin sulphate proteoglycans (CSPGs). Experimental spinal cord injury (SCI) has demonstrated rapid re-expression of CSPGs at and around the lesion site. The pharmacological digestion of CSPGs in such lesion models results in substantially enhanced axonal regeneration and a significant functional recovery. The potential therapeutic relevance of interfering with CSPG expression or function following experimental injuries seems clear, however, the spatio-temporal pattern of expression of individual members of the CSPG family following human spinal cord injury is only poorly defined. In the present correlative investigation, the expression pattern of CSPG family members NG2, neurocan, versican and phosphacan was studied in the human spinal cord. Methods: An immunohistochemical investigation in post mortem samples of control and lesioned human spinal cords was performed. All patients with traumatic SCI had been clinically diagnosed as having "complete" injuries and presented lesions of the maceration type. Results: In sections from control spinal cord, NG2 immunoreactivity was restricted to stellate-shaped cells corresponding to oligodendrocyte precursor cells. The distribution patterns of phosphacan, neurocan and versican in control human spinal cord parenchyma were similar, with a fine reticular pattern being observed in white matter (but also located in gray matter for phosphacan). Neurocan staining was also associated with blood vessel walls. Furthermore, phosphacan, neurocan and versican were present in the myelin sheaths of ventral and dorsal nerve roots axons. After human SCI, NG2 and phosphacan were both detected in the evolving astroglial scar. Neurocan and versican were detected exclusively in the lesion epicentre, being associated with infiltrating Schwann cells in the myelin sheaths of invading peripheral nerve fibres from lesioned dorsal roots. Conclusion: NG2 and phosphacan were both present in the evolving astroglial scar and, therefore, might play an important role in the blockade of successful CNS regeneration. Neurocan and versican, however, were located at the lesion epicentre, associated with Schwann cell myelin on regenerating peripheral nerve fibres, a distribution that was unlikely to contribute to failed CNS axon regeneration. The present data points to the importance of such correlative investigations for demonstrating the clinical relevance of experimental data.	[Buss, Armin; Pech, Katrin; Noth, Johannes] Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neurol, Aachen, Germany; [Kakulas, Byron A.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; [Martin, Didier] Univ Liege, Sart Tilman Hosp, Dept Neurosurg, B-4000 Liege, Belgium; [Schoenen, Jean] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Schoenen, Jean] Univ Liege, Dept Neuroanat, B-4000 Liege, Belgium; [Brook, Gary A.] Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neuropathol, Aachen, Germany		Buss, A (corresponding author), Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neurol, Pauwelsstr 30, Aachen, Germany.	arminbuss@hotmail.com; pech13@gmx.de; bkakulas@cyllene.uwa.edu.au; didier.martin@chu.ulg.ac.be; jschoenen@ulg.ac.be; jnoth@ukaachen.de; gbrook@ukaachen.de	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; MARTIN, Didier/0000-0001-7325-4958	Deutsche Stiftung Querschnittsl hmung (DSQ)	The authors thank S. Lecouturier for excellent technical assistance and Prof. B. Stallcup for technical discussion. This work was supported by a grant from the Deutsche Stiftung Querschnittsl hmung (DSQ).	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; Bruce JH, 2000, J NEUROTRAUM, V17, P781, DOI 10.1089/neu.2000.17.781; Buss A, 2008, SPINAL CORD, V46, P364, DOI 10.1038/sj.sc.3102148; Buss A, 2007, BRAIN, V130, P940, DOI 10.1093/brain/awl374; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Condic ML, 2002, NEUROREPORT, V13, pA37, DOI 10.1097/00001756-200203040-00002; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Garwood J, 1999, J NEUROSCI, V19, P3888; Grimpe B, 2002, PROG BRAIN RES, V137, P333; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Maeda N, 1996, DEVELOPMENT, V122, P647; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; McTigue DM, 2006, J NEUROPATH EXP NEUR, V65, P406, DOI 10.1097/01.jnen.0000218447.32320.52; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Pearlman A L, 1996, Prog Brain Res, V108, P117; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tan AM, 2006, J NEUROSCI, V26, P4729, DOI 10.1523/JNEUROSCI.3900-05.2006; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690	37	60	65	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JUL 15	2009	9								32	10.1186/1471-2377-9-32			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	491DH	WOS:000269557100001	19604403	Green Published, gold			2022-02-06	
J	Kaneko, T; Kasaoka, S; Miyauchi, T; Fujita, M; Oda, Y; Tsuruta, R; Maekawa, T				Kaneko, Tadashi; Kasaoka, Shunji; Miyauchi, Takashi; Fujita, Motoki; Oda, Yasutaka; Tsuruta, Ryosuke; Maekawa, Tsuyoshi			Serum glial fibrillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest	RESUSCITATION			English	Article						Cardiac arrest; Therapeutic hypothermia; Brain ischemia	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; REGAINING CONSCIOUSNESS; CEREBRAL-ISCHEMIA; HYPOTHERMIA; S-100; DAMAGE; ENCEPHALOPATHY; S100B; GFAP	Aim of the study: Serum glial fibrillary acidic protein (GFAP) has recently been identified as a specific predictor of brain damage and neurological outcome in patients with head trauma. In this study, serum GFAP was assessed as a predictor of neurological outcome in post-cardiac-arrest (PCA) patients. Methods: This study was a retrospective, single-medical-center analysis, conducted in the intensive care unit of a university hospital. Forty-four sequential PCA patients with cardiogenic or non-cardiogenic arrest were included. The patients were treated with or without therapeutic hypothermia (TH). Serum samples were collected from the patients at 12, 24, and 48 h after the return of spontaneous circulation (ROSC). Serum GFAP concentrations were measured by enzyme-linked immunosorbent assay and compared in patients with good and poor neurological outcomes, evaluated over a period of 6 months using Glasgow Outcome Scale. Results: Serum GFAP was significantly higher in patients with a poor outcome at 12 and 24 h without TH and at 48 h with TH (P<0.05). GFAP (>0.1 ng dL(-1)) was a specific predictor of poor neurological outcome at 6 months with or without TH treatment. Conclusions: Although this study is preliminary, serum GFAP after ROSC reflected a poor neurological outcome in PCA patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Kaneko, Tadashi; Kasaoka, Shunji; Miyauchi, Takashi; Fujita, Motoki; Oda, Yasutaka; Tsuruta, Ryosuke; Maekawa, Tsuyoshi] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr AMEC3, Yamaguchi, Japan		Kaneko, T (corresponding author), Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr AMEC3, 1-1-1 Minamikogushi, Yamaguchi, Japan.	kaneyui-ygc@umin.ac.jp	Kaneko, Tadashi/AAD-1516-2022	Kaneko, Tadashi/0000-0002-7171-7231	Japanese Ministry of Health, Labor, and WelfareMinistry of Health, Labour and Welfare, Japan [19791329]	This clinical study was supported by a research project grant from the Japanese Ministry of Health, Labor, and Welfare (number 19791329).; We are very grateful to Hitomi Ikemoto for her valuable technical assistance in all measurements. We also express our thanks to Masako Ueda for assistance in the grant related paper work.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2001, CIRCULATION, V103, P2694; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Hachimi-Idrissi S, 2005, RESUSCITATION, V64, P187, DOI 10.1016/j.resuscitation.2004.08.008; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Hara A, 2005, CIRCULATION, V112, P84, DOI 10.1161/CIRCULATIONAHA.104.527077; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kaneko T, 2005, CRIT CARE MED, V33, pA18, DOI 10.1097/00003246-200512002-00071; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012	22	60	62	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2009	80	7					790	794		10.1016/j.resuscitation.2009.04.003			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	468RH	WOS:000267837100019	19411130				2022-02-06	
J	Echemendia, RJ; Herring, S; Bailes, J				Echemendia, R. J.; Herring, S.; Bailes, J.			Who should conduct and interpret the neuropsychological assessment in sports-related concussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				HIGH-SCHOOL; FOOTBALL PLAYERS; TESTING USEFUL; RECOVERY; PERFORMANCE; RETURN; IMPAIRMENT; MANAGEMENT; INJURY; IMPACT	Objective: This paper seeks to (i) describe the education and training of clinical neuropsychologists, (ii) discuss the significant differences between test administration and clinical assessment, (iii) outline the complex factors involved in psychometric test theory and test interpretation, and (iv) provide a framework for the role of clinical neuropsychologists in the interpretation and administration of neuropsychological instruments within the sports context. Design: Review of pertinent professional practice, empirical and theoretical literature. Intervention: Pubmed, Medline and Psych Info databases were reviewed. In total, 35 articles and 2 books were reviewed. Results: The decision to return an athlete to play following sports-related brain injury is complex and requires the analysis of several sources of data. The decision is determined by a team physician; ideally within the context of a multidisciplinary team that employs comprehensive concussion surveillance and management, including baseline and post-injury neuropsychological assessment. Neuropsychologists possess the training and skill sets necessary to provide unique expertise in the assessment of cognitive functioning and post-injury neurocognitive and psychological assessment. Conclusions: Baseline neuropsychological testing is a technical procedure that can be conducted by technicians under the supervision/guidance of a neuropsychologist. Post-injury assessment requires advanced neuropsychological expertise that is best provided by a clinical neuropsychologist. Significant international differences exist with respect to the training and availability of clinical neuropsychologists, which require modification of these views on a country by country basis.	[Echemendia, R. J.] Psychol & Neurobehav Associates Inc, State Coll, PA 16801 USA; [Herring, S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, S.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA USA; [Herring, S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Bailes, J.] W Virginia Univ, Sch Med, Dept Neurol Surg, Morgantown, WV 26506 USA		Echemendia, RJ (corresponding author), Psychol & Neurobehav Associates Inc, 204 E Calder Way,St 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Axelrod B, 2000, ARCH CLIN NEUROPSYCH, V15, P379, DOI 10.1093/arclin/15.5.379; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT, 1989, MILD HEAD INJURY, P257; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; *DIV 40 TASK FORC, 1989, CLIN NEUROPSYCHOL, V3, P23; ECHEMENDIA R, 2008, CONC SPORT CLIN S NE; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; IVERSON G, 2004, TRAUMATIC BRAIN INJU; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2005, J ATHL TRAINING, V40, P152; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; *NAT AC NEUR, 2001, ARCH CLIN NEUROPSYCH, V15, P379; Randolph C, 2005, J ATHL TRAINING, V40, P139	36	60	60	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I32	I35		10.1136/bjsm.2009.058164			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100006	19433423				2022-02-06	
J	Povlishock, JT; Wei, EP				Povlishock, John T.; Wei, Enoch P.			Posthypothermic Rewarming Considerations following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			axonal damage; contusion; microvascular damage and dysfunction; posthypothermic rewarming; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC HYPOTHERMIA; CYCLOSPORINE-A; AXONAL INJURY; CEREBRAL MICROCIRCULATION; THERAPEUTIC HYPOTHERMIA; PROLONGED HYPOTHERMIA; MODERATE HYPOTHERMIA; OXYGEN RADICALS; DAMAGE	To date, considerable attention has been focused upon the use of hypothermia as a therapeutic strategy for attenuating many of the damaging consequences of traumatic brain injury (TBI). Despite the promise of hypothermic intervention following TBI, many questions remain regarding the optimal use of hypothermic intervention, including, but not limited to, the rewarming rates needed to assure optimal brain protection. In this review, we revisit the relatively limited literature examining the issue of hypothermia and differing rewarming rates following TBI. Considering both experimental and clinical literature, evidence is presented that the rate of posthypothermic rewarming is an important variable for influencing the protective effects of hypothermic intervention following TBI. In the experimental setting, posttraumatic hypothermia followed by slow rewarming appears to provide maximal protection in terms of traumatically induced axonal damage, microvascular damage and dysfunction, and contusional expansion. In contrast, hypothermia followed by rapid rewarming not only reverses the protective effects associated with hypothermic intervention, but in many cases, exacerbates the traumatically induced pathology and its functional consequences. While similar evaluations have not been conducted in the clinical setting, multiple lines of clinical evidence suggest the benefits of posttraumatic hypothermia are optimized through the use of slow rewarming, with the suggestion that such a strategy reduces the potential for rebound vasodilation, elevated intracranial pressure (ICP), and impaired neurocognitive recovery. Collectively, this review highlights not only the benefits of hypothermic intervention, but also the rate of posthypothermic rewarming as an important variable in assuring maximal efficacy following the use of hypothermic intervention.	[Povlishock, John T.; Wei, Enoch P.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057175, R01NS045824] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD055813, R01 HD055813-24, R01HD055813] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045824, R21 NS057175-01A2, R21 NS057175, R01NS045824, R01 NS045824-01A1, R21NS057175-01] Funding Source: Medline		Alzaga AG, 2006, RESUSCITATION, V70, P369, DOI 10.1016/j.resuscitation.2006.01.017; Berger C, 2007, EXP NEUROL, V204, P131, DOI 10.1016/j.expneurol.2006.10.002; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; BLOCH M, 1967, BRAIN, V90, P769, DOI 10.1093/brain/90.4.769; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grigore AM, 2002, ANESTH ANALG, V94, P4, DOI 10.1097/00000539-200201000-00002; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; Kontos H A, 1983, Physiologist, V26, P165; Kontos H A, 1981, Trans Am Clin Climatol Assoc, V92, P111; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1981, FED PROC, V40, P2326; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Vigue B, 2006, ANN FR ANESTH, V25, P838, DOI 10.1016/j.annfar.2006.03.017; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WEI EP, 1985, AM J PHYSIOL, V248, pH157, DOI 10.1152/ajpheart.1985.248.2.H157; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	39	60	61	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					333	340		10.1089/neu.2008.0604			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900006	19292695	Green Accepted, Green Published			2022-02-06	
J	Rainey, T; Lesko, M; Sacho, R; Lecky, F; Childs, C				Rainey, Timothy; Lesko, Mehdi; Sacho, Raphael; Lecky, Fiona; Childs, Charmaine			Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: Results using a single (24 h) time-point	RESUSCITATION			English	Article						Head injury; Biomarkers; S100B; Brain damage; Outcome; Glasgow outcome score (GOS)	SEVERE HEAD-INJURY; PROTEIN S-100B; EMERGENCY; CARE; MARKERS; DAMAGE	Background and objectives: In recent years, biochemical markers have been employed to predict the outcome of patients with traumatic brain injury (TBI). In mild TBI, S100B has shown the most promise as a marker Of Outcome. The objective of this study in patients with severe TBI was to: show the range of serum S100B levels during the acute phase after trauma: determine if S100B has potential to discriminate favourable from unfavourable Outcome in patients with similar brain injury severity scores and to establish an S100B 'cut-off' predictive for death. Methods: All patients with severe TBI, admitted to this neurointensive care unit within 24h of injury were eligible for inclusion in the study. One serum blood sample was obtained from each patient at the 24 h post-injury time-point. S100B levels were measured using enzyme-linked immunosorbent assay. Injuries were coded using an internationally recognised injury severity scoring system (ISS). Three-month follow-tip was undertaken with outcome assessed using the Glasgow outcome Score (GOS). Results: One hundred patients were recruited. Serum S100B levels ranged from 0.08 to 12.62 mu g L-1 S100B levels were significantly higher in patients with a GOS of 1 (death) 2 and 3 (unfavourable outcome) compared with those with GOS 4 and 5 (good recovery). In this study a cut-off point of 0.53 mu g L-1 has sensitivity of >80% and specificity of 60% to predict unfavourable Outcome and 49% to predict death. Conclusion: In 100 patients studied with similar brain injury severity scores, serum S100B measured at the 24-h time-point after injury is significantly associated with Outcome but a cut-off 0.53 mu g L-1 does not have good prognostic performance. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Rainey, Timothy; Sacho, Raphael; Childs, Charmaine] Univ Manchester, Salford Royal NHS Fdn Trust, Sch Translat Med, Brain Injury Res Grp, Salford M6 8HD, Lancs, England; [Lesko, Mehdi; Lecky, Fiona] Univ Manchester, Salford Royal NHS Fdn Trust, TARN, Salford M6 8HD, Lancs, England		Childs, C (corresponding author), Univ Manchester, Salford Royal NHS Fdn Trust, Sch Translat Med, Brain Injury Res Grp, Clin Sci Bldg, Salford M6 8HD, Lancs, England.	charmaine.childs@manchester.ac.uk	Childs, Charmaine/G-9928-2012				Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lameire Norbert, 2004, Curr Opin Crit Care, V10, P468, DOI 10.1097/01.ccx.0000144939.24897.71; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Netto CBO, 2006, ARCH MED RES, V37, P683, DOI 10.1016/j.arcmed.2005.11.005; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vissers RJ, 1999, J EMERG MED, V17, P1027, DOI 10.1016/S0736-4679(99)00136-5; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	28	60	66	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	MAR	2009	80	3					341	345		10.1016/j.resuscitation.2008.11.021			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	420GB	WOS:000264275900011	19150161				2022-02-06	
J	Itoh, T; Satou, T; Ishida, H; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Ishida, Hiroyuki; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Hiroyuki			The relationship between SDF-1 alpha/CXCR4 and neural stem cells appearing in damaged area after traumatic brain injury in rats	NEUROLOGICAL RESEARCH			English	Article						Neural stem cell; traumatic brain injury; nestin; SDF-1 alpha; CXCR4	CHEMOKINE RECEPTOR CXCR4; LEUKOCYTE RECRUITMENT; SUBVENTRICULAR ZONE; DENTATE GYRUS; ADULT BRAIN; EXPRESSION; MIGRATION; PROLIFERATION; NEUROGENESIS; LOCALIZATION	Objective: The actual relationship between neural stem cells and SDF-1 alpha/CXCR4 after brain injury has not yet been elucidated, although recent studies have speculated that stromal cell-derived factor-1 alpha (SDF-1 alpha) and its receptor, CXCR4, could contribute to neural stem cells migration after brain injury. In the present study, the temporal relationship between neural stem cells (NSCs) and SDF-1 alpha/CXCR4 around a damaged area was investigated using a rat traumatic brain injury (TBI) model. Methods: We used molecular biology techniques and immunohistochemistry to investigate the relationship between SDF-1 alpha/CXCR4 expression and NSCs existence around a damaged area after TBI in the rat brain. Results: SDF-1 alpha mRNA expression and SDF-1 alpha protein synthesis did not increase after TBI. However, SDF-1 alpha leaked from the injured area and diffused into the cortex 1-3 days after TBI. Subsequently, the levels of CXCR4 mRNA expression and CXCR4 protein synthesis increased significantly. Many small cells with a nestin-positive cytoplasm and fibers also showed immunopositivity for both CXCR4 and SOX-2, but not for GFAP, 3-7 days after TBI. Moreover, a proportion of the CXCR4-positive cells and fibers also showed immunostaining for neurofilaments. Discussion: These results suggest that the leaked SDF-1 alpha attracted CXCR4-positive NSCs as well as elongated nerve fibers. It is considered that the SDF-1 alpha/CXCR4 system in the brain contributes to neural stem cells appearance and maturation after TBI. Therefore, exploitation of the SDF-1 alpha/CXCR4 system around a damaged area may improve the brain dysfunction after TBI. [Neurol Res 2009; 31: 90-102]	[Itoh, Tatsuki; Satou, Takao; Ishida, Hiroyuki; Ito, Hiroyuki] Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan; [Satou, Takao] Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Inst Life Sci, Div Sports Med, Osaka, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan		Itoh, T (corresponding author), 377-2 Ohnohigashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp					Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bagri A, 2002, DEVELOPMENT, V129, P4249; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Banisadr G, 2002, EUR J NEUROSCI, V16, P1661, DOI 10.1046/j.1460-9568.2002.02237.x; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Felszeghy K, 2004, NEUROIMMUNOMODULAT, V11, P404, DOI 10.1159/000080151; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2005, NEUROL RES, V27, P429, DOI 10.1179/016164105X18476; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Ji JF, 2004, NEUROSCI LETT, V355, P236, DOI 10.1016/j.neulet.2003.11.024; Kobayashi Y, 2003, BIOL PHARM BULL, V26, P1596, DOI 10.1248/bpb.26.1596; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Ni HT, 2004, DEV BRAIN RES, V152, P159, DOI 10.1016/j.devbrainres.2004.06.015; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Piper DR, 2001, J NEUROSCI RES, V66, P356, DOI 10.1002/jnr.1228; Pujol F, 2005, J CELL SCI, V118, P1071, DOI 10.1242/jcs.01694; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Stumm RK, 2003, J NEUROSCI, V23, P5123; Stumm RK, 2002, J NEUROSCI, V22, P5865; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Youn BS, 2000, IMMUNOL REV, V177, P150, DOI 10.1034/j.1600-065X.2000.17701.x; Zeiffer U, 2004, CIRC RES, V94, P776, DOI 10.1161/01.RES.0000121105.72718.5C; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	41	60	65	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	FEB	2009	31	1					90	102		10.1179/174313208X332995			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	415BA	WOS:000263908100013	19228460				2022-02-06	
J	Berger, RP; Ta'Asan, S; Rand, A; Lokshin, A; Kochanek, P				Berger, Rachel P.; Ta'Asan, Shlomo; Rand, Alex; Lokshin, Anna; Kochanek, Patrick			Multiplex Assessment of Serum Biomarker Concentrations in Well-Appearing Children With Inflicted Traumatic Brain Injury	PEDIATRIC RESEARCH			English	Article							TUMOR-NECROSIS-FACTOR; ABUSIVE HEAD TRAUMA; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; INFANTS; INTERLEUKIN-6; CYTOKINE; MARKERS; ASSOCIATION	Proper diagnosis of mild inflicted traumatic brain injury (ITBI) is difficult; children often present without a history of trauma and with nonspecific symptoms, such as vomiting. Previous Studies suggest that biomarkers may be able to screen for brain injury in this population, but these studies focused on only a few biomarkers. We hypothesized that using multiplex bead technology we would be able to identify multiple differences in the serum biomarker profile between in children with ITBI and those without brain injury. We compared the concentrations of 44 serum biomarkers in 16 infants with mild ITBI and 20 infants without brain injury. There were significant group differences in the concentrations of nine of the 44 markers. Vascular cellular adhesion molecule (VCAM) (p < 0.00) and IL-6 (IL-6) (p < 0.00) had the most significant group differences; IL-6 was higher after ITBI, whereas VCAM was lower. Using VCAM and IL-6 in classification algorithms, we could discriminate the groups with a sensitivity and specificity of 87% and 90%, respectively. The results suggest significant changes in the serum biomarker profile after mild ITBI. Future research is needed to determine whether these biomarkers can screen for brain injury in infants with nonspecific symptoms. (Pediatr Res 65: 97-102, 2009)	[Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; [Lokshin, Anna] Univ Pittsburgh, Luminex Core Facil, Pittsburgh, PA 15213 USA; [Berger, Rachel P.; Kochanek, Patrick] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Ta'Asan, Shlomo; Rand, Alex] Carnegie Mellon Univ, Dept Math Sci, Pittsburgh, PA 15213 USA		Berger, RP (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15217 USA.	rberger@pitt.edu	Ta'asan, Shlomo/B-8366-2017	Ta'asan, Shlomo/0000-0002-6085-7124; Kochanek, Patrick/0000-0002-2627-913X	University of Pittsburgh Center for Injury Research and ControlUniversity of Pittsburgh	Supported by University of Pittsburgh Center for Injury Research and Control [R.B., P.K.]	Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BREIMAN JR, 1984, CLASSIFICATION REGRE, P18; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Browning JG, 2005, EMERG MED J, V22, P33, DOI 10.1136/emj.2004.016196; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2002, NEUROSURG CLIN N AM, V13, P149, DOI 10.1016/S1042-3680(02)00002-5; Ellaway BA, 2004, ARCH DIS CHILD, V89, P845, DOI 10.1136/adc.2003.035493; ENGEL A, 1994, INFECTION, V22, P160, DOI 10.1007/BF01716695; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FRIEDMAN J, 2001, ELEMENTS STAT LEARNI, P415; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jiang B, 2003, CLIN DIAGN LAB IMMUN, V10, P995, DOI 10.1128/CDLI.10.6.995-1001.2003; Kaiser L, 2001, J MED VIROL, V64, P262, DOI 10.1002/jmv.1045; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; MANGASARIAN OL, 1995, OPER RES, V43, P570, DOI 10.1287/opre.43.4.570; MANGASARIAN OL, 1990, SIAM PROC S, P22; MANGASARIAN OL, 1965, OPER RES, V13, P444, DOI 10.1287/opre.13.3.444; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Sato M, 2003, PEDIATRICS, V112, P1103, DOI 10.1542/peds.112.5.1103; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777	39	60	62	0	3	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	JAN	2009	65	1					97	102		10.1203/PDR.0b013e31818c7e27			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	386VM	WOS:000261910700017	18787505	Bronze			2022-02-06	
J	Galbiati, S; Recla, M; Pastore, V; Liscio, M; Bardoni, A; Castelli, E; Strazzer, S				Galbiati, Susanna; Recla, Monica; Pastore, Valentina; Liscio, Mariarosaria; Bardoni, Alessandra; Castelli, Enrico; Strazzer, Sandra			Attention Remediation Following Traumatic Brain Injury in Childhood and Adolescence	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; attention components; cognitive deficit; neuropsychological treatment; ecological context	COGNITIVE REHABILITATION; SUSTAINED ATTENTION; WORKING-MEMORY; CHILDREN; DEFICITS; MANAGEMENT; SEVERITY	Traumatic brain injury (TBI) frequently affects both the basic and the superordinate components of attention; deficits vary according to patient age. This study evaluated the efficacy of a specific remediation intervention for attention. Sixty-five TBI patients (aged 6-18 years) with attention deficit were assessed at baseline and at I-year follow-up: 40 patients received attention-specific neuropsychological training for 6 months, and the control group comprised 25 patients. Cognitive assessment included a Wechsler Intelligence Scale (e.g., A. Orsini, 1993) and the Continuous Performance Test II (CPT II; C. K. Conners, 2000). The Vineland Adaptive Behavior Scales (VABS; S. Sparrow, D. Balla & D. V. Cicchetti, 1984) was administered to assess the treatment's ecological validity. At baseline, all patients presented with a mild intellectual disability and pathological scores on the CPT II. At follow-up, significant differences were found between the 2 groups on the CPT 11 and VABS: The clinical group improved more than the control group. Specific remediation training for attention, including a combination of a process-specific approach and metacognitive strategies, significantly improved attention performance. Improvement in attention skills also affected adaptive skills positively.	[Galbiati, Susanna; Recla, Monica; Pastore, Valentina; Liscio, Mariarosaria; Bardoni, Alessandra; Strazzer, Sandra] IRCCS E Medea, I-23842 Bosisio Parini, Lecco, Italy; [Castelli, Enrico] Osped Pediat Bambin Gesu, Rome, Italy		Strazzer, S (corresponding author), IRCCS E Medea, Via Don Luigi Monza 20, I-23842 Bosisio Parini, Lecco, Italy.	sandrastrazzer@yahoo.it	Castelli, Enrico/J-1887-2012; Galbiati, Susanna/AAH-6883-2019; Recla, Monica/ABG-1905-2020; Strazzer, Sandra/AAH-5712-2019; BARDONI, ALESSANDRA/AAH-7233-2019; Pastore, Valentina/AAH-6831-2019	Galbiati, Susanna/0000-0001-7209-4251; Recla, Monica/0000-0002-3001-8872; Strazzer, Sandra/0000-0001-8414-6565; BARDONI, ALESSANDRA/0000-0001-8404-3857; Pastore, Valentina/0000-0002-3170-3070			Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Conners C. K., 2000, CONNERS CONTINUOUS P; Conners CK., 1995, CONNERS CONTINUOUS P; DINUOVO S, 1992, ATTENZIONE CONCENTRA; ESLINGER P, 2002, NEUROPSYCHOLOGICAL I; Fernandez-Guinea S, 2001, REV NEUROLOGIA, V33, P373, DOI 10.33588/rn.3304.2000193; HANNEY M, 1994, 22 ANN M INT NEU SOC; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jha AP, 2002, COGNITIVE BRAIN RES, V15, P61, DOI 10.1016/S0926-6410(02)00216-1; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; LISCIO M, 2003, DAL COMA REINSERIMEN; Mackworth NH., 1957, ADV SCI, V53, P389; MARZOCCHI GM, 2000, ATTENZIONE METACOGNI; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Michaud L. J., 1995, TRAUMATIC HEAD INJUR, P247; Michel J A, 2006, Eura Medicophys, V42, P59; Mulligan Shelley, 2001, Physical and Occupational Therapy in Pediatrics, V20, P25, DOI 10.1300/J006v20n04_03; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nag S, 1999, NEUROL INDIA, V47, P32; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; Oh Hyun Soo, 2005, Taehan Kanho Hakhoe Chi, V35, P270; Olesen PJ, 2007, CEREB CORTEX, V17, P1047, DOI 10.1093/cercor/bhl0l4; Orsini A, 1997, WISC R CONTRIBUTO TA; Orsini A, 1993, WISC R CONTRIBUTO TA; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Pavawalla SP, 2006, J INT NEUROPSYCH SOC, V12, P802, DOI 10.1017/S135561770606098X; Penkman Louise, 2004, Pediatr Rehabil, V7, P111, DOI 10.1080/13638490310001649417; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRATHER P, 1991, ATTENZIONE SUOI DIST; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHUHFRIED, 1996, REHACOM; Shalev L, 2007, CHILD NEUROPSYCHOL, V13, P382, DOI 10.1080/09297040600770787; Shapiro ES, 1998, J LEARN DISABIL, V31, P545, DOI 10.1177/002221949803100604; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Thomson J. B., 1995, J INT NEUROPSYCH SOC, V1, P149; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; TROMP E, 1991, J CLIN EXPT NEUROPSY, V13, P167; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; van't Hooft I, 2003, ACTA PAEDIATR, V92, P935, DOI 10.1080/08035250310004586; vant Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	60	60	61	0	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2009	23	1					40	49		10.1037/a0013409			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	391CA	WOS:000262209300004	19210031				2022-02-06	
J	Kennedy, MRT; Wozniak, JR; Muetzel, RL; Mueller, BA; Chiou, HH; Pantekoek, K; Lim, KO				Kennedy, Mary R. T.; Wozniak, Jeffrey R.; Muetzel, Ryan L.; Mueller, Bryon A.; Chiou, Hsin-Huei; Pantekoek, Kari; Lim, Kelvin O.			White matter and neurocognitive changes in adults with chronic traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Diffusion tensor imaging; Anisotropy; Brain injury; Executive functions; Cognition	DIFFUSE AXONAL INJURY; HEAD-INJURY; PERFORMANCE; IMPAIRMENT	Diffusion tensor imaging was used to investigate white matter (WM) integrity in adults with traumatic brain injury (TBI) and healthy adults as controls. Adults with TBI had sustained severe vehicular injuries on the average of 7 years earlier. A multivariate analysis of covariance with verbal IQ as the covariate revealed that adults with TBI had lower fractional anisotropy and higher mean diffusivity than controls, specifically in the three regions of interest (ROIs), the centrum semiovale (CS), the superior frontal (SPF), and the inferior frontal (INF). Adults with TBI averaged in the normal range in motor speed and two of three executive functions and were below average in delayed verbal recall and inhibition, whereas controls were above average. Time since injury, but not age, was associated with WM changes in the SPF ROI, whereas age, but not time since injury, was associated with WM changes in the INF ROI, suggesting that the effects of WM on time since injury may interact with age. To understand the utility of WM changes in chronic recovery, larger sample sizes are needed to investigate associations between cognition and WM integrity of severely injured individuals who have substantial cognitive impairment compared to severely injured individuals with little cognitive impairment. (JINS, 2009, 15, 130-136.)	[Kennedy, Mary R. T.; Chiou, Hsin-Huei; Pantekoek, Kari] Univ Minnesota, Dept Speech Language Hearing Sci, Minneapolis, MN 55455 USA; [Wozniak, Jeffrey R.; Muetzel, Ryan L.; Mueller, Bryon A.; Pantekoek, Kari; Lim, Kelvin O.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA		Kennedy, MRT (corresponding author), Univ Minnesota, Dept Speech Language Hearing Sci, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenneG47@umn.edu	Lim, Kelvin/AAF-6833-2020; Muetzel, Ryan/AAA-8730-2022	Muetzel, Ryan/0000-0003-3215-1287; Wozniak, Jeffrey/0000-0002-7132-8519; Lim, Kelvin/0000-0002-2390-7268	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR008079-13, P41 RR008079] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS057091-05, P30 NS057091-02, P30 NS057091, P30 NS057091-03, P30 NS057091-01, P30 NS057091-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR008079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057091] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Cohen J., 2013, STAT POWER ANAL BEHA; Delis D.C., 2000, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kertesz A., 1982, W APHASIA BATTERY; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Le Bihan D, 1995, DIFFUSION PERFUSION; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	36	60	63	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					130	136		10.1017/S1355617708090024			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300014	19128536	Green Accepted			2022-02-06	
J	Limond, J; Dorris, L; McMillan, TM				Limond, Jenny; Dorris, Liam; McMillan, Thomas M.			Quality of life in children with acquired brain injury: Parent perspectives 1-5 years after injury	BRAIN INJURY			English	Article						Acquired brain injury; Quality of life; child; rehabilitation	HEAD-INJURY; ADOLESCENTS; CHILDHOOD; HEALTH; RELIABILITY; VALIDITY; OUTCOMES; SCALE	Primary objective: To obtain parental ratings of children's quality of life, cognitive, emotional and behavioural functioning, as well as ratings of service provision, following traumatic brain injury (TBI). Research design: A retrospective, cross-sectional study. Methods and procedures: Parents of 47 children with mild or moderate-severe TBI completed standardized questionnaires evaluating quality of life (PedsQL 4.0) and cognitive, emotional and behavioural functioning (Strengths and Difficulties Questionnaire). Data collected was compared with published normative data for these scales. Views regarding parental experiences of care and their ratings of service provision were also obtained. Results: Quality of life was significantly lower in 13-times as many children with TBI than expected from the normative population. Parents reported that more than 43% of children with TBI had cognitive, emotional and behavioural difficulties that impacted on their daily life. Whilst high levels of social deprivation were found, this did not fully explain the significantly raised levels of difficulties. Another factor associated with this poor outcome was the absence of systematic, routine follow-up or intervention. Conclusions: Parents frequently reported poor quality of life and cognitive, emotional and behavioural problems in their children following TBI. These preliminary findings indicate that children, after TBI, are at risk of developing persistent clinical problems and require follow-up beyond the acute period of their recovery.	[Dorris, Liam] Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland; [Limond, Jenny; Dorris, Liam; McMillan, Thomas M.] Univ Glasgow, Fac Med, Glasgow, Lanark, Scotland		Dorris, L (corresponding author), Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland.	liam.dorris@ggc.scot.nhs.uk	Dorris, Liam/AAK-2273-2021	Dorris, Liam/0000-0002-9502-3154	NHS	This study was funded by NHS Greater Glasgow and Clyde. The authors would like to thank Shona Forsyth and Karen Mackenzie for help with administrative aspects of the study.	BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hysing M, 2007, J CHILD PSYCHOL PSYC, V48, P785, DOI 10.1111/j.1469-7610.2007.01755.x; JENNETT B, 1977, LANCET, V1, P878; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meltzer H, 2000, MENTAL HLTH CHILDREN; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Scottish Executive National Statistics, 2006, SCOTT IND MULT DEPR; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Upton Penney, 2005, Health Qual Life Outcomes, V3, P22, DOI 10.1186/1477-7525-3-22; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; VARNI JW, 2005, PEDIAT QUALITY LIFE	20	60	60	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					617	622	PII 912684241	10.1080/02699050902997870			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600005	19557564				2022-02-06	
J	Trabold, R; Krieg, S; Scholler, K; Plesnila, N				Trabold, Raimund; Krieg, Sandro; Schoeller, Karsten; Plesnila, Nikolaus			Role of Vasopressin V-1a and V-2 Receptors for the Development of Secondary Brain Damage after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						antidiuretic hormone; arginine vasopressin; argipressin; AVP; brain edema; controlled cortical impact; mice; traumatic brain injury	CONTROLLED CORTICAL IMPACT; ARGININE-VASOPRESSIN; RAT-BRAIN; SUBARACHNOID HEMORRHAGE; ANTAGONIST SR-49059; CEREBRAL-ARTERIES; WATER TRANSPORT; STROKE PATIENTS; MESSENGER-RNA; NITRIC-OXIDE	Brain edema is still one of the most deleterious sequels of traumatic brain injury (TBI), and its pathophysiology is not sufficiently understood. The goal of the Current study was to investigate the role of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), an important regulator of tissue water homeostasis, for the formation of post-traumatic brain edema, intracranial pressure (ICP), brain damage, and functional deficits following brain trauma. C57/B16 mice (n = 112) were subjected to controlled cortical impact (CCI; 8 m/s, 1 mm). At 3 min after trauma, animals received 500 ng of the AVP V-1a-receptor antogonist (deamino-Pen(1), O-Me-Tyr(2), Arg(8)]Vasopressin) or 500ng of the AVP V-2-receptor antagonist (adamantaneacetyl(1), O-Et-D-Tyr(2),Val(4), Abu(6),Arg(8,9)]-Vasopressin) by intracerebroventricular injection. After trauma, cerebral water content (24 h), ICP (24 h), contusion volume (24 h and 7 days), and functional outcome (1-7 days) were assessed (n = 8 per experimental group). Post-traumatic inhibition of AVP V-1a receptors reduced ICP by 29% (p < 0.05), brain water content by 45% (p < 0.05), and secondary contusion expansion by 37% (p < 0.05), and it significantly improved motor function 6 and 7 days after trauma (p < 0.05). Inhibition of AVP V-2 receptors had no significant effect. The current results demonstrate that vasopressin V-1a receptors are involved in the pathogenesis of brain edema formation and the subsequent development of secondary brain damage after traumatic brain injury. Accordingly, our Study suggests that vasopressin V-1a receptors may represent a novel therapeutic target for the treatment of post-traumatic brain edema and secondary brain damage.	Univ Munich, Dept Neurosurg, Lab Expt Neurosurg, Munich, Germany; Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany		Plesnila, N (corresponding author), Klinikum Univ Muenchen Grosshadern, Marchioninistr 15, D-81366 Munich, Germany.	plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Krieg, Sandro M./L-8902-2016	Krieg, Sandro M./0000-0003-4050-1531			Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Cintra ED, 2004, ARQ NEURO-PSIQUIAT, V62, P226, DOI 10.1590/S0004-282X2004000200007; DELBIGIO MR, 1990, ACT NEUR S, V51, P14; FARACI FM, 1988, AM J PHYSIOL, V255, pH70, DOI 10.1152/ajpheart.1988.255.1.H70; Fernandez N, 2001, BRIT J PHARMACOL, V132, P1837, DOI 10.1038/sj.bjp.0704034; GarciaVillalon AL, 1996, BRIT J PHARMACOL, V118, P1848, DOI 10.1111/j.1476-5381.1996.tb15613.x; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659; Hertz L, 2000, J NEUROSCI RES, V62, P480, DOI 10.1002/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K; Hertz L, 2000, AM J PHYSIOL-ENDOC M, V278, pE1175, DOI 10.1152/ajpendo.2000.278.6.E1175; Huang Wei-dong, 2003, Chin J Traumatol, V6, P139; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KATO Y, 1995, DIFFERENTIATION, V59, P163, DOI 10.1046/j.1432-0436.1995.5930163.x; KATUSIC ZS, 1984, CIRC RES, V55, P575, DOI 10.1161/01.RES.55.5.575; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Laszlo FA, 1999, EUR J PHARMACOL, V364, P115, DOI 10.1016/S0014-2999(98)00836-X; LATZKOVITS L, 1993, AM J PHYSIOL, V264, pC603, DOI 10.1152/ajpcell.1993.264.3.C603; Liu X, 1996, Chin Med Sci J, V11, P93; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MARTIN DA, 1990, STROKE, V21, P1689; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; NAKAI M, 1987, J PHYSIOL-LONDON, V387, P441, DOI 10.1113/jphysiol.1987.sp016583; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; ONOUE H, 1994, AM J PHYSIOL, V267, pH880, DOI 10.1152/ajpheart.1994.267.3.H880; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Raggenbass M, 1998, PROG BRAIN RES, V119, P263; REEDER RF, 1986, J NEUROSURG, V64, P941, DOI 10.3171/jns.1986.64.6.0941; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; SUZUKI Y, 1992, J NEUROSURG, V77, P424, DOI 10.3171/jns.1992.77.3.0424; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TENEDIEVA VD, 1994, ACTA NEUROCHIR, P387; Tribollet E, 1999, NEUROENDOCRINOLOGY, V69, P113, DOI 10.1159/000054409; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Xu Miao, 2007, Chin J Traumatol, V10, P90; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	46	60	62	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1459	1465		10.1089/neu.2008.0597			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500007	19118456				2022-02-06	
J	Weichel, ED; Colyer, MH				Weichel, Eric D.; Colyer, Marcus H.			Combat ocular trauma and systemic injury	CURRENT OPINION IN OPHTHALMOLOGY			English	Article						closed-globe injury; combat ocular trauma; enucleation; intraocular foreign body; open-globe injury; traumatic brain injury	EYE INJURIES; WAR INJURIES; IRAQI FREEDOM; DESERT-SHIELD; PROTECTION; MANAGEMENT; STORM	Purpose of review To review the recent literature regarding combat ocular trauma during hostilities in Operations Iraqi Freedom and Enduring Freedom, describe the classification of combat ocular trauma, and offer strategies that may assist in the management of eye injuries. Recent findings Several recent publications have highlighted features of combat ocular trauma from Operation Iraqi Freedom. The most common cause of today's combat ocular injuries is unconventional fragmentary munitions causing significant blast injuries. These explosive munitions cause high rates of concomitant nonocular injuries such as traumatic brain injury, amputation, and other organ injuries. The most frequent ocular injuries include open-globe and adnexal lacerations. The extreme severity of combat-related open-globe injuries leads to high rates of primary enucleation and retained intraocular foreign bodies. Visual outcomes of intraocular foreign body injuries are similar to other series despite delayed removal, and no cases of endophthalmitis have occurred. Despite these advances, however, significant vision loss persists in cases of perforating globe injuries as well as open and closed-globe trauma involving the posterior segment. Summary This review summarizes the recent literature describing ocular and systemic injuries sustained during Operations Iraqi and Enduring Freedom. An emphasis on classification of ocular injuries as well as a discussion of main outcome measures and complications is discussed.	[Weichel, Eric D.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [Weichel, Eric D.] NEI, NIH, Bethesda, MD 20892 USA		Weichel, ED (corresponding author), Walter Reed Army Med Ctr, Ophthalmol Serv, 6900 Georgia Ave, Washington, DC 20307 USA.	eweichel@hotmail.com					Ari Adrienne B, 2006, Optometry, V77, P329, DOI 10.1016/j.optm.2006.03.015; BELKIN M, 1984, ISRAEL J MED SCI, V20, P333; BELLOWS JG, 1947, AM J OPHTHALMOL, V30, P309, DOI 10.1016/0002-9394(47)91977-6; Colyer MH, 2007, OPHTHALMOLOGY, V114, P1439, DOI 10.1016/j.ophtha.2006.10.052; COLYER MH, 2008, OPHTHALMOLOGY; COTTER F, 1991, MIL MED, V156, P126, DOI 10.1093/milmed/156.3.126; Duke-Elder S, 1972, SYSTEM OPHTHALMOLOGY; Freidlin J, 2006, OPHTHAL PLAST RECONS, V22, P133, DOI 10.1097/01.iop.0000203495.67894.c7; GOMBOS GM, 1969, AM J OPHTHALMOL, V68, P474, DOI 10.1016/0002-9394(69)90717-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Harlan J B Jr, 2002, Ophthalmol Clin North Am, V15, P153, DOI 10.1016/S0896-1549(02)00006-8; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; JAFFE NS, 1953, AMA ARCH OPHTHALMOL, V49, P591; Jankovic S, 1998, MIL MED, V163, P423, DOI 10.1093/milmed/163.6.423; Jankovic S, 1998, MIL MED, V163, P490, DOI 10.1093/milmed/163.7.490; Johnson AJ, 2007, J TRAUMA, V62, pS20, DOI 10.1097/TA.0b013e3180653eb7; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P139, DOI 10.1016/S0896-1549(02)00004-4; La Piana FG, 1997, DOC OPHTHALMOL, V93, P29, DOI 10.1007/BF02569045; Lakits A, 1998, OPHTHALMOLOGY, V105, P1679, DOI 10.1016/S0161-6420(98)99038-8; LOWREY A, 1954, Trans Pac Coast Otoophthalmol Soc Annu Meet, V35, P39; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; MADER TH, 1993, OPHTHALMOLOGY, V100, P1462; Parsons J., 1941, T OPHTHAL SOC UK, V61, P157; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCOTT GI, 1946, BRIT J OPHTHALMOL, V30, P42, DOI 10.1136/bjo.30.1.42; SIMMONS ST, 1984, OPHTHALMOLOGY, V91, P977; Steindorf K, 1914, BERL KLIN WOCHENSCHR, V51, P1789; STONE W, 1950, JAMA-J AM MED ASSOC, V142, P151, DOI 10.1001/jama.1950.02910210007002; Thach AB, 2005, OPHTHALMOLOGY, V112, P1829, DOI 10.1016/j.ophtha.2005.04.024; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; TREISTER G, 1969, AM J OPHTHALMOL, V68, P669, DOI 10.1016/0002-9394(69)91251-3; *US EY INJ REG, SOURC EY INJ; WARD TP, 2007, OPHTHALMOLOGY TIMES, P8; WEICHEL ED, 2007, RETINAL INSIDER, P82; WELCHEL ED, OPHTHALMOLO IN PRESS; Wong TY, 1997, MIL MED, V162, P744, DOI 10.1093/milmed/162.11.744; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2	39	60	62	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-8738			CURR OPIN OPHTHALMOL	Curr. Opin. Ophthalmol.	NOV	2008	19	6					519	525		10.1097/ICU.0b013e3283140e98			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	367WA	WOS:000260582100011	18854697				2022-02-06	
J	Ngai, KM; Levy, F; Hsu, EB				Ngai, K. M.; Levy, F.; Hsu, E. B.			Injury trends in sanctioned mixed martial arts competition: a 5-year review from 2002 to 2007	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT; CONCUSSION; STATEMENT; RISK	Background: Professional mixed martial arts (MMA) competition is a full-contact sport that has risen rapidly in popularity in recent years, However, there is limited information regarding the incidence of competition injuries after sanctioning by an athletic commission. Methods: We conducted a retrospective cohort study to examine MMA injury patterns during a 5 year period after sanctioning in the state of Nevada. Data from all regulated MMA competitions during the study period from March 2002 to September 2007 (1270 fight exposures) was obtained. Injury odds ratios were calculated by conditional logistic regression on match outcome, age, weight, and fight experience, using a pair-matched case-control design (n = 464) and by multiple logistic regression on match outcome, age, fight experience, weight, combat minutes, and scheduled rounds. Results: During the 635 professional MMA matches, 300 of the 1270 athletes sustained documented injuries with an injury rate of 23.6 per 100 fight participations. Most common reported injuries were lacerations and upper limb injuries. Severe concussion rate was 15.4 per 1000 athlete exposures, or 3% of all matches. No deaths or critical sports-related injuries resulted from any of the regulated matches during the study period. Age, weight and fight experience did not statistically increase the likelihood of injuries after controlling for other covariates Conclusions: Injury rates in regulated professional MMA competition are similar to other combat sports; the overall risk of critical sports-related injury seems to be low. Additional study is warranted to achieve a better understanding of injury trends and ways to further lower injury risk in MMA.	[Ngai, K. M.; Levy, F.; Hsu, E. B.] Johns Hopkins Med Inst, Dept Emergency Med, Baltimore, MD 21209 USA		Hsu, EB (corresponding author), Johns Hopkins Med Inst, Dept Emergency Med, 5801 Smith Ave,Davis Bldg,Suite 3220, Baltimore, MD 21209 USA.	ehsu1@jhmi.edu					BLEDSOE GH, 2006, BR J SPORTS MED 0209; BLEDSOE GH, S MED J, V98, P994; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; *BRIT MED ASS, 2007, BOX UPD BOARD SCI; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Kelly JP, 1997, NEUROLOGY, V48, P581; Kochhar T, 2005, BRIT J SPORT MED, V39, P444, DOI 10.1136/bjsm.2004.011270; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2007, BMJ-BRIT MED J, V335, P781, DOI 10.1136/bmj.39352.454792.80; *NEV STAT ATHL COM, ADV COMM BOX HLTH SA; *NEV STAT ATHL COM, RES; *NEV STAT ATHL COM, NEV TOP MMA GAT; *NEW JERS ATHL CON, LAW PUBL SAF; *NEW JERS STAT ATH, MIX MART ARTS UN RUL; Schamasch P, 2006, NEUROSURG FOCUS, V21, DOI DOI 10.3171/FOC.2006.21.4.4; WERTHEIM LJ, 2007, NEW MAIN EVENT; White C, 2007, BRIT MED J, V335, P469, DOI 10.1136/bmj.39328.486100.DB; ZAZRYN TR, BR J SPORTS MED, V37, P448; MIXED MARTIAL ARTS	21	60	64	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2008	42	8					686	689		10.1136/bjsm.2007.044891			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	338UY	WOS:000258536100011	18308883				2022-02-06	
J	Avramescu, S; Timofeev, I				Avramescu, Sinziana; Timofeev, Igor			Synaptic strength modulation after cortical trauma: A role in epileptogenesis	JOURNAL OF NEUROSCIENCE			English	Article						epilepsy; cortical trauma; synaptic efficacy; intrinsic excitability; homeostatic plasticity; in vivo	V PYRAMIDAL NEURONS; EXPLAIN POSTTRAUMATIC EPILEPTOGENESIS; HUMAN TEMPORAL-LOBE; NEOCORTICAL NEURONS; IN-VIVO; HOMEOSTATIC PLASTICITY; ANTIEPILEPTIC DRUGS; NEUROTROPHIC FACTOR; BRAIN-INJURY; RED NUCLEUS	Traumatic brain injuries are often followed by abnormal hyperexcitability, leading to acute seizures and epilepsy. Previous studies documented the rewiring capacity of neocortical neurons in response to various cortical and subcortical lesions. However, little information is available on the functional consequences of these anatomical changes after cortical trauma and the adaptation of synaptic connectivity to a decreased input produced by chronic deafferentation. In this study, we recorded intracellular (IC) activities of cortical neurons simultaneously with extracellular (EC) unit activities and field potentials of neighboring cells in cat cortex, after a large transection of the white matter underneath the suprasylvian gyrus, in acute and chronic conditions (at 2, 4, and 6 weeks) in ketamine-xylazine-anesthetized cats. Using EC spikes to compute the spike-triggered averages of IC membrane potential, we found an increased connection probability and efficacy between cortical neurons weeks after cortical trauma. Inhibitory interactions showed no significant changes in the traumatized cortex compared with control. The increased synaptic efficacy was accompanied by enhanced input resistance and intrinsic excitability of cortical neurons, as well as by increased duration of silent network periods. Our electrophysiological data revealed functional consequences of previously reported anatomical changes in the injured cortex. We suggest that homeostatic synaptic plasticity compensating the decreased activity in the undercut cortex leads to an uncontrollable cortical hyperexcitability and seizure generation.	[Avramescu, Sinziana; Timofeev, Igor] Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada		Timofeev, I (corresponding author), Univ Laval Robert Giffard, Ctr Rech, 2601 Chem Canardiere, Quebec City, PQ G1J 2G3, Canada.	igor.timofeev@phs.ulaval.ca	Timofeev, Igor/AAP-7529-2021; Timofeev, Igor/E-8828-2012	Timofeev, Igor/0000-0002-1389-5857			Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; AVRAMESCU S, 2006, SOC NEUR ABSTR, V32; Bausch SB, 2006, J NEUROPHYSIOL, V96, P2151, DOI 10.1152/jn.00355.2006; Berninger B, 1999, LEARN MEMORY, V6, P232; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748, DOI 10.1152/jn.1999.82.4.1748; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chen Q, 2007, J NEUROSCI, V27, P542, DOI 10.1523/JNEUROSCI.3607-06.2007; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Contreras D, 1996, J PHYSIOL-LONDON, V494, P251, DOI 10.1113/jphysiol.1996.sp021488; CONTRERAS D, 1995, J NEUROSCI, V15, P604; Crochet S, 2005, EUR J NEUROSCI, V21, P1030, DOI 10.1111/j.1460-9568.2005.03932.x; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Dinner Dudley S., 1993, P654; ESPLIN MS, 1994, EPILEPSIA, V35, P911, DOI 10.1111/j.1528-1157.1994.tb02533.x; FISHMAN PS, 1993, J NEUROTRAUM, V10, P457, DOI 10.1089/neu.1993.10.457; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; FUKUDA A, 1992, J NEUROPHYSIOL, V68, P28, DOI 10.1152/jn.1992.68.1.28; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HOUSER CR, 1990, J NEUROSCI, V10, P267; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; KUANG RZ, 1990, J COMP NEUROL, V302, P461, DOI 10.1002/cne.903020304; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; Lowenstein D H, 1996, Epilepsy Res Suppl, V11, P45; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Massimini M, 2001, J NEUROPHYSIOL, V85, P1346, DOI 10.1152/jn.2001.85.3.1346; Matsumura M, 1996, J NEUROSCI, V16, P7757; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCCORMICK DA, 1987, J PHYSIOL-LONDON, V393, P743, DOI 10.1113/jphysiol.1987.sp016851; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MORRIS ME, 1991, J NEUROPHYSIOL, V65, P157, DOI 10.1152/jn.1991.65.2.157; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Perucca E, 1998, EPILEPSIA, V39, P5, DOI 10.1111/j.1528-1157.1998.tb01268.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Rudolph M, 2007, J NEUROSCI, V27, P5280, DOI 10.1523/JNEUROSCI.4652-06.2007; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; SEIGNEUR J, 2007, SOC NEUR ABSTR, V33; Steriade M, 1998, J NEUROPHYSIOL, V79, P483, DOI 10.1152/jn.1998.79.1.483; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Trasande CA, 2007, J CLIN NEUROPHYSIOL, V24, P154, DOI 10.1097/WNP.0b013e318033787f; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; TSUKAHARA N, 1975, J NEUROPHYSIOL, V38, P1359, DOI 10.1152/jn.1975.38.6.1359; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; VILLABLANCA JR, 1988, BRAIN RES, V453, P17, DOI 10.1016/0006-8993(88)90139-4; Volgushev M, 2006, J NEUROSCI, V26, P5665, DOI 10.1523/JNEUROSCI.0279-06.2006; Waters J, 2006, J NEUROSCI, V26, P8267, DOI 10.1523/JNEUROSCI.2152-06.2006; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	75	60	60	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 2	2008	28	27					6760	6772		10.1523/JNEUROSCI.0643-08.2008			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	323BF	WOS:000257418300002	18596152	Bronze, Green Published			2022-02-06	
J	Talvik, I; Alexander, RC; Talvik, T				Talvik, Inga; Alexander, Randell C.; Talvik, Tiina			Shaken baby syndrome and a baby's cry	ACTA PAEDIATRICA			English	Article						crying; inflicted traumatic brain injury; trigger for child abuse	TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; YOUNG-CHILDREN; IMPACT SYNDROME; HEAD TRAUMA; 1ST YEAR; ABUSE; OUTCOMES; INFANTS; TOMOGRAPHY	The aim of this study was to investigate the relationship between crying of an infant and inflicted head injury by shaking and/or impact. During the period between January 1, 1997 and December 31, 2003, 26 cases of shaken baby syndrome (SBS) were identified in Estonia. The incidence of SBS was 28.7 per 100 000 children under 1 year of age during the whole study period. In this group there were four children from twin pairs: two twin boys and a girl from a twin pair and a boy from another twin pair. This represents 15.4% of the 26 cases. Twins in Estonia represent 2.12% of infant births. The mean age on admission was 3.9 months. According to outpatient records almost all parents (88.5%) in the study group (23/26) had contacted their family physicians and other specialists because of excessive crying or irritability of the baby prior to the admission to the hospital with SBS or death. We found that the time curve of crying was similar to the curve of highest incidence of cases of SBS except the crying curve began earlier. Conclusion. Our data confirm that the families with twins are at additional risk for SBS and parent's complaints of excessive crying of their infants should be taken as signal that parents need to be carefully counselled.	[Talvik, Inga; Talvik, Tiina] Tartu Univ Hosp, Childrens Clin, Tartu, Estonia; [Talvik, Tiina] Univ Tartu, Dept Paediat, EE-50090 Tartu, Estonia; [Alexander, Randell C.] Univ Florida Jacksonville, Jacksonville, FL USA; [Alexander, Randell C.] Florida Childrens Med Serv, Jacksonville, FL USA; [Alexander, Randell C.] Morehouse Sch Med, Atlanta, GA 30310 USA		Talvik, I (corresponding author), Tartu Univ Hosp, Childrens Clin, 6 Lunini St, Tartu, Estonia.	inga.talvik@kliinikum.ee					Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Alexander RC, 1996, ARCH PEDIAT ADOL MED, V150, P444; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2005, J DEV BEHAV PEDIATR, V26, P14; BARR RG, 1989, PEDIATRICS, V84, P514; Barr RG, 1998, CHILD CARE HLTH DEV, V24, P425; BARR RG, 1990, DEV MED CHILD NEUROL, V32, P356; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; BOWLBY J, 1958, INT J PSYCHOANAL, V39, P350; BRAZELTON TB, 1962, PEDIATRICS, V29, P579; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DYKES LJ, 1986, CHILD ABUSE NEGLECT, V10, P211, DOI 10.1016/0145-2134(86)90082-7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hiscock H, 2004, MED J AUSTRALIA, V181, P507, DOI 10.5694/j.1326-5377.2004.tb06414.x; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Kairys SW, 2001, PEDIATRICS, V108, P206; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEVITT C, 1994, CHILD ABUSE MED DIAG; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; McMahon C, 2001, AUST NZ J PSYCHIAT, V35, P581, DOI 10.1046/j.1440-1614.2001.00942.x; Mierisch RF, 2004, PEDIATR EMERG CARE, V20, P118, DOI 10.1097/01.pec.0000113883.10140.c2; Pounder DJ, 1997, AM J FOREN MED PATH, V18, P321, DOI 10.1097/00000433-199712000-00001; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Reijneveld SA, 2001, PEDIATRICS, V108, P893, DOI 10.1542/peds.108.4.893; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; STJAMESROBERTS I, 1991, J CHILD PSYCHOL PSYC, V32, P951; Talvik I, 2007, ACTA PAEDIATR, V96, P1164, DOI 10.1111/j.1651-2227.2007.00362.x; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	39	60	62	0	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0803-5253			ACTA PAEDIATR	Acta Paediatr.	JUN	2008	97	6					782	785		10.1111/j.1651-2227.2008.00778.x			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	296FJ	WOS:000255528600022	18397351				2022-02-06	
J	Hanten, G; Wilde, EA; Menefee, DS; Li, XQ; Lane, S; Vasquez, C; Chu, ZL; Ramos, MA; Yallampalli, R; Swank, P; Chapman, SB; Gamino, J; Hunter, JV; Levin, HS				Hanten, Gerri; Wilde, Elisabeth A.; Menefee, Deleene S.; Li, Xiaoqi; Lane, Summer; Vasquez, Carmen; Chu, Zili; Ramos, Marco A.; Yallampalli, Ragini; Swank, Paul; Chapman, Sandra B.; Gamino, Jacque; Hunter, Jill V.; Levin, Harvey S.			Correlates of social problem solving during the first year after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article						social problem solving; childhood TBI; Interpersonal Negotiations Strategies; MRI; diffusion tensor imaging; neuroimaging; cognition	CLOSED-HEAD INJURY; INTERPERSONAL NEGOTIATION STRATEGIES; PREFRONTAL CORTEX; CHILDHOOD; OUTCOMES; INTEGRATION; INHIBITION; DISORDER; BEHAVIOR; MEMORY	Effects of pediatric traumatic brain injury (TBI) on social problem-solving were examined in a longitudinal study of 103 children with moderate-to-severe TBI (n = 52) or orthopedic injury (01; n = 5 1) using the Interpersonal Negotiation Strategies task (INS). Children solved age-appropriate hypothetical social conflicts, with responses for four problem-solving steps scored by developmental level. The 01 group performed better than the TBI group, but rate of change in performance over time did not differ between groups, suggesting improvement in children with TBI was not due to recovery from injury. Strong relations between INS performance and memory and language skills emerged, but emotional processing was only weakly related to INS performance. Frontal focal lesions influenced INS performance in younger (but not older) children with TBI. Diffusion tensor imaging (DTI), revealed strong relationships between the INS and increased apparent diffusion coefficient (ADC) measures indexing connectivity in the dorsolateral and cingulate regions in both TBI and OI groups, and in the temporal and parietal regions in the TBI group. These findings inform studies of social problem-solving skills during the first year post TBI.	[Hanten, Gerri; Wilde, Elisabeth A.; Menefee, Deleene S.; Li, Xiaoqi; Vasquez, Carmen; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Lane, Summer; Chapman, Sandra B.; Gamino, Jacque] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA; [Chu, Zili; Ramos, Marco A.; Yallampalli, Ragini; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA; [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu	Menefee, Deleene/AAZ-3382-2021	Ramos, Marco/0000-0002-1649-7547	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: Medline		Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; CHAPMAN SB, 1999, BRAIN DAM B, P235; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Friederici AD, 2006, NEURON, V52, P941, DOI 10.1016/j.neuron.2006.12.002; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; SCHMITHORST VJ, IN PRESS HUMAN BRAIN; Schultz L.H., 1988, INTERPERSONAL NEGOTI; SELMAN RL, 1986, DEV PSYCHOL, V22, P450, DOI 10.1037/0012-1649.22.4.450; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wilke M, 2003, NEUROIMAGE, V20, P202, DOI 10.1016/S1053-8119(03)00199-X; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	50	60	60	0	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2008	22	3					357	370		10.1037/0894-4105.22.3.357			14	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	294AX	WOS:000255377600009	18444714				2022-02-06	
J	Jayakumar, AR; Rao, KVR; Panickar, KS; Moriyama, M; Reddy, PVB; Norenberg, MD				Jayakumar, Arumugam R.; Rao, K. V. Rama; Panickar, Kiran S.; Moriyama, M.; Reddy, P. V. B.; Norenberg, Michael D.			Trauma-induced cell swelling in cultured astrocytes	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						astrocytes; cell cultures; cell swelling; cytotoxic edema; mitochondrial permeability transition; mitogen-activated protein kinases; nitric oxide; oxidative stress; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; STRETCH-INDUCED INJURY; BRAIN-INJURY; OXIDATIVE STRESS; CYCLOSPORINE-A; NITRIC-OXIDE; IN-VITRO; CORTICAL CONTUSION; EDEMA FORMATION; FREE-RADICALS	Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury that account for most early deaths after traumatic brain injury. An important component of brain edema after traumatic brain injury is astrocyte swelling (cytotoxic edema). To examine the pathophysiologic mechanisms of trauma-induced astrocyte swelling, we used an in vitro fluid percussion trauma model. Exposure of cultured rat astrocytes to 5 atm of pressure resulted in significant cell swelling at I to 24 hours posttrauma that was maximal at 3 hours. Because oxidative/nitrosative stress, mitochondrial permeability transition (mPT), and mitogen-activated protein kinases (MAPKs) have been implicated in astrocyte swelling in other neurologic conditions, we examined their potential roles in this model. We previously showed increased free radical generation after in vitro trauma and show here that trauma to astrocytes increased the production of nitric oxide. Trauma also induced mPT and increased phosphorylation (activation) of MAPKs (extracellular signal-regulated kinase 1/2, c-Jun-N-terminal kinase, and p38-MAPK); these changes were diminished by antioxidants and the nitric oxide synthase inhibitor N-nitro-L-arginine methyl ester. Antioxidants, N-nitro-L-arginine methyl ester, the mPT inhibitor cyclosporin A, and inhibitors of MAPKs all significantly diminished trauma-induced astrocyte swelling. These findings demonstrate that direct mechanical injury to cultured astrocytes brings about cell swelling, and that blockade of oxidative/nitrosative stress, mPT, and MAPKs significantly reduce such swelling.	[Jayakumar, Arumugam R.; Rao, K. V. Rama; Reddy, P. V. B.; Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Panickar, Kiran S.] USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD 20705 USA; [Moriyama, M.] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835			Adams H., 1963, METHOD ENZYMAT AN, P539; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Aplin AE, 1999, J CELL SCI, V112, P695; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Blanc A, 2004, ANTIOXID REDOX SIGN, V6, P353, DOI 10.1089/152308604322899422; Brahma B, 2000, J NEUROCHEM, V74, P1263; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; BULLOCK MR, 1999, NEUROSURGERY, V45, P17; Cai S, 1998, AM J PHYSIOL-CELL PH, V275, pC1349, DOI 10.1152/ajpcell.1998.275.5.C1349; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chen CJ, 2000, J NEUROCHEM, V75, P1557, DOI 10.1046/j.1471-4159.2000.0751557.x; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Fukui S, 2003, ACT NEUR S, V86, P301; Gaitanaki C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/jeb.00483; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Haskew RE, 2002, J NEUROCHEM, V82, P903, DOI 10.1046/j.1471-4159.2002.01037.x; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUANG JA, 1995, BRAIN RES, V680, P16, DOI 10.1016/0006-8993(95)00209-9; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jacques-Fricke BT, 2006, J NEUROSCI, V26, P5656, DOI 10.1523/JNEUROSCI.0675-06.2006; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kawamata T, 1997, ACT NEUR S, V70, P191; Kerr PM, 1999, AM J PHYSIOL-HEART C, V276, pH496, DOI 10.1152/ajpheart.1999.276.2.H496; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MONGIN AA, 2005, NEUROGLIA, P550; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nicholls DG, 2005, CELL CALCIUM, V38, P311, DOI 10.1016/j.ceca.2005.06.011; Norenberg MD, 2007, NEUROCHEM INT, V50, P983, DOI 10.1016/j.neuint.2007.02.008; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; OLSON JE, 1992, CAN J PHYSIOL PHARM, V70, pS350, DOI 10.1139/y92-282; OLSON JE, 1992, METAB BRAIN DIS, V7, P183, DOI 10.1007/BF01000245; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Panickar K.S., 2006, SOC NEUR ABSTR, V180, P14; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2007, NEUROTOXICOLOGY, V28, P807, DOI 10.1016/j.neuro.2007.03.001; Rao KVR, 2004, J BIOL CHEM, V279, P32333, DOI 10.1074/jbc.M402096200; Rao KVR, 2003, J NEUROSCI RES, V74, P891, DOI 10.1002/jnr.10755; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; SACHS F, 1992, SOC GEN PHY, V47, P241; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schliess F, 2004, GLIA, V47, P21, DOI 10.1002/glia.20019; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Staub F, 1996, ACT NEUR S, V66, P56; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Zhang DX, 2007, AM J PHYSIOL-HEART C, V292, pH2023, DOI 10.1152/ajpheart.01283.2006; Zielinska M, 2002, NEUROCHEM RES, V27, P37, DOI 10.1023/A:1014894320421; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	81	60	62	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2008	67	5					417	427		10.1097/NEN.0b013e31816fc9d4			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	294YN	WOS:000255442300004	18431255	hybrid			2022-02-06	
J	Chung, RS; Hidalgo, J; West, AK				Chung, R. S.; Hidalgo, J.; West, A. K.			New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; emtin; megalin; metallothionein; neuron	TRAUMATIC BRAIN-INJURY; REACTIVE ASTROCYTES; INFLAMMATORY RESPONSE; ZINC; CNS; EXPRESSION; MEGALIN; COPPER; INTERLEUKIN-6; PROTECT	There is a large body of evidence demonstrating that metallothioneins (MTs) expressed in astrocytes following CNS injury, exhibit both neuroprotective and neuroregenerative properties and are critical for recovery outcomes. As these proteins lack signal peptides, and have well characterized free radical scavenging and heavy metal binding properties, the neuroprotective functions of MTs have been attributed to these intracellular roles. However, there is an increasing realization that the neuroprotective functions of MTs may also involve an extracellular component. In this issue of Journal of Neurochemistry, Ambjorn et al. reveal considerable insight into this novel function of MTs. In this review, we examine the seminal work of Ambjorn et al. in the context of our current understanding of the role of MT in astrocyte-neuron interactions in the injured brain, and also discuss the significant therapeutic potential of their work.	[Chung, R. S.; West, A. K.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; [Hidalgo, J.] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Dept Cellular Biol Physiol & Immunol, Barcelona, Spain; [Hidalgo, J.] Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, Barcelona, Spain		Chung, RS (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Chung, Roger/ABF-8395-2020; Hidalgo, Juan/C-9082-2011; West, Adrian/AAR-8857-2021	Hidalgo, Juan/0000-0003-0921-1122; Chung, Roger/0000-0002-9286-947X			Araque A, 2006, CURR OPIN INVEST DR, V7, P619; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Carrasco J, 1998, MOL BRAIN RES, V57, P221, DOI 10.1016/S0169-328X(98)00087-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Chung RS, 2004, NEUROSCIENCE, V123, P595, DOI 10.1016/j.neuroscience.2003.10.019; Escartin C, 2006, J NEUROCHEM, V99, P393, DOI 10.1111/j.1471-4159.2006.04083.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FITZGERALD M, 2007, IN PRESS EXP BRAIN R; GASULL T, 1994, AM J PHYSIOL, V266, pE760, DOI 10.1152/ajpendo.1994.266.5.E760; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; HANNILA SS, 2007, UNPUB EXP NEUROL; HIDALGO J, 1988, AM J PHYSIOL, V254, pE71, DOI 10.1152/ajpendo.1988.254.1.E71; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Klassen RB, 2004, AM J PHYSIOL-RENAL, V287, pF393, DOI 10.1152/ajprenal.00233.2003; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Mann JJ, 2005, APOPTOSIS, V10, P369, DOI 10.1007/s10495-005-0811-9; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NIELSON KB, 1984, J BIOL CHEM, V259, P4941; NIELSON KB, 1983, J BIOL CHEM, V258, P3063; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; PENKOWA M, 2006, IN PRESS J NEUROSCI; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; QUINTANA A, 2007, IN PRESS J NEUROSCI; SIDDIQ MM, 2006, SFN ABSTR; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Takahashi Y, 2005, J CELL PHYSIOL, V202, P563, DOI 10.1002/jcp.20158; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; West AK, 2004, REV NEUROSCIENCE, V15, P157; Wolff NA, 2006, J PHARMACOL EXP THER, V318, P782, DOI 10.1124/jpet.106.102574; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	46	60	64	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2008	104	1					14	20		10.1111/j.1171-4159.2007.05026.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	241QP	WOS:000251671200002	17986229				2022-02-06	
J	Demakis, GJ; Gervais, RO; Rohling, ML				Demakis, George J.; Gervais, Roger O.; Rohling, Martin L.			The effect of failure on cognitive and psychological symptom validity tests in litigants with symptoms of post-traumatic stress disorder	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; FAKE BAD SCALE; COMBAT VETERANS; COMPENSATION SEEKING; INTERPRETIVE METHOD; FORENSIC ASSESSMENT; BASE RATES; PTSD; MEMORY; SCORES	This study examined the influence of performance on cognitive and psychological symptom validity tests on neuropsychological and psychological test performance in claimants evaluated in a medico-legal context (N = 301) with symptoms of PTSD. A second purpose of this study was to examine the influence of the severity of PTSD symptoms on cognitive test performance after excluding patients who failed to put forth adequate best effort and who exaggerated psychiatric symptoms. Patients were administered a battery of neuropsychological measures that were aggregated into a composite measure, the Cognitive-Test Battery Mean (C-TBM). Patients were also administered a battery of psychological tests that were aggregated into another composite measure, the Psychological-Test Battery Mean (P-TBM). We found that failure on cognitive symptom validity tests was associated with significantly poorer neuropsychological functioning, but there was not a significant effect on psychological symptoms. Conversely, failure on psychological symptom validity tests was associated with higher levels of psychopathology, but there was not a significant effect on cognitive ability. Finally, once patients were screened for adequate effort and genuine symptom reporting, the severity of PTSD symptoms did not appear to influence cognitive ability. This is the first study that assessed both types of symptom validity testing in PTSD claimants, which is important given that previous literature has demonstrated cognitive impairment in PTSD and that individuals with PTSD tend to claim cognitive impairment. Implications of these findings are discussed with regard to the existing literature and the relationship between these two types of symptom validity tests.	[Demakis, George J.] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA; [Rohling, Martin L.] Univ S Alabama, Mobile, AL 36688 USA		Demakis, GJ (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@uncc.edu					Allen L., 1997, CARB 97 MANUAL COMPU; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beck A., 1996, BECK DEPRESSION INVE; Beck AT, 1993, BECK ANXIETY INVENTO; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Briere J., 2001, DETAILED ASSESSMENT; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher JN, 2001, MMPI 2 MANUAL ADM SC; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Daly OE, 2002, J TRAUMA STRESS, V15, P461, DOI 10.1023/A:1020913821272; DAVIDSON J, 1996, DAVIDSON TRAUMA SCAL; Delis DC, 1987, CALIFORNIA VERBAL LE; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; Elhai JD, 2004, ASSESSMENT, V11, P139, DOI 10.1177/1073191104264965; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1007/BF02103656; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Golier JA, 2002, AM J PSYCHIAT, V159, P1682, DOI 10.1176/appi.ajp.159.10.1682; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 2003, STORY RECALL TEST; Green P., 1996, WORD MEMORY TEST USE; Green P., 2003, WORD MEMORY TEST MAN; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREIFFENSTEIN MF, CLIN NEUROP IN PRESS; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Guriel Jennifer, 2003, Clin Psychol Rev, V23, P881; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jackson D. N., 1998, MULTIDIMENSIONAL APT, VII; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; *OFF INSP GEN, 2005, REV STAT VAR VA DIS; Resnick P.J., 1988, CLIN ASSESSMENT MALI; Rohling ML, 2004, NEUROPSYCHOL REV, V14, P155, DOI 10.1023/B:NERV.0000048182.55980.4b; Rosen GM, 2006, J ANXIETY DISORD, V20, P530, DOI 10.1016/j.janxdis.2005.03.004; Rosen GM, 2003, J ANXIETY DISORD, V17, P361, DOI 10.1016/S0887-6185(02)00200-1; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223	55	60	60	2	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	5					879	895		10.1080/13854040701564482			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	342HP	WOS:000258775500009	18756390				2022-02-06	
J	Thompson, HJ; Rivara, FP; Jurkovich, GJ; Wang, J; Nathens, AB; MacKenzie, EJ				Thompson, Hilaire J.; Rivara, Frederick P.; Jurkovich, Gregory J.; Wang, Jin; Nathens, Avery B.; MacKenzie, Ellen J.			Evaluation of the effect of intensity of care on mortality after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; critical care consultation; specialty care consultation; pulmonary artery catheter; older adult	PULMONARY-ARTERY CATHETER; ELDERLY-PATIENTS; OLDER PATIENTS; HOSPITAL MORTALITY; HIP-FRACTURES; OF-LIFE; ILL; OUTCOMES; AGE; SURVIVAL	Objectives: To evaluate the effect of age on intensity of care provided to traumatically brain-injured adults and to determine the influence of intensity of care on mortality at discharge and 12 months postinjury, controlling for injury severity. Design: Cohort study using the National Study on the Costs and Outcomes of Trauma (NSCOT) database. Risk ratio and Poisson regression analyses were performed using data weighted according to the population of eligible patients. Setting and Patients: A total of 18 level 1 and 51 level 2 non-trauma centers located in 14 states in the United States and 1,776 adults aged 25-84 yrs with a diagnosis of traumatic brain injury. Measurements: Injury severity was determined by the motor component of the Glasgow Coma Scale score, the Injury Severity Score, pupillary reactivity, and presence of midline shift. Factors evaluated as contributing to intensity of care included: admission to the intensive care unit, mechanical ventilation, placement of an intracranial pressure monitor, placement of a jugular bulb catheter, placement of a pulmonary artery catheter, critical care consultation, the number of specialty care consultations, mannitol use, treatment with barbiturate coma, decompressive craniectomy, number of nonneurosurgical procedures performed, the presence of a do-not-resuscitate order, and withdrawal of therapy. Main Results: Controlling for injury-related factors, sex, and comorbidity, as age increased, the overall likelihood of receiving various interventions decreased. After controlling for injury severity, sex, and comorbidity, factors associated with higher risk of in-hospital death were: being aged 75-84 yrs (relative risk [RR] 1.32, 95% confidence interval [CI] 1.13, 1.55), pulmonary artery catheter use (RR 1.56, 95% CI 1.30,1.86), intubation (RR 4.17, 95% Cl 2.28, 7.61), the presence of a do-not-resuscitate order (RR 3.21, 95% CI 2.21, 4.65), and withdrawal of,therapy (RR 2.33, 95% CI 1.69, 3.23). In contrast, a higher number of specialty care consultations (surgical consults: RR 0.63, 95% CI 0.54, 0.74; medical consults: RR 0.87, 95% CI 0.79, 0.95; and other consults: RR 0.43, 95% Cl 0.26, 0.69) were associated with decreased risk of death. The results were similar for factors associated with death at 12 months, with the exception that the number of medical consultations was not significant, whereas the number of nonneurosurgical procedures performed was associated with lower risk of death (RR 0.96, 95% Cl 0.92, 0.99), as was obtaining critical care consultation services (RR 0.84, 95% CI 0.71, 1.0). Conclusions: There is a lower intensity of care provided to older adults with traumatic brain injury. Although the specific contributions of specialists to patient management are unknown, their consultation was associated with decreased risk of inhospital death and death within 12 months. It is important that careproviders have an increased awareness of the potential contribution of multidisciplinary clinical decision making to patient outcomes in older traumatically brain-injured patients.	[Thompson, Hilaire J.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; [Rivara, Frederick P.; Jurkovich, Gregory J.; Wang, Jin] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Nathens, Avery B.] Univ Toronto, Sch Med, Toronto, ON, Canada; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA		Thompson, HJ (corresponding author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA.	hilairet@u.washington.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12RR023265] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5 K12 RR023265-04, K12 RR023265, K12 RR023265-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [L30 NR010534-02, L30 NR010534] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR316840] Funding Source: Medline		Adnet F, 2001, CRIT CARE MED, V29, P891, DOI 10.1097/00003246-200104000-00042; ANG DN, 2007, AM COLL SURG 93 ANN; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Fallon WF, 2006, J TRAUMA, V61, P1040, DOI 10.1097/01.ta.0000238652.48008.59; Fisher A, 2006, J ORTHOP TRAUMA, V20, P179; Fisher AA, 2006, J ORTHOP TRAUMA, V20, P172, DOI 10.1097/01.bot.0000202220.88855.16; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Friese RS, 2006, CRIT CARE MED, V34, P1597, DOI 10.1097/01.CCM.0000217918.03343.AA; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; KASS JE, 1992, CRIT CARE MED, V20, P1666, DOI 10.1097/00003246-199212000-00011; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1197/aemj.10.3.244; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MAYEROAKES SA, 1991, J AM GERIATR SOC, V39, P862, DOI 10.1111/j.1532-5415.1991.tb04452.x; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murdoch SD, 2000, BRIT J ANAESTH, V85, P611, DOI 10.1093/bja/85.4.611; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; NICOLAS F, 1987, INTENS CARE MED, V13, P9, DOI 10.1007/BF00263549; Nierman DM, 2001, CRIT CARE MED, V29, P1853, DOI 10.1097/00003246-200110000-00001; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PERMINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Rubin D.B., 1987, MULTIPLE IMPUTATION; Sakr Y, 2005, CHEST, V128, P2722, DOI 10.1378/chest.128.4.2722; Scheetz Linda J, 2004, Prehosp Emerg Care, V8, P268, DOI 10.1016/j.prehos.2003.12.027; Shinoda-Tagawa T, 2003, INJURY PREV, V9, P214, DOI 10.1136/ip.9.3.214; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x; [No title captured]	51	60	62	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					282	290		10.1097/01.CCM.0000297884.86058.8A			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YA	WOS:000255232100040	18007264	Green Accepted			2022-02-06	
J	Reicker, LI; Tombaugh, TN; Walker, L; Freedman, MS				Reicker, Lindsay I.; Tombaugh, Tom N.; Walker, Lisa; Freedman, Mark S.			Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speed	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						multiple sclerosis; information processing speed; reaction time; computerized tests of information processing; CTIP	SERIAL ADDITION TEST; CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; WORKING-MEMORY; TEST PASAT; CONCUSSION; ATTENTION; RECOVERY; TASK; IMPAIRMENT	The ability of a newly developed measure of information processing to detect deficits in cognitive functioning associated with multiple sclerosis (MS) was investigated. The Computerized Tests of Information Processing (CTIP; Tombaugh, T., & Rees, L. (1999). Computerized Tests of Information Processing (CTIP). Unpublished test. Ottawa, Ontario, Canada: Carleton University) was administered to 60 clinically definite MS patients and 60 healthy controls. MS patients responded significantly slower than controls on the reaction time tests composing the CTIP. Moreover, as the CTIP tests became more difficult (i.e. as processing demands increased), the difference between the performances of the two groups progressively increased. These results suggest the CTIP is sensitive to the cognitive deficits observed in MS and that this measure has the potential to serve as a viable alternative to traditional measures of information processing speed currently in use with MS patients. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Ottawa Hosp, Ottawa, ON, Canada		Reicker, LI (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.	lreicker@connect.carleton.ca	Walker, Lisa/AAH-7842-2019	Walker, Lisa/0000-0001-5865-7257			ALKER L, 2006, C EUR COMM TREATM RE; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Baird BJ, 2004, THESIS CARLETON U OT; Beck A., 1996, BECK DEPRESSION INVE; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; Chronicle EP, 1998, NEUROPSYCHOL REHABIL, V8, P273; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Denney DR, 2004, J INT NEUROPSYCH SOC, V10, P948, DOI 10.1017/S1355617704107030; ENTUS A, 1970, PERCEPT PSYCHOPHYS, V7, P143, DOI 10.3758/BF03208643; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fisk JD, 2001, J INT NEUROPSYCH SOC, V7, P363, DOI 10.1017/S1355617701733103; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kail R, 1997, AGING NEUROPSYCHOL C, V4, P157, DOI 10.1080/13825589708256644; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; PROCTOR RW, 1981, PSYCHOL REV, V88, P291, DOI 10.1037/0033-295X.88.4.291; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; REES L, 2001, NAN RES GRANTS LUNCH; REICKER LI, 2007, UNPUB ABILITY REACTI; Reitan R, 1985, HALSTEAD REITAN NEUR; Royan J, 2004, ARCH CLIN NEUROPSYCH, V19, P131, DOI 10.1016/S0887-6177(02)00216-0; Rudick R, 1997, ANN NEUROL, V42, P379, DOI 10.1002/ana.410420318; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; Smith AB, 1999, ORG LETT, V1, P2001, DOI 10.1021/ol991166b; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tombaugh T, 2001, 21 ANN M NAT AC NEUR; TOMBAUGH T, 1999, COMPUTERZIED TESTS I; Tombaugh T. N., 1992, PSYCHOL ASSESSMENT, V4, P193, DOI [DOI 10.1037/1040-3590.4.2.193, 10.1037/1040-3590.4.2.193]; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; TOMBAUGH TN, IN PRESS ARCH CLIN N; TOMBAUGH TN, 2006, NORMATIVE DATA COMPU; VANZOMEREN AH, 1978, NEUROLOGY NEUROSURGE, V4, P452; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	47	60	60	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2007	22	5					655	664		10.1016/j.acn.2007.04.008			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	191YZ	WOS:000248169200011	17532182	Bronze			2022-02-06	
J	Mannion, RJ; Cross, J; Bradley, P; Coles, JP; Chatfield, D; Carpenter, A; Pickard, JD; Menon, DK; Hutchinson, PJ				Mannion, Richard J.; Cross, Justin; Bradley, Peter; Coles, Jonathan P.; Chatfield, Doris; Carpenter, Adrian; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.			Mechanism-based MRI classification of traumatic brainstem injury and its relationship to outcome	JOURNAL OF NEUROTRAUMA			English	Article						brainstem; injury; MRI; outcome; traumatic	SEVERE HEAD-INJURY; PROGNOSIS	While computed tomography (CT) is the appropriate technique for the urgent detection of hematomas and contusions in the cerebral hemispheres, it is much less effective at documenting diffuse injury and posterior fossa lesions, and is therefore only partially predictive of outcome. More recently, magnetic resonance imaging (MRI) has been used, particularly to examine posterior fossa structures, but the relationship between brainstem injury and outcome is unclear and the types of brainstem injury are poorly understood. The aim of this study was to use acute MRI to examine the types of brainstem injury following severe traumatic brain injury (TBI) and their relationship to supratentorial injury. We also aimed to correlate these findings with outcome at 6 months (Glasgow Outcome Scale [GOS] score). Forty-six patients (mean age, 34 years, range, 16-70 years; 76% male) admitted to a regional neurocritical care unit with TBI requiring ventilation underwent CT and MRI (T2, FLAIR, gradient echo) scanning within 3 days (median, I day) of injury. GOS was ascertained by outpatient interview. Brainstem lesions were detected in 13 patients by MRI, only two of which were detected by CT. Eleven out of 13 patients with brainstem injury had an unfavorable outcome (death, vegetative state, or severe disability), of whom five died. Of the 33 patients without brainstem lesions, 18 had an unfavorable outcome, of whom four died. The direct relationship between brainstem lesions and unfavorable outcome was statistically significant (p < 0.05, chisquared test). With regard to supratentorial injury, all but two brainstem lesions were seen either in the context of severe diffuse axonal injury or a significant mass lesion, and all of these patients had a poor outcome. However, the two patients with brainstem injury and good outcome had relatively few supratentorial abnormalities. From these observations, we have devised a simple classification system that is useful clinically and has potential associations with outcome. Poor prognosis is common following major TBI but is more common in those with brainstem injury. However, brainstem injury is not an absolute indicator of poor outcome. Understanding the anatomy and extent of brainstem injury, as well as its relationship to supratentorial abnormalities, will facilitate a more accurate use of early MRI as a prognostic tool and assist in the counseling of families.	Addenbrookes Hosp, NHS Trust, Wolfson Brain Injury Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Anaesthet, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Radiol, Cambridge CB2 2QQ, England		Mannion, RJ (corresponding author), Addenbrookes Hosp, NHS Trust, Wolfson Brain Injury Unit, Box 166,Hills Rd, Cambridge CB2 2QQ, England.	richard.mannion@nhs.net		Coles, Jonathan/0000-0003-4013-679X	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G9439390, G0600986, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G9439390, G0600986] Funding Source: Medline		Aguas J, 2005, NEUROCIRUGIA, V16, P14; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; GENNARELLI TA, 2003, J EMERG MED S, V1, P5; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; [No title captured]	15	60	66	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					128	135		10.1089/neu.2006.0127			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100012	17263676				2022-02-06	
J	Fernandez-Ortega, JF; Prieto-Palomino, MA; Munoz-Lopez, A; Lebron-Gallardo, M; Cabrera-Ortiz, H; Quesada-Garcia, G				Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Munoz-Lopez, Alfonso; Lebron-Gallardo, Miguel; Cabrera-Ortiz, Hector; Quesada-Garcia, Guillermo			Prognostic influence and computed tomography findings in dysautonomic crises after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; computed tomography; dysautonomia; autonomic dysfunction	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES; BROMOCRIPTINE; DYSFUNCTION; SYSTEM	Background: Dysautonomic crises represent a relatively unknown complication in patients with severe traumatic brain injury (TBI). Few studies have been undertaken of their pathophysiology and prognostic repercussions. We studied the prevalence of dysautonomic crises after TBI, their radiologic substrate, influence on the clinical course in the intensive care unit (ICU), and effect on neurologic recovery. Methods: A case-control study involving 11 patients with dysautonomic crises admitted with TBI during a span of 1 year and 26 patients admitted with TBI but no crises during the first 3 months of the same year. The initial severity was assessed from Apache 11, Glasgow Coma Scale (GCS) scores, and computed tomography (CT) during the first 24 hours. Complications were assessed by the duration of ICU stay, days on mechanical ventilation, need for tracheotomy, and number of infectious complications. Neurologic recovery was assessed with the GCS at discharge from the ICU and with the Glasgow Outcome Scale 12 months later. Results: Both groups were similar at admission. The prevalence of dysautonomic crises was 9.3%. Patients with dysautonomic crises had more focal lesions on cranial CT than patients without crises, a significantly longer ICU stay, and a tendency to have a worse level of consciousness at discharge from the ICU but not 12 months later. Conclusions: Almost 10% of patients with severe TBI have dysautonomic crises during their ICU stay. Patients with dysautonomia were more likely to have focal intraparenchymal lesions, and crises were associated with greater morbidity and a longer ICU stay. Dysautonomic crises determined a worse short-term neurologic recovery.	Carlos Haya Reg Univ Hosp, Intens Care Unit, Malaga, Spain; Carlos Haya Reg Univ Hosp, Neurosurg Serv, Malaga, Spain		Fernandez-Ortega, JF (corresponding author), C Mirador Candado 1, Malaga 29018, Spain.	patferon@eresmas.com		Fernandez Ortega, Juan F/0000-0003-2130-1331			Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BHIGJEE AI, 1985, J NEUROL SCI, V71, P79; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; DARNELL RB, 1993, NEUROLOGY, V43, P579, DOI 10.1212/WNL.43.3_Part_1.579; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; Fernandez-Ortega JF., 2004, MED INTENSIVA, V28, P376; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1975, LANCET, V1, P480; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MAZEY RM, 1974, JAMA-J AM MED ASSOC, V230, P575, DOI 10.1001/jama.230.4.575; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; ROVNE R N, 1962, Trans Am Neurol Assoc, V87, P232; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SALOMON GH, 1973, J PEDIAT CHILD HLTH, V83, P277; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; TADAHIKO S, 1993, J NEUROSURG, V78, P501	24	60	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1129	1133		10.1097/01.ta.0000197634.83217.80			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	105TB	WOS:000242054100017	17099518				2022-02-06	
J	Meares, S; Shores, EA; Batchelor, J; Baguley, IJ; Chapman, J; Gurka, J; Marosszeky, JE				Meares, Susanne; Shores, E. Arthur; Batchelor, Jennifer; Baguley, Ian J.; Chapman, Jennifer; Gurka, Joseph; Marosszeky, Jeno E.			The relationship of psychological and cognitive factors and opioids in the development of the postconcussion syndrome in general trauma patients with mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; head injury; minor; neuropsychological; acute stress disorder; narcotic	ACUTE STRESS DISORDER; POST-CONCUSSION SYMPTOMS; HEAD-INJURY; SCALE; QUESTIONNAIRE; SENSITIVITY; COMPLAINTS; CRITERIA; MODERATE; TIME	The relationship of psychological and cognitive factors in the development of the postconcussion syndrome (PCS) following mild uncomplicated traumatic brain injury (mTBI) has received little study. This may be because of the widely held belief that neurological factors are the cause of early PCS symptoms, whereas psychological factors are responsible for enduring symptoms. To further understand these relationships, the association between PCS and neuropsychological and psychological outcome was investigated in 122 general trauma patients, many of whom had orthopedic injuries, around 5 days following mTBI. Apart from verbal fluency, participants with a PCS did not differ in their performances on neuropsychological measures compared to those without a PCS. Individuals with a PCS reported significantly more psychological symptoms. Large effect sizes present on the psychological measures showed that the difference between participants with a PCS and without was greater on psychological than on neuropsychological measures. Analyses also revealed a relationship between opioid analgesia and depression, anxiety and stress, and opioids and reduced learning. The results suggest,that psychological factors are present much earlier than has previously been considered in the development of the PCS.	Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia; Westmead Hosp, Dept Rehabil Med, Westmead, NSW, Australia		Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	ashores@psy.mq.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Meares, Susanne/0000-0002-3859-9974; Shores, Edwin A/0000-0003-1553-5131; Batchelor, Jennifer/0000-0003-4438-4993			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Babor TF, 2001, AUDIT ALCOHOL USE DI; BARONA A, 1986, INT J CLIN NEUROPSYC, V8, P169; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cartlidge N E, 1981, HEAD INJURY; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HORN GJ, 1996, DISS ABSTR INT, V56, P4583; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jensen MP, 2001, HDB PAIN ASSESSMENT; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; KAOUA BN, 2002, J CLIN EXPT NEUROPSY, V24, P713; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MILLER EN, 1999, CALCAP CALIFORNIA CO; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; RUTHERFORD WH, 1989, MILD HEAD INJURY; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1993, ICD10 CLASS MENT BEH; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zacny JP, 1995, EXP CLIN PSYCHOPHARM, V3, P432, DOI 10.1037/1064-1297.3.4.432; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	78	60	60	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2006	12	6					792	801		10.1017/S1355617706060978			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	104CA	WOS:000241932300004	17064443				2022-02-06	
J	Levine, B; Fujiwara, E; O'Connor, C; Richard, N; Kovacevic, N; Mandic, M; Restagno, A; Easdon, C; Robertson, IH; Graham, SJ; Cheung, G; Gao, FQ; Schwartz, ML; Black, SE				Levine, Brian; Fujiwara, Esther; O'Connor, Charlene; Richard, Nadine; Kovacevic, Natasa; Mandic, Marina; Restagno, Adriana; Easdon, Craig; Robertson, Ian H.; Graham, Simon J.; Cheung, Gordon; Gao, Fuqiang; Schwartz, Michael L.; Black, Sandra E.			In vivo characterization of traumatic brain injury neuropathology with structural and functional neuroimaging	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	diffuse axonal injury; magnetic resonance imaging; neuroplasticity; neuropsychology	CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; EVENT-RELATED FMRI; POSITRON-EMISSION-TOMOGRAPHY; WORKING-MEMORY LOAD; TECHNETIUM-99M-HMPAO SPECT; COMPUTERIZED-TOMOGRAPHY; MORPHOMETRIC-ANALYSIS; DEGENERATIVE CHANGES	Quantitative neuroimaging is increasingly used to study the effects of traumatic brain injury (TBI) on brain structure and function. This paper reviews quantitative structural and functional neuroimaging studies of patients with TBI, with an emphasis on the effects of diffuse axonal injury (DAI), the primary neuropathology in TBI. Quantitative structural neuroimaging has evolved from simple planometric measurements through targeted region-of-interest analyses to whole-brain analysis of quantified tissue compartments. Recent studies converge to indicate widespread volume loss of both gray and white matter in patients with moderate-to-severe TBI. These changes can be documented even when patients with focal lesions are excluded. Broadly speaking, performance on standard neuropsychological tests of speeded information processing are related to these changes, but demonstration of specific brain-behavior relationships requires more refined experimental behavioral measures. The functional consequences of these structural changes can be imaged with activation functional neuroimaging. Although this line of research is at an early stage, results indicate that TBI causes a more widely dispersed activation in frontal and posterior cortices. Further progress in analysis of the consequences of TBI on neural structure and function will require control of variability in neuropathology and behavior.	Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; Trinity Coll Dublin, Dept Psychol, Dublin, Ireland; Trinity Coll Dublin, Inst Neurosci, Dublin, Ireland; Sunnybrook Hlth Sci Ctr, Dept Surg Neurosurg, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Diagnost Imaging & Radiol, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, LC Campbell Cognit Neurol Res Unit, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON M4N 3M5, Canada		Levine, B (corresponding author), Rotman Res Inst, Baycrest Ctr Geriatr Care, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.utoronto.ca	Levine, Brian/O-2725-2019; Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; Fujiwara, Esther/F-8233-2011	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Fujiwara, Esther/0000-0003-4154-0145; Black, Sandra/0000-0001-7093-8289; Robertson, Ian H/0000-0001-8637-561X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01, R01 HD042385-03, R01 HD042385] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alavi A, 1997, J NUCL MED, V38, P1717; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Army Individual Test Battery, 1944, MAN DIR SCOR; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 1997, J NEUROSCI, V17, P391; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; COURVILLE CB, 1937, PAHTOLOGY CTR NERV 4; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Easdon C, 2004, BRAIN COGNITION, V54, P136; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; Friston KJ, 2004, NEUROIMAGE, V23, P21, DOI 10.1016/j.neuroimage.2004.04.021; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Goldstone BP, 2001, READ TEACH, V55, P362; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Halstead WC, 1947, BRAIN INTELLIGENCE Q; ICHISE M, 1994, J NUCL MED, V35, P217; Jacobs A, 1996, J NUCL MED, V37, P1605; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Liddle PF, 2001, HUM BRAIN MAPP, V12, P100, DOI 10.1002/1097-0193(200102)12:2<100::AID-HBM1007>3.0.CO;2-6; Logan Gordon D., 1994, P189; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mattay VS, 1997, NEUROREPORT, V8, P2977, DOI 10.1097/00001756-199709080-00034; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Price CJ, 2002, TRENDS COGN SCI, V6, P416, DOI 10.1016/S1364-6613(02)01976-9; Price CJ, 2001, J COGNITIVE NEUROSCI, V13, P419, DOI 10.1162/08989290152001853; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Smith A., 1978, SYMBOL DIGIT MODALIT; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spence SA, 2000, BRIT J PSYCHIAT, V176, P52, DOI 10.1192/bjp.176.1.52; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Verger K, 2001, BRAIN INJURY, V15, P211; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491; Yamaki T, 1996, J NUCL MED, V37, P1166; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zarahn E, 1999, COGNITIVE BRAIN RES, V7, P255, DOI 10.1016/S0926-6410(98)00029-9	123	60	65	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1396	1411		10.1089/neu.2006.23.1396			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500003	17020478	Green Accepted			2022-02-06	
J	Ooigawa, H; Nawashiro, H; Fukui, S; Otani, N; Osumi, A; Toyooka, T; Shima, K				Ooigawa, Hidetoshi; Nawashiro, Hiroshi; Fukui, Shinji; Otani, Naoki; Osumi, Atsushi; Toyooka, Terushige; Shima, Katsuji			The fate of Nissl-stained dark neurons following traumatic brain injury in rats: difference between neocortex and hippocampus regarding survival rate	ACTA NEUROPATHOLOGICA			English	Article						dark neuron; Nissl stain; traumatic brain injury; extracellular signal-regulated protein kinase	SIGNAL-REGULATED KINASE; LIGHT MICROSCOPIC RESPONSE; INDUCED STATUS EPILEPTICUS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; CONCUSSIVE HEAD-INJURY; SELECTIVE VULNERABILITY; FLUORO-JADE; SPATIAL PROFILE; CELL-DEATH	We studied the fate of Nissl-stained dark neurons (N-DNs) following traumatic brain injury (TBI). N-DNs were investigated in the cerebral neocortex and the hippocampus using a rat lateral fluid percussion injury model. Nissl stain, acid fuchsin stain and immunohistochemistry with phosphorylated extracellular signal-regulated protein kinase (pERK) antibody were used in order to assess posttraumatic neurons. In the neocortex, the number of dead neurons at 24 h postinjury was significantly less than that of the observed N-DNs in the earlier phase. Only a few N-DNs increased their pERK immunoreactivity. On the other hand, in the hippocampus the number of dead neurons was approximately the same number as that of the N-DNs, and most N-DNs showed an increased pERK immunoreactivity. These data suggest that not all N-DNs inevitably die especially in the neocortex after TBI. The fate of N-DNs is thus considered to differ depending on brain subfields.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan		Nawashiro, H (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	nawa1957@ndmc.ac.jp					Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ATILLO A, 1983, ACTA NEUROPATHOL, V59, P11, DOI 10.1007/BF00690312; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Cheung Eric C C, 2004, Sci STKE, V2004, pPE45; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Conti AC, 1998, J NEUROSCI, V18, P5663; COOPER JD, 1988, J ANAT, V157, P13; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csordas A, 2003, ACTA NEUROPATHOL, V106, P37, DOI 10.1007/s00401-003-0694-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Ishida K, 2004, NEUROSCIENCE, V125, P633, DOI 10.1016/j.neuroscience.2004.02.002; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Konigsmark B.W., 1970, CONT RES METHODS NEU, P315, DOI DOI 10.1007/978-3-642-85986-1_14; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Otani N, 2003, ACT NEUR S, V86, P287; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pei JJ, 2002, MOL BRAIN RES, V109, P45, DOI 10.1016/S0169-328X(02)00488-6; PETITO CK, 1984, J NEUROPATH EXP NEUR, V43, P141, DOI 10.1097/00005072-198403000-00004; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Subramaniam S, 2003, J BIOL CHEM, V278, P8904, DOI 10.1074/jbc.M210037200; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	50	60	64	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2006	112	4					471	481		10.1007/s00401-006-0108-2			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	089QC	WOS:000240894600008	16858608				2022-02-06	
J	Bahloul, M; Chaari, AN; Kallel, H; Khabir, A; Ayadi, A; Charfeddine, H; Hergafi, L; Chaari, AD; Chelly, HE; Ben Hamida, C; Rekik, N; Bouaziz, M				Bahloul, Mabrouk; Chaari, Anis N.; Kallel, Hatem; Khabir, Abdelmajid; Ayadi, Adnene; Charfeddine, Hanene; Hergafi, Leila; Chaari, Adel D.; Chelly, Hedi E.; Ben Hamida, Chokri; Rekik, Noureddine; Bouaziz, Mounir			Neurogenic pulmonary edema due to traumatic brain injury: Evidence of cardiac dysfunction	AMERICAN JOURNAL OF CRITICAL CARE			English	Article								BACKGROUND Acute neurogenic pulmonary edema, a common and underdiagnosed clinical entity, can occur after virtually any form of injury of the central nervous system and is a potential early contributor to pulmonary dysfunction inpatients with head injuries. OBJECTIVE To explore myocardial function inpatients with evident neurogenic pulmonary edema after traumatic head injury. METHODS During a 1-year period in a university hospital in Sfax, Tunisia, information was collected prospectively on patients admitted to the 22-bed intensive care unit because of isolated traumatic head injury who had neurogenic pulmonary edema. Data included demographic information, vital signs, neurological status, physiological status, and laboratory findings. All of the patients had computed tomography and plain radiography of the neck and determination of cardiac function. RESULTS All 7 patients in the sample had cardiac dysfunction. Evidence of myocardial damage was confirmed by echocardiography in 3 patients, pulmonary artery catheterization in 3 patients, and/or postmortem myocardial biopsy in 4 patients. Echocardiography studies, repeated 7 days after the initial study in one patient and 90 days afterward in another, showed complete improvement in wall motion, with a left ventricular ejection fraction of 0.65. CONCLUSION All patients who had neurogenic pulmonary edema due to traumatic head injury had myocardial dysfunction. The mechanisms of the dysfunction were multiple. The great improvement in wall motion seen in 2 patients indicated the presence of a stunned myocardium. Further studies are needed to understand the mechanisms of this cardiac dysfunction.	Ctr Hosp Univ Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia; Ctr Hosp Univ Habib Bourguiba, Serv Anatomopathol, Sfax, Tunisia; Ctr Hosp Univ Habib Bourguiba, Serv Med Legale, Sfax, Tunisia; Ctr Hosp Univ Hedi Chaker, Serv Cardiol, Sfax, Tunisia		Bahloul, M (corresponding author), Hop Habib Bourguiba, Serv Reanimat Med, Route El Ain Km 1, Sfax 3029, Tunisia.	bahloulmab@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; BACHOFEN H, 1993, AM REV RESPIR DIS, V147, P997, DOI 10.1164/ajrccm/147.4.997; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Cariou A, 1998, J CRIT CARE, V13, P198, DOI 10.1016/S0883-9441(98)90006-5; CARLSON RW, 1979, CHEST, V75, P731, DOI 10.1378/chest.75.6.731; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; de Chazal I, 2005, ANESTH ANALG, V100, P1147, DOI 10.1213/01.ANE.0000147704.90285.2A; Deehan SC, 1996, INTENS CARE MED, V22, P672, DOI 10.1007/BF01709745; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; FRASER RG, 1970, DIAGNOSIS DIS CHEST, P854; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; KOWALSKI ML, 1989, AM REV RESPIR DIS, V140, P101, DOI 10.1164/ajrccm/140.1.101; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; MARON MB, 1987, J APPL PHYSIOL, V62, P470, DOI 10.1152/jappl.1987.62.2.470; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; Parr MJA, 1996, BRIT MED J, V313, P681; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Samuels MA, 1987, AM J CARDIOL, V60, P15, DOI DOI 10.1016/0002-9149(87)90678-3; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; SIMON RP, 1993, NEUROL CLIN, V11, P309, DOI 10.1016/S0733-8619(18)30155-5; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; Wasowska-Krolikowska K, 2000, Med Sci Monit, V6, P1003; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; WRAY NP, 1978, AM REV RESPIR DIS, V118, P783, DOI 10.1164/arrd.1978.118.4.783; YABUMOTO M, 1986, NEUROSURGERY, V19, P300, DOI 10.1227/00006123-198608000-00025; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021	31	60	73	0	1	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264			AM J CRIT CARE	Am. J. Crit. Care	SEP	2006	15	5					462	470					9	Critical Care Medicine; Nursing	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Nursing	V44BT	WOS:000202978900005	16926367				2022-02-06	
J	Ghaffar, O; McCullagh, S; Ouchterlony, D; Feinstein, A				Ghaffar, Omar; McCullagh, Scott; Ouchterlony, Donna; Feinstein, Anthony			Randomized treatment trial in mild traumatic brain injury	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						traumatic brain injury (TBI); closed head injury; depression; neuropsychiatry; neuropsychological testing; treatment	MINOR HEAD-INJURY; ROUTINE FOLLOW-UP; BEHAVIORAL TOXICITY; MAJOR DEPRESSION; CONCUSSION; RECOVERY; QUESTIONNAIRE; IMPROVEMENT; POPULATION; MANAGEMENT	Objective: To determine whether multidisciplinary treatment of mild traumatic brain injury (MTBI) improves neurobehavioral outcome at 6 months postinjury. Methods: Subjects with MTBI were randomly assigned to treatment (n=97) or non-treatment (control, n=94) groups. Treated patients were assessed within 1 week of injury and thereafter managed by a multidisciplinary team according to clinical need for a further 6 months. Control subjects were not offered treatment. Six-month outcome measures included: severity of postconcussive symptoms (Rivermead Post-Concussion Disorder Questionnaire), psychosocial functioning (Rivermead Follow-up Questionnaire), psychological distress (General Health Questionnaire), and cognition (neurocognitive battery). Results: Treatment and control subjects were well-matched for demographic and MTBI severity data. In addition, the two groups did not differ on any outcome measure. However, in individuals with preinjury psychiatric difficulties (22.9% of the entire sample), subjects in the treatment group had significantly fewer depressive symptoms 6 months postinjury compared with untreated controls (P=.01). Conclusions: These findings suggest that routine treatment of all MTBI patients offers little benefit; rather, targeting individuals with preinjury psychiatric problems may prove a more rational and cost-effective approach. (c) 2006 Elsevier Inc. All rights reserved.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, St Michaels Hosp, Dept Rehabil Med, Toronto, ON M5B 1W8, Canada		Feinstein, A (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	ant.feinstein@utoronto.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AUSTIN MP, 1992, J AFFECT DISORDERS, V25, P21, DOI 10.1016/0165-0327(92)90089-O; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; FEINSTEIN A, 1992, BRAIN, V115, P1402; FEINSTEIN A, 2000, CAN J PUBLIC HLTH, V91, P5; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1989, MILD HEAD INJURY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hindmarch I, 1998, INT CLIN PSYCHOPHARM, V13, pS5, DOI 10.1097/00004850-199807006-00002; HINDMARCH I, 1995, INT CLIN PSYCHOPHARM, V9, P13, DOI 10.1097/00004850-199501004-00002; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KURTZKE JF, 1993, CLIN NEUROLOGY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mahon D, 1989, J Neurosci Nurs, V21, P382; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ridout F, 2003, HUM PSYCHOPHARM CLIN, V18, P261, DOI 10.1002/hup.494; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; STOUDEMIRE A, 1995, J NEUROPSYCH CLIN N, V7, P31; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; VEIEL HOF, 1997, J CLIN EXP NEUROPSYC, V19, P541; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42	52	60	60	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999			J PSYCHOSOM RES	J. Psychosomat. Res.	AUG	2006	61	2					153	160		10.1016/j.jpsychores.2005.07.018			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	074GJ	WOS:000239800400002	16880017				2022-02-06	
J	Boes, M; Kain, M; Kakar, S; Nicholls, F; Cullinane, D; Gerstenfeld, L; Einhorn, TA; Torneta, P				Boes, M; Kain, M; Kakar, S; Nicholls, F; Cullinane, D; Gerstenfeld, L; Einhorn, TA; Torneta, P			Osteogenic effects of traumatic brain injury on experimental fracture-healing	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							HEAD-INJURY; ENHANCED OSTEOGENESIS; HETEROTOPIC OSSIFICATION; GROWTH-FACTOR; FEMORAL FRACTURES; GENE-EXPRESSION; BONE-FORMATION; SPINAL-CORD; CELLS; ADULTS	Background: Heterotopic bone formation has been observed in patients with traumatic brain injury; however, an association between such an injury and enhanced fracture-healing remains unclear. To test the hypothesis that traumatic brain injury causes a systemic response that enhances fracture-healing, we established a reproducible model of traumatic brain injury in association with a standard closed fracture and measured the osteogenic response with an in vitro cell assay and assessed bone-healing with biomechanical testing. Methods: A standard closed femoral fracture was produced in forty-three Sprague-Dawley rats. Twenty-three of the rats were subjected to additional closed head trauma that produced diffuse axonal injury similar to that observed in patients with a traumatic brain injury. Twenty-one days after the procedure, all animals were killed and fracture-healing was assessed by measuring callus size and by mechanical testing. Sera from the animals were used in subsequent in vitro experiments to measure mitogenic effects on established cell lines of committed osteoblasts, fibroblasts, and mesenchymal stem cells. Results: Biomechanical assessment demonstrated that the brain-injury group had increased stiffness (p = 0.02) compared with the fracture-only group. There was no significant difference in torsional strength between the two groups. Cell culture studies showed a significant increase in the proliferative response of mesenchymal stem cells after exposure to sera from the brain-injury group compared with the response after exposure to sera from the fracture-only group (p = 0.0002). This effect was not observed in fibroblasts or committed osteoblasts. Conclusions: These results support data from previous studies that have suggested an increased osteogenic potential and an enhancement of fracture-healing secondary to traumatic brain injury. Our results further suggest that the mechanism for this enhancement is related to the presence of factors in the serum that have a mitogenic effect on undifferentiated mesenchymal stem cells. Clinical Relevance: Fracture-healing may be enhanced by an associated traumatic brain injury. Further understanding of this systemic response could lead to important insights about systemic therapeutic strategies for the enhancement of skeletal repair.	Boston Univ, Med Ctr, Dept Orthopaed, Boston, MA 02118 USA; Boston Univ, Sch Med, Orthopaed Res Lab, Boston, MA 02118 USA		Boes, M (corresponding author), Boston Univ, Med Ctr, Dept Orthopaed, Dowling 2 N,850 Harrison Ave, Boston, MA 02118 USA.	mattboes@hotmail.com; mikain@bmc.org; sanjeev.kakar@bmc.org; thomas.einhorn@bmc.org; ptornetta@pol.net		/0000-0002-0477-1211; Einhorn, Thomas/0000-0002-5075-4885; Tornetta, Paul/0000-0002-6448-8864			Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115; Asaumi K, 2000, BONE, V26, P625, DOI 10.1016/S8756-3282(00)00281-7; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623-200308000-00002; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; GARLAND DE, 1982, CLIN ORTHOP RELAT R, V166, P219; Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736-0266(03)00003-2; Kawamoto K, 2004, PROG BRAIN RES, V146, P369; Khare G N, 1995, Indian J Med Sci, V49, P281; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734; Siwek B, 1997, J BONE MINER RES, V12, P552, DOI 10.1359/jbmr.1997.12.4.552; SPENCER RF, 1990, S AFR J SURG, V28, P51; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; WHITE AA, 1977, J BONE JOINT SURG AM, V59, P189, DOI 10.2106/00004623-197759020-00009; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yamashiro T, 2001, BONE, V28, P404, DOI 10.1016/S8756-3282(01)00405-7	32	60	75	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	APR	2006	88A	4					738	743		10.2106/JBJS.D.02648			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	029KF	WOS:000236560500008	16595463				2022-02-06	
J	Labombarda, F; Gonzalez, S; Deniselle, MCG; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, F; Gonzalez, S; Deniselle, MCG; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone increases the expression of myelin basic protein and the number of cells showing NG(2) immunostairling in the lesioned spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						myelin basic protein; neuroprotection; NG(2)+ cells; oligodendrocytes; progesterone; spinal cord injury	OLIGODENDROCYTE PROGENITOR CELLS; PERIPHERAL NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; SCHWANN-CELLS; SLICE CULTURES; MESSENGER-RNA; GLIAL-CELLS; RAT-BRAIN; PROLIFERATION	It is now widely accepted that progesterone (PROG) brings neuroprotection in lesions of the peripheral and central nervous system. Spinal cord trauma leads to neuronal degeneration, astrogliosis, demyelination, and proliferation of oligodendrocyte-precursor cells (OPCs). In this work, we studied the effects of PROG on myelin-related parameters in rats with complete spinal cord transection (TRX). To this end, sham-operated controls and rats with TRX at thoracic level T10 received vehicle or PROG (4 mg/kg/day) during 3 days. Three variables were measured in the lumbar L4 region below the lesion: (1) expression of myelin basic protein (MBP) at the protein and mRNA levels; (2) density of NG(2)-immunopositive cells as markers for OPCs; and (3) number of cells immunopositive for RIP, an antibody staining mature oligodendrocytes. TRX decreased MBP immunostaining in the corticospinal tract (CST) and dorsal ascending tract (DAT) but not the ventral funiculus'(VF). NG(2)(+) cells, which were detected in low number in controls, increased after TRX in the gray and white matter. RIP-positive cell number, however, remained unchanged. PROG treatment of rats with TRX enhanced the expression of MBP protein and mRNA in CST and DAT, but not VF and highly stimulated the number of cells showing NG(2) immunostaining over untreated lesioned rats. Instead, density of RIP positive cells was similar in the PROG-treated and untreated lesioned groups. We propose that PROG effects on expression of MBP and the number of NG2 immunopositive cells may contribute to neuroprotection, as they go in parallel with previous results showing enhanced biochemical and morphological parameters of motoneurons of animals with TRX receiving PROG treatment.	Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; Hop Bicetre, INSERM, U488, Le Kremlin Bicetre, France		De Nicola, AF (corresponding author), Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011; Messier, Claude/A-2322-2008	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300; Messier, Claude/0000-0002-4791-1763			Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE RP, 1993, ADV NEUROL, V59, P75; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chan JR, 2001, P NATL ACAD SCI USA, V98, P14661, DOI 10.1073/pnas.251543398; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Du YZ, 2003, DEV NEUROSCI-BASEL, V25, P116, DOI 10.1159/000072261; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Greenwood K, 2003, MOL CELL NEUROSCI, V23, P544, DOI 10.1016/S1044-7431(03)00176-3; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; HUBBARD P, 2003, SPINAL RES, V1, P100; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Jung-Testas I, 1999, J STEROID BIOCHEM, V69, P97, DOI 10.1016/S0960-0760(98)00149-6; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li G, 2004, J NEUROTRAUM, V21, P1044, DOI 10.1089/0897715041651015; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Nguyen KB, 1999, ACTA NEUROPATHOL, V98, P39, DOI 10.1007/s004010051049; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; PAXINOS G, 1983, RAT BRAIN STEREOTAXI; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tolwani RJ, 2004, J NEUROSCI RES, V77, P662, DOI 10.1002/jnr.20181; VERDI JM, 1990, J BIOL CHEM, V265, P20314; Ye P, 2003, J NEUROSCI, V23, P4401	50	60	61	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					181	192		10.1089/neu.2006.23.181			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600007	16503802				2022-02-06	
J	Padayachee, L; Cooper, DJ; Irons, S; Ackland, HM; Thoinson, K; Rosenfeld, J; Kossmann, T				Padayachee, L; Cooper, DJ; Irons, S; Ackland, HM; Thoinson, K; Rosenfeld, J; Kossmann, T			Cervical spine clearance in unconscious traumatic brain injury patients: Dynamic flexion-extension fluoroscopy versus computed tomography with three-dimensional reconstruction	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Scientific Meeting of the Australian-and-New Zealand-Intensive-Care-Society	SEP 13, 2003	Perth, AUSTRALIA	Australia & New Zealand Intens Care Soc		cervical spine; traumatic brain injury; flexion-extension fluoroscopy	BLUNT TRAUMA; PROTOCOL; VIEWS	Background: An optimal protocol for clearing the cervical spine in unconscious patients with traumatic brain injury remains controversial. Protocols include plain radiographs and computed tomography (CT), and ligamentous injury may be identified with flexion-extension radiographs. We questioned whether cervical CT with three-dimensional (3D) reconstructions may obviate the need for flexion-extension radiology in the detection of occult ligamentous injury. Methods: Between July 1999 and November 2001, 276 unconscious traumatic brain injured patients admitted to The Alfred Hospital received cervical spine plain radiographs, CT with 3D reconstructions, and dynamic flexion-extension X-ray studies with fluoroscopy as part of a routine protocol. These patients were identified from a prospective intensive care unit database and all radiology reports were reviewed. Results: Dynamic flexion-extension X-ray studies with fluoroscopy identified no new fractures or instability; there were no instances of true-positive results. Dynamic flexion-extension was true-negative in 260 of 276 (94%) patients, falsely positive in six patients (2.2%) and falsely negative in one (0.4%) patient. In nine patients, dynamic flexion-extension was inadequate. Conclusion: Dynamic flexion-extension X-ray studies with fluoroscopy delayed cervical spine clearance and were almost always reported as normal. In a cervical spine clearance protocol for unconscious traumatic brain injury patients, dynamic flexion-extension Xray studies with fluoroscopy did not identify any patients with cervical fracture or instability not already identified by plain radiographs and fine-cut CT (CO to T2) with 3D reconstructions.	Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Intens Care, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Radiol, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3181, Australia		Cooper, DJ (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3181, Australia.	j.cooper@alfred.org.au	Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051			Ajani AE, 1998, ANAESTH INTENS CARE, V26, P487, DOI 10.1177/0310057X9802600502; Albrecht RM, 2003, AM SURGEON, V69, P261; Anglen J, 2002, J TRAUMA, V52, P54, DOI 10.1097/00005373-200201000-00011; Bolinger B, 2004, J TRAUMA, V56, P132, DOI 10.1097/01.TA.0000044629.69247.0A; Brooks RA, 2001, J TRAUMA, V50, P862; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; DAVIS JW, 1995, J TRAUMA, V39, P435; Davis JW, 2001, J TRAUMA, V50, P1044, DOI 10.1097/00005373-200106000-00011; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; Freedman I, 2005, J TRAUMA, V58, P1183, DOI 10.1097/01.TA.0000169807.96533.F2; Griffiths HJ, 2002, SKELETAL RADIOL, V31, P587, DOI 10.1007/s00256-002-0545-5; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026	15	60	64	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2006	60	2					341	345		10.1097/01.ta.0000195716.73126.12			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	018MF	WOS:000235767700018	16508493				2022-02-06	
J	Wen, TC; Rogido, M; Peng, H; Genetta, T; Moore, J; Sola, A				Wen, T. C.; Rogido, M.; Peng, H.; Genetta, T.; Moore, J.; Sola, A.			Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats	NEUROSCIENCE			English	Article						erythropoletin; neonatal focal stroke; neuroprotection; gender differences	TRAUMATIC BRAIN-INJURY; CEREBRAL HYPOXIA-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL-MODEL; PROTECTS NEURONS; PERINATAL STROKE; DAMAGE; MEMORY; MICE; MECHANISMS	Recently, we reported that erythropoletin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral Schema. On the other hand, erythropoietin treatment (1000 U/kg x three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4 +/- 48.2 mm(3) vs. 194.0 +/- 59.2 mm(3), P < 0.05; females: 85.4 +/- 31.6 mm(3) VS. 183.4 +/- 46.3 mm(3), P < 0.05). Interestingly, the reduction in the mean infarct volume in the erythropoletin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4 +/- 48.2 mm(3) VS. 85.4 +/- 31.6 mm(3), P < 0.05). At 12 weeks after focal cerebral Ischernia, the mean infarct volume in the erythropoletintreated males significantly increased to 181.0 +/- 50.4 mm(3) (P < 0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0 +/- 41.7 mm(3)). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischernia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5 +/- 2.0 vs. 24.5 +/- 2.5, P < 0.05) and 12 (12.5 +/- 2.0 vs. 20.0 +/- 2.0 P < 0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischernia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Emory Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, Atlanta, GA 30322 USA		Wen, TC (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	Tong_wen@oz.ped.emory.edu		Moore, James/0000-0003-0399-6432			Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Carswell HVO, 1999, HYPERTENSION, V33, P681, DOI 10.1161/01.HYP.33.2.681; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Dame C, 2001, BIOL NEONATE, V79, P228; deVeber G, 2000, Semin Pediatr Neurol, V7, P309, DOI 10.1053/spen.2000.20074; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Driscoll MC, 2003, BLOOD, V101, P2401, DOI 10.1182/blood.V101.6.2401; Edwards AD, 2000, PEDIATR RES, V47, P431, DOI 10.1203/00006450-200004000-00003; Edwards D, 2004, J PEDIATR-US, V145, P723, DOI 10.1016/j.jpeds.2004.08.062; Fisher JW, 2003, EXP BIOL MED, V228, P1; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Ifudu O, 2001, AM J KIDNEY DIS, V38, P518, DOI 10.1053/ajkd.2001.26842; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Lynch JK, 2001, CURR OPIN PEDIATR, V13, P499, DOI 10.1097/00008480-200112000-00002; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Ment LR, 2004, J PEDIATR-US, V145, P832, DOI 10.1016/j.jpeds.2004.07.035; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Nelson KB, 2004, LANCET NEUROL, V3, P150, DOI 10.1016/S1474-4422(04)00679-9; Partridge JC, 2005, PEDIATRICS, V116, pE263, DOI 10.1542/peds.2004-2274; Pritchett K, 2003, CONTEMP TOP LAB ANIM, V42, P53; Ramaswamy V, 2004, NEUROLOGY, V62, P2088, DOI 10.1212/01.WNL.0000129909.77753.C4; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Spandou E, 2004, NEUROSCI LETT, V366, P24, DOI 10.1016/j.neulet.2004.05.032; Stillger Adrienne, 1999, Indian Journal of Pediatrics, V66, P141, DOI 10.1007/BF02752373; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Vannucci RC, 1997, BIOL NEONATE, V72, P187; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; Wang CH, 2004, BIOCHEM BIOPH RES CO, V314, P1064, DOI 10.1016/j.bbrc.2004.01.005; Wen TC, 2004, BRAIN RES PROTOC, V13, P76, DOI 10.1016/j.brainresprot.2004.02.003; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; Zeng S M, 2001, J Gend Specif Med, V4, P35; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	52	60	61	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	139	3					803	811		10.1016/j.neuroscience.2006.02.057			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044RP	WOS:000237690400003	16581190				2022-02-06	
J	Danckert, JA; Allman, AAA				Danckert, JA; Allman, AAA			Time flies when you're having fun: Temporal estimation and the experience of boredom	BRAIN AND COGNITION			English	Article						attention; temporal perception; boredom	SCALAR EXPECTANCY-THEORY; TRAUMATIC BRAIN-INJURY; ATTENTIONAL BLINK; PRONENESS; PERCEPTION; REPRESENTATION; WORK; TASK	Boredom is a common experience in healthy individuals and may be elevated in various neurological or psychiatric conditions. As yet, very little is known about the cognitive or neural bases of the subjective experience of boredom. We examined temporal perception and the temporal allocation of attention in healthy individuals reporting high- or low-levels of boredom. We found no difference in high- or low-boredom-prone individuals in the temporal allocation of attention, while individuals who experienced low-levels of boredom tended to underestimate time more so than high-boredom-prone individuals. Furthermore, high-boredom-prone individuals demonstrated higher error values when estimating time indicating that the subjective perception of the passage of time may be a critical component to the experience of boredom. (c) 2005 Elsevier Inc. All rights reserved.	Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada		Danckert, JA (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	jdancker@uwaterloo.ca					Conti R, 2001, J PERS, V69, P1, DOI 10.1111/1467-6494.00134; Coull JT, 2004, SCIENCE, V303, P1506, DOI 10.1126/science.1091573; DAMRADFRYE R, 1989, J PERS SOC PSYCHOL, V57, P315; DRORY A, 1982, PERS PSYCHOL, V35, P141, DOI 10.1111/j.1744-6570.1982.tb02190.x; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; FISHER CD, 1993, HUM RELAT, V46, P395, DOI 10.1177/001872679304600305; GIBBON J, 1977, PSYCHOL REV, V84, P279, DOI 10.1037/0033-295X.84.3.279; GORDON A, 1997, PSYCHOL STUD, V0042, P00085; Hamilton J. A., 1981, PROGR EXPT PERSONALI, V10, P281; HAMILTON JA, 1984, PERS INDIV DIFFER, V5, P183, DOI 10.1016/0191-8869(84)90050-3; Harrington DL, 1998, J NEUROSCI, V18, P1085; Ivry RB, 1996, CURR OPIN NEUROBIOL, V6, P851, DOI 10.1016/S0959-4388(96)80037-7; Ivry RB, 2004, CURR OPIN NEUROBIOL, V14, P225, DOI 10.1016/j.conb.2004.03.013; Kass SJ, 2001, PERCEPT MOTOR SKILL, V92, P969, DOI 10.1177/003151250109203c01; Kass Steven J, 2003, J Atten Disord, V7, P83, DOI 10.1177/108705470300700202; KRAGERER FA, 2002, NEUROPSYCHOLOGIA, V40, P357; LEONG FTL, 1993, PERS INDIV DIFFER, V14, P233, DOI 10.1016/0191-8869(93)90193-7; Nisbett R., 1974, THOUGHT FEELING, P74; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Rakitin BC, 1998, J EXP PSYCHOL-ANIM B, V24, P15, DOI 10.1037/0097-7403.24.1.15; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; Rizzo M, 2001, NEUROLOGY, V57, P795, DOI 10.1212/WNL.57.5.795; Rolls E.T., 1999, BRAIN EMOTION; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; SMITH RP, 1981, HUM FACTORS, V23, P329, DOI 10.1177/001872088102300308; Sommers J, 2000, J CLIN PSYCHOL, V56, P149, DOI 10.1002/(SICI)1097-4679(200001)56:1<149::AID-JCLP14>3.0.CO;2-Y; Todman M, 2003, PSYCHIATRY, V66, P146, DOI 10.1521/psyc.66.2.146.20623; Vodanovich SJ, 2003, J PSYCHOL, V137, P569, DOI 10.1080/00223980309600636; VODANOVICH SJ, 1991, PSYCHOL REP, V69, P1139, DOI 10.2466/PR0.69.8.1139-1146; VODANOVICH SJ, 1990, J PERS ASSESS, V55, P115, DOI 10.1207/s15327752jpa5501&2_11; Wallace JC, 2003, PERS INDIV DIFFER, V34, P635, DOI 10.1016/S0191-8869(02)00050-8; Walsh KW., 1991, UNDERSTANDING BRAIN; Walsh V, 2003, TRENDS COGN SCI, V7, P483, DOI 10.1016/j.tics.2003.09.002; Walsh V, 2003, TRENDS COGN SCI, V7, P335, DOI 10.1016/S1364-6613(03)00166-9; WATT JD, 1991, PSYCHOL REP, V69, P323, DOI 10.2466/PR0.69.5.323-327; Watt JD, 1999, J PSYCHOL, V133, P303, DOI 10.1080/00223989909599743	36	60	65	2	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2005	59	3					236	245		10.1016/j.bandc.2005.07.002			10	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	997GV	WOS:000234234400003	16168546				2022-02-06	
J	Wagner, AK; Chen, XB; Kline, AE; Li, YM; Zafonte, RD; Dixon, CE				Wagner, AK; Chen, XB; Kline, AE; Li, YM; Zafonte, RD; Dixon, CE			Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; environmental enrichment; gender; dopamine transporter	CONTROLLED CORTICAL IMPACT; MEDIAL PREFRONTAL CORTEX; STRIATAL DOPAMINE; COGNITIVE FUNCTION; FRONTAL-CORTEX; BLOOD-FLOW; ESTROGEN; PROGESTERONE; AMPHETAMINE; NEUROTROPHIN	Dopamine (DA) systems are implicated in cognitive deficits following traumatic brain injury (TBI). Rodent studies have demonstrated that both environmental enrichment (EE) and sex hormones can influence DA systems. The dopamine transporter (DAT) plays a crucial role in regulating DA transmission, and previous work shows that DAT is decreased after TBI in mates. Therefore, the purpose of this study was to examine the effects of gender and EE on frontal cortex and striatal DAT expression after TBI. Sprague -Dawley male (n = 24) and cycling female rats (n = 24) were placed into EE or standard housing after controlled cortical impact (2.7 nun, 4.0 m/s) injury or sham surgery (eight groups, n = 6/group). Four weeks post-surgery, bilateral frontal cortex and striatal DAT expression was examined via Western blot. Results demonstrated that there was a significant effect of injury, EE, and region on DAT expression (P < 0.05 all comparisons) on female groups. There were no significant DAT decreases in any region as a result of injury, however, EE did promote significant post-injury DAT decreases in the striatum and ipsilateral frontal cortex (P < 0.05 all comparisons) compared to female shams housed in the standard environment. For males, there was a significant effect of injury, EE, and region for male groups (P < 0.05 all comparisons). There were decreases in DAT expression in three regions studied for injured males housed in the standard environment compared to sham males in the standard environment (P < 0.05 all comparisons), however, EE did not add significantly to post-injury DAT decreases in these regions. These results suggest that CCI causes larger relative decreases in DAT expression for males compared to females and that treatment with EE has larger effects on post-injury DAT expression for females than males. These findings may have some relevance to treatment paradigms using dopaminergic neurostimulants after TBI. (c) 2005 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnera@msx.upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833, R03HD041399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD41399, K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40125] Funding Source: Medline		Bardo MT, 2001, PSYCHOPHARMACOLOGY, V155, P278; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P53, DOI 10.1016/S0091-3057(99)00091-X; Bezard E, 2003, J NEUROSCI, V23, P10999; Blurton-Jones M, 2004, J COMP NEUROL, V468, P347, DOI 10.1002/cne.10989; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; ELOVIC E, 1996, MED REHABILITATION T, P1; GARRIS PA, 1994, J NEUROSCI, V14, P442; Gazzaley A, 2002, NEUROSCIENCE, V111, P853, DOI 10.1016/S0306-4522(02)00021-0; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; KLINE AE, 2001, MO CL BI CC, V2, P267; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kuppers E, 2000, J NEUROCYTOL, V29, P375, DOI 10.1023/A:1007165307652; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Lee I, 2003, J NEUROSCI, V23, P1517, DOI 10.1523/JNEUROSCI.23-04-01517.2003; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Moron JA, 2002, J NEUROSCI, V22, P389, DOI 10.1523/JNEUROSCI.22-02-00389.2002; Mundorf ML, 2001, J NEUROCHEM, V79, P130, DOI 10.1046/j.1471-4159.2001.00554.x; Neugebauer NM, 2004, DEV BRAIN RES, V153, P213, DOI 10.1016/j.devbrainres.2004.09.001; ODONNELL P, 1995, J NEUROSCI, V15, P3622; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PERIS J, 1991, BRAIN RES, V566, P255, DOI 10.1016/0006-8993(91)91706-7; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vafaei AA, 2004, BEHAV BRAIN RES, V149, P61, DOI 10.1016/S0166-4328(03)00209-2; Valentini V, 2004, J NEUROCHEM, V88, P917, DOI 10.1046/j.1471-4159.2003.02238.x; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; WAGNER AK, IN PRESS J NEUROCHEM; WELINGTON R, 2003, PSYCHOPHARMACOLOGY, V170, P51; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Winterfeld KT, 1998, J NEUROSCI RES, V52, P201, DOI 10.1002/(SICI)1097-4547(19980415)52:2<201::AID-JNR8>3.0.CO;2-E; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2004, BEHAV BRAIN RES, V148, P107, DOI 10.1016/S0166-4328(03)00190-6; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	62	60	63	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2005	195	2					475	483		10.1016/j.expneurol.2005.06.009			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	968VI	WOS:000232190600021	16023635				2022-02-06	
J	Wilson, BA; Emslie, H; Quirk, K; Evans, J; Watson, P				Wilson, BA; Emslie, H; Quirk, K; Evans, J; Watson, P			A randomized control trial to evaluate a paging system for people with traumatic brain injury	BRAIN INJURY			English	Article							MEMORY; NEUROPAGE	Although memory problems following acquired brain damage are common, some people are able to compensate for these problems through external aids. It was recently demonstrated that a paging system could reduce the everyday memory and planning problems for people with non-progressive brain injury. The 143 patients who participated in the study comprised several diagnostic groups. This paper reports on the sub-group of people with TBI (n = 63). This sub-group was part of the larger sample of 143 already published in the 2001 study. A randomized control cross-over design randomly allocated people to group A (pager first) or group B (waiting list first). Each participant chose their own tasks for which they needed reminders. During a 2 week baseline, successful task achievement was documented. Group A achieved 47.14% of tasks and group B 47.88%. People in group A then received a pager for 7 weeks. During the last 2 weeks of this 7 week period, task achievement was documented again. Group A now achieved 71.80% of tasks and group B (on the waiting list) achieved 49.05% (no different from baseline). Group A then returned their pagers and group B received pagers. During the last 2 weeks of this stage participants were monitored once more. At this point, people in group A had dropped back slightly but were still statistically significantly better than during the baseline (67.23%). Group B, meanwhile, were now achieving 73.62% of tasks. This was statistically significantly better than baseline and significantly better than group A, now in the post-pager phase. It is concluded that this paging system significantly reduces the everyday memory and planning problems of people with TBI.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge, England		Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge, England.	Barbara.wilson@mrc-cbu.cam.ac.uk		Watson, Peter/0000-0002-9436-0693			Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Everitt BS, 1995, CAMBRIDGE DICT STAT; Inglis EA, 2004, NEUROPSYCHOL REHABIL, V14, P77, DOI 10.1080/09602010343000129; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 2003, NEURO S B C, P329; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477	8	60	62	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					891	894		10.1080/02699050400002363			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500003	16296571				2022-02-06	
J	Zai, LJ; Yoo, S; Wrathall, JR				Zai, LJ; Yoo, S; Wrathall, JR			Increased growth factor expression and cell proliferation after contusive spinal cord injury	BRAIN RESEARCH			English	Article						GGF2; FGF2; CNTF; oligodendrocyte; astrocyte; glia; precursor; progenitor; BrdU; NG2	OLIGODENDROCYTE PRECURSOR CELLS; ROOT GANGLION NEURONS; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; NEUROTROPHIC FACTOR; GENE-EXPRESSION; MATURE OLIGODENDROCYTES; PROGENITOR CELLS; WHITE-MATTER; IN-VIVO	The damage caused by traumatic central nervous system (CNS) injury can be divided into two phases: primary and secondary. The initial injury destroys many of the local neurons and glia and triggers secondary mechanisms that result in further cell loss. Approximately 50 % of the astrocytes and oligodendrocytes in the spared white matter of the epicenter die by 24 h after spinal cord injury (SCI) but their densities return to normal levels by 6 weeks. This repopulation is largely due to the proliferation of local progenitors that divide in response of CNS injury. Previous studies indicate that the secondary events that cause cell death after SCI also increase the local levels of several growth factors that stimulate the proliferation of these endogenous progenitors. We compared the spatial pattern of the post-injury up-regulation of the pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if each could play a role in proliferation. Three days after a standard contusive SO or laminectomy, animals received intraperitoneal BrdU injections to label dividing cells and were perfused 2 h after the last injection. Immunohistochemistry for BrdU and basic fibroblast growth factor (FGF2) and in situ hybridization for ciliary neurotrophic factor (CNTF) and glial growth factor (GGF2) mRNA were used to compare the number of dividing cells with growth factor levels in sections 2 and 4 turn from the epicenter. All three growth factors are significantly up-regulated 3 days after SCI, when cell proliferation is maximal. The increase in GGF2 and FGF2 levels is highest in sections 2 mm rostral to the epicenter, mimicking BrdU incorporation. Addition of rhGGF2 to cultured cells isolated from the spinal cord 3 days after SCI increased the number of NG2+ glial progenitors. These data suggest that FGF2 and GGF2 may contribute to the spontaneous recovery observed after SO by stimulating the proliferation of local progenitors that help repopulate the injured cord. (c) 2005 Elsevier B.V. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA		Wrathall, JR (corresponding author), Georgetown Univ, Dept Neurosci, 3970 Reservoir Rd NW,NRB-EG31, Washington, DC 20057 USA.	wrathalj@georgetown.edu		Yoo, Soonmoon/0000-0002-1645-6809	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035647, F31 NS43019] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS043019, R01NS035647] Funding Source: NIH RePORTER		Albrecht PJ, 2003, NEUROBIOL DIS, V13, P89, DOI 10.1016/S0969-9961(03)00019-6; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Bambakidis Nicholas C, 2004, Spine J, V4, P16, DOI 10.1016/j.spinee.2003.07.004; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Cannella B, 1999, J NEUROIMMUNOL, V100, P233, DOI 10.1016/S0165-5728(99)00201-5; Cannella B, 1998, P NATL ACAD SCI USA, V95, P10100, DOI 10.1073/pnas.95.17.10100; Canoll PD, 1999, MOL CELL NEUROSCI, V13, P79, DOI 10.1006/mcne.1998.0733; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; Cook JL, 1998, MOL BRAIN RES, V55, P9, DOI 10.1016/S0169-328X(97)00350-1; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; FRESSINAUD C, 1993, DEV BIOL, V158, P317, DOI 10.1006/dbio.1993.1191; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GRINSPAN JB, 1993, J NEUROSCI RES, V36, P672, DOI 10.1002/jnr.490360608; Grossman SD, 1999, J NEUROSCI, V19, P5711, DOI 10.1523/JNEUROSCI.19-14-05711.1999; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hinks GL, 1999, MOL CELL NEUROSCI, V14, P153, DOI 10.1006/mcne.1999.0771; Horner PJ, 2000, J NEUROSCI, V20, P2218; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; Jiang FJ, 1999, J NEUROSCI RES, V57, P447, DOI 10.1002/(SICI)1097-4547(19990815)57:4<447::AID-JNR4>3.3.CO;2-2; Kojima A, 2000, J NEUROPATH EXP NEUR, V59, P687, DOI 10.1093/jnen/59.8.687; Kojima A, 2002, J NEUROTRAUM, V19, P223, DOI 10.1089/08977150252806974; Lee MY, 1998, NEUROSCI LETT, V255, P79, DOI 10.1016/S0304-3940(98)00710-1; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; Murakami Y, 2002, J NEUROL SCI, V198, P63, DOI 10.1016/S0022-510X(02)00080-1; NEUBERGER TJ, 1993, J NEUROCYTOL, V22, P449, DOI 10.1007/BF01181565; Ohta K, 2001, CELLS TISSUES ORGANS, V169, P410, DOI 10.1159/000047909; Oyesiku NM, 1997, J NEUROBIOL, V32, P251, DOI 10.1002/(SICI)1097-4695(199703)32:3<251::AID-NEU1>3.0.CO;2-6; RABEHEVSKY AG, 2000, EXP NEUROL, V164, P280; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Rosano C, 1999, GLIA, V27, P189, DOI 10.1002/(SICI)1098-1136(199909)27:3<189::AID-GLIA1>3.0.CO;2-I; Rosenberg LJ, 2005, GLIA, V49, P107, DOI 10.1002/glia.20096; Shi JY, 1998, J NEUROSCI, V18, P4627; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; SMITH GM, 1987, ANN NY ACAD SCI, V495, P185, DOI 10.1111/j.1749-6632.1987.tb23675.x; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Tokita Y, 2001, J NEUROSCI, V21, P1257; WATANABE H, 1975, ARCH NEUROL-CHICAGO, V32, P181, DOI 10.1001/archneur.1975.00490450061008; Wrathall JR, 1998, J NEUROSCI, V18, P8780; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	46	60	60	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 9	2005	1052	2					147	155		10.1016/j.brainres.2005.05.071			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	959BX	WOS:000231493000004	16005441				2022-02-06	
J	McCauley, SR; Boake, C; Pedroza, C; Brown, SA; Levin, HS; Goodman, HS; Merritt, SG				McCauley, SR; Boake, C; Pedroza, C; Brown, SA; Levin, HS; Goodman, HS; Merritt, SG			Postconcussional disorder - Are the DSM-IV criteria an improvement over the ICD-10?	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						postconcussional syndrome; head injuries; closed; outcome	NEUROBEHAVIORAL RATING-SCALE; TRAUMATIC BRAIN INJURY; HEAD-INJURY; SOCIAL SUPPORT; SYMPTOMS; VALIDITY; SEQUELAE; MODERATE; SENSITIVITY; PREDICTORS	Little is known about the characteristics and outcomes of patients diagnosed with postconcussional disorder (PCD) under the provisionally proposed criteria in the DSM-IV and how they differ from patients diagnosed with postconcussional syndrome (PCS) under the International Classification of Diseases, 10th edition clinical (ICD-10) criteria. This study investigated differences in outcome based on a diagnosis of PCD (DSM-IV) versus PCS (ICD-10 clinical criteria) as to which criteria set might be preferred for clinical practice. A consecutive series of adult patients with mild (N = 3 19) to moderate (N = 2 1) traumatic brain injury was assessed at 3 months postinjury with a brief neuropsychological battery and measures of specific outcome domains. In two separate series of analyses, patients with PCD were compared with those without PCD, and those with PCS were compared with those without PCS. Although the two criteria sets resulted in markedly different incidence rates, there was no substantial pattern of differences between the DSM-IV and ICD-10 in the outcome domains of psychiatric symptoms and disorders, social and community integration, health-related quality of life, or global outcome as measured by the Glasgow Outcome Scale-Extended. In spite of significant differences between the two diagnostic criteria sets and different incidence rates for PCD/PCS, outcome in all measured domains was very similar at 3 months postinjury. There is no compelling evidence, based on these outcome domains, to suggest which of the two diagnostic criteria sets should be clinically preferred.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA		McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.			Pedroza, Claudia/0000-0003-4235-1282	ODCDC CDC HHS [R49/CCR612707] Funding Source: Medline		AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOAKE C, IN PRESS J NEUROPSYC; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cohen J., 2013, STAT POWER ANAL BEHA; *COMM INJ SCAL, 1990, ABBR INJ SCAL; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; IVERSON GL, 2001, J COGNIT REHABIL, V19, P18; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LETSCH EA, 2003, DISS ABSTR INT B, V63, P3925; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MEYERS JE, 1995, REY COMPLEX FITURE T; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RUSSELL RW, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; *SAS, 2001, STAT AN SOFTW WIND; Smith A., 1982, SYMBOL DIGIT MODALIT; STOGNER BL, 2000, DISS ABSTR INT B, V61, P550; TEASDALE G, 1974, LANCET, V2, P81; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Williams, 1995, USERS GUIDE STRUCTUR; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO	48	60	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	AUG	2005	193	8					540	550		10.1097/01.nmd.0000172592.05801.71			11	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	954TK	WOS:000231177600007	16082299				2022-02-06	
J	O'Connor, C; Colantonio, A; Polatajko, H				O'Connor, C; Colantonio, A; Polatajko, H			Long term symptoms and limitations of activity of people with traumatic brain injury: A ten-year follow-up	PSYCHOLOGICAL REPORTS			English	Article							HEAD-INJURY; YOUNG-ADULTS; MILD; INDIVIDUALS; IMPAIRMENT; DEPRESSION; COMPLAINTS; RECOVERY; MODERATE; OUTCOMES	This study examined the effect of Traumatic Brain Injury 10 years post-injury. Frequencies of head injury symptoms and activity limitation by level of severity were measured in a consecutive series of 61 adults who were admitted to a tertiary-care center for traumatic brain injury. Irritability and Anxiety were the most frequently reported symptoms from the Head Injury Symptom Checklist. Bothered by noise and Bothered by light were the least frequently reported. Trouble hearing what is said in a group conversation and Trouble hearing what is said in a one-to-one conversation were the most commonly reported limitations of activity from the Health and Activity Limitations Survey. Overall, this study illustrates that symptoms remain many years following brain injury, irrespective of the injury's severity.	Univ Toronto, Toronto Rehabil Inst, Grad Dept Rehabil Sci, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M5S 1A1, Canada		Colantonio, A (corresponding author), Ctr Funct & Wellbeing, Rehabil Sci Bldg,500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.			Colantonio, Angela/0000-0003-2094-4765			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1977, LANCET, V1, P878; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ocana M, 2000, BRAIN COGNITION, V44, P83, DOI 10.1006/brcg.1999.1211; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; *STAT CAN, 1988, HLTH ACT LIM SURV US; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	35	60	60	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-2941	1558-691X		PSYCHOL REP	Psychol. Rep.	AUG	2005	97	1					169	179		10.2466/PR0.97.5.169-179			11	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	970MT	WOS:000232315000026	16279322				2022-02-06	
J	Straume-Naesheim, TM; Andersen, TE; Dvorak, J; Bahr, R				Straume-Naesheim, TM; Andersen, TE; Dvorak, J; Bahr, R			Effects of heading exposure and previous concussions on neuropsychological performance among Norwegian elite footballers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							COMPUTERIZED COGNITIVE ASSESSMENT; BRAIN-INJURY; SOCCER; IMPAIRMENT; FREQUENCY; RECOVERY; IMPACT	Background: Cross-sectional studies have indicated that neurocognitive performance may be impaired among football players. Heading the ball has been suggested as the cause, but recent reviews state that the reported deficits are more likely to be the result of head injuries. Objective: To examine the association between previous concussions and heading exposure with performance on computer based neuropsychological tests among professional Norwegian football players. Methods: Players in the Norwegian professional football league (Tippeligaen) performed two consecutive baseline neuropsychological tests (Cogsport) before the 2004 season (90.3% participation, n = 271) and completed a questionnaire assessing previous concussions, match heading exposure (self-reported number of heading actions per match), player career, etc. Heading actions for 18 players observed in two to four matches were counted and correlated with their self-reported values. Results: Neither match nor lifetime heading exposure was associated with neuropsychological test performance. Nineteen players scored below the 95% confidence interval for one or more subtasks, but they did not differ from the rest regarding the number of previous concussions or lifetime or match heading exposure. The number of previous concussions was positively associated with lifetime heading exposure (exponent (B) = 1.97(1.03-3.75), p =0.039), but there was no relation between previous concussions and test performance. Self-reported number of headings correlated well with the observed values (Spearman's rho = 0.77, p<0.001). Conclusion: Computerised neuropsyckological testing revealed no evidence of neuropsychological impairment due to heading exposure or previous concussions in a cohort of Norwegian professional football players.	Oslo Sports Trauma & Res Ctr, Oslo, Norway; FIFA Med Assessment & Res Ctr, Zurich, Switzerland; Norwegian Univ Sport & Phys Educ, Oslo, Norway		Straume-Naesheim, TM (corresponding author), Oslo Sports Trauma & Res Ctr, Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Andersen, Thor Einar/0000-0003-4172-4518; Bahr, Roald/0000-0001-5725-4237			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BANGSBO J, 1991, CAN J SPORT SCI, V16, P110; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, 2005, SPORTS NEUROPSYCHOLO; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Mollica CM, 2004, HUM PSYCHOPHARM CLIN, V19, P445, DOI 10.1002/hup.624; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Westerman R., 2001, ADF HLTH, V2, P29; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	44	60	61	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I70	I77		10.1136/bjsm.2005.019646			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	954KI	WOS:000231153600010	16046359	Green Published, Bronze			2022-02-06	
J	Withnall, C; Shewchenko, N; Gittens, R; Dvorak, J				Withnall, C; Shewchenko, N; Gittens, R; Dvorak, J			Biomechanical investigation of head impacts in football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SOCCER PLAYERS; BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION	Objectives: This study sought to measure the head accelerations induced from upper extremity to head and head to head impact during the game of football and relate this to the risk of mild traumatic brain injury using the Head Impact Power (HIP) index. Furthermore, measurement of upper neck forces and torques will indicate the potential for serious neck injury. More stringent rules or punitive sanctions may be warranted for intentional impact by the upper extremity or head during game play. Methods: Game video of 62 cases of head impact (38% caused by the upper extremity and 30% by the head of the opposing player) was provided by F-MARC. Video analysis revealed the typical impact configurations and representative impact speeds. Upper extremity impacts of elbow strike and lateral hand strike were re-enacted in the laboratory by five volunteer football players striking an instrumented Hybrid III pedestrian model crash test manikin. Head to head impacts were re-enacted using two instrumented test manikins. Results: Elbow to head impacts (1.7-4.6 m/s) and lateral hand strikes (5.2-9.3 m/s) resulted in low risk of concussion (<5%) and severe neck injury (<5%). Head to head impacts (1.5-3.0 m/s) resulted in high concussion risk (up to 67%) but low risk of severe neck injury (<5%). Conclusion: The laboratory simulations suggest little risk of concussion based on head accelerations and maximum HIP. There is no biomechanical justification for harsher penalties in this regard. However,. deliberate use of the head to impact another player's head poses a high risk of concussion, and justifies a harsher position by regulatory bodies. In either case the risk of serious neck injury is very low.	FIFA Med Assessment & Res Ctr, Zurich, Switzerland			withnall@biokinetics.com					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; ANDERSEN TE, 2003, BRIT J SPORT MED, V37, P326; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; DiMasi FP, 1995, TRANSFORMATION 9 ACC; FULLER C, 2005, BR J SPORTS MED S10, V20, pR30; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 1997, SAFETY SCI, V27, P115; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; MATSER E, 2001, BRIT J SPORT MED, V35, P373; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Nahum AM, 2002, ACCIDENTAL INJURY BI; Newman J, 2000, NEW BIOMECHANICAL 2; NEWMAN J, 2005, IN PRESS J BIOMECH; NEWMAN J, 1999, NEW BIOMECHANICAL 1; Newman J, 2000, 44 STAPP CAR CRASH C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; *SAE, 1995, SAE HDB; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	29	60	60	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I49	I57		10.1136/bjsm.2005.019182			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	954KI	WOS:000231153600007	16046356	Green Published, Bronze			2022-02-06	
J	Sherer, M; Nakase-Thompson, R; Yablon, SA; Gontkovsky, ST				Sherer, M; Nakase-Thompson, R; Yablon, SA; Gontkovsky, ST			Multidimensional assessment of acute confusion after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amnesia; brain injuries; confusion; delirium; rehabilitation	MEDICINE-AND-REHABILITATION; POSTTRAUMATIC AMNESIA; COGNITIVE TEST; HEAD-INJURIES; RATING-SCALE; PRACTICAL SCALE; DELIRIUM; VALIDATION; ORIENTATION; DEFINITION	Objectives: To describe the phenomenology of posttraumatic confusional state (PTCS) and to provide preliminary validation of a new procedure, the Confusion Assessment Protocol (CAP), for assessing PTCS. Design: Criterion standard investigation. Setting: Inpatient traumatic brain injury (TBI) rehabilitation program. Participants: Two consecutive series of patients (n = 62, n = 93) with TBI admitted for inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measures: Clinical diagnosis of delirium based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, classification of posttraumatic amnesia (PTA) based on the Galveston Orientation and Amnesia Test (GOAT), and Disability Rating Scale score at time of rehabilitation hospital discharge. Results: Agreement between the diagnosis of PTCS with the CAP and DSM-IV classification of delirium was 87%, and agreement between PTCS and PTA using GOAT criteria was 90%. Patients classified as in PTCS sustained more severe injuries and required longer rehabilitation stays. Confusion status was associated with poorer functional status at rehabilitation discharge. Conclusions: The CAP is a brief, structured, repeatable measure of multiple neurobehavioral aspects of PTCS. Confusion status as determined by CAP assessment contributed to prediction of outcome at rehabilitation discharge after adjustment for other potential predictors.	Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA		Sherer, M (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goodglass H, 1983, ASSESSMENT APHASIA R; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCEVOY JP, 1981, ANN INTERN MED, V95, P212, DOI 10.7326/0003-4819-95-2-212; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Neelon VJ, 1996, NURS RES, V45, P324, DOI 10.1097/00006199-199611000-00002; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russell WR, 1935, LANCET, V2, P762; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TEASDALE G, 1974, LANCET, V2, P81; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1994, AM PSYCHIATRIC PR, P189; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	31	60	61	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					896	904		10.1016/j.apmr.2004.09.029			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	928NM	WOS:000229278500008	15895334				2022-02-06	
J	Hart, T; Whyte, J; Polansky, M; Kersey-Matusiak, G; Fidler-Sheppard, R				Hart, T; Whyte, J; Polansky, M; Kersey-Matusiak, G; Fidler-Sheppard, R			Community outcomes following traumatic brain injury - Impact of race and preinjury status	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		community integration; outcome measurement; race; traumatic brain injury	SPINAL-CORD-INJURY; BLACK-WHITE DIFFERENCES; QUALITY-OF-LIFE; INTEGRATION QUESTIONNAIRE; PRACTICAL SCALE; RATING-SCALE; HEAD TRAUMA; MODEL; SATISFACTION; RETURN	Objective: To investigate the contribution of preinjury differences and potential biases in outcome measurement in explaining outcome differences between white and African American persons with moderate and severe traumatic brain injury (TBI). Design: Prospective, 2 group longitudinal study with retrospective self-assessment of preinjury status. Setting: Inpatient and outpatient TBI rehabilitation program: Participants: Ninety-four persons with moderate and severe TBI (55 whites and 39 African Americans) who provided data on both preinjury status and. 1-year outcome. Measures: Community Integration Questionnaire, aggression and depression subscales of Neurobehavioral Functioning Inventory-Revised, Satisfaction With Life Scale, other questions on demographic and social status; all measures were selected by a biracial focus group. Results: Whites and African Americans did not differ significantly on demographic factors ' except gender; nor on retrospective, self-reported preinjury status on any of the outcome measures. At 1 year post-TBI, African Americans reported significantly lower social integration subscale scores than whites. African Americans may also have lost more income than did whites. All other outcome measures were comparable between, group's and showed declines in community productivity, increases in depression symptoms, and lower satisfaction with life for both whites and African limericans compared to preinjury A higher rate of change in living situation post-TBI may partially account for lower levels of social integration for African Americans. Conclusion: Whites and African Americans who are comparable prior to injury may experience generally similar outcomes, but differences in social and financial outcomes require further investigation.	Moss Rehabilitat Res Inst, Philadelphia, PA 19141 USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA USA; Holy Family Univ, MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Holy Family Univ, Sch Nursing, Philadelphia, PA USA		Hart, T (corresponding author), Moss Rehabilitat Res Inst, 1200 W Tabor Rd,Korman Suite 213, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Hart T, 2003, REHABIL PSYCHOL, V48, P86, DOI 10.1037/0090-5550.48.2.86; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; *KESSL MED REH RES, 2002, TRAUM BRAIN INJ FACT, V8; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Neville HA, 2000, REHABIL PSYCHOL, V45, P89, DOI 10.1037/0090-5550.45.1.89; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P1603, DOI 10.1053/apmr.2002.35115; Raley RK, 1996, AM SOCIOL REV, V61, P973, DOI 10.2307/2096303; RALEY RK, 1995, J FAM ISSUES, V16, P77, DOI 10.1177/019251395016001005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Sue S, 1999, AM PSYCHOL, V54, P1070, DOI 10.1037/0003-066X.54.12.1070; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uswatte G, 1997, REHABIL PSYCHOL, V42, P61, DOI 10.1037/0090-5550.42.1.61; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	34	60	60	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					158	172		10.1097/00001199-200503000-00004			15	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200004	15803039				2022-02-06	
J	Rotondi, AJ; Sinkule, J; Spring, M				Rotondi, AJ; Sinkule, J; Spring, M			An interactive web-based intervention for persons with TBI and their families - Use and evaluation by female significant others	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; social support; Web site; intervention; female significant other; telehealth	TRAUMATIC BRAIN-INJURY; COMPUTER-MEDIATED COMMUNICATION; SEVERE HEAD-INJURY; SOCIAL SUPPORT; RELATIVES; CAREGIVERS; SYMPTOMS; DISTRESS; SPOUSES; TELEREHABILITATION	Objective: To assess the feasibility of providing in-home adjunctive and supportive services to per sons with traumatic brain injury (TBI) and their families via a Web site. Design: Nineteen families were provided with access to the Web site intervention for 6 months. Those who needed it were provided with a computer and Internet service in their homes. Participants: Adult women who were the significant others of adult males with moderate-to-severe TBI. Main Outcome Measure: Value and ease of use of the Web site. Each participant's usage of the Web site was automatically tracked including each page visited, time of day, and time spent on the page. Results: Female significant others found the Web site to be valuable and easy to use, and used it throughout the 6-month period. The on-line support group was the most used and valued module. Conclusions: Family caregivers will use Web-based interventions to help meet their needs for social support, information, and guidance following the return home of persons with TBI.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; Univ Pittsburgh, Dept Informat Sci, Pittsburgh, PA 15260 USA		Rotondi, AJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	rotondi@pitt.edu					Acorn S, 1992, J Neurosci Nurs, V24, P324; ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; Alemi F, 1997, J MED SYST, V21, P119, DOI 10.1023/A:1022846408428; ALEMI F, 1996, MED CARE, V34, P10; Brennan P F, 1994, Int J Technol Assess Health Care, V10, P258; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bull M J, 1990, West J Nurs Res, V12, P758, DOI 10.1177/019394599001200605; Campbell C H, 1988, Rehabil Nurs, V13, P320; CARNWATH TCM, 1987, BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Dew MA, 2004, J HEART LUNG TRANSPL, V23, P745, DOI 10.1016/j.healun.2003.07.002; DUCK SW, 1990, PERSONAL RELATIONSHI; Dunham PJ, 1998, AM J COMMUN PSYCHOL, V26, P281, DOI 10.1023/A:1022132720104; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; Gustafson D H, 1992, Proc Annu Symp Comput Appl Med Care, P161; Gustafson David, 1993, Journal of Psychosocial Oncology, V11, P69; Gustafson DH, 1999, AM J PREV MED, V16, P23, DOI 10.1016/S0749-3797(98)00104-4; HARE AP, 1962, HDB SMALL GROUP RES, P60; Hare AP, 1962, HDB SMALL GROUP RES; HORRIGAN J, 2003, EVER SHIFTING INTERN; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KIESLER S, 1984, AM PSYCHOL, V39, P1123, DOI 10.1037/0003-066X.39.10.1123; Kim M. S., 1991, ANN M INT COMM ASS M; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; KOLLOCK P, 1999, COMMUNITIES CYBERSPA, P109; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kristjanson L J, 1995, J Nurs Meas, V3, P109; Leathem J, 1996, BRAIN INJURY, V10, P27; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levy L. H., 1979, SELF HELP GROUPS COP, P234; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Liss HJ, 2002, REHABIL PSYCHOL, V47, P8, DOI 10.1037/0090-5550.47.1.8; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McKay HG, 2002, REHABIL PSYCHOL, V47, P31, DOI 10.1037/0090-5550.47.1.31; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; PIERCE G, 1994, COMMUNICATION SOCIAL, P241; RICE RE, 1987, COMMUN RES, V14, P85, DOI 10.1177/009365087014001005; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; ROBERTS LJ, 1991, AM J COMMUN PSYCHOL, V19, P715, DOI 10.1007/BF00938041; Rogers P M, 1984, J Neurosurg Nurs, V16, P343; Rolnick SJ, 1999, NURS OUTLOOK, V47, P78, DOI 10.1016/S0029-6554(99)90074-X; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; SPOONER T, 2001, AFRICAN AM INTERNET; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Winzelberg A, 1997, COMPUT HUM BEHAV, V13, P393, DOI 10.1016/S0747-5632(97)00016-2; ZEIGLER EA, 1987, J REHABIL, V53, P50; [No title captured]	66	60	61	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					173	185		10.1097/00001199-200503000-00005			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200005	15803040				2022-02-06	
J	Schuknecht, B; Graetz, K				Schuknecht, B; Graetz, K			Radiologic assessment of maxillofacial, mandibular, and skull base trauma	EUROPEAN RADIOLOGY			English	Article						computed tomography; cranial nerve; magnetic resonance; mandibula; maxillofacial injury; orbit; temporal bone; trauma	FRACTURES; CT; CLASSIFICATION; DIAGNOSIS; INJURIES	Cranio-maxillofacial injuries affect a significant proportion of trauma patients either in isolation or concurring with other serious injuries. Contrary to maxillofacial injuries that result from a direct impact, central skull base and lateral skull base (petrous bone) fractures usually are caused by a lateral or sagittal directed force to the skull and therefore are indirect fractures. The traditional strong role of conventional images in patients with isolated trauma to the viscerocranium is decreasing. Spiral multislice CT is progressively replacing the panoramic radiograph, Waters view, and axial films for maxillofacial trauma, and is increasingly being performed in addition to conventional films to detail and classify trauma to the mandible as well. Imaging thus contributes to accurately categorizing mandibular fractures based on location, into 11 alveolar, mandibular proper, and condylar fractures-the last are subdivided into intracapsular and extracapsular fractures. In the midface, CT facilitates attribution of trauma to the categories central, lateral, or combined centrolateral fractures. The last frequently encompass orbital trauma as well. CT is the imaging technique of choice to display the multiplicity of fragments, the degree of dislocation and rotation, or skull base involvement. Transsphenoid skull base fractures are classified into transverse and oblique types; lateral base (temporal bone) trauma is subdivided into longitudinal and transverse fractures. Supplementary MR examinations are required when a cranial nerve palsy occurs in order to recognize neural compression. Early and late complications of trauma related to the orbit, anterior cranial fossa, or lateral skull base due to infection, brain concussion, or herniation require CT to visualize the osseous prerequisites of complications, and MR to define the adjacent brain and soft tissue involvement.	Univ Zurich Hosp, Inst Neuroradiol, CH-8091 Zurich, Switzerland; MRI Med Radiodiagnost Inst, CH-8044 Zurich, Switzerland; Univ Zurich Hosp, Dept Maxillofacial Surg, CH-8091 Zurich, Switzerland		Schuknecht, B (corresponding author), Univ Zurich Hosp, Inst Neuroradiol, Frauenklin Str 10, CH-8091 Zurich, Switzerland.	image-solution@ggaweb.ch					ASSAEL LA, 1993, RADIOL CLIN N AM, V31, P209; Chacon GE, 2003, J ORAL MAXIL SURG, V61, P668, DOI 10.1053/joms.2003.50134; Donat TL, 1998, ARCH OTOLARYNGOL, V124, P1306, DOI 10.1001/archotol.124.12.1306; ERNST A, 2004, TRAUMATOLOGIE KOPFHA; Fabian TS, 1999, J TRAUMA, V47, P275, DOI 10.1097/00005373-199908000-00009; Freund M, 2002, EUR RADIOL, V12, P1127, DOI 10.1007/s00330-001-1167-3; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; GRAETZ K, 1986, THESIS BASEL; HAUG RH, 1993, CRANIOMAXILLOFACIAL, P90; Ho VT, 1996, AM J NEURORADIOL, V17, P134; Kuhn F, 1996, Eur J Ophthalmol, V6, P464; Le Fort R, 1901, REV CHIRURG, V23, P208; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; LEVY RA, 1992, AM J NEURORADIOL, V13, P885; Linnau KF, 2003, EUR J RADIOL, V48, P5, DOI 10.1016/S0720-048X(03)00203-1; Linneau KF, 2003, EUR J RADIOL, V48, P17, DOI 10.1016/S0720-048X(03)00205-5; Manson PN, 1999, PLAST RECONSTR SURG, V103, P1287, DOI 10.1097/00006534-199904040-00031; Martello JY, 1997, ANN PLAS SURG, V38, P223, DOI 10.1097/00000637-199703000-00006; MATHOG RH, 1984, MAXILLOFACIAL TRAUMA; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; Rhea JT, 1999, RADIOL CLIN N AM, V37, P489, DOI 10.1016/S0033-8389(05)70108-1; Salvolini U, 2002, EUR RADIOL, V12, P1253, DOI 10.1007/s00330-002-1445-8; SartorettiSchefer S, 1997, AM J NEURORADIOL, V18, P1115; Schuknecht B, 2003, NEUROIMAG CLIN N AM, V13, P605, DOI 10.1016/S1052-5149(03)00044-3; Schuknecht B, 1996, NEURORADIOLOGY, V38, P470; Stone JA, 1999, AM J NEURORADIOL, V20, P706; WEST OC, 1993, RADIOLOGY, V188, P329, DOI 10.1148/radiology.188.2.8327674; Yeakley J W, 1999, Curr Probl Diagn Radiol, V28, P65, DOI 10.1016/S0363-0188(99)90002-6; ZINGG M, 1992, J ORAL MAXIL SURG, V50, P778, DOI 10.1016/0278-2391(92)90266-3	29	60	66	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					560	568		10.1007/s00330-004-2631-7			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500017	15662492	Green Submitted, Green Accepted			2022-02-06	
J	Hauser, CJ				Hauser, CJ			Preclinical models of traumatic, hemorrhagic shock	SHOCK			English	Article; Proceedings Paper	Symposium on the Translational Biology of Shock and Sepsis	JUN 04-06, 2004	Lunenburg, CANADA			hemorrhagic shock; shock syndromes; tissue hypoperfusion; acidosis	BRAIN-INJURY; GUINEA-PIGS; NITRIC-OXIDE; LUNG INJURY; UNCONTROLLED HEMORRHAGE; INFLAMMATORY RESPONSE; NEUTROPHIL ACTIVATION; COMPLEMENT ACTIVATION; EXOGENOUS UBIQUITIN; FLUID RESUSCITATION		Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, Newark, NJ 07103 USA		Hauser, CJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, MSB G-524,185 S Orange Ave, Newark, NJ 07103 USA.	hausercj@UMDNJ.edu	Hauser, Carl J./Y-1189-2019	Hauser, Carl/0000-0003-3167-1846	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-59179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM059179] Funding Source: NIH RePORTER		AbdelZaher AO, 1996, JPN J PHARMACOL, V72, P247, DOI 10.1254/jjp.72.247; Adachi T, 1998, SHOCK, V9, P204, DOI 10.1097/00024382-199803000-00008; Adams CA, 2002, SHOCK, V18, P513, DOI 10.1097/00024382-200212000-00005; Aguilar MM, 1998, J TRAUMA, V45, P14, DOI 10.1097/00005373-199807000-00003; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Alam HB, 2003, J TRAUMA, V54, P1077, DOI 10.1097/01.TA.0000068258.99048.70; Anderson JT, 1997, J TRAUMA, V42, P592, DOI 10.1097/00005373-199704000-00003; Anderson JT, 1997, J TRAUMA, V42, P600; Block EFJ, 2004, J TRAUMA, V56, P999; Boura C, 2003, SHOCK, V19, P176, DOI 10.1097/00024382-200302000-00015; BROWN WJ, 1972, AM J PATHOL, V67, P41; Brundage SI, 2003, J SURG RES, V113, P74, DOI 10.1016/S0022-4804(03)00129-X; Bruscagin V, 2002, J TRAUMA, V52, P1147, DOI 10.1097/00005373-200206000-00021; CHA SC, 1992, CAN J PHYSIOL PHARM, V70, P669, DOI 10.1139/y92-085; Chang EF, 2003, J NEUROSCI, V23, P3689; Chiara O, 2003, CRIT CARE MED, V31, P1915, DOI 10.1097/01.CCM.0000074725.62991.42; Claridge JA, 2002, CRIT CARE MED, V30, P1815, DOI 10.1097/00003246-200208000-00024; Clasper JC, 2002, INJURY, V33, P157, DOI 10.1016/S0020-1383(01)00136-X; Cruz RJ, 2001, INJURY, V32, P17, DOI 10.1016/S0020-1383(00)00097-8; DEITCH EA, 1994, SHOCK, V1, P141, DOI 10.1097/00024382-199402000-00010; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DEMARIA EJ, 1987, J SURG RES, V43, P45, DOI 10.1016/0022-4804(87)90045-X; DEMLING RH, 1975, SURGERY, V77, P512; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; Dingley J, 1999, CRIT CARE MED, V27, P2435, DOI 10.1097/00003246-199911000-00019; Dodd KT, 1997, J TRAUMA, V43, P656, DOI 10.1097/00005373-199710000-00016; Doucet JJ, 2004, J TRAUMA, V56, P501, DOI 10.1097/01.TA.0000114536.98447.F7; Driessen B, 2003, CRIT CARE MED, V31, P1771, DOI 10.1097/01.CCM.0000063476.79749.C1; Eckhoff DE, 2002, SURGERY, V132, P302, DOI 10.1067/msy.2002.125718; Eissner B, 2002, EUR SURG RES, V34, P61, DOI 10.1159/000048889; Gonzalez RJ, 2001, J TRAUMA, V51, P1069, DOI 10.1097/00005373-200112000-00008; GORANSSON AM, 1982, ACTA CHIR SCAND, P153; Gorbunov NV, 2004, CRIT CARE MED, V32, P1028, DOI 10.1097/01.CCM.0000120051.79520.B6; Guan J, 2002, J TRAUMA, V52, P104, DOI 10.1097/00005373-200201000-00018; Harkness J. E., 1989, BIOL MED RABBITS ROD; HEIDEMAN M, 1978, J TRAUMA, V18, P696, DOI 10.1097/00005373-197810000-00002; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hewitt PM, 2002, INJURY, V33, P673, DOI 10.1016/S0020-1383(02)00095-5; JANSSON I, 1985, J TRAUMA, V25, P288, DOI 10.1097/00005373-198504000-00002; Jarrar D, 2000, ANN SURG, V231, P399, DOI 10.1097/00000658-200003000-00013; JONSSON A, 1979, AVIAT SPACE ENVIR MD, V50, P325; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; Kneidinger R, 1996, J LAB CLIN MED, V128, P515, DOI 10.1016/S0022-2143(96)90049-9; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Knoferl MW, 2001, SHOCK, V16, P479, DOI 10.1097/00024382-200116060-00013; KOCH T, 1993, CRIT CARE MED, V21, P1758, DOI 10.1097/00003246-199311000-00027; Krausz MM, 2003, SHOCK, V20, P444, DOI 10.1097/01.shk.0000094560.76615.91; Kretschmar K, 1991, Acta Histochem Suppl, V41, P265; Kuebler JF, 2003, SHOCK, V20, P144, DOI 10.1097/01.shk.0000072127.33223.f1; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; Lin YS, 2000, EUR J PHARMACOL, V394, P139, DOI 10.1016/S0014-2999(00)00126-6; Liu FF, 1996, RADIOTHER ONCOL, V40, P75, DOI 10.1016/0167-8140(96)01733-1; Liu LM, 2004, SHOCK, V21, P93, DOI 10.1097/01.shk.0000097247.97298.0e; Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011; Lu Qi, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P325; Mackrell PJ, 2001, SURGERY, V130, P826, DOI 10.1067/msy.2001.116669; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; MARTINS MA, 1990, CRIT CARE MED, V18, P515, DOI 10.1097/00003246-199005000-00011; McDonough KH, 2002, J TRAUMA, V53, P541, DOI 10.1097/00005373-200209000-00024; McDonough KH, 2000, J TRAUMA, V48, P1122, DOI 10.1097/00005373-200006000-00020; MEI JM, 1995, SHOCK, V4, P421; Mousavi M, 2001, INJURY, V32, P679, DOI 10.1016/S0020-1383(01)00048-1; Munster AMB, 2001, BLOOD COAGUL FIBRIN, V12, P477, DOI 10.1097/00001721-200109000-00008; NAKANE T, 1985, P NATL ACAD SCI USA, V82, P1247, DOI 10.1073/pnas.82.4.1247; Nielsen VG, 2001, ANESTH ANALG, V93, P1106, DOI 10.1097/00000539-200111000-00007; Nielsen VG, 2001, J CRIT CARE, V16, P64, DOI 10.1053/jcrc.2001.26292; Nwariaku F, 1996, J TRAUMA, V40, P564, DOI 10.1097/00005373-199604000-00007; Oda J, 2002, J TRAUMA, V52, P625, DOI 10.1097/00005373-200204000-00003; Pape HC, 1998, J TRAUMA, V45, P720, DOI 10.1097/00005373-199810000-00017; Pape HC, 1998, INTENS CARE MED, V24, P590, DOI 10.1007/s001340050620; PAPE HC, 1995, EUR J SURG, V161, P304; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; Premier RR, 1998, IMMUNOLOGY, V94, P363, DOI 10.1046/j.1365-2567.1998.00522.x; PRETORIUS JP, 1987, J TRAUMA, V27, P1344, DOI 10.1097/00005373-198712000-00005; REDL H, 1991, AM J PATHOL, V139, P461; REDL H, 1989, RESUSCITATION, V17, P77, DOI 10.1016/0300-9572(89)90081-6; REDL H, 1995, SHOCK, V3, P395; ROUHANA SW, 1985, J TRAUMA, V25, P490, DOI 10.1097/00005373-198506000-00004; Sato S, 1997, SHOCK, V8, P136, DOI 10.1097/00024382-199708000-00013; Schlag G, 1999, CRIT CARE MED, V27, P1900, DOI 10.1097/00003246-199909000-00031; SCHMAND JF, 1994, CRIT CARE MED, V22, P1076, DOI 10.1097/00003246-199407000-00005; SCHMIDT GH, 1967, J SURG RES, V7, P513, DOI 10.1016/0022-4804(67)90020-0; Soller BR, 2003, J SURG RES, V114, P195, DOI 10.1016/S0022-4804(03)00251-8; STAUB NC, 1974, LYMPHOLOGY, V7, P96; Strong VEM, 2000, SHOCK, V14, P374; Swafford AN, 2003, SHOCK, V20, P237, DOI 10.1097/00024382-200309000-00007; Szebeni J, 2003, SHOCK, V20, P347, DOI 10.1097/01.shk.0000082444.66379.17; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; van Iterson M, 2003, J TRAUMA, V55, P1111, DOI 10.1097/01.TA.0000101391.58216.DD; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WADE L, 1970, AM J VET RES, V31, P1375; White DJ, 2004, CRIT CARE MED, V32, P1338, DOI 10.1097/01.CCM.0000128571.39037.09; Wichmann MW, 1996, ARCH SURG-CHICAGO, V131, P995; WIGGERS CJ, 1950, PHYSL SHOCK, P121; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F; Zakaria ER, 2004, SHOCK, V21, P248, DOI 10.1097/01.shk.0000111824.07309.19	98	60	61	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock		2005	24			1			24	32		10.1097/01.shk.0000191387.18818.43			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	999XR	WOS:000234425400005	16374369				2022-02-06	
J	Mateer, CA; Sira, CS; O'Connell, ME				Mateer, CA; Sira, CS; O'Connell, ME			Putting humpty dumpty together again - The importance of integrating cognitive and emotional interventions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive rehabilitation; mood and anxiety disorders; multimodal interventions; psychotherapy	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; MEMORY PERFORMANCE; METAMEMORY; DEPRESSION; SUICIDE; STRESS	Acquired brain injury commonly results in both cognitive and emotional sequela, and it is increasingly recognized that these domains of functioning interact. Consequently, interventions directed at only or primarily one domain may be confounded by this interaction. To maximize treatment potential, we believe cognitive rehabilitation must integrate both cognitive and emotional interventions, and attend to belief systems about, and affective responses to, cognitive challenges. We review the scant literature addressing the impact of combined interventions for clients with acquired brain injury. Integrated with these reviews are 2 case studies that appear to break treatment "myths." Specifically, we address the notion that emotion-focused treatments are appropriate only for clients with awareness or insight and the notion that cognitive interventions arc ineffective, and potentially even contraindicated, for clients whose profile suggests emotional distress and functional, as opposed to neurological, impairments. In each of these cases, we demonstrate that combining cognitive and emotional interventions was not only effective but also even more valuable than previous treatment approaches aimed exclusively at one domain. We conclude by emphasizing the importance of understanding emotional response to, and beliefs about, cognitive difficulties in developing effective interventions.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	cmateer@uvic.ca	O'Connell, Megan/A-4691-2012				BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; CAVANAUGH JC, 1989, PSYCHOL AGING, V4, P365, DOI 10.1037/0882-7974.4.3.365; Dobson KS, 2001, HDB COGNITIVE BEHAV; ELLIOTT E, 1989, ADV PSYCHOL PSYCHOL; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hayes JS, 1998, ARCH CLIN NEUROPSYCH, V13, P27; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOBSON P, 2002, CRADLE THOUGHT EXPLO, V13; Jonker C, 1997, EDUC GERONTOL, V23, P115, DOI 10.1080/0360127970230203; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; ROSENTHAL M, 1990, REHABILIATION ADULT; SAWCHYN JM, IN PRESS J HEAD TRAU; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SIRA CS, 2004, 6 ANN REH PSYCH DIV; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SYMONDS CP, 1937, P ROY SOC MED, V30, P1092; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teasdale TW, 2001, J EPIDEMIOL COMMUN H, V55, P863, DOI 10.1136/jech.55.12.863; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; WEBMAN P, 1988, J HEAD TRAUMA REHAB, V3, P82; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; [No title captured]	35	60	60	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					62	75		10.1097/00001199-200501000-00007			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900006	15668571				2022-02-06	
J	Serbest, G; Horwitz, J; Barbee, K				Serbest, G; Horwitz, J; Barbee, K			The effect of Poloxamer-188 on neuronal cell recovery from mechanical injury	JOURNAL OF NEUROTRAUMA			English	Article						membrane damage; neuronal cells; Poloxamer; shear stress; traumatic brain injury	IN-VITRO MODEL; TRAUMATIC BRAIN-INJURY; STRAIN-RATE; PC12 CELLS; GROWTH; APOPTOSIS; GLUTAMATE; CALCIUM; DEATH; DIFFERENTIATION	Neuronal injury resulting from mechanical deformation is poorly characterized at the cellular level. The immediate structural consequences of the mechanical loading lead to a variety of inter- and intra-cellular signaling events that interact on multiple time and length scales. Thus, it is often difficult to establish cause-and-effect relationships such that appropriate treatment strategies can be devised. In this report, we showed that treating mechanically injured neuronal cells with an agent that promotes the resealing of disrupted plasma membranes rescues them from death at 24 h post-injury. A new in vitro model was developed to allow uniform mechanical loading conditions with precisely controlled magnitude and onset rate of loading. Injury severity increased monotonically with increasing peak shear stress and was strongly dependent on the rate of loading as assessed with the MTT cell viability assay, 24 h post-injury. Mechanical injury produced an immediate disruption of membrane integrity as indicated by a rapid and transient release of LDH. For the most severe injury, cell viability decreased approximately 40% with mechanical trauma compared to sham controls. Treatment of cells with Poloxamer 188 at 15 min post-injury restored long-term viability to control values. These data establish membrane integrity as a novel therapeutic target in the treatment of neuronal injury.	Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, Philadelphia, PA 19104 USA; Pharmacol Drexel Univ, Coll Med, Philadelphia, PA USA		Barbee, K (corresponding author), Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, Philadelphia, PA 19104 USA.	barbee@coe.drexel.edu	Barbee, Kenneth/F-4333-2014		ODCDC CDC HHS [R49/CCR316574-01-3] Funding Source: Medline		Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765, DOI 10.1152/ajpheart.1995.268.4.H1765; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Colowick S.C., 1993, METHODS ENZYMOLOGY, V2nd ed.; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; EDLICH RF, 1973, J SURG RES, V14, P277, DOI 10.1016/0022-4804(73)90029-2; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; Hannig J, 2000, RADIAT RES, V154, P171, DOI 10.1667/0033-7587(2000)154[0171:SSOMPB]2.0.CO;2; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heneka MT, 1998, J NEUROCHEM, V71, P88; KABANOV AV, 1995, MACROMOLECULES, V28, P2303, DOI 10.1021/ma00111a026; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; Kitazawa M, 2004, NEUROTOXICOLOGY, V25, P589, DOI 10.1016/j.neuro.2003.09.014; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; SCHMOLKA IR, 1977, J AM OIL CHEM SOC, V54, P110, DOI 10.1007/BF02894385; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; TAHIR SK, 1992, BIOCHEM CELL BIOL, V70, P1159, DOI 10.1139/o92-162; Terry MA, 1999, ANN NY ACAD SCI, V888, P274, DOI 10.1111/j.1749-6632.1999.tb07962.x; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Verma A, 2000, J HEAD TRAUMA REHAB, V15, P1149, DOI 10.1097/00001199-200010000-00008; Yang E, 2004, CELL MOL NEUROBIOL, V24, P181, DOI 10.1023/B:CEMN.0000018615.84358.33; ZHELEV DV, 1993, BIOCHIM BIOPHYS ACTA, V1147, P89, DOI 10.1016/0005-2736(93)90319-U	58	60	63	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					119	132		10.1089/neu.2005.22.119			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600008	15665607				2022-02-06	
J	Serra-Grabulosa, JM; Junque, C; Verger, K; Salgado-Pineda, P; Maneru, C; Mercader, JM				Serra-Grabulosa, JM; Junque, C; Verger, K; Salgado-Pineda, P; Maneru, C; Mercader, JM			Cerebral correlates of declarative memory dysfunctions in early traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; HIPPOCAMPAL-FORMATION; CHILDREN; MR; NEUROGENESIS; ADOLESCENTS; STRIATUM; ATROPHY; VOLUME	We investigated residual brain damage in subjects who suffered severe traumatic brain injury (TBI) in childhood, and its relationship with declarative memory impairment. Magnetic resonance imaging (MRI) volumetric data and memory performance were compared between 16 adolescents with antecedents of severe TBI and 16 matched normal controls. Volumes of grey matter, white matter, cerebrospinal fluid (CSF), hippocampus, and caudate nuclei were measured. Verbal memory was assessed by the Rey's Auditory Verbal Learning test and visual memory by the Rey's Complex Figure. TBI patients performed significantly worse than controls in both verbal and visual memory. Patients presented decreased white matter volume and increased CSF. The hippocampus was reduced, but not the caudate nuclei. Memory performance correlated with CSF. Plasticity is incomplete for structural and functional deficits in children with TBI. Hippocampal atrophy, white matter loss, and memory impairment remain until adolescence. Memory sequelae are related more to diffuse brain injury, as reflected by MRI findings of increased CSF, than to hippocampal injury.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona 08035, Spain; Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; Hosp Clin Barcelona, Ctr Diagnost Imatge, Barcelona, Spain		Serra-Grabulosa, JM (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Pg Vall Hebron 171, Barcelona 08035, Spain.	jmserra@ub.edu	Vendrell, Pere/B-4392-2011; Serra-Grabulosa, Josep M/S-8371-2019; Junque, Carme/B-4400-2011; Serra-Grabulosa, Josep M/B-4655-2011	Vendrell, Pere/0000-0001-8918-5440; Serra-Grabulosa, Josep M/0000-0002-4291-9432; Junque, Carme/0000-0002-6381-3063; Salgado-Pineda, Pilar/0000-0001-7720-0885			BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREE SL, 1995, AM J NEURORADIOL, V16, P637; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gunning-Dixon FM, 1998, AM J NEURORADIOL, V19, P1501; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Primus EA, 1997, BRAIN INJURY, V11, P577; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Verger K, 2000, BRAIN INJURY, V14, P495; Verger K, 2001, BRAIN INJURY, V15, P211	23	60	62	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2005	76	1					129	131		10.1136/jnnp.2004.027631			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	880GQ	WOS:000225777400030	15608014	Green Published, Bronze			2022-02-06	
J	Holmin, S; Hojeberg, B				Holmin, S; Hojeberg, B			In situ detection of intracerebral cytokine expression after human brain contusion	NEUROSCIENCE LETTERS			English	Article						brain injury; cytokine; human; inflammation; trauma	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; RAT-BRAIN; CEREBROSPINAL-FLUID; INTERLEUKIN-1; BARRIER; MECHANISMS; INCREASE; TRAUMA	The study was undertaken to analyze intracerebral expression of pro- and anti-inflammatory cytokines after traumatic brain injury (TBI) in man in order to compare the findings with previous experimental data regarding the pathogenesis of secondary brain injury. Contused brain tissue biopsies were obtained from 12 consecutive patients undergoing surgery for brain contusions 3 h to 5 days after trauma. Cytokine expression was analyzed by in situ hybridization and immunohistochemistry. In patients undergoing surgery less than 24 h after trauma, strong expression of both the pro-inflammatory cytokines interleukin (IL)-1-beta, IL-6 and interferon (IFN)-gamma and the anti-inflammatory cytokine IL-4 was detected. In patients undergoing surgery between 3 and 5 days after trauma, IL-4 expression was significantly lower (P < 0.05) compared to the patients operated early. IL-1-beta and IFN-gamma expression remained strong in comparison to IL-6 and IL-4 expression (P < 0.05). Immunohistochemistry for IL-1-beta confirmed that the protein was produced with a temporal and regional pattern that corresponded to in situ hybridization results. The study provides in situ data on intracerebral cytokine expression after contusion in the clinical setting. Strong intracerebral cytokine expression occurs in the perilesional zone both in the early and the delayed phase after traumatic brain injury in humans. The temporal regulation of pro- and anti-inflammatory cytokines differs which reveals different therapeutic windows for pharmacological intervention. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Neurol Sect, Dept Clin Neurosci, Stockholm, Sweden		Holmin, S (corresponding author), Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden.	staffan.holmin@kus.se		Holmin, Staffan/0000-0002-1628-1615			Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BULLOCK R, 1989, P 7 INT S INTR PRESS, P637; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CLAUDIO L, 1994, LAB INVEST, V70, P850; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Falcone M, 1998, J IMMUNOL, V160, P4822; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GORDON CR, 1990, ACT NEUR S, V51, P268; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCLAURIN RL, 1965, J NEUROSURG, V23, P296, DOI 10.3171/jns.1965.23.3.0296; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	40	60	62	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 14	2004	369	2					108	114		10.1016/j.neulet.2004.07.044			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	861SE	WOS:000224438100005	15450678				2022-02-06	
J	Boake, C; McCauley, SR; Levin, HS; Contant, CE; Song, JX; Brown, SA; Goodman, HS; Brundage, SI; Diaz-Marchan, PJ; Merritt, SG				Boake, C; McCauley, SR; Levin, HS; Contant, CE; Song, JX; Brown, SA; Goodman, HS; Brundage, SI; Diaz-Marchan, PJ; Merritt, SG			Limited agreement between criteria-based diagnoses of postconcussional syndrome	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; DISORDER; CONSCIOUSNESS; DEPRESSION; SCALE	The objectives of this study were to compare diagnoses of postconcussional syndrome between the International Classification of Diseases, 10th revision (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). The patient sample was comprised of 178 adults with mild-moderate traumatic brain injury (TBI). The study design was inception cohort, and the main outcome measure was a structured interview 3 months after injury. The results were that, despite concordance of DSM-IV and ICD-10 symptom criteria (kappa = 0.73), agreement between overall DAM-IV and ICD-10 diagnoses was slight (kappa = 0.13) because fewer patients met the DSM-IV cognitive deficit and clinical significance criteria. Agreement between DSM-IV postconcussional disorder and ICD-10 postconcussional syndrome appears limited by different prevalences and thresholds.	Univ Texas, Baylor Coll Med, Sch Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA		Boake, C (corresponding author), TIRR, 133 Moursund, Houston, TX 77030 USA.	corwin.boake@uth.tmc.edu			ODCDC CDC HHS [R49/CCR612707-01] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; BROWN S, 1994, DSM 4 SOURCEBOOK, V1, P319; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fleiss J.L., 1981, STAT METHODS RATES P; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gibbon M, 1998, STRUCTURED CLIN INTE; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus Jess F., 1994, P3; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McAllister Thomas W., 1994, P357; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; *SAS I, 1999, SAS SYST WIND REL 8; Smith, 1973, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, ICD 10 CLASSIFICATIO; World Health Organization, 1978, MENT DIS GLOSS GUID	27	60	61	0	1	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2004	16	4					493	499		10.1176/appi.neuropsych.16.4.493			7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	881VN	WOS:000225897600013	15616177				2022-02-06	
J	Levin, HS; Zhang, LF; Dennis, M; Ewing-Cobbs, L; Schachar, R; Max, J; Landis, JA; Roberson, G; Scheibel, RS; Miller, DL; Hunter, JV				Levin, HS; Zhang, LF; Dennis, M; Ewing-Cobbs, L; Schachar, R; Max, J; Landis, JA; Roberson, G; Scheibel, RS; Miller, DL; Hunter, JV			Psychosocial outcome of TBI in children with unilateral frontal lesions	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						children; frontal lesions; psychosocial outcome; TBI	CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; LOBE DAMAGE; PREFRONTAL CORTEX; DECISION-MAKING; PRACTICAL SCALE; DISORDERS; BEHAVIOR; EMOTION; AGE	To evaluate effects of unilateral frontal lesions on psychosocial and global outcome of traumatic brain injury (TBI) in children, Study 1 compared matched groups of 22 school aged children who had sustained TBI either with or without unilateral frontal lesions. Study 2 evaluated effects of unilateral extrafrontal lesions in 18 TBI patients as compared with 18 nonlesional TBI patients. Communication, Daily Living, and Socialization domains and the Maladaptive Behavior Scale of the Vineland Adaptive Behavior Scales (VABS) were used to assess psychosocial outcome, and the Glasgow Outcome Scale (GOS) measured global outcome. All patients underwent magnetic resonance imaging at least 3 months post injury. Children with frontal lesions had worse scores on the Daily Living and Socialization domains and a higher frequency of maladaptive behavior than those without frontal lesions, but there was no difference in cognitive function. Disability was twice as common in the frontal lesion group relative to children without frontal lesions. Volume of frontal lesion was related to the Socialization domain. Side of lesion had no effect, nor did presence of an extrafrontal lesion (Study 2). Unilateral frontal lesions adversely affect late psychosocial outcome of TBI in children.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX USA; Hosp Sick Children, Dept Psychol, Toronto, ON, Canada; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 2001, J NEUROL NEUROSUR PS, V71, P727, DOI 10.1136/jnnp.71.6.727; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Delis D.C., 1994, CVLT C CALIFORNIA VE; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JENNETT B, 1975, LANCET, V1, P480; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; SATTLER JM, 2002, ASSESSMENT CHILDREN, P189; Semel E., 1995, CLIN EVALUATION LANG, VThird; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	35	60	60	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					305	316		10.1017/S1355617704102129			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500001	15147589				2022-02-06	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Children show decreased dynamic balance after mild traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	3rd World Congress on Neurological Rehabilitation	APR 02-06, 2002	VENICE, ITALY			brain injuries; equilibrium; pediatrics; rehabilitation	CLOSED-HEAD INJURY; POSTURAL INSTABILITY; MOTOR-PERFORMANCE; CONCUSSION; ADULTS; SWAY; REHABILITATION; RELIABILITY; MANAGEMENT; FEEDBACK	Objective: To compare the balance skills of children after mild traumatic brain injury (TBI) with that of noninjured children matched for age, sex, and premorbid level of physical activity. Design: Cohort study. Setting: Pediatric trauma center. Participants: Thirty-eight children aged 7 to 16 years (mean, 12.2+/-2.8y) were recruited in each group. Children with mild TBI had a mean Glasgow Coma Scale score of 14.8 and were considered normal on a neurologic assessment at hospital discharge. Noninjured children were friends of those with mild TBI. Intervention: Assessments of balance were conducted at 1, 4, and 12 weeks after mild TBI and at corresponding time intervals for the controls. Main Outcome Measures: The balance subtest of the Bruininks-Oseretsky Test of Motor Proficiency (BOTMP), the Pediatric Clinical Test of Sensory Interaction for Balance (P-CTSIB), and the Postural Stress Test (PST) were used. Results: Over the time interval of the study, analyses of variance revealed that children with mild TBI performed significantly worse than the noninjured group on the BOTMP balance subtest (P<.001) and on the PST (P=.031), as well as on the eyes-closed conditions in the P-CTSIB tandem position (P=.05). Conclusions: Children with a mild TBI still showed balance deficits at 12 weeks postinjury. These deficits should be taken into consideration when planning a return to physical activities, particularly to those that require subtle balance skills.	McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Inst Readaptat Montreal, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada		Gagnon, I (corresponding author), McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Phys Therapy Dept, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon6@sympatico.ca		Gagnon, Isabelle/0000-0003-2043-1644			Bruininks, 1978, BRUININKS OSERETSKY; CHANDLER JM, 1990, PHYS THER, V70, P410, DOI 10.1093/ptj/70.7.410; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CROWE T K, 1990, Physical and Occupational Therapy in Pediatrics, V10, P1; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FORGET R, 1995, CAN J PHYSIOL PHARM, V73, P285, DOI 10.1139/y95-039; FORGET R, 1990, BRAIN RES, V508, P176, DOI 10.1016/0006-8993(90)91135-4; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; GAGNON I, 2002, NEROREHABIL NEURAL R, V16, P22; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Graham D.I., 1996, NEUROTRAUMA, P43; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HAAS G, 1989, DEV MED CHILD NEUROL, V31, P481; HARBURN KL, 1995, ARCH PHYS MED REHAB, V76, P317, DOI 10.1016/S0003-9993(95)80656-3; Hatzitaki V, 2002, J MOTOR BEHAV, V34, P161, DOI 10.1080/00222890209601938; HIRSCHFELD H, 1991, J NEUROPHYSIOL, V66, P12, DOI 10.1152/jn.1991.66.1.12; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369, DOI 10.1152/jn.1986.55.6.1369; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levin H.S., 1989, MILD HEAD INJURY; Levin HS, 1996, NEUROTRAUMA, P749; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Moss NE., 1994, CLIN REHABIL, V8, P149; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Reed ES, 1989, DEV POSTURE GAIT LIF, P3; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOLFSON LI, 1986, J AM GERIATR SOC, V34, P845, DOI 10.1111/j.1532-5415.1986.tb07256.x; Woollacott MH, 1996, J AGING PHYS ACTIV, V4, P214, DOI 10.1123/japa.4.3.214	45	60	60	0	13	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2004	85	3					444	452		10.1016/j.apmr.2003.06.014			9	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	801AC	WOS:000220067800015	15031831				2022-02-06	
J	Brewer-Smyth, K; Burgess, AW; Shults, J				Brewer-Smyth, K; Burgess, AW; Shults, J			Physical and sexual abuse, salivary cortisol, and neurologic correlates of violent criminal behavior in female prison inmates	BIOLOGICAL PSYCHIATRY			English	Article; Proceedings Paper	2002 State of the Science Meeting	SEP 26-28, 2002	WASHINGTON, D.C.	Amer Assoc Coll Nursing, Natl Inst Nursing Res		violent female prison inmates; traumatic brain injury; neuroendocrine; childhood abuse; suicide attempts; limbic system	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; INCARCERATED WOMEN; CHILDHOOD ABUSE; DEVELOPMENTAL TRAUMATOLOGY; PSYCHIATRIC-DISORDERS; AGGRESSIVE-BEHAVIOR; MENTAL-ILLNESS; BATTERED WOMEN; UNITED-STATES	Background: Both physical and emotional traumas have been related to neurologic and neuroendocrine abnormalities that may be associated with violent behavior. Methods: A modified case-control design was used for blinded comparison of 113 female inmates convicted of violent and nonviolent crimes. History of having been physically or sexually abused, neurologic history and physical examination, basal salivary cortisol levels, and associated variables were investigated to identify possible risk factors for violent compared to nonviolent criminal convictions. Results: Of all inmates studied, 95% had neurologic histories predating the current crime and/or neurologic examination abnormalities. Logistic regression revealed morning cortisol levels, number of years since last abuse, number of prior suicide attempts, and traumatic brain injuries with loss of consciousness to be significantly associated with current violent convictions, with a mean of two brain injuries with loss of consciousness per subject in the violent group. Conclusions: A greater number of traumatic brain injuries with loss of consciousness and suicide attempts, more recent abuse, and low morning basal salivary cortisol levels could be associated with dangerous violent criminal behavior, including murder, in female prison inmates. Future research should investigate neuroendocrine challenges, more psychiatric and violence measures, and different populations with longitudinal designs. (C) 2004 Society of Biological Psychiatry.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA		Brewer-Smyth, K (corresponding author), Univ Delaware, Coll Hlth & Nursing Sci, 313 McDowell Hall, Newark, DE 19716 USA.			Brewer-Smyth, PhD, RN, CRRN, FAAN, Kathleen/0000-0001-8468-6991	NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007036] Funding Source: NIH RePORTER; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR07036] Funding Source: Medline		ADNA RF, 1999, JAMA-J AM MED ASSOC, V282, P1652; BATES B, 1995, GUIDE PHYSICAL EXAMI; Beck A., 1996, BECK DEPRESSION INVE; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BREWERSMYTH K, 2001, THESIS UMI ANN ARBOR; Browne A, 1999, INT J LAW PSYCHIAT, V22, P301, DOI 10.1016/S0160-2527(99)00011-4; BURGESS AW, 1987, AM J PSYCHIAT, V144, P1431; BUYDENSBRANCHEY L, 1992, PSYCHONEUROENDOCRINO, V17, P45, DOI 10.1016/0306-4530(92)90075-I; Centers for Disease Control and Prevention, 1999, BRAIN INJ US REP C; Clerici M, 2000, ANN NY ACAD SCI, V917, P956; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1259, DOI 10.1016/S0006-3223(99)00044-X; De Bellis MD, 2001, DEV PSYCHOPATHOL, V13, P539, DOI 10.1017/S0954579401003078; DEBELLIS MD, 1999, BIOL PSYCHIAT, V45, P1235; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; FISHBEIN DH, 1990, CRIMINOLOGY, V28, P27, DOI 10.1111/j.1745-9125.1990.tb01317.x; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLDIER J, 1998, DEV PSYCHOPATHOL, V10, P857; Gur RC, 2002, CEREB CORTEX, V12, P998, DOI 10.1093/cercor/12.9.998; Halasz J, 2002, NEUROREPORT, V13, P1267; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Herzog AG, 2001, ARCH GEN PSYCHIAT, V58, P513, DOI 10.1001/archpsyc.58.5.513; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Jacobs AR, 1999, BIOL PSYCHIAT, V46, P856, DOI 10.1016/S0006-3223(99)00081-5; Jordan BK, 1996, ARCH GEN PSYCHIAT, V53, P513; Kalin NH, 1999, J CLIN PSYCHIAT, V60, P29; Kendall-Tackett KA, 2000, CHILD ABUSE NEGLECT, V24, P799, DOI 10.1016/S0145-2134(00)00136-8; King JA, 2001, PSYCHIAT CLIN NEUROS, V55, P71, DOI 10.1046/j.1440-1819.2001.00787.x; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; KIRSCHBAUM C, 1992, LIFE SCI, V50, P435, DOI 10.1016/0024-3205(92)90378-3; Krakowski M, 1988, NEUROPSY NEUROPSY BE, V1, P21; Krishnan KR, 1999, J CLIN PSYCHIAT, V60, P50; LEWIS DO, 1979, J AM ACAD CHILD PSY, V18, P307, DOI 10.1016/S0002-7138(09)61045-1; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; McBurnett K, 2000, ARCH GEN PSYCHIAT, V57, P38, DOI 10.1001/archpsyc.57.1.38; MCEWEN B, 1988, NEW ENGL J MED, V238, P171; Meyer IH, 1996, CHILD ABUSE NEGLECT, V20, P213, DOI 10.1016/S0145-2134(95)00137-9; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; MUENZENMAIER K, 1993, HOSP COMMUNITY PSYCH, V44, P666; NETTER FH, 1972, CIBA COLLECTION MED, V1; New AS, 2002, ARCH GEN PSYCHIAT, V59, P621, DOI 10.1001/archpsyc.59.7.621; *NIH, 1996, PROT HUM SUBJ 46; O'Keefe M, 1998, J TRAUMA STRESS, V11, P71, DOI 10.1023/A:1024457116085; Pajer K, 2001, ARCH GEN PSYCHIAT, V58, P297, DOI 10.1001/archpsyc.58.3.297; Pastore AL, 2000, SOURCEBOOK CRIMINAL; PINCUS JH, 1991, SEMIN NEUROL, V11, P146, DOI 10.1055/s-2008-1041216; Rasmussen K, 2001, J AM ACAD PSYCHIATRY, V29, P186; REEVES AG, 1969, ARCH NEUROL-CHICAGO, V20, P616, DOI 10.1001/archneur.1969.00480120062005; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; Schwartz EB, 1998, CHILD DEV, V69, P1503, DOI 10.2307/1132128; *SPSS, 1997, SPSS PROF STAT 10 0; *STAT, 1999, STAT STAT SOFTW REL; Steer RA, 1997, PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; STEIN M, 1996, SOC BIOL PSYCHIAT, V42, P680; Teplin LA, 1996, ARCH GEN PSYCHIAT, V53, P505; Treiman D M, 1991, Adv Neurol, V55, P341; *US DEP JUST BUR J, 1994, NCJ145321; *US DEP JUST FED B, 1998, PROF FEM OFF; Volavka J., 1995, NEUROBIOLOGY VIOLENC; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; WIDOM CS, 1989, PSYCHOL BULL, V106, P3, DOI 10.1037/0033-2909.106.1.3; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; Yehuda R, 1999, J CLIN PSYCHIAT, V60, P33; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; Zlotnick C, 1997, J NERV MENT DIS, V185, P761, DOI 10.1097/00005053-199712000-00007	75	60	60	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	JAN 1	2004	55	1					21	31		10.1016/S0006-3223(03)00705-4			11	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	759NH	WOS:000187743400003	14706421				2022-02-06	
J	Osteen, CL; Giza, CC; Hovda, DA				Osteen, CL; Giza, CC; Hovda, DA			Injury-induced alterations in N-methyl-D-aspartate receptor subunit composition contribute to prolonged (45)calcium accumulation following lateral fluid percussion	NEUROSCIENCE			English	Article						calcium; glutamate; ifenprodil; MK-801; N-methyl-D-aspartate receptor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPONTANEOUSLY HYPERTENSIVE-RATS; TRANSIENT CEREBRAL-ISCHEMIA; MESSENGER-RNA EXPRESSION; LONG-TERM POTENTIATION; AGE-RELATED-CHANGES; NMDA-RECEPTOR; IN-VITRO; POSTSYNAPTIC DENSITY-95; SYNAPTIC-TRANSMISSION	Cells that survive traumatic brain injury are exposed to changes in their neurochemical environment. One of these changes is a prolonged (48 h) uptake of calcium which, by itself, is not lethal. The N-methyl-D-aspartate receptor (NMDAR) is responsible for the acute membrane flux of calcium following trauma; however, it is unclear if it is involved in a flux lasting 2 days. We proposed that traumatic brain injury induced a molecular change in the NMDAR by modifying the concentrations of its corresponding subunits (NR1 and NR2). Changing these subunits could result in a receptor being more sensitive to glutamate and prolong its opening, thereby exposing cells to a sustained flux of calcium. To test this hypothesis, adult rats were subjected to a lateral fluid percussion brain injury and the NR1, NR2A and NR2B subunits measured within different regions. Although little change was seen in NR1, both NR2 subunits decreased nearly 50% compared with controls, particularly within the ipsilateral cerebral cortex. This decrease was sustained for 4 days with levels retuning to control values by 2 weeks. However, this decrease was not the same for both subunits, resulting in a decrease (over 30%) in the NR2A:NR2B ratio indicating that the NMDAR had temporarily become more sensitive to glutamate and would remain open longer once activated. Combining these regional and temporal findings with (41)calcium autoradiographic studies revealed that the degree of change in the subunit ratio corresponded to the extent of calcium accumulation. Finally, utilizing a combination of NMDAR and NR2B-specific antagonists it was determined that as much at 85% of the long term NMDAR-mediated calcium flux occurs through receptors whose subunits favor the NR2B subunit. These data indicate that TBI induces molecular changes within the NMDAR, contributing to the cells' post-injury vulnerability to glutamatergic stimulation. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Interdept Program Mol Cellular & Integrat Physiol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA		Hovda, DA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Room 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308, NS02197] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ARAKI T, 1990, BRAIN RES, V528, P114, DOI 10.1016/0006-8993(90)90202-M; BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BETZ AL, 1989, BASIC NEUROCHEMISTRY, P591; Bi XN, 2000, METH MOL B, V144, P203; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chizh BA, 2001, NEUROPHARMACOLOGY, V40, P212, DOI 10.1016/S0028-3908(00)00148-9; Clayton DA, 2002, J NEUROSCI, V22, P3628; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Coughenour LL, 2001, J PHARMACOL EXP THER, V296, P150; Dawson DA, 2001, BRAIN RES, V892, P344, DOI 10.1016/S0006-8993(00)03269-8; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dravolina OA, 2000, PHARMACOL BIOCHEM BE, V65, P611, DOI 10.1016/S0091-3057(99)00232-4; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Flint AC, 1997, J NEUROSCI, V17, P2469; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; Ghosh S, 1997, NEUROL RES, V19, P403, DOI 10.1080/01616412.1997.11740833; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GORMAN LK, 1995, J NEUROTRAUM, V12, P120; Guzikowski AP, 2000, J MED CHEM, V43, P984, DOI 10.1021/jm990428c; Healy DJ, 2000, SYNAPSE, V38, P294, DOI 10.1002/1098-2396(20001201)38:3<294::AID-SYN8>3.0.CO;2-U; HENS JJH, 1997, NEUOTRANSMITTER METH, P61; HEURTEAUX C, 1994, BRAIN RES, V659, P67, DOI 10.1016/0006-8993(94)90864-8; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; Hovda D.A., 1996, NEUROTRAUMA, P1459; Hsu JC, 1998, J CEREBR BLOOD F MET, V18, P768, DOI 10.1097/00004647-199807000-00008; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Husi H, 2001, J NEUROCHEM, V77, P281, DOI 10.1046/j.1471-4159.2001.00248.x; ISHII T, 1993, J BIOL CHEM, V268, P2836; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kew JNC, 1996, J PHYSIOL-LONDON, V497, P761, DOI 10.1113/jphysiol.1996.sp021807; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Magnusson KR, 2002, MOL BRAIN RES, V99, P40, DOI 10.1016/S0169-328X(01)00344-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Murray F, 2000, EUR J PHARMACOL, V397, P263, DOI 10.1016/S0014-2999(00)00263-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NAGASAWA H, 1990, BRAIN RES, V524, P196, DOI 10.1016/0006-8993(90)90690-D; Nash JE, 1999, EXP NEUROL, V155, P42, DOI 10.1006/exnr.1998.6963; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; RAPPAPORT ZH, 1987, STROKE, V18, P760, DOI 10.1161/01.STR.18.4.760; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Seeburg P., 1994, NMDA RECEPTOR, P147; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; SHIROTANI T, 1994, J CEREBR BLOOD F MET, V14, P831, DOI 10.1038/jcbfm.1994.104; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takagi N, 1997, J NEUROCHEM, V69, P1060; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WANG YH, 1995, J NEUROCHEM, V65, P176; Watanabe H, 1998, J CEREBR BLOOD F MET, V18, P686, DOI 10.1097/00004647-199806000-00011; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang L, 1997, J NEUROCHEM, V69, P1983	96	60	63	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	128	2					305	322		10.1016/j.neuroscience.2004.06.034			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	855AJ	WOS:000223944900009	15350643				2022-02-06	
J	Palzur, E; Vlodavsky, E; Mulla, H; Arieli, R; Feinsod, M; Soustiel, JF				Palzur, E; Vlodavsky, E; Mulla, H; Arieli, R; Feinsod, M; Soustiel, JF			Hyperbaric oxygen therapy for reduction of secondary brain damage in head injury: An animal model of brain contusion	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; cerebral contusion; head injury; hyperbaric oxygen; secondary brain damage	CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; CORTICAL IMPACT INJURY; NORMOBARIC HYPEROXIA; COMPUTED-TOMOGRAPHY; HYPOXIA-ISCHEMIA; INFARCT SIZE; CNS INJURY; RAT MODEL; APOPTOSIS	Cerebral contusions are one the most frequent traumatic lesions and the most common indication for secondary surgical decompression. The purpose of this study was to investigate the physiology of perilesional secondary brain damage and evaluate the value of hyperbaric oxygen therapy (HBOT) in the treatment of these lesions. Five groups of five Sprague-Dawley rats each were submitted to dynamic cortical deformation (DCD) induced by negative pressure applied to the cortex. Cerebral lesions produced by DCD at the vacuum site proved to be reproducible. The study protocol entailed the following: (1) DCD alone, (2) DCD and HBOT, (3) DCD and post-operative hypoxia and HBOT, (4) DCD, post-operative hypoxia and HBOT, and (5) DCD and normobaric hyperoxia. Animals were sacrificed after 4 days. Histological sections showed localized gross tissue loss in the cortex at injury site, along with hemorrhage. In all cases, the severity of secondary brain damage was assessed by counting the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and caspase 3-positive cells in successive perilesional layers, each 0.5 mm thick. Perilesional TUNEL positive cells suggested the involvement of apoptosis in group 1 (12.24% of positive cells in layer 1). These findings were significantly enhanced by post-operative hypoxia (31.75%, p < 0.001). HBOT significantly reduced the severity and extent of secondary brain damage expressed by the number of TUNEL positive cells in each layer and the volume of the lesion (4.7% and 9% of TUNEL positive cells in layer I in groups 2 and 4 respectively, p < 0.0001 and p < 0.003). Normobaric hyperoxia also proved to be beneficial although in a lesser extent. This study demonstrates that the vacuum model of brain injury is a reproducible model of cerebral contusion. The current findings also suggest that HBOT may limit the growth of cerebral contusions and justify further experimental studies.	Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Div Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Acute Brain Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Pathol, IL-31096 Haifa, Israel; Israel Def Forces Med Corps, Israel Naval Med Inst, Haifa, Israel		Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Div Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Arieli Ran, 1994, Journal of Basic and Clinical Physiology and Pharmacology, V5, P277; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DAVIS JN, 1973, SCIENCE, V182, P72, DOI 10.1126/science.182.4107.72; Demchenko IT, 2000, NITRIC OXIDE-BIOL CH, V4, P597, DOI 10.1006/niox.2000.0313; Demchenko IT, 1998, UNDERSEA HYPERBAR M, V25, P147; Eriskat J, 1997, ACT NEUR S, V70, P94; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; HUNT RC, 1978, EXP NEUROL, V62, P698, DOI 10.1016/0014-4886(78)90278-9; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KOHSHI K, 1991, Neurologia Medico-Chirurgica, V31, P575, DOI 10.2176/nmc.31.575; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTHEWS DSF, 1995, J NEUROL NEUROSUR PS, V59, P359, DOI 10.1136/jnnp.59.4.359; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nighoghossian N, 1997, J NEUROL SCI, V150, P27, DOI 10.1016/S0022-510X(97)05398-7; O'Dell DM, 2000, J NEUROSCI, V20, P4821; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PukaSundvall M, 1997, BRAIN RES, V750, P325, DOI 10.1016/S0006-8993(97)00024-3; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; ROPER SN, 1991, J NUCL MED, V32, P1684; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Teasdale G, 1996, NEUROLOGICAL SURG, P1533; Thomale UW, 2002, ACTA NEUROCHIR SUPPL, V81, P229; Veltkamp R, 2000, BRAIN RES, V853, P68, DOI 10.1016/S0006-8993(99)02250-7; Wada S, 2000, MAR BIOTECHNOL, V2, P285, DOI 10.1007/s101260000006; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	47	60	80	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					41	48		10.1089/089771504772695931			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700005	14987464				2022-02-06	
J	O'Hanlon, GM; Humphreys, PD; Goldman, RS; Halstead, SK; Bullens, RWM; Plomp, JJ; Ushkaryov, Y; Willison, HJ				O'Hanlon, GM; Humphreys, PD; Goldman, RS; Halstead, SK; Bullens, RWM; Plomp, JJ; Ushkaryov, Y; Willison, HJ			Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury	BRAIN			English	Article						Miller Fisher syndrome; neuromuscular junction; anti-ganglioside antibody; alpha-latrotoxin; calpain inhibitor	MILLER-FISHER-SYNDROME; WIDOW SPIDER VENOM; GUILLAIN-BARRE-SYNDROME; TRAUMATIC BRAIN-INJURY; ALPHA-LATROTOXIN; NEUROMUSCULAR-JUNCTION; PERIPHERAL-NERVE; WALLERIAN DEGENERATION; CELL-DEATH; RELEASE	Miller Fisher syndrome-associated anti-GQ1b ganglioside antibodies produce an acute complement-dependent neuroexocytic effect at the mouse neuromuscular junction (NMJ) that closely resembles the effect of alpha-latrotoxin (LTx). This pathophysiological effect is accompanied by morphological disruption of the nerve terminal involving the loss of major cytoskeletal components, including neurofilament. Both LTx and the membrane attack complex of complement form membrane pores that allow free ionic movement and we have previously hypothesized that Ca2+ ingress and the subsequent activation of Ca2+-dependent proteases, calpains, may lead to substrate degradation resulting in structural disorganization of the terminal. Here, we treated mouse NMJs in hemidiaphragm preparations with anti-GQ1b antibodies and complement, or with LTx in the presence and absence of extracellular Ca2+, and studied possible neuroprotective effects of the calpain inhibitors calpeptin and calpain inhibitor V. Both Ca2+ depletion and calpain inhibition protected the cytoskeleton from degradation, as assessed by immunohistological and ultrastructural analysis. Calpain inhibitors may therefore be useful therapeutically in limiting nerve terminal and axonal injury in autoimmune peripheral neuropathy and in human latrodectism.	Univ Glasgow, So Gen Hosp, Dept Neurol, Inst Neurol Sci,Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London, England; Leiden Univ, Med Ctr, Dept Neurophysiol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands		Willison, HJ (corresponding author), Univ Glasgow, So Gen Hosp, Dept Neurol, Inst Neurol Sci,Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland.		Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Halstead, Susan/0000-0001-7396-8969			Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; BADALAMENTE MA, 1995, J RECONSTR MICROSURG, V11, P429, DOI 10.1055/s-2007-1006557; BADALAMENTE MA, 1989, P NATL ACAD SCI USA, V86, P5983, DOI 10.1073/pnas.86.15.5983; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Buchwald B, 2001, NEUROLOGY, V56, P67, DOI 10.1212/WNL.56.1.67; Buchwald B, 1995, NEUROSCI LETT, V201, P163, DOI 10.1016/0304-3940(95)12155-2; Caba E, 2002, J NEUROSCI RES, V67, P787, DOI 10.1002/jnr.10163; Calupca MA, 1999, J NEUROPHYSIOL, V81, P498, DOI 10.1152/jn.1999.81.2.498; Castonguay A, 2001, Prog Brain Res, V132, P227; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Chan SO, 1998, NEUROCHEM RES, V23, P393, DOI 10.1023/A:1022417819356; Chen ZF, 1997, BRAIN RES, V769, P188, DOI 10.1016/S0006-8993(97)00848-2; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DUCHEN LW, 1981, J PHYSIOL-LONDON, V316, P279, DOI 10.1113/jphysiol.1981.sp013787; Glass JD, 2002, J NEUROL SCI, V196, P9, DOI 10.1016/S0022-510X(02)00013-8; Goodyear CS, 1999, J CLIN INVEST, V104, P697, DOI 10.1172/JCI6837; GORIO A, 1978, J NEUROCYTOL, V7, P193, DOI 10.1007/BF01217918; Henkel AW, 1999, CELL TISSUE RES, V296, P229, DOI 10.1007/s004410051284; Jiang QB, 2000, J NEUROCHEM, V74, P2101, DOI 10.1046/j.1471-4159.2000.0742101.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHI M, 2001, J PERIPHER NERV SYST, V6, P152; Newsholme P, 1999, BIOCHEM PHARMACOL, V57, P491, DOI 10.1016/S0006-2952(98)00311-6; O'Hanlon GM, 2002, NEUROCHEM RES, V27, P697, DOI 10.1023/A:1020284302718; O'Hanlon GM, 2001, BRAIN, V124, P893, DOI 10.1093/brain/124.5.893; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Plomp JJ, 1999, ANN NEUROL, V45, P189, DOI 10.1002/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTS M, 1994, LANCET, V343, P454, DOI 10.1016/S0140-6736(94)92694-8; Rochon D, 2001, J NEUROSCI, V21, P3819, DOI 10.1523/JNEUROSCI.21-11-03819.2001; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1977, BRAIN RES, V136, P1, DOI 10.1016/0006-8993(77)90126-3; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Wang MS, 2000, J NEUROPATH EXP NEUR, V59, P599, DOI 10.1093/jnen/59.7.599; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; Willison HJ, 1999, J NEUROIMMUNOL, V100, P3, DOI 10.1016/S0165-5728(99)00213-1; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200	45	60	60	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2003	126		11				2497	2509		10.1093/brain/awg254			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	735ZL	WOS:000186144800014	12937083				2022-02-06	
J	Erten, SF; Kocak, A; Ozdemir, I; Aydemir, S; Colak, A; Reeder, BS				Erten, SF; Kocak, A; Ozdemir, I; Aydemir, S; Colak, A; Reeder, BS			Protective effect of melatonin on experimental spinal cord ischemia	SPINAL CORD			English	Article						catalase; glutathione peroxidase; lipid peroxidation; melatonin; superoxide dismutase; spinal cord ischemia	IMPROVES NEUROLOGIC RECOVERY; CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; REPERFUSION INJURY; TRAUMATIC BRAIN; THORACIC AORTA; DOSE-RESPONSE; BLOOD-FLOW; MECHANISMS	Study design: Experimental animal model to assess ischemic spinal cord injury following occlusion of the thoraco-abdominal aorta. Objectives: To measure whether melatonin administered to rabbits before and after occlusion exerts an effect on the repair of ischemia-reperfusion (IR) injury. Setting: Medical Biology Laboratory, Inonu University, Malatya, Turkey. Methods: Rabbits were divided into three IR treatment groups and one sham-operated (ShOp) control group. The three treatment groups had their infrarenal aorta temporarily occluded for 25 min, while the ShOp group had laparotomy without aortic occlusion. Melatonin was administered either 10 min before aortic occlusion or 10 min after the clamp was removed. Physiologic saline was administered to the control animals. After treatment, the animals were euthanized and lumbosacral spinal cord tissue was removed for the determination of relevant enzyme activities. Results: Malondialdehyde levels, indicating the extent of lipid peroxidation, were found to be significantly increased in the nonmelatonin treated (IR) group when compared to the ShOp group. Melatonin, whether given to pre- or post occlusion groups, suppressed malondialdehyde levels below that of the ShOp group. Catalase (CAT) and glutathione peroxidase (GSH-Px) enzyme activities were increased in the IR group compared to the ShOp group. Melatonin given preocclusion resulted in a significant decrease in both CAT and GSH-Px enzyme levels. The superoxide dismutase ( SOD) enzyme activity was decreased in the ischemia-reperfusion treatment group. However, the melatonin treatment increased SOD enzyme activity to levels approximating that of the ShOp group. Conclusion: To our knowledge, this is the first study that shows the effects of melatonin administered both pre- and postischemia on induced oxidative damage to injured spinal cords. Our data also expands on reports that melatonin administration may significantly reduce the incidence of spinal cord injury following temporary aortic occlusion.	Stanford Univ, Fac Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Stanford, CA 94305 USA; Inonu Univ, Fac Med, Dept Neurosurg, Malatya, Turkey; Inonu Univ, Fac Sci, Dept Biochem, Malatya, Turkey; Inonu Univ, Fac Sci, Dept Mol Biol, Malatya, Turkey; Taksim First Aid Hosp, Dept Neurosurg, Istanbul, Turkey; Inonu Univ, Fac Med, Dept Med Biol & Genet, Malatya, Turkey		Reeder, BS (corresponding author), Stanford Univ, Fac Med, Dept Radiat Oncol, Div Radiat & Canc Biol, CCSR S 269 Campus Dr,Room 1255, Stanford, CA 94305 USA.		aydemir, songul/AAA-4291-2021	aydemir, songul/0000-0002-7921-0662			ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; CHEN LD, 1994, AM J PHYSIOL, V267, P57; CONNOLLY JE, 1986, J CARDIOVASC SURG, V27, P410; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; CUEVAS P, 1990, ACTA ANAT, V137, P303; CUEVAS P, 1989, ANAT EMBRYOL, V179, P251, DOI 10.1007/BF00326590; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; JOHNSON SH, 1993, STROKE, V24, P1547, DOI 10.1161/01.STR.24.10.1547; KASAI H, 1984, JPN J CANCER RES, V75, P841; KATIRCIOGLU SF, 1993, SURGERY, V114, P36; KAYNAR MY, 1988, TOKUSHIMA J EXP MED, V41, P133; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kouchoukos N T, 1993, Semin Thorac Cardiovasc Surg, V5, P47; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIM KH, 1986, ANN THORAC SURG, V42, P282, DOI 10.1016/S0003-4975(10)62735-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LuCK H., 1963, VERLAG CHEMIE, P885; Marini C P, 1993, Adv Card Surg, V4, P89; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1983, NEW ENGL J MED, V312, P59; NISHIBE M, 1989, Hokkaido Journal of Medical Science, V64, P301; OLDFIELD EH, 1982, J NEUROSURG, V56, P511, DOI 10.3171/jns.1982.56.4.0511; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; SCOTT MD, 1991, J LAB CLIN MED, V118, P7; SLATER TF, 1984, BIOCHEM J, V222, P1; SVENSSON LG, 1986, ANN SURG, V204, P38, DOI 10.1097/00000658-198607000-00005; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VERDANT A, 1988, ANN THORAC SURG, V46, P147, DOI 10.1016/S0003-4975(10)65887-0; WALDEN LRB, 1995, NEUROCHEM INT, V26, P497; ZIVIN JA, 1980, STROKE, V11, P200, DOI 10.1161/01.STR.11.2.200	43	60	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	OCT	2003	41	10					533	538		10.1038/sj.sc.3101508			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	725GL	WOS:000185535400002	14504608	Bronze			2022-02-06	
J	Mayberry, JC; Welker, KJ; Goldman, RK; Mullins, RJ				Mayberry, JC; Welker, KJ; Goldman, RK; Mullins, RJ			Mechanism of acute ascites formation after trauma resuscitation	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med			ABDOMINAL COMPARTMENT SYNDROME; ISOLATED EXTRAPERITONEAL INJURIES; INTRAPERITONEAL PRESSURE; SECONDARY; PREVENTION; CATS	Background: Severely injured patients have been observed to acutely develop ascites; however, the pathogenesis of this rare phenomenon is poorly understood. Objectives: To report the factors common among severely injured patients developing ascites and to formulate a hypothesis regarding its origin. Methods: Retrospective review of case series Results: We identified 9 injured patients between January 1, 1993, and December 31, 1998, who acutely developed significant amounts of ascites. The mean+/-SD estimated ascites volume was 2.0+/-0.8 L. All 9 patients had severe shock and were mechanically ventilated before abdominal decompression for the abdominal compartment syndrome. The mean+/-SD peak inspiratory pressure was 39.0+/-5.8 cm H2O. The mean+/-SD volumes of crystalloid and blood product infusion before decompression were 16.1+/-10.2 L and 5.2+/-4.8 L, respectively, in a mean+/-SD of 17+/-15 hours. In comparison, the mean+/-SD volumes of crystalloid and blood product trans-fusion among 100 contemporary, randomly selected patients undergoing trauma laparotomy were 5.1+/-5.5 L and 1.1+/-2.5 L, respectively (P<.001). Eight patients had only extra-abdominal injuries, while 1 patient had a combination of extra- and intra-abdominal injuries. Two patients were found to be cirrhotic by liver biopsy, but the other 7 patients had no known preexisting hepatic disease. Eight patients had absorbable mesh temporary abdominal closure, and 1 patient had primary fascial closure. There was persistent ascitic drainage in 5 patients; however, in all but 1 patient with cirrhosis, the drainage did not persist beyond 3 days. Two patients died, 1 of sepsis and the other of a closed head injury. Conclusions: Common denominators of posttraumatic ascites include shock, massive fluid resuscitation, and elevated intrathoracic pressure. The rapid onset of ascites in the setting of elevated intrathoracic pressure suggests that the patient's ability to clear ascitic fluid is overwhelmed.	Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97239 USA		Mayberry, JC (corresponding author), Oregon Hlth Sci Univ, Dept Surg, 3181 SW Sam Jackson Pk Rd,Mail Stop L223A, Portland, OR 97239 USA.			Mayberry, John/0000-0001-6978-9079			ADAIR T, 1982, LYMPHATIC IMAGING LY, V1; Biffl WL, 2001, AM J SURG, V182, P645, DOI 10.1016/S0002-9610(01)00814-5; BORLASE BC, 1990, J TRAUMA, V30, P1340, DOI 10.1097/00005373-199011000-00006; ELDOR J, 1991, RESUSCITATION, V21, P289, DOI 10.1016/0300-9572(91)90054-3; Garcia-Tsao G, 1995, Gastroenterologist, V3, P41; Hirvela E, 2000, J TRAUMA, V49, P747; Kopelman T, 2000, J TRAUMA, V49, P744, DOI 10.1097/00005373-200010000-00025; Latenser BA, 2002, J BURN CARE REHABIL, V23, P190, DOI 10.1097/00004630-200205000-00008; Lucas CE, 2001, J AM COLL SURGEONS, V192, P86, DOI 10.1016/S1072-7515(00)00761-4; Macalino Joel U, 2002, Asian J Surg, V25, P244, DOI 10.1016/S1015-9584(09)60184-6; Markert DJ, 1997, CLIN RADIOL, V52, P384, DOI 10.1016/S0009-9260(97)80135-3; Maxwell RA, 1999, J TRAUMA, V47, P995, DOI 10.1097/00005373-199912000-00001; Mayberry JC, 1999, LANCET, V354, P1749, DOI 10.1016/S0140-6736(99)00407-9; Mayberry JC, 1997, ARCH SURG-CHICAGO, V132, P957; Michielsen PP, 1996, ACTA GASTRO-ENT BELG, V59, P191; SCHILLING JA, 1952, J CLIN INVEST, V31, P602; VOLWILER W, 1950, GASTROENTEROLOGY, V14, P40, DOI 10.1016/S0016-5085(50)80111-7; ZARINS CK, 1978, CIRC RES, V43, P925, DOI 10.1161/01.RES.43.6.925; ZINK J, 1977, AM J PHYSIOL, V233, pH185, DOI 10.1152/ajpheart.1977.233.2.H185; ZINK J, 1977, GASTROENTEROLOGY, V73, P1119	20	60	69	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	JUL	2003	138	7					773	776		10.1001/archsurg.138.7.773			4	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	697RH	WOS:000183956700020	12860760	Bronze			2022-02-06	
J	Lubisch, W; Beckenbach, E; Bopp, S; Hofmann, HP; Kartal, A; Kastel, C; Lindner, T; Metz-Garrecht, M; Reeb, J; Regner, F; Vierling, M; Moller, A				Lubisch, W; Beckenbach, E; Bopp, S; Hofmann, HP; Kartal, A; Kastel, C; Lindner, T; Metz-Garrecht, M; Reeb, J; Regner, F; Vierling, M; Moller, A			Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: Discovery of potent water-soluble calpain inhibitors with oral bioavailability	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MU-CALPAIN; CYSTEINE PROTEINASES; BRAIN-INJURY; ACTIVATION; CALCIUM; PROTEOLYSIS; EXPRESSION; PEPTIDES; RAT	Novel benzoylalanine-derived ketoamides were prepared and evaluated for calpain I inhibition. Derivatives carrying vinylbenzyl amino residues in the P-2-P-3 region inhibited calpain in nanomolar concentrations and thus represent a novel class of nonpeptidic calpain inhibitors. Selected examples exhibited an improved pharmacokinetic profile including improved water-solubility and metabolic stability. In particular, these calpain inhibitors showed oral bioavailability in rats as demonstrated by N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethylaminomethylphenyl)ethen-1-yl]benzamide (5d). The closely related derivative N-(1-carbamoyl-1-oxohex-1-yl)-2-[E-2-(4-dimethylaminomethylphenyl)-ethen-1-yl]benzamide (5b) was evaluated for neuroprotective efficacy after experimental traumatic brain injury in a fluid percussion model in rats. When administered after injury, 5b reduced the number of damaged neurons by 41%, and this result would be in line with the suggested neuroprotective efficacy of calpain inhibition.	Abbott GmbH & Co KG, Neurosci Discovery Res, D-67008 Ludwigshafen, Germany		Lubisch, W (corresponding author), Abbott GmbH & Co KG, Neurosci Discovery Res, POB 210805, D-67008 Ludwigshafen, Germany.	wilfried.lubisch@abbott.com	Terrill, Eric/ABA-4169-2021				ANGELASTRO MR, 1990, J MED CHEM, V33, P11, DOI 10.1021/jm00163a002; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bort R, 1999, BIOCHEM PHARMACOL, V58, P787, DOI 10.1016/S0006-2952(99)00167-7; Chaterjee S, 1996, BIOORG MED CHEM LETT, V6, P1619, DOI 10.1016/S0960-894X(96)00286-7; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; Dear TN, 2000, GENOMICS, V68, P152, DOI 10.1006/geno.2000.6289; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; HARBESON SL, 1994, J MED CHEM, V37, P2918, DOI 10.1021/jm00044a013; HARRIS AL, 1995, BIOORG MED CHEM LETT, V5, P393, DOI 10.1016/0960-894X(95)00042-R; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li ZZ, 1996, J MED CHEM, V39, P4089, DOI 10.1021/jm950541c; Lombardo F, 2001, J MED CHEM, V44, P2490, DOI 10.1021/jm0100990; Lubisch W, 2000, BIOORG MED CHEM LETT, V10, P2187, DOI 10.1016/S0960-894X(00)00430-3; Lubisch W, 2002, BIOORG MED CHEM LETT, V12, P1335, DOI 10.1016/S0960-894X(02)00176-2; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; ODA A, 1993, J BIOL CHEM, V268, P12603; Reverter D, 2001, TRENDS CARDIOVAS MED, V11, P222, DOI 10.1016/S1050-1738(01)00112-8; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Shields DC, 1998, P NATL ACAD SCI USA, V95, P5768, DOI 10.1073/pnas.95.10.5768; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squier MKT, 1996, CELL DEATH DIFFER, V3, P275; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Tao M, 1996, BIOORG MED CHEM LETT, V6, P3009, DOI 10.1016/S0960-894X(96)00550-1; Urthaler F, 1997, CARDIOVASC RES, V35, P60, DOI 10.1016/S0008-6363(97)00099-0; VANDERSKLISH PW, 2000, INT J EXP PATHOL, V7, P1171; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; YOSHII N, 1999, 29 SOC NEUR ABSTR	48	60	61	0	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	JUN 5	2003	46	12					2404	2412		10.1021/jm0210717			9	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	684RM	WOS:000183220400016	12773044				2022-02-06	
J	Diaz-Parejo, P; Stahl, N; Xu, WB; Reinstrup, P; Ungerstedt, U; Nordstrom, CH				Diaz-Parejo, P; Stahl, N; Xu, WB; Reinstrup, P; Ungerstedt, U; Nordstrom, CH			Cerebral energy metabolism during transient hyperglycemia in patients with severe brain trauma	INTENSIVE CARE MEDICINE			English	Article						hyperglycemia; head injury; cerebral microdialysis; glucose; lactate; glutamate	ISCHEMIC CELL-DAMAGE; FOREBRAIN ISCHEMIA; LACTIC-ACIDOSIS; GLUCOSE LEVEL; PREISCHEMIC HYPERGLYCEMIA; DIABETES-MELLITUS; SKELETAL-MUSCLE; CYCLOSPORINE-A; HEAD-INJURY; RAT-BRAIN	Objective: To study whether transient hyperglycemia adversely affects cerebral energy metabolism in patients with severe traumatic brain lesions. Design and setting: Prospective, nonrandomized study in the neurosurgical intensive care unit of a university hospital. Patients: 108 patients treated for severe traumatic brain lesions. Interventions: All patients were treated according to neurosurgical intensive care routine including monitoring of, intracranial pressure. One microdialysis catheter was inserted via a burr hole frontally to that used for the intraventricular catheter ("better" position). In patients with focal lesions one or more catheters were inserted into cerebral cortex surrounding an evacuated focal contusion or underlying an evacuated hematoma ("worse" position). Perfusion rate was 0.3 mul/min and samples were taken every. 30 or 60 min. The levels of glucose, pyruvate, lactate, glutamate, and glycerol were analyzed and displayed bedside. Measurements and results: There were 18 episodes of moderate (12-15 mmol/1) and 6 episodes of pronounced (>15 mmol/1) hyperglycemia. Moderate hyperglycemia did not change intracerebral levels of lactate, pyruvate, glutamate, glycerol, or lactate/pyruvate ratio. Lactate concentrations increased during pronounced hyperglycemia. Pronounced cerebral lactic acidosis and a moderate increase in interstitial glycerol concentration indicating cell membrane degradation was observed in a single patient with pronounced, long-lasting hyperglycemia. Conclusions: Cerebral energy metabolism was affected by transient hyperglycemia only at blood glucose concentration above 15 mmol/l as shown by a moderate increase in interstitial lactate level.	Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden; Univ Hosp Virgen Rocio, Dept Intens Care, Seville, Spain; Kunming Med Coll, Intens Care Unit, Kunming, Peoples R China; Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden		Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden.			Stahl, Nils/0000-0003-2077-8103			BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENVENISTE H, 1989, J NEUROCHEM, V52, P1741, DOI 10.1111/j.1471-4159.1989.tb07252.x; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; EKHOLM A, 1995, EXP BRAIN RES, V104, P462; Forsyth R, 1996, DEV NEUROSCI-BASEL, V18, P360, DOI 10.1159/000111429; Forsyth RJ, 1996, NEUROCHEM INT, V28, P231, DOI 10.1016/0197-0186(95)00094-1; Fray AE, 1996, J PHYSIOL-LONDON, V496, P49, DOI 10.1113/jphysiol.1996.sp021664; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; Gisselsson L, 1999, J CEREBR BLOOD F MET, V19, P288, DOI 10.1097/00004647-199903000-00007; GISSELSSON L, 1992, J CEREBR BLOOD F MET, V12, P809, DOI 10.1038/jcbfm.1992.112; HICKNER RC, 1992, ACTA PHYSIOL SCAND, V146, P87, DOI 10.1111/j.1748-1716.1992.tb09396.x; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; JANSSON PA, 1988, AM J PHYSIOL, V255, pE218, DOI 10.1152/ajpendo.1988.255.2.E218; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KATSURA K, 1992, EUR J NEUROSCI, V4, P166, DOI 10.1111/j.1460-9568.1992.tb00863.x; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRISTIAN T, 1996, LIFE SCI, V59, P57; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LI PA, 1995, NEUROBIOL DIS, V2, P97, DOI 10.1006/nbdi.1995.0010; Li PA, 2000, STROKE, V31, P183, DOI 10.1161/01.STR.31.1.183; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; Mitchell A J, 1997, J Stroke Cerebrovasc Dis, V6, P377, DOI 10.1016/S1052-3057(97)80038-9; NORDSTROM C, 1976, ACTA PHYSL SCAND, V98, P248; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; PALJARVI L, 1983, ACTA NEUROPATHOL, V60, P232, DOI 10.1007/BF00691871; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROSDAHL H, 1993, J PHYSIOL-LONDON, V471, P637, DOI 10.1113/jphysiol.1993.sp019920; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Schinder AF, 1996, J NEUROSCI, V16, P6125; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SIESJO BK, 1978, BRAIN ENERGY METABOL, P192; TEASDALE G, 1974, LANCET, V2, P81; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; VANDENBERGHE, 2001, N ENGL J MED, V345, P1359; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; WOO J, 1990, ARCH NEUROL-CHICAGO, V47, P1174, DOI 10.1001/archneur.1990.00530110028011; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	51	60	62	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2003	29	4					544	550		10.1007/s00134-003-1669-3			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676NY	WOS:000182759600007	12655390				2022-02-06	
J	Engelberts, NHJ; Klein, M; Ader, HJ; Heimans, JJ; Trenite, DGAKN; van der Ploeg, HM				Engelberts, NHJ; Klein, M; Ader, HJ; Heimans, JJ; Trenite, DGAKN; van der Ploeg, HM			The effectiveness of cognitive rehabilitation for attention deficits in focal seizures: A randomized controlled study	EPILEPSIA			English	Article						cognitive rehabilitation; epilepsy; attention deficits; randomized controlled study	CLOSED-HEAD-INJURY; HEALTH SURVEY; BRAIN-INJURY; EPILEPSY; PROGRAM; MEMORY; RELIABILITY; EDUCATION; DISEASE; SF-36	Purpose: Cognitive deficits are one of the major limiting factors in the everyday life functioning of patients with focal Seizures. Although cognitive rehabilitation methods have been successfully applied to patients with other central nervous system (CNS) lesions, these methods have not yet been evaluated in cognitively impaired patients with epilepsy. The present study evaluated the effectiveness of two commonly used methods for attention deficits: (a) the Retraining Method, aimed at retraining impaired cognitive functions; and (b) the Compensation Method, aimed at teaching compensatory strategies while taking neuronal loss for granted. Methods: Fifty adult Outpatients with focal seizures and attention impairments receiving carbamazepine (CBZ) monotherapy were randomly assigned to the Retraining Method, the Compensation Method, or to a waiting-list control group. Established and self-reported neuropsychological outcomes and self-reported quality of life of these groups were evaluated at pretraining, posttraining, and at a 6-month follow-up measurement point and were completed by 44 patients. Results: Neuropsychological outcomes related to training, self-reported neuropsychological outcomes, and quality of life at the 6-month follow-up measurement point improved both in the Retraining Method group (n = 19) and the Compensation Method group (n = 17) relative to the waiting-list control group (n = 8). The Compensation Method was more effective in improving self-reported neuropsychological outcomes and quality of life, especially for patients with less education. The patients with active epilepsy benefited more from both methods than did the seizure-free patients. Conclusions: These data show that cognitive rehabilitation programs are effective for patients with focal seizures and attention deficits and should, therefore, be incorporated into comprehensive care programs.	Dutch Epilepsy Clin Fdn, Meer & Bosch, NL-2103 SW Heemstede, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1081 HV Amsterdam, Netherlands; Med Ctr Alkmaar, Dept Neurol, Alkmaar, Netherlands		Engelberts, NHJ (corresponding author), Dutch Epilepsy Clin Fdn, Meer & Bosch, Achterweg 5, NL-2103 SW Heemstede, Netherlands.	nengelberts@sein.nl	Trenite, Dorothee Nolst/ABG-5804-2020; Klein, Martin/C-4192-2012	Klein, Martin/0000-0003-4160-5746; Klein, Martin/0000-0001-5553-7911			Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Aldenkamp AP, 1991, NEUROPSYCHOL REHABIL, V1, P199; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CONNOR A, 1988, INT J CLIN NEUROPSYC, V10, P1; CORCORAN R, 1993, BRIT J CLIN PSYCHOL, V32, P199, DOI 10.1111/j.2044-8260.1993.tb01044.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dixon R.A., 1999, COGNITIVE NEUROREHAB, P59; Engel J, 2001, EPILEPSIA, V42, P316, DOI 10.1046/j.1528-1157.2001.t01-1-36500.x; FIMM B, 1988, THESIS; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Giovagnoli AR, 1997, EPILEPSY RES, V28, P119, DOI 10.1016/S0920-1211(97)00036-3; HAYES RL, 2000, COCHRANE DB SYST REV, V3; Hendriks MPH, 2001, CURR PROB E, V16, P87; HOUX PJ, 1993, PERCEPT MOTOR SKILL, V76, P195, DOI 10.2466/pms.1993.76.1.195; Johanson M, 2001, CURR PROB E, V16, P203; Kalviainen R, 1992, Seizure, V1, P255; Loetscher T., COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002842, DOI 10.1002/14651858.CD002842]; LOISEAU P, 1984, ACTA NEUROL SCAND, V69, P31, DOI 10.1111/j.1600-0404.1984.tb05666.x; LUTEIJN F, 1982, HANDLEIDING GRONINGE; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McNair D.M., 1981, PROFILE MOOD STATES; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Perrine K, 1999, NEUROLOGY, V53, pS39; Plohmann A, 1994, Schweiz Arch Neurol Psychiatr (1985), V145, P35; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; ROBERTSON IH, 1993, CURR OPIN NEUROL, V6, P756, DOI 10.1097/00019052-199310000-00013; RYAN R, 1980, EPILEPSIA, V21, P433, DOI 10.1111/j.1528-1157.1980.tb04091.x; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; TRENITE DGAK, 1987, ELECTROEN CLIN NEURO, V67, P167; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	39	60	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUN	2002	43	6					587	595		10.1046/j.1528-1157.2002.29401.x			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	573KH	WOS:000176828400004	12060017				2022-02-06	
J	Ginsberg, SD; Martin, LJ				Ginsberg, SD; Martin, LJ			Axonal transection in adult rat brain induces transsynaptic apoptosis and persistent atrophy of target neurons	JOURNAL OF NEUROTRAUMA			English	Article						afferent-derived trophic support; apoptosis; axotomy; deafferentation; mammillary nucleus; transneuronal injury; traumatic brain injury; fimbria-fornix	FIMBRIA-FORNIX TRANSECTION; MAMMILLARY BODY LESIONS; HIPPOCAMPAL EFFERENTS; GLUTAMATE RECEPTORS; DEPOLARIZING AGENTS; BASAL FOREBRAIN; MAMILLARY BODY; INJURY; SEPTUM; HYPOTHALAMUS	We used the fimbria-fornix (FIT) transection model of axonal injury to test the hypothesis that transneuronal degeneration occurs in the adult central nervous system in response to deafferentation. The medial mammillary nucleus, pars medialis (MMNm) was analyzed by light and electron microscopy at 3, 7, 14, and 30 days, and 6 months after unilateral FIT transection in adult rat to identify the time course of neuronal responses in a remote target. Presynaptic terminals and neuronal cell bodies degenerated in the MMNm ipsilateral to FF transection. Terminal degeneration occurred predominantly at 3 and 7 days postlesion. Between 14 and 30 days postlesion, neuronal number in the MMNm decreased (similar to 20 %). Two forms of neuronal degeneration were found in the MMNm after deafferentation. Some neurons died apoptotically. Other neurons underwent vacuolar degeneration. In these latter neurons, somatodendritic pathology occurred at 14 and 30 days and 6 months postlesion. The ultrastructure of this vacuolar degeneration was characterized by disorganization of the cytoplasm, formation of membrane-bound vacuolar cisternae and membranous inclusions, loss of organelles, cytoplasmic pallor, and chromatin alterations. This study shows that both anterograde axonal degeneration and transneuronal degeneration occur in a fornical target after FF axon transection. This transneuronal degeneration can be classified as sustained neuronal atrophy or transsynaptic apoptosis.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA		Martin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 558 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		, SDG/AAB-3329-2022	Ginsberg, Stephen/0000-0002-1797-4288	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG043375, R01AG016282] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG043375, P01 AG014449, AG16282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34100] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; ALLEN GV, 1988, J COMP NEUROL, V275, P39, DOI 10.1002/cne.902750105; ALLEN GV, 1989, J COMP NEUROL, V286, P311, DOI 10.1002/cne.902860303; Allen WF, 1944, J COMP NEUROL, V80, P283, DOI 10.1002/cne.900800208; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Amaral D. G., 1987, HDB PHYSL NERVOUS SY, VV, P211; BLEIER R, 1969, BRAIN RES, V15, P365, DOI 10.1016/0006-8993(69)90162-0; Buki A, 2000, J NEUROSCI, V20, P2825; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; CANTERAS NS, 1992, J COMP NEUROL, V324, P195, DOI 10.1002/cne.903240205; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; GINSBERG SD, 1995, J COMP NEUROL, V353, P539, DOI 10.1002/cne.903530406; Ginsberg SD, 1998, NEUROSCIENCE, V86, P1259, DOI 10.1016/S0306-4522(98)00136-5; Ginsberg SD, 1999, NEUROSCIENCE, V88, P1059, DOI 10.1016/S0306-4522(98)00288-7; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUDDEN B, 1880, ARCH PSYCHIAT NERVEN, V11, P428; GUILLERY RW, 1956, J ANAT, V90, P350; Heymach JV, 1997, NATURE, V389, P789, DOI 10.1038/39743; Krieg WJS, 1932, J COMP NEUROL, V55, P19, DOI 10.1002/cne.900550104; LANGLAIS PJ, 1990, J NEUROSCI, V10, P1664; MACLEAN PD, 1952, ELECTROEN CLIN NEURO, V4, P407, DOI 10.1016/0013-4694(52)90073-4; MAHUT H, 1972, NEUROPSYCHOLOGIA, V10, P65, DOI 10.1016/0028-3932(72)90043-7; MAIR WGP, 1979, BRAIN, V102, P749, DOI 10.1093/brain/102.4.749; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.3.CO;2-R; Martin LJ, 2001, INT J MOL MED, V7, P455; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Moudgil SS, 2000, STROKE, V31, P1418, DOI 10.1161/01.STR.31.6.1418; MOUNT HTJ, 1993, J NEUROSCI, V13, P3173; NAMURA S, 1994, BRAIN RES BULL, V35, P221, DOI 10.1016/0361-9230(94)90126-0; NAUTA W J H, 1969, P136; NAUTA WJH, 1956, J COMP NEUROL, V104, P247, DOI 10.1002/cne.901040205; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RAMNATH RR, 1992, NEUROSCIENCE, V51, P931, DOI 10.1016/0306-4522(92)90530-F; RAZ N, 1992, NEUROREPORT, V3, P713, DOI 10.1097/00001756-199208000-00016; Rose J, 1939, J ANAT, V74, P91; SAUNDERS RC, 1989, BEHAV BRAIN RES, V35, P85, DOI 10.1016/S0166-4328(89)80109-3; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; STICHEL CC, 1995, EUR J NEUROSCI, V7, P401, DOI 10.1111/j.1460-9568.1995.tb00336.x; STORMMATHISEN J, 1978, NEUROSCI LETT, V9, P65, DOI 10.1016/0304-3940(78)90049-6; SWANSON LW, 1975, SCIENCE, V189, P303, DOI 10.1126/science.49928; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; TAKATA M, 1995, INTEGR COMPUT-AID E, V2, P249; TONKISS J, 1992, EXP BRAIN RES, V90, P572; WALAAS I, 1980, NEUROSCIENCE, V5, P1691, DOI 10.1016/0306-4522(80)90088-3; ZHANG SX, 1995, J NEUROPATH EXP NEUR, V54, P255, DOI 10.1097/00005072-199503000-00012	57	60	60	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2002	19	1					99	109		10.1089/089771502753460277			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	517LD	WOS:000173611300009	11852982				2022-02-06	
J	Williams, S; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Graham, DI				Williams, S; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Graham, DI			In situ DNA fragmentation occurs in white matter up to 12 months after head injury in man	ACTA NEUROPATHOLOGICA			English	Article						human traumatic brain injury; white matter damage; TUNEL staining; apoptosis	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; CELL-DEATH; COMPRESSION TRAUMA; TEMPORAL PROFILE; APOPTOSIS; RAT; BCL-2; DEGENERATION	Using the terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labelling (TUNEL) histochemical technique, evidence for DNA fragmentation was sought in the hippocampus, cingulate gyrus and insula from 18 patients who survived for up to 12 months after head injury, and 15 matched controls. Both conventional (haematoxylin and eosin and Luxol-fast blue/cresyl violet) and immunohistochemical (glial fibrillary acidic protein, CD68) staining techniques were used to identify the cellular response and its time course in the regions of interest. Only the occasional TUNEL-positive ((+)) cell/unit area was seen in any area of the control brains. In contrast there were more TUNEL+ cells/unit area in the injured brains. TUNEL+ cells were present in white matter and their average numbers ranged from three to five per unit area for up to 3 months survival in the extreme capsule and the parasagittal white matter, with similar numbers in the hippocampus, and between two and three per unit area in the parasagittal white matter and hippocampus of the cases surviving up to 12 months post injury. Between one and two TUNEL+ cells/unit area were also seen in grey matter, of which most appeared as neurones. About 5% of the TUNEL+ cells in white matter had the morphological features of apoptosis: the corresponding figure in grey matter was less than 1%. In many instances the TUNEL+ cells were also CD68(+) and appeared by light microscopy to be macrophages. It was concluded that, as reflected by TUNEL histochemistry, long-term DNA fragmentation is present in white matter after traumatic brain injury in man.	So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Univ Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Graham, DI (corresponding author), So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Univ Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAMASHIMA K, 1999, J NEUROTRAUM, V16, P143; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Probst-Cousin S, 1998, J NEUROPATH EXP NEUR, V57, P814, DOI 10.1097/00005072-199809000-00002; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Sheng JG, 1998, J NEUROPATH EXP NEUR, V57, P714, DOI 10.1097/00005072-199807000-00008; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soares HD, 1995, J NEUROSCI, V15, P8223; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Troncoso JC, 1996, J NEUROPATH EXP NEUR, V55, P1134, DOI 10.1097/00005072-199611000-00004; WILLIAMS S, 1998, J NEUROTRAUM, V15, P871; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207	53	60	61	1	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2001	102	6					581	590		10.1007/s004010100410			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	495TZ	WOS:000172357600003	11761718				2022-02-06	
J	Jellinger, KA; Paulus, W; Wrocklage, C; Litvan, I				Jellinger, KA; Paulus, W; Wrocklage, C; Litvan, I			Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; ApoE allele frequency; closed traumatic brain injury	HEAD-INJURY; SENILE DEMENTIA; RISK; PREVALENCE; AD	In order to assess the impact of traumatic brain injury (TBI) and Apolipoprotein E (ApoE) allele frequency on the development of Alzheimer's disease (AD), we examined: (i) the incidence of AD pathology in 55 consecutive autopsy cases (mean age +/- SD 77.6 +/- 7.3 years) with residual closed TBI lesions and (ii) the frequency of TBI residuals in 53 age-matched autopsy proven AD cases. In both series, ApoE was evaluated from archival paraffin-em bedded brain material. The results were as follows: (i) In the TBI series, 12.7% showed Consortium to Establish a Registry for Alzheimer's disease (CERAD) definite and 9.1% probable AD, only one with ApoE epsilon4. From the remaining 43 non-AD cases, three had ApoE epsilon4. The prevalence of 21.8% AD in this small autopsy cohort was significantly higher than 3.3% in a recent large clinical series and 14% in the general population over the age of 70. (ii) In the AD cohort with ApoE epsilon4 allele frequency of 30% similar to other AD series, residuals of TBI were seen in 4 brains (7.5%), all lacking the ApoE epsilon4 allele. TBI incidence was slightly higher than 8.5% in the clinical MIRAGE study. The results of this first retrospective autopsy study of TBI, ApoE allele frequency, and AD confirms clinical studies suggesting severe TBI to be a risk factor for the development of AD particularly in subjects lacking ApoE epsilon4.	L Boltzmann Inst Clin Neurobiol, Vienna, Austria; Univ Munster, Sch Med, Inst Neuropathol, D-4400 Munster, Germany; HM Jackson Fdn, Cognit Neuropharmacol Unit, Bethesda, MD USA		Jellinger, KA (corresponding author), Otto Wagner Hosp, L Boltzmann Inst Clin Neurobiol, B Bldg,1 Baumgartner Hohe, A-1140 Vienna, Austria.		Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445			Bancher C, 1997, ACTA NEUROPATHOL, V94, P403, DOI 10.1007/s004010050726; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Corder EH, 1998, CELL MOL LIFE SCI, V54, P928, DOI 10.1007/s000180050223; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geldmacher DS, 1996, NEW ENGL J MED, V335, P330, DOI 10.1056/NEJM199608013350507; Gottlieb S, 2000, BRIT MED J, V321, P1100; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARRINGTON CR, 1994, AM J PATHOL, V145, P1472; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hy LX, 2000, NEUROLOGY, V55, P198, DOI 10.1212/WNL.55.2.198; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; REICHIES FM, 1997, NERVENARZT, V68, P719; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SMITH C, 2001, NEUROPATHOL APPL NEU, V27, P151; WROCKLAGE C, 1999, ACTA NEUROPATHOL, V99, P557	22	60	61	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	NOV	2001	8	6					707	710		10.1046/j.1468-1331.2001.00322.x			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	503NB	WOS:000172803600023	11784357				2022-02-06	
J	Newcomb-Fernandez, JK; Zhao, XR; Pike, BR; Wang, KKW; Kampfl, A; Beer, R; DeFord, SM; Hayes, RL				Newcomb-Fernandez, JK; Zhao, XR; Pike, BR; Wang, KKW; Kampfl, A; Beer, R; DeFord, SM; Hayes, RL			Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septo-hippocampal cultures	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; calpain; caspases; necrosis; stroke; TBI	CORTICAL IMPACT INJURY; TRAUMATIC BRAIN-INJURY; MAITOTOXIN INDUCES CALPAIN; FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; APOPTOTIC CELL-DEATH; ALPHA-SPECTRIN; FODRIN PROTEOLYSIS; DNA FRAGMENTATION; PROTEIN-SYNTHESIS	The contributions of calpain and caspase-3 to apoptosis and necrosis after central nervous system (CNS) trauma are relatively unexplored. No study has examined concurrent activation of calpain and caspase-3 in necrotic or apoptotic cell death after any CNS insult. Experiments used a model of oxygen-glucose deprivation (OGD) in primary septo-hippocampal cultures and assessed cell viability, occurrence of apoptotic and necrotic cell death phenotypes, and protease activation. Immunoblots using an antibody detecting calpain and caspase-3 proteolysis of alpha -spectrin showed greater accumulation of calpain-mediated breakdown products (BDPs) compared with caspase-3-mediated BDPs. Administration of calpain and caspase-3 inhibitors confirmed that activation of these proteases contributed to cell death, as inferred by lactate dehydrogenase. release. Oxygen-glucose deprivation resulted in expression of apoptotic and necrotic cell death phenotypes, especially in neurons. Immunocytochemical studies of calpain and caspase-3 activation in apoptotic cells indicated that these proteases are almost always concurrently activated during apoptosis. These data demonstrate that calpain and caspase-3 activation is associated with expression of apoptotic cell death phenotypes after OGD, and that calpain activation, in combination with caspase-3 activation, could contribute to the expression of apoptotic cell death by assisting in the degradation of important cellular proteins.	Univ Florida, Ctr Traumat Brain Injury Studies, Evelyn F & William McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI USA; Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria		Hayes, RL (corresponding author), Univ Florida, Ctr Traumat Brain Injury Studies, Evelyn F & William McKnight Brain Inst, Dept Neurosci, 100 Newell Dr,Box 100244, Gainesville, FL 32610 USA.		Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Buki A, 2000, J NEUROSCI, V20, P2825; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; Chen J, 1998, J NEUROSCI, V18, P4914; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Copin JC, 1998, BRAIN RES, V784, P25, DOI 10.1016/S0006-8993(97)00972-4; DiLoreto S, 1997, INT J DEV NEUROSCI, V15, P225; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Kalda A, 1998, NEUROSCI LETT, V240, P21, DOI 10.1016/S0304-3940(97)00914-2; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Lobner D, 1996, NEUROSCIENCE, V72, P335, DOI 10.1016/0306-4522(95)00561-7; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Pang Z, 1997, J NEUROSCI, V17, P3064; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; PURANAM KL, 1999, CRC METH NEUROSCI S, P129; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Schmechel D.E., 1999, CRC METH NEUROSCI S, P161; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	60	60	61	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2001	21	11					1281	1294		10.1097/00004647-200111000-00004			14	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	491AZ	WOS:000172087000004	11702043	Bronze			2022-02-06	
J	Hawley, CA				Hawley, CA			Return to driving after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						driving; brain injury	TRAUMATIC BRAIN INJURY; FIM+FAM; STROKE	Objectives-To determine whether patients who return to driving after head injury can be considered safe to do so and to compare the patient characteristics of those who return to driving with those who do not. Methods - In a multicentre qualitative study 10 rehabilitation units collectively registered 563 adults with traumatic brain injury during a 2.5 year period. Recruitment to the study varied from immediately after hospital admission to several years after injury, Patients and their families were interviewed around 3 to 6 months after recruitment. A total of 383 (67.5%) subjects were interviewed within 1 year of injury, of whom 270 (47.6%) were interviewed within 6 months of injury. Main outcome measures were the presence or absence of driving related problems reported by drivers and ex-drivers, and scores on driving related items of the functional independence/functional assessment measure (FIM+FAM). Result - Of the 563 patients 381 were drivers before the injury and 139 had returned to driving at interview. Many current drivers reported problems with behaviour (anger, aggression, irritability; 67 (48.2%)), memory (89(64%)), concentration and attention (39 (28.1%)), and vision (39 (28.1%)). Drivers reported most driving related problems as often as ex-drivers, main exceptions were epilepsy and community mobility. Current drivers scored significantly higher on the FIM+FAIM (were more independent), than ex-drivers. The driving group had sustained less severe head injuries than ex-drivers; nevertheless, 78 (56.2%) current drivers had received a severe head injury. Few (61 (16%)) previous drivers reported receiving formal advice about driving after injury. Conclusions - The existence of problems which could significantly affect driving does not prevent patients returning to driving after traumatic brain injury. Patients should be assessed for both mental and physical status before returning to driving after a head injury, and systems put in place to enable clear and consistent advice to be given to patients about driving.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; *DRIV MED GROUP, 1996, MED PRACT GLANC GUID; Fisk GD, 1998, BRAIN INJURY, V12, P683; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HAWLEY CA, 2000, BRIT J THERAPY REHAB, V7, P116; *HEADW, 1989, DRIV HEAD INJ; JENNETT B, 1995, MED ASPECTS FITNESS; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCMILLAN T, 1991, REHABILITATION PROGR; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MORTIMER RG, 1986, ISION VEHICLES; MUNTON G, 1995, MED ASPECTS FITNESS; *NHS HLTH ADV SERV, 1996, THERM REV MENT HLTH; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RIMEL RW, 1990, REHABILITATION ADULT; SCHUTTE P, 1995, MED ASPECTS FITNESS; SHUTE RH, 1990, OPHTHAL PHYSL OPT, V10, P327, DOI 10.1111/j.1475-1313.1990.tb00878.x; *SOC SERV INSP SOC, 1995, INF STRAT SYST REF C; *STAT U NEW YORK B, 1989, FAM DEC TREE; STILWELL J, 1998, REPORT NATL TRAUMATI; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TAYLOR JF, 1995, MED ASPECTS FITNESS; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	31	60	65	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2001	70	6					761	766		10.1136/jnnp.70.6.761			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	443RV	WOS:000169354900012	11385010	Green Published, Green Submitted, Bronze			2022-02-06	
J	Grados, MA; Slomine, BS; Gerring, JP; Vasa, R; Bryan, N; Denckla, MB				Grados, MA; Slomine, BS; Gerring, JP; Vasa, R; Bryan, N; Denckla, MB			Depth of lesion model in children and adolescents with moderate to severe traumatic brain injury: use of SPGR MRI to predict severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; magnetic resonance imaging; Glasgow coma scale; lesion depth	CLOSED-HEAD-INJURY; AXONAL INJURY; IMAGING FINDINGS; STEM; MEMORY; SCALE; COMA; SCHIZOPHRENIA; CONSCIOUSNESS; SURVIVAL	Objectives-The utility of a depth of lesion classification using an SPGR MRI sequence in children with moderate to severe traumatic brain injury (TBI) was examined. Clinical and depth of lesion classification measures of TBI severity were used to predict neurological and functional outcome after TBI. Methods-One hundred and six children, aged 4 to 19, with moderate to severe TBI admitted to a rehabilitation unit had an SPGR MRI sequence obtained 3 months after TBI. Acquired images were analyzed for location, number, and size of lesions. The Glasgow coma scale (GCS) was the clinical indicator of severity. The deepest lesion present was used for depth of lesion classification. Speed of injury was inferred from the type of injury. The disability rating scale at the time of discharge from the rehabilitation unit (DRS1) and at 1 year follow up (DRS2) were functional outcome measures. Results-The depth of lesion classification was significantly correlated with GCS Severity, number of lesions, and both functional measures, DRS1 and DRS2. This result was more robust for time 1, probably due to the greater number of psychosocial factors impacting on functioning at time 2. Lesion volume was not correlated with the depth of lesion model. In multivariate models, depth of lesion was most predictive of DRS1, whereas GCS was most predictive of DRS2. Conclusions-A depth of lesion classification of TBI severity may have clinical utility in predicting functional outcome in children and adolescents with moderate to severe TBI.	Kennedy Krieger Inst, Dept Psychiat, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Hosp Univ Penn, Dept Radiol, Philadelphia, PA USA		Grados, MA (corresponding author), Kennedy Krieger Inst, Dept Psychiat, 4th Floor,1750 E Fairmount, Baltimore, MD 21224 USA.	mjgrados@mail.jhmi.edu		Grados, Marco/0000-0002-6189-6264	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; Aylward EH, 1997, PSYCHIAT RES-NEUROIM, V75, P23, DOI 10.1016/S0925-4927(97)00026-7; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; Cassidy John W., 1994, P43; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Colletti PM, 1996, COMPUT MED IMAG GRAP, V20, P491, DOI 10.1016/S0895-6111(96)00045-6; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Friston KJ, 1996, BRIT MED BULL, V52, P644; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; *ISG TECHN, 1995, ALL SOFTW; JENKINS A, 1986, LANCET, V2, P445; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KIM RC, 1985, SURG NEUROL, V23, P525, DOI 10.1016/0090-3019(85)90250-2; KRIEGER D, 1993, CRIT CARE MED, V21, P1944, DOI 10.1097/00003246-199312000-00024; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paradiso S, 1997, NEUROPSY NEUROPSY BE, V10, P1; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Rand S, 1992, Top Magn Reson Imaging, V4, P7; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SALLOWAY S, 1997, NEUROPSYCHIATRY LIMB; SHOGRY MEC, 1992, J COMPUT ASSIST TOMO, V16, P48, DOI 10.1097/00004728-199201000-00009; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; *STAT CORP, 1999, STAT 6 0; STRICH SJ, 1961, LANCET, V2, P443; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Torres IJ, 1997, BIOL PSYCHIAT, V42, P1087, DOI 10.1016/S0006-3223(97)00024-3; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	46	60	62	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2001	70	3					350	358		10.1136/jnnp.70.3.350			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	405MG	WOS:000167163100013	11181858	Bronze, Green Published			2022-02-06	
J	Ronne-Engstrom, E; Cesarini, KG; Enblad, P; Hesselager, G; Marklund, N; Salci, K; Persson, L; Hillered, L				Ronne-Engstrom, E; Cesarini, KG; Enblad, P; Hesselager, G; Marklund, N; Salci, K; Persson, L; Hillered, L			Intracerebral microdialysis in neurointensive care: the use of urea as an endogenous reference compound	JOURNAL OF NEUROSURGERY			English	Article						microdialysis; urea; traumatic brain injury; cerebrovascular disease	AMINO-ACID RELEASE; QUANTITATIVE MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; HUMAN BRAIN; GLUTAMATE; ISCHEMIA; KINETICS; SEIZURE; INJURY; SPACE	Object. When evaluating the results of intracerebral microdialysis, the in vivo performance of the microdialysis probe must be considered, because this determines the fraction of the interstitial concentration obtained in the microdialysis samples. The in vivo performance is dependent on several factors, for example, the interstitial compartment's diffusion characteristics, which may vary during the course of the acute brain injury process. In the present study the authors investigated the method of controlling the in vivo performance by using urea, which is evenly distributed in all body fluid compartments, as an endogenous reference compound and by comparing the urea levels in three compartments: the brain (CNS), abdominal subcutaneous tissue (SC), and blood serum (BS). Methods. Sixty-nine patients with traumatic brain injury or cerebrovascular disease were included in the study. In 63 of these patients a CNS probe was used, an SC probe was used in 40, and both were used in 34. Urea was measured by enzymatic methods, at bedside for the microdialysis samples and in routine clinical laboratory studies for the BS samples, with the probe calibrated to give identical results. The correlation coefficient for CNS/SC urea was 0.88 (2414 samples), for CNS/BS urea it was 0.89 (180 samples), and for SC/BS urea it was 0.98 (112 samples). Conclusions. Urea levels in the CNS, SC, and BS were highly correlated, which supports the assumption that urea is evenly distributed. The CNS/SC urea ratio can therefore be used for monitoring the CNS probe's in vivo performance. Fluctuations in other substances measured with microdialysis are probably caused by biological changes in the brain, as long as the CNS/SC urea ratio remains constant.	Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden		Ronne-Engstrom, E (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.	elisabeth.ronne-engstrom@nc.uas.lul.se		Marklund, Niklas/0000-0002-9797-5626			BENVENISTE H, 1989, J NEUROCHEM, V52, P1741, DOI 10.1111/j.1471-4159.1989.tb07252.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; Boris-Moller F, 1998, MOL CHEM NEUROPATHOL, V35, P133, DOI 10.1007/BF02815120; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; DURING MJ, 1993, LANCET, V341, P1607; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; GARDNER EL, 1993, J NEUROSCI METH, V48, P173, DOI 10.1016/0165-0270(93)90091-5; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; JEEJEEBHOY KN, 1995, TXB CRITICAL CARE, P1106; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LINDEFORS N, 1989, J PHARMACOL METHOD, V22, P141, DOI 10.1016/0160-5402(89)90011-9; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228, DOI 10.1152/ajpendo.1987.253.2.E228; MATHEWS CK, 1990, BIOCHEMISTRY-US, P670; METRY GS, 1993, KIDNEY INT, V44, P622, DOI 10.1038/ki.1993.290; MORRISON PF, 1991, J NEUROCHEM, V57, P103, DOI 10.1111/j.1471-4159.1991.tb02105.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V85, P984; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; STAHLE L, 1990, EUR J PHARMACOL, V185, P187, DOI 10.1016/0014-2999(90)90639-N; STJERNSTROM H, 1993, INTENS CARE MED, V19, P423, DOI 10.1007/BF01724886; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WANG YF, 1993, PHARMACEUT RES, V10, P1411, DOI 10.1023/A:1018906821725; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5	29	60	61	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2001	94	3					397	402		10.3171/jns.2001.94.3.0397			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	405KB	WOS:000167157600004	11235942				2022-02-06	
J	Arciniegas, D; Olincy, A; Topkoff, J; McRae, K; Cawthra, E; Filley, CM; Reite, M; Adler, LE				Arciniegas, D; Olincy, A; Topkoff, J; McRae, K; Cawthra, E; Filley, CM; Reite, M; Adler, LE			Impaired auditory gating and P50 nonsuppression following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MINOR HEAD-INJURIES; NICOTINIC RECEPTORS; ALZHEIMERS-DISEASE; EVOKED-POTENTIALS; MENTAL-STATE; SCHIZOPHRENIA; HIPPOCAMPAL; ACETYLCHOLINE; RATS; CONCUSSION	Traumatic brain injury (TBI) can produce persistent attention and memory impairment that may in part be produced by impaired auditory sensory getting. The P50 evoked waveform response to paired auditory stimuli appears to be a useful measure of auditory gating. The first controlled measurement of the P50 ratio in TBI patients is described: when 20 patients with persistently symptomatic TBI were compared with 20 control subjects, the P50 ratio was significantly greater in the TBI group. The potential neurophysiologic and therapeutic implications of this finding in TBI patients who report symptoms consistent with impaired auditory gating are discussed.	Univ Colorado, Hlth Sci Ctr, Dept Psychiat & Neurol, Denver, CO 80262 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO USA; Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA; Vet Affairs Med Ctr, Serv Neurol, Denver, CO USA		Arciniegas, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat & Neurol, Campus Box C268-28,4200 E 9th Ave, Denver, CO 80262 USA.		Arciniegas, David/A-3792-2009		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH056601, R01MH047476] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH47476, MH56601, MH15442] Funding Source: Medline		Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; ADLER LE, IN PRESS BIOL PSYCHI; ALEXANDER MP, 1982, TRAUMATIC BRAIN INJU, P219; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BICKFORDWIMER PC, 1990, BIOL PSYCHIAT, V27, P183, DOI 10.1016/0006-3223(90)90648-L; BOUTROS N, 1995, PSYCHIAT RES, V57, P57, DOI 10.1016/0165-1781(95)02597-P; BOUTROS NN, 1991, CLIN ELECTROENCEPHAL, V22, P40, DOI 10.1177/155005949102200109; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; BUCHWALD JS, 1989, ELECTROEN CLIN NEURO, V74, P378, DOI 10.1016/0168-5597(89)90005-1; Cassidy John W., 1994, P43; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Clementz BA, 1998, AM J PSYCHIAT, V155, P1691, DOI 10.1176/ajp.155.12.1691; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Filley C., 1995, NEUROBEHAVIORAL ANAT; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREEDMAN R, 1994, HARVARD REV PSYCHIAT, V2, P179, DOI 10.3109/10673229409017136; Frith CD, 1996, NEUROIMAGE, V4, P210, DOI 10.1006/nimg.1996.0072; GARCIARILL E, 1995, NEUROSCIENCE, V66, P321, DOI 10.1016/0306-4522(94)00564-L; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1988, CLIN NEUROPHARMACOL, V12, P273; Guillery RW, 1998, TRENDS NEUROSCI, V21, P28, DOI 10.1016/S0166-2236(97)01157-0; GUPTA NK, 1986, NEUROLOGY, V36, P578, DOI 10.1212/WNL.36.4.578; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; Harris JG, 1996, SCHIZOPHR RES, V20, P253, DOI 10.1016/0920-9964(96)00009-6; JABBARI B, 1987, ELECTROEN CLIN NEURO, V67, P289, DOI 10.1016/0013-4694(87)90115-5; JENNETT B, 1975, LANCET, V1, P480; JOHNSON MR, 1993, BIOL PSYCHIAT, V33, P380, DOI 10.1016/0006-3223(93)90328-B; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1994, EPIDEMIOLOGY NEUROPS, P3; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; Lovell Mark R., 1994, P133; LUNTZLEYBMAN V, 1992, BRAIN RES, V587, P130, DOI 10.1016/0006-8993(92)91437-J; McAllister Thomas W., 1994, P357; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nagamoto HT, 1996, BIOL PSYCHIAT, V40, P181, DOI 10.1016/0006-3223(95)00371-1; NAGAMOTO HT, 1989, BIOL PSYCHIAT, V25, P549, DOI 10.1016/0006-3223(89)90215-1; OLBRICH HM, 1986, ACTA NEUROCHIR, V80, P116, DOI 10.1007/BF01812285; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rund BR, 1998, SCAND J PSYCHOL, V39, P101, DOI 10.1111/1467-9450.00062; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; Seidman LJ, 1998, BIOL PSYCHIAT, V44, P260, DOI 10.1016/S0006-3223(97)00392-2; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Stevens KE, 1997, PHARMACOL BIOCHEM BE, V57, P869, DOI 10.1016/S0091-3057(96)00466-2; Stevens KE, 1998, NEUROSCIENCE, V82, P701; STRUB RL, 1988, NEUROBEHAVIORAL DISO; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, PATHOPHYSIOLOGY HEAD, P4; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Venables PH, 1964, INPUT DYSFUNCTION SC, P1; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	71	60	60	0	2	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2000	12	1					77	85		10.1176/jnp.12.1.77			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	280JY	WOS:000085100700013	10678517				2022-02-06	
J	Pierallini, A; Pantano, P; Fantozzi, LM; Bonamini, M; Vichi, R; Zylberman, R; Pisarri, F; Colonnese, C; Bozzao, L				Pierallini, A; Pantano, P; Fantozzi, LM; Bonamini, M; Vichi, R; Zylberman, R; Pisarri, F; Colonnese, C; Bozzao, L			Correlation between MRI findings and long-term outcome in patients with severe brain trauma	NEURORADIOLOGY			English	Article						traumatic brain injury; magnetic resonance imaging; pulse sequences	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; DIFFUSE AXONAL INJURY; COMPUTERIZED-TOMOGRAPHY; PREDICTING SURVIVAL; RECOVERY; HEMORRHAGE; DIAGNOSIS; FLAIR; VARIABLES	Our aim was to relate MRT. findings in patients with severe traumatic brain injury (TBI) to clinical severity and long-term outcome. We studied 37 patients with severe TBI, who were submitted to clinical assessment for disability and cognition and to MRI 60-90 days after trauma. Clinical assessment was also performed 3, 6 and 12 months later. The number and volume of lesions in various cerebral structures were calculated semiautomatically from FLAIR and fast field-echo images. Possible correlations between total and regional lesion volume and clinical deficits were then investigated. The frontal and temporal lobes were most frequently involved. Total lesion volume on FLAIR images correlated significantly with clinical outcome, whereas that on FFE images did not. Regional analysis showed that FLAIR lesion volume in the corpus callosum correlated significantly with scores on disability and cognition scales at the first clinical assessment. FLAIR lesion volume in the frontal lobes correlated significantly with clinical scores 1 year later.	Univ Rome La Sapienza, Dept Neurol Sci, Neuroradiol Sect, I-00185 Rome, Italy; Hosp San Giovanni Battista, SMOM, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy		Pierallini, A (corresponding author), Univ Rome La Sapienza, Dept Neurol Sci, Neuroradiol Sect, I-00185 Rome, Italy.		colonnese, claudio/AAB-9727-2020; Pierallini, Alberto/AAB-3271-2021; Patrizia, Pantano/C-8214-2009	colonnese, claudio/0000-0003-4249-4689; Patrizia, Pantano/0000-0001-9659-8294			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Brooks D N, 1979, Int Rehabil Med, V1, P160; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; DEROSIER C, 1991, J NEURORADIOLOGY, V18, P309; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GODERSKY JC, 1990, ACT NEUR S, V51, P311; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P841, DOI 10.1097/00004728-199211000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kates R, 1996, Top Magn Reson Imaging, V8, P389; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P3255; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; Noguchi K, 1997, NEURORADIOLOGY, V39, P406, DOI 10.1007/s002340050433; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1974, LANCET, V2, P81; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	38	60	62	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	DEC	2000	42	12					860	867		10.1007/s002340000447			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	386NN	WOS:000166068600002	11198202				2022-02-06	
J	Jackson, RGM; Samra, GS; Radcliffe, J; Clark, GH; Price, CP				Jackson, RGM; Samra, GS; Radcliffe, J; Clark, GH; Price, CP			The early fall in levels of S-100 beta in traumatic brain injury	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article; Proceedings Paper	European Meeting on Biomarkers of Organ Damage and Dysfunction	APR 03-07, 2000	CAMBRIDGE, ENGLAND			S-100 protein; outcome; head injury; blood	SEVERE HEAD-INJURY; PROTEIN S-100; BARRIER CHANGES; SERUM LEVELS; BLOOD	Protein S-100 beta has been suggested as a prognostic marker in traumatic brain injury, However, little is known of its behaviour in the immediate post-injury period. With Ethics Committee approval, we recruited 30 patients with a history of head injury presenting to our Accident and Emergency Department. Blood was taken on arrival and at four hours post-injury. Serum S-100 beta was estimated using an immunoluminometric assay. Levels of S-100 beta were seen to fall rapidly with time. Half-time was distributed non-parametrically with a median of 198 minutes. Using the Mann-Whitney U test we found a statistically significant difference between non-desirable (Glasgow Outcome Score 1-3) and desirable (Glasgow Outcome Score 4-5) outcome on admission (p = 0.0155) but not at four hours (p = 0.1336). Levels of S-100 beta fell rapidly after its release following traumatic brain injury. Time after injury is therefore critical in assessing the significance of levels of S-100 beta, and sampling should be as early as possible to gain maximum information. If S-100 beta is to be assessed as a monitor of ongoing brain injury in the intensive therapy unit sampling must be frequent (e.g. every 4 hours) to be able to detect rises in serum levels before they have decayed to baseline.	Royal London Hosp, Acad Dept Anaesthesia & Intens Care, Anaesthet Unit, London E1 1BB, England; Royal London Hosp, Dept Clin Biochem, London E1 1BB, England		Samra, GS (corresponding author), Royal London Hosp, Acad Dept Anaesthesia & Intens Care, Anaesthet Unit, London E1 1BB, England.						Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; McKeating EG, 1998, ACT NEUR S, V71, P117; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	14	60	62	0	0	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621			CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	NOV	2000	38	11					1165	1167		10.1515/CCLM.2000.179			3	Medical Laboratory Technology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	395TD	WOS:000166596600020	11156351				2022-02-06	
J	Clark, WM; Raps, EC; Tong, DC; Kelly, RE				Clark, WM; Raps, EC; Tong, DC; Kelly, RE		Cervene Stroke Study Invest	Cervene (nalmefene) in acute ischemic stroke - Final results of a phase III efficacy study	STROKE			English	Article						narcotic antagonists; stroke; therapy	RECEPTOR ANTAGONIST NALMEFENE; CEREBRAL-ISCHEMIA; SPINAL-CORD; GLUTAMATE ANTAGONIST; RANDOMIZED TRIAL; TRAUMATIC INJURY; BRAIN ISCHEMIA; NALOXONE; TOLERABILITY; DEFICITS	Background and Purpose-The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (less than or equal to 6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene. an opioid antagonist with relative kappa receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients (<70 years old. Methods-This investigation was a phase III, placebo-controlled, double-blind, randomized study of a 24-hour infusion of nalmefene. Patients with acute ischemic stroke who had an onset of symptoms within 6 hours and a baseline score of greater than or equal to 4 on the NIH Stroke Scale were randomized to receive either 60 mg nalmefene administercd as a ID-mg bolus over 15 minutes and then a 50-mg infusion over 23.75 hours or placebo, The primary efficacy outcome was the proportion of patients achieving a score of greater than or equal to 60 on the Bathel Index and a rating of "moderate disability" or better on the Glasgow Outcome Scale at 12 weeks. Assessments were performed at baseline iprcdose), hours 12 and 24, days 2 and 7, and week 12, Results-A total of 368 patients were randomized at 42 centers, including 32 patients treated with recombinant tissue plasminogen activator and study drug. Nalmefene was well tolerated. Overall, there was no significant difference in 3-month functional outcome for nalmefene treatment compared with placebo on any of the planned analyses. A prospective secondary analysis also failed to find a treatment effect in patients <70 years old, Conclusions-Although nalmeferne appears to be safe and well tolerated. this study failed to find any treatment benefit in stroke patients treated within 6 hours.	Oregon Hlth Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Stanford Stroke Ctr, Palo Alto, CA USA; Louisiana State Univ, Ctr Med, Shreveport, LA 71130 USA		Clark, WM (corresponding author), Oregon Hlth Sci Univ, Oregon Stroke Ctr, UHS 44,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.						ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ALBERS G, 1997, STROKE, V28, P271; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Clark W, 1999, J Stroke Cerebrovasc Dis, V8, P224, DOI 10.1016/S1052-3057(99)80071-8; Clark W M, 1996, J Stroke Cerebrovasc Dis, V6, P35, DOI 10.1016/S1052-3057(96)80024-3; Clark WM, 1999, STROKE, V30, P2592, DOI 10.1161/01.STR.30.12.2592; CLARK WM, 1994, NEUROLOGY, V44, pA270; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Davis Stephen M., 1997, Stroke, V28, P271; EDWARDS K, 1996, NEUROLOGY, V46, P424; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FADEN AI, 1990, PROTECTION BRAIN ISC, P265; FALLIS RJ, 1984, STROKE, V15, P627, DOI 10.1161/01.STR.15.4.627; GRAHAM SH, 1993, BRAIN RES, V632, P346, DOI 10.1016/0006-8993(93)91175-R; GROTTA J, 1995, STROKE, V26, P602, DOI 10.1161/01.STR.26.4.602; Grotta James, 1997, Stroke, V28, P271; HAHN EF, 1975, J MED CHEM, V18, P259, DOI 10.1021/jm00237a008; HARIRI RJ, 1986, J NEUROSURG, V64, P780, DOI 10.3171/jns.1986.64.5.0780; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; JENNETT B, 1975, LANCET, V1, P480; KRUMINS SA, 1986, ANN NEUROL, V19, P498, DOI 10.1002/ana.410190514; LESKO L, 1997, STROKE, V28, P232; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; NAMBA S, 1986, JPN J PSYCHIAT NEUR, V40, P61; OLNEY JW, 1983, EXCITOTOXINS, P92; PERRARO F, 1984, LANCET, V1, P915; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANDOR P, 1986, J CEREBR BLOOD F MET, V6, P553, DOI 10.1038/jcbfm.1986.101; SCAVINI C, 1990, STROKE, V21, P943, DOI 10.1161/01.STR.21.6.943; VINK R, 1990, J NEUROSCI, V10, P3524; YUM SW, 1990, ARCH NEUROL-CHICAGO, V47, P277, DOI 10.1001/archneur.1990.00530030043014; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	38	60	62	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUN	2000	31	6					1234	1239		10.1161/01.STR.31.6.1234			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	319HJ	WOS:000087335200006	10835438	Bronze			2022-02-06	
J	Wallace, CA; Bogner, J				Wallace, CA; Bogner, J			Awareness of deficits: emotional implications for persons with brain injury and their significant others	BRAIN INJURY			English	Article							COMPETENCE RATING-SCALE; TRAUMATIC HEAD-INJURY; PSYCHOMETRIC PROPERTIES; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; PRIMARY CAREGIVERS; SELF-AWARENESS; FAMILY; RELATIVES; PATIENT	The relationship between emotional distress and differing perceptions of the extent of deficits was investigated with fifty individuals with brain injury and their significant others. Participants completed questionnaires assessing their perceptions of the individual's deficits in various areas (Patient Competency Rating Scale, PCRS). Difference scores were used as markers for awareness of deficits. Emotional distress of the individuals with brain injury and their significant others was assessed with the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Forty per cent of persons with brain injury and 34% of significant others reported symptoms suggestive of mild or greater depression, while 54% of persons with brain injury and 39% of significant others reported symptoms suggestive of experiencing mild or greater anxiety. Significant relationships were not found between the emotional distress of significant others and difference scores. Moderate-to-weak relationships were found between difference scores and the emotional distress of individuals with brain injury. The relationship between chronicity and awareness of deficits was in the opposite direction than predicted. The adjustment of significant others appears to be a function of the extent to which they perceive a resolution of deficits, time since injury, and other factors. Implications for rehabilitation and future research are discussed.	Bancroft Neurohlth, Haddonfield, NJ 08033 USA; Ohio State Univ, Columbus, OH 43210 USA		Bogner, J (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Bogner, Jennifer/E-2773-2011				ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Beck A. T., 1993, BECK DEPRESSION INVE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BECK AT, 1979, COGNITIVE THERAPY DE; Beck AT, 1993, BECK ANXIETY INVENTO; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DeLuca J., 1992, NEUROREHABILITATION, V2, P23, DOI [https://doi.org/10.3233/NRE-1992-2305, DOI 10.3233/NRE-1992-2305]; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EZBACHI O, 1991, J HEAD TRAUMA REHAB, V6, P71; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fluharty G, 1997, NEUROREHABILITATION, V9, P221, DOI 10.3233/NRE-1997-9307; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; HOUSE A, 1988, J NEUROL NEUROSUR PS, V51, P112, DOI 10.1136/jnnp.51.1.112; KRAMER JJ, 1992, 11 MENTAL MEASUREMEN, P72; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1994, REHABILITATION ADULT, P74; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; RIVERA JV, 1996, ARCH PHYSICAL MED RE, V77, P754; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I INC, 1985, SAS US GUID BAS VERS; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751	52	60	60	0	21	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2000	14	6					549	562					14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600005	10887888				2022-02-06	
J	Allen, GV; Gerami, D; Esser, MJ				Allen, GV; Gerami, D; Esser, MJ			Conditioning effects of repetitive mild neurotrauma on motor function in an animal model of focal brain injury	NEUROSCIENCE			English	Article						cerebral cortex; heat shock protein; GFAP; motor function; beam-walking test	HEAT-SHOCK-PROTEIN; GLUCOSE-REGULATED PROTEINS; RAT-BRAIN; NEURONAL DEGENERATION; MOLECULAR CHAPERONES; SPREADING DEPRESSION; VASCULAR DISRUPTION; CEREBRAL-ISCHEMIA; C-FOS; EXPRESSION	A weight drop model of brain injury was used to determine the effects of repetitive mild brain injury on motor function, heat shock protein and glial fibrillary acidic protein expression in the anesthetized, adult male, Sprague-Dawley rat. Repetitive mild brain injury was produced when animals received a series of three mild injuries spaced three days apart. A separate group of repetitive mild injured animals also received a subsequent severe brain injury between three and five days after the last mild injury. All animals were trained on a beam-walking test prior to surgery. The mild, repetitive mild and repetitive mild plus severe brain injury groups showed no motor deficits in the beam-walking test, whereas the animals with only severe brain injury showed significant motor deficits (increase in number of footslips) in the beam-walking test that recovered within eight days after injury. Both repetitive mild plus severe injury and severe injury only animals had cortical necrotic cavities of similar size in the region of the hindlimb meter cortex. Both the repetitive mild and severe brain-injured animals had marked heat shock protein 27 kDa and glial fibrillary acidic protein staining in the cerebral cortex. Fluoro-Jade, heat shock protein 27 kDa and 72 kDa labeling indicated that there were widespread effects on cortical, subcortical and spinal neurons and glial cells after repetitive mild brain injury. These results suggest that repetitive mild brain injury conditions the brain so that subsequent brain injury at the same site has no effect on motor function. Furthermore, repetitive mild injury-induced activation of processes distant to the primary injury site may have a role in activation of secondary sites involved in recovery of motor function. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Fac Med, Dept Pharmacol, Halifax, NS B3H 4H7, Canada		Allen, GV (corresponding author), Dalhousie Univ, Fac Med, Dept Anat & Neurobiol, Halifax, NS B3H 4H7, Canada.	gva@is.dal.ca					BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONNELLY TJ, 1992, CIRCULATION, V85, P769, DOI 10.1161/01.CIR.85.2.769; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Freyaldenhoven TE, 1997, BRAIN RES, V759, P9, DOI 10.1016/S0006-8993(97)00045-0; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kanayama G, 1997, PSYCHIAT CLIN NEUROS, V51, P157, DOI 10.1111/j.1440-1819.1997.tb02379.x; KATO H, 1991, BRAIN RES, V553, P238, DOI 10.1016/0006-8993(91)90831-F; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, J CEREBR BLOOD F MET, V11, P449, DOI 10.1038/jcbfm.1991.86; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KUBOTA M, 1989, NEUROSURG REV S1, V12, P333; Lewis SE, 1999, J NEUROSCI, V19, P8945, DOI 10.1523/JNEUROSCI.19-20-08945.1999; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; MANTHORPE M, 1986, ASTROCYTES, P315; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NEEDELS DL, 1986, NEUROSCIENCE, V18, P517, DOI 10.1016/0306-4522(86)90055-2; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Plumier JCL, 1997, J CEREBR BLOOD F MET, V17, P781; Plumier JCL, 1997, MOL BRAIN RES, V45, P239, DOI 10.1016/S0169-328X(96)00255-0; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Schmued LC, 1997, BRAIN RES, V759, P135, DOI 10.1016/S0006-8993(97)00173-X; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14	56	60	63	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2000	99	1					93	105		10.1016/S0306-4522(00)00185-8			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	343GA	WOS:000088692300010	10924955				2022-02-06	
J	Kroppenstedt, SN; Kern, M; Thomale, UW; Schneider, GH; Lanksch, WR; Unterberg, AW				Kroppenstedt, SN; Kern, M; Thomale, UW; Schneider, GH; Lanksch, WR; Unterberg, AW			Effect of cerebral perfusion pressure on contusion volume following impact injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral perfusion pressure; cortical impact injury; hypertension; hypobaric hypotension; intracranial pressure	CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; HEAD-INJURY; HYPOBARIC HYPOTENSION; OXYGEN-SATURATION; RAT; ISCHEMIA; MANAGEMENT; REDUCTION	Object. Although it is generally acknowledged that a sufficient cerebral perfusion pressure (CPP) is necessary for treatment of severe head injury, the optimum CPP is still a subject of debate. The purpose of this study was to investigate the effect of various levels of blood pressure and, thereby, CPP on posttraumatic contusion volume. Methods. The left hemispheres of 60 rats were subjected to controlled cortical impact injury (CCII). In one group of animals the mean arterial blood pressure (MABP) was lowered for 30 minutes to 80, 70, 60, 50, or 40 mm Hg 4 hours after contusion by using hypobaric hypotension. In another group of animals the MABP was elevated for 3 hours to 120 or 140 mm Hg 4 hours after contusion by administering dopamine. The MABP was not changed in respective control groups. Intracranial pressure (ICP) was monitored with an ICP microsensor. The rats were killed 28 hours after trauma occurred and contusion volume was assessed using hematoxylin and eosin-stained coronal slices. No significant change in contusion volume was caused by a decrease in MABP from 94 to 80 mm Hg (ICP 12 +/- 1 mm Hg), but a reduction of MABP to 70 mm Hg (ICP 9 +/- 1 mm Hg) significantly increased the contusion volume (p < 0.05). A further reduction of MABP led to an even more enlarged contusion volume. Although an elevation of MABP to 120 mm Hg (ICP 16 +/- 2 mm Hg) did not significantly affect contusion volume, there was a significant increase in the contusion volume at 140 mm Hg MABP (p < 0.05; ICP 18 +/- 1 mm HE) Conclusions. Under these experimental conditions, CPP should be kept within 70 to 105 mm Hg to minimize post traumatic contusion volume. A CPP of 60 mm HE and lower as well as a CPP of 120 mm HE and higher should be considered detrimental.	Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany		Kroppenstedt, SN (corresponding author), Humboldt Univ, Dept Neurosurg, Campus Virchow,Augustenburger Pl 1, D-13353 Berlin, Germany.			Schneider, Gerd-Helge/0000-0002-1301-2938			ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Busse R, 1997, BRAIN PATHOL, V7, P1377; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIRNAGL U, 1993, NEUROL RES, V15, P128; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Marmarou A, 1994, INTRACRANIAL PRESSUR, P302; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MENDELOW AD, 1993, INTRACRANIAL PRESSUR, V8, P544; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NORDSTROM CH, 1998, PATHOPHYSIOLOGICAL P, P67; Piper I. R., 1995, Journal of Neurotrauma, V12, P470; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Unterberg AW, 1997, ACT NEUR S, V70, P106	35	60	62	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1999	90	3					520	526		10.3171/jns.1999.90.3.0520			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	170KX	WOS:000078805800012	10067922				2022-02-06	
J	Berger, E; Leven, F; Pirente, N; Bouillon, B; Neugebauer, E				Berger, E; Leven, F; Pirente, N; Bouillon, B; Neugebauer, E			Quality of life after traumatic brain injury: A systematic review of the literature	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injuries; quality of life; head injury	SEVERE HEAD-INJURY; OF-LIFE; SOCIAL SUPPORT; FOLLOW-UP; SURGERY; IMPACT; SCALE; REHABILITATION; OUTCOMES; COMA	In modern industrial countries traumatic brain injury (TBI) is a common sequel after different kinds of accidents especially amongst young male adults. Apart from medical and economic consequences Quality of Life (QoL) after TBI becomes increasingly important in outcome assessment, Besides the classical domains of QoL (physical, psychological, social) cognitive impairments are playing an important role especially for TBI patients. In 1991 the Meran conference set important standards and formulated basic guidelines for defining and measuring QoL in surgery, but a special index for TBI patients has not yet been developed. Instead, QoL research concentrates on physical, medical, psychological and social problems only. Based on the existing QoL concept extended by the cognitive aspect it was the aim of this review to give an overview about the recent QoL research in TBI patients since 1991. Sixteen studies in TBI patients mentioning at least 2 domains of QoL (physical, psychological, social, cognitive) were published since 1991. Five of them considered all 4 domains of QoL. All studies except of one dealt with psychological and social problems. Only half of the studies considered cognitive impairments. Four studies tried to define QoL, but none of them included the cognitive component. There was no consensus regarding the definition and the choice of measurement instrument for QoL after TBI. This review of 16 studies considering outcome and QoL after TBI confirms that a homogenous and clinically relevant QoL concept for this group of patients is still missing. Further research in TBI patients should include all 4 domains of QoL.	Univ Cologne, Dept Surg 2, Biochem & Expt Div, D-51109 Cologne, Germany; Neurosurg Clin, Cologne, Germany; Univ Cologne, Dept Surg 2, D-5000 Cologne 41, Germany		Berger, E (corresponding author), Univ Cologne, Dept Surg 2, Biochem & Expt Div, Ostmerheimer Str 200, D-51109 Cologne, Germany.	eva.berger@uni-koeln.de					Aaronson N K, 1988, Oncology (Williston Park), V2, P69; Annoni J M, 1992, Disabil Rehabil, V14, P23; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bullinger M, 1996, Rehabilitation (Stuttg), V35, pXVII; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; BULLINGER M, 1996, REHABILITATION STUTT, V35, P27; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; EYPASCH E, 1990, THEOR SURG, V5, P3; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GAINOTTI G, 1993, REHABILITATION, V3, P259; Haffey W. J., 1990, NEUROPSYCHOLOGY EVER, P99; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HELLAWELL J, 1997, INT J REHABIL RES, V20, P345; JENNETT B, 1975, LANCET, V480, P480; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kaplan SP, 1991, CLIN NEUROPSYCHOL, V5, P360; KOCH U, 1998, REHABILITATIONSMEDIZ; KOLLER M, 1995, ANHANG, V2; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MAHONEY F I, 1965, Md State Med J, V14, P61; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NEUGEBAUER E, 1991, THEOR SURG, V6, P123; NEUGEBAUER E, 1991, THEOR SURG, V6, P121; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHAFMAYER A, 1989, CHIRURG, V60, P458; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SPILKER G, 1991, THEOR SURG, V6, P216; TEASDALE G, 1974, LANCET, V2, P81; TROIDL H, 1989, CHIRURG, V60, P445; VANBALEN HGG, 1996, DISABILITY REHABILIT, V18, P81; WAANDERS R, 1997, ACTA CHIR AUSTRIACA, P221; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817	43	60	61	0	4	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					93	102					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	183XN	WOS:000079579700003					2022-02-06	
J	Youssef, RM; Attia, MSED; Kamel, MI				Youssef, RM; Attia, MSED; Kamel, MI			Children experiencing violence II: Prevalence and determinants of corporal punishment in schools	CHILD ABUSE & NEGLECT			English	Article						corporal punishment; school; prevalence; behavior; Egypt	PEDIATRICIAN	Objective: This study was undertaken to reveal the prevalence and determinants of corporal punishment in preparatory (middle) and secondary (high) schools in Alexandria. Methods: A cross sectional survey targeting preparatory and secondary school students enrolled in main stream public schools was conducted. The multistage random sample technique was adopted to select a priori estimated sample of this population. They were requested to fill a self administered questionnaire to collect relevant information. Data were analyzed using the univariate and multivariate analyses. Results: A substantial proportion of boys (79.96%) and girls (61.53%) incurred physical punishment at the hand of their teachers. Teachers were using their hands, sticks, straps, shoes, and kicks to inflict such punishment without sparing a part of their students' body. Physical injuries were reported by a significantly higher percentage of boys (chi(1)(2) = 12.26, p = .00046) the most common being bumps and contusions followed by wounds and fractures. Moreover, it was only among boys that serious injuries such as loss of consciousness and concussion were encountered. Both univariate and multivariate analyses revealed that corporal punishment was more likely to be used in preparatory schools and on boys. Such means of punishment were also predicted by students' undesirable behavior as well as their poor achievement in academic tasks. Conclusion: This study indicates that corporal punishment in school is used extensively to discipline students whose behavior doesn't conform with the desired standard of educational institutions. However, since it is no longer perceived as a method of discipline, other alternatives can be used providing that teachers are equipped with the necessary skills for its application. (C) 1998 Elsevier Science Ltd.	Fac Med, Dept Publ Hlth, Alexandria, Egypt; High Inst Publ Hlth, Dept Family Hlth, Alexandria, Egypt		Youssef, RM (corresponding author), Fac Med, Dept Publ Hlth, Alexandria, Egypt.						Bergman B., 1990, Journal of the European Ceramic Society, V6, P3, DOI 10.1016/0955-2219(90)90028-E; CLARKE JR, 1982, CHILD YOUTH SERVICES, V4, P47; *COMM PSYCH ASP CH, 1983, PEDIATRICS, V72, P373; *COMM SCH HLTH, 1984, PEDIATRICS, V73, P258; DOLINS JC, 1994, PEDIATRICS, V94, P638; Dubanoski R A, 1983, Child Abuse Negl, V7, P271; EICHELBERGER SP, 1991, PEDIATRICS, V87, P570; FARLEY AC, 1978, INEQUALITY ED, V23, P57; HOSSNY MN, 1981, INTERPRETATION CRIMI; HYMAN IA, 1982, CHILDREN TODAY, V11, P10; KAMEL MI, UNPUB PATTERN SCH IN; Kaplan H.I., 1988, SYNOPSIS PSYCHIAT; Kish Leslie, 1965, SAMPLING SURVEY; MCCORMICK KF, 1992, JAMA-J AM MED ASSOC, V267, P3161, DOI 10.1001/jama.267.23.3161; *OFF GEN COUNS, 1992, JAMA-J AM MED ASSOC, V267, P3205; POOLE SR, 1991, PEDIATRICS, V88, P162; RUTTER M, 1980, PEDIATRICS, V65, P208, DOI 10.1542/peds.65.2.208; SCHULTZ EW, 1987, J SCHOOL HEALTH, V57, P432, DOI 10.1111/j.1746-1561.1987.tb03189.x; SIKORSKI JB, 1996, ISSUES CLIN CHILD PS, P393; USHKOW MC, 1991, PEDIATRICS, V88, P173; WESSEL MA, 1980, PEDIATRICS, V66, P639; Wilson F C, 1982, Child Abuse Negl, V6, P155; WISSOW LS, 1994, PEDIATRICS, V94, P587; Wolkind S, 1990, CHILD ADOLESCENT PSY, P83	24	60	62	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	OCT	1998	22	10					975	985		10.1016/S0145-2134(98)00084-2			11	Family Studies; Psychology, Social; Social Work	Social Science Citation Index (SSCI)	Family Studies; Psychology; Social Work	118FC	WOS:000075826900005	9793720				2022-02-06	
J	Ownsworth, TL; Oei, TPS				Ownsworth, TL; Oei, TPS			Depression after traumatic brain injury: conceptualization and treatment considerations	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; DISORDERS; REHABILITATION; ADJUSTMENT; RELATIVES	The understanding and treatment of depression that develops following traumatic brain injury (TBI) is still unclear and likely to be the result of a complex variety of interacting factors. Past researchers have developed ways to classify important variables related to patients' depression into broad domains such as: Pre-injury assets and liabilities, the nature and severity of brain injury; and reaction to difficulties. However, a better conceptualization of the problem is required in order to guide the assessment and treatment considerations for depressed patients with TBI. This review provides this conceptualization by postulating six theoretical relationships between depression and TBI. The degree of empirical support provided in the literature for there links is indicated. Research findings suggested that an individual with TBI is the most susceptible to depression when any of the following conditions exist: a pre-existing psychiatric disturbance is exacerbated; the injury sustained involved the left anterior region of the brain; and when her individual has poor insight into her deficits, attempts to resume her pre-injury roles and experiences significant failure. For each relationship, a likely outcome is predicted if the recommended treatment plan is not conducted. The present conceptualization and treatment considerations will be of substantial benefit to clinicians working in the area.	Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia		Oei, TPS (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.		Oei, Tian Po/K-4870-2012	Oei, Tian Po/0000-0001-9041-8803; Ownsworth, Tamara/0000-0003-1835-7094			ALEXANDER MP, 1975, PSYCHIAT ASPECTS NEU, P219; Barco PP, 1991, COGNITIVE REHABILITA, P129; Beck A.T., 1987, J COGNIT PSYCHOTHER, V1, P5; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1989, ASSESSMENT BEHAV CON, P61; EAMES P, 1989, ASSESSMENT BEH CONSE, P195; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fennell M., 1989, COGNITIVE BEHAV THER; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; GAULTIERI CT, 1988, BRAIN INJURY, V6, P219; GILES GM, 1993, BRAIN INJURY REHABIL; GLENN MB, 1989, J HEAD TRAUMA REHAB, V4, P85; GODFREY HP, 1995, FAMILY SUPPORT PROGR; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1996, FACILITATING PSYCHOS; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hartley L. L, 1995, COGNITIVE COMMUNICAT; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1989, ASSESSMENT BEHAV CON, P145; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KWON SM, 1994, CLIN PSYCHOL REV, V14, P331, DOI 10.1016/0272-7358(94)90032-9; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lezak, 1989, ASSESSMENT BEHAV CON, V7, P113; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LIPOWSKI ZJ, 1975, PSYCHIAT ASPECTS NEU, V1, P11; Lishman WA., 1978, ORGANIC PSYCHIAT PSY; MAPOU RL, 1993, HDB HEAD TRAUMA ACUT, P76; MATEER CA, 1991, CONITIVE REHABILITAT, P117; MCALLISTER TW, 1992, COMPR PSYCHIAT, V33, P296, DOI 10.1016/0010-440X(92)90036-P; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; McNair D.M., 1981, PROFILE MOOD STATES; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Morse P, 1992, CLIN SYNDROMES ADULT, P85; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NAUGLE RL, TRAUMATIC BRAIN INJU, P69; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P243; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO, P216; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; RICKLER KC, 1975, PSYCHIAT ASPECTS NEU, V2; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROSS LK, 1992, HDB HEAD TRAUMA ACUT, P151; SACKEIM HA, 1991, AM PSYCHOP, P209; SARGENT MM, 1989, NEUROPSYCHOLOGICAL T, P183; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Sohlberg M, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; ZENCIUS AH, 1994, PRACTICAL GUIDE HEAD	67	60	60	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					735	751		10.1080/026990598122133			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500002	9755365				2022-02-06	
J	Thatcher, RW; Biver, C; McAlaster, R; Camacho, M; Salazar, A				Thatcher, RW; Biver, C; McAlaster, R; Camacho, M; Salazar, A			Biophysical linkage between MRI and EEG amplitude in closed head injury	NEUROIMAGE			English	Article						EEG; MRI; T2 relaxation times; cognition; traumatic brain injury	MAGNETIC-RESONANCE IMAGES; RELAXATION-TIMES; DELTA WAVES; BRAIN; NMR; MECHANISMS; DIFFUSION; SEGMENTATION; DIAGNOSIS; SEQUENCES	Nuclear magnetic resonance of brain water proton (H-1) T2 relaxation times and measures of absolute amplitude of EEG were obtained from 19 closed head injured patients. The relationship between EEG and T2 relaxation time differed as a function of both EEG frequency and gray matter versus white matter. White matter T2 relaxation time was positively correlated with increased EEG amplitude in the delta frequency band (0.5-3.5 Hz). In contrast, lengthened gray matter T2 relaxation time was inversely correlated with EEG amplitude in the alpha and beta frequency bands (7-22 Hz). These findings are consistent with clinical EEG studies in which white matter lesions are related to increased EEG delta amplitude and gray matter lesions are related to decreased EEG alpha and beta frequency amplitude. Estimates of the severity of injury were obtained by neuropsychological measurements, in which lengthened T2 relaxation times in both the neocortical gray and white matter were correlated with diminished cognitive function. Decreased EEG beta and alpha amplitude and increased EEG delta amplitude were also correlated with diminished cognitive function. The findings imply a biophysical linkage between the state of protein-lipid structures of the brain as measured by the MRI and the scalp-recorded EEG. (C) 1998 Academic Press.	Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Def & Vet Head Injury Program, Washington, DC 20307 USA		Thatcher, RW (corresponding author), Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADVANI SH, 1982, OXFORD MED ENG SERIE, P3; Barlow J.S., 1993, ELECTROENCEPHALOGRAM; BENSAID AM, 1994, P SOC PHOTO-OPT INS, V2167, P454, DOI 10.1117/12.175079; BEZDEK JC, 1993, MED PHYS, V20, P1033, DOI 10.1118/1.597000; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; BOTTOMLEY PA, 1987, MED PHYS, V14, P1, DOI 10.1118/1.596111; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; BRAITENBERG V, 1972, SYNCHRONIZATION EEG, P47; CARPENDER MB, 1983, HUMAN NEUROANATOMY; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; Cohen J., 1983, APPL MULTIPLE REGRES; COOPER R, 1981, EEG TECHNOLOGY; DARWIN RH, 1986, RADIOLOGY, V160, P375, DOI 10.1148/radiology.160.2.3726116; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; DIXON RL, 1982, MED PHYS, V9, P807, DOI 10.1118/1.595189; DOES MD, 1995, MAGN RESON IMAGING, V13, P575, DOI 10.1016/0730-725X(94)00138-S; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; GOLDENSOHN ES, 1979, CURRENT PRACTICE CLI; GRAHAM DI, 1993, HEAD INJURY; HICKEY DS, 1986, BRIT J RADIOL, V59, P565, DOI 10.1259/0007-1285-59-702-565; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HUS EW, 1996, AM J PHYSIOL, V40, pC1895; JASPER H, 1953, ELECTROENCEPHALOGR S, V4, P168; KJOS BO, 1985, AM J ROENTGENOL, V144, P1165, DOI 10.2214/ajr.144.6.1165; KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210; KROEKER RM, 1986, J MAGN RESON, V69, P218, DOI 10.1016/0022-2364(86)90074-0; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; Levin HS., 1982, NEUROBEHAVIORAL CONS; MILLS CM, 1984, RADIOLOGY, V150, P87, DOI 10.1148/radiology.150.1.6689792; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; NICHOLSON C, 1980, NEUROSCI RES PROG B, V18, P177; Nunez P, 1981, ELECT FIELDS BRAIN; Nunez P.L., 1995, NEOCORTICAL DYNAMICS; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Otnes RK, 1972, DIGITAL TIME SERIES; Petsche, 1978, ARCHITECTONICS CEREB, P443; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R W, 1995, J Neuroimaging, V5, P35; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; VANZIJL PCM, 1991, P NATL ACAD SCI USA, V88, P3228, DOI 10.1073/pnas.88.8.3228; VELLEMAN PF, 1995, DATA DESK VERSION 5; Wehrli F. W, 1992, MAGNETIC RESONANCE I, P3; [No title captured]; [No title captured]	59	60	61	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAY	1998	7	4	1				352	367		10.1006/nimg.1998.0330			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	ZT101	WOS:000074048500008	9626675				2022-02-06	
J	Sick, TJ; Perez-Pinzon, M; Feng, ZZ				Sick, TJ; Perez-Pinzon, M; Feng, ZZ			Impaired expression of long-term potentiation in hippocampal slices 4 and 48 h following mild fluid-percussion brain injury in vivo	BRAIN RESEARCH			English	Article						long-term potentiation; concussion; synaptic plasticity; hippocampus	MODERATE HYPOTHERMIA; SPREADING DEPRESSION; SYNAPTIC PLASTICITY; AFFERENT-FIBERS; NMDA RECEPTORS; HEAD-INJURY; AMINO-ACIDS; CALCIUM; RATS; DEFICITS	The effect of fluid percussion brain injury on hippocampal long-term potentiation (LTP) was investigated in hippocampal slices in vitro. Mild to moderate (1.7-2.1 atm) lateral fluid percussion head injury or sham operation was produced in rats 4 or 48 h prior to harvesting brain slices from the ipsilateral hippocampus. Field excitatory post-synaptic potentials (fEPSPs) were recorded in stratum radiatum of hippocampal subfield CAI in response to electrical stimulation of the Schaffer collaterals. The initial slope of fEPSPs was used to investigate changes in synaptic strength prior to and following 100 or 200 Hz (1 s) tetanic stimulation. TBI significantly inhibited expression of LTP in hippocampal slices in vitro. Post-tetanus fEPSP slopes increased more than 100% in hippocampal slices from sham-operated animals but less than 50% in slices from rats following TBI. The data suggest that changes in functional synaptic plasticity in the hippocampus may contribute to cognitive disorders associated with TBI (traumatic brain injury). The data also indicate that TBI-induced effects on hippocampal LTP are robust and may be investigated in the hippocampal slice preparation in vitro. (C) 1998 Elsevier Science B.V.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33177 USA		Sick, TJ (corresponding author), Univ Miami, Sch Med, Dept Neurol, South Campus Bldg B,12500 SW 152 St, Miami, FL 33177 USA.	tsick@neuron.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774, DOI 10.1152/jn.1993.69.5.1774; DEBANNE D, 1994, NEWS PHYSIOL SCI, V9, P256; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMMOND C, 1994, TRENDS NEUROSCI, V17, P497, DOI 10.1016/0166-2236(94)90140-6; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; HANSEN AJ, 1990, CEREBRAL ISCHEMIA RE, P78; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KRNJEVIC K, 1974, CAN J PHYSIOL PHARM, V52, P852, DOI 10.1139/y74-110; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALTHESORENSSEN D, 1979, NEUROSCIENCE, V4, P1255, DOI 10.1016/0306-4522(79)90155-6; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROBERTS EL, 1988, BRAIN RES, V456, P113, DOI 10.1016/0006-8993(88)90352-6; SIEMKOWICZ E, 1981, STROKE, V12, P236, DOI 10.1161/01.STR.12.2.236; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEYLER TJ, 1995, BRAIN SLICES BASIC C, P1; UEMATSU D, 1988, J CEREBR BLOOD F MET, V8, P367, DOI 10.1038/jcbfm.1988.72; YOUNG JN, 1992, BRAIN RES, V573, P70, DOI 10.1016/0006-8993(92)90114-O	38	60	61	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 2	1998	785	2					287	292		10.1016/S0006-8993(97)01418-2			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZJ988	WOS:000073273800011	9518654				2022-02-06	
J	Stahel, PF; Kossmann, T; MorgantiKossmann, MC; Hans, VHJ; Barnum, SR				Stahel, PF; Kossmann, T; MorgantiKossmann, MC; Hans, VHJ; Barnum, SR			Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats	MOLECULAR BRAIN RESEARCH			English	Article						complement; chemotactic receptor; traumatic brain injury; neuron	TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; HUMAN CEREBROSPINAL-FLUID; CLOSED-HEAD-INJURY; ADULT-RAT; NEUTROPHIL ACCUMULATION; PNEUMOCOCCAL MENINGITIS; ANAPHYLATOXIN RECEPTOR; COMPLEMENT ACTIVATION; HUMAN ASTROCYTES	Several studies suggest the involvement of the complement system in the pathophysiology of traumatic brain injury (TBI). Since the intrathecal generation of anaphylatoxin C5a has been shown to mediate inflammatory effects within the central nervous system, we sought to characterize the cellular expression of the mRNA for the C5a receptor (C5aR, CD88) in brains of rats with experimental diffuse axonal injury (DAI) by in situ hybridization. Infiltrating leukocytes expressing C5aR mRNA were seen in meninges and lateral ventricles as early as 4 h after induction of DAI. The number of infiltrating C5aR-positive cells increased gradually up to 24 h after trauma. Within the brain parenchyma, up-regulation of C5aR mRNA expression was first seen in cerebellar Purkinje cells within 8 h. At 24 h after TBI, expression of C5aR mRNA was widespread bilaterally throughout the cortex and cerebellum, the cellular expression being restricted to pyramidal neurons and Purkinje cells. The intensity of C5aR transcript signals on neurons increased further up to 96 h after trauma. Ligand binding of C5a to its receptor on neurons might mediate previously unknown functions, thus possibly leading to neurotoxicity and secondary neuronal damage after TBI. (C) 1997 Elsevier Science B.V.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ZURICH HOSP,DEPT SURG,DIV TRAUMA SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,DEPT SURG,DIV RES,CH-8091 ZURICH,SWITZERLAND					Morganti-Kossmann, Cristina/0000-0002-0807-2063	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS029719] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29719] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BECKER P, 1987, ANAESTHESIST, V36, P301; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DAVIS WD, 1992, CLIN EXP RHEUMATOL, V10, P455; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; ERNST JD, 1984, INFECT IMMUN, V46, P81, DOI 10.1128/IAI.46.1.81-86.1984; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas I., 1996, Neurobiology of Aging, V17, pS183, DOI 10.1016/S0197-4580(96)80738-X; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GIULIAN D, 1993, J NEUROSCI, V13, P29; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Horuk R, 1997, J IMMUNOL, V158, P2882; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KADURUGAMUWA JL, 1989, J INFECT DIS, V160, P715, DOI 10.1093/infdis/160.4.715; KASUYA H, 1989, J NEUROSURG, V71, P741, DOI 10.3171/jns.1989.71.5.0741; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kochanek P M, 1993, Crit Care Med, V21, pS333, DOI 10.1097/00003246-199309001-00016; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kossmann T, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P263; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Luer MS, 1996, PHARMACOTHERAPY, V16, P830; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P158; MullerLadner U, 1996, J NEUROL SCI, V144, P135, DOI 10.1016/S0022-510X(96)00217-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; OPPERMANN M, 1994, IMMUNOLOGY, V82, P516; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RINK A, 1995, AM J PATHOL, V147, P1575; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROTH J, 1992, LAB INVEST, V67, P263; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SPIEGEL K, IN PRESS INFLAMMATOR; Stahel PF, 1997, J IMMUNOL, V159, P861; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; TUOMANEN E, 1986, MICROB PATHOGENESIS, V1, P15, DOI 10.1016/0882-4010(86)90028-8; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; XIA M, 1996, J NEUROPATHOL EXP NE, V55, P619; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635	62	60	60	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	OCT 15	1997	50	1-2					205	212		10.1016/S0169-328X(97)00189-7			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YF868	WOS:A1997YF86800026	9406936				2022-02-06	
J	Lucius, R; Sievers, J				Lucius, R; Sievers, J			Postnatal retinal ganglion cells in vitro: Protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes	BRAIN RESEARCH			English	Article						retinal ganglion cell; axonal regeneration; astrocyte; reactive oxygen species; neurotoxicity	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; ACTIVATED MICROGLIA; SUPPORT SURVIVAL; CULTURED NEURONS; MAMMALIAN BRAIN; FREE-RADICALS; ADULT MICE; RAT-BRAIN; GLUTATHIONE	Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or Alzheimer's disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We therefore studied the potential role of astrocytes against neurotoxic effects of ROS in cocultures of rat cortical astrocytes with regenerating postnatal retinal ganglion cells (RGC). The sydnonimine SIN-1, which spontaneously decomposes to yield nitric oxide (NO) and superoxide anion radicals, led to axonal degeneration at concentrations between 1 mu M and 10 mu M. Comparable effects were seen after addition of iron salts (Fe2(+)/Fe3(+)), which catalyze the generation of hydroxyl radicals. In contrast, in cocultures of RGC with astrocytes or after addition of free radical scavengers there was no neurotoxic/neurodegenerative effect of ROS as compared with control cultures. Vitamin E (1-10 mu M) and vitamin C (10-100 mu M) abolished the neurotoxic effect of both SIN-1 or iron ions. Beside this, there was an additional effect concerning the number and the length of neurites growing out from the retinal explant: in cocultures both parameters were greatly enhanced. These results suggest that (i) astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC axonal regeneration, and (iii) free radical production after tissue injury may partly contribute to the failure of axonal regeneration in the adult mammalian central nervous system.			Lucius, R (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST ANAT,OLSHAUSENSTR 40,D-24118 KIEL,GERMANY.		Lucius, Ralph/B-1614-2010; Sievers, Jobst/A-8672-2010				ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; ALLCUTT D, 1984, DEV BRAIN RES, V16, P219, DOI 10.1016/0165-3806(84)90027-0; ALLCUTT D, 1984, DEV BRAIN RES, V16, P231, DOI 10.1016/0165-3806(84)90028-2; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BUSCIGILO J, 1996, NATURE, V378, P776; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, J IMMUNOL, V151, P1473; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEGROOT H, 1993, FEBS LETT, V315, P139, DOI 10.1016/0014-5793(93)81150-X; Demopoulos H, 1979, NEURAL TRAUMA, P63; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D., 1992, CURR TOP NEUROL, V12, P23; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Kirschner PB, 1996, BRAIN RES, V713, P178, DOI 10.1016/0006-8993(95)01513-2; LANGEVELD CH, 1995, NEUROSCI LETT, V192, P13, DOI 10.1016/0304-3940(95)11596-O; LIESI P, 1983, J CELL BIOL, V96, P920, DOI 10.1083/jcb.96.3.920; LIESI P, 1986, EXP CELL RES, V163, P175, DOI 10.1016/0014-4827(86)90570-7; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LIU DX, 1994, J NEUROCHEM, V62, P37; LUCIUS R, 1995, J NEUROCHEM, V64, P1841; Lucius R, 1996, INT J DEV NEUROSCI, V14, P387; MAKAR TK, 1994, J NEUROCHEM, V62, P45; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; RATAN RR, 1994, J NEUROCHEM, V62, P376; RICHARDSON A, 1993, GLIA, V7, P25, DOI 10.1002/glia.440070107; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; THANOS S, 1989, EUR J NEUROSCI, V1, P19, DOI 10.1111/j.1460-9568.1989.tb00770.x; TIDOW S, 1988, SENSE ORGANS, P347; VARON S, 1984, J NEUROSCI, V4, P654; ZIELASEK J, 1992, CELL IMMUNOL, V141, P114	48	60	60	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 16	1996	743	1-2					56	62		10.1016/S0006-8993(96)01029-3			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WC373	WOS:A1996WC37300008	9017230				2022-02-06	
J	Reilly, JF; Kumari, VG				Reilly, JF; Kumari, VG			Alterations in fibroblast growth factor receptor expression following brain injury	EXPERIMENTAL NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; RAT CEREBRAL-CORTEX; MESSENGER-RNA; FGF RECEPTOR; FACTOR BFGF; DIFFERENTIAL EXPRESSION; ASTROCYTE PROLIFERATION; REACTIVE ASTROCYTES; ASTROGLIAL REACTION	Traumatic injuries to the central nervous system result in astrogliosis and the formation of a dense scar at the site of the wound. Basic fibroblast growth factor (bFGF) has mitogenic and morphogenic effects on astrocytes, and an interaction between bFGF and its receptor is likely to play a role in astrogliosis. We examined trauma-induced changes in the spatial and temporal expression of FGF receptor (FGFR) in adult rats over a 28-day period following a stereotaxic lesion through the cortex and hippocampus. Immunohistochemistry and image analysis were used to evaluate the changes. Antibody characterization studies strongly suggested that staining represented FGFR 1, but did not rule out possible cross-reactivity with FGFR 2 or 3. Double immunohistochemistry for FGFR and glial fibrillary acidic protein demonstrated that mature astrocytes expressed FGFR. Expression was increased on astrocytes adjacent to the wound cavity by Day 2 postlesion. Staining increased further through Day 10 and decreased to control values by Day 28, except for a sustained increase in staining of reactive astrocytes immediately adjacent to the wound cavity. Basic FGF was detected in the nuclei of cells staining for FGFR, suggesting that FGFR-expressing astrocytes also contained bFGF. These data demonstrate a time course for astrocyte expression of FGFR that precedes and parallels the time course for astrocyte hypertrophy. Our observations suggest that endogenous bFGF, acting directly on FGFR-expressing astrocytes, may contribute to astrogliosis. (C) 1996 Academic Press, Inc.			Reilly, JF (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT HUMAN ANAT & CELL BIOL,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG006159] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 06159] Funding Source: Medline		ALONSO G, 1993, J NEUROSCI RES, V34, P523, DOI 10.1002/jnr.490340505; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FINKLESTEIN SP, 1990, STROKE, V21, P122; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GUILIAN D, 1989, Journal of Neuroscience, V9, P4416; Hajos F., 1993, Neurobiology (Budapest), V1, P123; HANNEKEN A, 1992, EXP EYE RES, V54, P1011, DOI 10.1016/0014-4835(92)90166-P; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; ITOH N, 1994, MOL BRAIN RES, V21, P344, DOI 10.1016/0169-328X(94)90265-8; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; LOGAN A, 1992, J NEUROSCI, V12, P3828; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MENON VK, 1994, EXP NEUROL, V129, P142, DOI 10.1006/exnr.1994.1155; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; SAITO H, 1991, BIOCHEM BIOPH RES CO, V174, P136, DOI 10.1016/0006-291X(91)90496-T; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAMI K, 1993, EXP BRAIN RES, V97, P185; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; TORRIGLIA A, 1994, NEUROSCI LETT, V172, P125, DOI 10.1016/0304-3940(94)90678-5; VANDERWAL EA, 1994, NEUROSCIENCE, V60, P311, DOI 10.1016/0306-4522(94)90245-3; VENKATESWARAN S, 1992, HYBRIDOMA, V11, P729, DOI 10.1089/hyb.1992.11.729; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403	52	60	61	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	1996	140	2					139	150		10.1006/exnr.1996.0124			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VA089	WOS:A1996VA08900004	8690057				2022-02-06	
J	Veltman, JC; Brouwer, WH; vanZomeren, AH; vanWolffelaar, PC				Veltman, JC; Brouwer, WH; vanZomeren, AH; vanWolffelaar, PC			Central executive aspects of attention in subacute severe and very severe closed head injury patients: Planning, inhibition, flexibility, and divided attention	NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; WORKING-MEMORY; DEFICITS	Central executive aspects of attention were investigated in a group of 20 closed head injury (CHI) patients with an average posttraumatic amnesia duration of 23.9 days, tested in the first half year after injury. Four aspects were distinguished: planning, inhibition, flexibility, and divided attention. Tasks allowed assessment of these with experimental or statistical control for the individual speed of information processing. This precaution appears necessary because slow information processing is a pervasive effect of CHI and may cause spurious effects on complex cognitive tasks under time pressure. Strong effects of CHI were shown on speed of information processing. Controlling this factor, central executive aspects of attention were normal, on average. A tentative analysis of the results in relation to severity indicated that less severely injured patients are better in this respect than controls, and more severely injured patients are worse. In comparison with the healthy control group, the performance of those with milder injuries appears to be characterized by greater cautiousness and increased mental effort.	UNIV GRONINGEN HOSP, DEPT NEUROPSYCHOL, NL-9700 RB GRONINGEN, NETHERLANDS; UNIV GRONINGEN, TRAFF RES CTR, HAREN, NETHERLANDS								ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALLPORT A, 1993, ATTENTION PERFORM, V14, P183; AZOUVI P, 1995, J INT NEUROPSYCH SOC, V1, P213; Brouwer W.H., 1985, THESIS U GRONINGEN N; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; CANTAGALLO A, 1995, J INT NEUROPSYCH SOC, V1, P198; CLIFTON GL, 1980, J NEUROSURG, V52, P619; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; FASOTTI L, 1995, TRAUMATIC BRAIN INJU, P141; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A.R., 1966, HIGHER CORTICAL FUNC; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1989, THEORY FUNCTION BRID, P28; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1993, ATTENTION PERFORM, V14, P395; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STANKOV L, 1988, PSYCHOL AGING, V3, P59, DOI 10.1037/0882-7974.3.1.59; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TROMP E, 1991, J CLIN EXPT NEUROPSY, V13, P828; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; VANWOLFFELAAR PC, 1991, COMP PSYCH, V3, P187; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; VILKKI J, 1995, J INT NEUROPSYCH SOC, V1, P208; Weiskrantz L., 1993, ATTENTION SELECTION, P152; WICKENS C. D., 1984, VARIETIES ATTENTION, P63; WITTENBORN TR, 1943, PSYCHOMETRIKA, V8, P19; [No title captured]; [No title captured]; [No title captured]; [No title captured]	40	60	60	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					357	367		10.1037/0894-4105.10.3.357			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200006					2022-02-06	
J	Ikonomidou, C; Qin, YQ; Labruyere, J; Kirby, C; Olney, JW				Ikonomidou, C; Qin, YQ; Labruyere, J; Kirby, C; Olney, JW			Prevention of trauma-induced neurodegeneration in infant rat brain	PEDIATRIC RESEARCH			English	Article							METHYL-D-ASPARTATE; ISCHEMIC NEURONAL DEGENERATION; EXCITATORY AMINO-ACIDS; CEREBRAL-ISCHEMIA; NMDA ANTAGONISTS; GLUTAMATE; INJURY; NEUROTOXICITY; DAMAGE; RECEPTORS	Recent evidence implicates the endogenous excitatory neurotransmitters, glutamate (Glu) and aspartate, in the pathophysiology of traumatic injury in the adult CNS, bur it is not known whether similar excitotoxic mechanisms mediate traumatic injury in the immature CNS. Therefore, we developed a model of brain contusion injury in infant rats and used this model to study the nature and evolution of the acute cytopathologic changes and to evaluate the ability of Glu receptor antagonists to protect the immature brain against such changes. Seven-day-old rat pups were subjected to contusion injury and were killed 0, 0.5, 1, 2, 4, and 6 h later for histologic evaluation of the brain. Physical rearing of thr dura and minor disruption of underlying brain tissue was noted at 0 h. At 30 min a discrete zone of neuronal necrosis began to appear at thr bolder of the trauma site; this zone progressively expanded over a period of 1 h. The cytopathologic changes closely resembled the type of changes Glu is known to cause; these changes consisted of swollen dendrites, degenerating neurons with pyknotic nuclei and markedly swollen cytoplasm, and dark cells with vacuolated cytoplasm. The noncompetitive N-metyl-D-aspartate (NMDA) antagonist, dizocilpine maleate, when administered 30 min before or 1 h after trauma, significantly attenuated the lesion. The competitive NMDA antagonist, 3-((2)-carboxypiperazine-1-yl)-propyl-1-phosphonate, was also neuroprotective. The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate receptor antagonist 2,3-dihydro-6-nitro-7-sulfamoyl-benzo(f)quinoxaline did not significantly suppress the lesion when given as three treatments (30 mg/kg each) 30 min before plus 15 and 75 min after the insult. These findings suggest that traumatic injury in the infant rat brain is mediated by endogenous excitotoxins (Glu and aspartate) acting at NMDA receptors and can be substantially mitigated by timely treatment with NMDA receptor antagonists.	WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA; ST LOUIS CHILDRENS HOSP, DEPT PEDIAT NEUROL, ST LOUIS, MO 63110 USA					Ikonomidou, Chrysanthy/0000-0002-8961-226X			AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Corso T. D., 1994, Society for Neuroscience Abstracts, V20, P1531; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; GROTTA J, 1994, STROKE, V25, P255; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HERRLING PL, 1994, NEUROPSYCHOPHARMACOL, V10, pS591; HOFFMANN P, 1991, KLIN WOCHENSCHR, V69, P72; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; IKONOMIDOU C, 1989, Society for Neuroscience Abstracts, V15, P767; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATO N, 1993, P NATL ACAD SCI USA, V90, P7114, DOI 10.1073/pnas.90.15.7114; KAUFMAN BA, 1994, PEDIATR ANN, V23, P18, DOI 10.3928/0090-4481-19940101-07; KLOSE R, 1982, ANAESTHESIST, V31, P33; LANGREHR D, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2269; MARSHALL BE, 1990, PHARMACOL BASIS THER, P285; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, J NEUROSCI, V9, P1701; OLNEY JW, 1972, J NEUROPATH EXP NEUR, V31, P464, DOI 10.1097/00005072-197207000-00006; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PFENNINGER E, 1984, ANAESTHESIST, V33, P82; Pfenninger E, 1985, Eur J Anaesthesiol, V2, P297; REICHER D, 1987, STROKE, V18, P445, DOI 10.1161/01.STR.18.2.445; Schulte am Esch J, 1978, ACTA NEUROCHIR, V45, P15; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; STEWART L, 1993, 2 INT NEUR S GLASG, P76; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THORSEN T, 1980, ACTA ANAESTH SCAND, V24, P1, DOI 10.1111/j.1399-6576.1980.tb01494.x; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q	47	60	64	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	JUN	1996	39	6					1020	1027		10.1203/00006450-199606000-00015			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	UN555	WOS:A1996UN55500015	8725264	Bronze			2022-02-06	
J	Cicerone, KD; Smith, LC; Ellmo, W; Mangel, HR; Nelson, P; Chase, RF; Kalmar, K				Cicerone, KD; Smith, LC; Ellmo, W; Mangel, HR; Nelson, P; Chase, RF; Kalmar, K			Neuropsychological rehabilitation of mild traumatic brain injury	BRAIN INJURY			English	Article							CONCUSSION	A significant minority of patients who have sustained a mild traumatic brain injury (MTBI) may exhibit persistent disability. There have been few attempts to describe and evaluate the effectiveness of neurorehabilitation for these patients. We conducted a retrospective analysis of the results of a neuropsychological rehabilitation programme for 20 patients with MTBI. Based upon the ability to resume productive functioning after treatment, 10 patients were determined to exhibit a good outcome and 10 patients were considered to exhibit a poor outcome. Patients with good outcome exhibited significant pre-post-treatment improvements on both neuropsychological measures of cognitive functioning and self-reported post-concussive symptoms. Patients with poor outcome demonstrated little improvement in either area, and in some cases showed a decline in functioning. The results are consistent with the view that there may be significant variability in recovery and response to treatment after MTBI. There is a continued need to identify which patients may benefit from neurorehabilitation, develop specially tailored interventions, and conduct controlled, prospective studies in this area.	JFK JOHNSON REHABIL INST,EDISON,NJ								Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; KEPPEL G, 1983, DESIGN ANAL; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MATEER C, 1992, POSTCONCUSSIVE DISOR, P143; Mateer CA, 1990, COGNITIVE REHABILITA, P68; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Reitan R.M., 1993, HALSTEADREITAN NEURO; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SHUMWAYCOOK A, 1990, NEUROL CLIN, V8, P441, DOI 10.1016/S0733-8619(18)30366-9; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1974, WECHSLER INTELLIGENC	24	60	60	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1996	10	4					277	286		10.1080/026990596124458			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	UJ541	WOS:A1996UJ54100005	9044693				2022-02-06	
J	Curt, A; Dietz, V				Curt, A; Dietz, V			Traumatic cervical spinal cord injury: Relation between somatosensory evoked potentials, neurological deficit, and hand function	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							NERVE-STIMULATION; QUADRIPLEGIA; RECOVERY; LESIONS; ULNAR; BRAIN; MOTOR; SEP	Objective: Median and ulnar somatosensory evoked potentials (SEP) in the assessment of cervical spinal cord injury (SCI) in relation to the outcome of hand function. Design: Cohort analytical study. Setting: Spinal cord injury center, university hospital. Patients: Consecutively sampled, 23 acute and 46 chronic tetraplegics. Main Outcome Measures: (1) Median and ulnar SEP recordings graded in 5 categories, from normal to absent; (2) clinical examination of algesia/aesthesia in dermatomes C5/6 and C8/Th1 graded in categories of normal, impaired, and loss of sensation; (3) clinical examination of hand function graded in 4 categories, from active to inactive hand function. Results: Pathological median and ulnar SEP were found in 46% and 76% of patients, respectively. A differentiation between upper (C3-C6) and lower (C6/C7-Th1) cervical SCI was possible by comparing the SEP N20 latencies (but not amplitudes) of both nerves (Mann-Whitney U test, p < .01). In follow-up examinations over 6 months the N20 amplitude increased significantly (ANCOVA, p < .001), while the N20 latency did not change. By both ulnar SEP recordings and assessment of the sensory deficit in dermatome C8/Th1 the outcome of hand function, ie, the development of active or inactive hand function, could be predicted (Mann-Whitney U test, p < .01). Conclusion: Median and ulnar SEP are valuable to indicate the level of injury, the degree of sensory impairment and to predict the outcome of hand function even in unconscious patients. They can improve the diagnostic assessment of cervical SCI. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation			Curt, A (corresponding author), UNIV HOSP BALGRIST, SWISS PARAPLEG CTR, FORCHSTR 340, CH-8008 ZURICH, SWITZERLAND.						BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BUCHNER H, 1991, EEG-EMG-Z ELEK ELEKT, V22, P51; CURTIN M, 1994, PARAPLEGIA, V32, P159, DOI 10.1038/sc.1994.29; DEMOL BAJM, 1990, THORAC CARDIOV SURG, V38, P146, DOI 10.1055/s-2007-1014009; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; DORFMAN LJ, 1980, J NEUROSURG, V52, P654, DOI 10.3171/jns.1980.52.5.0654; HASHIMOTO T, 1991, SPINAL CORD MONITORI, P431; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; IZUMI T, 1991, SPINAL CORD MONITORI, P445; JACOBS SR, 1992, ARCH PHYS MED REHAB, V73, P790; JONES SJ, 1979, J NEUROL NEUROSUR PS, V42, P107, DOI 10.1136/jnnp.42.2.107; KIWERSKI J, 1981, PARAPLEGIA, V19, P31, DOI 10.1038/sc.1981.9; KOVINDHA A, 1992, PARAPLEGIA, V30, P502, DOI 10.1038/sc.1992.105; LARREA LG, 1988, ELECTROEN CLIN NEURO, V71, P180, DOI 10.1016/0168-5597(88)90003-2; LIVINGSTONE EF, 1984, ARCH PHYS MED REHAB, V65, P726; NAGATA S, 1991, SPINAL CORD MONITORI, P526; NUWER MR, 1994, ELECTROEN CLIN NEURO, V91, P6, DOI 10.1016/0013-4694(94)90012-4; RESTUCCIA D, 1992, NEUROLOGY, V42, P1054, DOI 10.1212/WNL.42.5.1054; RESTUCCIA D, 1993, NEUROLOGY, V43, P2269, DOI 10.1212/WNL.43.11.2269; RESTUCCIA D, 1994, J NEUROL NEUROSUR PS, V57, P301, DOI 10.1136/jnnp.57.3.301; ROWED DW, 1978, SURG NEUROL, V9, P203; ROWED DW, 1982, EARLY MANAGEMENT ACU, P167; SEDGWICK EM, 1980, J NEUROL NEUROSUR PS, V43, P823, DOI 10.1136/jnnp.43.9.823; TURANO G, 1991, BRAIN, V114, P663, DOI 10.1093/brain/114.1.663; VEILLEUX M, 1987, ELECTROEN CLIN NEURO, V68, P415, DOI 10.1016/0168-5597(87)90053-0; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P756; YIANNIKAS C, 1986, ARCH NEUROL-CHICAGO, V43, P1264, DOI 10.1001/archneur.1986.00520120046015; YORK DH, 1983, SPINE, V8, P832, DOI 10.1097/00007632-198311000-00004; Young W., 1982, EARLY MANAGEMENT ACU, P153	31	60	62	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					48	53		10.1016/S0003-9993(96)90219-1			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200010	8554473				2022-02-06	
J	BACK, W; SCHAMHARDT, HC; HARTMAN, W; BARNEVELD, A				BACK, W; SCHAMHARDT, HC; HARTMAN, W; BARNEVELD, A			KINEMATIC DIFFERENCES BETWEEN THE DISTAL PORTIONS OF THE FORELIMBS AND HIND LIMBS OF HORSES AT THE TROT	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							KINETICS	In literature, it has been hypothesized that the concussion at impact in the equine forelimb is larger than that in the hind limb, and therefore, eventually more clinical lameness may develop in the distal portion of the forelimbs. As the functional anatomy of the distal forelimb and hind limb segments is similar, a study was undertaken to compare the kinematics of hoof and fetlock in the forelimbs and hind limbs. For this purpose, the trot of 24 clinically normal (sound) horses on a treadmill (4 m/s) was recorded, using modem gait analysis equipment. It appeared that vertical hoof velocity at impact and the resulting vertical hoof acceleration were higher in the forelimb than in the hind limb, In contrast, horizontal hoof velocity at impact and the resulting horizontal acceleration were higher in the hind limb. Just after impact the fetlock was more rapidly extended in the forelimb than the hind limb. The peak maximal and minimal accelerations of that joint also were significantly (P < 0.05) higher in the forelimb than in the hind limb. Results of this study indicate that, at the beginning of the stance phase, the distal portion of the forelimb is subjected to more kinematic stress than the distal portion of the hind limb. The higher angular velocity of the fetlock can be interpreted as more rapid loading of this joint, whereas the higher peak accelerations represent the higher oscillatory changes in fetlock movement. It is known from literature that repetitive impulsive joint loading and rapid oscillations in joint movement, even within physiologic limits, contribute to development of osteoarthrosis. Therefore, the differences between distal forelimb and hind limb kinematics found in this study may be related to the generally known higher incidence of chronic lameness in the forelimbs.	UNIV UTRECHT,FAC VET MED,DEPT VET ANAT,3584 CM UTRECHT,NETHERLANDS		BACK, W (corresponding author), UNIV UTRECHT,FAC VET MED,DEPT GEN & LARGE ANIM SURG,YALELAAN 12,3584 CM UTRECHT,NETHERLANDS.						ANTONSSON EK, 1995, J BIOMECH, V18, P39; BACK W, 1995, EQUINE VET J, V27, P39, DOI 10.1111/j.2042-3306.1995.tb03030.x; BACK W, 1995, EQUINE VET J, V27, P31, DOI 10.1111/j.2042-3306.1995.tb03029.x; BACK W, 1994, EQUINE VET J S, V17, P3; BARREY E, 1991, EQUINE EXERCISE PHYS, V3, P97; BENOIT P, 1993, ACTA ANAT, V46, P109; CAMPO LJM, 1991, VET COMP ORTHOPAED T, V4, P120; Clayton H M, 1990, Equine Vet J Suppl, P86; CLAYTON HM, 1994, EQUINE VET J, V26, P230, DOI 10.1111/j.2042-3306.1994.tb04375.x; DOW SM, 1991, EQUINE VET J, V23, P266, DOI 10.1111/j.2042-3306.1991.tb03715.x; DYHREPOULSEN P, 1994, EQUINE VET J, V26, P362, DOI 10.1111/j.2042-3306.1994.tb04404.x; FLEISS O, 1984, ARCH TIERARZTL FORTB, V8, P116; Fredricson I, 1972, Acta Vet Scand Suppl, V37, P1; HERRING L, 1992, J EQUINE VET SCI, V12, P172, DOI 10.1016/S0737-0806(06)81476-0; HJERTEN G, 1993, ACTA ANAT, V146, P193; HJERTEN G, 1994, EQUINE VET J S, V17, P48; Johnston C., 1991, EQUINE EXERCISE PHYS, V3, P167; KOBLUK CN, 1989, EQUINE VET J, V21, P48, DOI 10.1111/j.2042-3306.1989.tb02089.x; MERKENS HW, 1994, EQUINE VET J S, V17, P67; RADIN EL, 1991, J ORTHOPAED RES, V9, P398, DOI 10.1002/jor.1100090312; RIEMERSMA DJ, 1988, AM J VET RES, V49, P1344; RIEMERSMA DJ, 1988, AM J VET RES, V49, P1353; ROEPSTORFF L, 1994, EQUINE VET J S, V17, P71; Schamhardt H.C., 1991, EQUINE EXERCISE PHYS, V3, P120; Schamhardt HC, 1994, EQUINE VET J S, V17, P75, DOI DOI 10.1111/J.2042-3306.1994.TB04879.X; Snedecor G.W., 1982, STATISTICAL METHODS; Stashak T S., 1987, ADAMS LAMENESS HORSE, V76, p[88, 102]; VANOLDRUITENBOR.MM, 1995, EQUINE EXER PHYSL, V4, P413; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	29	60	60	0	12	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD, SCHAUMBURG, IL 60173-4360	0002-9645			AM J VET RES	Am. J. Vet. Res.	NOV	1995	56	11					1522	1528					7	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	TC132	WOS:A1995TC13200023	8585667				2022-02-06	
J	KREUTZER, JS; MARWITZ, JH; WITOL, AD				KREUTZER, JS; MARWITZ, JH; WITOL, AD			INTERRELATIONSHIPS BETWEEN CRIME, SUBSTANCE-ABUSE, AND AGGRESSIVE BEHAVIORS AMONG PERSONS WITH TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							HEAD-INJURY	Professionals have suggested that aggessiveness, substance abuse, and criminality contribute to poor outcomes after brain injury. There is considerable research regarding post-injury aggressive behaviour, but limited information concerning criminal behaviour and alcohol use patterns. With a sample of 327 patients varying in severity of traumatic brain injury, the present investigation examined alcohol use patterns, arrest histories, behavioural characteristics, and psychiatric treatment histories. Relative to the uninjured population, analysis revealed relatively high incidence of heavy drinking, both pre- and post-injury, among patients with a history of arrest. Increases in abstinence rates were found regardless of arrest history. In addition, a history of arrest was associated with a seater likelihood of psychiatric treatment. Findings also indicated relatively high levels of aggressive behaviours. Discussion focuses on implications for evaluation, rehabilitation, and future research.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA 23298		KREUTZER, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,RICHMOND,VA 23298, USA.						ABRAMS D, 1993, J HEAD TRAUMA REHABI, V4, P59; BAUNACH P, 1988, REPORT NATION CRIME, P30; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; GAILBRAITH S, 1976, BRIT J SURG, V63, P735; GLOW BA, 1989, ALCOHOLISM SUBSTANCE, P65; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HURLEY J, 1990, ALCOHOL HLTH; JOHNSON P, 1977, ADM281760200; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1987, GENERAL HLTH HIST QU; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P212; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MILLER JD, 1983, ADM831277; NOBEL EP, 1978, HE2083132 US DHEW RE; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; ZAWITZ MW, 1988, NCJ105506 US DEP JUS; 1985, ALCOHOL USE PERSONS	25	60	60	0	9	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1995	9	8					757	768		10.3109/02699059509008232			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	TH499	WOS:A1995TH49900001	8605509				2022-02-06	
J	FUKUDA, K; PANTER, SS; SHARP, FR; NOBLE, LJ				FUKUDA, K; PANTER, SS; SHARP, FR; NOBLE, LJ			INDUCTION OF HEME OXYGENASE-1 (HO-1) AFTER TRAUMATIC BRAIN INJURY IN THE RAT	NEUROSCIENCE LETTERS			English	Article						HEME OXYGENASE; HEMORRHAGE; RATS; TRAUMATIC BRAIN INJURY	MESSENGER-RNA; PROTEIN; ANTIOXIDANT; EXPRESSION; BILIRUBIN; HSP32	The induction of heme oxygenase-1 (HO-1), the 32 kDa heat shock protein, was examined in the traumatized rat brain. At 24 h after either mild or severe brain injury or sham surgery, HO-1 was immunolocalized in fixed sections of brain. After mild brain injury, hemorrhage was apparent in the subarachnoid space, external capsule and cerebellum. HO-1 was induced in similar areas in macrophages in the subarachnoid space and in glia in the cortex adjacent to the site of impact, the ipsilateral hippocampus, external capsule and cerebellum. After severe brain injury, extensive hemorrhage occurred in the external capsule, hippocampus and cerebellum. HO-1 was induced in glia in these areas of hemorrhage but was more extensive than that seen after mild injury and included the contralateral external capsule and hippocampus. These findings demonstrate remarkable induction of HO-1 in glia in the injured brain. Since heme is a potent inducer of HO-1, it is likely that the subarachnoid and/or intraparenchymal blood induced HO-1 in the glia where the heme was metabolized to biliverdin, iron, and carbon monoxide.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121						NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543, NS28167] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028167, P01NS014543, P50NS014543] Funding Source: NIH RePORTER		BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1989, CARCINOGENESIS, V11, P787; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MATZ P, 1995, UNPUB J CEREB BLOOD; NIMURA T, 1995, UNPUB STROKE; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	18	60	61	0	3	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 20	1995	199	2					127	130		10.1016/0304-3940(95)12042-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TE035	WOS:A1995TE03500012	8584240				2022-02-06	
J	LANKFORD, DA; WELLMAN, JJ; OHARA, C				LANKFORD, DA; WELLMAN, JJ; OHARA, C			POSTTRAUMATIC NARCOLEPSY IN MILD-TO-MODERATE CLOSED-HEAD INJURY	SLEEP			English	Article; Proceedings Paper	4th International Conference on Narcolepsy	OCT 17-18, 1993	PARIS, FRANCE			POSTTRAUMATIC NARCOLEPSY; HEAD INJURY; SECONDARY NARCOLEPSY; HLA TYPING; NARCOLEPSY		Scattered reports exist describing secondary narcolepsy that develops following disease or organic insult to the brain. The present study is concerned with one particular type of secondary narcolepsy, posttraumatic narcolepsy, which we define as ''narcolepsy that develops following a head injury in a previously asymptomatic individual''. We obtained data on nine patients who had been previously diagnosed with mild to moderate closed head injury and who had unresolved sleep complaints. All patients presented with complaints of excessive daytime somnolence and/or sleep attacks. Patients also presented with a mix of cataplexy, hypnagogic hallucinations and/ or sleep paralysis. All patients had undergone previous neurological and/or neuropsychological evaluation and testing, with seven of the nine patients having the Halstead-Reitan Neuropsychological Test Battery. Human leucocyte antigen (HLA) tissue typing was obtained in six of the nine cases. The standard protocol was utilized, consisting of overnight polysomnography with a Multiple Sleep Latency Test (MSLT) the following day. All patients' histories were negative for narcolepsy or any other significant sleep disorders prior to the head injury. The results of the neuropsychological testing indicated that all patients fell within the mild to moderate impairment range. The results of overnight polysomnography and MSLT data, along with patient histories, indicated a diagnosis of narcolepsy in all cases. The results of HLA typing indicated that three patients were DR2 positive, two were DR4 positive and one was DQW1 positive. We conclude that narcolepsy may be ''dormant'' and that, in cases genetically at risk, even a minor injury to the central nervous system can cause that person to become symptomatic. In other cases, our data call into question the relationship of HLA type to narcolepsy, then point to the possibility of additional variance in narcolepsy.			LANKFORD, DA (corresponding author), SLEEP DISORDERS CTR GEORGIA,ATLANTA,GA, USA.						BROUGHTON RJ, 1990, HDB SLEEP DISORDERS, P197; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; GUILLEMINAULT C, 1989, PRINCIPLES PRACTICE, P338; Honda Y., 1990, HDB SLEEP DISORDERS, P217; HONDA Y, 1989, 3RD SEL P INT S NARC, P27; MACCARIO M, 1987, MIL MED, V152, P370, DOI 10.1093/milmed/152.7.370; PARKES JD, 1985, SLEEP ITS DISORDERS; 1990, INT CLASSIFICATION S	9	60	61	1	5	AMER SLEEP DISORDERS ASSOC	ROCHESTER	1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806	0161-8105			SLEEP	Sleep	DEC	1994	17	8		S			S25	S28		10.1093/sleep/17.suppl_8.S25			4	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QD081	WOS:A1994QD08100007	7701196	Bronze			2022-02-06	
J	KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA				KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA			HIPPOCAMPAL PATHOLOGY IN FATAL HUMAN HEAD-INJURY WITHOUT HIGH INTRACRANIAL-PRESSURE	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; AMINO-ACIDS; DAMAGE; RAT	Traumatically induced hippocampal damage is a frequent sequela of fatal human head injury and is traditionally considered to be the result of decreased cerebral perfusion secondary to raised intracranial pressure (ICP). However, in previous studies employing an experimental model of acceleration head injury, hippocampal lesions have been observed in the absence of high ICP. To further elucidate the role of raised ICP in the production of posttraumatic hippocampal neuronal damage, 14 cases of fatal human nonmissile head injury, in which the measured ICP was less than 20 mm Hg, were subjected to light microscopic evaluation for the frequency and anatomic distribution of hippocampal damage. The mean maximal ICP of the 14 patients was 17.6 mm Hg. Detailed light microscopic evaluation revealed hippocampal lesions in 12 of the 14 cases studied (86%). These lesions were typically bilateral foci of selective neuronal loss in the CA1 subfield of the hippocampus. The nature and distribution of hippocampal lesions were similar to those previously reported both in fatal human head injury associated with elevated ICP and in experimental acceleration head injury without raised ICP. These results provide further evidence that the occurrence of hippocampal neuronal loss following head injury is not exclusively dependent on elevated PCP. Other mechanisms, such as pathologic excitation of neurons, may be involved.	UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW,SCOTLAND								ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; BULLOCK R, 1990, ACT NEUR S, V51, P274; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; INGLIS FM, 1990, ACT NEUR S, V51, P277; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1993, J NEURTRAUMA S1, V10, P142; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; [No title captured]	26	60	61	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					317	324		10.1089/neu.1994.11.317			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100007	7996585				2022-02-06	
J	AIHARA, N; TANNO, H; HALL, JJ; PITTS, LH; NOBLE, LJ				AIHARA, N; TANNO, H; HALL, JJ; PITTS, LH; NOBLE, LJ			IMMUNOCYTOCHEMICAL LOCALIZATION OF IMMUNOGLOBULINS IN THE RAT-BRAIN - RELATIONSHIP TO THE BLOOD-BRAIN-BARRIER	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						IMMUNOCYTOCHEMISTRY; IMMUNOGLOBULIN G; NEURONAL ACCUMULATION OF PROTEIN	CENTRAL NERVOUS-SYSTEM; RETROGRADE AXONAL-TRANSPORT; PROTEIN EXTRAVASATION; ENDOTHELIAL-CELLS; MOTOR NEURONS; MOUSE; IGG; INJURY; PERMEABILITY; PEROXIDASE	The central nervous system has been traditionally regarded as an immunologically privileged area. This feature has been in part attributed to the blood-brain barrier, which provides a restrictive interface to circulating immunoglobulins (IgG). Recent kinetic studies suggest that the barrier to immune proteins is not absolute, but rather may be regulated by a specific transfer mechanism. In this study, we confirm the presence of IgG in the central nervous system by immunocytochemistry and demonstrate a close anatomical relationship between the distribution of this protein and the blood-brain barrier. IgG was immunolocalized in the normal rat brain by using monoclonal and polyclonal antibodies to IgG and its subclasses. On the basis of an initial evaluation, the most appropriate antibodies and dilutions were selected for subsequent analyses. In the first study, IgG and albumin were immunolocalized in adjacent sections. In the second study, horseradish peroxidase (HRP) was given intravenously prior to sacrifice, in order to examine artifacts related to perfusion fixation. The distribution of HRP and IgG was then examined in adjacent sections. In the third study, IgG was immunolocalized in sections of brain after mild traumatic head injury. A monoclonal antibody to IgG2a and a polyclonal antibody to IgG were selected on the basis of specificity and consistent, mutual localization. Distinct, patchy, perivascular staining, infrequently associated with labeled neurons, was noted throughout the brain. Electron microscopy confirmed the perivascular localization; IgG was localized along the basal lamina of microvasculature and within the adjacent parenchyma. Albumin and HRP did not exhibit a similar pattern of perivascular immunostaining. After head injury, prominent immunostaining for IgG was observed in the injured hemisphere. In summary, these data indicate that the normal rat brain contains IgG, which dramatically increases after head injury. The distinct perivascular distribution in the normal brain suggests local microvascular permeability. This permeability is selective for IgG, since albumin does not share a similar perivascular localization. The neuronal staining which is closely associated with perivascular label may reflect one intracellular route for extravasated IgG. (C) 1994 Wiley-Liss, Inc.*	SAN FRANCISCO GEN HOSP, DEPT NEUROSURG, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94110 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023324, P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS RO1 NS23324, NINDS NS14543] Funding Source: Medline		AZZI G, 1990, BIOL CELL, V68, P31, DOI 10.1016/0248-4900(90)90283-9; BALIN BJ, 1986, J COMP NEUROL, V251, P260, DOI 10.1002/cne.902510209; BRIGHTMA.MW, 1970, J NEUROL SCI, V10, P215, DOI 10.1016/0022-510X(70)90151-6; Brightman M W, 1968, Prog Brain Res, V29, P19; BROADWELL RD, 1976, J COMP NEUROL, V166, P257, DOI 10.1002/cne.901660302; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; FABIAN RH, 1987, NEUROLOGY, V37, P1780, DOI 10.1212/WNL.37.11.1780; FISHMAN PS, 1989, J NEUROPATH EXP NEUR, V48, P212, DOI 10.1097/00005072-198903000-00008; HANSSON GK, 1984, P NATL ACAD SCI-BIOL, V81, P3103, DOI 10.1073/pnas.81.10.3103; HUGHES CCW, 1986, NEUROSCI LETT, V68, P100, DOI 10.1016/0304-3940(86)90237-5; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOZLOWSKI GP, 1992, PROG BRAIN RES, V91, P149; KRISTENSSON K, 1971, BRAIN RES, V32, P399, DOI 10.1016/0006-8993(71)90332-5; MOOS T, 1991, NEUROSCI LETT, V127, P1, DOI 10.1016/0304-3940(91)90879-X; NAG S, 1981, J NEUROPATH EXP NEUR, V40, P327, DOI 10.1097/00005072-198105000-00092; NYLAND H, 1982, ACTA PATH MICRO IM C, V90, P217; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; POLLACK IF, 1990, EXP NEUROL, V108, P114, DOI 10.1016/0014-4886(90)90017-M; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SEITZ RJ, 1985, ACTA NEUROPATHOL, V68, P15, DOI 10.1007/BF00688950; SPARROW JR, 1981, BRAIN RES, V212, P159, DOI 10.1016/0006-8993(81)90044-5; SPARROW JR, 1980, J HISTOCHEM CYTOCHEM, V28, P570, DOI 10.1177/28.6.6993552; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TENGVAR C, 1986, ACTA NEUROPATHOL, V71, P177, DOI 10.1007/BF00688038; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; Westergaard E, 1980, Adv Neurol, V28, P55; WESTERGAARD E, 1973, J COMP NEUROL, V152, P17, DOI 10.1002/cne.901520103; YAMAMOTO T, 1987, NEUROLOGY, V37, P843, DOI 10.1212/WNL.37.5.843; ZLOKOVIC BV, 1990, EXP NEUROL, V107, P263, DOI 10.1016/0014-4886(90)90144-H	35	60	62	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	APR 22	1994	342	4					481	496		10.1002/cne.903420402			16	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	NF979	WOS:A1994NF97900001	8040362				2022-02-06	
J	HAUG, HZ; SAVAGE, JD; LIKAVEC, MJ; CONFORTI, PJ				HAUG, HZ; SAVAGE, JD; LIKAVEC, MJ; CONFORTI, PJ			A REVIEW OF 100 CLOSED HEAD-INJURIES ASSOCIATED WITH FACIAL FRACTURES	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article									CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; HOSP ST RAPHAEL, DEPT ORAL & MAXILLOFACIAL SURG, NEW HAVEN, CT 06511 USA; METROHLTH MED CTR, NEUROSURG, CLEVELAND, OH USA		HAUG, HZ (corresponding author), METROHLTH MED CTR, DIV ORAL & MAXILLOFACIAL SURG, 3395 SCRANTON RD, CLEVELAND, OH 44109 USA.						ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; BECKER DP, 1986, NEUROLOGICAL SURGERY, P2016; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HEIMGARTNERCANDINAS B, 1978, J MAXILLOFAC SURG, V6, P293, DOI 10.1016/S0301-0503(78)80109-X; KAUFMAN MS, 1984, J ORAL MAXIL SURG, V42, P250, DOI 10.1016/0278-2391(84)90457-9; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; Murray J F, 1975, Clin Plast Surg, V2, P131; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; STEIDLER NE, 1980, J ORAL SURG, V9, P259; TEASDALE G, 1974, LANCET, V2, P81; TURVEY TA, 1977, J ORAL SURG, V35, P887; WAGNER WF, 1979, J ORAL SURG, V37, P97; ZALLEN RD, 1975, J ORAL SURG, V33, P431	15	60	63	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	MAR	1992	50	3					218	222		10.1016/0278-2391(92)90315-Q			5	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	HF680	WOS:A1992HF68000003	1542064				2022-02-06	
J	ROPER, SN; MENA, I; KING, WA; SCHWEITZER, J; GARRETT, K; MEHRINGER, CM; MCBRIDE, D				ROPER, SN; MENA, I; KING, WA; SCHWEITZER, J; GARRETT, K; MEHRINGER, CM; MCBRIDE, D			AN ANALYSIS OF CEREBRAL BLOOD-FLOW IN ACUTE CLOSED-HEAD INJURY USING TECHNETIUM-99M-HMPAO SPECT AND COMPUTED-TOMOGRAPHY	JOURNAL OF NUCLEAR MEDICINE			English	Article							FLUID-PERCUSSION INJURY; BRAIN INJURY; ACUTE PHASE; PERFUSION	Technetium-99m-hexamethylpropyleneamine (HMPAO) SPECT and x-ray CT were compared in 15 patients with acute closed-head injury. There were 44 focal lesions in all. Fifteen (34%) lesions were seen on both x-ray and SPECT. Seventeen (39%) lesions were seen only on SPECT. Twelve (27%) of the lesions were seen on x-ray tomography only. Of the lesions seen on x-ray tomography but not on SPECT, two were subarachnoid hemorrhage, two were thin subdural hematomas, and eight were contusions. This study shows that SPECT can detect focal disturbances of cerebral blood flow that are not seen on x-ray tomography. It also suggests that there are two types of contusions: those with a decreased cerebral blood flow (i.e., detectable on SPECT) and those with a cerebral blood flow equal to that of the surrounding brain.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV NUCL MED,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV NEURORADIOL,TORRANCE,CA 90509		ROPER, SN (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,SCH MED,DIV NEUROSURG,10833 LECONTE AVE,TORRANCE,CA 90509, USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; COLD GE, 1986, ACTA ANAESTH SCAND, V30, P453, DOI 10.1111/j.1399-6576.1986.tb02452.x; DeWitt D S, 1988, Brain Inj, V2, P291, DOI 10.3109/02699058809150899; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUTREVOU MD, 1987, S AFR J SURG, V25, P95; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEONARD JP, 1986, J NUCL MED, V27, P1819; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1979, NEURAL TRAUMA, P41; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PODREKA I, 1987, J NUCL MED, V28, P1657; SHARP PF, 1986, J NUCL MED, V27, P171; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	23	60	60	0	2	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 22090-5316	0161-5505			J NUCL MED	J. Nucl. Med.	SEP	1991	32	9					1684	1687					4	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	GD043	WOS:A1991GD04300009	1880569				2022-02-06	
J	CLINTON, J; AMBLER, MW; ROBERTS, GW				CLINTON, J; AMBLER, MW; ROBERTS, GW			POSTTRAUMATIC ALZHEIMERS-DISEASE - PREPONDERANCE OF A SINGLE PLAQUE TYPE	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						ALZHEIMERS DISEASE; AMYLOID; BETA-PROTEIN (BETA-PROTEIN); PLAQUES, TRAUMA	DEMENTIA; DEPOSITS; BRAINS; IMMUNOCYTOCHEMISTRY	The cause of Alzheimer's disease is unknown. Several factors have been proposed including head trauma. At present, the link between head injury and a subsequent neurodegenerative process is largely circumstantial, except in the case of dementia pugilistica (punch drunk syndrome) found in boxers. Recent studies have shown that the brains of boxers with this syndrome contain large numbers of 'diffuse' beta-protein immunoreactive plaques. We supposed that this plaque type might be associated with trauma induced Alzheimer-like degeneration. In order to test this hypothesis we have re-investigated a previously reported case of post-traumatic premature Alzheimer's disease. Immunocytochemistry using antibodies to amyloid beta-protein revealed large numbers of 'diffuse' non-Congophilic plaques with little or no neuritic component. A similar preponderance of this plaque type is present in the brains of boxers with dementia pugilistica. Our observations support the idea of a trauma induced Alzheimer-like degenerative process and indicate that such a condition is associated with a marked preponderance of 'diffuse' plaques.	ST MARYS HOSP,SCH MED,DEPT ANAT & CELL BIOL,LONDON W2 1PG,ENGLAND; RHODE ISL HOSP,DEPT PATHOL,PROVIDENCE,RI 02902								CHANDRA V, 1986, NEUROLOGY, V36, P209, DOI 10.1212/WNL.36.2.209; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1959, J MENT SCI, V105, P714, DOI 10.1192/bjp.105.440.714; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; DAVIES L, 1988, NEUROLOGY, V38, P1688, DOI 10.1212/WNL.38.11.1688; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; IKEDA S, 1989, LAB INVEST, V60, P113; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KITAMOTO T, 1987, LAB INVEST, V57, P230; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MAJOCHA RE, 1988, P NATL ACAD SCI USA, V85, P6182, DOI 10.1073/pnas.85.16.6182; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; PROBST A, 1987, ACTA NEUROPATHOL, V74, P133, DOI 10.1007/BF00692843; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1988, NEUROLOGY, V38, P1534, DOI 10.1212/WNL.38.10.1534; ROBERTS GW, 1988, LANCET, V2, P1456; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591; [No title captured]	24	60	61	0	2	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	1991	17	1					69	74		10.1111/j.1365-2990.1991.tb00695.x			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	FB769	WOS:A1991FB76900009	2057052				2022-02-06	
J	Jenkins, LW; Lyeth, BG; Lewelt, W; Moszynski, K; Dewitt, DS; Balster, RL; Miller, LP; Clifton, GL; Young, HF; Hayes, RL				Jenkins, L. W.; Lyeth, B. G.; Lewelt, W.; Moszynski, K.; Dewitt, D. S.; Balster, R. L.; Miller, L. P.; Clifton, G. L.; Young, H. F.; Hayes, R. L.			Combined Pretrauma Scopolamine and Phencyclidine Attenuate Posttraumatic Increased Sensitivity to Delayed Secondary Ischemia	JOURNAL OF NEUROTRAUMA			English	Article							PROTEIN-KINASE-C; EXCITATORY AMINO-ACIDS; LONG-TERM POTENTIATION; BRAIN-INJURY; GRANULE CELLS; RAT; RECEPTORS; METABOLISM; VULNERABILITY; ANTAGONISTS	Fasted Wistar rats were given a mild level of traumatic brain injury (TBI) and then subjected to 6 min of transient forebrain ischemia 24 h posttrauma. One group was given simultaneous 1 mg/kg scopolamine and 4 mg/kg phencyclidine intraperitoneally (IP) 15 min before trauma and another group an equal volume of plasmalyte A solution. After 7 days of postinjury survival, placebo-treated rats demonstrated increased posttraumatic vulnerability to secondary ischemie CAI neuronal death even 24 h after trauma. This finding confirmed that increased posttraumatic ischemie vulnerability persists for at least 24 h even following mild trauma. Combined muscarinic receptor and N-methyl-Daspartate (NMDA) receptor coupled ion channel blockade given and present during the mild TBI statistically attenuated this enhanced secondary ischemie CAI neuronal death and thus posttraumatic increased ischemie vulnerability. Placebo-treated rats had 335.3 +/- 93.6 CAI neurons/10(6)mu m(2) and drug-treated rats had 844.8 +/- 184.9 CAI neurons/10(6)mu m(2). This result suggests that muscarinic and/or NMDA receptor-mediated events confined to TBI and the early posttraumatic period are in part responsible for the phenomenon of increased posttraumatic ischemie vulnerability.	[Jenkins, L. W.; Lyeth, B. G.; Moszynski, K.; Clifton, G. L.; Young, H. F.; Hayes, R. L.] Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Lewelt, W.] Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA; [Balster, R. L.] Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; [Dewitt, D. S.] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC USA; [Miller, L. P.] Vet Adm Med Ctr, Div Neurosci, Washington, DC 20422 USA		Jenkins, LW (corresponding author), Med Coll Virginia, Div Neurosurg, Box 693,MCV Stn, Richmond, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS19550, NS21458, NS19355]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS019355, R01NS019550] Funding Source: NIH RePORTER	We gratefully acknowledge the careful editorial contribution of Fay Akers. This work was supported by NIH Grants NS19550 (LWJ), NS21458 (RLH), and NS19355 (DSD).	Akers R.F., 1987, J NEUROSCI, V7, P3876; BARABAN JM, 1987, TRENDS NEUROSCI, V10, P57, DOI 10.1016/0166-2236(87)90022-1; CHOI DW, 1988, J NEUROSCI, V8, P185; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GOSSELIN RE, 1955, J PHARMACOL EXP THER, V115, P217; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HAYES R L, 1988, Society for Neuroscience Abstracts, V14, P1153; HAYES R L, 1987, Society for Neuroscience Abstracts, V13, P1254; Hayes R.L., 1988, MILD HEAD I IN PRESS; Hayes R.L., 1988, J NEUROSURG UNPUB; Hayes R.L., 1989, J NEUROTRAUM, V5, P287; Jahr C.E., 1987, NATURE, V325, P276; Jenkins L.W., 1989, BRAIN RES UNPUB; Jenkins L.W., 1988, MILD HEAD INJURY CON, V3; Jenkins L.W., 1988, NEUROTRAUMA MONITORI, V4; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALSER SC, 1957, J PHARMACOL EXP THER, V121, P449; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; Lyeth B.G., 1988, NEUROTRAUMA IN PRESS, V4; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; McNamara J O, 1986, Adv Neurol, V44, P303; MISRA AL, 1980, LIFE SCI, V27, P2501, DOI 10.1016/0024-3205(80)90529-9; Miyazaki S., 1989, 7 INT S INT IN PRESS, V7; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; RASMUSSEN H, 1983, CALCIUM CELL FUNCTIO, V4, P2; SAVAGE DD, 1983, J COMP NEUROL, V221, P106, DOI 10.1002/cne.902210109; SIESJO BK, 1986, ANN NY ACAD SCI, V462, P207, DOI 10.1111/j.1749-6632.1986.tb51255.x; SIESJO BK, 1985, CEREBROVASC DIS, P187; WAHL D, 1985, ARZNEIMITTEL-FORSCH, V35, P255; WORLEY PF, 1988, SCIENCE, V239, P1428, DOI 10.1126/science.2831626	45	60	60	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					275	U40		10.1089/neu.1988.5.275			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300002	2854856				2022-02-06	
J	Leddy, JJ; Hinds, AL; Miecznikowski, J; Darling, S; Matuszak, J; Baker, JG; Picano, J; Willer, B				Leddy, John J.; Hinds, Andrea L.; Miecznikowski, Jeffrey; Darling, Scott; Matuszak, Jason; Baker, John G.; Picano, John; Willer, Barry			Safety and Prognostic Utility of Provocative Exercise Testing in Acutely Concussed Adolescents: A Randomized Trial	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						exercise; tolerance; treadmill test; sport; concussion; adolescent	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; NEUROCOGNITIVE PERFORMANCE; VOLUNTARY EXERCISE; UP-REGULATION; HIGH-SCHOOL; SYMPTOMS; RECOVERY; RELIABILITY	Objective: To evaluate (1) systematic assessment of exercise tolerance in adolescents shortly after sport-related concussion (SRC) and (2) the prognostic utility of such assessment. Design: Prospective randomized controlled trial. Setting: University and community sports medicine centers. Participants: Adolescents with SRC (1-9 days from injury). Sixty-five were randomized and 54 completed the study (mean age 15 years, 4 days after injury). Interventions: Buffalo Concussion Treadmill Test (BCTT, n = 27) or not (controls, n = 27) on visit day #1. Heart rate threshold (HRt) at symptom exacerbation represented level of exercise tolerance. Participants reported symptoms daily for 14 days and then had follow-up BCTT (n = 54). Recovery was defined as returning to normal level of symptoms and exercise tolerance, verified by independent physician examination. Main Outcome Measures: Days to recovery and typical (<= 21 days) versus prolonged recovery (>21 days). Mixed effects linear models and linear regression techniques examined symptom reports and time to recovery. Linear regression assessed the association of HRt with recovery time. Results: Days to recovery (P = 0.7060) and typical versus prolonged recovery (P = 50.1195) were not significantly different between groups. Symptom severity scores decreased in both groups over 14 days (P=0.0001), were similar (P=0.2984), and did not significantly increase the day after the BCTT (P = 0.1960). Lower HRt on visit day #1 was strongly associated with prolonged recovery time (P = 0.0032). Conclusions: Systematic evaluation of exercise tolerance using the BCTT within 1 week after SRC did not affect recovery. The degree of early exercise intolerance after SRC was important for prognosis. This has implications for school academic and team preparation.	[Leddy, John J.; Hinds, Andrea L.; Darling, Scott; Baker, John G.] SUNY Buffalo, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Miecznikowski, Jeffrey] SUNY Buffalo, Dept Biostat, Buffalo, NY USA; [Matuszak, Jason] SUNY Buffalo, Excelsior Orthoped, Buffalo, NY USA; [Matuszak, Jason] SUNY Buffalo, Dept Family Med, Buffalo, NY USA; [Baker, John G.] SUNY Buffalo, Nucl Med, Buffalo, NY USA; [Picano, John] SUNY Buffalo, Dept Internal Med, Buffalo, NY USA; [Willer, Barry] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA		Leddy, JJ (corresponding author), UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			Ralph C. Wilson Foundation; Program for Understanding Childhood Concussion and Stroke; Robert Rich Family Foundation; Buffalo Sabres Foundation; National Football League Charities; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance of Christopher Stawitz, ATC and Anthony Surace, ATC, for their tremendous efforts in diligently collecting much of the clinical data. We gratefully appreciate the support of The Ralph C. Wilson Foundation, Program for Understanding Childhood Concussion and Stroke, The Robert Rich Family Foundation, The Buffalo Sabres Foundation, and the National Football League Charities for their financial support.	[Anonymous], 2013, R LANG ENV STAT COMP; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Dematteo C, 2015, MED SCI SPORT EXER, V47, P2283, DOI 10.1249/MSS.0000000000000682; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Sallis R, 2015, PHYSICIAN SPORTSMED, V43, P22, DOI 10.1080/00913847.2015.1001938; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	31	59	60	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2018	28	1					13	20		10.1097/JSM.0000000000000431			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	GB0JM	WOS:000428732000004	29257777	Green Accepted			2022-02-06	
J	Doherty, CP; O'Keefe, E; Wallace, E; Loftus, T; Keaney, J; Kealy, J; Humphries, MM; Molloy, MG; Meaney, JF; Farrell, M; Campbell, M				Doherty, Colin P.; O'Keefe, Eoin; Wallace, Eugene; Loftus, Teresa; Keaney, James; Kealy, John; Humphries, Marian M.; Molloy, Michael G.; Meaney, James F.; Farrell, Michael; Campbell, Matthew			Blood-Brain Barrier Dysfunction as a Hallmark Pathology in Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Blood-brain harrier; Chronic traumatic encephalopathy; Claudin-5; Tight junctions	INJURY	Chronic traumatic encephalopathy (CTE) is a neurodegenerative condition associated with repetitive mild traumatic brain injury. In recent years, attention has focused on emerging evidence linking the development of CTE to concussive injuries in athletes and military personnel; however, the underlying molecular pathobiology of CTE remains unclear. Here, we provide evidence that the blood brain barrier (BBB) is disrupted in regions of dense perivascular p-Tau accumulation in a case of CTE. Immunoreactivity patterns of the BBB-associated tight junction components claudin-5 and zonula occludens-1 were markedly discontinuous or absent in regions of perivascular p-Tau deposition; there was also immunohistochemical evidence of a BBB in these foci. Because the patient was diagnosed premortem clinically as having progressive supranuclear palsy (PSP), we also compromised that the CTE alterations appear to be distinct from those in the brain of a patient with PSP. This report represents the first description of BBB dysfunction in a pathologically proven CTE case and suggests a vascular component in the postconcussion cascade of events that may ultimately lead to development of a progressive degenerative disorder. BBB dysfunction may represent a correlate of neural dysfunction in live subjects suspected of being at risk for development of CTE.	[Doherty, Colin P.; Wallace, Eugene] St James Hosp, Hosp 5, Hlth Care Ctr, Dept Neurol, Dublin, Ireland; [O'Keefe, Eoin; Keaney, James; Kealy, John; Humphries, Marian M.; Campbell, Matthew] Univ Dublin, Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland; [Loftus, Teresa; Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Keaney, James] Univ Sch Vet Med, Basseterre, St Kitts & Nevi; [Molloy, Michael G.] Univ Coll Cork, Dept Med, Cork, Ireland; [Meaney, James F.] St James Hosp, Dept Radiol, Dublin, Ireland		Campbell, M (corresponding author), Univ Dublin, Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland.	matthew.campbell@tcd.ie	; Kealy, John/A-6515-2010	Doherty, Colin/0000-0002-8869-8567; Kealy, John/0000-0002-0503-4379; Meaney, James FM/0000-0003-1596-4972	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/YI/B2614, 08/IN.I/B2033]; Health Research Board of Ireland; Bright Focus FoundationBrightFocus Foundation; St James' Hospital Research Foundation	This work was supported by grants from Science Foundation Ireland (12/YI/B2614; 08/IN.I/B2033), The Health Research Board of Ireland, the Bright Focus Foundation and St James' Hospital Research Foundation.	Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412; Kon T, 2012, NEUROPATHOLOGY, V32, P267, DOI 10.1111/j.1440-1789.2011.01249.x; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334	16	59	59	0	29	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2016	75	7					656	662		10.1093/jnen/nlw036			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DR3BG	WOS:000379777000004	27245243	Bronze, Green Published			2022-02-06	
J	Stanne, TM; Aberg, ND; Nilsson, S; Jood, K; Blomstrand, C; Andreasson, U; Blennow, K; Zetterberg, H; Isgaard, J; Svensson, J; Jern, C				Stanne, Tara M.; Aberg, N. David; Nilsson, Staffan; Jood, Katarina; Blomstrand, Christian; Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik; Isgaard, Jorgen; Svensson, Johan; Jern, Christina			Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke	STROKE			English	Article						brain-derived neurotrophic factor; pathogenesis; risk factors; serum; stroke	RECOVERY; INJURY; BDNF; NGF	Background and Purpose-Brain-derived neurotrophic factor (BDNF) plays important roles in brain plasticity and repair, and it influences stroke outcomes in animal models. Circulating BDNF concentrations are lowered in patients with traumatic brain injury, and low BDNF predicts poor recovery after this injury. We sought to investigate whether circulating concentrations of BDNF are altered in the acute phase of ischemic stroke and whether they are associated with short- or long-term functional outcome. Methods-Serum concentrations of BDNF were measured in the Sahlgrenska Academy Study on Ischemic Stroke. The main outcomes were modified Rankin Scale (mRS) good (mRS score of 0-2) versus poor (mRS score of 3-6) at 3 months and 2 years after stroke, and good (mRS score of 0-2) versus poor (mRS score of 3-5) at 7 years after stroke. Results-Acute concentrations of BDNF were significantly lower in ischemic stroke cases (n=491) compared with controls (n=513). BDNF concentrations were not significantly associated with 3-month outcome. However, patients with BDNF in the lowest tertile had an increased risk of experiencing a poor outcome both at 2-year and 7-year follow-up, and these associations were independent of vascular risk factors and stroke severity (odds ratio, 2.6; confidence intervals, 1.4-4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1-3.9; P=0.028, respectively). Conclusions-Circulating concentrations of BDNF protein are lowered in the acute phase of ischemic stroke, and low levels are associated with poor long-term functional outcome. Further studies are necessary to confirm these associations and to determine the predictive value of BDNF in stroke outcomes.	[Stanne, Tara M.; Jern, Christina] Univ Gothenburg, Sahlgrenska Acad, Dept Med & Clin Genet, Gothenburg, Sweden; [Aberg, N. David; Isgaard, Jorgen; Svensson, Johan] Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Gothenburg, Sweden; [Aberg, N. David; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Gothenburg, Sweden; [Jood, Katarina; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden; [Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Nilsson, Staffan] Chalmers, Math Sci, Gothenburg, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, London, England		Stanne, TM (corresponding author), Inst Biomed, Dept Med & Clin Genet, POB 445, SE-40530 Gothenburg, Sweden.	tara.stanne@gu.se	Aberg, N. David/O-4068-2019	Nilsson, Staffan/0000-0003-4748-0446	Swedish Medical Society (Svenska Lakaresallskapet); Swedish Government [ALFGBG-11206, ALFGBG-147771, ALFGBG-148861, ALFGBG-144341]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2013-3595]; Swedish Heart Lung FoundationSwedish Heart-Lung Foundation [20130315]; Swedish Stroke Association; Goteborg Foundation for Neurological Research; Goteborg Medical Society [036/14]	This study was supported by the Swedish Medical Society (Svenska Lakaresallskapet), grants from the Swedish Government (ALFGBG-11206, ALFGBG-147771, ALFGBG-148861, and ALFGBG-144341), the Swedish Research Council (2013-3595), the Swedish Heart Lung Foundation (20130315), the Swedish Stroke Association, the Goteborg Foundation for Neurological Research, and the Goteborg Medical Society (036/14).	Chaldakov GN, 2004, PROG BRAIN RES, V146, P279, DOI 10.1016/S0079-6123(03)46018-4; Golden E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010099; Hope TMH, 2013, NEUROIMAGE-CLIN, V2, P424, DOI 10.1016/j.nicl.2013.03.005; Jood K, 2005, STROKE, V36, P1383, DOI 10.1161/01.STR.0000169944.46025.09; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Li J, 2014, J AFFECT DISORDERS, V168, P373, DOI 10.1016/j.jad.2014.07.011; Manni L, 2005, INT J CARDIOL, V102, P169, DOI 10.1016/j.ijcard.2004.10.041; Pikula A, 2013, STROKE, V44, P2768, DOI 10.1161/STROKEAHA.113.001447; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331	9	59	66	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUL	2016	47	7					1943	1945		10.1161/STROKEAHA.115.012383			3	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	DR4AX	WOS:000379844900058	27301948	Bronze, Green Submitted			2022-02-06	
J	Winston, CN; Noel, A; Neustadtl, A; Parsadanian, M; Barton, DJ; Chellappa, D; Wilkins, TE; Alikhani, AD; Zapple, DN; Villapol, S; Planel, E; Burns, MP				Winston, Charisse N.; Noel, Anastasia; Neustadtl, Aidan; Parsadanian, Maia; Barton, David J.; Chellappa, Deepa; Wilkins, Tiffany E.; Alikhani, Andrew D.; Zapple, David N.; Villapol, Sonia; Planel, Emmanuel; Burns, Mark P.			Dendritic Spine Loss and Chronic White Matter Inflammation in a Mouse Model of Highly Repetitive Head Trauma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BRAIN-INJURY CAUSES; AMYLOID-BETA ACCUMULATION; ALZHEIMERS-DISEASE; AXONAL INJURY; OPTIC-NERVE; TRANSGENIC MODEL; MEMORY DEFICITS; RAT MODEL; MILD; TAU	Mild traumatic brain injury (mTBI) is an emerging risk for chronic behavioral, cognitive, and neurodegenerative conditions. Athletes absorb several hundred mTBIs each year; however, rodent models of repeat mTBI (rmTBI) are often Limited to impacts in the single digits. Herein, we describe the effects of 30 rmTBIs, examining structural and pathological changes in mice up to 365 days after injury. We found that single mTBI causes a brief loss of consciousness and a transient reduction in dendritic spines, reflecting a loss of excitatory synapses. Single mTBI does not cause axonal injury, neuroinflammation, or cell death in the gray or white matter. Thirty rmTBIs with a 1-day interval between each mTBI do not cause dendritic spine loss; however, when the interinjury interval is increased to 7 days, dendritic spine Loss is reinstated. Thirty rmTBIs cause white matter pathology characterized by positive silver and Ruoro-Jade B staining, and microglial proliferation and activation. This pathology continues to develop through 60 days, and is still apparent at 365 days, after injury. However, rmTBIs did not increase beta-amyloid Levels or tau phosphorylation in the 3xTg-AD mouse model of Alzheimer disease. Our data reveal that single mTBI causes a transient loss of synapses, but that rmTBIs habituate to repetitive injury within a short time period. rmTBI causes the development of progressive white matter pathology that continues for months after the final impact.	[Winston, Charisse N.; Neustadtl, Aidan; Parsadanian, Maia; Barton, David J.; Chellappa, Deepa; Wilkins, Tiffany E.; Alikhani, Andrew D.; Zapple, David N.; Villapol, Sonia; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Noel, Anastasia; Planel, Emmanuel] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada; [Planel, Emmanuel] CHU Quebec, Res Ctr, Neurosci, Quebec City, PQ, Canada		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20057 USA.; Planel, E (corresponding author), CHUL, RC-9800,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	emmanuel@planel.org; mpb37@georgetown.edu	Villapol, Sonia/D-1949-2014; Barton, David J/C-9282-2011	Barton, David J/0000-0003-0976-0383; Planel, Emmanuel/0000-0001-5128-0565; Burns, Mark P/0000-0003-4750-2000; Villapol, Sonia/0000-0002-6174-4113; alikhani, ahmad/0000-0001-9857-8844	Georgetown University's Neural Injury and Plasticity Training Program [T32NS041218]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS067417]; Promote Diversity in Health-Related Research supplement; Alzheimer Society of Canada; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-106423, PCN-102993]; Fonds de Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [16205, 20048]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [354722]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081068, T32NS041218, R03NS067417] Funding Source: NIH RePORTER	Supported by Georgetown University's Neural Injury and Plasticity Training Program grant T32NS041218, supported by the NIH (C.N.W.; principal investigators Dr. Jean Wrathall and Dr. Kathleen Maguire-Zeiss); the National Institute of Neurological Disorders and Stroke grant R01 NS067417 (M.P.B.); a Promote Diversity in Health-Related Research supplement (M.P.B.); a donation from K.P.B. Corporation (M.P.B.); Alzheimer Society of Canada postdoctoral awards (An.N.); the Canadian Institute of Health Research grants MOP-106423 and PCN-102993 (E.P.); Fonds de Recherche en Sante du Quebec grants 16205 and 20048 (E.P.); and the Natural Sciences and Engineering Research Council of Canada grant 354722 (E.P.).	Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bretteville A, 2008, J ALZHEIMERS DIS, V14, P431; BRION JP, 1993, J NEUROCHEM, V61, P2071, DOI 10.1111/j.1471-4159.1993.tb07444.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Committee for the Update of the Guide for the Care and Use of Laboratory Animals Institute to Laboratory Animal Research, 2011, GUIDE CARE USE LAB A; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Duff K, 2005, NAT MED, V11, P826, DOI 10.1038/nm0805-826; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Petry FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094251; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Xu LY, 2015, EXP NEUROL, V273, P168, DOI 10.1016/j.expneurol.2015.08.014	62	59	59	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2016	186	3					552	567		10.1016/j.ajpath.2015.11.006			16	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	DE9WY	WOS:000370991800011	26857506	Bronze, Green Published			2022-02-06	
J	Liu, M; Wu, W; Li, H; Li, S; Huang, LT; Yang, YQ; Sun, Q; Wang, CX; Yu, Z; Hang, CH				Liu, Ming; Wu, Wei; Li, Hua; Li, Song; Huang, Li-tian; Yang, Yi-qing; Sun, Qing; Wang, Chun-xi; Yu, Zhuang; Hang, Chun-hua			Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Functional outcome; Necroptosis; Necrostatin-1; Spinal cord injury	BRAIN-INJURY; IN-VIVO; APOPTOSIS; NECROSIS; RATS; INFLAMMATION; NECROSTATIN; ANTAGONIST; RECOVERY; NEURONS	Background: Necroptosis is an emerging programmed necrosis other than traditional necrosis and apoptosis. Until recently, there have not been studies that have investigated a relationship between necroptosis and pathogenesis of cell death after spinal cord injury (SCI). Objective: To investigate whether necroptosis takes part in the early pathophysiological processes of traumatic SCI in mice. Methods: Female ICR mice were randomized equally into three groups: the sham, the vehicle-treated + SCI group, and the Nec-1-treated + SCI group. To induce SCI, the mice were subjected to a laminectomy at T9 and compression with a vascular clip. After mice were sacrificed 24 hours post-SCI, propidium iodide (PI)positive cells were detected using in vivo PI labeling. Morphological analyses were performed by hematoxylin and eosin staining and Nissl staining. The samples were evaluated for apoptosis by the in situ TUNEL assay. The expression of caspase-3 was assessed by western blot. Locomotor behavior of hindlimb was evaluated by BMS (Basso mouse scale) score at 1, 3, 5, 7, and 14 days post-injury. Results: Compared with dimethyl sulfoxide -treated mice, necrostatin-1-treated mice showed decreased PI-positive cells (P < 0.05), alleviated tissue damage, more surviving neuron at 24 hours after SCI (P < 0.05), and improved functional recovery from days 7 to 14 (P < 0.05). Necrostatin-1 did not reduce the expression of caspase-3 and the number of TUNEL-positive cells at 24 hours after SCI (P > 0.05). Conclusions: Necroptosis contributes to necroptotic cell death and influences functional outcome after SCI in adult mice. The inhibition of necroptosis by necrostatin-1 may have therapeutic potential for patients with SCI.	[Liu, Ming; Li, Song; Huang, Li-tian; Hang, Chun-hua] Southern Med Univ Guangzhou, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Ming] Ningde Municipal Hosp, Dept Neurosurg, Ningde, Peoples R China; [Wu, Wei; Li, Hua; Yang, Yi-qing; Sun, Qing; Wang, Chun-xi; Yu, Zhuang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China		Hang, CH (corresponding author), Southern Med Univ Guangzhou, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Li, Hua/0000-0001-5893-535X	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 81371294]; Nature Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]; Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China [CXZZ12_0067]	This work was funded in part by grants from the National Natural Science Foundation, China (No. 81171170, 81371294) and Nature Science Foundation of Jiangsu Province, China (BK2010459) and Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China (CXZZ12_0067).	Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; Chen KB, 2011, SPINE, V36, P1350, DOI 10.1097/BRS.0b013e3181f014ec; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Dunai Z, 2011, PATHOL ONCOL RES, V17, P791, DOI 10.1007/s12253-011-9433-4; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Oerlemans MIFJ, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0270-8; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wang ZF, 2013, EXP THER MED, V5, P107, DOI 10.3892/etm.2012.745; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang N, 2012, INDIAN J MED RES, V135, P287	29	59	62	1	17	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	NOV	2015	38	6					745	753		10.1179/2045772314Y.0000000224			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU8KC	WOS:000363790300008	24970278	Green Published			2022-02-06	
J	Fu, TS; Jing, RW; McFaull, SR; Cusimano, MD				Fu, Terence S.; Jing, Rowan; McFaull, Steven R.; Cusimano, Michael D.			Management of severe blunt hepatic injury in the era of computed tomography and transarterial embolization: A systematic review and critical appraisal of the literature	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	101st Annual Congress of the Swiss-Society-of-Surgery73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	MAY 21-23, 2014SEP 09-13, 2014	Bern, SWITZERLANDPhiladelphia, PA	Swiss Soc SurgAmer Assoc Surg Trauma			TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POPULATION; TRENDS; EPIDEMIOLOGY; HOSPITALIZATIONS; MORTALITY; VISITS; CARE; AGE		[Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, Injury Prevent Res Off, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [McFaull, Steven R.] Publ Hlth Agcy Canada, Ottawa, ON, Canada		Cusimano, MD (corresponding author), St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Div Neurosurg,Dept Surg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946, the Ontario Neurotrauma Foundation.	Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Canadian Institute for Health Information, 2012, CIHI DAT QUAL STUD 2; Canadian Institute of Health Information (CIHI), 2006, HEAD INJ CAN DEC CHA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cusimano MD, 2008, INJURY PREV, V14, P113, DOI 10.1136/ip.2007.017533; Faul M, 2010, TRAUMATIC BRAIN INJU; Fingerhut L., 2002, EXTERNAL CAUSE INJUR; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mayhew D.R., 2005, BEST PRACTICES GRADU; Peloso PM, 2004, J REHABIL MED S43, P2004; Phillips LA, 2009, CAN J NEUROL SCI, V36, P605, DOI 10.1017/S0317167100008118; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Russell KF, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003300.pub3; Simniceanu A, 2014, TRAFFIC INJ PREV, V15, P734, DOI 10.1080/15389588.2013.867483; Solomon R, 2014, CAN PUBLIC POL, V40, P15, DOI 10.3138/cpp.2012-102; Stephenson S, 2004, INJURY PREV, V10, P379, DOI 10.1136/ip.2004.005561; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, STANDARDS SURVEILLAN; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	31	59	60	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2015	79	3					449	455		10.1097/TA.0000000000000733			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CQ4JV	WOS:000360571900021	26535433	Green Accepted			2022-02-06	
J	Trotter, BB; Robinson, ME; Milberg, WP; McGlinchey, RE; Salat, DH				Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.			Military blast exposure, ageing and white matter integrity	BRAIN			English	Article						CNS injury; imaging; concussion; traumatic brain injury; neuropathology; axon degeneration	TRAUMATIC BRAIN-INJURY; REDUCED CORTICAL THICKNESS; AGE-RELATED-CHANGES; DIFFUSION-TENSOR; FRACTIONAL ANISOTROPY; COGNITIVE IMPAIRMENT; HEAD-INJURY; INDUCED NEUROTRAUMA; SPATIAL STATISTICS; ALZHEIMERS-DISEASE	Mild traumatic brain injury, or concussion, is associated with a range of neural changes including altered white matter structure. There is emerging evidence that blast exposure-one of the most pervasive causes of casualties in the recent overseas conflicts in Iraq and Afghanistan-is accompanied by a range of neurobiological events that may result in pathological changes to brain structure and function that occur independently of overt concussion symptoms. The potential effects of brain injury due to blast exposure are of great concern as a history of mild traumatic brain injury has been identified as a risk factor for age-associated neurodegenerative disease. The present study used diffusion tensor imaging to investigate whether military-associated blast exposure influences the association between age and white matter tissue structure integrity in a large sample of veterans of the recent conflicts (n = 190 blast-exposed; 59 without exposure) between the ages of 19 and 62 years. Tract-based spatial statistics revealed a significant blast exposure x age interaction on diffusion parameters with blast-exposed individuals exhibiting a more rapid cross-sectional age trajectory towards reduced tissue integrity. Both distinct and overlapping voxel clusters demonstrating the interaction were observed among the examined diffusion contrast measures (e.g. fractional anisotropy and radial diffusivity). The regions showing the effect on fractional anisotropy included voxels both within and beyond the boundaries of the regions exhibiting a significant negative association between fractional anisotropy and age in the entire cohort. The regional effect was sensitive to the degree of blast exposure, suggesting a 'dose-response' relationship between the number of blast exposures and white matter integrity. Additionally, there was an age-independent negative association between fractional anisotropy and years since most severe blast exposure in a subset of the blast-exposed group, suggesting a specific influence of time since exposure on tissue structure, and this effect was also independent of post-traumatic stress symptoms. Overall, these data suggest that blast exposure may negatively affect brain-ageing trajectories at the microstructural tissue level. Additional work examining longitudinal changes in brain tissue integrity in individuals exposed to military blast forces will be an important future direction to the initial findings presented here.	[Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Translat Res Ctr Traumat Brain Injury & Stress Di, RR&TBI Ctr Excellence, Boston, MA 02130 USA; [Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA 02130 USA; [Trotter, Benjamin B.; Robinson, Meghan E.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA; [Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA; [Salat, David H.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA		Salat, DH (corresponding author), VA Boston Healthcare Syst, 182 JP 150 S Huntington Ave, Boston, MA 02130 USA.	salat@nmr.mgh.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR010827]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR010827] Funding Source: NIH RePORTER	This work was supported by funding from the Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence; Contract grant number: B9254-C (R.E.M. and W.P.M.) and NIH R01NR010827. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Andersson JL, 2007, TR07JA1 FMRIB FMRIB TECH REP TRO7J; Andersson JL, 2007, FMRIB TECH REP TRO7J FMRIB TECHNICAL REPO; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bartzokis G, 2004, J ALZHEIMERS DIS, V6, pS53; Bartzokis G, 2004, NEUROBIOL AGING, V25, P843, DOI 10.1016/j.neurobiolaging.2003.09.005; Bartzokis G, 2004, NEUROBIOL AGING, V25, P49, DOI 10.1016/j.neurobiolaging.2003.08.001; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fortier CB, 2014, ALCOHOL CLIN EXP RES, V38, P2925, DOI 10.1111/acer.12568; Fortier CB, 2011, ALCOHOL CLIN EXP RES, V35, P2193, DOI 10.1111/j.1530-0277.2011.01576.x; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jacobs HIL, 2013, HUM BRAIN MAPP, V34, P77, DOI 10.1002/hbm.21412; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kochunov P, 2014, PSYCHIAT RES-NEUROIM, V223, P148, DOI 10.1016/j.pscychresns.2014.05.004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; Leritz EC, 2014, HUM BRAIN MAPP, V35, P1085, DOI 10.1002/hbm.22236; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Menke RAL, 2012, ARCH NEUROL-CHICAGO, V69, P1493, DOI 10.1001/archneurol.2012.1122; Molko N, 2002, STROKE, V33, P2902, DOI 10.1161/01.STR.0000041681.25514.22; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Nieuwenhuijsen K, 2003, OCCUP ENVIRON MED, V60, P77; NOMURA Y, 1994, AM J NEURORADIOL, V15, P231; Nusbaum AO, 2001, AM J NEURORADIOL, V22, P136; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Rosas HD, 2006, MOVEMENT DISORD, V21, P1317, DOI 10.1002/mds.20979; Salat DH, 2006, STROKE, V37, P1759, DOI 10.1161/01.STR.0000227328.86353.a7; Salat DH, 2012, NEUROIMAGE, V59, P181, DOI 10.1016/j.neuroimage.2011.07.033; Salat DH, 2005, ANN NY ACAD SCI, V1064, P37, DOI 10.1196/annals.1340.009; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang SM, 2006, RADIOLOGY, V239, P831, DOI 10.1148/radiol.2393050573; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027	103	59	59	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG 1	2015	138		8				2278	2292		10.1093/brain/awv139			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CQ4MJ	WOS:000360578700024	26033970	Green Published			2022-02-06	
J	Kerr, ZY; Yeargin, S; McLeod, TCV; Nittoli, VC; Mensch, J; Dodge, T; Hayden, R; Dompier, TP				Kerr, Zachary Y.; Yeargin, Susan; McLeod, Tamara C. Valovich; Nittoli, Vincent C.; Mensch, James; Dodge, Thomas; Hayden, Ross; Dompier, Thomas P.			Comprehensive Coach Education and Practice Contact Restriction Guidelines Result in Lower Injury Rates in Youth American Football	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; pediatrics; prevention	HEAD IMPACT EXPOSURE; PLAYERS; CONCUSSION	Background: Research evaluating the effect of comprehensive coach education and practice contact restriction in youth football injury rates is sparse. In 2012, USA Football released their Heads Up Football coaching education program (HUF), and Pop Warner Football (PW) instituted guidelines to restrict contact during practice. Purpose: To compare injury rates among youth football players aged 5 to 15 years by whether their leagues implemented HUF and/or were PW-affiliated. Study Design: Cohort study; Level of evidence, 2. Methods: Athletic trainers (ATs) evaluated and tracked injuries at each practice and game during the 2014 youth football season. Players were drawn from 10 leagues across 4 states. The non-Heads Up Football (NHUF) group consisted of 704 players (none of whom were PW-affiliated) from 29 teams within 4 leagues. The HUF+PW group consisted of 741 players from 27 teams within 2 leagues. The HUF-only group consisted of 663 players from 44 teams within 4 leagues. Injury rates and injury rate ratios (IRRs) were reported with 95% CIs. Results: A total of 370 injuries were reported during 71,262 athlete-exposures (AEs) (rate, 5.19/1000 AEs). Compared with the NHUF group (7.32/1000 AEs), the practice injury rates were lower for the HUF+PW group (0.97/1000 AEs; IRR, 0.13; 95% CI, 0.08-0.21) and the HUF-only group (2.73/1000 AEs; IRR, 0.37; 95% CI, 0.26-0.53). Compared with the NHUF group (13.42/1000 AEs), the game injury rate was lower for the HUF+PW group (3.42/1000 AEs; IRR, 0.25; 95% CI, 0.15-0.44) but not for the HUF-only group (13.76/1000 AEs; IRR, 1.02; 95% CI, 0.73-1.43). Also, the HUF+PW game injury rate was lower than that of HUF-only (IRR, 0.20; 95% CI, 0.12-0.36). Higher injury rates were typically found in those aged 11 to 15 years compared with those aged 5 to 10 years. However, stronger effects related to HUF implementation and PW affiliation were seen among 11- to 15-year-olds. When restricted to concussions only, the sole difference was found between the practice concussion rates among 11-to 15-yearolds in the HUF+PW (0.14/1000 AEs) and NHUF groups (0.79/1000 AEs) (IRR, 0.18; 95% CI, 0.04-0.85). Conclusion: These findings support comprehensive coach education and practice contact restrictions as effective methods of injury mitigation. Future research should continue evaluating similar programming within other levels of competition and sports.	[Kerr, Zachary Y.; Yeargin, Susan; McLeod, Tamara C. Valovich; Nittoli, Vincent C.; Mensch, James; Dodge, Thomas; Hayden, Ross; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA		Dompier, TP (corresponding author), Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	tdompier@datalyscenter.org	Valovich McLeod, Tamara/AAU-9435-2020; Mensch, James/P-9291-2017	Valovich McLeod, Tamara/0000-0001-9082-8722; Mensch, James/0000-0001-5644-0580; Kerr, Zachary/0000-0003-1423-1259			Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Fainaru S, YOUTH FOOTBALL PARTI; Institute of Medicine, SPORTS REL CONC YOUT; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Moran M., 2015, NEUROL TODAY, V15, P1; Pop Warner Football, RUL CHANG REG PRACT; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; USA Football, HEADS UP FOOTB; USA Football, FOOTB SPONS; Wallerson R, YOUTH PARTICIPATION	17	59	59	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JUL	2015	3	7							2325967115594578	10.1177/2325967115594578			8	Orthopedics; Sport Sciences	Emerging Sources Citation Index (ESCI)	Orthopedics; Sport Sciences	DE1KB	WOS:000370384700006	26674011	Green Published, gold			2022-02-06	
J	Magasi, S; Wong, A; Gray, DB; Hammel, J; Baum, C; Wang, CC; Heinemann, AW				Magasi, Susan; Wong, Alex; Gray, David B.; Hammel, Joy; Baum, Carolyn; Wang, Chia-Chiang; Heinemann, Allen W.			Theoretical Foundations for the Measurement of Environmental Factors and Their Impact on Participation Among People With Disabilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Environment; Patient-centered outcomes; Psychometrics; Rehabilitation; Research; Social participation; Social theory	TRAUMATIC BRAIN-INJURY; SELF-RATED HEALTH; QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; BUILT ENVIRONMENT; MOMENTARY ASSESSMENT; SOCIAL DETERMINANTS; INSIDER PERSPECTIVE; CLINICAL-RESEARCH; COMMUNITY	The ascendance of the World Health Organization's International Classification of Functioning, Disability and Heath (ICF) as the global standard for describing and characterizing aspects of disability has refocused attention on the role that environmental factors (EFs) have on the health and participation of people with disabilities, both as individuals and as a group. There has been a rise in the development of instruments designed to measure EFs alone and in relation to participation. Some instrument developers have used the ICF as a theoretical base for instrument development and to substantiate content validity claims. We contend that this is a misapplication of the ICF. There is a need to step back and reexamine the role that environmental theories can play in developing a conceptually driven approach to measuring the interaction between EFs and participation. For this review, we draw on the fields of social, community, and developmental psychology; disability studies; gerontology; public health; and rehabilitation. We discuss different approaches to the measurement of EFs. We suggest that given the complex nature of EFs and their influence on participation, there is a need for a fresh approach to EF measurement. The thoughtful application of theories and the use of advanced psychometric, measurement, and e-technologies and data visualization methods may enable researchers and clinicians to better quantify, document, and communicate the dynamic interrelationship between EFs and participation and health outcomes for people with disabilities at the individual, group, and population levels. (C) 2015 by the American Congress of Rehabilitation Medicine.	[Magasi, Susan; Hammel, Joy] Univ Illinois, Dept Occupat Therapy, Chicago, IL 60612 USA; [Magasi, Susan; Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Wong, Alex; Gray, David B.; Baum, Carolyn] Washington Univ, Dept Occupat Therapy, St Louis, MO USA; [Gray, David B.; Baum, Carolyn] Washington Univ, Dept Neurol, St Louis, MO USA; [Hammel, Joy] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL USA; [Baum, Carolyn] Univ Illinois, Dept Social Work, Chicago, IL USA; [Wang, Chia-Chiang] SUNY Buffalo, Sch & Educ Psychol, Dept Counseling, Buffalo, NY 14260 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA		Magasi, S (corresponding author), Univ Illinois, Dept Occupat Therapy, 1919 W Taylor St,Rm 327, Chicago, IL 60612 USA.	smagas1@uic.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Wong, Alex/0000-0002-4423-2685	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant [H133B090024]; Craig H. Neilsen Foundation [290474]	Supported in part by The National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant (grant no. H133B090024); and the Craig H. Neilsen Foundation (grant no 290474). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Disability and Rehabilitation Research or the Craig H. Neilsen Foundation.	Adler N, 2010, WOMENS HLTH RES PROG, P11; AERA APA NCME, 1999, STAND ED PSYCH TEST, P10; Alvarelhao J, 2012, J REHABIL MED, V44, P1, DOI 10.2340/16501977-0905; Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Barker R., 1968, ECOLOGICAL PSYCHOL; Botticello AL, 2014, ANN EPIDEMIOL, V24, P545, DOI 10.1016/j.annepidem.2014.05.003; Bricout JC, 2006, SCAND J DISABIL RES, V8, P1, DOI 10.1080/15017410500335229; Bronfenbrenner U, 1992, 6 THEORIES CHILD DEV, P285; Bronfenbrenner U., 2006, HDB CHILD PSYCHOL, P793, DOI DOI 10.1002/9780470147658.CHPSY0114; Bronfenbrenner U., 1999, MEASURING ENV LIFE S, P3, DOI [DOI 10.1037/10317-001, 10.1037/10317-001]; Brownson RC, 2009, AM J PREV MED, V36, pS99, DOI 10.1016/j.amepre.2009.01.005; Cannuscio C, 2003, ANN INTERN MED, V139, P395, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00003; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D, 2012, NEUROLOGY, V78, P1860, DOI 10.1212/WNL.0b013e318258f744; Cerniauskaite M, 2011, DISABIL REHABIL, V33, P281, DOI 10.3109/09638288.2010.529235; Chen YW, 2014, DISABIL HEALTH J, V7, P361, DOI 10.1016/j.dhjo.2014.04.004; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Clarke P, 2009, MATURITAS, V64, P14, DOI 10.1016/j.maturitas.2009.07.011; Clarke P, 2009, SOC SCI MED, V69, P964, DOI 10.1016/j.socscimed.2009.06.041; Clarke PJ, 2011, SOC SCI MED, V72, P1674, DOI 10.1016/j.socscimed.2011.03.025; Csikszentmihalyi M., 2007, EXPERIENCE SAMPLING; Dashner JL, 2012, 2012 AM OCC THER ASS; Dickinson HO, 2010, ARCH PHYS MED REHAB, V91, P1310, DOI 10.1016/j.apmr.2010.03.012; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers Marcel P J M, 2003, J Allied Health, V32, P38; Dijkers MPJM, 2002, SPINAL CORD, V40, P351, DOI 10.1038/sj.sc.3101310; Escorpizo Reuben, 2011, Am J Phys Med Rehabil, V90, pS66, DOI 10.1097/PHM.0b013e318230fbf9; FEINSTEIN AR, 1987, J CHRON DIS, V40, P635, DOI 10.1016/0021-9681(87)90027-0; Feng J, 2010, HEALTH PLACE, V16, P175, DOI 10.1016/j.healthplace.2009.09.008; Fougeyrollas P, 1997, ICIDH ENV FACTORS IN, V9, P32; Garcia SF, 2015, ARCH PHYS MED REHAB, V96, P596, DOI 10.1016/j.apmr.2014.06.019; George LK, 2005, J GERONTOL B-PSYCHOL, V60, P135; Gilbert KL, 2013, J HEALTH PSYCHOL, V18, P1385, DOI 10.1177/1359105311435983; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; GLAAD, 2013, WE AR TV REP 2012 20; Granholm E, 2008, SCHIZOPHRENIA BULL, V34, P507, DOI 10.1093/schbul/sbm113; Gray DB, 2008, DISABIL REHABIL, V30, P434, DOI 10.1080/09638280701625377; Gray JA, 2012, DISABIL HEALTH J, V5, P87, DOI 10.1016/j.dhjo.2011.12.002; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hammel J, 2006, TOP STROKE REHABIL, V13, P43, DOI 10.1310/5X2G-V1Y1-TBK7-Q27E; Hammel J, 2015, ARCH PHYS MED REHAB, V96, P578, DOI 10.1016/j.apmr.2014.12.008; Heinemann AW, 2015, ARCH PHYS MED REHAB, V96, P589, DOI 10.1016/j.apmr.2013.11.024; Heinemann AW, 2013, ARCH PHYS MED REHAB, V94, P2157, DOI 10.1016/j.apmr.2013.05.017; Heller T, 2011, DISABILITY LIFE COUR; Johnston MV, 2009, CHALLENGE EVIDENCE D; Kawachi I, 1999, AM J PUBLIC HEALTH, V89, P1187, DOI 10.2105/AJPH.89.8.1187; Kim D, 2006, J EPIDEMIOL COMMUN H, V60, P116, DOI 10.1136/jech.2005.038281; Lawton MP., 1973, PSYCHOL ADULT DEV AG, P619, DOI [DOI 10.1037/10044-020, 10.1037/10044-020]; Levasseur Melanie, 2007, Can J Occup Ther, V74 Spec No., P233; Lewin K., 1951, FIELD THEORY SOCIAL; Lewin Kurt, 1931, ENV FORCES CHILD BEH; Lounsbury DW, 2009, AM J COMMUN PSYCHOL, V44, P213, DOI 10.1007/s10464-009-9266-4; Magasi S, 2012, QUAL LIFE RES, V21, P739, DOI 10.1007/s11136-011-9990-8; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; NARAYAN D, 2001, CURRENT SOCIOLOGY, V0049; Noreau L, 2010, ARCH PHYS MED REHAB, V91, pS44, DOI 10.1016/j.apmr.2009.10.037; Priestley M, 2001, DISABILITY LIFE COUR; PUTNAM RD, 1995, J DEMOCRACY, V0006; Reed GM, 2005, REHABIL PSYCHOL, V50, P122, DOI 10.1037/0090-5550.50.2.122; Reinhardt JD, 2011, DISABIL REHABIL, V33, P2151, DOI 10.3109/09638288.2011.573053; Reinhardt JD, 2010, TOPICS SPINAL CORD I, V15, P26, DOI DOI 10.1310/SCI1504-26; Rothstein B, 2003, NEW POLIT ECON, V8, P49, DOI 10.1080/1356346032000078723; Rushton G, 2003, ANNU REV PUBL HEALTH, V24, P43, DOI 10.1146/annurev.publhealth.24.012902.140843; Schaie KW., 1989, COURSE LATER LIFE, P15; Schneidert M, 2003, DISABIL REHABIL, V25, P588, DOI 10.1080/0963828031000137090; Schulz A, 2004, HEALTH EDUC BEHAV, V31, P455, DOI 10.1177/1090198104265598; Schwartz LA, 2014, J PEDIATR PSYCHOL, V39, P588, DOI 10.1093/jpepsy/jsu028; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Szreter S, 2004, INT J EPIDEMIOL, V33, P650, DOI 10.1093/ije/dyh013; Tarlov A, 1996, SOCIAL DETERMINANTS, P71; Trull TJ, 2009, PSYCHOL ASSESSMENT, V21, P457, DOI 10.1037/a0017653; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS44, DOI 10.1016/j.apmr.2011.04.024; U.S. Department of Health and Human Services Food and Drug Administration, 2009, FOOD DRUG ADM GUID I; Vygotsky Lev., 1978, MIND SOC DEV HIGHER; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WHO, 2001, IR DDEFICIENCY AN AS, P1; Whyte J, 2008, ARCH PHYS MED REHAB, V89, P203, DOI 10.1016/j.apmr.2007.11.026; Woolcock M, 1998, THEOR SOC, V27, P151, DOI 10.1023/A:1006884930135; Wright BA., 1983, PHYS DISABILITY PSYC	84	59	60	2	52	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					569	577		10.1016/j.apmr.2014.12.002			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100001	25813889				2022-02-06	
J	Zhang, JJ; Cheah, CC				Zhang, Juanjuan; Cheah, Chien Chern			Passivity and Stability of Human-Robot Interaction Control for Upper-Limb Rehabilitation Robots	IEEE TRANSACTIONS ON ROBOTICS			English	Article						Adaptive control; human-robot interaction; rehabilitation robotics	STROKE PATIENTS; THERAPY; EXOSKELETON	Each year, stroke and traumatic brain injury leave millions of survivors with motion control loss, which results in great demand for recovery training. The great labor intensity in traditional human-based therapies has recently boosted the research on rehabilitation robotics. Existing controllers for rehabilitative robotics cannot solve the closed-loop system stability with uncertain nonlinear dynamics and conflicting human-robot interactions. This paper presents a theoretical framework that establishes the passivity of the closed-loop upper-limb rehabilitative robotic systems and allows rigorous stability analysis of human-robot interaction. Position-dependent stiffness and position-dependent desired trajectory are employed to resolve the possible conflicts in motions between patient and robot. The proposed method also realizes the "assist-as-needed" strategy. In addition, it handles human-robot interactions in such a way that correct movements are encouraged and incorrect ones are suppressed to make the training process more effective. While guaranteeing these properties, the proposed controller allows parameter adjustment to provide flexibility for therapists to adjust and fine tune depending on the conditions of the patients and the progress of their recovery. Simulation and experiment results are presented to illustrate the performance of the method.	[Zhang, Juanjuan] Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA; [Zhang, Juanjuan; Cheah, Chien Chern] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore		Zhang, JJ (corresponding author), Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA.	juanjuaz@andrew.cmu.edu; ecccheah@ntu.edu.sg	Cheah, Chien-Chern/A-5024-2011	Cheah, Chien Chern/0000-0003-3728-9277; Zhang, Juanjuan/0000-0002-3833-487X			Aguirre-Ollinger G, 2012, IEEE T NEUR SYS REH, V20, P68, DOI 10.1109/TNSRE.2011.2176960; Arimoto S., 1996, CONTROL THEORY NONLI; Banala SK, 2007, INT C REHAB ROBOT, P401, DOI 10.1109/ICORR.2007.4428456; Cai LL, 2006, J NEUROSCI, V26, P10564, DOI 10.1523/JNEUROSCI.2266-06.2006; Cheah CC, 2003, IEEE T ROBOTIC AUTOM, V19, P692, DOI 10.1109/TRA.2003.814517; Finley MA, 2005, J REHABIL RES DEV, V42, P683, DOI 10.1682/JRRD.2004.12.0153; Freud S., 1895, STANDARD EDITION; Haddadin S, 2010, INT J SOC ROBOT, V2, P235, DOI 10.1007/s12369-010-0053-z; Hallett M, 1999, NEUROSCIENTIST, V5, P324, DOI 10.1177/107385849900500518; Hanneton S, 1997, BIOL CYBERN, V77, P381, DOI 10.1007/s004220050398; HOGAN N, 1985, J DYN SYST-T ASME, V107, P1, DOI 10.1115/1.3140702; Hogan N., 1992, Proceedings. IEEE International Workshop on Robot and Human Communication (Cat. No.92TH0469-7), P161, DOI 10.1109/ROMAN.1992.253895; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Kazerooni H, 2005, IEEE INT CONF ROBOT, P4353; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Marchal-Crespo L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-20; Masiero S, 2011, J REHABIL RES DEV, V48, P355, DOI 10.1682/JRRD.2010.04.0063; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Saglia JA, 2010, IEEE INT CONF ROBOT, P2221, DOI 10.1109/ROBOT.2010.5509883; Sawicki GS, 2009, J EXP BIOL, V212, P21, DOI 10.1242/jeb.017269; SHATZ CJ, 1992, SCI AM, V267, P61, DOI 10.1038/scientificamerican0992-60; Slotine J.-J. E, 1991, APPL NONLINEAR CONTR, V199; SLOTINE JJE, 1987, INT J ROBOT RES, V6, P49, DOI 10.1177/027836498700600303; Stienen AHA, 2010, IEEE T BIO-MED ENG, V57, P728, DOI 10.1109/TBME.2009.2018628; TAKEGAKI M, 1981, J DYN SYST-T ASME, V103, P119, DOI 10.1115/1.3139651; Vitiello N, 2013, IEEE T ROBOT, V29, P220, DOI 10.1109/TRO.2012.2211492; Zhang JJ, 2013, IEEE INT CONF ROBOT, P2201, DOI 10.1109/ICRA.2013.6630873; [No title captured]; [No title captured]	30	59	63	3	100	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1552-3098	1941-0468		IEEE T ROBOT	IEEE Trans. Robot.	APR	2015	31	2					233	245		10.1109/TRO.2015.2392451			13	Robotics	Science Citation Index Expanded (SCI-EXPANDED)	Robotics	CF2EV	WOS:000352361300001					2022-02-06	
J	Delaney, JS; Lamfookon, C; Bloom, GA; Al-Kashmiri, A; Correa, JA				Delaney, J. Scott; Lamfookon, Charles; Bloom, Gordon A.; Al-Kashmiri, Ammar; Correa, Jose A.			Why University Athletes Choose Not to Reveal Their Concussion Symptoms During a Practice or Game	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; symptoms; team sports; university; reasons	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; HEAD-INJURIES; SOCCER PLAYERS; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; CONSENSUS STATEMENT; SPORT HELD; EPIDEMIOLOGY; PREVENTION	Objective: To determine why athletes decide not to seek medical attention during a game or practice when they believe they have suffered a concussion. Design: A retrospective survey. Setting: University Sport Medicine Clinic. Participants: A total of 469 male and female university athletes from several varsity team sports were participated in the study. Main Outcome Measures: Athletes were surveyed about the previous 12 months to identify specific reasons why those athletes who believed they had suffered a concussion during a game or practice decided not to seek attention at that time, how often these reasons occurred, and how important these reasons were in the decision process. Results: Ninety-two of the 469 athletes (19.6%) believed they had suffered a concussion within the previous 12 months while playing their respective sport, and 72 of these 92 athletes (78.3%) did not seek medical attention during the game or practice at least once during that time. Sports in which athletes were more likely to not reveal their concussion symptoms were football and ice hockey. The reason "Did not feel the concussion was serious/severe and felt you could still continue to play with little danger to yourself," was listed most commonly (55/92) as a cause for not seeking medical attention for a presumed concussion. Conclusions: A significant percentage of university athletes who believed they had suffered a concussion chose not to seek medical attention at the time of injury. Improved education of players, parents, and coaches about the dangers of continuing to play with concussion symptoms may help improve reporting.	[Delaney, J. Scott] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. Scott] McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; [Lamfookon, Charles] McGill Univ, Royal Coll Emergency Med, Residency Program, Montreal, PQ, Canada; [Bloom, Gordon A.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Al-Kashmiri, Ammar] Khoula Hosp, Dept Emergency Med, Muscat, Oman; [Correa, Jose A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	j.delaney@staff.mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				[Anonymous], 1999, JAMA, V282, P974; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Rutherford DS, 1999, CLIN J SPORT MED, V9, P209, DOI 10.1097/00042752-199910000-00005; Shapcott EJB, 2007, NEUROREHABILITATION, V22, P161; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1	39	59	59	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2015	25	2					113	125		10.1097/JSM.0000000000000112			13	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	CD3RP	WOS:000350998200007	24949831				2022-02-06	
J	Ni, HB; Jin, W; Zhu, TS; Wang, J; Yuan, BY; Jiang, J; Liang, WB; Ma, ZL				Ni, Hongbin; Jin, Wei; Zhu, Tiansheng; Wang, Jing; Yuan, Baoyu; Jiang, Jian; Liang, Weibang; Ma, Zhengliang			Curcumin modulates TLR4/NF-kappa B inflammatory signaling pathway following traumatic spinal cord injury in rats	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Curcumin; Toll-like receptor 4; Nuclear factor-kappa B; Inflammation; Spinal cord injury	TOLL-LIKE RECEPTORS; KAPPA-B ACTIVATION; BRAIN-INJURY; MICE; NEUROPROTECTION; EXPRESSION; CYTOKINES; PROTECTS	Background: Curcumin, a polyphenolic compound extracted from the plant turmeric, has protective effects on spinal cord injury (SCI) through attenuation of inflammatory response. This study was designed to detect whether curcumin modulates toll-like receptor 4 (TLR4) and the nuclear factor-kappa B (NF-kappa B) inflammatory signaling pathway in the injured rat spinal cord following SCI. Methods: Adult male Sprague-Dawley rats were subjected to laminectomy at T8-T9 and compression with a vascular clip. There were three groups: (a) sham group; (b) SCI group; and (g) SCI + curcumin group. We measured TLR4 gene and protein expression by real-time polymerase chain reaction and western blot analysis; NF-kappa B activity by electrophoretic mobility shift assay, inflammatory cytokines tumor necrosis factor-a, interleukin-1 beta, and interleukin-6 levels by enzyme-linked immunosorbent assay, hindlimb locomotion function by Basso, Beattie, and Bresnahan rating, spinal cord edema by wet/dry weight method, and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) analysis. Results: The results showed that SCI induced the up-regulation of TLR4, NF-kappa B, and inflammatory cytokines in the injured rat spinal cord. Treatment with curcumin following SCI markedly down-regulated the levels of these agents related to the TLR4/NF-kappa B inflammatory signaling pathway. Administration of curcumin also significantly ameliorated SCI induced hind limb locomotion deficits, spinal cord edema, and apoptosis. Conclusions: Post-SCI curcumin administration attenuates the TLR4/NF-kappa B inflammatory signaling pathway in the injured spinal cord, and this may be a mechanism whereby curcumin improves the outcome following SCI.	[Ni, Hongbin; Ma, Zhengliang] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Dept Anesthesiol, Nanjing 210008, Jiangsu, Peoples R China; [Jin, Wei; Zhu, Tiansheng; Wang, Jing; Yuan, Baoyu; Jiang, Jian; Liang, Weibang] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China		Ma, ZL (corresponding author), Drum Tower Hosp, Dept Anesthesiol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	njglyy110@163.com		yuan, baoyu/0000-0002-2498-7829	Drum Tower Hospital of China	This work was supported by grants from Drum Tower Hospital of China. We thank Dr Lizhi Xu and Dr Gengbao Feng for technical assistance.	ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Arslan F, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704202; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Casula M, 2011, NEUROSCIENCE, V179, P233, DOI 10.1016/j.neuroscience.2011.02.001; Cemil B, 2010, ACTA NEUROCHIR, V152, P1583, DOI 10.1007/s00701-010-0702-x; Chen F, 1999, CLIN CHEM, V45, P7; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Jeong CW, 2012, J CARDIOVASC PHARM T, V17, P387, DOI 10.1177/1074248412438102; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2011, ANN CLIN LAB SCI, V41, P25; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jobin C, 1999, J IMMUNOL, V163, P3474; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Liang WB, 2010, BIOMATERIALS, V31, P8634, DOI 10.1016/j.biomaterials.2010.07.084; Lin MS, 2011, J SURG RES, V166, P280, DOI 10.1016/j.jss.2009.07.001; Loannou S, 2010, MEDIAT INFLAMM, V2010; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Ormond DR, 2012, J NEUROSURG-SPINE, V16, P497, DOI 10.3171/2012.1.SPINE11769; Shukla PK, 2008, NEUROCHEM RES, V33, P1036, DOI 10.1007/s11064-007-9547-y; Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35; Strimpakos AS, 2008, ANTIOXID REDOX SIGN, V10, P511, DOI 10.1089/ars.2007.1769; Sun YH, 2011, J NEUROTRAUM, V28, P2513, DOI 10.1089/neu.2011.1958; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Xiao XF, 2012, J SURG RES, V176, pE31, DOI 10.1016/j.jss.2011.11.1032; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Yu Wen-Guang, 2011, Indian J Med Res, V134, P717, DOI 10.4103/0971-5916.91009	36	59	70	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	MAR	2015	38	2					199	206		10.1179/2045772313Y.0000000179			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CD4RX	WOS:000351072300011	24621048	Green Published			2022-02-06	
J	Doshi, H; Wiseman, N; Liu, J; Wang, WT; Welch, RD; O'Neil, BJ; Zuk, C; Wang, X; Mika, V; Szaflarski, JP; Haacke, EM; Kou, ZF				Doshi, Hardik; Wiseman, Natalie; Liu, Jun; Wang, Wentao; Welch, Robert D.; O'Neil, Brian J.; Zuk, Conor; Wang, Xiao; Mika, Valerie; Szaflarski, Jerzy P.; Haacke, E. Mark; Kou, Zhifeng			Cerebral Hemodynamic Changes of Mild Traumatic Brain Injury at the Acute Stage	PLOS ONE			English	Article							OXYGEN EXTRACTION FRACTION; DEOXYGENATED BLOOD-VOLUME; IN-VIVO MEASUREMENT; HEAD-INJURY; AXONAL INJURY; INTRACRANIAL HYPERTENSION; QUANTITATIVE MEASUREMENTS; GLUCOSE-METABOLISM; ENERGY-METABOLISM; MR SUSCEPTOMETRY	Mild traumatic brain injury (mTBI) is a significant public health care burden in the United States. However, we lack a detailed understanding of the pathophysiology following mTBI and its relation to symptoms and recovery. With advanced magnetic resonance imaging (MRI), we can investigate brain perfusion and oxygenation in regions known to be implicated in symptoms, including cortical gray matter and subcortical structures. In this study, we assessed 14 mTBI patients and 18 controls with susceptibility weighted imaging and mapping (SWIM) for blood oxygenation quantification. In addition to SWIM, 7 patients and 12 controls had cerebral perfusion measured with arterial spin labeling (ASL). We found increases in regional cerebral blood flow (CBF) in the left striatum, and in frontal and occipital lobes in patients as compared to controls (p = 0.01, 0.03, 0.03 respectively). We also found decreases in venous susceptibility, indicating increases in venous oxygenation, in the left thalamostriate vein and right basal vein of Rosenthal (p = 0.04 in both). mTBI patients had significantly lower delayed recall scores on the standardized assessment of concussion, but neither susceptibility nor CBF measures were found to correlate with symptoms as assessed by neuropsychological testing. The increased CBF combined with increased venous oxygenation suggests an increase in cerebral blood flow that exceeds the oxygen demand of the tissue, in contrast to the regional hypoxia seen in more severe TBI. This may represent a neuroprotective response following mTBI, which warrants further investigation.	[Doshi, Hardik; Liu, Jun; Wang, Xiao; Mika, Valerie; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA; [Wiseman, Natalie; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Translat Neurosci Program, Detroit, MI USA; [Liu, Jun] Cent S Univ, Sch Publ Hlth, Xiangya Hosp 2, Dept Radiol, Changsha, Hunan, Peoples R China; [Wang, Wentao] South Cent Univ Nationalities, Coll Comp Sci, Wuhan, Peoples R China; [Welch, Robert D.; O'Neil, Brian J.; Mika, Valerie] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Zuk, Conor; Wang, Xiao; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA; [Wang, Xiao] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan Province, Peoples R China; [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA		Kou, ZF (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA.	zhifeng_kou@wayne.edu	Mika, Valerie H./AAO-2816-2020	Wiseman, Natalie/0000-0003-0884-6425	International Society for Magnetic Resonance in Medicine; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]	Supported by a Seed Grant from the International Society for Magnetic Resonance in Medicine (PI: ZFK) and a research grant from the Department of Defense (award number W81XWH-11-1-0493; PI: EMH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate MG, 2008, NEUROCRIT CARE, V9, P319, DOI 10.1007/s12028-008-9119-2; Abdul-Khaliq H, 2000, BIOMED TECH, V45, P328, DOI 10.1515/bmte.2000.45.11.328; An HY, 2001, NMR BIOMED, V14, P441, DOI 10.1002/nbm.717; An HY, 2002, MAGNET RESON MED, V47, P958, DOI 10.1002/mrm.10148; An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008; Ashburner J., 1997, HUM BRAIN FUNCT, P1; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bouma G J, 1995, New Horiz, V3, P384; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; BRANDT RB, 1984, P SOC EXP BIOL MED, V175, P328; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; CHIEN D, 1994, MAGNET RESON MED, V32, P540, DOI 10.1002/mrm.1910320419; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Faul M, 2010, TRAUMATIC BRAIN INJU; Fernandez-Seara MA, 2006, MAGN RESON MED, V55, P967, DOI 10.1002/mrm.20892; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Golay X, 2001, MAGN RESON MED, V46, P282, DOI 10.1002/mrm.1189; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; He X, 2008, MAGN RESON MED, V60, P882, DOI 10.1002/mrm.21719; He X, 2007, MAGN RESON MED, V57, P115, DOI 10.1002/mrm.21108; Holmes AP, 1997, HUMAN BRAIN FUNCTION, P59; HOPPEL BE, 1993, MAGN RESON MED, V30, P715, DOI 10.1002/mrm.1910300609; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Krep H, 2004, RESUSCITATION, V63, P73, DOI 10.1016/j.resuscitation.2004.03.023; Langham MC, 2010, J AM COLL CARDIOL, V55, P598, DOI 10.1016/j.jacc.2009.08.068; Langham MC, 2009, MAGN RESON MED, V62, P333, DOI 10.1002/mrm.21981; Langham MC, 2009, MAGN RESON MED, V61, P626, DOI 10.1002/mrm.21499; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li DB, 1998, MAGNET RESON MED, V39, P685, DOI 10.1002/mrm.1910390503; Li DB, 1998, JMRI-J MAGN RESON IM, V8, P1236, DOI 10.1002/jmri.1880080609; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Liu YJ, 1999, MAGNET RESON MED, V41, P407, DOI 10.1002/(SICI)1522-2594(199902)41:2<407::AID-MRM27>3.3.CO;2-W; Lu HZ, 2008, MAGN RESON MED, V60, P357, DOI 10.1002/mrm.21627; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Nonaka H, 2003, NEUROPATHOLOGY, V23, P111, DOI 10.1046/j.1440-1789.2003.00486.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oja JME, 1999, J CEREBR BLOOD F MET, V19, P1289, DOI 10.1097/00004647-199912000-00001; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Pandian DSJ, 2008, J MAGN RESON IMAGING, V28, P727, DOI 10.1002/jmri.21487; Pomschar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055447; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qin Q, 2011, MAGN RESON MED, V65, P471, DOI 10.1002/mrm.22556; Sedlacik J, 2010, MAGN RESON MED, V63, P910, DOI 10.1002/mrm.22274; Sedlacilk J, 2009, Z MED PHYS, V19, P48, DOI 10.1016/j.zemedi.2008.07.005; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Tang J, 2012, MAGN RESON MED; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Weiskoff R, 1991, QUANTITATIVE VIVO BL, P307; WRIGHT GA, 1991, JMRI-J MAGN RESON IM, V1, P275, DOI 10.1002/jmri.1880010303; Xu F, 2009, MAGN RESON MED, V62, P141, DOI 10.1002/mrm.21994; Yablonskiy DA, 1997, MAGN RESON MED, V37, P214, DOI 10.1002/mrm.1910370213; Yablonskiy DA, 1997, MAGNET RESON MED, V37, P872, DOI 10.1002/mrm.1910370611; YABLONSKIY DA, 1994, MAGNET RESON MED, V32, P749, DOI 10.1002/mrm.1910320610; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505; [No title captured]	86	59	60	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0118061	10.1371/journal.pone.0118061			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	WOS:000349444900257	25659079	Green Published, gold, Green Submitted			2022-02-06	
J	Scholten, AC; Haagsma, JA; Panneman, MJM; van Beeck, EF; Polinder, S				Scholten, Annemieke C.; Haagsma, Juanita A.; Panneman, Martien J. M.; van Beeck, Ed F.; Polinder, Suzanne			Traumatic Brain Injury in the Netherlands: Incidence, Costs and Disability-Adjusted Life Years	PLOS ONE			English	Article							QUALITY-OF-LIFE; HEAD-INJURIES; ECONOMIC BURDEN; HEALTH; WORK; PREVENTION; DISORDERS; MORTALITY; DISEASES; OUTCOMES	Objective: Traumatic brain injury (TBI) is a major cause of death and disability, leading to great personal suffering and huge costs to society. Integrated knowledge on epidemiology, economic consequences and disease burden of TBI is scarce but essential for optimizing healthcare policy and preventing TBI. This study aimed to estimate incidence, cost-of-illness and disability-adjusted life years (DALYs) of TBI in the Netherlands. Methods: This study included data on all TBI patients who were treated at an Emergency Department (ED - National Injury Surveillance System), hospitalized (National Medical Registration), or died due to their injuries in the Netherlands between 2010-2012. Direct healthcare costs and indirect costs were determined using the incidence-based Dutch Burden of Injury Model. Disease burden was assessed by calculating years of life lost (YLL) owing to premature death, years lived with disability (YLD) and DALYs. Incidence, costs and disease burden were stratified by age and gender. Results: TBI incidence was 213.6 per 100,000 person years. Total costs were (sic)314.6 (USD $433.8) million per year and disease burden resulted in 171,200 DALYs (on average 7.1 DALYs per case). Men had highest mean costs per case ((sic)19,540 versus (sic)14,940), driven by indirect costs. 0-24-year-olds had high incidence and disease burden but low economic costs, whereas 25-64-year-olds had relatively low incidence but high economic costs. Patients aged 65+ had highest incidence, leading to considerable direct healthcare costs. 0-24-year-olds, men aged 25-64 years, traffic injury victims (especially bicyclists) and home and leisure injury victims (especially 0-5-year-old and elderly fallers) are identified as risk groups in TBI. Conclusions: The economic and health consequences of TBI are substantial. The integrated approach of assessing incidence, costs and disease burden enables detection of important risk groups in TBI, development of prevention programs that target these risk groups and assessment of the benefits of these programs.	[Scholten, Annemieke C.; Haagsma, Juanita A.; van Beeck, Ed F.; Polinder, Suzanne] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Panneman, Martien J. M.] Consumer & Safety Inst, Res Dept, Amsterdam, Netherlands		Scholten, AC (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.	a.scholten@erasmusmc.nl					Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; [Anonymous], 2014, US INFLATION CALCULA; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Consumer and Safety Institute, 2011, FACT SHEET SPORTS IN; Consumer and Safety Institute, 2011, FACT SHEET BIC ACC; Consumer and Safety Institute, 2013, FACT SHEET TRAUM BRA; Consumer and Safety Institute, 2012, FACT SHEET SPORTS IN; Consumer Safety Institute, 2005, DUTCH BURD INJ MOD; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Eurostat, 2014, HICP INFL RAT; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gommer A, 2010, YEARS LIFE LOST MORB; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Haagsma JA, 2012, B WORLD HEALTH ORGAN, V90, P513, DOI 10.2471/BLT.11.095109; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Hoang Hanh T M, 2008, Cost Eff Resour Alloc, V6, P17, DOI 10.1186/1478-7547-6-17; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Meerding WJ, 2006, EUR J PUBLIC HEALTH, V16, P271, DOI 10.1093/eurpub/ckl006; Meerding WJ, 2010, INT J INJ CONTROL SA, V17, P13, DOI 10.1080/17457300903523237; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mulder S, 2002, INJURY PREV, V8, P74, DOI 10.1136/ip.8.1.74; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL., 1996, GLOBAL BURDEN DIS CO; Nielen M, 2014, INCIDENCE PREVALENCE; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2004, SURVEILLANCE BASED A; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; Statistics Netherlands (CBS), 2014, POP DAT; Statistics Netherlands (CBS), 2014, MOB NETH; Statistics Netherlands (CBS), 2014, CONS PRIC INFL 1963; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman DJ., 1995, GUIDELINES SURVEILLA; Van der Stegen R, 2009, DISCRIPTION METHODS; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; WHO, 2004, WORLD REPORT ROAD TR	63	59	59	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e110905	10.1371/journal.pone.0110905			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS0BL	WOS:000343943500064	25343447	Green Published, gold			2022-02-06	
J	Weil, ZM; Gaier, KR; Karelina, K				Weil, Zachary M.; Gaier, Kristopher R.; Karelina, Kate			Injury timing alters metabolic, inflammatory and functional outcomes following repeated mild traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Glucose metabolism; Repeated injury; Learning and memory; Functional outcomes; Inflammation	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; TEMPORAL WINDOW; COGNITIVE DEFICITS; DYNAMIC CHANGES; IMPACT; VULNERABILITY; CONCUSSION; MICE	Repeated head injuries are a major public health concern both for athletes, and members of the police and armed forces. There is ample experimental and clinical evidence that there is a period of enhanced vulnerability to subsequent injury following head trauma. Injuries that occur close together in time produce greater cognitive, histological, and behavioral impairments than do injuries separated by a longer period. Traumatic brain injuries alter cerebral glucose metabolism and the resolution of altered glucose metabolism may signal the end of the period of greater vulnerability. Here, we injured mice either once or twice separated by three or 20 days. Repeated injuries that were separated by three days were associated with greater axonal degeneration, enhanced inflammatory responses, and poorer performance in a spatial learning and memory task. A single injury induced a transient but marked increase in local cerebral glucose utilization in the injured hippocampus and sensorimotor cortex, whereas a second injury, three days after the first, failed to induce an increase in glucose utilization at the same time point. In contrast when the second injury occurred substantially later (20 days after the first injury), an increase in glucose utilization occurred that paralleled the increase observed following a single injury. The increased glucose utilization observed after a single injury appears to be an adaptive component of recovery, while mice with 2 injuries separated by three days were not able to mount this response, thus this second injury may have produced a significant energetic crisis such that energetic demands outstripped the ability of the damaged cells to utilize energy. These data strongly reinforce the idea that too rapid return to activity after a traumatic brain injury can induce permanent damage and disability, and that monitoring cerebral energy utilization may be a tool to determine when it is safe to return to the activity that caused the initial injury. (C) 2014 Elsevier Inc. All rights reserved.	[Weil, Zachary M.; Gaier, Kristopher R.; Karelina, Kate] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA		Weil, ZM (corresponding author), Biomed Res Tower 618,460 W 12th Ave, Columbus, OH USA.	Zachary.weil@osumc.edu	Weil, Zachary M/B-5003-2008; Weil, Zachary M/A-2439-2008	Weil, Zachary M/0000-0003-3758-1809; Weil, Zachary M/0000-0003-3758-1809; Karelina Weil, Kate/0000-0002-6628-0768			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Demeurisse G, 2000, ACTA NEUROL BELG, V100, P77; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Fogal B, 2005, J NEUROIMMUNOL, V161, P93, DOI 10.1016/j.jneuroim.2004.12.007; Fogal B, 2008, J NEUROCHEM, V106, P1, DOI 10.1111/j.1471-4159.2008.05315.x; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1990, ACT NEUR S, V51, P331; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Neigh GN, 2009, STROKE, V40, P3601, DOI 10.1161/STROKEAHA.109.564146; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Robertson CS, 2011, J NEUROTRAUM, V28, P727, DOI 10.1089/neu.2010.1476; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	62	59	59	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2014	70						108	116		10.1016/j.nbd.2014.06.016			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN6FW	WOS:000340691400011	24983210				2022-02-06	
J	Bedard, M; Felteau, M; Marshall, S; Cullen, N; Gibbons, C; Dubois, S; Maxwell, H; Mazmanian, D; Weaver, B; Rees, L; Gainer, R; Klein, R; Moustgaard, A				Bedard, Michel; Felteau, Melissa; Marshall, Shawn; Cullen, Nora; Gibbons, Carrie; Dubois, Sacha; Maxwell, Hillary; Mazmanian, Dwight; Weaver, Bruce; Rees, Laura; Gainer, Rolf; Klein, Rupert; Moustgaard, Amy			Mindfulness-Based Cognitive Therapy Reduces Symptoms of Depression in People With a Traumatic Brain Injury: Results From a Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; mindfulness; randomized controlled trial; traumatic brain injury	INDIVIDUALS; PREVENTION; GUIDELINES; AWARENESS; SCALE; PHQ-9	Objective: We sought to determine if we could reduce symptoms of depression in individuals with a traumatic brain injury using mindfulness-based cognitive therapy. Setting: The study was conducted in a community setting. Participants: We enrolled adults with symptoms of depression after a traumatic brain injury. Design: We conducted a randomized controlled trial; participants were randomized to the 10-week mindfulness-based cognitive therapy intervention arm or to the wait-list control arm. Main Measures: The primary outcome measure was symptoms of depression using the Beck Depression Inventory-II. Results: The parallel group analysis revealed a greater reduction in Beck Depression Inventory-II scores for the intervention group (6.63, n = 38,) than the control group (2.13, n = 38, P =.029). A medium effect size was observed (Cohen d = 0.56). The improvement in Beck Depression Inventory-II scores was maintained at the 3-month follow-up. Conclusion: These results are consistent with those of other researchers that use mindfulness-based cognitive therapy to reduce symptoms of depression and suggest that further work to replicate these findings and improve upon the efficacy of the intervention is warranted.	[Bedard, Michel; Dubois, Sacha] Lakehead Univ, Dept Hlth Sci, Thunder Bay, ON P7B 5E1, Canada; [Bedard, Michel; Dubois, Sacha; Weaver, Bruce] Northern Ontario Sch Med, Thunder Bay, ON, Canada; [Bedard, Michel; Gibbons, Carrie; Dubois, Sacha; Maxwell, Hillary] St Josephs Care Grp, Res Dept, Thunder Bay, ON, Canada; [Felteau, Melissa] St Francis Xavier Univ, Antigonish, NS B2G 1C0, Canada; [Marshall, Shawn] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Inst Rehabil Res & Dev, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Hosp Rehabil Ctr, Electromyog Lab, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Hosp Rehabil Ctr, Acquired Brain Injury Rehabil Program, Ottawa, ON, Canada; [Cullen, Nora] West Pk Healthcare Ctr, Toronto, ON, Canada; [Cullen, Nora] Toronto Rehab, NeuroRehabil, Toronto, ON, Canada; [Cullen, Nora] Univ Toronto, Div Physiatry, Toronto, ON, Canada; [Mazmanian, Dwight; Klein, Rupert] Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada; [Rees, Laura] Ottawa Hosp, Dept Psychol, Ottawa, ON, Canada; [Gainer, Rolf] Brookhaven Hosp, Tulsa, OK USA; [Gainer, Rolf] Neurol Rehabil Inst Ontario, Etobicoke, ON, Canada; [Moustgaard, Amy] Royal Ottawa Mental Hlth Ctr, Ottawa, ON, Canada		Bedard, M (corresponding author), Lakehead Univ, Dept Hlth Sci, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	mbedard@lakeheadu.ca		Cullen, Nora/0000-0001-6359-9418; Dubois, Sacha/0000-0003-3579-6072	Ontario Neurotrauma Foundation [ABI-MIND2-476]; Canada Research Chair ProgramCanada Research Chairs	This study was funded by the Ontario Neurotrauma Foundation (grant ABI-MIND2-476). Michel Bedard was a Canada Research Chair in Aging and Health at the time this study was conducted (www.chairs.gc.ca); he acknowledges the support of the Canada Research Chair Program.	Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bedard M, 2005, J COGNITIVE REHABILI, P2, DOI DOI 10.1080/0963828031000090489; Bedard Michel, 2012, Adv Mind Body Med, V26, P14; Cardaciotto L, 2008, ASSESSMENT, V15, P204, DOI 10.1177/1073191107311467; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; D'Amico EJ, 2001, BEHAV RES METH INS C, V33, P479, DOI 10.3758/BF03195405; Derogatis L. R., 1994, SCL 90 R ADM SCORING, VThird; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Foley E, 2010, J CONSULT CLIN PSYCH, V78, P72, DOI 10.1037/a0017566; Gibbons C, 2014, MINDFULNESS, V5, P232, DOI 10.1007/s12671-012-0170-x; Gracey F., 2002, ADV CLIN NEUROSCI RE, V2, P18; Grossman P, 2011, CONTEMP BUDDHISM, V12, P219, DOI 10.1080/14639947.2011.564841; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kabat-Zinn J., 2009, FULL CATASTROPHE LIV; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lau MA, 2006, J CLIN PSYCHOL, V62, P1445, DOI 10.1002/jclp.20326; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Ma SH, 2004, J CONSULT CLIN PSYCH, V72, P31, DOI 10.1037/0022-006X.72.1.31; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; National Collaborating Centre for Mental Health, 2009, NICE CLIN GUID 90 DE, V23; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Segal Z. V., 2002, MINDFULNESS BASED CO; Segal ZV, 2010, ARCH GEN PSYCHIAT, V67, P1256, DOI 10.1001/archgenpsychiatry.2010.168; Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037/0022-006X.68.4.615; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Williams M, 2007, MINDFULWAY DEPRESSIO	38	59	59	0	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					E13	E22		10.1097/HTR.0b013e3182a615a0			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300002	24052092				2022-02-06	
J	Taylor, SE; Morganti-Kossmann, C; Lifshitz, J; Ziebell, JM				Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.			Rod Microglia: A Morphological Definition	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CELL-DEATH; RAT; ACTIVATION; MOUSE; PHYSIOLOGY; RESPONSES; SENSOR; MICE; CNS	Brain microglial morphology relates to function, with ramified microglia surveying the micro-environment and amoeboid microglia engulfing debris. One subgroup of microglia, rod microglia, have been observed in a number of pathological conditions, however neither a function nor specific morphology has been defined. Historically, rod microglia have been described intermittently as cells with a sausage-shaped soma and long, thin processes, which align adjacent to neurons. More recently, our group has described rod microglia aligning end-to-end with one another to form trains adjacent to neuronal processes. Confusion in the literature regarding rod microglia arises from some reports referring to the sausage-shaped cell body, while ignoring the spatial distribution of processes. Here, we systematically define the morphological characteristics of rod microglia that form after diffuse brain injury in the rat, which differ morphologically from the spurious rod microglia found in uninjured sham. Rod microglia in the diffuse-injured rat brain show a ratio of 1.79 +/- 0.03 cell length: cell width at day 1 post-injury, which increases to 3.35 +/- 0.05 at day 7, compared to sham (1.17 +/- 0.02). The soma length: width differs only at day 7 post-injury (2.92 +/- 0.07 length: width), compared to sham (2.49 +/- 0.05). Further analysis indicated that rod microglia may not elongate in cell length but rather narrow in cell width, and retract planar (side) processes. These morphological characteristics serve as a tool for distinguishing rod microglia from other morphologies. The function of rod microglia remains enigmatic; based on morphology we propose origins and functions for rod microglia after acute neurological insult, which may provide biomarkers or therapeutic targets.	[Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85006 USA; [Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Taylor, Samuel E.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA; [Lifshitz, Jonathan] Arizona State Univ, Dept Psychol, Neurosci Program, Tempe, AZ 85287 USA		Ziebell, JM (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85006 USA.	jmziebell@email.arizona.edu	Ziebell, Jenna/Y-4496-2019	Ziebell, Jenna/0000-0003-2497-4347; Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052]; Mission Support Fund at Phoenix Children's Hospital; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER	Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052 and the Mission Support Fund at Phoenix Children's Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; GRAEBER MB, 1994, NEUROPATH APPL NEURO, V20, P178; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2011, J NEUROPATH EXP NEUR, V70, P481, DOI 10.1097/NEN.0b013e31821db3aa; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Spielmeyer W, 1922, HISTOPATHOLOGIE NERV; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Taylor SE, 2013, CURRENT PROTOCOLS ES; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tremblay ME, 2011, NEURON GLIA BIOL, V7, P67, DOI 10.1017/S1740925X12000038; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wierzba-Bobrowicz T, 2002, FOLIA NEUROPATHOL, V40, P125; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	39	59	62	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e97096	10.1371/journal.pone.0097096			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI3UI	WOS:000336789500034	24830807	gold, Green Published, Green Submitted			2022-02-06	
J	Yan, EB; Satgunaseelan, L; Paul, E; Bye, N; Nguyen, P; Agyapomaa, D; Kossmann, T; Rosenfeld, JV; Morganti-Kossmann, MC				Yan, Edwin B.; Satgunaseelan, Laveniya; Paul, Eldho; Bye, Nicole; Phuong Nguyen; Agyapomaa, Doreen; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, Maria Cristina			Post-Traumatic Hypoxia Is Associated with Prolonged Cerebral Cytokine Production, Higher Serum Biomarker Levels, and Poor Outcome in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						TBI; CSF/serum-albumin quotient; inflammation; biomarker; hypoxia	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; BARRIER FUNCTION; CELL-DEATH; TNF-ALPHA; PROTEIN; CHILDREN; S100B; NEUROINFLAMMATION; MARKERS	Secondary hypoxia is a known contributor to adverse outcomes in patients with traumatic brain injury (TBI). Based on the evidence that hypoxia and TBI in isolation induce neuroinflammation, we investigated whether TBI combined with hypoxia enhances cerebral cytokine production. We also explored whether increased concentrations of injury biomarkers discriminate between hypoxic (Hx) and normoxic (Nx) patients, correlate to worse outcome, and depend on blood-brain barrier (BBB) dysfunction. Forty-two TBI patients with Glasgow Coma Scale <= 8 were recruited. Cerebrospinal fluid (CSF) and serum were collected over 6 days. Patients were divided into Hx (n=22) and Nx (n=20) groups. Eight cytokines were measured in the CSF; albumin, S100, myelin basic protein (MBP) and neuronal specific enolase (NSE) were quantified in serum. CSF/serum albumin quotient was calculated for BBB function. Glasgow Outcome Scale Extended (GOSE) was assessed at 6 months post-TBI. Production of granulocye macrophage-colony stimulating factor (GM-CSF) was higher, and profiles of GM-CSF, interferon (IFN)-gamma and, to a lesser extent, tumor necrosis factor (TNF), were prolonged in the CSF of Hx but not Nx patients at 4-5 days post-TBI. Interleukin (IL)-2, IL-4, IL-6, and IL-10 increased similarly in both Hx and Nx groups. S100, MBP, and NSE were significantly higher in Hx patients with unfavorable outcome. Among these three biomarkers, S100 showed the strongest correlations to GOSE after TBI-Hx. Elevated CSF/serum albumin quotients lasted for 5 days post-TBI and displayed similar profiles in Hx and Nx patients. We demonstrate for the first time that post-TBI hypoxia is associated with prolonged neuroinflammation, amplified extravasation of biomarkers, and poor outcome. S100 and MBP could be implemented to track the occurrence of post-TBI hypoxia, and prompt adequate treatment.	[Yan, Edwin B.; Satgunaseelan, Laveniya; Bye, Nicole; Phuong Nguyen; Morganti-Kossmann, Maria Cristina] Monash Univ, Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Satgunaseelan, Laveniya; Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3181, Australia; [Yan, Edwin B.; Bye, Nicole; Rosenfeld, Jeffrey V.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Paul, Eldho; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Paul, Eldho; Morganti-Kossmann, Maria Cristina] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Kossmann, Thomas] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA		Morganti-Kossmann, MC (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Rosenfeld, Jeffrey V/B-7249-2011	Paul, Eldho/0000-0003-1263-7255; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Satgunaseelan, Laveniya/0000-0002-7435-0834	Victorian Neurotrauma Initiative/Traffic Accident Commission [D009]; National Health Medical Research CouncilNational Health and Medical Research Council of Australia [436815]; Henry O'Hara Surgical Research Trust; L.E.W. Carty Charitable Fund.	We thank Ann Sutherland from Victorian State Trauma Outcomes Registry and Department of Epidemiology, Monash University, and Shirley Vallance and Lynne Murray from the Intensive Care Unit, Alfred Health, for providing the GOSE scores, and David O'Reilly for partial albumin measurements. We thank Sarah Hellewell for her intellectual input on this project, and for manuscript preparation. This study was funded by Victorian Neurotrauma Initiative/Traffic Accident Commission project grant D009 and Research Fellowships to Drs. Morganti-Kossmann, Yan, and Bye; the National Health Medical Research Council Project Grant #436815; The Henry O'Hara Surgical Research Trust to Dr. Satgunaseelan, and the L.E.W. Carty Charitable Fund.	Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2011, PM&R, V3, pS31, DOI 10.1016/j.pmrj.2011.03.016; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Deng Yi Yu, 2011, Front Biosci (Schol Ed), V3, P884; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jellema RK, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-13; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kong T, 2009, J NEUROSURG, V111, P155, DOI 10.3171/2008.12.JNS08172; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marshall LF, 1991, J NEUROSURG S, V75, P14; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann C. M., 1997, MOL PSYCHIATR, V2, P133; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Roman J, 2010, AM J RESP CELL MOL, V42, P123, DOI 10.1165/rcmb.2008-0139OC; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Sugiyama Y, 2011, STROKE, V42, P770, DOI 10.1161/STROKEAHA.110.597799; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	60	59	60	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					618	629		10.1089/neu.2013.3087			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000003	24279428	Green Published			2022-02-06	
J	Fischer, BL; Parsons, M; Durgerian, S; Reece, C; Mourany, L; Lowe, MJ; Beall, EB; Koenig, KA; Jones, SE; Newsome, MR; Scheibel, RS; Wilde, EA; Troyanskaya, M; Merkley, TL; Walker, M; Levin, HS; Rao, SM				Fischer, Barbara L.; Parsons, Michael; Durgerian, Sally; Reece, Christine; Mourany, Lyla; Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Jones, Stephen E.; Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Walker, Mark; Levin, Harvey S.; Rao, Stephen M.			Neural Activation during Response Inhibition Differentiates Blast from Mechanical Causes of Mild to Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast-related TBI; brain activation; fMRI; inhibitory control; mechanical TBI; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; DEFAULT MODE; NEUROPSYCHOLOGICAL OUTCOMES; NETWORK; IRAQ; AFGHANISTAN; COMPLAINTS; PRESSURE; VETERANS; EXPOSURE	Military personnel involved in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) commonly experience blast-induced mild to moderate traumatic brain injury (TBI). In this study, we used task-activated functional MRI (fMRI) to determine if blast-related TBI has a differential impact on brain activation in comparison with TBI caused primarily by mechanical forces in civilian settings. Four groups participated: (1) blast-related military TBI (milTBI; n=21); (2) military controls (milCON; n=22); (3) non-blast civilian TBI (civTBI; n=21); and (4) civilian controls (civCON; n=23) with orthopedic injuries. Mild to moderate TBI (MTBI) occurred 1 to 6 years before enrollment. Participants completed the Stop Signal Task (SST), a measure of inhibitory control, while undergoing fMRI. Brain activation was evaluated with 2 (mil, civ)x2 (TBI, CON) analyses of variance, corrected for multiple comparisons. During correct inhibitions, fMRI activation was lower in the TBI than CON subjects in regions commonly associated with inhibitory control and the default mode network. In contrast, inhibitory failures showed significant interaction effects in the bilateral inferior temporal, left superior temporal, caudate, and cerebellar regions. Specifically, the milTBI group demonstrated more activation than the milCON group when failing to inhibit; in contrast, the civTBI group exhibited less activation than the civCON group. Covariance analyses controlling for the effects of education and self-reported psychological symptoms did not alter the brain activation findings. These results indicate that the chronic effects of TBI are associated with abnormal brain activation during successful response inhibition. During failed inhibition, the pattern of activation distinguished military from civilian TBI, suggesting that blast-related TBI has a unique effect on brain function that can be distinguished from TBI resulting from mechanical forces associated with sports or motor vehicle accidents. The implications of these findings for diagnosis and treatment of TBI are discussed.	[Fischer, Barbara L.] Wm S Middleton Mem Vet Affairs Hosp, GRECC, Madison, WI USA; [Parsons, Michael; Reece, Christine; Mourany, Lyla; Rao, Stephen M.] Cleveland Clin, Neurol Inst, Cleveland, OH 44195 USA; [Durgerian, Sally] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Jones, Stephen E.] Cleveland Clin, Imaging Inst, Cleveland, OH 44195 USA; [Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Levin, Harvey S.] Vet Affairs Med Ctr, Houston, TX 77030 USA; [Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Walker, Mark] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA; [Walker, Mark] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA		Rao, SM (corresponding author), Cleveland Clin, Schey Ctr Cognit Neuroimaging, Neurol Inst, 9500 Euclid Ave U10, Cleveland, OH 44195 USA.	raos2@ccf.org	Koenig, Katherine/K-1564-2019; Merkley, Tricia L./AAN-2989-2020; Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460; Merkley, Tricia/0000-0002-0897-8391; Durgerian, Sally/0000-0003-3931-9679; Koenig, Katherine/0000-0002-1504-7130	U.S. Department of DefenseUnited States Department of Defense [W81XWH-08-2-0124, W81XWH-10-1-0609]; Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Project [B6812C]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER	This study was supported by grants from the U.S. Department of Defense (W81XWH-08-2-0124, W81XWH-10-1-0609).; Supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Project #B6812C Traumatic Brain Injury Center of Excellence.	[Anonymous], 1944, ARM IND TEST GEN AB; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Binder JR, 2011, TRENDS COGN SCI, V15, P527, DOI 10.1016/j.tics.2011.10.001; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis D.C., 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Green P., 2005, WORD MEMORY TEST WIN; Hammeke T. A., 2003, NEUROPSYCHIATRY, P1149; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kuo JR, 2012, ARCH GEN PSYCHIAT, V69, P1080, DOI 10.1001/archgenpsychiatry.2012.73; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Minamoto T, 2010, BRAIN RES, V1335, P63, DOI 10.1016/j.brainres.2010.03.088; O'Connor DA, 2012, NEUROIMAGE, V62, P1841, DOI 10.1016/j.neuroimage.2012.05.040; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; Spitzer R. L., 1990, STRUCTURED CLIN INTE; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F., 1993, 9 ANN C ISTSS SAN AN; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197	64	59	59	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					169	179		10.1089/neu.2013.2877			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600003	24020449	Green Published			2022-02-06	
J	Davis, GA; Purcell, LK				Davis, Gavin A.; Purcell, Laura K.			The evaluation and management of acute concussion differs in young children	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Children; Children's injuries; Head injuries	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; BASE-LINE VALUES; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; YOUTH SPORTS; MILD	Background There are many reasons why concussion in children needs to be considered different from adults. The Zurich (2008) recommendations on the management of concussion in children are restricted to children less than to 10years of age. It does not include recommendations for children aged 5-10years. The aim of this study is to review the current literature on (1) concussion assessment at the sideline and during recovery stages, especially in the age group 5-15years, and (2) the management of concussion in children and adolescents. Methods A literature review using the MEDLINE database was undertaken. Articles were selected that included evaluation and/or management in children aged 5-15years. Results There are no sideline assessment tools validated for use in this age group. There are a number of different symptom scales that have been validated during different stages of the follow-up assessment in children. No single paediatric concussion assessment tool has been validated for use from sideline through to all stages of recovery. Reliability studies have been published on Balance Error Scoring System in children, but validity studies in this age group have not been published. The management of concussion includes withdrawal from play on the day and cognitive and physical rest. The priority of concussion management in children is to return to learn; while this is usually rapid, there are some children in whom a graduated return to school is required, which should include a number of accommodations. Conclusions A young child is physically, cognitively and emotionally very different from adults, and requires the use of a different set of tools for the diagnosis, recovery-assessment and management of concussion. Age-specific, validated diagnostic tools are required, and management of concussion in children should focus attention on return to learn before considering return to play.	[Davis, Gavin A.] Austin Hlth, Dept Neurosurg, Cabrini Hlth, Melbourne, Vic, Australia; [Davis, Gavin A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Purcell, Laura K.] McMaster Univ, Dept Pediat, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Purcell, Laura K.] Elliott Sports Med Clin, Burlington, ON, Canada		Davis, GA (corresponding author), Cabrini Hlth, Dept Neurosurg, Cabrini Med Ctr, Suite 53, Malvern, Vic 3144, Australia.	gadavis@netspace.net.au	Meijer, Anna/K-5118-2016				Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Davis GA., 2012, MILD TRAUMATIC BRAIN, P99; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2013, BR J SPORTS MED, DOI 10.1136/bjsports-2012-091579; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Holbourn AHS, 1943, LANCET, V2, P438; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Janusz JA, 2012, MILD TRAUMATIC BRAIN, DOI [10.1249/JSR.0b013-31819c7-87, DOI 10.1249/JSR.0B013-31819C7-87]; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Munoz-Sanchez M, 2005, CHILD NERV SYST, V21, P128, DOI 10.1007/s00381-004-1036-x; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	53	59	59	1	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					98	U102		10.1136/bjsports-2012-092132			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	276KK	WOS:000328749000009	23613516				2022-02-06	
J	Pawlikowska-Pawlega, B; Dziubhiska, H; Krol, E; Trebacz, K; Jarosz-Wilkolazka, A; Paduch, R; Gawron, A; Gruszecki, WI				Pawlikowska-Pawlega, Bolena; Dziubhiska, Halina; Krol, Elzbieta; Trebacz, Kazimierz; Jarosz-Wilkolazka, Anna; Paduch, Roman; Gawron, Antoni; Gruszecki, Wieslaw I.			Characteristics of quercetin interactions with liposomal and vacuolar membranes	BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES			English	Article						Flavonoids; DPPC liposomes; Spectroscopy study; Patch-clamp; Electron microscopy	ANTIBIOTIC AMPHOTERICIN-B; HYDROGEN-PEROXIDE; LIPID-MEMBRANES; FLAVONOID QUERCETIN; OXIDATIVE STRESS; ANTIOXIDANT; TRANSPORT; CELLS; APIGENIN; BINDING	Quercetin (3,3',4',5,7-pentahydroxyflavone) is claimed to exert many beneficial health effects. With application of H-1 NMR (nuclear magnetic resonance) and FTIR (Fourier-transform infrared) techniques, quercetin interaction with liposomes formed with dipalmitoylphosphatidylcholine (DPPC) was analyzed. Patch-clamp technique was employed to study quercetin effects at single channel level of vacuolar membranes in the liverwort Conocephalum conicum. Light and electron microscopy were applied to study quercetin effects on human negroid cervix carcinoma cells (HeLa). Enzymatic measurements along with DPPH (1,1-diphenyl-2-picrylhydrazyl) bioassay were performed to investigate the influence of quercetin on antioxidant enzymes and reactive oxygen species (ROS) production. The inclusion of quercetin to the membrane exerted pronounced ordering effect on the motional freedom of lipids in the head group region as manifested by broadening of the H-1 NMR spectral line representing the choline groups. FTIR analysis revealed quercetin incorporation into DPPC liposomes via hydrogen bonding between its own hydroxyl groups and lipid polar head groups in the C-O-P-O-C segment Both, FUR and NMR techniques indicated also quercetin spectral effects in the region corresponding to alkyl chains. Patch-clamp experiments showed that quercetin stabilizes tonoplast and promotes a close state of SV channels. Microscopic observations of HeLa cells revealed characteristic changes in ultrastructure and morphology of the examined cells in comparison to control cells. Pretreatment of HeLa cells with quercetin alleviated H2O2-induced cell injury by improving redox balance as indicated by the increase in glutathione content and SOD (superoxide dismutase) levels as well as by the decrease in ROS level. \In conclusion, the incorporation, distribution and the changes of biophysical properties of the membranes are very important for the effectiveness of phenolic compounds as antioxidant and anticancer factors. (C) 2013 Elsevier B.V. All rights reserved.	[Pawlikowska-Pawlega, Bolena; Gawron, Antoni] Marie Curie Sklodowska Univ, Dept Comparat Anat & Anthropol, PL-20033 Lublin, Poland; [Pawlikowska-Pawlega, Bolena] Marie Curie Sklodowska Univ, Electron Microscopy Lab, PL-20033 Lublin, Poland; [Dziubhiska, Halina; Krol, Elzbieta; Trebacz, Kazimierz] Marie Curie Sklodowska Univ, Dept Biophys, PL-20033 Lublin, Poland; [Jarosz-Wilkolazka, Anna] Marie Curie Sklodowska Univ, Dept Biochem, PL-20033 Lublin, Poland; [Paduch, Roman] Marie Curie Sklodowska Univ, Dept Virol & Immunol, PL-20033 Lublin, Poland; [Gruszecki, Wieslaw I.] Marie Curie Sklodowska Univ, Dept Biophys, PL-20031 Lublin, Poland		Pawlikowska-Pawlega, B (corresponding author), Marie Curie Sklodowska Univ, Dept Comparat Anat & Anthropol, PL-20033 Lublin, Poland.	bozka1996@o2.pl; halinadziubinska@umcs.lublin.pl; elzbietakrol@uni-wuerzburg.de; kazimierz.trebacz@poczta.umcs.lublin.pl; anna.wilkolazka@poczta.umcs.lublin.pl; rpaduch@poczta.umcs.lublin.pl; agawron@poczta.umcs.lublin.pl; wieslaw.gruszecki@umcs.pl	Jarosz-Wilkolazka, Anna/AAM-8144-2021; Jarosz-Wilkolazka, Anna/B-3763-2014	Pawlikowska-Pawlega, Bozena/0000-0001-5559-8546; Paduch, Roman/0000-0001-9779-7252; Trebacz, Kazimierz/0000-0001-5642-9955; Jarosz-Wilkolazka, Anna/0000-0002-8222-4379; Gruszecki, Wieslaw/0000-0002-8245-3913	Foundation for Polish Science within the framework of the TEAM program	This work has been partially performed within the project "Molecular Spectroscopy for BioMedical studies" financed by the Foundation for Polish Science within the framework of the TEAM program.	Adamkiewicz P, 2013, J MOL STRUCT, V1046, P44, DOI 10.1016/j.molstruc.2013.04.053; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Areias FM, 2001, BIOCHEM PHARMACOL, V62, P111, DOI 10.1016/S0006-2952(01)00621-9; Bei WJ, 2005, LIFE SCI, V76, P1975, DOI 10.1016/j.lfs.2004.09.031; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008; Boue SM, 2003, J CHROMATOGR A, V991, P61, DOI 10.1016/S0021-9673(03)00209-7; Burda S, 2001, J AGR FOOD CHEM, V49, P2774, DOI 10.1021/jf001413m; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Cazarolli LH, 2008, MINI-REV MED CHEM, V8, P1429, DOI 10.2174/138955708786369564; Chen JW, 2002, ACTA PHARMACOL SIN, V23, P667; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen TJ, 2006, TOXICOLOGY, V223, P113, DOI 10.1016/j.tox.2006.03.007; Choi YJ, 2003, J NUTR, V133, P985, DOI 10.1093/jn/133.4.985; Cieslik-Boczula K, 2012, VIB SPECTROSC, V62, P64, DOI 10.1016/j.vibspec.2012.05.010; Cogolludo A, 2007, CARDIOVASC RES, V73, P424, DOI 10.1016/j.cardiores.2006.09.008; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; Desiraju GR, 2005, CHEM COMMUN, P2995, DOI 10.1039/b504372g; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; DUDEJA PK, 1995, ARCH BIOCHEM BIOPHYS, V319, P309, DOI 10.1006/abbi.1995.1298; ELIAS KS, 1987, APPL ENVIRON MICROB, V53, P1928, DOI 10.1128/AEM.53.8.1928-1933.1987; Erlejman AG, 2004, FREE RADICAL RES, V38, P1311, DOI 10.1080/10715760400016105; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; Frangne N, 2002, PLANT PHYSIOL, V128, P726, DOI 10.1104/pp.010590; Gabrielska J, 1996, BBA-BIOMEMBRANES, V1285, P167, DOI 10.1016/S0005-2736(96)00152-6; Gabrielska J, 2006, FEBS LETT, V580, P2677, DOI 10.1016/j.febslet.2006.04.021; Gagos M, 2005, MOL MEMBR BIOL, V22, P433, DOI 10.1080/09687860500287832; Ganbold M, 2010, J ETHNOPHARMACOL, V131, P396, DOI 10.1016/j.jep.2010.07.014; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Goutman JD, 2004, BRIT J PHARMACOL, V141, P717, DOI 10.1038/sj.bjp.0705657; Goutman JD, 2003, EUR J PHARMACOL, V461, P79, DOI 10.1016/S0014-2999(03)01309-8; Govil G., 2012, INT J CURR PHARM RES, V4, P70; Gutla PVK, 2010, BIOPHYS J, V98, p534A, DOI 10.1016/j.bpj.2009.12.2900; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hendrich AB, 2006, ACTA PHARMACOL SIN, V27, P27, DOI 10.1111/j.1745-7254.2006.00238.x; Hendrich AB, 2002, EUR J PHARM SCI, V16, P201, DOI 10.1016/S0928-0987(02)00106-9; HUNT GRA, 1980, BIOCHIM BIOPHYS ACTA, V601, P678, DOI 10.1016/0005-2736(80)90568-4; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; Klein M, 1997, FEBS LETT, V420, P86, DOI 10.1016/S0014-5793(97)01492-0; Kondo N, 2000, J PLANT RES, V113, P311, DOI 10.1007/PL00013863; Lee EH, 2002, BIOPHYS J, V82, P1266, DOI 10.1016/S0006-3495(02)75483-0; Lenne-Gouverneur AF, 1999, MOL MEMBR BIOL, V16, P157, DOI 10.1080/096876899294616; Li WG, 2000, ARTERIOSCL THROM VAS, V20, P1473, DOI 10.1161/01.ATV.20.6.1473; Lopez-Revuelta A, 2006, CHEM-BIOL INTERACT, V161, P79, DOI 10.1016/j.cbi.2006.03.004; Mansour R.B., 2011, LIPIDS HLTH DIS, V10, P1; Movileanu L, 2000, INT J PHARMACEUT, V205, P135, DOI 10.1016/S0378-5173(00)00503-2; Murota K, 2002, J NUTR, V132, P1956, DOI 10.1093/jn/132.7.1956; Nguyen H, 2003, J PHARM SCI-US, V92, P250, DOI 10.1002/jps.10283; Nurminskii V.N., 2009, IZV AKAD NAUK BIOL+, V1, P5; Ollila F, 2002, ARCH BIOCHEM BIOPHYS, V399, P103, DOI 10.1006/abbi.2001.2759; Oteiza Patricia I, 2005, Clin Dev Immunol, V12, P19, DOI 10.1080/10446670410001722168; Paduch R, 2008, POL J ENVIRON STUD, V17, P569; Pampel A, 2003, CHEM PHYS LETT, V379, P555, DOI 10.1016/j.cplett.2003.08.093; Pawlikowska-Pawle B, 2007, ACTA PHYSIOL PLANT, V29, P143, DOI 10.1007/s11738-006-0018-x; Pawlikowska-Pawlega B, 2000, ACTA PHYSIOL PLANT, V22, P61, DOI 10.1007/s11738-000-0009-2; Pawlikowska-Pawlega B, 2003, BIOCHEM PHARMACOL, V66, P605, DOI 10.1016/S0006-2952(03)00344-7; Pawlikowska-Pawlega B, 2007, BBA-BIOMEMBRANES, V1768, P2195, DOI 10.1016/j.bbamem.2007.05.027; Pawlikowska-Pawlega B, 2013, BBA-BIOMEMBRANES, V1828, P518, DOI 10.1016/j.bbamem.2012.10.013; Pawlikowska-Pawlega B, 2012, BBA-BIOMEMBRANES, V1818, P1785, DOI 10.1016/j.bbamem.2012.03.020; Pawlikowska-Pawlega B, 2011, ACTA PHYSIOL PLANT, V33, P1335, DOI 10.1007/s11738-010-0666-8; Pawlikowska-Pawlega B, 2009, J PLANT PHYSIOL, V166, P712, DOI 10.1016/j.jplph.2008.09.014; Pazdzioch-Czochra M, 2003, CELL BIOL INT, V27, P325, DOI 10.1016/S1065-6995(02)00282-2; Psotova J, 2004, PHYTOTHER RES, V18, P516, DOI 10.1002/ptr.1462; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; SAIJA A, 1995, FREE RADICAL BIO MED, V19, P481, DOI 10.1016/0891-5849(94)00240-K; Scheidt HA, 2004, BBA-BIOMEMBRANES, V1663, P97, DOI 10.1016/j.bbamem.2004.02.004; Schonknecht G, 2008, PLANT SIGNAL BEHAV, V3, P404, DOI 10.1093/pcp/pcm147; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/S1360-1385(96)80312-8; Siarheyeva A, 2006, BIOCHEMISTRY-US, V45, P6203, DOI 10.1021/bi0524870; Singh M, 2007, MITOCHONDRION, V7, P367, DOI 10.1016/j.mito.2007.07.003; SINICROPE FA, 1992, J BIOL CHEM, V267, P24995; Suhara T, 1998, J IMMUNOL, V160, P4042; Summanen J, 2001, EUR J PHARMACOL, V414, P125, DOI 10.1016/S0014-2999(01)00774-9; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; Suthiparinyanont S., 2007, AM J AGR BIOL SCI, V2, P31, DOI DOI 10.3844/AJABSSP.2007.31.35; Takahashi L, 1998, PLANT PHYSIOL BIOCH, V36, P495, DOI 10.1016/S0981-9428(98)80174-5; Tarahovsky YS, 2008, MOL CELL BIOCHEM, V314, P65, DOI 10.1007/s11010-008-9766-9; TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039; Trebacz K, 2000, PROTOPLASMA, V213, P39, DOI 10.1007/BF01280503; Trebacz K, 2007, PLANT CELL PHYSIOL, V48, P1747, DOI 10.1093/pcp/pcm147; Treutter D, 2006, ENVIRON CHEM LETT, V4, P147, DOI 10.1007/s10311-006-0068-8; Tsuchiya H, 2002, BIOFACTORS, V16, P45, DOI 10.1002/biof.5520160301; Tsuchiya H, 2010, FOOD CHEM, V120, P1089, DOI 10.1016/j.foodchem.2009.11.057; Ulug M, 2011, AFR J PHARM PHARMACO, V5, P894; van Dijk C, 2000, BIOCHEM PHARMACOL, V60, P1593, DOI 10.1016/S0006-2952(00)00488-3; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vargas AJ, 2010, NUTR REV, V68, P418, DOI 10.1111/j.1753-4887.2010.00301.x; Wojtowicz K, 1996, FOLIA HISTOCHEM CYTO, V34, P49; Zhang F, 1997, PLANT SOIL, V192, P141, DOI 10.1023/A:1004284727885	91	59	59	1	41	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2736	1879-2642		BBA-BIOMEMBRANES	Biochim. Biophys. Acta-Biomembr.	JAN	2014	1838	1	B				254	265		10.1016/j.bbamem.2013.08.014			12	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	AA0UX	WOS:000330814000018	24001508	Bronze			2022-02-06	
J	Rachmany, L; Tweedie, D; Li, YZ; Rubovitch, V; Holloway, HW; Miller, J; Hoffer, BJ; Greig, NH; Pick, CG				Rachmany, Lital; Tweedie, David; Li, Yazhou; Rubovitch, Vardit; Holloway, Harold W.; Miller, Jonathan; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice	AGE			English	Article						Mild traumatic brain injury; Glucagon-like peptide-1; Exendin-4; Liraglutide; Neuroprotection; Brain trauma; Incretin; Alzheimer's disease; Glutamate toxicity; Oxidative stress	CLINICAL-PRACTICE GUIDELINES; ANXIETY-LIKE BEHAVIOR; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; SOCIAL RECOVERY; SPATIAL MEMORY; RODENT MODELS; RISK-FACTOR; CELL-DEATH	Mild traumatic brain injury (mTBI) represents a major and increasing public health concern and is both the most frequent cause of mortality and disability in young adults and a chief cause of morbidity in the elderly. Albeit mTBI patients do not show clear structural brain defects and, generally, do not require hospitalization, they frequently suffer from long-lasting cognitive, behavioral, and emotional problems. No effective pharmaceutical therapy is available, and existing treatment chiefly involves intensive care management after injury. The diffuse neural cell death evident after mTBI is considered mediated by oxidative stress and glutamate-induced excitotoxicity. Prior studies of the long-acting GLP-1 receptor agonist, exendin-4 (Ex-4), an incretin mimetic approved for type 2 diabetes mellitus treatment, demonstrated its neurotrophic/protective activity in cellular and animal models of stroke, Alzheimer's and Parkinson's diseases, and, consequent to commonalities in mechanisms underpinning these disorders, Ex-4 was assessed in a mouse mTBI model. In neuronal cultures in this study, Ex-4 ameliorated H2O2-induced oxidative stress and glutamate toxicity. To evaluate in vivo translation, we administered steady-state Ex-4 (3.5 pM/kg/min) or saline to control and mTBI mice over 7 days starting 48 h prior to or 1 h post-sham or mTBI (30 g weight drop under anesthesia). Ex-4 proved well-tolerated and fully ameliorated mTBI-induced deficits in novel object recognition 7 and 30 days post-trauma. Less mTBI-induced impairment was evident in Y-maze, elevated plus maze, and passive avoidance paradigms, but when impairment was apparent Ex-4 induced amelioration. Together, these results suggest that Ex-4 may act as a neurotrophic/neuroprotective drug to minimize mTBI impairment.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Tweedie, David; Li, Yazhou; Holloway, Harold W.; Greig, Nigel H.] NIA, Lab Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Greig, Nigel H.] NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA		Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, BRC Room 05 C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	Greign@grc.nia.nih.gov		Miller, Jonathan/0000-0001-5441-1751	National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Sackler School of Medicine, Tel-Aviv University; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by the Intramural Research Program of both the National Institute on Aging, National Institutes of Health, and the Sackler School of Medicine, Tel-Aviv University.	Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Banks WA, 2004, J PHARMACOL EXP THER, V309, P469, DOI 10.1124/jpet.103.063222; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barnett AH, 2012, DIABETES OBES METAB, V14, P304, DOI 10.1111/j.1463-1326.2011.01523.x; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Calara F, 2005, CLIN THER, V27, P210, DOI 10.1016/j.clinthera.2005.02.008; Chaudhuri A, 2012, J CLIN ENDOCR METAB, V97, P198, DOI 10.1210/jc.2011-1508; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Drucker DJ, 2008, LANCET, V372, P1240, DOI 10.1016/S0140-6736(08)61206-4; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Erreger K, 2012, PHYSIOL BEHAV, V106, P574, DOI 10.1016/j.physbeh.2012.03.014; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Gallwitz B, 2011, DRUGS, V71, P1675, DOI 10.2165/11592810-000000000-00000; Garber AJ, 2011, DIABETES CARE, V34, pS279, DOI 10.2337/dc11-s231; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Grant P, 2011, J DIABETES COMPLICAT, V25, P244, DOI 10.1016/j.jdiacomp.2011.03.002; Hamilton A, 2009, NEUROREPORT, V20, P1161, DOI 10.1097/WNR.0b013e32832fbf14; Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359-6446(05)03370-2; Holscher Christian, 2010, Recent Pat CNS Drug Discov, V5, P109; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Howard PK, 2011, ADV EMERG NURS J, V33, P274, DOI 10.1097/TME.0b013e318233d43c; Hunter K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-33; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Pawaskar M, 2012, CURR MED RES OPIN, V28, P991, DOI 10.1185/03007995.2012.686901; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Porter D, 2012, PEPTIDES, V35, P1, DOI 10.1016/j.peptides.2012.03.014; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sharma S, 2010, LIFE SCI, V87, P521, DOI 10.1016/j.lfs.2010.09.004; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Strawn JR, 2008, J PSYCHIATR RES, V42, P787, DOI 10.1016/j.jpsychires.2007.08.007; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006; Zitnay GA, 2005, ACT NEUR S, V93, P131; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	89	59	59	1	39	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0161-9152	1574-4647		AGE	Age	OCT	2013	35	5					1621	1636		10.1007/s11357-012-9464-0			16	Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology	219XO	WOS:000324545200008	22892942	Green Published			2022-02-06	
J	Dustrude, ET; Wilson, SM; Ju, WN; Xiao, YC; Khanna, R				Dustrude, Erik T.; Wilson, Sarah M.; Ju, Weina; Xiao, Yucheng; Khanna, Rajesh			CRMP2 Protein SUMOylation Modulates NaV1.7 Channel Trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; RESPONSE MEDIATOR PROTEIN-2; TRAUMATIC BRAIN-INJURY; SPINAL SENSORY NEURONS; ROOT GANGLION NEURONS; GROWTH CONE COLLAPSE; SUMO MODIFICATION; SLOW INACTIVATION; NEUROPATHIC PAIN; ANTICONVULSANT LACOSAMIDE	Voltage-gated sodium channel (NaV) trafficking is incompletely understood. Post-translational modifications of NaVs and/or auxiliary subunits and protein-protein interactions have been posited as NaV-trafficking mechanisms. Here, we tested if modification of the axonal collapsin response mediator protein 2 (CRMP2) by a small ubiquitin-like modifier (SUMO) could affect NaV trafficking; CRMP2 alters the extent of NaV slow inactivation conferred by the anti-epileptic (R)-lacosamide, implying NaV-CRMP2 functional coupling. Expression of a CRMP2 SUMOylation-incompetent mutant (CRMP2-K374A) in neuronal model catecholamine A differentiated (CAD) cells did not alter lacosamide-induced NaV slow inactivation compared with CAD cells expressing wild type CRMP2. Like wild type CRMP2, CRMP2-K374A expressed robustly in CAD cells. Neurite outgrowth, a canonical CRMP2 function, was moderately reduced by the mutation but was still significantly higher than enhanced GFP-transfected cortical neurons. Notably, huwentoxin-IV-sensitive NaV1.7 currents, which predominate in CAD cells, were significantly reduced in CAD cells expressing CRMP2-K374A. Increasing deSUMOylation with sentrin/SUMO-specific protease SENP1 or SENP2 in wild type CRMP2-expressing CAD cells decreased NaV1.7 currents. Consistent with a reduction in current density, biotinylation revealed a significant reduction in surface NaV1.7 levels in CAD cells expressing CRMP2-K374A; surface NaV1.7 expression was also decreased by SENP1 + SENP2 overexpression. Currents in HEK293 cells stably expressing NaV1.7 were reduced by CRMP2-K374A in a manner dependent on the E2-conjugating enzyme Ubc9. No decrement in current density was observed in HEK293 cells co-expressing CRMP2-K374A and NaV1.1 or NaV1.3. Diminution of sodium currents, largely NaV1.7, was recapitulated in sensory neurons expressing CRMP2-K374A. Our study elucidates a novel regulatory mechanism that utilizes CRMP2 SUMOylation to choreograph NaV1.7 trafficking.	[Dustrude, Erik T.; Wilson, Sarah M.; Khanna, Rajesh] Indiana Univ Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Ju, Weina; Xiao, Yucheng; Khanna, Rajesh] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA		Khanna, R (corresponding author), 950 West Walnut St,R2 Bldg,Rm 478, Indianapolis, IN 46202 USA.	khanna5@iu.edu		Khanna, Rajesh/0000-0002-9066-2969	National Institutes of Health Clinical and Translational Sciences Grant from the Indiana Clinical and Translational Sciences Institute [RR025761]; NCRR Project Development Team; Indiana State Department of Health-Spinal Cord and Brain Injury Fund [A70-9-079138]; National Scientist Development Grant from the American Heart Association [SDG5280023]; Neurofibromatosis New Investigator Award from the Department of Defense/Congressionally Directed Medical Research Program [NF1000099]; Stark fellowships; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Clinical and Translational Sciences Grant RR025761 from the Indiana Clinical and Translational Sciences Institute funded by NCRR Project Development Team. This work was also supported by the Indiana State Department of Health-Spinal Cord and Brain Injury Fund A70-9-079138 (to R. K.), National Scientist Development Grant SDG5280023 from the American Heart Association (to R. K.), and Neurofibromatosis New Investigator Award NF1000099 from the Department of Defense/Congressionally Directed Medical Research Program (to R. K.).; Supported in part by Stark fellowships.	Anckar J, 2007, BIOCHEM SOC T, V35, P1409, DOI 10.1042/BST0351409; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Benson M, 2009, SUMO REGULATION OF CELLULAR PROCESSES, P117, DOI 10.1007/978-90-481-2649-1_7; Benson MD, 2007, P NATL ACAD SCI USA, V104, P1805, DOI 10.1073/pnas.0606702104; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2012, FEBS LETT, V586, P3813, DOI 10.1016/j.febslet.2012.09.022; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Casini S, 2010, CARDIOVASC RES, V85, P691, DOI 10.1093/cvr/cvp352; Catterall WA, 2010, J PHYSIOL-LONDON, V588, P1849, DOI 10.1113/jphysiol.2010.187484; Chan AW, 2007, CHANNELS, V1, DOI 10.4161/chan.3694; Chi XX, 2007, J NEUROPHYSIOL, V98, P2683, DOI 10.1152/jn.00437.2007; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; Dib-Hajj SD, 2013, NAT REV NEUROSCI, V14, P49, DOI 10.1038/nrn3404; Duprez E, 1999, J CELL SCI, V112, P381; Errington AC, 2008, MOL PHARMACOL, V73, P157, DOI 10.1124/mol.107.039867; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Escayg A, 2010, EPILEPSIA, V51, P1650, DOI 10.1111/j.1528-1167.2010.02640.x; Estacion M, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-92; Feliciangeli S, 2007, CELL, V130, P563, DOI 10.1016/j.cell.2007.06.012; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Hodgdon KE, 2012, NEUROSCIENCE, V206, P237, DOI 10.1016/j.neuroscience.2011.12.045; Hong SS, 2004, J BIOL CHEM, V279, P29341, DOI 10.1074/jbc.M404167200; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Ju WN, 2013, CHANNELS, V7, P153, DOI 10.4161/chan.24224; Khanna R, 2012, FUTUR NEUROL, V7, P749, DOI 10.2217/FNL.12.68; Kim CH, 2001, MOL BRAIN RES, V95, P153, DOI 10.1016/S0169-328X(01)00226-1; Kim DY, 2007, NAT CELL BIOL, V9, P755, DOI 10.1038/ncb1602; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; King AM, 2012, ACS CHEM NEUROSCI, V3, P1037, DOI 10.1021/cn300129d; Konopacki FA, 2011, P NATL ACAD SCI USA, V108, P19772, DOI 10.1073/pnas.1111575108; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Leterrier C, 2010, NEUROSCI LETT, V486, P92, DOI 10.1016/j.neulet.2010.08.079; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lopez-Santiago LF, 2006, J NEUROSCI, V26, P7984, DOI 10.1523/JNEUROSCI.2211-06.2006; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Martin S, 2007, NAT REV NEUROSCI, V8, P948, DOI 10.1038/nrn2276; Merrill JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008794; Momin A, 2008, CURR OPIN NEUROBIOL, V18, P383, DOI 10.1016/j.conb.2008.08.017; Morinaka A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001127; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Park KD, 2010, ORG BIOMOL CHEM, V8, P2803, DOI 10.1039/c000987c; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Pertin M, 2005, J NEUROSCI, V25, P10970, DOI 10.1523/JNEUROSCI.3066-05.2005; Plant LD, 2011, J GEN PHYSIOL, V137, P441, DOI 10.1085/jgp.201110604; Plant LD, 2010, P NATL ACAD SCI USA, V107, P10743, DOI 10.1073/pnas.1004712107; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rusconi R, 2007, J NEUROSCI, V27, P11037, DOI 10.1523/JNEUROSCI.3515-07.2007; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shao DM, 2009, INT J BIOCHEM CELL B, V41, P1471, DOI 10.1016/j.biocel.2009.01.016; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Stenmark P, 2007, J NEUROCHEM, V101, P906, DOI 10.1111/j.1471-4159.2006.04401.x; Takahashi N, 2003, NEUROSCIENCE, V121, P441, DOI 10.1016/S0306-4522(03)00432-9; Theile JW, 2011, MOL PHARMACOL, V80, P724, DOI 10.1124/mol.111.072751; Vacher H, 2012, EPILEPSIA, V53, P21, DOI 10.1111/epi.12032; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wang YY, 2011, ACS CHEM NEUROSCI, V2, P317, DOI 10.1021/cn200024z; Wang YY, 2011, ACS CHEM NEUROSCI, V2, P90, DOI 10.1021/cn100089b; Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; Wilkinson KA, 2008, NEUROSCI LETT, V436, P239, DOI 10.1016/j.neulet.2008.03.029; Wilkinson KA, 2010, BRAIN RES REV, V64, P195, DOI 10.1016/j.brainresrev.2010.04.002; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wilson SM, 2012, NEUROSCIENCE, V210, P451, DOI 10.1016/j.neuroscience.2012.02.038; Wilson SM, 2012, J BIOL CHEM, V287, P35065, DOI 10.1074/jbc.M112.378695; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; Wolff C, 2012, CNS NEUROSCI THER, V18, P493, DOI 10.1111/j.1755-5949.2012.00313.x; Xiao YC, 2008, J BIOL CHEM, V283, P27300, DOI 10.1074/jbc.M708447200; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	80	59	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2013	288	34					24316	24331		10.1074/jbc.M113.474924			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302NW	WOS:000330612300004	23836888	Green Published, hybrid			2022-02-06	
J	Dal Monte, O; Krueger, F; Solomon, JM; Schintu, S; Knutson, KM; Strenziok, M; Pardini, M; Leopold, A; Raymont, V; Grafman, J				Dal Monte, Olga; Krueger, Frank; Solomon, Jeffrey M.; Schintu, Selene; Knutson, Kristine M.; Strenziok, Maren; Pardini, Matteo; Leopold, Anne; Raymont, Vanessa; Grafman, Jordan			A voxel-based lesion study on facial emotion recognition after penetrating brain injury	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						facial emotion recognition; voxel-based lesion symptom mapping; labeling task; basic emotions; traumatic brain injury	ANTERIOR TEMPORAL INVOLVEMENT; IMPAIRED RECOGNITION; FUNCTIONAL NEUROANATOMY; COGNITIVE-ABILITIES; PREFRONTAL CORTEX; RIGHT-HEMISPHERE; FRONTAL-CORTEX; HUMAN AMYGDALA; NEURAL BASES; EXPRESSIONS	The ability to read emotions in the face of another person is an important social skill that can be impaired in subjects with traumatic brain injury (TBI). To determine the brain regions that modulate facial emotion recognition, we conducted a whole-brain analysis using a well-validated facial emotion recognition task and voxel-based lesion symptom mapping (VLSM) in a large sample of patients with focal penetrating TBIs (pTBIs). Our results revealed that individuals with pTBI performed significantly worse than normal controls in recognizing unpleasant emotions. VLSM mapping results showed that impairment in facial emotion recognition was due to damage in a bilateral fronto-temporo-limbic network, including medial prefrontal cortex (PFC), anterior cingulate cortex, left insula and temporal areas. Beside those common areas, damage to the bilateral and anterior regions of PFC led to impairment in recognizing unpleasant emotions, whereas bilateral posterior PFC and left temporal areas led to impairment in recognizing pleasant emotions. Our findings add empirical evidence that the ability to read pleasant and unpleasant emotions in other people's faces is a complex process involving not only a common network that includes bilateral fronto-temporo-limbic lobes, but also other regions depending on emotional valence.	[Dal Monte, Olga; Schintu, Selene; Knutson, Kristine M.; Raymont, Vanessa; Grafman, Jordan] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Dal Monte, Olga] Univ Turin, Dept Neuropsychol, I-10123 Turin, Italy; [Dal Monte, Olga; Schintu, Selene] Henry M Jackson Fdn, Rockville, MD 20852 USA; [Krueger, Frank; Strenziok, Maren] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Solomon, Jeffrey M.] Expert Image Anal LLC, Potomac, MD 20859 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; [Leopold, Anne] Univ Utrecht, Social & Hlth Psychol Dept, NL-3508 Utrecht, Netherlands; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21287 USA; [Raymont, Vanessa] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW72WY, England; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ 07052 USA		Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	fkrueger@gmu.edu	Dal Monte, Olga/P-3759-2018; Pardini, Matteo/F-8414-2010; Schintu, Selene/ABF-7032-2020	Dal Monte, Olga/0000-0002-7823-4769; Pardini, Matteo/0000-0002-4740-1982; Schintu, Selene/0000-0002-6362-3905; Knutson, Kristine/0000-0003-4626-4514; Grafman, Jordan H./0000-0001-8645-4457	National Naval Medical Center	The authors are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities as well as S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding and G. Tasick for their invaluable help with the testing of participants and organization of this study. For further information about the Vietnam Head Injury Study, please contact Dr. Grafman at: jgrafman@kesslerfoundation.org	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AHERN GL, 1979, NEUROPSYCHOLOGIA, V17, P693, DOI 10.1016/0028-3932(79)90045-9; Alves NT, 2009, LATERALITY, V14, P256, DOI 10.1080/13576500802362927; Anderson AK, 2000, PSYCHOL SCI, V11, P106, DOI 10.1111/1467-9280.00224; Anderson ND, 2011, J COGNITIVE NEUROSCI, V23, P3804, DOI 10.1162/jocn_a_00050; Beer JS, 2003, J PERS SOC PSYCHOL, V85, P594, DOI 10.1037/0022-3514.85.4.594; Benedetti F, 2009, SCHIZOPHR RES, V114, P154, DOI 10.1016/j.schres.2009.06.021; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; Bora E, 2008, PSYCHIAT RES, V160, P23, DOI 10.1016/j.psychres.2007.05.017; BOROD JC, 1980, NEUROPSYCHOLOGIA, V18, P237, DOI 10.1016/0028-3932(80)90070-6; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Carver CS, 2001, PERS SOC PSYCHOL REV, V5, P345, DOI 10.1207/S15327957PSPR0504_4; Clark US, 2010, J INT NEUROPSYCH SOC, V16, P1127, DOI 10.1017/S1355617710001037; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DAVIDSON RJ, 1992, BRAIN COGNITION, V20, P125, DOI 10.1016/0278-2626(92)90065-T; Davidson RJ, 2000, MED RAD DIA IMG, P487; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Decety J, 2010, DEV NEUROSCI-BASEL, V32, P257, DOI 10.1159/000317771; Derntl B, 2011, SOC NEUROSCI-UK, V6, P482, DOI 10.1080/17470919.2011.579800; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; EKMAN P, 1992, PSYCHOL REV, V99, P550, DOI 10.1037/0033-295X.99.3.550; Ekman P., 1976, PICTURES FACIAL AFFE; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Frank MG, 2001, J PERS SOC PSYCHOL, V80, P75, DOI 10.1037/0022-3514.80.1.75; Fusar-Poli P, 2009, J PSYCHIATR NEUROSCI, V34, P418; GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384; Geva S, 2011, BRAIN, V134, P3071, DOI 10.1093/brain/awr232; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; Goodkind MS, 2012, HUM BRAIN MAPP, V33, P753, DOI 10.1002/hbm.21251; Gorno-Tempini ML, 2001, NEUROIMAGE, V14, P465, DOI 10.1006/nimg.2001.0811; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grossmann T, 2007, EUR J NEUROSCI, V25, P909, DOI 10.1111/j.1460-9568.2007.05379.x; Habel U, 2007, NEUROPSYCHOLOGIA, V45, P2369, DOI 10.1016/j.neuropsychologia.2007.01.023; Hall J, 2004, BRIT J PSYCHIAT, V185, P169, DOI 10.1192/bjp.185.2.169; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; Heberlein AS, 2008, J COGNITIVE NEUROSCI, V20, P721, DOI 10.1162/jocn.2008.20049; Heberlein AS, 2004, J COGNITIVE NEUROSCI, V16, P1143, DOI 10.1162/0898929041920423; Heller W, 1998, CURR DIR PSYCHOL SCI, V7, P26, DOI 10.1111/1467-8721.ep11521823; Henry JD, 2009, J INT NEUROPSYCH SOC, V15, P277, DOI 10.1017/S1355617709090195; Henson RNA, 2002, NEUROIMAGE, V15, P83, DOI 10.1006/nimg.2001.0940; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ille R, 2011, J PSYCHIATR NEUROSCI, V36, P383, DOI 10.1503/jpn.100143; Izard C. E., 1971, FACE EMOTION; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kaplan E., 2001, BOSTON NAMING TEST; Kessels RPC, 2007, BEHAV NEUROL, V18, P31, DOI 10.1155/2007/868431; Kimberg DY, 2007, J COGNITIVE NEUROSCI, V19, P1067, DOI 10.1162/jocn.2007.19.7.1067; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Koenigs M, 2010, J NEUROSCI, V30, P16041, DOI 10.1523/JNEUROSCI.3745-10.2010; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; LABARBERA JD, 1976, CHILD DEV, V47, P535, DOI 10.2307/1128816; Leopold A, 2012, SOC COGN AFFECT NEUR, V7, P871, DOI 10.1093/scan/nsr071; Mah L, 2004, AM J PSYCHIAT, V161, P1247, DOI 10.1176/appi.ajp.161.7.1247; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Marinkovic K, 2000, COGN NEUROPSYCHOL, V17, P187, DOI 10.1080/026432900380562; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McNeil M., 1994, REVISED TOKEN TEST; Miller LA, 2012, BEHAV NEUROL, V25, P53, DOI [10.1155/2012/683052, 10.3233/BEN-2012-0349]; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Murphy FC, 2003, COGN AFFECT BEHAV NE, V3, P207, DOI 10.3758/CABN.3.3.207; Nakamura K, 1999, J NEUROPHYSIOL, V82, P1610, DOI 10.1152/jn.1999.82.3.1610; Narumoto J, 2000, NEUROREPORT, V11, P2571, DOI 10.1097/00001756-200008030-00044; Nelson CA, 1996, DEV PSYCHOBIOL, V29, P577; Nelson CA, 2001, INFANT CHILD DEV, V10, P3, DOI 10.1002/icd.239; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Rosen HJ, 2006, NEUROPSYCHOLOGIA, V44, P365, DOI 10.1016/j.neuropsychologia.2005.06.012; Schwartz MF, 2009, BRAIN, V132, P3411, DOI 10.1093/brain/awp284; SILBERMAN EK, 1986, BRAIN COGNITION, V5, P322, DOI 10.1016/0278-2626(86)90035-7; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Szekely E, 2011, EMOTION, V11, P425, DOI 10.1037/a0022587; Tsuchida A, 2012, CEREB CORTEX, V22, P2904, DOI 10.1093/cercor/bhr370; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vuilleumier P, 2001, NEURON, V30, P829, DOI 10.1016/S0896-6273(01)00328-2; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Walker GM, 2011, BRAIN LANG, V117, P110, DOI 10.1016/j.bandl.2010.09.008; Warrington E. K., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WECHSLER MEMORY SCAL; Whalen PJ, 1998, J NEUROSCI, V18, P411; Wiedemann G, 1999, ARCH GEN PSYCHIAT, V56, P78, DOI 10.1001/archpsyc.56.1.78; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Young A., 2002, FACIAL EXPRESSIONS E	107	59	59	0	37	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	AUG	2013	8	6					632	639		10.1093/scan/nss041			8	Neurosciences; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	205OU	WOS:000323454700004	22496440	Green Published, hybrid			2022-02-06	
J	Farrer, TJ; Frost, RB; Hedges, DW				Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.			Prevalence of traumatic brain injury in juvenile offenders: A meta-analysis	CHILD NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Juvenile offense; Delinquency	PROBLEM-SOLVING SKILLS; MILD HEAD-INJURY; AGGRESSIVE-BEHAVIOR; CHILDREN; DELINQUENCY; ADOLESCENTS	Studies of traumatic brain injury (TBI) among adult populations demonstrate that such injuries can lead to aggressive behaviors. Related findings suggest that incarcerated individuals have high rates of brain injuries. Such studies suggest that traumatic brain injury may be related to the etiology and recidivism of criminal behavior. Relatively few studies have examined the prevalence of TBI using a delinquent juvenile sample. In order to assess the relationship between TBI and juvenile offender status, the current study used meta-analytic techniques to examine the odds of having a TBI among juvenile offenders. Across 9 studies, we found that approximately 30% of juvenile offenders have sustained a previous brain injury. Across 5 studies that used a control group, a calculated summary odds ratio of 3.37 suggests that juvenile offenders are significantly more likely to have a TBI compared to controls. Results suggest that the rate of TBIs within the juvenile offender population is significant and that there may be a relationship between TBIs and juvenile criminal behavior.	[Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hedges, Dawson W.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA		Farrer, TJ (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT,POB 25543, Provo, UT 84602 USA.	thomasfarrer@yahoo.com		Farrer, Thomas J./0000-0001-8092-6214			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Center for Disease Control, 2011, TRAUM BRAIN INJ; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Faul M, 2010, TRAUMATIC BRAIN INJU; Forrest CB, 2000, PEDIATRICS, V105, P286; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hux D, 1998, BRAIN INJURY, V12, P667; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KELDGORD RE, 1968, ACAD THER, V4, P93, DOI 10.1177/105345126800400203; Kenny DT, 2007, CONT ISSUES CRIME JU, V107, P1; KRYNICKI VE, 1978, J NERV MENT DIS, V166, P59, DOI 10.1097/00005053-197801000-00009; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEVINE MD, 1985, AM J DIS CHILD, V139, P50, DOI 10.1001/archpedi.1985.02140030052028; LEWIS DO, 1985, AM J PSYCHIAT, V142, P1161; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; McCrea M.A., 2007, MILD TRAUMATIC BRAIN; MOFFITT TE, 1988, J AM ACAD CHILD PSY, V27, P233, DOI 10.1097/00004583-198803000-00017; PALFREY JS, 1983, PUBLIC HEALTH REP, V98, P449; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Riley A W, 1996, Inj Prev, V2, P266, DOI 10.1136/ip.2.4.266; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; YEUDALL LT, 1982, J NERV MENT DIS, V170, P257, DOI 10.1097/00005053-198205000-00001	39	59	59	1	25	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY 1	2013	19	3					225	234		10.1080/09297049.2011.647901			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	122BS	WOS:000317290900001	22372420				2022-02-06	
J	Yallampalli, R; Wilde, EA; Bigler, ED; McCauley, SR; Hanten, G; Troyanskaya, M; Hunter, JV; Chu, ZL; Li, XQ; Levin, HS				Yallampalli, Ragini; Wilde, Elisabeth A.; Bigler, Erin D.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Hunter, Jill V.; Chu, Zili; Li, Xiaoqi; Levin, Harvey S.			Acute White Matter Differences in the Fornix Following Mild Traumatic Brain Injury Using Diffusion Tensor Imaging	JOURNAL OF NEUROIMAGING			English	Article						Diffusion tensor imaging; mild traumatic brain injury; fornix	AXONAL INJURY; HIPPOCAMPAL; CONCUSSION; RESPONSES; ATROPHY; MEMORY	The integrity of the fornix using diffusion tensor imaging (DTI) in adolescent participants with acute mild traumatic brain injury (mTBI) compared to a demographically matched control group was examined. Fractional anisotropy (FA) in the fornix was elevated in the mild traumatic brain injured group. Performance on the Automated Neuropsychological Assessment Metrics (ANAM) was lower in the group with mTBI. A relation was found between lower performance on cognitive tasks and higher FA. The potential role of fornix injury as a basis of memory and processing speed deficits in mTBI is discussed.	[Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA; [Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA		Wilde, EA (corresponding author), Baylor Coll Med, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056202-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by Grant NS056202-02 awarded to Harvey S. Levin by the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We would also like to thank the patients and their families for involvement in this study. The information in this manuscript and the manuscript itself has never been published either electronically or in print. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen J., 2013, STAT POWER ANAL BEHA; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; Griffiths PD, 2009, NEURORADIOLOGY, V51, P337, DOI 10.1007/s00234-009-0506-y; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Loftus M, 2000, EXP NEUROL, V163, P180, DOI 10.1006/exnr.2000.7361; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Pugliese L, 2009, NEUROIMAGE, V47, P427, DOI 10.1016/j.neuroimage.2009.05.014; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Saeki N, 2001, NEURORADIOLOGY, V43, P547, DOI 10.1007/s002340100549; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Singh M, MAGN RESON IMAGING, V28, P22; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	30	59	60	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284			J NEUROIMAGING	J. Neuroimaging	APR	2013	23	2					224	227		10.1111/j.1552-6569.2010.00537.x			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	126LN	WOS:000317617800016	21988147				2022-02-06	
J	Yeh, CC; Chen, TL; Hu, CJ; Chiu, WT; Liao, CC				Yeh, Chun-Chieh; Chen, Ta-Liang; Hu, Chaur-Jong; Chiu, Wen-Ta; Liao, Chien-Chang			Risk of epilepsy after traumatic brain injury: a retrospective population-based cohort study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							LATE POSTTRAUMATIC SEIZURES; OUTCOMES; CHILDREN	Objective To investigate the associated risk of epilepsy after traumatic brain injury (TBI) in a population-based retrospective cohort study. Methods Using Taiwan's National Health Insurance Research Database of reimbursement claims, we conducted a retrospective cohort study of 19 336 TBI patients and 540 322 non-TBI participants aged >= 15 years as reference group. Data on newly developed epilepsy after TBI with 5-8 years' follow-up during 2000 to 2008 were collected. HRs and 95% CIs for the risk of epilepsy associated with TBI were analysed with multivariate Cox proportional hazards regressions. Results Compared with the non-TBI cohort, the adjusted HRs of developing epilepsy among TBI patients with skull fracture, severe or mild brain injury were 10.6 (95% CI 7.14 to 15.8), 5.05 (95% CI 4.40 to 5.79) and 3.02 (95% CI 2.42 to 3.77), respectively. During follow-up, men exhibited higher risks of post-TBI epilepsy. Patients who had mixed types of cerebral haemorrhage were at the highest risk of epilepsy compared with the non-TBI cohort (HR 7.83, 95% CI 4.69 to 13.0). The risk of post-TBI epilepsy was highest within the first year after TBI (HR 38.2, 95% CI 21.7 to 67.0). Conclusions The risk of epilepsy after TBI varied by patient gender, age, latent interval and complexity of TBI. Integrated care for early identification and treatment of post-trauma epilepsy were crucial for TBI patients.	[Yeh, Chun-Chieh] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei 110, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Hlth Policy Res Ctr, Taipei 110, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Dept Neurol, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan		Liao, CC (corresponding author), Taipei Med Univ Hosp, Dept Anesthesiol, 252 Wuxing St, Taipei 110, Taiwan.	jacky48863027@yahoo.com.tw	Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564	Foundation for Anaesthesia Education and Research fellowship grant, Taipei Medical University, Taipei, Taiwan	This research was supported by a Foundation for Anaesthesia Education and Research fellowship grant, Taipei Medical University, Taipei, Taiwan.	Alldredge BK, 1999, NEUROLOGY, V53, pS68; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Chang CC, 2012, EPILEPSIA, V53, P987, DOI 10.1111/j.1528-1167.2012.03448.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chou YC, 2012, J REHABIL MED, V44, P319, DOI 10.2340/16501977-0935; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Eleftheriadis N, 2003, ACTA NEUROL SCAND, V107, P142, DOI 10.1034/j.1600-0404.2003.02092.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GLENN CM, 1992, PEDIATR NEPHROL, V6, P182, DOI 10.1007/BF00866310; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haut SR, 2006, LANCET NEUROL, V5, P148, DOI 10.1016/S1474-4422(06)70348-9; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MORRIS HH, 1993, EPILEPSIA, V34, P1038, DOI 10.1111/j.1528-1157.1993.tb02131.x; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Wang IK, 2011, STROKE, V42, P716, DOI 10.1161/STROKEAHA.110.594523; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	31	59	60	1	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2013	84	4					441	445		10.1136/jnnp-2012-302547			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	103XH	WOS:000315952300018	23117492				2022-02-06	
J	Achim, AM; Guitton, M; Jackson, PL; Boutin, A; Monetta, L				Achim, Amelie M.; Guitton, Matthieu; Jackson, Philip L.; Boutin, Andree; Monetta, Laura			On What Ground Do We Mentalize? Characteristics of Current Tasks and Sources of Information That Contribute to Mentalizing Judgments	PSYCHOLOGICAL ASSESSMENT			English	Article						theory of mind; mentalizing; attributions; social cognition; ecological validity	HIGH-FUNCTIONING AUTISM; TEMPORO-PARIETAL JUNCTION; TRAUMATIC BRAIN-INJURY; SOCIAL COGNITION; ASPERGER-SYNDROME; EMOTION RECOGNITION; SPECTRUM CONDITIONS; EMPATHIC ACCURACY; MIND IMPAIRMENTS; DAMAGED PATIENTS	Mentalizing is an aspect of social cognition that is garnering increased interest. Although a wide variety of experimental tasks are available to measure mentalizing abilities in adults, the most widely used tasks typically focus on specific aspects of mentalizing, and mentalizing judgments are performed based on a limited set of information about the agent and the context. Here, we present the Eight Sources of Information Framework (8-SIF), a model that describes the sources of information that can contribute to mentalizing judgments both in real life and in the context of mentalizing tasks. This model is then used to systematically review and analyze the most classical mentalizing tasks, with a particular focus on the sources of information provided as a basis for mentalizing judgments in these tasks. Next, mentalizing tasks with improved ecological validity are also examined, highlighting the greater richness and diversity of the sources of information provided in such tasks relative to the most classical tasks. We believe that the 8-SIP is an important first step to increase awareness of the sources of information that can contribute to mentalizing judgments and to favor investigations of the potential impact of these sources of information on mentalizing performance in different populations.	[Achim, Amelie M.; Guitton, Matthieu; Jackson, Philip L.; Boutin, Andree; Monetta, Laura] Univ Laval, Inst Univ Sante Mentale Quebec, Ctr Rech, Quebec City, PQ, Canada; [Achim, Amelie M.] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada; [Guitton, Matthieu] Univ Laval, Dept Otorhinolaryngol & Ophtalmol, Quebec City, PQ, Canada; [Jackson, Philip L.] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada; [Boutin, Andree; Monetta, Laura] Univ Laval, Dept Readapt, Quebec City, PQ, Canada		Achim, AM (corresponding author), Inst Univ Sante Mentale Quebec, Ctr Rech, Quebec F-4500 2601 Canardiere, Quebec City, PQ, Canada.	amelie.achim@crulrg.ulaval.ca	Monetta, Laura/AAK-7657-2020	Jackson, Philip/0000-0001-8991-3217			Baddeley A., 2009, MEMORY; Barnes JL, 2009, AUTISM RES, V2, P148, DOI 10.1002/aur.79; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bazin N, 2009, PSYCHIAT RES, V167, P28, DOI 10.1016/j.psychres.2007.12.010; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beaumont R, 2006, AUTISM, V10, P365, DOI 10.1177/1362361306064416; BLESS H, 2004, SOCIAL COGNITION IND; Brunet-Gouet E, 2011, PSYCHIAT RES, V190, P23, DOI 10.1016/j.psychres.2010.11.029; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Champagne-Lavau Maud, 2009, Cogn Neuropsychiatry, V14, P217, DOI 10.1080/13546800903004114; CHANDLER M, 1989, CHILD DEV, V60, P1263, DOI 10.1111/j.1467-8624.1989.tb04001.x; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Cutting AL, 1999, CHILD DEV, V70, P853, DOI 10.1111/1467-8624.00061; Dziobek I, 2006, J AUTISM DEV DISORD, V36, P623, DOI 10.1007/s10803-006-0107-0; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; FONAGY P, 1991, INFANT MENT HEALTH J, V12, P201, DOI 10.1002/1097-0355(199123)12:3<201::AID-IMHJ2280120307>3.0.CO;2-7; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Giora R, 1999, HUMOR, V12, P425, DOI 10.1515/humr.1999.12.4.425; Golan O, 2006, SOC NEUROSCI-UK, V1, P111, DOI 10.1080/17470910600980986; GOPNIK A, 1988, CHILD DEV, V59, P26, DOI 10.2307/1130386; Green MF, 2008, SCHIZOPHRENIA BULL, V34, P1211, DOI 10.1093/schbul/sbm145; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Hasson U, 2008, NEURON, V57, P452, DOI 10.1016/j.neuron.2007.12.009; Heavey L, 2000, J AUTISM DEV DISORD, V30, P225, DOI 10.1023/A:1005544518785; ICKES W, 1990, J PERS SOC PSYCHOL, V59, P730, DOI 10.1037/0022-3514.59.4.730; Keysar B, 2000, PSYCHOL SCI, V11, P32, DOI 10.1111/1467-9280.00211; Keysers Christian, 2009, P3, DOI 10.1007/978-1-59745-479-7_1; Klin A, 2000, J CHILD PSYCHOL PSYC, V41, P831, DOI 10.1111/1469-7610.00671; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Meins E, 2002, CHILD DEV, V73, P1715, DOI 10.1111/1467-8624.00501; Mendelsohn A, 2009, LEARN MEMORY, V16, P142, DOI 10.1101/lm.1157709; Mitchell JP, 2006, BRAIN RES, V1079, P66, DOI 10.1016/j.brainres.2005.12.113; Nili U, 2010, NEURON, V66, P949, DOI 10.1016/j.neuron.2010.06.009; Ouellet J, 2010, J INT NEUROPSYCH SOC, V16, P287, DOI 10.1017/S1355617709991329; Pell MD, 2009, J NONVERBAL BEHAV, V33, P107, DOI 10.1007/s10919-008-0065-7; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.2307/1130734; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Pijnenborg GHM, 2009, J INT NEUROPSYCH SOC, V15, P239, DOI 10.1017/S1355617709090341; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Saxe R, 2005, NEUROPSYCHOLOGIA, V43, P1391, DOI 10.1016/j.neuropsychologia.2005.02.013; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; TULVING E, 1984, BEHAV BRAIN SCI, V7, P223, DOI 10.1017/S0140525X0004440X; Vanhalle C, 2000, APHASIOLOGY, V14, P1127, DOI 10.1080/02687030050174665; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Wellman HM, 2004, CHILD DEV, V75, P523, DOI 10.1111/j.1467-8624.2004.00691.x; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	63	59	59	1	38	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2013	25	1					117	126		10.1037/a0029137			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	104EH	WOS:000315974000011	22731676				2022-02-06	
J	Esposito, E; Cuzzocrea, S				Esposito, Emanuela; Cuzzocrea, Salvatore			Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Glial cells; N-acylethanolamine; neuroprotection; spinal cord	PERIPHERAL CANNABINOID RECEPTOR; FATTY-ACID AMIDES; MAST-CELLS; N-ACYLETHANOLAMINES; ENDOCANNABINOID SYSTEM; ACUTE-INFLAMMATION; CEREBRAL-ISCHEMIA; GROWTH-FACTOR; CB2 RECEPTOR; EYE TISSUES	The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this N-acylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.	[Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy		Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it		Cuzzocrea, Salvatore/0000-0001-6131-3690	PON "RC"Ministry of Education, Universities and Research (MIUR) [01_02512]	This study was partially supported by PON "R&C" 01_02512, 2007-2013.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Annuzzi G, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-43; Artmann A, 2008, BBA-MOL CELL BIOL L, V1781, P200, DOI 10.1016/j.bbalip.2008.01.006; Balvers MGJ, 2009, J CHROMATOGR B, V877, P1583, DOI 10.1016/j.jchromb.2009.04.010; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Benvenuti F, 1968, Boll Soc Ital Biol Sper, V44, P809; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bischoff SC, 2009, SEMIN IMMUNOPATHOL, V31, P185, DOI 10.1007/s00281-009-0165-4; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; Cerrato S, 2010, VET IMMUNOL IMMUNOP, V133, P9, DOI 10.1016/j.vetimm.2009.06.011; Chapman KD, 2000, CHEM PHYS LIPIDS, V108, P221, DOI 10.1016/S0009-3084(00)00198-5; Chapman KD, 2004, PROG LIPID RES, V43, P302, DOI 10.1016/j.plipres.2004.03.002; Chen J, 2005, BIOCHEM BIOPH RES CO, V330, P1062, DOI 10.1016/j.bbrc.2005.03.095; COBURN AF, 1954, J EXP MED, V100, P425, DOI 10.1084/jem.100.5.425; Conigliaro R, 2011, MINERVA MED, V102, P141; Conti S, 2002, BRIT J PHARMACOL, V135, P181, DOI 10.1038/sj.bjp.0704466; Costa B, 2002, BRIT J PHARMACOL, V137, P413, DOI 10.1038/sj.bjp.0704900; D'Agostino G, 2012, NEUROPSYCHOPHARMACOL, V37, P1784, DOI 10.1038/npp.2012.25; D'Argenio G, 2007, J MOL MED, V85, P523, DOI 10.1007/s00109-007-0192-3; Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50; Eberlein B, 2008, J EUR ACAD DERMATOL, V22, P73, DOI 10.1111/j.1468-3083.2007.02351.x; Eklund KK, 2007, IMMUNOL REV, V217, P38, DOI 10.1111/j.1600-065X.2007.00504.x; Enna S.J., 2009, XPHARM COMPREHENSIVE, P1; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Figueiredo C, 2008, J NEUROCHEM, V107, P73, DOI 10.1111/j.1471-4159.2008.05577.x; Franklin A, 2003, J NEUROSCI, V23, P7767; GANLEY OH, 1958, J LAB CLIN MED, V51, P709; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Ghafouri N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027257; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Guida G., 2010, DOLOR, V25, P35; Guindon J, 2006, EUR J PHARMACOL, V550, P68, DOI 10.1016/j.ejphar.2006.08.045; Harvima IT, 2008, ARCH DERMATOL RES, V300, P461, DOI 10.1007/s00403-008-0874-x; Hoareau L, 2009, OBESITY, V17, P431, DOI 10.1038/oby.2008.591; Holdsworth SR, 2008, J AM SOC NEPHROL, V19, P2254, DOI 10.1681/ASN.2008010015; Ito Akihiko, 2008, Journal of Smooth Muscle Research, V44, P83, DOI 10.1540/jsmr.44.83; Izzo AA, 2008, J MOL MED, V86, P89, DOI 10.1007/s00109-007-0248-4; Jacobsson SOP, 2001, BRIT J PHARMACOL, V132, P1743, DOI 10.1038/sj.bjp.0704029; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Jumpertz R, 2011, J CLIN ENDOCR METAB, V96, P787, DOI 10.1210/jc.2010-2028; Kallendrusch S., 2010, P ICRS 2010 20 ANN S; Koch M, 2011, NEUROTOX RES, V19, P330, DOI 10.1007/s12640-010-9166-2; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; Kumar V, 2010, MOL IMMUNOL, V48, P14, DOI 10.1016/j.molimm.2010.07.009; Lambert DM, 1999, CURR MED CHEM, V6, P757; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; LONG DA, 1956, LANCET, V270, P464; Lundequist A, 2011, CELL MOL LIFE SCI, V68, P965, DOI 10.1007/s00018-010-0587-0; Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Moon TC, 2010, MUCOSAL IMMUNOL, V3, P111, DOI 10.1038/mi.2009.136; Moriconi A, 2010, CURR MED CHEM, V17, P1411, DOI 10.2174/092986710790980069; Muccio GG, 2008, ANAL BIOCHEM, V373, P220, DOI 10.1016/j.ab.2007.09.030; Muccioli GG, 2008, NEUROPHARMACOLOGY, V54, P16, DOI 10.1016/j.neuropharm.2007.05.015; Murillo-Rodniguez E, 2006, LIFE SCI, V79, P30, DOI 10.1016/j.lfs.2005.12.028; Naccarato M, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-47; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; O'Sullivan SE, 2010, IMMUNOBIOLOGY, V215, P611, DOI 10.1016/j.imbio.2009.09.007; Ozalp A, 2009, ANAL BIOCHEM, V395, P68, DOI 10.1016/j.ab.2009.08.005; PERLIK F, 1971, ACTA PHYSIOL HUNG, V39, P395; Petrosino S., 2008, 33rd World Small Animal Veterinary Association Congress, Dublin, Ireland, 20-24 August 2008, P707; Petrosino S, 2010, ALLERGY, V65, P698, DOI 10.1111/j.1398-9995.2009.02254.x; Petrosino S., 2009, HDB NEUROCHEMISTRY M, P75, DOI [10.1007/978-0-387-30378-9_5, DOI 10.1007/978-0-387-30378-9_5]; Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011; Petrosino S, 2010, BIOCHIMIE, V92, P724, DOI 10.1016/j.biochi.2010.01.006; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Re G, 2007, VET J, V173, P21, DOI 10.1016/j.tvjl.2005.10.003; Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401; Sasso O, 2012, PAIN, V153, P33, DOI 10.1016/j.pain.2011.08.010; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Schreiber D, 2007, ANAL BIOCHEM, V361, P162, DOI 10.1016/j.ab.2006.11.027; Scuderi C, 2011, J CELL MOL MED, V15, P2664, DOI 10.1111/j.1582-4934.2011.01267.x; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Wise LE, 2008, NEUROPHARMACOLOGY, V54, P181, DOI 10.1016/j.neuropharm.2007.06.003	94	59	61	0	6	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2013	12	1					55	61		10.2174/1871527311312010010			7	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	104MB	WOS:000315996300010	23394520				2022-02-06	
J	Cantor, JB; Bushnik, T; Cicerone, K; Dijkers, MP; Gordon, W; Hammond, FM; Kolakowsky-Hayner, SA; Lequerica, A; Nguyen, M; Spielman, LA				Cantor, Joshua B.; Bushnik, Tamara; Cicerone, Keith; Dijkers, Marcel P.; Gordon, Wayne; Hammond, Flora M.; Kolakowsky-Hayner, Stephanie A.; Lequerica, Anthony; Michael Nguyen; Spielman, Lisa A.			Insomnia, Fatigue, and Sleepiness in the First 2 Years After Traumatic Brain Injury: An NIDRR TBI Model System Module Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic brain injury; comorbidity; fatigue; insomnia; sleep; traumatic brain injury	LATENCY TEST MSLT; GENERAL-POPULATION; DAYTIME SLEEPINESS; OBJECTIVE MEASURES; HYGIENE PRACTICES; QUALITY INDEX; RISK-FACTORS; HEAD-INJURY; PREVALENCE; NEUROENDOCRINE	Objective: To determine the prevalence of insomnia and posttraumatic brain injury (TBI) fatigue (PTBIF) in individuals with moderate to severe TBI, to explore the relationship between PTBIF and insomnia and their association with outcomes. Design: Cross-sectional study. Setting: Five National Institute of Disability and Rehabilitation Research TBI Model Systems. Participants: Three hundred thirty-four individuals with TBI who completed 1-year (n = 213) or 2-year (n = 121) follow-up interviews between 2008 and 2012. Main Outcome Results: Insomnia occurred in 11% to 24% and PTBIF in 33% to 44% of the individuals. Insomnia and fatigue were both related to sleep disturbance, sleep hygiene, satisfaction with life, anxiety, and depression. PTBIF was associated with greater disability and sleepiness. Insomnia without fatigue was rare (2%-3%) but PTBIF without insomnia occurred in 21% to 23% of the individuals. Comorbidity occurred in 9% to 22% of the individuals. Conclusions: Although PTBIF and insomnia are closely related and both associated with poorer quality of life, they are affected independently by a variety of factors, especially psychopathology and sleep quality. A majority of individuals with PTBIF do not have insomnia; and PTBIF appears to be related to disability severity and daytime sleepiness, where insomnia is not. Demographic and injury variables are not strong predictors of insomnia or PTBIF.	[Cantor, Joshua B.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Bushnik, Tamara] NYU Langone Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Cicerone, Keith] Johnson Rehabil Inst, Edison, NJ USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Bushnik, Tamara; Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Lequerica, Anthony] Kessler Fdn Res Ctr, W Orange, NJ USA; [Lequerica, Anthony] Univ Med & Dent New Jersey, Newwark, NJ USA		Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mountsinai.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019; Heinemann, Allen W/K-6283-2012	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Heinemann, Allen W/0000-0003-2782-7326; Bushnik, Tamara/0000-0003-3328-257X; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research [H133A070033, H133A070038, H133A070042, H133A070037, H133A070030]	This research was funded by National Institute on Disability and Rehabilitation Research grants H133A070033, H133A070038, H133A070042, H133A070037, and H133A070030 and carried out by Traumatic Brain Injury Model Systems Centers. The authors thank all the data collectors and participants in this research for their time and effort.	*AM AC SLEEP MED, 2001, INT CLASS SLEEP DIS; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bastien CH, 2000, J SLEEP RES, V9, P49, DOI 10.1046/j.1365-2869.2000.00182.x; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Belanger L, 2004, J ANXIETY DISORD, V18, P561, DOI 10.1016/S0887-6185(03)00031-8; BELZA BL, 1995, J RHEUMATOL, V22, P639; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Brown FC, 2002, BEHAV MED, V28, P33, DOI 10.1080/08964280209596396; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Buysse D J, 1989, Psychiatry Res, V28, P193; Buysse DJ, 2008, J CLIN SLEEP MED, V4, P563; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chan-Chee C, 2011, REV EPIDEMIOL SANTE, V59, P409, DOI 10.1016/j.respe.2011.05.005; Collen J, 2012, CHEST; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P1126, DOI 10.1016/j.apmr.2011.02.017; Corrigan J., 2000, CTR OUTCOME MEASUREM; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Jansson-Frojmark M, 2008, SLEEP, V31, P881, DOI 10.1093/sleep/31.6.881; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LeBlanc M, 2009, SLEEP, V32, P1027, DOI 10.1093/sleep/32.8.1027; Leger D, 2011, SLEEP MED, V12, P454, DOI 10.1016/j.sleep.2010.12.012; LICHSTEIN KL, 1994, SLEEP, V17, P693, DOI 10.1093/sleep/17.8.693; Mastin DF, 2006, J BEHAV MED, V29, P223, DOI 10.1007/s10865-006-9047-6; Morin CM, 2012, LANCET, V379, P1129, DOI 10.1016/S0140-6736(11)60750-2; MORIN CM, 1989, PSYCHOL AGING, V4, P290, DOI 10.1037/0882-7974.4.3.290; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Ohayon MM, 2012, J PSYCHIATR RES, V46, P422, DOI 10.1016/j.jpsychires.2011.06.008; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Seicean S, 2011, SLEEP, V34, P1021, DOI 10.5665/SLEEP.1154; Singareddy R, 2012, SLEEP MED, V13, P346, DOI 10.1016/j.sleep.2011.10.033; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Taylor DJ, 2011, BEHAV SLEEP MED, V9, P107, DOI 10.1080/15402002.2011.557992; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wright J., 2000, CTR OUTCOME MEASUREM; Yang CM, 2010, J HEALTH PSYCHOL, V15, P147, DOI 10.1177/1359105309346342; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	63	59	59	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E1	E14		10.1097/HTR.0b013e318270f91e			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200001	23131966				2022-02-06	
J	Fogelberg, DJ; Hoffman, JM; Dikmen, S; Temkin, NR; Bell, KR				Fogelberg, Donald J.; Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy R.; Bell, Kathleen R.			Association of Sleep and Co-Occurring Psychological Conditions at 1 Year After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Comorbidity; Rehabilitation; Sleep	CHRONIC INSOMNIA; QUALITY INDEX; DEPRIVATION; DISTURBANCE; PAIN; PERFORMANCE; DEPRESSION; DISORDER; THERAPY; SCALE	Fogelberg DJ, Hoffman JM, Dikmen S. Temkin NR, Bell KR. Association of sleep and co-occurring psychological conditions at 1 year after traumatic brain injury. Arch Phys Med Rehabil 2012;93: 1313-8. Objectives: To compare individuals' sleep 1 year after traumatic brain injury (TBI) with that of a healthy comparison group, and examine the relationship between sleep, co-occurring conditions, and functional status in those with TBI. Design occurred at 1 year after TBI. Setting: Inpatient acute rehabilitation for TBI and community follow-up at 1 year postinjury. Participants: Individuals with TBI (N = 174) were recruited from consecutive admissions to an inpatient rehabilitation unit and enrolled into the TBI Model Systems study. Participant mean age was 38, and mean Glasgow Coma Scale score on admission was 9.3. Seventy-eight percent of the sample were men. Interventions: None. Main Outcome Measures: Sleep was assessed with the Pittsburgh Seep Quality Index (PSQI). Depression, anxiety, and pain were measured with the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 Scale, and an analog pain rating scale, respectively. Results: Participants with TBI reported significantly greater sleep difficulties than the healthy comparison group. Forty-four percent of participants with TBI reported significant sleep problem; (PSQI>5). Participants with 1 or more co-occurring conditions (depression, pain, or anxiety) had significantly worse sleep than those without such a condition. The highest level of sleep problems was reported by participants with multiple co-occurring conditions. Sleep problems were also associated with poor functional status. Conclusions: Sleep difficulties are a frequent problem at 1 year after TBI, and often co-occur with depression, anxiety, and pain. Assessment and treatment of sleep difficulties should be included in clinical practice. Future research on the potential causal relationship among co-occurring conditions may assist in additional intervention planning.	[Fogelberg, Donald J.; Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy R.; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Fogelberg, DJ (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	fogelber@uw.edu		Bell, Kathleen/0000-0002-0928-2046; Fogelberg, Donald/0000-0002-8188-4252	National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems [HI33A070032]	Supported by the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems (grant no. HI33A070032).	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Baker FC, 1999, J PSYCHOSOM RES, V47, P335, DOI 10.1016/S0022-3999(99)00017-3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; Corrigan J., 2000, SATISFACTION LIFE SC; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hamilton BB, 1987, REHABILITATION OUTCO; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harrison Y, 2000, J EXP PSYCHOL-APPL, V6, P236, DOI 10.1037//1076-898X.6.3.236; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Jensen MP, 2011, HDB PAIN ASSESSMENT; Johnson EO, 1998, SLEEP, V21, P178, DOI 10.1093/sleep/21.2.178; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roehrs T, 2006, SLEEP, V29, P145, DOI 10.1093/sleep/29.2.145; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Venkatraman V, 2007, SLEEP, V30, P603, DOI 10.1093/sleep/30.5.603; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wright J, 2000, DISABILITY RATING SC; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	44	59	60	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1313	1318		10.1016/j.apmr.2012.04.031			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700003	22840828				2022-02-06	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Haitsma, IK; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Haitsma, Ian K.; Ribbers, Gerard M.			A Prospective Study on Employment Outcome 3 Years After Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Prognosis; Prospective studies; Rehabilitation	FUNCTIONAL ASSESSMENT MEASURE; ASSESSMENT MEASURE FIM+FAM; GLASGOW COMA SCALE; INTERRATER RELIABILITY; HEAD-INJURY; FOLLOW-UP; RETURN; WORK; TBI; REHABILITATION	Objectives: To evaluate the employment outcome in patients with moderate to severe traumatic brain injury (TBI) and to identify which patients are at risk of unemployment 3 years after injury. Design: Prospective cohort study. Setting: Patients with moderate and severe TBI discharged from the neurosurgery departments of 3 level 1 trauma centers in The Netherlands. Participants: Patients aged 18 to 65 years (N=113; mean age +/- SD, 33.2 +/- 13.1y; 73% men) who were hospitalized with moderate (26% of patients) to severe (74% of patients) TBI. Interventions: Not applicable. Main Outcome Measures: The main outcome measure was employment status. Potential predictors included patient characteristics, injury severity factors, functional outcome measured at discharge from the acute hospital with the Glasgow Outcome Scale (GOS), Barthel Index (BO, and FIM, and cognitive functioning measured with the Functional Assessment Measure (FAM). Results: Ninety-four patients (83%) completed the 3-year follow-up. The employment rate dropped from 80% preinjury to 15% at 3 months postinjury and gradually increased to 55% after 3 years. The employment rate significantly increased from 3 months up to I year, but it did not change significantly from 1 to 3 years postinjury. Age, length of hospital stay, discharge to a nursing home (vs home), psychiatric symptoms, and BI, GOS, FIM, and FAM scores were found to be significant univariate determinants for employment status. By using multiple logistic regression analysis, the FAM score (adjusted odds ratio 1.1; P<.000) and psychiatric symptoms (adjusted odds ratio .08; P<.019) were selected as independent predictors for employment status. A FAM cutoff score of less than 65 to identify patients at risk of long-term unemployment had a good diagnostic value. Conclusions: Patients with TBI with psychiatric symptoms and impaired cognitive functioning at hospital discharge are at the highest risk of long-term unemployment. These factors should be the focus of vocational rehabilitation. (c) 2012 by the American Congress of Rehabilitation Medicine	[Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Erasmus MC, Dept Rehabil Med & Phys Therapy, Rotterdam, Netherlands; [Haitsma, Ian K.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Ribbers, GM (corresponding author), Rotterdam NeuroRehabil Res, POB 23181, NL-3001 KD Rotterdam, Netherlands.	g.ribbers@rijndam.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404			Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Collin C, 1988, Int Disabil Stud, V10, P61; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wright J, CTR OUTCOME MEASUREM	36	59	60	1	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2012	93	6					993	999		10.1016/j.apmr.2012.01.018			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	952JQ	WOS:000304789200011	22502806				2022-02-06	
J	Baker, DG; Nash, WP; Litz, BT; Geyer, MA; Risbrough, VB; Nievergelt, CM; O'Connor, DT; Larson, GE; Schork, NJ; Vasterling, JJ; Hammer, PS; Webb-Murphy, JA				Baker, Dewleen G.; Nash, William P.; Litz, Brett T.; Geyer, Mark A.; Risbrough, Victoria B.; Nievergelt, Caroline M.; O'Connor, Daniel T.; Larson, Gerald E.; Schork, Nicholas J.; Vasterling, Jennifer J.; Hammer, Paul S.; Webb-Murphy, Jennifer A.		MRS Team	Predictors of Risk and Resilience for Posttraumatic Stress Disorder Among Ground Combat Marines: Methods of the Marine Resiliency Study	PREVENTING CHRONIC DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; US MILITARY COHORT; MENTAL-HEALTH; PTSD; IRAQ; DEPLOYMENT; WAR; AFGHANISTAN; DIAGNOSES; SYMPTOMS	The Marine Resiliency Study (MRS) is a prospective study of factors predictive of posttraumatic stress disorder (PTSD) among approximately 2,600 Marines in 4 battalions deployed to Iraq or Afghanistan. We describe the MRS design and predeployment participant characteristics. Starting in 2008, our research team conducted structured clinical interviews on Marine bases and collected data 4 times: at predeployment and at 1 week, 3 months, and 6 months postdeployment. Integrated with these data are medical and career histories from the Career History Archival Medical and Personnel System (CHAMPS) database. The CHAMPS database showed that 7.4% of the Marines enrolled in MRS had at least 1 mental health diagnosis. Of enrolled Marines, approximately half (51.3%) had prior deployments. We found a moderate positive relationship between deployment history and PTSD prevalence in these baseline data.	[Baker, Dewleen G.; Nash, William P.; Nievergelt, Caroline M.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Litz, Brett T.; Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Geyer, Mark A.; Risbrough, Victoria B.; O'Connor, Daniel T.] Univ Calif San Diego, San Diego, CA 92103 USA; [Larson, Gerald E.] USN, Hlth Res Ctr, San Diego, CA 92152 USA; [Schork, Nicholas J.] Scripps Translat Sci Inst, La Jolla, CA USA; [Hammer, Paul S.] Def Ctr Excellence Stress & Mental Hlth Traumat B, Arlington, VA USA; [Webb-Murphy, Jennifer A.] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92152 USA		Baker, DG (corresponding author), VA San Diego Healthcare Syst, VA Ctr Stress & Mental Hlth 116A, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	dgbaker@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; Litz, Brett/0000-0002-0479-8887; Schork, Nicholas/0000-0003-0920-5013; Nievergelt, Caroline/0000-0001-5766-8923	VA Health Service Research and Development [SDR 09-0128]; Marine Corps and Navy Bureau of Medicine and Surgery; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	This study was funded by VA Health Service Research and Development project no. SDR 09-0128 and by the Marine Corps and Navy Bureau of Medicine and Surgery. We acknowledge special assistance from members of VA Center of Excellence for Stress and Mental Health, VA San Diego Research and Fiscal Services, and the 1st Marine Division and Navy Medicine at 29 Palms and at Camp Pendleton. Acknowledged also are core MRS team members Amela Ahmetovic, Nilima Biswas, William H. Black, Mahalah R. Buell, Teresa Carper, Andrew De La Rosa, Benjamin Dickstein, Heather Ellis-Johnson, Caitlin Fernandes, Susan Fesperman, David Fink, Summer Fitzgerald, Steven Gerard, Abigail A. Goldsmith, Gali Goldwaser, Patricia Gorman, Jorge A. Gutierrez, John A. Hall, Jr, Laura Harder, Pia Heppner, Alexandra Kelada, Jennifer Lemmer, Morgan LeSuer-Mandernack, Manjula Mahata, Arame Motazedi, Elin Olsson, Ines Pandzic, Anjana H. Patel, Dhaval H. Patel, Sejal Patel, Shetal M. Patel, Taylor Perin-Kash, James O.E. Pittman, Stephanie Raducha, Brenda Thomas, Elisa Tsan, Maria Anna Valencerina, Chelsea Wallace, Kate Yurgil, Kuixing Zhang, and the many intermittent on-site MRS clinician-interviewers and data collection staff.	Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; Baker DG, 2009, MIL MED, V174, P773; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Brinton TJ, 1996, HYPERTENSION, V28, P599, DOI 10.1161/01.HYP.28.4.599; Defense Manpower Data Center, 2011, GLOB WAR TERR CAS MI; Highfill-McRoy RM, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-88; Institute of Medicine, 2008, TREATM POSTTR STRESS; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V304, P1427, DOI 10.1001/jama.2010.1327; Larson GE, 2011, PSYCHIAT SERV, V62, P15, DOI 10.1176/ps.62.1.pss6201_0015; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Litz BT, 2009, CLIN PSYCHOL REV, V29, P695, DOI 10.1016/j.cpr.2009.07.003; Magruder KM, 2009, PSYCHIAT ANN, V39, P778, DOI 10.3928/00485713-20090728-04; Nash WP, 2010, ARCH PHYS MED REHAB, V91, P1673, DOI 10.1016/j.apmr.2010.06.035; Peleg T, 2006, CNS SPECTRUMS, V11, P589, DOI 10.1017/S109285290001364X; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Risbrough V, 2010, CURR TOP BEHAV NEURO, V2, P205, DOI 10.1007/7854_2009_11; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seasholtz TM, 2006, HYPERTENSION, V47, P937, DOI 10.1161/01.HYP.0000217364.45622.f0; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Talilien T, 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	25	59	59	0	25	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1545-1151			PREV CHRONIC DIS	Prev. Chronic Dis.	MAY	2012	9								110134	10.5888/pcd9.110134			11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	977HU	WOS:000306648100005	22575082	Green Published, Green Submitted			2022-02-06	
J	O'Connell, KM; Littleton-Kearney, MT; Bridges, E; Bibb, SC				O'Connell, Karen M.; Littleton-Kearney, Marguerite T.; Bridges, Elizabeth; Bibb, Sandra C.			Evaluating the Joint Theater Trauma Registry as a Data Source to Benchmark Casualty Care	MILITARY MEDICINE			English	Article							OPERATION-ENDURING-FREEDOM; SEVERE HEAD-INJURY; BRAIN-INJURY; SECONDARY INSULTS; PROGNOSTIC VALUE; BLOOD-PRESSURE; HYPOTHERMIA; HYPOXIA; IMPACT; DEATH	Just as data from civilian trauma registries have been used to benchmark and evaluate civilian trauma care, data contained within the Joint Theater Trauma Registry (JTTR) present a unique opportunity to benchmark combat care. Using the iterative steps of the benchmarking process, we evaluated data in the JTTR for suitability and established benchmarks for 24-hour mortality in casualties with polytrauma and a moderate or severe blunt traumatic brain injury (TBI). Mortality at 24 hours was greatest in those with polytrauma and a severe blunt TBI. No mortality was seen in casualties with polytrauma and a moderate blunt TBI. Secondary insults after TBI, especially hypothermia and hypoxemia, increased the odds of 24-hour mortality. Data contained in the JTTR were found to be suitable for establishing benchmarks. JTTR data may be useful in establishing benchmarks for other outcomes and types of combat injuries.	[O'Connell, Karen M.; Littleton-Kearney, Marguerite T.; Bibb, Sandra C.] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA; [Bridges, Elizabeth] Univ Washington, Sch Nursing, Seattle, WA 98195 USA		O'Connell, KM (corresponding author), Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				Uniformed Services University of the Health Sciences	Funding for this study was received from the Uniformed Services University of the Health Sciences Intramural Grants.	American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; American College of Surgeons Committee on Trauma, 1999, RES OPT CAR INJ PAT; American Society for Quality, BENCHM; American Trauma Society, TRAUM REG COURS; Arthurs Z, 2006, AM J SURG, V191, P610, DOI 10.1016/j.amjsurg.2006.02.010; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CDC, INJ PREV CONTR TRAUM; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clarke S P, 2000, Can J Nurs Res, V32, P109; De Jong Marla J, 2008, J Trauma Nurs, V15, P174, DOI 10.1097/01.JTN.0000343322.70334.12; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; DeWitt D S, 1995, New Horiz, V3, P376; Doolan Daniel M, 2009, Res Theory Nurs Pract, V23, P203; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Eastridge BJ, 2010, J TRAUMA, V69, pS5, DOI 10.1097/TA.0b013e3181e421f3; Eastridge Brian J, 2009, Am J Surg, V198, P852, DOI 10.1016/j.amjsurg.2009.04.029; Elf K, 2008, NEUROL RES, V30, P1097, DOI 10.1179/174313208X319125; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hess JR, 2008, TRANSFUSION, V48, P1763, DOI 10.1111/j.1537-2995.2008.01743.x; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kowalak JP, 2003, BEST PRACTICES GUIDE; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Nesbitt M, 2010, J TRAUMA, V69, pS162, DOI 10.1097/TA.0b013e3181e45b83; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; U. S. Army Institute of Surgical Research, US ARM I SURG RES JO; United States Army Institute of Surgical Research, JOINT THEAT TRAUM SY, V1; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	41	59	62	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAY	2012	177	5					546	552		10.7205/MILMED-D-11-00422			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936XK	WOS:000303623100013	22645881	Bronze			2022-02-06	
J	Lutton, C; Young, YW; Williams, R; Meedeniya, ACB; Mackay-Sim, A; Goss, B				Lutton, Cameron; Young, Yun Wai; Williams, Richard; Meedeniya, Adrian C. B.; Mackay-Sim, Alan; Goss, Ben			Combined VEGF and PDGF Treatment Reduces Secondary Degeneration after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; degeneration; immunohistochemistry; inflammation; plasma membrane; synaptic loss and deafferentation; traumatic brain injury; vascular reactivity	ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL FORMATION; CELLS; INFLAMMATION; ANGIOGENESIS; CONTUSION; SYSTEM; BB; REGENERATION; MACROPHAGES	Trauma to the spinal cord creates an initial physical injury damaging neurons, glia, and blood vessels, which then induces a prolonged inflammatory response, leading to secondary degeneration of spinal cord tissue, and further loss of neurons and glia surrounding the initial site of injury. Angiogenesis is a critical step in tissue repair, but in the injured spinal cord angiogenesis fails; blood vessels formed initially later regress. Stabilizing the angiogenic response is therefore a potential target to improve recovery after spinal cord injury (SCI). Vascular endothelial growth factor (VEGF) can initiate angiogenesis, but cannot sustain blood vessel maturation. Platelet-derived growth factor (PDGF) can promote blood vessel stability and maturation. We therefore investigated a combined application of VEGF and PDGF as treatment for traumatic spinal cord injury, with the aim to reduce secondary degeneration by promotion of angiogenesis. Immediately after hemisection of the spinal cord in the rat we delivered VEGF and PDGF and to the injury site. One and 3 months later the size of the lesion was significantly smaller in the treated group compared to controls, and there was significantly reduced gliosis surrounding the lesion. There was no significant effect of the treatment on blood vessel density, although there was a significant reduction in the numbers of macrophages/microglia surrounding the lesion, and a shift in the distribution of morphological and immunological phenotypes of these inflammatory cells. VEGF and PDGF delivered singly exacerbated secondary degeneration, increasing the size of the lesion cavity. These results demonstrate a novel therapeutic intervention for SCI, and reveal an unanticipated synergy for these growth factors whereby they modulated inflammatory processes and created a microenvironment conducive to axon preservation/sprouting.	[Lutton, Cameron; Williams, Richard; Goss, Ben] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane Spine Reference Ctr, Brisbane, Qld 4059, Australia; [Young, Yun Wai; Meedeniya, Adrian C. B.; Mackay-Sim, Alan] Griffith Univ Brisbane, Natl Ctr Adult Stem Cell Res, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld, Australia		Lutton, C (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane Spine Reference Ctr, Musk Ave, Brisbane, Qld 4059, Australia.	c.lutton@qut.edu.au	Williams, Richard P/B-2029-2012; Mackay-Sim, Alan/C-3431-2008; Lutton, Cameron J/H-2020-2011; Goss, Ben/F-1867-2010	Mackay-Sim, Alan/0000-0003-4446-5371; Goss, Ben/0000-0003-0518-1229	Institute of Health and Biomedical Innovation, Queensland University of Technology; National Centre for Adult Stem Cell Research, Griffith University; Australian Department of Health and AgeingAustralian GovernmentDepartment of Health & Ageing; Queensland Government; Queensland Orthopaedic Research Trust	The authors are grateful to The Institute of Health and Biomedical Innovation, Queensland University of Technology, for seed funding, the National Centre for Adult Stem Cell Research, Griffith University, and the Australian Department of Health and Ageing for a Ph.D. stipend for Y.-W.Y. We appreciate the assistance of the animal house staff at the Medical Engineering Research Facility (Queensland University of Technology). B. G. gratefully acknowledges the Queensland Government for a Smart State Fellowship, and the Queensland Orthopaedic Research Trust for ongoing support.	BARD JBL, 1986, J HISTOCHEM CYTOCHEM, V34, P1237, DOI 10.1177/34.9.3734422; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Bezuidenhout L, 2007, J LEUKOCYTE BIOL, V81, P1496, DOI 10.1189/jlb.1106687; Bittner B, 2000, INT J PHARM, V205, P195, DOI 10.1016/S0378-5173(00)00481-6; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; DAYNES RA, 1991, J EXP MED, V174, P1323, DOI 10.1084/jem.174.6.1323; Enge M, 2003, NEUROCHEM RES, V28, P271, DOI 10.1023/A:1022421001288; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GLENN JA, 1992, J ANAT, V180, P109; Hao XJ, 2007, CARDIOVASC RES, V75, P178, DOI 10.1016/j.cardiores.2007.03.028; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Iihara K, 1997, J CEREBR BLOOD F MET, V17, P1097, DOI 10.1097/00004647-199710000-00012; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood-2008-09-176776; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Korpisalo P, 2008, CIRC RES, V103, P1092, DOI 10.1161/CIRCRESAHA.108.182287; Kwon B.K., 2010, J NEUROTRAUM, V27, P1; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Norazit A, 2011, NEUROSCIENCE, V192, P652, DOI 10.1016/j.neuroscience.2011.06.035; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Romero-Sandoval A, 2008, BRAIN RES, V1219, P116, DOI 10.1016/j.brainres.2008.05.004; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Smirkin A, 2010, J CEREBR BLOOD F MET, V30, P603, DOI 10.1038/jcbfm.2009.233; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Tchaikovski V, 2008, ARTERIOSCL THROM VAS, V28, P322, DOI 10.1161/ATVBAHA.107.158022; van Neerven S, 2010, J NEUROTRAUM, V27, P1781, DOI 10.1089/neu.2010.1484; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; WILSON E, 1987, P NATL ACAD SCI USA, V84, P2213, DOI 10.1073/pnas.84.8.2213; Xiyang YB, 2009, J NEUROTRAUM, V26, P275, DOI 10.1089/neu.2007.0374; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	49	59	61	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					957	+		10.1089/neu.2010.1423			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900023	21568693	Green Published			2022-02-06	
J	Foster, AM; Armstrong, J; Buckley, A; Sherry, J; Young, T; Foliaki, S; James-Hohaia, T; Theadom, A; McPherson, KM				Foster, Allison M.; Armstrong, Jonathan; Buckley, Ann; Sherry, Joanne; Young, Tony; Foliaki, Soana; James-Hohaia, Te Miria; Theadom, Alice; McPherson, Kathryn M.			Encouraging family engagement in the rehabilitation process: a rehabilitation provider's development of support strategies for family members of people with traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Acquired brain injury; adult; family needs; interdisciplinary rehabilitation services; neurorehabilitation; program evaluation and quality improvement; TBI	PARTICIPATORY ACTION RESEARCH; SOCIAL SUPPORT; CAREGIVERS; DISTRESS; QUALITY; IMPACT; INTERVENTION; ADOLESCENTS; PREDICTORS; EXPERIENCE	Purpose: After a moderate to severe traumatic brain injury, it is widely recommended that family members be actively engaged in the client's rehabilitation journey because evidence suggests that this is associated with better outcomes. The ability of family members to fully engage in rehabilitation may be hindered by the barriers (logistical and psychological) they encounter. However, rehabilitation services can facilitate family engagement through a person-centred approach that provides support to remove barriers. Limited published guidance exists regarding practical and effective methods for delivering such support. This paper describes how one rehabilitation service has developed an eight-tiered approach. Key messages and implications: Family support is provided by explicit structuring of services to include (i) early engagement, (ii) meeting cultural needs, (iii) keeping families together, (iv) actively listening, (v) active involvement, (vi) education, (vii) skills training, and (viii) support for community re-integration. Implementation of these support strategies are individualised based on the expressed needs of each family. Families report a high level of satisfaction with the service. Conclusion: A practice-based quality improvement model identified challenges, implemented changes, and observed/evaluated the results to successfully develop a multifaceted strategy for supporting families, thereby encouraging their engagement in rehabilitation. Ongoing refinements and evaluation are planned.	[Armstrong, Jonathan; Theadom, Alice; McPherson, Kathryn M.] Auckland Univ Technol, Auckland, New Zealand		Foster, AM (corresponding author), 180 Metcalfe Rd, Auckland 0612, New Zealand.	allison.foster@abi-rehab.co.nz		Theadom, Alice/0000-0003-0351-6216; McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bernat JL, 2009, ANN NY ACAD SCI, V1157, P117, DOI 10.1111/j.1749-6632.2008.04124.x; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Campbell C H, 1988, Rehabil Nurs, V13, P320; Charles N, 2007, NEUROREHABILITATION, V22, P61; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cloninger CR, 2011, J EVAL CLIN PRACT, V17, P371, DOI 10.1111/j.1365-2753.2010.01583.x; Das-Gupta R, 2002, DISABIL REHABIL, V24, P654, DOI 10.1080/09638280110109282; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Esselman PC, 2002, J HEAD TRAUMA REHAB, V17, P257, DOI 10.1097/00001199-200206000-00007; Faleafa Monique, 2009, Pac Health Dialog, V15, P28; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Gauld S, 2011, DISABIL REHABIL, V33, P1901, DOI 10.3109/09638288.2010.550382; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Giuliano K K, 2000, Dimens Crit Care Nurs, V19, P30, DOI 10.1097/00003465-200019010-00008; Gzil F, 2007, DISABIL REHABIL, V29, P1616, DOI 10.1080/09638280701618620; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harwood M, 2010, DISABIL REHABIL, V32, P972, DOI 10.3109/09638281003775378; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jayadevappa R., 2011, OPEN HLTH SERV POLIC, V4, P15, DOI 10.2174/1874924001104010015; Kayes NM, HUMAN TECHNOLOGIES R; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Laroi F, 2003, BRAIN INJURY, V17, P175, DOI 10.1080/0269905021000010140; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Minkler M, 2000, PUBLIC HEALTH REP, V115, P191, DOI 10.1093/phr/115.2.191; Minnes P, 2000, BRAIN INJURY, V14, P737; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Panting A, 1972, REHABILITATION, V38, P33; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Shaw LR, 1997, BRAIN INJURY, V11, P219; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Siegert RJ, 2007, DISABIL REHABIL, V29, P1604, DOI 10.1080/09638280701618794; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Turner-Stokes L, ENGAGING HEARTS MIND; White GW, 2004, ARCH PHYS MED REHAB, V85, pS3, DOI 10.1016/j.apmr.2003.08.109	44	59	60	0	27	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2012	34	22					1855	1862		10.3109/09638288.2012.670028			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	013FG	WOS:000309290700002	22489631				2022-02-06	
J	Ma, HY; Yu, B; Kong, L; Zhang, YY; Shi, YX				Ma, Haiying; Yu, Bo; Kong, Li; Zhang, Yuanyuan; Shi, Yuxiu			Neural Stem Cells Over-Expressing Brain-Derived Neurotrophic Factor (BDNF) Stimulate Synaptic Protein Expression and Promote Functional Recovery Following Transplantation in Rat Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Neural stem cell; Traumatic brain injury; Transplantation; Brain-derived neurotrophic factor; Synaptogenesis	RETINAL GANGLION-CELLS; SPINAL-CORD; GROWTH-FACTOR; GENE-TRANSFER; GAP-43; DIFFERENTIATION; SYNAPTOPHYSIN; SURVIVAL; HIPPOCAMPUS; INCREASES	Brain-derived neurotrophic factor (BDNF) plays an essential regulatory role in the survival and differentiation of various neural cell types during brain development and after injury. In this study, we used neural stem cells (NSCs) genetically modified to encode BDNF gene (BDNF/NSCs) and naive NSCs transplantation and found that BDNF/NSCs significantly improved neurological motor function following traumatic brain injury (TBI) on selected behavioral tests. Our data clearly demonstrate that the transplantation of BDNF/NSCs causes overexpression of BDNF in the brains of TBI rats. The number of surviving engrafted cells and the proportion of engrafted cells with a neuronal phenotype were significantly greater in BDNF/NSCs than in naive NSCs-transplanted rats. The expression of pre- and post-synaptic proteins and a regeneration-associated gene in the BDNF/NSCs-transplanted rats was significantly increased compared to that in NSCs-transplanted rats, especially at the early stage of post-transplantation. These data suggest that neurite growth and overexpression of synaptic proteins in BDNF/NSC-stransplanted rats are associated with the overexpression of BDNF, which is hypothesized to be one of the mechanisms underlying the improved functional recovery in motor behavior at the early stage of cell transplantation following TBI. Therefore, the protective effect of the BDNF-modified NSCs transplantation is greater than that of the naive NSCs transplantation.	[Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Dept Histol & Embryol, Shenyang, Liaoning, Peoples R China; [Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Inst Pathol & Pathophysiol, Shenyang, Liaoning, Peoples R China; [Ma, Haiying; Kong, Li; Zhang, Yuanyuan] Dalian Med Univ, Dept Histol & Embryol, Dalian, Liaoning, Peoples R China; [Yu, Bo] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China; [Zhang, Yuanyuan] Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA		Shi, YX (corresponding author), China Med Univ, Dept Histol & Embryol, Shenyang, Liaoning, Peoples R China.	yuxishi@163.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30850001]; Education Bureau, Liaoning Province, China [20072167, 2008779, 2008851]	We thank Professor Xuehu Ma from the Stem Cell and Tissue Engineering Laboratory of the Dalian University of Technology for his support in culturing the NSCs. This work was supported by grants No. 30850001 from the National Nature Science Foundation of China and Nos. 20072167, 2008779 and 2008851 from the S&T Research Project of Education Bureau, Liaoning Province, China.	AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; AHMED S, 1995, J NEUROSCI, V15, P5765; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Fauza DO, 2008, SURGERY, V144, P367, DOI 10.1016/j.surg.2008.05.009; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.0.CO;2-B; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; Iwamoto Y, 1996, NEUROREPORT, V7, P609, DOI 10.1097/00001756-199601310-00056; JACOBS KM, 1993, J COMP NEUROL, V336, P151, DOI 10.1002/cne.903360112; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Klocker N, 2001, NEUROBIOL DIS, V8, P103, DOI 10.1006/nbdi.2000.0329; Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Ma XH, 2010, CRYOBIOLOGY, V60, P184, DOI 10.1016/j.cryobiol.2009.10.013; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Moro K, 2006, BRAIN RES, V1076, P1, DOI 10.1016/j.brainres.2005.12.119; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Stanisz AM, 2000, ANN NY ACAD SCI, V917, P268; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; Willson ML, 2008, BRAIN, V131, P1099, DOI 10.1093/brain/awn024; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x	47	59	69	1	25	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JAN	2012	37	1					69	83		10.1007/s11064-011-0584-1			15	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	920KT	WOS:000302404000010	21901549				2022-02-06	
J	Rapoport, MJ				Rapoport, Mark J.			Depression Following Traumatic Brain Injury Epidemiology, Risk Factors and Management	CNS DRUGS			English	Article							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; HEAD-INJURY; EMOTIONAL DISTRESS; 1ST YEAR; MILD; MODERATE; SYMPTOMS	It is important for clinicians to recognize major depression following traumatic brain injury (TBI) because of its association with poor global and psychosocial outcome, postconcussive symptoms and cognitive deficits. The purpose of this review is to provide an up-to-date selective review of the current understanding of epidemiology, risk factors and management of major depression following TBI. Many studies of prevalence of depression following TBI have not used accepted structured criteria for the diagnoses, but those that did found wide ranges of rates, from 17% to 61%. The risk factors for development of depression following TBI are poorly understood, but past psychiatric history, frontal lesions and atrophy, and family dysfunction have been shown in more than one study to play important roles. There are few controlled trials of the treatment of major depression in patients with TBI using accepted diagnostic criteria for major depression, as well as defined criteria for response and remission. As such, it is important for clinicians to use best practice guidelines for the treatment of major depression in the absence of TBI.	[Rapoport, Mark J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Geriatr Traumat Brain Injury Clin, Dept Psychiat, Toronto, ON, Canada		Rapoport, MJ (corresponding author), FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Rapoport, Mark/AAD-8581-2020		Ontario Neurotrauma Foundation; Physician's Services Inc. Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alzheimer's Society of Canada; Transport Canada	Speaker's honoraria: Janssen-Ortho (April 2008); Alzheimer's Society of Toronto (February 2009). Grant funding: Ontario Neurotrauma Foundation, Physician's Services Inc. Foundation, Canadian Institute of Health Research, Alzheimer's Society of Canada and Transport Canada.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kant R, 1999, J NEUROPSYCH CLIN N, V11, P32, DOI 10.1176/jnp.11.1.32; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.3275/7045, 10.1007/BF03350340]; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Rao V, J NEUROPSYCHIATRY CL, V22, P231; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2010, J CLIN PSYCHIAT, V71, P1125, DOI 10.4088/JCP.09m05086blu; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Schonberger M, 2010, NEUROPSYCHOL REHABIL, V20, P813, DOI 10.1080/09602011003620077; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silver JM, 2008, NEUROPSYCHIATRY BEHA; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Weddell RA, 2010, ARCH PHYS MED REHAB, V91, P897, DOI 10.1016/j.apmr.2010.01.020; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206	75	59	60	0	23	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2012	26	2					111	121		10.2165/11599560-000000000-00000			11	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	898OA	WOS:000300750500003	22296315				2022-02-06	
J	Sekhon, MS; McLean, N; Henderson, WR; Chittock, DR; Griesdale, DEG				Sekhon, Mypinder S.; McLean, Nielson; Henderson, William R.; Chittock, Dean R.; Griesdale, Donald E. G.			Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury	CRITICAL CARE			English	Article							BLOOD-CELL TRANSFUSION; HEAD-INJURY; ANEMIA; INCREASES; INFECTIONS; METABOLISM; IMPACT	Introduction: The critical care management of traumatic brain injury focuses on preventing secondary ischemic injury. Cerebral oxygen delivery is dependent upon the cerebral perfusion pressure and the oxygen content of blood, which is principally determined by hemoglobin. Despite its importance to the cerebral oxygen delivery, the precise hemoglobin concentration to provide adequate oxygen delivery to injured neuronal tissue in TBI patients is controversial with limited evidence to provide transfusion thresholds. Methods: We conducted a retrospective cohort study of severe TBI patients, investigating the association between mean 7-day hemoglobin concentration and hospital mortality. Demographic, physiologic, intensive care interventions, clinical outcomes and daily hemoglobin concentrations were recorded for all patients. Patients were all cared for at a tertiary, level 1 trauma center in a mixed medical and surgical intensive unit. Patients were divided into quartiles based on their mean 7-day hemoglobin concentration: < 90 g/L, 90 -99 g/L, 100 -109 g/L and > 110 g/L. Multivariable log-binomial regression was used to model the association between mean daily hemoglobin concentration and hospital mortality. Results: Two hundred seventy-three patients with traumatic brain injury were identified and 169 were included in the analysis based on inclusion/exclusion criteria. Of these, 77% of the patients were male, with a mean age of 38 (SD 17) years and a median best GCS of 6 (IQR 5 - 7). One hundred fifteen patients (68%) received a red blood cell (RBC) transfusion. In RBCs administered in the ICU, the median pre-transfusion hemoglobin was 79 g/L (IQR 73 85). Thirty-seven patients (22%) died in hospital. Multivariable analysis revealed that mean 7-day hemoglobin concentration < 90 g/L was independently associated with an increased risk of hospital mortality (RR 3.1, 95% CI 1.5 - 6.3, p = 0.03). Other variables associated with increased mortality on multivariable regression were insertion of external ventricular drain, age and decreased GCS. Red blood cell transfusion was not associated with mortality following multivariable adjustment. Conclusions: A mean 7-day hemoglobin concentration of < 90g/L is associated with increased hospital mortality in patients with severe traumatic brain injury.	[Sekhon, Mypinder S.; McLean, Nielson; Henderson, William R.; Chittock, Dean R.; Griesdale, Donald E. G.] Univ British Columbia, Vancouver Gen Hosp, Div Crit Care Med, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Univ British Columbia, Vancouver Gen Hosp, Dept Anesthesia Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada		Griesdale, DEG (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Div Crit Care Med, Dept Med, 855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	donald.griesdale@vch.ca	Griesdale, Donald/AAT-7762-2021	Griesdale, Donald/0000-0001-5985-8624			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Claridge JA, 2002, AM SURGEON, V68, P566; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Desjardins P, 2012, CRIT CARE, V16, DOI 10.1186/cc11293; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hill GE, 2003, J TRAUMA, V54, P908, DOI 10.1097/01.TA.0000022460.21283.53; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Malone D, 2003, J TRAUMA, V54, P666; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Oddo M, 2012, INTENSIVE CARE MED; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taylor RW, 2006, CRIT CARE MED, V34, P2302, DOI 10.1097/01.CCM.0000234034.51040.7F; Taylor RW, 2002, CRIT CARE MED, V30, P2249, DOI 10.1097/00003246-200210000-00012; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	32	59	63	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2012	16	4							R128	10.1186/cc11431			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	066CP	WOS:000313197800015	22817913	Green Published, gold			2022-02-06	
J	Johnson, VE; Stewart, W; Trojanowski, JQ; Smith, DH				Johnson, Victoria E.; Stewart, William; Trojanowski, John Q.; Smith, Douglas H.			Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans	ACTA NEUROPATHOLOGICA			English	Article						TDP-43; 43 kDa transactive response (TAR) DNA binding protein; Traumatic brain injury; Head injury; Diffuse axonal injury; DAI; Neurodegeneration; Dementia; Alzheimer's disease; Long-term survival; Single versus repetitive TBI	TAR-DNA-BINDING; FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; NUCLEAR FACTOR TDP-43; SEVERE HEAD-INJURY; PROTEIN MISFOLDING DISEASES; FOOTBALL-LEAGUE PLAYER; DIFFUSE AXONAL INJURY; BETA-AMYLOID PROTEIN; ALZHEIMERS-DISEASE	The pathologic phosphorylation and sub-cellular translocation of neuronal transactive response-DNA binding protein (TDP-43) was identified as the major disease protein in frontotemporal lobar degeneration (FTLD) with ubiquitinated inclusions, now termed FTLD-TDP, and amyotrophic lateral sclerosis (ALS). More recently, TDP-43 proteinopathy has been reported in dementia pugilistica or chronic traumatic encephalopathy caused by repetitive traumatic brain injury (TBI). While a single TBI has been linked to the development of Alzheimer's disease and an increased frequency of neurofibrillary tangles, TDP-43 proteinopathy has not been examined with survival following a single TBI. Using immunohistochemistry specific for both pathological phosphorylated TDP-43 (p-TDP-43) and phosphorylation-independent TDP-43 (pi-TDP-43), we examined acute (n = 23: Survival < 2 weeks) and long-term (n = 39; 1-47 years survival) survivors of a single TBI versus age-matched controls (n = 47). Multiple regions were examined including the hippocampus, medial temporal lobe, cingulate gyrus, superior frontal gyrus and brainstem. No association was found between a history of single TBI and abnormally phosphorylated TDP-43 (p-TDP-43) inclusions. Specifically, just 3 of 62 TBI cases displayed p-TDP-43 pathology versus 2 of 47 control cases. However, while aggregates of p-TDP-43 were not increased acutely or long-term following TBI, immunoreactivity to phosphorylation-independent TDP-43 was commonly increased in the cytoplasm following TBI with both acute and long-term survival. Moreover, while single TBI can induce multiple long-term neurodegenerative changes, the absence of TDP-43 proteinopathy may indicate a fundamental difference in the processes induced following single TBI from those of repetitive TBI.	[Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Stewart, William] Univ Glasgow, Div Clin Neurosci, Glasgow, Lanark, Scotland; [Stewart, William] So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Trojanowski, John Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Sch Med, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu		Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, AG10124, AG17546, NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P01NS056202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG038911, P30AG010124, R01AG017546] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants NS038104, AG10124, AG17546 and NS056202. We would also like to thank Ms. Janice E. Stewart for her technical assistance with immunohistochemical staining procedures.	Abhyankar MM, 2007, J BIOL CHEM, V282, P36143, DOI 10.1074/jbc.M705811200; Acharya KK, 2006, DEV BIOL, V295, P781, DOI 10.1016/j.ydbio.2006.04.443; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Arai T, 2009, ACTA NEUROPATHOL, V117, P125, DOI 10.1007/s00401-008-0480-1; Ayala YM, 2006, FEBS LETT, V580, P1339, DOI 10.1016/j.febslet.2006.01.052; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buratti E, 2004, AM J HUM GENET, V74, P1322, DOI 10.1086/420978; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2008, FRONT BIOSCI-LANDMRK, V13, P867, DOI 10.2741/2727; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Geser F, 2010, ARCH NEUROL-CHICAGO, V67, P1238, DOI 10.1001/archneurol.2010.254; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Geser F, 2009, ARCH NEUROL-CHICAGO, V66, P180, DOI 10.1001/archneurol.2008.558; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; Higashi S, 2007, BRAIN RES, V1184, P284, DOI 10.1016/j.brainres.2007.09.048; Hu WT, 2008, ACTA NEUROPATHOL, V116, P215, DOI 10.1007/s00401-008-0400-4; Huber A., 1993, J NEUROTRAUMA S1, V10, pS180; Igaz LM, 2008, AM J PATHOL, V173, P182, DOI 10.2353/ajpath.2008.080003; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Inukai Y, 2008, FEBS LETT, V582, P2899, DOI 10.1016/j.febslet.2008.07.027; Johnson VE, 2011, BRAIN PATHO IN PRESS; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kanazawa M, 2011, J NEUROCHEM, V116, P957, DOI 10.1111/j.1471-4159.2010.06860.x; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lee EB, 2011, NAT REV NEU IN PRESS; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; McDonald KK, 2011, HUM MOL GENET, V20, P1400, DOI 10.1093/hmg/ddr021; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mercado PA, 2005, NUCLEIC ACIDS RES, V33, P6000, DOI 10.1093/nar/gki897; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakashima-Yasuda H, 2007, ACTA NEUROPATHOL, V114, P221, DOI 10.1007/s00401-007-0261-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Neumann M, 2009, ACTA NEUROPATHOL, V117, P137, DOI 10.1007/s00401-008-0477-9; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwab C, 2008, J NEUROPATH EXP NEUR, V67, P1159, DOI 10.1097/NEN.0b013e31818e8951; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2008, J NEUROPATH EXP NEUR, V67, P555, DOI 10.1097/NEN.0b013e31817713b5; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang HY, 2004, GENOMICS, V83, P130, DOI 10.1016/S0888-7543(03)00214-3; Wang IF, 2008, TRENDS MOL MED, V14, P479, DOI 10.1016/j.molmed.2008.09.001	75	59	60	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2011	122	6					715	726		10.1007/s00401-011-0909-9			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	854CC	WOS:000297471200006	22101322	Green Accepted			2022-02-06	
J	Yang, CP; Gilley, JA; Zhang, G; Kernie, SG				Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.			ApoE is required for maintenance of the dentate gyrus neural progenitor pool	DEVELOPMENT			English	Article						Neurogenesis; Neural stem cell; Hippocampus; Mouse	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; STEM-CELL NICHES; ADULT NEUROGENESIS; APOLIPOPROTEIN-E; HIPPOCAMPAL NEUROGENESIS; IN-VIVO; STEM/PROGENITOR CELLS; ALZHEIMERS-DISEASE; SONIC HEDGEHOG	Many genes regulating adult neurogenesis have been identified and are known to play similar roles during early neuronal development. We recently identified apolipoprotein E (ApoE) as a gene the expression of which is essentially absent in early brain progenitors but becomes markedly upregulated in adult dentate gyrus stem/progenitor cells. Here, we demonstrate that ApoE deficiency impairs adult dentate gyrus development by affecting the neural progenitor pool over time. We utilized ApoE-deficient mice crossed to a nestin-GFP reporter to demonstrate that dentate gyrus progenitor cells proliferate more rapidly at early ages, which is subsequently accompanied by an overall decrease in neural progenitor cell number at later time points. This appears to be secondary to over-proliferation early in life and ultimate depletion of the Type 1 nestin-and GFAP-expressing neural stem cells. We also rescue the proliferation phenotype with an ApoE-expressing retrovirus, demonstrating that ApoE works directly in this regard. These data provide novel insight into late hippocampal development and suggest a possible role for ApoE in neurodegenerative diseases.	[Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA		Kernie, SG (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, 3959 Broadway,CHN 10-24, New York, NY 10032 USA.	sk3516@columbia.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS048192]; Sarah M. and Charles E. Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER	Financial support is from NIH grant R01 NS048192 (to S. G. K.) and the Sarah M. and Charles E. Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children. Deposited in PMC for release after 12 months.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Bersenev A, 2008, J CLIN INVEST, V118, P2832, DOI 10.1172/JCI35808; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen J, 2009, GENESIS, V47, P122, DOI 10.1002/dvg.20465; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Deguchi K, 2003, J NEUROPATH EXP NEUR, V62, P676, DOI 10.1093/jnen/62.6.676; Ding HK, 2008, LEARN MEMORY, V15, P290, DOI 10.1101/lm.905008; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Eidukevicius R, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-122; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; Fujita SC, 1999, NEUROSCI RES, V35, P123, DOI 10.1016/S0168-0102(99)00075-9; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gilley JA, 2011, HIPPOCAMPUS, V21, P33, DOI 10.1002/hipo.20719; Gritti A, 2007, NEURON GLIA BIOL, V3, P309, DOI 10.1017/S1740925X0800001X; GUNDERSEN HJG, 1980, MICROSC ACTA, V83, P409; Guo Y, 2008, MICROSURG, V28, P54, DOI 10.1002/micr.20443; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Huang Z, 2009, MOL CELL NEUROSCI, V42, P11, DOI 10.1016/j.mcn.2009.06.003; Joksimovic M, 2009, NAT NEUROSCI, V12, P125, DOI 10.1038/nn.2243; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Li G, 2009, CELL STEM CELL, V5, P634, DOI 10.1016/j.stem.2009.10.015; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seki T, 2002, J NEUROSCI RES, V69, P772, DOI 10.1002/jnr.10366; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; SHAPIRO HM, 1981, CYTOMETRY, V2, P143, DOI 10.1002/cyto.990020302; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Slezak M, 2003, TRENDS NEUROSCI, V26, P531, DOI 10.1016/j.tins.2003.08.005; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	63	59	61	0	10	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991			DEVELOPMENT	Development	OCT 15	2011	138	20					4351	4362		10.1242/dev.065540			12	Developmental Biology	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology	822YD	WOS:000295085600003	21880781	Green Published, Bronze			2022-02-06	
J	Bachelani, AM; Bautz, JT; Sperry, JL; Corcos, A; Zenati, M; Billiar, TR; Peitzman, AB; Marshall, GT				Bachelani, Arshad M.; Bautz, Joshua T.; Sperry, Jason L.; Corcos, Alain; Zenati, Mazen; Billiar, Timothy R.; Peitzman, Andrew B.; Marshall, Gary T.			Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury	SURGERY			English	Article							PREINJURY ANTICOAGULATION; ANTIPLATELET AGENTS; ELDERLY-PATIENTS; UNITED-STATES; HEAD-INJURY; RESISTANCE; IMPACT; PREVENTION; HEMORRHAGE; OUTCOMES	Background. Platelet transfusion is utilized increasingly for traumatic brain injury (TBI) for the reversal of aspirin (ASA) therapy. Assessment of platelet inhibition and reversal by platelet transfusion after TBI has not been adequately characterized. Methods. A retrospective cohort analysis of TBI patients at a level I trauma center (January 2008-December 2009) was performed. The Aspirin Response Test (ART; VerifyNow) was used to assess platelet inhibition in TBI patients and guide platelet transfusion in patients with ASA-induced suppression. A follow-up ART was obtained after platelet administration. Primary endpoints were progression of intracranial hemorrhage on computed tomography, need for craniotomy, and mortality. Results. We analyzed 84 patients (median age, 78 [interquartile range, 64-86)]; 54% male). ASA use was documented in 36 (42%) patients. Initial ART indicated platelet dysfunction in 54 (64%) patients, including 42% of patients without a documented history of ASA use. Of the patients with a documented history of ASA, 2.4% had a normal ART Of those with an initial ART of <550 ASA response units, 45 received platelets. Repeat ART demonstrated reversal of inhibition in 29 patients (64.4%). Initial responders to transfusion received a greater volume of platelets, suggesting a dose-response relationship. Logistic regression revealed a trend toward higher mortality in nonresponders to transfusion (P = .09). Receiver operating characteristic curve analysis revealed that ART results increased prediction of poor outcome compared with ASA history alone (area under the curve = 0.760 and 0.775, respectively). Conclusion. The ART should be used to better target and guide platelet transfusions in TBI patients with known or suspected ASA use history. Patients with occult platelet dysfunction can be identified, unnecessary platelet transfusions avoided, and the adequate volume of platelets administered to correct drug-induced dysfunction. A dose response relationship between quantity of platelets transfused and reversal of ASA inhibition was observed. (Surgery 2011;150:836-43.)	[Bachelani, Arshad M.; Bautz, Joshua T.; Sperry, Jason L.; Corcos, Alain; Zenati, Mazen; Billiar, Timothy R.; Peitzman, Andrew B.; Marshall, Gary T.] Univ Pittsburgh, Med Ctr, Div Gen Surg & Trauma, Dept Surg,Mercy & Presbyterian Hosp, Pittsburgh, PA 15213 USA		Marshall, GT (corresponding author), Univ Pittsburgh, Med Ctr, Div Gen Surg & Trauma, Dept Surg, 200 Lothrop St,F1266-2, Pittsburgh, PA 15213 USA.	marshallgt@upmc.edu	Zenati, Mazen S/C-2020-2012	Marshall, Gary/0000-0003-1398-5366; Bachelani, Arshad/0000-0002-9001-7062			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042; [Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P101; Blais N, 2009, THROMB HAEMOSTASIS, V102, P404, DOI 10.1160/TH09-02-0126; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Feher G, 2009, CLIN GENET, V75, P1, DOI 10.1111/j.1399-0004.2008.01105.x; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Gasparyan AY, 2008, J AM COLL CARDIOL, V51, P1829, DOI 10.1016/j.jacc.2007.11.080; Greer DM, 2010, CNS DRUGS, V24, P1027, DOI 10.2165/11539160-000000000-00000; Kinsella k, 2001, AGING WORLD 2001; Michelson, 2002, PLATELETS; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Moore L, 2006, J TRAUMA, V60, P305, DOI 10.1097/01.ta.0000200840.89685.b0; Norfolk DR, 1998, BRIT J HAEMATOL, V101, P609; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Smock KJ, 2010, AM J HEMATOL, V85, P358, DOI 10.1002/ajh.21674; Stead LG, 2010, CLIN NEUROL NEUROSUR, V112, P275, DOI 10.1016/j.clineuro.2009.12.002; Stroncek DF, 2007, LANCET, V370, P427, DOI 10.1016/S0140-6736(07)61198-2; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	25	59	60	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2011	150	4					836	842		10.1016/j.surg.2011.07.059			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	838SB	WOS:000296311400060	22000198				2022-02-06	
J	Deng-Bryant, Y; Prins, ML; Hovda, DA; Harris, NG				Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.			Ketogenic Diet Prevents Alterations in Brain Metabolism in Young but not Adult Rats after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ketogenic diet; nuclear magnetic resonance spectroscopy; phosphorus; proton; TBI	PROTON-MAGNETIC-RESONANCE; CORTICAL IMPACT INJURY; CEREBRAL GLUCOSE-UTILIZATION; MITOCHONDRIAL DYSFUNCTION; N-ACETYLASPARTATE; MICROWAVE IRRADIATION; P-31-NMR SPECTROSCOPY; EMISSION-TOMOGRAPHY; NAD(+) DEPLETION; CONTUSION INJURY	Previous studies have shown that the change of cerebral metabolic rate of glucose (CMRglc) in response to traumatic brain injury (TBI) is different in young (PND35) and adult rats (PND70), and that prolonged ketogenic diet treatment results in histological and behavioral neuroprotection only in younger rat brains. However, the mechanism(s) through which ketones act in the injured brain and the biochemical markers of their action remain unknown. Therefore, the current study was initiated to: 1) determine the effect of injury on the neurochemical profile in PND35 compared to PND70 rats; and 2) test the effect of early post-injury administration of ketogenic diet on brain metabolism in PND35 versus PND70 rats. The data show that alterations in energy metabolites, amino acid, and membrane metabolites were not evident in PND35 rats on standard diet until 24 h after injury, when the concentration of most metabolites was reduced from sham-injured values. In contrast, acute, but transient deficits in energy metabolism were measured at 6 h in PND70 rats, together with deficits in N-acetylaspartate that endured until 24 h. Administration of a ketogenic diet resulted in significant increases in plasma beta-hydroxybutyrate (beta OHB) levels. Similarly, brain beta OHB levels were significantly elevated in all injured rats, but were elevated by 43% more in PND35 rats compared to PND70 rats. As a result, ATP, creatine, and phosphocreatine levels at 24 h after injury were significantly improved in the ketogenic PND35 rats, but not in the PND70 group. The improvement in energy metabolism in the PND35 brains was accompanied by the recovery of NAA and reduction of lactate levels, as well as amelioration of the deficits of other amino acids and membrane metabolites. These results indicate that the PND35 brains are more resistant to the injury, indicated by a delayed deficit in energy metabolism. Moreover, the younger brains revert to ketones metabolism more quickly than do the adult brains, resulting in better neurochemical and cerebral metabolic recovery after injury.	[Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Deng-Bryant, Y (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave,Room 2W15, Silver Spring, MD 20910 USA.	ying.d.bryant@us.army.mil	; Prins, Mayumi/J-9571-2015	Harris, Neil/0000-0002-1965-6750; Prins, Mayumi/0000-0001-7694-9739	UCLA Brain Injury Research Center; National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS055910, NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, R01NS055910] Funding Source: NIH RePORTER	We thank Dr. Brenda Bartnik-Olson for helpful comments on the manuscript and Dr. David McArthur for help with statistics. This work was supported by the UCLA Brain Injury Research Center and National Institutes of Health Award Numbers NS055910 and NS058489 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not necessarily represent official views of the NINDS or the National Institutes of Health.	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alfieri RR, 2006, J PHYSIOL-LONDON, V576, P391, DOI 10.1113/jphysiol.2006.115006; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Benton RL, 2000, NEUROSCI LETT, V291, P1, DOI 10.1016/S0304-3940(00)01362-8; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Briellmann RS, 2005, EPILEPSIA, V46, P760, DOI 10.1111/j.1528-1167.2005.47604.x; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brooks WM, 1999, J RHEUMATOL, V26, P81; Caramanos Z, 2005, BRAIN, V128, P2483, DOI 10.1093/brain/awh640; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GLONEK T, 1982, J NEUROCHEM, V39, P1210, DOI 10.1111/j.1471-4159.1982.tb12557.x; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GUIDOTTI A, 1974, NEUROPHARMACOLOGY, V13, P1115, DOI 10.1016/0028-3908(74)90061-6; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; Harris NG, 1996, J NEUROCHEM, V67, P2030; Harris NG, 1997, J NEUROCHEM, V68, P305; HOVDA DA, 1990, ACT NEUR S, V51, P331; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lehmann C, 2009, BRAIN RES, V1297, P1, DOI 10.1016/j.brainres.2009.08.070; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McKenna MC, 1996, J NEUROCHEM, V66, P386; MEDINA MA, 1975, J NEUROCHEM, V24, P223, DOI 10.1111/j.1471-4159.1975.tb11868.x; MICCHELI A, 1988, CELL MOL BIOL, V34, P591; Morell P, 1996, NEUROCHEM RES, V21, P463, DOI 10.1007/BF02527711; NEHLIG A, 1988, J NEUROSCI, V8, P2321; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parsons MW, 2000, NEUROLOGY, V55, P498, DOI 10.1212/WNL.55.4.498; PETITO CK, 1992, BRAIN RES, V569, P275, DOI 10.1016/0006-8993(92)90639-Q; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI 10.1089/neu.2008-0769; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035; SHARPLESS NS, 1978, BRAIN RES, V140, P171, DOI 10.1016/0006-8993(78)90248-2; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWAAB DF, 1971, J NEUROCHEM, V18, P2085, DOI 10.1111/j.1471-4159.1971.tb05067.x; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Trehout D, 2002, NMR BIOMED, V15, P393, DOI 10.1002/nbm.794; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	81	59	60	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1813	1825		10.1089/neu.2011.1822			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000013	21635175	Green Published			2022-02-06	
J	Hemphill, JC; Andrews, P; De Georgia, M				Hemphill, J. Claude; Andrews, Peter; De Georgia, Michael			Multimodal monitoring and neurocritical care bioinformatics	NATURE REVIEWS NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; BLOOD-FLOW; PROGNOSTIC-SIGNIFICANCE; APPROXIMATE ENTROPY; PHYSIOLOGICAL DATA; DATA-ACQUISITION; CONTINUOUS EEG	Neurocritical care bioinformatics is a new field that focuses on the acquisition, storage and analysis of physiological and other data relevant to the bedside care of patients with acute neurological conditions such as traumatic brain injury or stroke. The main focus of neurocritical care for these conditions relates to prevention, detection and management of secondary brain injury, which relies heavily on monitoring of systemic and cerebral parameters (such as blood-pressure level and intracranial pressure). Advanced neuromonitoring tools also exist that enable measurement of brain tissue oxygen tension, cerebral oxygen utilization, and aerobic metabolism. The ability to analyze these advanced data for real-time clinical care, however, remains intuitive and primitive. Advanced statistical and mathematical tools are now being applied to the large volume of clinical physiological data routinely monitored in neurocritical care with the goal of identifying better markers of brain injury and providing clinicians with improved ability to target specific goals in the management of these patients. This Review provides an introduction to the concepts of multimodal monitoring for secondary brain injury in neurocritical care and outlines initial and future approaches using informatics tools for understanding and applying these data to clinical care.	[Hemphill, J. Claude] San Francisco Gen Hosp, Dept Neurol, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Andrews, Peter] Western Gen Hosp, Dept Crit Care, Edinburgh EH4 2XU, Midlothian, Scotland; [De Georgia, Michael] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Neurol Inst, Ctr Neurocrit Care, Cleveland, OH 44106 USA		Hemphill, JC (corresponding author), San Francisco Gen Hosp, Dept Neurol, Brain & Spinal Injury Ctr, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	chemphill@sfgh.ucsf.edu	Demchuk, Andrew M/E-1103-2012; Hemphill, Claude/AAY-5630-2021	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U10 NS058931]; European Society of Intensive Care Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U10NS058931] Funding Source: NIH RePORTER	J. C. Hemphill is funded in part by grant U10 NS058931 from the US NIH. P. Andrews has received funding from the European Society of Intensive Care Medicine for the Eurotherm3235 Trial.	Ali Tanya, 2010, Med Health R I, V93, P8; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Andrews Peter J D, 2004, Curr Opin Crit Care, V10, P110, DOI 10.1097/00075198-200404000-00006; Andrews PJD, 2005, CRIT CARE, V9, P638, DOI 10.1186/cc3922; Andrews PJD, 2004, INTENS CARE MED, V30, P1730, DOI 10.1007/s00134-004-2376-4; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; *ASTM INT, 2009, F2921 ASTM INT; AXELROD S, 1987, NEPHRON, V45, P202, DOI 10.1159/000184117; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS45; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Buchman T G, 1995, J Intensive Care Med, V10, P234; Buchman TG, 1996, J TRAUMA, V41, P599, DOI 10.1097/00005373-199610000-00002; Buchman Timothy G, 2004, Curr Opin Crit Care, V10, P378, DOI 10.1097/01.ccx.0000139369.65817.b6; Buchman TG, 2010, CRIT CARE, V14, DOI 10.1186/cc8868; Buchman TG, 2009, CRIT CARE MED, V37, P1167, DOI 10.1097/CCM.0b013e3181987bbc; Burr RL, 2008, IEEE T BIO-MED ENG, V55, P2509, DOI 10.1109/TBME.2008.2001286; Burykin A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.06.013; CARTER LP, 1993, ACTA NEUROCHIR, P43; Chambers IR, 2006, ACTA NEUROCHIR SUPPL, V96, P7; Chambers I, 2008, ACTA NEUROCHIR SUPPL, V102, P223, DOI 10.1007/978-3-211-85578-2_43; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Citerio G, 2004, INTENS CARE MED, V30, P1882, DOI 10.1007/s00134-004-2377-3; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Coveney PV, 2005, J R SOC INTERFACE, V2, P267, DOI 10.1098/rsif.2005.0045; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Diedler J, 2010, NEUROCRIT CARE, V12, P313, DOI 10.1007/s12028-010-9350-5; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Fahy Brenda G, 2002, Anesthesiol Clin North Am, V20, P441, DOI 10.1016/S0889-8537(01)00011-6; Forsyth RJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002043.pub2; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Gawande Atul, 2007, NEW YORKER 1210; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; GOLDBERGER AL, 1992, APPLIED CHAOS, P321; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; GOMEZ H, 2010, C P IEEE ENG MED BIO, V1, P2358; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Hemphill JC, 2005, NEUROCRIT CARE, V3, P260, DOI 10.1385/NCC:3:3:260; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Jacono FJ, 2010, J HEALTHC ENG, V1, P337, DOI 10.1260/2040-2295.1.3.337; Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x; Kirkness CJ, 2008, ACTA NEUROCHIR SUPPL, V102, P105, DOI 10.1007/978-3-211-85578-2_21; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; Kumar S, 2010, HEALTH INFORM J, V16, P306, DOI 10.1177/1460458210380523; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McQuatt A, 2001, METHOD INFORM MED, V40, P373, DOI 10.1055/s-0038-1634195; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; Mussalo H, 2001, CLIN PHYSIOL, V21, P594, DOI 10.1046/j.1365-2281.2001.00359.x; Nakagawa K, 2011, NEUROCRIT CARE, V15, P101, DOI 10.1007/s12028-010-9446-y; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Otero A, 2009, ARTIF INTELL MED, V47, P219, DOI 10.1016/j.artmed.2009.08.002; Papaioannou VE, 2006, J CRIT CARE, V21, P95, DOI 10.1016/j.jcrc.2005.12.007; Peelen L, 2010, J BIOMED INFORM, V43, P273, DOI 10.1016/j.jbi.2009.10.002; Piper I, 2010, ACTA NEUROCHIR, V152, P1859, DOI 10.1007/s00701-010-0719-1; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROPPER AH, 1992, ANN NEUROL, V32, P564, DOI 10.1002/ana.410320413; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; RYAN SM, 1994, J AM COLL CARDIOL, V24, P1700, DOI 10.1016/0735-1097(94)90177-5; Saeed M, 2011, CRIT CARE MED, V39, P952, DOI 10.1097/CCM.0b013e31820a92c6; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Smielewski P, 2005, ACT NEUR S, V95, P43; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stuart RM, 2010, NEUROCRIT CARE, V13, P355, DOI 10.1007/s12028-010-9414-6; Stuart RM, 2010, NEUROCRIT CARE, V12, P188, DOI 10.1007/s12028-010-9330-9; Szabo BM, 1997, AM J CARDIOL, V79, P978, DOI 10.1016/S0002-9149(97)00026-X; Tatsuoka C, 2002, J ROY STAT SOC C-APP, V51, P337, DOI 10.1111/1467-9876.00272; Thome C, 2001, J NEUROSURG, V95, P402, DOI 10.3171/jns.2001.95.3.0402; Toweill Daniel L, 2003, Pediatr Crit Care Med, V4, P308, DOI 10.1097/01.PCC.0000074260.93430.6A; TRIEDMAN JK, 1993, HYPERTENSION, V21, P236, DOI 10.1161/01.HYP.21.2.236; Ursino M, 1998, ACT NEUR S, V71, P306; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; van Boven AJ, 1998, AM HEART J, V135, P571, DOI 10.1016/S0002-8703(98)70269-8; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vath A, 2000, ZBL NEUROCHIR, V61, P2, DOI 10.1055/s-2000-8258; Vikman S, 1999, CIRCULATION, V100, P2079, DOI 10.1161/01.CIR.100.20.2079; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; Zenker S, 2007, PLOS COMPUT BIOL, V3, P2072, DOI 10.1371/journal.pcbi.0030204	96	59	64	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4758	1759-4766		NAT REV NEUROL	Nat. Rev. Neurol.	AUG	2011	7	8					451	460		10.1038/nrneurol.2011.101			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803YK	WOS:000293618800009	21750522	Bronze			2022-02-06	
J	Yurgelun-Todd, DA; Bueler, CE; McGlade, EC; Churchwell, JC; Brenner, LA; Lopez-Larson, MP				Yurgelun-Todd, Deborah A.; Bueler, C. Elliott; McGlade, Erin C.; Churchwell, John C.; Brenner, Lisa A.; Lopez-Larson, Melissa P.			Neuroimaging Correlates of Traumatic Brain Injury and Suicidal Behavior	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging; magnetic resonance imaging; suicide; TBI	WHITE-MATTER ABNORMALITIES; LATE-LIFE DEPRESSION; HUMAN CEREBRAL-CORTEX; DIFFUSION-TENSOR; CORPUS-CALLOSUM; MICROSTRUCTURAL ABNORMALITIES; GEOMETRICALLY ACCURATE; DEPENDENT SUBJECTS; BIPOLAR DISORDER; MRI	Introduction: There is an urgent need to define the neurobiological and cognitive underpinnings of suicidal ideation and behavior in veterans with traumatic brain injury (TBI). Separate studies implicate frontal white matter systems in the pathophysiology of TBI, suicidality, and impulsivity. We examined the relationship between the integrity of major frontal white matter (WM) systems on measures of impulsivity and suicidality in veterans with TBI. Methods: Fifteen male veterans with TBI and 17 matched healthy controls (HC) received clinical ratings, measures of impulsivity and MRI scans on a 3T magnet. Diffusion tensor imaging (DTI) data for the genu and cingulum were analyzed using Freesurfer and FSL. Correlations were performed for fractional anisotropy (FA) (DTI) values and measures of suicidality and impulsivity for veterans with TBI. Results: Significantly decreased in FA values in the left cingulum (P = 0.02), and left (P = 0.02) and total genu (P = 0.01) were observed in the TBI group relative to controls. Measures of impulsivity were significantly greater for the TBI group and total and right cingulum FA positively correlated with current suicidal ideation and measures of impulsivity (P < 0.03). Conclusion: These data demonstrate a significant reduction in FA in frontal WM tracts in veterans with mild TBI that was associated with both impulsivity and suicidality. These findings may reflect a neurobiological vulnerability to suicidal risk related to white matter microstructure.	[Yurgelun-Todd, Deborah A.; Bueler, C. Elliott; McGlade, Erin C.; Churchwell, John C.; Lopez-Larson, Melissa P.] Univ Utah, Inst Brain, Salt Lake City, UT 84108 USA; [Yurgelun-Todd, Deborah A.; Lopez-Larson, Melissa P.] Univ Utah, Sch Med, Salt Lake City, UT 84108 USA; [Yurgelun-Todd, Deborah A.; McGlade, Erin C.; Lopez-Larson, Melissa P.] VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, Salt Lake City, UT USA; [Brenner, Lisa A.] VA VISN 19 MIRECC, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA		Yurgelun-Todd, DA (corresponding author), Univ Utah, Inst Brain, 383 Colorow Dr, Salt Lake City, UT 84108 USA.	deborah.yurgelun-todd@hsc.utah.edu	Brenner, Lisa A./AAG-2442-2019; McGlade, Erin C/K-1157-2016	McGlade, Erin C/0000-0003-2234-1984	VISN 19 MIRECC;  [5I01CX000253-02]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH087831] Funding Source: NIH RePORTER	This work was supported by research grants from Merit review 5I01CX000253-02 and VISN 19 MIRECC.	Abe O, 2004, J COMPUT ASSIST TOMO, V28, P533, DOI 10.1097/00004728-200407000-00016; Aguilar EJ, 2008, PROG NEURO-PSYCHOPH, V32, P1673, DOI 10.1016/j.pnpbp.2008.06.016; Ahearn EP, 2001, BIOL PSYCHIAT, V50, P266, DOI 10.1016/S0006-3223(01)01098-8; Alexopoulos GS, 2008, AM J PSYCHIAT, V165, P238, DOI 10.1176/appi.ajp.2007.07050744; Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Andersson JL, 2007, TR07JA1 FMRIB FMRIB TECH REP TRO7J; ANDERSSON JLR, 2011, TR07JA2 FMRIB; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Barnea-Goraly N, 2009, BIOL PSYCHIAT, V66, P238, DOI 10.1016/j.biopsych.2009.02.025; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bender TW, 2011, J AFFECT DISORDERS, V129, P301, DOI 10.1016/j.jad.2010.07.023; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Briere J., 1995, TRAUMA SYMPTOM INVEN; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cirino PT, 2002, ASSESSMENT, V9, P145, DOI 10.1177/10791102009002005; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; First M.B., 1996, STRUCTURED CLIN INTE; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gorlyn Marianne, 2005, Int J Adolesc Med Health, V17, P205; HAMILTON A, 1969, BRIT J PSYCHIAT, P76; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Horesh N, 2001, Crisis, V22, P27, DOI 10.1027//0227-5910.22.1.27; Hwang JP, 2010, J GERIATR PSYCH NEUR, V23, P171, DOI 10.1177/0891988710363713; Jia ZY, 2010, AM J PSYCHIAT, V167, P1381, DOI 10.1176/appi.ajp.2010.09101513; KAROL RL, 2003, NEUROPSYCHOLOGICAL I; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Konrad A, 2010, EUR J NEUROSCI, V31, P912, DOI 10.1111/j.1460-9568.2010.07110.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Li LJ, 2007, BRAIN RES, V1168, P124, DOI 10.1016/j.brainres.2007.06.094; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Maser JD, 2002, SUICIDE LIFE-THREAT, V32, P10, DOI 10.1521/suli.32.1.10.22183; Matsuo K, 2010, NEUROSCI LETT, V469, P75, DOI 10.1016/j.neulet.2009.11.047; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAuliffe C, 2008, BRIT J CLIN PSYCHOL, V47, P43, DOI 10.1348/014466507X230958; McNair D. M., 1992, REVISED MANUAL PROFI; Minami T, 2003, NEUROPSYCHOBIOLOGY, V47, P141, DOI 10.1159/000070583; Moeller FG, 2005, NEUROPSYCHOPHARMACOL, V30, P610, DOI 10.1038/sj.npp.1300617; Monkul ES, 2007, MOL PSYCHIATR, V12, P360, DOI 10.1038/sj.mp.4001919; Mori S, 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Oquendo M. A., 2003, STANDARDIZED EVALUAT, P103; Parker RS, 2002, NEUROREHABILITATION, V17, P131; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Paulus MP, 2007, SCIENCE, V318, P602, DOI 10.1126/science.1142997; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Robertson IH, 2008, ARCH PHYS MED REHAB, V89, pS1, DOI 10.1016/j.apmr.2008.10.001; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salo R, 2009, BIOL PSYCHIAT, V65, P122, DOI 10.1016/j.biopsych.2008.08.004; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Taber K. H., 2007, J NEUROPSYCHIATRY CL, V19; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Taylor WD, 2004, AM J PSYCHIAT, V161, P1293, DOI 10.1176/appi.ajp.161.7.1293; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041; Versace A, 2010, BIOL PSYCHIAT, V68, P560, DOI 10.1016/j.biopsych.2010.04.036; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wei CW, 2008, ARCH PHYS MED REHAB, V89, pS85, DOI 10.1016/j.apmr.2008.07.005; Wessa M, 2009, BIPOLAR DISORD, V11, P504, DOI 10.1111/j.1399-5618.2009.00718.x; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yang Q, 2007, INT PSYCHOGERIATR, V19, P757, DOI 10.1017/S1041610207004875; Yoo SY, 2007, ACTA PSYCHIAT SCAND, V116, P211, DOI 10.1111/j.1600-0447.2007.01046.x; Yurgelun-Todd DA, 2007, BIPOLAR DISORD, V9, P504, DOI 10.1111/j.1399-5618.2007.00395.x; Zanetti MV, 2009, EUR ARCH PSY CLIN N, V259, P316, DOI 10.1007/s00406-009-0002-8	98	59	59	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					276	289		10.1097/HTR.0b013e31822251dc			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700005	21734511				2022-02-06	
J	Newcombe, V; Chatfield, D; Outtrim, J; Vowler, S; Manktelow, A; Cross, J; Scoffings, D; Coleman, M; Hutchinson, P; Coles, J; Carpenter, TA; Pickard, J; Williams, G; Menon, D				Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Vowler, Sarah; Manktelow, Anne; Cross, Justin; Scoffings, Daniel; Coleman, Martin; Hutchinson, Peter; Coles, Jonathan; Carpenter, T. Adrian; Pickard, John; Williams, Guy; Menon, David			Mapping Traumatic Axonal Injury Using Diffusion Tensor Imaging: Correlations with Functional Outcome	PLOS ONE			English	Article							SEVERE HEAD-INJURY; BRAIN-INJURY; MR-IMAGES; SCALE; DISEASE; LESIONS; BURDEN; STATE	Background: Traumatic brain injury is a major cause of morbidity and mortality worldwide. Ameliorating the neurocognitive and physical deficits that accompany traumatic brain injury would be of substantial benefit, but the mechanisms that underlie them are poorly characterized. This study aimed to use diffusion tensor imaging to relate clinical outcome to the burden of white matter injury. Methodology/Principal Findings: Sixty-eight patients, categorized by the Glasgow Outcome Score, underwent magnetic resonance imaging at a median of 11.8 months (range 6.6 months to 3.7 years) years post injury. Control data were obtained from 36 age-matched healthy volunteers. Mean fractional anisotropy, apparent diffusion coefficient (ADC), and eigenvalues were obtained for regions of interest commonly affected in traumatic brain injury. In a subset of patients where conventional magnetic resonance imaging was completely normal, diffusion tensor imaging was able to detect clear abnormalities. Significant trends of increasing ADC with worse outcome were noted in all regions of interest. In the white matter regions of interest worse clinical outcome corresponded with significant trends of decreasing fractional anisotropy. Conclusions/Significance: This study found that clinical outcome was related to the burden of white matter injury, quantified by diffusivity parameters late after traumatic brain injury. These differences were seen even in patients with the best outcomes and patients in whom conventional magnetic resonance imaging was normal, suggesting that diffusion tensor imaging can detect subtle injury missed by other techniques. An improved in vivo understanding of the pathology of traumatic brain injury, including its distribution and extent, may enhance outcome evaluation and help to provide a mechanistic basis for deficits that remain unexplained by other approaches.	[Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Manktelow, Anne; Coles, Jonathan; Menon, David] Univ Cambridge, Univ Div Anaesthesia, Cambridge, England; [Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Manktelow, Anne; Coleman, Martin; Hutchinson, Peter; Coles, Jonathan; Carpenter, T. Adrian; Pickard, John; Williams, Guy; Menon, David] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Vowler, Sarah] Univ Cambridge, Ctr Appl Med Stat, Dept Publ Hlth & Primary Care, Cambridge, England; [Cross, Justin; Scoffings, Daniel] Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; [Hutchinson, Peter; Pickard, John] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge, England		Newcombe, V (corresponding author), Univ Cambridge, Univ Div Anaesthesia, Cambridge, England.	vfjn2@wbic.cam.ac.uk	Scoffings, Daniel/AAA-1649-2022	Outtrim, Joanne/0000-0001-8118-6430; Newcombe, Virginia/0000-0001-6044-9035; Coles, Jonathan/0000-0003-4013-679X	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Gates Cambridge Trust; Overseas Research Studentship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation; Royal College of Anaesthetists; Evelyn Trust; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, G9439390, G0001354B, G0001237, G0600986, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2009-14-007] Funding Source: researchfish	This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 65883]), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. VN was supported by the Gates Cambridge Trust and an Overseas Research Studentship. JC and DS are supported by the NIHR Cambridge Biomedical Research Centre. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. JPC is supported by a Clinician Scientist Award from the Academy of Medical Sciences/Health Foundation. DKM is supported by the BOC Professorship of the Royal College of Anaesthetists and the Evelyn Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; NIOGI SN, 2008, AJNR AM J NEURORADIO; Patrick PD, 2007, BRAIN INJURY, V21, P63, DOI 10.1080/02699050601111401; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SIDAROS A, 2007, BRAIN; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	28	59	63	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2011	6	5							e19214	10.1371/journal.pone.0019214			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	759EZ	WOS:000290224800017	21573228	Green Published, gold, Green Submitted			2022-02-06	
J	Jayakumar, AR; Panickar, KS; Curtis, KM; Tong, XY; Moriyama, M; Norenberg, MD				Jayakumar, Arumugam R.; Panickar, Kiran S.; Curtis, Kevin M.; Tong, Xiao Y.; Moriyama, Mitsuaki; Norenberg, Michael D.			Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; bumetanide; cell swelling; Na+-K+-2Cl(-)-cotransporter-1; trauma	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; NA+-K+-2CL(-) COTRANSPORTER; NA+/CA2+ EXCHANGER; OXIDATIVE STRESS; NKCC ACTIVITY; EDEMA; RAT; PHOSPHORYLATION; ACTIVATION	P>Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury (TBI). An important early component of the edema associated with TBI is astrocyte swelling (cytotoxic edema). Mechanisms for such swelling, however, are poorly understood. Ion channels/transporters/exchangers play a major role in cell volume regulation, and a disturbance in one or more of these systems may result in cell swelling. To examine potential mechanisms in TBI-mediated brain edema, we employed a fluid percussion model of in vitro barotrauma and examined the role of the ion transporter Na+-K+-2Cl(-)-cotransporter 1 (NKCC1) in trauma-induced astrocyte swelling as this transporter has been strongly implicated in the mechanism of cell swelling in various neurological conditions. Cultures exposed to trauma (3, 4, 5 atm pressure) caused a significant increase in NKCC1 activity (21%, 42%, 110%, respectively) at 3 h. At 5 atm pressure, trauma significantly increased NKCC1 activity at 1 h and it remained increased for up to 3 h. Trauma also increased the phosphorylation (activation) of NKCC1 at 1 and 3 h. Inhibition of MAPKs and oxidative/nitrosative stress diminished the trauma-induced NKCC1 phosphorylation as well as its activity. Bumetanide, an inhibitor of NKCC1, significantly reduced the trauma-induced astrocyte swelling (61%). Silencing NKCC1 with siRNA led to a reduction in trauma-induced NKCC1 activity as well as in cell swelling. These findings demonstrate the critical involvement of NKCC1 in the astrocyte swelling following in vitro trauma, and suggest that blocking NKCC1 activity may represent a useful therapeutic strategy for the cytotoxic brain edema associated with the early phase of TBI.	[Jayakumar, Arumugam R.; Panickar, Kiran S.; Tong, Xiao Y.; Moriyama, Mitsuaki; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL USA; [Curtis, Kevin M.; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL USA; [Jayakumar, Arumugam R.; Curtis, Kevin M.; Norenberg, Michael D.] Res & Educ Inc, S Florida Fdn, Vet Affairs Med Ctr, Miami, FL 33125 USA; [Panickar, Kiran S.] USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD 20705 USA; [Moriyama, Mitsuaki] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835; Curtis, Kevin/0000-0002-7480-1818	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. We thank Alina Fernandez-Revuelta for the preparation of cell cultures.	Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Akimova OA, 2006, J BIOL CHEM, V281, P31317, DOI 10.1074/jbc.M602117200; Andersen GO, 2004, AM J PHYSIOL-HEART C, V286, pH1354, DOI 10.1152/ajpheart.00549.2003; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Flatman PW, 2008, CURR OPIN NEPHROL HY, V17, P186, DOI 10.1097/MNH.0b013e3282f5244e; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; Gimenez I, 2003, J BIOL CHEM, V278, P26946, DOI 10.1074/jbc.M303435200; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; HALL ED, 1993, RES P ARNMD, V71, P81; HOFFMANN EK, 1985, FED PROC, V44, P2513; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iwamoto T, 2004, J PHARMACOL SCI, V96, P27, DOI 10.1254/jphs.FMJ04002X6; Jayakumar AR, 2008, J NEUROCHEM, V104, P135; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2011, J HEPATOL, V54, P272, DOI 10.1016/j.jhep.2010.06.041; Jayakumar AR, 2010, METAB BRAIN DIS, V25, P31, DOI 10.1007/s11011-010-9180-3; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kintner DB, 2007, AM J PHYSIOL-CELL PH, V292, pC1113, DOI 10.1152/ajpcell.00412.2006; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KRAUS JF, 1996, NEUROTRAUMA, P12; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LARSEN FS, 2001, LIVER TRANSP, V17, pC22; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MONGIN AA, 2005, NEUROGLIA, P550; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; Norenberg MD, 2009, METAB BRAIN DIS, V24, P103, DOI 10.1007/s11011-008-9113-6; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Reinert M, 2000, Neurosurg Focus, V8, pe10; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sugimoto H, 1997, J CEREBR BLOOD F MET, V17, P44, DOI 10.1097/00004647-199701000-00006; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939, DOI 10.1152/jn.1999.81.4.1939; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaziri ND, 1999, HYPERTENSION, V34, P1237, DOI 10.1161/01.HYP.34.6.1237; Vitari AC, 2006, BIOCHEM J, V397, P223, DOI 10.1042/BJ20060220; Wong JA, 2001, AM J PHYSIOL-REG I, V281, pR561, DOI 10.1152/ajpregu.2001.281.2.R561; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009; Zhao HY, 2004, J PHYSIOL-LONDON, V560, P123, DOI 10.1113/jphysiol.2004.066423; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019	74	59	63	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2011	117	3					437	448		10.1111/j.1471-4159.2011.07211.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	749KJ	WOS:000289464500008	21306384	Bronze			2022-02-06	
J	Corrigan, F; Pham, CLL; Vink, R; Blumbergs, PC; Masters, CL; van den Heuvel, C; Cappai, R				Corrigan, Frances; Pham, Chi L. L.; Vink, Robert; Blumbergs, Peter C.; Masters, Colin L.; van den Heuvel, Corinna; Cappai, Roberto			The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains	BRAIN RESEARCH			English	Article						Amyloid precursor protein; Growth factor like domain; E2 domain; sAPP alpha; Traumatic brain injury	ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; HIPPOCAMPAL-NEURONS; SECRETED FORMS; CELL-SURFACE; APP; PATHOPHYSIOLOGY; EXPRESSION; SEQUENCE; FAMILY	The amyloid precursor protein (APP) is known to increase following traumatic brain injury (TBI). This increase in levels of APP may be deleterious to outcome due to the production of neurotoxic A beta. Conversely, this upregulation may be beneficial as cleavage of APP via the alternative non-amyloidogenic pathway produces the soluble alpha form of APP (sAPP alpha), which is known to have many neuroprotective and neurotrophic functions. Indeed it has previously been shown that treatment with sAPP alpha following a diffuse injury in rats improves outcome. However, the exact location within the sAPP alpha molecule which contains this neuroprotective activity has yet to be determined. The sAPP alpha peptide can consist of up to 6 domains, with the main isoform in the brain missing the 4th and 5th. Of the remaining domains, the D1 and D6a domains seem the most likely as they have been shown to have beneficial actions in vitro. This present study examined the effects of in vivo posttraumatic administration via an intracerebroventricular injection of the D1, 02 and D6a domains of sAPP alpha on outcome following moderate-impact acceleration TBI in rats. While treatment with either the D1 or D6a domains was found to significantly improve motor and cognitive outcome, as assessed on the rotarod and Y maze, treatment with the D2 domain had no effect. Furthermore axonal injury was reduced in D1 and D6a domain treated animals, but not those that received the D2 domain. As the D1 and D6a domains contain a heparin binding region while the 02 domain does not, this suggests that sAPP alpha mediates its neuroprotective response through its ability to bind to heparin sulfate proteoglycans. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.	[Pham, Chi L. L.; Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Pham, Chi L. L.; Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Inst Med & Vet Sci, Hansen Inst, Adelaide, SA 5000, Australia		Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Cappai, Roberto/0000-0002-9505-8496; Corrigan, Frances/0000-0001-6150-8893; , Corinna/0000-0003-0664-8935	Brain Foundation (Australia); Neurosurgical Research Foundation (Australia)	This study was supported, in part, by a research grant from the Brain Foundation (Australia), and the Neurosurgical Research Foundation (Australia).	Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Dahms SO, 2010, P NATL ACAD SCI USA, V107, P5381, DOI 10.1073/pnas.0911326107; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JIN LW, 1994, J NEUROSCI, V14, P5461; MAAS AI, NEUROTHERAPEUTICS, V7, P115; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masliah E, 1997, NEUROSCIENCE, V78, P135, DOI 10.1016/S0306-4522(96)00553-2; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Morimoto T, 1998, J NEUROSCI, V18, P9386; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SMALL DH, 1994, J NEUROSCI, V14, P2117; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15	40	59	60	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 10	2011	1378						137	143		10.1016/j.brainres.2010.12.077			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	739PN	WOS:000288730300014	21215734				2022-02-06	
J	Green, DM; O'Phelan, KH; Bassin, SL; Chang, CWJ; Stern, TS; Asai, SM				Green, Deborah M.; O'Phelan, Kristine H.; Bassin, Sarice L.; Chang, Cherylee W. J.; Stern, Tracy S.; Asai, Susan M.			Intensive Versus Conventional Insulin Therapy in Critically Ill Neurologic Patients	NEUROCRITICAL CARE			English	Article						Insulin; Glucose; Intensive care unit; Mortality; Stroke; Traumatic brain injury; Intensive insulin therapy; ICU	GLUCOSE LEVEL; BRAIN-INJURY; HYPERGLYCEMIA; THROMBOLYSIS; METABOLISM; STROKE; IMPACT	Previous studies of glycemic control in non-neurologic ICU patients have shown conflicting results. The purpose was to investigate whether intensive insulin therapy (IIT) to keep blood glucose levels from 80 to 110 mg/dl or conventional treatment to keep levels less than 151 mg/dl was associated with a reduction of mortality and improved functional outcome in critically ill neurologic patients. Within 24 h of ICU admission, mechanically ventilated adult neurologic patients were enrolled after written informed consent and randomized to intensive or conventional control of blood glucose levels with insulin. Primary outcome measure was death within 3 months. Secondary outcome measures included 90-day modified Rankin scale (mRS) score, ICU, and hospital LOS. 81 patients were enrolled. The proportion of deaths was higher among IIT patients but this was not statistically significant (36 vs. 25%, P = 0.34). When good versus poor outcome at 3 months was dichotomized to mRS score 0-2 versus 3-6, respectively, there was no difference in outcome between the two groups (76.2 vs. 75% had a poor 3-month outcome, P = 1.0). There was also no difference in ICU or hospital LOS. Hypoglycemia (< 60 mg/dl) and severe hypoglycemia (< 40 mg/dl) were more common in the intensive arm (48 vs. 11%, P = 0.0006; and 4 vs. 0%, P = 0.5, respectively). There was no benefit to IIT in this small critically ill neurologic population. This is the first glycemic control study to specifically examine both critically ill stroke and traumatic brain injury (TBI) patients and functional outcome. Given these results, IIT cannot be recommended over conventional control.	[Green, Deborah M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [O'Phelan, Kristine H.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Bassin, Sarice L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Chang, Cherylee W. J.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Stern, Tracy S.; Asai, Susan M.] Queens Med Ctr, Honolulu, HI USA		Green, DM (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.	deborah.green@bmc.org	Chang, Cherylee/Y-8450-2019; Chang, Cherylee/ABG-2080-2020	Green-LaRoche, MD, Deborah/0000-0001-8158-0788	American Heart AssociationAmerican Heart Association; HMSA Foundation; Abbott LaboratoriesAbbott Laboratories; Queen Emma Foundation	This research was supported by grants from the American Heart Association, HMSA Foundation, Abbott Laboratories, and The Queen Emma Foundation. The Glucommander software was provided by American Healthways for a several month trial period though not specifically for the study, and was later purchased by the medical center. The findings and conclusions of this study do not necessarily represent the views of The Queen's Medical Center. Special thanks to the following people who contributed to the data collection, statistical analysis and advice regarding the study: Gheorghe Doros, PhD, Harlan Meyer, MD, PhD, Johnna Delcastillo, Lyle Oshita, RN, Edward Helekahi, RN, Eileen Cacal, RN, and Lisa Wagner, RN.	Baird TA, 2003, STROKE, V34, P2208, DOI 10.1161/01.STR.0000085087.41330.FF; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Davidson PC, 2005, DIABETES CARE, V28, P2418, DOI 10.2337/diacare.28.10.2418; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Els T, 2002, CEREBROVASC DIS, V13, P89, DOI 10.1159/000047756; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Kase CS, 2001, NEUROLOGY, V57, P1603, DOI 10.1212/WNL.57.9.1603; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F	20	59	64	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2010	13	3					299	306		10.1007/s12028-010-9417-3			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	685UO	WOS:000284653800002	20697836				2022-02-06	
J	Witt, ST; Lovejoy, DW; Pearlson, GD; Stevens, MC				Witt, Suzanne T.; Lovejoy, David W.; Pearlson, Godfrey D.; Stevens, Michael C.			Decreased prefrontal cortex activity in mild traumatic brain injury during performance of an auditory oddball task	BRAIN IMAGING AND BEHAVIOR			English	Article						fMRI; Mild TBI; Auditory oddball; Working memory; Executive function	CLOSED-HEAD-INJURY; WORKING-MEMORY CAPACITY; EVENT-RELATED POTENTIALS; NEUROPSYCHOLOGICAL DEFICITS; INDIVIDUAL-DIFFERENCES; TARGET DETECTION; FMRI; ATTENTION; P300; CONCUSSION	Up to one-third of patients with mild traumatic brain injury (TBI) demonstrate persistent cognitive deficits in the 'executive' function domain. Mild TBI patients have shown prefrontal cortex activity deficits during the performance of executive tasks requiring active information maintenance and manipulation. However, it is unclear whether these deficits are related to the executive processes themselves, or to the degree of mental effort. To determine whether prefrontal deficits also would be found during less effortful forms of executive ability, fMRI images were obtained on 31 mild TBI patients and 31 control participants during three-stimulus auditory oddball task performance. Although patients and controls had similar topographical patterns of brain activity, region-of-interest analysis revealed significantly decreased activity in right dorsolateral prefrontal cortex for mild TBI patients during target stimulus detection. Between-group analyses found evidence for potential compensatory brain activity during target detection and default-mode network dysfunction only during the detection of novel stimuli.	[Witt, Suzanne T.; Pearlson, Godfrey D.; Stevens, Michael C.] Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06106 USA; [Lovejoy, David W.] Hartford Hosp, Dept Neurosurg, Hartford, CT 06106 USA; [Lovejoy, David W.] Univ Connecticut, Sch Med, Dept Traumatol & Emergency Med, Farmington, CT USA; [Pearlson, Godfrey D.; Stevens, Michael C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Pearlson, Godfrey D.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA		Witt, ST (corresponding author), Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, 200 Retreat Ave,Whitehall Bldg, Hartford, CT 06106 USA.	stwitt@harthosp.org	Stevens, Michael/M-7678-2017; Witt, Suzanne/AAW-1413-2021	Stevens, Michael/0000-0002-3799-5465; Witt, Suzanne/0000-0002-5530-0807			Alvarez-Nunez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17; ALVES W, 1993, J HEAD TRAUMA REHAB, V8, P60; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; Calhoun VD, 2004, NEUROIMAGE, V22, P252, DOI 10.1016/j.neuroimage.2003.12.029; Calhoun VD, 2006, NEUROIMAGE, V30, P544, DOI 10.1016/j.neuroimage.2005.08.060; Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Carpenter PA, 2000, CURR OPIN NEUROBIOL, V10, P195, DOI 10.1016/S0959-4388(00)00074-X; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Colflesh GJH, 2007, PSYCHON B REV, V14, P699, DOI 10.3758/BF03196824; Conway A. R. A., 2007, VARIATION WORKING ME; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Elliott EM, 2006, EUR J COGN PSYCHOL, V18, P90, DOI 10.1080/09541440500216044; First M.B., 1996, STRUCTURED CLIN INTE; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Freire L, 2002, IEEE T MED IMAGING, V21, P470, DOI 10.1109/TMI.2002.1009383; Freire L, 2001, NEUROIMAGE, V14, P709, DOI 10.1006/nimg.2001.0869; FRIEDMAN D, 1993, PSYCHOL AGING, V8, P120, DOI 10.1037/0882-7974.8.1.120; Friedman D, 2009, HUM BRAIN MAPP, V30, P1144, DOI 10.1002/hbm.20587; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gronwall D, 1989, MILD HEAD INJURY, P153; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Josephs O, 1999, PHILOS T R SOC B, V354, P1215, DOI 10.1098/rstb.1999.0475; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiehl KA, 2005, NEUROIMAGE, V25, P899, DOI 10.1016/j.neuroimage.2004.12.035; Kiehl KA, 2001, PSYCHOPHYSIOLOGY, V38, P133, DOI 10.1017/S0048577201981867; Kirino E, 2000, J NEUROSCI, V20, P6612, DOI 10.1523/JNEUROSCI.20-17-06612.2000; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Linden DEJ, 2005, NEUROSCIENTIST, V11, P563, DOI 10.1177/1073858405280524; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCarthy G, 1997, J NEUROPHYSIOL, V77, P1630, DOI 10.1152/jn.1997.77.3.1630; McCrea M., 2008, MILD TRAUMATIC BRAIN; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; Naatanen R, 2004, CLIN NEUROPHYSIOL, V115, P140, DOI 10.1016/j.clinph.2003.04.001; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Poole BJ, 2009, Q J EXP PSYCHOL, V62, P1430, DOI 10.1080/17470210802479329; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Redick TS, 2006, APPL COGNITIVE PSYCH, V20, P713, DOI 10.1002/acp.1224; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; SMITH ME, 1990, ELECTROEN CLIN NEURO, V76, P235, DOI 10.1016/0013-4694(90)90018-F; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stevens MC, 2005, PSYCHOPHYSIOLOGY, V42, P636, DOI 10.1111/j.1469-8986.2005.00368.x; Stevens MC, 2005, NEUROIMAGE, V26, P782, DOI 10.1016/j.neuroimage.2005.02.044; Stevens MC, 2007, AM J PSYCHIAT, V164, P1737, DOI 10.1176/appi.ajp.2007.06050876; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Strobel A, 2008, NEUROIMAGE, V40, P869, DOI 10.1016/j.neuroimage.2007.10.065; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; von Wild KRH, 2008, ACT NEUR S, V101, P55; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	109	59	60	0	13	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2010	4	3-4					232	247		10.1007/s11682-010-9102-3			16	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658SB	WOS:000282508600004	20703959				2022-02-06	
J	Ban, SP; Son, YJ; Yang, HJ; Chung, YS; Lee, SH; Han, DH				Ban, Seung Pil; Son, Young-Je; Yang, Hee-Jin; Chung, Yeong Seob; Lee, Sang Hyung; Han, Dae Hee			Analysis of Complications Following Decompressive Craniectomy for Traumatic Brain Injury	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Decompressive craniectomy; Traumatic brain injury; Complication	INTRACRANIAL HYPERTENSION; HEAD-INJURY; PRESSURE; HEMICRANIECTOMY; MANAGEMENT; MORTALITY	Objective : Adequate management of increased intracranial pressure (ICP) is critical in patients with traumatic brain injury (TBI), and decompressive craniectomy is widely used to treat refractory increased ICP. The authors reviewed and analyzed complications following decompressive craniectomy for the management of TBI. Methods : A total of 89 consecutive patients who underwent decompressive craniectomy for TBI between February 2004 and February 2009 were reviewed retrospectively. Incidence rates of complications secondary to decompressive craniectomy were determined, and analyses were performed to identify clinical factors associated with the development of complications and the poor outcome. Results : Complications secondary to decompressive craniectomy occurred in 48 of the 89 (53.9%) patients. Furthermore, these complications occurred in a sequential fashion at specific times after surgical intervention; cerebral contusion expansion (2.2 +/- 1.2 days), newly appearing subdural or epidural hematoma contralateral to the craniectomy defect (1.5 +/- 0.9 days), epilepsy (2.7 +/- 1.5 days), cerebrospinal fluid leakage through the scalp incision (7.0 +/- 4.2 days), and external cerebral herniation (5.5 +/- 3.3 days). Subdural effusion (10.8 +/- 5.2 days) and postoperative infection (9.8 +/- 3.1 days) developed between one and four weeks postoperatively. Trephined and post-traumatic hydrocephalus syndromes developed after one month postoperatively (at 79.5 +/- 23.6 and 49.2 +/- 14.1 days, respectively). Conclusion : A poor GCS score (<= 8) and an age of >= 65 were found to be related to the occurrence of one of the above-mentioned complications. These results should help neurosurgeons anticipate these complications, to adopt management strategies that reduce the risks of complications, and to improve clinical outcomes.	[Ban, Seung Pil; Son, Young-Je; Yang, Hee-Jin; Chung, Yeong Seob; Lee, Sang Hyung; Han, Dae Hee] Seoul Natl Univ, Dept Neurosurg, Boramae Med Ctr, Seoul 156707, South Korea		Son, YJ (corresponding author), Seoul Natl Univ, Dept Neurosurg, Boramae Med Ctr, 39 Boramae Gil, Seoul 156707, South Korea.	petitprince1024@hanmail.net	Lee, Sang Hyung/J-5581-2012; Chung, Young Seob/J-5644-2012				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Cooper P R, 1976, Surg Neurol, V5, P25; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; DeWitt D S, 1995, New Horiz, V3, P376; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; GAAB MR, 1990, ACT NEUR S, V51, P326; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Zunt Joseph R, 2010, Handb Clin Neurol, V96, P125, DOI 10.1016/S0072-9752(09)96009-2	31	59	67	1	5	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	SEP	2010	48	3					244	250		10.3340/jkns.2010.48.3.244			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	670DY	WOS:000283402600010	21082053	Green Published, gold			2022-02-06	
J	Pauly, S; Klatte, F; Strobel, C; Schmidmaier, G; Greiner, S; Scheibel, M; Wildemann, B				Pauly, S.; Klatte, F.; Strobel, C.; Schmidmaier, G.; Greiner, S.; Scheibel, M.; Wildemann, B.			CHARACTERIZATION OF TENDON CELL CULTURES OF THE HUMAN ROTATOR CUFF	EUROPEAN CELLS & MATERIALS			English	Article						Rotator cuff; tendon healing; tenocyte; tendon-like cells; cell culture; tendon-bone	MEDIAL COLLATERAL LIGAMENT; DOUBLE-ROW REPAIR; GROWTH-FACTORS; IN-VITRO; TENASCIN-C; MUSCULOSKELETAL TISSUES; GENE-EXPRESSION; ASCORBIC-ACID; FIBROBLASTS; COLLAGEN	Rotator cuff tears are common soft tissue injuries of the musculoskeletal system that heal by formation of repair tissue and may lead to high retear rates and joint dysfunction. In particular, tissue from chronic, large tendon tears is or such degenerative nature that it may be prone to retear after surgical repair. Besides several biomechanical approaches, biologically based strategies such as application of growth factors may be promising for increasing cell activity and production of extracellular tendon matrix at the tendon-to-bone unit. As it precondition for subsequent experimental growth factor application, the aim of the present study was to establish and characterize a human rotator cuff tendon cell culture. Long head biceps (LHB)- and supraspinatus muscle (SSP)- tendon samples from donor patients undergoing shoulder surgery were cultivated and examined at the RNA level for expression of collagen type-I, -II and -III, biglycan, decorin, tenascin-C, aggrecan, osteocalcin, tenomodulin and scleraxis (by Real-time PCR). Finally, results were compared to chondrocytes and osteoblasts as control cells. An expression pattern was found which may reflect a human rotator cuff tenocyte-like cell culture. Both SSP and LHB tenocyte-like cells differed from chondrocyte cell cultures in terms of reduced expression of collagen type-II (p <= 0.05) and decorin while higher levels of collagen type-I were seen (P <= 0.05). With respect to osteoblasts, tenocyte-like cells expressed lower levels of osteocalcin (p <= 0.05) as well as tenascin C, biglycan and collagen type-III. Expression of scleraxis, tenomodulin and aggrecan was similar between all cell types. This study represents a characterization of tenocyte-like cells from the human rotator cuff as close as possible. It helps analyzing their biological properties and allows further studies to improve production of tendon matrix and osteofibroblastic integration at the tendon-bone unit following tendon repair.	[Pauly, S.; Klatte, F.; Strobel, C.; Schmidmaier, G.; Greiner, S.; Scheibel, M.; Wildemann, B.] Charite, Ctr Musculoskeletal Surg, Julius Wolff Inst, D-13353 Berlin, Germany; [Klatte, F.; Strobel, C.; Wildemann, B.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany		Wildemann, B (corresponding author), Charite, Ctr Musculoskeletal Surg, Julius Wolff Inst, Augustenburger Pl 1, D-13353 Berlin, Germany.	britt.wildemann@charite.de	Klatte-Schulz, Franka/B-6734-2017; Wildemann, Britt/G-7732-2012	Wildemann, Britt/0000-0002-8365-1188; Klatte-Schulz, Franka/0000-0001-6079-228X	European Society for Shoulder and Elbow Surgery (ESSES/SECEC)	The authors gratefully thank the European Society for Shoulder and Elbow Surgery (ESSES/SECEC, a non-profit organization) for generously providing a research grant. We thank Dr. Schulze-Tanzil and colleagues for the discussion regarding the tendon cell culture. We furthermore thank Dr. Ringe and colleagues for kindly providing primal chondrocyte cell cultures serving as a control.	Almarza AJ, 2008, ANN BIOMED ENG, V36, P1927, DOI 10.1007/s10439-008-9565-1; Angel MJ, 2006, SPORTS MED ARTHROSC, V14, P138, DOI 10.1097/00132585-200609000-00005; Anitua E, 2006, J BIOMED MATER RES A, V77A, P285, DOI 10.1002/jbm.a.30585; Archambault JM, 2007, J ORTHOP RES, V25, P617, DOI 10.1002/jor.20347; Batten ML, 1996, J ORTHOPAED RES, V14, P736, DOI 10.1002/jor.1100140509; Bayne O., 1984, SURG SHOULDER, P167; Baysal D, 2005, AM J SPORT MED, V33, P1346, DOI 10.1177/0363546505275130; Bishop J, 2006, J SHOULDER ELB SURG, V15, P290, DOI 10.1016/j.jse.2005.09.017; Blevins FT, 1997, ORTHOP CLIN N AM, V28, P1, DOI 10.1016/S0030-5898(05)70260-1; Boileau P, 2005, J BONE JOINT SURG AM, V87A, P1229, DOI 10.2106/JBJS.D.02035; Brune T, 2007, EUR CELLS MATER, V14, P78, DOI 10.22203/eCM.v014a08; Chang J, 2000, PLAST RECONSTR SURG, V105, P148, DOI 10.1097/00006534-200001000-00025; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586; Chuen FS, 2004, J HISTOCHEM CYTOCHEM, V52, P1151, DOI 10.1369/jhc.3A6232.2004; Cole BJ, 2007, J SHOULDER ELB SURG, V16, P579, DOI 10.1016/j.jse.2006.12.011; Costa MA, 2006, TISSUE ENG, V12, P1937, DOI 10.1089/ten.2006.12.1937; de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; Ehlers TW, 1998, COMP BIOCHEM PHYS A, V121, P355, DOI 10.1016/S1095-6433(98)10144-7; Flatow EL, 1996, J BONE JOINT SURG AM, V78A, P1785, DOI 10.2106/00004623-199611000-00028; Fu SC, 2008, J ORTHOP RES, V26, P374, DOI 10.1002/jor.20483; FUKUDA H, 1990, CLIN ORTHOP RELAT R, P75; GERBER C, 1994, J BONE JOINT SURG BR, V76B, P371, DOI 10.1302/0301-620X.76B3.8175836; Gigante A, 2004, J SHOULDER ELB SURG, V13, P328, DOI 10.1016/j.jse.2003.12.015; GUMINA S, 2009, MUSCULOSKELET SUR S1, V93, pS65; GUOGUANG Y, 2004, J BIOMECH, V37, P1543; HEFTI F, 1995, ORTHOPADE, V24, P237; Hsu C, 2004, J HAND SURG-AM, V29A, P551, DOI 10.1016/j.jhsa.2004.04.020; Ibold Y, 2009, TISSUE CELL, V41, P249, DOI 10.1016/j.tice.2008.12.001; Itaya T, 2009, J PERIODONTAL RES, V44, P425, DOI 10.1111/j.1600-0765.2008.01137.x; Jarvinen TAH, 2000, SCAND J MED SCI SPOR, V10, P376, DOI 10.1034/j.1600-0838.2000.010006376.x; Jelinsky SA, 2010, J ORTHOP RES, V28, P289, DOI 10.1002/jor.20999; Kannus P, 2000, SCAND J MED SCI SPOR, V10, P312, DOI 10.1034/j.1600-0838.2000.010006312.x; Kannus P, 1998, HISTOCHEM J, V30, P799, DOI 10.1023/A:1003448106673; Kardestuncer T, 2006, CLIN ORTHOP RELAT R, P234, DOI 10.1097/01.blo.0000205879.50834.fe; Klein MB, 2002, J HAND SURG-AM, V27A, P615, DOI 10.1053/jhsu.2002.34004; Lafosse L, 2007, J BONE JOINT SURG AM, V89A, P1533, DOI 10.2106/JBJS.F.00305; LEE J, 1995, J ORTHOP RES, V13, P435, DOI 10.1002/jor.1100130318; Li F, 2008, CELL MOTIL CYTOSKEL, V65, P332, DOI 10.1002/cm.20263; Lorbach O, 2008, AM J SPORT MED, V36, P1504, DOI 10.1177/0363546508314424; Maffulli N, 2000, AM J SPORT MED, V28, P499, DOI 10.1177/03635465000280040901; Maffulli N, 2002, BRIT J SPORT MED, V36, P315, DOI 10.1136/bjsm.36.5.315; Mahar A, 2007, ARTHROSCOPY, V23, P1265, DOI 10.1016/j.arthro.2007.07.010; Martin JA, 2003, BIORHEOLOGY, V40, P321; Marui T, 1997, J ORTHOPAED RES, V15, P18, DOI 10.1002/jor.1100150104; Matthews TJW, 2006, J BONE JOINT SURG BR, V88B, P489, DOI 10.1302/0301-620X.88B4.16845; Mazzocca AD, 2007, J SHOULDER ELB SURG, V16, p222S, DOI 10.1016/j.jse.2007.02.113; Molloy T, 2003, SPORTS MED, V33, P381, DOI 10.2165/00007256-200333050-00004; Neumann K, 2007, J CELL BIOCHEM, V102, P626, DOI 10.1002/jcb.21319; PATTE D, 1990, CLIN ORTHOP RELAT R, P81; PAULY S, 2010, ARTHROSCOPY IN PRESS; Rahaman MN, 2005, BIOTECHNOL BIOENG, V91, P261, DOI 10.1002/bit.20292; Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181; Riley GP, 1996, AM J PATHOL, V149, P933; Rios CG, 2007, TECH ORTHOP, V22, P2, DOI 10.1097/01.bto.0000261728.04529.0b; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Schulze-Tanzil G, 2004, HISTOCHEM CELL BIOL, V122, P219, DOI 10.1007/s00418-004-0694-9; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Scutt N, 2008, J Orthop Surg Res, V3, P32, DOI 10.1186/1749-799X-3-32; Severud EL, 2003, ARTHROSCOPY, V19, P234, DOI 10.1053/jars.2003.50036; Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036; Son E, 2007, NUTRITION, V23, P745, DOI 10.1016/j.nut.2007.06.013; STOLL C, 2010, J ORTHOP RE IN PRESS; Takahashi S, 2002, TOHOKU J EXP MED, V198, P207, DOI 10.1620/tjem.198.207; Tempfer H, 2009, ACTA ORTHOP, V80, P357, DOI 10.3109/17453670902988360; Theisen C, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-9; Thomopoulos S, 2005, J HAND SURG-AM, V30A, P441, DOI 10.1016/j.jhsa.2004.12.006; Thomopoulos S, 2007, J ORTHOP RES, V25, P1358, DOI 10.1002/jor.20444; Tsai AD, 2003, J CELL BIOCHEM, V90, P777, DOI 10.1002/jcb.10666; Wang B, 2008, BIOMATERIALS, V29, P2954, DOI 10.1016/j.biomaterials.2008.03.038; Wolf EM, 2004, ARTHROSCOPY, V20, P5, DOI 10.1016/j.arthro.2003.11.001; WONG M, 1992, J BIOL CHEM, V267, P5592; Yang GG, 2004, J BIOMECH, V37, P1543, DOI 10.1016/j.jbiomech.2004.01.005; Yao L, 2006, TISSUE ENG, V12, P1843, DOI 10.1089/ten.2006.12.1843; Yokota A, 2005, J SHOULDER ELB SURG, V14, p72S, DOI 10.1016/j.jse.2004.09.021; Yoon J. H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P22; [No title captured]	79	59	60	0	16	AO RESEARCH INSTITUTE DAVOS-ARI	DAVOS	CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND	1473-2262			EUR CELLS MATER	Eur. Cells Mater.	JUL-DEC	2010	20						84	97		10.22203/eCM.v020a08			14	Cell & Tissue Engineering; Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering; Materials Science; Orthopedics	652LA	WOS:000282006700005	20661865	Bronze, Green Submitted			2022-02-06	
J	Theus, MH; Ricard, J; Bethea, JR; Liebl, DJ				Theus, Michelle H.; Ricard, Jerome; Bethea, John R.; Liebl, Daniel J.			EphB3 Limits the Expansion of Neural Progenitor Cells in the Subventricular Zone by Regulating p53 During Homeostasis and Following Traumatic Brain Injury	STEM CELLS			English	Article						Traumatic brain injury; Ephrin; Eph; Subventricular zone; p53	CONTROLLED CORTICAL IMPACT; ADULT MAMMALIAN FOREBRAIN; STEM-CELLS; AXON-GUIDANCE; GROWTH-FACTOR; STIMULATES NEUROGENESIS; NEUROBLASTS MIGRATE; NEURONAL MIGRATION; COMMISSURAL AXONS; OLFACTORY-BULB	Ephrins and Eph receptor(s) have recently been implicated in regulating neurogenesis in the adult subventricular zone (SVZ) and rostral migratory stream. Here, we examined the role of ephrinB3-EphB3 signaling in mediating the SVZ response to traumatic brain injury (TBI). Analysis of EphB3 expression showed colocalization with glial fibrillary acidic protein-positive neural stem progenitor cells (NSPCs) and doublecortin-positive neuroblasts, whereas ephrinB3 was expressed outside the neurogenic region. TBI resulted in a significant reduction in EphB3 expression, which coincided with enhanced NSPC survival and proliferation at 3 and 7 days postinjury. Analysis of mice lacking either ephrinB3 (ephrinB3(-/-)) or EphB3 (EphB3(-/-)) showed a significant increase in bromodeoxyuridine (BrdU) incorporation and Ki67 immunoreactivity in the SVZ. Interestingly, cell death was dissimilar between knockout mice, where cell death was reduced in EphB3(-/-) but increased in ephrinB3(-/-) mice. Lateral ventricle infusion of soluble preclustered ephrinB3-Fc reversed the proliferative and cell death defects in ephrinB3(-/-) but not EphB3(-/-) mice and prevented TBI-induced proliferation in wild-type NSPCs. Coincidently, tumor suppressor p53 expression was increased following EphB3 stimulation and is reduced in the absence of either EphB3 or ephrinB3. Furthermore, pharmacological inhibition and siRNA knockdown of p53-attenuated ephrinB3-Fc-mediated growth suppression while having no effect on cell death in cultured NSPCs. These data demonstrate that EphB3 signaling suppresses NSPC proliferation in a p53-dependent manner, induces cell death in the absence of ligand stimulation and is transiently reduced in the SVZ to initiate the expansion and survival of endogenous adult NSPCs following Tin. STEM CELLS 2010:28:1231-1242	[Liebl, Daniel J.] Univ Miami, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Liebl, DJ (corresponding author), Univ Miami, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	dliebl@med.miami.edu		Ricard, Jerome/0000-0002-9019-4165	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049545, NS30291, NS007459, NS064699]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, F32NS064699, R01NS051709, R01NS049545, T32NS007459] Funding Source: NIH RePORTER	We thank Drs. Mark Henkemeyer and Mike Xu for their generous gift of the mutant mice. This work was supported by NIH/NINDS NS049545 (to D.J.L.), NS30291 (to D.J.L.), NS007459 (to M.H.T.), NS064699 (to M.H.T.), and the Miami Project to Cure Paralysis.	ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arakawa H, 2005, CELL DEATH DIFFER, V12, P1057, DOI 10.1038/sj.cdd.4401601; Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BAIER H, 1994, SCIENCE, V265, P1541, DOI 10.1126/science.8079167; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; Bergemann AD, 1998, ONCOGENE, V16, P471, DOI 10.1038/sj.onc.1201557; Betarbet R, 1996, INT J DEV NEUROSCI, V14, P921, DOI 10.1016/S0736-5748(96)00066-4; Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076; Bose I, 2007, J BIOSCIENCES, V32, P991, DOI 10.1007/s12038-007-0103-3; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; del Rio G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000463; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Geng Y, 2010, J HISTOCHEM CYTOCHEM, V58, P265, DOI 10.1369/jhc.2009.954024; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Grunwald IC, 2002, CURR OPIN NEUROBIOL, V12, P250, DOI 10.1016/S0959-4388(02)00323-9; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Ivanov AI, 2005, PHYSIOL GENOMICS, V21, P152, DOI 10.1152/physiolgenomics.00043.2004; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Kempermann G, 1999, SCI AM, V280, P48, DOI 10.1038/scientificamerican0599-48; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Kuribayashi K, 2008, ADV EXP MED BIOL, V615, P201, DOI 10.1007/978-1-4020-6554-5_10; Li YY, 1998, AM J PHYSIOL-HEART C, V274, pH331, DOI 10.1152/ajpheart.1998.274.1.H331; Li YY, 2001, AM J PHYSIOL-HEART C, V281, pH2738, DOI 10.1152/ajpheart.2001.281.6.H2738; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medrano S, 2005, BIOCHEM BIOPH RES CO, V331, P828, DOI 10.1016/j.bbrc.2005.03.194; Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016; Mehlen P, 2004, CELL MOL LIFE SCI, V61, P1854, DOI 10.1007/s00018-004-3467-7; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mendes SW, 2006, J NEUROSCI, V26, P882, DOI 10.1523/JNEUROSCI.3162-05.2006; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Middeldorp J, 2010, DEVELOPMENT, V137, P313, DOI 10.1242/dev.041632; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Orike N, 1996, CURR BIOL, V6, P108, DOI 10.1016/S0960-9822(02)00435-9; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Wiltrout C, 2007, NEUROCHEM INT, V50, P1028, DOI 10.1016/j.neuint.2007.04.011; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yan YP, 2006, EUR J NEUROSCI, V24, P45, DOI 10.1111/j.1460-9568.2006.04872.x; Yokoyama N, 2001, NEURON, V29, P85, DOI 10.1016/S0896-6273(01)00182-9; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou J, 2004, CURR MOL MED, V4, P741, DOI 10.2174/1566524043359926; Zhu DY, 2003, J NEUROSCI, V23, P223	99	59	60	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	JUL	2010	28	7					1231	1242		10.1002/stem.449			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	636OF	WOS:000280746400012	20496368	Green Accepted, Bronze			2022-02-06	
J	Yang, ZY; Duan, HM; Mo, LH; Qiao, H; Li, XG				Yang, Zhaoyang; Duan, Hongmei; Mo, Linhong; Qiao, Hui; Li, Xiaoguang			The effect of the dosage of NT-3/chitosan carriers on the proliferation and differentiation of neural stem cells	BIOMATERIALS			English	Article						Chitosan carriers; NT-3; Neural stem cells; Cell differentiation; Neuron	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; PROGENITOR CELLS; ADULT RATS; PARKINSONS-DISEASE; GENE-THERAPY; NEUROTROPHIN-3; TRANSPLANTATION	This study aimed to determine the optimal dosage range of NT-3 in the soluble form or loaded with chitosan carriers by using NT-3/chitosan carriers to support the survival and proliferation of neural stem cells (NSCs) and induce them to differentiate into desired phenotypes. NSCs were co-cultured with chitosan carriers loaded with different doses of NT-3. As the control, NSCs were cultured in the defined medium, into which were added different doses of NT-3 in the soluble form every day. The ELISA kit was used to study the NT-3 releasing kinetics, which showed that, in the initial co-culture stage from 1 h to 14 weeks, the chitosan carriers loaded with different doses of NT-3 released NT-3 stably and constantly. The 3-(4,5-dimethylthiazol-2-y1)-2, 5-diphenyltetrazolium bromide (MTT) assay was conducted to measure the cell viability, and the immunocytochemical methods were adopted to quantitatively analyze the phenotypes differentiating from the NSCs. Compared to the 100 ng NT-3 daily addition group (1400 ng over 14 days), the 25 ng, 50 ng and 200 ng NT-3 daily addition group showed dramatically shorter processes length and much lower differentiation percentage from NSCs into neurons. By contrast, the NT-3 (25 ng)-chitosan carriers group had not only higher cell viability, but also similar processes length and differentiation percentage from NSCs into neurons to the 100 ng NT-3 daily addition group. The method developed in this study significantly reduced the NT-3 amount required to support the survival, proliferation and differentiation of NSCs in vitro. Meanwhile, the chitosan carriers used here provided an ideal 3-dimensional scaffold for the adhesion, migration, proliferation and differentiation of NSC and the differentiated cells. Therefore, this method may open a new field for the large-scaled culture and amplification of NSCs in vitro to replace the lost neural cells, meanwhile lower the consumption of neurotrophic factors in the cell transplantation therapy of brain and spinal injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Yang, Zhaoyang; Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Beijing 100191, Peoples R China; [Duan, Hongmei; Mo, Linhong; Li, Xiaoguang] Capital Med Univ, Beijing Inst Neurosci, Beijing 100069, Peoples R China; [Qiao, Hui] Ningxia Med Univ, Publ Heath Sch, Ningxia 750004, Peoples R China		Li, XG (corresponding author), Beihang Univ, Sch Biol Sci & Med Engn, XueYuan Rd 37, Beijing 100191, Peoples R China.	lxgchina@sina.com		Duan, Hongmei/0000-0003-2261-2182	National 863 Project [2006AA02A129]; Department of Science and Technology, Beijing, ChinaDepartment of Science & Technology (India) [D09080703660902]	This work was supported by The National 863 Project (Grant No. 2006AA02A129), and Key Project of Department of Science and Technology (Grant No. D09080703660902), Beijing, China. The authors would like to express heartfelt thanks to Liwei Zhang for kind help and constructive comments.	Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Burdick JA, 2006, BIOMATERIALS, V27, P452, DOI 10.1016/j.biomaterials.2005.06.034; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Cheng H, 2007, BIOCHEM BIOPH RES CO, V357, P938, DOI 10.1016/j.bbrc.2007.04.049; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Dutton R, 1999, J NEUROSCI, V19, P2601; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAO EJ, 2004, CHIN J REHABIL THEOR, V10, P28; Grill R, 1997, J NEUROSCI, V17, P5560; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Hapner SJ, 2006, DEV BIOL, V297, P182, DOI 10.1016/j.ydbio.2006.05.007; Hung CH, 2006, BIOMATERIALS, V27, P4461, DOI 10.1016/j.biomaterials.2006.04.021; IIKHANIZADEH S, 2007, BIOMATERIALS, V28, P3936; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; Li XG, 2006, PROG NAT SCI-MATER, V16, P1051; Li XG, 2006, CHINESE SCI BULL, V51, P918, DOI 10.1007/s11434-006-0918-6; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lu HX, 2008, BRAIN RES BULL, V77, P158, DOI 10.1016/j.brainresbull.2008.02.037; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Taylor SJ, 2006, J CONTROL RELEASE, V116, P204, DOI 10.1016/j.jconrel.2006.07.005; Tzeng SF, 2002, J BIOMED SCI, V9, P10, DOI 10.1159/000048194; Wang JH, 2006, BIOMATERIALS, V27, P3441, DOI 10.1016/j.biomaterials.2006.02.002; Wang Y, 2007, J NEUROIMMUNE PHARM, V2, P243, DOI 10.1007/s11481-007-9074-2; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Yan J, 2004, J COMP NEUROL, V480, P101, DOI 10.1002/cne.20344; Young TH, 2005, BIOMATERIALS, V26, P4291, DOI 10.1016/j.biomaterials.2004.10.043; Zhao LX, 2004, EXP NEUROL, V190, P396, DOI 10.1016/j.expneurol.2004.06.025; ZHENG LH, 2002, THEORY PRACTICE NEUR, P195; ZIGMOND SH, J CELL BIOL, V88, P644	43	59	70	0	46	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JUN	2010	31	18					4846	4854		10.1016/j.biomaterials.2010.02.015			9	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	597SY	WOS:000277783100008	20346501				2022-02-06	
J	Wiesmann, M; Steinmeier, E; Magerkurth, O; Linn, J; Gottmann, D; Missler, U				Wiesmann, M.; Steinmeier, E.; Magerkurth, O.; Linn, J.; Gottmann, D.; Missler, U.			Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cerebrospinal fluid; critical care; head injury; neuroimaging; neurotraumatology	FIBRILLARY ACIDIC PROTEIN; SEVERE HEAD-INJURY; S-100B PROTEIN; SERUM; PROGNOSIS; COMA; DAMAGE; CLASSIFICATION; INDICATORS; STEM	Objective - To investigate the predictive value of early serum levels of S100B and glial fibrillary acidic protein (GFAP) in traumatic brain injury. Methods - Sixty patients admitted within 24 h of trauma were included. Neurological status on admission (Glasgow Coma Scale), initial cranial computed tomography (CCT) studies (Marshall Computed Tomographic Classification), and outcome after 6 months (Glasgow Outcome Scale) were evaluated. S100B and GFAP levels were determined on admission and 24 h after trauma. Results - Blood levels of S100B and GFAP were elevated following head trauma and quantitatively reflected the severity of trauma. S100B levels after 24 h and on admission were of higher predictive value than CCT findings or clinical examination. GFAP, but not S100B levels rapidly declined after trauma. Conclusions - Blood levels of S100B and GFAP indicate the severity of brain damage and are correlated with neurological prognosis after trauma. Both methods can yield additional prognostic information if combined with clinical and CCT findings.	[Wiesmann, M.; Magerkurth, O.; Linn, J.; Gottmann, D.] Univ Munich, Dept Neuroradiol, Munich, Germany; [Wiesmann, M.] Helios Kliniken Schwerin, Dept Neuroradiol, Schwerin, Germany; [Steinmeier, E.] Ernst Moritz Arndt Univ Greifswald, Dept Otorhinolaryngol Head & Neck Surg, Greifswald, Germany; [Missler, U.] Evangel Krankenhaus Duisburg Nord, Dept Neuroradiol, Duisburg, Germany		Wiesmann, M (corresponding author), Univ Klinikum Munchen Grosshadern, Abt Neuroradiol, Marchioninist 15, D-81377 Munich, Germany.	martin.wiesmann@med.uni-muenchen.de	Linn, Jennifer/AAE-1567-2021; Magerkurth, Olaf/AAH-5482-2020; Linn, Jennifer/H-8202-2013	Linn, Jennifer/0000-0003-0797-2761			Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; Hoelper BM, 2000, ACT NEUR S, V76, P265; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KAKARIEKA A, 1997, TRAUMATIC SUBARACHNO; MARION DW, 1996, NEUROTRAUMA, P767; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 2000, CLIN CHEM, V46, P993; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Missler U, 1999, CLIN CHEM, V45, P138; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Wiesmann M, 1998, RADIOLOGE, V38, P645, DOI 10.1007/s001170050405; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAURA A, 1981, Neurologia Medico-Chirurgica, V21, P685	37	59	64	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	2010	121	3					178	185		10.1111/j.1600-0404.2009.01196.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	548TV	WOS:000273991300006	19804476				2022-02-06	
J	Carrera, E; Kim, DJ; Castellani, G; Zweifel, C; Czosnyka, Z; Kasparowicz, M; Smielewski, P; Pickard, JD; Czosnyka, M				Carrera, Emmanuel; Kim, Dong-Joo; Castellani, Gianluca; Zweifel, Christian; Czosnyka, Zofia; Kasparowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek			What Shapes Pulse Amplitude of Intracranial Pressure?	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow autoregulation; cerebral blood flow velocity; intracranial pressure; neurodegenerative disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; VOLUME; WAVE; AUTOREGULATION; TRANSMISSION; THRESHOLD; SYSTEM; SPACE	The pulsatile component of intracranial pressure (ICP) has been shown to be a predictor of outcome in normal pressure hydrocephalus (NPH) and traumatic brain injury (TBI). Experimental studies have demonstrated that the pulse amplitude of ICP (AMP(ICP)) is dependent on the mean ICP (mICP), and on the pulse amplitude of the cerebral arterial blood volume (AMP(CaBV)), according to the exponential craniospinal compliance curve. In this study, we compared the influence of mICP and AMP(CaBV) on AMP(ICP) in patients with NPH (infusion study) and TBI (spontaneous recording). We retrospectively analyzed 25 NPH and 43 TBI patients with continuous monitoring of ICP and cerebral blood flow velocity (CBFV), as assessed with transcranial doppler. AMP(CaBV) was extracted from the CBFV waveform. The influence of mICP and AMP(CaBV) on AMP(ICP) were determined using partial coefficients a, b, and c of the multiple regression model: AMP(ICP)-a* mICP+b* AMP(CaBV)+c. AMP(ICP) was more dependent on mICP in NPH patients than in TBI patients (partial coefficient a-0.93 versus-0.03; p<0.001). On the contrary, AMP(ICP) was more dependent on AMP(CaBV) in patients with TBI than in those with NPH (b-0.86 versus 0.10; p<0.001). This study shows that AMP(ICP) depends mostly on changes in mean ICP during cerebrospinal fluid (CSF) infusion studies in patients with NPH, and on changes in cerebral arterial blood volume (AMP(CaBV)) in TBI patients. Further clinical studies will reveal whether AMP(ICP) is a better indicator of clinical severity and outcome than mICP in TBI and NPH patients.	[Carrera, Emmanuel; Kim, Dong-Joo; Castellani, Gianluca; Zweifel, Christian; Czosnyka, Zofia; Kasparowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 2QQ, England		Carrera, E (corresponding author), Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Addenbrookes Hosp, Level 4,A Block, Cambridge CB2 2QQ, England.	emmanuelcarrera@yahoo.com		Carrera, Emmanuel/0000-0003-0045-5382; Smielewski, Peter/0000-0001-5096-3938	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; SICPA Foundation; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Centre; Cambridge University Hospital Foundation; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the Swiss National Science Foundation, the SICPA Foundation, The Foundation for Polish Science, and the National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation.	AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AVEZAAT CJ, 1984, CEREBROSPINAL FLUID, P57; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CZOSNYKA M, 1988, ACTA NEUROCHIR, V93, P140, DOI 10.1007/BF01402897; CZOSNYKA M, 1990, ACTA NEUROCHIR, V105, P112, DOI 10.1007/BF01669992; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE2; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; Eide PK, 2007, ACTA ANAESTH SCAND, V51, P1273, DOI 10.1111/j.1399-6576.2007.01433.x; Eide PK, 2006, ACTA NEUROCHIR, V148, P1267, DOI 10.1007/s00701-006-0908-0; Eide PK, 2006, ACTA NEUROCHIR, V148, P1151, DOI 10.1007/s00701-006-0896-0; Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X; HAMER J, 1977, J NEUROSURG, V46, P36, DOI 10.3171/jns.1977.46.1.0036; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; LANGFITT TW, 1964, J NEUROSURG, V21, P998, DOI 10.3171/jns.1964.21.11.0998; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; Ratanalert S, 2004, SURG NEUROL, V61, P429, DOI 10.1016/S0090-3019(03)00579-2; Schuhmann MU, 2008, PEDIATR NEUROSURG, V44, P269, DOI 10.1159/000131675; SZEWCZYKOWSKI J, 1977, J NEUROSURG, V47, P19, DOI 10.3171/jns.1977.47.1.0019; TAKIZAWA H, 1987, NEUROSURGERY, V20, P355, DOI 10.1227/00006123-198703000-00001; VANEIJNDHOVEN JHM, 1986, NEUROSURGERY, V19, P507, DOI 10.1227/00006123-198610000-00004	28	59	60	0	14	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					317	324		10.1089/neu.2009.0951			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800004	19852586				2022-02-06	
J	Schonberger, M; Ponsford, J; Olver, J; Ponsford, M				Schonberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael			A longitudinal study of family functioning after TBI and relatives' emotional status	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury (TBI); Family functioning; Relatives; Emotional status; Distress; Anxiety; Depression	TRAUMATIC BRAIN-INJURY; SOCIAL SUPPORT; CAREGIVER BURDEN; HEAD-INJURY; FOLLOW-UP; PSYCHOLOGICAL DISTRESS; REHABILITATION PROGRAM; ASSESSMENT DEVICE; DEPRESSION SCALE; HOSPITAL ANXIETY	The objectives of the study were to examine family functioning and relatives' emotional state after traumatic brain injury (TBI), and to test a model of the relationship between neurobehavioural status, family functioning and relatives' emotional status at two and five years post-injury. The relatives of 98 adult individuals who had sustained severe TBI were followed up 2 and 5 years post-injury and completed the Family Assessment Device, the Hospital Anxiety and Depression Scale, and rated the neurobehavioural status (cognitive, behavioural, emotional, social) of their injured relative, using the Structured Outcomes Questionnaire. A structural equation model, based on existing research, was developed and tested on 66 of the participants. The level of family functioning and the rates of clinically relevant levels of anxiety and depression did not change over time (p .05). The starting path model was revised. The final model had an excellent fit, 2(16) = 15.20, p = .51; CFI = 1.00, RMSEA .001, p for test of close fit = .66. In this model, poor family functioning and symptoms of anxiety and depression in the relatives were predicted by behavioural and mood changes in the injured individual. The relationship between family functioning and relatives' mood was reciprocal. The findings suggest the need for timely investigation and institution of interventions. Support is needed both for individual family members in dealing with their emotional distress as well as for the family as a whole, with the aim of maximising quality of life for those with TBI and their relatives.	[Schonberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schonberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia		Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	michael.schoenberger@web.de		Olver, John/0000-0001-7069-1191	Victorian Neurotrauma Initiative; Transport Accident Commission	This study was supported by the Victorian Neurotrauma Initiative and the Transport Accident Commission.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; Brooks D. N., 1987, J HEAD TRAUMA REHAB, V2, P1; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burke L, 2003, INT REV PSYCHIATR, V15, P243, DOI 10.1080/0954026031000136866; Butterworth P, 2008, SOC PSYCH PSYCH EPID, V43, P758, DOI 10.1007/s00127-008-0366-5; CARNWATH CM, 1987, BRIT MED J, V294, P409; Chan J, 2007, INT J REHABIL RES, V30, P137, DOI 10.1097/MRR.0b013e32813a2f11; Charles N, 2007, NEUROREHABILITATION, V22, P61; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Ergh TC, 2001, CLIN NEUROPSYCHOL, V15, P271; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI 10.1037/1082-989X.9.4.466; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Joreskog K, 1999, LARGE CAN STANDARDIZ; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kessing LV, 1999, AM J EPIDEMIOL, V149, P404; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEIF L, 1993, BRAIN INJURY, V7, P543; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marshall AJ, 2008, J FAM NURS, V14, P56, DOI 10.1177/1074840707312717; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Minnes P, 2000, BRAIN INJURY, V14, P737; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; Snaith R., 1983, HOSP ANXIETY DEPRESS; Spielberger C.D., 1992, J FAMILY PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; van Wijngaarden B, 2004, J AFFECT DISORDERS, V81, P211, DOI 10.1016/S0165-0327(03)00168-X; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Yonkers KA, 2003, DEPRESS ANXIETY, V17, P173, DOI 10.1002/da.10106	60	59	59	0	19	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					813	829	PII 927100089	10.1080/09602011003620077			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300002	20859828				2022-02-06	
J	Derrett, S; Langley, J; Hokowhitu, B; Ameratunga, S; Hansen, P; Davie, G; Wyeth, E; Lilley, R				Derrett, S.; Langley, J.; Hokowhitu, B.; Ameratunga, S.; Hansen, P.; Davie, G.; Wyeth, E.; Lilley, R.			Prospective outcomes of injury study	INJURY PREVENTION			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; RACIAL-DISCRIMINATION; MAJOR TRAUMA; NEW-ZEALAND; DISABILITY; WORK; HEALTH; DETERMINANTS; IMPACT	Background: In New Zealand (NZ), 20% of adults report a disability, of which one-third is caused by injury. No prospective epidemiological studies of predictors of disability following all-cause injury among New Zealanders have been undertaken. Internationally, studies have focused on a limited range of predictors or specific injuries. Although these studies provide useful insights, applicability to NZ is limited given the importance of NZ's unique macro-social factors, such as NZ's no-fault accident compensation and rehabilitation scheme, the Accident Compensation Corporation (ACC). Objectives: (1) To quantitatively determine the injury, rehabilitation, personal, social and economic factors leading to disability outcomes following injury in NZ. (2) To qualitatively explore experiences and perceptions of injury-related outcomes in face-to-face interviews with 15 Maori and 15 other New Zealanders, 6 and 12 months after injury. Setting: Four geographical regions within NZ. Design: Prospective cohort study with telephone interviews 1, 4 and 12 months after injury. Participants: 2500 people (including 460 Maori), aged 18-64 years, randomly selected from ACC's entitlement claims register (people likely to be off work for at least 1 week or equivalent). Data: Telephone interviews, electronic hospital and ACC injury data. Exposures include demographic, social, economic, work-related, health status, participation and/or environmental factors. Outcome measures: Primary: disability (including WHODAS II) and health-related quality of life (including EQ-5D). Secondary: participation (paid and unpaid activities), life satisfaction and costs. Analysis: Separate regression models will be developed for each of the outcomes. Repeated measures outcomes will be modelled using general estimating equation models and generalised linear mixed models.	[Derrett, S.; Langley, J.; Davie, G.; Lilley, R.] Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin Sch Med, Dunedin, New Zealand; [Hokowhitu, B.] Univ Otago, Te Tumu Sch Maori Pacific & Indigenous Studies, Dunedin, New Zealand; [Ameratunga, S.] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1, New Zealand; [Hansen, P.] Univ Otago, Dept Econ, Dunedin, New Zealand; [Wyeth, E.] Univ Otago, Dept Prevent & Social Med, Ngai Tahu Maori Hlth Res Unit, Dunedin Sch Med, Dunedin, New Zealand		Langley, J (corresponding author), Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin Sch Med, Dunedin, New Zealand.	john.langley@ipru.otago.ac.nz		Hokowhitu, Brendan/0000-0002-1913-1559; Davie, Gabrielle/0000-0001-5466-5364; Ameratunga, Shanthi/0000-0001-8042-2251; Derrett, Sarah/0000-0003-2867-0498; Wyeth, Emma/0000-0002-6869-5190	Health Research Council of New ZealandHealth Research Council of New Zealand; Accident Compensation Corporation, Wellington, New Zealand	This study is funded by the Health Research Council of New Zealand and the Accident Compensation Corporation, Wellington, New Zealand.	*ACC COMP CORP, 2006, ENT CLAIM AG 18 65 Y; *ACC COMP CORP, 2006, PERS COMM RES TEAM; *ACC COMP CORP, 2005, ACC INJ STAT; Adams M., 2002, AFTERMATH SOCIAL EC; AMERATUNGA S, ANN EMERGEN IN PRESS; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS1, DOI 10.1053/apmr.2000.20614; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Bishop, 1997, ED RES PERSPECTIVES, V24, P28; Bishop R, 1996, COLLABORATIVE RES ST; BISHOP R, 1994, NZ J ED STUDIES, V29, P1; BISMARCK M, 2006, MAUR OR MAOR HLTH S; BRAY A, 2002, SAFE LIVES PEOPLE IN; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Broughton J, 2000, NEW ZEAL MED J, V113, P511; Brych SB, 2001, J BURN CARE REHABIL, V22, P401, DOI 10.1097/00004630-200111000-00010; CLANDININ D, 1991, NARRATIVE STORY PRAC; Cole DC, 2002, CAN MED ASSOC J, V166, P749; Creswell J.W., 2017, RES DESIGN QUALITATI; CRICHTON S, 2005, 1857 IZA DP I STUD L; Devlin N, 2000, 180 U YORK; Dionne CE, 2005, CAN MED ASSOC J, V172, P1559, DOI 10.1503/cmaj.1041159; Frank Arthur W., 1997, WOUNDED STORYTELLER; Harris R, 2006, SOC SCI MED, V63, P1428, DOI 10.1016/j.socscimed.2006.04.009; Harris R, 2006, LANCET, V367, P2005, DOI 10.1016/S0140-6736(06)68890-9; Hendrie Delia, 2004, Aust Health Rev, V28, P363; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Hurst R, 2003, DISABIL REHABIL, V25, P572, DOI 10.1080/0963828031000137072; JENSEN J, 2005, SOC POLICY J N Z, P134; JENSEN J, 2005, DISABILITY WORK PART; KING A, 2000, NZ HLTH STRATEGY; Kingi J., 2000, MAORI CONCEPTS DISAB; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; KUIJER W, 2005, DISABILITY REHABILIT, P379; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Langley J, 2000, NEW ZEAL MED J, V113, P508; LANGLEY J, 1998, NGA TATAURANGA INJUR; Lather P., 1991, GETTING SMART FEMINI; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Lydell M, 2005, J REHABIL MED, V37, P281, DOI 10.1080/16501970510030255; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MAPSTONE J, 2006, STRATEGIES IMPROVE R; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; *MIN HLTH, 2004, LIV DIS NZ; Ministry of Health, 2001, PRIOR MAOR PAC HLTH; Nilsen Per, 2006, Int J Inj Contr Saf Promot, V13, P7, DOI 10.1080/17457300500167651; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; *OFF DIS ISS, 2005, INCL DIS PERSP TOOLK; Oliver M., 1996, UNDERSTANDING DISABI; Ottosson C, 2005, J TRAUMA, V58, P553, DOI 10.1097/01.TA.0000152634.66513.AF; Peden M., 2002, INJURY CHART BOOK GR; Post MWM, 1999, CLIN REHABIL, V13, P5, DOI 10.1191/026921599701532072; Priestley M., 2003, DISABILITY LIFE COUR; Richardson G, 2005, INT J TECHNOL ASSESS, V21, P423, DOI 10.1017/S0266462305050592; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Shakespeare Tom, 2001, EXPLORING THEORIES E, V2; STAMM TA, 2005, AUSTR OCCUPATIONAL T, P1; *STAT NZ TAT AOT, 2002, DIS COUNTS 2001; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; SULLIVAN M, 1996, PARAPLEGIC BODIES SE; TRIPP DH, 1983, INTERCHANGE, V14, P32, DOI 10.1007/BF01810469; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; Uppal S, 2006, SOC SCI MED, V63, P525, DOI 10.1016/j.socscimed.2006.01.016; Ustun TB, 2003, DISABIL REHABIL, V25, P565, DOI 10.1080/0963828031000137063; VANBEECK E, 2005, DRAFT GUIDELINES CON, P1; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Ville I, 2006, DISABIL REHABIL, V28, P423, DOI 10.1080/09638280500192561; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Wade DT, 2000, BMJ-BRIT MED J, V320, P1385, DOI 10.1136/bmj.320.7246.1385; Wang PP, 2006, DISABIL REHABIL, V28, P135, DOI 10.1080/09638280500167761; Wolcott HF., 1994, TRANSFORMING QUALITA; World Health Organization, 2001, ICF INT CLASS FUNCT; World Health Organization (WHO), 2002, WHO TRADITIONAL MED	74	59	59	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2009	15	5								10.1136/ip.2009.022558			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	502UJ	WOS:000270485400019	19805606				2022-02-06	
J	Park, S; Ahn, J; Gee, AO; Kuntz, AF; Esterhai, JL				Park, SangDo; Ahn, Jaimo; Gee, Albert O.; Kuntz, Andrew F.; Esterhai, John L.			Compartment Syndrome in Tibial Fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						compartment syndrome; tibial fractures; risk factors; age; tibia; fasciotomy	RISK; SKIN; AGE	Objectives: Compartment syndrome is a devastating complication of tibial fractures. The purpose of this study was to investigate the rate of clinically determined compartment syndrome requiring surgical intervention in tibial fractures by anatomical region and to identify the associated patient and injury factors. Design: Retrospective cohort. Setting: University level I trauma center. Patients/Participants: Acute tibial fractures in 414 patients from January 1, 2004 through October 31, 2006. Methods: Tibial fractures in 414 patients met the inclusion and exclusion criteria. The fractures were classified into 3 groups (proximal, diaphyseal, and distal) based on the anatomic location of the fractures (AO/OTA fractures 41, 42, and 43, respectively). To determine the patient and injury factors associated with the development of compartment syndrome in tibia] fractures, the following data were obtained: patient age and sex, mechanism of injury, presence of associated fractures, presence of concomitant head/chest/abdominal/pelvic injury, blood pressure upon admission, open versus closed fracture (Gustilo-Anderson classification if open), status of the fibula, and AO/OTA classification of the tibial fracture. Main Outcome Measures: Rate of clinically determined compartment syndrome requiring fasciotomy by anatomical region of the tibia. Results: The rate of compartment syndrome was highest in the diaphyseal group (8.1 %, P < 0.05) followed by proximal (1.6%) and distal (1.4%) groups. The diaphyseal group was further analyzed according to patient and injury factors. Patients who developed compartment syndrome were significantly younger (27.5 years +/- 11.7 SD versus 39.0 years +/- 16.7 SD, P = 0.003, Student t test) than those who did not develop compartment syndrome. The mean arterial pressures upon admission of the patients who developed compartment syndrome were also found to be slightly higher (107 versus 98.5 mm Hg, P = 0.039, Student t test) but not significantly so after Bonferrom adjustment. In multivariate regression analysis, decreasing age remained the only statistically significant independent predictor for the development of compartment syndrome (P = 0.006, regression coefficient = -0.0589) in diaphyseal tibial fractures. Conclusions: Tibial fractures of the diaphysis are more frequently associated with development of compartment syndrome than proximal or distal tibial fractures. More specifically, young patients with diaphyseal fractures are at risk for developing this complication and warrant increased vigilance and suspicion for compartment syndrome. A prospective study with sufficient power is needed to further identify risk factors associated with compartment syndrome in tibial fractures.	[Park, SangDo; Ahn, Jaimo; Gee, Albert O.; Kuntz, Andrew F.; Esterhai, John L.] Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA		Park, S (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein Paavil,3400 Spruce St, Philadelphia, PA 19104 USA.	sangdo.park@uphs.upenn.edu		Kuntz, Andrew/0000-0003-3053-5500			Barei DP, 2004, J ORTHOP TRAUMA, V18, P649, DOI 10.1097/00005131-200411000-00001; BLICK SS, 1986, J BONE JOINT SURG AM, V68A, P1348, DOI 10.2106/00004623-198668090-00007; BOURNE RB, 1989, CLIN ORTHOP RELAT R, P97; DELEE JC, 1981, CLIN ORTHOP RELAT R, P175; Egol KA, 2005, J ORTHOP TRAUMA, V19, P448, DOI 10.1097/01.bot.0000171881.11205.80; HALPERN AA, 1980, J TRAUMA, V20, P786, DOI 10.1097/00005373-198009000-00013; LEVY AS, 1994, J ORTHOP TRAUMA, V8, P154, DOI 10.1097/00005131-199404000-00013; LOVELL CR, 1987, BRIT J DERMATOL, V117, P419, DOI 10.1111/j.1365-2133.1987.tb04921.x; McQueen MM, 1996, J BONE JOINT SURG BR, V78B, P95, DOI 10.1302/0301-620X.78B1.0780095; McQueen MM, 2000, J BONE JOINT SURG BR, V82B, P200, DOI 10.1302/0301-620X.82B2.9799; Torp S, 1975, STRUCTURE FIBROUS BI, V26, P197; TURNIPSEED WD, 1995, J VASC SURG, V21, P810, DOI 10.1016/S0741-5214(05)80012-6; Varani J, 2006, AM J PATHOL, V168, P1861, DOI 10.2353/ajpath.2006.051302; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P	14	59	60	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	AUG	2009	23	7					514	518		10.1097/BOT.0b013e3181a2815a			5	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	477TV	WOS:000268542700005	19633461				2022-02-06	
J	Covassin, T; Elbin, R; Stiller-Ostrowski, JL				Covassin, Tracey; Elbin, Robert, III; Stiller-Ostrowski, Jennifer L.			Current Sport-Related Concussion Teaching and Clinical Practices of Sports Medicine Professionals	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; Vienna guidelines; grading scales; position statements	MANAGEMENT; STATEMENT	Context: Various consensus and position statements recommend a multifaceted approach when diagnosing a possible concussion. The effectiveness of these materials depends largely on their content being disseminated to educators and to those in the clinical setting. Objective: To identify the concussion management methods and guidelines currently taught in the athletic training classroom and clinical settings and to track the dissemination of the Vienna guidelines throughout the educational curriculum. Design: A 17-question Internet survey. Setting: A Web link was e-mailed to the program directors and certified athletic trainers holding educational positions in athletic training at 300 accredited programs in the United States. Patients or Other Participants: 513 program directors and athletic trainers. Main Outcome Measure(s): Survey questions addressed education level, years of certification, employment setting, concussion assessment and return-to-play guidelines used in the clinical setting and the classroom, and clinical and teaching preferences for existing position statements and concussion grading systems. The Vienna guidelines' "simple" and "complex" definitions of concussions were provided with the return-to-play stepwise approach. Results: The National Athletic Trainers' Association position statement was the most widely used method of assessing, managing (61%), and making return-to-play decisions (47%) among participants. More than half of participants (66%) had never heard of the Vienna guidelines. After reading the Vienna guidelines' definitions and return-to-play criteria, nearly three-fourths of participants agreed with them. In addition, 68% said that they would use them, and 84% reported that they would teach them to students. Conclusions: The majority of program directors and certified athletic trainers used a multidimensional approach to assess and manage a concussion. The National Athletic Trainers' Association position statement and Vienna guidelines were underused in both the classroom and clinical settings.	[Covassin, Tracey; Elbin, Robert, III; Stiller-Ostrowski, Jennifer L.] Michigan State Univ, E Lansing, MI 48823 USA		Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48823 USA.	covassin@msu.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; *BOARD CERT, 2006, ROL DEL STUD; Cantu RC, 2001, J ATHL TRAINING, V36, P244; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Ferrara Michael S., 2001, J Athl Train, V36, P145; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; *NAT ATHL TRAIN AS, 2006, ATHL TRAIN ED COMP; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Oliaro S, 2001, J ATHL TRAINING, V36, P257; SCIFERS JR, 2008, SPECIAL TESTS NEUROL, P65; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	16	59	59	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2009	44	4					400	404		10.4085/1062-6050-44.4.400			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	474EZ	WOS:000268266600009	19593422	Bronze, Green Published			2022-02-06	
J	Choo, AMT; Liu, J; Liu, ZW; Dvorak, M; Tetzlaff, W; Oxland, TR				Choo, Anthony Min-Te; Liu, Jie; Liu, Zhuowei; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.			Modeling spinal cord contusion, dislocation, and distraction: Characterization of vertebral clamps, injury severities, and node of Ranvier deformations	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Spinal cord injury; Animal models; Injury mechanisms; Vertebral clamps; Hemorrhage; Nodes of Ranvier	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; AXONAL CONDUCTION; K+ CHANNELS; RAT; MECHANISM; DEVICE; MOUSE; PERMEABILITY; DISPLACEMENT	Spinal cord contusion and transection models are widely used for studying spinal cord injury (SCI). Clinically, however, other biomechanical injury mechanisms such as vertebral dislocation and distraction frequently occur, but these injuries are difficult to produce in animals. We mechanically characterize a vertebral clamping strategy that enables the modeling of vertebral dislocation and distraction injuries in addition to the standard contusion paradigm - in the rat cervical spine. These vertebral clamps have a stiffness of 83.6 +/- 18.9 N/mm and clamping strength 64.7 +/- 10.2 N which allows injuries to be modeled at high-speed (similar to 100 cm/s). Logistic regression indicated that a moderate-to-severe injury, with an acute mortality rate of 10%, occurs at 2.6 mm of C4/5 dorso-ventral dislocation and 4.1 mm of rostro-caudal distraction between C4 and C5. Injuries produced by dislocation and distraction exhibited features of axonal damage that were absent in contusion injuries. We conducted morphometric analysis at the nodes of Ranvier using immunohistochemistry for potassium channels (Kv1.2) in the juxtaparanodal region. Following distraction injuries, elongated nodes of Ranvier were observed up to 4 mm rostral to the lesion. In contrast, contusion injuries produced distortions in nodal geometry which were restricted to the vicinity of the lesion. The greatest deformations in node of Ranvier geometry occurred at the dislocation epicenter. Given the importance of white matter damage in SCI pathology, the distinctiveness of these injury patterns demonstrate that the dislocation and distraction injury models complement existing contusion models. Together, these three animal models span a broader clinical spectrum for more reliably gauging the potential human efficacy of therapeutic strategies. (C) 2009 Elsevier B.V. All rights reserved.	[Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Dept Orthopaed, Div Orthopaed Engn Res, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Dept Mech Engn, Div Orthopaed Engn Res, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Univ British Columbia, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Jie; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Vancouver, BC V6T 1Z4, Canada; [Choo, Anthony Min-Te; Liu, Jie; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.] Univ British Columbia, Vancouver, BC V6T 1Z4, Canada		Oxland, TR (corresponding author), Vancouver Coastal Hlth Res Inst, Dept Orthopaed, Div Orthopaed Engn Res, 910 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.	toxland@interchange.ubc.ca	Tetzlaff, Wolfram/AAY-4430-2020		Canada Research Chairs ProgramCanada Research Chairs; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; British Columbia Neurotrauma Fund; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Rix Family Leading Edge Endowment Fund; George W. Bagby Research Fund	This work was supported by the Canada Research Chairs Program, Canada Foundation for Innovation, British Columbia Neurotrauma Fund, Canadian Institutes for Health Research, Rix Family Leading Edge Endowment Fund and the George W. Bagby Research Fund.	Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; ANDERSON TE, 1985, J NEUROSURG, V62, P115, DOI 10.3171/jns.1985.62.1.0115; ANDERSON TE, 1982, J NEUROSCI METH, V6, P327, DOI 10.1016/0165-0270(82)90033-4; BAUSSART B, 2006, NEUROBIOL DIS; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BREIG A, 1970, J BIOMECH, V3, P7, DOI 10.1016/0021-9290(70)90046-1; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; CHOO AM, 2007, THESIS U BRIT COLUMB; Choo AMT, 2003, J BIOMECH, V36, P259, DOI 10.1016/S0021-9290(02)00361-5; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; D Cardenas D, 2007, SPINAL CORD, V45, P158, DOI 10.1038/sj.sc.3101947; Dabney KW, 2004, SPINE, V29, P2357, DOI 10.1097/01.brs.0000143108.65385.74; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOHRMANN GJ, 1978, J NEUROSURG, V48, P993, DOI 10.3171/jns.1978.48.6.0993; El-Bohy AA, 1998, EXP NEUROL, V150, P143, DOI 10.1006/exnr.1997.6757; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Giacobetti FB, 1997, SPINE, V22, P188, DOI 10.1097/00007632-199701150-00011; GRUNER JA, 1922, J NEUROTRAUM, V9, P126; GRUNER JA, 1922, J NEUROTRAUM, V9, P123; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jensen JM, 2003, J NEUROPHYSIOL, V90, P2334, DOI 10.1152/jn.00868.2002; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; KIWERSKI J, 1991, PARAPLEGIA, V29, P531, DOI 10.1038/sc.1991.76; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Lyons R.G., 1997, UNDERSTANDING DIGITA, P32; Maiman D J, 1989, J Spinal Disord, V2, P14; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nightingale RW, 1996, J BONE JOINT SURG AM, V78A, P412, DOI 10.2106/00004623-199603000-00013; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Norman G, 2000, BIOSTATISTICS BARE E; NOYES DH, 1987, EXP NEUROL, V95, P535, DOI 10.1016/0014-4886(87)90298-6; NOYES DH, 1987, MED BIOL ENG COMPUT, V25, P335, DOI 10.1007/BF02447434; Onifer SM, 2005, EXP NEUROL, V192, P25, DOI 10.1016/j.expneurol.2004.10.016; PANJABI MM, 1995, J SPINAL DISORD, V8, P39; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pitas I, 2001, 3 D IMAGE PROCESSING; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; SILBERSTEIN M, 1994, PARAPLEGIA, V32, P817, DOI 10.1038/sc.1994.129; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOMERSON SK, 1987, EXP NEUROL, V96, P82, DOI 10.1016/0014-4886(87)90170-1; SOMERSON SK, 1986, ANAL ELECTROMECHANIC; Sparrey CJ, 2008, SPINE, V33, pE812, DOI 10.1097/BRS.0b013e3181894fd3; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Young W, 2002, PROG BRAIN RES, V137, P231	59	59	64	2	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2009	181	1					6	17		10.1016/j.jneumeth.2009.04.007			12	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	463RT	WOS:000267450300002	19383514				2022-02-06	
J	Aarabi, B; Chesler, D; Maulucci, C; Blacklock, T; Alexander, M				Aarabi, Bizhan; Chesler, David; Maulucci, Christopher; Blacklock, Tiffany; Alexander, Melvin			Dynamics of subdural hygroma following decompressive craniectomy: a comparative study	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; subdural hygroma; head injury; intracranial pressure	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ASSISTED VOLUMETRIC-ANALYSIS; CEREBROSPINAL-FLUID; CHOROID-PLEXUS; INTRACRANIAL HYPERTENSION; PRESSURE; HEMATOMA; MANAGEMENT; EFFUSION	Object. This retrospective comparative cohort study was aimed at discovering the risk factors associated with subdural hygroma (SDG) following decompressive craniectomy (DC) to relieve intracranial hypertension in severe head injury. Methods. Sixty-eight of 104 patients who had undergone DC during a 48-month period and survived > 30 days were eligible for this study. To assess the dynamics of subdural fluid collections, the authors compared CT scanning data from and the characteristics of 39 patients who had SDGs with the data in 29 patients who did not have hygromas. Variables significant in the appearance, evolution, and resolution of this complication were analyzed in a 36-week longitudinal study. Results. The earliest imaging evidence of SDG was seen during the 1st week after DC. The SDG volume peaked between Weeks 3 and 4 post-DC and was gradually resolved by the 17th week. Among the mechanisms of injury, motor vehicle accidents were most often linked to the development of an SDG after DC (p < 0.0007), and falls were least often associated (p < 0.005). Moreover, patients with diffuse brain injury were more prone to this complication (p < 0.0299) than those with an evacuated mass (p < 0.0001). There were no statistically significant differences between patients with and without hygromas in terms of age, sex, Glasgow Coma Scale score, intraventricular and subarachnoid hemorrhage, levels of intracranial pressure and cerebral perfusion pressure, timing of decompression, and the need for CSF diversion. More than 90% of the SDGs were ipsilateral to the side of the craniectomy, and 3 (8%) of 39 SDGs showed evidence of internal bleeding at similar to 8 weeks postinjury. Surgical evacuation was needed in 4 patients with SDGs. Conclusions. High dynamic accidents and patients with diffuse injury were more prone to SDGs. Close to 8% of SDGs converted themselves into subdural hematomas at similar to 2 months postinjury. Although SDGs developed in 39 (similar to 60%) of 68 post-DC patients, surgical evacuation was needed in only 4. (DOI: 10.3171/2009.3.FOCUS0947)	[Aarabi, Bizhan; Chesler, David; Maulucci, Christopher] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Blacklock, Tiffany; Alexander, Melvin] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Aarabi, B (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S-12-D, Baltimore, MD 21201 USA.	baarabi@smail.umaryland.edu		Maulucci, Christopher/0000-0002-7777-3971; Andrews, Tiffany/0000-0002-2874-2298			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AARABI B, 2008, 26 ANN NAT NEUR S HE; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; ARNASON O, 1983, ACTA NEUROCHIR, V67, P231, DOI 10.1007/BF01401424; BORN JD, 1984, ACTA NEUROL BELG, V84, P174; Borzone M, 1983, J Neurosurg Sci, V27, P161; Boulton M, 1997, AM J PHYSIOL-REG I, V272, pR1613, DOI 10.1152/ajpregu.1997.272.5.R1613; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; Cohen I, 1927, ARCH NEURO PSYCHIATR, V18, P709, DOI 10.1001/archneurpsyc.1927.02210050041004; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; CSERR HF, 1977, EXP EYE RES, V25, P461, DOI 10.1016/S0014-4835(77)80041-9; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; Dandy WE, 1955, PRACTICE SURG, P291; Dandy WE, 1932, PRACTICE SURG, P306; DAVELLA D, 1980, J NEUROSURG, V53, P656, DOI 10.3171/jns.1980.53.5.0656; Deltour P, 1999, JBR-BTR, V82, P155; DEROUGEMONT AA, 1960, J NEUROPHYSIOL, V23, P485; ENDTZ LJ, 1978, SURG NEUROL, V10, P305; Feng JF, 2008, MED HYPOTHESES, V70, P1147, DOI 10.1016/j.mehy.2007.11.014; FRENCH BN, 1978, SURG NEUROL, V9, P145; GAAB MR, 1990, ACT NEUR S, V51, P326; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Han CY, 2005, OTOLARYNG CLIN N AM, V38, P569, DOI 10.1016/j.otc.2005.01.005; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Johnston I, 2000, CHILD NERV SYST, V16, P776, DOI 10.1007/s003810000383; Johnston M, 2005, NEUROPATH APPL NEURO, V31, P632, DOI 10.1111/j.1365-2990.2005.00679.x; Kapoor KG, 2008, BRAIN RES BULL, V77, P327, DOI 10.1016/j.brainresbull.2008.08.009; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Koh L, 2006, ANAT EMBRYOL, V211, P335, DOI 10.1007/s00429-006-0085-1; KOIZUMI H, 1981, Neurologia Medico-Chirurgica, V21, P397; KOIZUMI H, 1987, SURG NEUROL, V27, P147, DOI 10.1016/0090-3019(87)90286-2; Lang JK, 1999, SURG NEUROL, V52, P630, DOI 10.1016/S0090-3019(99)00144-5; Lee KS, 2000, J KOREAN MED SCI, V15, P560, DOI 10.3346/jkms.2000.15.5.560; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Li G, 2008, CHIN J TRAUMATOL, V11, P253, DOI 10.1016/S1008-1275(08)60052-8; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; Liu Yu-guang, 2004, Chin J Traumatol, V7, P188; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASUZAWA T, 1984, BRAIN RES, V302, P357, DOI 10.1016/0006-8993(84)90250-6; Mori K, 2000, SURG NEUROL, V53, P303, DOI 10.1016/S0090-3019(00)00199-3; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murata Keiji, 1993, Neurologia Medico-Chirurgica, V33, P691, DOI 10.2176/nmc.33.691; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; Nagra G, 2006, AM J PHYSIOL-REG I, V291, pR1383, DOI 10.1152/ajpregu.00235.2006; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NILSSON C, 1992, AM J PHYSIOL, V262, pR20, DOI 10.1152/ajpregu.1992.262.1.R20; OHNO K, 1987, J NEUROL NEUROSUR PS, V50, P1694, DOI 10.1136/jnnp.50.12.1694; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; PARK CK, 1994, ACTA NEUROCHIR, V127, P41, DOI 10.1007/BF01808545; Park SH, 2008, J CLIN NEUROSCI, V15, P868, DOI 10.1016/j.jocn.2007.08.003; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; RABE EF, 1968, NEUROLOGY, V18, P559, DOI 10.1212/WNL.18.6.559; RABE EF, 1962, NEUROLOGY, V12, P79, DOI 10.1212/WNL.12.2.79; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Su FW, 2008, J CLIN NEUROSCI, V15, P305, DOI 10.1016/j.jocn.2006.08.019; Sucu HK, 2005, STROKE, V36, P998, DOI 10.1161/01.STR.0000162714.46038.0f; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; TRIPATHI BJ, 1974, J PHYSIOL-LONDON, V239, P195, DOI 10.1113/jphysiol.1974.sp010563; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WELCH K, 1963, AM J PHYSIOL, V205, P617, DOI 10.1152/ajplegacy.1963.205.3.617; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang XF, 2009, MED PRIN PRACT, V18, P16, DOI 10.1159/000163040; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; ZEUTHEN T, 1978, BIOCHIM BIOPHYS ACTA, V511, P517, DOI 10.1016/0005-2736(78)90287-0	78	59	68	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E8	10.3171/2009.3.FOCUS0947			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400008	19485721	Bronze			2022-02-06	
J	Covacu, R; Arvidsson, L; Andersson, A; Khademi, M; Erlandsson-Harris, H; Harris, RA; Svensson, MA; Olsson, T; Brundin, L				Covacu, Ruxandra; Arvidsson, Lisa; Andersson, Asa; Khademi, Mohsen; Erlandsson-Harris, Helena; Harris, Robert A.; Svensson, Mikael A.; Olsson, Tomas; Brundin, Lou			TLR Activation Induces TNF-alpha Production from Adult Neural Stem/Progenitor Cells	JOURNAL OF IMMUNOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DORSAL-VENTRAL POLARITY; INTERFERON-GAMMA; STEM-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PROGENITOR CELLS; GENE-PRODUCT	Adult neural stem cells (NSCs) are believed to facilitate CNS repair and tissue regeneration. However, it is not yet clear how these cells are influenced when the cellular environment is modified during neurotrauma or neuroinflammatory conditions. In this study, we determine how different proinflammatory cytokines modulate the expression of TLR2 and TLR4 in NSCs and how these cells respond to TLR2 and TLR4 agonists. Primary cultures of neural stem/progenitor cells isolated from the subventricular zone of brains from adult Dark Agouti rats were exposed to 1) supernatants from activated macrophages; 2) proinflammatory cytokines IFN-gamma, TNF-alpha, or both; and 3) agonists for TLR2 and TLR4. Both TLR2 and TLR4 were expressed during basal conditions and their mRNA levels were further increased following cytokine exposure. TLR4 was up-regulated by IFN-gamma and this effect was reversed by TNF-alpha. TLR2 expression was increased by supernatants from activated macrophages and by TNF-a, which synergized with IFN-gamma. TLR agonists induced the expression of TNF-alpha mRNA. Importantly, TNF-alpha could be translated into protein and released into the supernatants where it was quantified by cytokine ELISA. In conclusion, we demonstrate that NSCs constitutively express TLR2 and TLR4 and that their expression is increased as a consequence of exposure to proinflammatory mediators. Additionally, activation of these receptors can induce production of proinflammatory cytokines. These findings suggest that NSCs may be primed to participate in cytokine production during neuroinflammatory or traumatic conditions. The Journal of Immunology, 2009, 182: 6889-6895.	[Covacu, Ruxandra] Karolinska Inst, Karolinska Hosp, Ctr Mol Med,Dept Clin Neurosci, Neuroimmunol Unit,Div Neuroimmunol, S-17176 Stockholm, Sweden; [Arvidsson, Lisa; Svensson, Mikael A.] Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; [Erlandsson-Harris, Helena] Karolinska Inst, Dept Med, Div Rheumatol, Stockholm, Sweden		Covacu, R (corresponding author), Karolinska Inst, Karolinska Hosp, Ctr Mol Med,Dept Clin Neurosci, Neuroimmunol Unit,Div Neuroimmunol, L8-04, S-17176 Stockholm, Sweden.	Ruxandra.Covacu@ki.se	Harris, Robert A./I-6234-2019; Svensson, Mikael/F-8662-2012	Harris, Robert A./0000-0003-4990-509X; Svensson, Mikael/0000-0003-1179-7003; Brundin, Lou/0000-0003-4408-7817; Covacu, Ruxandra/0000-0003-3183-2988; Khademi, Mohsen/0000-0003-0801-1444; Olsson, Tomas/0000-0002-2938-1877	Torsten and Ragnar Soderberg Foundation; Montel Williams Foundation; The Swedish Society for Neurologically; Karolinska InstitutetKarolinska Institutet	This work was supported by Torsten and Ragnar Soderberg Foundation, Montel Williams Foundation, The Swedish Society for Neurologically, Disabled, and Karolinska Institutet.	Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Andersson A, 2004, J LEUKOCYTE BIOL, V76, P1118, DOI 10.1189/jlb.0704385; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427; Brundin L, 2003, BRAIN PATHOL, V13, P322; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Einstein O, 2003, MOL CELL NEUROSCI, V24, P1074, DOI 10.1016/j.mcn.2003.08.009; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Hansen BS, 2006, J NEUROIMMUNOL, V172, P94, DOI 10.1016/j.jneuroim.2005.11.006; Hoshino K, 1999, J IMMUNOL, V162, P3749; Imitola J, 2004, AM J PATHOL, V164, P1615, DOI 10.1016/S0002-9440(10)63720-0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Klassen HJ, 2003, CYTOKINE, V22, P101, DOI 10.1016/S1043-4666(03)00120-0; LI MH, 1994, J SURG RES, V57, P85, DOI 10.1006/jsre.1994.1115; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; Mita Y, 2001, IMMUNOL LETT, V78, P97, DOI 10.1016/S0165-2478(01)00241-3; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Papavasiliou AK, 1996, J NEUROSCI RES, V46, P49, DOI 10.1002/(SICI)1097-4547(19961001)46:1<49::AID-JNR7>3.3.CO;2-2; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pearl-Yafe M, 2007, SHOCK, V27, P226, DOI 10.1097/01.shk.0000239765.80033.37; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Phulwani NK, 2008, J IMMUNOL, V181, P3841, DOI 10.4049/jimmunol.181.6.3841; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rieser C, 1998, BLOOD, V91, P3112, DOI 10.1182/blood.V91.9.3112.3112_3112_3117; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sheng WS, 2005, J LEUKOCYTE BIOL, V78, P1233, DOI 10.1189/jlb.0405221; Syed MM, 2007, J NEUROCHEM, V103, P1461, DOI 10.1111/j.1471-4159.2007.04838.x; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tamandl D, 2003, SHOCK, V20, P224, DOI 10.1097/00024382-200309000-00005; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Ueda Y, 2005, J EXP MED, V201, P1771, DOI 10.1084/jem.20041419; Ueda Y, 2004, J EXP MED, V199, P47, DOI 10.1084/jem.20031104; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zekki H, 2002, BRAIN PATHOL, V12, P308	50	59	64	0	8	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUN 1	2009	182	11					6889	6895		10.4049/jimmunol.0802907			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	448JG	WOS:000266258300032	19454685	Bronze			2022-02-06	
J	Kumar, S; Rao, SL; Chandramouli, BA; Pillai, SV				Kumar, Sanjay; Rao, Shobini L.; Chandramouli, Bangalore A.; Pillai, Shibu V.			Reduction of Functional Brain Connectivity in Mild Traumatic Brain Injury during Working Memory	JOURNAL OF NEUROTRAUMA			English	Article						EEG coherence; MTBI; working memory	CLOSED HEAD-INJURY; SHORT-TERM-MEMORY; UNIVERSITY-STUDENTS; EEG COHERENCE; SYNCHRONIZATION; ABNORMALITIES; DYSFUNCTION; ACTIVATION; CORTEX; SPECT	Working memory deficits are present in patients with mild traumatic brain injury (MTBI). Functional connectivity of different brain regions is required for adequate working memory. Brain injury is associated with disrupted connectivity due to microscopic axonal damage. In this investigation, we sought to investigate functional brain connectivity during working memory in MTBI patients. A sample of 30 MTBI patients and 30 age-, education-, and gender- matched normal controls were studied. Working memory was assessed with the Sternberg's verbal and visuo-spatial working memory tasks. Electro-encephalography ( EEG) was recorded from 128 channels while subjects performed working memory tasks and during eyes closed resting condition. EEG coherence was computed in theta; lower and upper alpha; and lower and upper beta frequency bands during the encoding, retention, and retrieval stages of working memory as well as during eyes-closed rest. We found that the MTBI patients had impaired verbal and visuo-spatial working memory. The different stages of working memory were associated with poor intrahemispheric coherence in long-range (fronto-parietal) and mid-range (fronto-temporal and temporo-parietal) regions as well as poor interhemispheric coherence in the frontal and temporal regions in the MTBI patients. The deficit in coherence was present in theta, alpha, and beta frequency bands. However, the MTBI and the control group had comparable coherence values in intra- and inter-hemispheric regions during eyes closed rest. We suggest that the inter- and intra-hemispheric functional connectivity is impaired in MTBI during working memory performance.	[Kumar, Sanjay] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; [Kumar, Sanjay; Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bangalore 560029, Karnataka, India; [Chandramouli, Bangalore A.; Pillai, Shibu V.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India		Kumar, S (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	s.kumar.1@bham.ac.uk		Kumar, Sanjay/0000-0001-5018-4184	NIMHANS fellowship; Department of Biotechnology, Ministry of Science and Technology ( Government of India)Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India	This work was supported by an NIMHANS fellowship for Ph. D. work to S. Kumar and a Department of Biotechnology, Ministry of Science and Technology ( Government of India) grant to S. L. Rao.	Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Cudmore LJ, 2000, BRAIN COGNITION, V44, P86; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Fiebach CJ, 2006, NEURON, V51, P251, DOI 10.1016/j.neuron.2006.06.007; Fiez JA, 2001, J CLIN EXP NEUROPSYC, V23, P19, DOI 10.1076/jcen.23.1.19.1221; GRAY BG, 1992, J NUCL MED, V33, P52; Hogan MJ, 2003, INT J PSYCHOPHYSIOL, V49, P147, DOI 10.1016/S0167-8760(03)00118-1; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kirchhoff BA, 2000, J NEUROSCI, V20, P6173, DOI 10.1523/JNEUROSCI.20-16-06173.2000; Klimesch W, 1996, INT J PSYCHOPHYSIOL, V24, P61, DOI 10.1016/S0167-8760(96)00057-8; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Knyazeva MG, 2001, BRAIN RES REV, V36, P119, DOI 10.1016/S0165-0173(01)00087-X; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubler A, 2003, NEUROIMAGE, V20, P1298, DOI 10.1016/S1053-8119(03)00400-2; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; RAY WJ, 1985, SCIENCE, V228, P750, DOI 10.1126/science.3992243; Reitan RM, 2000, ARCH CLIN NEUROPSYCH, V15, P433, DOI 10.1016/S0887-6177(99)00038-4; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SALTZBERG B, 1986, INT J BIOMED COMPUT, V18, P77, DOI 10.1016/0020-7101(86)90050-4; Sarnthein J, 1998, P NATL ACAD SCI USA, V95, P7092, DOI 10.1073/pnas.95.12.7092; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; TEASDALE G, 1974, LANCET, V2, P81; Weiss S, 2000, NEUROREPORT, V11, P2357, DOI 10.1097/00001756-200008030-00005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf RC, 2006, NEUROPSYCHOLOGIA, V44, P2558, DOI 10.1016/j.neuropsychologia.2006.05.015; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043	49	59	59	2	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					665	675		10.1089/neu.2008.0644			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500003	19331523				2022-02-06	
J	Purcell, L				Purcell, L.			What are the most appropriate return-to-play guidelines for concussed child athletes?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; HIGH-SCHOOL; YOUNG ATHLETE; COLLEGIATE; RECOVERY; MANAGEMENT; INJURY; AGE	Objective: To examine concussion literature for specific guidelines regarding return to play (RTP) following sport-related concussion in child athletes. To make recommendations regarding the most appropriate RTP guidelines for child athletes following sport-related concussion. Design: A literature review of concussion literature. Intervention: A literature search was conducted using Medline and Embase databases from 1998 to 2008. More than 60 articles and two websites were reviewed. Results: There is a paucity of research on sport-related concussion in child athletes, particularly younger children (age 5-12 years). In particular, there is no research on RTP guidelines for child athletes following sport-related concussion. Child athletes take longer to recover from concussions than adults. Concussion symptoms may resolve before cognitive function has completely recovered. Concussion assessment and management in children can be confounded by their growth and development, as well as the lack of trained medical personnel involved with youth sports. There are no child-specific assessment tools for concussion. Conclusions: RTP decisions in children should be made cautiously and should be individualised. No concussed child athlete should be allowed to RTP the same day. Physical and cognitive rest is very important to allow for the resolution of concussion symptoms. Child athletes should remain symptom free for several days before starting a medically supervised stepwise exertion protocol. Further research is needed to elucidate the effects of concussion in children and to determine the most appropriate RTP guidelines. Child-specific concussion assessment tools need to be developed to improve concussion assessment and management in children.	London Hlth Sci Ctr, Childrens Emergency Dept, London, ON N6C 2V5, Canada		Purcell, L (corresponding author), London Hlth Sci Ctr, Childrens Emergency Dept, 800 Commissioners Rd E, London, ON N6C 2V5, Canada.	lpurcell1015@rogers.com					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention, WHAT TRAUM BRAIN INJ; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; GIOIA GA, 2004, 2 INT S CONC SPORT 5; Gordon Kevin E, 2006, Semin Pediatr Neurol, V13, P243, DOI 10.1016/j.spen.2006.09.005; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Patel DR, 2002, PEDIATR CLIN N AM, V49, P505, DOI 10.1016/S0031-3955(02)00003-2; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	28	59	59	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I51	I55		10.1136/bjsm.2009.058214			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100009	19433426				2022-02-06	
J	Wester, BA; Lee, RH; LaPlaca, MC				Wester, B. A.; Lee, R. H.; LaPlaca, M. C.			Development and characterization of in vivo flexible electrodes compatible with large tissue displacements	JOURNAL OF NEURAL ENGINEERING			English	Article							TRAUMATIC BRAIN-INJURY; MICROELECTRODE ARRAYS; CORTEX; OSCILLATIONS; POTENTIALS; IMPLANT; EEG	Electrical activity is the ultimate functional measure of neuronal tissue and recording that activity remains a key technical challenge in neuroscience. The mechanical mismatch between rigid electrodes and compliant brain tissue is a critical limitation in applications where movement is an inherent component. An electrode that permits recording of neural activity, while minimizing tissue disruption, is beneficial for applications that encompass both normal physiological movements and those which require consistent recording during large tissue displacements. In order to test the extreme of this range of movement, flexible electrodes were developed to record activity during and immediately following cortical impact in the rat. Photolithography techniques were used to fabricate flexible electrodes that were readily insertable into the brain Using a parylene C base and gold conduction lines and contact pads, permitting custom geometry. We found that this electrode configuration retained mechanical and electrical integrity following both durability Studies and large movements within the cortex. This novel flexible electrode configuration provides a novel platform for experimentally examining neuronal activity during a range of brain movements.	[Wester, B. A.; Lee, R. H.; LaPlaca, M. C.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; [Wester, B. A.] Georgia Inst Technol, Sch Elect Engn, Microelect Res Ctr, Atlanta, GA 30332 USA		Wester, BA (corresponding author), Georgia Inst Technol, Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	brock@gitech.edu; rhlee@bme.gatech.edu; michelle.laplaca@bme.gatech.edu	Wester, Brock/H-2217-2013	Wester, Brock/0000-0002-1500-2143	NSFNational Science Foundation (NSF) [DGE-0333411]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS/NIMH/NIBIB NS046851, NIBIB EB000786]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046851] Funding Source: NIH RePORTER	This work was supported by the NSF (DGE-0333411) and the NIH (NINDS/NIMH/NIBIB NS046851 and N113113 EB000786). The authors wish to thank Dr Yoonsu Choi for his guidance with fabrication processing, Mr Scott Kasprzak and Dr Ken Gall for support with mechanical testing, Dr George C McConnell for suraical trainino, Dr Jim Ross for help with impedance testing and Mr Ashish Patil for assistance with mechanical and electrical evaluation.	Chou SL, 2008, ELECTROCHEM COMMUN, V10, P1724, DOI 10.1016/j.elecom.2008.08.051; DI S, 1991, BRAIN RES, V546, P106, DOI 10.1016/0006-8993(91)91164-V; Fee MS, 2000, NEURON, V27, P461, DOI 10.1016/S0896-6273(00)00057-X; Fujimoto K, 2008, JPN J APPL PHYS, V47, P8644, DOI 10.1143/JJAP.47.8644; HOOGERWERF AC, 1994, IEEE T BIO-MED ENG, V41, P1136, DOI 10.1109/10.335862; Jensen W, 2006, IEEE T BIO-MED ENG, V53, P934, DOI 10.1109/TBME.2006.872824; Jones MS, 1999, J NEUROPHYSIOL, V82, P1599, DOI 10.1152/jn.1999.82.3.1599; Juergens E, 1999, EXP BRAIN RES, V129, P247, DOI 10.1007/s002210050895; Lawn, 1993, FRACTURE BRITTLE SOL; Lee H, 2005, J NEURAL ENG, V2, P81, DOI 10.1088/1741-2560/2/4/003; Lee KK, 2004, J MICROMECH MICROENG, V14, P32, DOI 10.1088/0960-1317/14/1/305; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Myllymaa S, 2008, TISSUE ENG PT A, V14, P735; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OBRIEN DP, 2001, 14 IEEE INT C MICR M; ORTEGA A, 2006, COL I C; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Rousche PJ, 2001, IEEE T BIO-MED ENG, V48, P361, DOI 10.1109/10.914800; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SUZUKI T, 2003, P 1 INT IEEE EMBS CA; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Takeuchi S, 2005, LAB CHIP, V5, P519, DOI 10.1039/b417497f; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Yu HY, 2008, J MICROELECTROMECH S, V17, P1178, DOI 10.1109/JMEMS.2008.927749	24	59	60	0	14	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	APR	2009	6	2							024002	10.1088/1741-2560/6/2/024002			7	Engineering, Biomedical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	438LF	WOS:000265556200002	19255461				2022-02-06	
J	Jehle, T; Dimitriu, C; Auer, S; Knoth, R; Vidal-Sanz, M; Gozes, I; Lagreze, WA				Jehle, T.; Dimitriu, C.; Auer, S.; Knoth, R.; Vidal-Sanz, M.; Gozes, I.; Lagreze, W. A.			The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						neuropeptide; NAP; optic nerve crush; retinal ischemia; neuroprotection	VASOACTIVE-INTESTINAL-PEPTIDE; CLOSED-HEAD INJURY; IN-VIVO; NEUROTROPHIC FACTOR; AXONAL REGENERATION; NEURONAL SURVIVAL; RAT MODEL; ACTIVATED MICROGLIA; DEATH; DEGENERATION	Background NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations. We already discovered that NAP increases the survival of retinal ganglion cells (RGC) in vitro, and supports neurite outgrowth in retinal explants at femtomolar concentrations. The aim of this study was to investigate the effects of NAP on RGC survival after transient retinal ischemia and optic nerve crush. Methods RGC of male Wistar rats were labelled retrogradely with 6 l FluoroGold injected stereotactically into both superior colliculi. Seven days later, retinal ischemia was induced by elevating the intraocular pressure to 120 mm Hg for 60 minutes or by crushing one optic nerve for 10 s after a partial orbitotomy. NAP was either injected intraperitoneally in the concentration of 100 mg/kg 1 day before, directly after, and on the first and the second days after damage, or intravitreally (0.05 or 0.5 mu g/eye) directly after the optic nerve crush. Controls received the same concentrations of a control peptide. Densities of surviving RGC and activated microglial cells (AMC) were quantified in a masked fashion 10 days after damage by counting FluoroGold-labelled cells. Results After retinal ischemia, intraperitoneal injections of NAP increased the number of surviving RGC by 40% (p<0.005) compared to the control group. After optic nerve crush, NAP raised the number of surviving RGC by 31% (p=0.07) when injected intraperitoneally and by 54% (p<0.05) when administered intravitreally. Conclusions NAP acts neuroprotectively in vivo after retinal ischemia and optic nerve crush, and may have potential in treating optic nerve diseases.	[Jehle, T.; Dimitriu, C.; Auer, S.; Lagreze, W. A.] Univ Eye Hosp Freiburg, D-79106 Freiburg, Germany; [Knoth, R.] Univ Freiburg, Freiburg, Germany; [Vidal-Sanz, M.] Univ Murcia, Fac Med, Dept Ophthalmol, Murcia, Spain; [Gozes, I.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel		Jehle, T (corresponding author), Univ Eye Hosp Freiburg, Killianstr 5, D-79106 Freiburg, Germany.	thomas.jehle@uniklinik-freiburg.de	Vidal-Sanz, Manuel/J-6989-2016	Vidal-Sanz, Manuel/0000-0002-9216-1615			Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1; Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; BELOKOPYTOV M, 2006, INVEST OPHTHALMOL VI, V47; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bodeutsch N, 2000, GLIA, V32, P91, DOI 10.1002/1098-1136(200010)32:1<91::AID-GLIA90>3.0.CO;2-X; Braun, 1999, Expert Opin Investig Drugs, V8, P1599, DOI 10.1517/13543784.8.10.1599; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Brenneman DE, 1998, ANN NY ACAD SCI, V865, P207, DOI 10.1111/j.1749-6632.1998.tb11180.x; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Cellerino A, 2003, J COMP NEUROL, V467, P97, DOI 10.1002/cne.10908; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; Gellrich NC, 2002, J CRANIO MAXILL SURG, V30, P230, DOI 10.1054/jcms.2002.0312; Glazner GW, 1999, J NEUROCHEM, V73, P2341, DOI 10.1046/j.1471-4159.1999.0732341.x; Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067; GOZES I, 1987, HUM GENET, V75, P41; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; Jehle T, 2001, OPHTHALMOLOGE, V98, P237, DOI 10.1007/s003470170155; Jehle T, 2000, N-S ARCH PHARMACOL, V362, P74, DOI 10.1007/s002100000265; JEHLE T, 2007, INVEST OPHTHALMOL VI, V48; Kacza J, 2001, J NEUROCYTOL, V30, P801, DOI 10.1023/A:1019641404940; Kacza J, 1997, INFLAMM RES, V46, P430, DOI 10.1007/s000110050219; Kaplan DR, 2006, CELL, V125, P224, DOI 10.1016/j.cell.2006.03.031; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lafuente MP, 2002, EXP EYE RES, V74, P181, DOI 10.1006/exer.2001.1122; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Lagreze WA, 2005, INVEST OPHTH VIS SCI, V46, P933, DOI 10.1167/iovs.04-0766; Lagreze WA, 1998, INVEST OPHTH VIS SCI, V39, P1063; Leahy KM, 2004, EXP EYE RES, V79, P131, DOI 10.1016/j.exer.2004.02.007; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; THANOS S, 1993, J NEUROSCI, V13, P455; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1; THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Watanabe M, 2002, PROG RETIN EYE RES, V21, P529, DOI 10.1016/S1350-9462(02)00037-X; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122	59	59	63	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	SEP	2008	246	9					1255	1263		10.1007/s00417-007-0746-7			9	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	330HV	WOS:000257932500007	18414890				2022-02-06	
J	Tapia-Perez, JH; Sanchez-Aguilar, M; Torres-Corzo, JG; Gordillo-Moscoso, A; Martinez-Perez, P; Madeville, P; de la Cruz-Mendoza, E; Chalita-Williams, J				Tapia-Perez, J. Humberto; Sanchez-Aguilar, Martin; Torres-Corzo, Jaime G.; Gordillo-Moscoso, Antonio; Martinez-Perez, Patricia; Madeville, Peter; de la Cruz-Mendoza, Esperanza; Chalita-Williams, Juan			Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758)	JOURNAL OF NEUROTRAUMA			English	Article						amnesia; inflammation; rosuvastatin	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ATORVASTATIN REDUCTION; GALVESTON ORIENTATION; NEURONAL SURVIVAL; RATS; INFLAMMATION; SIMVASTATIN; THROMBOSIS; INCREASE; OBJECT	Amnesia is a common sequela following traumatic brain injury (TBI), for which there is no current treatment. Pleiotropic effects of statins have demonstrated faster recovery of spatial memory after TBI in animals. We conducted a double-blind randomized clinical trial add-on of patients with TBI (16-50 years of age), with Glasgow Coma Scale (GCS) scores of 9-13, and intracranial lesions as demonstrated by computed tomography (CT) scan. We excluded those patients with recent head injury or severe disability; administration of known drugs as modifiers of statin metabolism; multisystemic trauma; prior use of mannitol, barbiturate, corticosteroids, indomethacin or calcium antagonists; surgical or isolated lesion in brainstem; allergy to statins; previous hepatopathy or myopathy; previous management in another clinic; or pregnancy. Each patient received the same treatment and was randomly allocated to receive either rosuvastatin (RVS) or placebo over a period of 10 days. The primary outcome measures assessed were amnesia and disorientation times using Galveston Orientation Amnesia Test. Additionally, we evaluated plasma levels of interleukin (IL) 1 beta, tumor necrosis factor (TNF) alpha, and IL-6, as well as disability at 3 months. We analyzed eight patients with RVS and 13 controls with similar basal characteristics. Using Cox regression analysis, administration of RVS showed a reduction of amnesia time with a hazard ratio of 53.76 (95% confidence interval [CI], 1.58-1824.64). This was adjusted for early intubation, basal leukocytes, basal Marshall and Fisher score, change of IL-1 beta levels, and lesion side. IL-6 values at day 3 were increased in the RVS group (p = 0.04). No difference was detected in disability at 3 months. While statins may reduce amnesia time after TBI, possibly by immunomodulation, further trials are needed in order to confirm this positive association.	[Tapia-Perez, J. Humberto; de la Cruz-Mendoza, Esperanza] Univ Autonoma San Luis Potosi, Fac Med, Nucl Med Lab, San Luis Potosi 78210, SLP, Mexico; [Tapia-Perez, J. Humberto; Torres-Corzo, Jaime G.; Chalita-Williams, Juan] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, SLP, Mexico		Tapia-Perez, JH (corresponding author), Univ Autonoma San Luis Potosi, Fac Med, Nucl Med Lab, Av Venustiano Carranza 2405, San Luis Potosi 78210, SLP, Mexico.	lehwand@hotmail.com		TORRES-CORZO, JAIME G./0000-0002-3981-0831			Amarenco P, 2006, NEW ENGL J MED, V355, P549; BLESSING R, 2005, STROKE, V36, P2024; BROWNE RH, 1995, STAT MED, V14, P1933, DOI 10.1002/sim.4780141709; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; *COMBI, 2008, DIS RAT SCAL; Curtis CE, 2000, NEUROPSYCHOLOGIA, V38, P1503, DOI 10.1016/S0028-3932(00)00062-2; Curtis CE, 2000, NEUROREPORT, V11, P2203, DOI 10.1097/00001756-200007140-00028; Fletcher B, 2005, CIRCULATION, V112, P3184, DOI 10.1161/CIRCULATIONAHA.105.169180; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Maguire EA, 2001, NEUROIMAGE, V13, P743, DOI 10.1006/nimg.2000.0712; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Silva SCFE, 2007, REV LAT-AM ENFERM, V15, P651, DOI 10.1590/S0104-11692007000400020; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Tseng MY, 2007, J NEUROSURG, V107, P1092, DOI 10.3171/JNS-07/12/1092; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031	28	59	59	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					1011	1017		10.1089/neu.2008.0554			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700007	18690806				2022-02-06	
J	Schlenk, F; Nagel, A; Graetz, D; Sarrafzadeh, AS				Schlenk, Florian; Nagel, Alexandra; Graetz, Daniela; Sarrafzadeh, Asita S.			Hyperglycemia and cerebral glucose in aneurysmal subarachnoid hemorrhage	INTENSIVE CARE MEDICINE			English	Article						subarachnoid hemorrhage; cerebral metabolism; microdialysis; glucose; hyperglycemia; hyperglycolysis	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; ISCHEMIC NEUROLOGICAL DEFICITS; COMBINED MICRODIALYSIS; BEDSIDE MICRODIALYSIS; STRESS HYPERGLYCEMIA; HEAD-INJURY; VASOSPASM; METABOLISM; LACTATE	Objective: To determine whether hyperglycemia exerts deleterious effects via cerebral energy metabolism and to illuminate the effects of cerebral high/low glucose in patients with aneurysmal subarachnoid hemorrhage. Design and setting: Prospective, nonrandomized single-center study over a 2-year period in an intensive care unit at a primary-level university hospital. Patients: 28 subarachnoid hemorrhage patients (age 53 +/- 10 years, WFNS grade 2.8 +/- 1.5)classified as asymptomatic (n = 5) or symptomatic with acute focal or delayed ischemic neurological deficits (n = 23). Measurements and results: Hyperglycemia (> 7.8 mmol/l; > 140 mg/dl) was more frequent in symptomatic patients and was reflected in higher glycerol concentrations than in asymptomatic patients. In all patients a microdialysis catheter was inserted into the tissue at risk; dialysates were collected hourly for 10 days. Cerebral low-glucose episodes (< 0.6 mmol/l) and high-glucose episodes (> 2.6 mmol/l) occurred independently of blood glucose levels. During high-glucose episodes cerebral microdialysate levels were normal, while cerebral low glucose, occurring more frequently in symptomatic patients, was associated with severe cellular distress (increase in lactate/pyruvate ratio, glutamate, glycerol) and with unfavorable outcome if combined with hyperglycemia. Conclusions: Although hyperglycemia was more frequent in symptomatic patients and associated with high glycerol levels, hyperglycemia was not related to cerebral high glucose. It appears that the association of adverse outcome with acute-phase hyperglycemia is not mediated by cerebral glucose metabolism. Cerebral low glucose was associated with severe metabolic distress and may present a target for therapy to improve clinical outcome.	[Schlenk, Florian; Nagel, Alexandra; Graetz, Daniela; Sarrafzadeh, Asita S.] Charite Campus Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany		Sarrafzadeh, AS (corresponding author), Charite Campus Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Alberti O, 2000, CLIN NEUROL NEUROSUR, V102, P78, DOI 10.1016/S0303-8467(00)00067-6; Allport LE, 2004, STROKE, V35, P1886, DOI 10.1161/01.STR.0000133687.33868.71; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Bell DA, 2005, BRIT J NEUROSURG, V19, P21, DOI 10.1080/02688690500089423; BEREK K, 1992, LANCET, V339, P68, DOI 10.1016/0140-6736(92)90202-E; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; DRAKE CG, 1988, J NEUROSURG, V68, P985; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; Kerner A, 2007, NEUROL RES, V29, P647, DOI 10.1179/016164107X248983; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Oertel MF, 2007, J CLIN NEUROSCI, V14, P948, DOI 10.1016/j.jocn.2006.11.002; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schurr A, 2001, J NEUROSCI RES, V66, P782, DOI 10.1002/jnr.10065; Seaquist ER, 2001, DIABETES, V50, P2203, DOI 10.2337/diabetes.50.10.2203; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WOO E, 1988, STROKE, V19, P1359, DOI 10.1161/01.STR.19.11.1359	40	59	64	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2008	34	7					1200	1207		10.1007/s00134-008-1044-5			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318WL	WOS:000257123400006	18320167				2022-02-06	
J	Thal, SC; Wyschkon, S; Pieter, D; Engelhard, K; Werner, C				Thal, Serge C.; Wyschkon, Sebastian; Pieter, Dana; Engelhard, Kristin; Werner, Christian			Selection of endogenous control genes for normalization of gene expression analysis after experimental brain trauma in mice	JOURNAL OF NEUROTRAUMA			English	Article						control gene; housekeeping gene; PCR; real-time; traumatic brain injury	POLYMERASE CHAIN-REACTION; REAL-TIME; HOUSEKEEPING GENES; RIBOSOMAL-RNA; BETA-ACTIN; RT-PCR; VALIDATION; STANDARDS; TISSUE; ASSAYS	Quantitative measurements of gene expression require correction for tissue sample size, RNA quantity, and reverse transcription efficiency. This can be achieved by normalization with control genes. The study was designed to identify candidates not altered after brain trauma. Male C57Bl/6 mice were anesthetized with isoflurane, and a pneumatic brain trauma was induced by controlled cortical impact (CCI) on the right parietal cortex. Brains were removed at 15 min, and 3, 6, 12 and 24 h after CCI and from naive animals (n = 6 each). Absolute copies of six control genes (beta-2-microglobin [B2M], cyclophilin A, beta-actin, hypoxanthine ribosyltransferase [HPRT], porphobilinogen deaminase [PBGD], and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) and one example target gene (iNOS) were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR; Lightcycler(R)) in the traumatic focus and contralateral tissue. Control gene expression was stable until 12 h after CCI. At 24 h after CCI expression of B2M, cyclophilin A and HPRT remained stable in the contusion, while expression of beta-actin, GAPDH, and PBGD increased. Due to variations between animals (+/- 85%), increases in beta-actin (+/- 64%) and GAPDH (+59%) did not reach the level of significance. In non-contused tissue, expression of all genes dropped 24 h after CCI (range, -17% to -61%). Due to low variations between animals and stable expression after CCI, B2M and cyclophilin A seem to be suitable to serve as single normalizer. Normalization of the example target gene iNOS resulted in varying relative expression extending from onefold (PBDG) to 10-fold (HPRT). The results suggest that the knowledge of the temporal profile of control genes is essential to properly interpret results of mRNA quantification.	[Thal, Serge C.; Wyschkon, Sebastian; Pieter, Dana; Engelhard, Kristin; Werner, Christian] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, D-55131 Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Wyschkon, Sebastian/0000-0001-9434-3343			Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; Cronin Maureen, 2004, Clin Chem, V50, P1464, DOI 10.1373/clinchem.2004.035675; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Goidin D, 2001, ANAL BIOCHEM, V295, P17, DOI 10.1006/abio.2001.5171; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Nishida Y, 2006, J PHARMACOL SCI, V101, P52, DOI 10.1254/jphs.FP0050881; Ohl F, 2005, J MOL MED, V83, P1014, DOI 10.1007/s00109-005-0703-z; Peters IR, 2007, VET IMMUNOL IMMUNOP, V117, P55, DOI 10.1016/j.vetimm.2007.01.011; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; SPANAKIS E, 1993, NUCLEIC ACIDS RES, V21, P3809, DOI 10.1093/nar/21.16.3809; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Talaat AM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf103; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang CM, 2004, BIOTECHNIQUES, V36, P508, DOI 10.2144/04363RN06; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	20	59	60	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					785	794		10.1089/neu.2007.0497			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000006	18627256				2022-02-06	
J	Kashluba, S; Paniak, C; Casey, JE				Kashluba, Shauna; Paniak, Chris; Casey, Joseph E.			Persistent symptoms associated with factors identified by the who task force on mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						adults; functional outcome; premorbid factors; symptom persistence; TBI.	EMOTIONAL RISK-FACTORS; CLOSED-HEAD-INJURY; MISERABLE MINORITY; PATIENT COMPLAINTS; RANDOMIZED-TRIAL	The current study examined the role offactors identified by the World Health Organization's Task Force on Mild Traumatic Brain Injury as being associated with poor outcome after mild traumatic brain injury. Employing symptom severity ratings at 3 months post-injury greater than "mild, " subgroups of Higher-Severity (20%) and Lower-Severity (80%) participants were identified. Findings revealed that individuals who report greatersymptom complaints at 3 months post-MTBI may be identifiable soon after injury on the basis of the magnitude and severity of early self-reported symptoms, pre-morbidpsychological issues, and involvement in compensation-seeking. Injury severity factors did not differ between the groups.	[Kashluba, Shauna; Casey, Joseph E.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Paniak, Chris] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Paniak, Chris] Univ Alberta, Edmonton, AB, Canada		Casey, JE (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada.	jecasey@uwindsor.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; CARROLL LJ, 2004, J REHABIL MED S, V43, pS84; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	29	59	59	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAR	2008	22	2					195	208		10.1080/13854040701263655			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	279ZA	WOS:000254393500002	17853135				2022-02-06	
J	Corrigan, JD; Lineberry, LA; Komaroff, E; Langlois, JA; Selassie, AW; Wood, KD				Corrigan, John D.; Lineberry, Lee A.; Komaroff, Eugene; Langlois, Jean A.; Selassie, Anbesaw W.; Wood, Kenneth D.			Employment after traumatic brain injury: Differences between men and women	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; rehabilitation; sex	VOCATIONAL-REHABILITATION CLIENTS; POSTTRAUMATIC-STRESS-DISORDER; COMMUNITY INTEGRATION; GENDER-DIFFERENCES; FOLLOW-UP; OUTCOME MEASURES; ACUTE PREDICTORS; SYSTEMATIC BIAS; MAJOR TRAUMA; RETURN	Corrigan JD, Lineberry LA, Komaroff E, Langlois JA, Selassie AW, Wood KD. Employment after traumatic brain injury: differences between men and women. Arch Phys Med Rehabil 2007;88:1400-9. Objective: To determine whether there are sex differences in employment 1 year after traumatic brain injury. Design: Prospective cohort. Setting: Acute care hospitals in South Carolina and Traumatic Brain Injury Model Systems TBIMS) rehabilitation centers. Participants: Subjects in the TBIMS national dataset and the South Carolina Traumatic Brain Injury Follow-up Registry who were expected to be working before injury and followed at 1 year postinjury. Interventions: Not applicable. Main Outcome Measure: Change in employment from preinjury to 1 year postinjury. Results: When other measured influences on change in hours worked were held constant, there were significant interactions for sex by age and sex by marital status. Compared with men, women were more likely to decrease hours or stop working, except in the oldest age group (55-64y) in which men were more likely to stop working. For women, there was a pattern showing better employment outcomes as age increased. Decreased employment for women was most evident for married women, who were much more likely to reduce hours or stop working. There was also a tendency for divorced women to be more likely to stop working when compared with divorced men. Conclusions: These findings run counter to the current literature. Although definitive explanations must await future studies, causal factors arising from differential societal behavior toward women as well as discriminatory attitudes about women and employment deserve further study.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Med Univ S Carolina, Dept Biostat, Charleston, SC 29425 USA; Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.l@osu.edu	Corrigan, John D./E-2921-2011		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; *CDCP DIV AC CAR R, 1999, TRAUM BRAIN INJ US R; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holbrook TL, 2002, J TRAUMA, V53, P882, DOI 10.1097/00005373-200211000-00012; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; *J HOPK U TRIAN IN, 1997, X ICDMAP 90 SOFTW US; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MCMAHON B, 2002, EVALUATION PROGRESSI; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; NOSEK MA, 2006, BRAIN INJ PROF, V3, P28; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P25; RENNISON CM, 2003, INTIMATE PARTNER VIO; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SELASSIE A, 2004, S CAROLINA TRAUMATIC, P118; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; TJADEN P, 2000, FUL REPORT PREVALENC; *TRAUM BRAIN INJ N, TBI MOD SYST NAT DAT; *US BUR LAB STAT, EMPL CHAR FAM 2006; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; [No title captured]	58	59	59	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1400	1409		10.1016/j.apmr.2007.08.006			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	229AT	WOS:000250774400005	17964879				2022-02-06	
J	McMillan, TM; Teasdale, GM				McMillan, T. M.; Teasdale, G. M.			Death rate is increased for at least 7 years after head injury: a prospective study	BRAIN			English	Article						head; brain; injury mortality; outcome	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; LIFE EXPECTANCY; YOUNG-PEOPLE; MORTALITY; DISABILITY; AGE; EPIDEMIOLOGY; DEPRIVATION; VARIABLES	Although a high mortality rate among patients recently admitted to hospital with severe head injury is well recognized, less is known about their later mortality and very little about the ensuing lifestyle and less-severe injuries that lead to death. The aims of this study were to determine the rate of death in the first and six subsequent years after head injury, in a prospectively identified cohort admitted to hospital, and investigate the factors associated with death comparing these with general death rates in Scottish populations. A structured sample of 767 patients aged 14 years and over was identified at the time of admission to hospital after a head injury and followed up 7 years later. A trace exercise was conducted to identify those deceased. The General Register of Scotland confirmed death and provided information about cause of death. Seven years after head injury, 206/767 (27%) people had died. Compared to the Glasgow population, risk of death was high after head injury in months 1-2 (23 times), 3-12 (3 times) and 13-84 (2 times), and overall was especially raised in younger people, even late (13-84 months) after injury (7 times). Mortality was only associated with greater severity of head injury during year 1. Pre-injury medical history was associated both with earlier and later deaths, but risk of death remained higher in those with no such history. Later deaths were often associated with lifestyle post-injury. The primary causes of death after head injury were the same as those in the general population. Compared to the general population, the death rate after admission to hospital with head injury remains high for at least 7 years, and is particularly high for those aged under 55 years. Interventions aimed at change in lifestyle may reduce this continuing excess mortality.	Univ Glasgow, Gartnavel Royal Hosp, Glasgow G12 OXH, Lanark, Scotland; NHS Qual Improvement Scotland, Glasgow GI 2NP, Lanark, Scotland; Univ Glasgow, Div Clin Neurosci, Glasgow, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, 1055 Great Westerm Rd, Glasgow G12 OXH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Baguley I, 2000, BRAIN INJURY, V14, P505; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KRAUS J, 2000, NEUROSURG FOCUS, P8; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Ritchie MA, 2000, ONLINE J KNOWL SYN N, V7; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; [No title captured]	39	59	59	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2007	130		10				2520	2527		10.1093/brain/awm185			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218UC	WOS:000250039500006	17686808	Bronze, Green Published			2022-02-06	
J	Pieracci, FM; Eachempati, SR; Shou, J; Hydo, LJ; Barie, PS				Pieracci, Fredric M.; Eachempati, Soumitra R.; Shou, Jian; Hydo, Lynn J.; Barie, Philip S.			Use of long-term anticoagulation is associated with traumatic intracranial hemorrhage and subsequent mortality in elderly patients hospitalized after falls: Analysis of the New York state administrative database	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		anticoagulation; intracranial hemorrhage; traumatic brain injury; geriatrics; falls	PREINJURY WARFARIN USE; NONVALVULAR ATRIAL-FIBRILLATION; RISK-FACTORS; STROKE PREVENTION; INJURY; PREVALENCE; REVERSAL; IMPACT	Background: Previous studies addressing the relationship between anticoagulation and risk of traumatic intracranial hemorrhage (ICH) have provided conflicting results, and have examined infrequently elderly patients after falls. We used a statewide hospital discharge database to test the hypothesis that long-term anticoagulation (LTA) increases the likelihood of traumatic ICH and subsequent mortality in this patient population. Methods: Patients aged 65 years or older and hospitalized as the result of a fall were extracted from the New York State Statewide Planning and Cooperative Systems Database for the year 2004. LTA, ICH, and additional injuries including skull fracture, vertebral fracture, rib fracture, lower extremity fracture, thoracic visceral injury, and abdominal visceral injury were defined using corresponding International Classification for Disease, Ninth Edition coding. Covariates included age, gender, and comorbidity. Additional outcomes included length of stay and mortality. Multivariable logistic regression was used to identify independent predictors of traumatic ICH and subsequent mortality. Results: A total of 47,717 patients met the inclusion criteria. Falls were associated with a traumatic ICH in 2,517 patients (5.1%), and the mortality rate of patients with a fall-related, traumatic ICH was 15.5% (n = 394). A total of 1,511 (3.2%) patients hospitalized after a fall used LTA. Based on univariate analysis, ICH was the only injury that occurred more commonly in patients who used LTA, when compared with those who did not (8.0% vs. 5.3%, respectively, p < 0.0001). Furthermore, although overall mortality did not differ by use of LTA, mortality after ICH was significantly higher in patients who used LTA when compared with those who did not (21.9% vs. 15.2%, respectively, p = 0.04). Controlling for age, gender, and comorbidity, patients on LTA were 50% more likely to sustain a traumatic ICH after a fall (odds ratio = 1.50; 95% confidence interval, 1.23-1.81; p < 0.0001). Furthermore, among patients who sustained an ICH, mortality was 1.57-fold greater in patients on LTA (odds ratio = 1.57; 95% confidence interval, 1.02-2.45; p = 0.04). Conclusions: These data indicate that use of LTA is independently associated with traumatic ICH and subsequent mortality in elderly patients hospitalized after a fall.	Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA		Pieracci, FM (corresponding author), Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA.	frp9005@med.cornell.edu	Barie, Philip/AAN-8811-2020				Arboix A, 2000, DIABETES CARE, V23, P1527, DOI 10.2337/diacare.23.10.1527; Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2006, ARCH INTERN MED, V166, P241, DOI 10.1001/archinte.166.2.241; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gage BF, 1992, J NEUROL NEUROSUR PS, V55, P653; Garvin R, 2006, J FAM PRACTICE, V55, P157; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jensen J, 2002, ANN INTERN MED, V136, P733, DOI 10.7326/0003-4819-136-10-200205210-00008; Johnston JA, 2003, ARCH INTERN MED, V163, P1705, DOI 10.1001/archinte.163.14.1705; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; Lankshmirarayan K, 2006, STROKE, V37, P1969; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; McCormick D, 2001, ARCH INTERN MED, V161, P2458, DOI 10.1001/archinte.161.20.2458; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; *NAT TRAUM DAT, 2005, AM COLL SURG; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Punthakee X, 2002, THROMB RES, V108, P31, DOI 10.1016/S0049-3848(02)00398-5; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; SINGER D, 2004, CHEST, V16, pS4239; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Tinetti ME, 1990, GERIATR MED, V2nd, P528; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Weisbord SD, 2001, J GEN INTERN MED, V16, P743, DOI 10.1046/j.1525-1497.2001.10432.x; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong KS, 1999, STROKE, V30, P2326, DOI 10.1161/01.STR.30.11.2326	41	59	60	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					519	524		10.1097/TA.0b013e31812e519b			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	211DA	WOS:000249503300007	18073595				2022-02-06	
J	Jacobs, R; Harvey, AS; Anderson, V				Jacobs, Rani; Harvey, A. Simon; Anderson, Vicki			Executive function following focal frontal lobe lesions: Impact of timing of lesion on outcome	CORTEX			English	Article						executive functional; frontal lesions; childhood; injury age	TRAUMATIC BRAIN-INJURY; DEVELOPMENTAL-CHANGES; HEAD-INJURY; EARLY ONSET; CHILDREN; CHILDHOOD; BEHAVIOR; CORTEX; RECOVERY; INFANTS	While it is generally agreed that outcome following cerebral insult during childhood differs from that seen following similar pathology in adulthood, the specific relationship between timing of cerebral lesion and outcome, and the mechanism associated with observed neurobehavioral changes, remains controversial. Data from children with focal lesions suggests a non-linear relationship between age at injury and language function (e.g., Bates et al., 1999). With respect to executive function, animal models also demonstrate a non-linear relationship, and suggest that outcome is tightly linked to underlying neuronal changes (e.g., Kolb et al., 2000). Whether these models easily translate to humans, where brain morphology, cognitive function and environmental influences are more complex, is not clear. To date, focal lesion research in children has been restricted to individual case studies or, to samples of children with lesions to regions subsuming language function, or those who have undergone hemispherectomy for the treatment of intractable epilepsy. This study aimed to build on current knowledge, investigating executive function in 38 children with focal lesions involving prefrontal cortex. Aetiology and timing of lesions was diverse. Results are consistent with animal research suggesting a non-linear relationship between age at injury and outcome, with "critical periods" during development when the frontal lobes are particularly vulnerable to insult, and others when outcome is more optimal. Our findings indicate that children with prenatal lesions are at greatest risk of neurobehavioral deficits. Children with lesions sustained in middle childhood demonstrate least severe impairments across executive domains, possibly due to a period of peak synaptogenesis and dendritic arborization during this developmental stage, in keeping with animal models and research investigating frontal lobe development.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Neurol, Parkville, Vic 3052, Australia		Jacobs, R (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	rani.jacobs@mcri.edu.au					ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Andersen J, 2001, J HYDROL, V247, P200, DOI 10.1016/S0022-1694(01)00384-5; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; ANDERSON P, 2001, THESIS U MELBOURNE; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; ARAM DM, 1994, NEUROPSYCHOLOGIA, V32, P85, DOI 10.1016/0028-3932(94)90071-X; AYLWARD GP, 1992, J DEV BEHAV PEDIATR, V13, P222; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; BATES E, 1999, DEV DISORDERS; BERTENTHAL BI, 1987, CHILD DEV, V58, P560, DOI 10.1111/j.1467-8624.1987.tb01401.x; CORBALLIS MC, 1978, BEHAV BRAIN SCI, V1, P261, DOI 10.1017/S0140525X00074471; Daniel A., 1983, POWER PRIVILEGE PRES; Dawson G, 2000, DEV PSYCHOPATHOL, V12, P695, DOI 10.1017/S0954579400004089; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; DENNIS M, 2000, PATIENT BASED APPROA; Diamond A, 1996, DEV PSYCHOBIOL, V29, P315, DOI 10.1002/(SICI)1098-2302(199605)29:4<315::AID-DEV2>3.0.CO;2-T; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.2307/1130099; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; ESCALONA SK, 1982, PEDIATRICS, V70, P670; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Gioia GA IP, 2000, BEHAV RATING INVENTO; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.2307/1130201; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; Hebb DO, 1947, AM PSYCHOL, V2, P737; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; HUDSPETH WJ, 1992, INT J PSYCHOPHYSIOL, V12, P19, DOI 10.1016/0167-8760(92)90039-E; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jacobs R., 2001, CLIN NEUROPSYCHOL, V2, P101; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477, DOI 10.1152/jn.1938.1.6.477; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; KOLB B, 1985, BEHAV NEUROSCI, V99, P691, DOI 10.1037/0735-7044.99.4.691; Kolb B, 1997, BEHAV BRAIN RES, V89, P61, DOI 10.1016/S0166-4328(97)00058-2; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; KOLB B, 1981, J COMP PHYSIOL PSYCH, V95, P863, DOI 10.1037/h0077849; Kolb B, 1998, BEHAV BRAIN RES, V91, P143, DOI 10.1016/S0166-4328(97)00111-3; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; KOLB B, 2002, PRINCIPLES FRONTAL L; KOLB B, 1998, NEUROSCI BIOBEHAV R, V22, P123; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Milner B, 1974, Neurosci Res Program Bull, V12, P213; MOSHER F, 1986, PHILOS TRANSCRIPTS B, V298, P199; NASS R, 1989, BRAIN COGNITION, V9, P258, DOI 10.1016/0278-2626(89)90035-3; Northam EA, 2001, DIABETES CARE, V24, P1541, DOI 10.2337/diacare.24.9.1541; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Pentland LM, 2000, CHILD NEUROPSYCHOL, V6, P87, DOI 10.1076/chin.6.2.87.7055; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROVET JF, 1987, DIABETES CARE, V10, P510, DOI 10.2337/diacare.10.4.510; Rutherford M A, 1997, Eur J Paediatr Neurol, V1, P13, DOI 10.1016/S1090-3798(97)80005-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smibert E, 1996, BRIT J CANCER, V73, P825, DOI 10.1038/bjc.1996.145; Stuss Donald T, 2002, PRINCIPLES FRONTAL L; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THATCHER R, 1997, DEV PREFRONTAL CORTE; VarghaKhadem F, 1997, BRAIN, V120, P159, DOI 10.1093/brain/120.1.159; VARGHAKHADEM F, 1985, BRAIN, V108, P677, DOI 10.1093/brain/108.3.677; VARGHAKHADEM F, 1994, J CHILD NEUROL, V9, pS67; Webb SJ, 2001, DEV NEUROPSYCHOL, V19, P147, DOI 10.1207/S15326942DN1902_2; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; [No title captured]; [No title captured]	86	59	61	0	26	ELSEVIER MASSON, CORP OFF	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	AUG	2007	43	6					792	805		10.1016/S0010-9452(08)70507-0			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	194VG	WOS:000248371300012	17710830				2022-02-06	
J	Samuelsson, C; Hillered, L; Zetterling, M; Enblad, P; Hesselager, G; Ryttlefors, M; Kumlien, E; Lewen, A; Marklund, N; Nilsson, P; Salci, K; Ronne-Engstrom, E				Samuelsson, Carolina; Hillered, Lars; Zetterling, Maria; Enblad, Per; Hesselager, Goran; Ryttlefors, Mats; Kumlien, Eva; Lewen, Anders; Marklund, Niklas; Nilsson, Pelle; Salci, Konstantin; Ronne-Engstrom, Elisabeth			Cerebral glutamine and glutamate levels in relation to compromised energy metabolism: a microdialysis study in subarachnoid hemorrhage patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain; glutamate; glutamine; lactate; microdialysis; pyruvate	TRAUMATIC BRAIN-INJURY; IN-VIVO; INTRACEREBRAL MICRODIALYSIS; NEUROINTENSIVE CARE; AMINO-ACIDS; EXTRACELLULAR METABOLITES; BEDSIDE MICRODIALYSIS; C-13 NMR; RELEASE; HIPPOCAMPUS	Astrocytic glutamate (Git) uptake keeps brain interstitial Git levels low. Within the astrocytes Git is converted to glutamine (Gin), which is released and reconverted to Git in neurons. The Git-Gin cycle is energy demanding and impaired energy metabolism has been suggested to cause low interstitial Gin/Glt ratios. Using microdialysis (MD) measurements from visually noninjured cortex in 33 neurointensive care patients with subarachnoid hemorrhage, we have determined how interstitial Git and Gin, as a reflection of the Git-Gin cycle turnover, relate to perturbed energy metabolism. A total of 3703 hourly samples were analyzed. The lactate/pyruvate (UP) ratios correlated to the Gln/Glt ratios (r = -0.66), but this correlation was not stronger than the correlation between UP and Git (r=0.68) or the correlation between lactate and Glt (r=0.65). A novel observation was a linear relationship between interstitial pyruvate and Gin (r = 0.52). There were 13 periods (404 h) of 'energy crisis', defined by UP ratios above 40. All were associated with high interstitial Git levels. Periods with UP ratios above 40 and low pyruvate levels were associated with decreased interstitial Gin levels, suggesting ischemia and failing astrocytic Gin synthesis. Periods with UP ratios above 40 and normal or high pyruvate levels were associated with increased interstitial Gin levels, which may represent an astrocytic hyperglycolytic response to high interstitial Git levels. The results imply that moderately elevated UP ratios cannot always be interpreted as failing energy metabolism and that interstitial pyruvate levels may discriminate whether or not there is sufficient astrocytic capacity for Glt-Gln cycling in the brain.	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden		Samuelsson, C (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	carolina.samuelsson@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Kumlien, Eva/0000-0002-1952-8791; Marklund, Niklas/0000-0002-9797-5626			Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Buck CR, 2003, EXP NEUROL, V181, P149, DOI 10.1016/S0014-4886(03)00043-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dohmen C, 2003, STROKE, V34, P2152, DOI 10.1161/01.STR.0000083624.74929.32; Engstrom ER, 2005, NEUROSCI LETT, V384, P7, DOI [10.1016/j.neurlet.2005.04.030, 10.1016/j.neulet.2005.04.030]; HAWKINS RA, 2006, J NUTR, V136; Hertz L, 2006, NEUROCHEM INT, V48, P416, DOI 10.1016/j.neuint.2005.12.021; Hertz L, 2004, NEUROCHEM INT, V45, P285, DOI 10.1016/j.neuint.2003.08.016; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Kanamori K, 2004, J NEUROCHEM, V90, P203, DOI 10.1111/j.1471-4159.2004.02478.x; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; Kawai N, 1999, J CEREBR BLOOD F MET, V19, P79, DOI 10.1097/00004647-199901000-00009; Labiner DM, 1999, NEUROCHEM RES, V24, P1379, DOI 10.1023/A:1022528522373; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; Raman L, 2005, DEV BRAIN RES, V156, P202, DOI 10.1016/j.devbrainres.2005.02.013; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shen J, 1999, P NATL ACAD SCI USA, V96, P8235, DOI 10.1073/pnas.96.14.8235; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; Suojaranta-Ylinen R, 1996, Nutrition, V12, P327; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3	41	59	62	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2007	27	7					1309	1317		10.1038/sj.jcbfm.9600433			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	180OL	WOS:000247375000002	17228333	Bronze			2022-02-06	
J	Dixon, G; Thornton, EW; Young, CA				Dixon, Guy; Thornton, Everard W.; Young, Carolyn A.			Perceptions of self-efficacy and rehabilitation among neurologically disabled adults	CLINICAL REHABILITATION			English	Article; Proceedings Paper	15th Meeting of the European-Neurological-Society	JUN 18-22, 2005	Vienna, AUSTRIA	European Neurol Soc			QUALITATIVE-ANALYSIS; MULTIPLE-SCLEROSIS; PATIENT MOTIVATION; FOLLOW-UP; VALIDATION; PEOPLE; STROKE; PARTICIPATION; SCALE; LIFE	Objective: To explore constructs relevant to self-efficacy in neurological rehabilitation. Design: Qualitative methods using semi-structured interviews. Setting: Specialist neurological rehabilitation unit, Liverpool, UK. Subjects: Twenty-four patients (12 male) with experience of inpatient rehabilitation, aged 17-59 (mean 38.1) years at onset, with diagnoses of stroke (n = 8), traumatic brain injury (n = 6) or other monophasic neurological impairment (n = 10). Results: Eleven themes emerged from the data that reflect self-efficacy beliefs: self-reliance and independence were deemed important and many patients recognized the importance of determination, making time to take an active role and working in partnership with the multidisciplinary team. Patients had complex information needs but were able to use goal setting and the vicarious experiences of other inpatients to map out the stages of their own recovery. It was important for patients to be able to recognize for themselves that they were making progress and they valued external reassurance on this from other patients, staff and visitors. A number of difficulties were identified that interfered with their developing self-efficacy in rehabilitation, such as structuring their time. Two different models for rehabilitation emerged from the data, 'recovery' and 'adaptation'. Conclusions: Patients consistently identified 11 factors falling in the supraordinate themes of self, others and process, and these influenced their self-efficacy to participate in neurological rehabilitation. Patients consider rehabilitation in terms of either an 'adaptation' or 'recovery' model.	Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England; Univ Liverpool, Dept Psychol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Div Neurol Sci, Liverpool L69 3BX, Merseyside, England		Young, CA (corresponding author), Walton Ctr Neurol & Neurosurg, Lower Lane, Liverpool L9 7LJ, Merseyside, England.	Carolyn.young@thewaltoncentre.nhs.uk		Young, Carolyn/0000-0003-1745-7720			Airlie J, 2001, CLIN REHABIL, V15, P259, DOI 10.1191/026921501668362643; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; Bandura A., 1997, SELF EFFICACY EXERCI; Barnes MP, 2003, J NEUROL NEUROSUR PS, V74, P3; Bowling A, 2002, RES METHODS HLTH; Burns R.B., 2000, INTRO RES METHODS, V4th; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; DeVellis R, 2003, SCALE DEVELOPMENT TH; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Grahn B, 2000, DISABIL REHABIL, V22, P639, DOI 10.1080/096382800445443; Hewlett S, 2001, RHEUMATOLOGY, V40, P1221, DOI 10.1093/rheumatology/40.11.1221; Kobau R, 2003, EPILEPSY BEHAV, V4, P217, DOI 10.1016/S1525-5050(03)00057-X; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P1599, DOI 10.1016/j.apmr.2004.03.027; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; Maclean N, 2000, SOC SCI MED, V50, P495; Maclean N, 2000, BMJ-BRIT MED J, V321, P1051, DOI 10.1136/bmj.321.7268.1051; Maclean N, 2002, STROKE, V33, P444, DOI 10.1161/hs0202.102367; O'Connell B, 2001, J Qual Clin Pract, V21, P120, DOI 10.1046/j.1440-1762.2001.00426.x; PAJARES F, 1997, ADV MOTIVATION ACHIE, V10; Rigby SA, 2003, MULT SCLER J, V9, P73, DOI 10.1191/1352458503ms870oa; SALMON P, 2000, PSYCHOL MED SURG; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P394, DOI 10.1016/S0003-9993(96)90091-X; Schwarzer R., 1995, MEASURES HLTH PSYCHO; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Wiles R, 2002, DISABIL REHABIL, V24, P841, DOI 10.1080/09638280210142158; Wottrich AW, 2004, DISABIL REHABIL, V26, P1198, DOI 10.1080/09638280410001724889	27	59	60	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAR	2007	21	3					230	240		10.1177/0269215506071784			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation	149QO	WOS:000245161900004	17329280				2022-02-06	
J	Alm, PA; Risberg, J				Alm, Per A.; Risberg, Jarl			Stuttering in adults: The acoustic startle response, temperamental traits, and biological factors	JOURNAL OF COMMUNICATION DISORDERS			English	Article							DEFICIT-HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; DOPAMINE ACTIVITY; EARLY-CHILDHOOD; ANTICIPATORY ANXIETY; RAT-BRAIN; PROLACTIN; CHILDREN; ESTROGEN	The purpose of this study was to investigate the relation between stuttering and a range of variables of possible relevance, with the main focus on neuromuscular reactivity, and anxiety. The explorative analysis also included temperament, biochemical variables, heredity, preonset lesions, and altered auditory feedback (AAF). An increased level of neuromuscular reactivity in stuttering adults has previously been reported by [Guitar, B. (2003). Acoustic startle responses and temperament in individuals who stutter. Journal of Speech Language and Hearing Research, 46, 233-240], also indicating a link to anxiety and temperament. The present study included a large number of variables in order to enable analysis of subgroups and relations between variables. Totally 32 stuttering adults were compared with nonstuttering controls. The acoustic startle eyeblink response was used as a measure of neuromuscular reactivity. No significant group difference was found regarding startle, and startle was not significantly correlated with trait anxiety, stuttering severity, or AAF. Startle was mainly related to calcium and prolactin. The stuttering group had significantly higher scores for anxiety and childhood ADHD. Two subgroups of stuttering were found, with high versus low traits of childhood ADHD, characterized by indications of preonset lesions versus heredity for stuttering. The study does not support the view that excessive reactivity is a typical characteristic of stuttering. The increased anxiety is suggested to mainly be an effect of experiences of stuttering. Learning outcomes: As a result of reading this article, the reader will be able to: (a) critically discuss the literature regarding stuttering in relation to acoustic startle, anxiety, and temperament; (b) describe the effect of calcium on neuromuscular reactivity; (c) discuss findings supporting the importance of early neurological incidents in some cases of stuttering, and the relation between such incidents and traits of ADHD or ADD; and (d) discuss the role of genetics in stuttering. (c) 2006 Elsevier Inc. All rights reserved.	Lund Univ, Dept Clin Neurosci, Lund, Sweden; Lund Univ, Dept Psychol, Lund, Sweden		Alm, PA (corresponding author), Harlemans Vag 4A, SE-22730 Lund, Sweden.	per.alm1@yahoo.com		Alm, Per/0000-0003-1506-5897			Alm PA, 2004, J FLUENCY DISORD, V29, P123, DOI 10.1016/j.jfludis.2004.02.001; Alm PA, 2004, J COMMUN DISORD, V37, P325, DOI 10.1016/j.jcomdis.2004.03.001; AMBROSE NG, 1993, J SPEECH HEAR RES, V36, P701, DOI 10.1044/jshr.3604.701; Ambrose NG, 1997, J SPEECH LANG HEAR R, V40, P567, DOI 10.1044/jslhr.4003.567; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson JD, 2003, J SPEECH LANG HEAR R, V46, P1221, DOI 10.1044/1092-4388(2003/095); Appelberg B, 2002, PSYCHONEUROENDOCRINO, V27, P661, DOI 10.1016/S0306-4530(01)00067-1; APPELBERG B, 2000, SCHIZOPHR RES, P183; Armario A, 1996, PSYCHONEUROENDOCRINO, V21, P17, DOI 10.1016/0306-4530(95)00048-8; Backman L, 2000, AM J PSYCHIAT, V157, P635; BECKER L, 2000, INTERNET; Ben-Jonathan N, 2001, ENDOCR REV, V22, P724, DOI 10.1210/er.22.6.724; BOHME G, 1968, FOLIA PHONIATR, V20, P239; BOHME G, 1977, STOTTER SYNDROM; Bohmelt A.H., 1999, STARTLE MODIFICATION, P72, DOI DOI 10.1017/CBO9780511665523.006; BRADY JP, 1991, AM J PSYCHIAT, V148, P1309; Breier A, 1998, AM J PSYCHIAT, V155, P1440, DOI 10.1176/ajp.155.10.1440; BURTIES CA, 1999, TIETZ TXB CLIN CHEM; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; CHOKROVERTY S, 1992, ELECTROEN CLIN NEURO, V85, P236, DOI 10.1016/0168-5597(92)90111-N; COSTA D, 1986, ACTIV NERV SUPER, V28, P155; COSTA D, 1986, ACTIV NERV SUPER, V28, P156; COX N, 2000, ASHA LEADER, V5; CRAIG A, 1990, J SPEECH HEAR DISORD, V55, P290, DOI 10.1044/jshd.5502.290; Craig A, 2003, J SPEECH LANG HEAR R, V46, P1197, DOI 10.1044/1092-4388(2003/093); Davis M., 1999, STARTLE MODIFICATION, P95, DOI DOI 10.1017/CBO9780511665523.007; Davis S, 2002, EXP NEUROL, V176, P229, DOI 10.1006/exnr.2002.7926; Decker Michael J, 2002, Sleep Breath, V6, P205, DOI 10.1055/s-2002-36531; DEPUE RA, 1994, J PERS SOC PSYCHOL, V67, P485, DOI 10.1037/0022-3514.67.3.485; Drayna D, 1999, AM J HUM GENET, V65, P1473, DOI 10.1086/302625; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; Embrechts M, 2000, P 3 WORLD C FLUENC D, P557; Emiliano ABF, 2004, NEUROPSYCHOPHARMACOL, V29, P833, DOI 10.1038/sj.npp.1300412; Ezrati-Vinacour R, 2004, J FLUENCY DISORD, V29, P135, DOI 10.1016/j.jfludis.2004.02.003; Farde L, 1997, NATURE, V385, P590, DOI 10.1038/385590a0; FOWLIE GM, 1978, J FLUENCY DISORD, V3, P233, DOI 10.1016/0094-730X(78)90023-2; GRILLON C, 1991, PSYCHOPHYSIOLOGY, V28, P588, DOI 10.1111/j.1469-8986.1991.tb01999.x; Guitar B, 2003, J SPEECH LANG HEAR R, V46, P233, DOI 10.1044/1092-4388(2003/018); Guyton AC., 1996, TXB MED PHYSL, V9 ed; Herbst A, 1997, OBSTET GYNECOL, V90, P125, DOI 10.1016/S0029-7844(97)00177-4; HERNANDEZ ML, 1994, J NEURAL TRANSM-GEN, V96, P63, DOI 10.1007/BF01277929; Hill H, 1944, J SPEECH DISORD, V9, P289, DOI 10.1044/jshd.0904.289; HOWARD R, 1992, PSYCHOL MED, V22, P695, DOI 10.1017/S0033291700038137; Ingemarsson I, 1997, BRIT J OBSTET GYNAEC, V104, P1123, DOI 10.1111/j.1471-0528.1997.tb10934.x; Jennings PJ, 1998, BEHAV NEUROSCI, V112, P154, DOI 10.1037/0735-7044.112.1.154; JOBORN H, 1990, CLIN PHYSIOL, V10, P37, DOI 10.1111/j.1475-097X.1990.tb00082.x; KALINOWSKI J, 1993, LANG SPEECH, V36, P1; Kuppers E, 2000, J NEUROCYTOL, V29, P375, DOI 10.1023/A:1007165307652; Lewis KE, 1997, EUR J DISORDER COMM, V32, P441; MALLARD EC, 1995, NEUROSCIENCE, V65, P827, DOI 10.1016/0306-4522(94)00504-X; Mauskop A, 2002, HEADACHE, V42, P242, DOI 10.1046/j.1526-4610.2002.02075.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Messenger M, 2004, J FLUENCY DISORD, V29, P201, DOI 10.1016/j.jfludis.2004.06.002; MILLER S, 1992, J SPEECH HEAR RES, V35, P789, DOI 10.1044/jshr.3504.789; MORRISON J, 1999, PSYCHOL PROBLEMS MAS; MUCCIOLI G, 1991, NEUROENDOCRINOLOGY, V53, P47, DOI 10.1159/000125696; *NIH, 2003, MEDL PLUS; Oliveira MC, 1996, BRAZ J MED BIOL RES, V29, P521; OYLER ME, 1994, THESIS U COLORADO; PASTUSZKO A, 1994, BIOCHEM MED METAB B, V51, P1, DOI 10.1006/bmmb.1994.1001; POULOS MG, 1991, J SPEECH HEAR RES, V34, P5, DOI 10.1044/jshr.3401.05; Riaz N, 2005, AM J HUM GENET, V76, P647, DOI 10.1086/429226; ROUSEY CG, 1986, J FLUENCY DISORD, V11, P257, DOI 10.1016/0094-730X(86)90013-6; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SCHACHAR R, 2002, CHILD ADOLESCENT PSY, P399; SCHALLING D, 1987, ACTA PSYCHIAT SCAND, V76, P172, DOI 10.1111/j.1600-0447.1987.tb02881.x; SCHEDLOWSKI M, 1992, LIFE SCI, V50, P1201, DOI 10.1016/0024-3205(92)90319-K; SCHILLING A, 1960, HNO, V8, P205; SCHILLING A, 1963, PSYCHOL BEITR, V7, P353; Schleier E, 1991, Otolaryngol Pol, V45, P141; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Shugart YY, 2004, AM J MED GENET A, V124A, P133, DOI 10.1002/ajmg.a.20347; Sobrinho LG, 1998, PSYCHOTHER PSYCHOSOM, V67, P133, DOI 10.1159/000012273; Spielberger C. D, 1983, STAI MANUAL STATE TR; Swerdlow N.R., 1999, STARTLE MODIFICATION, P114, DOI DOI 10.1017/CBO9780511665523; Taylor R.M., 1996, TAYLOR JOHNSON TEMPE; Thiblin I, 1999, BRIT J PHARMACOL, V126, P1301, DOI 10.1038/sj.bjp.0702412; Thys-Jacobs S, 2000, J AM COLL NUTR, V19, P220, DOI 10.1080/07315724.2000.10718920; Toft PB, 1999, PEDIATR NEUROL, V21, P602, DOI 10.1016/S0887-8994(99)00046-6; Tsang KL, 2000, NEUROLOGY, V54, P2292, DOI 10.1212/WNL.54.12.2292; VANLOON GR, 1983, BRAIN RES BULL, V10, P539, DOI 10.1016/0361-9230(83)90152-1; VICTOR M, 2001, ADAMS VICTORS PRINCI; Viswanath N, 2004, HUM BIOL, V76, P401, DOI 10.1353/hub.2004.0050; Volkow ND, 1998, AM J PSYCHIAT, V155, P344; Volpe J., 2001, NEUROLOGY NEWBORN; VRANA SR, 1988, J ABNORM PSYCHOL, V97, P487, DOI 10.1037/0021-843X.97.4.487; WAKABA YY, 1997, P 2 WORLD C FLUENC D, P84; WALKER ST, 1973, PERCEPT MOTOR SKILL, V36, P926, DOI 10.2466/pms.1973.36.3.926; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Watkins RV, 1999, J SPEECH LANG HEAR R, V42, P1125, DOI 10.1044/jslhr.4205.1125; West R, 1939, Q J SPEECH, V25, P23, DOI 10.1080/00335633909380434; Wu JC, 1997, NEUROREPORT, V8, P767, DOI 10.1097/00001756-199702100-00037; Yairi E., 2005, EARLY CHILDHOOD STUT; ZIMMERMANN G, 1980, J SPEECH HEAR RES, V23, P122, DOI 10.1044/jshr.2301.122	96	59	60	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	JAN-FEB	2007	40	1					1	41		10.1016/j.jcomdis.2006.04.001			41	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	128QG	WOS:000243672400001	16814317				2022-02-06	
J	Nolin, P; Heroux, L				Nolin, Pierre; Heroux, Louise			Relations among sociodemographic, neurologic, clinical, and neuropsychologic variables, and vocational status following mild traumatic brain injury - A follow-up study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; MTBI; return to work; subjective complaints; vocational status	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; MOTOR-VEHICLE ACCIDENTS; WORK; RETURN; COMPLAINTS; QUESTIONNAIRE; COMPENSATION; RECOVERY; SEQUELAE	objectives: To explore the long-term relations among sociodemographic, neurologic, clinical, and neuropsychologic variables, and vocational status in persons with mild traumatic brain injury (MTBI), and to identify the symptoms that determine whether or not these individuals return to work. Design: Longitudinal quasi-experimental between-groups design. Participants: Eighty-five MTBI subjects aged between 16 and 65 years. Setting: The emergency ward of the TroisRivieres Regional Hospital Centre in Quebec, Canada. Main Outcome Measures: Age, gender, Glasgow Coma Scale score, duration of posttraumatic amnesia, duration of retrograde amnesia, total of symptoms at emergency, time elapsed since the trauma, Paced Auditory Serial Addition Task, Stroop, Color Word Test, California Verbal Learning Test, and the number of symptoms at follow-up (12 to 36 months posttrauma). Results: Only the total number of symptoms reported at follow-up was related to vocational status. The majority of individuals had returned to work 1 year or more post-MTBI. Individuals who had not returned to work reported the greatest number of symptoms, which could be linked to their affective status. Six affective symptoms, 5 cognitive symptoms, 6 physical symptoms, and 8 symptoms relating to social and daily life activities differentiated the participants who had returned to work from those who had not. Conclusions: Patient characteristics, injury severity indicators, and cognitive functions were not associated with vocational status. To better understand post-MTBI vocational status, it is important to focus on subjective complaints that arise following the injury.	Univ Quebec Trois Rivieres, Dept Psychol, Child & Family Dev Res Unit, Trois Rivieres, PQ G9A 5H7, Canada		Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Child & Family Dev Res Unit, POB 500, Trois Rivieres, PQ G9A 5H7, Canada.	Pierre.Nolin@uqtr.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 1996, CLIN REHABILITATION; Bartelski J, 1996, ACTA PHYS POL B, V27, P911; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HURT DH, 2000, NEUROPSYCHOLOGICAL M, P215; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Nolin P, 2001, REV NEUROPSYCHOL, V11, P23; NOLIN P, 1999, REV QUEBECOISE PSYCH, V20, P39; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	50	59	61	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					514	526		10.1097/00001199-200611000-00006			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400006	17122682				2022-02-06	
J	Conde, JR; Streit, WJ				Conde, Jessica R.; Streit, Wolfgang J.			Effect of aging on the microglial response to peripheral nerve injury	NEUROBIOLOGY OF AGING			English	Article						microglia; aging; senescence; facial nerve axotomy; microglial proliferation; H-3-thymidine; programmed cell death; TUNEL	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; FACIAL-NERVE; AGED RATS; FOOD RESTRICTION; CEREBRAL-CORTEX; ADVANCING AGE; SPINAL-CORD; CELLS; ACTIVATION	Microglial morphology and immunophenotype have been studied extensively in aging-related neurodegenerative diseases, but to a lesser extent in the normally aged CNS, and little is known about how aging affects the ability of microglia to respond to neuronal injury. The goal of the current study was to determine if aging affects the ability of microglia to divide during the early response to facial nerve axotomy. In addition, we investigated the incidence of microglial cell death during later post-axotomy time points to determine if aging had an effect on microglial turnover. We employed DNA labeling with H-3-thymidine, TUNEL and lectin histochemistry after facial nerve axotomy in young (3 months), middle-aged (15 months), and old (30 months) Fisher344-Brown Norway hybrid rats. Proliferation of microglia in old rats remained significantly higher than in young rats 4 days after injury, suggesting that regulation of microglial proliferation changes with aging. There was no aging-related difference in microglial TUNEL staining at 7, 14 or 21 days post-axotomy. Lectin histochemistry in the unoperated facial nucleus revealed aging-related morphological changes in resting microglia, including hypertrophy of the cytoplasm with dense perinuclear staining. Aging-related differences in activated microglia on the lesioned side were more subtle, although many activated microglia of aged animals continued to exhibit dense perinuclear lectin reactivity. We propose that aging-related changes in morphology in conjunction with a less regulated proliferative response in the aged facial nucleus may be a reflection of microglial senescence. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA		Streit, WJ (corresponding author), Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, POB 100244, Gainesville, FL 32610 USA.	jconde@ufl.edu; streit@mbi.ufl.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 023665] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023665] Funding Source: NIH RePORTER		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; BARRON KD, 1990, BRAIN RES, V523, P219, DOI 10.1016/0006-8993(90)91490-8; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Cammermeyer J, 1965, Ergeb Anat Entwicklungsgesch, V38, P1; Chen SZ, 2002, J NEUROIMMUNOL, V133, P46, DOI 10.1016/S0165-5728(02)00354-5; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; DELRIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P489; DiPatre PL, 1997, J NEUROPATH EXP NEUR, V56, P143, DOI 10.1097/00005072-199702000-00004; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hurley SD, 2003, NEUROBIOL AGING, V24, P511, DOI 10.1016/S0197-4580(02)00097-0; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005; KREUTZBERG GW, 1966, ACTA NEUROPATHOL, V7, P149, DOI 10.1007/BF00686781; KREUTZBERG GW, 1968, ACTA NEUROPATH BER S, V4, P141; Kullberg S, 2001, BRAIN RES, V899, P169, DOI 10.1016/S0006-8993(01)02222-3; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016; Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.3.CO;2-7; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Peters A, 2002, CEREB CORTEX, V12, P27, DOI 10.1093/cercor/12.1.27; RAIVICH G, 1993, J HISTOCHEM CYTOCHEM, V41, P579, DOI 10.1177/41.4.8450197; Raivich Gennadij, 2002, P166; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Sloane JA, 1999, NEUROBIOL AGING, V20, P395, DOI 10.1016/S0197-4580(99)00066-4; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Streppel M, 1998, NEUROBIOL AGING, V19, P83, DOI 10.1016/S0197-4580(97)00163-2; Strohmeyer R, 2001, J ALZHEIMERS DIS, V3, P131, DOI 10.3233/JAD-2001-3118; Stuesse SL, 2000, NEUROSCI LETT, V287, P121, DOI 10.1016/S0304-3940(00)01142-3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; SVENSSON M, 1994, J ANAT, V185, P537; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tseng GF, 1996, BRAIN RES, V715, P32, DOI 10.1016/0006-8993(95)01418-7; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; VAUGHAN DW, 1990, ANAT REC, V228, P211, DOI 10.1002/ar.1092280212; VAUGHAN DW, 1992, J COMP NEUROL, V323, P219, DOI 10.1002/cne.903230207	55	59	59	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	OCT	2006	27	10					1451	1461		10.1016/j.neurobiolaging.2005.07.012			11	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	084MN	WOS:000240537200012	16159684				2022-02-06	
J	Josan, VA; Sgouros, S				Josan, V. A.; Sgouros, S.			Early decompressive craniectomy may be effective in the treatment of refractory intracranial hypertension after traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article; Proceedings Paper	31st Annual Meeting of the International-Society-for-Pediatric-Neurosurgery	SEP 14-18, 2003	MONACO	Int Soc Pediatr Neurosurg		decompressive craniectomy; head injury; refractory intracranial hypertension	SEVERE HEAD-INJURIES; SURGICAL DECOMPRESSION; CHILDREN; MANAGEMENT; PRESSURE; EDEMA; AGE	Introduction: We compared the effect of early decompressive craniectomy (< 24 h) vs non-operative treatment on the outcome of children with refractory intracranial hypertension after severe traumatic brain injury. Material and methods: We retrospectively reviewed 12 consecutive patients treated between 1999 and 2001 for refractory intracranial hypertension after isolated severe head injury without any intracranial haematomas. In all patients, treatment included sedation, paralysis and IV mannitol under intracranial pressure monitoring. Early decompressive craniectomy was carried out in six patients (mean age: 13 years) at mean time from injury of 7 h (range: 2-18 h), whereas six patients (mean age: 11.5 years) were managed with non-operative treatment. The Marshall Grading system was used to score the severity of radiological abnormalities in CT scans. The Glasgow Outcome Scale (GOS) at 1-year follow-up was used as outcome measure. Results:The mean Marshall grade was 3 in the craniectomy group and 2 in the non-operative group. All patients in the craniectomy group survived: four patients scored 5 and two patients scored 4 on the GOS. In the non-operative group, two patients (33%) died, one of whom received late decompressive craniectomy at 9 days, while three patients scored 5 and one patient scored 3 on the GOS. Conclusion: In children who suffered severe head injury with refractory intracranial hypertension without intracranial haematoma, early decompressive craniectomy employed in the first few hours after injury before the onset of irreversible ischaemic changes may be an effective method to treat the secondary deterioration that commonly leads to death or severe neurological deficit.	Birmingham Childrens Hosp, Dept Paediat Neurosurg, Birmingham B4 6NH, W Midlands, England		Sgouros, S (corresponding author), Birmingham Childrens Hosp, Dept Paediat Neurosurg, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.	S.Sgouros@bham.ac.uk	Sgouros, Spyridon/AAH-1361-2020	Sgouros, Spyridon/0000-0003-4615-0808			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JENNETT B, 1975, LANCET, V1, P480; KIRKHAM FJ, 1986, DEV MED CHILD NEUROL, V28, P506; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LD, 1991, J NEUROSURG, V75, P514; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Zimmerman R, 1994, NEUROIMAG CLIN N AM, P349	26	59	62	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2006	22	10					1268	1274		10.1007/s00381-006-0064-0			7	Clinical Neurology; Pediatrics; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	087CY	WOS:000240721300012	16496158				2022-02-06	
J	Ganesalingam, K; Sanson, A; Anderson, V; Yeates, KO				Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki; Yeates, Keith Owen			Self-regulation and social and behavioral functioning following childhood traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		traumatic brain injury; children; self-regulation; social and behavioral functioning; injury severity; postinjury outcomes	CLOSED-HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; LONGITUDINAL STABILITY; EXTERNALIZING PROBLEMS; INHIBITORY CONTROL; MIDDLE CHILDHOOD; RATING-SCALE; CHILDREN; ATTENTION; IMPULSIVITY	This study examined the impact of childhood traumatic brain injury (TBI) on self-regulation and social and behavioral functioning, and the role of self-regulation as a predictor of children's social and behavioral functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Self-regulation and social and behavioral functioning were assessed 2 to 5 years following injury. Children with TBI displayed deficits in self-regulation and social and behavioral functioning, after controlling for socioeconomic status (SES), although the magnitude of the deficits was not related to injury severity. Self-regulation accounted for significant variance in children's social and behavioral functioning, after controlling for SES and group membership. Self-regulation may be an important determinant of children's social and behavioral functioning following TBI.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Res Inst, Columbus, OH USA		Ganesalingam, K (corresponding author), Columbus Childrens Hosp, Childrens Res Inst, Childrens Dr, Columbus, OH 43205 USA.	GanesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Sanson, Ann/0000-0003-4910-3310			ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; Banerjee M., 1997, DEV SOCIAL COGNITION, P241; Barkley R.A., 1997, ADHD NATURE SELF CON; Benson D.F., 1986, FRONTAL LOBES; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bradley SJ., 2000, AFFECT REGULATION DE; CAMPBELL SB, 1995, J CHILD PSYCHOL PSYC, V36, P113, DOI 10.1111/j.1469-7610.1995.tb01657.x; CASPI A, 1995, CHILD DEV, V66, P55, DOI 10.1111/j.1467-8624.1995.tb00855.x; CASPI A, 1995, DEV PSYCHOPATHOL, V0002, P00472; CICCHETTI D, 1994, MONOGRAPHS SOC RES C, V59, P228; Coie J.D., 1998, HDB CHILD PSYCHOL, VVol. 3, P779, DOI DOI 10.1002/9780470147658; Dagenbach D. E., 1994, INHIBITORY PROCESSES; Daniel A., 1983, POWER PRIVILEGE PRES; Davis P, 1997, NZ SOCIOECONOMIC IND; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dodge KA, 1997, J ABNORM PSYCHOL, V106, P37, DOI 10.1037/0021-843X.106.1.37; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Ganzeboom HBG, 1996, SOC SCI RES, V25, P201, DOI 10.1006/ssre.1996.0010; Gresham FM., 1990, SOCIAL SKILLS RATING; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Krueger RF, 1996, J PERS, V64, P107, DOI 10.1111/j.1467-6494.1996.tb00816.x; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Luria A.R., 1973, WORKING BRAIN; Manly T., 1999, TEST EVERYDAY ATTENT; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; Olson SL, 1999, J ABNORM CHILD PSYCH, V27, P151, DOI 10.1023/A:1021915615677; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; OLSON SL, 1989, J CLIN CHILD PSYCHOL, V18, P176, DOI 10.1207/s15374424jccp1802_9; OLSON SL, 1990, J ABNORM CHILD PSYCH, V18, P317, DOI 10.1007/BF00916568; Olson SL, 2000, J ABNORM CHILD PSYCH, V28, P119, DOI 10.1023/A:1005166629744; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RODRIGUEZ ML, 1989, J PERS SOC PSYCHOL, V57, P358, DOI 10.1037/0022-3514.57.2.358; Rothbart M.K., 2006, HDB CHILD PSYCHOL, V6th ed., P99, DOI DOI 10.1002/9780470147658.CHPSY0303; Saarni C., 1997, EMOTIONAL DEV EMOTIO; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; Schore AN, 1996, DEV PSYCHOPATHOL, V8, P59, DOI 10.1017/S0954579400006970; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A, 2001, DEV PSYCHOL, V37, P321, DOI 10.1037//0012-1649.37.3.321; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	67	59	59	0	24	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2006	12	5					609	621		10.1017/S1355617706060796			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychiatry; Psychology	081ZE	WOS:000240355300003	16961942				2022-02-06	
J	Alexander, MP				Alexander, MP			Impairments of procedures for implementing complex language are due to disruption of frontal attention processes	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						discourse; executive function; attention; aphasia; cerebellum; caudate	SUPPLEMENTARY MOTOR AREA; TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; DYNAMIC APHASIA; BASAL GANGLIA; LOBE DAMAGE; LESIONS; ANTERIOR; CHILDREN; CORTEX	Production of complex discourse-lengthy, open-ended utterances and narratives-requires intact basic language operations, but it also requires a series of learned procedures for construction of complex, goal-directed communications. The progression of clinical disorders from transcortical motor aphasia to dynamic aphasia to discourse impairments represents it progression of procedural deficits from basic morpho-syntax to complex grammatical structures to narrative and a progression of lesions from posterior frontal to polar and/or lateral frontal to medial frontal. Two cases of impaired utilization of language exemplify the range of impairments from clearly agrammatic. nonfluency to less and less "aphasic" and more and more executive impairments from aphasic a. transcortical motor aphasia to dynamic aphasia to narrative discourse disorder. The clinical phenomenology of these disorders gradually comes to be more accurately defined in the terminology of executive deficits than that of aphasia. The executive deficits are, in turn, based on impairments in various components of attention. Specific impairments in energizing attention and setting response criteria associated, respectively, with lesions in superior medial and left ventrolateral frontal regions may cause defective recruitment of the procedures of complex language assembly.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Behav Neurol Unit, Boston, MA 02215 USA		Alexander, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Behav Neurol Unit, KS 253,330 Brookline Ave, Boston, MA 02215 USA.	malexand@bidmc.harvard.edu					ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; ALEXANDER MP, 1990, NEUROLOGY, V40, P353, DOI 10.1212/WNL.40.2.353; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; BURGESS PW, 2005, SPEED CONTROL AGE HO; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2003, PEDIATR NEUROL, V29, P34, DOI 10.1016/S0887-8994(03)00012-2; CHAPMAN SB, 1989, BRAIN LANG, V36, P651, DOI 10.1016/0093-934X(89)90092-8; Chatterjee A, 1997, CORTEX, V33, P419, DOI 10.1016/S0010-9452(08)70228-4; COSTELLO AD, 1989, CORTEX, V25, P103; Crosson B, 2001, J COGNITIVE NEUROSCI, V13, P272, DOI 10.1162/089892901564225; Crozier S, 1999, NEUROPSYCHOLOGIA, V37, P1469, DOI 10.1016/S0028-3932(99)00054-8; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davis GA, 1997, BRAIN LANG, V56, P183; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FREEDMAN M, 1984, NEUROLOGY, V34, P409, DOI 10.1212/WNL.34.4.409; FREEMON FR, 1971, J NEUROL NEUROSUR PS, V34, P693, DOI 10.1136/jnnp.34.6.693; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gasparini M, 1999, EUR J NEUROL, V6, P353, DOI 10.1046/j.1468-1331.1999.630353.x; GELMERS HJ, 1983, J NEUROL NEUROSUR PS, V46, P1052, DOI 10.1136/jnnp.46.11.1052; GODEFROY O, 1992, ARCH NEUROL-CHICAGO, V49, P1285, DOI 10.1001/archneur.1992.00530360087023; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Goodglass H, 1983, ASSESSMENT APHASIA R; Grindrod CM, 2005, BRAIN COGNITION, V57, P70, DOI 10.1016/j.bandc.2004.08.023; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; Kaplan E, 1983, BOSTON NAMING TEST; Luria A R, 1967, Acta Neurol Psychiatr Belg, V67, P1045; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; Marien P, 2001, BRAIN LANG, V79, P580, DOI 10.1006/brln.2001.2569; Marien P, 1996, J NEUROL SCI, V144, P34, DOI 10.1016/S0022-510X(96)00059-7; MASDEU JC, 1978, NEUROLOGY, V28, P1220, DOI 10.1212/WNL.28.12.1220; MEGA MS, 1994, NEUROLOGY, V44, P1824, DOI 10.1212/WNL.44.10.1824; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; MOHR JP, 1978, NEUROLOGY, V28, P311, DOI 10.1212/WNL.28.4.311; NADEAU SE, 1988, BRAIN, V111, P1111, DOI 10.1093/brain/111.5.1111; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Robinson G, 1998, BRAIN, V121, P77, DOI 10.1093/brain/121.1.77; RUBENS AB, 1976, STUDIES NEUROLINGUIS, V1, P293; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SILVERI MC, 1994, NEUROLOGY, V44, P2047, DOI 10.1212/WNL.44.11.2047; Sirigu A, 1998, CORTEX, V34, P771, DOI 10.1016/S0010-9452(08)70780-9; Sowell ER, 1999, NEUROIMAGE, V9, P587, DOI 10.1006/nimg.1999.0436; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2002, NEUROPSYCHOLOGY, V16, P500, DOI 10.1037//0894-4105.16.4.500; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Ullman MT, 1997, J COGNITIVE NEUROSCI, V9, P266, DOI 10.1162/jocn.1997.9.2.266; VANDONGEN HR, 1985, ANN NEUROL, V17, P306, DOI 10.1002/ana.410170316; Von Stockert T. R, 1974, BRAIN LANG, V1, P277; YAKOVLEV PI, 1961, ARCH NEUROL-CHICAGO, V5, P364, DOI 10.1001/archneur.1961.00450160014002	63	59	62	1	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2006	12	2					236	247		10.1017/S1355617706060309			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	031CC	WOS:000236680700009	16573857				2022-02-06	
J	Burns, TL; Ineck, JR				Burns, TL; Ineck, JR			Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain	ANNALS OF PHARMACOTHERAPY			English	Article						analgesia; cannabinoids; chronic pain	CLOSED-HEAD INJURY; RAT-BRAIN; DEXANABINOL HU-211; NEUROPATHIC PAIN; ORAL DELTA-9-TETRAHYDROCANNABINOL; INTRAMUSCULAR LEVONANTRADOL; MEDICINAL EXTRACTS; NMDA ANTAGONIST; ANANDAMIDE; RECEPTOR	OBJECTIVE: To review the literature concerning the physiology of the endocannabinoid system, current drug development of cannabinoid agonists, and current clinical research on the use of cannabinoid agonists for analgesia. DATA SOURCES: Articles were identified through a search of MEDLINE (1966-August 2005) using the key words cannabis, cannabinoid, cannabi*, cannabidiol, nabilone, THC, pain, and analgesia. No search limits were included. Additional references were located through review of the bibliographies of the articles identified. STUDY SELECTION AND DATA EXTRACTION: Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. Studies or reviews using animal models of pain were also included. Articles that related to the physiology and pharmacology of the endocannabinoid system were evaluated. DATA SYNTHESIS: The discovery of cannabinoid receptors and endogenous ligands for these receptors has led to increased drug development of cannabinoid agonists. New cannabimimetic agents have been associated with fewer systemic adverse effects than delta-9-tetrahydrocannabinol, including recent development of cannabis medicinal extracts for sublingual use (approved in Canada), and have had promising results for analgesia in initial human trials. Several synthetic cannabinoids have also been studied in humans, including 2 cannabinoid agonists available on the international market, CONCLUSIONS: Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a potential addition to the arsenal of treatment options.	Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA; Creighton Univ, Med Ctr, Omaha, NE 68178 USA		Ineck, JR (corresponding author), Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA.	jineck@creighton.edu	Cote, Mathieu/A-6735-2008	Burns, Tammy/0000-0002-1278-8515			[Anonymous], 2003, Drugs R D, V4, P306; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Berman JS, 2004, PAIN, V112, P299, DOI 10.1016/j.pain.2004.09.013; Breivogel CS, 1998, NEUROBIOL DIS, V5, P417, DOI 10.1006/nbdi.1998.0229; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Buggy DJ, 2003, PAIN, V106, P169, DOI 10.1016/S0304-3959(03)00331-2; Burstein SH, 2004, LIFE SCI, V75, P1513, DOI 10.1016/j.lfs.2004.04.010; Burstein SH, 1999, PHARMACOL THERAPEUT, V82, P87, DOI 10.1016/S0163-7258(98)00069-2; CABRAL GA, 1991, ADV BIOSCI, V80, P93; CAMPBELL JA, 2001, BRIT MED J, V323, P1; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; Compton DR, 1997, J PHARMACOL EXP THER, V283, P1138; Costa B, 2004, BRIT J PHARMACOL, V141, P4, DOI 10.1038/sj.bjp.0705587; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CRONIN CM, 1981, J CLIN PHARMACOL, V21, pS43, DOI 10.1002/j.1552-4604.1981.tb02572.x; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, CURR MED CHEM, V6, P721; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dogrul A, 2004, NEUROSCI LETT, V368, P82, DOI 10.1016/j.neulet.2004.06.060; Dogrul A, 2003, PAIN, V105, P11, DOI 10.1016/S0304-3959(03)00068-X; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Goutopoulos A, 2002, PHARMACOL THERAPEUT, V95, P103, DOI 10.1016/S0163-7258(02)00250-4; GROTENHERMEN F, 2002, CANNABIS CANNABINOID; Hamann W, 1999, LANCET, V353, P560, DOI 10.1016/S0140-6736(98)05429-4; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; JAIN AK, 1981, J CLIN PHARMACOL, V21, pS320, DOI 10.1002/j.1552-4604.1981.tb02610.x; Joy JE, 1999, MARIJUANA MED ASSESS; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; KNOLLER N, 1998, C NEUR SURG SEATTL O; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1995, J NEUROSCI, V15, P6552; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; Malan TP, 2003, CURR OPIN PHARMACOL, V3, P62, DOI 10.1016/S1471-4892(02)00004-8; Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McPartland J. M., 2001, Journal of Cannabis Therapeutics, V1, P103, DOI 10.1300/J175v01n03_08; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5; Notcutt W, 2004, ANAESTHESIA, V59, P440, DOI 10.1111/j.1365-2044.2004.03674.x; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; PATON WDM, 1975, ANNU REV PHARMACOL, V15, P191, DOI 10.1146/annurev.pa.15.040175.001203; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f; Rice ASC, 2003, PROG PAIN RES MANAG, V24, P437; Romero J, 2002, PHARMACOL THERAPEUT, V95, P137, DOI 10.1016/S0163-7258(02)00253-X; Rosenberg RN, 2003, ARCH NEUROL-CHICAGO, V60, P1520, DOI 10.1001/archneur.60.11.1520; Schweitzer P, 2000, J NEUROSCI, V20, P51, DOI 10.1523/JNEUROSCI.20-01-00051.2000; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; STEELE N, 1980, CANCER TREAT REP, V64, P219; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; THOMPSON GR, 1973, TOXICOL APPL PHARM, V25, P363, DOI 10.1016/0041-008X(73)90310-4; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa; Walker JM, 1999, LIFE SCI, V65, P665, DOI 10.1016/S0024-3205(99)00289-1; Walker JM, 2002, PHARMACOL THERAPEUT, V95, P127, DOI 10.1016/S0163-7258(02)00252-8; YAKSH TL, 1981, J CLIN PHARMACOL, V21, pS334, DOI 10.1002/j.1552-4604.1981.tb02612.x; Zurier RB, 1998, ARTHRITIS RHEUM-US, V41, P163, DOI 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.3.CO;2-0	75	59	62	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	FEB	2006	40	2					251	260		10.1345/aph.1G217			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	015QA	WOS:000235564700011	16449552				2022-02-06	
J	Keenan, HT; Runyan, DK; Nocera, M				Keenan, HT; Runyan, DK; Nocera, M			Child outcomes and family characteristics 1 year after severe inflicted or noninflicted traumatic brain injury	PEDIATRICS			English	Article						traumatic brain injury; child abuse; outcomes; shaken infant syndrome	PEDIATRIC INTENSIVE-CARE; YOUNG-CHILDREN; PRACTICAL SCALE; HEAD-INJURY; COMA; TERM	OBJECTIVE. To assess outcomes 1 year after severe traumatic brain injury (TBI) among young children and to compare outcomes between children with inflicted versus noninflicted injuries. STUDY DESIGN. Prospective cohort study. METHODS. All North Carolina-resident children who were hospitalized between January 2000 and December 2001 in any of the state's 9 PICUs and who survived a severe TBI that occurred on or before their second birthday were eligible to participate. Child health status, child use of ancillary medical resources, and family characteristics were determined through maternal caregiver interviews similar to 1 year after injury. Comparisons were made between family characteristics and child outcomes according to injury type. RESULTS. Seventy-two interviews of maternal caregivers were completed among 112 survivors (64.3%). Children with inflicted injuries (n = 41) had worse outcomes than did children with noninflicted injuries (n = 31), as measured with the Pediatric Outcome Performance Category and Stein-Jessup Functional Status II ( Revised) tools. However, similar to 50% of children with inflicted injuries had only mild deficits or better. Children with inflicted injuries had a higher use of ancillary medical resources. Families caring for the children did not differ substantively, with a large proportion of single, working, minority mothers. CONCLUSIONS. Children with inflicted TBIs had worse outcomes than did children with other TBIs 1 year after injury. However, outcomes for these children were better than those reported previously. Many families caring for children after severe TBI are socially disadvantaged. Interventions to improve child outcomes may include enhanced family support.	Univ Utah, Intermt Injury Res Control Ctr, Salt Lake City, UT 84158 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84158 USA; Univ N Carolina, Dept Social Med, Chapel Hill, NC 27514 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27514 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27514 USA		Keenan, HT (corresponding author), Univ Utah, Intermt Injury Res Control Ctr, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040, K23 HD041040-01A2, K23 HD041040-03] Funding Source: Medline; ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline		Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; JENNETT B, 1975, LANCET, V1, P480; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; *NATL CTR INJ PREV, 2005, TRAUM BRAIN INJ US; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; RUNYAN DK, 2001, WELL BEING CHILDREN; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Simpson L, 2005, AMBUL PEDIATR, V5, P6, DOI 10.1367/A04-119R.1; SPARROW S, 1984, VINELAND ADAPTIVE BH; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	28	59	59	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					317	324		10.1542/peds.2005-0979			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	014PC	WOS:000235491100008	16452349	Green Accepted, Green Submitted			2022-02-06	
J	Anson, K; Ponsford, J				Anson, K; Ponsford, J			Who benefits? Outcome following a coping skills group intervention for traumatically brain injured individuals	BRAIN INJURY			English	Article						coping; psychological outcome; cognitive behaviour therapy and self-awareness	SICKNESS IMPACT PROFILE; CLOSED-HEAD-INJURY; SELF-AWARENESS; DEPRESSION SCALE; HOSPITAL ANXIETY; IMPAIRED AWARENESS; ADULTS; DEFICITS; REHABILITATION; AGGRESSION	Primary objective: To investigate the variables associated with positive psychological outcome following a group intervention for 33 individuals with traumatic brain injury. Research design: Evaluation study which used multiple regression analysis to examine the variables associated with change in psychological adjustment following a 10-session cognitive behaviour therapy-based group. Methods and procedures: The predictor variables were age at injury, time since injury, injury severity, self-awareness, premorbid intellectual function, memory function, executive function and level of depression and anxiety prior to intervention. Main outcomes and results: The predictor variables contributed a significant proportion of the variance in percentage change in depression. The major finding was that better outcomes following intervention were associated with greater self-awareness of injury-related deficits. Conclusions: The present study identified a number of variables that were associated with improvement in depression following psychological intervention and may assist future treatment resources to be directed most effectively.	Epworth Hosp Melbourne, Melbourne, Vic, Australia		Anson, K (corresponding author), 36 Auburn Parade, E Hawthorn, Vic 3123, Australia.	katie.anson@gmail.com					Aeschleman S. R., 1999, J RATION-EMOT COGN-B, V17, P51, DOI DOI 10.1023/A:1023073130972; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Burgess P, 1996, BEHAV ASSESSMENT DYS; Christensen B, 1994, ADV MED PSYCHOTHERAP, V7, P23; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DOYLE M, 2001, EPW INN REH C MELB A; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hubble MA, 1999, HEART SOUL CHANGE WH; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; OWNSWORTH T, 2001, ASSBI 24 BRAIN IMP C; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC, P244; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rosenberg M., 1965, SOC ADOLESCENT SELF; Rosenberg M., 1986, CONCEIVING SELF; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Snaith R., 1994, HOSP ANXIETY DEPRESS; Spielberger C. D., 1999, STATE TRAIT ANGER EX; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; Wrightsman, 1993, MEASURES PERSONALITY, P115, DOI DOI 10.1016/B978-0-12-590241-0.50008-3; [No title captured]	62	59	59	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					1	13		10.1080/02699050500309791			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000001	16403695				2022-02-06	
J	Hudak, AM; Caesar, RR; Frol, AB; Krueger, K; Harper, CR; Temkin, NR; Dikmen, SS; Carlile, M; Madden, C; Diaz-Arrastia, R				Hudak, AM; Caesar, RR; Frol, AB; Krueger, K; Harper, CR; Temkin, NR; Dikmen, SS; Carlile, M; Madden, C; Diaz-Arrastia, R			Functional outcome scales in traumatic brain injury: A comparison, of the Glasgow Outcome Scale (extended) and the Functional Status Examination	JOURNAL OF NEUROTRAUMA			English	Article						Abbreviated Injury Scale; Functional Status Examination; Glasgow Outcome Scale; Injury Severity Score; traumatic brain injury	HEAD-INJURY; STRUCTURED INTERVIEWS; CLASSIFICATION; RELIABILITY; DISABILITY; COMMUNITY; VALIDITY; MODERATE	Clinical trials aimed at developing therapies for traumatic brain injury (TBI) require outcome measures that are reliable, validated, and easily administered. The most widely used of these measures, the Glasgow Outcome Scale (GOS) and the GOS-Extended (GOS-E), have been criticized as suffering from ceiling effects. In an attempt to develop a more useful and dynamic outcome measure, the Functional Status Examination (FSE) was developed, which grades outcome across 10 functional domains. The FSE has been demonstrated to be reliable and sensitive in monitoring recovery after TBI. This manuscript compares FSE with GOS-E in a cohort of patients with a wide range of injury severities. 177 individuals who survived at least 6 months after TBI were studied. The FSE and GOS-E were administered 6-12 months after injury. FSE and GOS-E scores correlated well with each other. FSE scores were distributed throughout the range, indicating that ceiling and floor effects were not present. Physiologic measures of injury severity (Glasgow Coma Score [GCS]) did not correlate with anatomic measures (Abbreviated Injury Scale [AIS] and Injury Severity Score [ISS]). GCS correlated weakly with both outcome measures, but AIS/ISS did not. We conclude that FSE and GOS-E are reliable outcome measures for TBI survivors, and FSE may offer some advantages over GOS-E due its ability to provide a more detailed description of deficits. The majority of the variance in outcome is not accounted for by currently available measures of injury severity.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75390 USA; Baylor Inst Rehabil, Dallas, TX USA; Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Phys Med & Rehabil, Seattle, WA 98195 USA		Hudak, AM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Anne.Hudak@UTSouthwestem.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 48179, U01 HD 42652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; CDC, 1999, TRAUM BRAIN INJ US R; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hamilton BB, 1987, REHABILITATION OUTCO, P137; JENNETT B, 1975, LANCET, V1, P480; Kirkness Catherine J, 2002, J Neurosci Nurs, V34, P134; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; World Health Organization, 2007, INT CLASS FUNCT DIS	22	59	61	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1319	1326		10.1089/neu.2005.22.1319			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000006	16305320				2022-02-06	
J	Bledsoe, GH; Li, GH; Levy, F				Bledsoe, GH; Li, GH; Levy, F			Injury risk in professional boxing	SOUTHERN MEDICAL JOURNAL			English	Article						boxing; head injury; professional sports	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; DEMENTIA-PUGILISTICA; BOXERS; CONCUSSION; SPORTS	Objective: Although a popular endeavor, boxing has fallen under increased scrutiny because of its association with traumatic brain injury. However, few studies have investigated the overall epidemiology of boxing injuries from representative samples, and no study has ever documented the incidence of injuries in female boxers. This study is a review of professional boxing data from the state of Nevada from September 2001 through March 2003. Materials and Methods: Medical and outcome data for all professional boxing matches occurring in Nevada between September 2001 and March 2003 (n = 524 matches) were analyzed on the basis of a pair-matched, case-control design. Cases were boxers who received an injury during the boxing matches. Boxers who were not injured served as control subjects. Both conditional and unconditional logistic regression models were used to assess risk factors for injury. Results: The overall incidence rate of injury was 17.1 per 100 boxer-matches, or 3.4 per 100 boxer-rounds. Facial laceration accounted for 51% of all injuries, followed by hand injury (17%), eye injury (14%), and nose injury (5%). Male boxers were significantly more likely than female boxers to receive injuries (3.6 versus 1.2 per 100 boxer-rounds, P = 0.01). Male boxing matches also ended in knockouts and technical knockouts more often than did female matches (P < 0.001). The risk of injury for those who lost the matches was nearly twice the risk for the winners. Those who lost by knockout had double the risk of injury compared with those who lost by other means. Neither age nor weight was significantly associated with the risk of injury. Conclusions: The injury rate in professional boxing matches is high, particularly among male boxers. Superficial facial lacerations are the most common injury reported. Male boxers have a higher rate of knockout and technical knockouts than female boxers. Further research is necessary to determine the outcomes of injury, particularly the long-term neurologic outcome differences between sexes.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21287 USA		Bledsoe, GH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 600 N Wolfe St,Marburg B-186, Baltimore, MD 21287 USA.	gbledso1@jhmi.edu					ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Bents RT, 2003, MED SCI SPORT EXER, V35, P1645, DOI 10.1249/01.MSS.0000089340.89660.EB; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; Constantoyannis C, 2004, BRIT J SPORT MED, V38, P78, DOI 10.1136/bjsm.2002.001123; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Hazar M, 2002, BRIT J SPORT MED, V36, P428, DOI 10.1136/bjsm.36.6.428; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; NOBLE C, 1987, AM J SPORT MED, V15, P342, DOI 10.1177/036354658701500408; Ooi A, 2003, EUR J CARDIO-THORAC, V24, P1043, DOI 10.1016/S1010-7940(03)00579-7; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; Powell JW, 2001, J ATHL TRAINING, V36, P307; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Ross RT, 1999, MIL MED, V164, P68, DOI 10.1093/milmed/164.1.68; Unterharnscheidt F, 1995, Rev Neurol, V23, P847; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1013; Unterharnscheidt F, 1995, Rev Neurol, V23, P833; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	31	59	62	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	OCT	2005	98	10					994	998		10.1097/01.smj.0000182498.19288.e2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	982RC	WOS:000233178300009	16295814				2022-02-06	
J	Lange, RT; Iverson, GL; Zakrzewski, MJ; Ethel-King, PE; Franzen, MD				Lange, RT; Iverson, GL; Zakrzewski, MJ; Ethel-King, PE; Franzen, MD			Interpreting the trail making test following traumatic brain injury: Comparison of traditional time scores and derived indices	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	109th Annual Convention of the American-Psychological-Association	AUG 24-28, 2001	SAN FRANCISCO, CA	Amer Psychol Assoc			DRUG-ABUSE; SAMPLE; AGE; PERFORMANCE; DEPRESSION; IMPAIRMENT; ETHNICITY; DEMENTIA; UTILITY; SEX	The purpose of this study was to examine the clinical application of traditional time scores and various derived indices from the Trail Making Test (THT) in a sample of 571 patients with acute traumatic brain injury (TBI). Participants were classified into four injury severity groups. A clear linear relation between injury severity and THT performance was demonstrated, with the more severely brain injured patients performing more poorly on most measures. Hierarchical logistic regression analysis of THT time scores across binary extreme groups based on injury severity resulted in high classification rates for patients with very mild TBI (93.0% correctly classified) and low classification rates for patients with moderate to severe TBI (50.0% correctly classified). However, TMT derived indices did not provide a unique contribution to test interpretation beyond what is already available from Part A and B separately.	Riverview Hosp, Coquitlam, BC V3C 4J2, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA		Lange, RT (corresponding author), Riverview Hosp, 124 ADMIN Bldg,2601 Lougheed Highway, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Basso MR, 2003, J CLIN EXP NEUROPSYC, V25, P893, DOI 10.1076/jcen.25.7.893.16489; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GRANT I, 1987, J CLIN PSYCHIAT, V48, P319; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; Heilbronner R L, 1991, Arch Clin Neuropsychol, V6, P251, DOI 10.1016/0887-6177(91)90002-Q; Horton AM, 2003, INT J NEUROSCI, V113, P595, DOI 10.1080/00207450390162317; Horton AM, 2003, ARCH CLIN NEUROPSYCH, V18, P49, DOI 10.1016/S0887-6177(01)00183-4; Horton AM, 2002, INT J NEUROSCI, V112, P429, DOI 10.1080/00207450290025563; Horton AM, 2002, INT J NEUROSCI, V112, P1075, DOI 10.1080/00207450290026067; Horton AM, 2002, INT J NEUROSCI, V112, P565, DOI 10.1080/00207450290025653; Horton AM, 2002, INT J NEUROSCI, V112, P225, DOI 10.1080/00207450212021; Horton AM, 2001, INT J NEUROSCI, V110, P173, DOI 10.3109/00207450108986544; Horton AM, 2001, INT J NEUROSCI, V111, P123, DOI 10.3109/00207450108986557; Horton AM, 2001, INT J NEUROSCI, V111, P101, DOI 10.3109/00207450108986555; Horton AM, 2001, INT J NEUROSCI, V109, P281, DOI 10.3109/00207450108986539; Horton AM, 2001, INT J NEUROSCI, V108, P281, DOI 10.3109/00207450108986518; Kim MS, 2003, PSYCHIAT RES-NEUROIM, V123, P109, DOI 10.1016/S0925-4927(03)00045-3; KLESGES RC, 1984, J CLIN NEUROPSYCHOLO, V1, P29; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; McCaffrey R J, 1989, Arch Clin Neuropsychol, V4, P393, DOI 10.1016/0887-6177(89)90030-9; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; Reitan R, 1985, HALSTEAD REITAN NEUR; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1959, J NERV MENT DIS, V129, P257, DOI 10.1097/00005053-195909000-00006; Reitan RM, 1992, TRAIL MAKING TEST MA; Roberts C, 2003, INT J NEUROSCI, V113, P747, DOI 10.1080/00207450390200062; Roberts C, 2002, INT J NEUROSCI, V112, P337, DOI 10.1080/00207450212031; Roberts C, 2002, INT J NEUROSCI, V112, P985, DOI 10.1080/00207450290025987; Roberts C, 2002, INT J NEUROSCI, V112, P575, DOI 10.1080/00207450290025662; Roberts C, 2001, INT J NEUROSCI, V110, P99, DOI 10.3109/00207450108994225; Roberts C, 2001, INT J NEUROSCI, V109, P273, DOI 10.3109/00207450108986538; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sellers A. H., 1992, PSYCHOTHERAPY PRIVAT, V11, P47; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; *US WAR DEP ADJ GE, 1994, MAN ARM IND TEST	52	59	59	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2005	27	7					897	906		10.1080/1380339049091290			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Neurosciences & Neurology	970GN	WOS:000232293400010	16183622				2022-02-06	
J	Withnall, C; Shewchenko, N; Wonnacott, M; Dvorak, J				Withnall, C; Shewchenko, N; Wonnacott, M; Dvorak, J			Effectiveness of headgear in football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; BRAIN-INJURY; CONCUSSION; IMPACT; SKILL	Objectives: Commercial headgear is currently being used by football players of all ages and skill levels to provide protection from heading and direct impact. The clinical and biomechanical effectiveness of the headgear in attenuating these types of impact is not well defined or understood. This study was conducted to determine whether football headgear has an effect on head impact responses. Methods: Controlled laboratory tests were conducted with a human volunteer and surrogate head/neck system. The impact attenuation of three commercial headgears during ball impact speeds of 6-30 m/s and in head to head contact with a closing speed of 2-5 m/s was quantified. The human subject, instrumented to measure linear and angular head accelerations, was exposed to low severity impacts during heading in the unprotected and protected states. High severity heading contact and head to head impacts were studied with a biofidelic surrogate headform instrumented to measure linear and angular head responses. Subject and surrogate responses were compared with published injury assessment functions associated with mild traumatic brain injury (MTBI). Results: For ball impacts, none of the headgear provided attenuation over the full range of impact speeds. Head responses with or without headgear were not significantly different (p>0.05) and remained well below levels associated with MTBI. In head to head impact tests the headgear provided an overall 33% reduction in impact response. Conclusion: The football headgear models tested did not provide benefit during ball impact. This is. probably because of the large amount of ball deformation relative to headband thickness. However, the headgear provided measurable benefit during head to head impacts.	FIFA Med Assessment & Res Ctr, Zurich, Switzerland			withnall@biokinetics.com					Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2003, J ATHL TRAINING, V38, P220; CPSC, 2002, SOCC HEAD INJ CAL YE; DIMASI FP, 1995, HS808282 DOT NAT HIG; Dvorak J, 2000, AM J SPORT MED, V28, pS3; *FULL90SPORTS, 2003, SOCC REB SPEED COMP; *FULL90SPORTS, 2003, RED HEAD INJ SOCC; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HUBBARD R, 1974, HYBRID, V3, P95; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Junge A, 2000, AM J SPORT MED, V28, pS47; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; MERTZ HJ, 1971, 15TH P STAPP CAR CRA, P207; Newman J., 1999, INT RES COUNC BIOM I; Newman J, 2000, 44 STAPP CAR CRASH C; Peterson L, 2000, AM J SPORT MED, V28, pS51; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; *SAE, 1995, SAE HDB; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; ZIEJEWSKI M, 2003, BRAIN INJ ASS 20 ANN	33	59	59	2	26	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I40	I48		10.1136/bjsm.2005.019174			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	954KI	WOS:000231153600006	16046355	Green Published, Bronze			2022-02-06	
J	Bulger, EM; Copass, MK; Sabath, DR; Maier, RV; Jurkovich, GJ				Bulger, EM; Copass, MK; Sabath, DR; Maier, RV; Jurkovich, GJ			The use of neuromuscular blocking agents to facilitate prehospital intuhation does not impair outcome after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma		prehospital; endotracheal intubation; neuromuscular blocking agents; paralytics	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURIES; HYPOTENSION; FIELD; HYPOXIA	Background: Several studies have demonstrated that the success rate of prehospital intubation is improved by the use of neuromuscular blocking agents (NMBAs). However, a recent study has reported that prehospital intubation with NMBAs worsens outcome after traumatic brain injury (TBI). We sought to determine the effect of the use of NMBAs to facilitate prehospital intubation on outcome after TBI. Methods: All patients admitted to our Level I trauma center with a head Abbreviated Injury Scale score >= 3 were identified by the trauma registry (January 1998-June 2003). Patient records were matched with prehospital databases. Patients were further stratified on the basis of prehospital Glasgow Coma Scale (GCS) score into mild (GCS score of 14115), moderate (GCS score of 9-13), and severe (GCS score < 9) TBI. Outcome included mortality and good outcome (survival to discharge with a GCS score of 14/15). Results: There were 3,052 patients who were identified as having been transported directly from the field. Complete prehospital data were available for 2,012 patients (66%). Of these, 920 were mild TBI (intubation rate, 17.4%), 293 moderate TBI (intubation rate, 57.7%), and 799 severe TBI (intubation rate, 95%). Overall, 72% of intubated patients received NMBAs. There were no significant differences in demographics or injury severity between the groups. Patients not receiving NMBAs were more likely to be hypotensive and have prehospital cardiopulmonary resuscitation (p = 0.001). The unadjusted mortality for the patients intubated with NMBAs was 25% versus 37% for those not receiving NMBAs (p < 0.001). When adjusted for confounding variables, patients intubated with NMBAs were more likely to survive (odds ratio, 0.63; 95% confidence interval, 0.41-0.97; p = 0.04) and have a good outcome (odds ratio, 1.7; 95% confidence interval, 1.2-2.6; p = 0.006) than those in the no-NMBA group. Conclusion: The use of NMBAs to facilitate prehospital intubation improves outcome for patients with TBI. The value of prehospital intubation for TBI remains to be determined; however, any trial evaluating nonintubation for TBI must be compared with NMBA-facilitated intubation to be valid.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Neurol, Seattle, WA 98104 USA		Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 359796,325 9Th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Krisanda T J, 1992, Prehosp Disaster Med, V7, P121; LAVERY RF, 1992, PREHOSP DISASTER MED, V7, P144; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	20	59	60	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					718	723		10.1097/01.TA.0000159239.14181.BC			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	919VS	WOS:000228646300016	15824647				2022-02-06	
J	Van Goethem, JWM; Maes, M; Ozsarlak, O; van den Hauwe, L; Parizel, PM				Van Goethem, JWM; Maes, M; Ozsarlak, O; van den Hauwe, L; Parizel, PM			Imaging in spinal trauma	EUROPEAN RADIOLOGY			English	Article						spine, trauma; spine, fractures; spine, injuries; spine, MR; spine, CT	FLEXION-EXTENSION RADIOGRAPHS; LOW-RISK CRITERIA; CERVICAL-SPINE; BLUNT TRAUMA; CORD-INJURY; HELICAL CT; COMPUTED-TOMOGRAPHY; DECISION RULE; FRACTURES; CHILDREN	Because it may cause paralysis, injury to the spine is one of the most feared traumas, and spinal cord injury is a major cause of disability. In the USA approximately 10,000 traumatic cervical spine fractures and 4000 traumatic thoracolumbar fractures are diagnosed each year. Although the number of individuals sustaining paralysis is far less than those with moderate or severe brain injury, the socioeconomic costs are significant. Since most of the spinal trauma patients survive their injuries, almost one out of 1000 inhabitants in the USA are currently being cared for partial or complete paralysis. Little controversy exists regarding the need for accurate and emergent imaging assessment of I e traumatized spine in order to evaluate spinal stability and integrity of neural elements. Because clinicians fear missing occult spine injuries, they obtain radiographs for nearly all patients who present with blunt trauma. We are influenced on one side by fear of litigation and the possible devastating medical, psychologic and financial consequences of cervical spine injury, and on the other side by pressure to reduce health care costs. A set of clinical and/or anamnestic criteria, however, can be very useful in identifying patients who have an extremely low probability of injury and who consequently have no need for imaging studies. Multidetector (or multislice) computed tomography (MDCT) is the preferred primary imaging modality in blunt spinal trauma patients who do need imaging. Not only is CT more accurate in diagnosing spinal injury, it also reduces imaging time and patient manipulation. Evidence-based research has established that MDCT improves patient outcome and saves money in comparison to plain film. This review discusses the use, advantages and disadvantages of the different imaging techniques used in spinal trauma patients and the criteria used in selecting patients who do not need imaging. Finally an overview of different types of spinal injuries is given.	Univ Antwerp, Univ Ziekenhuis Antwerpen, Dept Radiol, B-2650 Edegem, Belgium; Algemeen Ziekenhuis Maria Middelares, Dept Radiol, B-9100 St Niklaas, Belgium		Van Goethem, JWM (corresponding author), Univ Antwerp, Univ Ziekenhuis Antwerpen, Dept Radiol, Wilrijkstr 10, B-2650 Edegem, Belgium.	johan.vangoethem@ua.ac.be		Parizel, Paul M./0000-0002-0221-2854			Belanger E, 2000, J NEUROSURG, V93, P294, DOI 10.3171/spi.2000.93.2.0294; Bensch FV, 2004, EUR RADIOL, V14, P618, DOI 10.1007/s00330-003-2090-6; Besman A, 2003, AM SURGEON, V69, P1010; Blackmore CC, 2003, NEUROIMAG CLIN N AM, V13, P283, DOI 10.1016/S1052-5149(03)00024-8; Bogduk N, 2001, CLIN BIOMECH, V16, P267, DOI 10.1016/S0268-0033(01)00003-1; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; Cirak B, 2004, J PEDIATR SURG, V39, P607, DOI 10.1016/j.jpedsurg.2003.12.011; CROWE H, 1964, Calif Med, V100, P12; Daffner RH, 2001, AM J ROENTGENOL, V177, P677, DOI 10.2214/ajr.177.3.1770677; Dai LY, 2004, J TRAUMA, V56, P348, DOI 10.1097/01.TA.0000035089.51187.43; DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003; Dickinson G, 2004, ANN EMERG MED, V43, P507, DOI 10.1016/j.annemergmed.2003.10.036; Dwek JR, 2000, AM J ROENTGENOL, V174, P1617, DOI 10.2214/ajr.174.6.1741617; ELKHOURY GY, 1992, CLIN NEUR, V38, P261; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; FALCONE S, 1994, AM J NEURORADIOL, V15, P747; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; GEBHARD JS, 1994, ORTHOP REV S, V23, P9; Geck MJ, 2001, J SPINAL DISORD, V14, P371, DOI 10.1097/00002517-200110000-00001; Goldberg W, 2001, ANN EMERG MED, V38, P17, DOI 10.1067/mem.2001.116150; Griffen MM, 2004, J TRAUMA, V56, P457; Gunzburg R, 2003, Pain Res Manag, V8, P24; Hanson JA, 2000, AM J ROENTGENOL, V174, P713, DOI 10.2214/ajr.174.3.1740713; Harris JH, 1996, RADIOLOGY ACUTE CERV; Hoffman JR, 2000, NEW ENGL J MED, V343, P1339; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Holmes JF, 2002, J TRAUMA, V53, P524, DOI 10.1097/00005373-200209000-00021; Insko EK, 2002, J TRAUMA, V53, P426, DOI 10.1097/00005373-200209000-00005; Jackson R Sean, 2002, J Am Acad Orthop Surg, V10, P271; Jenkins M G, 1999, Eur J Emerg Med, V6, P215; Linsenmaier U, 2002, EUR RADIOL, V12, P1728, DOI 10.1007/s00330-001-1225-x; Mann FA, 2003, EUR J RADIOL, V48, P39, DOI 10.1016/S0720-048X(03)00196-7; Mower WR, 2002, J TRAUMA, V53, P1198, DOI 10.1097/00005373-200212000-00039; Obenauer S, 2002, EUR RADIOL, V12, P2107, DOI 10.1007/s00330-001-1253-6; Oner FC, 1999, EUR SPINE J, V8, P194, DOI 10.1007/s005860050156; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; Pollack CV, 2001, ANN EMERG MED, V38, P8, DOI 10.1067/mem.2001.116810; Potter K, 2003, BRIT J RADIOL, V76, P347, DOI 10.1259/bjr/11881183; ROGERS LF, 1971, AMER J ROENTGENOL RA, V111, P844, DOI 10.2214/ajr.111.4.844; Sagiuchi T, 2002, J COMPUT ASSIST TOMO, V26, P654, DOI 10.1097/00004728-200207000-00032; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; Stiell IG, 2000, ACAD EMERG MED, V7, P566; Taylor J R, 1993, Ann Acad Med Singap, V22, P187; Touger M, 2002, ANN EMERG MED, V40, P287, DOI 10.1067/mem.2002.125708; Van Goethem J W M, 2003, JBR-BTR, V86, P230; VanGoethem JWM, 1996, EUR J RADIOL, V22, P30, DOI 10.1016/0720-048X(95)00696-N; Vellman WP, 2003, SPINE, V28, P941; Wallis BJ, 1996, PAIN, V66, P223, DOI 10.1016/0304-3959(96)03044-8; Weisskopf M, 1999, UNFALLCHIRURG, V102, P942, DOI 10.1007/s001130050508; Wilmink JT, 1999, EUR RADIOL, V9, P1259, DOI 10.1007/s003300050832; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006; WOODRING JH, 1992, J TRAUMA, V33, P698, DOI 10.1097/00005373-199211000-00019; Yue JJ, 2004, SPINE, V29, pE181, DOI 10.1097/00007632-200405010-00021	55	59	60	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2005	15	3					582	590		10.1007/s00330-004-2625-5			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	912OT	WOS:000228089500019	15696292				2022-02-06	
S	Stein, DG		Singh, M; Simpkins, JW		Stein, DG			The case for progesterone	FUTURE OF HORMONE THERAPY: WHAT BASIC SCIENCE AND CLINICAL STUDIES TEACH US	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on the Future of Estrogen and Hormone Therapy in Postmenopausal Women	NOV 05-07, 2004	Ft Worth, TX	Univ N Texas Hlth Sci Ctr		progesterone; neurosteroids; hormone therapy; menopause; aging; brain damage; recovery	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; HEALTHY POSTMENOPAUSAL WOMEN; FRONTAL CORTICAL CONTUSION; MORRIS WATER MAZE; ESTROUS-CYCLE; OVARIECTOMIZED RATS; LIPID-PEROXIDATION; STEROID-HORMONES; FEMALE RATS	Recent clinical trials in hormone therapy (HT) for women approaching or past menopause have been disappointing. Most women who have been taking conjugated equine estrogens combined with synthetic progestins have been encouraged to stop these supplements because of increased health risks. The results of the clinical trials may be accurate about the risks associated with the synthetic compounds and combinations, but the data do not reflect what might have been the case if 17 beta-estradiol had been tested with natural progesterone instead of synthetic medroxyprogesterone acetate. For the most part, in almost all work on HT, estrogens have been given the primary focus despite the fact that progesterone has important properties that can enhance the repair of neurodegenerative and traumatic injuries to the central nervous system. This article reviews some of those properties and discusses the evidence suggesting that, if HT is to be reconsidered, progesterone should be given more attention as a potent neurotrophic agent that may play an important role in reducing or preventing motor, cognitive, and sensory impairments that can accompany senescence in both males and females.	Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 1648 Pierce Dr,NE,Evans Bldg Rm 261, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS38664, 1 R01 NS40825] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664, R01NS040825] Funding Source: NIH RePORTER		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baulieu EE, 2000, HUM REPROD, V15, P1; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Behl C, 1999, TRENDS PHARMACOL SCI, V20, P441, DOI 10.1016/S0165-6147(99)01392-9; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brass LM, 2004, STROKE, V35, P2644, DOI 10.1161/01.STR.0000143218.20061.ac; Cargill RS, 1999, J NEUROTRAUM, V16, P983; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chesler EJ, 2000, HORM BEHAV, V38, P234, DOI 10.1006/hbeh.2000.1626; de Wit H, 2001, PSYCHONEUROENDOCRINO, V26, P697, DOI 10.1016/S0306-4530(01)00024-5; DIAZVELIZ G, 1994, PSYCHONEUROENDOCRINO, V19, P387, DOI 10.1016/0306-4530(94)90018-3; Djebaili MJ, 2003, J NEUROTRAUM, V20, P1060; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Ehring GR, 1998, J EXP MED, V188, P1593, DOI 10.1084/jem.188.9.1593; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Epting LK, 1998, BEHAV NEUROSCI, V112, P1304, DOI 10.1037/0735-7044.112.6.1304; FULOP Z, 1992, 22 ANN M SOC NEUR AN, V18, P178; Galea LAM, 2000, HORM BEHAV, V37, P86, DOI 10.1006/hbeh.1999.1560; Gangula PRR, 2002, BIOL REPROD, V67, P1881, DOI 10.1095/biolreprod.102.007682; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibbs RB, 2003, J NEUROENDOCRINOL, V15, P477, DOI 10.1046/j.1365-2826.2003.01012.x; Gibbs RB, 1996, J NEUROSCI, V16, P1049; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HAMPSON E, 1988, BEHAV NEUROSCI, V102, P456, DOI 10.1037/0735-7044.102.3.456; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hunt JS, 1997, J REPROD IMMUNOL, V35, P87, DOI 10.1016/S0165-0378(97)00060-0; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kelly RW, 1997, BIOCHEM BIOPH RES CO, V239, P557, DOI 10.1006/bbrc.1997.7502; Kuebler JF, 2003, ARCH SURG-CHICAGO, V138, P727, DOI 10.1001/archsurg.138.7.727; Li CJ, 2004, P NATL ACAD SCI USA, V101, P2185, DOI 10.1073/pnas.0307313101; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lowery D. W., 2002, J NEUROTRAUM, V19, P1286; Malcolm Shannon G., 2000, Journal of Neurotrauma, V17, P967; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; MELCANGI RA, 2003, STEROIDS NERV SYST, V1007, P406; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.3.CO;2-5; Pettus EH, 2000, J NEUROCHEM, V75, P383, DOI 10.1046/j.1471-4159.2000.0750383.x; PETTUS EH, IN PRESS BRAIN RES; Robert R, 1997, NITRIC OXIDE-BIOL CH, V1, P453, DOI 10.1006/niox.1997.0157; Roof R. L., 1994, Society for Neuroscience Abstracts, V20, P191; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubinow MJ, 2004, BEHAV NEUROSCI, V118, P863, DOI 10.1037/0735-7044.118.4.863; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; SEGARRA AC, 2004, PRINCIPLES GENDER SP, V1, P96; Soares HD, 1995, J NEUROSCI, V15, P8223; Soderpalm AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7; Solis-Ortiz S, 2004, PSYCHONEUROENDOCRINO, V29, P1047, DOI 10.1016/j.psyneuen.2003.10.007; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010	89	59	61	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-584-2	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1052						152	169		10.1196/annals.1347.011			18	Endocrinology & Metabolism; Multidisciplinary Sciences; Obstetrics & Gynecology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Science & Technology - Other Topics; Obstetrics & Gynecology	BDE44	WOS:000233076700011	16024758				2022-02-06	
J	Stranjalis, G; Korfias, S; Papapetrou, C; Kouyialis, A; Boviatsis, E; Psachoulia, C; Sakas, DE				Stranjalis, G; Korfias, S; Papapetrou, C; Kouyialis, A; Boviatsis, E; Psachoulia, C; Sakas, DE			Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; MHI; mild or minor or ultra-mild head injury; outcome; S-100B; TBI	BRAIN INJURY; CLASSIFICATION; CONCUSSION; MANAGEMENT	Protein S-100B is an established serum marker of primary and secondary brain damage and stroke. A group of patients after mild head injury (MHI) develop post-concussion symptoms that interfere with the ability in the short-term to return to work or undertake certain activities. The aim of this study was to examine the correlation of serum S-100B with short-term outcome after MHI. We studied 100 subjects who were referred to the Emergency Department (ED) after a MHI. All subjects had a GCS of 15 either with or without loss of consciousness (LOC) and/or post-traumatic amnesia (PTA). Serum S-100B was collected within 3 h from the injury and a value of greater than or equal to0.15 mug/L was considered as abnormal. Subjects with other injuries, including scalp or cervical spine, were excluded, as well as those with alcohol/narcotic drug consumption or history of serious physical/mental illness. An independent observer measured the return to work/activities within one week. Thirty-two (32%) subjects had elevated S-100B. The failure to return to work/activities was significantly correlated with elevated S-100B: subjects with increased S-100B had a failure rate of 37.5% versus 4.9% of those with normal values (p = 0.0001). In MHI, the elevated S-100B seemed to correlate with an unfavorable short-term outcome. This might be useful in (1) selecting patients who need closer observation, hospitalization, and further investigations (such as CT scan or MRI), and (2) the prognosis of genuine post-concussion symptoms, that interfere with return to work or activities, versus other causes such as premorbid personality, labyrinthine dysfunction, whiplash syndrome, post-injury stress, occupational injury, litigation, and malingering.	Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece; Evangelismos Med Ctr, Dept Biochem, Athens, Greece		Stranjalis, G (corresponding author), 32 Skoufa St, Athens 10673, Greece.	stranjal@otenet.gr	Pillay, Nischalan/F-9536-2012				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Kraus J, 1996, NEUROTRAUMA, P13; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION D, 1991, TRAUMATIC BRAIN INJU, P24; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	20	59	60	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2004	21	8					1070	1075		10.1089/0897715041651088			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	846AK	WOS:000223286800009	15319006				2022-02-06	
J	Turkstra, LS; Dixon, TM; Baker, KK				Turkstra, LS; Dixon, TM; Baker, KK			Theory of Mind and social beliefs in adolescents with traumatic brain injury	NEUROREHABILITATION			English	Article						brain injury; adolescent; theory of mind; social	PRAGMATIC LANGUAGE-SKILLS; HEAD-INJURY; CHILDREN; INDIVIDUALS; CHILDHOOD; DAMAGE	Impairments in social performance are common consequences of TBI, yet the neuropsychological basis of these impairments is not well understood. This is particularly true for adolescents, who have the highest incidence of TBI and are at a critical stage of developing social and relationship skills. To address this, adolescents with TBI were compared to their typically developing peers on a social cognition task that included Theory of Mind (ToM) questions. As ToM may be necessary for the development of culture-specific social knowledge, the two groups also were compared in regard to their social beliefs. There were significant differences between injured and uninjured adolescents in social cognition, with group differences increasing as a function of the requirement for ToM. There were few differences in self-reported social knowledge and social beliefs. The implication of this discrepancy for the rehabilitation of adolescents with TBI is discussed.	Case Western Reserve Univ, Cleveland, OH 44106 USA		Turkstra, LS (corresponding author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-00163] Funding Source: Medline		Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMON W, 1982, CHILD DEV, V53, P841, DOI 10.1111/j.1467-8624.1982.tb01347.x; Damon W., 1983, SOCIAL PERSONALITY D; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DEPOMPEI R, 1999, REHABILITATION ADULT, P393; Dunn J., 1994, CHILDRENS EARLY UNDE, P297; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; GARCIA L, 1997, DEV SOCIAL COGNITION, P365; GERACI RI, 1980, SOCIAL KNOWLEDGE INT; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Hartley L. L, 1995, COGNITIVE COMMUNICAT; JENNETT B, 1975, LANCET, V1, P480; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LAPSLEY DK, 1986, DEV PSYCHOL, V22, P800, DOI 10.1037/0012-1649.22.6.800; Larson R., 1984, BEING ADOLESCENT CON; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lewis JK, 2000, J HEAD TRAUMA REHAB, V15, P930, DOI 10.1097/00001199-200006000-00006; Marschark M, 2000, J CHILD PSYCHOL PSYC, V41, P1067, DOI 10.1017/S0021963099006496; McDonald S, 1998, CLIN LINGUIST PHONET, V12, P237, DOI 10.3109/02699209808985224; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCDONALD S, 1998, UNPUB FIELD TEST DAT; McNeny R., 1999, REHABILITATION ADULT, P242; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; Rollins, 1998, AWARENESS SOCIAL INF; Rosenberg M., 1979, CONCEIVING SELF; Russell PA, 1998, J CHILD PSYCHOL PSYC, V39, P903, DOI 10.1017/S0021963098002844; Shaffer DR., 2000, SOCIAL PERSONALITY D, V4; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; STEINBERG L, 1999, ADOLESCENCE; STRUCHEN M, 2003, SOCIAL COMMUNICATION; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1998, APHASIOLOGY, V12, P421, DOI 10.1080/02687039808249541; Turkstra LS, 2001, J COMMUN DISORD, V34, P151, DOI 10.1016/S0021-9924(00)00046-0; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; *WH ORG, 2001, INT CLASS FUNCT DIS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	51	59	59	0	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					245	256					12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000007	15502257				2022-02-06	
J	Wilson, MS; Gibson, CJ; Hamm, RJ				Wilson, MS; Gibson, CJ; Hamm, RJ			Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; dopamine; D2-like dopamine receptors; haloperidol; olanzapine; antipsychotic agents	MOTOR CORTEX INJURY; CLOSED HEAD-INJURY; ANTIPSYCHOTIC-DRUGS; WATER MAZE; AMPHETAMINE; ACQUISITION	Objective: Traumatic brain injury can cause a variety of impairments, including persistent alterations in personality, mood, and cognition. Antipsychotic agents are frequently used to treat pathologic behaviors in traumatic brain injury patients, but the influence of prolonged administration of such drugs on cognition after injury is unknown. The effects of two antipsychotic drugs on cognitive recovery after traumatic brain injury were assessed using the fluid percussion model in rats. Design: The typical antipsychotic, haloperidol, and the third-generation antipsychotic, olanzapine, were administered via intraperitoneal injection beginning 24 hr after injury and continuing daily for the duration of the study. Morris water maze performance was assessed on days 11-15 postinjury. Results: Haloperidol, an antagonist acting on D2-like dopamine receptors, exacerbated the cognitive deficits induced by injury, as injured rats treated with 0.30 mg/kg haloperidol performed worse in the Morris water maze than injured rats treated with vehicle. Conclusions: Our results demonstrate the importance of the D2 receptor in cognitive recovery after traumatic brain injury. Also, the data illustrate that some classes of antipsychotic drugs may influence cognitive recovery, and further research is needed to determine the optimal pharmacologic treatment of aggression, agitation, and other pathologic behaviors in patients with traumatic brain injury.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Creighton Univ, Dept Psychol, Omaha, NE 68178 USA		Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, 808 W Franklin St, Richmond, VA 23284 USA.						Andersson C, 2002, NEUROPSYCHOPHARMACOL, V27, P143, DOI 10.1016/S0893-133X(02)00287-7; Bai O, 2003, J NEUROSCI RES, V71, P127, DOI 10.1002/jnr.10440; Bascunana H, 2000, REV NEUROLOGIA, V30, P850, DOI 10.33588/rn.3009.99434; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; Fowler S B, 1995, J Neurosci Nurs, V27, P119; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Maguire GA, 2002, AM J HEALTH-SYST PH, V59, pS4, DOI 10.1093/ajhp/59.suppl_5.S4; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PLOEGER GE, 1994, BEHAV NEUROSCI, V108, P927, DOI 10.1037/0735-7044.108.5.927; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; Terry AV, 2002, PSYCHOPHARMACOLOGY, V164, P360, DOI 10.1007/s00213-002-1230-z; VINCENT FM, 1986, NEUROSURGERY, V18, P190, DOI 10.1227/00006123-198602000-00013; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	59	59	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2003	82	11					871	879		10.1097/01.PHM.0000091982.33232.CB			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	734TX	WOS:000186075000009	14566156				2022-02-06	
J	Urbahns, K; Horvath, E; Stasch, JP; Mauler, F				Urbahns, K; Horvath, E; Stasch, JP; Mauler, F			4-phenyl-4H-pyrans as IKCa channel blockers	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article							RAT CEREBRAL-CORTEX; BINDING; BRAIN; RECEPTORS; ANTAGONISTS; INHIBITION	4.Phenyl-4H-pyrans have been identified as potent and specific IKCa channel blockers. Their synthesis and structure-activity relationships are described. A selected derivative, rac-11, reduces the infarct volume in a rat subdural hematoma model of traumatic brain injury after iv administration. (C) 2003 Elsevier Ltd. All rights reserved.	Bayer AG, Pharma Res Ctr, Inst Med Chem, D-42096 Wuppertal, Germany; Pharma Res Ctr, Inst CNS Res, D-42096 Wuppertal, Germany; Pharma Res Ctr, Inst Cardiovasc Res, D-42096 Wuppertal, Germany		Urbahns, K (corresponding author), Bayer Yakuhim Ltd, Res Ctr Kyoto, 6-5-1-3 Kunimidai, Kyoto 6190219, Japan.	klaus.urbahns.ku1@bayer.co.jp					ANGEL I, 1991, FUNDAM CLIN PHARM, V5, P107, DOI 10.1111/j.1472-8206.1991.tb00704.x; [Anonymous], 1991, ANGEW CHEM, V103, P1587; BROWN GB, 1986, J NEUROSCI, V6, P2064; ELLORY JC, 1994, BRIT J PHARMACOL, V111, P903, DOI 10.1111/j.1476-5381.1994.tb14823.x; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P147; HUGUES M, 1982, J BIOL CHEM, V257, P2762; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; LEE HR, 1984, LIFE SCI, V35, P721, DOI 10.1016/0024-3205(84)90340-0; LEWIN AH, 1989, MOL PHARMACOL, V35, P189; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; SCHOEMAKER H, 1985, EUR J PHARMACOL, V111, P273; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739, DOI 10.1152/ajprenal.2001.280.5.F739; SCHWAB A, 1998, CURR RES ION CHANNEL, V3, P126; SORENSEN RG, 1989, MOL PHARMACOL, V36, P689; TAS PWL, 1988, NEUROSCI LETT, V94, P279, DOI 10.1016/0304-3940(88)90031-6; TRIGGLE DJ, 1989, MED RES REV, V9, P123, DOI 10.1002/med.2610090203; URBAHNS K, 1997, Patent No. 0758648; WAGNER JA, 1988, J NEUROSCI, V8, P3354; Wegner M, 1996, Hypertens Res, V19, P229, DOI 10.1291/hypres.19.229; WOLINSKY J, 1969, J ORG CHEM, V34, P3169, DOI 10.1021/jo01262a077	24	59	60	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	AUG 18	2003	13	16					2637	2639		10.1016/S0960-894X(03)00560-2			3	Chemistry, Medicinal; Chemistry, Organic	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Chemistry	709AQ	WOS:000184602900004	12873483				2022-02-06	
J	Shih, HC; Hu, SC; Yang, CC; Ko, TJ; Wu, JK; Lee, CH				Shih, HC; Hu, SC; Yang, CC; Ko, TJ; Wu, JK; Lee, CH			Alcohol intoxication increases morbidity in drivers involved in motor vehicle accidents	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						alcohol intoxication; morbidity; trauma	TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; ETHANOL; SEVERITY; CONSUMPTION	We prospectively examined the correlation of alcohol intoxication with injury severity, morbidity, and mortality in drivers involved in motor vehicle accidents in a prospective cohort study. The study enrolled 923 injured patients, of whom 421 were legally intoxicated (blood alcohol concentration [BAC] greater than or equal to 50 mg/dL) and 502 were nonintoxicated (BAC < 50 mg/dL). The intoxicated drivers had a significantly higher injury severity score (ISS), lower Glasgow Coma Score, lower systolic blood pressure; higher rate in old age, male sex, greater rate of habitual drinking, greater lack of use of safety gear, and greater accident-related morbidity. After logistic regression analysis, alcohol intoxication was not associated with severe injury (ISS greater than or equal to 9); however, alcohol intoxication analyzed either as a preinjury or postinjury risk factor, was one of the predictors for morbidity. Severe head injury was the only predictor of mortality. In conclusion, although alcohol intoxication is not associated with an increased incidence of severe injury or mortality in drivers involved in motor vehicle crashes, it is one of the significant predictors for morbidity after injury. Copyright 2003, Elsevier Science (USA). All rights reserved.	Vet Gen Hosp, Dept Emergency Med, Taipei, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan		Shih, HC (corresponding author), Vet Gen Hosp, Dept Emergency Med, 201 Shih Pai Rd,Sec 2, Taipei, Taiwan.						BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BLOMQVIST S, 1987, J TRAUMA, V27, P40, DOI 10.1097/00005373-198701000-00007; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; DESIDERIO MA, 1987, J TRAUMA, V27, P267, DOI 10.1097/00005373-198703000-00007; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KOLELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; Szabo G, 1999, ALCOHOL ALCOHOLISM, V34, P830, DOI 10.1093/alcalc/34.6.830; SZABO G, 1994, J CLIN IMMUNOL, V14, P340, DOI 10.1007/BF01546318; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	24	59	60	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2003	21	2					91	94		10.1053/ajem.2003.50025			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	663VQ	WOS:000182027400001	12671806				2022-02-06	
J	Johnstone, B; Mount, D; Schopp, LH				Johnstone, B; Mount, D; Schopp, LH			Financial and vocational outcomes 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cost of illness; rehabilitation; rehabilitation, vocational; treatment outcome		Objective: To characterize financial and vocational outcomes among persons with traumatic brain injury (TBI) in terms of employment status, earned and private income, and public assistance received at the time of injury and at 1 year after injury. Design: Nonexperimental, longitudinal study. Setting: Inpatient TBI rehabilitation unit and participants' community of residence. Participants: Thirty-five persons with new TBI from 1 national Traumatic Brain Injury Model Systems center. Interventions: Not applicable. Main Outcome Measures: Employment status, earned and private monthly income, and public assistance received monthly at the time of injury and at 1-year follow-up. Results: From the time of injury until 1-year follow-up, the percentage of persons employed decreased from 69% to 31%; the percentage unemployed increased from 11% to 49%; the average earned monthly income declined 51% (from $1491 to $726); and the mean total public assistance received per month increased 275% (from $153 to $421). Conclusion: Assuming that this study sample is representative of national statistics for TBI, during the first year after injury, TBI is associated with an estimated $642 million in lost wages, $96 million in lost income taxes, and $353 million in increased public assistance.	Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, Columbia, MO 65212 USA		Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, 1 Hosp Dr,DC046-46, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			[Anonymous], TRAUMATIC BRAIN INJU; [Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; HURT GD, 2000, NEUROPSYCHOLOGICAL M, P215; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149	5	59	59	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					238	241		10.1053/apmr.2003.50097			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700013	12601655				2022-02-06	
J	Velazquez, JLP; Frantseva, MV; Naus, CC				Velazquez, JLP; Frantseva, MV; Naus, CC			Gap junctions and neuronal injury: Protectants or executioners?	NEUROSCIENTIST			English	Article						brain; connexins; gap junctions; ischemia; trauma	INTERCELLULAR COMMUNICATION; HYPOXIA-REOXYGENATION; ISCHEMIA; CELLS; BRAIN; RAT; CONNEXIN43; DAMAGE; HYPERCONTRACTURE; VULNERABILITY	The authors review concepts and recent experimental observations that relate gap junctional communication to the pathophysiology of neuronal injury, specifically ischemic or traumatic damage. The role played by this type of direct intercellular communication during the progression of the injuries can be conceived to be either detrimental or beneficial, depending on the arguments employed. The data indicate that, far from being a simple matter of judgment, the contribution of gap junctions to cell injury is a complicated phenomenon that depends on the specific insult and network in which it operates.	Hosp Sick Children, Dept Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Div Neurol, Brain & Behav Program, Toronto, ON M5S 1A1, Canada; Univ British Columbia, Dept Anat, Vancouver, BC V5Z 1M9, Canada			jose-luis.perez-velazquez@sickkids.ca					Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Blanc EM, 1998, J NEUROCHEM, V70, P958; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; Chandross KJ, 1996, MOL CELL NEUROSCI, V7, P501, DOI 10.1006/mcne.1996.0036; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Daleau P, 1999, J MOL CELL CARDIOL, V31, P1391, DOI 10.1006/jmcc.1999.0973; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; GarciaDorado D, 1997, CIRCULATION, V96, P3579; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Martinez AD, 2000, BRAIN RES REV, V32, P250, DOI 10.1016/S0165-0173(99)00086-7; Nagaoka T, 1999, J HISTOCHEM CYTOCHEM, V47, P937, DOI 10.1177/002215549904700711; Nishida M, 2000, ENDOTHELIUM-NEW YORK, V7, P279, DOI 10.3109/10623320009072214; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Oguro K, 2001, J NEUROSCI, V21, P7534, DOI 10.1523/JNEUROSCI.21-19-07534.2001; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; ROHLMANN A, 1993, NEUROSCI LETT, V154, P206, DOI 10.1016/0304-3940(93)90208-3; Rozental R, 2000, BRAIN RES REV, V32, P189, DOI 10.1016/S0165-0173(99)00097-1; ROZENTAL R, 2001, METHODS MOL BIOL, V154; Ruiz-Meana M, 1999, CIRC RES, V85, P280, DOI 10.1161/01.RES.85.3.280; Sai KM, 2001, CANCER LETT, V173, P163, DOI 10.1016/S0304-3835(01)00616-4; Scemes E, 1998, GLIA, V24, P74, DOI 10.1002/(SICI)1098-1136(199809)24:1<74::AID-GLIA8>3.3.CO;2-J; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sutor B, 2000, CEREB CORTEX, V10, P684, DOI 10.1093/cercor/10.7.684; Trosko JE, 1998, TOXICOL LETT, V103, P71, DOI 10.1016/S0378-4274(98)00288-4; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; WARNER DS, 1995, ANESTHESIOLOGY, V82, P1237, DOI 10.1097/00000542-199505000-00019	36	59	62	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2003	9	1					5	9		10.1177/1073858402239586			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	639RD	WOS:000180642300009	12580335				2022-02-06	
J	Yan, HQ; Kline, AE; Ma, XC; Li, YM; Dixon, CE				Yan, HQ; Kline, AE; Ma, XC; Li, YM; Dixon, CE			Traumatic brain injury reduces dopamine transporter protein expression in the rat frontal cortex	NEUROREPORT			English	Article						dopamine transporter (DAT); frontal cortex; rat; traumatic brain injury (TBI); Western blot	SUBSTANTIA-NIGRA; TYROSINE-HYDROXYLASE; PARKINSONS-DISEASE; PREFRONTAL CORTEX; CEREBRAL-CORTEX; MESSENGER-RNA; COCAINE; INNERVATION; AMPHETAMINE; NUCLEUS	Disturbances in dopamine neurotransmission contribute to frontal lobe dysfunction after traumatic brain injury. The changes in dopamine neurotransmission may be mediated by alterations in the dopamine transporter, which plays a key role in maintaining dopamine homeostasis. To determine whether the dopamine transporter system is altered after traumatic brain injury, dopamine transporter protein was examined bilaterally in the rat frontal cortex by Western blot at 1, 7 and 28 days after controlled cortical impact or sham injury (n = 6/group). Dopamine transporter protein expression was decreased in the injured (ipsilateral) cortex at 7 days and bilaterally at 28 days in injured vs sham control rats. The decrease in dopamine transporter protein levels may reflect a traumatic brain-injury-induced down-regulation of dopamine transporter and/or a loss of dopaminergic fibers.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS040125, P50NS030318, P01NS030318, R01NS033150] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40125, NS33150, NS30318] Funding Source: Medline		BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; DESCARRIES L, 1987, NEUROSCIENCE, V21, P807, DOI 10.1016/0306-4522(87)90038-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Harrington KA, 1996, MOL BRAIN RES, V36, P157, DOI 10.1016/0169-328X(95)00278-Z; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MOGHADDAM B, 1989, SYNAPSE, V4, P156, DOI 10.1002/syn.890040209; NIZNIK HB, 1991, J NEUROCHEM, V56, P192, DOI 10.1111/j.1471-4159.1991.tb02580.x; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SIMON H, 1980, NATURE, V286, P150, DOI 10.1038/286150a0; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; UHL GR, 1994, ANN NEUROL, V35, P494, DOI 10.1002/ana.410350421; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	25	59	65	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	OCT 28	2002	13	15					1899	1901		10.1097/00001756-200210280-00013			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	619ML	WOS:000179479700013	12395087				2022-02-06	
J	Trombly, CA; Radomski, MV; Trexel, C; Burnett-Smith, SE				Trombly, CA; Radomski, MV; Trexel, C; Burnett-Smith, SE			Occupational therapy and achievement of self-identified goals by adults with acquired brain injury: Phase II	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	2000	WASHINGTON, D.C.	Amer Occupat Therapy Assoc		Canadian Occupational Performance Measure; Community Integration Questionnaire; goal attainment scaling; goal-specific therapy	COMMUNITY INTEGRATION QUESTIONNAIRE; COGNITIVE REHABILITATION; POSTTRAUMATIC AMNESIA; OUTCOMES EVALUATION; TBI REHABILITATION; HEAD-INJURY; REINTEGRATION	OBJECTIVE The purpose of this study was to investigate the association between participation in goal-specific outpatient occupational therapy and improvement in self-identified goals in adults with acquired brain injury. METHOD Thirty-one persons with traumatic brain injury of mixed chronicity participated at three sites located in different regions of the United States. Using a repeated-measures design, therapy that usually was offered at each site to achieve specific goals was followed by a no-treatment period Participants completed the Canadian Occupational Performance Measure Performance subscale (COPM-P) and Satisfaction subscale (COPM-S), and the Community Integration Questionnaire (CIQ) at admission, discharge, and 1 to 18 weeks after discharge Goal attainment scales were developed at admission and scored at discharge; the differences for each site were tested, using dependent t tests. Gains for the treatment period (admission to discharge) in COPM subscales and the CIQ were compared with gains during the no-treatment period (discharge to follow-up) for each site, using dependent Nests. The results were synthesized meta-analytically across the sites. RESULTS The participants identified a total of 149 goals, 81 % of which were achieved Goal attainment T scores improved significantly (Z=7.52, p<.001), and the combined effect size was large (r=94) The COPM-P (Z=4 13, p<001) and COPM-S (Z=4 25, p<001) showed significantly greater gains during the treatment (average 15.3 weeks) versus the no-treatment (average 9.9 weeks) period Effect size estimates were large 71 and .76, respectively Gain scores of the CIQ did not differ significantly (Z=.75, p=22, r=29) between periods CONCLUSION. Participation in goal-specific outpatient occupational therapy that focused on teaching compensatory strategies was strongly associated with achievement of self-identified goals and reduction of disability in adults with mild to moderate brain injury.	Boston Univ, Dept Occupat Therapy, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Sister Kenny Rehabil Serv, Outpatient Brain Injury Clin, Minneapolis, MN USA; Progress Rehabil Associates, Brain Injury Rehabil Ctr, Portland, OR USA; Community Reentry Program Legacy Hlth Syst, Portland, OR USA; Santa Monica Coll, Acquired Brain Injury Program, Disabled Student Serv, Santa Monica, CA USA		Trombly, CA (corresponding author), Boston Univ, Dept Occupat Therapy, Sargent Coll Hlth & Rehabil Sci, 635 Commonwealth Ave, Boston, MA 02215 USA.	ctrombly@bu.edu					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BANJA J, 1994, ARCH PHYS MED REHAB, V75, pSC19; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Clark M S, 1983, Int Rehabil Med, V5, P41; Cohen J., 2013, STAT POWER ANAL BEHA; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; *CTR EV BAS MED, 2001, LEV EVID GRAD REC; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Giles GM, 1999, AM J OCCUP THER, V53, P406, DOI 10.5014/ajot.53.4.406b; Giles GM, 1997, AM J OCCUP THER, V51, P256, DOI 10.5014/ajot.51.4.256; Gutman SA, 1999, AM J OCCUP THER, V53, P101, DOI 10.5014/ajot.53.1.101; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JOHNSTONE EC, 1980, BRIT J CLIN PHARMACO, V10, P5, DOI 10.1111/j.1365-2125.1980.tb00497.x; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Law M, 1990, Can J Occup Ther, V57, P82; Law M., 1994, CANADIAN OCCUPATIONA, V2; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALKMUS D, 1980, REHABILITATION HEAD; McColl M A, 2000, Can J Occup Ther, V67, P22; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NEISTADT ME, 1994, AM J OCCUP THER, V48, P877, DOI 10.5014/ajot.48.10.877; Nelson DL, 1996, AM J OCCUP THER, V50, P223, DOI 10.5014/ajot.50.3.223; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P349, DOI 10.5014/ajot.47.4.349; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; *RANCH LOS AM HOSP, 1985, MEAS COGN FUNCT REH; Rockwood K, 1996, NEUROEPIDEMIOLOGY, V15, P330, DOI 10.1159/000109923; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; ROCKWOOD K, 1990, J CLIN EPIDEMIOL, V46, P1113; Rosenthal R., 1984, METAANALYTIC PROCEDU; ROSNOW RL, 1988, J COUNS PSYCHOL, V35, P203, DOI 10.1037/0022-0167.35.2.203; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; SIETSEMA JM, 1993, AM J OCCUP THER, V47, P19, DOI 10.5014/ajot.47.1.19; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Trombly C, 1999, AM J OCCUP THER, V53, P407, DOI 10.5014/ajot.53.4.407; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; ZWEBER B, 1990, Occupational Therapy in Health Care, V7, P45, DOI 10.1080/J003v07n01_05	57	59	60	0	10	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2002	56	5					489	498		10.5014/ajot.56.5.489			10	Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Rehabilitation	594UT	WOS:000178070000002	12269503				2022-02-06	
J	Yamada, H; Sakai, A; Yamada, E; Nishimura, T; Matsumura, M				Yamada, H; Sakai, A; Yamada, E; Nishimura, T; Matsumura, M			Spontaneous closure of traumatic macular hole	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							OPTICAL COHERENCE TOMOGRAPHY; DISAPPEARANCE; VITRECTOMY; SURGERY	PURPOSE: To investigate the mechanism by which traumatic macular hole closes spontaneously. DESIGN: Consecutive observational case series of three patients with unilateral traumatic macular hole who consulted medical staff at the Kansai Medical University between 1997 and 2000. METHODS: Three patients who sustained unilateral blunt trauma to the eye and developed traumatic macular hole were followed with ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography (OCT). RESULTS: Case 1 was an 11-year-old boy. He had neither a macular hole nor prominent macular edema at his first consultation, but a macular hole opened 3 weeks later. OCT showed macular edema and a full,thickness macular hole. The tissue around the edge of the macular hole protruded inward toward the center and finally closed spontaneously 18 weeks later. Case 2 was a 19,year,old man. He had a tiny rough-edged macular hole at his first consultation with a local ophthalmologist. OCT showed macular hole enlargement and worsening of the macular edema during follow up. The macular hole finally closed 4 months after injury. Case 3 was a 15-year-old boy. He had a tiny rough,edged macular hole at his first consultation with a local ophthalmologist. The macular hole finally closed 6 months after injury. CONCLUSION: Macular hole can be a result of severe damage from ocular concussion or damage to the retina. For 6 months following injury, traumatic macular hole should probably be observed rather than surgically re, paired, because of the possibility that the macular hole may close spontaneously. (C) 2002 by Elsevier Science Inc. All rights reserved.			Yamada, H (corresponding author), Kansai Med Univ, Dept Ophthalmol, 10-15 Fumizonocho, Moriguchi, Osaka 5708507, Japan.						Amari F, 1999, RETINA-J RET VIT DIS, V19, P410, DOI 10.1097/00006982-199909000-00007; deBustros S, 1996, RETINA-J RET VIT DIS, V16, P451, DOI 10.1097/00006982-199616050-00018; DELORI F, 1969, INVEST OPHTH VISUAL, V8, P290; Frangieh G T, 1981, Retina, V1, P311, DOI 10.1097/00006982-198101040-00008; Freeman WR, 1997, ARCH OPHTHALMOL-CHIC, V115, P11, DOI 10.1001/archopht.1997.01100150013002; GarciaArumi J, 1997, RETINA-J RET VIT DIS, V17, P372; GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3; Imai M, 1999, AM J OPHTHALMOL, V128, P621, DOI 10.1016/S0002-9394(99)00200-7; KELLY NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P654, DOI 10.1001/archopht.1991.01080050068031; Knapp H., 1869, ARCH AUGENHEILKD, V1, P6; Kusaka S, 1997, AM J OPHTHALMOL, V123, P837, DOI 10.1016/S0002-9394(14)71136-5; LEWIS H, 1986, AM J OPHTHALMOL, V102, P172, DOI 10.1016/0002-9394(86)90139-X; Mikajiri K, 1999, AM J OPHTHALMOL, V128, P655, DOI 10.1016/S0002-9394(99)00203-2; OGLIVIE F, 1900, T OPHTHAL SOC UK, V20, P202; Parmar DN, 1999, RETINA-J RET VIT DIS, V19, P470, DOI 10.1097/00006982-199919050-00026; RYAN EH, 1994, ARCH OPHTHALMOL-CHIC, V112, P1545, DOI 10.1001/archopht.1994.01090240051025; SCHEPENS CL, 1955, AM J OPHTHALMOL, P631; Takahashi H, 1999, AM J OPHTHALMOL, V128, P519, DOI 10.1016/S0002-9394(99)00173-7; TAKAHASHI R, 1992, ACTA OPHTHALMOL JPN, V39, P327; WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1607; YOKOZUKA K, 1991, JPN J CLIN OPHTHAL, V45, P1121; [No title captured]; [No title captured]; [No title captured]	24	59	73	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394			AM J OPHTHALMOL	Am. J. Ophthalmol.	SEP	2002	134	3					340	347	PII S0002-9394(02)01535-0	10.1016/S0002-9394(02)01535-0			8	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	587TY	WOS:000177660300004	12208244				2022-02-06	
J	Cicerone, KD; Azulay, J				Cicerone, KD; Azulay, J			Diagnostic utility of attention measures in postconcussion syndrome	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; MILD HEAD-INJURY; SENSITIVITY	Neuropsychological evaluation may be of particular relevance in the detection of subtle cognitive impairments after mild traumatic brain injury (MTBI), including the subgroup of MTBI patients with a persistent postconcussion syndrome (PCS). Attention measures may be the most sensitive indicators of dysfunction associated with MTBI; however, previous studies have typically relied on the analysis of overall group differences, which may not reflect the diagnostic accuracy of attention measures when applied to individuals with MTBI. In the present study, subjects with persistent symptoms at least 3 months following a mild traumatic brain injury were compared with a sample of community living, normal control subjects in order to evaluate the sensitivity, specificity, and diagnostic accuracy of attention measures. Patients with PCS, screened with conservative inclusion and exclusion criteria, and a matched normal control group were administered six clinical tests of attention: Digit Span, Trail Making Test, Part A and Part B, Stroop Color-Word Test, Continuous Performance Test of Attention (CPTA), Paced Auditory Serial Addition Test (PASAT), and Ruff 2 & 7 Selective Attention Test. Consistent with prior research, these measures exhibited a wide range of sensitivity and specificity to possible cognitive impairment among patients. Attention measures may be the most sensitive indicators of dysfunction associated with PCS. Measures with high specificity (e.g., Stroop Color, and 2 & 7 Processing Speed) were shown to have strong positive predictive value, while measures with high sensitivity (e.g., CPTA) demonstrated strong negative predictive value for diagnosing PCS. Examination of the Odds Ratios indicated that measures assessing processing speed had a reliable, positive association with PCS, while measures without a processing speed component did not. Implications for making informed clinical decisions are discussed.	JFK Johnson Rehabil Inst, Edison, NJ 08820 USA		Cicerone, KD (corresponding author), JFK Johnson Rehabil Inst, 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; [Anonymous], 1996, Neurology, V47, P592; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bieliauskas LA, 1997, J CLIN EXP NEUROPSYC, V19, P889, DOI 10.1080/01688639708403769; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BRADSHAW M, 1999, J INT NEUROPSYCH SOC, V6, P186; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; CICERONE KD, 2002, UNPUB NATURE ATTENTI; GOLDEN C, 1978, STROOP COLOR WONT TE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heaton RK, 1991, COMPREHENSIVE NORMS; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; Reason J., 1993, ATTENTION SELECTION, P406; Ruff RM, 1999, BRAIN INJURY, V13, P943; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Sackett D., 2000, EVIDENCE BASED MED; SCHMIDT M, 1994, ARCH CLIN NEUROPSYCH, V9, P383, DOI 10.1016/0887-6177(94)90002-7; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D, 1987, MEMORY SCALE REVISED; Wolfson, 1993, HALSTEAD REITAN NEUR; Wong TM, 1999, ARCH CLIN NEUROPSYCH, V14, P728	28	59	60	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2002	16	3					280	289		10.1076/clin.16.3.280.13849			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	664UZ	WOS:000182081500007	12607141				2022-02-06	
J	Hansen, HS; Moesgaard, B; Petersen, G; Hansen, HH				Hansen, HS; Moesgaard, B; Petersen, G; Hansen, HH			Putative neuroprotective actions of N-acyl-ethanolamines	PHARMACOLOGY & THERAPEUTICS			English	Article; Proceedings Paper	International Symposium on Endocannabinoids	OCT, 2000	MADRID, SPAIN			N-acyl-ethanolamine phospholipids; anandamide; neurodegeneration; ischemia; brain; necrosis	CANNABINOID-RECEPTOR-LIGAND; FREE FATTY-ACIDS; PROTEIN-KINASE-C; ANANDAMIDE INDUCES APOPTOSIS; PLATELET-ACTIVATING-FACTOR; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; RAT CEREBRAL-CORTEX; ARACHIDONIC-ACID; ACYLETHANOLAMINE PHOSPHOLIPIDS	N-Acyl-ethanotamines (NAEs) and their precursors, N-acyl-ethanolamine phospholipids (NAPEs), are present in the mammalian brain at levels of a few hundred picomoles/gram tissue and a few nanomoles/gram tissue, respectively. NAE-containing arachidonic acid is called anandamide, and it has attracted particular attention since it is a partial agonist for the cannabinoid receptors, for which 2-arachidonoylglycerol is the full agonist. In addition, anandamide may also activate the vanilloid receptor. Anandamide usually amounts to 1-10% of NAEs, as the vast majority of N-acyl groups are saturated and monounsaturated fatty acids. Formation of NAPE and NAE is catalyzed by an N-acyltransferase and an NAPE-hydrolyzing phospholipase D. respectively, two enzymes that have been characterized only preliminary. Interestingly, NAPEs and NAEs accumulate in the brain in response to neurodegenerative insults at a time when other phospholipids are subjected to rapid degradation. This is an important biosynthetic aspect of NAPE and NAE, as NAEs may be neuroprotective by a number of different mechanisms involving both receptor activation and non-receptor-mediated effects, e.g. by binding to cannabinoid receptors and interfering with ceramide turnover, respectively. (C) 2002 Elsevier Science Inc. All rights reserved.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark		Hansen, HS (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, Univ Pk 2, DK-2100 Copenhagen, Denmark.			Hansen, Harald S./0000-0001-7360-7418			Agranoff Bernard W., 1999, P47; AKOKA S, 1988, CHEM PHYS LIPIDS, V46, P43, DOI 10.1016/0009-3084(88)90112-0; Ameri A, 1999, BRIT J PHARMACOL, V126, P1831, DOI 10.1038/sj.bjp.0702478; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Berdyshev EV, 2001, WORLD REV NUTR DIET, V88, P207; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Braida D, 2000, NEUROSCI LETT, V296, P69, DOI 10.1016/S0304-3940(00)01634-7; Cadas H, 1997, J NEUROSCI, V17, P1226; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Deutsch J, 1997, NEUROCHEM RES, V22, P759, DOI 10.1023/A:1022030306359; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DOMINGO JC, 1994, CHEM PHYS LIPIDS, V69, P229, DOI 10.1016/0009-3084(94)90004-3; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; EPPS DE, 1982, J BIOL CHEM, V257, P1383; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Geddes JW, 1997, NEUROBIOL AGING, V18, P305, DOI 10.1016/S0197-4580(97)80312-0; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Gulaya NM, 1998, CHEM PHYS LIPIDS, V97, P49, DOI 10.1016/S0009-3084(98)00093-0; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; Hansen HS, 1997, J NEUROCHEM, V69, P753; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hillard CJ, 1997, J LIPID RES, V38, P2383; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Katsura K, 2000, J NEUROCHEM, V75, P2521, DOI 10.1046/j.1471-4159.2000.0752521.x; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KISHIRO K, 1988, ANAL BIOCHEM, V175, P516, DOI 10.1016/0003-2697(88)90576-3; KLEIN J, 1993, BRAIN RES, V630, P337, DOI 10.1016/0006-8993(93)90674-C; Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; KOZUKA M, 1995, NEUROCHEM RES, V20, P23, DOI 10.1007/BF00995148; Kubota M, 1996, NEUROL RES, V18, P337; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Moesgaard B, 1999, J LIPID RES, V40, P515; Moesgaard B, 2000, J LIPID RES, V41, P985; Moesgaard B, 2002, COMP BIOCHEM PHYS B, V131, P475, DOI 10.1016/S1096-4959(02)00003-9; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Narita K, 2000, NEUROL RES, V22, P393, DOI 10.1080/01616412.2000.11740689; NATARAJAN V, 1981, BIOCHIM BIOPHYS ACTA, V664, P445, DOI 10.1016/0005-2760(81)90067-9; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; NEWMAN JL, 1986, CHEM PHYS LIPIDS, V42, P249, DOI 10.1016/0009-3084(86)90084-8; Nishida K, 1996, STROKE, V27, P514, DOI 10.1161/01.STR.27.3.514; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PARINANDI NL, 1988, FEBS LETT, V237, P49, DOI 10.1016/0014-5793(88)80169-8; PERLIK F, 1971, ACTA PHYSIOL HUNG, V39, P395; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Phillis JW, 2000, BRAIN RES, V884, P155, DOI 10.1016/S0006-8993(00)02938-3; Ping SE, 1998, J NEUROSCI RES, V54, P206, DOI 10.1002/(SICI)1097-4547(19981015)54:2<206::AID-JNR8>3.0.CO;2-I; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Ross RA, 2000, EUR J PHARMACOL, V401, P121, DOI 10.1016/S0014-2999(00)00437-4; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sugiura T, 2001, NEUROSCI LETT, V297, P175, DOI 10.1016/S0304-3940(00)01691-8; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Wiesner DA, 1996, GLYCOCONJUGATE J, V13, P327, DOI 10.1007/BF00731508; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Wiesner DA, 1997, J BIOL CHEM, V272, P9868	109	59	60	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0163-7258			PHARMACOL THERAPEUT	Pharmacol. Ther.	AUG	2002	95	2					119	126	PII S0163-7258(02)00251-6	10.1016/S0163-7258(02)00251-6			8	Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	592XE	WOS:000177961500003	12182959				2022-02-06	
J	Ricker, JH; Rosenthal, M; Garay, E; DeLuca, J; Germain, A; Abrahan-Fuchs, K; Schmidt, KU				Ricker, JH; Rosenthal, M; Garay, E; DeLuca, J; Germain, A; Abrahan-Fuchs, K; Schmidt, KU			Telerehabilitation needs: A survey of persons with acquired brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; telemedicine; telerehabilitation		Objective: To survey individuals with acquired brain injury to assess multiple facets of interest, access, and familiarity necessary to implement new telerehabilitation technologies. Design: Anonymous mail survey. Setting: Community. Participants: Seventy-one respondents to a survey. These individuals had experienced acquired brain injury (predominantly severe traumatic brain injury [TBI]) and were living in the community. Surveys were mailed by a state chapter of the Brain Injury Association to a random selection of members with acquired brain injury. Main Outcome Measure: Survey designed specifically for this investigation. Results: The survey responses indicate that there is great interest in the possibility of accessing telerehabilitative services among individuals with acquired brain injury. In particular, there was strong interest expressed in services that could be used to assist with problems in memory, attention, problem-solving, and activities of daily living. Conclusions: Telemedicine, and more specifically telerehabilitation, holds great promise as an adjunct to traditional clinical service delivery. Little research in thus area has been applied, however, to individuals with acquired brain injuries. Although on the surface, telerehabilitation seems to be an appropriate assessment and treatment modality for individuals with brain injury, it will only succeed if those individuals have the interest-and tine access-necessary to use new and evolving technologies.	KMRREC Neuropsychol, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Siemens Corp Res Inc, Strateg Business Dev Grp, Princeton, NJ USA; Siemens AG, Siemens Med Solut, D-8520 Erlangen, Germany		Ricker, JH (corresponding author), KMRREC Neuropsychol, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jricker@kmrrec.org		Ricker, Joseph/0000-0003-3415-991X			Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Burns RB, 1998, ASSIST TECHNOL, V10, P126, DOI 10.1080/10400435.1998.10131970; Girone M, 2000, Stud Health Technol Inform, V70, P89; Grimes G J, 2000, Stud Health Technol Inform, V70, P113; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Lathan CE, 1999, TELEMED J, V5, P169, DOI 10.1089/107830299312131; Liu LL, 2000, J TELEMED TELECARE, V6, P47, DOI 10.1258/1357633001935554; Mathewson C, 2000, J Wound Ostomy Continence Nurs, V27, P269; Palsbo S E, 2000, Manag Care Q, V8, P56; Popescu VG, 2000, IEEE T INF TECHNOL B, V4, P45, DOI 10.1109/4233.826858; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Vesmarovich S, 1999, Adv Wound Care, V12, P264	12	59	61	3	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					242	250		10.1097/00001199-200206000-00005			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400005	12086577				2022-02-06	
J	Struchen, MA; Atchison, TB; Roebuck, TM; Caroselli, JS; Sander, AM				Struchen, MA; Atchison, TB; Roebuck, TM; Caroselli, JS; Sander, AM			A multidimensional measure of caregiving appraisal: Validation of the caregiver appraisal scale in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult; assessment; brain injury; caregivers; family	BLUNT HEAD-INJURY; FAMILY CAREGIVERS; BEHAVIORAL-CHANGE; RELATIVES VIEW; FOLLOW-UP; BURDEN	Objective: To investigate the factor structure and concurrent validity of the Caregiver Appraisal Scale (CA,S) in a sample of caregivers of adults with traumatic brain injury (TBI). Design: Prospective cohort study, Setting: Two sites: (1) Outpatient clinics associated with a comprehensive inpatient brain injury rehabilitation program and (2) a comprehensive residential postacute rehabilitation program in the Southern United States. Participants: One hundred forty-nine caregivers of adults with TBI enrolled in the TBI Model Systems Project and 92 caregivers of adults with TBI admitted to a residential postacute rehabilitation program. Most caregivers were women and either parents or spouses of the injured person. Main Outcome Measures: Caregiver Appraisal Scale (CAS) Subjective Burden Scale (SBS); Objective Burden Scale (OBS); General Health Questionnaire (GHQ), Results: Principal components analysis with varimax rotation yielded four factors: perceived burden (PB). caregiver relationship satisfaction (CRS), caregiving ideology (CI), and caregiving mastery, (CM), which were found to be fairly stable across treatment settings. Adequate concurrent validity was demonstrated for the perceived burden factor, and adequate internal consistency was found for three of four scales, Conclusions: Preliminary support for the use of the CAS in caregivers of adults with TBI was obtained. However, further scale development, particularly for the CM factor, will Likely improve the stability and usefulness of this instrument.	Baylor Coll Med, Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX 77030 USA; Univ Houston, Houston, TX USA; Transit Learning Ctr, Galveston, TX USA		Struchen, MA (corresponding author), Baylor Coll Med, Inst Rehabil & Res, Brain Injury Res Ctr, 2455 S Braeswood, Houston, TX 77030 USA.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Folkman S., 1984, STRESS; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holroyd J., 1987, MANUAL QUESTIONNAIRE; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Holroyd J., 1974, J COMMUNITY PSYCHOL, V2, P92, DOI [10.1002/1520-6629(197401)2:1, DOI 10.1002/1520-6629(197401)2:1]; Hughes C B, 1996, J Pediatr Nurs, V11, P347, DOI 10.1016/S0882-5963(96)80079-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lawton M. P., 1989, J GERONTOL, V44, P61, DOI 10.1093/geronj/44.3.P61; LEVINE MS, 1997, QUANTITATIVE APPL SO; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Minnes P, 2000, BRAIN INJURY, V14, P737; *NAT I HLTH, 2001, PREMIER OUTLOOK PERI, V2, P7; *NIH, REH PERS TRAUM BRAIN; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Panting A, 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Smith A M, 1998, Rehabil Nurs, V23, P252; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Zarit S. H., 1987, MEMORY BEHAV PROBLEM; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; [No title captured]	45	59	60	2	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					132	154		10.1097/00001199-200204000-00005			23	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500005	11909511				2022-02-06	
J	Gibson, JB; Maxwell, RA; Schweitzer, JB; Fabian, TC; Proctor, KG				Gibson, JB; Maxwell, RA; Schweitzer, JB; Fabian, TC; Proctor, KG			Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute	SHOCK			English	Article						swine; hemoglobin-based oxygen carrying compound; diaspirin cross-linked hemoglobin; cerebral perfusion pressure; jugular bulb oximetry	CROSS-LINKED HEMOGLOBIN; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; HEMODILUTION; OXYGEN; MODEL; RATS; CO2-REACTIVITY; AUTOREGULATION; ISCHEMIA	The original purpose of this study was to compare initial resuscitation of hemorrhagic hypotension after traumatic brain injury (TBI) with saline and shed blood. Based on those results, the protocol was modified and saline was compared to a blood substitute, diaspirin cross-linked hemoglobin (DCLHb). Two series of experiments were performed in anesthetized and mechanically ventilated (FiO(2) = 0.4) pigs (35-45 kg). In Series 1, fluid percussion TBI (6-8 ATM) was followed by a 30% hemorrhage. At 120 min post-TBI, initial resuscitation consisted of either shed blood (n = 7) or a bolus of 3x shed blood volume as saline (n = 13). Saline supplements were then administered to all pigs to maintain a systolic arterial blood pressure (SAP) of >100 mmHg and a heart rate (HR) of <110 beats/min. In Series 2, TBI (4-5 ATM) was followed by a 35% hemorrhage. At 60 min post-TBI, initial resuscitation consisted of either 500 mL of DCLHb (n = 6) or 500 mL of saline (n = 5). This was followed by saline supplements to all pigs to maintain a SAP of >100 mmHg and a HR of <110 beats/min. In Series 1, most systemic markers of resuscitation (e.g., SAP, HR, cardiac output, filling pressures, lactate, etc.) were normalized, but there were 0/7 vs. 5/13 deaths within 5 h (P = 0.058) with blood vs. saline. At constant arterial O-2 saturation (SaO(2)), mixed venous O-2 saturation (SvO(2)), cerebral perfusion pressure (CPP), and cerebral venous O-2 saturation (ScvO(2)) were all higher, intracranial pressure (ICP) was lower, and CO2 reactivity was preserved with blood vs. saline (all P < 0.05). In Series 2, SAP, ICP, CPP, and lactate were higher with DCLHb vs. saline (all P < 0.05). Cardiac output was lower even though filling pressure was markedly elevated with DCLHb vs. saline (both P < 0.05). Neither SvO(2) nor cerebrovascular CO2 reactivity were improved, and ScvO(2) was lower with DCLHb vs. saline (P < 0.05). All survived at least 72 h with neuropathologic changes that included sub-arachnoid hemorrhage, midline cerebellar necrosis, and diffuse axonal injury. These changes were similar with DCLHb vs. saline. Thus, whole blood was more effective than saline for resuscitation of TBI, whereas DCLHb was no more, and according to many variables, less effective than saline resuscitation. These experimental results are comparable to those in a recent multicenter trial using DCLHb for the treatment of severe traumatic shock. Further investigations in similar experimental models might provide some plausible explanations why DCLHb unexpectedly increased mortality in patients.	Univ Miami, Sch Med, Daughtry Family Dept Surg, Miami, FL 33101 USA; Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; E Tennessee State Univ, Quillen Coll Med, Dept Pathol, Johnson City, TN 37403 USA		Proctor, KG (corresponding author), Univ Miami, Sch Med, Daughtry Family Dept Surg, POB 016960 D40,1800 NW 10th Ave, Miami, FL 33101 USA.		Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628			*AM COLL SURG, 1997, ADV TRAUM LIF SUPP C; Bullock R, 1995, GUIDELINES MANAGEMEN; Burhop KE, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199911001-00030; Chappell JE, 1996, J TRAUMA, V41, P781, DOI 10.1097/00005373-199611000-00003; Chappell JE, 1997, J NEUROSURG, V86, P131, DOI 10.3171/jns.1997.86.1.0131; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohn SM, 1997, CRIT CARE MED, V25, P484, DOI 10.1097/00003246-199703000-00018; COLE DJ, 1993, ANESTHESIOLOGY, V78, P335, DOI 10.1097/00000542-199302000-00018; Cole DJ, 1999, CRIT CARE MED, V27, P972, DOI 10.1097/00003246-199905000-00038; COLE DJ, 1993, CAN J NEUROL SCI, V20, P30, DOI 10.1017/S0317167100047363; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Fischer SR, 1999, AM J PHYSIOL-HEART C, V276, pH2194, DOI 10.1152/ajpheart.1999.276.6.H2194; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Hess JR, 1996, SEMIN HEMATOL, V33, P369; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Intaglietta M, 1999, MICROCIRCULATION, V6, P247, DOI 10.1080/713773960; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; LEFFLER CW, 1986, PROSTAGLANDINS, V31, P183, DOI 10.1016/0090-6980(86)90045-6; MALHOTRA AK, 2000, SHOCK, V13, P60; Maxwell RA, 2000, J TRAUMA, V49, P200, DOI 10.1097/00005373-200008000-00005; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGrath B J, 1995, New Horiz, V3, P523; Piper IR, 1998, BRIT J ANAESTH, V80, P639, DOI 10.1093/bja/80.5.639; Pope A, 1999, FLUID RESUSCITATION; Prielipp R C, 1995, New Horiz, V3, P456; Rieger A, 1997, NEUROSURGERY, V41, P462, DOI 10.1097/00006123-199708000-00027; ROBERTS SB, 1995, OBES RES, V3, P3, DOI 10.1002/j.1550-8528.1995.tb00002.x; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; TODD MM, 1994, J NEUROTRAUM, V11, P149, DOI 10.1089/neu.1994.11.149; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	37	59	61	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAR	2002	17	3					234	244		10.1097/00024382-200203000-00013			11	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	626ML	WOS:000179876600013	11900344				2022-02-06	
J	Zhang, L; Abreu, BC; Masel, B; Scheibel, RS; Christiansen, CH; Huddleston, N; Ottenbacher, KJ				Zhang, L; Abreu, BC; Masel, B; Scheibel, RS; Christiansen, CH; Huddleston, N; Ottenbacher, KJ			Virtual reality in the assessment of selected cognitive function after brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						virtual reality; traumatic brain injury; cognitive function; assessment	SEVERE HEAD-INJURY; REHABILITATION; TECHNOLOGY; ADULTS; STATE	Objective: To assess selected cognitive functions of persons with traumatic brain injury using a computer-simulated virtual reality environment. Study Design: A computer-simulated virtual kitchen was used to assess the ability of 30 patients with brain injury and 30 volunteers without brain injury to process and sequence information. The overall assessment score was based on the number of correct responses and the time needed to complete daily living tasks. Identical daily living tasks were tested and scored in participants with and without brain injury. Each subject was evaluated twice within 7 to 10 days. A total of 30 tasks were categorized as follows: information processing, problem solving, logical sequencing, and speed of responding. Results: Persons with brain injuries consistently demonstrated a significant decrease in the ability to process information (P = 0.04-0.01), identify logical sequencing (P = 0.04-0.01), and complete the overall assessment (P < 0.01), compared with volunteers without brain injury. The time needed to process tasks, representing speed of cognitive responding, was also significantly different between the two groups (P < 0.01). Conclusion: A computer-generated virtual reality environment represents a reproducible tool to assess selected cognitive functions and can be used as a supplement to traditional rehabilitation assessment in persons with acquired brain injury.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA		Zhang, L (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.		, Charles/V-6218-2019	Christiansen, Charles/0000-0003-0542-1042; Ottenbacher, Kenneth/0000-0001-5990-3982			Abreu BC, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P51; BERG EA, 1948, J GEN PSYCHOL, V39, P22; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Christiansen C, 1996, J MED VIRTUAL REALIT, V1, P6; Dellasega C, 1994, J Community Health Nurs, V11, P129, DOI 10.1207/s15327655jchn1103_1; Dizio P, 1992, PRESENCE-TELEOP VIRT, V1, P319; ELIS DC, 1987, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hettinger L. J., 1992, PRESENCE, V1, P306; Kennedy R.S., 1992, PRESENCE TELEOPERATO, V1, P295, DOI [10.1162/pres.1992.1.3.295, DOI 10.1162/PRES.1992.1.3.295]; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; NEISTADT ME, 1994, AM J OCCUP THER, V48, P431, DOI 10.5014/ajot.48.5.431; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Puls I, 1999, STROKE, V30, P2291, DOI 10.1161/01.STR.30.11.2291; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Riva G, 1998, ST HEAL T, V58, P120; Rizzo A, 1998, CYBERPSYCHOLOGY BEHA, V1, P59, DOI DOI 10.1089/CPB.1998.1.59; Rizzo AA, 1997, ST HEAL T, V44, P123; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; Schuttler J, 1995, ANAESTHESIST, V44, P850, DOI 10.1007/s001010050221; SINGBARTL G, 1985, ANASTH INTENSIV NOTF, V20, P251, DOI 10.1055/s-2007-1003119; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; *STAT U NY BUFF, 1997, GUID UN DAT SET MED; WECSHLER D, 1939, MEASUREMENT ADULT IN; WILKINSON GS, 1984, WIDE RANGE ACHIEVEME; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; [No title captured]	30	59	63	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2001	80	8					597	604		10.1097/00002060-200108000-00010			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	454BR	WOS:000169953000009	11475481				2022-02-06	
J	Marshall, SW; Spencer, RJ				Marshall, SW; Spencer, RJ			Concussion in rugby: The hidden epidemic	JOURNAL OF ATHLETIC TRAINING			English	Article						injury; epidemiology	INJURIES; UNION; PLAYERS; SEASON; SCHOOL	Objective: To determine the incidence of concussion in high school rugby players and compare the findings with the relevant published literature. Design and Setting: Prospective data collection in one US high school rugby program. Subjects: Two teams followed for 3 years. Measurements: Injury rate, injury severity, and time withheld from competition. Results: Seventeen concussions were recorded, accounting for 25% of all reported injuries. The incidence rate for concussion was 3.8 per 1000 athlete-exposures (95% confidence interval, 2.0-5.7) or 11.3 per 100 player-seasons (95% confidence interval, 5.9-16.7). Of the 17 concussions, 14 were Cantu grade 1, 2 were grade 2, and 1 was grade 3. Concussions accounted for 25% of all days lost from rugby participation due to injury. Conclusions: The incidence of concussion in this study was higher than previously reported in other studies. Methodologic limitations and administrative rules that required suspension for injured players may have suppressed reporting in previous epidemiologic studies. The incidence of concussion in rugby is probably much higher than previously suggested.	Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Highland High Sch, Salt Lake City, UT USA		Marshall, SW (corresponding author), Univ N Carolina, Injury Prevent Res Ctr, CB 7505 Chase Hall, Chapel Hill, NC 27599 USA.			Marshall, Stephen/0000-0002-2664-9233			Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; CLARK DR, 1990, S AFR MED J, V77, P559; DALLEY DR, 1992, NZ J SPORTS MED, V20, P2; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; GARRAWAY M, 1995, LANCET, V345, P1485; HUGHES DC, 1994, CLIN J SPORT MED, V4, P249; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; NATHAN M, 1983, S AFR MED J, V64, P132; ROUX CE, 1987, S AFR MED J, V71, P307; SUGERMAN S, 1985, AUST J SPORTS MED EX, V15, P5; Wetzler MJ, 1996, AM J SPORT MED, V24, P454, DOI 10.1177/036354659602400408; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	14	59	60	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					334	338					5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	557NC	WOS:000175913800020	12937506				2022-02-06	
J	Nesbitt, AD; Cooper, PJ; Kohl, P				Nesbitt, AD; Cooper, PJ; Kohl, P			Rediscovering commotio cordis	LANCET			English	Article							CHEST-WALL IMPACT; SUDDEN-DEATH; CARDIAC CONCUSSION; SPORTS		Univ Oxford, Physiol Lab, Cardiac Mechanoelect Feedback Grp, Oxford OX1 3PT, England; Univ Oxford, John Radcliffe Hosp, Sch Med, Oxford OX3 9DU, England		Kohl, P (corresponding author), Univ Oxford, Physiol Lab, Cardiac Mechanoelect Feedback Grp, Parks Rd, Oxford OX1 3PT, England.			Kohl, Peter/0000-0003-0416-6270			Albers A, 1966, Lebensversicher Med, V18, P9; BERNSTEIN R, 1896, Z KLIN MED, V29, P519; BRUNNER W, 1939, ZB CHIRURG, V39, P2145; Casper Johann Ludwig, 1857, PRACTISCHES HDB GERI; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; DEUTSCH F, 1930, WIEN ARCH INTERN MED, V20, P279; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FROEDE RC, 1979, J FORENSIC SCI, V24, P752; GLATZEL H, 1936, DEUT MED WOCHENSCHR, V10, P377; GOGLER E, 1962, UNFALLOPFER STRASSEN, P51; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GREINER H, 1953, Monatsschr Unfallheilkd Versicherungsmed, V56, P90; HADOM W, 1940, SCHWEIZ Z UNFALLHEIL, V1, P156; HADOM W, 1940, SCHWEIZ Z UNFALLHEIL, V1, P227; ISFORT A, 1969, MON UNFALL VERISCH-V, V72, P409; JACOBI, 1937, ARCH ORTHOPAD UNFALL, V42, P418; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; Kohl P, 2001, CARDIOVASC RES, V50, P280, DOI 10.1016/S0008-6363(01)00194-8; Kohl P, 1999, PROG BIOPHYS MOL BIO, V71, P91, DOI 10.1016/S0079-6107(98)00038-8; Kohl P, 1999, HEART, V82, P397, DOI 10.1136/hrt.82.3.397; Link MS, 1999, CIRCULATION, V100, P413, DOI 10.1161/01.CIR.100.4.413; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Link MS, 1999, HEART, V81, P109, DOI 10.1136/hrt.81.2.109; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; Maron BJ, 1999, J CARDIOVASC ELECTR, V10, P114, DOI 10.1111/j.1540-8167.1999.tb00648.x; Meola F, 1879, GIORNALE INT SCI MED, V1, P923; Michalodimitrakis EN, 1997, AM J FOREN MED PATH, V18, P282, DOI 10.1097/00000433-199709000-00010; NELATON A, 1876, ELEMENTS PATHOLOGIE; NORDMANN M, 1942, Z KREISLAUFFORSCH, V11, P361; RIEDINGER F, 1903, HDB PRAKTISCHEN CHIR, P373; RIEDINGER F, 1882, BRUSTERSCHUTTERUNG F, P221; Schlomka G., 1934, ERG INN MED KINDERHK, V47, P1, DOI 10.1007/ 978-3-642-90672-5_1.; SELVIN P, 1998, WASHINGTON POST 0530; SPUHLER O, 1937, SCHWEIZ MED WOCHENSC, V26, P571; Walther G, 1968, Lebensversicher Med, V20, P136; Wirth E, 1973, Beitr Gerichtl Med, V30, P458	38	59	62	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 14	2001	357	9263					1195	1197		10.1016/S0140-6736(00)04338-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423RX	WOS:000168192100033	11323067				2022-02-06	
J	Matharu, MS; Goadsby, PJ				Matharu, MS; Goadsby, PJ			Post-traumatic chronic paroxysmal hemicrania (CPH) with aura	NEUROLOGY			English	Article							CLUSTER HEADACHE	The authors describe a patient who developed chronic paroxysmal hemicrania (CPH) in close temporal relationship to a head injury. The subsequent attacks of CPH were associated with a typical migrainous sensory and motor aura. Administration of indomethacin 75 mg daily resulted in isolated occurrence of autonomic and aura symptoms in the absence of pain symptoms. The patient became completely asymptomatic on indomethacin 100 mg daily. Migrainous aura may be seen with trigeminal-autonomic headaches and may represent the expression of an aura-susceptibility gene rather than typical migraine headache biology.	Inst Neurol, Headache Grp, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England		Goadsby, PJ (corresponding author), Inst Neurol, Headache Grp, Queen Sq, London WC1N 3BG, England.	peterg@brain.ion.ucl.ac.uk	Goadsby, Peter J/B-2267-2009; Matharu, Manjit/AAN-9786-2020; Matharu, Manjit/AAY-3064-2021; Goadsby, Peter J/Z-1970-2019	Matharu, Manjit/0000-0002-4960-2294; Goadsby, Peter J/0000-0003-3260-5904			ANTONACI F, 1989, HEADACHE, V29, P648, DOI 10.1111/j.1526-4610.1989.hed2910648.x; Bahra A, 2000, NEUROLOGY, V54, pA20; GEANEY DP, 1983, J NEUROL NEUROSUR PS, V46, P860, DOI 10.1136/jnnp.46.9.860; MEDINA JL, 1981, ARCH NEUROL-CHICAGO, V38, P705, DOI 10.1001/archneur.1981.00510110065010; PAREJA JA, 1995, HEADACHE, V35, P111, DOI 10.1111/j.1526-4610.1995.hed3502111.x; PEARCE SHS, 1987, J NEUROL NEUROSUR PS, V50, P1599; RAPOPORT AM, 1981, CEPHALALGIA, V1, P67, DOI 10.1111/j.1468-2982.1981.tb00011.x; Silberstein SD, 2000, NEUROLOGY, V54, P219, DOI 10.1212/WNL.54.1.219; SJAASTAD O, 1986, HDB CLIN NEUROLOGY, P257; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	10	59	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 23	2001	56	2					273	275		10.1212/WNL.56.2.273			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	393GY	WOS:000166461900029	11160973				2022-02-06	
J	Chiaretti, A; De Benedictis, R; Polidori, G; Piastra, M; Iannelli, A; Di Rocco, C				Chiaretti, A; De Benedictis, R; Polidori, G; Piastra, M; Iannelli, A; Di Rocco, C			Early post-traumatic seizures in children with head injury	CHILDS NERVOUS SYSTEM			English	Article						pediatric head injury; post-traumatic seizures	POSTTRAUMATIC SEIZURES; EPILEPSY; PREDICTORS	Post-traumatic seizures (PTS) can be a serious complication of head injury, because they can cause secondary brain damage through increased metabolic requirements, raised intracranial pressure, cerebral hypoxia, and/or excessive release of neurotransmitters. In children, early PTS are more frequent than late ones. In this retrospective study we conducted an epidemiological analysis and tried to identify potential risk factors for the onset of early PTS in children hospitalized for head injury in our Paediatric Intensive Care Unit. The severity of injury was assessed using the Glasgow Coma Scale (GCS), while the outcome of traumatized children was defined using the Glasgow Outcome Score (GOS). Early PTS were diagnosed in 15 out of the 125 children hospitalized (12%). Most of the children (73.3%), developed seizures within 24 h of the trauma (immediate PTS). Among the risk factors, a very important role was played by the severity of the injury; in fact, the incidence of early PTS among patients with GCS less than or equal to8 was ten times greater than that among children with GCS 13-15. Other risk factors that significantly influenced the onset of early PTS, were age (60% of children with early PTS were less than 3 years old) and severe cerebral edema. Overall, children with early PTS had a worse outcome than the other patients. In fact, 53% had a GOS of less than or equal to3 compared to 19.1% of those without early PTS (P<001). In particular, considering children with severe head injury, 80% of those with early PTS had a GOS of <less than or equal to> 3, compared to 41% of those without early PTS (P<0.05). In conclusion, PTS can be a serious complication of head injury in children, because they can worsen secondary brain damage. Appropriate management of head-trauma patients must include suitable and immediate prophylaxis with anti-epileptic drugs.	Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Dept Pediat Neurosurg, Rome, Italy		Chiaretti, A (corresponding author), Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, Largo A Gemelli 8, I-00168 Rome, Italy.	raffdebe@tin.it					Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Black P, 1975, CIBA F S, V34, P215; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HENDRICK EB, 1968, J TRAUM, V8, P547; JENNETT B, 1975, LANCET, V1, P480; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Moshe S L, 1987, Epilepsia, V28 Suppl 1, pS3, DOI 10.1111/j.1528-1157.1987.tb05753.x; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	19	59	59	1	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	DEC	2000	16	12					862	866		10.1007/s003810000368			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	383MR	WOS:000165887000008	11156302				2022-02-06	
J	Berman, RF; Verweij, BH; Muizelaar, JP				Berman, RF; Verweij, BH; Muizelaar, JP			Neurobehavioral protection by the neuronal calcium channel blocker Ziconotide in a model of traumatic diffuse brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; calcium channel blocker; neurobehavioral deficit; neurobehavioral protection; rat	N-TYPE; OMEGA-CONOPEPTIDES; MITOCHONDRIAL DYSFUNCTION; CELL-DEATH; ISCHEMIA; RELEASE; ANTINOCICEPTION; ACCUMULATION; INHIBITION; GLUTAMATE	Object. Abnormal accumulation of intracellular calcium following traumatic brain injury (TBI) is thought to contribute to a cascade of cellular events that lead to neuropathological conditions. Therefore, the possibility that specific calcium channel antagonists might exert neuroprotective effects in TBI has been of interest. The focus of this study was to examine whether Ziconotide produces such neuroprotective effects. Methods. The authors report that the acceleration-deceleration model of TBI developed by Marmarou, et al., induces a long-lasting deficit of neuromotor and behavioral function. The voltage-sensitive calcium channel blocker Ziconotide (also known as SNX-111 and CI-1009) exerts neuroprotective effects in this model of diffuse brain injury (DBI) in rats. The dose and time of injection of Ziconotide chosen for the present study was based on the authors' previous biochemical studies of mitochondria. Rats were trained in a series of motor and memory tasks, following which they were subjected to DBI using the Marmarou, ct al., model. At 3, 5, and 24 hours, all rats were injected with 2 mg/kg Ziconotide for a total cumulative dose of 6 mg/kg Ziconotide. Control brain-injured animals were injected with an equal volume of saline vehicle at each of these time points. The rats were tested for motor and cognitive performance at 1,3,7, 14, 21,28, 35, and 42 days postinjury. Saline-treated rats displayed severe motor and cognitive deficits after DBI. Compared with saline-treated control animals, rats treated with Ziconotide displayed better motor performance during inclined plane, beam balance, and beam walk tests; improved memory while in the radial arm maze; and improved learning while in the Morris water maze. Conclusions. These results demonstrated that the acceleration-deceleration model, which had been developed by Marmarou, et al., induces severe motor and cognitive deficits. We also demonstrated that Ziconotide exhibits substantial neuroprotective activity in this model of TBI. Improvement was observed in both motor and cognitive tasks, even though treatment was not initiated until 3 hours after injury. These findings support the development of neuronal N-type calcium channel antagonists as useful therapeutic agents in the treatment of TBI.	Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sacramento, CA 95817 USA		Muizelaar, JP (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurosurg, 4860 Y St,Room 3740, Sacramento, CA 95817 USA.	J.Paul.Muizelaar@UCDMC.ucdavis.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39090] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A20016] Funding Source: Medline		BOWERSOX SS, 1995, J PHARMACOL EXP THER, V273, P248; Bowersox SS, 1996, J PHARMACOL EXP THER, V279, P1243; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CHAPLAN SR, 1994, J PHARMACOL EXP THER, V269, P1117; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folkerts M. M., 1998, J NEUROTRAUM, V13, P610; FOX JA, 1995, PFLUG ARCH EUR J PHY, V429, P873, DOI 10.1007/BF00374813; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOVDA DA, 1994, ACTA NEUROCHIR, P521; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; Igelmund P, 1996, EXP BRAIN RES, V109, P22; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OOBOSHI H, 1992, J NEUROCHEM, V58, P298, DOI 10.1111/j.1471-4159.1992.tb09310.x; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHAPIRA Y, 1989, Neurological Research, V11, P169; SMITH DH, 1996, NOVEL THERAPIES CNS, P137; SMITH ML, 1993, J CEREB BLOOD FLOW S, V13, pS700; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; XIAO WH, 1995, J PHARMACOL EXP THER, V274, P666; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	37	59	61	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					821	828		10.3171/jns.2000.93.5.0821			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800014	11059664				2022-02-06	
J	Max, JE; Koele, SL; Castillo, CC; Lindgren, SD; Arndt, S; Bokura, H; Robin, DA; Smith, WL; Sato, Y				Max, JE; Koele, SL; Castillo, CC; Lindgren, SD; Arndt, S; Bokura, H; Robin, DA; Smith, WL; Sato, Y			Personality change disorder in children and adolescents following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; children and adolescents; personality change disorder	SCHOOL-AGE-CHILDREN; FRONTAL-LOBE DAMAGE; CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; RELIABILITY; IMPACT; SCHIZOPHRENIA; PREVALENCE; CHILDHOOD; VALIDITY	The occurrence of personality change due to traumatic brain injury (PC), and its clinical and neuroimaging correlates were investigated. Ninety-four children, ages 5 through 14 at the time of hospitalization following traumatic brain injury (TBI; severe TBI N = 37; mild-moderate TBI N = 57), were assessed. Standardized psychiatric, adaptive functioning, cognitive functioning, family functioning, family psychiatric history, severity of injury, and neuroimaging assessments were conducted. The Neuropsychiatric Rating Schedule (NPRS) was used to establish a diagnosis of PC. Approximately 40% of consecutively hospitalized severe TBI participants had ongoing persistent PC an average of 2 years postinjury. An additional approximately 20% had a history of a remitted and more transient PC. PC occurred in 5% of mild-moderate TBI but was always transient. Interrater reliability for the diagnosis of PC was good (Kappa = .70). In severe TBI participants, persistent PC was significantly associated with severity of injury, particularly impaired consciousness over 100 hr, adaptive and intellectual functioning decrements, and concurrent diagnosis of secondary attention deficit hyperactivity disorder, but was not significantly related to any psychosocial adversity variables. These findings suggest that PC is a frequent diagnosis following severe TBI in children and adolescents, but is much less common following mild-moderate TBI.	Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp, San Diego, CA USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; San Diego State Univ, Dept Commun Disorders, San Diego, CA 92182 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA; Univ Iowa, Mental Hlth Clin Res Ctr, Iowa City, IA 52242 USA; Cedar Ctr, Cedar Rapids, IA USA; Yasugi Daiichi Hosp, Dept Neurol, Shimane, Japan; Wayne State Univ, Childrens Hosp Michigan, Dept Radiol, Detroit, MI 48202 USA		Max, JE (corresponding author), 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.	jmax@ucsd.edu	Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH031593, P30MH043271, R01MH031593, R01MH040856, P50MH043271] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH40856, MH31593] Funding Source: Medline		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Barkley R.A., 1997, ADHD NATURE SELF CON; BENDER L, 1956, PSYCHOPATHOLOGY CHIL, P66; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Damasio A., 1994, DESCARTES ERROR EMOT; Damasio H., 1989, LESION ANAL NEUROPSY; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P110; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; HARRINGTON JA, 1958, J MENT SCI, V104, P1205, DOI 10.1192/bjp.104.437.1205; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; HJERN B, 1964, ACTA PAEDIATR SC   S, V152, P5; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kasanin J, 1929, J NERV MENT DIS, V69, P385, DOI 10.1097/00005053-192904000-00002; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J AM ACAD PSYCHIATRY, V26, P247; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; MCCUBBIN HI, 1980, FAMILY ASSESSMENT RE, P97; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; OTTO U, 1960, PAEDOPSYCHIATRICA, V27, P6; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUNE V, 1970, ACTA PAEDIATR SC   S, V209, P1; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; Shaffer D, 1975, Ciba Found Symp, P191; Silver Jonathan M., 1994, P631; Strecker EA, 1924, ARCH NEURO PSYCHIATR, V12, P443, DOI 10.1001/archneurpsyc.1924.02200040092006; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	54	59	59	0	20	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2000	6	3					279	289		10.1017/S1355617700633039			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	304DH	WOS:000086467200003	10824500				2022-02-06	
J	Blaha, GR; Raghupathi, R; Saatman, KE; Mcintosh, TK				Blaha, GR; Raghupathi, R; Saatman, KE; Mcintosh, TK			Brain-derived neurotrophic factor administration after traumatic brain injury in the rat does not protect against behavioral or histological deficits	NEUROSCIENCE			English	Article						cortex; hippocampus; learning; memory; neurotrophin	CEREBELLAR GRANULE NEURONS; NERVE GROWTH-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; SEPTAL CHOLINERGIC NEURONS; RETINAL GANGLION-CELLS; LONG-TERM POTENTIATION; REDUCES INFARCT SIZE; ADULT-RAT; MESSENGER-RNA; FACTOR BDNF	Brain-derived neurotrophic factor has been shown to be neuroprotective in models of excitotoxicity, axotomy and cerebral ischemia. The present study evaluated the therapeutic potential of brain-derived neurotrophic factor following traumatic brain injury in the rat. Male Sprague-Dawley rats (N= 99) were anesthetized and subjected to lateral fluid percussion brain injury of moderate severity (2.4-2.8 arm) or sham injury. Four hours after injury, the animals were reanesthetized, an indwelling, intraparenchymal cannula was implanted, and infusion of brain-derived neurotrophic factor or phosphate-buffered saline vehicle was initiated from a mini-osmotic pump and continued for two weeks. In Study 1 (N= 48), vehicle or 12 mu g/day of brain-derived neurotrophic factor was infused into the dorsal hippocampus. Tn Study 2 (N = 51), vehicle or brain-derived neurotrophic factor at a high (12 mu g/day) or low dose (1.2 mu g/day) was infused into the injured parietal cortex. All animals were evaluated for neurological motor function at two days, one week and two weeks post-injury. Cognitive function (learning and memory) was assessed at two weeks post-injury using a Morris Water Maze. At two weeks post-injury, neuronal loss in the hippocampal CA3 and dentate hilus and in the injured cortex was evaluated. In Study 2, neuronal loss was also quantified in the thalamic medial geniculate nucleus. All of the above outcome measures demonstrated significant deleterious effects of brain injury (P < D.05 compared to sham). However, post-traumatic brain-derived neurotrophic factor infusion did not significantly affect neuromotor function, learning, memory or neuronal loss in the hippocampus, cortex or thalamus when compared to vehicle infusion in brain-injured animals, regardless of the infusion site or infusion dose (P > 0.05 for each). In contrast to previous studies of axotomy, ischemia and excitotoxicity, our data indicate that brain-derived neurotrophic factor is not protective against behavioral or histological deficits caused by experimental traumatic brain injury using the delayed, posttraumatic infusion protocol examined in these studies. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Mcintosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NSO8803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALTAR CA, 1994, J NEUROCHEM, V63, P1021; ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; ANDERSON KD, 1995, J COMP NEUROL, V357, P296, DOI 10.1002/cne.903570209; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; Baxter GT, 1997, J NEUROSCI, V17, P2683; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; BURKE MA, 1994, EXP NEUROL, V130, P178, DOI 10.1006/exnr.1994.1197; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUGICHDJORDJEVIC MM, 1995, EUR J NEUROSCI, V7, P1831, DOI 10.1111/j.1460-9568.1995.tb00703.x; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferrer I, 1998, BRAIN PATHOL, V8, P253; Frank L, 1997, EXP NEUROL, V145, P62, DOI 10.1006/exnr.1997.6440; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; Jian Z, 1996, CELL SIGNAL, V8, P365, DOI 10.1016/0898-6568(96)00069-1; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Knusel B, 1996, EXP NEUROL, V139, P121, DOI 10.1006/exnr.1996.0087; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; LARMET Y, 1995, NEUROREPORT, V6, P1937, DOI 10.1097/00001756-199510020-00027; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; Liu Y, 1999, J NEUROSCI, V19, P4370; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Mamounas LA, 1995, J NEUROSCI, V15, P7929; Marsh HN, 1996, J NEUROCHEM, V67, P952; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORSE JK, 1993, J NEUROSCI, V13, P4146; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SAUER H, 1993, BRAIN RES, V626, P37, DOI 10.1016/0006-8993(93)90560-A; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sobreviela T, 1996, J COMP NEUROL, V375, P417; SPRANGER M, 1997, J CEREBR BLOOD FL S1, V17, pS370; Taga K, 1997, ANESTHESIOLOGY, V87, P918, DOI 10.1097/00000542-199710000-00027; Tanaka T, 1997, J NEUROSCI, V17, P2959; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Utley DS, 1996, ARCH OTOLARYNGOL, V122, P407; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yan Q, 1997, J COMP NEUROL, V378, P135; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	91	59	62	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	99	3					483	493		10.1016/S0306-4522(00)00214-1			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	348TX	WOS:000089003500009	11029540				2022-02-06	
J	Rao, AM; Hatcher, JF; Dempsey, RJ				Rao, AM; Hatcher, JF; Dempsey, RJ			CDP-choline: Neuroprotection in transient forebrain ischemia of gerbils	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						arachidonic acid; leukotriene C-4; CA(1) neuronal death; phosphatidylcholine; hippocampus; S-adenosyl-L-methionine; apoptosis	EXPERIMENTAL FOCAL ISCHEMIA; ADENOSYL-L-METHIONINE; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; FREE FATTY-ACIDS; CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; PHOSPHOLIPASE A(2); NEURONAL DEATH; RAT-BRAIN	CDP-choline is a rate-limiting intermediate in the biosynthesis of phosphatidylcholine (PtdCho), an important component of the neural cell membrane, The ability of CDP-choline to alter phospholipid metabolism is an important function in the treatment of ischemic injury. Exogenous treatment with CDP-choline stimulates PtdCho synthesis and prevents release of free fatty acids (FFA), especially arachidonic acid (AA), after ischemia/reperfusion. Phase III clinical trials of CDP-choline in the treatment of stroke are currently underway, Here we report the neuroprotection by CDP-choline in transient forebrain ischemia of gerbils, CDP-choline significantly attenuated the blood-brain barrier (BBB) dysfunction after ischemia with 6-hr reperfusion, and considerably reduced the increase of AA in FFA and leukotriene C-4 (LTC4) synthesis at 1 day. Edema was significantly elevated after 1 and 2 days, but attained maximum at 3-day reperfusion, CDP-choline substantially attenuated edema at 3 days, Ischemia resulted in 80 +/- 8% CA(1) hippocampal neuronal death after 6-day reperfusion, and CDP-choline provided 65 +/- 6% neuroprotection, CDP-choline may act by increasing PtdCho synthesis via two pathways: (1) conversion of 1,2-diacylglycerol to PtdCho, and (2) biosynthesis of S-adenosyl-L-methionine, thus stabilizing the membrane and reducing AA release and metabolism to leukotriene C-4 This would result in decreased toxicity due to AA, leukotrienes, oxygen radicals, lipid peroxidation, and altered glutamate uptake, thus limiting BBB dysfunction, edema and providing neuroprotection, (C) 1999 Wiley-Liss, Inc.	Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA		Rao, AM (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, F4-313,600 Highland Ave, Madison, WI 53792 USA.	adibhat1@neurosurg.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS028000] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 28000, P01 NS31220] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ABE K, 1989, ANN NY ACAD SCI, V559, P259; Aronowski J, 1996, NEUROL RES, V18, P570; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CESTARO B, 1994, ACTA NEUROL SCAND, V89, P32, DOI 10.1111/j.1600-0404.1994.tb05407.x; CHAN PH, 1984, FED PROC, V43, P210; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x; GALLETTI P, 1991, J NEUROL SCI, V103, pS19; Gimenez R, 1998, EUR J PHARMACOL, V344, P149, DOI 10.1016/S0014-2999(98)00035-1; Hall ED, 1996, ADV NEUROL, V71, P247; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HORROCKS L A, 1981, Progress in Lipid Research, V20, P531; IKEDA M, 1986, J NEUROCHEM, V47, P123; Kasner SE, 1997, ANN EMERG MED, V30, P642, DOI 10.1016/S0196-0644(97)70084-2; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KIRINO T, 1986, STROKE, V17, P455, DOI 10.1161/01.STR.17.3.455; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Knapp S, 1999, BRAIN RES, V822, P52, DOI 10.1016/S0006-8993(99)01072-0; Lombardi G, 1996, BRIT J PHARMACOL, V117, P189, DOI 10.1111/j.1476-5381.1996.tb15173.x; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; MATSUI Y, 1987, EUR J PHARMACOL, V144, P211, DOI 10.1016/0014-2999(87)90521-8; MURPHY EJ, 1993, PHOSPHOLIPIDS SIGNAL, P353; MYKITA S, 1986, J NEUROCHEM, V47, P223; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NISHINO H, 1994, BRAIN RES BULL, V35, P51, DOI 10.1016/0361-9230(94)90215-1; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; Ohtsuki T, 1996, BRAIN RES, V736, P353, DOI 10.1016/0006-8993(96)00948-1; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1998, NEUROSCI LETT, V256, P65, DOI 10.1016/S0304-3940(98)00780-0; Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SATO H, 1988, BIOCHEM BIOPH RES CO, V150, P491, DOI 10.1016/0006-291X(88)90547-5; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; SECADES JJ, 1995, METHOD FIND EXP CLIN, V17, P1; TROVARELLI G, 1983, NEUROCHEM RES, V8, P1597, DOI 10.1007/BF00964161; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; WATANABE T, 1994, J PHARMACOL EXP THER, V271, P1624; WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T; WERNS SW, 1990, TRENDS PHARMACOL SCI, V11, P161, DOI 10.1016/0165-6147(90)90068-J; Yamaguchi S, 1998, CAN J ANAESTH, V45, P226, DOI 10.1007/BF03012907; Yamamoto T, 1997, BRAIN RES, V762, P240, DOI 10.1016/S0006-8993(97)00490-3; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135	70	59	60	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 1	1999	58	5					697	705		10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.0.CO;2-B			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	259BM	WOS:000083874200011	10561698				2022-02-06	
J	Bareyre, FM; Saatman, KE; Helfaer, MA; Sinson, G; Weisser, JD; Brown, AL; McIntosh, TK				Bareyre, FM; Saatman, KE; Helfaer, MA; Sinson, G; Weisser, JD; Brown, AL; McIntosh, TK			Alterations in ionized and total blood magnesium after experimental traumatic brain injury: Relationship to neurobehavioral outcome and neuroprotective efficacy of magnesium chloride	JOURNAL OF NEUROCHEMISTRY			English	Article						ionized magnesium; fluid percussion; magnesium; rats; traumatic brain injury	INTRACELLULAR FREE MG-2+; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; CALCIUM; RATS; METABOLISM; STROKE; CATECHOLAMINES; HEPATOCYTES; ANTAGONIST	Experimental evidence suggests that magnesium plays a role in the pathophysiological sequelae of brain injury. The present study examined the variation of blood ionized and total magnesium, as well as potassium, sodium, and ionized calcium, after experimental fluid percussion brain injury in rats. Blood ionized magnesium concentration significantly declined from 0.45 +/- 0.02 to 0.32 +/- 0.02 mM by 30 min postinjury and stayed depressed for the 24-h study period in vehicle-treated rats. Blood total magnesium concentration was 0.59 +/- 0.01 mM and remained stable over time in brain-injured vehicle-treated animals. When magnesium chloride (125 mu mol/rat) was administered 1 h postinjury, ionized magnesium levels were restored by 2 h postinjury and remained at normal values up to 24 h following brain trauma. Magnesium treatment also significantly reduced posttraumatic neuromotor impairments 1 and 2 weeks after the insult, but failed to attenuate spatial learning deficits. A significant positive and linear correlation could be established between ionized magnesium levels measured 24 h postinjury and neuromotor outcome at 1 and 2 weeks. We conclude that acute ionized magnesium measurement may be a predictor of long-term neurobehavioral outcome following head injury and that delayed administration of magnesium chloride can restore blood magnesium concentration and attenuate neurological motor deficits in brain-injured rats.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NSO8803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		ALTURA B M, 1985, Magnesium, V4, P245; Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; Altura B T, 1984, Magnesium, V3, P195; Altura B. T., 1992, Magnesium and Trace Elements, V10, P90; ALTURA BM, 1994, SCAND J CLIN LAB INV, V54, P5, DOI 10.3109/00365519409095206; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1981, FED PROC, V40, P2672; ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; ALTURA BM, 1995, ALCOHOL, V12, P131, DOI 10.1016/0741-8329(94)00072-7; ALTURA BM, 1997, FRONT BIOSCI, V2, P9; Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; ALTURA BT, 1980, NEUROSCI LETT, V20, P323, DOI 10.1016/0304-3940(80)90168-8; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P53, DOI 10.3109/00365519409095211; ALTURA BT, 1980, MED HYPOTHESES, V6, P753, DOI 10.1016/0306-9877(80)90093-6; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P83, DOI 10.3109/00365519409095214; Bara M., 1984, MAGNESIUM, V3, P212; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BROUGHTON A, 1968, LANCET, V2, P1156; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHAUDRY IH, 1982, AM J PHYSIOL, V242, pR604, DOI 10.1152/ajpregu.1982.242.5.R604; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLOWES GHA, 1957, ANN SURG, V146, P530, DOI 10.1097/00000658-195710000-00002; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Ema M, 1991, Magnes Trace Elem, V10, P269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FINK R, 1992, MAGNES TRACE ELEM, V10, P1; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; GUNTHER T, 1995, MOL CELL BIOCHEM, V144, P141, DOI 10.1007/BF00944393; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; JOBORN H, 1985, CLIN ENDOCRINOL, V23, P219, DOI 10.1111/j.1365-2265.1985.tb00217.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KING LR, 1965, SURG GYNECOL OBSTETR, V120, P761; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; MARK JB, 1961, SURG GYNECOL OBSTET, V113, P213; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McLaurin R L, 1972, Clin Neurosurg, V19, P281; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Regan RF, 1998, J NEUROCHEM, V70, P77; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SAWYER RB, 1970, ARCH SURG-CHICAGO, V100, P343; SEELIG MS, 1994, J AM COLL NUTR, V13, P429; SHAPIRA Y, 1989, Neurological Research, V11, P169; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1990, J NEUROSCI, V10, P3524; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MG2PLUS EXCITABLE ME, P125; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	75	59	62	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	1999	73	1					271	280		10.1046/j.1471-4159.1999.0730271.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	207PV	WOS:000080946000032	10386980				2022-02-06	
J	Bell, BD; Primeau, M; Sweet, JJ; Lofland, KR				Bell, BD; Primeau, M; Sweet, JJ; Lofland, KR			Neuropsychological functioning in migraine headache, nonheadache chronic pain, and mild traumatic brain injury patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	25th Meeting of the International-Neuropsychological-Society	FEB 05-08, 1997	ORLANDO, FL	Int Neuropsychol Soc			CEREBRAL BLOOD-FLOW; COGNITIVE IMPAIRMENT; EMISSION TOMOGRAPHY; EVOKED-POTENTIALS; MEMORY; SAMPLE; MRI	There are conflicting reports in the literature concerning the neuropsychological functioning of migraine headache patients. The finding in some studies that migraineurs performed more poorly than healthy controls led to the hypothesis that chronic migraine may result in subtle but persistent cerebral dysfunction. Reports describing acute and between-headache neurophysiological disturbances in migraineurs lent support to this hypothesis. To elucidate the cognitive status of these patients, we administered a brief neuropsychological battery to 60 individuals with migraine headache (HA), nonheadache chronic pain (PAIN), or mild traumatic brain injury (MTBI). The PAIN group was included to test the hypothesis that cognitive difficulty in migraineurs might result from the discomfort, depression, medications, etc. often associated with chronic pain, rather than from brain dysfunction. The MTBI patients were considered a useful comparison for the migraineurs because their level of impairment was also expected to be mild, at worst A MANOVA, with three cognitive index scores as the dependent variables, revealed that the three groups differed significantly. Follow-up contrasts demonstrated that the MTBI group was significantly more impaired on the memory index compared to the HA and PAIN groups, which did not differ from each other. The use of two different normative-based cutoffs to identify individuals who were impaired on the test battery revealed that the frequency of impairment within the two groups of pain patients, but not the MTBI patients, was within normal limits. Thus, the results did not support a link between migraine headache and cognitive impairment (C) 1999 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Finch Univ Hlth Sci Chicago Med Sch, N Chicago, IL 60064 USA; Evanston Hosp Corp, Evanston, IL USA; Northwestern Univ, Evanston, IL 60208 USA; Pain & Rehabil Clin Chicago, Chicago, IL USA		Bell, BD (corresponding author), Univ Wisconsin Hosp & Clin, Dept Neurol H4 676, 600 Highland Ave, Madison, WI 53792 USA.						American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ARDILA A, 1988, CEPHALALGIA, V8, P67, DOI 10.1046/j.1468-2982.1988.0802067.x; Benton A., 1978, MULTILINGUAL APHASIA; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOLTER JF, 1990, MULTIDIGIT MEMORY TE; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Burker E, 1989, NEUROPSYCHOLOGY, V3, P61, DOI 10.1037//0894-4105.3.2.61; Cavestri R, 1995, Minerva Med, V86, P257; Cooney BS, 1996, HEADACHE, V36, P616, DOI 10.1046/j.1526-4610.1996.3610616.x; CUETTER AC, 1983, HEADACHE, V23, P195; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; DEBENEDITTIS G, 1995, HEADACHE, V35, P264; EDMEADS J, 1984, CAN J NEUROL SCI, V11, P363, DOI 10.1017/S0317167100045716; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; GLOVER V, 1989, TRENDS PHARMACOL SCI, V10, P1, DOI 10.1016/0165-6147(89)90089-8; Golden CJ, 1978, STROOP COLOR WORD TE; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 1992, COMPREHENSIVE NORMS; Heilbronner R L, 1989, Arch Clin Neuropsychol, V4, P299; HIRSCH AR, 1992, HEADACHE, V32, P233, DOI 10.1111/j.1526-4610.1992.hed3205233.x; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; JAIN S, 1986, HEADACHE, V26, P19, DOI 10.1111/j.1526-4610.1986.hed2601019.x; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; KOEHLER SM, 1991, J CLIN EXP NEUROPSYC, V13, P60; LANCE JW, 1993, NEUROLOGY, V43, P11; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVINE SR, 1987, STROKE, V18, P1164, DOI 10.1161/01.STR.18.6.1164; LIPTON RB, 1993, NEUROLOGY, V43, P6; MAZZUCCHI A, 1988, HEADACHE, V28, P488, DOI 10.1111/j.1526-4610.1988.hed2807488.x; MERSKEY HM, 1986, PAIN S3, V25, pS1; MONTAGNA P, 1995, CEPHALALGIA, V15, P323, DOI 10.1046/j.1468-2982.1995.1504323.x; PUCA F, 1985, MIGRAINE CLIN RES AD, P1; Raskin N, 1988, HEADACHE; Reitan R., 1979, MANUAL ADM NEUROPSYC; ROBBINS L, 1992, HEADACHE, V32, P507, DOI 10.1111/j.1526-4610.1992.hed3210507.x; ROSE FC, 1988, BASIC MECH HEADACHE, P3; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Ruff R. M., 1989, MILD HEAD INJURY, P176; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan L, 1996, NEUROPSYCHOLOGY, V10, P176, DOI 10.1037/0894-4105.10.2.176; SCHLAKE HP, 1990, HEADACHE, V30, P129, DOI 10.1111/j.1526-4610.1990.hed3003129.x; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; SMITH GE, 1992, J CLIN EXP NEUROPSYC, V14, P211, DOI 10.1080/01688639208402824; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; TAGLIATI M, 1995, EVOKED POTENTIAL, V96, P1, DOI 10.1016/0013-4694(94)00211-3; TFELTHANSEN P, 1994, PHARMACOL TOXICOL, V75, P72, DOI 10.1111/j.1600-0773.1994.tb02003.x; Trahan Donald E, 1992, Clin Neuropsychol, V6, P241, DOI 10.1080/13854049208401858; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x; [No title captured], DOI DOI 10.1080/13854048808520093; [No title captured], DOI DOI 10.1093/ARCLIN/5.1.23	60	59	60	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	1999	14	4					389	399		10.1016/S0887-6177(98)00020-1			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	186WP	WOS:000079753900005	14590592	Bronze			2022-02-06	
J	Mathias, JL; Coats, JL				Mathias, JL; Coats, JL			Emotional and cognitive sequelae to mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FRONTAL-LOBE DYSFUNCTION; PSYCHOSOCIAL FUNCTION; CROSS-VALIDATION; PERSONALITY; DISTURBANCE; SYMPTOMS; MODERATE; SCALE	This study compared the emotional functioning and cognitive abilities (i.e., verbal fluency, executive functioning, memory, and attention) of 27 patients with mild traumatic brain injury (MTBI) to that of 27 controls. With the exception of verbal fluency, the cognitive abilities of the MTBI group appeared to be intact. Emotional functioning was assessed using the Neuropsychology Behavior and Affect Profile (NBAP), a revised version of the Neurobehavioural Rating Scale and the Headley Court Psychosocial Rating Scale. The NBAP demonstrated good internal reliability, criterion validity, and construct validity. The MTBI group showed significantly higher levels of post injury depression than controls on the NEAR Pre injury levels of depression in the MTBI group were also higher than the controls but both the patient reports and those of family members confirmed an increase in depression following MTBI.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia		Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	psyj-mat@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			ABSHER JR, 1995, APHASIOLOGY, V9, P181, DOI 10.1080/02687039508248705; ALFANO DP, 1991, NEUROPSYCHOLOGY, V5, P35; Bennett TL, 1989, COGNITIVE REHABILITA, V7, P20; Benson D.F., 1986, FRONTAL LOBES; Benton AL, 1991, FRONTAL LOBE FUNCTIO; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FOS LA, 1995, INT NEUR SOC AUSTR S; Gass CS, 1997, ARCH CLIN NEUROPSYCH, V12, P199, DOI 10.1016/S0887-6177(96)00032-7; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; GRONWALL D, 1974, LANCET, V2, P605; HAMILTON JM, 1995, BRAIN INJURY, V9, P479, DOI 10.3109/02699059509008207; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JENKINS A, 1986, LANCET, V2, P445; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Nelson H.E., 1982, NATL ADULT READING T; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NELSON L, 1994, NEUROBEHAVIORAL BEHA; Nelson LD, 1995, PSYCHOL ASSESSMENT, V7, P404, DOI 10.1037/1040-3590.7.3.404; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RANSEN J, 1990, COGNITIVE REHABILITA, V8, P8; Robertson I., 1994, TEST EVERYDAY ATTENT; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1996, PSYCHOL ASSESSMENT, V8, P115; Spreen O, 1991, COMPENDIUM NEUROPSYC; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TEASDALE G, 1974, LANCET, V2, P81; *WHO, 1989, ALC US DIS ID TEST; [No title captured]	54	59	60	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1999	21	2					200	215		10.1076/jcen.21.2.200.930			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	226CL	WOS:000082002700005	10425517				2022-02-06	
J	Ochi, F; Esquenazi, A; Hirai, B; Talaty, M				Ochi, F; Esquenazi, A; Hirai, B; Talaty, M			Temporal-spatial feature of gait after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						gait analysis; temporal-spatial variables; traumatic brain injury	HEMIPLEGIC GAIT; PARAMETERS; WALKING	The temporal-spatial characteristics of the gait of patients with traumatic brain injury (TBI) were investigated and compared with those of normal gait and the gait of stroke survivors. A slower walking velocity is evident in the TBI population when compared with normal. The average walking speed of TBI survivors is faster than that of stroke patients and is mainly related to a longer step length. TBI survivors produce a gait pattern with a prolonged stance period for the unaffected limb, without prolonged stance period for the affected limb, and a shorter step length for the unaffected limb.	MossRehab Hosp, Gait & Mot Anal Lab, Philadelphia, PA 19141 USA; Natl Def Med Coll, Dept Rehabil Med, Tokorozawa, Saitama, Japan		Ochi, F (corresponding author), MossRehab Hosp, Gait & Mot Anal Lab, 1200 Tabor Rd, Philadelphia, PA 19141 USA.						BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; CRAIK RL, 1992, POSTURE GAIT CONTROL, pR2; DUTTER L, 1992, PHYS THER, V72, pS39; Elovic E, 1996, MED REHABILITATION T; ESQUENAZI A, 1993, REHABILITATION MED P; ESQUENAZI A, 1991, PHYS MED REH CLIN N, V2, P473; HARRIS GF, 1994, ARCH PHYS MED REHAB, V75, P216; LEIPER CI, 1991, PHYS THER, V71, P791, DOI 10.1093/ptj/71.11.791; MAYER N H, 1987, Society for Neuroscience Abstracts, V13, P1174; MIZRAHI J, 1982, SCAND J REHABIL MED, V14, P133; Murray M P, 1970, Arch Phys Med Rehabil, V51, P637; Murray M P, 1966, Am J Phys Med, V45, P8; MURRAY MP, 1964, J BONE JOINT SURG AM, V46, P335, DOI 10.2106/00004623-196446020-00009; PEAT M, 1976, ARCH PHYS MED REHAB, V57, P421; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P128, DOI 10.1097/00002060-199703000-00008; TAYLOR DR, 1980, P INT C REH ENG; WALL JC, 1979, SCAND J REHABIL MED, V11, P95; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550	18	59	61	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					105	115		10.1097/00001199-199904000-00002			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800002	10191370				2022-02-06	
J	Levine, B; Freedman, M; Dawson, D; Black, S; Stuss, DT				Levine, B; Freedman, M; Dawson, D; Black, S; Stuss, DT			Ventral frontal contribution to self-regulation: Convergence of episodic memory and inhibition	NEUROCASE			English	Article							TRAUMATIC BRAIN INJURY; HUMAN PREFRONTAL CORTEX; CLOSED-HEAD-INJURY; RECOLLECTIVE EXPERIENCE; ORBITOFRONTAL CORTEX; STRATEGY APPLICATION; RETROGRADE-AMNESIA; LEARNING-DEFICITS; WORKING-MEMORY; OLDER ADULTS	Ventral frontal brain damage is associated with impaired self-regulation of behaviour in unstructured situations (self-regulatory disorder; SRD). This report attempts to integrate this brain-behaviour correlation with earlier animal literature on disinhibition and recent cognitive neuroscience literature on the frontal lobes and episodic memory. Data are presented from patient ML (Levine et at, Brain 1998; 121: 1951-73), who has isolated retrograde amnesia, ventral frontal dysfunction and SRD. Impaired strategic self-regulation of behaviour was documented with psychosocial outcome questionnaires and two laboratory analogues of real-life unstructured situations: a strategy application task and a gambling task. Previous findings of deficits in anterograde episodic memory (i.e. re-experiencing) using the remember/ know distinction were replicated and extended. The role of disinhibition as a mechanism for SRD was supported by ML's severely impaired performance on object alternation, a task with documented sensitivity to disinhibition following ventral frontal dysfunction in non-human primates and humans. It is argued that autonoetic awareness (i.e. awareness of the self as a continuous entity across time) supports self-regulation of behaviour in unstructured situations by providing access to a network of accumulated episodic information. This information is held on-line to facilitate inhibition of inappropriate actions arising from prepotent environmental or internal stimuli. In patients with SRD, these on-line maintenance and inhibition mechanisms are inoperative, resulting in inappropriate behaviour in unstructured situations. Therefore, patients with SRD should be impaired on both tests of episodic re-experiencing and inhibition.	Univ Toronto, Dept Psychol, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Baycrest Ctr Geriatr Care,Sunnybrook Hlth Sci Ctr, Rotman Res Inst,Div Neurol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Mt Sinai Hosp, Toronto, ON M6A 2E1, Canada; Univ Toronto, Behav Neurol Program, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Occupat Therapy, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada			levine@psych.utoronto.ca	Levine, Brian/O-2725-2019; Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; Dawson, Deirdre/I-8882-2014	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre/0000-0001-7517-6121; Black, Sandra/0000-0001-7093-8289			Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BRUTKOWSKI S, 1961, CENTRAL PERIPHERAL M, P133; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COURVILLE CB, 1937, PATHOLOGY CENTRAL 4; CRAIK FIM, 1990, PSYCHOL AGING, V5, P148, DOI 10.1037/0882-7974.5.1.148; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DENOBELE E, 1835, ANN MED; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Dias R, 1997, J NEUROSCI, V17, P9285; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; FREEDMAN M, 1987, ARCH NEUROL-CHICAGO, V44, P394, DOI 10.1001/archneur.1987.00520160036011; FREEDMAN M, 1989, BRAIN COGNITION, V11, P114, DOI 10.1016/0278-2626(89)90009-2; FUNAHASHI S, 1993, J NEUROSCI, V13, P1479; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; GARDINER JM, 1991, MEM COGNITION, V19, P617, DOI 10.3758/BF03197157; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; Jacobsen CF., 1936, COMP PSYCHOL, V13, P1, DOI DOI 10.1001/ARCHNEURPSYC.1935.02250150108009; Jacoby LL, 1997, CARN S COGN, P13; JENNETT B, 1975, LANCET, V1, P480; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Keith R., 1987, ADV CLIN REHABILITAT, V1, P10; KNOWLTON BJ, 1995, J EXP PSYCHOL LEARN, V21, P699, DOI 10.1037/0278-7393.21.3.699; Kopelman M D, 1994, Memory, V2, P211, DOI 10.1080/09658219408258945; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Markowitsch HJ, 1996, NEUROCASE, V2, P357; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCOLL MA, 1995, DISABIL REHABIL, V17, P24, DOI 10.3109/09638289509166624; MCINTYRE JS, 1987, CAN J PSYCHOL, V41, P175, DOI 10.1037/h0084154; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; Norman KA, 1997, MEM COGNITION, V25, P838, DOI 10.3758/BF03211328; NOSEK M, 1982, REHABILITATION COUNS, V36, P21; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OSCARBERMAN M, 1991, FRONTAL LOBE FUNCTIO, P256; Pandya DN, 1996, RES PER NEUROSCI, P13; Pandya DN, 1987, FRONTAL LOBES REVISI, P41; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAJARAM S, 1993, MEM COGNITION, V21, P89, DOI 10.3758/BF03211168; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; RUGG MD, 1998, J MEM LANG, V38, P1; Rushworth MFS, 1997, J NEUROSCI, V17, P4829; Sanides F., 1970, Advances Primatol, V1, P137; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; STUSS DT, 1981, BIOL PSYCHIAT, V16, P1085; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1999, IN PRESS FRONTAL LOB; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; WILLER B, 1994, BRAIN INJURY REHABIL; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Yonelinas AP, 1998, NEUROPSYCHOLOGY, V12, P323, DOI 10.1037/0894-4105.12.3.323; [No title captured]; [No title captured]	80	59	61	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1355-4794			NEUROCASE	Neurocase		1999	5	3					263	275		10.1080/13554799908402731			13	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	219RU	WOS:000081621500009					2022-02-06	
J	O'Neill, DF; McGlone, MR				O'Neill, DF; McGlone, MR			Injury risk in first-time snowboarders versus first-time skiers	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								Between 1994 and 1996 we studied injury patterns in more than 22,000 first-time snowboarders and first-time skiers to determine the comparative injury risk of these two popular sports coexisting in winter resort areas. The first-time participants included in this study had no previous experience in their activity of choice and enrolled in Learn to Snowboard and Learn to Ski programs in two major northeastern ski resorts. Data were gathered from physician evaluations at the medical clinics at each mountain. Two hundred seventy-three (4%) of the first-time snowboarders (N = 6585), and 641 (4%) of the first-time skiers (N = 15,795) sustained an injury. Injuries were further evaluated by location (upper extremity, lower extremity, head, and trunk area) and severity (emergent versus nonemergent). Snowboarders had a higher percentage of upper extremity injuries (53%), while skiers had a higher percentage of lower extremity injuries (63%). Snowboarders, however, sustained a significantly higher incidence of emergent injuries (such as fracture, concussion, dislocation, lost teeth) necessitating immediate intervention. While there have been other reports describing injuries in these activities, no previous study attempted to look at the first-time participants with similar age, experience, and equipment to determine comparative risk. We conclude that for the first-time participant, snowboarding does show a higher incidence of emergent injuries.	Plymouth Sports & Orthopaed Clin, Plymouth, NH 03264 USA		O'Neill, DF (corresponding author), Plymouth Sports & Orthopaed Clin, 19 Avery St, Plymouth, NH 03264 USA.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; Fischler L., 1996, SCHWEIZ RUNDSCH MED, V24, P777; GANONG RB, 1992, PHYSICIAN SPORTSMED, V20, P114, DOI 10.1080/00913847.1992.11947543; Giacobetti FB, 1997, AM J SPORT MED, V25, P223, DOI 10.1177/036354659702500215; JANES P, 1996, BIOMECHANICS     NOV, P16; JOHNSON RJ, 1990, POSTGRAD MED, V88, P36; MCLENNAN JC, 1991, J MUSCULOSKELETAL ME, V8, P75; Pigozzi F, 1997, ORTHOPEDICS, V20, P505; PINO EC, 1989, AM J SPORT MED, V17, P778, DOI 10.1177/036354658901700610; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; WARME WJ, 1995, AM J SPORT MED, V23, P597, DOI 10.1177/036354659502300514	13	59	59	0	4	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1999	27	1					94	97					4	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	159ZL	WOS:000078205800016	9934425				2022-02-06	
J	Sugerman, HJ; Bloomfield, GL; Saggi, BW				Sugerman, HJ; Bloomfield, GL; Saggi, BW			Multisystem organ failure secondary to increased intraabdominal pressure	INFECTION			English	Article							INTRA-ABDOMINAL PRESSURE; PLANNED MULTIPLE LAPAROTOMIES; BLOOD-FLOW; INTRACRANIAL-PRESSURE; COMPARTMENT SYNDROME; VOLUME EXPANSION; RENAL-FUNCTION; WALL DEFECTS; CLOSURE; CELIOTOMY	Acutely increased intraabdominal pressure can lead to multisystem organ dysfunction. Organ dysfunction consists of acute pulmonary failure secondary to compressive atelectasis and associated with high peak inspiratory pressures and impaired gas exchange, acute renal failure with marked oliguria without hypernaturia, intestinal and hepatic ischemia possibly leading to bacterial translocation or necrosis with peritonitis, increased intracranial pressures which may cause brain dysfunction or aggravate head injury edema, venous thrombosis and thromboembolism, and abdominal wall ischemia or necrosis. The diagnosis is made clinically in a patient,vith high peak inspiratory pressures, oliguria and an apparently tight abdomen, although urinary bladder pressure greater than or equal to 20 cm H2O pressure is suggestive. However, chronically increased intraabdominal pressure as is seen in the morbidly obese, pregnancy and cirrhosis may be misleading. As to treatment, once the diagnosis is made, the patient's abdomen should be opened and the tension relieved. The intestinal contents need to be protected and evaporative water loss minimized by either closing the skin and not the fascia or, if this is not possible, using an impermeable protective dressing. If the abdomen is difficult to close at the primary operation, it is best to prevent the development of an acute abdominal compartment syndrome by closing only the skin or leaving it open and using an impermeable dressing. In conclusion, the acute abdominal compartment syndrome has become increasingly recognized as a cause for multisystem organ failure. Recognition of the problem or prevention is mandatory for optimal patient survival.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Gen Surg Trauma Div, Richmond, VA 23298 USA		Sugerman, HJ (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Gen Surg Trauma Div, POB 980519,MCV Stn, Richmond, VA 23298 USA.						Bloomfield GL, 1996, J TRAUMA, V40, P936, DOI 10.1097/00005373-199606000-00012; Bloomfield GL, 1997, J TRAUMA, V42, P997, DOI 10.1097/00005373-199706000-00002; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Bloomfield GL, 1995, J TRAUMA, V39, P1168, DOI 10.1097/00005373-199512000-00028; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; DIAMANT M, 1978, ANESTHESIOLOGY, V48, P23, DOI 10.1097/00000542-197801000-00005; DIEBEL L, 1992, AM SURGEON, V58, P573; DIEBEL LN, 1992, J TRAUMA, V33, P45, DOI 10.1097/00005373-199207000-00010; DIEBEL LN, 1992, J TRAUMA, V33, P279, DOI 10.1097/00005373-199208000-00019; FABIAN TC, 1994, ANN SURG, V219, P643, DOI 10.1097/00000658-199406000-00007; FIETSAM R, 1989, AM SURGEON, V55, P396; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; HIRSHBERG A, 1994, J TRAUMA, V37, P365, DOI 10.1097/00005373-199409000-00005; IBERTI TJ, 1987, CRIT CARE MED, V15, P1140, DOI 10.1097/00003246-198712000-00014; IRGAU I, 1995, ARCH SURG-CHICAGO, V130, P1011; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; KASHTAN J, 1981, J SURG RES, V30, P249, DOI 10.1016/0022-4804(81)90156-6; LACEY SR, 1987, J PEDIATR SURG, V22, P1207, DOI 10.1016/S0022-3468(87)80739-X; MELDRUM DR, 1995, AM J SURG, V170, P537, DOI 10.1016/S0002-9610(99)80011-7; Mijangos Jose L., 1994, Surgical Forum, V45, P583; MORRIS JA, 1993, ANN SURG, V217, P576, DOI 10.1097/00000658-199305010-00019; MUTOH T, 1991, J APPL PHYSIOL, V70, P2611, DOI 10.1152/jappl.1991.70.6.2611; PLATELL CFE, 1990, AUST NZ J SURG, V60, P213, DOI 10.1111/ans.1990.60.3.213; RICHARDS WO, 1983, ANN SURG, V197, P183, DOI 10.1097/00000658-198302000-00010; RICHARDSON JD, 1976, J SURG RES, V20, P401, DOI 10.1016/0022-4804(76)90112-8; Ridings PC, 1995, J TRAUMA, V39, P1071, DOI 10.1097/00005373-199512000-00010; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; SHELLEY MP, 1981, J SURG RES, V59, P800; SMITH JH, 1985, ARCH INTERN MED, V145, P553, DOI 10.1001/archinte.145.3.553; Sugerman H, 1997, J INTERN MED, V241, P71, DOI 10.1046/j.1365-2796.1997.89104000.x; WITTMANN DH, 1993, EUR J SURG, V159, P75; WITTMANN DH, 1990, WORLD J SURG, V14, P218, DOI 10.1007/BF01664876	33	59	68	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0300-8126	1439-0973		INFECTION	Infection	JAN-FEB	1999	27	1					57	62		10.1007/BF02565176			6	Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Infectious Diseases	163TB	WOS:000078420700013	10206792				2022-02-06	
J	Kreutz, MR; Bockers, TM; Bockmann, J; Seidenbecher, CI; Kracht, B; Vorwerk, CK; Weise, J; Sabel, BA				Kreutz, MR; Bockers, TM; Bockmann, J; Seidenbecher, CI; Kracht, B; Vorwerk, CK; Weise, J; Sabel, BA			Axonal injury alters alternative splicing of the retinal NR1 receptor: The preferential expression of the NR1b isoforms is crucial for retinal ganglion cell survival	JOURNAL OF NEUROSCIENCE			English	Article						NMDA receptors; NR1; NR2; alternative splicing; retina; antisense targeting; optic nerve crush; in situ hybridization; RT-PCR; Western blots; lesion	EXPERIMENTAL BRAIN INJURY; EXCITATORY AMINO-ACIDS; SUBUNIT MESSENGER-RNA; D-ASPARTATE RECEPTORS; N-TERMINAL DOMAIN; ADULT-RAT RETINA; PROTEIN-KINASE-C; NMDA RECEPTOR; GLUTAMATE-RECEPTOR; OPTIC-NERVE	Cellular-specific splicing of the retinal NMDAR1 receptor (NR1) and expression of NMDAR2 receptor (NR2) subunits in response to optic nerve injury was investigated by in situ hybridization in adult rats. A controlled optic nerve crush led to a clear alteration in the expression of alternatively spliced NR1 variants in the retinal ganglion cell layer (GCL). The NR1-2b and NR1-4b isoforms were preferentially expressed between 2 d and 1 week after injury, whereas expression for all other isoforms remained either unchanged or decreased to barely detectable levels within 4 weeks. Cellular silver grain density for NR2 subunits also declined in the GCL after trauma. To directly test the hypothesis that NR1b expression is crucial for cell survival after axonal trauma, we administered intraocularly an antisense oligonucleotide against the NR1b isoform 2 and 3 d after injury. This led to a drastic loss of retrogradely labeled retinal ganglion cells (RGCs). Antisense targeting clearly reduced retinal NR1 protein levels, as judged by Western blot analysis, but had no effect on the cell number in control retinas. These findings point toward injury-specific changes in alternative splicing of the NR1 receptor, which are crucial for the survival of RGCs after partial axonal trauma. We therefore propose that this reflects an adaptive, rather than a pathogenic, cellular response to neurotrauma.	Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Otto Von Guericke Univ, Inst Med Psychol, AG Mol & Cellular Neurobiol, D-39120 Magdeburg, Germany; Univ Munster, Inst Anat, AG Mol Neuroendocrinol, D-48129 Munster, Germany		Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, Brennecke Str 6, D-39118 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; AOKI C, 1994, J NEUROSCI, V14, P5202; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BIEN A, 1996, SOC NEUR ABSTR, V126, P2; BIEN A, 1998, IN PRESS J NEUROTRAU; BOCKERS TM, 1994, NEUROREPORT, V5, P965; BRANDSTATTER JH, 1994, EUR J NEUROSCI, V6, P1100, DOI 10.1111/j.1460-9568.1994.tb00607.x; BRESNICK GH, 1989, ARCH OPHTHALMOL-CHIC, V107, P339, DOI 10.1001/archopht.1989.01070010349021; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; DELLAVEDOVA F, 1994, NEUROREPORT, V5, P581; Demediuk P, 1990, Adv Neurol, V52, P225; DREYER EB, 1994, NEUROREPORT, V5, P629, DOI 10.1097/00001756-199401000-00024; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA Y, 1977, BRAIN RES, V119, P327, DOI 10.1016/0006-8993(77)90314-6; GENNARALLI TA, 1989, J NEUROSURG, V7, P244; GRACY KN, 1995, J COMP NEUROL, V362, P71, DOI 10.1002/cne.903620105; HAMASSAKIBRITTO DE, 1993, J NEUROSCI, V13, P1888; HARTVEIT E, 1995, EUR J NEUROSCI, V7, P1472, DOI 10.1111/j.1460-9568.1995.tb01142.x; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUGHES TE, 1992, VISUAL NEUROSCI, V8, P49, DOI 10.1017/S0952523800006489; KALLONIATIS M, 1993, J COMP NEUROL, V336, P174, DOI 10.1002/cne.903360203; Kraus JE, 1996, MOL BRAIN RES, V41, P97, DOI 10.1016/0169-328X(96)00072-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; Massey S.C., 1990, Progress in Retinal Research, V9, P399, DOI 10.1016/0278-4327(90)90013-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULLER F, 1992, NEUROSCI LETT, V138, P179, DOI 10.1016/0304-3940(92)90500-7; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; PIEHL F, 1995, EUR J NEUROSCI, V7, P2101, DOI 10.1111/j.1460-9568.1995.tb00632.x; SABEL BA, 1995, EXP BRAIN RES, V106, P93; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZVIVES MV, 1994, EUR J NEUROSCI, V6, P9, DOI 10.1111/j.1460-9568.1994.tb00243.x; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SCHOBER W, 1977, Zeitschrift fuer Mikroskopisch-Anatomische Forschung (Leipzig), V91, P397; Schwartz M, 1996, INVEST OPHTH VIS SCI, V37, P2245; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; SILVEIRA LCL, 1994, J NEUROCYTOL, V23, P75, DOI 10.1007/BF01183863; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUGIOKA K, 1992, J MATER RES, V7, P185, DOI 10.1557/JMR.1992.0185; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TRAYNELIS SF, 1995, SCIENCE, V268, P877; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P2382; Wang JKT, 1996, J NEUROCHEM, V66, P865; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; ZIMMER M, 1995, GENE, V159, P219, DOI 10.1016/0378-1119(95)00044-7; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	66	59	59	0	0	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 15	1998	18	20					8278	8291					14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	126WL	WOS:000076317600016	9763472				2022-02-06	
J	Stover, JF; Stocker, R				Stover, JF; Stocker, R			Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						head injury; barbiturate coma	BETA-LACTAM ANTIBIOTICS; ANESTHETICS; METABOLISM; INVITRO; PHARMACOKINETICS; METRONIDAZOLE; COMPLICATIONS; INHIBITION; THERAPY; DISEASE	Objectives: Barbiturate coma is employed in brain-injured patients whenever increases in intracranial pressure remain unresponsive to less aggressive therapeutic regimens. Barbiturate-mediated neuroprotection, however, is weakened by an increased infection rate related to barbiturate-induced immunosuppression. Coadministration of barbiturates with antibiotics known to induce bone marrow suppression could, in turn, potentiate barbiturate-mediated immunosuppression. Adverse drug reactions and interactions of thiopental with antibiotics in terms of leukopenia, infection rate, and bone marrow suppression were investigated. Methods: White blood cells were measured daily, tracheobronchial secretion and urine were examined for bacterial growth twice a week or if an infection was suspected. Results: A total of 52 patients with severe isolated head injury were consecutively investigated. Due to increased intracranial pressure (ICP), which did not respond to analgosedation, barbiturate coma was performed in 23 cases. The other 29 patients remained analgosedated. Leukocytes and neutrophils were reversibly and significantly decreased in all patients, mostly sustained under thiopental. The pulmonary infection rate due to Gramnegative organisms was nearly doubled during barbiturate coma. Reversible agranulocytosis and bone marrow suppression attributed to antibiotics developed in six patients after thiopental administration. Mortality rate, however, was not increased by these adverse effects. Conclusions: Barbiturate coma may cause reversible leukopenia and an increased infection rate. Long-term administration of thiopental may also promote reversible antibiotic-induced bone marrow suppression. The mechanisms and site of interaction between thiopental and antibiotics cannot be assessed by the present study and remain to be clarified. However, during and after barbiturate coma, close monitoring of leukocytes and infections and careful selection of antibiotics is required.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland		Stover, JF (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.						BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; BURCH PG, 1983, ANESTHESIOLOGY, V58, P146, DOI 10.1097/00000542-198302000-00008; CHIU PJS, 1977, ANTIMICROB AGENTS CH, V11, P821, DOI 10.1128/AAC.11.5.821; COHEN PJ, 1973, ANESTHESIOLOGY, V39, P153, DOI 10.1097/00000542-197308000-00007; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421, DOI 10.1152/ajpheart.1985.249.2.H421; EBERHARDT KEW, 1992, INFECTION, V20, P16; EPSTEIN B, 1955, J CLIN INVEST, V34, P500; FARRELL G, 1984, HEPATOLOGY, V4, P722, DOI 10.1002/hep.1840040427; HORBER FF, 1989, EUR J CLIN PHARMACOL, V36, P389, DOI 10.1007/BF00558301; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; KRESS HG, 1987, ANAESTHESIST, V36, P356; LEBOWITZ PW, 1983, ANESTHESIOLOGY, V59, P381, DOI 10.1097/00000542-198311000-00003; Mandl DL, 1997, ANN PHARMACOTHER, V31, P1321, DOI 10.1177/106002809703101109; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MILLER JD, 1971, BRAIN RES, V34, P411; MOUDGIL GC, 1981, CAN ANAESTH SOC J, V28, P597, DOI 10.1007/BF03007159; NEFTEL KA, 1985, J INFECT DIS, V152, P90, DOI 10.1093/infdis/152.1.90; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; OLAISON L, 1990, J ANTIMICROB CHEMOTH, V25, P449, DOI 10.1093/jac/25.3.449; ROSENBERG PJ, 1977, ANESTHESIOLOGY, V46, P322, DOI 10.1097/00000542-197705000-00003; ROWLAND M, 1990, CLIN PHARMACOKINET, V18, P184, DOI 10.2165/00003088-199018030-00002; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHNEIDER MU, 1984, CHEMOTHERAPY, V30, P345, DOI 10.1159/000238292; SINGH N, 1993, AM J MED, V94, P251, DOI 10.1016/0002-9343(93)90056-U; STOCKER R, 1995, INTEGRATED APPROACH, P196; SUTTON LN, 1987, J NEUROSURG, V67, P381, DOI 10.3171/jns.1987.67.3.0381; TABURET AM, 1989, CLIN PHARMACOL THER, V45, P373, DOI 10.1038/clpt.1989.43; TODD MM, 1987, NEUROSURGERY, V20, P559, DOI 10.1227/00006123-198704000-00009; WHITE CM, 1980, BRIT MED J, V280, P647, DOI 10.1136/bmj.280.6214.647-b; WISE R, 1991, ANTIMICROB AGENTS CH, V35, P1081, DOI 10.1128/AAC.35.6.1081	32	59	61	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0031-6970			EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	SEP	1998	54	7					529	534		10.1007/s002280050508			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	134NL	WOS:000076749400007	9832294				2022-02-06	
J	Cecil, KM; Lenkinski, RE; Meaney, DF; McIntosh, TK; Smith, DH				Cecil, KM; Lenkinski, RE; Meaney, DF; McIntosh, TK; Smith, DH			High-field proton magnetic resonance spectroscopy of a swine model for axonal injury	JOURNAL OF NEUROCHEMISTRY			English	Article						diffuse axonal injury; N-acetylaspartate; spectroscopy	TRAUMATIC BRAIN INJURY; L-ASPARTIC ACID; HEAD-INJURY; N-ACETYLASPARTATE; RAT-BRAIN	A miniature swine model for diffuse brain injury has recently been developed that replicates the inertial loading conditions associated with relational acceleration during automotive accidents. The swine model induces diffuse axonal pathology without macroscopic injury such as contusions and hematomas, thus affording a unique opportunity to study axonal injury with noninvasive techniques such as magnetic resonance imaging (MRI) and spectroscopy (MRS). In the present study, we evaluated this diffuse injury model with proton MRS, in vivo, using a high-field (4.0-T) MR scanner, since MRS has been demonstrated as a sensitive probe for detecting neurochemical abnormalities. Our study examined a region of the swine brain at timepoints before and after brain injury. Spectroscopic results indicate that N-acetylaspartate/creatine is diminished by at least 20% in regions of confirmed axonal pathology, whereas conventional MRI did not detect any abnormalities. These findings suggest that MRS has high sensitivity in diagnosing microscopic pathology following diffuse brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,Suite 105, Philadelphia, PA 19104 USA.		Lenkinski, Robert/F-9045-2014; smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122; Cecil, Kim/0000-0001-8233-5485; Lenkinski, Robert/0000-0001-7371-5048	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR02305] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CECIL KM, 1997, P INT SOC MAGN RES M, P1199; CECIL KM, 1998, IN PRESS J NEUROSURG; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CLARKE DD, 1975, J NEUROCHEM, V24, P479, DOI 10.1111/j.1471-4159.1975.tb07665.x; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; FRAHM J, 1991, NMR BIOMED, V4, P201, DOI 10.1002/nbm.1940040408; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; Hochachka P.W., 1980, LIVING OXYGEN CLOSED; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEWIS LD, 1974, J NEUROCHEM, V23, P673, DOI 10.1111/j.1471-4159.1974.tb04390.x; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; PERRY TL, 1971, J NEUROCHEM, V18, P521, DOI 10.1111/j.1471-4159.1971.tb11980.x; RABINOWITZ JL, 1976, BIOCHEM J, V157, P271, DOI 10.1042/bj1570271; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; SMITH DH, 1995, J NEUROTRAUM, V12, P967; SMITH DH, 1994, J NEUROTRAUM, V11, P128; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; URENJAK J, 1992, J NEUROCHEM, V59, P55, DOI 10.1111/j.1471-4159.1992.tb08875.x; WHEREAT AF, 1967, J BIOL CHEM, V242, P4013	36	59	65	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAY	1998	70	5					2038	2044					7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZJ393	WOS:000073210500030	9572290				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Neuroprotective effects of MgSO4 and MgCl2 in closed head injury: A comparative phosphorus NMR study	JOURNAL OF NEUROTRAUMA			English	Article						brain; magnetic resonance; trauma; magnesium; treatment	TRAUMATIC BRAIN INJURY; NUCLEAR-MAGNETIC-RESONANCE; DIFFUSE AXONAL INJURY; FREE MAGNESIUM; INTRACELLULAR MAGNESIUM; SMOOTH-MUSCLE; FREE MG-2+; RATS; METABOLISM; ISCHEMIA	Previous studies have shown that free magnesium levels decline after traumatic brain injury and that magnesium salt administration improves posttraumatic outcome. These earlier studies, however, have been limited to models of injury that do not produce a significant degree of diffuse axonal injury and have used either MgSO4 or MgCl2 as the magnesium salt. The present study compares the neuroprotective efficacy of MgSO4 and MgCl2 in a severe model of diffuse axonal injury in rats using phosphorus nuclear magnetic resonance spectroscopy and the rotarod test to monitor effects on metabolism and neurologic outcome, respectively. Both MgSO4 and MgCl2 given as a bolus of 100 mu moles/kg at 30 min after severe, closed head injury significantly improved brain intracellular free magnesium concentration and neurologic outcome. These findings suggest that both salts penetrate the blood-brain barrier after brain trauma, enter injured tissue, and subsequently improve neurologic outcome.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia		Heath, DL (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; Bara M., 1984, MAGNESIUM, V3, P212; Bara Michel, 1994, Magnesium Research, V7, P11; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Corbett RJT, 1996, NEUROREPORT, V8, P287; CUNNINGHAM CC, 1986, ALCOHOL CLIN EXP RES, V10, P246, DOI 10.1111/j.1530-0277.1986.tb05084.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FAGIAN MM, 1986, BIOCHIM BIOPHYS ACTA, V852, P262, DOI 10.1016/0005-2728(86)90231-8; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARFINKEL L, 1985, Magnesium, V4, P60; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, CENTRAL NERVOUS SYST, P173; HEADRICK JP, 1991, J MOL CELL CARDIOL, V23, P991, DOI 10.1016/0022-2828(91)91635-5; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; PETROFF OAC, 1985, NEUROLOGY, V35, P1681, DOI 10.1212/WNL.35.12.1681; Povlishock JT, 1996, ACT NEUR S, V66, P81; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; WALLIS RA, 1996, J NEUROTRAUM, V13, P626; WILLIAMS GD, 1995, MAGNET RESON MED, V33, P853, DOI 10.1002/mrm.1910330618; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	48	59	65	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					183	189		10.1089/neu.1998.15.183			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500003	9528918				2022-02-06	
J	Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG				Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG			Predictors of family functioning after traumatic brain injury in children and adolescents	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children; adolescents; psychiatric disorder; family function	RELIABILITY; SEVERITY; SCALE	Objective: To assess factors predictive of family outcome in the first 2 years after traumatic brain injury (TBI) in children and adolescents. Method: Subjects were children aged 6 to 14 at the time they were hospitalized after TBI. The study used a prospective follow-up design. Assessments of preinjury factors (psychiatric, family functioning, and family life events), injury factors (severity of injury), and postinjury factors (coping and development of a psychiatric disorder, never before present, i.e., "novel") were conducted using standard clinical scales. The outcome measure was family function as assessed with standardized family functioning interviews (at 12 and 24 months after TBI) and primary caretaker self-report questionnaires (at 3 and 6 months after TBI). Results: Fifty subjects enrolled, and the analyses focused on 37, 41, 43, and 42 subjects assessed at the 3-, 6-, 12-, and 24-month follow-up evaluations, respectively. The strongest influences on family functioning after childhood TBI are preinjury family functioning, the development of a "novel" psychiatric disorder in the child, and preinjury family life events or stressors. Conclusions: These data suggest that there are families, identifiable through clinical assessment, at increased risk for family dysfunction after a child's TBI. Early identification and treatment of the child's psychopathology and family dysfunction may attenuate the associated morbidity.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA; SW Missouri State Univ, Springfield, IL USA; Cedar Ctr, Psychiat Grp, Cedar Rapids, IA USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BARRY CT, 1997, INT NEUR SOC 25 ANN; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; KRAUS JF, 1987, PEDIATRICS, V79, P501; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, IN PRESS J AM ACAD C; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609	25	59	59	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1998	37	1					83	90		10.1097/00004583-199801000-00021			8	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	YW319	WOS:000071922000020	9444904				2022-02-06	
J	Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ				Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ			Measurement and treatment of agitation following traumatic brain injury .2. A Survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HALOPERIDOL; SCALE	Objective: Determine national patterns of measuring and treating agitation after traumatic brain injury (TBI) by physiatrists with expressed interest in treating TBI survivors. Design: A 70% random sample of members of the Brain Injury Special interest Group of the American Academy of Physical Medicine and Rehabilitation was surveyed by telephone. Main Outcome Measure: The survey instrument was designed to determine the most common pharmacologic interventions for agitation and, where possible, match each drug with the target behavioral and cognitive characteristics for which it is prescribed. Data were also collected on the manner in which participants measured agitation and judged treatment efficacy. Results: One hundred twenty-nine of 157 responded, yielding an 82% response rate. The majority of respondents were not measuring agitation in a standard fashion. The five most frequently prescribed drugs by the expert stratum were carbamazepine, tricyclic antidepressants (TCAs), trazodone, amantadine, and beta-blockers. In comparison, the nonexperts most often reported prescribing carbamazepine, beta-blockers, haloperidol, TCAs, and benzodiazepines. Desyrel (p = .06) and amantadine (p = .001) were significantly mon likely to be chosen by experts than by nonexperts. Experts chose haloperidol significantly less often than nonexperts (p = .01). Prescription of sedating drugs such as haloperidol or benzodiazepines was not found to be associated with the acuity of injury of TBI patients in the respondent's practice, practice setting, or years of practice since completing residency. Choice of haloperidol to treat agitation was not significantly associated with the degree to which explosive anger, verbal aggression, or physical aggression were considered important to the respondent's definition of agitation. Conclusions: The majority of physiatrists surveyed did not formally measure agitation. Treatment strategies differ significantly between general physiatrists and those who specialize in the treatment of patients with TBI. The breadth of pharmacologic agents and strategies identified in this survey probably reflects the lack of research specific to the pathophysiology of the disorder of posttraumatic agitation. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PREVENT MED,COLUMBUS,OH 43210; UNIV MISSOURI,MED INFORMAT GRP,COLUMBIA,MO		Fugate, LP (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,1018 DODD HALL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Mysiw, Walter/E-3724-2011; Levy, Carlos/AAN-7226-2020	Johnson, Jane/0000-0002-8825-5926	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD007892] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD07892-01] Funding Source: Medline		CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DILLMAN DA, 1978, MAIL TELEPHONE SURVE, P173; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	7	59	60	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1997	78	9					924	928		10.1016/S0003-9993(97)90051-4			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	XV776	WOS:A1997XV77600002	9305262				2022-02-06	
J	Gerszten, PC; Albright, AL; Barry, MJ				Gerszten, PC; Albright, AL; Barry, MJ			Effect on ambulation of continuous intrathecal baclofen infusion	PEDIATRIC NEUROSURGERY			English	Article						ambulation; baclofen; cerebral palsy; traumatic brain injury	SELECTIVE POSTERIOR RHIZOTOMY; SEVERE SPINAL SPASTICITY; CEREBRAL-PALSY; ORIGIN	Intrathecal baclofen (ITB) infusion has been shown to be an effective treatment for spasticity secondary to both cerebral palsy and spinal cord injury. Its effect on the ambulatory status of individuals with cerebral spasticity, however, has not previously been addressed. We reviewed the effect of ITB on functional ambulation in 24 patients who were ambulatory to some extent, either with or without assistive devices. Twenty-one pumps were placed in patients with spastic cerebral palsy and 3 in patients with spasticity secondary to traumatic brain injury (13 boys and 11 girls, mean age 18 years). The mean ITB dose was 200 mu g/day (range 22-550 mu g/day) and the mean length of follow-up was 52 months. Ambulation was retrospectively graded on four functional levels: community, household, non-functional, and non-ambulatory. The level of ambulation improved by one functional level in 9 patients, did not change for 12 patients, and was worse in 3 patients. Gait was considered to be improved in 20 of 24 patients by the patients or their families. The overall functional improvement not directly related to ambulation was found to be improved in 20 patients, unchanged in 2 patients, and worse in 2 patients. ITB allows for improved ambulation in a certain subset of patients with lower extremity spasticity. It is not contraindicated in patients who rely upon their spasticity for support during ambulation. ITB infusion allows for baclofen dosage titration to balance between extensor tone for support and suppression of hyperactive reflexes which may impede normal locomotion.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA		Albright, AL (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, 375 5th Ave, Pittsburgh, PA 15213 USA.						ALBRIGHT AL, 1995, PEDIATR NEUROSURG, V23, P82; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Bodensteiner JB, 1996, J CHILD NEUROL, V11, P75, DOI 10.1177/088307389601100201; Burke D., 1988, FUNCTIONAL RECOVERY, P401; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DIETZ V, 1992, MED SPORT SCI, V36, P225; Feldman RG, 1980, SPASTICITY DISORDERE, P41; GAGE JR, 1991, GAIT ANAL CEREBRAL P, P1; HOFFER MM, 1973, J BONE JOINT SURG AM, VA 55, P137, DOI 10.2106/00004623-197355010-00014; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; LANDAU WM, 1988, NEUROLOGY, V38, P1496, DOI 10.1212/WNL.38.9.1496; LATASH ML, 1990, J NEUROSURG, V72, P388, DOI 10.3171/jns.1990.72.3.0388; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MEYTHALER JM, 1992, ARCH PHYS MED REHAB, V73, P794; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Shetter AG, 1996, NEUROSURG QUART, V6, P194, DOI 10.1097/00013414-199609000-00003; SHETTER AG, 1993, PERSPECT NEUROL SURG, V4, P109; STEINBOK P, 1991, CAN J NEUROL SCI, V18, P232	28	59	60	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	JUL	1997	27	1					40	44		10.1159/000121223			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	YV064	WOS:000071786000006	9486835				2022-02-06	
J	Lomnitski, L; Kohen, R; Chen, Y; Shohami, E; Trembovler, V; Vogel, T; Michaelson, DM				Lomnitski, L; Kohen, R; Chen, Y; Shohami, E; Trembovler, V; Vogel, T; Michaelson, DM			Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article; Proceedings Paper	2nd European Pharmacology Biochemistry and Behavior Conference	JAN 05-12, 1997	MORZINE, FRANCE			Alzheimer's disease; apolipoprotein; head trauma; apolipoprotein E-deficient mice; reducing currents; antioxidants	FAMILIAL ALZHEIMERS-DISEASE; OXIDATIVE STRESS; METABOLISM; EXPRESSION	Recent animal model studies using apolipoprotein E (apoE)-deficient (knockout) mice revealed that these mice have memory deficits and neurochemical derangements and that they recover from closed head injury less adequately than control mice. In the present study, we examined the possibility that the diminished recovery of apoE-deficient mice from head injury is related to a reduction in their ability to counteract oxidative damage. Measurements of reducing agents by cyclic voltammetry revealed that cortical homogenates of apoE-deficient and control mice contain similar levels of these compounds, whose oxidation potentials for the two groups of mice are at 400 +/- 40 mV and 900 +/- 50 mV. The responses of the apoE-deficient and control groups to closed head injury were both biphasic and were composed of initial reductions followed by subsequent increases in the levels of reducing antioxidant equivalents. However, the two groups differed markedly in the magnitude of their response. This difference was most pronounced with the 400-mV reducing compounds, such that at 4 h after injury their levels in injured control mice increased over twofold relative to the noninjured control mice, whereas the corresponding anodic current of the apoE-deficient mice recovered only to its original level and did not increase further even by 24 h after injury. In vitro studies using recombinant apoE allele E3 and beta very low density lipoprotein revealed that this lipoprotein can delay Cu2+-induced lipid peroxidation. This suggests that the inability of the apoE-deficient mice to respond to brain injury by a surge in brain reducing compounds may be related, at least in part, to direct antioxidant activity of apoE. (C) 1997 Elsevier Science Inc.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT NEUROBIOCHEM,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACEUT,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACOL,JERUSALEM,ISRAEL; GEN BIOTECHNOL,REHOVOT,ISRAEL								BEITYANNAI E, 1995, J CEREBR BLOOD FL S1, V15, pS713; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BONDY SC, 1995, P SOC EXP BIOL MED, V208, P337; CHEN Y, IN PRESS NEUROSCIENC; CHEVION S, 1997, IN PRESS FREE RADIC; CLARKE GA, 1993, EUR J CELL BIOL, V61, P108; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FAINARU M, 1988, ARTERIOSCLEROSIS, V8, P130, DOI 10.1161/01.ATV.8.2.130; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; KOHEN R, 1993, J HARM TOXICOL METHO, V29, P485; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LOMNITSKI L, 1997, NEUROCHEMISTRY; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Pinchuk I, 1996, FREE RADICAL RES, V24, P351, DOI 10.3109/10715769609088033; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696	25	59	61	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	APR	1997	56	4					669	673		10.1016/S0091-3057(96)00412-1			5	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	WV401	WOS:A1997WV40100018	9130293				2022-02-06	
J	Ohkawa, S; Fukatsu, K; Miki, S; Hashimoto, T; Sakamoto, J; Doi, T; Nagai, Y; Aono, T				Ohkawa, S; Fukatsu, K; Miki, S; Hashimoto, T; Sakamoto, J; Doi, T; Nagai, Y; Aono, T			5-aminocoumarans: Dual inhibitors of lipid peroxidation and dopamine release with protective effects against central nervous system trauma and ischemia	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; ALPHA-TOCOPHEROL; ANTIOXIDANT ACTIVITY; VITAMIN-E; FOREBRAIN ISCHEMIA; RAT-BRAIN; DERIVATIVES; INJURY; METHAMPHETAMINE; NEUROTOXICITY	A series of 2,3-dihydro-5-benzofuranamines (5-aminocoumarans) were developed for the treatment of traumatic and ischemic central. nervous system (CNS) injury. Compounds within this class were extremely effective inhibitors of lipid peroxidation in vitro and antagonized excitatory behavior coupled with peroxidative injury induced by spinal intrathecal injection of FeCl2 (mouse-FeCl2-it assay) in vivo. Selected compounds were tested for antagonistic activity on methamphetamine (MAP)-induced hypermotility resulting from dopamine release in the mouse brain. Among the compounds synthesized, compound 26n (2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidinyl)meth]-5-benzofuranamine) exhibited potent effects in these assays (inhibition of lipid peroxidation, IC50 = 0.07 mu M; mouse-FeCl2-it assay, ID50 = 10.4 mg/kg, po; MAP-induced hypermotility, 98% inhibition, 10 mg/kg, ip). The S-(+)-form of compound 26n dihydrochloride (TAK-218), which has 30 times more potent antagonistic activity on MAP-induced hypermotility than the R-(-)-form, improved more significantly the survival rate in the cerebral ischemia model (rat, 1-3 mg/kg, ip) during the period of 1-14 days after ischemia and decreased functional disorders in the traumatic brain injury model (rat, 0.1-1 mg/kg, ip) 3-14 days after injury. These results imply a role for dopamine in deterioration of CNS function after ischemic and traumatic injury. TAK-218 is a promising compound for the treatment of stroke and CNS trauma and is now under clinical investigation.			Ohkawa, S (corresponding author), TAKEDA CHEM IND LTD, PHARMACEUT RES LABS 1, YODOGAWA KU, 17-85 JUSOHONMACHI 2 CHOME, OSAKA 532, JAPAN.						BETTS W H, 1985, Journal of Free Radicals in Biology and Medicine, V1, P273, DOI 10.1016/0748-5514(85)90131-X; BLOCK F, 1995, BRAIN RES BULL, V36, P257, DOI 10.1016/0361-9230(94)00200-K; BROMONT C, 1989, STROKE, V20, P918, DOI 10.1161/01.STR.20.7.918; BURTON GW, 1983, J AM CHEM SOC, V105, P5950, DOI 10.1021/ja00356a057; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CADET JL, 1994, J NEUROCHEM, V62, P380; CHOI DW, 1987, J NEUROSCI, V7, P369; CLEMENS JA, 1988, LIFE SCI, V42, P707, DOI 10.1016/0024-3205(88)90463-8; CLEMENS JA, 1993, STROKE, V24, P716, DOI 10.1161/01.STR.24.5.716; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; DEARDEN JC, 1978, EUR J MED CHEM, V13, P415; DENISOV ET, 1987, CHEM REV, V87, P1313, DOI 10.1021/cr00082a003; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FORT AW, 1961, J ORG CHEM, V26, P332, DOI 10.1021/jo01061a014; FUKUDA N, 1985, JPN PHARMACOL THER, V13, P5021; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; GRISAR JM, 1991, J MED CHEM, V34, P257, DOI 10.1021/jm00105a040; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1986, EXP BRAIN RES S, V13, P63; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HEGEDUS LS, 1976, J AM CHEM SOC, V98, P3901, DOI 10.1021/ja00429a028; INGOLD KU, 1986, FEBS LETT, V205, P117, DOI 10.1016/0014-5793(86)80877-8; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; LEROSEN AL, 1948, J AM CHEM SOC, V70, P2705, DOI 10.1021/ja01188a025; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; MUKAI K, 1987, B CHEM SOC JPN, V60, P2163, DOI 10.1246/bcsj.60.2163; MUKAI K, 1988, CHEM PHYS LIPIDS, V46, P31, DOI 10.1016/0009-3084(88)90110-7; OHKAWA S, 1991, J MED CHEM, V34, P267, DOI 10.1021/jm00105a042; OKAMOTO K, 1986, CHEM PHARM BULL, V34, P2821; OSHIRO Y, 1991, J MED CHEM, V34, P2014, DOI 10.1021/jm00111a014; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; RUBIN JJ, 1980, EXP NEUROL, V67, P472, DOI 10.1016/0014-4886(80)90119-3; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SHULGIN AT, 1960, J ORG CHEM, V25, P2037, DOI 10.1021/jo01081a605; SKINNER WA, 1970, EXPERIENTIA, V26, P502, DOI 10.1007/BF01898471; Smith LI, 1940, J AM CHEM SOC, V62, P1863, DOI 10.1021/ja01864a064; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; WAUQUIER A, 1988, ANN NY ACAD SCI, V522, P478; WEINBERGER J, 1985, STROKE, V16, P864, DOI 10.1161/01.STR.16.5.864; WEINGARTEN H, 1967, J ORG CHEM, V32, P3246, DOI 10.1021/jo01285a088; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WOODWARD B, 1985, J MOL CELL CARDIOL, V17, P485, DOI 10.1016/S0022-2828(85)80053-5; YAO H, 1988, EXPERIENTIA, V44, P506, DOI 10.1007/BF01958929	47	59	59	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	FEB 14	1997	40	4					559	573		10.1021/jm960411j			15	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	WH748	WOS:A1997WH74800020	9046347				2022-02-06	
J	Sandel, ME; Williams, KS; Dellapietra, L; Derogatis, LR				Sandel, ME; Williams, KS; Dellapietra, L; Derogatis, LR			Sexual functioning following traumatic brain injury	BRAIN INJURY			English	Article							STROKE; HEMISPHERE; HEMIPLEGIA	In this study we investigated sexual functioning in 52 outpatients with a history of traumatic brain injury to determine: (1) the prevalence of reported sexual dysfunction; and (2) the relationship between sexual functioning and age, severity and locus of injury, time since injury, and physical and cognitive function. Reports of sexual functioning indicated a reduction below levels within non-injured populations, but only to statistically significant levels on two scales of the Derogatis Interview of Sexual Function (DISF): Orgasm and Drive/Desire. Location of injury was related to sexuality in that patients with frontal lobe lesions reported an overall higher level of sexual satisfaction and functioning than those individuals without frontal lobe lesions. Time since injury was inversely related to reports of levels of sexual arousal; that is, patients with more recent injuries reported greater levels of arousal than those not recently injured. Right hemisphere injuries also correlated with higher scores on reports of sexual arousal and sexual experiences.	MAGEE MEM REHABILITAT CTR,PHILADELPHIA,PA; MED COLL PENN & HAHNEMANN UNIV,PHILADELPHIA,PA 19102		Sandel, ME (corresponding author), HOSP UNIV PENN,DEPT REHABIL MED,5 W GATES,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.						BERROL S, 1989, SEX DISABIL, P203; COSLETT HB, 1986, ARCH NEUROL-CHICAGO, V43, P1036, DOI 10.1001/archneur.1986.00520100048013; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Derogatis L, 1987, DEROGATIS INTERVIEW; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Goddess E, 1979, MED ASPECTS HUMAN SE, V13, P6; Griffith ER, 1990, REHABILITATION ADULT, P206; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; KALLIOMAKI JL, 1961, FERTIL STERIL, V12, P156; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; MONGA TN, 1986, ARCH PHYS MED REHAB, V67, P415; MORRIS PLP, 1992, NEUROPSY NEUROPSY BE, V5, P75; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SANDEL ME, 1996, MED REHABILITATION T, P557; SATZ P, 1962, J CLIN PSYCHOL, V18, P7; SJOGREN K, 1983, SCAND J REHABIL MED, V15, P63; SJOGREN K, 1983, SCAND J REHABIL MED, V15, P55; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; WALKER AE, 1959, J NEUROSURG, V16, P600, DOI 10.3171/jns.1959.16.6.0600; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WILLIAMS JM, 1991, MEMORY ASSESSMENT SC; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P729, DOI 10.1016/0360-3016(90)90503-C	25	59	59	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1996	10	10					719	728		10.1080/026990596123981			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	VH730	WOS:A1996VH73000002	8879662				2022-02-06	
J	Alsop, DC; Murai, H; Detre, JA; McIntosh, TK; Smith, DH				Alsop, DC; Murai, H; Detre, JA; McIntosh, TK; Smith, DH			Detection of acute pathologic changes following experimental traumatic brain injury using diffusion-weighted magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; traumatic brain injury; diffusion; diffuse axonal injury	AXONAL INJURY; HEAD-INJURY; RAT; ARTIFACTS; MODEL; MRI	Standard magnetic resonance imaging (MRI) has been shown to be remarkably insensitive to acute changes following traumatic brain injury. Because diffusion-weighted MRI has recently demonstrated excellent sensitivity to acute ischemic injury and other CNS abnormalities, we evaluated the use of diffusion MRI for the detection of pathologic changes in the rat brain during the first hours following parasagittal fluid percussion brain injury. Diffusion MRI was able to demonstrate a significant diffusion decrease in the primary cortical contusion injury and a comparable decrease in the ipsilateral thalamus. Tissue damage in the thalamus region is much weaker than in the cortex, but the thalamus is a primary site of axonal and dendritic injury in this model. T2 imaging in the same subjects showed slight enhancement in the neighborhood of the injured cortex but was unable to demonstrate injury elsewhere. Diffusion imaging was superior to T2 at demonstrating injury and the prominent diffusion decrease in the thalamus suggests that diffusion MRI is preferentially sensitive to axonal or dendritic injury.	UNIV PENN,MED CTR,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104		Alsop, DC (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007; Alsop, David C/J-5764-2013	Alsop, David C/0000-0002-8206-1995	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS026818, R55NS026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ANDERSON AW, 1994, MAGNET RESON MED, V32, P379, DOI 10.1002/mrm.1910320313; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1994, RADIOLOGY, V191, P1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; KARLICEK RF, 1980, J MAGN RESON, V37, P75, DOI 10.1016/0022-2364(80)90095-5; LATOUR LL, 1994, MAGNET RESON MED, V32, P189, DOI 10.1002/mrm.1910320207; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORI S, 1994, P SOC MAGN RES 1994, P135; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; ORDIDGE RJ, 1994, MAGN RESON IMAGING, V12, P455, DOI 10.1016/0730-725X(94)92539-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WONG EC, 1994, P SMR 2 ANN M SAN FR, P136; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214	27	59	61	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					515	521		10.1089/neu.1996.13.515			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600004	8913968				2022-02-06	
J	Pravdenkova, SV; Basnakian, AG; James, SJ; Andersen, BJ				Pravdenkova, SV; Basnakian, AG; James, SJ; Andersen, BJ			DNA fragmentation and nuclear endonuclease activity in rat brain after severe closed head injury	BRAIN RESEARCH			English	Article						closed head injury; head trauma; apoptosis; cell death; Ca/Mg-dependent endonuclease; nucleus; DNA fragmentation	PROGRAMMED CELL-DEATH; APOPTOSIS; MECHANISMS; ACTIVATION; CALCIUM; CYCLE; MODEL	Previous studies have suggested that brain cells undergo apoptotic cell death during several neurodegenerative disorders such as Alzheimer's disease, Parkinsonism and ischemic stroke. In the present study, apoptotic DNA fragmentation and activation of nuclear endonuclease were evaluated in rat brain cells after head trauma. Severe closed head injury was induced in rats by the impact of a 450-g weight dropped from a height of 2 m. A 12% mortality was experienced after head trauma. Brain cell nuclei and DNA were isolated at intervals of 3, 10, 24 h, 3 and 10 days after head trauma. DNA fragmentation was measured by the random oligonucleotide-primed synthesis (ROPS) assay and was significantly increased with the maximum level of DNA fragmentation occurring at 10 h after trauma. The DNA and nuclei yields decreased 10 h after injury and remained at a reduced level at all subsequent sampling intervals. The DNA fragmentation induced after severe head trauma was accompanied by an increase in the activity of the Ca/Mg-dependent endonuclease associated with apoptosis. These data indicate that severe head injury is associated with significant brain cell death by apoptosis.	UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205; NATL CTR TOXICOL RES,DIV NUTR TOXICOL,US FDA,JEFFERSON,AR 72079; NYU MED CTR,NEW YORK,NY 10016								ALLES A, 1991, FASEB J, V5, P2127, DOI 10.1096/fasebj.5.8.2022310; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1; BASNAKIAN AG, 1994, NUCLEIC ACIDS RES, V22, P2714, DOI 10.1093/nar/22.13.2714; BASNAKIAN AG, 1995, CURRENT PROTOCOLS MO, P1; BREDESEN DE, 1994, APOPTOSIS, V2, P397; BUDHRAMMAHADEO V, 1994, NEUROSCI LETT, V165, P18, DOI 10.1016/0304-3940(94)90699-8; CALNE DB, 1994, NEUROLOGY, V44, P5; DIGUARDO G, 1993, RES VIROLOGY, V144, P409, DOI 10.1016/S0923-2516(06)80057-9; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FAIRBAIRN DW, 1994, FEMS MICROBIOL LETT, V115, P341, DOI 10.1111/j.1574-6968.1994.tb06661.x; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli TA, 1993, HEAD INJURY, P137; GRAHAM A, 1993, DEVELOPMENT, V119, P233; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; HOOPER C, 1990, J NIH RES, V2, P46; KESSLER JA, 1993, NEURON, V11, P1223; KHODAREV N N, 1979, Biokhimiya, V44, P622; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIGHELI A, 1994, J NEUROPATH EXP NEUR, V53, P606, DOI 10.1097/00005072-199411000-00008; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROSE CD, 1993, NEURODEGENERATION, V2, P287; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	33	59	64	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 12	1996	729	2					151	155		10.1016/S0006-8993(96)00222-3			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VE644	WOS:A1996VE64400002	8876983				2022-02-06	
J	Fletcher, JM; Levin, HS; Lachar, D; Kusnerik, L; Harward, H; Mendelsohn, D; Lilly, MA				Fletcher, JM; Levin, HS; Lachar, D; Kusnerik, L; Harward, H; Mendelsohn, D; Lilly, MA			Behavioral outcomes after pediatric closed head injury: Relationships with age, severity, and lesion size	JOURNAL OF CHILD NEUROLOGY			English	Article							FOLLOW-UP; CHILDREN; SEQUELAE; MILD	This study investigated the behavioral outcomes and adaptive functioning of 138 children with mild to severe closed head injury in the 6- to 16-year age range. Each child was evaluated with the Personality Inventory for Children-Revised. A subset of this sample (n = 77) received the Vineland Adaptive Behavior Scales. Results revealed little evidence for group differences based on severity of closed head injury on scales associated with psychopathology on the Personality Inventory for Children-Revised. However, children with severe closed head injury were viewed as experiencing more difficulties than children with mild-moderate closed head injury on those components of the Personality Inventory for Children-Revised most closely associated with cognitive functions. In addition, on the Vineland Adaptive Behavior Scales, severely injured children had lower scores on the Communication and Socialization scales than children with mild-moderate injury, Relationships between the size of frontal and extrafrontal lesions from concurrent magnetic resonance imaging and behavioral outcomes were not apparent. This study suggests that outcome measures assessing adaptive behavior and cognitive functions are more sensitive to severity of closed head injury than parent-based scales of internalizing and externalizing psychopathology.	UNIV TEXAS,SCH MED,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77030; UNIV MARYLAND MED SYST,DIV NEUROSURG,BALTIMORE,MD; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235		Fletcher, JM (corresponding author), UNIV TEXAS,SCH MED,DEPT PEDIAT,6431 FANNIN,MSB 7142,HOUSTON,TX 77030, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BLAU A, 1936, ARCH PSYCHIAT NEUROL, V35, P733; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Damasio H., 1989, LESION ANAL NEUROPSY; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Kahn E, 1934, NEW ENGL J MED, V210, P748, DOI 10.1056/NEJM193404052101405; KLINE RB, 1985, J PEDIATR PSYCHOL, V10, P461, DOI 10.1093/jpepsy/10.4.461; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LACHAR D, 1993, USE PSYCHOL TESTING, P479; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1989, MILD HEAD INJURY, P189; Newby R F, 1986, Arch Clin Neuropsychol, V1, P157, DOI 10.1016/0887-6177(86)90015-6; PEARSON DA, 1994, J SCHOOL PSYCHOL, V32, P33, DOI 10.1016/0022-4405(94)90027-2; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rourke B. P., 1991, LEARNING DISABILITIE; TEASDALE G, 1974, LANCET, V2, P81; WIRT RD, 1990, MULTIDIMENSIONAL DES	25	59	59	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	JUL	1996	11	4					283	290		10.1177/088307389601100404			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	UV227	WOS:A1996UV22700004	8807417				2022-02-06	
J	Romner, B; Bellner, J; Kongstad, P; Sjoholm, H				Romner, B; Bellner, J; Kongstad, P; Sjoholm, H			Elevated transcranial Doppler flow velocities after severe head injury: Cerebral vasospasm or hyperemia?	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; ischemia; hyperemia; head injury; vasospasm; transcranial Doppler	SEVERE BRAIN INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; ARTERIAL SPASM; ULTRASOUND; TOMOGRAPHY; PRESSURE; TIME; COMA	Sixty-seven patients (45 males and 22 females) aged 2 to 70 years (mean 36 years) who had suffered closed head injury were investigated with daily transcranial Doppler (TCD) recordings. A total of 470 TCD recordings (mean 7) were made during Days 1 to 14 after admission. Blood flow velocities were determined in the middle cerebral artery (MCA) and the extracranial internal carotid artery (ICA). Twenty-seven (40%) of the 67 patients demonstrated traumatic subarachnoid hemorrhage (tSAH) on the first computerized tomography (CT) scan after the injury. Flow velocities exceeded 100 cm/second in 22 patients. Eleven (41%) of the 27 patients who showed tSAH on the first CT scan developed velocities greater than 100 cm/second, as compared to 11 (28%) of 40 patients without tSAH on CT. Two patients in whom a thick layer of tSAH was revealed on the first CT scan had MCA flow velocities exceeding 200 cm/second for several days. Measurements of cerebral blood flow (CBF) with single-photon emission CT (SPECT) were performed in six tSAH patients who showed TCD flow velocities exceeding 120 cm/second (uni- or bilaterally) to determine whether the increase in velocity reflected vasospasm or hyperemia. The SPECT studies verified ischemia in five patients but revealed general hyperemia in one. The bilateral increase in MCA flow velocities in the latter case was due to high-volume flow through the MCA secondary to elevated CBF rather than arterial narrowing. In one patient with a thick layer of subarachnoid blood on a CT scan obtained at admission, MCA flow velocities exceeded 220 cm/second bilaterally on Day 8 after the head injury. A SPECT measurement obtained on the same day reflected bilateral ischemia. In this patient flow velocities decreased, with a corresponding normalization of CBF, after 5 days of intravenous nimodipine administration. The MCA/ICA ratio correlated well with the distribution of CBF in the six patients studied using SPECT. This report suggests that vasospasm is an important secondary posttraumatic insult in patients suffering severe head injury and, in some cases, is probably treatable by administration of intravenous calcium channel blockers.	UNIV LUND HOSP,DEPT NEUROPHYSIOL,S-22185 LUND,SWEDEN		Romner, B (corresponding author), UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROLIMUND P, 1988, LANCET, V1, P1173; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; JAMIESON DG, 1989, COMPUT MED IMAG GRAP, V13, P61, DOI 10.1016/0895-6111(89)90079-7; Kakarieka A., 1995, Journal of Neurotrauma, V12, P375; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MASDEU JC, 1994, NEUROLOGY, V44, P1970, DOI 10.1212/WNL.44.10.1970; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	31	59	64	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1996	85	1					90	97		10.3171/jns.1996.85.1.0090			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UT668	WOS:A1996UT66800013	8683288				2022-02-06	
J	Collins, LF; Long, CJ				Collins, LF; Long, CJ			Visual reaction time and its relationship to neuropsychological test performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; CEREBRAL-DYSFUNCTION; RECOVERY	The purpose of this study was to investigate the relationship between simple and choice reaction time (RT) measures and neuropsychological test performance (as assessed by the Impairment Index of the Halstead-Reitan Neuropsychological Test Battery). Both median RT scores and intraindividual variability of RT scores were evaluated in three groups: impaired TBI, nonimpaired TBI, and normal controls. In all three groups, there was a statistically significant correlation between both reaction time measures and level of cognitive functioning. In addition, SRT speed of information processing (as measured by CRT), and intraindividual variability of RT scores continued to be impaired in many brain-damaged individuals who, according to the Impairment Index, had fully recovered from their cognitive deficits. Median RT scores were better able to discriminate between impaired TBI patients and normal controls; bur intraindividual variability of RT scores was better able to discriminate between nonimpaired TBI patients and normal controls. It was concluded that, by adding the two short RT tests to the neuropsychological test battery, more accurate predictions can be made about a patient's level of cognitive functioning and the nature of treatment needed for continued recovery. Copyright (C) 1996 National Academy of Neuropsychology			Collins, LF (corresponding author), UNIV MEMPHIS,DEPT PSYCHOL,MEMPHIS,TN 38152, USA.						BENTON AL, 1958, CONFIN NEUROL, V19, P247; BLACKBURN H L, 1955, Confin Neurol, V15, P327; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; BRUHN P, 1971, CORTEX, V7, P279; ELSASS P, 1986, ACTA NEUROL SCAND, V73, P225; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; GOLDSTEIN G, 1990, HDB PSYCHOL ASSESSME, P197; GRONWALL D, 1974, LANCET, V2, P605; HICKS LH, 1970, PSYCHOL BULL, V74, P377, DOI 10.1037/h0033064; JENSEN AR, 1992, PERS INDIV DIFFER, V13, P869, DOI 10.1016/0191-8869(92)90004-9; MARGOLIN DI, 1992, COGNITIVE NEUROPSYCH, P18; MARGOLIN DI, 1992, COGNITIVE NEUROPSYCH, P9; Miller E, 1970, Cortex, V6, P121; ODONNELL WE, 1984, J CLIN PSYCHOL, V21, P553; POSNER MI, 1982, ANNU REV PSYCHOL, V33, P477, DOI 10.1146/annurev.ps.33.020182.002401; Reitan RM, 1985, HALSTEADREITAN NEURO; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WESTERN SL, IN PRESS ARCH CLIN N; WILLANGER R, 1970, INTELLECTUAL IMPAIRM; [No title captured]	21	59	59	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	7					613	623		10.1016/0887-6177(97)81255-3			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	VT623	WOS:A1996VT62300006	14588445	Bronze			2022-02-06	
J	RAGHUPATHI, R; MCINTOSH, TK; SMITH, DH				RAGHUPATHI, R; MCINTOSH, TK; SMITH, DH			CELLULAR-RESPONSES TO EXPERIMENTAL BRAIN INJURY	BRAIN PATHOLOGY			English	Article							IMMEDIATE-EARLY GENES; HEAT-SHOCK PROTEIN; RAT-BRAIN; C-FOS; STATUS EPILEPTICUS; NERVOUS-SYSTEM; EXPRESSION; HIPPOCAMPUS; ISCHEMIA; JUN	Little is known regarding the molecular (genomic) events associated with the pathophysiology of traumatic brain injury (TBI). This review focusses on the experimental efforts to date elucidating the acute alterations in expression of immediate early genes (IEGs), heat shock proteins (HSPs) and cytokines following experimental brain injury. The immediate early genes, c-fos, c-jun and junB were observed to be bilaterally induced in the cortex and hippocampus as early as 5 min following lateral fluid-percussion (FP) brain injury in the rat. While levels of c-fos and junB mRNA returned to control levels by 2h, c-jun mRNA remained elevated up to 6h post-injury. Increased levels of mRNA for the inducible heat-shock protein (hsp72) were observed up to 12h following injury and were restricted to the cortex ipsilateral to the impact site. Mild induction of the glucose-regulated proteins (grp78 and grp94), which share sequence homology with hsp72, was apparent in the ipsilateral cortex. The cytokines IL-1 beta and TNF alpha were induced at 1h following FP brain injury and remained elevated up to 6h post-injury. These data, while indicative of the complex genomic response to TBI, are also suggestive of the trauma-induced activation of multiple signal transduction pathways.			RAGHUPATHI, R (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,7 HAYDEN HALL,3320 SMITH WALK,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818, NS 08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R55NS026818, R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BENJAMIN IJ, 1989, J CLIN INVEST, V89, P1685; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dekosky S. T., 1994, Society for Neuroscience Abstracts, V20, P193; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; FAN L, 1994, J NEUROTRAUM, V11, P108; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PIERCE JES, 1995, J NEUROTRAUM, V12, P134; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rink A. D., 1994, Society for Neuroscience Abstracts, V20, P250; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; SHENG M, 1989, NEURON, V4, P477; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SUN FY, 1995, BRAIN RES, V661, P63; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	51	59	60	0	1	INT SOC NEUROPATHOLOGY	ZURICH	ISN JOURNAL PO BOX, CH-8033 ZURICH, SWITZERLAND	1015-6305			BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					437	442		10.1111/j.1750-3639.1995.tb00622.x			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400010	8974626				2022-02-06	
J	YAKOVLEV, AG; FADEN, AI				YAKOVLEV, AG; FADEN, AI			MOLECULAR STRATEGIES IN CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article						CNS TRAUMA; DIFFERENTIAL DISPLAY; IN SITU HYBRIDIZATION; NORTHERN BLOT ANALYSIS; NUCLEASE PROTECTION ASSAY; POLYMERASE CHAIN REACTION REVERSE TRANSCRIPTION; SUBTRACTIVE HYBRIDIZATION	SPINAL-CORD INJURY; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; POLYMERASE CHAIN-REACTION; EXCITATORY AMINO-ACIDS; DELAYED NEURONAL DEATH; INVIVO GENE-TRANSFER; FACTOR MESSENGER-RNA; C-FOS PROTEIN; RAT-BRAIN	Traumatic or ischemic injuries to the central nervous system (CNS) initiate reactive biochemical changes, some of which are autodestructive and others neuroprotective. Identification of these endogenous factors and their regulation will help to clarify mechanisms of secondary tissue damage and may lead to novel therapies. Recently developed molecular approaches offer opportunities for identifying genes involved in these reactive processes. Three types of molecular strategies are reviewed and examples are provided to demonstrate how each may be applied to elucidate basic mechanisms underlying posttraumatic or postischemic death.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BABA H, 1994, NEUROCHEM RES, V19, P1091, DOI 10.1007/BF00968721; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793, DOI 10.1523/JNEUROSCI.10-12-03793.1990; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BANTLE JA, 1976, CELL, V8, P739; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Chikaraishi D.M., 1979, BIOCHEMISTRY-US, V18, P3250; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1993, CRITICAL REV NEUROBI, P175; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FRIEDMAN WJ, 1992, J NEUROSCI RES, V33, P37, DOI 10.1002/jnr.490330106; GESCHWIND MD, 1994, MOL BRAIN RES, V24, P327, DOI 10.1016/0169-328X(94)90146-5; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; GINZBERG D, 1994, BRAIN RES, V661, P75; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P154; GUNN AJ, 1990, BRAIN RES, V531, P105, DOI 10.1016/0006-8993(90)90763-2; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; HERRICK CA, 1990, EOS-RIV IMMUNOL, V10, P166; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; ISAACSON SH, 1994, CELL VIS, V1, P25; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KAPLAN BB, 1982, MOL APPROACHES NEURO, P71; LASALLE GL, 1993, SCIENCE, V259, P986; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; NEUMANHAEFELIN T, 1994, J CEREB BLOOD FLOW M, V4, P206; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; NUOVO GJ, 1993, AM J SURG PATHOL, V17, P683, DOI 10.1097/00000478-199307000-00005; OUACH TT, 1993, ANN NY ACAD SCI, V679, P418; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; RAWE SE, 1981, NEUROSURGERY, V9, P40, DOI 10.1227/00006123-198107000-00007; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; RIDOUX V, 1994, NEUROREPORT, V5, P801, DOI 10.1097/00001756-199403000-00016; ROSEN MB, 1994, TOXICOL METHOD, V4, P135, DOI 10.3109/15376519409061541; SANDLER AN, 1967, J NEUROSURG, V5, P638; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SUN FY, 1995, IN PRESS BRAIN RES; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.ne.11.030188.001105; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TORTOSA A, 1994, J NEUROL SCI, V121, P10, DOI 10.1016/0022-510X(94)90149-X; Toulmond S., 1994, Society for Neuroscience Abstracts, V20, P193; UEKI K, 1994, ANN NEUROL, V36, P670, DOI 10.1002/ana.410360421; USUI H, 1994, J NEUROSCI, V14, P4915; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WORLEY PF, 1990, PROG BRAIN RES, V86, P277; WU G, 1993, BIOCHEM CELL BIOL, V71, P372, DOI 10.1139/o93-055; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99	83	59	59	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					767	777		10.1089/neu.1995.12.767			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600002	8594206				2022-02-06	
J	MATHIESEN, T; BENEDIKTSDOTTIR, K; JOHNSSON, H; LINDQVIST, M; VONHOLST, H				MATHIESEN, T; BENEDIKTSDOTTIR, K; JOHNSSON, H; LINDQVIST, M; VONHOLST, H			INTRACRANIAL TRAUMATIC AND NONTRAUMATIC HEMORRHAGIC COMPLICATIONS OF WARFARIN TREATMENT	ACTA NEUROLOGICA SCANDINAVICA			English	Article						BRAIN; HEMORRHAGE; ANTICOAGULATION TREATMENT; COMPLICATION	INTRACEREBRAL HEMORRHAGE; ANTICOAGULANT TREATMENT; THALAMIC HEMORRHAGE; THERAPY; POPULATION	An increased referral of patients with anticoagulation related haemorrhages necessitated an analysis of causes and outcome of these complications in a patient group that reflected Swedish therapeutic traditions of anticoagulation treatment. Prospectively, all patients from Stockholm evaluated for warfarin related intracranial haemorrhage occuring during 1987 were analysed and their 6 month outcome recorded. Sixty-eight patients were included. The results of intracranial haemorrhagic complications were catastrophic with a 77% mortality rate. Their incidence was much higher than expected. Forty-one patients had non-traumatic intracerebral haematomas, 1 had a non-traumatic subarachnoid haemorrhage and 26 had traumatic injuries, In the 42 patients with non-traumatic haemorrhages, the indications for anticoagulation were cerebral ischaemic events in a majority (27/42). The remaining 15 patients had different indications for anticoagulation. They also had an increased frequency of hypertension (p<0.05). In the 26 patients with traumatic haematomas, only 6/26 patients had previous cerebral ischaemic injuries (p<0.01). Valvular heart prothesis was their most common indication (11/26) for anticoagulation. Caution in instituting anticoagulation therapy in patients with hypertension or cerebrovascular disease, which is an important indication for anticoagulation in Sweden, is mandatory. Adherence to strict treatment regimens and their continous reevaluation may help to avoid complications. The finding of more patients than expected with haemorrhagic complications is not compatible with the risk evaluations used to justify anticoagulation therapy in the patient groups studied. Clinical practice must have changed with time, showing that risk evaluations from controlled trials or retrospectively collected clinical data from selected patients are not necessarily applicable for long-term clinical practice.	KAROLINSKA HOSP & INST,DEPT NEUROSURG,STOCKHOLM,SWEDEN; KAROLINSKA HOSP & INST,DEPT NEURORADIOL,STOCKHOLM,SWEDEN; KAROLINSKA HOSP & INST,DEPT INTERNAL MED,STOCKHOLM,SWEDEN				mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919			BARRAQUERBORDAS L, 1981, STROKE, V12, P524, DOI 10.1161/01.STR.12.4.524; BARRON KD, 1959, NEUROLOGY, V9, P447, DOI 10.1212/WNL.9.7.447; BEWERMEYER H, 1989, NERVENARZT, V60, P268; CERVIN A, 1992, LAKARTIDNINGEN, V89, P208; FISHER CM, 1971, J NEUROPATH EXP NEUR, V30, P536, DOI 10.1097/00005072-197107000-00015; FORFAR JC, 1979, BRIT HEART J, V42, P128; FORSTING M, 1991, CEREBROVASC DIS, V1, P97, DOI 10.1159/000108824; FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726; FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972; HIER DB, 1977, ANN NEUROL, V1, P152, DOI 10.1002/ana.410010209; HIRSH J, 1989, CHEST S, V95, P5; JENNETT B, 1981, MANAGEMENT HEAD INJU, P77; KANAYA M, 1983, HYPERTENSIVE INTRACE, P147; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; Levine M N, 1990, Baillieres Clin Haematol, V3, P815, DOI 10.1016/S0950-3536(05)80029-0; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; ROPPER AH, 1980, ANN NEUROL, V8, P141, DOI 10.1002/ana.410080203; SNYDER M, 1977, SURG NEUROL, V7, P31; WALSHE TM, 1977, NEUROLOGY, V27, P217, DOI 10.1212/WNL.27.3.217; WEISBERG LA, 1985, J NEUROL NEUROSUR PS, V48, P1078, DOI 10.1136/jnnp.48.11.1078; WEISBERG LA, 1986, NEUROLOGY, V31, P897; WELLS CE, 1960, ARCH NEUROL-CHICAGO, V3, P553, DOI 10.1001/archneur.1960.00450050073008; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; WINTZEN AR, 1982, ARCH NEUROL-CHICAGO, V39, P69, DOI 10.1001/archneur.1982.00510140003001	26	59	59	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	1995	91	3					208	214					7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QQ561	WOS:A1995QQ56100011	7793238				2022-02-06	
J	HEADRICK, JP; BENDALL, MR; FADEN, AI; VINK, R				HEADRICK, JP; BENDALL, MR; FADEN, AI; VINK, R			DISSOCIATION OF ADENOSINE LEVELS FROM BIOENERGETIC STATE IN EXPERIMENTAL BRAIN TRAUMA - POTENTIAL ROLE IN SECONDARY INJURY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRAUMATIC BRAIN INJURY; ADENOSINE; ADENOSINE AGONISTS	MAGNETIC-RESONANCE SPECTROSCOPY; EXPERIMENTAL HEAD-INJURY; EXCITATORY AMINO-ACIDS; ENERGY-METABOLISM; ENDOGENOUS ADENOSINE; RAT HIPPOCAMPUS; CEREBRAL-CORTEX; NMDA RECEPTORS; RELEASE; ISCHEMIA	Intracellular bioenergetic state and extracellular adenosine levels were monitored in rat brain prior to and following traumatic brain injury (TBI) using phosphorus magnetic resonance spectroscopy and microdialysis, respectively. Fluid percussion-induced TBI (2.6 +/- 0.2 atm) resulted in significant reductions in free cytosolic [Mg2+], cytosolic [ATP]/[ADP][P-i], and Delta G(ATP) and elevations in cytosolic [ADP] and [5'-AMP]. Intracellular ATP concentration and pH did not change significantly after trauma. Mitochondrial capacity for oxidative phosphorylation (indexed by V/V-max) increased significantly from similar to 0.45 prior to injury to similar to 0.58 following TBI. All metabolic changes were maximal at 2-3 h post-TBI. Conversely, extracellular adenosine concentrations increased transiently following TBI, with levels peaking at 10 min posttrauma, then declining rapidly to preinjury values by 50 min. Thus, despite pronounced long-term depression in bioenergetic status and a marked rise in [5'-AMP], formation and release of adenosine were elevated only transiently within the first hour following TBI. Since steady-state adenosine levels were essentially unchanged beyond 1 h posttrauma, mooted neuroprotective actions of endogenous adenosine would be minimized. Intracerebroventricular injections of 2-chloroadenosine (0.5 and 2.5 nmol) immediately prior to TBI dose-dependently attenuated metabolic disturbances and improved posttraumatic neurologic outcome (p < 0.05). The observations indicate that (a) TBI results in dissociation of adenosine release from intracellular bioenergetic state, a phenomenon possibly contributing to secondary injury following TBI; and Co) supplementing brain with an adenosine agonist attenuates irreversible injury.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007		HEADRICK, JP (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT MOLEC SCI,TOWNSVILLE,QLD 4811,AUSTRALIA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634] Funding Source: Medline		BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BURKE SP, 1988, J NEUROCHEM, V51, P1541, DOI 10.1111/j.1471-4159.1988.tb01123.x; CHEN Y, 1992, BRIT J PHARMACOL, V106, P632, DOI 10.1111/j.1476-5381.1992.tb14387.x; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORADETTI R, 1984, EUR J PHARMACOL, V104, P19; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638; DRAGUNOW M, 1988, TRENDS PHARMACOL SCI, V9, P193, DOI 10.1016/0165-6147(88)90079-X; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FASTBOM J, 1986, NEUROSCI LETT, V65, P127, DOI 10.1016/0304-3940(86)90291-0; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1991, AM J PHYSIOL, V260, pH165, DOI 10.1152/ajpheart.1991.260.1.H165; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HSU SSF, 1991, AM J PHYSIOL, V261, pH398, DOI 10.1152/ajpheart.1991.261.2.H398; JHAMANDAS K, 1980, CAN J PHYSIOL PHARM, V58, P1262, DOI 10.1139/y80-193; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MADISON DV, 1987, BIOPHYS J, V51, P30; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, CONT ISSUES NEUROLOG, V1, P35; MILLER LP, 1992, J NEUROTRAUMA, V9, P563; NAGATA H, 1984, J NEUROCHEM, V42, P1001, DOI 10.1111/j.1471-4159.1984.tb12703.x; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NIOKA S, 1991, Neurological Research, V13, P25; PARK TS, 1988, J CEREBR BLOOD F MET, V8, P822, DOI 10.1038/jcbfm.1988.138; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PROCTOR WR, 1983, NEUROSCI LETT, V35, P197, DOI 10.1016/0304-3940(83)90550-5; ROUCHER P, 1991, J CEREBR BLOOD F MET, V11, P453, DOI 10.1038/jcbfm.1991.87; STONE TW, 1981, BRIT J PHARMACOL, V74, P171, DOI 10.1111/j.1476-5381.1981.tb09970.x; STONE TW, 1990, ADENOSINE ADENINE NU, P329; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Van Wylen D G, 1988, Am J Physiol, V255, pH1211; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; VONLUBITZ DKJE, 1988, STROKE, V19, P1133, DOI 10.1161/01.STR.19.9.1133; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; ZUCCHI R, 1990, J MOL CELL CARDIOL, V22, P815, DOI 10.1016/0022-2828(90)90092-G	57	59	60	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1994	14	5					853	861		10.1038/jcbfm.1994.107			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	PC770	WOS:A1994PC77000018	8063880	Bronze			2022-02-06	
J	SCHALEN, W; HANSSON, L; NORDSTROM, G; NORDSTROM, CH				SCHALEN, W; HANSSON, L; NORDSTROM, G; NORDSTROM, CH			PSYCHOSOCIAL OUTCOME 5-8 YEARS AFTER SEVERE TRAUMATIC BRAIN-LESIONS AND THE IMPACT OF REHABILITATION SERVICES	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; SELF-REPORT; AGGRESSIVE TREATMENT; RELATIVES; RECOVERY; FAMILY; MANAGEMENT; MORTALITY; PATIENT	This study addresses three questions. First, what is the long-term psychosocial outcome for severely head-injured patients? Second, is an increased survival rate associated with an increase in the number of patients with a poor quality of life? Third, do rehabilitation services affect the final outcome? The long-term outcome was assessed by means of questionnaires for self-ratings, interviews with patients and relatives and neurophysical examinations. One hundred and six patients initially judged as good recovery/moderate disability (GR/MD) 6 months post-injury participated in the study. Forty to 50% of these patients showed co-ordination disturbances; more than 20% had speech disorders and cranial nerve deficits. Twenty-eight per cent had psychiatric symptom scores on the Hopkins Symptom Checklist (HSCL) indicating need of treatment. Social function according to the Social Adjustment Scale-Self-Report (SAS-SR) showed that 40% had problems concerning interpersonal relations and 20-30% had problems within the field of leisure activities, but few problems were reported on work activities and economy. The Comprehensive Psychopathological Rating Scale (CPRS) revealed that hostile feelings, failing memory and fatiguability were common symptoms and were reported by relatives in 71%, 52% and 48%, respectively, but the mean distress levels were moderate. A correlation was seen between quality of life reported by relatives and the degree of mental and social disability according to the Bond Outcome Scale, but the correlation to neurophysical handicap was rather weak. The majority of patients were able to return to a productive social life. The proportion of patients with a poor long-term outcome did not increase after introduction of an aggressive management protocol for head injuries. Data indicated that improvements in facilities for rehabilitation may positively affect psychosocial adjustment.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT PSYCHIAT, S-22185 LUND, SWEDEN								ASBERG M, 1978, ACTA PSYCHIAT SCAND, V271, P1; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; EISENBERG HM, 1991, J NEUROSURG, V75, pUS1; GLASS RM, 1978, ARCH GEN PSYCHIAT, V35, P1189; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; Goldberg DP, 1972, DETECTION PSYCHIATRI; HANSSON L, IN PRESS PSYCHIATRIC; HESBACHER PT, 1980, J CLIN PSYCHIAT, V41, P6; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1987, BRAIN INJURY, V2, P131; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P1250; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395	43	59	59	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1994	8	1					49	64		10.3109/02699059409150958			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	MQ291	WOS:A1994MQ29100006	8124317				2022-02-06	
J	GANONG, CA; KAPPY, MS				GANONG, CA; KAPPY, MS			CEREBRAL SALT WASTING IN CHILDREN - THE NEED FOR RECOGNITION AND TREATMENT	AMERICAN JOURNAL OF DISEASES OF CHILDREN			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; SUBARACHNOID HEMORRHAGE; INAPPROPRIATE ANTIDIURESIS; CEREBROSPINAL-FLUID; HYPONATREMIA; HORMONE; SECRETION; HUMANS; BRAIN; PRESSURE	Objectives.-To describe a salt-wasting syndrome in children with central nervous system (CNS) insults and to differentiate it from the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and diabetes insipidus so that it may be more readily diagnosed and treated. Design.-Case reports. Setting.-Community teaching hospital. Patients.-Two inpatients with CNS insults (closed head trauma in one and seizure disorder, spastic diplegia, mental retardation, and hydrocephalus in the other). Selection Criteria.-Evidence of hyponatremia accompanied by elevated urine sodium concentration and excessive urine output. Interventions.-Volume-for-volume urine replacement with 0.9% and/or 3% sodium chloride. Oral salt supplementation was required for brief periods to maintain normal plasma sodium concentration after discharge from the hospital. Measurements and Main Results.-Both patients had hyponatremia, high urine sodium concentrations, hypovolemia, and excessive urine output while receiving maintenance fluids. They also had elevated plasma atrial natriuretic hormone (ANH) concentrations, decreased aldosterone concentrations, and increased plasma renin activity for their degree of hyponatremia and negative fluid balance. Both patients maintained normal serum electrolyte concentrations with appropriate treatment. Conclusions.-These patients showed true salt wasting associated with acute or chronic CNS injury, with hormonal patterns consistent with ''inappropriate'' ANH secretion and distinct from the SIADH. It is important to distinguish cerebral salt wasting (CSW) from the two other major disturbances of water metabolism seen following CNS injury (ie, SIADH and diabetes insipidus), because incorrect diagnosis and treatment could greatly increase morbidity in CSW. The etiologic roles of ANH or brain natriuretic peptide in CSW need to be further elucidated.			GANONG, CA (corresponding author), ST JOSEPHS HOSP,CTR CHILDRENS HLTH,DEPT PEDIAT EDUC,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ALMUFTI H, 1984, AM J MED, V77, P740, DOI 10.1016/0002-9343(84)90377-2; ANDERSON JV, 1987, CLIN SCI, V72, P305, DOI 10.1042/cs0720305; ANDREWS BT, 1986, NEUROSURGERY, V18, P469, DOI 10.1227/00006123-198604000-00015; BIOLLAZ J, 1987, KIDNEY INT, V32, P537, DOI 10.1038/ki.1987.242; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; BURRELL LM, 1991, AM J PHYSIOL, V260, pR475, DOI 10.1152/ajpregu.1991.260.3.R475; COGAN E, 1988, AM J MED, V84, P409, DOI 10.1016/0002-9343(88)90260-4; COOPER WC, 1965, ARCH INTERN MED, V116, P113, DOI 10.1001/archinte.1965.03870010115014; CORT JH, 1954, LANCET, V1, P752; DILLINGHAM MA, 1986, SCIENCE, V231, P1572, DOI 10.1126/science.3006248; DOCZI T, 1988, NEUROSURGERY, V23, P16, DOI 10.1227/00006123-198807000-00003; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; GOLBERG M, 1960, NEW ENGL J MED, V263, P1037; KAMOI K, 1990, J CLIN ENDOCR METAB, V70, P1385, DOI 10.1210/jcem-70-5-1385; KAPPY MS, 1989, CLIN RES, V37, pA193; LARAGH JH, 1985, NEW ENGL J MED, V313, P1330; LEVIN ER, 1988, J CLIN ENDOCR METAB, V66, P1080, DOI 10.1210/jcem-66-5-1080; MANGOONIAN C, 1988, J CLIN ENDOCR METAB, V67, P571; MANGOS JA, 1964, PEDIATRICS, V34, P503; MCGREGOR A, 1990, J CLIN ENDOCR METAB, V70, P1103, DOI 10.1210/jcem-70-4-1103; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MULROW PJ, 1987, J STEROID BIOCHEM, V27, P941, DOI 10.1016/0022-4731(87)90171-3; NELSON PB, 1984, J NEUROSURG, V60, P233, DOI 10.3171/jns.1984.60.2.0233; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; OSTER JR, 1983, ARCH INTERN MED, V143, P2187, DOI 10.1001/archinte.143.11.2187; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; SAGNELLA GA, 1986, LANCET, V1, P179; SHIMODA M, 1989, ACTA NEUROCHIR, V97, P53, DOI 10.1007/BF01577740; STIDHAM G, 1987, PEDIATR RES, V21, pA207; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Teran N, 1991, J Cardiothorac Vasc Anesth, V5, P343, DOI 10.1016/1053-0770(91)90157-O; TULASSAY T, 1987, J PEDIATR-US, V111, P329, DOI 10.1016/S0022-3476(87)80449-3; WEIDMANN P, 1986, J CLIN INVEST, V77, P734, DOI 10.1172/JCI112368; WIJDICKS EFM, 1985, ANN NEUROL, V18, P211, DOI 10.1002/ana.410180208; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206; YAMAMOTO N, 1987, Neurological Surgery, V15, P1019	36	59	60	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0002-922X			AM J DIS CHILD	Am. J. Dis. Child.	FEB	1993	147	2					167	169		10.1001/archpedi.1993.02160260057022			3	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	KL363	WOS:A1993KL36300019	8427239				2022-02-06	
J	GALE, SD; BURR, RB; BIGLER, ED; BLATTER, D				GALE, SD; BURR, RB; BIGLER, ED; BLATTER, D			FORNIX DEGENERATION AND MEMORY IN TRAUMATIC BRAIN INJURY	BRAIN RESEARCH BULLETIN			English	Article						HUMAN; TRAUMATIC BRAIN INJURY; MEMORY; MAGNETIC RESONANCE IMAGING; FORNIX	CLOSED-HEAD-INJURY; ATROPHY; SIZE	Fornix-to-brain ratios (FBR) based on postinjury magnetic resonance (MR) studies were calculated on a group of 27 female traumatic brain injury (TBI) patients and 18 female medical controls by taking the widest aspect of the fornix at the level of the anterior horns and third ventricle and determining a fornix surface area. The FBR was significantly reduced in the TBI group (FBR = 0.1121) as compared to the normal control group (FBR = 0. 1766). Despite these significant FBR findings indicating prominent atrophic changes of the fornix in TBI patients, the FBR did not relate systematically to neuropsychological outcome. These findings clearly indicate fornix vulnerability in TBI and that current quantitative MR methods are sensitive enough to detect such changes. However, fornix degeneration constitutes only one of many contributing factors to the anatomic basis of TBI-induced cognitive disturbances, as fornix atrophy did not relate systematically to neuropsychological outcome.	BRIGHAM YOUNG UNIV, DEPT PSYCHOL, 1086 SWKT, PROVO, UT 84602 USA; LDS HOSP, SALT LAKE CITY, UT 84604 USA								Amaral D. G., 1987, HDB PHYSL NERVOUS SY, VV, P211; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E. D., 1989, NEUROPSY NEUROPSY BE, V2, P189; BOTEZMARQUARD T, 1992, ARCH NEUROL-CHICAGO, V49, P321, DOI 10.1001/archneur.1992.00530270141032; CARPENTER MB, 1983, FHUMAN NEUROANATOMY; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS., 1982, NEUROBEHAVIORAL CONS; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Roberts M, 1970, ATLAS HUMAN BRAIN SE; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SQUIRE LR, 1987, HDB PHYSL 1, V5, P295; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; YEO RA, 1991, J CLIN EXP NEUROPSYC, V13, P63	24	59	59	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.		1993	32	4					345	349		10.1016/0361-9230(93)90198-K			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LU134	WOS:A1993LU13400003	8221124				2022-02-06	
J	SEGALOWITZ, SJ; UNSAL, A; DYWAN, J				SEGALOWITZ, SJ; UNSAL, A; DYWAN, J			CNV EVIDENCE FOR THE DISTINCTIVENESS OF FRONTAL AND POSTERIOR NEURAL PROCESSES IN A TRAUMATIC BRAIN-INJURED POPULATION	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; DELAYED-RESPONSE; MEMORY; LESIONS; NEURONS; MONKEYS; LOBES	The association between certain behavioral tests of executive functions in humans and the integrity of the prefrontal lobes has rested primarily on studies comparing subjects with frontal versus other loci of damage. Another approach is to compare the within-group variation on a physiological index of frontal functioning with the behavioral tests of interest. ln the present study, subjects with traumatic brain injury (TBI) were given four behavioural measures of executive function, two measures of posterior nonexecutive function, and a Contingent Negative Variation (CNV) task, a proposed electrophysiological index of frontal-lobe functioning. We found that three of the four executive function tests were significantly related to the CNV, accounting for 23-52% of the variance, while the CNV did not correlate at all with the posterior tasks.			SEGALOWITZ, SJ (corresponding author), BROCK UNIV, DEPT PSYCHOL, ST CATHARINES L2S 3A1, ONTARIO, CANADA.						Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DREWE E A, 1974, Cortex, V10, P159; DYWAN J, 1990, BRAIN COGNITION, V39, P600; DYWAN JA, 1987, J CLIN EXP NEUROPSYC, V9, P270; FANTI B, 1991, IN PRESS NEUROPSYCHO; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; FUSTER JM, 1973, BRAIN RES, V61, P79, DOI 10.1016/0006-8993(73)90517-9; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.2307/1130201; GROLLKNAPP E, 1980, ELECTROEN CLIN NEURO, P746; HAMSHER KD, 1979, ARCH NEUROL-CHICAGO, V36, P837, DOI 10.1001/archneur.1979.00500490051008; Heaton R.K., 1981, WISCONSIN CARD SORTI; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KOJIMA S, 1984, BRAIN RES, V291, P229, DOI 10.1016/0006-8993(84)91255-1; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; LEVIN HS, 1982, NEUROBEHAVIOURAL CON, P3; LOVELESS NE, 1976, ELECTROENCEPHALOGR S, V33, P19; Lutzenberger W, 1980, Prog Brain Res, V54, P427, DOI 10.1016/S0079-6123(08)61655-6; MARKOWITSCH HJ, 1977, PSYCHOL BULL, V84, P817, DOI 10.1037/0033-2909.84.5.817; McCallum W., 1988, HDB ELECTROENCEPHALO, V3, P427; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; MITTENBERG W, 1989, J CLIN EXP NEUROPSYC, V11, P918, DOI 10.1080/01688638908400945; OLBRICH HM, 1986, FORTSCHR NEUROL PSYC, V54, P182, DOI 10.1055/s-2007-1001863; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Rebert CS, 1973, ELECTROENCEPHALOGR S, VS33, P173; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RITTER W, 1980, PSYCHOPHYSIOLOGY, V17, P222, DOI 10.1111/j.1469-8986.1980.tb00138.x; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUCHKIN DS, 1986, ELECTROEN CLIN NEURO, V63, P445, DOI 10.1016/0013-4694(86)90127-6; SEGALOWITZ SJ, 1990, BRAIN COGNITION, V39, P601; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1981, BIOL PSYCHIAT, V16, P1085; STUSS DT, IN PRESS J NEUROPSYC; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TECCE JJ, 1978, HUMAN EVOKED POTENTI, P475; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1974, WECHSLER ADULT INTEL; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIEGERSMA S, 1990, NEUROPSYCHOLOGIA, V28, P95, DOI 10.1016/0028-3932(90)90089-7; WOHLBERG GW, 1973, ARCH GEN PSYCHIAT, V28, P533; YAMAMOTO T, 1986, BRAIN WAVES EEG, V14, P103	54	59	60	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1992	14	4					545	565		10.1080/01688639208402844			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	JK552	WOS:A1992JK55200009	1400918				2022-02-06	
J	MATEER, CA; WILLIAMS, D				MATEER, CA; WILLIAMS, D			EFFECTS OF FRONTAL-LOBE INJURY IN CHILDHOOD	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article								The impact of frontal lobe damage may be viewed in terms of compromise to three general areas of ability: self-regulation, the allocation of attentional resources, and the ability to act on knowledge. These cognitive and behavioral functions are associated with major inputs to frontal structures from specific cortical and subcortical brain regions. Case studies of four children who sustained traumatic frontal lobe injury showed persistent patterns of cognitive and behavioral change marked by impaired attention, academic production deficits, irritability, distractibility, and social problems in the absence of apparent intellectual, linguistic, or perceptual compromise. Persisting deficits, interacting with growth and changes in environmental demands, compromise adaptation in home, school, and other social contexts.			MATEER, CA (corresponding author), GOOD SAMARITAN NEUROPSYCHOL SERV, 1322 3RD ST SE, SUITE 250, PUYALLUP, WA 98372 USA.						Benson D.F., 1986, FRONTAL LOBES; BRICKENKAMP R, 1975, TEST D2 CONCENTRATIO; BRODY EB, 1952, PSYCHOSOM MED, V14, P406, DOI 10.1097/00006842-195209000-00007; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DAMASIO AR, 1985, CLIN NEUROPSYCHOLOGY, P360; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; Golden CJ, 1978, STROOP COLOR WORD TE; HAAS DC, 1975, ARCH NEUROL-CHICAGO, V32, P727, DOI 10.1001/archneur.1975.00490530049003; HAMMILL DD, 1985, DETROIT TESTS APTITU, V2; Kaufman A. S, 1983, KAUFMAN ASSESSMENT B; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A.R., 1973, WORKING BRAIN; MESULAM MM, 1985, PRINCIPLES BEHAVIORA; MEYER D R, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P235; MILLER MH, 1976, PHYSIOL BEHAV, V17, P209, DOI 10.1016/0031-9384(76)90065-2; MILLNER B, 1971, BRIT MED J, V27, P272; MISHKIN M, 1969, NEUROPSYCHOLOGIA, V7, P537; Monroe M., 1966, GROUP DIAGNOSTIC REA; MORGAN D, 1988, TEACHING BEHAVIORALL; REITAN RM, 1964, MANUAL ADM SCORING R; Rey A., 1964, EXAMEN CLIN PSYCHOL; SANTOSTEFANO S, 1987, COGNITIVE CONTROL BA; Schaefer CE, 1989, HDB PARENT TRAINING; SINGH SD, 1976, J PSYCHOL, V51, P144; SLOSSON RL, 1981, SLOSSON INTELLIGENCE; STUSS DT, 1987, BNI Q, V3, P28; WEBSTER R, 1981, LEARNING EFFICIENCY; Wechsler D., 1974, WECHSLER INTELLIGENC	29	59	61	0	19	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1991	7	3					359	376		10.1080/87565649109540498			18	Psychology, Developmental; Psychology; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	GH705	WOS:A1991GH70500006					2022-02-06	
J	RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN				RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN			EVENT RELATED POTENTIALS FROM CLOSED HEAD-INJURY PATIENTS IN AN AUDITORY ODDBALL TASK - EVIDENCE OF DYSFUNCTION IN STIMULUS CATEGORIZATION	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV GLASGOW,DEPT PSYCHOL MED,GLASGOW G12 8QQ,SCOTLAND; DUNDEE ROYAL INFIRM,DEPT SURG NEUROL,DUNDEE,SCOTLAND		RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,MRC,COGNIT NEUROSCI RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.						BRECHER M, 1987, ELECTROEN CLIN NEURO, V66, P369; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CURRY SH, 1983, THESIS U BRISTOL; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; Donchin E., 1978, EVENT RELATED BRAIN, P349; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; Gronwall DM, 1974, PSYCHOL EFFECTS CONS; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; KESELMAN HJ, 1980, PSYCHOPHYSIOLOGY, V17, P499, DOI 10.1111/j.1469-8986.1980.tb00190.x; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1127, DOI 10.1136/jnnp.38.11.1127; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; NAATANEN R, 1975, BIOL PSYCHOL, V2, P237, DOI 10.1016/0301-0511(75)90038-1; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; RITTER W, 1983, PSYCHOPHYSIOLOGY, V20, P168, DOI 10.1111/j.1469-8986.1983.tb03283.x; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V14, P64; [No title captured]	29	59	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1988	51	5					691	698		10.1136/jnnp.51.5.691			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	N5140	WOS:A1988N514000017	3404166	Bronze, Green Published			2022-02-06	
J	RELANDER, M; TROUPP, H; BJORKEST.G				RELANDER, M; TROUPP, H; BJORKEST.G			CONTROLLED TRIAL OF TREATMENT FOR CEREBRAL CONCUSSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									HELSINKI UNIV, CENT HOSP, NEUROSURG CLIN, HELSINKI, FINLAND								CAIRNS H, 1941, P ROY SOC MED, V35, P299; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Guttmann E, 1943, BRIT MED J, V1943, P94; HILTON J, CITED INDIRECTLY; MULLER R, 1956, ARCH NEURO PSYCHIATR, V76, P597; OLESEN S, 1963, UGESKRIFT LAEGER, V64, P123; RELANDER M, 1971, AKTIV BEHANDLING LAT; Russell WR, 1942, BMJ-BRIT MED J, V1942, P521, DOI 10.1136/bmj.2.4269.521; SILFVERSKIOLD BP, 1951, ACTA PSYCHIATRIC S74, P264; SYMONDS C, 1962, LANCET, V1, P1	10	59	59	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal		1972	4	5843					777	779		10.1136/bmj.4.5843.777			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	O3691	WOS:A1972O369100018	4646510	Green Published			2022-02-06	
J	Capizzi, A; Woo, J; Verduzco-Gutierrez, M				Capizzi, Allison; Woo, Jean; Verduzco-Gutierrez, Monica			Traumatic Brain Injury An Overview of Epidemiology, Pathophysiology, and Medical Management	MEDICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Head injury; Acquired brain injury; Concussion; Disorders of consciousness	GALVESTON ORIENTATION; CONSCIOUSNESS; DISORDERS; DIAGNOSIS	Traumatic brain injury (TBI) is an acquired insult to the brain from an external mechanical force that may result in temporary or permanent impairment. The goal of this article is to provide a general review of the epidemiology, pathophysiology and medical management of adult patients with TBI for providers practicing outside the field of physical medicine and rehabilitation. The medical and rehabilitation management of moderate to severe TBI is the focus of this article, with a brief discussion of the management of mild injuries.	[Capizzi, Allison] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Phys Med & Rehabil, 1333 Moursund St, Houston, TX 77030 USA; [Woo, Jean] Baylor Coll Med, H Ben Taub Dept Phys Med & Rehabil, 7200 Cambridge St, Houston, TX 77030 USA; [Verduzco-Gutierrez, Monica] Univ Texas Hlth Sci Ctr Houston, Brain Injury & Stroke Programs, Dept Phys Med & Rehabil, McGovern Med Sch,TIRR Mem Hermann Hosp, 1333 Moursund St, Houston, TX 77030 USA		Verduzco-Gutierrez, M (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brain Injury & Stroke Programs, Dept Phys Med & Rehabil, McGovern Med Sch,TIRR Mem Hermann Hosp, 1333 Moursund St, Houston, TX 77030 USA.	Monica.verduzco-gutierrez@uth.tmc.edu		Verduzco-Gutierrez, Monica/0000-0003-0964-5908			[Anonymous], 2017, MEDICARE BENEFIT POL; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Centers for Disease Control and Prevention, 2014, SURV REP TRAUM BRAIN; Cifu D., 2016, BRADDOMS PHYS MED RE, P964; Compton E, 2018, NURS CLIN N AM, V53, P459, DOI 10.1016/j.cnur.2018.05.003; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cuccurullo SJ, 2010, PHYS MED REHABILITAT, P49; Dixon KJ, 2017, PHYS MED REH CLIN N, V28, P215, DOI 10.1016/j.pmr.2016.12.001; Eapen B., 2018, REHABILITATION TRAUM; Eapen BC, 2017, PHYS MED REH CLIN N, V28, P245, DOI 10.1016/j.pmr.2016.12.003; Fins Joseph J, 2012, Virtual Mentor, V14, P221, DOI 10.1001/virtualmentor.2012.14.3.stas1-1203; Giacino JT, 2018, NEUROLOGY, V91, P450, DOI 10.1212/WNL.0000000000005926; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Hammond FM, 2019, J NEUROTRAUM, V36, P1136, DOI 10.1089/neu.2018.5954; Jackson George L, 2008, N C Med J, V69, P43; Kalra ID, 2017, J HEAD TRAUMA REHAB, V32, pE61, DOI 10.1097/HTR.0000000000000359; Kapoor D, 2014, SINGAP MED J, V55, pE123, DOI 10.11622/smedj.2013264; Katz DI, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P2; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Magee DJ, 2014, ORTHOPEDIC PHYS ASSE, P84; McCrea MA, 2017, PHYS MED REH CLIN N, V28, P271, DOI 10.1016/j.pmr.2016.12.005; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Oberholzer M, 2019, MED SCI, V7, P1; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Tapia RN, 2017, PHYS MED REH CLIN N, V28, P287, DOI 10.1016/j.pmr.2016.12.006; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468	31	58	61	16	39	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0025-7125	1557-9859		MED CLIN N AM	Med. Clin. N. Am.	MAR	2020	104	2					213	+		10.1016/j.mcna.2019.11.001			27	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KR5JE	WOS:000517653900005	32035565		Y	N	2022-02-06	
J	Kuwar, R; Rolfe, A; Di, L; Xu, HY; He, L; Jiang, YQ; Zhang, SJ; Sun, D				Kuwar, Ram; Rolfe, Andrew; Di, Long; Xu, Hongyu; He, Liu; Jiang, Yuqi; Zhang, Shijun; Sun, Dong			A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Neuroinflammation; NLRP3; Inflammasome; Cytokines	INNATE IMMUNE-RESPONSE; PROTEIN-3 INFLAMMASOME; CEREBROSPINAL-FLUID; RAT-BRAIN; ACTIVATION; INTERLEUKIN-1; PATHWAYS; NEUTRALIZATION; CONTRIBUTES; EXPRESSION	BackgroundNeuroinflammation is an essential player in many neurological diseases including traumatic brain injury (TBI). Recent studies have identified that inflammasome complexes are responsible for inflammatory responses in many pathological conditions. Inflammasomes are intracellular multiprotein complexes which regulate the innate immune response, activation of caspase-1, production of pro-inflammatory cytokines IL-1 and IL-18, and induction of cell death (pyroptosis). Among inflammasome family members, the nucleotide-binding domain leucine-rich repeats family protein 3 (NLRP3) is the most extensively studied and its activation is induced following TBI. As a novel target, drug development targeting the formation and activation of NLRP3 inflammasome is a prospective therapy for TBI. We have recently developed a small molecule JC124 with specificity on NLRP3 inflammasome. In this study, we explored the therapeutic value of JC124 for TBI treatment.MethodsAdult male Sprague-Dawley rats were subjected to a moderate cortical impact injury. Following TBI, animals received 4 doses of JC124 treatment with the first dose starting at 30min, the second dose at 6h after TBI, the third and fourth doses at 24 or 30h following TBI, respectively. Animals were sacrificed at 2days post-injury. Brain tissues were processed either for ELISA and western blotting analysis for inflammatory response, or for histological examination to assess degenerative neurons, acute inflammatory cell response and lesion volume.ResultsWe found that post-injury treatment with JC124 significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. Injured animals treated with JC124 also had significantly reduced protein expression levels of NLRP3, ASC, IL-1 beta, TNF, iNOS, and caspase-1.ConclusionOur data suggest that our novel NLRP3 inhibitor has a specific anti-inflammatory effect to protect the injured brain following TBI.	[Kuwar, Ram; Rolfe, Andrew; Di, Long; Xu, Hongyu; Sun, Dong] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Di, Long; Xu, Hongyu; He, Liu; Jiang, Yuqi; Zhang, Shijun] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Med Coll Virginia Campus, Richmond, VA 23298 USA		Kuwar, R (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	ram.kuwar@vcuhealth.org; dong.sun@vcuhealth.org		Sun, Dong/0000-0002-3837-7319	Commonwealth of Virginia Health Research Board [236-14-15]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG058673]; Alzheimer's Drug Discovery Foundation [20150601]; Commonwealth of Virginia Center on Aging - Alzheimer's and Related Disease Research Award Fund [18-2]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG058673] Funding Source: NIH RePORTER	This work was supported by Commonwealth of Virginia Health Research Board grant (CHRB #236-14-15, DS). It is also supported in part by NIA/NIH (R01AG058673, SZ), Alzheimer's Drug Discovery Foundation (20150601, SZ), Commonwealth of Virginia Center on Aging - Alzheimer's and Related Disease Research Award Fund (18-2, SZ).	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Baldwin AG, 2016, J MED CHEM, V59, P1691, DOI 10.1021/acs.jmedchem.5b01091; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Fulp J, 2018, J MED CHEM, V61, P5412, DOI 10.1021/acs.jmedchem.8b00733; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Irrera N, 2017, CLIN SCI, V131, P487, DOI 10.1042/CS20160645; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Ismael S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24350-x; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Marchetti C, 2015, J CARDIOVASC PHARM, V66, P1, DOI 10.1097/FJC.0000000000000247; Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Perregaux DG, 2001, J PHARMACOL EXP THER, V299, P187; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Ren HL, 2018, STROKE, V49, P184, DOI 10.1161/STROKEAHA.117.018904; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Sun D, 2000, J NEUROPATH EXP NEUR, V59, P1031, DOI 10.1093/jnen/59.12.1031; Sun D, 2011, J NEUROTRAUM, V28, P961, DOI 10.1089/neu.2010.1697; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tramutola A, 2016, J ALZHEIMERS DIS, V52, P359, DOI 10.3233/JAD-151105; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Winkler S, 2015, SEMIN IMMUNOPATHOL, V37, P419, DOI 10.1007/s00281-015-0494-4; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yin J, 2018, MOL NEUROBIOL, V55, P1977, DOI 10.1007/s12035-017-0467-9; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	59	58	63	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 11	2019	16								81	10.1186/s12974-019-1471-y			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	HU7DC	WOS:000465440300001	30975164	Green Published, gold			2022-02-06	
J	Williams, AM; Dennahy, IS; Bhatti, UF; Halaweish, I; Xiong, Y; Chang, PP; Nikolian, VC; Chtraklin, K; Brown, J; Zhang, YL; Zhang, ZG; Chopp, M; Buller, B; Alam, HB				Williams, Aaron M.; Dennahy, Isabel S.; Bhatti, Umar F.; Halaweish, Ihab; Xiong, Ye; Chang, Panpan; Nikolian, Vahagn C.; Chtraklin, Kiril; Brown, Jordana; Zhang, Yanlu; Zhang, Zheng Gang; Chopp, Michael; Buller, Benjamin; Alam, Hasan B.			Mesenchymal Stem Cell-Derived Exosomes Provide Neuroprotection and Improve Long-Term Neurologic Outcomes in a Swine Model of Traumatic Brain Injury and Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						exosomes; hemorrhagic shock; mesenchymal stem cells; traumatic brain injury	MARROW STROMAL CELLS; NEUROVASCULAR PLASTICITY; EXTRACELLULAR VESICLES; FUNCTIONAL RECOVERY; VALPROIC ACID; RATS; MICROVESICLES; DELIVERY; BENEFIT	Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) remains a leading cause of preventable death worldwide. Mesenchymal stem cell-derived exosomes have demonstrated promise in small animal models of neurologic injury. To investigate the effects of exosome treatment in a clinically realistic large animal model, Yorkshire swine underwent TBI and HS. Animals were maintained in shock for 2 h before resuscitation with normal saline (NS). Animals were then resuscitated either with NS (3 x volume of shed blood) or with the same volume of NS with delayed exosome administration (1 x 10(13) particles/4 mL) (n = 5/cohort). Exosomes were administered 9 h post-injury, and on post-injury days (PID) 1, 5, 9, and 13. Neurologic severity scores (NSS) were assessed for 30 days, and neurocognitive functions were objectively measured. Exosome-treated animals had significantly lower NSS (p < 0.05) during the first five days of recovery. Exosome-treated animals also had a significantly shorter time to complete neurologic recovery (NSS = 0) compared with animals given NS alone (days to recovery: NS = 16.8 +/- 10.6; NS + exosomes = 5.6 +/- 2.8; p = 0.03). Animals treated with exosomes initiated neurocognitive testing earlier (days to initiation: NS = 9.6 +/- 0.5 vs. NS + exosomes = 4.2 +/- 0.8; p = 0.008); however, no difference was seen in time to mastery of tasks. In conclusion, treatment with exosomes attenuates the severity of neurologic injury and allows for faster neurologic recovery in a clinically realistic large animal model of TBI and HS.	[Williams, Aaron M.; Dennahy, Isabel S.; Bhatti, Umar F.; Halaweish, Ihab; Chang, Panpan; Nikolian, Vahagn C.; Chtraklin, Kiril; Brown, Jordana; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Xiong, Ye; Zhang, Yanlu] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael; Buller, Benjamin] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Xiong, Ye/0000-0001-9770-6031			Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281-010-0233-9; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Dorayappan KDP, 2016, GYNECOL ONCOL, V142, P199, DOI 10.1016/j.ygyno.2016.03.036; Faul M XL, 2010, TRAUMATIC BRAIN INJU; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Ohno S, 2013, ADV DRUG DELIVER REV, V65, P398, DOI 10.1016/j.addr.2012.07.019; Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; Zhang L, 2013, CELL TRANSPLANT, V22, P1569, DOI 10.3727/096368912X658674; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhu W, 2012, CANCER LETT, V315, P28, DOI 10.1016/j.canlet.2011.10.002	39	58	59	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					54	60		10.1089/neu.2018.5711			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000453863000005	29690826	Bronze			2022-02-06	
J	Seabury, SA; Gaudette, E; Goldman, DR; Markowitz, AJ; Brooks, J; McCrea, MA; Okonkwo, DO; Manley, GT				Seabury, Seth A.; Gaudette, Etienne; Goldman, Dana R.; Markowitz, Amy J.; Brooks, Jordan; McCrea, Michael A.; Okonkwo, David O.; Manley, Geoffrey T.		TRACK-TBI Investigators	Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and Concussion Results From the TRACK-TBI Study	JAMA NETWORK OPEN			English	Article							HEAD COMPUTED-TOMOGRAPHY; EARLY INTERVENTION; UNITED-STATES; UTILITY; HOSPITALIZATION; KNOWLEDGE; OUTCOMES; DEATHS; VISITS; IMPACT	IMPORTANCE Mild traumatic brain injury (mTBI) affects millions of Americans each year. Lack of consistent clinical practice raises concern that many patients with mTBI may not receive adequate follow-up care. OBJECTIVE To characterize the provision of follow-up care to patients with mTBI during the first 3 months after injury. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data on patients with mTBI enrolled in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study between February 26, 2014, and August 25, 2016. We examined site-specific variations in follow-up care, the types of clinicians seen by patients receiving follow-up care, and patient and injury characteristics associated with a higher likelihood of receiving follow-up care. The TRACK-TBI study is a prospective, multicenter, longitudinal observational study of patients with TBI presenting to the emergency department of 1 of 11 level I US trauma centers. Study data included patients with head trauma who underwent a computed tomography (CT) scan within 24 hours of injury, had a Glasgow Coma Scale score of 13 to 15, were aged 17 years or older, and completed follow-up care surveys at 2 weeks and 3 months after injury (N = 831). MAIN OUTCOMES AND MEASURES Follow-up care was defined as hospitals providing TBI educational material at discharge, hospitals calling patients to follow up, and patients seeing a physician or other medical practitioner within 3 months after the injury. Unfavorable outcomes were assessed with the Rivermead Post Concussion Symptoms Questionnaire. RESULTS Of 831 patients (289 [35%) female; 483 [58%) non-Hispanic white; mean [SD] age, 40.3 [16.9] years), less than half self-reported receiving TBI educational material at discharge (353 patients [42%]) or seeing a physician or other health care practitioner within 3 months after injury (367 patients [44%)). Follow-up care varied by study site: adjusting for patient characteristics, the provision of educational material varied from 19% to 72% across sites. Of 236 patients with a positive finding on a CT scan, 92 (39%) had not seen a medical practitioner 3 months after the injury. Adjusting for injury severity and demographics, patient admission to the hospital ward or intensive care unit, patient income, and insurance status were not associated with the probability of seeing a medical practitioner. Among the patients with 3 or more moderate to severe postconcussive symptoms, only 145 of 279 (52%) reported having seen a medical practitioner by 3 months. CONCLUSIONS AND RELEVANCE There are gaps in follow-up care for patients with mTBI after hospital discharge, even those with a positive finding on CT or who continue to experience postconcussive symptoms.	[Seabury, Seth A.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA; [Seabury, Seth A.] Univ Southern Calif, Keck Sch Med, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA; [Gaudette, Etienne; Goldman, Dana R.] Univ Southern Calif, Sch Pharm, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA; [Goldman, Dana R.] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Price Sch Publ Policy, Los Angeles, CA 90089 USA; [Markowitz, Amy J.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Brooks, Jordan; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA		Seabury, SA (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.; Seabury, SA (corresponding author), Univ Southern Calif, Keck Sch Med, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA.	seabury@usc.edu	Yue, John K/P-1348-2015; Goldman, Dana P/E-7667-2013	Yue, John K/0000-0001-9694-7722; Goldman, Dana P/0000-0001-8498-6396; Hemphill, Claude/0000-0003-4019-7525; Wang, Kevin/0000-0002-9343-6473; Badjatia, Neeraj/0000-0003-1509-9034; Bodien, Yelena/0000-0003-4858-2903; Markowitz, Amy/0000-0001-9314-2814	National Institute of Neurological Disorders and Stroke, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5U01NS086090-02]; Research to Prevent Blindness, New York, New YorkResearch to Prevent Blindness (RPB); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	This study was supported by grant 5U01NS086090-02 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health. Funding was also provided by Research to Prevent Blindness, New York, New York.	af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Huynh T, 2006, AM SURGEON, V72, P1162; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lin CY, 2011, J AM GERIATR SOC, V59, P1947, DOI 10.1111/j.1532-5415.2011.03572.x; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; McIsaac Kathryn E, 2016, CMAJ Open, V4, pE746, DOI 10.9778/cmajo.20160072; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Toth M, 2017, HEALTH SERV RES, V52, P1473, DOI 10.1111/1475-6773.12543; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	30	58	58	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	MAY	2018	1	1							e180210	10.1001/jamanetworkopen.2018.0210			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4PB	WOS:000452508700013	30646055	Green Published, gold			2022-02-06	
J	Pischiutta, F; Micotti, E; Hay, JR; Marongiu, I; Sammali, E; Tolomeo, D; Vegliante, G; Stocchetti, N; Forloni, G; De Simoni, MG; Stewart, W; Zanier, ER				Pischiutta, Francesca; Micotti, Edoardo; Hay, Jennifer R.; Marongiu, Ines; Sammali, Eliana; Tolomeo, Daniele; Vegliante, Gloria; Stocchetti, Nino; Forloni, Gianluigi; De Simoni, Maria-Grazia; Stewart, William; Zanier, Elisa R.			Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Long-term outcome; Neurodegeneration; White matter damage; Neuroimaging; Inflammation	CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE; FOLLOW-UP; WALLERIAN DEGENERATION; RODENT MODELS; AXONAL INJURY; MOUSE MODEL; MICE BRAIN; ENCEPHALOPATHY; RECOVERY	There is increasing recognition that traumatic brain injury (TBI) may initiate long-term neurodegenerative processes, particularly chronic traumatic encephalopathy. However, insight into the mechanisms transforming an initial biomechanical injury into a neurodegenerative process remain elusive, partly as a consequence of the paucity of informative pre-clinical models. This study shows the functional, whole brain imaging and neuropathological consequences at up to one year survival from single severe TBI by controlled cortical impact in mice. TBI mice displayed persistent sensorimotor and cognitive deficits. Longitudinal T2 weighted magnetic resonance imaging (MRI) showed progressive ipsilateral (il) cortical, hippocampal and striatal volume loss, with diffusion tensor imaging demonstrating decreased fractional anisotropy (FA) at up to one year in the il-corpus callosum (CC: - 30%) and external capsule (EC: - 21%). Parallel neuropathological studies indicated reduction in neuronal density, with evidence of microgliosis and astrogliosis in the il-cortex, with further evidence of microgliosis and astrogliosis in the il-thalamus. One year after TBI there was also a decrease in FA in the contralateral (cl) CC (- 17%) and EC (- 13%), corresponding to histopathological evidence of white matter loss (cl-CC: 68%; cl-EC: 30%) associated with ongoing microgliosis and astrogliosis. These findings indicate that a single severe TBI induces bilateral, long-term and progressive neuropathology at up to one year after injury. These observations support this model as a suitable platform for exploring the mechanistic link between acute brain injury and late and persistent neurodegeneration.	[Pischiutta, Francesca; Micotti, Edoardo; Marongiu, Ines; Sammali, Eliana; Tolomeo, Daniele; Vegliante, Gloria; Forloni, Gianluigi; De Simoni, Maria-Grazia; Zanier, Elisa R.] Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, Milan, Italy; [Hay, Jennifer R.; Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland; [Hay, Jennifer R.; Stewart, William] Queen Elizabeth Univ Hosp, Dept Lab Med, Glasgow, Lanark, Scotland; [Sammali, Eliana] Fdn IRCCS Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] ICU Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy		Zanier, ER (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, Lab Acute Brain Injury & Therapeut Strategies, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	elisa.zanier@marionegri.it	Micotti, Edoardo/J-9359-2018; Vegliante, Gloria/ABF-9054-2021; Forloni, Gianluigi/AAB-2115-2020; De Simoni, Maria Grazia/I-6021-2012; Pischiutta, Francesca/AAA-7927-2020; Sammali, Eliana/AAA-2464-2019; Zanier, Elisa/AAA-8095-2020	Micotti, Edoardo/0000-0002-5995-2992; Vegliante, Gloria/0000-0002-7563-0889; Forloni, Gianluigi/0000-0001-5374-3914; De Simoni, Maria Grazia/0000-0001-6695-5297; Pischiutta, Francesca/0000-0002-7151-0812; Zanier, Elisa/0000-0002-3011-8718; Tolomeo, Daniele/0000-0002-5219-6397; Stewart, William/0000-0003-2199-2582	Ministero della SaluteMinistry of Health, Italy [RG86200]; ESICM Rita Levi Montalcini Award; IBRO/PERC InEurope Short Stay Funding Program; "Fondazione Umberto Veronesi" (FUV)Fondazione Umberto Veronesi; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, NS094003]; NHS Research Scotland Career Researcher Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, R01NS094003] Funding Source: NIH RePORTER; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/R005036/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/R005036/1] Funding Source: researchfish	Partially supported by Ministero della Salute (within the framework of ERA-NET NEURON, RG86200), ESICM Rita Levi Montalcini Award to Elisa R. Zanier, and IBRO/PERC InEurope Short Stay Funding Program to Francesca Pischiutta. Francesca Pischiutta received a fellowship from "Fondazione Umberto Veronesi" (FUV, 2016). Dr. William Stewart is supported by NIH grants NS038104, NS094003 and by an NHS Research Scotland Career Researcher Fellowship.	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Blasio D, 2017, J CEREBR BLOOD F MET, V37, P938, DOI 10.1177/0271678X16647397; DEAN RL, 1981, EXP AGING RES, V7, P427, DOI 10.1080/03610738108259823; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Griesbach Grace S, 2015, Handb Clin Neurol, V128, P681, DOI 10.1016/B978-0-444-63521-1.00042-X; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Okie S, 2016, NEW ENGL J MED, V375, P180, DOI 10.1056/NEJMms1604272; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; PALMGREN AXEL, 1960, ACTA ZOOL [STOCKHOLM], V41, P239; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; PerrotSinal TS, 1996, BEHAV NEUROSCI, V110, P1309, DOI 10.1037/0735-7044.110.6.1309; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pischiutta F, 2016, CRIT CARE MED, V44, pE1118, DOI 10.1097/CCM.0000000000001864; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Rigon A, 2016, J NEUROTRAUM, V33, P977, DOI 10.1089/neu.2014.3847; Robinson S, 2016, J NEUROSURG-PEDIATR, V17, P739, DOI 10.3171/2015.10.PEDS15554; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shinjo R, 2014, NEUROSCI LETT, V579, P80, DOI 10.1016/j.neulet.2014.07.018; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2013, CNS NEUROSCI THER, V19, P695, DOI 10.1111/cns.12128; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zarruk JG, 2011, REV NEUROLOGIA, V53, P607, DOI 10.33588/rn.5310.2011016; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	72	58	58	1	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2018	300						167	178		10.1016/j.expneurol.2017.11.003			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT1JZ	WOS:000422893300016	29126888	Green Accepted			2022-02-06	
J	Kamdar, BB; Huang, M; Dinglas, VD; Colantuoni, E; von Wachter, TM; Hopkins, RO; Needham, DM				Kamdar, Biren B.; Huang, Minxuan; Dinglas, Victor D.; Colantuoni, Elizabeth; von Wachter, Till M.; Hopkins, Ramona O.; Needham, Dale M.		Natl Heart Lung Blood Inst Acute R	Joblessness and Lost Earnings after ARDS in a 1-Year National Multicenter Study Abstracts	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						employment; intensive care unit; income; health insurance	ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; CARE RESOURCE USE; ONE-YEAR OUTCOMES; INTENSIVE-CARE; CRITICAL ILLNESS; UNITED-STATES; FOLLOW-UP	Rationale: Following acute respiratory distress syndrome (ARDS), joblessness is common but poorly understood. Objectives: To evaluate the timing of return to work after ARDS, and associated risk factors, lost earnings, and changes in healthcare coverage Methods: Over 12-month longitudinal follow-up, ARDS survivors from 43 U.S. ARDSNet hospitals provided employment and healthcare coverage data via structured telephone interviews. Factors associated with the timing of return to work were assessed using Fine and Gray regression analysis. Lost earnings were estimated using Bureau of Labor Statistics data. Measurements and Main Results: Of 922 consenting survivors, 386 (42%) were employed before ARDS (56% male; mean +/- SD age, 45 +/- 13 yr), with seven dying by 12-month follow-up. Of 379 previously employed 12-month survivors, 166 (44%) were jobless at 12-month follow-up. Accounting for competing risks of death and retirement, half of enrolled and previously employed survivors returned to work by 13 weeks after hospital discharge, with 68% ever returning by 12 months. Delays in return to work were associated with longer hospitalization and older age among nonwhite survivors. Over 12-month follow-up, 274 (71%) survivors accrued lost earnings, averaging $26,9496 +/- 22,447 (60% of pre-ARDS annual earnings). Jobless survivors experienced a 14% (95% confidence interval, 5-22%; P = 0.002) absolute decrease in private health insurance (from 44% pre-ARDS) and a 16% (95% confidence interval, 7-24%; P < 0.001) absolute increase in Medicare and Medicaid (from 33%). Conclusions: At 12 months after ARDS, nearly one-half of previously employed survivors were jobless. Post-ARDS joblessness is associated with readily identifiable patient and hospital variables and accompanied by substantial lost earnings and a shift toward government-funded healthcare coverage.	[Kamdar, Biren B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; [Huang, Minxuan; Dinglas, Victor D.; Colantuoni, Elizabeth; Needham, Dale M.] Johns Hopkins Univ, Outcomes Crit Illness & Surg Grp, Baltimore, MD USA; [Huang, Minxuan; Dinglas, Victor D.; Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,5th Floor, Baltimore, MD 21205 USA; [Needham, Dale M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; [Colantuoni, Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [von Wachter, Till M.] Univ Calif Los Angeles, Dept Econ, Los Angeles, CA 90024 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Pulm & Crit Care Div, Murray, UT USA; [Hopkins, Ramona O.] Intermt Med Ctr, Ctr Humanizing Crit Care, Murray, UT USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA		Needham, DM (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,5th Floor, Baltimore, MD 21205 USA.	dale.needham@jhmi.edu	/AAV-9838-2020	/0000-0002-9245-6229; Dinglas, Victor/0000-0001-5238-2790; Colantuoni, Elizabeth/0000-0002-0091-9434; Hite, Robert Duncan/0000-0002-2625-8750; Lanspa, Michael/0000-0003-0968-4755	Career Development Award from UCLA Clinical and Translational Science Institute (National Institutes of Health-National Center for Advancing Translational Science UCLA) [UL1TR000124, UL1TR001881]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [N01HR56170, R01HL091760, 3R01HL091760-02S1]; ARDS Network trials [HHSN268200536165C, HHSN268200536176C, HHSN268200536179C]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P2CHD041022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124, UL1TR001881] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL056170, R01HL091760] Funding Source: NIH RePORTER	Supported by a Career Development Award from the UCLA Clinical and Translational Science Institute (National Institutes of Health-National Center for Advancing Translational Science UCLA UL1TR000124 and UL1TR001881, B.B.K.). NHLBI funded this follow-up study (N01HR56170, R01HL091760, and 3R01HL091760-02S1) and the ARDS Network trials (contracts HHSN268200536165C to HHSN268200536176C and HHSN268200536179C).	Adhikari NKJ, 2009, CHEST, V135, P678, DOI 10.1378/chest.08-0974; Babor TF, 2001, AUDIT ALCOHOL USE DI; Bernard G, 1997, SEPSIS, V1, P43, DOI DOI 10.1023/A:1009711301483; Cameron JI, 2016, NEW ENGL J MED, V374, P1831, DOI 10.1056/NEJMoa1511160; Chelluri L, 2002, CHEST, V121, P549; Coopersmith CM, 2012, CRIT CARE MED, V40, P1072, DOI 10.1097/CCM.0b013e31823c8d03; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Dobkin C. C, 2016, EC CONSEQUENCES HOSP; Dupont J, 2008, PRODUCTIVITY MEASURE; Fakhry SM, 1996, J TRAUMA, V41, P999, DOI 10.1097/00005373-199612000-00010; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Geskus RB, 2011, BIOMETRICS, V67, P39, DOI 10.1111/j.1541-0420.2010.01420.x; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Huang MX, 2016, CRIT CARE MED, V44, P954, DOI 10.1097/CCM.0000000000001621; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McGee HM, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-9; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MUNDT DJ, 1989, ARCH INTERN MED, V149, P68, DOI 10.1001/archinte.149.1.68; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Needham DM, 2014, AM J RESP CRIT CARE, V189, P1214, DOI 10.1164/rccm.201401-0158OC; Needham DM, 2013, AM J RESP CRIT CARE, V188, P567, DOI 10.1164/rccm.201304-0651OC; Norman BC, 2016, CRIT CARE MED, V44, P2003, DOI 10.1097/CCM.0000000000001849; PARNO JR, 1984, MED CARE, V22, P167, DOI 10.1097/00005650-198402000-00008; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Ruhl AP, 2017, CRIT CARE MED, V45, P196, DOI 10.1097/CCM.0000000000002088; Ruhl AP, 2015, ANN AM THORAC SOC, V12, P392, DOI 10.1513/AnnalsATS.201409-422OC; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.2307/2335876; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047	40	58	59	0	4	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2017	196	8								10.1164/rccm.201611-2327OC			16	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	FJ8CG	WOS:000412988500003	28448162	Green Published			2022-02-06	
J	Hume, PA; Theadom, A; Lewis, GN; Quarrie, KL; Brown, SR; Hill, R; Marshall, SW				Hume, Patria A.; Theadom, Alice; Lewis, Gwyn N.; Quarrie, Kenneth L.; Brown, Scott R.; Hill, Rosamund; Marshall, Stephen W.			A Comparison of Cognitive Function in Former Rugby Union Players Compared with Former Non-Contact-Sport Players and the Impact of Concussion History	SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; LONG-TERM; RECURRENT CONCUSSION; CONSENSUS STATEMENT; EARLY ADULTHOOD; RISK; IMPAIRMENT; DEPRESSION; LEAGUE	Aim This study investigated differences in cognitive function between former rugby and non-contact-sport players, and assessed the association between concussion history and cognitive function. Methods Overall, 366 former players (mean +/- standard deviation [SD] age 43.3 +/- 8.2 years) were recruited from October 2012 to April 2014. Engagement in sport, general health, sports injuries and concussion history, and demographic information were obtained from an online self-report questionnaire. Cognitive functioning was assessed using the online CNS Vital Signs neuropsychological test battery. Cohen's d effect size statistics were calculated for comparisons across player groups, concussion groups (one or more self-reported concussions versus no concussions) and between those groups with CNS Vital Signs age- matched norms (US norms). Individual differences within groups were represented as SDs. Results The elite-rugby group (n = 103) performed worse on tests of complex attention, processing speed, executive functioning, and cognitive flexibility than the non-contact-sport group (n = 65), and worse than the community-rugby group (n = 193) on complex attention. The community-rugby group performed worse than the non-contact group on executive functioning and cognitive flexibility. Compared with US norms, all three former player groups performed worse on verbal memory and reaction time; rugby groups performed worse on processing speed, cognitive flexibility and executive functioning; and the community-rugby group performed worse on composite memory. The community-rugby group and non-contact-sport group performed slightly better than US norms on complex attention, as did the elite-rugby group for motor speed. All three player groups had greater individual differences than US norms on composite memory, verbal memory and reaction time. The elite-rugby group had greater individual differences on processing speed and complex attention, and the community-rugby group had greater individual differences on psychomotor speed and motor speed. The average number of concussions recalled per player was greater for elite rugby and community rugby than non-contact sport. Former players who recalled one or more concussions (elite rugby, 85 %; community rugby, 77 %; non-contact sport, 23 %) had worse scores on cognitive flexibility, executive functioning, and complex attention than players who did not recall experiencing a concussion. Conclusions Past participation in rugby or a history of concussion were associated with small to moderate neurocognitive deficits (as indicated by worse CNS Vital Signs scores) in athletes post retirement from competitive sport.	[Hume, Patria A.; Brown, Scott R.] Auckland Univ Technol, Sports Performance Res Inst New Zealand, Fac Hlth & Environm Sci, Private Bag 92006, Auckland 1142, New Zealand; [Theadom, Alice] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Lewis, Gwyn N.] Auckland Univ Technol, Hlth & Rehabil Res Inst, Auckland, New Zealand; [Quarrie, Kenneth L.] New Zealand Rugby, Wellington, New Zealand; [Hill, Rosamund] Auckland City Hosp, Dept Neurol, Auckland, New Zealand; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA		Hume, PA (corresponding author), Auckland Univ Technol, Sports Performance Res Inst New Zealand, Fac Hlth & Environm Sci, Private Bag 92006, Auckland 1142, New Zealand.	patria.hume@aut.ac.nz	Hume, Patria/AAN-5514-2021; Hume, Patria Anne/P-1084-2017	Hume, Patria/0000-0003-1847-8128; Hume, Patria Anne/0000-0003-1847-8128; Brown, Scott/0000-0003-3063-8040	World Rugby (IRB); Sport Performance Research Institute New Zealand (SPRINZ); National Institute for Stroke and Applied Neurosciences (NISAN); Health and Rehabilitation Research Institute (HRRI) of AUT; NZR	The study was funded by World Rugby (IRB), the Sport Performance Research Institute New Zealand (SPRINZ), the National Institute for Stroke and Applied Neurosciences (NISAN), and the Health and Rehabilitation Research Institute (HRRI) of AUT, and NZR.	Alberts JL., 2015, KINESIOL REV, V4, P39, DOI [10.1123/kr.2014-0080, DOI 10.1123/KR.2014-0080]; Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arnaiz E, 2004, J NEUROL NEUROSUR PS, V75, P1275, DOI 10.1136/jnnp.2003.015032; Austin D, 2011, J STRENGTH COND RES, V25, P1659, DOI 10.1519/JSC.0b013e3181da781c; Boyd A., 2015, CNS VITAL SIGNS MANU; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Bruscoli M, 2004, INT PSYCHOGERIATR, V16, P129, DOI 10.1017/S1041610204000092; Carney N, 2014, NEUROSURGERY, V75, pS1, DOI 10.1227/NEU.0000000000000434; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dretsch MN, 2015, J NEUROTRAUM, V32, P1301, DOI 10.1089/neu.2014.3810; England Professional Rugby Injury Surveillance Project Steering Group, 2014, ENGL PROF RUGB INJ S; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hopkins WG, 2002, SCALE MAGNITUDES EFF; Hume PA, 2015, IRB NZR AUT RUGBYHEA; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; King D, 2014, J SCI MED SPORT, V17, P250, DOI 10.1016/j.jsams.2013.05.007; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King DA, 2016, J NEUROSURG-PEDIATR, V18, P65, DOI 10.3171/2015.12.PEDS15605; Kirkwood G, 2015, BRIT J SPORT MED, V49, P506, DOI 10.1136/bjsports-2014-093774; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Quarrie KL, 2014, BRIT J SPORT MED, V48, P1589, DOI 10.1136/bjsports-2014-094112; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Statistics New Zealand, 2006, STAT NZ CENS DAT; Theadom A, 2014, J SCI MED SPORT, V17, P591, DOI 10.1016/j.jsams.2014.02.001; West S, 2011, NEUROREHABILIT NEURA, V25, P3, DOI [10.1177/1545968310392352, DOI 10.1177/1545968310392352]	53	58	58	1	47	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JUN	2017	47	6					1209	1220		10.1007/s40279-016-0608-8			12	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EV7HD	WOS:000401945600013	27558141				2022-02-06	
J	Gill, J; Merchant-Borna, K; Jeromin, A; Livingston, W; Bazarian, J				Gill, Jessica; Merchant-Borna, Kian; Jeromin, Andreas; Livingston, Whitney; Bazarian, Jeffrey			Acute plasma tau relates to prolonged return to play after concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; ICE HOCKEY PLAYERS; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; EXERCISE; ENCEPHALOPATHY; BIOMARKERS; MANAGEMENT; IMPACT	Objective: To determine whether tau changes after sport-related concussion (SRC) relate to return to play (RTP). Methods: Collegiate athletes underwent preseason plasma sampling and cognitive testing and were followed. After a SRC (n = 46), athletes and controls (n 5 37) had sampling at 6 hours, and at 24 hours, 72 hours, and 7 days after SRC. A sample of 21 nonathlete controls were compared at baseline. SRC athletes were grouped by long (. 10 days, n = 23) and short (< 10 days, n = 18) RTP. Total tau was measured using an ultrasensitive immunoassay. Results: Both SRC and athlete controls had significantly higher mean tau at baseline compared to nonathlete healthy controls (F-101,(3) = 19.644, p, < 0.01). Compared to SRC athletes with short RTP, those with long RTP had higher tau concentrations overall, after controlling for sex (F-39,1 = 3.59, p = 0.022), compared to long RTP athletes, at 6 (p, 0.01), 24 (p, 0.01), and 72 hours (p = 0.02). Receiver operator characteristic analyses showed that higher plasma tau 6 hours postSRC was a significant predictor of RTP.10 days (area under the curve 0.81; 95% confidence interval 0.62-0.97, p = 0.01). Conclusions: Elevated plasma tau concentration within 6 hours following a SRC was related to having a prolonged RTP, suggesting that tau levels may help inform RTP.	[Gill, Jessica; Livingston, Whitney] NINR, NIH, Bethesda, MD 20892 USA; [Merchant-Borna, Kian; Bazarian, Jeffrey] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY USA; [Jeromin, Andreas] Quanterix Corp, Lexington, MA USA		Gill, J (corresponding author), NINR, NIH, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017		NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Nursing Research Intramural Research Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000033] Funding Source: NIH RePORTER	This work was supported by funds from the NIH/NICHD (award no.K24HD064754) and the NIH, National Institute of Nursing Research Intramural Research Program.	Stocchero CMA, 2014, APPL PHYSIOL NUTR ME, V39, P340, DOI 10.1139/apnm-2013-0308; Anderson JM, 2008, BRAIN, V131, P1736, DOI 10.1093/brain/awn119; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Knaepen K, 2010, SPORTS MED, V40, P765, DOI 10.2165/11534530-000000000-00000; Kobeissy, 2015, BRAIN NEUROTRAUMA MO; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AUST FAM PHYSICIAN, V39, P12; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCulloch KL, 2015, J HEAD TRAUMA REHAB, V30, P56, DOI 10.1097/HTR.0000000000000104; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Saur L, 2014, BRAIN STRUCT FUNCT, V219, P293, DOI 10.1007/s00429-012-0500-8; Shahim P, 2015, DIVING HYPERB MED, V45, P240; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028	35	58	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 7	2017	88	6					595	602		10.1212/wnl.0000000000003587			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EP4HR	WOS:000397342100015	28062722	Green Published, hybrid			2022-02-06	
J	Erdodi, LA; Abeare, CA; Lichtenstein, JD; Tyson, BT; Kucharski, B; Zuccato, BG; Roth, RM				Erdodi, Laszlo A.; Abeare, Christopher A.; Lichtenstein, Jonathan D.; Tyson, Bradley T.; Kucharski, Brittany; Zuccato, Brandon G.; Roth, Robert M.			Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Processing Speed Scores as Measures of Noncredible Responding: The Third Generation of Embedded Performance Validity Indicators	PSYCHOLOGICAL ASSESSMENT			English	Article						performance validity testing; embedded validity indicators; processing speed; WAIS-IV; coding	TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY TEST; LEARNING TEST-II; CLASSIFICATION ACCURACY; SYMPTOM VALIDITY; DIGIT SPAN; NEUROPSYCHOLOGICAL TESTS; INCOMPLETE EFFORT; CROSS-VALIDATION; CLINICAL UTILITY	Research suggests that select processing speed measures can also serve as embedded validity indicators (EVIs). The present study examined the diagnostic utility of Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) subtests as EVIs in a mixed clinical sample of 205 patients medically referred for neuropsychological assessment (53.3% female, mean age = 45.1). Classification accuracy was calculated against 3 composite measures of performance validity as criterion variables. A PSI <= 79 produced a good combination of sensitivity (.23-.56) and specificity (.92-.98). A Coding scaled score <= 5 resulted in good specificity (.94-1.00), but low and variable sensitivity (.04-.28). A Symbol Search scaled score <= 6 achieved a good balance between sensitivity (.38-.64) and specificity (.88-.93). A Coding-Symbol Search scaled score difference >= 5 produced adequate specificity (.89-.91) but consistently low sensitivity (.08-.12). A 2-tailed cutoff on the Coding/Symbol Search raw score ratio (<= 1.41 or >= 3.57) produced acceptable specificity (.87-.93), but low sensitivity (.15-.24). Failing >= 2 of these EVIs produced variable specificity (.81-.93) and sensitivity (.31-.59). Failing >= 3 of these EVIs stabilized specificity (.89-.94) at a small cost to sensitivity (.23-.53). Results suggest that processing speed based EVIs have the potential to provide a cost-effective and expedient method for evaluating the validity of cognitive data. Given their generally low and variable sensitivity, however, they should not be used in isolation to determine the credibility of a given response set. They also produced unacceptably high rates of false positive errors in patients with moderate-to-severe head injury. Combining evidence from multiple EVIs has the potential to improve overall classification accuracy.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Kucharski, Brittany; Zuccato, Brandon G.] Univ Windsor, Dept Psychol, Dartmouth, NS, Canada; [Erdodi, Laszlo A.; Lichtenstein, Jonathan D.; Tyson, Bradley T.; Roth, Robert M.] Geisel Sch Med, Dept Psychiat, Neuropsychol Serv, Dartmouth, NS, Canada; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA		Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Boone K.B., 2013, CLIN PRACTICE FORENS; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Green P., 2013, CLIN PRACTICE FORENS; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton R. K., 2004, REVISED COMPREHENSIV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kolb B., 2009, FUNDAMENTALS HUMAN N; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Loring DW, 2010, NEUROLOGY, V74, P685, DOI 10.1212/WNL.0b013e3181d0cd12; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Pearson, 2009, ADV CLIN SOLUTIONS W; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D., 2008, WECHSLER ADULT INTEL; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	47	58	58	0	26	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	FEB	2017	29	2					148	157		10.1037/pas0000319			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	EN5MZ	WOS:000396051100003	27124099				2022-02-06	
J	Korley, FK; Kelen, GD; Jones, CM; Diaz-Arrastia, R				Korley, Frederick K.; Kelen, Gabor D.; Jones, Courtney M.; Diaz-Arrastia, Ramon			Emergency Department Evaluation of Traumatic Brain Injury in the United States, 2009-2010	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency department; epidemiology; head CT scan; imaging; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; INTRACRANIAL LESIONS; OUTCOME PREDICTION; MILD; BIOMARKERS; MANAGEMENT; DIAGNOSIS; ACCURACY	Objective: To determine the dimensions of traumatic brain injury (TBI) evaluation in US emergency department (EDs) to inform potential application of novel diagnostic tests. Setting: US EDs. Participants: National Hospital Ambulatory Medical Care Survey of ED visits in 2009 and 2010 where TBI was evaluated (1) and diagnosed either clinically or (2) with head computed tomographic (CT) scans. Design: Retrospective cross-sectional. Results: TBI was evaluated during 4.8 (95% confidence interval [CI], 4.2-5.4) million visits per year; and head CT scan was performed in 82% of TBI evaluations (3.9 [95% CI, 3.4-4.4] million visits per year). TBI was diagnosed in 52% of evaluations (2.5 [95% CI, 2.1-2.8] million visits per year). Among those who received head CT scans, 9% had CT evidence of traumatic abnormalities. Among patients evaluated for TBI who had a Glasgow Coma Scale score recorded, 94.5% were classified as having mild TBI, 2.1% as moderate TBI, and 3.5% as severe TBI. Among patients with International Classification of Diseases, Ninth Revision, Clinical Modification, codes permitting the calculation of head Abbreviated Injury Scale scores 9.0%, 85.0%, 2.5%, 3.2%, 0.3%, and 0% had head Abbreviated Injury Scale scores of 1, 2, 3, 4, 5, and 6, respectively. Of patients evaluated for TBI, 31% had other head/face/neck injuries, 10% had spine and back injuries, 7% had torso injuries, and 14% had extremity injuries. Conclusion: The ED is the main gateway to medical care for millions of patients evaluated for TBI each year. Novel diagnostic tests are needed to improve ED diagnosis and management of TBI.	[Korley, Frederick K.; Kelen, Gabor D.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Davis Bldg,Ste 3220,5801 Smith Ave, Baltimore, MD 21209 USA; [Jones, Courtney M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Korley, FK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, Davis Bldg,Ste 3220,5801 Smith Ave, Baltimore, MD 21209 USA.	fkorley1@jhmi.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Kelen, Gabor/0000-0002-3236-8286	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z99 NS999999] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER		[Anonymous], TRAUM BRAIN INJ US F; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bender R, 1998, STAT MED, V17, P946, DOI 10.1002/(SICI)1097-0258(19980430)17:8<946::AID-SIM2823>3.0.CO;2-3; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2010 NHAMCS MICR FIL; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Centers for Disease Control and Prevention, AMB HLTH CAR SURV; Centers for Disease Control and Prevention National Center for Health Statistics., 2009, 2009 NHAMCS MICR FIL; Chong VE, 2015, J SURG RES, V199, P177, DOI 10.1016/j.jss.2015.03.086; Clark DE., ICDPIC STATA MODULE; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Faul M, 2010, TRAUMATIC BRAIN INJU; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Institute of Medicine, 2013, BEST CARE LOWER COST; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marr A., 2004, CENTRAL NERVOUS SYST; McCaig L F, 1994, Vital Health Stat 1, P1; McCaig LF, 2007, 2006 DAT US C; McCaig LF, 2012, ANN EMERG MED, V60, P716, DOI 10.1016/j.annemergmed.2012.07.010; McHugh M, 2012, ACAD EMERG MED, V19, P106, DOI 10.1111/j.1553-2712.2011.01240.x; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Owens PL, 2010, ANN EMERG MED, V56, P150, DOI 10.1016/j.annemergmed.2009.11.022; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Prichep LS, 2015, J NEUROTRAUM, V32, P17, DOI 10.1089/neu.2014.3365; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zarzaur BL, 2010, J AM COLL SURGEONS, V211, P216, DOI 10.1016/j.jamcollsurg.2010.03.036; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	48	58	61	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					379	387		10.1097/HTR.0000000000000187			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800009	26360006	Green Accepted			2022-02-06	
J	Tator, CH; Davis, HS; Dufort, PA; Tartaglia, MC; Davis, KD; Ebraheem, A; Hiploylee, C				Tator, Charles H.; Davis, Hannah S.; Dufort, Paul A.; Tartaglia, Maria Carmella; Davis, Karen D.; Ebraheem, Ahmed; Hiploylee, Carmen			Postconcussion syndrome: demographics and predictors in 221 patients	JOURNAL OF NEUROSURGERY			English	Article						postconcussion syndrome; concussion; traumatic brain injury; chronic traumatic encephalopathy	TRAUMATIC BRAIN-INJURY; SCHOOL FOOTBALL PLAYERS; MILD HEAD-INJURY; RISK-FACTORS; MINOR HEAD; CONCUSSION; SYMPTOMS; RECOVERY; DISORDER; EPIDEMIOLOGY	OBJECTIVE The objective of this study was to determine the demographics and predictors of postconcussion syndrome (PCS) in a large series of patients using a novel definition of PCS. METHODS The authors conducted a retrospective cohort study of 284 consecutive concussed patients, 221 of whom had PCS on the basis of at least 3 symptoms persisting at least 1 month. This definition of PCS was uniformly employed and is unique in accepting an expanded list of symptoms, in shortening the postconcussion interval to 1 month from 3 months, and in excluding those with focal injuries such as hemorrhages and contusions. RESULTS The 221 cases showed considerable heterogeneity in clinical features of PCS. They averaged 3.3 concussions, with a range of 0 to 12 or more concussions, and 62.4% occurred during sports and recreation. The median duration of PCS was 7 months at the time of examination, with 11.8% lasting more than 2 years, and 23.1% with PCS had only 1 concussion. The average patient age was 27 years (range 10-74 years). The average number of persistent symptoms was 8.1; 26.2% had a previous psychiatric condition, attention-deficit disorder/attention-deficit hyperactivity disorder, a learning disability, or previous migraine headaches. The prevalence of arachnoid cysts and Chiari malformation in PCS exceeded the general population. Additionally, involvement in litigation, presence of extracranial injuries, amnesia and/or loss of consciousness, and female sex were predictive of reporting a high number of symptoms. A prior history of psychiatric conditions or migraines, cause of injury, number of previous concussions, and age did not significantly predict symptom number. Only the number of symptoms reported predicted the duration of PCS. To predict the number of symptoms for those who fulfilled PCS criteria according to the International Classification of Diseases, 10th Revision (ICD-10), and the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), the number of previous concussions was significant. CONCLUSIONS PCS is commonly associated with multiple concussions, but 23.1% in the present series occurred after only 1 concussion. Most patients with PCS had multiple symptoms persisting for months or years. The median duration of PCS was 7 months, with a range up to 26 years. In only 11.3%, the PCS had ended at the time of consultation. Not all predictors commonly cited in the literature align with the findings in this study. This is likely due to differences in the definitions of PCS used in research. These results suggest that the use of ICD-10 and DSM-IV to diagnose PCS may be biased toward those who are vulnerable to concussions or with more severe forms of PCS. It is thus important to redefine PCS based on evidence-based medicine.	[Tator, Charles H.; Davis, Hannah S.; Dufort, Paul A.; Tartaglia, Maria Carmella; Davis, Karen D.; Ebraheem, Ahmed; Hiploylee, Carmen] Toronto Western Hosp, Canadian Concuss Ctr, Toronto, ON, Canada; [Tator, Charles H.; Davis, Karen D.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Tartaglia, Maria Carmella; Davis, Karen D.] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Davis, Karen D.] Toronto Western Hosp, 399 Bathurst St,Rm 4W-422, Toronto, ON M5T 2S8, Canada		Tator, CH (corresponding author), Toronto Western Hosp, 399 Bathurst St,Rm 4W-422, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca			Canadian Concussion Centre at the Toronto Western Hospital - Toronto General and Western Hospital Foundation	Funds for this study were provided by the Canadian Concussion Centre at the Toronto Western Hospital, which is funded by the Toronto General and Western Hospital Foundation.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Meadows J, 2000, J NEUROSURG, V92, P920, DOI 10.3171/jns.2000.92.6.0920; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Speer Marcy C, 2003, J Genet Couns, V12, P297, DOI 10.1023/A:1023948921381; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Wan MJ, 2008, NEUROSURGERY, V63, P748, DOI 10.1227/01.NEU.0000325498.04975.C0; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	43	58	60	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2016	125	5					1206	1216		10.3171/2015.6.JNS15664			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DZ8FK	WOS:000386106100021	26918481	Bronze			2022-02-06	
J	Byrne, JP; Mason, SA; Gomez, D; Hoeft, C; Subacius, H; Xiong, W; Neal, M; Pirouzmand, F; Nathens, AB				Byrne, James P.; Mason, Stephanie A.; Gomez, David; Hoeft, Christopher; Subacius, Haris; Xiong, Wei; Neal, Melanie; Pirouzmand, Farhad; Nathens, Avery B.			Timing of Pharmacologic Venous Thromboembolism Prophylaxis in Severe Traumatic Brain Injury: A Propensity-Matched Cohort Study	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; INTRACRANIAL HEMORRHAGE; AMERICAN-COLLEGE; HEAD TRAUMA; CHEMOPROPHYLAXIS; ANTICOAGULATION; PROGRESSION; PREDICTORS; PREVENTION	BACKGROUND: Patients with severe traumatic brain injury (sTBI) are at high risk for developing venous thromboembolism (VTE). Nonetheless, pharmacologic VTE prophylaxis is often delayed out of concern for precipitating extension of intracranial hemorrhage (ICH). The purpose of this study was to compare the effectiveness of early vs late VTE prophylaxis in patients with sTBI, and to characterize the risk of subsequent ICH-related complication. STUDY DESIGN: Adults with isolated sTBI (head Abbreviated Injury Scale score >= 3 and total Glasgow Coma Scale score <= 8) who received VTE prophylaxis with low-molecular-weight or unfractionated heparin were derived from the American College of Surgeons Trauma Quality Improvement Program (2012 to 2014). Patients were divided into EP (<72 hours) or LP (>= 72 hours) groups. Propensity score matching was used to minimize selection bias. The primary end point was VTE (pulmonary embolism or deep vein thrombosis). Secondary outcomes were defined as late neurosurgical intervention (>= 72 hours) or death. RESULTS: We identified 3,634 patients with sTBI. Early prophylaxis was given in 43% of patients. Higher head injury severity, presence of ICH, and early neurosurgery were associated with late prophylaxis. Propensity score matching yielded a well-balanced cohort of 2,468 patients. Early prophylaxis was associated with lower rates of both pulmonary embolism (odds ratio = 0.48; 95% CI, 0.25-0.91) and deep vein thrombosis (odds ratio = 0.51; 95% CI, 0.36-0.72), but no increase in risk of late neurosurgical intervention or death. CONCLUSIONS: In this observational study of patients with sTBI, early initiation of VTE prophylaxis was associated with decreased risk of pulmonary embolism and deep vein thrombosis, but no increase in risk of late neurosurgical intervention or death. Early prophylaxis may be safe and should be the goal for each patient in the context of appropriate risk stratification. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.)	[Byrne, James P.; Mason, Stephanie A.; Xiong, Wei; Pirouzmand, Farhad; Nathens, Avery B.] Univ Toronto, Sunnybrook Res Inst, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Byrne, James P.; Mason, Stephanie A.; Nathens, Avery B.] Univ Toronto, Clin Epidemiol Program, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Byrne, James P.; Mason, Stephanie A.; Gomez, David; Nathens, Avery B.] Univ Toronto, Div Gen Surg, Toronto, ON, Canada; [Pirouzmand, Farhad; Nathens, Avery B.] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Hoeft, Christopher; Subacius, Haris; Xiong, Wei; Neal, Melanie; Nathens, Avery B.] Amer Coll Surg, Trauma Qual Improvement Program, Chicago, IL USA		Byrne, JP (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave,Room D-574, Toronto, ON M4N 3M5, Canada.	jpbyrne@gmail.com		Byrne, James/0000-0002-3760-8509; Gomez, David/0000-0002-0926-2547	De Souza Chair in Trauma Research	Dr Nathens is supported by funds from the De Souza Chair in Trauma Research.	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; American College of Surgeons, TRAUM QUAL IMPR PROG; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Barrera LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008303.pub2; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Chelladurai Yohalakshmi, 2013, F1000Res, V2, P132, DOI 10.12688/f1000research.2-132.v1; Depew AJ, 2008, AM SURGEON, V74, P906; Dietch ZC, 2015, SURGERY, V158, P379, DOI 10.1016/j.surg.2015.03.052; Farooqui A, 2013, J NEUROSURG, V119, P1576, DOI 10.3171/2013.8.JNS13424; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Haut ER, 2011, J TRAUMA, V70, P27, DOI 10.1097/TA.0b013e3182077d55; Haut ER, 2009, J TRAUMA, V66, P994, DOI 10.1097/TA.0b013e3181991adc; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; Hubbard AE, 2010, EPIDEMIOLOGY, V21, P467, DOI 10.1097/EDE.0b013e3181caeb90; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Li SJ, 2016, J TRAUMA ACUTE CARE, V80, P381, DOI 10.1097/TA.0000000000000935; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nickele CM, 2013, NEUROCRIT CARE, V18, P184, DOI 10.1007/s12028-012-9786-x; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, P1434, DOI 10.1097/TA.0b013e31825ac49e; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Rogers SO, 2007, J TRAUMA, V62, P562; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 2010, AM J OPHTHALMOL, V149, P7, DOI 10.1016/j.ajo.2009.08.024; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saadeh Y, 2012, J TRAUMA ACUTE CARE, V73, P426, DOI 10.1097/TA.0b013e31825a758b; Scales DC, 2010, CRIT CARE, V14, DOI 10.1186/cc8980; Shackford SR, 2004, ANN SURG, V240, P496; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Singh S, 2013, 13EHC0821 AG HEALTHC; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004	41	58	59	2	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2016	223	4					621	+		10.1016/j.jamcollsurg.2016.06.382			16	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	DX9FC	WOS:000384698000012	27453296				2022-02-06	
J	Kontos, AP; Sufrinko, A; Elbin, RJ; Puskar, A; Collins, MW				Kontos, Anthony P.; Sufrinko, Alicia; Elbin, R. J.; Puskar, Alicia; Collins, Michael W.			Reliability and Associated Risk Factors for Performance on the Vestibular/Ocular Motor Screening (VOMS) Tool in Healthy Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						college; concussion; baseline testing; vestibular; ocular motor	MOTION SICKNESS; SEX-DIFFERENCES; NORMATIVE DATA; CONCUSSION; SUSCEPTIBILITY; CONVERGENCE; SYMPTOMS; MIGRAINE; SPORTS; PREVALENCE	Background: The Vestibular/Ocular Motor Screening (VOMS) is a newly developed screening tool that evaluates vestibular and ocular motor symptom (eg, headache, dizziness, nausea, fogginess) provocation after a sport-related concussion. Baseline data on the VOMS are needed to extend the application of this measure to broad age groups and to document normal variations in performance. Purpose: The primary purpose of this study was to examine the internal consistency of the VOMS in a large sample of healthy, nonconcussed collegiate athletes. The secondary purpose was to investigate the effects of patient sex and history of motion sickness, migraines, and concussions on baseline VOMS scores. Study Design: Cohort study; Level of evidence, 2. Methods: A total of 263 National Collegiate Athletic Association Division I athletes (mean SD age, 19.85 1.35 years) completed self-reported demographic and medical history at preseason physical examinations and baseline screening. Internal consistency of the VOMS was assessed with Cronbach . A series of univariate nonparametric tests ((2) with odds ratios [ORs] and 95% CIs) were used to examine the associations among medical history risk factors and VOMS clinical cutoff scores (score of 2 for any individual VOMS symptom, near point of convergence [NPC] distance of 5 cm), with higher scores representing greater symptom provocation. Results: Internal consistency of the VOMS was high (Cronbach = .97), and 89% of athletes scored below cutoff levels (ie, 11% false-positive rate). Female athletes (OR, 2.99 [95% CI, 1.34-6.70]; P = .006) and those with a personal history of motion sickness (OR, 7.73 [95% CI, 1.94-30.75]; P = .009) were more likely to have 1 VOMS scores above cutoff levels. No risk factors were associated with increased odds of an abnormal NPC distance. Conclusion: The VOMS possesses internal consistency and an acceptable false-positive rate among healthy Division I collegiate student-athletes. Female sex and a history of motion sickness were risk factors for VOMS scores above clinical cutoff levels among healthy collegiate student-athletes. Results support a comprehensive baseline evaluation approach that includes an assessment of premorbid vestibular and oculomotor symptoms.	[Kontos, Anthony P.; Sufrinko, Alicia; Elbin, R. J.; Puskar, Alicia; Collins, Michael W.] Univ Pittsburgh, Pittsburgh, PA USA; [Kontos, Anthony P.; Sufrinko, Alicia; Puskar, Alicia; Collins, Michael W.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA; [Elbin, R. J.] Univ Arkansas, Off Sport Concuss Res, Fayetteville, AR 72701 USA		Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; Grand Alliance of the Concussion Assessment, Research and Education Consortium; National Collegiate Athletic Association; Department of Defense (United States Army Medical Research Acquisition Activity)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program [W81XWH-14-2-0151]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: M.W.C. is a cofounder and 10% shareholder of ImPACT Applications Inc. This research was supported in part by grants to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) and from the Grand Alliance of the Concussion Assessment, Research and Education Consortium, funded in part by the National Collegiate Athletic Association and the Department of Defense (United States Army Medical Research Acquisition Activity). This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program (award No. W81XWH-14-2-0151).	Black FO, 2002, AM J OBSTET GYNECOL, V186, pS204, DOI 10.1067/mob.2002.122602; Boldingh MI, 2011, CEPHALALGIA, V31, P1211, DOI 10.1177/0333102411409074; Borsting Eric, 2005, Optometry, V76, P588, DOI 10.1016/j.optm.2005.07.007; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bucci MP, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00981; Buckley TA, 2014, CONCUSSIONS ATHLETIC, P139, DOI [10.1007/978-1-4939-0295-8, DOI 10.1007/978-1-4939-0295-8]; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Cullen KE, 2012, TRENDS NEUROSCI, V35, P185, DOI 10.1016/j.tins.2011.12.001; Dobie T, 2001, AVIAT SPACE ENVIR MD, V72, P13; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Elbin RJ, 2013, TRANSL STROKE RES, V4, P425, DOI 10.1007/s12975-012-0237-y; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Furman Joseph M, 2012, Continuum (Minneap Minn), V18, P1102, DOI 10.1212/01.CON.0000421621.18407.96; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jokerst MD, 1999, AVIAT SPACE ENVIR MD, V70, P962; KAYAN A, 1984, BRAIN, V107, P1123, DOI 10.1093/brain/107.4.1123; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Langhagen T, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00292; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maples WC, 2007, OPTOMETRY VISION SCI, V84, P224, DOI 10.1097/OPX.0b013e3180339f44; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mostofsky SH, 2001, NEUROLOGY, V57, P423, DOI 10.1212/WNL.57.3.423; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdin L, 2015, J NEUROL NEUROSUR PS, V86, P585, DOI 10.1136/jnnp-2014-308331; Park AHY, 1998, PERCEPT MOTOR SKILL, V87, P1202, DOI 10.2466/pms.1998.87.3f.1202; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Saman Yougan, 2012, Front Neurol, V3, P116, DOI 10.3389/fneur.2012.00116; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Zur O, 2015, DISABIL REHABIL, V37, P2197, DOI 10.3109/09638288.2014.1002577	43	58	58	2	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2016	44	6					1400	1406		10.1177/0363546516632754			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DO5KJ	WOS:000377821700012	26980845				2022-02-06	
J	Solomon, GS; Kuhn, AW; Zuckerman, SL; Casson, IR; Viano, DC; Lovell, MR; Sills, AK				Solomon, Gary S.; Kuhn, Andrew W.; Zuckerman, Scott L.; Casson, Ira R.; Viano, David C.; Lovell, Mark R.; Sills, Allen K.			Participation in Pre-High School Football and Neurological, Neuroradiological, and Neuropsychological Findings in Later Life: A Study of 45 Retired National Football League Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; football; National Football League; exposure; youth	TEST-RETEST RELIABILITY; CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; CONSTRUCT-VALIDITY; ONLINE VERSION; IMPACT; SENSITIVITY; SYMPTOMS	Background: A recent study found that an earlier age of first exposure (AFE) to tackle football was associated with long-term neurocognitive impairment in retired National Football League (NFL) players. Purpose: To assess the association between years of exposure to pre-high school football (PreYOE) and neuroradiological, neurological, and neuropsychological outcome measures in a different sample of retired NFL players. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Forty-five former NFL players were included in this study. All participants prospectively completed extensive history taking, a neurological examination, brain magnetic resonance imaging, and a comprehensive battery of neuropsychological tests. To measure the associations between PreYOE and these outcome measures, multiple regression models were utilized while controlling for several covariates. Results: After applying a Bonferroni correction for multiple comparisons, none of the neurological, neuroradiological, or neuropsychological outcome measures yielded a significant relationship with PreYOE. A second Bonferroni-corrected analysis of a subset of these athletes with self-reported learning disability yielded no significant relationships on paper-and-pencil neurocognitive tests but did result in a significant association between learning disability and computerized indices of visual motor speed and reaction time. Conclusion: The current study failed to replicate the results of a prior study, which concluded that an earlier AFE to tackle football might result in long-term neurocognitive deficits. In 45 retired NFL athletes, there were no associations between PreYOE and neuroradiological, neurological, and neuropsychological outcome measures.	[Solomon, Gary S.; Zuckerman, Scott L.; Sills, Allen K.] Vanderbilt Univ, Vanderbilt Sports Concuss Ctr, Sch Med, Dept Neurol Surg, Med Ctr North T-4224, Nashville, TN 37212 USA; [Kuhn, Andrew W.] Univ Michigan Hlth Syst, MedSport Sports Med & Phys Therapy, Ann Arbor, MI USA; [Casson, Ira R.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Dept Neurol, Hempstead, NY 11550 USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI USA; [Viano, David C.] Wayne State Univ, Dept Biomed Engn & Radiol, Detroit, MI USA; [Lovell, Mark R.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA		Solomon, GS; Sills, AK (corresponding author), Vanderbilt Univ, Vanderbilt Sports Concuss Ctr, Sch Med, Dept Neurol Surg, Med Ctr North T-4224, Nashville, TN 37212 USA.	gary.solomon@vanderbilt.edu	Kuhn, Andrew W/AAM-4820-2020; Solomon, Gary/K-9011-2019	Kuhn, Andrew W/0000-0003-1836-7575; 	Tennessee Titans (National Football League [NFL]); Nashville Predators (National Hockey League); athletic departments of several universities; NFL	One or more of the authors has declared the following potential conflict of interest or source of funding: No grants or outside funding supported this work. G.S.S. receives consulting fees from the Tennessee Titans (National Football League [NFL]), the Nashville Predators (National Hockey League), and the athletic departments of several universities. In addition, he is a member of the ImPACT Advisory Board, receives reimbursement for expenses to board meetings, and also receives royalties from book sales. M.R.L. is chairman and chief scientific officer of ImPACT and served as a member of the NFL's Mild Traumatic Brain Injury (MTBI) Committee from 1994 to 2009. I.R.C. served as a member of the MTBI Committee from 1994 to 2009 and as a cochair from 2007 to 2009. He has consulted for law firms and insurance companies. D.C.V. served as a member of the MTBI Committee from 1994 to 2009 and as a cochair from 2007 to 2009. A.K.S. serves as an unaffiliated neurological consultant for NFL games. Examinations of the 45 NFL retirees were sponsored by the NFL and coordinated with the NFL Players Association.	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Andrikopoulos J, 2015, NEUROLOGY; [Anonymous], 1906, JAMA-J AM MED ASSOC, VXLVI, P122; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babyak MA, RESCALING CONTINUOUS; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Delis D.C., 2000, CALIFORNIA VERBAL LE; Diamond AB, 2014, PHYSICIAN SPORTSMED, V42, P20, DOI 10.3810/psm.2014.09.2071; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Foley C, 2014, CURR SPORT MED REP, V13, P390, DOI 10.1249/JSR.0000000000000104; Folstein M. F., 2001, MINI MENTAL STATE EX; HOLM S, 1979, SCAND J STAT, V6, P65; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kutcher JS., WEAK SCI MAKES BIG M; Larrabee G. J., 2015, NEUROLOGY; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Lezak M, 2004, CONTROLLED WORD ASS; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Maroon JC, 2015, NEUROLOGY; Mautner K, 2015, CLIN J SPORT MED, V25, P355, DOI 10.1097/JSM.0000000000000151; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Partington JE, 1949, PSYCHOL SERV CTR B, V1, P9; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	62	58	57	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2016	44	5					1106	1115		10.1177/0363546515626164			10	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	DL4JD	WOS:000375599600004	26888877				2022-02-06	
J	Feng, Y; Cui, Y; Gao, JL; Li, MH; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Cui, CM; Cui, JZ				Feng, Yan; Cui, Ying; Gao, Jun-ling; Li, Ming-hang; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia; Wang, Kai-jie; Cui, Chang-meng; Cui, Jian-zhong			Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-kappa B signaling pathway in experimental traumatic brain injury	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						resveratrol; autophagy; traumatic brain injury; Toll-like receptor 4; inflammation	CELL-DEATH; CEREBRAL-ISCHEMIA; INNATE IMMUNITY; DIABETIC MICE; RATS; PATHOPHYSIOLOGY; APOPTOSIS; MODEL; TOLL; CONTRIBUTES	Previous research has demonstrated that traumatic brain injury (TBI) activates autophagy and a neuroinflammatory cascade that contributes to substantial neuronal damage and behavioral impairment, and Toll-like receptor 4 (TLR4) is an important mediator of this cascade. In the present study, we investigated the hypothesis that resveratrol (RV), a natural polyphenolic compound with potent multifaceted properties, alleviates brain damage mediated by TLR4 following TBI. Adult male Sprague Dawley rats, subjected to controlled cortical impact (CCI) injury, were intraperitoneally injected with RV (100 mg/kg, daily for 3 days) after the onset of TBI. The results demonstrated that RV significantly reduced brain edema, motor deficit, neuronal loss and improved spatial cognitive function. Double immunolabeling demonstrated that RV decreased microtubule-associated protein 1 light chain 3 (LC3), TLR4-positive cells co-labeled with the hippocampal neurons, and RV also significantly reduced the number of TLR4-positive neuron-specific nuclear protein (NeuN) cells following TBI. Western blot analysis revealed that RV significantly reduced the protein expression of the autophagy marker proteins, LC3II and Beclin1, in the hippocampus compared with that in the TBI group. Furthermore, the levels of TLR4 and its known downstream signaling molecules, nuclear factor-kappa B (NF-kappa B), and the inflammatory cytokines, interleukin (IL)-1 beta and tumor necrosis factor (TNF)-alpha were also decreased after RV treatment. Our results suggest that RV reduces neuronal autophagy and inflammatory reactions in a rat model of TBI. Thus, we suggest that the neuroprotective effect of RV is associated with the TLR4/NF-kappa B signaling pathway.	[Feng, Yan; Cui, Chang-meng; Cui, Jian-zhong] Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China; [Cui, Ying; Wang, Kai-jie; Cui, Jian-zhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-ling; Li, Ming-hang; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-ling; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia] Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan 063000, Hebei, Peoples R China		Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alayev A, 2015, J CELL BIOCHEM, V116, P450, DOI 10.1002/jcb.24997; Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Baumgarten G, 2001, J INFECT DIS, V183, P1617, DOI 10.1086/320712; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bursch W, 2000, J CELL SCI, V113, P1189; Chang YP, 2015, J CELL PHYSIOL, V230, P1567, DOI 10.1002/jcp.24903; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li JB, 2015, MOL MED REP, V11, P1120, DOI 10.3892/mmr.2014.2955; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu L, 2014, INT J MOL SCI, V15, P6925, DOI 10.3390/ijms15046925; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Seay MD, 2007, CELL HOST MICROBE, V2, P69, DOI 10.1016/j.chom.2007.07.008; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Wang B, 2014, J CELL MOL MED, V18, P1599, DOI 10.1111/jcmm.12312; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Youn HS, 2005, J IMMUNOL, V175, P3339, DOI 10.4049/jimmunol.175.5.3339; Zhang C, 2012, INT J MOL MED, V29, P557, DOI 10.3892/ijmm.2012.885; Zhen L, 2015, ACTA PHARMACOL SIN, V36, P221, DOI 10.1038/aps.2014.131; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	43	58	70	0	8	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	APR	2016	37	4					921	930		10.3892/ijmm.2016.2495			10	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	DI4TS	WOS:000373492900006	26936125	Green Published, hybrid, Green Submitted			2022-02-06	
J	Barlow, KM; Crawford, S; Brooks, BL; Turley, B; Mikrogianakis, A				Barlow, Karen M.; Crawford, Susan; Brooks, Brian L.; Turley, Brenda; Mikrogianakis, Angelo			The Incidence of Postconcussion Syndrome Remains Stable Following Mild Traumatic Brain Injury in Children	PEDIATRIC NEUROLOGY			English	Article						mild traumatic brain injury; concussion; postconcussion syndrome; incidence; diagnostic criteria	POST-CONCUSSIVE SYMPTOMS; EMERGENCY-DEPARTMENT; ADOLESCENTS; PREDICTORS; EPIDEMIOLOGY; DURATION; CRITERIA	BACKGROUND: Improving our knowledge about the natural history and persistence of symptoms following mild traumtic brain injury is a vital step in improving the provision of health cares to children with postconcuss ion syndrome. The purposes of this study were to (1) determine the incidence and persistence of symptoms after mild traumatic brain injury and (2) ascertain whether Diagnostic and Statistical. Manual of Mental Disorders, Fourth Edition (DSM-IV), symptom criteria for postconcussion syndrome in adult are appropriate for use in children. METHODS: A tertiary care pediatric emergency department was the setting for this study. This was a prospective observational follow-up cohort study of children (ages 2 to 18 years) with mild traumatic brain injury. Data were collected in person during the acute presentation, and subseqnent follow-up was performed by telephone at 7-10 days and 1, 2, and 3 months postinjury. Postconcussion Symptom Inventory for parents and children was used. The DSM-IV diagnostic criteria for postconcussion syndrome were explored using receiver operating characteristic curve analysis. RESULTS: A total of 467 children (62.5% boys, median age 12.04, range 2.34-18.0) with mild traumatic brain injury participated. The median time until symptom resolution was 29.0 days (95% confidence intervals: 26.09-31.91). Three months after injury, 11.8% of children with mild traumatic brain injury remained symptomatic. Receiver operating curve characteristic analysis of the postconcussion syndrome criteria successfully classified symptomatic participants at three months postinjury; the adolescent receiver operating characteristic curve was excellent with the area under the curve being 0.928 (P < 0.001, standard error 0.019). CONCLUSIONS: Consistent with our previous study, 11.8% of children presenting to the emergency room with a mild traumatic brain injury remain symptomatic at 3 months postinjury. This is the first study to demonstrate stable incidence rates of postconcussion syndrome in children and that modified DSM-IV criteria can be used to successfully classify postconcussion syndrome in children. Although most children report a decay in symptoms over time, 10% of children develop symptoms even though they initially had a good outcome. Caution should be used when using only parent report as a surrogate for childhood outcomes following a concussion.	[Barlow, Karen M.; Brooks, Brian L.; Mikrogianakis, Angelo] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Crawford, Susan] Alberta Hlth Serv, Calgary, AB, Canada; [Brooks, Brian L.; Turley, Brenda] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada		Barlow, KM (corresponding author), Alberta Childrens Prov Gen Hosp, Pediat & Clin Neurosci, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014; Mikrogianakis, Angelo/AAW-5929-2021	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507; Mikrogianakis, Angelo/0000-0002-8854-0620	Albert Children's Hospital Foundation Grant [10000779]; Psychological Assessment Resources, Inc	Supported by the Albert Children's Hospital Foundation Grant (Project number: 10000779). BLB receives funding from a test publisher (Psychological Assessment Resources, Inc), book royalties from Oxford University Press, and in-kind research support from CNS Vital Signs.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barlow KM, 2014, J CHILD NEU IN PRESS; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; GROSS H, 1993, J NEUROPSYCH CLIN N, V5, P224; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Simon R, 2005, J CLIN ONCOL, V23, P7332, DOI 10.1200/JCO.2005.02.8712; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Vincent, 2008, J INT NEUROPSYCH SOC, V1, P204; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	31	58	58	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	DEC	2015	53	6					491	497		10.1016/j.pediatrneurol.2015.04.011			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	CZ2VG	WOS:000366962100005	26421987				2022-02-06	
J	Li, YZ; Bader, M; Tamargo, I; Rubovitch, V; Tweedie, D; Pick, CG; Greig, NH				Li, Yazhou; Bader, Miaad; Tamargo, Ian; Rubovitch, Vardit; Tweedie, David; Pick, Chaim G.; Greig, Nigel H.			Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cAMP-response element binding protein; glucagon-like peptide-1; liraglutide; neuroprotection; traumatic brain injury	GLUCAGON-LIKE PEPTIDE-1; REVERSES BEHAVIORAL IMPAIRMENTS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; GENE-EXPRESSION; ANIMAL-MODEL; HEAD-INJURY; RECEPTOR; GLP-1; EXENDIN-4	Traumatic brain injury (TBI), a brain dysfunction for which there is no present effective treatment, is often caused by a concussive impact to the head and affects an estimated 1.7 million Americans annually. Our laboratory previously demonstrated that exendin-4, a long-lasting glucagon-like peptide 1 receptor (GLP-1R) agonist, has neuroprotective effects in cellular and animal models of TBI. Here, we demonstrate neurotrophic and neuroprotective effects of a different GLP-1R agonist, liraglutide, in neuronal cultures and a mouse model of mild TBI (mTBI). Liraglutide promoted dose-dependent proliferation in SH-SY5Y cells and in a GLP-1R over-expressing cell line at reduced concentrations. Pre-treatment with liraglutide rescued neuronal cells from oxidative stress-and glutamate excitotoxicity-induced cell death. Liraglutide produced neurotrophic and neuroprotective effects similar to those of exendin-4 in vitro. The cAMP/PKA/pCREB pathway appears to play an important role in this neuroprotective activity of liraglutide. Furthermore, our findings in cell culture were well-translated in a weight drop mTBI mouse model. Post-treatment with a clinically relevant dose of liraglutide for 7 days in mice ameliorated memory impairments caused by mTBI when evaluated 7 and 30 days post trauma. These data cross-validate former studies of exendin-4 and suggest that liraglutide holds therapeutic potential for the treatment of mTBI.	[Li, Yazhou; Tamargo, Ian; Tweedie, David; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Bader, Miaad; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel		Li, YZ (corresponding author), Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA.	liyaz@mail.nih.gov; greign@mail.nih.gov			Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Ari and Regine Aprijaskis Fund at Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (ii) the Ari and Regine Aprijaskis Fund at Tel-Aviv University, and (iii) a grant from the Israel Science Foundation, grant number 108/09. No competing financial interests exist.	Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barger SW, 2004, FRONT BIOSCI-LANDMRK, V9, P3286, DOI 10.2741/1481; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Buse JB, 2013, LANCET, V381, P117, DOI 10.1016/S0140-6736(12)61267-7; Buse JB, 2009, LANCET, V374, P39, DOI 10.1016/S0140-6736(09)60659-0; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Celikyurt IK, 2014, MED SCI MONIT BASIC, V20, P112, DOI 10.12659/MSMBR.891168; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Culmsee Carsten, 2006, Current Alzheimer Research, V3, P269, DOI 10.2174/156720506778249461; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Dragunow M, 2004, FRONT BIOSCI, V9, P100, DOI 10.2741/1197; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hakon J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120074; Holscher C, 2014, ALZHEIMERS DEMENT, V10, pS47, DOI 10.1016/j.jalz.2013.12.009; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Khatri N, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00199; Kim MJ, 2006, J ENDOCRINOL, V188, P623, DOI 10.1677/joe.1.06480; Kinzig KP, 2003, J NEUROSCI, V23, P6163; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mondragon A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104873; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ohtake N, 2014, REGUL PEPTIDES, V190, P1, DOI 10.1016/j.regpep.2014.04.003; Parthsarathy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058784; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scott LJ, 2014, DRUGS, V74, P2161, DOI 10.1007/s40265-014-0321-6; Sharma AN, 2015, METAB BRAIN DIS, V30, P719, DOI 10.1007/s11011-014-9627-z; Sharma MK, 2014, J NEUROCHEM, V128, P459, DOI 10.1111/jnc.12469; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shin S, 2014, MOL METAB, V3, P803, DOI 10.1016/j.molmet.2014.08.001; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Van de Velde S, 2011, P NATL ACAD SCI USA, V108, P16876, DOI 10.1073/pnas.1114228108; Velmurugan K, 2012, ENDOCRINOLOGY, V153, P1116, DOI 10.1210/en.2011-1895; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	82	58	60	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2015	135	6					1203	1217		10.1111/jnc.13169			15	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CZ6DT	WOS:000367192100014	25982185	Bronze, Green Accepted			2022-02-06	
J	Gunawardana, CG; Mehrabian, M; Wang, XZ; Mueller, I; Lubambo, IB; Jonkman, JEN; Wang, H; Schmitt-Ulms, G				Gunawardana, C. Geeth; Mehrabian, Mohadeseh; Wang, Xinzhu; Mueller, Iris; Lubambo, Isabela B.; Jonkman, James E. N.; Wang, Hansen; Schmitt-Ulms, Gerold			The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome	MOLECULAR & CELLULAR PROTEOMICS			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PROTEIN-TAU; ALPHA-SYNUCLEIN; PATHOGENETIC IMPLICATIONS; NEUROFIBRILLARY TANGLES; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; TRANSGENIC MICE; NEURONAL CELLS	The tau protein is central to the etiology of several neurodegenerative diseases, including Alzheimer's disease, a subset of frontotemporal dementias, progressive supranuclear palsy and dementia following traumatic brain injury, yet the proteins it interacts with have not been studied using a systematic discovery approach. Here we employed mild in vivo crosslinking, isobaric labeling, and tandem mass spectrometry to characterize molecular interactions of human tau in a neuroblastoma cell model. The study revealed a robust association of tau with the ribonucleoproteome, including major protein complexes involved in RNA processing and translation, and documented binding of tau to several heat shock proteins, the proteasome and microtubule-associated proteins. Follow-up experiments determined the relative contribution of cellular RNA to the tau interactome and mapped interactions to N- or C-terminal tau domains. We further document that expression of P301L mutant tau disrupts interactions of the C-terminal half of tau with heat shock proteins and the proteasome. The data are consistent with a model whereby a higher propensity of P301L mutant tau to aggregate may reflect a perturbation of its chaperone-assisted stabilization and proteasome-dependent degradation. Finally, using a global proteomics approach, we show that heterologous expression of a tau construct that lacks the C-terminal domain, including the microtubule binding domain, does not cause a discernible shift of the proteome except for a significant direct correlation of steady-state levels of tau and cystatin B.	[Gunawardana, C. Geeth; Mehrabian, Mohadeseh; Wang, Xinzhu; Mueller, Iris; Lubambo, Isabela B.; Wang, Hansen; Schmitt-Ulms, Gerold] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5T 2S8, Canada; [Mehrabian, Mohadeseh; Wang, Xinzhu; Schmitt-Ulms, Gerold] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; [Jonkman, James E. N.] Univ Hlth Network, Adv Opt Microscopy Facil, Toronto, ON M5G 1L7, Canada		Schmitt-Ulms, G (corresponding author), Tanz Ctr Res Neurodegenerat Dis, 60 Leonard Ave,Krembil Discovery Tower, Toronto, ON M5T 2S8, Canada.	g.schmittulms@utoronto.ca	wang, hansen/I-2510-2019	wang, hansen/0000-0003-4414-3372; Jonkman, James/0000-0001-6888-8550; Wang, Xinzhu/0000-0002-1438-1153; Muller, Iris/0000-0001-8542-0175	China-Canada Initiative on Alzheimer's Disease and Related Disorders; Canadian Institute of Health Research (CIHR), CanadaCanadian Institutes of Health Research (CIHR); National Natural Science Foundation NNSF, ChinaNational Natural Science Foundation of China (NSFC); postdoctoral CIHR fellowship; Ontario Trillium Scholarship; W. Garfield Weston Foundation; Canadian Foundation for Innovation (CFI)Canada Foundation for Innovation	This work was supported by an operating grant from the "China-Canada Initiative on Alzheimer's Disease and Related Disorders," a partnership initiative between the Canadian Institute of Health Research (CIHR), Canada, and the National Natural Science Foundation NNSF, China. The mass spectrometry component was enabled by a generous donation, kindly provided by the Irwin family, and a leading edge fund (LEF) infrastructure grant from the Canadian Foundation for Innovation (CFI). C.G.G. gratefully acknowledges support from a postdoctoral CIHR fellowship, M.M. contributed to this project supported by funding from an Ontario Trillium Scholarship, and G.S. received generous support from the W. Garfield Weston Foundation.	Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benussi L, 2005, EXP CELL RES, V308, P78, DOI 10.1016/j.yexcr.2005.04.021; Blair LJ, 2013, J CLIN INVEST, V123, P4158, DOI 10.1172/JCI69003; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Chambraud B, 2010, P NATL ACAD SCI USA, V107, P2658, DOI 10.1073/pnas.0914957107; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Dawson HN, 2001, J CELL SCI, V114, P1179; Dorval V, 2006, J BIOL CHEM, V281, P9919, DOI 10.1074/jbc.M510127200; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Farias GA, 2002, J CELL BIOCHEM, V85, P315, DOI 10.1002/jcb.10133; Fulga TA, 2007, NAT CELL BIOL, V9, P139, DOI 10.1038/ncb1528; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Karagoz GE, 2014, CELL, V156, P963, DOI 10.1016/j.cell.2014.01.037; King ME, 2006, J CELL BIOL, V175, P541, DOI 10.1083/jcb.200605187; King OD, 2012, BRAIN RES, V1462, P61, DOI 10.1016/j.brainres.2012.01.016; Kozielski F, 2011, AMINO ACIDS, V41, P363, DOI 10.1007/s00726-010-0649-5; Lee G, 1998, J CELL SCI, V111, P3167; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leverenz JB, 2007, BRAIN, V130, P1360, DOI 10.1093/brain/awm069; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Li QW, 1998, BIOCHEM BIOPH RES CO, V250, P502, DOI 10.1006/bbrc.1998.9271; Liu YY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.403451; Marcus JN, 2011, J NEUROGENET, V25, P127, DOI 10.3109/01677063.2011.626471; Mehrabian M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114594; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mukrasch MD, 2009, PLOS BIOL, V7, P399, DOI 10.1371/journal.pbio.1000034; NELSON PT, 1993, BRAIN RES, V600, P285, DOI 10.1016/0006-8993(93)91385-6; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P123; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; Patterson KR, 2011, BIOCHEMISTRY-US, V50, P10300, DOI 10.1021/bi2009147; Perreault S, 2009, J NEUROPATH EXP NEUR, V68, P503, DOI 10.1097/NEN.0b013e3181a1fc49; Portelius E, 2008, J PROTEOME RES, V7, P2114, DOI 10.1021/pr7008669; Qureshi HY, 2011, J BIOL CHEM, V286, P5055, DOI 10.1074/jbc.M110.178905; Reynolds CH, 2008, J BIOL CHEM, V283, P18177, DOI 10.1074/jbc.M709715200; Rothbauer U, 2008, MOL CELL PROTEOMICS, V7, P282, DOI 10.1074/mcp.M700342-MCP200; Rudrabhatla P, 2011, FASEB J, V25, P3896, DOI 10.1096/fj.11-181297; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Sandberg A, 2014, J PROTEOMICS, V96, P133, DOI 10.1016/j.jprot.2013.10.035; Schraen-Maschke S, 2008, BIOMARK MED, V2, P363, DOI 10.2217/17520363.2.4.363; Shaner NC, 2007, J CELL SCI, V120, P4247, DOI 10.1242/jcs.005801; Sjoberg MK, 2006, J CELL SCI, V119, P2025, DOI 10.1242/jcs.02907; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; SUPRENANT KA, 1993, J CELL SCI, V104, P445; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Thompson AD, 2012, ACS CHEM BIOL, V7, P1677, DOI 10.1021/cb3002599; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang XS, 2006, PROTEIN PEPTIDE LETT, V13, P679, DOI 10.2174/092986606777790566; Wang YP, 2007, P NATL ACAD SCI USA, V104, P10252, DOI 10.1073/pnas.0703676104; Watts JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000608; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; Yang DS, 2011, BRAIN, V134, P258, DOI 10.1093/brain/awq341; Zhang XM, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M112.436402; Zieske LR, 2006, J EXP BOT, V57, P1501, DOI 10.1093/jxb/erj168	74	58	59	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	1535-9476	1535-9484		MOL CELL PROTEOMICS	Mol. Cell. Proteomics	NOV	2015	14	11					3000	3014		10.1074/mcp.M115.050724			15	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CX3ZA	WOS:000365636800013	26269332	Green Published, hybrid			2022-02-06	
J	Zhang, B; Bailey, WM; Braun, KJ; Gensel, JC				Zhang, Bei; Bailey, William M.; Braun, Kaitlyn J.; Gensel, John C.			Age decreases macrophage IL-10 expression: Implications for functional recovery and tissue repair in spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Microglia; Contusion; Brain; Monocyte: IL-12p40; IL-12; Neuroprotection; Inflammation; Macrophage polarization; Macrophage polarity; Traumatic; Neurotrauma; Aged; Aging; Adult; Digigait; Grid walk; Locomotor; BMS	MONOCYTE-DERIVED MACROPHAGES; ALTERNATIVE ACTIVATION; LOCOMOTOR RECOVERY; SYNAPTIC PROTEINS; OXIDATIVE STRESS; DOWN-REGULATION; TIME-COURSE; BRAIN; INTERLEUKIN-10; MICROGLIA	Macrophages with different activation states are present after spinal cord injury (SCI). M1 macrophages purportedly promote secondary injury processes while M2 cells support axon growth. The average age at the time of SCI has increased in recent decades, however, little is known about how different physiological factors contribute to macrophage activation states after SCI. Here we investigate the effect of age on IL-10, a key indicator of M2 macrophage activation. Following mild-moderate SCI in 4 and 14 month old (MO) mice we detected significantly reduced IL-10 expression with age in the injured spinal cord. Specifically, CD86/IL-10 positive macrophages, also known as M2b or regulatory macrophages, were reduced in 14 vs. 4 MO SCI animals. This age-dependent shift in macrophage phenotype was associated with impaired functional recovery and enhanced tissue damage in 14-month-old SCI mice. In vitro, M2b macrophages release anti-inflammatory cytokines without causing neurotoxicity, suggesting that imbalances in the M2b response in 14-month-old mice may be contributing to secondary injury processes. Our data indicate that age is an important factor that regulates SCI inflammation and recovery even to mild-moderate injury. Further, alterations in macrophage activation states may contribute to recovery and we have identified the M2b phenotype as a potential target for therapeutic intervention. (C) 2015 Elsevier Inc. All rights reserved.	[Zhang, Bei; Bailey, William M.; Braun, Kaitlyn J.; Gensel, John C.] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Gensel, JC (corresponding author), Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.	gensel.1@uky.edu		, John/0000-0001-8980-108X	Cardinal Hill Endowment; Craig H. Neilsen Foundation; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS051220 P30]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	We would like to thank Peter Rock, John Godbout, Ashley Fenn, Phillip Popovich, Amy Tovar, Linda Simmerman, Michael Orr, and Chris Richards for technical advice and support. The current project was made possible by support from a Cardinal Hill Endowment to Joe Springer, the Craig H. Neilsen Foundation, and the NINDS NS051220 P30 grant to the University of Kentucky.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BURGESS AW, 1985, J BIOL CHEM, V260, P6004; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Dlakic WM, 2007, J VIROL, V81, P4615, DOI 10.1128/JVI.02628-06; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elcombe SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060086; Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Furlan JC, 2009, J NEUROTRAUM, V26, P1707, DOI [10.1089/neu.2009.0888, 10.1089/neu.2009-0888]; Furlan JC, 2010, NEUROBIOL AGING, V31, P434, DOI 10.1016/j.neurobiolaging.2008.05.003; Genovese T, 2009, J NEUROCHEM, V108, P1360, DOI 10.1111/j.1471-4159.2009.05899.x; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gensel JC, 2015, J NEUROSCI, V35, P9966, DOI 10.1523/JNEUROSCI.0337-15.2015; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gwak YS, 2004, J NEUROTRAUM, V21, P983, DOI 10.1089/0897715041650999; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; Hayashi Y, 2008, J NEUROSCI, V28, P8624, DOI 10.1523/JNEUROSCI.1957-08.2008; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hooshmand MJ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-15; Huang W, 2014, PM&R, V6, P332, DOI 10.1016/j.pmrj.2013.10.006; Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kuo HS, 2011, J NEUROSCI, V31, P4137, DOI 10.1523/JNEUROSCI.2592-10.2011; Kuzumaki N, 2010, SYNAPSE, V64, P721, DOI 10.1002/syn.20800; London A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00034; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497; McEwen ML, 2006, J NEUROTRAUM, V23, P1632, DOI 10.1089/neu.2006.23.1632; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Mosser David M, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1402s83; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; National Spinal Cord Injury Statistical Center, 2013, J Spinal Cord Med, V36, P1, DOI 10.1179/1079026813Z.000000000136; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Richwine AF, 2005, BRAIN BEHAV IMMUN, V19, P512, DOI 10.1016/j.bbi.2004.12.005; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shin T, 2013, MOL NEUROBIOL, V47, P1011, DOI 10.1007/s12035-013-8398-6; Siegenthaler MM, 2008, EXP NEUROL, V213, P363, DOI 10.1016/j.expneurol.2008.06.015; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Stout RD, 2005, IMMUNOL REV, V205, P60, DOI 10.1111/j.0105-2896.2005.00260.x; Sudduth TL, 2013, J NEUROSCI, V33, P9684, DOI 10.1523/JNEUROSCI.1220-13.2013; Thawer SG, 2013, J NEUROIMMUNOL, V261, P7, DOI 10.1016/j.jneuroim.2013.04.008; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Wang X, 2007, J NEUROCHEM, V103, P2380, DOI 10.1111/j.1471-4159.2007.04978.x; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Zhang B, 2014, EXP NEUROL, V258, P112, DOI 10.1016/j.expneurol.2014.04.007; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	67	58	61	3	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2015	273						83	91		10.1016/j.expneurol.2015.08.001			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW7BB	WOS:000365151800008	26263843	Green Accepted			2022-02-06	
J	Bossers, SM; Schwarte, LA; Loer, SA; Twisk, JWR; Boer, C; Schober, P				Bossers, Sebastiaan M.; Schwarte, Lothar A.; Loer, Stephan A.; Twisk, Jos W. R.; Boer, Christa; Schober, Patrick			Experience in Prehospital Endotracheal Intubation Significantly Influences Mortality of Patients with Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							RAPID-SEQUENCE INTUBATION; GLASGOW COMA SCALE; HEAD-INJURY; YOUNG-PEOPLE; FOLLOW-UP; IMPACT; MANAGEMENT; MODERATE; OUTCOMES; FIELD	Background Patients with severe traumatic brain injury (TBI) are at high risk for airway obstruction and hypoxia at the accident scene, and routine prehospital endotracheal intubation has been widely advocated. However, the effects on outcome are unclear. We therefore aim to determine effects of prehospital intubation on mortality and hypothesize that such effects may depend on the emergency medical service providers' skill and experience in performing this intervention. Methods and Findings PubMed, Embase and Web of Science were searched without restrictions up to July 2015. Studies comparing effects of prehospital intubation versus non-invasive airway management on mortality in non-paediatric patients with severe TBI were selected for the systematic review. Results were pooled across a subset of studies that met predefined quality criteria. Random effects meta-analysis, stratified by experience, was used to obtain pooled estimates of the effect of prehospital intubation on mortality. Meta-regression was used to formally assess differences between experience groups. Mortality was the main outcome measure, and odds ratios refer to the odds of mortality in patients undergoing prehospital intubation versus odds of mortality in patients who are not intubated in the field. The study was registered at the International Prospective Register of Systematic Reviews (PROSPERO) with number CRD42014015506. The search provided 733 studies, of which 6 studies including data from 4772 patients met inclusion and quality criteria for the meta-analysis. Prehospital intubation by providers with limited experience was associated with an approximately twofold increase in the odds of mortality (OR 2.33, 95% CI 1.61 to 3.38, p<0.001). In contrast, there was no evidence for higher mortality in patients who were intubated by providers with extended level of training (OR 0.75, 95% CI 0.52 to 1.08, p = 0.126). Metaregression confirmed that experience is a significant predictor of mortality (p = 0.009). Conclusions Effects of prehospital endotracheal intubation depend on the experience of prehospital healthcare providers. Intubation by paramedics who are not well skilled to do so markedly increases mortality, suggesting that routine prehospital intubation of TBI patients should be abandoned in emergency medical services in which providers do not have ample training, skill and experience in performing this intervention.	[Bossers, Sebastiaan M.; Schwarte, Lothar A.; Loer, Stephan A.; Boer, Christa; Schober, Patrick] Vrije Univ Amsterdam, Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Schwarte, Lothar A.; Schober, Patrick] Vrije Univ Amsterdam, Med Ctr, Helicopter Emergency Med Serv Lifeliner 1, Amsterdam, Netherlands; [Twisk, Jos W. R.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Boer, Christa] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands		Schober, P (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands.	p.schober@vumc.nl	Bossers, Sebastiaan/AAE-1085-2020; Schober, Patrick/G-7400-2012	Bossers, Sebastiaan/0000-0002-2396-2777; Schober, Patrick/0000-0003-0814-081X; Boer, Christa/0000-0002-7781-6951	Dutch Brain Foundation [F2010(1)-14]	This article was funded by the Dutch Brain Foundation, project number F2010(1)-14 (https://www.hersenstichting.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Blyth A, 2014, BMJ-BRIT MED J, P348; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; BOIDIN MP, 1985, BRIT J ANAESTH, V57, P306, DOI 10.1093/bja/57.3.306; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bukur M, 2011, J SURG RES, V170, pE117, DOI 10.1016/j.jss.2011.04.005; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; Hammell CL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1683; Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Humphries RL, 2008, CURRENT DIAGNOSIS TR, P313; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; Irvin CB, 2010, PREHOSP DISASTER MED, V25, P541, DOI 10.1017/S1049023X00008736; Karamanos E, 2014, PREHOSP DISASTER MED, V29, P32, DOI 10.1017/S1049023X13008947; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; SAFAR P, 1959, J APPL PHYSIOL, V14, P760, DOI 10.1152/jappl.1959.14.5.760; Salomone JP, 2008, TRAUMA, P121; SINGBARTL G, 1985, ANASTH INTENSIV NOTF, V20, P251, DOI 10.1055/s-2007-1003119; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Stubbs B., 2017, BMJ, V7, P1, DOI [10.1038/s41467-019-10003-8, 10.1038/s41598-017-07579-w, DOI 10.1136/BMJ.B2535]; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tuma M, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/135986; Tuominen R, 2012, BRAIN INJURY, V26, P1697, DOI 10.3109/02699052.2012.722256; Vandromme MJ, 2011, J TRAUMA, V71, P1615, DOI 10.1097/TA.0b013e31822a30a1; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2014, EMERG MED J, V31, P186, DOI 10.1136/emermed-2012-202101; Wells G., NEWCASTLE OTTAWA SCA; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	59	58	59	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2015	10	10							e0141034	10.1371/journal.pone.0141034			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU1VG	WOS:000363309200054	26496440	Green Submitted, Green Published, gold			2022-02-06	
J	Wang, YC; Reis, C; Applegate, R; Stier, G; Martin, R; Zhang, JH				Wang, Yuechun; Reis, Cesar; Applegate, Richard, II; Stier, Gary; Martin, Robert; Zhang, John H.			Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Innate cerebroprotection; Stroke; Ischemia; Preconditioning; Postconditioning; Perconditioning	ENDOPLASMIC-RETICULUM STRESS; FOCAL CEREBRAL-ISCHEMIA; GLIAL GLUTAMATE TRANSPORTER-1; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; GERBIL HIPPOCAMPUS; GLOBAL-ISCHEMIA; RAT-BRAIN; TNF-ALPHA; BEHAVIORAL DEFICITS	In the area of brain injury and neurodegenerative diseases, a plethora of experimental and clinical evidence strongly indicates the promise of therapeutically exploiting the endogenous adaptive system at various levels like triggers, mediators and the end-effectors to stimulate and mobilize intrinsic protective capacities against brain injuries. It is believed that ischemic pre-conditioning and post-conditioning are actually the strongest known interventions to stimulate the innate neuroprotective mechanism to prevent or reverse neurodegenerative diseases including stroke and traumatic brain injury. Recently, studies showed the effectiveness of ischemic per-conditioning in some organs. Therefore the term ischemic conditioning, including all interventions applied pre-, per- and post-ischemia, which spans therapeutic windows in 3 time periods, has recently been broadly accepted by scientific communities. In addition, it is extensively acknowledged that ischemia-mediated protection not only affects the neurons but also all the components of the neurovascular network (consisting of neurons, glial cells, vascular endothelial cells, pericytes, smooth muscle cells, and venule/veins). The concept of cerebroprotection has been widely used in place of neuroprotection. Intensive studies on the cellular signaling pathways involved in ischemic conditioning have improved the mechanistic understanding of tolerance to cerebral ischemia. This has added impetus to exploration for potential pharmacologic mimetics, which could possibly induce and maximize inherent protective capacities. However, most of these studies were performed in rodents, and the efficacy of these mimetics remains to be evaluated in human patients. Several classical signaling pathways involving apoptosis, inflammation, or oxidation have been elaborated in the past decades. Newly characterized mechanisms are emerging with the advances in biotechnology and conceptual renewal. In this review we are going to focus on those recently reported methodological and mechanistic discoveries in the realm of ischemic conditioning. Due to the varied time differences of ischemic conditioning in different animal models and clinical trials, it is important to define optimal timing to achieve the best conditioning induced neuroprotection. This brings not only an opportunity in the treatment of stroke, but challenges as well, as data is just becoming available and the procedures are not yet optimized. The purpose of this review is to shed light on exploiting these ischemic conditioning modalities to protect the cerebrovascular system against diverse injuries and neurodegenerative disorders. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Yuechun; Zhang, John H.] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; [Reis, Cesar; Applegate, Richard, II; Stier, Gary; Martin, Robert; Zhang, John H.] Loma Linda Univ, Med Ctr, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Wang, Yuechun] Jinan Univ, Sch Med, Dept Physiol, Guangzhou, Guangdong, Peoples R China		Zhang, JH (corresponding author), Loma Linda Univ, Sch Med, Dept Anesthesiol, 11041 Campus St,Risley Hall,Room 219, Loma Linda, CA 92354 USA.	johnzhang3910@Yahoo.com		Applegate II, Richard/0000-0002-1454-4549	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS082184, R01NS043338] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043338, P01 NS082184] Funding Source: Medline		Abete P, 1997, J AM COLL CARDIOL, V30, P947, DOI 10.1016/S0735-1097(97)00256-8; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Andjelkovic AV, 2003, J CEREBR BLOOD F MET, V23, P1348, DOI 10.1097/01.WCB.0000091762.61714.FE; Ates E, 2002, TRANSPLANTATION, V74, P1247, DOI 10.1097/01.TP.0000032752.61372.36; AUCHAMPACH JA, 1992, CARDIOVASC RES, V26, P1054, DOI 10.1093/cvr/26.11.1054; Bacigaluppi Marco, 2010, Open Neurol J, V4, P34, DOI 10.2174/1874205X01004020034; Bahjat FR, 2013, TRANSL STROKE RES, V4, P89, DOI 10.1007/s12975-012-0223-4; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Bastide M, 2003, J CEREBR BLOOD F MET, V23, P399, DOI 10.1097/01.WCB.0000050064.57184.F2; Bell KFS, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/689524; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bi Qi, 2011, Zhonghua Nei Ke Za Zhi, V50, P140; Bickler PE, 2009, NEUROSCIENCE, V160, P51, DOI 10.1016/j.neuroscience.2009.02.013; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bu QX, 2014, BRAIN RES, V1558, P100, DOI 10.1016/j.brainres.2014.02.034; Burda J, 2003, NEUROCHEM RES, V28, P1213, DOI 10.1023/A:1024232513106; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Chen DD, 2014, TRANSL STROKE RES, V5, P156, DOI 10.1007/s12975-013-0320-z; Chen F, 2014, PROG NEUROBIOL, V115, P246, DOI 10.1016/j.pneurobio.2013.12.007; Chen Jiao-Jiao, 2008, Neurosci Bull, V24, P183, DOI 10.1007/s12264-008-0183-6; CHOI DW, 1987, J NEUROSCI, V7, P357; Connolly M, 2013, CLIN NEUROL NEUROSUR, V115, P2124, DOI 10.1016/j.clineuro.2013.07.038; Danielisova V, 2005, NEUROCHEM RES, V30, P559, DOI 10.1007/s11064-005-2690-4; Dave KR, 2005, J NEUROSCI RES, V82, P665, DOI 10.1002/jnr.20674; DeFazio RA, 2009, J CEREBR BLOOD F MET, V29, P375, DOI 10.1038/jcbfm.2008.126; del Zoppo G J, 2000, Thromb Res, V98, P73, DOI 10.1016/S0049-3848(00)00218-8; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Della-Morte D, 2012, PHARMACOGENOMICS, V13, P1741, DOI [10.2217/PGS.12.157, 10.2217/pgs.12.157]; Deng J, 2014, PROG NEUROBIOL, V115, P210, DOI 10.1016/j.pneurobio.2014.01.001; Dezfulian C, 2013, TRANSL STROKE RES, V4, P19, DOI 10.1007/s12975-012-0224-3; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Ding YH, 2005, ACTA NEUROPATHOL, V109, P237, DOI 10.1007/s00401-004-0943-y; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Douen AG, 2000, J NEUROCHEM, V75, P812, DOI 10.1046/j.1471-4159.2000.0750812.x; Durukan Aysan, 2010, Exp Transl Stroke Med, V2, P2, DOI 10.1186/2040-7378-2-2; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Frassdorf J, 2009, J THORAC CARDIOV SUR, V137, P1436, DOI 10.1016/j.jtcvs.2008.04.034; Furuya K, 2005, J NEUROSURG, V103, P715, DOI 10.3171/jns.2005.103.4.0715; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046092; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Ghiardi GJ, 1999, VISION RES, V39, P2519, DOI 10.1016/S0042-6989(99)00038-3; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Gong SJ, 2012, NEUROCHEM RES, V37, P527, DOI 10.1007/s11064-011-0639-3; Gonzalez NR, 2013, ACTA NEUROCHIR SUPPL, V115, P193, DOI 10.1007/978-3-7091-1192-5_36; Hahn CD, 2011, STROKE, V42, P2960, DOI 10.1161/STROKEAHA.111.622340; Halkos ME, 2004, ANN THORAC SURG, V78, P961, DOI 10.1016/j.athoracsur.2004.03.033; Hao L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/468748; Hashiguchi A, 2004, J CEREBR BLOOD F MET, V24, P271, DOI 10.1097/01.WCB.0000110539.96047.FC; Hayakawa K, 2010, J CEREBR BLOOD F MET, V30, P871, DOI 10.1038/jcbfm.2009.257; Hayes K, 2008, ACTA NEUROPATHOL, V115, P289, DOI 10.1007/s00401-008-0340-z; He Z, 2005, CURR NEUROVASC RES, V2, P365, DOI 10.2174/156720205774962674; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Hepponstall M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048284; Hoda MN, 2014, TRANSL STROKE RES, V5, P484, DOI 10.1007/s12975-013-0318-6; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Huber R, 1999, NEUROREPORT, V10, P1543, DOI 10.1097/00001756-199905140-00027; Igarashi Y, 1999, BIOCHEM BIOPH RES CO, V261, P108, DOI 10.1006/bbrc.1999.0992; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jiang T, 2015, MOL NEUROBIOL, V51, P220, DOI 10.1007/s12035-014-8725-6; Jneid H, 2005, CARDIOVASC DRUG THER, V19, P211, DOI 10.1007/s10557-005-2466-8; Johnson WD, 2011, FOOD CHEM TOXICOL, V49, P3319, DOI 10.1016/j.fct.2011.08.023; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; KATO H, 1992, BRAIN RES BULL, V29, P395, DOI 10.1016/0361-9230(92)90074-8; KATO H, 1992, BRAIN RES BULL, V29, P559, DOI 10.1016/0361-9230(92)90123-F; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; Keep RF, 2014, TRANSL STROKE RES, V5, P535, DOI 10.1007/s12975-014-0363-9; Kharbanda RK, 2002, CIRCULATION, V106, P2881, DOI 10.1161/01.CIR.0000043806.51912.9B; Kim EJ, 2008, J CEREBR BLOOD F MET, V28, P1329, DOI 10.1038/jcbfm.2008.26; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Koch S, 2014, J CEREBR BLOOD F MET, V34, P933, DOI 10.1038/jcbfm.2014.42; Koch S, 2013, TRANSL STROKE RES, V4, P15, DOI 10.1007/s12975-012-0220-7; Koch S, 2013, TRANSL STROKE RES, V4, P1, DOI 10.1007/s12975-012-0252-z; Koch S, 2012, STROKE, V43, P1455, DOI 10.1161/STROKEAHA.111.646919; Koch S, 2011, STROKE, V42, P1387, DOI 10.1161/STROKEAHA.110.605840; Koch S, 2010, TRANSL STROKE RES, V1, P161, DOI 10.1007/s12975-010-0025-5; Koch Sebastian, 2007, J Stroke Cerebrovasc Dis, V16, P114, DOI 10.1016/j.jstrokecerebrovasdis.2007.01.002; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Kondo T, 1996, NEUROSCI LETT, V208, P101, DOI 10.1016/0304-3940(96)12555-6; Konstantinov IE, 2004, PHYSIOL GENOMICS, V19, P143, DOI 10.1152/physiolgenomics.00046.2004; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kunze A, 2014, TRANSL STROKE RES, V5, P569, DOI 10.1007/s12975-014-0337-y; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lalancette-Hebert M, 2012, J NEUROSCI, V32, P10383, DOI 10.1523/JNEUROSCI.1498-12.2012; Lange-Asschenfeldt C, 2004, J CEREBR BLOOD F MET, V24, P636, DOI 10.1097/01.WCB.0000121235.42748.BF; Lavignon M, 1992, Antisense Res Dev, V2, P315; Lee S. R., 2014, TRANSL STROKE RES; Lehotsky J, 2004, GEN PHYSIOL BIOPHYS, V23, P401; Lehotsky J, 2002, FRONT BIOSCI-LANDMRK, V7, pD53, DOI 10.2741/lehotsky; Lehotsky J, 2002, GEN PHYSIOL BIOPHYS, V21, P31; Lehotsky J, 2009, ANAT REC, V292, P2002, DOI 10.1002/ar.20970; Leng TD, 2014, PROG NEUROBIOL, V115, P189, DOI 10.1016/j.pneurobio.2013.12.008; Li WJ, 2006, J CEREBR BLOOD F MET, V26, P181, DOI 10.1038/sj.jcbfm.9600180; Lin HW, 2011, ANTIOXID REDOX SIGN, V14, P1853, DOI 10.1089/ars.2010.3467; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu AJ, 2011, J NEUROCHEM, V119, P202, DOI 10.1111/j.1471-4159.2011.07396.x; Liu C, 2005, NEUROSCIENCE, V134, P69, DOI 10.1016/j.neuroscience.2005.03.036; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144, DOI 10.1152/ajpcell.2000.278.1.C144; Liu JL, 2014, PROG NEUROBIOL, V115, P138, DOI 10.1016/j.pneurobio.2013.11.004; Liu XR, 2014, TRANSL STROKE RES, V5, P692, DOI 10.1007/s12975-014-0359-5; Liu XQ, 2009, ACTA PHARMACOL SIN, V30, P1071, DOI 10.1038/aps.2009.105; Liu XH, 2007, BIOCHEM BIOPH RES CO, V359, P628, DOI 10.1016/j.bbrc.2007.05.129; Liu YH, 2006, CAN J ANAESTH, V53, P194, DOI 10.1007/BF03021827; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lorgis L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048513; Luo TF, 2013, TRANSL STROKE RES, V4, P581, DOI 10.1007/s12975-013-0299-5; Ma J., 2012, COCHRANE DB SYST REV, V9; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Mangoni AA, 2010, PHARMACOEPIDEM DR S, V19, P490, DOI 10.1002/pds.1945; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Meller R, 2013, TRANSL STROKE RES, V4, P40, DOI 10.1007/s12975-012-0246-x; Meng R, 2012, NEUROLOGY, V79, P1853, DOI 10.1212/WNL.0b013e318271f76a; Mergenthaler P, 2011, J PHYSIOL-LONDON, V589, P4147, DOI 10.1113/jphysiol.2011.209718; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakajima T, 2002, NEUROSCI LETT, V331, P13, DOI 10.1016/S0304-3940(02)00752-8; Nakajima T, 2004, J VET MED SCI, V66, P521, DOI 10.1292/jvms.66.521; Nakamura H, 2006, LIFE SCI, V78, P1713, DOI 10.1016/j.lfs.2005.08.008; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Narayanan SV, 2013, CURR OPIN NEUROL, V26, P1, DOI 10.1097/WCO.0b013e32835bf200; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nepal S, 2013, BBA-MOL CELL RES, V1833, P2111, DOI 10.1016/j.bbamcr.2013.05.013; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Otani H, 2008, ANTIOXID REDOX SIGN, V10, P207, DOI 10.1089/ars.2007.1679; Ovbiagele B, 2013, STROKE, V44, P2361, DOI 10.1161/STR.0b013e31829734f2; Park JA, 2003, BIOCHEM BIOPH RES CO, V311, P247, DOI 10.1016/j.bbrc.2003.09.129; Pauly M, 2012, AM J PATHOL, V181, P583, DOI 10.1016/j.ajpath.2012.04.004; Pavlikova M, 2009, CELL MOL NEUROBIOL, V29, P909, DOI 10.1007/s10571-009-9374-6; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; Perez-Pinzon MA, 2007, COMP BIOCHEM PHYS A, V147, P291, DOI 10.1016/j.cbpa.2006.08.032; Perez-Pinzon MA, 2012, J CEREBR BLOOD F MET, V32, P1362, DOI 10.1038/jcbfm.2012.32; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; Petcu EB, 2008, CURR NEUROVASC RES, V5, P214, DOI 10.2174/156720208786413424; Petegnief V, 2013, TRANSL STROKE RES, V4, P663, DOI 10.1007/s12975-013-0277-y; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Pignataro G, 2014, TRANSL STROKE RES, V5, P145, DOI 10.1007/s12975-013-0308-8; Plamondon H, 1999, J CEREBR BLOOD F MET, V19, P1296, DOI 10.1097/00004647-199912000-00002; Puisieux F, 2000, EUR J PHARMACOL, V389, P71, DOI 10.1016/S0014-2999(99)00893-6; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Racay P, 2007, NEUROCHEM RES, V32, P1823, DOI 10.1007/s11064-007-9437-3; Racay P, 2009, CELL MOL NEUROBIOL, V29, P901, DOI 10.1007/s10571-009-9373-7; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ramzy D, 2006, CARDIOVASC RES, V70, P174, DOI 10.1016/j.cardiores.2006.01.020; Raval AP, 2003, J NEUROSCI, V23, P384, DOI 10.1523/JNEUROSCI.23-02-00384.2003; Rehni AK, 2007, PHARMACOL REP, V59, P192; Reshef A, 1996, BRAIN RES, V741, P252, DOI 10.1016/S0006-8993(96)00939-0; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Satoh K, 2011, BRAIN RES, V1382, P266, DOI 10.1016/j.brainres.2011.01.049; Schultz JE, 1997, J MOL CELL CARDIOL, V29, P1055, DOI 10.1006/jmcc.1996.0358; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Schwartz Longacre L, 2011, CIRCULATION, V124, P1172, DOI 10.1161/CIRCULATIONAHA.111.032698; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sepulveda MR, 2008, MOL CELL NEUROSCI, V38, P461, DOI 10.1016/j.mcn.2008.02.012; Shah NH, 2014, TRANSL STROKE RES, V5, P38, DOI 10.1007/s12975-013-0297-7; Shao B, 2012, CURR DRUG TARGETS, V13, P188, DOI 10.2174/138945012799201702; Sheng R, 2012, AUTOPHAGY, V8, P310, DOI 10.4161/auto.18673; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Sommer C, 2003, ACTA NEUROPATHOL, V105, P197, DOI 10.1007/s00401-002-0632-7; Sommer C, 2002, STROKE, V33, P1698, DOI 10.1161/01.STR.0000016404.14407.77; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stroev S A, 2009, Neurosci Behav Physiol, V39, P1, DOI 10.1007/s11055-008-9091-5; Stroev SA, 2004, J NEUROSCI RES, V78, P563, DOI 10.1002/jnr.20282; Sun HS, 2013, ACTA PHARMACOL SIN, V34, P24, DOI 10.1038/aps.2012.138; Tanaka K, 2003, ANESTHESIOLOGY, V98, P935, DOI 10.1097/00000542-200304000-00021; Tang LH, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/107091; Tewari Anurag, 2014, J Anaesthesiol Clin Pharmacol, V30, P160, DOI 10.4103/0970-9185.130001; Urban P, 2009, CELL MOL NEUROBIOL, V29, P181, DOI 10.1007/s10571-008-9309-7; Urikova A, 2006, CELL MOL NEUROBIOL, V26, P1343, DOI 10.1007/s10571-006-9030-3; Vinten-Johansen J, 2011, J CARDIOVASC PHARM T, V16, P260, DOI 10.1177/1074248411415270; Voellmy R, 2004, PROG NUCLEIC ACID RE, V78, P143, DOI 10.1016/S0079-6603(04)78004-6; Wali B, 2014, BRAIN, V137, P486, DOI 10.1093/brain/awt319; Wang LT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079814; Wang MM, 2013, TRANSL STROKE RES, V4, P3, DOI 10.1007/s12975-012-0219-0; Wang X, 2014, NEUROSCIENCE, V274, P393, DOI 10.1016/j.neuroscience.2014.05.053; Warzecha Z, 2007, J PHYSIOL PHARMACOL, V58, P303; Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A; Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005; Wei N, 2013, CNS NEUROSCI THER, V19, P753, DOI 10.1111/cns.12123; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wick A, 2002, J NEUROSCI, V22, P6401; Willis CL, 2004, GLIA, V45, P325, DOI 10.1002/glia.10333; Wootton LL, 2004, BBA-BIOMEMBRANES, V1664, P189, DOI 10.1016/j.bbamem.2004.05.009; Wu JC, 2006, ACTA BIOCH BIOPH SIN, V38, P219, DOI 10.1111/j.1745-7270.2006.00156.x; Xie ZL, 2011, DIABETES, V60, P1770, DOI 10.2337/db10-0351; Yokobori S, 2013, TRANSL STROKE RES, V4, P25, DOI 10.1007/s12975-012-0226-1; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zemke D, 2004, NEUROTOXICOLOGY, V25, P895, DOI 10.1016/j.neuro.2004.03.009; Zhang J., 2012, COCHRANE DB SYST REV, V5; Zhang Y, 2001, LIFE SCI, V68, P1013, DOI 10.1016/S0024-3205(00)01004-3; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhao L, 2006, J CEREBR BLOOD F MET, V26, P1128, DOI 10.1038/sj.jcbfm.9600269; Zheng S, 2003, NEUROSCIENCE, V118, P99, DOI 10.1016/S0306-4522(02)00767-4; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172; Zhou AM, 2004, NEUROSCI RES, V48, P397, DOI 10.1016/j.neures.2003.12.010; Zhou YL, 2011, STROKE, V42, P439, DOI 10.1161/STROKEAHA.110.592162	218	58	62	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		26	40		10.1016/j.expneurol.2015.04.009			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	CV6AS	WOS:000364353700005	25900056	Green Accepted			2022-02-06	
J	Zehendner, CM; Sebastiani, A; Hugonnet, A; Bischoff, F; Luhmann, HJ; Thal, SC				Zehendner, Christoph M.; Sebastiani, Anne; Hugonnet, Andre; Bischoff, Florian; Luhmann, Heiko J.; Thal, Serge C.			Traumatic brain injury results in rapid pericyte loss followed by reactive pericytosis in the cerebral cortex	SCIENTIFIC REPORTS			English	Article							BARRIER; RECEPTOR; HEALTH; CELLS; KEY	Accumulating evidence suggests a pivotal role of PDGFR beta positive cells, a specific marker for central nervous system (CNS) pericytes, in tissue scarring. Identification of cells that contribute to tissue reorganization in the CNS upon injury is a crucial step to develop novel treatment strategies in regenerative medicine. It has been shown that pericytes contribute to scar formation in the spinal cord. It is further known that ischemia initially triggers pericyte loss in vivo, whilst brain trauma is capable of inducing pericyte detachment from cerebral vessels. These data point towards a significant role of pericytes in CNS injury. The temporal and spatial dynamics of PDGFR beta cells and their responses in traumatic brain injury are poorly understood. Here we show that PDGFR beta positive cells initially decline in the acute phase following experimental traumatic brain injury. However, PDGFR beta positive cells increase significantly in the trauma zone days after brain injury. Using various pericyte markers we identify these cells to be pericytes that are demarcated by reactive gliosis. Our data indicate that brain trauma causes a biphasic response of pericytes in the early phase of brain trauma that may be of relevance for the understanding of pathological cellular responses in traumatic brain injury.	[Zehendner, Christoph M.; Luhmann, Heiko J.] Johannes Gutenberg Univ Mainz, Inst Physiol, Univ Med Ctr, D-55122 Mainz, Germany; [Sebastiani, Anne; Hugonnet, Andre; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, D-55122 Mainz, Germany		Zehendner, CM (corresponding author), Goethe Univ Frankfurt, Inst Cardiovasc Regenerat, Dept Cardiol, ZIM 3, Frankfurt, Germany.	zehendner@med.uni-frankfurt.de; thal@uni-mainz.de	Thal, Serge/D-6593-2011; Luhmann, Heiko J./N-8797-2019	Thal, Serge/0000-0002-1222-8729; Luhmann, Heiko J./0000-0002-7934-8661	Johannes Gutenberg-University of Mainz; ECCPS clinical career grant (DFG)German Research Foundation (DFG); LOEWE Cell and Gene Therapy grant (State of Hesse); Goethe University Frankfurt; DFGGerman Research Foundation (DFG)European Commission [SFB 834]	We thank Beate Krumm for excellent technical assistance. This study was supported by DFG grants to HJL and SCT. CMZ received support from: the Johannes Gutenberg-University of Mainz (Start up grant), ECCPS clinical career grant (DFG), LOEWE Cell and Gene Therapy grant (State of Hesse) and a start up grant from the Goethe University Frankfurt. FB is supported by a scholarship of the DFG (SFB 834). We thank the IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB) in Mainz for confocal image acquisition.	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Birbrair A, 2013, AM J PHYSIOL-CELL PH, V305, pC1098, DOI 10.1152/ajpcell.00171.2013; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Chintalgattu V, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005066; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Fernandez-Klett F, 2013, J CEREBR BLOOD F MET, V33, P428, DOI 10.1038/jcbfm.2012.187; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Karow M, 2013, BIOESSAYS, V35, P771, DOI 10.1002/bies.201300055; Karow M, 2012, CELL STEM CELL, V11, P471, DOI 10.1016/j.stem.2012.07.007; Krueger M, 2010, GLIA, V58, P1, DOI 10.1002/glia.20898; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Shen J, 2012, J CEREBR BLOOD F MET, V32, P353, DOI 10.1038/jcbfm.2011.136; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Timaru-Kast R, 2015, J NEUROTRAUM, V32, P1777, DOI 10.1089/neu.2014.3784; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022; Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081637; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	31	58	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 3	2015	5								13497	10.1038/srep13497			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ3VW	WOS:000360533000001	26333872	gold, Green Published			2022-02-06	
J	Lawrence, DW; Hutchison, MG; Comper, P				Lawrence, David W.; Hutchison, Michael G.; Comper, Paul			Descriptive Epidemiology of Musculoskeletal Injuries and Concussions in the National Football League, 2012-2014	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						National Football League (NFL); concussion; epidemiology; injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; UPPER EXTREMITY INJURIES; PROFESSIONAL FOOTBALL; BRAIN-INJURY; ICE HOCKEY; PART I; PLAYERS; COLLEGIATE; SPORTS	Background: The risk of all-cause injury and concussion associated with football is significant. The National Football League (NFL) has implemented changes to increase player safety warranting investigation into the incidence and patterns of injury. Purpose: To document the incidence and patterns of all-cause injury and concussions in the NFL. Study Design: Descriptive epidemiology study. Methods: Injury data were collected prospectively from official NFL injury reports over 2 regular seasons from 2012 to 2014, with identification of injury incidence rates and patterns. Concussion rate ratios were calculated using previously reported NFL rates. Results: A total of 4284 injuries were identified, including 301 concussions. The all-cause injury rate was 395.8 per 1000 athletes at risk (AAR) and concussion incidence was 27.8 per 1000 AAR. Only 2.3% of team games were injury free. Wide receivers, tight ends, and defensive backs had the highest incidence of injury and concussion. Concussion incidence was 1.61-fold higher in 2012 to 2014 compared with 2002 to 2007. The knee was injured most frequently, followed by the ankle, hamstring, shoulder, and head. Conclusion: The incidence of all-cause injury and concussion in the NFL is significant. Concussion injury rates are higher than previous reports, potentially reflecting an improvement in recognition and awareness. Injury prevention efforts should continue to reduce the prevalence of injury associated with football.	[Lawrence, David W.; Hutchison, Michael G.; Comper, Paul] Univ Toronto, Toronto, ON, Canada		Lawrence, DW (corresponding author), St Michaels Hosp, Dept Family & Community Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.	dw.lawrence@mail.utoronto.ca					[Anonymous], INJ REP; [Anonymous], ASS PRESS; Anzell AR, 2013, J STRENGTH COND RES, V27, P277, DOI 10.1519/JSC.0b013e31827f4c08; Archer T, SOURCES ROMO TORE RI; Barzilai P, KNEE INJURIES WORRY; Boublik M, 2013, AM J SPORT MED, V41, P1841, DOI 10.1177/0363546513490655; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Carlisle JC, 2008, AM J SPORT MED, V36, P1945, DOI 10.1177/0363546508318198; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; CBS Sports, NFL INJ; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick R, 2007, J ATHL TRAINING, V42, P221; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Elliott MCCW, 2011, AM J SPORT MED, V39, P843, DOI 10.1177/0363546510394647; Feeley BT, 2008, AM J SPORT MED, V36, P2187, DOI 10.1177/0363546508319898; Feeley BT, 2008, AM J SPORT MED, V36, P1597, DOI 10.1177/0363546508316021; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gissane C, 2002, SPORTS MED, V32, P211, DOI 10.2165/00007256-200232030-00004; Goldberg DS, 2013, J LEGAL MED, V34, P157, DOI 10.1080/01947648.2013.800792; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King H, 2014, J PHYS ACT IN PRESS; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lindenfeld T N, 1988, Am J Sports Med, V16 Suppl 1, pS69; Lynch TS, 2013, AM J SPORT MED, V41, P2904, DOI 10.1177/0363546513504284; Mall NA, 2008, AM J SPORT MED, V36, P1938, DOI 10.1177/0363546508318197; McKay CD, 2014, BRIT J SPORT MED, V48, P57, DOI 10.1136/bjsports-2013-092860; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Collegiate Athletic Association, NAT FED HIGH SCH NCA; National Football League, 2014, NFL RET PLAY PROT; National Football League Head Neck and Spine Committee, NAT FOOTB LEAG HEAD; Osbahr DC, 2013, ORTHOPEDICS, V36, pE1378, DOI 10.3928/01477447-20131021-18; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stovitz SD, 2012, BRIT J SPORT MED, V46, P960, DOI 10.1136/bjsports-2011-090693; Tuominen M, 2015, BRIT J SPORT MED, V49, P30, DOI 10.1136/bjsports-2014-093688	37	58	58	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	MAY	2015	3	5							2325967115583653	10.1177/2325967115583653			7	Orthopedics; Sport Sciences	Emerging Sources Citation Index (ESCI)	Orthopedics; Sport Sciences	DE1IT	WOS:000370381200004	26675321	gold, Green Published			2022-02-06	
J	Chin, LM; Keyser, RE; Dsurney, J; Chan, L				Chin, Lisa M.; Keyser, Randall Eugene; Dsurney, John; Chan, Leighton			Improved Cognitive Performance Following Aerobic Exercise Training in People With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Exercise; Neuropsychological tests; Questionnaires; Rehabilitation	DEPRESSION FOLLOWING MILD; OLDER-ADULTS; IMPAIRMENT; QUALITY; MUSCULOSKELETAL; INTERVENTIONS; EPIDEMIOLOGY; INDIVIDUALS; RECOVERY; DISEASE	Objective: To examine cognitive function in individuals with traumatic brain injury (TBI) prior to and after participation in an aerobic exercise training program. Design: Pre-post intervention study. Setting: Medical research center. Participants: Volunteer sample of individuals (N=7) (age, 33.3 +/- 7.9y) with chronic nonpenetrating TBI (injury severity: 3=mild, 4=moderate; time since most current injury: 4.0 +/- 5.5y) who were ambulatory. Intervention: Twelve weeks of supervised vigorous aerobic exercise training performed 3 times a week for 30 minutes on a treadmill. Main Outcome Measures: Cognitive function was assessed using the Trail Making Test Part A (TMT-A), Trail Making Test Part B (TMT-B), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Sleep quality and depression were measured with the Pittsburgh Sleep Quality Index (PSQI) and Beck Depression Inventory, version 2 (BDI-II). Indices of cardiorespiratory fitness were used to examine the relation between improvements in cognitive function and cardiorespiratory fitness. Results: After training, improvements in cognitive function were observed with greater scores on the TMT-A (10.3 +/- 6.8; P=.007), TMT-B (9.6 +/- 7.0; P=.011), and RBANS total scale (13.3 +/- 9.3; P=.009). No changes were observed in measures of the PSQI and BDI-II. The magnitude of cognitive improvements was also strongly related to the gains in cardiorespiratory fitness. Conclusions: These findings suggest that vigorous aerobic exercise training may improve specific aspects of cognitive function in individuals with TBI and cardiorespiratory fitness gains may be a determinant of these improvements. Archives of Physical Medicine and Rehabilitation 2015;96:754-9 (C) 2015 by the American Congress of Rehabilitation Medicine	[Chin, Lisa M.; Keyser, Randall Eugene] George Mason Univ, Dept Rehabil Sci, Fairfax, VA 22030 USA; [Chin, Lisa M.; Keyser, Randall Eugene; Dsurney, John; Chan, Leighton] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA; [Dsurney, John; Chan, Leighton] Ctr Neurosci & Regenerat Med, Bethesda, MD USA		Chin, LM (corresponding author), George Mason Univ, Dept Rehabil Sci, 4400 Univ Dr, Fairfax, VA 22030 USA.	lchin2@gmu.edu	Chin, Lisa MK/O-4706-2014	Chin, Lisa MK/0000-0002-0178-739X	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G192HI-H]; National Institutes of Health Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by the Center for Neuroscience and Regenerative Medicine (grant no. G192HI-H) and the National Institutes of Health Clinical Center (rehabilitation medicine department intramural funds).	Ahlskog JE, 2011, MAYO CLIN PROC, V86, P876, DOI 10.4065/mcp.2011.0252; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Banks S, 2011, ENCY CLIN NEUROPSYCH, P506; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chin LMK, 2015, J HEAD TRAUMA REHAB, V30, P382, DOI 10.1097/HTR.0000000000000062; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Farina N, 2014, INT PSYCHOGERIATR, V26, P9, DOI 10.1017/S1041610213001385; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gates N, 2013, AM J GERIAT PSYCHIAT, V21, P1086, DOI 10.1016/j.jagp.2013.02.018; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Heaton R. K., 2004, REVISED COMPREHENSIV; Hindin SB, 2012, J AM GERIATR SOC, V60, P136, DOI 10.1111/j.1532-5415.2011.03761.x; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hootman JM, 2002, MED SCI SPORT EXER, V34, P838, DOI 10.1097/00005768-200205000-00017; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kluding PM, 2011, J NEUROL PHYS THER, V35, P11, DOI 10.1097/NPT.0b013e318208ee6c; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reitan RM, 1993, TUCSON NEUROPSYCHOLO; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Stuchlik A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00106; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041	42	58	60	1	42	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					754	759		10.1016/j.apmr.2014.11.009			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100025	25433219	Green Accepted			2022-02-06	
J	Ulam, F; Shelton, C; Richards, L; Davis, L; Hunter, B; Fregni, F; Higgins, K				Ulam, F.; Shelton, C.; Richards, L.; Davis, L.; Hunter, B.; Fregni, F.; Higgins, K.			Cumulative effects of transcranial direct current stimulation on EEG oscillations and attention/working memory during subacute neurorehabilitation of traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Transcranial direct current stimulation; Traumatic brain injury, EEG oscillations	WORKING-MEMORY; NEUROPLASTICITY; MECHANISMS; DEFICITS; CORTEX	Objective: To investigate in a randomized, double-blind design, cumulative effects of anodal tDCS on EEG oscillations and neuropsychological tests among patients with traumatic brain injury (TBI) undergoing subacute neurorehabilitation. Methods: Twenty-six patients were randomly assigned to active (n = 13) or sham (n = 13) tDCS groups. EEGs were recorded at 6 different time points, assessing both immediate and cumulative effects of tDCS on EEG oscillations. Twenty minute sessions of 1 mA anodal stimulation to the left dorsolateral prefrontal cortex (F3, cathode placed at right supraorbital site, Fp2), were provided on 10 consecutive days. Neuropsychological tests were administered before and after the series of tDCS sessions. Results: Theta was significantly reduced for active tDCS patients following the first tDCS session. Delta decreased and alpha increased, both significantly, for the active tDCS group after 10 consecutive tDCS sessions. No significant changes were seen for sham group. Decreases in delta were significantly correlated with improved performance on neuropsychological tests for the active tDCS group to far greater degree than for the sham group. Participants in the active tDCS group who had excess slow EEG activity in their initial recordings showed greater improvement on neuropsychological tests than other groups. Conclusion: Results suggest that 10 anodal tDCS sessions may beneficially modulate regulation of cortical excitability for patients with TBI. Significance: EEG-guided tDCS warrants further investigation as a potential intervention for TBI during subacute neurorehabilitation. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Ulam, F.; Shelton, C.; Richards, L.; Davis, L.; Hunter, B.; Fregni, F.; Higgins, K.] Univ Missouri Hlth Syst, Missouri Rehabil Ctr, Kansas City, MO USA		Ulam, F (corresponding author), 600 North Main St, Mt Vernon, MO 65712 USA.	ulamf@health.missouri.edu		Fregni, Felipe/0000-0001-9359-8643	Missouri Rehabilitation Center; University of Missouri Healthcare System	We would like to thank Missouri Rehabilitation Center and the University of Missouri Healthcare System for supporting us in our endeavors to conduct this research. We would especially like to thank Dr. Kusai Umran for medical oversight of patients in the study. We would like to thank Dr. Steve Patterson, former Executive Director of MRC, and Mike Powell, MBA, Current Executive Director, for their encouragement and flexibility in allowing us to pursue our research interests. We also appreciate the assistance of Sarah Atallah with data preparation and entry.	Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Arul-Anandam AP, 2009, J AFFECT DISORDERS, V117, P137, DOI 10.1016/j.jad.2009.01.016; Baker JM, 2010, STROKE, V41, P1229, DOI 10.1161/STROKEAHA.109.576785; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; De Rojas JO, 2013, NEUROSURGERY, V72, P267, DOI 10.1227/NEU.0b013e31827b93c0; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Faria P, 2012, EPILEPSY BEHAV, V25, P417, DOI 10.1016/j.yebeh.2012.06.027; Faul F., 2010, TRAUMATIC BRAIN INJU; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hyun June, 2011, Clin Psychopharmacol Neurosci, V9, P78, DOI 10.9758/cpn.2011.9.2.78; Jacobson L, 2012, CLIN NEUROPHYSIOL, V123, P979, DOI 10.1016/j.clinph.2011.09.016; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; McCullagh S., 2011, TRAUMATIC BRAIN INJU, P279; MOULTON RJ, 1988, CAN J NEUROL SCI, V15, P82, DOI 10.1017/S0317167100027244; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Ulam F, 2013, J NEUROTHER, V17, P275; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Williams JA, 2009, J REHABIL MED, V41, P305, DOI 10.2340/16501977-0356; Wirth M, 2011, NEUROPSYCHOLOGIA, V49, P3989, DOI 10.1016/j.neuropsychologia.2011.10.015; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	36	58	61	3	27	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2015	126	3					486	496		10.1016/j.clinph.2014.05.015			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4RX	WOS:000349616700011	24947595				2022-02-06	
J	Huang, YL; Kuo, YS; Tseng, YC; Chen, DYT; Chiu, WT; Chen, CJ				Huang, Yen-Lin; Kuo, Ying-Sheng; Tseng, Ying-Chi; Chen, David Yen-Ting; Chiu, Wen-Ta; Chen, Chi-Jen			Susceptibility-weighted MRI in mild traumatic brain injury	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; CEREBRAL MICROBLEEDS; GRADIENT-ECHO; HEMORRHAGE; CHILDREN; ESWAN; PHASE	Objective:To compare the frequency of microbleeds identified by susceptibility-weighted MRI (SWMRI) in patients with mild traumatic brain injury (mTBI) and normal controls, and correlate these findings with neuropsychological tests.Methods:Research ethics committee approval and patient written informed consents were obtained. One hundred eleven patients with mTBI without parenchymal hemorrhage on CT and conventional MRI received SWMRI as well as a digit span and continuous performance test. One hundred eleven healthy volunteers without history of traumatic brain injury were enrolled as the control group and received conventional MRI with additional SWMRI study. We analyzed the number and location of microbleeds in both groups.Results:Twenty-six patients with mTBI and 12 control subjects presented microbleeds on SWMRI (p = 0.0197). Sixty microbleeds were found in 26 patients with mTBI and 15 microbleeds in 12 control subjects. The mTBI group showed notably more microbleeds in the cortex/subcortical region (52 microbleeds, 86.7%, vs 3 microbleeds, 20%; p < 0.0001). Conversely, the control group showed more microbleeds in the central brain (9 microbleeds, 60%, vs 3 microbleeds, 5%; p < 0.0001). There was no statistical difference in number of microbleeds in the cerebellum and brainstem (p = 0.2598 and p = 0.4932, respectively). Patients with mTBI who had detected microbleeds had lower digit span scores than the patients with negative SWMRI findings (p = 0.017).Conclusion:Presence of mTBI-related microbleeds showed a neuropsychological defect on short-term memory function, indicating that the presence of microbleeds could be a possible severity biomarker for mTBI. Addition of the SWMRI technique to the MRI protocol for patients with mTBI is recommended.	[Huang, Yen-Lin; Kuo, Ying-Sheng; Tseng, Ying-Chi; Chen, David Yen-Ting; Chen, Chi-Jen] Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan		Chen, CJ (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, Taipei, Taiwan.	08889@shh.org.tw					Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Boeckh-Behrens T, 2012, EUR J RADIOL, V81, P1238, DOI 10.1016/j.ejrad.2011.02.057; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12287; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Guo LF, 2013, CLIN NEURORADIOL, V23, P197, DOI 10.1007/s00062-012-0196-4; Guo LF, 2013, CLIN NEURORADIOL, V23, P121, DOI 10.1007/s00062-012-0185-7; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hodel J, 2014, EUR RADIOL, V24, P762, DOI 10.1007/s00330-013-3061-1; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Pittella JEH, 2003, J FORENSIC SCI, V48, P626; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Shoamanesh A, 2011, CEREBROVASC DIS, V32, P528, DOI 10.1159/000331466; Tatsumi S, 2008, CEREBROVASC DIS, V26, P142, DOI 10.1159/000139661; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	31	58	61	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 10	2015	84	6					580	585		10.1212/WNL.0000000000001237			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CC6VT	WOS:000350507800013	25576634				2022-02-06	
J	Kroshus, E; Kubzansky, LD; Goldman, RE; Austin, SB				Kroshus, Emily; Kubzansky, Laura D.; Goldman, Roberta E.; Austin, S. Bryn			Norms, Athletic Identity, and Concussion Symptom Under-Reporting Among Male Collegiate Ice Hockey Players: A Prospective Cohort Study	ANNALS OF BEHAVIORAL MEDICINE			English	Article						Concussion; Norms; Sports medicine; Symptom reporting	PHYSICIAN-OBSERVED CONCUSSION; TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; WHITE-MATTER; SPORT; KNOWLEDGE; EPIDEMIOLOGY; TRANSLATION; EDUCATION; COHESION	Many athletes fail to report concussion symptoms to coaches or medical personnel, putting them at risk for potentially catastrophic neurologic consequences if additional brain trauma is sustained prior to full recovery. The purpose of this study was to determine whether concussion reporting norms prior to the start of the athletic season predicted reporting symptoms of a possible concussion during the season, and whether this association was moderated by athletic identity. Members of six National Collegiate Athletic Association Division 1 men's ice hockey teams (n = 116) completed written surveys before and after the 2012-2013 collegiate ice hockey season. Participants who at pre-season perceived that "most athletes" were likely to report symptoms of a concussion were themselves more likely to report symptoms during the season. Athletic identity weakly moderated this association. Perceived reporting norms may be an important target of interventions aimed at reducing symptom under-reporting among athletes.	[Kroshus, Emily; Kubzansky, Laura D.; Goldman, Roberta E.; Austin, S. Bryn] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Goldman, Roberta E.] Brown Univ, Alpert Sch Med, Providence, RI 02912 USA; [Austin, S. Bryn] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Austin, S. Bryn] Boston Childrens Hosp, Div Adolescent Young Adult Med, Boston, MA USA		Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.	emk329@mail.harvard.edu		Goldman, Roberta/0000-0001-7801-0530	National Collegiate Athletic Association	This research was partially supported by the National Collegiate Athletic Association's 2012-2013 Graduate Student Research Grant.	Agel J, 2007, J ATHL TRAINING, V42, P241; Aronson E., 2007, SOCIAL PSYCHOL; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Borden BP, 2007, AM J SPORTS MED, V35, P1075; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brewer B. W., 2001, ACAD ATHLETIC J, V15, P103; BREWER BW, 1993, INT J SPORT PSYCHOL, V24, P237; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cialdini R. B., 1998, HDB SOCIAL PSYCHOL; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Finch CF, 2011, BRIT J SPORT MED, V45, P1253, DOI 10.1136/bjsports-2011-090230; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Grossbard JR, 2009, ADDICT BEHAV, V34, P352, DOI 10.1016/j.addbeh.2008.11.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaBrie JW, 2010, ADDICT BEHAV, V35, P1094, DOI 10.1016/j.addbeh.2010.08.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORTS MED, V20, P1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moreira MT, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006748.pub2; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; National Collegiate Athletic Association, 2012, 2012 2013 NCAA SPORT; National Collegiate Athletic Association, 2012, 2011 2012 NCAA SPORT; Neighbors C, 2010, PSYCHOL ADDICT BEHAV, V24, P522, DOI 10.1037/a0019944; Pescosolido AT, 2012, SMALL GR RES, V43, P744, DOI 10.1177/1046496412465020; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rovio E, 2009, SMALL GR RES, V40, P421, DOI 10.1177/1046496409334359; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; U. S. Department of Health and Human Services Centers for Disease Control and Prevention, 2012, YOUTH RISK BEH SURV; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wiechman S. A., 1997, Journal of Sport Behavior, V20, P199; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Winston FK, 2010, INJURY PREV, V16, P107, DOI 10.1136/ip.2009.021972	60	58	59	0	22	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0883-6612	1532-4796		ANN BEHAV MED	Ann. Behav. Med.	FEB	2015	49	1					95	103		10.1007/s12160-014-9636-5			9	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	CC0TX	WOS:000350050800013	25236670				2022-02-06	
J	Ponsford, J; Janzen, S; McIntyre, A; Bayley, M; Velikonja, D; Tate, R				Ponsford, Jennie; Janzen, Shannon; McIntyre, Amanda; Bayley, Mark; Velikonja, Diana; Tate, Robyn		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part I: Posttraumatic Amnesia/Delirium	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; guidelines; knowledge translation; posttraumatic amnesia; traumatic brain injury	CLOSED-HEAD-INJURY; AGITATED BEHAVIOR SCALE; WESTMEAD PTA SCALE; REHABILITATION THERAPIES; COMMUNITY INTEGRATION; REALITY ORIENTATION; CONFUSIONAL STATE; AMNESIA DURATION; CLINICAL UTILITY; CORTEX INJURY	Introduction: After traumatic brain injury (TBI) and emergence from coma, the majority of people experience posttraumatic amnesia (PTA), characterized by confusion, disorientation, retrograde and anterograde amnesia, poor attention, and sometimes agitation and delusions. An international team of researchers and clinicians developed recommendations for assessment and management of PTA. Methods: The experts met to select recommendations, then reviewed literature to ensure they were current. The team then prioritized recommendations for implementation and developed audit criteria to evaluate the adherence to the best practice recommendations. Results: Evidence in support of assessment and management strategies during PTA is weak. It is recommended that duration of PTA be assessed prospectively using a validated tool. Consideration should also be given to use of a delirium assessment tool. No cognitive or pharmacological treatments are known to reduce PTA duration. Recommendations for environmental manipulations to reduce agitation during PTA are made. Minimizing use of neuroleptic medication is supported by animal research and 1 retrospective study. Conclusions: The duration of PTA is an important predictor of late outcome after TBI and should be monitored prospectively with a standardized tool. Neuroleptic medication should be avoided. There is a significant need for controlled studies evaluating the impact of therapy during PTA.	[Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Janzen, Shannon; McIntyre, Amanda] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia; [Velikonja, Diana] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University; Ontario Neurotrauma Foundation (ONF)	We gratefully acknowledge the support of the Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University, and the Ontario Neurotrauma Foundation (ONF) for their support of this project.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Amato S, 2012, REHABIL NURS, V37, P19, DOI 10.1002/RNJ.00001; Andriessen TMJC, 2009, BRAIN INJURY, V23, P345, DOI 10.1080/02699050902791414; Appraisal of Guidelines Research and Evaluation, AGREE ADV SCI PRACT; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bayley M., 2007, ABIKUS EVIDENCE BASE; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; COPE DN, 1987, J HEAD TRAUMA REHAB, V2, P1; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; De Guise E, 2005, BRAIN INJURY, V19, P263, DOI 10.1080/02699050400004971; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fleming J, 1999, BRAIN INJURY, V13, P417; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harmsen M, 2004, BRAIN INJURY, V18, P787, DOI 10.1080/02699050410001671757; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jennett B, 1981, MANAGEMENT HEAD INJU; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kean J, 2010, BRAIN INJURY, V24, P1222, DOI 10.3109/02699052.2010.498008; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Leach K, 2006, BRAIN INJURY, V20, P1241, DOI 10.1080/02699050601049874; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; McCarter RJ, 2007, BRAIN INJURY, V21, P1393, DOI 10.1080/02699050701793793; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Moffat N., 1984, CLIN MANAGEMENT MEMO, P63; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Nott MT, 2008, BRAIN INJURY, V22, P669, DOI 10.1080/02699050802227170; Patton G, 1992, NEUROPSYCHOL REHABIL, V2, P169; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J., 2012, TRAUMATIC BRAIN INJU, V2nd Edition; Ponsford J, J HEAD TRAU IN PRESS; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford JL, 2013, J NEUROTRAUM, V30, P1498, DOI 10.1089/neu.2012.2843; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2007, BRAIN INJURY, V18, P131; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Snow P, 2012, TRAUMATIC BRAIN INJU, P34; Soo CA., 2005, BRAIN IMPAIR, V6, P75, DOI [DOI 10.1375/BRIM.2005.6.2.75, 10.1375/brim.2005.6.2.75]; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; Symonds CP, 1943, LANCET, V1, P7; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Watanabe TK, 1998, BRAIN INJURY, V12, P81; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	107	58	58	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					307	320		10.1097/HTR.0000000000000074			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300008	24984094				2022-02-06	
J	Cui, CM; Cui, Y; Gao, JL; Sun, LQ; Wang, YC; Wang, KJ; Li, R; Tian, YX; Song, SX; Cui, JZ				Cui, Changmeng; Cui, Ying; Gao, Junling; Sun, Liqian; Wang, Yongchao; Wang, Kaijie; Li, Ran; Tian, Yanxia; Song, Sixin; Cui, Jianzhong			Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						TBI; Glutamate excitotoxicity; GLT-1; Ceftriaxone; Autophagy; Functional recovery	GLUTAMATE TRANSPORTER EXPRESSION; CELL-DEATH; AUTOPHAGY; ISCHEMIA; CONTRIBUTES; DEFICITS; MICE	Traumatic brain injury (TBI) is a leading cause of mortality and disability in children and young adults worldwide. Neurologic impairment is caused by both immediate brain tissue disruption and post-injury cellular and molecular events that worsen the primary neurologic insult. The beta-lactam antibiotic ceftriaxone (CTX) has been reported to induce neuroprotection in animal models of diverse neurologic diseases via up-regulation of GLT-1. However, no studies have addressed the neuroprotective role of CTX in the setting of TBI, and whether the mechanism is involved in the modulation of neuronal autophagy remains totally unclear. The present study was designed to determine the hypothesis that administration of CTX could significantly enhance functional recovery in a rat model of TBI and whether CTX treatment could up-regulate GLT-1 expression and suppress post-TBI neuronal autophagy. The results demonstrated that daily treatment with CTX attenuated TBI-induced brain edema and cognitive function deficits in rats. GLT-1 is down-regulated following TBI and this phenomenon can be reversed by treatment of CTX. In addition, we also found that CTX significantly reduced autophagy marker protein, LC3 II, in hippocampus compared to the TBI group. These results suggest that CTX might provide a new therapeutic strategy for TBI and this protection might be associated with up-regulation of GLT-1 and suppression of neuronal autophagy.	[Cui, Changmeng; Cui, Jianzhong] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Peoples R China; [Cui, Ying; Sun, Liqian; Wang, Kaijie; Cui, Jianzhong] Tangshan Workers Hosp, Tangshan 063000, Peoples R China; [Gao, Junling; Wang, Yongchao; Li, Ran; Tian, Yanxia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Peoples R China; [Song, Sixin] Taishan Med Univ, Dept Neurosurg, Affiliated Hosp, Taishan 271000, Peoples R China		Cui, CM (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei, ChinaNatural Science Foundation of Hebei Province [H2012401071]	This research was supported by the Natural Science Foundation of Hebei, China, Grant Number H2012401071.	Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Chu CT, 2008, AM J PATHOL, V172, P284, DOI 10.2353/ajpath.2008.071064; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481, DOI 10.1152/ajprenal.1999.277.4.F481; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Ketheeswaranathan P, 2011, BRAIN RES, V1418, P93, DOI 10.1016/j.brainres.2011.08.029; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Lai Y, 2007, J CEREB BLOOD FLOW M, V28, P540; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maragakis NJ, 2004, GLIA, V45, P133, DOI 10.1002/glia.10310; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mimura K, 2011, REPROD SCI, V18, P1193, DOI 10.1177/1933719111410710; NAU R, 1993, ANTIMICROB AGENTS CH, V37, P1518, DOI 10.1128/AAC.37.7.1518; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Rasmussen B, 2011, DRUG ALCOHOL DEPEN, V118, P484, DOI 10.1016/j.drugalcdep.2011.03.022; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Shacka JJ, 2007, NEUROSCI LETT, V414, P57, DOI 10.1016/j.neulet.2006.12.025; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0	24	58	62	0	8	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2014	35	5					695	700		10.1007/s10072-013-1585-4			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI4BJ	WOS:000336810100008	24277205				2022-02-06	
J	Blaya, MO; Bramlett, HM; Naidoo, J; Pieper, AA; Dietrich, WD				Blaya, Meghan O.; Bramlett, Helen M.; Naidoo, Jacinth; Pieper, Andrew A.; Dietrich, W. Dalton			Neuroprotective Efficacy of a Proneurogenic Compound after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adult hippocampal neurogenesis; functional recovery; hippocampal-dependent memory; neuroprotection; traumatic brain injury	MAJOR TRAUMA; SEVERITY; MORTALITY; MODERATE; PATTERN; CARE; TBI	Traumatic brain injury (TBI) is characterized by histopathological damage and long-term sensorimotor and cognitive dysfunction. Recent studies have reported the discovery of the P7C3 class of aminopropyl carbazole agents with potent neuroprotective properties for both newborn neural precursor cells in the adult hippocampus and mature neurons in other regions of the central nervous system. This study tested, for the first time, whether the highly active P7C3-A20 compound would be neuroprotective, promote hippocampal neurogenesis, and improve functional outcomes after experimental TBI. Sprague-Dawley rats subjected to moderate fluid percussion brain injury were evaluated for quantitative immunohistochemical and behavioral changes after trauma. P7C3-A20 (10?mg/kg) or vehicle was initiated intraperitoneally 30?min postsurgery and twice per day every day thereafter for 7 days. Administration of P7C3-A20 significantly reduced overall contusion volume, preserved vulnerable anti-neuronal nuclei (NeuN)-positive pericontusional cortical neurons, and improved sensorimotor function 1 week after trauma. P7C3-A20 treatment also significantly increased both bromodeoxyuridine (BrdU)- and doublecortin (DCX)-positive cells within the subgranular zone of the ipsilateral dentate gyrus 1 week after TBI. Five weeks after TBI, animals treated with P7C3-A20 showed significantly increased BrdU/NeuN double-labeled neurons and improved cognitive function in the Morris water maze, compared to TBI-control animals. These results suggest that P7C3-A20 is neuroprotective and promotes endogenous reparative strategies after TBI. We propose that the chemical scaffold represented by P7C3-A20 provides a basis for optimizing and advancing new pharmacological agents for protecting patients against the early and chronic consequences of TBI.	[Blaya, Meghan O.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA; [Naidoo, Jacinth] UT Southwestern Med Ctr, Dept Biochem, Dallas, TX USA; [Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City Dept Vet Affairs, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City Dept Vet Affairs, Iowa City, IA 52242 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	andrew-pieper@uiowa.edu; ddietrich@miami.edu	Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291]; Veterans AffairsUS Department of Veterans Affairs [1 I01 BX000521]; Transformative RO1 grant [NIMH 1RO1MH087986]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089443] Funding Source: NIH RePORTER	The authors thank Mr. David Sequeira, Mrs. Ofelia Furones-Alonso, and Ms. Jessie Truettner for their technical contributions to this study. The authors also thank Dr. Pantelis Tsoulfas for his critical review of the manuscript. The studies were funded by the National Institutes of Health (NS030291; to W. D. D.), Veterans Affairs (1 I01 BX000521; to H. M. B.), a Transformative RO1 grant (NIMH 1RO1MH087986) awarded to A. A. P. and Steven L. McKnight, and unrestricted endowment funds provided to Steven L. McKnight from an anonymous donor.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arregui-Dalmases C, 2010, ACCIDENT ANAL PREV, V42, P1164, DOI 10.1016/j.aap.2010.01.005; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL UPD 19; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bener A, 2010, BRAIN INJURY, V24, P74, DOI 10.3109/02699050903508192; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Clarke CF, 2012, NZMJ, V125, P1; EuroSafe, 2013, INJ EUR UN REP INJ S; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lanting L. C., 2009, NATL PUBLIC HLTH COM; Leijdesdorff HA, 2012, J TRAUMA ACUTE CARE, V72, P1363, DOI 10.1097/TA.0b013e318250cced; Lin MR, 2009, ACCIDENT ANAL PREV, V41, P710, DOI 10.1016/j.aap.2009.03.010; Liu B., 2008, COCHRANE DATABASE SY, V1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2012, EUR J PUBLIC HEALTH, V10, P1; Majdan M, 2011, BRAIN INJURY, V25, P797, DOI 10.3109/02699052.2011.581642; Perez K, 2012, ACCIDENT ANAL PREV, V46, P37, DOI 10.1016/j.aap.2011.12.004; Richards D, 2012, ACCIDENT ANAL PREV, V47, P16, DOI 10.1016/j.aap.2012.01.009; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SKLAR DP, 1989, AM J EMERG MED, V7, P387, DOI 10.1016/0735-6757(89)90044-2; SWOV Institute for Road Safety Research, 2011, FACT SHEET ROAD FAT; SWOV Institute for Road Safety Research, 2009, FACT SHEET CYCL; SWOV Institute for Road Safety Research, 2007, FACT SHEET MOT MOP H; TEASDALE G, 1974, LANCET, V2, P81; Thompson DC, 1999, COCHRANE DATABASE SY, V4; Tokdemir M., 2009, MED SCI MONIT, V1, pPI1; Van Camp L A, 1998, Eur J Emerg Med, V5, P207; World Health Organization, 2009, GLOB STAT REP ROAD S	31	58	59	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					476	486		10.1089/NEU.2013.3135			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600246	24070637	Green Published			2022-02-06	
J	Jung, SY; Kim, DY; Yune, TY; Shin, DH; Baek, SB; Kim, CJ				Jung, Sun-Young; Kim, Dae-Young; Yune, Tae Young; Shin, Dong-Hoon; Baek, Sang-Bin; Kim, Chang-Ju			Treadmill exercise reduces spinal cord injury-induced apoptosis by activating the PI3K/Akt pathway in rats	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						spinal cord injury; treadmill exercise; motor function; apoptosis; neurotrophic factors	TRAUMATIC BRAIN-INJURY; DEATH; EXPRESSION; RECOVERY; SURVIVAL; BCL-2; HEMISECTION; PLASTICITY; ISCHEMIA; PROMOTES	Apoptosis occurring secondary to spinal cord injury (SCI) causes further neural damage and functional loss. In this study, a rat model was used to investigate the effect of treadmill exercise on SCI-induced apoptosis and expression of neurotrophic factors. To produce SCI, a contusion injury (10 g x 25 mm) was applied subsequent to laminectomy at the T9-T10 level. Following SCI, treadmill exercise was performed for six weeks. Hindlimb motor function was evaluated with a grid-walking test. The expression of neurotrophic factors and the level of apoptosis at the site of SCI were determined by western blotting. SCI reduced hindlimb motor function and suppressed expression of neurotrophin (NT)-3 and insulin-like growth factor (IGF)-1. Expression of phosphatidylinositol 3-kinase (PI3K), the ratio of phosphorylated Akt to Akt (pAkt/Akt) and the ratio of B-cell lymphoma 2 (Bcl-2) to Bax (Bcl-2/Bax) were decreased, and cleaved caspase-3 expression was increased by SCI. Treadmill exercise enhanced hindlimb motor function and increased expression of nerve growth factor (NGF), NT-3 and IGF-1 in the SCI rats. Treadmill exercise increased PI3K expression, the pAkt/Akt and the Bcl-2/Bax ratios, and suppressed cleaved caspase-3 expression in the injured spinal cord. This study demonstrated that treadmill exercise promotes the recovery of motor function by suppressing apoptosis in the injured spinal cord. The beneficial effect of exercise may be attributed to the increase in expression of neurotrophic factors via activation of the PI3K/Akt pathway.	[Jung, Sun-Young; Kim, Dae-Young; Kim, Chang-Ju] Kyung Hee Univ, Dept Physiol, Coll Med, Seoul 130701, South Korea; [Yune, Tae Young] Kyung Hee Univ, Dept Biochem & Mol Biol, Coll Med, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Shin, Dong-Hoon] Korea Univ, Grad Sch Life Sci & Biotechnol, Dept Food & Biotechnol, Seoul 136701, South Korea; [Baek, Sang-Bin] Univ Ulsan, Gangneung Asan Hosp, Dept Psychiat, Kangnung 210711, South Korea		Kim, CJ (corresponding author), Kyung Hee Univ, Dept Physiol, Coll Med, 26 Kyungheedae Ro, Seoul 130701, South Korea.	changju@khu.ac.kr	Kim, Chang Ju/M-4216-2017	Kim, Chang Ju/0000-0003-4749-5795	Kyung Hee University [KHU 20100848]	This study was supported by the 2010 Research Fund from Kyung Hee University (grant no. KHU 20100848).	Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan G, 2010, J IMMUNOL, V184, P3213, DOI 10.4049/jimmunol.0903025; Chao OY, 2012, NEUROSCIENCE, V202, P318, DOI 10.1016/j.neuroscience.2011.11.016; Chen MJ, 2005, MOL BRAIN RES, V135, P181, DOI 10.1016/j.molbrainres.2004.12.001; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Leon RD, 2006, J NEUROTRAUM, V23, P1147, DOI 10.1089/neu.2006.23.1147; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Goldshmit Y, 2008, J NEUROTRAUM, V25, P449, DOI 10.1089/neu.2007.0392; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Hennigan A, 2007, BIOCHEM SOC T, V35, P424, DOI 10.1042/BST0350424; Hwang L, 2013, INT J MOL MED, V31, P1047, DOI 10.3892/ijmm.2013.1301; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li Y, 2013, J BIOMED RES, V27, P43, DOI 10.7555/JBR.27.20120051; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Lobner D, 2002, BRAIN RES, V954, P42, DOI 10.1016/S0006-8993(02)03337-1; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Pierchala BA, 2004, J BIOL CHEM, V279, P27986, DOI 10.1074/jbc.M312237200; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x; Shin DY, 2012, INT J MOL SCI, V13, P14158, DOI 10.3390/ijms131114158; Sung YH, 2012, LIFE SCI, V91, P1309, DOI 10.1016/j.lfs.2012.10.003; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tillerson JL, 2003, NEUROSCIENCE, V119, P899, DOI 10.1016/S0306-4522(03)00096-4; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Upadhyay D, 2003, AM J RESP CELL MOL, V29, P180, DOI 10.1165/rcmb.2002-0269OC; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Yang Dongmei, 2012, World J Neurosci, V2, P74; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Ying Z, 2003, BRAIN RES, V987, P93, DOI 10.1016/S0006-8993(03)03258-X; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	44	58	70	0	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	MAR	2014	7	3					587	593		10.3892/etm.2013.1451			7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	AC7GG	WOS:000332695500011	24520250	gold, Green Published, Green Submitted			2022-02-06	
J	Angelucci, F; Ricci, V; Gelfo, F; Martinotti, G; Brunetti, M; Sepede, G; Signorelli, M; Aguglia, E; Pettorruso, M; Vellante, F; Di Giannantonio, M; Caltagirone, C				Angelucci, Francesco; Ricci, Valerio; Gelfo, Francesca; Martinotti, Giovanni; Brunetti, Marcella; Sepede, Gianna; Signorelli, Maria; Aguglia, Eugenio; Pettorruso, Mauro; Vellante, Federica; Di Giannantonio, Massimo; Caltagirone, Carlo			BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure	BRAIN AND COGNITION			English	Article						Post-traumatic stress disorder; Trauma exposure; BDNF; ELISA	ADMINISTERED PTSD SCALE; NERVE GROWTH-FACTOR; FACTOR VAL66MET POLYMORPHISM; NEUROTROPHIC FACTOR BDNF; DOPAMINERGIC-NEURONS; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; SEXUAL-ABUSE; HUMAN BRAIN; SCHIZOPHRENIA	Post-traumatic stress disorder (PTSD) is a syndrome resulting from exposure to a severe traumatic event that poses threatened death or injury and produces intense fear and helplessness. The neural structures implicated in PTSD development belong to the limbic system, an important region for emotional processing. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that serves as survival factor for selected populations of central nervous system (CNS) neurons and plays a role in the limbic system by regulating synaptic plasticity, memory processes and behavior. Impaired BDNF production in the brain can lead to a variety of CNS dysfunctions including symptoms associated with PTSD. However, so far fewer studies have investigated this neurotrophin in patients with PTSD. Furthermore, given the multiple role of BDNF in various CNS disorders, it cannot be excluded that traumatic events per se may influence neurotrophin levels, without a direct association to the PTSD syndrome. To elucidate these issues, in this study we analyzed BDNF serum levels in two groups of subjects: patients with trauma exposure who developed PTSD, and subjects with trauma exposure who did not develop PTSD. We found that BDNF serum levels were lower in PTSD patients as compared to related control subjects. Thus, these data suggest that BDNF might be involved in pathophysiology of PTSD and consequently therapeutic approaches aimed at restoring BDNF serum levels may be beneficial to this pathology. (C) 2013 Elsevier Inc. All rights reserved.	[Angelucci, Francesco; Ricci, Valerio; Gelfo, Francesca; Caltagirone, Carlo] IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, I-00179 Rome, Italy; [Martinotti, Giovanni; Brunetti, Marcella; Sepede, Gianna; Vellante, Federica; Di Giannantonio, Massimo] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Signorelli, Maria; Aguglia, Eugenio] Univ Catania, Dept Psychiat, I-95124 Catania, Italy; [Pettorruso, Mauro] Univ Cattolica Sacro Cuore, Dept Neurosci, Rome, Italy		Angelucci, F (corresponding author), IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, I-00179 Rome, Italy.	f.angelucci@hsantalucia.it	Signorelli, Maria/E-6155-2010; De Berardis, Domenico/F-9343-2018; Signorelli, Maria S/A-7422-2016; GELFO, FRANCESCA/AAC-6060-2022; Ricci, Valerio/AAL-7972-2021; Pettorruso, Mauro/D-3620-2017; Sepede, Gianna/AAE-8711-2019; Martinotti, Giovanni/AAC-7592-2022; Signorelli, Maria/E-6155-2010	Signorelli, Maria/0000-0002-6941-9454; De Berardis, Domenico/0000-0003-4415-5058; Signorelli, Maria S/0000-0002-6941-9454; Pettorruso, Mauro/0000-0002-4164-3040; Martinotti, Giovanni/0000-0002-7292-2341; Signorelli, Maria/0000-0001-5835-4176; GELFO, FRANCESCA/0000-0002-3935-2164; aguglia, eugenio/0000-0003-2146-7737	Italian Ministry of HealthMinistry of Health, Italy	Supported by Italian Ministry of Health.	ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andero R, 2012, GENES BRAIN BEHAV, V11, P503, DOI 10.1111/j.1601-183X.2012.00801.x; Angelucci F, 2005, EUR NEUROPSYCHOPHARM, V15, P311, DOI 10.1016/j.euroneuro.2004.11.005; Angelucci F, 2004, PROG BRAIN RES, V146, P151, DOI 10.1016/S0079-6123(03)46011-1; Angelucci F, 2003, INT J NEUROPSYCHOPH, V6, P225, DOI 10.1017/S1461145703003468; BECK KD, 1994, PROG NEUROBIOL, V44, P497, DOI 10.1016/0301-0082(94)90009-4; Berger W, 2010, PROG NEURO-PSYCHOPH, V34, P1279, DOI 10.1016/j.pnpbp.2010.07.008; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bonne O, 2011, J CLIN PSYCHIAT, V72, P1124, DOI 10.4088/JCP.09m05106blu; Bremner J. Douglas, 2006, CNS & Neurological Disorders-Drug Targets, V5, P503; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Chao L., 2013, PSYCHIAT RES; Choi SW, 2011, PSYCHIAT RES, V186, P427, DOI 10.1016/j.psychres.2010.07.028; Cohen H, 2012, NEUROPSYCHOPHARMACOL, V37, P350, DOI 10.1038/npp.2011.230; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Croce N, 2013, MOL CELL BIOCHEM, V376, P189, DOI 10.1007/s11010-013-1567-0; Croce N, 2011, NEURODEGENER DIS, V8, P300, DOI 10.1159/000323468; Cunha ABM, 2006, NEUROSCI LETT, V398, P215, DOI 10.1016/j.neulet.2005.12.085; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Dennis NA, 2011, HIPPOCAMPUS, V21, P980, DOI 10.1002/hipo.20809; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Elfving B, 2010, J NEUROSCI METH, V187, P73, DOI 10.1016/j.jneumeth.2009.12.017; Felmingham KL, 2013, BIOL PSYCHIAT, V3223, P1034; First M., 1997, STRUCTURED CLIN INTE; Gelfo F, 2012, CNS NEUROSCI THER, V18, P487, DOI 10.1111/j.1755-5949.2012.00314.x; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Gil-Bea FJ, 2011, HIPPOCAMPUS, V21, P999, DOI 10.1002/hipo.20812; Gonul AS, 2011, WORLD J BIOL PSYCHIA, V12, P110, DOI 10.3109/15622975.2010.507786; Hajcak G, 2009, GENES BRAIN BEHAV, V8, P80, DOI 10.1111/j.1601-183X.2008.00447.x; Hauck S, 2010, PROG NEURO-PSYCHOPH, V34, P459, DOI 10.1016/j.pnpbp.2010.01.010; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; Hemmings SMJ, 2013, PROG NEURO-PSYCHOPH, V40, P273, DOI 10.1016/j.pnpbp.2012.10.011; HOVENS JE, 1994, J CLIN PSYCHOL, V50, P325, DOI 10.1002/1097-4679(199405)50:3<325::AID-JCLP2270500304>3.0.CO;2-M; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Johansen JP, 2011, CELL, V147, P509, DOI 10.1016/j.cell.2011.10.009; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kuczewski N, 2010, EUR J NEUROSCI, V32, P1239, DOI 10.1111/j.1460-9568.2010.07378.x; Laske C, 2011, INT J NEUROPSYCHOPH, V14, P399, DOI 10.1017/S1461145710001008; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Lonsdorf TB, 2010, BEHAV NEUROSCI, V124, P9, DOI 10.1037/a0018261; Martinotti G, 2012, J BIOL REG HOMEOS AG, V26, P347; Martinotti G, 2011, J ECT, V27, pE44, DOI 10.1097/YCT.0b013e318205e1c0; Nathan PJ, 2011, CURR OPIN PHARMACOL, V11, P540, DOI 10.1016/j.coph.2011.06.008; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rasmusson AM, 2002, NEUROPSYCHOPHARMACOL, V27, P133, DOI 10.1016/S0893-133X(02)00286-5; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Stevens J.S., 2013, J PSYCHIAT RES; Teixeira AL, 2010, BIOMARK MED, V4, P871, DOI 10.2217/BMM.10.111; van Wingen G, 2010, NEUROIMAGE, V50, P1212, DOI 10.1016/j.neuroimage.2010.01.058; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Zhang HP, 2006, AM J MED GENET B, V141B, P387, DOI 10.1002/ajmg.b.30332; Zhang XY, 2012, PSYCHOPHARMACOLOGY, V222, P277, DOI 10.1007/s00213-012-2643-y; Zhen YF, 2013, PSYCHOPHARMACOLOGY, V227, P93, DOI 10.1007/s00213-012-2942-3	59	58	62	2	33	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	FEB	2014	84	1					118	122		10.1016/j.bandc.2013.11.012			5	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	295AM	WOS:000330089000013	24362070				2022-02-06	
J	Eckner, JT; Kutcher, JS; Broglio, SP; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Broglio, Steven P.; Richardson, James K.			Effect of sport-related concussion on clinically measured simple reaction time	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Evaluation; Head injuries	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; RELIABLE CHANGE INDEXES; FOOTBALL PLAYERS; COGNITIVE CHANGE; ASSESSMENT TOOLS; TEST PROTOCOL; RECOVERY; IMPACT; SENSITIVITY	Background Reaction time (RT) is a valuable component of the sport concussion assessment battery. RT is typically measured using computers running specialised software, which limits its applicability in some athletic settings and populations. To address this, we developed a simple clinical test of RT (RTclin) that involves grasping a falling measuring stick. Purpose To determine the effect of concussion on RTclin and its sensitivity and specificity for concussion. Materials and methods Concussed athletes (n=28) and non-concussed control team-mates (n=28) completed RTclin assessments at baseline and within 48h of injury. Repeated measures analysis of variance compared mean baseline and follow-up RTclin values between groups. Sensitivity and specificity were calculated over a range of reliable change confidence levels. Results RTclin differed significantly between groups (p<0.001): there was significant prolongation from baseline to postinjury in the concussed group (p=0.003), with a trend towards improvement in the control group (p=0.058). Sensitivity and specificity were maximised when a critical change value of 0ms was applied (ie, any increase in RTclin from baseline was interpreted as abnormal), which corresponded to a sensitivity of 75%, specificity of 68% and a 65% reliable change confidence level. Conclusions RTclin appears sensitive to the effects of concussion and distinguished concussed and non-concussed athletes with similar sensitivity and specificity to other commonly used concussion assessment tools. Given its simplicity, low cost and minimal time requirement, RTclin should be considered a viable component of the sports medicine provider's multifaceted concussion assessment battery.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Eckner, James T.; Kutcher, Jeffrey S.; Broglio, Steven P.] Univ Michigan, Michigan NeuroSport, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E,Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			Rehabilitation Medicine Scientist Training Program [5K12HD001097]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	Dr Eckner received a K-12 career development award from the Rehabilitation Medicine Scientist Training Program which supported his effort on this project (grant number 5K12HD001097).	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Cohen J., 2013, STAT POWER ANAL BEHA; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Frerichs RJ, 2005, ARCH CLIN NEUROPSYCH, V20, P321, DOI 10.1016/j.acn.2004.08.002; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	49	58	58	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					112	U175		10.1136/bjsports-2012-091579			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	276KK	WOS:000328749000012	23314889	Green Accepted			2022-02-06	
J	French, LM; Lange, RT; Brickell, TA				French, Louis M.; Lange, Rael T.; Brickell, Tracey A.			Subjective cognitive complaints and neuropsychological test performance following military-related traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive complaints; military; Neurobehavioral Symptom Inventory; neurocognitive measures; Personality Assessment Inventory; psychological distress; PTSD Checklist; self-reported symptoms; servicemembers; traumatic brain injury.	MILD HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; POSTCONCUSSION-LIKE SYMPTOMS; SELF-REPORT; BASE RATES; LITIGATION STATUS; OIF/OEF VETERANS; RESPONSE BIAS; CHRONIC PAIN	This study examined the relation between neuropsychological test performance and self-reported cognitive complaints following traumatic brain injury (TBI). Participants were 109 servicemembers from the U. S. military who completed a neuropsychological evaluation within the first 2 yr following mild-severe TBI. Measures included the Personality Assessment Inventory (PAI), Posttraumatic Stress Disorder Symptom Checklist-Civilian version (PCL-C), Neurobehavioral Symptom Inventory (NSI), and 17 select measures from a larger neurocognitive test battery that corresponded to three self-reported cognitive complaints from the NSI (i.e., memory, attention/concentration, and processing speed/organization). Self-reported cognitive complaints were significantly correlated with psychological distress (PCL-C total: r = 0.50-0.58; half the PAI clinical scales: r = 0.40-0.58). In contrast, self-reported cognitive complaints were not significantly correlated with overall neurocognitive functioning (with the exception of five measures). There was a low rate of agreement between neurocognitive test scores and self-reported cognitive complaints. For the large minority of the sample (38.5%-45.9%), self-reported cognitive complaints were reported in the presence of neurocognitive test scores that fell within normal limits. In sum, self-reported cognitive complaints were not associated with neurocognitive test performance, but rather were associated with psychological distress. These results provide information to contextualize cognitive complaints following TBI.	[French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [French, Louis M.; Brickell, Tracey A.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 2013, STAT POWER ANAL BEHA; Conners K., 2002, CONNERS CONTINUOUS P; Delis D.C., 2000, CALIFORNIA VERBAL LE; Donovan NJ, 2011, BRAIN INJURY, V25, P348, DOI 10.3109/02699052.2011.556105; Dujardin K, 2010, J NEUROL, V257, P79, DOI 10.1007/s00415-009-5268-2; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P., 2003, GREENS WORD MEMORY T; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howard L, 2005, J NEUROL NEUROSUR PS, V76, P1558, DOI 10.1136/jnnp.2004.057851; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Johnson I, 2011, COMPR PSYCHIAT, V52, P688, DOI 10.1016/j.comppsych.2010.12.008; King EG, 2013, REHABIL PSYCHOL, V58, P272, DOI 10.1037/a0033116; Kinsinger SW, 2010, NEUROPSYCHOLOGY, V24, P573, DOI 10.1037/a0019222; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Liik M, 2009, EPILEPSY RES, V84, P194, DOI 10.1016/j.eplepsyres.2009.02.006; Logan BW, 2013, BEHAV SCI LAW, V31, P803, DOI 10.1002/bsl.2092; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Marino SE, 2009, EPILEPSY BEHAV, V14, P459, DOI 10.1016/j.yebeh.2008.12.007; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meyers JE., 1995, REY COMPLEX FIGURE T; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morey, 1991, PERSONALITY ASSESSME; Poppelreuter M, 2004, EUR J CANCER, V40, P43, DOI 10.1016/j.ejca.2003.08.001; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Reitan RM, 1992, TRAIL MAKING TEST MA; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholten J, 2013, J HEAD TRAUMA REHAB, V28, P219, DOI 10.1097/HTR.0b013e318291daca; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spencer RJ, 2013, J REHABIL RES DEV, V50, P1, DOI 10.1682/JRRD.2012.01.0018; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vogel A, 2011, LUPUS, V20, P35, DOI 10.1177/0961203310382430; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Worthen MD, 2011, PSYCHOL INJ LAW, V4, P187, DOI 10.1007/s12207-011-9115-2; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	80	58	58	0	6	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	6					933	949		10.1682/JRRD.2013.10.0226			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AT0OT	WOS:000344635900011	25479042	Bronze			2022-02-06	
J	Ji, SB; Ghadyani, H; Bolander, RP; Beckwith, JG; Ford, JC; McAllister, TW; Flashman, LA; Paulsen, KD; Ernstrom, K; Jain, S; Raman, R; Zhang, LY; Greenwald, RM				Ji, Songbai; Ghadyani, Hamidreza; Bolander, Richard P.; Beckwith, Jonathan G.; Ford, James C.; McAllister, Thomas W.; Flashman, Laura A.; Paulsen, Keith D.; Ernstrom, Karin; Jain, Sonia; Raman, Rema; Zhang, Liying; Greenwald, Richard M.			Parametric Comparisons of Intracranial Mechanical Responses from Three Validated Finite Element Models of the Human Head	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Sports-related concussion; Injury threshold; Finite element model; Head impact exposure	TRAUMATIC BRAIN-INJURY; FOOTBALL; PREDICTION; IMPACTS; BIOMECHANICS; GENERATION; KINEMATICS; SIMON	A number of human head finite element (FE) models have been developed from different research groups over the years to study the mechanisms of traumatic brain injury. These models can vary substantially in model features and parameters, making it important to evaluate whether simulation results from one model are readily comparable with another, and whether response-based injury thresholds established from a specific model can be generalized when a different model is employed. The purpose of this study is to parametrically compare regional brain mechanical responses from three validated head FE models to test the hypothesis that regional brain responses are dependent on the specific head model employed as well as the region of interest (ROI). The Dartmouth Scaled and Normalized Model (DSNM), the Simulated Injury Monitor (SIMon), and the Wayne State University Head Injury Model (WSUHIM) were selected for comparisons. For model input, 144 unique kinematic conditions were created to represent the range of head impacts sustained by male collegiate hockey players during play. These impacts encompass the 50th, 95th, and 99th percentile peak linear and rotational accelerations at 16 impact locations around the head. Five mechanical variables (strain, strain rate, strain 9 strain rate, stress, and pressure) in seven ROIs reported from the FE models were compared using Generalized Estimating Equation statistical models. Highly significant differences existed among FE models for nearly all output variables and ROIs. The WSUHIM produced substantially higher peak values for almost all output variables regardless of the ROI compared to the DSNM and SIMon models (p < 0.05). DSNM also produced significantly different stress and pressure compared with SIMon for all ROIs (p < 0.05), but such differences were not consistent across ROIs for other variables. Regardless of FE model, most output variables were highly correlated with linear and rotational peak accelerations. The significant disparities in regional brain responses across head models regardless of the output variables strongly suggest that model-predicted brain responses from one study should not be extended to other studies in which a different model is utilized. Consequently, response-based injury tolerance thresholds from a specific model should not be generalized to other studies either in which a different model is used. However, the similar relationships between regional responses and the linear/rotational peak accelerations suggest that each FE model can be used independently to assess regional brain responses to impact simulations in order to perform statistical correlations with medical images and/or well-selected experiments with documented injury findings.	[Ji, Songbai; Ghadyani, Hamidreza; Paulsen, Keith D.; Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg, Lebanon, NH USA; [Bolander, Richard P.; Beckwith, Jonathan G.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Ford, James C.; McAllister, Thomas W.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Ernstrom, Karin; Jain, Sonia; Raman, Rema] UCSD, Biostat Res Ctr, Dept Family & Prevent Med, La Jolla, CA USA; [Raman, Rema] UCSD, Dept Neurosci, La Jolla, CA USA; [Zhang, Liying] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA		Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	songbai.ji@dartmouth.edu	Ford, James/AAF-7039-2020; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	National Operating Committee on Standards for Athletic Equipment [NOCSAE 07-04, 14-19]; National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; Riddell, Inc. (Chicago, IL); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638, R44HD040743] Funding Source: NIH RePORTER	We would like to thank Dr. Erik Takhounts for providing support with the SIMon model. This work was supported by the National Operating Committee on Standards for Athletic Equipment (NOCSAE 07-04, 14-19) and by the National Institute for Child Health and Human Development at the National Institutes of Health (R01HD048638). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Danelson KA, 2008, STAPP CAR C, V52, P59; Domont A., 1992, P 36 STAPP CAR CRASH, DOI [10.4271/922527, DOI 10.4271/922527]; Franklyn Melanie, 2005, Stapp Car Crash J, V49, P1; Gadd C. W., 1966, 10 STAPP CAR CRASH C; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Horgan T.J., 2005, FINITE ELEMENT MODEL; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A., 2003, P IRCOBI C LISB PORT; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Nahum AM, 1977, P STAPP CAR CRASH CO; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J, 2000, 44 STAPP CAR CRASH C; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Takhounts EG, 2008, STAPP CAR C, V52, P1; Versace J., 1971, 15 STAPP CAR CRASH C; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Yang King H, 2006, Stapp Car Crash J, V50, P429; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Zhang L, 2011, IRCOBI IMP BIOM, V74, P315; Zhang L., 2004, SAE T; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	42	58	60	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2014	42	1					11	24		10.1007/s10439-013-0907-2			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	AB7MV	WOS:000331975400002	24077860	Green Accepted			2022-02-06	
J	Huang, XT; Zhang, YQ; Li, SJ; Li, SH; Tang, Q; Wang, ZT; Dong, JF; Zhang, JN				Huang, Xin-Tao; Zhang, Yong-Qiang; Li, Sheng-Jie; Li, Sheng-Hui; Tang, Qing; Wang, Zhi-Tao; Dong, Jing-Fei; Zhang, Jian-Ning			Intracerebroventricular Transplantation of Ex Vivo Expanded Endothelial Colony-Forming Cells Restores Blood-Brain Barrier Integrity and Promotes Angiogenesis of Mice with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						endothelial colony-forming cells; endothelial progenitor cells; transplantation; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; UMBILICAL-CORD BLOOD; PROGENITOR CELLS; PRECURSOR CELLS; STROKE; NEOVASCULARIZATION; RATS; REGENERATION; MOBILIZATION; PATHOPHYSIOLOGY	Endothelial progenitor cells (EPCs) play a key role in tissue repair and regeneration. Previous studies have shown a positive correlation between the number of circulating EPCs and clinical outcomes of patients with traumatic brain injury (TBI). A recent study has further shown that intravenous infusion of human umbilical cord blood-derived endothelial colony-forming cells (ECFCs) improves outcomes of mice subjected to experimental TBI. This follow-up study was designed to determine whether intracerebroventricular (i.c.v.) infusion of ECFCs, which may reduce systemic effects of these cells, could repair the blood-brain barrier (BBB) and promote angiogenesis of mice with TBI. Adult nude mice were exposed to fluid percussion injury and transplanted i.c.v. with ECFCs on day 1 post-TBI. These ECFCs were detected at the TBI zone 3 days after transplantation by SP-DiIC(18)(3) and fluorescence in situ hybridization. Mice with ECFCs transplant had reduced Evans blue extravasation and brain water content, increased expression of ZO-1 and claudin-5, and showed a higher expression of angiopoietin 1. Consistent with the previous report, mice with ECFCs transplant had also increased microvascular density. Modified neurological severity score and Morris water maze test indicated significant improvements in motor ability, spatial acquisition and reference memory in mice receiving ECFCs, compared to those receiving saline. These data demonstrate the beneficial effects of ECFC transplant on BBB integrity and angiogenesis in mice with TBI.	[Huang, Xin-Tao; Zhang, Yong-Qiang; Li, Sheng-Jie; Li, Sheng-Hui; Wang, Zhi-Tao; Zhang, Jian-Ning] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin 300052, Peoples R China; [Huang, Xin-Tao] Shanxi Med Univ, Hosp 1, Dept Neurosurg, Taiyuan, Peoples R China; [Tang, Qing] Tianjin Med Univ, Dept Immunol, Tianjin, Peoples R China; [Dong, Jing-Fei] Puget Sound Blood Ctr, Seattle, WA 98104 USA; [Dong, Jing-Fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com		Huang, Xintao/0000-0002-9683-9518	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361]; Tianjin Health Bureau Technology Foundation [07KZ26]	The authors acknowledge Wei-yun Cui, Li Liu, and Lei Zhou for their excellent technical support. The work was supported by the National Natural Science Foundation of China (grant no.: 81271361) and the Tianjin Health Bureau Technology Foundation (grant no.: 07KZ26).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baudin B, 2007, NAT PROTOC, V2, P481, DOI 10.1038/nprot.2007.54; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Gill M, 2001, CIRC RES, V88, P167; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hansen TM, 2008, CURR NEUROVASC RES, V5, P236, DOI 10.2174/156720208786413433; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Khoo CP, 2008, REGEN MED, V3, P863, DOI 10.2217/17460751.3.6.863; Lev EI, 2005, J VASC RES, V42, P408, DOI 10.1159/000087370; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Liu L, 2011, CRIT CARE MED, V39, P1760, DOI 10.1097/CCM.0b013e3182186cee; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Mukai N, 2008, EXP CELL RES, V314, P430, DOI 10.1016/j.yexcr.2007.11.016; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pfaff D, 2006, J LEUKOCYTE BIOL, V80, P719, DOI 10.1189/jlb.1105652; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Richardson MR, 2011, J MOL CELL CARDIOL, V50, P266, DOI 10.1016/j.yjmcc.2010.07.009; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	46	58	64	2	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2080	2088		10.1089/neu.2013.2996			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500010	23957220	Green Published			2022-02-06	
J	Tajiri, N; Kaneko, Y; Shinozuka, K; Ishikawa, H; Yankee, E; McGrogan, M; Case, C; Borlongan, CV				Tajiri, Naoki; Kaneko, Yuji; Shinozuka, Kazutaka; Ishikawa, Hiroto; Yankee, Ernest; McGrogan, Michael; Case, Casey; Borlongan, Cesar V.			Stem Cell Recruitment of Newly Formed Host Cells via a Successful Seduction? Filling the Gap between Neurogenic Niche and Injured Brain Site	PLOS ONE			English	Article							MARROW STROMAL CELLS; PROGENITOR CELLS; SB623 CELLS; MODEL; ISCHEMIA; NEUROPROTECTION; DIFFERENTIATION; PLASTICITY; NEURONS; STROKE	Here, we report that a unique mechanism of action exerted by stem cells in the repair of the traumatically injured brain involves their ability to harness a biobridge between neurogenic niche and injured brain site. This biobridge, visualized immunohistochemically and laser captured, corresponded to an area between the neurogenic subventricular zone and the injured cortex. That the biobridge expressed high levels of extracellular matrix metalloproteinases characterized initially by a stream of transplanted stem cells, but subsequently contained only few to non-detectable grafts and overgrown by newly formed host cells, implicates a novel property of stem cells. The transplanted stem cells manifest themselves as pathways for trafficking the migration of host neurogenic cells, but once this biobridge is formed between the neurogenic site and the injured brain site, the grafted cells disappear and relinquish their task to the host neurogenic cells. Our findings reveal that long-distance migration of host cells from the neurogenic niche to the injured brain site can be achieved through transplanted stem cells serving as biobridges for initiation of endogenous repair mechanisms. This is the first report of a stem cell-paved "biobridge". Indeed, to date the two major schools of discipline in stem cell repair mechanism primarily support the concept of "cell replacement" and bystander effects of "trophic factor secretion". The present novel observations of a stem cell seducing a host cell to engage in brain repair advances basic science concepts on stem cell biology and extracellular matrix, as well as provokes translational research on propagating this stem cell-paved biobridge beyond cell replacement and trophic factor secretion for the treatment of traumatic brain injury and other neurological disorders.	[Tajiri, Naoki; Kaneko, Yuji; Shinozuka, Kazutaka; Ishikawa, Hiroto; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA; [Yankee, Ernest; McGrogan, Michael; Case, Casey] Sanbio Inc, Mountain View, CA USA		Borlongan, CV (corresponding author), Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012; Kaneko, Yuji/J-6447-2012	Borlongan, Cesar/0000-0002-2966-9782; Ishikawa, Hiroto/0000-0003-0760-7203; Shinozuka, Kazutaka/0000-0002-6435-4460	Sanbio Inc.; James and Esther King Biomedical Research Foundation [1KG01-33966]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5U01NS055914-04, 1R01NS071956-01A1]; Celgene Cellular TherapeuticsBristol-Myers SquibbCelgene Corporation; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS055914, R01NS071956] Funding Source: NIH RePORTER	Financial support for this study was through Sanbio Inc. CVB is additionally funded by the James and Esther King Biomedical Research Foundation 1KG01-33966, NIH 5U01NS055914-04 and NIH 1R01NS071956-01A1, Celgene Cellular Therapeutics, KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizman I, 2009, J NEUROSCI RES, V87, P3198, DOI 10.1002/jnr.22146; Andres RH, 2011, BRAIN, V134, P1777, DOI 10.1093/brain/awr094; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Chen JL, 2011, STROKE, V42, P445, DOI 10.1161/STROKEAHA.110.596486; Dao M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-81; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Hassani Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050444; Hawkes SP, 2010, METHODS MOL BIOL, V622, P257, DOI 10.1007/978-1-60327-299-5_16; Hong SH, 2011, CELL STEM CELL, V9, P24, DOI 10.1016/j.stem.2011.06.002; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; Kim Y, 2011, SCIENCE, V334, P1706, DOI 10.1126/science.1211222; Lee HS, 2010, STEM CELLS, V28, P501, DOI 10.1002/stem.294; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Lin CH, 2013, NEUROBIOL DIS, V58, P76, DOI 10.1016/j.nbd.2013.05.006; Liu ZW, 2011, STROKE, V42, P740, DOI 10.1161/STROKEAHA.110.607226; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mazzocchi-Jones D, 2009, EUR J NEUROSCI, V30, P2134, DOI 10.1111/j.1460-9568.2009.07006.x; Mezey E, 2011, J CELL BIOCHEM, V112, P2683, DOI 10.1002/jcb.23216; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; Pastori C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002754; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Pollock K, 2006, EXP NEUROL, V199, P143, DOI 10.1016/j.expneurol.2005.12.011; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Seol HJ, 2011, CANCER LETT, V311, P152, DOI 10.1016/j.canlet.2011.07.001; Sobrino T, 2012, J NEUROSCI RES, V90, P1788, DOI 10.1002/jnr.23068; Tate CC, 2010, CELL TRANSPLANT, V19, P973, DOI 10.3727/096368910X494885; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI [10.1089/neu.2009-0959, 10.1089/neu.2009.0959]; Trueman R C, 1800, Curr Top Behav Neurosci, V15, P357, DOI 10.1007/7854_2012_223; Wang L, 2011, J CEREBR BLOOD F MET, V31, P640, DOI 10.1038/jcbfm.2010.138; Wang XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038932, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0045036, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0040711, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0040084]; Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	48	58	61	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e74857	10.1371/journal.pone.0074857			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	WOS:000324515600159	24023965	Green Published, gold, Green Submitted			2022-02-06	
J	Ahman, S; Saveman, BI; Styrke, J; Bjornstig, U; Stalnacke, BM				Ahman, Sara; Saveman, Britt-Inger; Styrke, Johan; Bjornstig, Ulf; Stalnacke, Britt-Marie			LONG-TERM FOLLOW-UP OF PATIENTS WITH MILD TRAUMATIC BRAIN INJURY: A MIXED-METHODS STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; brain concussion; post-concussion symptoms; post-traumatic stress disorder	POST-CONCUSSION SYMPTOMS; POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; SF-36 HEALTH SURVEY; QUALITY-OF-LIFE; HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; SERUM-LEVELS; ACUTE-PHASE; POPULATION	Objective: To characterize the long-term consequences of mild traumatic brain injury regarding post-concussion symptoms, post-traumatic stress, and quality of life; and to investigate differences between men and women. Design: Retrospective mixed-methods study. Subjects/patients and methods: Of 214 patients with mild traumatic brain injury seeking acute care, 163 answered questionnaires concerning post-concussion symptoms (Rivermead Post-concussion Symptoms Questionnaire; RPQ), post-traumatic stress (Impact of Event Scale; IES), and quality of life (Short Form Health Survey; SF-36) 3 years post-injury. A total of 21 patients underwent a medical examination in connection with the survey. The patients were contacted 11 years later, and 10 were interviewed. Interview data were analysed with content analysis. Results: The mean total RPQ score was 12.7 (standard deviation; SD 12.9); 10.5 (SD 11.9) for men and 15.9 (SD 13.8) for women (p=0.006). The 5 most common symptoms were fatigue (53.4%), poor memory (52.5%), headache (50.9%), frustration (47.9%) and depression (47.2%). The mean total IES score was 9.6 (SD 12.9) 7.1 (SD 10.3) for men and 13.0 (SD 15.2) for women (p=0.004). In general, the studied population had low scores on the Short Form Health Survey (SF-36). The interviews revealed that some patients still had disabling post-concussion symptoms and consequences in many areas of life 11 years after the injury event. Conclusion: Long-term consequences were present for approximately 50% of the patients 3 years after mild traumatic brain injury and were also reported 11 years after mild traumatic brain injury. This needs to be taken into account by healthcare professionals and society in general when dealing with people who have undergone mild traumatic brain injury.	[Ahman, Sara; Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, SE-90185 Umea, Sweden; [Saveman, Britt-Inger] Umea Univ, Dept Nursing, SE-90185 Umea, Sweden; [Styrke, Johan; Bjornstig, Ulf] Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden		Stalnacke, BM (corresponding author), Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	brittmarie.stalnacke@rehabmed.umu.se	Styrke, Johan/AAE-1193-2021				Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Strandberg T, 2009, SOC WORK HEALTH CARE, V48, P276, DOI 10.1080/00981380802599240; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; TEASDALE G, 1974, LANCET, V2, P81; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	40	58	59	3	26	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					758	764		10.2340/16501977-1182			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500010	24002311	gold, Green Published			2022-02-06	
J	Bloodgood, B; Inokuchi, D; Shawver, W; Olson, K; Hoffman, R; Cohen, E; Sarmiento, K; Muthuswamy, K				Bloodgood, Bonny; Inokuchi, Derek; Shawver, Willis; Olson, Kristina; Hoffman, Rosanne; Cohen, Elyse; Sarmiento, Kelly; Muthuswamy, Kavitha			Exploration of Awareness, Knowledge, and Perceptions of Traumatic Brain Injury Among American Youth Athletes and Their Parents	JOURNAL OF ADOLESCENT HEALTH			English	Article						Brain injuries; Traumatic brain injury; Concussion; Adolescents; Athletic injuries; Awareness; Health knowledge; Health attitudes; Health practices	SPORT-RELATED CONCUSSION; HIGH-SCHOOL; FOOTBALL PLAYERS; UNITED-STATES; MISCONCEPTIONS; RECOVERY; CHILDREN	Purpose: Although much effort is underway by the Centers for Disease Control and Prevention (CDC) and other organizations to highlight the seriousness of traumatic brain injury, including concussions, among young athletes, little is known about how these athletes and their parents view this injury and how much they know about it. Methods: Online surveys were conducted with youth who participate in sports (n = 252) and with the parents of youth who participate in sports (n = 300) to explore the ways in which these audiences view concussion and messaging related to concussion. Results: More than four out of five youth and parents reported that they had heard about concussions, although awareness was significantly higher for some subgroups, including parents of children 10-13 years old, and parents who reported using the Internet several times daily. Youth ages 13-15 years were significantly more likely to strongly agree that concussions are a "critical issue," as compared with youth ages 16-18 years. Among parents, significantly more mothers than fathers agreed that concussions are a critical issue. More than half of youth participants strongly disagreed that their friends would think they were "dumb for caring about concussions," with girls significantly more likely to strongly disagree than boys. When parents were asked to identify organizations they would trust as a reliable source of information for concussions, the most frequently cited organization was the CDC. Conclusions: Results of this study demonstrate a high level of awareness about concussion among youth athletes and parents of youth athletes. However, important distinctions among subgroups of both youth and parents-such as by race/ethnicity, age, sex, and Internet use-suggest directions for future communication and research efforts. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.	[Bloodgood, Bonny; Hoffman, Rosanne; Cohen, Elyse] ICF Int, Fairfax, VA USA; [Inokuchi, Derek; Shawver, Willis; Olson, Kristina] FHI 360, Washington, DC USA; [Sarmiento, Kelly; Muthuswamy, Kavitha] Ctr Dis Control & Prevent, Atlanta, GA USA		Shawver, W (corresponding author), FHI 360 Social Mkt & Commun Ctr, 1875 Connecticut Ave NW, Washington, DC 20009 USA.	wshawver@fhi360.org			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [200-2007-20009]	This research was supported by the Centers for Disease Control and Prevention through Contract no. 200-2007-20009, Order 0014. The authors would like to thank Sanda Pecina, of FHI 360, for her contributions to the project.	Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bertakis KD, 2000, J FAM PRACTICE, V49, P147; Bruce D A, 1982, Clin Sports Med, V1, P495; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; COLLINS M, 2004, CURR OPIN ORTHOP, V15, P100; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finkelstein E., 2006, INCIDENCE EC BURDEN; Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7; Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Michigan Governor's Council on Physical Fitness Health and Sports, POS STAT PREV INJ AM; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Russo S, 2006, CURR OPIN PEDIATR, V18, P376; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Theye Fred, 2004, Clin Med Res, V2, P165; Wakefield M, 2003, J HEALTH COMMUN, V8, P229, DOI 10.1080/10810730305686; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	37	58	58	0	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	JUL	2013	53	1					34	39		10.1016/j.jadohealth.2013.01.022			6	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Public, Environmental & Occupational Health; Pediatrics	169GP	WOS:000320768200007	23583508	Green Accepted			2022-02-06	
J	Fife, TD; Giza, C				Fife, Terry D.; Giza, Christopher			Posttraumatic Vertigo and Dizziness	SEMINARS IN NEUROLOGY			English	Article						postconcussive syndrome; postconcussive dizziness; vertigo; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PAROXYSMAL POSITIONAL VERTIGO; POST-CONCUSSION SYNDROME; MINOR HEAD-INJURY; TEMPORAL BONE-FRACTURES; POSTCONCUSSION SYNDROME; CLINICAL CHARACTERISTICS; CEREBELLAR INJURY; MENIERES-DISEASE; STEM INJURY	Dizziness and vertigo are common symptoms following minor head trauma. Although these symptoms resolve within a few weeks in many patients, in some the symptoms may last much longer and impede ability to return to work and full functioning. Causes of persisting or recurrent dizziness may include benign paroxysmal positional vertigo, so-called labyrinthine concussion, unilateral vestibular nerve injury or damage to the utricle or saccule, perilymphatic fistula, or less commonly traumatic endolymphatic hydrops. Some dizziness after head trauma is due to nonlabyrinthine causes that may be related to structural or microstructural central nervous system injury or to more complicated interactions between migraine, generalized anxiety, and issues related to patients self-perception, predisposing psychological states, and environmental and stress-related factors. In this article, the authors review both the inner ear causes of dizziness after concussion and also the current understanding of chronic postconcussive dizziness when no peripheral vestibular cause can be identified.	[Fife, Terry D.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Fife, Terry D.] Univ Arizona, Dept Neurol, Coll Med, Phoenix, AZ USA; [Giza, Christopher] Mattel Childrens Hosp UCLA, Div Neurol, Dept Pediat, Los Angeles, CA USA; [Giza, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Fife, TD (corresponding author), Barrow Neurol Inst, 240 W Thomas Rd,Suite 301, Phoenix, AZ 85013 USA.	tfife@email.arizona.edu	Fife, Terry/M-1135-2019				Agrup C, 2007, J NEUROL NEUROSUR PS, V78, P114, DOI 10.1136/jnnp.2006.092064; Ahn SK, 2011, J TRAUMA, V70, P442, DOI 10.1097/TA.0b013e3181d0c3d9; Balaban CD, 2011, J VESTIBUL RES-EQUIL, V21, P315, DOI 10.3233/VES-2011-0428; Best C, 2006, J NEUROL NEUROSUR PS, V77, P658, DOI 10.1136/jnnp.2005.072934; Bisdorff Alexandre R, 2011, Ther Adv Neurol Disord, V4, P183, DOI 10.1177/1756285611401647; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Curthoys IS, 2013, SEMIN NEUROL, V33, P231, DOI 10.1055/s-0033-1354595; Curthoys IS, 2000, CURR OPIN NEUROL, V13, P27, DOI 10.1097/00019052-200002000-00006; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DiBiase P, 1997, OTOLARYNG CLIN N AM, V30, P1117; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Fife TD, 2013, ENCY NEUROLOGICAL SC; Fife Terry D, 2012, Continuum (Minneap Minn), V18, P1060, DOI 10.1212/01.CON.0000418376.80099.24; Fife TD, 2009, SEMIN NEUROL, V29, P500, DOI 10.1055/s-0029-1241041; Fotuhi M, 2009, J NEUROL, V256, P711, DOI 10.1007/s00415-009-5050-5; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; GLASSCOCK ME, 1992, AM J OTOL, V13, P333; GOODHILL V, 1980, J LARYNGOL OTOL, V94, P123, DOI 10.1017/S0022215100088563; Goodman B, 2013, NEUROL, V80; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kleffelgaard I, 2012, DISABIL REHABIL, V34, P788, DOI 10.3109/09638288.2011.619624; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; LINDSAY JR, 1970, ANN OTO RHINOL LARYN, V79, P699, DOI 10.1177/000348947007900403; Liu HJ, 2012, ACTA OTO-LARYNGOL, V132, P803, DOI 10.3109/00016489.2012.657359; Loder E, 2012, HEADACHE, V52, P930, DOI 10.1111/j.1526-4610.2012.02185.x; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Manzari L, 2012, EUR ARCH OTO-RHINO-L, V269, P2441, DOI 10.1007/s00405-012-2127-z; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Middleton K, 2010, CLIN J SPORT MED, V20, P491, DOI 10.1097/JSM.0b013e3181fac088; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P181, DOI 10.1016/S0194-5998(95)70102-8; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; PULEC JL, 1972, LARYNGOSCOPE, V82, P1703, DOI 10.1288/00005537-197209000-00011; Rowlands RG, 2009, J LARYNGOL OTOL, V123, P182, DOI 10.1017/S0022215108002569; Segal S, 2003, OTOL NEUROTOL, V24, P387, DOI 10.1097/00129492-200305000-00007; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smitherman TA, 2013, HEADACHE, V53, P775, DOI 10.1111/head.12063; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Staab JP, 2007, ARCH OTOLARYNGOL, V133, P170, DOI 10.1001/archotol.133.2.170; Staab JP, 2003, LARYNGOSCOPE, V113, P1714, DOI 10.1097/00005537-200310000-00010; Ulug T, 2006, J OTOLARYNGOL, V35, P380, DOI 10.2310/7070.2006.0069; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WEISSMAN JL, 1992, AM J NEURORADIOL, V13, P1183; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	74	58	60	1	31	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	JUL	2013	33	3					238	243		10.1055/s-0033-1354599			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	220ZC	WOS:000324625300011	24057827				2022-02-06	
J	Freund, P; Curt, A; Friston, KJ; Thompson, A				Freund, Patrick; Curt, Armin; Friston, Karl J.; Thompson, Alan			Tracking Changes following Spinal Cord Injury: Insights from Neuroimaging	NEUROSCIENTIST			English	Article						neuroimaging; atrophy; cortical reorganization; disability	VOXEL-BASED MORPHOMETRY; MULTIPLE-SCLEROSIS; MOTOR CORTEX; FUNCTIONAL RECOVERY; CORTICAL THICKNESS; WHITE-MATTER; IN-VIVO; BRAIN; ATROPHY; REORGANIZATION	Traumatic spinal cord injury is often disabling and recovery of function is limited. As a consequence of damage, both spinal cord and brain undergo anatomical and functional changes. Besides clinical measures of recovery, biomarkers that can detect early anatomical and functional changes might be useful in determining clinical outcome-during the course of rehabilitation and recovery-as well as furnishing a tool to evaluate novel treatment interventions and their mechanisms of action. Recent evidence suggests an interesting three-way relationship between neurological deficit and changes in the spinal cord and of the brain and that, importantly, noninvasive magnetic resonance imaging techniques, both structural and functional, provide a sensitive tool to lay out these interactions. This review describes recent findings from multimodal imaging studies of remote anatomical changes (i.e., beyond the lesion site), cortical reorganization, and their relationship to clinical disability. These developments in this field may improve our understanding of effects on the nervous system that are attributable to the injury itself and will allow their distinction from changes that result from rehabilitation (i.e., functional retraining) and from interventions affecting the nervous system directly (i.e., neuroprotection or regeneration).	[Freund, Patrick; Thompson, Alan] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London WCN1 3BG, England; [Freund, Patrick; Curt, Armin] Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland; [Freund, Patrick; Friston, Karl J.] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WCN1 3BG, England		Freund, P (corresponding author), UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, Queens Sq, London WCN1 3BG, England.	p.freund@ucl.ac.uk	Friston, Karl/D-9230-2011; Thompson, Alan J/C-2654-2008; Freund, Patrick/D-4193-2013	Friston, Karl/0000-0001-7984-8909; Thompson, Alan J/0000-0002-4333-8496; Freund, Patrick/0000-0002-4851-2246	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Wellcome Trust in the United KingdomWellcome Trust	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Swiss National Science Foundation (Grant No. PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No. PASMP3-124194), and the Wellcome Trust in the United Kingdom.	Aguilar J, 2010, J NEUROSCI, V30, P7528, DOI 10.1523/JNEUROSCI.0379-10.2010; Andre Jalal B, 2010, Top Magn Reson Imaging, V21, P367, DOI 10.1097/RMR.0b013e31823e65a1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bodini B, 2009, HUM BRAIN MAPP, V30, P2852, DOI 10.1002/hbm.20713; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Calancie B, 1996, ELECTROMYOGR MOTOR C, V101, P304, DOI 10.1016/0924-980X(96)95194-2; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Cheran S, 2011, J NEUROTRAUM, V28, P1881, DOI 10.1089/neu.2010.1741; Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Curt A, 2012, SPINAL CORD, V50, P352, DOI 10.1038/sc.2011.113; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Endo T, 2009, NEUROSCIENTIST, V15, P291, DOI 10.1177/1073858408329508; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, 2011, J NEUROTRAUM, V28, P1329, DOI 10.1089/neu.2011.1955; Felix MS, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00045; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Ghosh A, 2012, CEREB CORTEX, V22, P1309, DOI 10.1093/cercor/bhr191; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Guleria S, 2008, J NEUROSCI RES, V86, P2271, DOI 10.1002/jnr.21664; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Horsfield MA, 2010, NEUROIMAGE, V50, P446, DOI 10.1016/j.neuroimage.2009.12.121; Hubli M, 2012, NEUROREHAB NEURAL RE, V26, P188, DOI 10.1177/1545968311420844; Hutton C, 2008, NEUROIMAGE, V40, P1701, DOI 10.1016/j.neuroimage.2008.01.027; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; Jurkiewicz MT, 2010, NEUROREHAB NEURAL RE, V24, P136, DOI 10.1177/1545968309347680; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Lang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030461; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Lundell H, 2011, NEUROIMAGE, V54, P1254, DOI 10.1016/j.neuroimage.2010.09.009; Miller DH, 2002, BRAIN, V125, P1676, DOI 10.1093/brain/awf177; Mohammadi S, 2012, MAGN RESON MED, V68, P882, DOI 10.1002/mrm.23308; Mohammadi S, 2012, NEUROIMAGE, V60, P562, DOI 10.1016/j.neuroimage.2011.12.009; Morelli JN, 2010, INVEST RADIOL, V45, P29, DOI 10.1097/RLI.0b013e3181c65c11; Nicotra A, 2006, BRAIN, V129, P718, DOI 10.1093/brain/awh699; Nishimura Y, 2007, SCIENCE, V318, P1150, DOI 10.1126/science.1147243; Petersen JA, 2012, J NEUROTRAUM, V29, P1556, DOI 10.1089/neu.2011.2027; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Schmid MR, 2005, AM J ROENTGENOL, V184, P1744, DOI 10.2214/ajr.184.6.01841744; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Thurnher MM, 2009, MAGN RESON IMAGING C, V17, P225, DOI 10.1016/j.mric.2009.02.004; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wannier T, 2005, J NEUROTRAUM, V22, P703, DOI 10.1089/neu.2005.22.703; Ward NS, 2004, ANN NEUROL, V55, P829, DOI 10.1002/ana.20099; Weiskopf N, 2011, NEUROIMAGE, V54, P2116, DOI 10.1016/j.neuroimage.2010.10.023; Wilm BJ, 2009, NMR BIOMED, V22, P174, DOI 10.1002/nbm.1298; Woollett K, 2011, CURR BIOL, V21, P2109, DOI 10.1016/j.cub.2011.11.018; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Yague JG, 2011, EXP NEUROL, V227, P252, DOI 10.1016/j.expneurol.2010.11.011	82	58	63	0	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	APR	2013	19	2					116	128		10.1177/1073858412449192			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	134YP	WOS:000318252000006	22730072	Green Published, hybrid			2022-02-06	
J	Moye, J; Marson, DC; Edelstein, B				Moye, Jennifer; Marson, Daniel C.; Edelstein, Barry			Assessment of Capacity in an Aging Society	AMERICAN PSYCHOLOGIST			English	Article						capacity; competency; decision making; informed consent; assessment	MILD COGNITIVE IMPAIRMENT; DECISION-MAKING CAPACITY; DECLINING FINANCIAL CAPACITY; TRAUMATIC BRAIN-INJURY; TO-MODERATE DEMENTIA; ALZHEIMERS-DISEASE; OLDER-ADULTS; PHYSICIAN JUDGMENTS; DRIVING SIMULATOR; MEDICAL DECISIONS	Over the past 40 years, the assessment and scientific study of capacity in older adults has emerged as a distinct field of clinical and research activity for psychologists. This new field reflects the convergence of several trends: the aging of American society, the growing incidence and prevalence of dementia, and the patient rights, deinstitutionalization, and disability rights movements. Because of these forces, capacity issues now permeate the fabric of everyday life, whether in the form of guardianship petitions, questions of capacity to consent to treatment, the ability to make a new will, or participation in human research. In seeking to resolve these issues, families, clinicians, and legal professionals increasingly turn to psychologists to assess a capacity and to provide empirically supported judgments that properly balance autonomy and protection for the individual. Psychologists have taken a leading role in the development of functional assessment instruments that measure important aspects of the capacity construct. In addition, psychology has been a major contributor to the scientific study of capacity. In collaboration with colleagues from medicine and law, psychologists have articulated crucial theoretical frameworks that integrate legal, clinical, and ethical dimensions of the capacity problem. This article focuses on the evolution of theory, law, science, and practice in the evaluation of capacity in older adults and its recent culmination in a series of interdisciplinary handbooks sponsored by the American Psychological Association and the American Bar Association.	[Moye, Jennifer] VA Boston Healthcare Syst, Brockton, MA 02301 USA; [Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA; [Marson, Daniel C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA; [Marson, Daniel C.] Univ Alabama Birmingham, Alzheimers Dis Ctr, Birmingham, AL USA; [Edelstein, Barry] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA		Moye, J (corresponding author), VA Boston Healthcare Syst, Brockton Campus,940 Belmont St, Brockton, MA 02301 USA.	jennifer.moye@va.gov	Moye, Jennifer A/F-2240-2017; Moye, Jennifer/AAM-1282-2021	Moye, Jennifer A/0000-0002-3434-347X; Moye, Jennifer/0000-0002-3434-347X	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG021927, R01 AG021927, R56 AG021927] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD053074, R01 HD053074] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R29 MH057104] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD053074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R29MH057104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021927, R56AG021927] Funding Source: NIH RePORTER		Administration on Aging, 2010, PROF OLD AM 2009; American Bar Association Commission on Law and Aging American Psychological Association, 2006, JUD DET CAP OLD AD G; American Bar Association Commission on Law and Aging & American Psychological Association, 2008, ASS OLD AD DIM CAP H; American Bar Association Commission on Law and Aging and American Psychological Association, 2005, ASS OLD AD DIM CAP H; American Psychological Association Office on Aging, 2012, CAP ASS TRAIN NEEDS; Anderer S. J., 1997, THESIS ALLEGHENY U H; Appelbaum P. S., 1992, MANUAL PERCEPTIONS D; APPELBAUM PS, 1981, AM J PSYCHIAT, V138, P1462; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Appelbaum PS, 1991, CLIN HDB PSYCHIAT LA; Bagenstos S., 2009, LAW CONTRADICTIONS D; Berg JW, 2001, INFORM CONSENT LEGAL; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Braun MM, 2009, GENERATIONS, V33, P78; BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; Brown PJ, 2011, ARCH GEN PSYCHIAT, V68, P617, DOI 10.1001/archgenpsychiatry.2011.57; Burgdorf Jr R. L., 2008, TEXAS J CIVIL LIBERT, V13, P242; Centers for Disease Control and Prevention & The Merck Company Foundation, 2007, STAT AG HLTH AM 2007; Clow HE, 2002, J AM GERIATR SOC, V50, P1879, DOI 10.1046/j.1532-5415.2002.50520.x; Dawes, 2010, RATIONAL CHOICE UNCE; Department of Veterans Affairs, 1997, CLIN ASS COMP DET PR; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Dreer LE, 2008, REHABIL PSYCHOL, V53, P486, DOI 10.1037/a0013798; Dumont MP, 2008, INT J MENT HEALTH, V37, P61, DOI 10.2753/IMH0020-7411370405; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Dymek MP, 1999, J FORENSIC NEUROPSYC, V1, P27, DOI DOI 10.1300/J151V01N01_; Edelstein B, 1993, M AM PSYCH ASS TOR O; Edelstein B., 1999, HOPEMONT CAPACITY AS; Fairchild AL, 2004, PUBLIC HEALTH REP, V119, P362, DOI 10.1016/j.phr.2004.04.016; Financial Industry Regulatory Authority, 2010, SEN INV ISS DIM CAP; Ganzini L, 2003, PSYCHOSOMATICS, V44, P237, DOI 10.1176/appi.psy.44.3.237; Gold DA, 2012, J CLIN EXP NEUROPSYC, V34, P11, DOI 10.1080/13803395.2011.614598; Griffith HR, 2010, J AM GERIATR SOC, V58, P265, DOI 10.1111/j.1532-5415.2009.02679.x; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; Grisso T., 2003, EVALUATING COMPETENC; GRISSO T, 1993, MANUAL THINKING RATI; Grisso T., 1998, MACARTHUR COMPETENCE; Grisso T, 1992, MANUAL UNDERSTANDING; GRISSO T, 1986, EVALUATING COMPETENC; GRISSO T, 1994, NEUROPSYCHOLOGICAL A, P119, DOI DOI 10.1037/10157-006; Gurrera RJ, 2006, NEUROLOGY, V66, P1367, DOI 10.1212/01.wnl.0000210527.13661.d1; GUTHEIL TG, 1982, CLIN HDB PSYCHIAT LA; Havens JJ, 2003, J GIFT PLANNING, V7, P11; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hornung CA, 1998, J AM GERIATR SOC, V46, P280, DOI 10.1111/j.1532-5415.1998.tb01038.x; Jacoby R, 2007, BRIT MED J, V335, P155, DOI 10.1136/bmj.39232.706840.AD; Jankowiak J. L., 2011, CLIN NEUROLOGY AGING, P159; Karlawish JHT, 2002, J AM GERIATR SOC, V50, P2019, DOI 10.1046/j.1532-5415.2002.50615.x; Kim SYH, 2002, PSYCHIATR SERV, V53, P1322, DOI 10.1176/appi.ps.53.10.1322; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; Lee HC, 2003, AM J OCCUP THER, V57, P324, DOI 10.5014/ajot.57.3.324; little william, 1955, OXFORD UNIVERSAL DIC; Liu KRY, 2007, ACTA NEUROL SCAND, V116, P91, DOI 10.1111/j.1600-0404.2007.00800.x; Loeb, 1996, INDEPENDENT LIVING S; Lockenhoff CE, 2011, PSYCHOL AGING, V26, P274, DOI 10.1037/a0023280; Marson D., 2000, NEURODEGENERATIVE DE, P425; Marson D., 2012, FORENSIC NEUROPSYCHO, P401; Marson DC, 2000, ARCH NEUROL-CHICAGO, V57, P877, DOI 10.1001/archneur.57.6.877; Marson DC, 2000, J AM GERIATR SOC, V48, P911, DOI 10.1111/j.1532-5415.2000.tb06887.x; Marson DC, 2005, ARCH PHYS MED REHAB, V86, P889, DOI 10.1016/j.apmr.2004.09.020; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; Marson DC, 1997, J AM GERIATR SOC, V45, P458, DOI 10.1111/j.1532-5415.1997.tb05171.x; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; Marson DC, 1997, J AM GERIATR SOC, V45, P453, DOI 10.1111/j.1532-5415.1997.tb05170.x; Marson DC, 2008, ENCY PSYCHOL LAW, V1, P313; Marson DC, 2012, CIVIL CAPACITIES CLI, P39; Martin R, 2008, AM J GERIAT PSYCHIAT, V16, P209, DOI 10.1097/JGP.0b013e318157cb00; Mata R, 2011, ANN NY ACAD SCI, V1235, P18, DOI 10.1111/j.1749-6632.2011.06200.x; MAZUR DJ, 1986, MED DECIS MAKING, V6, P224, DOI 10.1177/0272989X8600600407; McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2; Misra S, 2008, BIPOLAR DISORD, V10, P303, DOI 10.1111/j.1399-5618.2007.00525.x; Moye J, 2006, J GEN INTERN MED, V21, P78, DOI 10.1111/j.1525-1497.2005.00288.x; Moye J, 2004, GERONTOLOGIST, V44, P166, DOI 10.1093/geront/44.2.166; Moye J., 2004, ETHICS LAW AGING REV, V10, P39; Moye J, 2007, J GERONTOL B-PSYCHOL, V62, pP3, DOI 10.1093/geronb/62.1.P3; Moye J, 2007, BEHAV SCI LAW, V25, P425, DOI 10.1002/bsl.762; Moye J, 2006, CLIN PSYCHOL REV, V26, P1054, DOI 10.1016/j.cpr.2005.04.013; Moye J, 2011, JAMA-J AM MED ASSOC, V305, P936, DOI 10.1001/jama.2011.247; Moye J, 2007, CLIN GERONTOLOGIST, V31, P37, DOI 10.1080/07317110802072140; National Center on Elder Abuse, 2005, 15 QUEST ANSW ELD AB; National Conference of Commissioners on Uniform State Laws, 1982, UN GUARD PROPT P ACT; National Conference of Commissioners on Uniform State Laws, 1997, UN GUARD PROPT P ACT; Nedd H., 1998, US TODAY, P1; Palmer B. W., 2012, CIVIL CAPACITIES CLI, P69; Palmer BW, 2007, J INT NEUROPSYCH SOC, V13, P1047, DOI 10.1017/S1355617707071299; Palmer BW, 2007, J CLIN PSYCHIAT, V68, P689, DOI 10.4088/JCP.v68n0505; Park D. C., 2011, HDB PSYCHOL AGING, P109, DOI [10.1016/B978-0-12-380882-0.00007-3, DOI 10.1016/B978-0-12-380882-0.00007-3]; PARK DC, 1992, PSYCHOL AGING, V7, P252, DOI 10.1037/0882-7974.7.2.252; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC ETH; Quinn MJ., 2004, GUARDIANSHIPS ADULTS; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; Rogerson MD, 2011, AM PSYCHOL, V66, P614, DOI 10.1037/a0025215; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; Sabatino C. P., 2000, J MENTAL HLTH AGING, V6, P119; Salthouse T, 2012, ANNU REV PSYCHOL, V63, P201, DOI 10.1146/annurev-psych-120710-100328; Sherod MG, 2009, J INT NEUROPSYCH SOC, V15, P258, DOI 10.1017/S1355617709090365; Strough J, 2011, ANN NY ACAD SCI, V1235, P57, DOI 10.1111/j.1749-6632.2011.06208.x; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Twamley EW, 2002, AM J PSYCHIAT, V159, P2013, DOI 10.1176/appi.ajp.159.12.2013; Viertio S, 2012, EUR PSYCHIAT, V27, P409, DOI 10.1016/j.eurpsy.2010.12.005; Widera E, 2011, JAMA-J AM MED ASSOC, V305, P698, DOI 10.1001/jama.2011.164; WILLIS SL, 1993, LIFE SPAN DEV PSYCH, P33; Wong JG, 2000, PSYCHOL MED, V30, P295, DOI 10.1017/S0033291700001768; Woodhead EL, 2011, PSYCHOL AGING, V26, P285, DOI 10.1037/a0021608	106	58	59	1	50	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	APR	2013	68	3					158	171		10.1037/a0032159			14	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	125EO	WOS:000317522000004	23586491	Green Accepted			2022-02-06	
J	Stansbury, LG; Hess, AS; Thompson, K; Kramer, B; Scalea, TM; Hess, JR				Stansbury, Lynn G.; Hess, Aaron S.; Thompson, Kwaku; Kramer, Betsy; Scalea, Thomas M.; Hess, John R.			The clinical significance of platelet counts in the first 24 hours after severe injury	TRANSFUSION			English	Article							TRAUMATIC BRAIN-INJURY; MASSIVE TRANSFUSION; MORTALITY; ADMISSION; COAGULATION; PROGRESSION; PATTERNS; RATIOS; IMPACT; TIME	BACKGROUND: Admission platelet (PLT) counts are known to be associated with all-cause mortality for seriously injured patients admitted to a trauma center. The course of subsequent PLT counts, their implications, and the effects of PLT therapy are less well known. STUDY DESIGN AND METHODS: Trauma center patients who were directly admitted from the scene of injury, received 1 or more units of uncrossmatched red blood cells in the first hour of care, survived for at least 15 minutes, and had a PLT count measured in the first hour were analyzed for the association of their admission and subsequent PLT counts in the first 24 hours with injury severity and hemorrhagic and central nervous system (CNS) causes of in-hospital mortality. RESULTS: Over an 8.25-year period, 1292 of 45,849 direct trauma admissions met entry criteria. Admission PLT counts averaged 228x109 +/- 90x109/L and decreased by 104x109/L by the second hour and 1x109/L each hour thereafter. The admission count was not related to time to admission. Each 1-point increase in the injury severity score was associated with a 1x109/L decrease in the PLT count at all times in the first 24 hours of care. Admission PLT counts were strongly associated with hemorrhagic and CNS injury mortality and subsequent PLT counts. Effects of PLT therapy could not be ascertained. DISCUSSION: Admission PLT counts in critically injured trauma patients are usually normal, decreasing after admission. Low PLT counts at admission and during the course of trauma care are strongly associated with mortality.	[Stansbury, Lynn G.; Hess, Aaron S.; Thompson, Kwaku; Kramer, Betsy; Scalea, Thomas M.; Hess, John R.] Univ Maryland, Program Trauma Epidemiol & Pathol, Sch Med, Baltimore, MD 20201 USA		Hess, JR (corresponding author), Univ Maryland, Blood Bank, Med Ctr, N2W50a,22 South Greene St, Baltimore, MD 20201 USA.	jhess@umm.edu	Hess, John R./K-4001-2013; Hess, Aaron/AAZ-3279-2021	Hess, John R./0000-0001-8596-4420; 			[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bizzozero, 1882, VIRCHOWS ARCH PATHOL, V90, P261, DOI DOI 10.1007/BF01931360; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brown LM, 2011, J TRAUMA, V71, pS337, DOI 10.1097/TA.0b013e318227f67c; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; CROSBY WH, 1954, BLOOD, V9, P439, DOI 10.1182/blood.V9.5.439.439; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; Hess JR, 2009, TRANSFUSION, V49, P34, DOI 10.1111/j.1537-2995.2008.01944.x; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Kautza BC, 2012, J TRAUMA ACUTE CARE, V72, P106, DOI 10.1097/TA.0b013e3182410a3c; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Patton GC, 2009, LANCET, V374, P881, DOI 10.1016/S0140-6736(09)60741-8; PEPPER H, 1960, SURG GYNECOL OBSTET, V110, P319; REED RL, 1986, ANN SURG, V203, P40, DOI 10.1097/00000658-198601000-00008; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Sambasivan CN, 2011, J TRAUMA, V71, pS329, DOI 10.1097/TA.0b013e318227edd3; Saxena R, 1999, STROKE, V30, P993, DOI 10.1161/01.STR.30.5.993; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stainsby D, 2000, BRIT J ANAESTH, V85, P487, DOI 10.1093/bja/85.3.487; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034	27	58	61	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	APR	2013	53	4					783	789		10.1111/j.1537-2995.2012.03828.x			7	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	123DI	WOS:000317368200017	22882316				2022-02-06	
J	Fricker, M; Vilalta, A; Tolkovsky, AM; Brown, GC				Fricker, Michael; Vilalta, Anna; Tolkovsky, Aviva M.; Brown, Guy C.			Caspase Inhibitors Protect Neurons by Enabling Selective Necroptosis of Inflamed Microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC BRAIN-INJURY; PRIMARY PHAGOCYTOSIS; CELL-DEATH; CEREBRAL-ISCHEMIA; VIABLE NEURONS; RIP1 KINASE; TNF-ALPHA; NEURODEGENERATION; ACTIVATION; APOPTOSIS	Microglia are resident brain macrophages, which can cause neuronal loss when activated in infectious, ischemic, traumatic, and neurodegenerative diseases. Caspase-8 has both prodeath and prosurvival roles, mediating apoptosis and/or preventing RIPK1-mediated necroptosis depending on cell type and stimulus. We found that inflammatory stimuli (LPS, lipoteichoic acid, or TNF-alpha) caused an increase in caspase-8 IETDase activity in primary rat microglia without inducing apoptosis. Inhibition of caspase-8 with either Z-VAD-fmk or IETD-fmk resulted in necrosis of activated microglia. Inhibition of caspases with Z-VAD-fmk did not kill non-activated microglia, or astrocytes and neurons in any condition. Necrostatin-1, a specific inhibitor of RIPK1, prevented microglial caspase inhibition-induced death, indicating death was by necroptosis. In mixed cerebellar cultures of primary neurons, astrocytes, and microglia, LPS induced neuronal loss that was prevented by inhibition of caspase-8 (resulting in microglial necroptosis), and neuronal death was restored by rescue of microglia with necrostatin-1. We conclude that the activation of caspase-8 in inflamed microglia prevents their death by necroptosis, and thus, caspase-8 inhibitors may protect neurons in the inflamed brain by selectively killing activated microglia.	[Fricker, Michael; Vilalta, Anna; Brown, Guy C.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Tolkovsky, Aviva M.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 OPY, England		Fricker, M (corresponding author), Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2305, Australia.	michael.fricker@gmail.com	FRICKER, MICHAEL/ABE-2316-2021	Vilalta, Anna/0000-0002-2183-072X; Fricker, Michael/0000-0002-8587-1774; Brown, Guy/0000-0002-3610-1730	Wellcome Trust GrantWellcome Trust [RG50995]	This work was supported by Wellcome Trust Grant RG50995.	Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2013, CELL DEATH DIFFER, V20, P366, DOI 10.1038/cdd.2012.133; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Feng YZ, 2003, EUR J PHARMACOL, V481, P169, DOI 10.1016/j.ejphar.2003.09.016; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Green DR, 2011, MOL CELL, V44, P9, DOI 10.1016/j.molcel.2011.09.003; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Inoue S, 2006, ANESTH ANALG, V102, P1548, DOI 10.1213/01.ane.0000202381.40516.8d; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Kinsner A, 2005, J NEUROCHEM, V95, P1132, DOI 10.1111/j.1471-4159.2005.03422.x; Neher JJ, 2007, BIOCHEM SOC T, V35, P1166, DOI 10.1042/BST0351166; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Venero JL, 2011, CELL DEATH DIFFER, V18, P1679, DOI 10.1038/cdd.2011.107; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Wiessner C, 2000, CELL MOL BIOL, V46, P53	28	58	61	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2013	288	13					9145	9152		10.1074/jbc.M112.427880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	116DG	WOS:000316862200034	23386613	Green Published, hybrid			2022-02-06	
J	Titus, DJ; Sakurai, A; Kang, Y; Furones, C; Jergova, S; Santos, R; Sick, TJ; Atkins, CM				Titus, David J.; Sakurai, Atsushi; Kang, Yuan; Furones, Concepcion; Jergova, Stanislava; Santos, Rosmery; Sick, Thomas J.; Atkins, Coleen M.			Phosphodiesterase Inhibition Rescues Chronic Cognitive Deficits Induced by Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; SPATIAL MEMORY; DORSAL HIPPOCAMPUS; RAT HIPPOCAMPUS; TRANSCRIPTION FACTORS; INDUCED IMPAIRMENTS; PROTEIN-SYNTHESIS; MOUSE MODEL; HEAD-INJURY	Traumatic brain injury (TBI) modulates several cell signaling pathways in the hippocampus critical for memory formation. Previous studies have found that the cAMP-protein kinase A signaling pathway is downregulated after TBI and that treatment with a phosphodiesterase (PDE) 4 inhibitor rolipram rescues the decrease in cAMP. In the present study, we examined the effect of rolipram on TBI-induced cognitive impairments. At 2 weeks after moderate fluid-percussion brain injury or sham surgery, adult male Sprague Dawley rats received vehicle or rolipram (0.03 mg/kg) 30 min before water maze acquisition or cue and contextual fear conditioning. TBI animals treated with rolipram showed a significant improvement in water maze acquisition and retention of both cue and contextual fear conditioning compared with vehicle-treated TBI animals. Cue and contextual fear conditioning significantly increased phosphorylated CREB levels in the hippocampus of sham animals, but not in TBI animals. This deficit in CREB activation during learning was rescued in TBI animals treated with rolipram. Hippocampal long-term potentiation was reduced in TBI animals, and this was also rescued with rolipram treatment. These results indicate that the PDE4 inhibitor rolipram rescues cognitive impairments after TBI, and this may be mediated through increased CREB activation during learning.	[Titus, David J.; Sakurai, Atsushi; Kang, Yuan; Furones, Concepcion; Jergova, Stanislava; Santos, Rosmery; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Sick, Thomas J.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA		Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu		Titus, David/0000-0001-7819-734X; Jergova, Stanislava/0000-0002-9096-7770; Atkins, Coleen/0000-0003-4718-7493	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069721, NS056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069721, R01NS056072] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health Grants NS069721 and NS056072 and the Miami Project to Cure Paralysis. We thank Dr. W. Dalton Dietrich for critical reading of the manuscript.	Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; ASANUMA M, 1993, RES COMMUN CHEM PATH, V82, P279; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; BOISSARD CG, 1992, NEUROSCIENCE, V48, P807, DOI 10.1016/0306-4522(92)90268-7; Bourtchouladze R, 2003, P NATL ACAD SCI USA, V100, P10518, DOI 10.1073/pnas.1834280100; Bourtchouladze R, 1998, LEARN MEMORY, V5, P365; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown KL, 2011, BEHAV BRAIN RES, V225, P290, DOI 10.1016/j.bbr.2011.07.044; Bruno O, 2009, J MED CHEM, V52, P6546, DOI 10.1021/jm900977c; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chwang WB, 2006, LEARN MEMORY, V13, P322, DOI 10.1101/lm.152906; Clark RE, 2001, HIPPOCAMPUS, V11, P176, DOI 10.1002/hipo.1035; Crain SM, 2008, BRAIN RES, V1231, P16, DOI 10.1016/j.brainres.2008.07.015; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Dlaboga D, 2006, BRAIN RES, V1096, P104, DOI 10.1016/j.brainres.2006.04.032; Egawa T, 1997, JPN J PHARMACOL, V75, P275, DOI 10.1254/jjp.75.275; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Giorgi M, 2004, BEHAV BRAIN RES, V154, P99, DOI 10.1016/j.bbr.2004.01.024; Giralt A, 2011, HUM MOL GENET, V20, P4232, DOI 10.1093/hmg/ddr351; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Imanishi T, 1997, EUR J PHARMACOL, V321, P273, DOI 10.1016/S0014-2999(96)00969-7; Kobori N, 2011, NEUROSCIENCE, V172, P293, DOI 10.1016/j.neuroscience.2010.10.048; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Maren S, 1997, BEHAV BRAIN RES, V88, P261, DOI 10.1016/S0166-4328(97)00088-0; Matus-Amat P, 2004, J NEUROSCI, V24, P2431, DOI 10.1523/JNEUROSCI.1598-03.2004; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; Navakkode S, 2004, J NEUROSCI, V24, P7740, DOI 10.1523/JNEUROSCI.1796-04.2004; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; PHILLIPS RG, 1994, LEARN MEMORY, V1, P34; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Ploski JE, 2008, J NEUROSCI, V28, P12383, DOI 10.1523/JNEUROSCI.1662-08.2008; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Robichaud A, 2002, BRIT J PHARMACOL, V135, P113, DOI 10.1038/sj.bjp.0704457; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; RUDY JW, 1994, BEHAV NEUROSCI, V108, P227, DOI 10.1037/0735-7044.108.2.227; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Runyan JD, 2005, LEARN MEMORY, V12, P232, DOI 10.1101/lm.92405; Rutten K, 2009, NEUROPSYCHOPHARMACOL, V34, P1914, DOI 10.1038/npp.2009.24; Schafe GE, 1999, LEARN MEMORY, V6, P97; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHOFFELMEER ANM, 1985, N-S ARCH PHARMACOL, V330, P74, DOI 10.1007/BF00586712; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van Staveren WCG, 2001, BRAIN RES, V888, P275, DOI 10.1016/S0006-8993(00)03081-X; Vecsey CG, 2009, NATURE, V461, P1122, DOI 10.1038/nature08488; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wiltgen BJ, 2006, J NEUROSCI, V26, P5484, DOI 10.1523/JNEUROSCI.2685-05.2006; WINSKY L, 1987, J PHARMACOL EXP THER, V241, P223; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HT, 2004, NEUROPSYCHOPHARMACOL, V29, P1432, DOI 10.1038/sj.npp.1300440	86	58	63	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 20	2013	33	12					5216	5226		10.1523/JNEUROSCI.5133-12.2013			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	111XB	WOS:000316553800015	23516287	Green Accepted, Green Published, Bronze			2022-02-06	
J	Keshavan, MS; Kaneko, Y				Keshavan, Matcheri S.; Kaneko, Yoshio			Secondary psychoses: an update	WORLD PSYCHIATRY			English	Article						Secondary psychoses; temporal lobe epilepsy; velocardiofacial syndrome; NMDA receptor encephalitis; schizophrenia	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CARDIO-FACIAL SYNDROME; SCHIZOPHRENIA-LIKE PSYCHOSIS; TRAUMATIC BRAIN INJURY; PRADER-WILLI-SYNDROME; LATE-ONSET PSYCHOSIS; MULTIPLE-SCLEROSIS; PSYCHIATRIC-ILLNESS; ALZHEIMERS-DISEASE; MITOCHONDRIAL ENCEPHALOMYOPATHY	Psychotic disorders due to a known medical illness or substance use are collectively termed secondary psychoses. In this paper, we first review the historic evolution of the concept of secondary versus primary psychosis and how this distinction supplanted the earlier misleading classification of psychoses into organic and functional. We then outline the clinical features and approach to the diagnosis of secondary psychotic disorders. Features such as atypical presentation, temporal relation to detectable medical cause, evidence of direct physiological causal relationship to the etiological agent, and the absence of evidence of a primary psychotic illness that may better explain the presentation suggest consideration of a secondary psychosis. Finally, we discuss how careful studies of secondary psychotic disorders can help elucidate the pathophysiology of primary, or idiopathic, psychotic disorders such as schizophrenia. We illustrate this issue through a discussion of three secondary psychotic disorders - psychoses associated with temporal lobe epilepsy, velocardiofacial syndrome, and N-methyl D-aspartate (NMDA) receptor encephalitis - that can, respectively, provide neuroanatomical, genetic, and neurochemical models of schizophrenia pathogenesis.	[Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Keshavan, Matcheri S.; Kaneko, Yoshio] Harvard Univ, Sch Med, Boston, MA USA; [Kaneko, Yoshio] Longwood Psychiat Residency Training Program, Boston, MA USA		Keshavan, MS (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.						ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Alisky JM, 2006, MED HYPOTHESES, V67, P1090, DOI 10.1016/j.mehy.2006.01.059; Almeida OP, 2007, AUST NZ J PSYCHIAT, V41, P274, DOI 10.1080/00048670601172772; Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ando N, 2004, NEUROPSYCHOPHARMACOL, V29, P1251, DOI 10.1038/sj.npp.1300427; ANG AWK, 1995, PSYCHOSOM MED, V57, P299, DOI 10.1097/00006842-199505000-00013; Appenzeller S, 2008, RHEUMATOL INT, V28, P237, DOI 10.1007/s00296-007-0410-x; Babulas V, 2006, AM J PSYCHIAT, V163, P927, DOI 10.1176/appi.ajp.163.5.927; BENES FM, 1989, SCHIZOPHRENIA BULL, V15, P585, DOI 10.1093/schbul/15.4.585; Benes FM, 2003, CURR OPIN PSYCHIATR, V16, P317, DOI 10.1097/00001504-200305000-00007; Beniczky S, 2002, EUR J NEUROL, V9, P175, DOI 10.1046/j.1468-1331.2002.00353.x; Bo Mortensen P, 2007, BIOL PSYCHIAT, V61, P688, DOI 10.1016/j.biopsych.2006.05.024; Bourgeois JA, 2010, ACTA PSYCHIAT SCAND, V121, P78, DOI 10.1111/j.1600-0447.2009.01419.x; BOWEN JD, 1993, DRUG AGING, V3, P349, DOI 10.2165/00002512-199303040-00005; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; Brown AS, 2001, BIOL PSYCHIAT, V49, P473, DOI 10.1016/S0006-3223(01)01068-X; Brown AS, DEV NEUROBI IN PRESS; Brownlie BEW, 2000, EUR J ENDOCRINOL, V142, P438, DOI 10.1530/eje.0.1420438; Cami J, 2000, J CLIN PSYCHOPHARM, V20, P455, DOI 10.1097/00004714-200008000-00010; Carrieri PB, 2011, J NEUROPSYCH CLIN N, V23, pE6, DOI 10.1176/appi.neuropsych.23.2.E6; Chow EWC, 2006, SCHIZOPHR RES, V87, P270, DOI 10.1016/j.schres.2006.04.007; Cole JC, 2003, PHARMACOL THERAPEUT, V98, P35, DOI 10.1016/S0163-7258(03)00003-2; Curran C, 2004, BRIT J PSYCHIAT, V185, P196, DOI 10.1192/bjp.185.3.196; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Dalmau A, 1999, EUR PSYCHIAT, V14, P366, DOI 10.1016/S0924-9338(99)00234-5; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; de Holanda NCP, 2011, J NEUROPSYCH CLIN N, V23, P384, DOI 10.1176/jnp.23.4.jnp384; DENKO JD, 1962, ACTA PSYCHIAT SCAND, V38, P7; Dolder CR, 2004, AIDS, V18, pS35, DOI 10.1097/00002030-200401001-00006; Dubovsky AN, 2012, PSYCHOSOMATICS, V53, P103, DOI 10.1016/j.psym.2011.12.007; Edwards-Lee T, 2000, BEHAVIOR AND MOOD DISORDERS IN FOCAL BRAIN LESIONS, P419; EdwardsLee T, 1997, BRAIN, V120, P1027, DOI 10.1093/brain/120.6.1027; ERARD R, 1980, J PSYCHEDEL DRUG, V12, P235, DOI 10.1080/02791072.1980.10471432; EVANS DL, 1983, AM J PSYCHIAT, V140, P218; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; FEINBERG M, 1993, DRUG AGING, V3, P335, DOI 10.2165/00002512-199303040-00004; FEINSTEIN A, 1992, BRIT J PSYCHIAT, V161, P680, DOI 10.1192/bjp.161.5.680; Feinstein A, 2004, CAN J PSYCHIAT, V49, P157, DOI 10.1177/070674370404900302; Fergusson DM, 2005, ADDICTION, V100, P354, DOI 10.1111/j.1360-0443.2005.01001.x; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; FOLSTEIN SE, 1987, AM J HUM GENET, V41, P168; FREYTAG HW, 1979, NERVENARZT, V50, P128; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; GALASKO D, 1988, PSYCHIAT CLIN N AM, V11, P151; GODFREY PSA, 1990, LANCET, V336, P392, DOI 10.1016/0140-6736(90)91942-4; Gonzalez-Burgos G, 2010, CURR PSYCHIAT REP, V12, P335, DOI 10.1007/s11920-010-0124-8; Guler E, 2011, INT PSYCHOGERIATR, V23, P666, DOI 10.1017/S104161021000181X; Gustafson L, 1992, Baillieres Clin Neurol, V1, P559; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; HALL RCW, 1983, PSYCHOSOMATICS, V24, P7, DOI 10.1016/S0033-3182(83)73255-X; Hambrecht M, 1996, NERVENARZT, V67, P36; HARE EH, 1959, J MENT SCI, V105, P594, DOI 10.1192/bjp.105.440.594; HARRIS MJ, 1991, J CLIN PSYCHIAT, V52, P369; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Harrison PJ, 2003, ANN NY ACAD SCI, V1003, P94, DOI 10.1196/annals.1300.006; Heinrich Thomas W., 2003, Prim Care Companion J Clin Psychiatry, V5, P260; Herrington R. N., 1969, CURRENT PROBLEMS NEU, P1; HOLLISTER LE, 1991, J PSYCHIATR NEUROSCI, V16, P194; Huang Chin-Chang, 1992, Journal of the Formosan Medical Association, V91, P502; Hung Y-J, 2012, GEN HOSP PSYCHIAT, V34; Hutto B, 2001, PSYCHOSOMATICS, V42, P453, DOI 10.1176/appi.psy.42.6.453; Hutto BR, 1997, COMPR PSYCHIAT, V38, P305, DOI 10.1016/S0010-440X(97)90925-1; Illes J, 2006, SCIENCE, V311, P783, DOI 10.1126/science.1124665; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Irwin R, 1997, AUST NZ J PSYCHIAT, V31, P762, DOI 10.3109/00048679709062692; Jansen KLR, 2000, J PSYCHOACTIVE DRUGS, V32, P419, DOI 10.1080/02791072.2000.10400244; Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004; KAHAN VL, 1950, J MENT SCI, V96, P1043, DOI 10.1192/bjp.96.405.1043; Kanner AM, 1996, ARCH NEUROL-CHICAGO, V53, P258, DOI 10.1001/archneur.1996.00550030070024; Kates WR, 2011, BIOL PSYCHIAT, V69, P945, DOI 10.1016/j.biopsych.2010.10.027; Katsigiannopoulos K, 2010, PSYCHOSOMATICS, V51, P449, DOI 10.1176/appi.psy.51.5.449-a; Keshavan MS, 2011, SCHIZOPHR RES, V126, P1, DOI 10.1016/j.schres.2010.10.006; Keshavan MS, 2008, SCHIZOPHR RES, V106, P89, DOI 10.1016/j.schres.2008.07.020; KLAUS MV, 1989, ARCH DERMATOL, V125, P1644, DOI 10.1001/archderm.125.12.1644; KLOTZ M, 1957, PSYCHIAT QUART, V31, P669, DOI 10.1007/BF01568758; Kobayashi Nobuyuki, 2011, J Med Case Rep, V5, P534, DOI 10.1186/1752-1947-5-534; Kosmidis MH, 2010, INT REV PSYCHIATR, V22, P55, DOI 10.3109/09540261003589612; Kramer W, 1966, Psychiatr Neurol Neurochir, V69, P43; Kumral E, 2004, NEUROLOGY, V62, P110, DOI 10.1212/WNL.62.1.110; Larson CP, 1940, AM J PSYCHIAT, V97, P49, DOI 10.1176/ajp.97.1.49; Lawrie SM, 1997, SCHIZOPHR RES, V25, P155, DOI 10.1016/S0920-9964(97)00019-4; Lee Min-Joo, 2012, Korean J Pediatr, V55, P111, DOI 10.3345/kjp.2012.55.3.111; LEVITT AJ, 1988, BRIT J PSYCHIAT, V153, P266, DOI 10.1192/bjp.153.2.266b; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; Lisanby, 1998, Semin Clin Neuropsychiatry, V3, P12; LOGSDAIL SJ, 1988, BRIT J PSYCHIAT, V152, P246, DOI 10.1192/bjp.152.2.246; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; MALAMUD N, 1967, ARCH NEUROL-CHICAGO, V17, P113, DOI 10.1001/archneur.1967.00470260003001; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; Martin NJ, 2000, INT PSYCHOGERIATR, V12, P117, DOI 10.1017/S1041610200006244; Masalha R, 2001, ISRAEL MED ASSOC J, V3, P701; MEADOR KJ, 1994, CAN J NEUROL SCI, V21, pS12, DOI 10.1017/S0317167100040762; Mendel L B, 1907, Science, V26, P765, DOI 10.1126/science.26.674.765; MILLER BL, 1986, J CLIN PSYCHIAT, V47, P204; MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541; Moghaddam B, 2003, NEURON, V40, P881, DOI 10.1016/S0896-6273(03)00757-8; MULDER DW, 1952, JAMA-J AM MED ASSOC, V150, P173, DOI 10.1001/jama.1952.03680030005003; Murphy KC, 1999, ARCH GEN PSYCHIAT, V56, P940, DOI 10.1001/archpsyc.56.10.940; Nagaratnam N, 2000, GEN HOSP PSYCHIAT, V22, P129, DOI 10.1016/S0163-8343(00)00064-5; Nye Elizabeth, 2002, Emerg Med (Fremantle), V14, P447, DOI 10.1046/j.1442-2026.2002.00385.x; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Papa A, 2003, AM J EMERG MED, V21, P250, DOI 10.1016/S0735-6757(03)00022-6; Papolos DF, 1996, AM J PSYCHIAT, V153, P1541; Patten SB, 2005, NEUROLOGY, V65, P1123, DOI 10.1212/01.wnl.0000178998.95293.29; Paulsen JS, 2000, J INT NEUROPSYCH SOC, V6, P815, DOI 10.1017/S1355617700677081; Payinda G, 2000, AM J PSYCHIAT, V157, P660, DOI 10.1176/appi.ajp.157.4.660; Pego-Reigosa JM, 2008, RHEUMATOLOGY, V47, P1498, DOI 10.1093/rheumatology/ken260; PETERS NL, 1989, ARCH INTERN MED, V149, P2414, DOI 10.1001/archinte.149.11.2414; POST RM, 1975, AM J PSYCHIAT, V132, P225; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Prakash R, 2008, GEN HOSP PSYCHIAT, V30, P581, DOI 10.1016/j.genhosppsych.2008.04.011; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rapoport MJ, 2001, INT J GERIATR PSYCH, V16, P123, DOI 10.1002/1099-1166(200102)16:2<123::AID-GPS260>3.0.CO;2-1; Rathbun JK, 1996, INT J NEUROSCI, V85, P221, DOI 10.3109/00207459608986684; Rizvi AA, 2007, SOUTH MED J, V100, P837, DOI 10.1097/SMJ.0b013e318063ed4e; Ropacki SA, 2005, AM J PSYCHIAT, V162, P2022, DOI 10.1176/appi.ajp.162.11.2022; RUDIN DO, 1981, BIOL PSYCHIAT, V16, P837; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sachdev PS., 2010, SECONDARY SCHIZOPHRE; Sathya A, 2009, SINGAP MED J, V50, pe65; Schenk V W, 1967, Psychiatr Neurol Neurochir, V70, P31; SCHOFIELD A, 1983, IRISH MED J, V76, P495; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; Schrestha S, 2009, PSYCHOSOMATICS, V50, P640, DOI 10.1176/appi.psy.50.6.640-a; SELECKI B R, 1965, Med J Aust, V1, P383; Sewell DD, 1996, SCHIZOPHRENIA BULL, V22, P465, DOI 10.1093/schbul/22.3.465; Shakibai SV, 2005, PSYCHOSOMATICS, V46, P569, DOI 10.1176/appi.psy.46.6.569; Shashi V, 2006, CLIN GENET, V69, P234, DOI 10.1111/j.1399-0004.2006.00569.x; Shashi V, 2010, PSYCHIAT RES-NEUROIM, V181, P1, DOI 10.1016/j.pscychresns.2009.07.003; SHEDLACK KJ, 1994, BIOL PSYCHIAT, V35, P147, DOI 10.1016/0006-3223(94)91207-6; Shenton Martha E, 2010, Dialogues Clin Neurosci, V12, P317; SHIWACH R, 1994, ACTA PSYCHIAT SCAND, V90, P241, DOI 10.1111/j.1600-0447.1994.tb01587.x; SHPRINTZEN RJ, 1992, AM J MED GENET, V42, P141, DOI 10.1002/ajmg.1320420131; SIBLEY JT, 1992, J RHEUMATOL, V19, P47; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SLATER E, 1963, BRIT J PSYCHIAT, V109, P95, DOI 10.1192/bjp.109.458.95; SNAVELY SR, 1984, ANN INTERN MED, V101, P92, DOI 10.7326/0003-4819-101-1-92; Sobhan T, 2004, PSYCHIAT SERV, V55, P830, DOI 10.1176/appi.ps.55.7.830; STANDAGE KF, 1975, PSYCHOL MED, V5, P152, DOI 10.1017/S0033291700056403; Starkstein SE, 1992, NEUROPSY NEUROPSY BE, V5, P114; Stojanovich L, 2007, AUTOIMMUN REV, V6, P421, DOI 10.1016/j.autrev.2007.02.007; SUZUKI T, 1989, J NEUROL NEUROSUR PS, V52, P920, DOI 10.1136/jnnp.52.7.920-a; Tandon R, 2008, SCHIZOPHR RES, V102, P1, DOI 10.1016/j.schres.2008.04.011; Taycan O, 2006, GEN HOSP PSYCHIAT, V28, P359, DOI 10.1016/j.genhosppsych.2006.02.006; Thirthalli J, 2006, CURR OPIN PSYCHIATR, V19, P239, DOI 10.1097/01.yco.0000218593.08313.fd; Tor P. C., 2007, SMJ Singapore Medical Journal, V48, P354; Torrey EF, 2007, SCHIZOPHRENIA BULL, V33, P727, DOI 10.1093/schbul/sbm026; Torta R, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00883.x; Tran TM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-74; Trimble MR, 1991, PSYCHOSES EPILEPSY; Velasco PJ, 1999, PSYCHOSOMATICS, V40, P486; Vogels A, 2004, AM J MED GENET A, V127A, P238, DOI 10.1002/ajmg.a.30004; Vogels A, 2003, J MED GENET, V40, P72, DOI 10.1136/jmg.40.1.72; WAGGONER RW, 1954, AM J PSYCHIAT, V110, P904, DOI 10.1176/ajp.110.12.904; WARD MM, 1991, J RHEUMATOL, V18, P535; Watson LC, 2002, PSYCHOSOMATICS, V43, P413, DOI 10.1176/appi.psy.43.5.413; WEINBERGER DR, 1995, SCHIZOPHR RES, V16, P87, DOI 10.1016/0920-9964(95)00013-C; Wilson SAK, 1912, BRIT MED J, V1912, P1645; Yolken RH, 2009, PARASITE IMMUNOL, V31, P706, DOI 10.1111/j.1365-3024.2009.01131.x	163	58	61	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-5545			WORLD PSYCHIATRY	World Psychiatry	FEB	2013	12	1					4	15		10.1002/wps.20001			12	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	157BN	WOS:000319870500002	23471787	Green Published, Bronze			2022-02-06	
J	Pop, V; Sorensen, DW; Kamper, JE; Ajao, DO; Murphy, MP; Head, E; Hartman, RE; Badaut, J				Pop, Viorela; Sorensen, Dane W.; Kamper, Joel E.; Ajao, David O.; Murphy, M. Paul; Head, Elizabeth; Hartman, Richard E.; Badaut, Jerome			Early brain injury alters the blood-brain barrier phenotype in parallel with beta-amyloid and cognitive changes in adulthood	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						amyloid; claudin 5; endothelial; juvenile; P-glycoprotein; traumatic brain injury	P-GLYCOPROTEIN EXPRESSION; ALZHEIMERS-DISEASE; DEPOSITION; IMPAIRMENT; PATHOLOGY	Clinical studies suggest that traumatic brain injury (TBI) hastens cognitive decline and development of neuropathology resembling brain aging. Blood-brain barrier (BBB) disruption following TBI may contribute to the aging process by deregulating substance exchange between the brain and blood. We evaluated the effect of juvenile TBI (jTBI) on these processes by examining long-term alterations of BBB proteins, beta-amyloid (A beta) neuropathology, and cognitive changes. A controlled cortical impact was delivered to the parietal cortex of male rats at postnatal day 17, with behavioral studies and brain tissue evaluation at 60 days post-injury (dpi). Immunoglobulin G extravasation was unchanged, and jTBI animals had higher levels of tight-junction protein claudin 5 versus shams, suggesting the absence of BBB disruption. However, decreased P-glycoprotein (P-gp) on cortical blood vessels indicates modifications of BBB properties. In parallel, we observed higher levels of endogenous rodent A beta in several brain regions of the jTBI group versus shams. In addition at 60 dpi, jTBI animals displayed systematic search strategies rather than relying on spatial memory during the water maze. Together, these alterations to the BBB phenotype after jTB1 may contribute to the accumulation of toxic products, which in turn may induce cognitive differences and ultimately accelerate brain aging. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 205-214; doi:10.1038/jcbfm.2012.154; published online 14 November 2012	[Pop, Viorela; Sorensen, Dane W.; Badaut, Jerome] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Sorensen, Dane W.; Ajao, David O.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Murphy, M. Paul; Head, Elizabeth] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA		Badaut, J (corresponding author), Loma Linda Univ, Sch Med Coleman Pavil, Dept Pediat Pharmacol & Physiol, Room A1120 11175,Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176	NSFNational Science Foundation (NSF) [MRI-DBI 0923559]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG005119] Funding Source: NIH RePORTER	The authors thank Dr Andre Obenaus (Loma Linda University) for project assistance and Monica Rubalcava for a portion of imaging performed at the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core (LLUSM AIM) supported by NSF Grant, MRI-DBI 0923559 (to SM Wilson).	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Andras IE, 2010, MOL CELL NEUROSCI, V43, P232, DOI 10.1016/j.mcn.2009.11.004; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Bart J, 2007, BRIT J CANCER, V97, P322, DOI 10.1038/sj.bjc.6603864; Bertolizio G, 2011, PEDIATR ANESTH, V21, P1198, DOI 10.1111/j.1460-9592.2011.03695.x; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Brenn Anja, 2011, Int J Alzheimers Dis, V2011, P690121, DOI 10.4061/2011/690121; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; del Valle J, 2011, NEURODEGENER DIS, V8, P421, DOI 10.1159/000324757; Faul M, 2010, TRAUMATIC BRAIN INJU; Honer WG, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.38; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Istrate AN, 2012, BIOPHYS J, V102, P136, DOI 10.1016/j.bpj.2011.11.4006; Jicha GA, 2006, ARCH NEUROL-CHICAGO, V63, P674, DOI 10.1001/archneur.63.5.674; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kooij G, 2010, J AUTOIMMUN, V34, P416, DOI 10.1016/j.jaut.2009.10.006; Liao CW, 2008, PARASITE IMMUNOL, V30, P525, DOI 10.1111/j.1365-3024.2008.01048.x; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43; Papp KV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021688; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2012, NEUROBIOL AGING, V33, P108, DOI 10.1016/j.neurobiolaging.2010.02.008; Robinson JL, 2011, BRAIN, V134, P3705, DOI 10.1093/brain/awr308; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Ueno M, 2010, CURR MED CHEM, V17, P1125, DOI 10.2174/092986710790827816; van Assema DME, 2012, BRAIN, V135, P181, DOI 10.1093/brain/awr298; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; Vogelgesang S, 2002, PHARMACOGENETICS, V12, P535, DOI 10.1097/00008571-200210000-00005; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	38	58	59	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2013	33	2					205	214		10.1038/jcbfm.2012.154			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	087CT	WOS:000314739600008	23149553	Green Published, Bronze			2022-02-06	
J	Terpolilli, NA; Kim, SW; Thal, SC; Kuebler, WM; Plesnila, N				Terpolilli, Nicole A.; Kim, Seong-Woong; Thal, Serge C.; Kuebler, Wolfgang M.; Plesnila, Nikolaus			Inhaled nitric oxide reduces secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain edema; brain trauma; cerebral blood flow; microcirculation; nitric oxide	CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; PERSISTENT PULMONARY-HYPERTENSION; RESPIRATORY-DISTRESS-SYNDROME; L-ARGININE; PLATELET-AGGREGATION; HEAD-INJURY; PERMEABILITY; RAT; ISCHEMIA	Ischemia, especially pericontusional ischemia, is one of the leading causes of secondary brain damage after traumatic brain injury (1131). So far efforts to improve cerebral blood flow (CBF) after TBI were not successful because of various reasons. We previously showed that nitric oxide (NO) applied by inhalation after experimental ischemic stroke is transported to the brain and induces vasodilatation in hypoxic brain regions, thus improving regional ischemia, thereby improving brain damage and neurological outcome. As regional ischemia in the traumatic penumbra is a key mechanism determining secondary posttraumatic brain damage, the aim of the current study was to evaluate the effect of NO inhalation after experimental TBI. NO inhalation significantly improved CBF and reduced intracranial pressure after TBI in male C57 BI/6 mice. Long-term application (24 hours NO inhalation) resulted in reduced lesion volume, reduced brain edema formation and less blood brain barrier disruption, as well as improved neurological function. No adverse effects, e.g., on cerebral auto-regulation, systemic blood pressure, or oxidative damage were observed. NO inhalation might therefore be a safe and effective treatment option for TBI patients. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 311-318; doi: 10.1038/jcbfm.2012.176; published online 28 November 2012	[Terpolilli, Nicole A.] Univ Munich, Med Ctr, Dept Neurosurg, D-81377 Munich, Germany; [Terpolilli, Nicole A.; Kim, Seong-Woong; Thal, Serge C.] Univ Munich, Med Ctr, Inst Surg Res, D-81377 Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, D-81377 Munich, Germany; [Kuebler, Wolfgang M.] Li Ka Shing Knowledge Inst St Michaels, Keenan Res Ctr, Toronto, ON, Canada		Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Max Lebsche Pl 30, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Thal, Serge/D-6593-2011; Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019	Thal, Serge/0000-0002-1222-8729; Kuebler, Wolfgang/0000-0003-4100-2961	GEMI Fund	This work was supported by the GEMI Fund (NP). Parts of the present study are part of the PhD thesis of NT.	Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bode-Boger SM, 2005, CELL MOL BIOL, V51, P307, DOI 10.1170/T632; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI200112761; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DIRNAGL U, 1993, NEUROL RES, V15, P128; El Kebir D, 2005, CHEST, V128, P2910, DOI 10.1378/chest.128.4.2910; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; FILEP JG, 1993, BRIT J PHARMACOL, V108, P323, DOI 10.1111/j.1476-5381.1993.tb12803.x; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Guillen J, 2012, J AM ASSOC LAB ANIM, V51, P311; He P, 1997, AM J PHYSIOL-HEART C, V272, pH176, DOI 10.1152/ajpheart.1997.272.1.H176; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2002, ACT NEUR S, V81, P347; HOGMAN M, 1994, ACTA PHYSIOL SCAND, V151, P125, DOI 10.1111/j.1748-1716.1994.tb09728.x; Kermarrec N, 1998, AM J RESP CRIT CARE, V158, P833, DOI 10.1164/ajrccm.158.3.9709097; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; KINSELLA JP, 1993, J PEDIATR-US, V123, P103, DOI 10.1016/S0022-3476(05)81551-3; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Lundblad C, 2007, MICROVASC RES, V74, P1, DOI 10.1016/j.mvr.2007.03.001; Mayhan WG, 2000, BRAIN RES, V866, P101, DOI 10.1016/S0006-8993(00)02254-X; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Neye N, 2012, INTENS CARE MED, V38, P1381, DOI 10.1007/s00134-012-2605-1; OLIVER JA, 1992, J CELL PHYSIOL, V151, P506, DOI 10.1002/jcp.1041510309; PARKER JO, 1990, EUR J CLIN PHARMACOL, V38, pS21, DOI 10.1007/BF01417561; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SAMAMA CM, 1995, ANESTHESIOLOGY, V83, P56, DOI 10.1097/00000542-199507000-00007; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sokol J, 2003, ANESTH ANALG, V97, P989, DOI [10.1213/01.ANE.0000078819.45523.26, 10.1213/01.ANE.0000078819.48523.26]; Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wong D, 2004, EXP NEUROL, V190, P446, DOI 10.1016/j.expneurol.2004.08.008; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	47	58	60	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2013	33	2					311	318		10.1038/jcbfm.2012.176			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	087CT	WOS:000314739600020	23188422	Bronze, Green Published			2022-02-06	
J	Budde, MD; Shah, A; McCrea, M; Cullinan, WE; Pintar, FA; Stemper, BD				Budde, Matthew D.; Shah, Alok; McCrea, Michael; Cullinan, William E.; Pintar, Frank A.; Stemper, Brian D.			Primary blast traumatic brain injury in the rat: relating diffusion tensor imaging and behavior	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; blast neurotrauma; memory dysfunction; diffusion tensor imaging; magnetic resonance imaging		The incidence of traumatic brain injury (TBI) among military personnel is at its highest point in U.S. history. Experimental animal models of blast have provided a wealth of insight into blast injury. The mechanisms of neurotrauma caused by blast, however, are still under debate. Specifically, it is unclear whether the blast shockwave in the absence of head motion is sufficient to induce brain trauma. In this study, the consequences of blast injury were investigated in a rat model of primary blastTBl. Animals were exposed to blast shock waves with peak reflected overpressures of either 100 or 450 kPa (39 and 110 kPa incident pressure, respectively) and subsequently underwent a battery of behavioral tests. Diffusion tensor imaging (DTI), a promising method to detect blast injury in humans, was performed on fixed brains to detect and visualize the spatial dependence of blast injury. Blast TBI caused significant deficits in memory function as evidenced by the Morris Water Maze, but limited emotional deficits as evidenced by the Open Field Test and Elevated Plus Maze. Fractional anisotropy, a metric derived from DTI, revealed significant brain abnormalities in blast-exposed animals. A significant relationship between memory deficits and brain microstructure was evident in the hippocampus, consistent with its role in memory function. The results provide fundamental insight into the neurological consequences of blast TBI, including the evolution of injury during the sub-acute phase and the spatially dependent pattern of injury. The relationship between memory dysfunction and microstructural brain abnormalities may provide insight into the persistent cognitive difficulties experienced by soldiers exposed to blast neurotrauma and may be important to guide therapeutic and rehabilitative efforts.	[Budde, Matthew D.; Shah, Alok; McCrea, Michael; Pintar, Frank A.; Stemper, Brian D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53295 USA; [McCrea, Michael; Pintar, Frank A.; Stemper, Brian D.] Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA; [Cullinan, William E.] Marquette Univ, Dept Biomed Sci, Coll Hlth & Sci, Milwaukee, WI 53233 USA		Budde, MD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, VA Med Ctr Res 151, 5000 West Natl Ave, Milwaukee, WI 53295 USA.	mdbudde@mcw.edu	Stemper, Brian/AAX-7611-2020		Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Department of Neurosurgery; Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin [5520207]	This project was partially funded through a grant from the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service, the Department of Neurosurgery, and the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin (5520207 to Matthew D. Budde).	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI 10.1016/j.mri.2011.12.003; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holdeman TC, 2009, PSYCHIAT SERV, V60, P273, DOI 10.1176/appi.ps.60.2.273; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kim JH, 2007, NMR BIOMED, V20, P352, DOI 10.1002/nbm.1138; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; LONG JB, 2009, NEUROTRAUMA, V26, P827, DOI DOI 10.1089/NEU.2008.0748; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Newlander SM, 2014, J MAGN RESON IMAGING, V39, P387, DOI 10.1002/jmri.24157; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wood GW, 2013, INJURY PREV, V19, P19, DOI 10.1136/injuryprev-2011-040277; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	57	58	58	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								154	10.3389/fneur.2013.00154			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000151	24133481	Green Published, gold			2022-02-06	
J	Thal, SC; Luh, C; Schaible, EV; Timaru-Kast, R; Hedrich, J; Luhmann, HJ; Engelhard, K; Zehendner, CM				Thal, Serge C.; Luh, Clara; Schaible, Eva-Verena; Timaru-Kast, Ralph; Hedrich, Jana; Luhmann, Heiko J.; Engelhard, Kristin; Zehendner, Christoph M.			Volatile Anesthetics Influence Blood-Brain Barrier Integrity by Modulation of Tight Junction Protein Expression in Traumatic Brain Injury	PLOS ONE			English	Article							ISOFLURANE ANESTHESIA; OCCLUDIN EXPRESSION; NEUROVASCULAR UNIT; CEREBRAL VESSELS; EDEMA FORMATION; SEVOFLURANE; FLOW; GLUTAMATE; ISCHEMIA; WATER	Disruption of the blood-brain barrier (BBB) results in cerebral edema formation, which is a major cause for high mortality after traumatic brain injury (TBI). As anesthetic care is mandatory in patients suffering from severe TBI it may be important to elucidate the effect of different anesthetics on cerebral edema formation. Tight junction proteins (TJ) such as zonula occludens-1 (ZO-1) and claudin-5 (cl5) play a central role for BBB stability. First, the influence of the volatile anesthetics sevoflurane and isoflurane on in-vitro BBB integrity was investigated by quantification of the electrical resistance (TEER) in murine brain endothelial monolayers and neurovascular co-cultures of the BBB. Secondly brain edema and TJ expression of ZO-1 and cl5 were measured in-vivo after exposure towards volatile anesthetics in native mice and after controlled cortical impact (CCI). In in-vitro endothelial monocultures, both anesthetics significantly reduced TEER within 24 hours after exposure. In BBB co-cultures mimicking the neurovascular unit (NVU) volatile anesthetics had no impact on TEER. In healthy mice, anesthesia did not influence brain water content and TJ expression, while 24 hours after CCI brain water content increased significantly stronger with isoflurane compared to sevoflurane. In line with the brain edema data, ZO-1 expression was significantly higher in sevoflurane compared to isoflurane exposed CCI animals. Immunohistochemical analyses revealed disruption of ZO-1 at the cerebrovascular level, while cl5 was less affected in the pericontusional area. The study demonstrates that anesthetics influence brain edema formation after experimental TBI. This effect may be attributed to modulation of BBB permeability by differential TJ protein expression. Therefore, selection of anesthetics may influence the barrier function and introduce a strong bias in experimental research on pathophysiology of BBB dysfunction. Future research is required to investigate adverse or beneficial effects of volatile anesthetics on patients at risk for cerebral edema.	[Thal, Serge C.; Luh, Clara; Schaible, Eva-Verena; Timaru-Kast, Ralph; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Mainz, Germany; [Hedrich, Jana; Luhmann, Heiko J.; Zehendner, Christoph M.] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Univ Med Ctr, D-6500 Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Mainz, Germany.	thal@uni-mainz.de; zehendner@uni-mainz.de	Luhmann, Heiko J./N-8797-2019; Thal, Serge/D-6593-2011	Luhmann, Heiko J./0000-0002-7934-8661; Thal, Serge/0000-0002-1222-8729	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [TH1430/3-1]; Focus Program Translational Neurosciences (FTN); University Medical Center of the Johannes Gutenberg-University; University Medical Center of the Johannes Gutenberg-University Mainz; IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB), Mainz	This work was supported by grants of the Deutsche Forschungsgemeinschaft (TH1430/3-1), the Focus Program Translational Neurosciences (FTN) and a stage 1 grant of the University Medical Center of the Johannes Gutenberg-University to SCT. CMZ is supported by a stage 1 grant of the University Medical Center of the Johannes Gutenberg-University Mainz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicting financial interest to declare.; The authors want to thank Dana Pieter, Tobias Hirnet, Sabine Rickheim-Lowack, Beate Kohler and Beate Krumm for her excellent technical assistance. Support by the IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB), Mainz is gratefully acknowledged.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; Dittmar MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038260; Eberspacher E, 2009, ACTA ANAESTH SCAND, V53, P774, DOI 10.1111/j.1399-6576.2009.01954.x; FISCHER S, 1995, ANESTHESIOLOGY, V82, P451, DOI 10.1097/00000542-199502000-00015; Fischer S, 1996, BRAIN RES, V707, P47, DOI 10.1016/0006-8993(95)01219-2; Fukui K, 2010, J CLIN NEUROPHYSIOL, V27, P110, DOI 10.1097/WNP.0b013e3181d64da1; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hoffmann U, 2013, ACTA NEUROCHIR SUPPL, V115, P161, DOI 10.1007/978-3-7091-1192-5_31; Holmstrom A, 2004, J NEUROSURG ANESTH, V16, P136, DOI 10.1097/00008506-200404000-00005; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Iida H, 1998, ANESTHESIOLOGY, V89, P954, DOI 10.1097/00000542-199810000-00020; Jiang WG, 1998, BIOCHEM BIOPH RES CO, V244, P414, DOI 10.1006/bbrc.1998.8288; Kandatsu N, 2005, ANESTHESIOLOGY, V102, P1182, DOI 10.1097/00000542-200506000-00018; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Lu H, 1998, ANESTH ANALG, V87, P854, DOI 10.1097/00000539-199810000-00020; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; LUNDEEN G, 1983, ANESTH ANALG, V62, P499; MANOHAR M, 1984, J PHARMACOL EXP THER, V231, P640; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; Mills CD, 1997, J NEUROTRAUM, V14, P943, DOI 10.1089/neu.1997.14.943; Ritz MF, 2006, INT J NEUROSCI, V116, P191, DOI 10.1080/00207450500341555; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; SCHETTINI A, 1979, BRIT J ANAESTH, V51, P1117, DOI 10.1093/bja/51.12.1117; Seo JH, 2012, CURRENT PHARM DESIGN; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; SMITH AL, 1976, ANESTHESIOLOGY, V45, P64, DOI 10.1097/00000542-197607000-00012; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Stover JF, 2004, ACTA NEUROCHIR, V146, P819, DOI 10.1007/s00701-004-0281-9; Tetrault S, 2008, EUR J NEUROSCI, V28, P1330, DOI 10.1111/j.1460-9568.2008.06443.x; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wachtel M, 2001, J NEUROCHEM, V78, P155, DOI 10.1046/j.1471-4159.2001.00399.x; Werner C, 2009, CAN J ANAESTH, V56, P883, DOI 10.1007/s12630-009-9166-y; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zehendner CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016760; Zehendner CM, 2009, J CEREBR BLOOD F MET, V29, P1879, DOI 10.1038/jcbfm.2009.103; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	48	58	62	3	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2012	7	12							e50752	10.1371/journal.pone.0050752			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	052ML	WOS:000312201900015	23251381	Green Published, gold			2022-02-06	
J	Ghosh, M; Garcia-Castillo, D; Aguirre, V; Golshani, R; Atkins, CM; Bramlett, HM; Dietrich, WD; Pearse, DD				Ghosh, Mousumi; Garcia-Castillo, Daniela; Aguirre, Vladimir; Golshani, Roozbeh; Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.			Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury	GLIA			English	Article						cyclic AMP; phosphodiesterase; Rolipram; TNF-a; IL-1 ss; inflammation; CNS	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; FACTOR-ALPHA PRODUCTION; MESSENGER-RNA; FUNCTIONAL RECOVERY; INTERFERON-GAMMA; GENE-EXPRESSION; PROTEIN-LEVELS; SCHWANN-CELLS; UP-REGULATION	Cyclic AMP suppresses immune cell activation and inflammation. The positive feedback loop of proinflammatory cytokine production and immune activation implies that cytokines may not only be regulated by cyclic AMP but also conversely regulate cyclic AMP. This study examined the effects of tumor necrosis factor (TNF)-a and interleukin (IL)-1 beta on cyclic AMP-phosphodiesterase (PDE) signaling in microglia in vitro and after spinal cord injury (SCI) or traumatic brain injury (TBI). TNF-a or IL-1 beta stimulation produced a profound reduction (>90%) of cyclic AMP within EOC2 microglia from 30 min that then recovered after IL-1 beta but remained suppressed with TNF-a through 24 h. Cyclic AMP was also reduced in TNF-a-stimulated primary microglia, albeit to a lesser extent. Accompanying TNF-a-induced cyclic AMP reductions, but not IL-1 beta, was increased cyclic AMP-PDE activity. The role of PDE4 activity in cyclic AMP reductions was confirmed by using Rolipram. Examination of pde4 mRNA revealed an immediate, persistent increase in pde4b with TNF-a; IL-1 beta increased all pde4 mRNAs. Immunoblotting for PDE4 showed that both cytokines increased PDE4A1, but only TNF-a increased PDE4B2. Immunocytochemistry revealed PDE4B nuclear translocation with TNF-a but not IL-1 beta. Acutely after SCI/TBI, where cyclic AMP levels are reduced, PDE4B was localized to activated OX-42+ microglia; PDE4B was absent in OX-42+ cells in uninjured spinal cord/cortex or inactive microglia. Immunoblotting showed PDE4B2 up-regulation from 24 h to 1 wk post-SCI, the peak of microglia activation. These studies show that TNF-a and IL-1 beta differentially affect cyclic AMP-PDE signaling in microglia. Targeting PDE4B2 may be a putative therapeutic direction for reducing microglia activation in CNS injury and neurodegenerative diseases. (c) 2012 Wiley Periodicals, Inc.	[Pearse, Damien D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Miami, FL 33101 USA; [Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Neurosci Program, Miami, FL 33101 USA; [Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Dept Vet Affairs Med Ctr, Miami, FL 33101 USA		Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	DPearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Atkins, Coleen/0000-0003-4718-7493	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [056281, 056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS056281] Funding Source: NIH RePORTER	Grant sponsor: NINDS; Grant numbers: 056281 and 056072; Grant sponsor: Miami Project to Cure Paralysis.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Arp J, 2003, MOL CELL BIOL, V23, P8042, DOI 10.1128/MCB.23.22.8042-8057.2003; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Barakat DJ, 2005, CELL TRANSPLANT, V14, P225, DOI 10.3727/000000005783983106; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Chandrasekaran A, 2008, CELL SIGNAL, V20, P139, DOI 10.1016/j.cellsig.2007.10.003; D'Sa C, 2002, J NEUROCHEM, V81, P745, DOI 10.1046/j.1471-4159.2002.00878.x; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Dunne A, 2003, SCI STKE, V25, P171; Ghosh M, 2012, GLIA, V60, P979, DOI 10.1002/glia.22330; Ghosh M, 2010, TRANSL NEUROSCI, V1, P101, DOI 10.2478/v10134-010-0012-0; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hannibal J, 1999, NEUROENDOCRINOLOGY, V70, P73, DOI 10.1159/000054461; Hurley SD, 1999, GLIA, V25, P304, DOI 10.1002/(SICI)1098-1136(19990201)25:3<304::AID-GLIA10>3.0.CO;2-W; Huston E, 2008, P NATL ACAD SCI USA, V105, P12791, DOI 10.1073/pnas.0805167105; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kleppisch Thomas, 2009, V191, P71, DOI 10.1007/978-3-540-68964-5_5; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; Levi G, 1998, BIOCHIMIE, V80, P899, DOI 10.1016/S0300-9084(00)88886-0; LONDESBOROUGH J, 1982, MOL CELL BIOCHEM, V46, P65; Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039; Lugnier C, 1999, BBA-GEN SUBJECTS, V1472, P431, DOI 10.1016/S0304-4165(99)00145-2; LUPIDI G, 1990, ITAL J BIOCHEM, V39, P30; Ma DM, 1999, MOL PHARMACOL, V55, P50, DOI 10.1124/mol.55.1.50; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; McCahill A, 2008, CELL SIGNAL, V20, P2071, DOI 10.1016/j.cellsig.2008.07.017; Mecha M, 2011, EASY FAST WAY OBTAIN, DOI [10.1038/protex.2011.218, DOI 10.1038/PROTEX.2011.218]; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ortis F, 2010, DIABETES, V59, P358, DOI 10.2337/db09-1159; PANG XP, 1992, J BIOL CHEM, V267, P12826; Patel V, 2010, J NEUROTRAUM, V27, P789, DOI 10.1089/neu.2008.0809; Patrizio M, 2004, GLIA, V48, P241, DOI 10.1002/glia.20074; PATRIZIO M, 1995, GLIA, V14, P94, DOI 10.1002/glia.440140204; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2001, NEUROSCIENCE, V107, P143, DOI 10.1016/S0306-4522(01)00320-7; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Reyes-Irisarri E, 2007, J NEUROPATH EXP NEUR, V66, P923, DOI 10.1097/nen.0b013e3181567c31; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Sebastiani G, 2006, NEUROBIOL AGING, V27, P691, DOI 10.1016/j.neurobiolaging.2005.03.024; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; SHARIF SF, 1993, NEUROL RES, V15, P109; Steininger TS, 2011, BRAIN RES, V1407, P1, DOI 10.1016/j.brainres.2011.06.050; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Walker WS, 1995, J NEUROIMMUNOL, V63, P163, DOI 10.1016/0165-5728(95)00146-8; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang P, 1999, MOL PHARMACOL, V56, P170, DOI 10.1124/mol.56.1.170; Wang XF, 2006, ACTA NEUROPATHOL, V111, P220, DOI 10.1007/s00401-005-0016-x; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm2; Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829; Whitaker CM, 2008, NEUROSCI LETT, V438, P200, DOI 10.1016/j.neulet.2008.03.087; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410	74	58	59	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2012	60	12					1839	1859		10.1002/glia.22401			21	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	026GM	WOS:000310262600003	22865690	Green Accepted			2022-02-06	
J	Wade, SL; Walz, NC; Carey, J; McMullen, KM; Cass, J; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.; Cass, Jennifer; Mark, Erin; Yeates, Keith Owen			A Randomized Trial of Teen Online Problem Solving: Efficacy in Improving Caregiver Outcomes After Brain Injury	HEALTH PSYCHOLOGY			English	Article						acquired brain injury; telehealth; adolescent; problem solving; caregiver	PEDIATRIC TRAUMATIC INJURY; FAMILY INTERVENTION; INITIAL YEAR; CHILDREN; PREDICTORS; BEHAVIOR; ADOLESCENTS; ADAPTATION; PROGRAM; BURDEN	Objective: To examine the results of a randomized clinical trial (RCT) of Teen Online Problem Solving (TOPS), an online problem solving therapy model, in increasing problem-solving skills and decreasing depressive symptoms and global distress for caregivers of adolescents with traumatic brain injury (TBI). Method: Families of adolescents aged 11-18 who sustained a moderate to severe TB I between 3 and 19 months earlier were recruited from hospital trauma registries. Participants were assigned to receive a web-based, problem-solving intervention (TOPS, n = 20), or access to online resources pertaining to TBI (Internet Resource Comparison; IRC; n = 21). Parent report of problem solving skills, depressive symptoms, global distress, utilization, and satisfaction were assessed pre- and posttreatment. Groups were compared on follow-up scores after controlling for pretreatment levels. Family income was examined as a potential moderator of treatment efficacy. Improvement in problem solving was examined as a mediator of reductions in depression and distress. Results: Forty-one participants provided consent and completed baseline assessments, with follow-up assessments completed on 35 participants (16 TOPS and 19 IRC). Parents in both groups reported a high level of satisfaction with both interventions. Improvements in problem solving skills and depression were moderated by family income, with caregivers of lower income in TOPS reporting greater improvements. Increases in problem solving partially mediated reductions in global distress. Conclusions: Findings suggest that TOPS may be effective in improving problem solving skills and reducing depressive symptoms for certain subsets of caregivers in families of adolescents with TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G050239]	This work was supported by grant #H133G050239 from the National Institute of Disability and Rehabilitation Research, U.S. Department of Education. This study is registered at www.clinicaltrials.gov. Clinicaltrials.gov identifier: NCT00409058	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 2005, ARCH PHYS MED REHAB, V86, P175, DOI 10.1016/j.apmr.2004.02.026; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Boschen K., 2005, NEUROREHABILITATION, V19, P363; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; D'Zurilla T.J., 1990, PSYCHOL ASSESSMENT, V2, P156, DOI DOI 10.1037/1040-3590.2.2.156; Derogatis L. R., 1994, USE PSYCHOL TESTING, P217; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Nezu CM., 2007, SOLVING LIFES PROBLE; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SILVERBERG SB, 1987, J YOUTH ADOLESCENCE, V16, P293, DOI 10.1007/BF02139096; SILVERBERG SB, 1990, DEV PSYCHOL, V26, P658, DOI 10.1037/0012-1649.26.4.658; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Teasdale G., 1974, LANCET, V304, P248; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; [No title captured], DOI DOI 10.1177/014662167700100306	30	58	58	1	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0278-6133			HEALTH PSYCHOL	Health Psychol.	NOV	2012	31	6					767	776		10.1037/a0028440			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	036IA	WOS:000311018400012	22746261				2022-02-06	
J	Wang, YY; Adamson, C; Yuan, WH; Altaye, M; Rajagopal, A; Byars, AW; Holland, SK				Wang, Yingying; Adamson, Chris; Yuan, Weihong; Altaye, Mekibib; Rajagopal, Akila; Byars, Anna W.; Holland, Scott K.			Sex differences in white matter development during adolescence: A DTI study	BRAIN RESEARCH			English	Article						Adolescence; Diffusion tensor imaging; Sex differences; Tract based spatial statistics; White matter development	TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTIONS; RADIAL DIFFUSIVITY; MATURATION; CHILDHOOD; AGE; CHILDREN; MRI; MICROSTRUCTURE; CONNECTIVITY	Adolescence is a complex transitional period in human development, composing physical maturation, cognitive and social behavioral changes. The objective of this study is to investigate sex differences in white matter development and the associations between intelligence and white matter microstructure in the adolescent brain using diffusion tensor imaging (DTI) and tract-based spatial statistics (TBSS). In a cohort of 16 typically-developing adolescents aged 13 to 17 years, longitudinal DTI data were recorded from each subject at two time points that were one year apart. We used TBSS to analyze the diffusion indices including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Our results suggest that boys (13-18 years) continued to demonstrate white matter maturation, whereas girls appeared to reach mature levels earlier. In addition, we identified significant positive correlations between FA and full-scale intelligence quotient (IQ) in the right inferior fronto-occipital fasciculus when both sexes were looked at together. Only girls showed significant positive correlations between FA and verbal IQ in the left cortico-spinal tract and superior longitudinal fasciculus. The preliminary evidence presented in this study supports that boys and girls have different developmental trajectories in white matter microstructure. (c) 2012 Elsevier B.V. All rights reserved.	[Wang, Yingying; Yuan, Weihong; Rajagopal, Akila; Holland, Scott K.] Cincinnati Childrens Hosp, Pediat Neuroimaging Res Consortium, Cincinnati, OH USA; [Yuan, Weihong; Holland, Scott K.] Cincinnati Childrens Hosp, Dept Radiol, Cincinnati, OH USA; [Altaye, Mekibib] Cincinnati Childrens Hosp, Dept Biostat & Epidemiol, Cincinnati, OH USA; [Wang, Yingying; Byars, Anna W.] Cincinnati Childrens Hosp, Div Neurol, Cincinnati, OH USA; [Wang, Yingying; Holland, Scott K.] Univ Cincinnati, Dept Biomed Engn, Cincinnati, OH USA; [Adamson, Chris] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Wang, YY (corresponding author), Pediat Neuroimaging Res Ctr, MLC 5033,3333 Burnet Ave, Cincinnati, OH 45229 USA.	yingying.wang@cchmc.org	Altaye, Mekibib/N-5274-2015; Wang, Yingying/I-2705-2018	Holland, Scott/0000-0003-3719-0875; Wang, Yingying/0000-0001-6502-1388	U.S. National Institute of Health (NIH grant)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD38578]; Victorian Government's Operational Infrastructure Support Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	This study was supported in part by a grant from the U.S. National Institute of Health (NIH grant R01-HD38578, P.I. SK Holland). The study was also supported in part by the Victorian Government's Operational Infrastructure Support Program. The authors acknowledge the assistance of Ms. Amanda Huber, Ms. Sara Robertson and Ms. Julie Franks, for helping with recruitment and data collection, and Mr. Kendall O'Brien and Ms. Amanda Woods, for performing all the MRI scans.	Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Basser PJ, 1997, ANN NY ACAD SCI, V820, P123, DOI 10.1111/j.1749-6632.1997.tb46192.x; Bava S, 2011, BRAIN RES, V1375, P41, DOI 10.1016/j.brainres.2010.12.051; Bava S, 2010, BRAIN RES, V1327, P38, DOI 10.1016/j.brainres.2010.02.066; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Brizendine L., 2006, FEMALE BRAIN; Casey BJ, 2008, ANN NY ACAD SCI, V1124, P111, DOI 10.1196/annals.1440.010; Clayden JD, 2012, CEREB CORTEX, V22, P1738, DOI 10.1093/cercor/bhr243; Cohen RZ, 1999, AM J PSYCHIAT, V156, P1059; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Focke NK, 2008, NEUROIMAGE, V40, P728, DOI 10.1016/j.neuroimage.2007.12.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1997, PROG NEURO-PSYCHOPH, V21, P1185, DOI 10.1016/S0278-5846(97)00158-9; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Herting MM, 2012, CEREB CORTEX, V22, P1979, DOI 10.1093/cercor/bhr246; Holland SK, 2007, INT J AUDIOL, V46, P533, DOI 10.1080/14992020701448994; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI 10.2307/1390807; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Le Bihan D, 1991, Magn Reson Q, V7, P1; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; Lenroot RK, 2010, BRAIN COGNITION, V72, P46, DOI 10.1016/j.bandc.2009.10.008; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lobel U, 2009, NEURORADIOLOGY, V51, P253, DOI 10.1007/s00234-008-0488-1; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Mabbott DJ, 2009, BRAIN RES, V1294, P80, DOI 10.1016/j.brainres.2009.07.046; Metwalli NS, 2010, BRAIN RES, V1348, P156, DOI 10.1016/j.brainres.2010.05.067; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nguyen D, 2011, EPILEPSY RES, V94, P189, DOI 10.1016/j.eplepsyres.2011.02.001; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Paus T, 2010, BRAIN COGNITION, V72, P26, DOI 10.1016/j.bandc.2009.06.002; Perrin JS, 2009, NEUROIMAGE, V45, P1055, DOI 10.1016/j.neuroimage.2009.01.023; Rametti G, 2011, J PSYCHIATR RES, V45, P949, DOI 10.1016/j.jpsychires.2010.11.007; Ramsden S, 2011, NATURE, V479, P113, DOI 10.1038/nature10514; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schmithorst VJ, 2008, HUM BRAIN MAPP, V29, P696, DOI 10.1002/hbm.20431; Schmithorst VJ, 2007, NEUROIMAGE, V35, P406, DOI 10.1016/j.neuroimage.2006.11.046; Schmithorst VJ, 2010, BRAIN COGNITION, V72, P16, DOI 10.1016/j.bandc.2009.06.005; Schmithorst VJ, 2009, INTELLIGENCE, V37, P164, DOI 10.1016/j.intell.2008.07.001; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Schneiderman JS, 2007, NEUROPSYCHOBIOLOGY, V55, P96, DOI 10.1159/000104277; Schwartz ED, 2005, NEUROREPORT, V16, P73, DOI 10.1097/00001756-200501190-00017; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stice E, 2001, DEV PSYCHOL, V37, P608, DOI 10.1037//0012-1649.37.5.608; Tamnes CK, 2010, HUM BRAIN MAPP, V31, P1609, DOI 10.1002/hbm.20962; Wechsler D., 2011, WECHSLER ABBREVIATED; Wickham H., 2006, GGPLOT IMPLEMENTATIO; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	69	58	59	0	40	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 10	2012	1478						1	15		10.1016/j.brainres.2012.08.038			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	028HU	WOS:000310414200001	22954903	Green Accepted, Green Published			2022-02-06	
J	Ahmed, OH; Sullivan, SJ; Schneiders, AG; McCrory, PR				Ahmed, Osman H.; Sullivan, S. John; Schneiders, Anthony G.; McCrory, Paul R.			Concussion information online: evaluation of information quality, content and readability of concussion-related websites	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							KNOWLEDGE TRANSFER; SOCIAL NETWORKING; HEALTH; INTERNET; PATIENT; EDUCATION; LEAFLETS	Background The internet plays an important role in the dissemination of health information to the general public. Information on orthopaedic sports medicine websites has been shown to be of a varying standard, and to date there has been no evaluation of the overall quality of concussion-related websites. Methods A four-stage methodological sampling technique was used to identify concussion-related websites. Websites were assessed for the presence of a quality standard (the HONcode), their adherence to current expert concussion knowledge using a custom-developed concussion checklist ('CONcheck'), and their readability using the established Flesch Reading Ease (FRE) and Flesch-Kincaid Grade Level (FKGL). Results 43 Websites were identified from the search strategy with the majority (70%) not HONcode certified. A wide distribution of scores was seen for the CONcheck (0-22), FRE (16.3-77.4) and FKGL (6-17.8). Statistical analysis using independent t tests between websites with the HONcode and websites without the HONcode showed no significant differences between the two groups for CONcheck (t(41) = 0.571, p = 0.571), FRE (t(41) = 0.808, p = 0.424) and FKGL(t(41) = -0.964, p = 0.341) scores. Conclusions The variability in the standard of concussion-related websites highlights the need for sports medicine website providers to consider the delivery, content and readability of information to the public.	[Ahmed, Osman H.; Sullivan, S. John; Schneiders, Anthony G.] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin 9054, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia		Sullivan, SJ (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879	International Rugby Board	This study was facilitated by funding from the International Rugby Board.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Alla S, 2011, BRIT J SPORT MED, V45, P132, DOI 10.1136/bjsm.2010.074088; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Burneo JG, 2006, EPILEPSY BEHAV, V8, P299, DOI 10.1016/j.yebeh.2005.09.008; Clauson KA, 2010, J ALTERN COMPLEM MED, V16, P119, DOI 10.1089/acm.2008.0611; D'Alessandro DM, 2001, ARCH PEDIAT ADOL MED, V155, P807, DOI 10.1001/archpedi.155.7.807; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Farr JN, 1951, J APPL PSYCHOL, V35, P333, DOI 10.1037/h0062427; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gustafson DH, 2004, BMJ-BRIT MED J, V328, P1150, DOI 10.1136/bmj.328.7449.1150; Hanif F, 2009, INFORM HEALTH SOC CA, V34, P231, DOI 10.3109/17538150903359030; Harland Juliet, 2007, Health Informatics J, V13, P207, DOI 10.1177/1460458207079837; Kunst H, 2002, BRIT MED J, V324, P581, DOI 10.1136/bmj.324.7337.581; Lewiecki EM, 2006, OSTEOPOROSIS INT, V17, P741, DOI 10.1007/s00198-005-0042-5; Macdonald S, 2010, EMERG MED J, V27, P279, DOI 10.1136/emj.2009.075424; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moore C, 2004, NZ MED J, V117, P1; Pappano D, 2008, CLIN PEDIATR, V47, P930, DOI 10.1177/0009922808320600; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell GP, 2002, BMJ-BRIT MED J, V324, P557, DOI 10.1136/bmj.324.7337.557; Sambandam SN, 2007, ARTHROSCOPY, V23, P509, DOI 10.1016/j.arthro.2006.12.007; Starman JS, 2010, J BONE JOINT SURG AM, V92A, P1612, DOI 10.2106/JBJS.I.00821; Steininger K, 2010, INT J HEALTHC TECHNO, V11, P13, DOI 10.1504/IJHTM.2010.033272; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Vallance JK, 2008, PATIENT EDUC COUNS, V72, P342, DOI 10.1016/j.pec.2008.03.010; van der Marel S, 2009, INFLAMM BOWEL DIS, V15, P1891, DOI 10.1002/ibd.20976; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	28	58	58	2	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2012	46	9					675	683		10.1136/bjsm.2010.081620			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	961QR	WOS:000305482800011	21504964				2022-02-06	
J	Au, AK; Aneja, RK; Bell, MJ; Bayir, H; Feldman, K; Adelson, PD; Fink, EL; Kochanek, PM; Clark, RSB				Au, Alicia K.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Huelya; Feldman, Keri; Adelson, P. David; Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.			Cerebrospinal Fluid Levels of High-Mobility Group Box 1 and Cytochrome C Predict Outcome after Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; child abuse; cytochrome c; high mobility group box 1	SPECTRIN BREAKDOWN PRODUCTS; CHROMATIN PROTEIN HMGB1; ABUSIVE HEAD TRAUMA; IN-VIVO; APOPTOSIS; RELEASE; BIOMARKERS; CHILDREN; DANGER; SIGNAL	High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is passively released from damaged and necrotic cells, and actively released from immune cells. In contrast, cytochrome c is released from mitochondria in apoptotic cells, and is considered a reliable biomarker of apoptosis. Thus, HMGB1 and cytochrome c may in part reflect the degree of necrosis and apoptosis present after traumatic brain injury (TBI), where both are felt to contribute to cell death and neurological morbidity. Ventricular cerebrospinal fluid (CSF) was obtained from children admitted to the intensive care unit (ICU) after TBI (n = 37). CSF levels of HMGB1 and cytochrome c were determined at four time intervals (0-24 h, 25-48 h, 49-72 h, and > 72 h after injury) using enzyme-linked immunosorbent assay (ELISA). Lumbar CSF from children without TBI served as controls (n = 12). CSF HMGB1 levels were: control = 1.78 +/- 0.29, 0-24 h = 5.73 +/- 1.45, 25-48 h = 5.16 +/- 1.73, 49-72 h = 4.13 +/- 0.75, > 72 h = 3.80 +/- 0.90 ng/mL (mean +/- SEM). Peak HMGB1 levels were inversely and independently associated with favorable Glasgow Outcome Scale (GOS) scores at 6 mo (0.49 [0.24-0.97]; OR [5-95% CI]). CSF cytochrome c levels were: control = 0.37 +/- 0.10, 0-24 h = 0.69 +/- 0.15, 25-48 h = 0.82 +/- 0.48, 49-72 h = 1.52 +/- 1.08, > 72 h = 1.38 +/- 1.02 ng/mL (mean +/- SEM). Peak cytochrome c levels were independently associated with abusive head trauma (AHT; 24.29 [1.77-334.03]) and inversely and independently associated with favorable GOS scores (0.42 [0.18-0.99]). In conclusion, increased CSF levels of HMGB1 and cytochrome c were associated with poor outcome after TBI in infants and children. These data are also consistent with the designation of HMGB1 as a "danger signal." Distinctly increased CSF cytochrome c levels in infants and children with AHT and poor outcome suggests that apoptosis may play an important role in this unique patient population.	[Au, Alicia K.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Huelya; Feldman, Keri; Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.; Bayir, Huelya] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Pediat, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA; [Bayir, Huelya] Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Adelson, P. David] Phoenix Childrens Hosp, Childrens Neurosci Inst, Phoenix, AZ USA		Au, AK (corresponding author), 4401 Penn Ave,Suite 2000, Pittsburgh, PA 15224 USA.	auak@upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019; Fink, Ericka/AAU-9792-2021	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686]; National Institute for Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM098474] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute of Child Health and Human Development T32 HD040686 (AKA), and the National Institute for Neurological Diseases and Stroke R01 NS30318 (RSBC, PMK).	Adachi N, 2004, CLIN CHIM ACTA, V342, P127, DOI 10.1016/j.cccn.2003.12.011; Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Ahlemeyer B, 2002, BRAIN RES, V934, P107, DOI 10.1016/S0006-8993(02)02365-X; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Barczyk K, 2005, INT J CANCER, V116, P167, DOI 10.1002/ijc.21037; Ben-Ari Z, 2003, J INTERN MED, V254, P168, DOI 10.1046/j.1365-2796.2003.01171.x; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573; Faul M, 2010, TRAUMATIC BRAIN INJU; Fink MP, 2007, CRIT CARE, V11, DOI 10.1186/cc6088; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; Guenther E, 2010, J PEDIATR-US, V157, P821, DOI 10.1016/j.jpeds.2010.04.072; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Palumbo R, 2004, BIOCHEM PHARMACOL, V68, P1165, DOI 10.1016/j.bcp.2004.03.048; Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rock KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/s00281-004-0173-3; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001	50	58	59	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2013	2021		10.1089/neu.2011.2171			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800002	22540160	Green Published			2022-02-06	
J	Drag, LL; Spencer, RJ; Walker, SJ; Pangilinan, PH; Bieliauskas, LA				Drag, Lauren L.; Spencer, Robert J.; Walker, Sara J.; Pangilinan, Percival H.; Bieliauskas, Linas A.			The Contributions of Self-reported Injury Characteristics and Psychiatric Symptoms to Cognitive Functioning in OEF/OIF Veterans with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychology; Head injuries; Anxiety; Depression; PTSD; Military	POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN PATIENTS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; WAR VETERANS; DEPRESSION; COMPLAINTS; CONCUSSION; IRAQ; METAANALYSIS	Mild traumatic brain injury (mTBI) affects a significant number of combat veterans returning from Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Although resolution of mTBI symptoms is expected over time, some individuals continue to report lingering cognitive difficulties. This study examined the contributions of self-reported mTBI injury characteristics (e.g., loss of consciousness, post-traumatic amnesia) and psychiatric symptoms to both subjective and objective cognitive functioning in a sample of 167 OEF/OIF veterans seen in a TBI clinic. Injury characteristics were not associated with performance on neuropsychological tests but were variably related to subjective ratings of cognitive functioning. Psychiatric symptoms were highly prevalent and fully mediated most of the relationships between injury characteristics and cognitive ratings. This indicates that mTBI characteristics such as longer time since injury and loss of consciousness or post-traumatic amnesia can lead to increased perceived cognitive deficits despite having no objective effects on cognitive performance. Psychiatric symptoms were associated with both cognitive ratings and neuropsychological performance, illustrating the important role that psychiatric treatment can potentially play in optimizing functioning. Finally, subjective cognitive ratings were not predictive of neuropsychological performance once psychiatric functioning was statistically controlled, suggesting that neuropsychological assessment provides valuable information that cannot be gleaned from self-report alone. (JINS, 2012, 18, 576-584)	[Drag, Lauren L.] VA Palo Alto Healthcare Syst, Res Serv, Palo Alto, CA USA; [Spencer, Robert J.; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Mental Hlth Serv, Ann Arbor, MI USA; [Walker, Sara J.; Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA; [Pangilinan, Percival H.] VA Ann Arbor Healthcare Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA		Drag, LL (corresponding author), 3801 Miranda Ave,118J, Palo Alto, CA 94304 USA.	lauren.drag@va.gov					Arnstein P, 1999, PAIN, V80, P483, DOI 10.1016/S0304-3959(98)00220-6; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COMUNIAN AL, 1989, PERCEPT MOTOR SKILL, V69, P755, DOI 10.2466/pms.1989.69.3.755; Defense and Veterans Brain Injury Center, 2011, DEP DEF NUMB TRAUM B; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Golier J, 2002, PSYCHIAT CLIN N AM, V25, P295, DOI 10.1016/S0193-953X(01)00004-1; Government Accountability Office, 2005, VA DIS BEN ROUT MON; Government Accountability Office, 2008, MILD TRAUM BRAIN INJ; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langenecker S.A., 2009, NEUROPSYCHOLOGICAL A, P523; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meyers JE., 1995, REY COMPLEX FIGURE T; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Randolph C., 1998, REPEATABLE BATTERY A; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Weathers F.W., 1993, 9 ANN C ISTSS; Wechsler, 2008, WAIS 4 ADM SCORING M; Zachary, 2000, SHIPLEY I LIVING SCA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	58	58	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					576	584		10.1017/S1355617712000203			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500019	22390876				2022-02-06	
J	Gao, JB; Hu, J; Tung, WW				Gao, Jianbo; Hu, Jing; Tung, Wen-wen			Entropy measures for biological signal analyses	NONLINEAR DYNAMICS			English	Article						Approximate entropy; Sample entropy; Scale-dependent Lyapunov exponent; Seizure detection	TIME-SERIES; APPROXIMATE ENTROPY; KOLMOGOROV-ENTROPY; INFORMATION-THEORY; POSTURAL-CONTROL; NOISE; CHAOS; PREDICTABILITY; CONCUSSION; COMPLEXITY	Entropies are among the most popular and promising complexity measures for biological signal analyses. Various types of entropy measures exist, including Shannon entropy, Kolmogorov entropy, approximate entropy (ApEn), sample entropy (SampEn), multiscale entropy (MSE), and so on. A fundamental question is which entropy should be chosen for a specific biological application. To solve this issue, we focus on scaling laws of different entropy measures and introduce an ensemble forecasting framework to find the connections among them. One critical component of the ensemble forecasting framework is the scale-dependent Lyapunov exponent (SDLE), whose scaling behavior is found to be the richest among all the entropy measures. In fact, SDLE contains all the essential information of other entropy measures, and can act as a unifying multiscale complexity measure. Furthermore, SDLE has a unique scale separation property to aptly deal with nonstationarity and characterize high-dimensional and intermittent chaos. Therefore, SDLE can often be the first choice for exploratory studies in biology. The effectiveness of SDLE and the ensemble forecasting framework is illustrated by considering epileptic seizure detection from EEG.	[Gao, Jianbo] PMB Intelligence LLC, W Lafayette, IN 47996 USA; [Gao, Jianbo] Wright State Univ, Dayton, OH 45435 USA; [Hu, Jing] Affymetrix Inc, Santa Clara, CA 95051 USA; [Tung, Wen-wen] Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA		Gao, JB (corresponding author), PMB Intelligence LLC, POB 2077, W Lafayette, IN 47996 USA.	jbgao.pmb@gmail.com			Div Of Civil, Mechanical, & Manufact InnNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1031958] Funding Source: National Science Foundation		Abramov R, 2005, J ATMOS SCI, V62, P65, DOI 10.1175/JAS-3373.1; Adeli H, 2007, IEEE T BIO-MED ENG, V54, P205, DOI 10.1109/TBME.2006.886855; Andrzejak RG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.061907; ATMANSPACHER H, 1987, FOUND PHYS, V17, P939, DOI 10.1007/BF00734321; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cao YH, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.046217; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cellucci CJ, 1997, CHAOS, V7, P414, DOI 10.1063/1.166214; COHEN A, 1985, PHYS REV A, V31, P1872, DOI 10.1103/PhysRevA.31.1872; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Cover T. M, 2006, ELEMENTS INFORM THEO; ECKMANN JP, 1985, REV MOD PHYS, V57, P617, DOI 10.1103/RevModPhys.57.617; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gao J., 2007, MULTISCALE ANAL COMP; Gao JB, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.066204; Gao J.B., EUROPHYS LETT UNPUB; Gao J.B., CHAOS SOLIT IN PRESS; Gao JB, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016117; GAO JB, 1994, PHYS REV E, V49, P3807, DOI 10.1103/PhysRevE.49.3807; Gao JB, 1999, INT J MOD PHYS B, V13, P3283, DOI 10.1142/S0217979299003027; GAO JB, 1993, PHYS LETT A, V181, P153, DOI 10.1016/0375-9601(93)90913-K; Gao JB, 1999, PHYS REV LETT, V82, P1132, DOI 10.1103/PhysRevLett.82.1132; Gao JB, 2013, QUANT FINANC, V13, P265, DOI 10.1080/14697688.2011.580774; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gao JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024331; Gao JB, 2011, COGN NEURODYNAMICS, V5, P171, DOI 10.1007/s11571-011-9151-3; Gao JB, 2010, IEEE SIGNAL PROC LET, V17, P237, DOI 10.1109/LSP.2009.2037773; Gao JB, 2009, CHINESE ANN MATH B, V30, P569, DOI 10.1007/s11401-009-0108-3; GASPARD P, 1993, PHYS REP, V235, P291, DOI 10.1016/0370-1573(93)90012-3; GRASSBERGER P, 1983, PHYS REV A, V28, P2591, DOI 10.1103/PhysRevA.28.2591; Haven K, 2005, J COMPUT PHYS, V206, P334, DOI 10.1016/j.jcp.2004.12.008; Hu J, 2004, CHAOS SOLITON FRACT, V22, P807, DOI 10.1016/j.chaos.2004.02.061; Hu J, 2006, IEEE T BIO-MED ENG, V53, P2606, DOI 10.1109/TBME.2006.883825; Hu J, 2010, ANN BIOMED ENG, V38, P854, DOI 10.1007/s10439-009-9863-2; Hu J, 2009, CHAOS, V19, DOI 10.1063/1.3152007; Hu J, 2009, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2009/02/P02066; Hwang SK, 2000, PHYS REV E, V61, P5162, DOI 10.1103/PhysRevE.61.5162; KENNEL MB, 1992, PHYS REV A, V45, P3403, DOI 10.1103/PhysRevA.45.3403; Kleeman R, 2002, J ATMOS SCI, V59, P2057, DOI 10.1175/1520-0469(2002)059<2057:MDPUUR>2.0.CO;2; LEMPEL A, 1976, IEEE T INFORM THEORY, V22, P75, DOI 10.1109/TIT.1976.1055501; LIEBERT W, 1991, EUROPHYS LETT, V14, P521, DOI 10.1209/0295-5075/14/6/004; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PACKARD NH, 1980, PHYS REV LETT, V45, P712, DOI 10.1103/PhysRevLett.45.712; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; SAUER T, 1991, J STAT PHYS, V65, P579, DOI 10.1007/BF01053745; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Takens F, 1981, LECT NOTES MATH DYN, V898, P366, DOI DOI 10.1007/BFB0091924; Tung WW, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.046210	51	58	59	4	48	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0924-090X	1573-269X		NONLINEAR DYNAM	Nonlinear Dyn.	MAY	2012	68	3			SI		431	444		10.1007/s11071-011-0281-2			14	Engineering, Mechanical; Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Mechanics	921MT	WOS:000302482400008					2022-02-06	
J	Hallert, O; Li, Y; Brismar, H; Lindgren, U				Hallert, Ola; Li, Yan; Brismar, Harald; Lindgren, Urban			The direct anterior approach: initial experience of a minimally invasive technique for total hip arthroplasty	JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH			English	Article						MIS arthroplasty; Anterior incision; Complication; THR	APPLIED ANATOMY; REPLACEMENT	Background: Less invasive approaches for hip arthroplasty have been developed in order to decrease traumatisation of soft tissue and shorten hospital stay. However, the benefits with a new technique can be at the expense of a new panorama of problems. This manuscript describes, with emphasis on postoperative complications, our experience from the first 200 cases of unilateral hip replacement using the direct anterior minimally invasive (MIS) approach. Methods: A straight incision in front of the greater trochanter was used and the tensor muscle was approached subfascially and retracted laterally. The joint was opened and the femoral head was removed. Usually excellent acetabular exposure was obtained. In order to get access to the proximal femur, the hip capsule was released posterolaterally so that the femur could be lifted using a special retractor behind the tip of the trochanter. After insertion of the prostheses, the wound was closed using running sutures in the fascia overlying the tensor, sub- and intracutaneously. Results: There was a small influence of BMI on the duration of surgery, and obese patients tended to have the cup positioned at a higher degree of deviation. There were in total 17 complications of which 5 necessitated revision surgery; 3 peroperative femoral fractures and 2 dislocations. Another 4 dislocations were treated with closed reduction and did not recur. 3 cases of nerve injury were noted, all resolved within 12 months. Three cases of DVT were diagnosed as well as 2 cases of postoperative infection; none of these led to chronic disability. Conclusions: The technique is perhaps more technically demanding than the lateral approaches used today due to the somewhat limited surgical exposure. Morbidly obese or very muscular patients as well as patients with a short femoral neck or acetabular protrusion can represent particular problems. Our results indicate that there are certain risks when adopting this procedure but the complications noted are avoidable.	[Hallert, Ola; Li, Yan; Brismar, Harald; Lindgren, Urban] Karolinska Inst, Div Orthoped, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden		Li, Y (corresponding author), Karolinska Inst, Div Orthoped, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden.	Yan.Li@ki.se	Brismar, Hjalmar/E-8524-2011	Brismar, Hjalmar/0000-0003-0578-4003	Stryker(R) Sweden	Funds were received from Stryker (R) Sweden.	ACKLAND MK, 1986, J BONE JOINT SURG BR, V68, P409, DOI 10.1302/0301-620X.68B3.3733807; Barton C, 2009, ORTHOP CLIN N AM, V40, P371, DOI 10.1016/j.ocl.2009.04.004; Benoit B, 2009, ORTHOP CLIN N AM, V40, P357, DOI 10.1016/j.ocl.2009.02.002; Bremer AK, 2011, J BONE JT SURG B, V7, P886; Chen LH, 2009, CLIN ANAT, V22, P250, DOI 10.1002/ca.20750; de Verteuil R, 2008, HEALTH TECHNOL ASSES, V12, DOI 10.3310/HTA12260; Howell JR, 2004, ORTHOP CLIN N AM, V35, P107, DOI 10.1016/S0030-5898(03)00112-3; Howell JR, 2004, ORTHOP CLIN N AM, V35, P153, DOI 10.1016/S0030-5898(03)00137-8; Jewett BA, 2011, CLIN ORTHOP RELAT R, V469, P503, DOI 10.1007/s11999-010-1568-1; Masonis J, 2008, ORTHOPEDICS, V31, P129; Matta JM, 2005, CLIN ORTHOP RELAT R, P115, DOI 10.1097/01.blo.0000194309.70518.cb; Mayr E, 2009, CLIN BIOMECH, V24, P812, DOI 10.1016/j.clinbiomech.2009.07.010; Meneghini RM, 2006, CLIN ORTHOP RELAT R, P293, DOI 10.1097/01.blo.0000238859.46615.34; Nakata K, 2009, J ARTHROPLASTY, V24, P698, DOI 10.1016/j.arth.2008.04.012; Rachbauer F, 2006, ORTHOPADE, V35, P723, DOI 10.1007/s00132-006-0964-4; Rosenberg AG, 2007, J ARTHROPLASTY, V22, P102, DOI 10.1016/j.arth.2006.12.114; Siguier T, 2004, CLIN ORTHOP RELAT R, P164, DOI 10.1097/01.blo.0000136651.21191.9f; Woolson ST, 2009, J ARTHROPLASTY, V24, P999, DOI 10.1016/j.arth.2009.04.001	18	58	64	2	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-799X			J ORTHOP SURG RES	J. Orthop. Surg. Res.	APR 25	2012	7								17	10.1186/1749-799X-7-17			6	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	993JF	WOS:000307853900001	22533964	Green Published, gold			2022-02-06	
J	Adelson, PD; Pineda, J; Bell, MJ; Abend, NS; Berger, RP; Giza, CC; Hotz, G; Wainwright, MS				Adelson, P. David; Pineda, Jose; Bell, Michael J.; Abend, Nicholas S.; Berger, Rachel P.; Giza, Christopher C.; Hotz, Gillian; Wainwright, Mark S.			Common Data Elements for Pediatric Traumatic Brain Injury: Recommendations from the Working Group on Demographics and Clinical Assessment	JOURNAL OF NEUROTRAUMA			English	Article						clinical studies; common data elements; data coding; data collection; pediatric; standardization; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; PROGNOSTIC VALUE; PSYCHOLOGICAL HEALTH; CEREBROSPINAL-FLUID; SECONDARY INSULTS; COMA SCALE; SEVERITY; CHILDREN; PREVALENCE	The Common Data Elements (CDEs) initiative is a National Institutes of Health (NIH) interagency effort to standardize naming, definitions, and data structure for clinical research variables. Comparisons of the results of clinical studies of neurological disorders have been hampered by variability in data coding, definitions, and procedures for sample collection. The CDE project objective is to enable comparison of future clinical trials results in major neurological disorders, including traumatic brain injury (TBI), stroke, multiple sclerosis, and epilepsy. As part of this effort, recommendations for CDEs for research on TBI were developed through a 2009 multi-agency initiative. Following the initial recommendations of the Working Group on Demographics and Clinical Assessment, a separate workgroup developed recommendations on the coding of clinical and demographic variables specific to pediatric TBI studies for subjects younger than 18 years. This article summarizes the selection of measures by the Pediatric TBI Demographics and Clinical Assessment Working Group. The variables are grouped into modules which are grouped into categories. For consistency with other CDE working groups, each variable was classified by priority (core, supplemental, and emerging). Templates were produced to summarize coding formats, guide selection of data points, and provide procedural recommendations. This proposed standardization, together with the products of the other pediatric TBI working groups in imaging, biomarkers, and outcome assessment, will facilitate multi-center studies, comparison of results across studies, and high-quality meta-analyses of individual patient data.	[Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Pineda, Jose] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Pineda, Jose] Washington Univ, Sch Med, Dept Neurol, Div Crit Care Med, St Louis, MO 63110 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Neurol, Philadelphia, PA 19104 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neurol,Dept Pediat, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg,UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Crit Care, Feinberg Sch Med, Chicago, IL 60611 USA		Wainwright, MS (corresponding author), Childrens Mem Hosp, Div Neurol 51, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	Pineda, Jose/W-2806-2019; Adelson, David/W-2083-2019		NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; U.S. Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR); National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The meetings and activities of the pediatric WG Demographics and Clinical Assessment group were supported by funding in the context of the interagency initiative towards an integrated approach to Research in Psychological Health and Traumatic Brain Injury (NIH-NINDS; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center, and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (NS 042691).; This project was jointly supported by the NIH/NINDS and the U.S. Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holden KR, 1999, J CHILD NEUROL, V14, P708, DOI 10.1177/088307389901401104; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kennedy J., 2009, J REHABIL RES DEV, V44, P895; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas Andrew I R, 2009, Crit Care, V13, P1016, DOI 10.1186/cc8163; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Marcin JP, 2002, CRIT CARE MED, V30, pS457, DOI 10.1097/00003246-200211001-00011; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pollina J, 2001, PEDIATR NEUROSURG, V35, P113, DOI 10.1159/000050403; PRYOR HB, 1968, J PEDIATR-US, V73, P593, DOI 10.1016/S0022-3476(68)80275-6; Rooks VJ, 2008, AM J NEURORADIOL, V29, P1082, DOI 10.3174/ajnr.A1004; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Wynia MK, 2010, NEW ENGL J MED, V362, P846, DOI 10.1056/NEJMsb0910799	54	58	58	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					639	653		10.1089/neu.2011.1952			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500004	21939389	Green Published, Green Submitted			2022-02-06	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Roig, T.; Tormos, J. M.; Bargallo, N.; Vendrell, P.			White matter integrity related to functional working memory networks in traumatic brain injury	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; DEFAULT-MODE; CORPUS-CALLOSUM; STRUCTURAL CONNECTIVITY; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; NEUROPATHOLOGY; ACTIVATION; INFERENCE	Objective: This study explores the functional and structural patterns of connectivity underlying working memory impairment after severe traumatic axonal injury. Methods: We performed an fMRI n-back task and acquired diffusion tensor images (DTI) in a group of 19 chronic-stage patients with severe traumatic brain injury (TBI) and evidence of traumatic axonal injury and 19 matched healthy controls. We performed image analyses with FSL software and fMRI data were analyzed using probabilistic independent component analysis. Fractional anisotropy (FA) maps from DTI images were analyzed with FMRIB's Diffusion Toolbox. Results: We identified working memory and default mode networks. Global FA values correlated with both networks and FA whole-brain analysis revealed correlations in several tracts associated with the functional activation. Furthermore, working memory performance in the patient group correlated with the functional activation patterns and with the FA values of the associative fasciculi. Conclusion: Combining structural and functional neuroimaging data, we were able to describe structural white matter changes related to functional network alterations and to lower performance in working memory in chronic TBI. Neurology (R) 2012;78:852-860	[Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Vendrell, P.] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Vendrell, P.] Inst Biomed Res August Pi i Sunyer IDIBAPS, Barcelona, Spain; [Roig, T.; Tormos, J. M.] Inst Univ Neurorehabil Guttmann, Badalona, Spain; [Bargallo, N.] Hosp Clin Barcelona, Ctr Diagnost Imatge Hosp Clin Barcelona CDIC, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Sala-Llonch, Roser/L-4135-2015; Vendrell, Pere/B-4392-2011; Bargallo, Nuria/G-6854-2016; Junque, Carme/B-4400-2011; Sala-Llonch, Roser/E-7882-2012	Sala-Llonch, Roser/0000-0003-3576-0475; Vendrell, Pere/0000-0001-8918-5440; Bargallo, Nuria/0000-0001-6284-5402; Junque, Carme/0000-0002-6381-3063; Sala-Llonch, Roser/0000-0003-3576-0475; Tormos Munoz, Jose Maria/0000-0002-8764-2289	Institute of Biomedical Research August Pi i Sunyer (IDIBAPS); MAPFRE Foundation	E.M. Palacios was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) and research support from the MAPFRE Foundation. R. Sala-Llonch was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS). Dr. Junque, Dr. Vendrell, Dr. Tormos, Dr. Roig, and Dr. Bargallo report no disclosures.	Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonzano L, 2009, NEUROIMAGE, V44, P9, DOI 10.1016/j.neuroimage.2008.08.015; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Kanwisher N, 2010, P NATL ACAD SCI USA, V107, P11163, DOI 10.1073/pnas.1005062107; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Minear M, 2004, BEHAV RES METH INS C, V36, P630, DOI 10.3758/BF03206543; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D., 1999, ESCALA INTELIGENCIA; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	38	58	58	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR	2012	78	12					852	860		10.1212/WNL.0b013e31824c465a			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	914GO	WOS:000301937700007	22345222	Green Published			2022-02-06	
J	Chen, CC; Hung, TH; Wang, YH; Lin, CW; Wang, PY; Lee, CY; Chen, SF				Chen, Chien-Cheng; Hung, Tai-Ho; Wang, Yen-Ho; Lin, Chii-Wann; Wang, Pei-Yi; Lee, Chun-Yen; Chen, Szu-Fu			Wogonin Improves Histological and Functional Outcomes, and Reduces Activation of TLR4/NF-kappa B Signaling after Experimental Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; TOLL-LIKE RECEPTORS; SCUTELLARIA-BAICALENSIS GEORGI; FLUORO-JADE-B; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS; FLAVONOID WOGONIN; RAT MODEL; IN-VIVO	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and behavioral impairment. This study was undertaken to investigate the effects of wogonin, a flavonoid with potent antiinflammatory properties, on functional and histological outcomes, brain edema, and toll-like receptor 4 (TLR4)- and nuclear factor kappa B (NF-kappa B)-related signaling pathways in mice following TBI. Methodology/Principal Findings: Mice subjected to controlled cortical impact injury were injected with wogonin (20, 40, or 50 mg.kg(-1)) or vehicle 10 min after injury. Behavioral studies, histology analysis, and measurement of blood-brain barrier (BBB) permeability and brain water content were carried out to assess the effects of wogonin. Levels of TLR4/NF-kappa B-related inflammatory mediators were also examined. Treatment with 40 mg.kg(-1) wogonin significantly improved functional recovery and reduced contusion volumes up to post-injury day 28. Wogonin also significantly reduced neuronal death, BBB permeability, and brain edema beginning at day 1. These changes were associated with a marked reduction in leukocyte infiltration, microglial activation, TLR4 expression, NF-kappa B translocation to nucleus and its DNA binding activity, matrix metalloproteinase-9 activity, and expression of inflammatory mediators, including interleukin-1 beta, interleukin-6, macrophage inflammatory protein-2, and cyclooxygenase-2. Conclusions/Significance: Our results show that post-injury wogonin treatment improved long-term functional and histological outcomes, reduced brain edema, and attenuated the TLR4/NF-kappa B-mediated inflammatory response in mouse TBI. The neuroprotective effects of wogonin may be related to modulation of the TLR4/NF-kappa B signaling pathway.	[Chen, Chien-Cheng; Wang, Pei-Yi; Lee, Chun-Yen; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chen, Chien-Cheng; Lin, Chii-Wann] Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Wang, Yen-Ho] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Wang, Yen-Ho] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan		Chen, CC (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/ABD-1800-2020; Chen, Szu-Fu/K-5040-2012; Lin, Chii-Wann/B-5527-2009; Hung, Tai-Ho/C-7584-2011	Lin, Chii-Wann/0000-0002-8721-3441; Hung, Tai-Ho/0000-0003-2354-7060	National Science Council of Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [98-2314-B-350-001-MY3]; Cheng Hsin General Hospital	This work was supported by the National Science Council of Taiwan, R.O.C. (98-2314-B-350-001-MY3 to S.-F.C.) and the Cheng Hsin General Hospital (C.-C.C., S.-F.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chang YL, 2001, MOL PHARMACOL, V60, P507; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chi YS, 2003, BIOCHEM PHARMACOL, V66, P1271, DOI 10.1016/S0006-2952(03)00463-5; Cho J, 2004, BIOL PHARM BULL, V27, P1561, DOI 10.1248/bpb.27.1561; Cho JS, 2004, EUR J PHARMACOL, V485, P105, DOI 10.1016/j.ejphar.2003.11.064; Conti AC, 1998, J NEUROSCI, V18, P5663; Dong XQ, 2011, INFLAMM RES, V60, P533, DOI 10.1007/s00011-010-0300-7; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Huang GC, 2007, INT IMMUNOPHARMACOL, V7, P1054, DOI 10.1016/j.intimp.2007.04.001; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim H, 2001, NEUROSCI LETT, V309, P67, DOI 10.1016/S0304-3940(01)02028-6; Lee H, 2003, FASEB J, V17, P1943, DOI 10.1096/fj.03-0057fje; Lee SO, 2006, BIOCHEM BIOPH RES CO, V351, P118, DOI 10.1016/j.bbrc.2006.10.006; Lee YM, 2011, J CARDIOVASC PHARM, V58, P133, DOI 10.1097/FJC.0b013e31821a5078; LIU XF, 1990, MOL PHARMACOL, V37, P911; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Peng J, 2009, J ETHNOPHARMACOL, V124, P257, DOI 10.1016/j.jep.2009.04.031; Piao HZ, 2008, INT IMMUNOPHARMACOL, V8, P1658, DOI 10.1016/j.intimp.2008.07.018; Piao HZ, 2004, ARCH PHARM RES, V27, P930, DOI 10.1007/BF02975846; Qi Q, 2009, PHYTOTHER RES, V23, P417, DOI 10.1002/ptr.2645; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shen SC, 2006, NEUROSCIENCE, V140, P477, DOI 10.1016/j.neuroscience.2006.02.028; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Son D, 2004, EUR J PHARMACOL, V493, P99, DOI 10.1016/j.ejphar.2004.04.017; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Tai MC, 2005, CNS DRUG REV, V11, P141; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Wakabayashi I, 2000, EUR J PHARMACOL, V406, P477, DOI 10.1016/S0014-2999(00)00695-6; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	49	58	66	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2012	7	1							e30294	10.1371/journal.pone.0030294			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	907XU	WOS:000301454400106	22272328	Green Submitted, gold, Green Published			2022-02-06	
J	Rohling, ML; Larrabee, GJ; Millis, SR				Rohling, Martin L.; Larrabee, Glenn J.; Millis, Scott R.			The "Miserable Minority" Following Mild Traumatic Brain Injury: Who Are They and do Meta-Analyses Hide Them?	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Miserable minority; Meta-analysis; Post-concussion syndrome	COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; BASE RATES; SYMPTOMS; VALIDITY; OUTCOMES; MYTHS	Ruff et al. (1994; Ruff, Camenzuli, & Mueller, 1996) hypothesized that some mild traumatic brain injury (MTBI) patients will suffer chronic symptomatic complaints and impairments, identifying this subgroup as the "miserable minority.'' However, several meta-analyses of the effects of MTBI have been published (e. g., Rohling et al., 2011) showing no significant cognitive impairments following recovery. Recently Pertab, James, and Bigler (2009) suggested that meta-analysis might be obscuring impairments in some MTBI patients, presenting a hypothetical score distribution to illustrate their claim. Our statistical analyses of their hypothetical figure and of several other potential distributions containing an impaired subgroup that varied as a function of effect size and base rate of occurrence did not support the existence of a miserable minority that is obscured in meta-analyses by the larger group of MTBI patients experiencing full recovery. Indeed, given our recent published MTBI effect size of -0.07 (Rohling et al., 2011), for an impaired subgroup to exist, the level of impairment would have to be just under a tenth of a standard deviation, equivalent to a WMS-IV Index score value of 1 point. At effect sizes this small, any cut score chosen on a test to diagnose patients would result in more false positives than true positives. This greatly increases the risk of misdiagnosis in persons who are susceptible to misattribution, expectancy effects, and "diagnosis threat,'' thereby increasing the risk of iatrogenic illness.	[Rohling, Martin L.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI USA		Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, Suite 2000 Univ Commons, Mobile, AL 36688 USA.	mrohling@usouthal.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brulot MM, 1997, CLIN NEUROPSYCHOL, V11, P391, DOI 10.1080/13854049708400468; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein M, 2009, CLIN NEUROPSYCHOL, V23, P286, DOI 10.1080/13854040802104873; Heaton RK, 1991, COMPREHENSIVE NORMS; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Rohling ML, 2011, PSYCHOL BULL, V137, P708, DOI 10.1037/a0023327; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 2008, WECHSLER ADULT INTEL; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	39	58	58	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	2					197	213		10.1080/13854046.2011.647085			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	936EO	WOS:000303573900002	22256957				2022-02-06	
J	Castel, AD; Humphreys, KL; Lee, SS; Galvan, A; Balota, DA; McCabe, DP				Castel, Alan D.; Humphreys, Kathryn L.; Lee, Steve S.; Galvan, Adriana; Balota, David A.; McCabe, David P.			The Development of Memory Efficiency and Value-Directed Remembering Across the Life Span: A Cross-Sectional Study of Memory and Selectivity	DEVELOPMENTAL PSYCHOLOGY			English	Article						memory; life span cognition; selective attention; metacognition; cognitive aging	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; INHIBITORY CONTROL; EXECUTIVE FUNCTION; AGE-DIFFERENCES; RISK-TAKING; ATTENTION; CHILDREN; DEMENTIA; CAPACITY	Although attentional control and memory change considerably across the life span, no research has examined how the ability to strategically remember important information (i.e., value-directed remembering) changes from childhood to old age. The present study examined this in different age groups across the life span (N = 320, 5-96 years old). A selectivity task was used in which participants were asked to study and recall items worth different point values in order to maximize their point score. This procedure allowed for measures of memory quantity/capacity (number of words recalled) and memory efficiency/selectivity (the recall of high-value items relative to low-value items). Age-related differences were found for memory capacity, as young adults recalled more words than the other groups. However, in terms of selectivity, younger and older adults were more selective than adolescents and children. The dissociation between these measures across the life span illustrates important age-related differences in terms of memory capacity and the ability to selectively remember high-value information.	[Castel, Alan D.; Humphreys, Kathryn L.; Lee, Steve S.; Galvan, Adriana] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Balota, David A.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [McCabe, David P.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA		Castel, AD (corresponding author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA.	castel@ucla.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG03991, P50 AG005681-26, P50 AG005681, P01 AG003991, AG10145, AG05681, P01 AG003991-16] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010145, P01AG003991, P50AG005681] Funding Source: NIH RePORTER		Adcock RA, 2006, NEURON, V50, P507, DOI 10.1016/j.neuron.2006.03.036; Ariel R, 2009, J EXP PSYCHOL GEN, V138, P432, DOI 10.1037/a0015928; Balota D. A., 2001, HDB NEUROPSYCHOLOGY, P51, DOI DOI 10.1037/A0014888; Balota DA, 2007, BEHAV RES METHODS, V39, P445, DOI 10.3758/BF03193014; Baltes P. B., 1990, SUCCESSFUL AGING PER, DOI 10.1017/CBO9780511665684; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Bialystok E., 2006, LIFESPAN COGNITION M; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Castel AD, 2002, MEM COGNITION, V30, P1078, DOI 10.3758/BF03194325; Castel AD, 2007, PSYCHOL LEARN MOTIV, V48, P225, DOI 10.1016/S0079-7421(07)48006-9; Castel AD, 2007, MEM COGNITION, V35, P689, DOI 10.3758/BF03193307; Castel AD, 2011, NEUROPSYCHOLOGY, V25, P15, DOI 10.1037/a0020298; Castel AD, 2009, NEUROPSYCHOLOGY, V23, P297, DOI 10.1037/a0014888; Cepeda NJ, 2001, DEV PSYCHOL, V37, P715, DOI 10.1037/0012-1649.37.5.715; Cowan N, 2006, DEV PSYCHOL, V42, P1089, DOI 10.1037/0012-1649.42.6.1089; Coyle TR, 1997, DEV PSYCHOL, V33, P372, DOI 10.1037/0012-1649.33.2.372; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; Durston S, 2006, DEVELOPMENTAL SCI, V9, P1, DOI 10.1111/j.1467-7687.2005.00454.x; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; Galvan A, 2007, DEVELOPMENTAL SCI, V10, pF8, DOI 10.1111/j.1467-7687.2006.00579.x; Galvan A, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.006.2010; Galvan A, 2006, J NEUROSCI, V26, P6885, DOI 10.1523/JNEUROSCI.1062-06.2006; Games P. A., 1976, J EDUC STAT, V1, P113, DOI DOI 10.2307/1164979; Geier CF, 2010, CEREB CORTEX, V20, P1613, DOI 10.1093/cercor/bhp225; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; HASHER L, 1991, J EXP PSYCHOL LEARN, V17, P163, DOI 10.1037/0278-7393.17.1.163; Hertzog C, 2010, DEV PSYCHOL, V46, P939, DOI 10.1037/a0019812; Hess T. M., 2000, GENERATIVE MENTAL PR, P129, DOI DOI 10.1007/978-94-011-4373-8_5; JONES TC, 1995, EUR J COGN PSYCHOL, V7, P65, DOI 10.1080/09541449508520158; Koriat A, 1996, PSYCHOL REV, V103, P490, DOI 10.1037/0033-295X.103.3.490; Koriat A, 2007, CAMB HANDB PSYCHOL, P289; Levene H., 1960, CONTRIBUTIONS PROBAB, P278; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; McCabe DP, 2010, NEUROPSYCHOLOGY, V24, P222, DOI 10.1037/a0017619; McGillivray S, 2011, PSYCHOL AGING, V26, P137, DOI 10.1037/a0022681; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Moscovitch M., 2000, OXFORD HDB MEMORY, P609; Park DC, 1996, PSYCHOL AGING, V11, P621, DOI 10.1037/0882-7974.11.4.621; Park Denise C., 2006, LIFESPAN COGNITION M, P128, DOI DOI 10.1093/ACPROF:OSO/9780195169539.003.0009; PLUDE DJ, 1994, ACTA PSYCHOL, V86, P227, DOI 10.1016/0001-6918(94)90004-3; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Riediger M, 2006, PSYCHOL AGING, V21, P173, DOI 10.1037/0882-7974.21.1.173; Riediger M., 2006, HDB PSYCHOL AGING, DOI DOI 10.1016/B978-012101264-9/50016-1; Shin H, 2007, COGNITIVE DEV, V22, P197, DOI 10.1016/j.cogdev.2006.10.001; Stuss D. T., 2002, PRINCIPLES FRONTAL L, DOI [10.1093/acprof:oso/9780195134971.001.0001, DOI 10.1093/ACPROF:OSO/9780195134971.001.0001]; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Tse CS, 2010, NEUROPSYCHOLOGY, V24, P300, DOI 10.1037/a0018274; Waszak F, 2010, DEV PSYCHOL, V46, P337, DOI 10.1037/a0018541; Watkins M. J., 1999, SELECTIVITY MEMORY E; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Winocur G., 1992, HDB AGING COGNITION, P315; Zelazo PD, 2004, ACTA PSYCHOL, V115, P167, DOI 10.1016/j.actpsy.2003.12.005	58	58	61	0	24	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0012-1649	1939-0599		DEV PSYCHOL	Dev. Psychol.	NOV	2011	47	6					1553	1564		10.1037/a0025623			12	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	842QH	WOS:000296613600006	21942664	Green Accepted			2022-02-06	
J	Raz, E; Jensen, JH; Ge, Y; Babb, JS; Miles, L; Reaume, J; Grossman, RI; Inglese, M				Raz, E.; Jensen, J. H.; Ge, Y.; Babb, J. S.; Miles, L.; Reaume, J.; Grossman, R. I.; Inglese, M.			Brain Iron Quantification in Mild Traumatic Brain Injury: A Magnetic Field Correlation Study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MULTIPLE-SCLEROSIS; UNITED-STATES; IMMATURE RAT; PATHOPHYSIOLOGY; METABOLISM	BACKGROUND AND PURPOSE: Experimental studies have suggested a role for iron accumulation in the pathology of TBI. Magnetic field correlation MR imaging is sensitive to the presence of non-heme iron. The aims of this study are to 1) assess the presence, if any, and the extent of iron deposition in the deep gray matter and regional white matter of patients with mTBI by using MFC MR imaging; and 2) investigate the association of regional brain iron deposition with cognitive and behavioral performance of patients with mTBI. MATERIALS AND METHODS: We prospectively enrolled 28 patients with mTBI. Eighteen healthy subjects served as controls. The subjects were administered the Stroop color word test, the Verbal Fluency Task, and the Post-Concussion Symptoms Scale. The MR imaging protocol (on a 3T imager) consisted of conventional brain imaging and MFC sequences. After the calculation of parametric maps, MFC was measured by using a region of interest approach. MFC values across groups were compared by using analysis of covariance, and the relationship of MFC values and neuropsychological tests were evaluated by using Spearman correlations. RESULTS: Compared with controls, patients with mTBI demonstrated significant higher MFC values in the globus pallidus (P = .002) and in the thalamus (P = .036). In patients with mTBI, Stroop test scores were associated with the MFC value in frontal white matter (r = -0.38, P = .043). CONCLUSIONS: MFC values were significantly elevated in the thalamus and globus pallidus of patients with mTBI, suggesting increased accumulation of iron. This supports the hypothesis that deep gray matter is a site of injury in mTBI and suggests a possible role for iron accumulation in the pathophysiological events after mTBI.	[Inglese, M.] Mt Sinai Sch Med, Dept Neurol & Radiol, New York, NY 10029 USA; [Raz, E.; Jensen, J. H.; Ge, Y.; Babb, J. S.; Miles, L.; Reaume, J.; Grossman, R. I.] NYU, Sch Med, Dept Radiol, New York, NY USA; [Raz, E.] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy		Inglese, M (corresponding author), Mt Sinai Sch Med, Dept Neurol, Annenberg 14-89,Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	matilde.inglese@mssm.edu	Ge, Yulin/D-9060-2019; Inglese, Matilde/AAH-3189-2020; Jensen, Jens H/A-8334-2009; Ge, Yulin/L-7052-2019	Ge, Yulin/0000-0002-2320-6031; Inglese, Matilde/0000-0002-9610-0297; Jensen, Jens H/0000-0003-3219-4287; Babb, James/0000-0003-1798-1186	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS039135, R01 NS051323]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This study was supported by the National Institute of Health grants R01 NS039135 and R01 NS051323.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Campbell A, 2001, BRAIN RES BULL, V55, P125, DOI 10.1016/S0361-9230(01)00455-5; Connor JR, 2001, PEDIATR NEUROL, V25, P118, DOI 10.1016/S0887-8994(01)00303-4; CRAELIUS W, 1982, ARCH PATHOL LAB MED, V106, P397; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Ge Y, 2007, AM J NEURORADIOL, V28, P1639, DOI 10.3174/ajnr.A0646; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jensen JH, 2006, MAGN RESON MED, V55, P1350, DOI 10.1002/mrm.20907; Jensen JH, 2009, MAGN RESON MED, V61, P481, DOI 10.1002/mrm.21823; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lull N, 2010, NEUROLOGIA, V25, P174; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sipe JC, 2002, DEV NEUROSCI-BASEL, V24, P188, DOI 10.1159/000065701; Sukstanskii AL, 2003, J MAGN RESON, V163, P236, DOI 10.1016/S1090-7807(03)00131-9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trenerry MR, 1989, STROOP NEUROPSYCHOLO	32	58	58	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV	2011	32	10					1851	1856		10.3174/ajnr.A2637			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	859PM	WOS:000297888300017	21885717	hybrid, Green Published, Green Accepted			2022-02-06	
J	Wang, LZ; Cheung, JTM; Pu, F; Li, DY; Zhang, M; Fan, YB				Wang, Lizhen; Cheung, Jason Tak-Man; Pu, Fang; Li, Deyu; Zhang, Ming; Fan, Yubo			Why Do Woodpeckers Resist Head Impact Injury: A Biomechanical Investigation	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CANCELLOUS BONE; ARCHITECTURE; DENSITY; BEHAVIOR; HISTORY; TISSUE; SPORT; SKULL; MASS	Head injury is a leading cause of morbidity and death in both industrialized and developing countries. It is estimated that brain injuries account for 15% of the burden of fatalities and disabilities, and represent the leading cause of death in young adults. Brain injury may be caused by an impact or a sudden change in the linear and/or angular velocity of the head. However, the woodpecker does not experience any head injury at the high speed of 6-7 m/s with a deceleration of 1000 g when it drums a tree trunk. It is still not known how woodpeckers protect their brain from impact injury. In order to investigate this, two synchronous high-speed video systems were used to observe the pecking process, and the force sensor was used to measure the peck force. The mechanical properties and macro/micro morphological structure in woodpecker's head were investigated using a mechanical testing system and micro-CT scanning. Finite element (FE) models of the woodpecker's head were established to study the dynamic intracranial responses. The result showed that macro/micro morphology of cranial bone and beak can be recognized as a major contributor to non-impact-injuries. This biomechanical analysis makes it possible to visualize events during woodpecker pecking and may inspire new approaches to prevention and treatment of human head injury.	[Wang, Lizhen; Pu, Fang; Li, Deyu; Fan, Yubo] Beihang Univ, Key Lab Biomech & Mechanobiol, Minist Educ, Sch Biol Sci & Med Engn, Beijing, Peoples R China; [Wang, Lizhen; Zhang, Ming] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China; [Cheung, Jason Tak-Man] Li Ning Sports Sci Res Ctr, Beijing, Peoples R China		Wang, LZ (corresponding author), Beihang Univ, Key Lab Biomech & Mechanobiol, Minist Educ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.	ming.zhang@polyu.edu.hk; yubofan@buaa.edu.cn	Zhang, Ming/F-8331-2011	Zhang, Ming/0000-0002-6027-4594	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [10925208, 11120101001]; Hong Kong Polytechnic UniversityHong Kong Polytechnic University [G-U624]; National Key Lab of Virtual Reality Technology	This project was funded by National Natural Science Foundation of China under the Grant 10925208, 11120101001 (http://www.nsfc.gov.cn/Portal0/default124.htm) and by the Hong Kong Polytechnic University under the grant G-U624 (http://www.polyu.edu.hk/cpa/polyu/index.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to acknowledge the support from the National Key Lab of Virtual Reality Technology.	BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BOCK WJ, 1964, J MORPHOL, V114, P1, DOI 10.1002/jmor.1051140102; Bock WJ, 1999, OSTRICH, V70, P23, DOI 10.1080/00306525.1999.9639746; BOCK WJ, 1966, AUK, V83, P10, DOI 10.2307/4082976; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; CARTER DR, 1987, J BIOMECH, V20, P785, DOI 10.1016/0021-9290(87)90058-3; Corporation LST, 2006, LS DYNA KEYW US MAN; COWIN SC, 1986, J BIOMECH ENG-T ASME, V108, P83, DOI 10.1115/1.3138584; Cowin SC, 1998, J BIOMECH, V31, P759, DOI 10.1016/S0021-9290(98)00078-5; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Giesen EBW, 2001, J BIOMECH, V34, P799, DOI 10.1016/S0021-9290(01)00030-6; Holbourn AHS, 1943, LANCET, V2, P438; HOSEY RR, 1982, HOMEOMORPHIC FINITE, P379; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; Kabel J, 1999, BONE, V25, P481, DOI 10.1016/S8756-3282(99)00190-8; King AI, 2003, IRCOBI C LISB PORT; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Linde F, 1988, Eng Med, V17, P23; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MAY PRA, 1976, LANCET, V1, P454; MAY PRA, 1979, ARCH NEUROL-CHICAGO, V36, P370, DOI 10.1001/archneur.1979.00500420080011; MLIKOVSKY J, 1989, Vestnik Ceskoslovenske Spolecnosti Zoologicke, V53, P252; Oda J, 2006, JSME INT J A-SOLID M, V49, P390, DOI 10.1299/jsmea.49.390; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; RICE JC, 1988, J BIOMECH, V21, P155, DOI 10.1016/0021-9290(88)90008-5; ROESLER H, 1987, J BIOMECH, V20, P1025, DOI 10.1016/0021-9290(87)90020-0; Ruan J. S., 1994, IMPACT BIOMECHANICS; Ruimerman R, 2001, COMPUTER METHODS BIO, V4, P433, DOI DOI 10.1080/10255840108908019; Schwab IR, 2002, BRIT J OPHTHALMOL, V86, P843, DOI 10.1136/bjo.86.8.843; SPRING LOWELL W., 1965, CONDOR, V67, P457, DOI 10.2307/1365612; Stalnaker R.L., 1969, MECH PROPERTIES HEAD; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Yang King H, 2006, Stapp Car Crash J, V50, P429; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024	39	58	67	4	110	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2011	6	10							e26490	10.1371/journal.pone.0026490			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841NR	WOS:000296519600022	22046293	Green Published, gold, Green Submitted			2022-02-06	
J	Strumwasser, A; Kwan, RO; Yeung, L; Miraflor, E; Ereso, A; Castro-Moure, F; Patel, A; Sadjadi, J; Victorino, GP				Strumwasser, Aaron; Kwan, Rita O.; Yeung, Louise; Miraflor, Emily; Ereso, Alex; Castro-Moure, Frederico; Patel, Atul; Sadjadi, Javid; Victorino, Gregory P.			Sonographic Optic Nerve Sheath Diameter as an Estimate of Intracranial Pressure in Adult Trauma	JOURNAL OF SURGICAL RESEARCH			English	Article						trauma ultrasound; optic nerve sheath diameter; ONSD; traumatic brain injury; intracranial pressure; ICP; sonographic technique	SEVERE HEAD-INJURY; BRAIN-INJURY; CLINICAL-EVALUATION; CODMAN MICROSENSOR; ULTRASOUND; AUTOREGULATION; COMPLICATIONS	Background. Intracranial pressure (ICP) is currently measured with invasive monitoring. Sonographic optic nerve sheath diameter (ONSD) may provide a noninvasive estimate of ICP. Our hypothesis was that bedside ONSD accurately estimates ICP in acutely injured patients. The specific aims were (1) to determine the accuracy of ONSD in estimating elevated ICP, (2) to correlate ONSD and ICP in unilateral and bilateral head injuries, and (3) to determine the effect of ICP monitor placement on ONSD measurements. Materials and Methods. A blinded prospective study of adult trauma patients requiring ICP monitoring was performed at a University-based urban trauma center. The ONSD was measured by ultrasound pre- and post-placement of an ICP monitor (Camino Bolt or Ventriculostomy). Results. One-hundred fourteen measurements were obtained in 10 trauma patients requiring ICP monitoring. Pre- and post-ONSD were compared with side of injury in the presence of an ICP monitor. ROC analysis demonstrated ONSD poorly estimates elevated ICP (AUC = 0.36). Overall sensitivity, specificity, PPV, NPV, and accuracy for estimating ICP with ONSD were 36%, 38%, 40%, 16%, and 37%. Poor correlation of ONSD to ICP was observed with unilateral (R-2 = 0.45, P < 0.01) and bilateral (R-2 = 0.21, P = 0.01) injuries. ICP monitor placement did not affect ONSD measurements on the right (P = 0.5), left (P = 0.4), or right and left sides combined (P = 0.3). Conclusions. Sonographic ONSD as a surrogate for elevated ICP in lieu of invasive monitoring is not reliable due to poor accuracy and correlation. (C) 2011 Elsevier Inc. All rights reserved.	[Strumwasser, Aaron; Kwan, Rita O.; Yeung, Louise; Miraflor, Emily; Ereso, Alex; Castro-Moure, Frederico; Patel, Atul; Sadjadi, Javid; Victorino, Gregory P.] UCSF E Bay, Dept Surg, Oakland, CA 94602 USA		Victorino, GP (corresponding author), UCSF E Bay, Dept Surg, 1411 E 31st St, Oakland, CA 94602 USA.	gregory.victorino@ucsfmedctr.org					Ball CG, 2009, CAN J SURG, V52, pE173; Banister K, 2000, PHYSIOL MEAS, V21, P473, DOI 10.1088/0967-3334/21/4/304; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; BRAIN TRAUM FD, 2000, J NEUROTRAUM, V17, P457; Chambers IR, 1998, ACT NEUR S, V71, P42; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; Cowley NJ, 2008, TRAUMA, V10, P35, DOI 10.1177/1460408608089322; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Demetriades D, 2003, ANNU REV MED, V54, P1, DOI 10.1146/annurev.med.54.101601.152512; Fernandes HM, 1998, ACT NEUR S, V71, P44; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Grathwohl KW, 2008, ANESTHESIOLOGY, V109, P44, DOI 10.1097/ALN.0b013e31817c02e3; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Hashimoto Beverly E, 2008, Ultrasound Q, V24, P31, DOI 10.1097/RUQ.0b013e31816b8cdf; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; McGahan JP, 2002, J ULTRAS MED, V21, P789, DOI 10.7863/jum.2002.21.7.789; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Rose JS, 2004, EMERG MED CLIN N AM, V22, P581, DOI 10.1016/j.emc.2004.04.007; Rozycki GS, 1998, SURG CLIN N AM, V78, P295, DOI 10.1016/S0039-6109(05)70314-5; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Signorini DF, 1998, BRIT J NEUROSURG, V12, P223; Smith J, 2010, POSTGRAD MED J, V86, P285, DOI 10.1136/pgmj.2008.076711; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Soundappan SVS, 2005, INJURY, V36, P970, DOI 10.1016/j.injury.2005.02.026; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; Valentino M, 2007, SEMIN ULTRASOUND CT, V28, P130, DOI 10.1053/j.sult.2007.01.008; Wang M, 2008, ULTRASOUND MED BIOL, V34, P1944, DOI 10.1016/j.ultrasmedbio.2008.06.001; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50	38	58	61	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2011	170	2					265	271		10.1016/j.jss.2011.03.009			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	823NH	WOS:000295128600026	21550065				2022-02-06	
J	Abend, NS; Topjian, AA; Gutierrez-Colina, AM; Donnelly, M; Clancy, RR; Dlugos, DJ				Abend, Nicholas S.; Topjian, Alexis A.; Gutierrez-Colina, Ana M.; Donnelly, Maureen; Clancy, Robert R.; Dlugos, Dennis J.			Impact of Continuous EEG Monitoring on Clinical Management in Critically Ill Children	NEUROCRITICAL CARE			English	Article						Seizure; Status epilepticus; Pediatric; Critically Ill; Electroencephalogram; EEG monitoring	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; NEONATAL SEIZURES; PATTERNS; ELECTROENCEPHALOGRAPHY; ICU	Continuous EEG (cEEG) monitoring is being used with increasing frequency in critically ill patients, most often to detect non-convulsive seizures. While cEEG is non-invasive and feasible in the critical care setting, it is also expensive and labor intensive, and there has been little study of its impact on clinical care. We aimed to determine prospectively the impact of cEEG on clinical management in critically ill children. Critically ill children (non-neonates) with acute encephalopathy underwent cEEG. Study enrollment and data collection were prospective. 100 children were studied. EEG monitoring led to specific clinical management changes in 59 children. These included initiating or escalating anti-seizure medications in 43 due to seizure detection, demonstrating that a specific event (subtle movement or vital sign change) was not a seizure in 21, or obtaining urgent neuroimaging that led to a clinical change in 3. In the remaining 41 children, cEEG ruled out the presence of non-convulsive seizures but did not lead to a specific change in clinical management. EEG monitoring led to changes in clinical management in the majority of patients, suggesting it may have an important role in management of critically ill children. Further study is needed to determine whether the management changes elicited by cEEG improve outcome.	[Abend, Nicholas S.; Gutierrez-Colina, Ana M.; Donnelly, Maureen; Clancy, Robert R.; Dlugos, Dennis J.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Abend, Nicholas S.; Clancy, Robert R.; Dlugos, Dennis J.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Topjian, Alexis A.] Childrens Hosp Philadelphia, Div Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA		Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	abend@email.chop.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-NS049453]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12NS049453] Funding Source: NIH RePORTER	This study is supported by NIH K12-NS049453 to Dr. Abend.	Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2008, PEDIATR EMERG CARE, V24, P705, DOI 10.1097/PEC.0b013e318188fcac; Abend NS, 2008, EPILEPSIA, V49, P349, DOI 10.1111/j.1528-1167.2007.01425.x; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.2310/7010.2001.17060; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; COEN RW, 1982, J PEDIATR-US, V100, P628, DOI 10.1016/S0022-3476(82)80773-7; de Vos CC, 2008, J CLIN NEUROPHYSIOL, V25, P77, DOI 10.1097/WNP.0b013e31816ef725; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gerber PA, 2008, J CLIN NEUROPHYSIOL, V25, P241, DOI 10.1097/WNP.0b013e318182ed67; Glass HC, 2009, J PEDIATR-US, V155, P318, DOI 10.1016/j.jpeds.2009.03.040; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Ronen GM, 2007, NEUROLOGY, V69, P1816, DOI 10.1212/01.wnl.0000279335.85797.2c; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Young GB, 1996, NEUROLOGY, V47, P83	36	58	59	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					70	75		10.1007/s12028-010-9380-z			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100011	20499208	Green Accepted			2022-02-06	
J	Lotocki, G; Vaccari, JD; Alonso, O; Molano, JS; Nixon, R; Safavi, P; Dietrich, WD; Bramlett, HM				Lotocki, George; Vaccari, Juan de Rivero; Alonso, Ofelia; Molano, Juliana Sanchez; Nixon, Ryan; Safavi, Padideh; Dietrich, W. Dalton; Bramlett, Helen M.			Oligodendrocyte vulnerability following traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						Myelin; Oligodendrocyte; Apoptosis; Brain trauma	SPINAL-CORD-INJURY; WHITE-MATTER; HEAD-INJURY; AXONAL INJURY; APOPTOSIS; PROTEIN; DAMAGE	Experimental and clinical findings demonstrate that traumatic brain injury (TBI) results in injury to both gray and white matter structures. The purpose of this study was to document patterns of oligodendrocyte vulnerability to TBI. Sprague Dawley rats underwent sham operated procedures or moderate fluid percussion brain injury. Quantitative immunohistochemical analysis was performed on animals perfusion-fixed at 3 (n = 9) or 7 (n = 9) days post-surgery. Within the ipsilateral external capsule and corpus callosum, numbers of APC-CC1 immunoreactive oligodendrocytes were significantly decreased at 3 or 7 days post-TBI compared to sham rats (p < 0.03). At both posttraumatic survival periods, double-labeling studies indicated that oligodendrocytes showed increased Caspase 3 activation compared to sham. These data demonstrate regional patterns of oligodendrocyte vulnerability after TBI and that oligodendrocyte cell loss may be due to Caspase 3-mediated cell death mechanisms. Further studies are needed to test therapeutic interventions that prevent trauma-induced oligodendrocyte cell death, subsequent demyelination and circuit dysfunction. (c) 2011 Elsevier Ireland Ltd. All rights reserved.	[Vaccari, Juan de Rivero; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Lotocki, George; Vaccari, Juan de Rivero; Alonso, Ofelia; Molano, Juliana Sanchez; Nixon, Ryan; Safavi, Padideh; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Med Ctr, Bruce W Carter Dept Vet Affairs, Miami, FL USA		Bramlett, HM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 3-18, Miami, FL 33136 USA.	hbramlett@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Nixon, Ryan/0000-0002-5759-4415	 [NS030291];  [NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS056072, P50NS030291] Funding Source: NIH RePORTER	This work was supported by NS030291 and NS042133.	Bhat RV, 1996, GLIA, V17, P169; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1998, NEUROPATHOLOGY, V3, P160; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gootjes L, 2004, DEMENT GERIATR COGN, V18, P180, DOI 10.1159/000079199; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kujala P, 1997, BRAIN, V120, P289, DOI 10.1093/brain/120.2.289; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McDonald JW, 2002, NEUROSCIENCE, V115, P931, DOI 10.1016/S0306-4522(02)00342-1; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schulz R, 2008, CELL TISSUE RES, V334, P327, DOI 10.1007/s00441-008-0714-5; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186	33	58	62	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 25	2011	499	3					143	148		10.1016/j.neulet.2011.05.056			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	809WQ	WOS:000294087800001	21669255	Green Accepted			2022-02-06	
J	Elliott, MB; Tuma, RF; Amenta, PS; Barbe, MF; Jallo, JI				Elliott, Melanie B.; Tuma, Ronald F.; Amenta, Peter S.; Barbe, Mary F.; Jallo, Jack I.			Acute Effects of a Selective Cannabinoid-2 Receptor Agonist on Neuroinflammation in a Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact injury; glial response; inflammation; neurotransmitters; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD NEUROCHEMICALS; SUBSTANCE-P; CB2 RECEPTORS; FUNCTIONAL-CHARACTERIZATION; MURINE MACROPHAGES; CEREBRAL EDEMA; MICE; NEUROPROTECTION; INFLAMMATION	Proposed therapeutic strategies for attenuating secondary traumatic brain injury (TBI) include modulation of acute neuroimmune responses. The goal of this study was to examine the acute effects of cannabinoid-2 receptor (CB(2)R) modulation on behavioral deficits, cerebral edema, perivascular substance P, and macrophage/microglial activation in a murine model of TBI. Thirty male C57BL/6 mice underwent sham surgery, or cortical contusion impact injury (CCI). CCI mice received vehicle or the CB(2)R agonist 0-1966 at 1 and 24 h after injury. Performance on the rotarod, forelimb cylinder, and open-field tests were evaluated before and at 48 h after sham or CCI surgery. Cerebral edema was evaluated using the wet-dry weight technique. Immunohistochemical analysis was used to examine changes in substance P and macrophage/microglia-specific Iba1 protein immunoreactivity. Locomotor performance and exploratory behavior were significantly improved in mice receiving 0-1966 (CB(2)R agonist) compared to vehicle-treated mice. Significant reductions were found for cerebral edema, number of perivascular areas of substance P immunoreactivity, and number of activated macrophages/microglial cells in the injured brains of 0-1966-treated mice compared to vehicle-treated mice. The findings show that the effects of the CB(2)R agonist 0-1966 on edema, substance P immunoreactivity, and macrophage/microglial activation, were associated with recovery of acute motor and exploratory deficits. This study provides evidence of acute neuroprotective effects derived from selective CB(2)R activation that may represent an avenue for further development of novel therapeutic agents in the treatment of TBI.	[Elliott, Melanie B.; Amenta, Peter S.; Jallo, Jack I.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Tuma, Ronald F.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19122 USA; [Barbe, Mary F.] Temple Univ, Sch Med, Dept Anat & Cell Biol, Philadelphia, PA 19122 USA		Elliott, MB (corresponding author), Thomas Jefferson Univ, Dept Neurosurg, 1025 Walnut St, Philadelphia, PA 19107 USA.	melanie.elliott@jefferson.edu		Barbe, Mary/0000-0002-5235-9803; Jallo, Jack/0000-0002-5512-1729			Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Carrier EJ, 2005, CNS NEUROL DISORD-DR, V4, P657, DOI 10.2174/156800705774933023; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elliott MB, 2010, NEUROSCIENCE, V170, P929, DOI 10.1016/j.neuroscience.2010.07.041; Elliott MB, 2009, NEUROSCIENCE, V158, P922, DOI 10.1016/j.neuroscience.2008.10.050; Elliott MB, 2008, BRAIN RES, V1218, P103, DOI 10.1016/j.brainres.2008.04.029; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Elliott MB, 2009, NEUROSCI LETT, V454, P34, DOI 10.1016/j.neulet.2009.01.037; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kingery WS, 2003, BONE, V33, P927, DOI 10.1016/j.bone.2003.07.003; Klein TW, 2006, J NEUROIMMUNE PHARM, V1, P50, DOI 10.1007/s11481-005-9007-x; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; Lombard C, 2007, CLIN IMMUNOL, V122, P259, DOI 10.1016/j.clim.2006.11.002; Marriott I, 1998, CELL IMMUNOL, V183, P113, DOI 10.1006/cimm.1998.1248; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; Mouton P. R., 2002, PRINCIPLES PRACTICES; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	48	58	58	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					973	981		10.1089/neu.2010.1672			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600011	21332427	Green Submitted			2022-02-06	
J	Adams, JH; Jennett, B; Murray, LS; Teasdale, GM; Gennarelli, TA; Graham, DI				Adams, J. Hume; Jennett, Bryan; Murray, Lilian S.; Teasdale, Graham M.; Gennarelli, Thomas A.; Graham, David I.			Neuropathological Findings in Disabled Survivors of a Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						assessment by Glasgow Outcome Scale; neuropathology; permanent disability; head injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; GLASGOW OUTCOME SCALE; SUDDEN UNEXPECTED DEATH; VEGETATIVE STATE; DAMAGE; DISABILITY; EPILEPSY; CHILDREN; DIAGNOSIS	We investigated how the occurrence and severity of the main neuropathological types of traumatic brain injury (TBI) influenced the severity of disability after a head injury. Eighty-five victims, each of whom had lived at least a month after a head injury but then died, were studied. Judged by the Glasgow Outcome Scale (GOS), before death 35 were vegetative, 30 were severely and 20 were moderately disabled. Neuropathological assessment showed that 71 (84%) victims had sustained cerebral contusions, 49 (58%) had diffuse axonal injury (DAI), 57 (67%), had ischemic brain damage (IBD), 58 (68%) had symmetrical ventricular enlargement, and in 47 (55%) intracranial pressure (ICP) had been increased. Thirty-five (41%) had undergone evacuation of an intracranial hematoma. Brainstem damage was seen in only 11 (13%). Analysis (chi(2) test for trends) of the relationship between these features and outcome showed that findings of DAI, raised ICP, thalamic damage, or ventricular enlargement (all p < 0.005), and IBD (p = 0.04) were associated with an increasingly worse outcome. Conversely, moderate or severe contusions (p = 0.001) were increasingly associated with better outcomes, and evacuation of a hematoma was associated (p = 0.001) with outcomes likely to be better than vegetative. We conclude that diffuse or multifocal neuropathological patterns of TBI from primary axonal injury or secondary ischemic damage are most likely to be associated with the most severely impaired outcomes after a head injury.	[Murray, Lilian S.] Univ Glasgow, Western Infirm, Gardiner Inst, Sch Med, Glasgow G11 6NT, Lanark, Scotland; [Adams, J. Hume; Graham, David I.] Univ Glasgow, Fac Med, Inst Neurol Sci, So Gen Hosp,Dept Neuropathol, Glasgow G11 6NT, Lanark, Scotland; [Jennett, Bryan; Teasdale, Graham M.] Univ Glasgow, Fac Med, Inst Neurol Sci, So Gen Hosp,Dept Neurosurg, Glasgow G11 6NT, Lanark, Scotland; [Gennarelli, Thomas A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA		Murray, LS (corresponding author), Univ Glasgow, Western Infirm, Gardiner Inst, Sch Med, Glasgow G11 6NT, Lanark, Scotland.	Lilian.Murray@glasgow.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; BIGLER ED, 1984, INT J NEUROSCI, V24, P295, DOI 10.3109/00207458409089820; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1993, HEAD INJURY, P137; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Thom M, 1997, EPILEPSIA, V38, pS32, DOI 10.1111/j.1528-1157.1997.tb06123.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031	48	58	59	2	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					701	709		10.1089/neu.2010.1733			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100271	21401319				2022-02-06	
J	Farahvar, A; Gerber, LM; Chiu, YL; Haertl, R; Carney, N; Ghajar, J				Farahvar, Arash; Gerber, Linda M.; Chiu, Ya-Lin; Haertl, Roger; Carney, Nancy; Ghajar, Jamshid			Response to intracranial hypertension treatment as a predictor of death in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; treatment response; mortality rate; death; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; AGGRESSIVE TREATMENT; MANAGEMENT; OUTCOMES; ICP; AUTOREGULATION; GUIDELINES; TRIAL	Object. The normalization of increased intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI) is assumed to limit secondary brain injury and improve outcome. Despite evidence-based recommendations for monitoring and treatment of elevated ICP, there are few studies that show an association between response to ICP-directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to ICP-lowering therapy on risk of death within the first 2 weeks of injury in patients who sustained TBI and are older than 16 years. Methods. The current study is based on 1426 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) of whom 388 were treated for elevated ICP (> 25 mm Hg) between 2000 and 2008 at 22 trauma centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and hypotension, which are all known early prognostic indicators of death. Treatment of elevated ICP consisted of administration of mannitol, hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting ICP response to treatment and predicting death at 2 weeks were evaluated using logistic regression analyses. Results. Increasing age and fewer hours of elevated ICP on Day I were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to ICP-lowering therapy (p = 0.03), younger age (p <0.0001), fewer hours of elevated ICP (p <0.0001). and absence of arterial hypotension on Day 1 (p = 0.001) significantly predicted reduced risk of death. Conclusions. Patients who responded to ICP-lowering treatment had a 64% lower risk of death at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of death. (DOI: 10.3171/2010.11.JNS101116)	[Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; [Gerber, Linda M.; Chiu, Ya-Lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10021 USA; [Farahvar, Arash] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, MN USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Epidemiol, Portland, OR 97201 USA		Ghajar, J (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, Starr Bldg,Room 651,525 E 68th St,Box 99, New York, NY 10021 USA.	jam@ghajar.net			New York State Department of Health; New York Presbyterian Hospital	The authors would like to thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their support.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BORN JD, 1984, NEUROCHIRURGIE, V30, P329; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; EDDY VA, 1995, AM SURGEON, V61, P24; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FALCAO ALE, 1995, ARQ NEURO-PSIQUIAT, V53, P390, DOI 10.1590/S0004-282X1995000300004; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Lane PL, 2000, CAN J SURG, V43, P442; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Marmarou A, 2005, ACT NEUR S, V95, P277; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peterson E, 2009, J TRAUMA, V67, P944, DOI 10.1097/TA.0b013e3181ae6e6d; Ratanalert Sanguansin, 1992, Journal of the Medical Association of Thailand, V75, P644; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zhang W, 1997, Zhonghua Wai Ke Za Zhi, V35, P114	38	58	65	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2011	114	5					1471	1478		10.3171/2010.11.JNS101116			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	755FW	WOS:000289913900044	21214327				2022-02-06	
J	Toien, K; Bredal, IS; Skogstad, L; Myhren, H; Ekeberg, O				Toien, Kirsti; Bredal, Inger S.; Skogstad, Laila; Myhren, Hilde; Ekeberg, Oivind			Health related quality of life in trauma patients. Data from a one-year follow up study compared with the general population	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							INTENSIVE-CARE-UNIT; POSTTRAUMATIC-STRESS-DISORDER; MAJOR TRAUMA; MULTIPLE TRAUMA; FUNCTIONAL CONSEQUENCES; DEPRESSION SCALE; RECOVERY PROJECT; HOSPITAL ANXIETY; CRITICAL ILLNESS; BRAIN-INJURY	Background: Trauma patients have impaired health-related quality of life (HRQOL) after trauma. The aim of the study was to assess HRQOL during the first year after trauma and hospital stay in trauma patients admitted to an intensive-care unit (ICU) for > 24 hours compared with non-ICU trauma patients and the general population, and to identify predictors of HRQOL. Methods: A prospective one-year follow-up study of 242 trauma patients received by the trauma team of a trauma referral centre in Norway was performed. HRQOL was measured using the Medical Outcomes Study Short Form 36 (SF-36) at 3 and 12 months. Results: The mean age of the cohort was 42.3 years (95% CI, 40.4-44.3 years). The median Injury Severity Score (ISS) was 10, interquartile range 16. The HRQOL improved significantly from the 3 to the 12 months follow up in the trauma patients. However their scores were significantly lower for most subscales of SF-36 compared to the general population. Significant differences between ICU and non-ICU patients at 12 months were observed only for physical functioning and role physical subscales. Optimism was an independent predictor of good HRQOL at 12 months, in all dimensions (beta, 0.95-2.45). A higher depression score at baseline predicted lower HRQOL in four of eight dimensions (beta -1.1 to -1.70). In addition, better physical functioning was predicted by lower age (beta, -0.20), and having head injury (reference) as the most severe injury vs. spine or extremity injuries (beta, -9.49 and -10.85), and better mental health by higher age (beta, 0.21) and being employed or studying before the trauma (beta, 12.27). In addition to optimism good general health was predicted by lower score for post-traumatic stress (PTS) symptoms at baseline (beta, -0.27) and lower ISS score (beta -10.59). Conclusions: The HRQOL improved significantly from the 3 to the 12 months follow up in our sample. However their scores were significantly lower for most subscales of SF-36 compared to the general population. Significant differences between ICU and non-ICU patients were observed for only two subscales. Better HRQOL at 12 months was predicted mainly by optimism, low score for depression and PTS symptoms at baseline. High ISS predicted low general health exclusively.	[Toien, Kirsti; Skogstad, Laila] Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Res & Dev, NO-0424 Oslo, Norway; [Toien, Kirsti] Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Crit Care Nursing, NO-0424 Oslo, Norway; [Bredal, Inger S.] Ulleval Hosp, Oslo Univ Hosp, Unit Breast & Endocrine Surg, NO-0424 Oslo, Norway; [Bredal, Inger S.] Univ Oslo, Fac Med, Inst Hlth & Soc, NO-0315 Oslo, Norway; [Myhren, Hilde] Ulleval Hosp, Oslo Univ Hosp, Dept Cardiol, NO-0424 Oslo, Norway; [Ekeberg, Oivind] Ulleval Hosp, Oslo Univ Hosp, Dept Acute Med, NO-0424 Oslo, Norway; [Ekeberg, Oivind] Univ Oslo, Fac Med, Dept Behav Sci Med, NO-0317 Oslo, Norway		Toien, K (corresponding author), Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Res & Dev, POB 4956, NO-0424 Oslo, Norway.	kirsti.toien@uus.no			Oslo University Hospital; Health region east; University of Oslo	KT was funded by Oslo University Hospital throughout the study. LS was funded by Health region east and Oslo University Hospital. ISB and OE were funded by Oslo University Hospital and University of Oslo. HM received her funding from Health region east.	Aitken LM, 2007, INJURY, V38, P19, DOI 10.1016/j.injury.2006.05.020; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; [Anonymous], 1998, ABBREVIATED INJURY S; Baranyi A, 2010, PSYCHOSOMATICS, V51, P237, DOI 10.1176/appi.psy.51.3.237; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Borg T, 2010, INJURY, V41, P400, DOI 10.1016/j.injury.2009.11.006; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; Crosby RD, 2003, J CLIN EPIDEMIOL, V56, P395, DOI 10.1016/S0895-4356(03)00044-1; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; Granja C, 2008, CRIT CARE MED, V36, P2801, DOI 10.1097/CCM.0b013e318186a3e7; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2001, J TRAUMA, V50, P91, DOI 10.1097/00005373-200101000-00016; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; Kopjar B, 1996, Inj Prev, V2, P135, DOI 10.1136/ip.2.2.135; Loge JH, 1998, J CLIN EPIDEMIOL, V51, P1069, DOI 10.1016/S0895-4356(98)00098-5; Loge JH, 1998, SCAND J SOC MED, V26, P250; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Mata GV, 1996, J TRAUMA, V41, P326, DOI 10.1097/00005373-199608000-00022; Matsuoka Y, 2009, PSYCHIAT CLIN NEUROS, V63, P235, DOI 10.1111/j.1440-1819.2009.01928.x; McClure RJ, 1996, ACCIDENT ANAL PREV, V28, P443, DOI 10.1016/0001-4575(96)00012-7; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Myhren H, 2010, CRIT CARE, V14, DOI 10.1186/cc8870; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Richmond TS, 2009, PSYCHOL MED, V39, P1709, DOI 10.1017/S0033291709005376; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; Schou I, 2005, PSYCHO-ONCOLOGY, V14, P718, DOI 10.1002/pon.896; Schou I, 2004, PSYCHO-ONCOLOGY, V13, P309, DOI 10.1002/pon.747; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Toien K, 2010, J TRAUMA, V69, P1552, DOI 10.1097/TA.0b013e3181e125f3; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Ware J., 2000, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1997, SF 36 HLTH SURVEY MA; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	59	58	59	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 8	2011	19								22	10.1186/1757-7241-19-22			12	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	760KH	WOS:000290322700001	21477280	Green Published, gold			2022-02-06	
J	Rao, KVR; Reddy, PVB; Curtis, KM; Norenberg, MD				Rao, Kakulavarapu V. Rama; Reddy, Pichili V. B.; Curtis, Kevin M.; Norenberg, Michael D.			Aquaporin-4 Expression in Cultured Astrocytes after Fluid Percussion Injury	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; astrocyte swelling; brain edema; Na+,K+,Cl- co-transporter; oxidative/nitrative stress; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; FOCAL CEREBRAL-ISCHEMIA; V1A RECEPTOR ANTAGONIST; CORTICAL IMPACT INJURY; OXIDATIVE STRESS; WATER CHANNELS; CYCLOSPORINE-A; PERMEABILITY TRANSITION	The development of cytotoxic brain edema resulting in increased intracranial pressure is a major cause of death occurring in the early phase of traumatic brain injury (TBI). Such edema predominantly develops as a consequence of astrocyte swelling. We recently documented that fluid percussion injury (FPI) to cultured astrocytes causes cell swelling. Since aquaporin-4 (AQP4) has been strongly implicated in the development of brain edema/astrocyte swelling in various neurological conditions, this study examined the effect of in vitro trauma on AQP4 protein expression in cultured astrocytes. Exposure of astrocytes to FPI resulted in a significant upregulation of AQP4 protein in the plasma membrane due to neosynthesis, as cycloheximide blocked the trauma-induced AQP4 upregulation. Silencing the aqp4 gene by siRNA resulted in a significant reduction in trauma-induced astrocyte swelling, indicating a critical role of AQP4 in this process. We recently documented that oxidative/nitrative stress (ONS), the mitochondrial permeability transition (mPT), and activation of mitogen-activated protein kinases (MAPKs), contribute to trauma-induced astrocyte swelling in culture. We now show that inhibition of these factors reduces the upregulation of AQP4 following trauma. Since TBI has been shown to activate nuclear factor-kappa B (NF-kappa B), as well as the Na+, K+, Cl- co-transporter (NKCC), both of which are implicated in brain edema/astrocyte swelling in other conditions, we also examined the effect of BAY 11-7082 and bumetanide, inhibitors of NF-kappa B and NKCC, respectively, and found that these agents also significantly inhibited the trauma-induced-AQP4 upregulation. Our findings show that in vitro trauma upregulates AQP4, and that ONS, MAPKs, mPT, NF-kappa B, and NKCC are involved in its upregulation.	[Rao, Kakulavarapu V. Rama; Reddy, Pichili V. B.; Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Curtis, Kevin M.; Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33125 USA		Norenberg, MD (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu	Curtis, Kevin/B-8020-2011	Curtis, Kevin/0000-0002-7480-1818	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. We are grateful to Alina Fernandez for preparation of astrocyte cultures.	Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauer R, 1999, EXP TOXICOL PATHOL, V51, P143, DOI 10.1016/S0940-2993(99)80088-8; Bemeur C, 2005, NEUROCHEM INT, V46, P399, DOI 10.1016/j.neuint.2004.11.007; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Gaitanaki C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/jeb.00483; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hao W, 2009, BRAIN RES, V1282, P156, DOI 10.1016/j.brainres.2009.05.041; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; JAYAKUMAR AR, NEUROBIOL D IN PRESS; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nielsen S, 1997, J NEUROSCI, V17, P171; Norenberg MD, 2005, METAB BRAIN DIS, V20, P303, DOI 10.1007/s11011-005-7911-7; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pasantes-Morales H, 2010, NEUROSCIENCE, V168, P871, DOI 10.1016/j.neuroscience.2009.11.074; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Rao KVR, 2010, AM J PATHOL, V176, P1400, DOI 10.2353/ajpath.2010.090756; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	79	58	70	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					371	381		10.1089/neu.2010.1705			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600004	21204635				2022-02-06	
J	Jacobs, B; Beems, T; van der Vliet, TM; Diaz-Arrastia, RR; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; van der Vliet, Ton M.; Diaz-Arrastia, Ramon R.; Borm, George F.; Vos, Pieter E.			Computed Tomography and Outcome in Moderate and Severe Traumatic Brain Injury: Hematoma Volume and Midline Shift Revisited	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; hematoma; midline shift; outcome; severe traumatic brain injury	SEVERE HEAD-INJURY; COMA DATA-BANK; ADMISSION CHARACTERISTICS; PROGNOSTIC MODELS; CLASSIFICATION; PREDICTION; VALIDATION; HEMORRHAGE; IMPACT; LESION	Intracranial lesion volume and midline shift are powerful outcome predictors in moderate and severe traumatic brain injury (TBI), and therefore they are used in TBI and computed tomography (CT) classification schemes, like the Traumatic Coma Data Bank (TCDB) classification. In this study we aimed to explore the prognostic value of lesion volume and midline shift in moderate and severe TBI as measured from acute cranial CT scans. Also, we wanted to determine interrater reliability for the evaluation of these CT abnormalities. We included all consecutive moderate and severe TBI patients admitted to our hospital who were aged >= 16 years, over an 8-year period, as part of the prospective Radboud University Brain Injury Cohort Study. Six months post-trauma we assessed outcomes using the Glasgow Outcome Scale-Extended (GOS-E). We analyzed 605 patients and found an association of both lesion volume and midline shift with outcome; increases were associated with a higher frequency of patients with an unfavorable outcome or death. A cut-off value, such as that used in the TCDB CT classification (lesion volume 25 mL and midline shift 5 mm), was not found. The average interrater difference in volume measurement was 6.8 mL, and it was 0.2 mm for the determination of degree of shift. Using lesion volume and midline shift as continuous variables in prognostic models might be preferable over the use of threshold values, although an association of these variables with outcome in relation to other CT abnormalities was not tested. The data provided here will be useful for stratification of patients enrolled in clinical trials of neuroprotective therapies.	[Jacobs, Bram; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] Radboud Univ Nijmegen, Dept Radiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Borm, George F.] Radboud Univ Nijmegen, Dept Epidemiol Biostat & HTA, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA		Vos, PE (corresponding author), Radboud Univ Nijmegen, Dept Neurol 935, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012	Diaz-Arrastia, Ramon/0000-0001-6051-3594			*AAAM, 2001, ABBR INJ SCAL 1990 R; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P597; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOKSEY M, 1993, BRIT J NEUROSURG, V7, P611, DOI 10.3109/02688699308995090; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	51	58	58	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					203	215		10.1089/neu.2010.1558			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700004	21294647				2022-02-06	
J	Petzold, A; Tisdall, MM; Girbes, AR; Martinian, L; Thom, M; Kitchen, N; Smith, M				Petzold, Axel; Tisdall, Martin M.; Girbes, Armand R.; Martinian, Lillian; Thom, Maria; Kitchen, Neil; Smith, Martin			In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study	BRAIN			English	Article						extracellular fluid; interstitial fluid; neurocritical care; neurodegeneration; neurofilaments	DIFFUSE AXONAL INJURY; POSITRON-EMISSION-TOMOGRAPHY; NEUROFILAMENT HEAVY-CHAIN; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-BLOOD-FLOW; PC12 CELLS; THERAPEUTIC HYPOTHERMIA; NORMOBARIC HYPEROXIA; OXYGEN-TOXICITY; PHOSPHORYLATION	Traumatic brain injury causes diffuse axonal injury and loss of cortical neurons. These features are well recognized histologically, but their in vivo monitoring remains challenging. In vivo cortical microdialysis samples the extracellular fluid adjacent to neurons and axons. Here, we describe a novel neuronal proteolytic pathway and demonstrate the exclusive neuro-axonal expression of Pavlov's enterokinase. Enterokinase is membrane bound and cleaves the neurofilament heavy chain at positions 476 and 986. Using a 100 kDa microdialysis cut-off membrane the two proteolytic breakdown products, extracellular fluid neurofilament heavy chains NfH(476-986) and NfH(476-1026), can be quantified with a relative recovery of 20%. In a prospective clinical in vivo study, we included 10 patients with traumatic brain injury with a median Glasgow Coma Score of 9, providing 640 cortical extracellular fluid samples for longitudinal data analysis. Following high-velocity impact traumatic brain injury, microdialysate extracellular fluid neurofilament heavy chain levels were significantly higher (6.18 +/- 2.94 ng/ml) and detectable for longer (> 4 days) compared with traumatic brain injury secondary to falls (0.84 +/- 1.77 ng/ml, < 2 days). During the initial 16 h following traumatic brain injury, strong correlations were found between extracellular fluid neurofilament heavy chain levels and physiological parameters (systemic blood pressure, anaerobic cerebral metabolism, excessive brain tissue oxygenation, elevated brain temperature). Finally, extracellular fluid neurofilament heavy chain levels were of prognostic value, predicting mortality with an odds ratio of 7.68 (confidence interval 2.15-27.46, P = 0.001). In conclusion, this study describes the discovery of Pavlov's enterokinase in the human brain, a novel neuronal proteolytic pathway that gives rise to specific protein biomarkers (NfH(476-986) and Nf(H476-1026)) applicable to in vivo monitoring of diffuse axonal injury and neuronal loss in traumatic brain injury.	[Petzold, Axel] Natl Hosp Neurol & Neurosurg, Dept Neuroimmunol, Tavistock Intens Care Unit, London WC1N 3BG, England; [Petzold, Axel; Tisdall, Martin M.] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, London WC1N 3BG, England; [Petzold, Axel] UCL Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; [Petzold, Axel; Girbes, Armand R.] Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1081 HV Amsterdam, Netherlands; [Martinian, Lillian; Thom, Maria] UCL Inst Neurol, Div Neuropathol, London WC1N 3BG, England; [Kitchen, Neil] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, London WC1N 3BG, England; [Smith, Martin] Natl Hosp Neurol & Neurosurg, Ctr Neuroanaesthesia, London WC1N 3BG, England; [Smith, Martin] Natl Hosp Neurol & Neurosurg, Tavistock Intens Care Unit, London WC1N 3BG, England		Petzold, A (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuroimmunol, Tavistock Intens Care Unit, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Smith, Martin/B-2616-2009; Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749; Tisdall, Martin/0000-0001-8880-8386	Department of Health's National Institute for Health Research Centres, University College London Hospitals; Wellcome Clinical Research Fellow [075608]; Department of Health's NIHR Biomedical Research CentreNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701458] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish	Wellcome Clinical Research Fellow (Grant No. 075608 to M. T.); Department of Health's National Institute for Health Research Centres funding scheme, University College London Hospitals (partial). This work was undertaken at UCLH/UCL, who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre funding scheme.	Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Afinowi R, 2009, J NEUROSCI METH, V181, P95, DOI 10.1016/j.jneumeth.2009.02.021; Arieli R, 2008, EUR J APPL PHYSIOL, V104, P867, DOI 10.1007/s00421-008-0843-2; Arieli R, 2006, AVIAT SPACE ENVIR MD, V77, P1153; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; Boulware KT, 2006, P NATL ACAD SCI USA, V103, P7583, DOI 10.1073/pnas.0511108103; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Corbo J, 2004, ANN EMERG MED, V44, P57, DOI 10.1016/j.annemergmed.2003.11.010; Dashiell SM, 2002, J NEUROCHEM, V81, P1263, DOI 10.1046/j.1471-4159.2002.00927.x; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Ericsson C, 2007, ACTA ONCOL, V46, P10, DOI 10.1080/02841860600847061; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gieron MA, 1998, PEDIATR NEUROL, V19, P382, DOI 10.1016/S0887-8994(98)00072-1; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kirkpatrick J B, 1983, Acta Neurochir Suppl (Wien), V32, P115; Kitson R, 2005, CRITICAL CARE, V9, pE28; Langlois J. A., 2006, TRAUMATIC BRAIN INJU, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEE VMY, 1985, J NEUROSCI, V5, P3039; Leissring MA, 2008, J BIOL CHEM, V283, P29645, DOI 10.1074/jbc.R800022200; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LINDENBAUM MH, 1987, J BIOL CHEM, V262, P605; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Littell RC, 1998, J ANIM SCI, V76, P1216; Ma M, 2009, EXP NEUROL, V215, P119, DOI 10.1016/j.expneurol.2008.09.024; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Pavlov IP, 1910, WORK DIGESTIVE GLAND; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2008, EXP NEUROL, V213, P326, DOI 10.1016/j.expneurol.2008.06.008; Petzold A, 2007, NEUROL RES, V29, P691, DOI 10.1179/016164107X240080; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Sairanen T, 2009, ACTA NEUROPATHOL, V118, P541, DOI 10.1007/s00401-009-0559-3; Schepowalnikow N, 1899, THESIS ST PETERSBURG; Schutze K, 2007, METHOD CELL BIOL, V82, P649, DOI 10.1016/S0091-679X(06)82023-6; Shaw, 1998, NEUROFILAMENTS; Shin HK, 2007, BRAIN, V130, P1631, DOI 10.1093/brain/awm071; Smith M, 2003, TRAUMA, V5, P1; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; Sulejczak D, 2008, FOLIA NEUROPATHOL, V46, P213; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vilen ST, 2008, EXP CELL RES, V314, P914, DOI 10.1016/j.yexcr.2007.10.025; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1	80	58	61	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	FEB	2011	134		2				464	483		10.1093/brain/awq360			20	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	716RI	WOS:000286990800014	21278408	Green Published, hybrid, Green Submitted			2022-02-06	
J	Genet, F; Jourdan, C; Schnitzler, A; Lautridou, C; Guillemot, D; Judet, T; Poiraudeau, S; Denormandie, P				Genet, Francois; Jourdan, Claire; Schnitzler, Alexis; Lautridou, Christine; Guillemot, Didier; Judet, Thierry; Poiraudeau, Serge; Denormandie, Philippe			Troublesome Heterotopic Ossification after Central Nervous System Damage: A Survey of 570 Surgeries	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HUMORAL-FACTORS; EARLY EXCISION; BONE-FORMATION; RISK-FACTORS; HEAD-TRAUMA; RESECTION; CLASSIFICATION; ELBOW	Background: Heterotopic ossification (HO) is a frequent complication after central nervous system (CNS) damage but has seldom been studied. We aimed to investigate features of HO for the first time in a large sample and the rate of early recurrence of HO in terms of the time of surgery. Methodology/Principal Findings: We retrospectively analyzed data from an anonymous prospective survey of patients undergoing surgery between May 1993 and November 2009 in our institution for troublesome HO related to acquired neurological disease. Demographic and HO characteristics and neurological etiologies were recorded. For 357 consecutive patients, we collected data on 539 first surgeries for HO (129 surgeries for multiple sites). During the follow-up, recurrences requiring another surgery appeared in 31 cases (5.8% [31/539]; 95% confidence interval [CI]: 3.8%-7.8%; 27 patients). Most HO requiring surgery occurred after traumatic brain injury (199 patients [55.7%]), then spinal cord injury (86 [24.0%]), stroke (42 [11.8%]) and cerebral anoxia (30 [8.6%]). The hip was the primary site of HO (328 [60.9%]), then the elbow (115 [21.3%]), knee (77 [14.3%]) and shoulder (19 [3.5%]). For all patients, 181 of the surgeries were performed within the first year after the CNS damage, without recurrence of HO. Recurrence was not associated with etiology (p = 0.46), sex (p = 1.00), age at CNS damage (p = 0.2), multisite localization (p = 0.34), or delay to surgery (p = 0.7). Conclusions/Significance: In patients with CNS damage, troublesome HO and recurrence occurs most frequently after traumatic brain injury and appears frequently in the hip and elbow. Early surgery for HO is not a factor of recurrence.	[Genet, Francois; Jourdan, Claire; Schnitzler, Alexis] Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches, France; [Lautridou, Christine; Judet, Thierry; Denormandie, Philippe] Hop Raymond Poincare, Serv Chirurg Orthoped & Traumatol, Garches, France; [Guillemot, Didier] Hop Raymond Poincare, Unite Fonct Sante Publ, Garches, France; [Poiraudeau, Serge] Hop Cochin, Serv Med Phys & Readaptat, F-75674 Paris, France		Genet, F (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches, France.	francois.genet@rpc.aphp.fr	POIRAUDEAU, SERGE/P-5301-2016; Guillemot, Didier/AAN-3051-2020	Poiraudeau, Serge/0000-0002-1988-9124; Guillemot, Didier/0000-0002-8497-1765			Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053; Beingessner DM, 2000, J HAND SURG-AM, V25A, P483, DOI 10.1053/jhsu.2000.6922; BRAVOPAYNO P, 1992, PARAPLEGIA, V30, P740, DOI 10.1038/sc.1992.142; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613; Chalidis B, 2007, J NEUROTRAUM, V24, P1675, DOI 10.1089/neu.2007.0342; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; Cipriano C, 2009, ORTHOPEDICS, V32; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Cullen N, 2007, BRAIN INJURY, V21, P215, DOI 10.1080/02699050701202027; da Paz AC, 2007, MED HYPOTHESES, V68, P67, DOI 10.1016/j.mehy.2006.06.035; de Palma L, 2002, ORTHOPEDICS, V25, P665; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Fuller DA, 2005, CLIN ORTHOP RELAT R, P197, DOI 10.1097/01.blo.0000170718.86747.da; GARLAND DE, 1989, CLIN ORTHOP RELAT R, P169; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Genet F, 2009, J BONE JOINT SURG BR, V91B, P1493, DOI 10.1302/0301-620X.91B11.22305; HARAN M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003321.PUB3; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Lazarus MD, 1999, NEUROREHABILITATION, V12, P145; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; Pelissier J., 2002, Annales de Readaptation et de Medecine Physique, V45, P188, DOI 10.1016/S0168-6054(02)00202-7; Riklin C, 2003, SPINAL CORD, V41, P192, DOI 10.1038/sj.sc.3101421; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; Shehab D, 2002, J NUCL MED, V43, P346; Silver J R, 1969, Paraplegia, V7, P220; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Toffoli AM, 2008, BRAIN INJURY, V22, P511, DOI 10.1080/02699050802158235; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628	37	58	60	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16632	10.1371/journal.pone.0016632			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	WOS:000286834300104	21304993	Green Published, Green Submitted, gold			2022-02-06	
J	Wishart, HA; Roth, RM; Saykin, AJ; Rhodes, CH; Tsongalis, GJ; Pattin, KA; Moore, JH; McAllister, TW				Wishart, Heather A.; Roth, Robert M.; Saykin, Andrew J.; Rhodes, C. Harker; Tsongalis, Gregory J.; Pattin, Kristine A.; Moore, Jason H.; McAllister, Thomas W.			COMT Va158Met Genotype and Individual Differences in Executive Function in Healthy Adults	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognition; Neuropsychological tests; Executive control; Catechol-O-methyltransferase; Polymorphism; Epistasis	CATECHOL-O-METHYLTRANSFERASE; VAL(108/158) MET GENOTYPE; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; VAL(158)MET POLYMORPHISM; MOLECULAR-GENETICS; KINASE GENE; DOPAMINE; COGNITION; HIPPOCAMPAL	The Val158Met polymorphism of the catechol-O-methyltransferase (COMT) gene may be related to individual differences in cognition, likely via modulation of prefrontal dopamine catabolism. However, the available studies have yielded mixed results, possibly in part because they do not consistently account for other genes that affect cognition. We hypothesized that COMT Met allele homozygosity, which is associated with higher levels of prefrontal dopamine, would predict better executive function as measured using standard neuropsychological testing, and that other candidate genes might interact with COMT to modulate this effect. Participants were 95 healthy, right-handed adults who underwent genotyping and cognitive testing. COMT genotype predicted executive ability as measured by the Trail-Making Test, even after covarying for demographics and Apolipoprotein E (APOE), brain-derived neurotrophic factor (BDNF), and ankyrin repeat and kinase domain containing 1 (ANKK 1) genotype. There was a COMT-ANKK 1 interaction in which individuals having both the COMT Val allele and the ANKK 1 T allele showed the poorest performance. This study suggests the heterogeneity in COMT effects reported in the literature may be due in part to gene gene interactions that influence central dopaminergic systems. (JINS, 2011, 17, 174-180)	[Wishart, Heather A.] Dartmouth Med Sch, DHMC, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03756 USA; [Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN USA; [Rhodes, C. Harker; Tsongalis, Gregory J.] Dartmouth Med Sch, Dept Pathol, Lebanon, NH 03756 USA; [Pattin, Kristine A.; Moore, Jason H.] Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA		Wishart, HA (corresponding author), Dartmouth Med Sch, DHMC, Dept Psychiat, Neuropsychol Program, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	wishart@dartmouth.edu	Moore, Jason H./AAV-9645-2021; Saykin, Andrew/A-1318-2007	Moore, Jason H./0000-0002-5015-1099; Saykin, Andrew/0000-0002-1376-8532	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS045830, R03NS056228, R01NS40472]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG3248, PP1214]; Hitchcock Foundation; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771]; National Institute on Disability and Rehabilitation Research [H133670031, H133G000136]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176]; Ira DeCamp Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA101318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472, R03NS056228, K23NS045830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER	Supported in part by the National Institute of Neurological Disorders and Stroke (K23NS045830, R03NS056228, R01NS40472), National Multiple Sclerosis Society (RG3248, PP1214), Hitchcock Foundation, National Institute on Aging (R01AG019771), National Institute on Disability and Rehabilitation Research (H133670031, H133G000136), National Institute of Child Health and Development (R01HD048176) and Ira DeCamp Foundation. No conflicts exist.	Barnett JH, 2008, BIOL PSYCHIAT, V64, P137, DOI 10.1016/j.biopsych.2008.01.005; BARNETT JH, 2009, BIOL PSYCHIAT, V65, pE3; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542; Bookheimer S, 2009, ANNU REV CLIN PSYCHO, V5, P343, DOI 10.1146/annurev.clinpsy.032408.153625; Briand LA, 2007, PROG NEUROBIOL, V83, P69, DOI 10.1016/j.pneurobio.2007.06.007; Cerasa A, 2008, NEUROREPORT, V19, P405, DOI 10.1097/WNR.0b013e3282f5f784; Colzato LS, 2010, NEUROPSYCHOLOGIA, V48, P2764, DOI 10.1016/j.neuropsychologia.2010.04.023; Cowansage Kiriana K, 2010, Curr Mol Pharmacol, V3, P12; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dickinson D, 2009, NEUROSCIENCE, V164, P72, DOI 10.1016/j.neuroscience.2009.05.014; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Funke B, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-19; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Koch W, 2002, CLIN CHEM LAB MED, V40, P1123, DOI 10.1515/CCLM.2002.197; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Meyer-Lindenberg A, 2006, MOL PSYCHIATR, V11, P867, DOI 10.1038/sj.mp.4001860; Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Parasuraman R, 2002, NEUROPSYCHOLOGY, V16, P254, DOI 10.1037//0894-4105.16.2.254; Ponce G, 2009, NEUROTOX RES, V16, P50, DOI 10.1007/s12640-009-9046-9; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reitz C, 2009, NEUROSCIENCE, V164, P174, DOI 10.1016/j.neuroscience.2009.04.006; Reuter M, 2006, INT J NEUROPSYCHOPH, V9, P155, DOI 10.1017/S1461145705005419; Reuter M, 2005, BEHAV BRAIN RES, V164, P93, DOI 10.1016/j.bbr.2005.06.002; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Savitz J, 2006, BRAIN RES REV, V51, P125, DOI 10.1016/j.brainresrev.2005.10.006; Stelzel C, 2009, EUR J NEUROSCI, V29, P1056, DOI 10.1111/j.1460-9568.2009.06647.x; Tan HY, 2007, P NATL ACAD SCI USA, V104, P12536, DOI 10.1073/pnas.0610125104; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Xu HY, 2007, SCHIZOPHR RES, V90, P104, DOI 10.1016/j.schres.2006.10.001; Zinkstok J, 2006, NEUROSCI LETT, V405, P34, DOI 10.1016/j.neulet.2006.06.034	38	58	58	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2011	17	1					174	180		10.1017/S1355617710001402			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	702KX	WOS:000285894700019	21144101	Green Accepted			2022-02-06	
J	Robertson, CS; Zager, EL; Narayan, RK; Handly, N; Sharma, A; Hanley, DF; Garza, H; Maloney-Wilensky, E; Plaum, JM; Koenig, CH; Johnson, A; Morgan, T				Robertson, Claudia S.; Zager, Eric L.; Narayan, Raj K.; Handly, Neal; Sharma, Alok; Hanley, Daniel F.; Garza, Homero; Maloney-Wilensky, Eileen; Plaum, Justin M.; Koenig, Carolyn H.; Johnson, Anne; Morgan, Timothy			Clinical Evaluation of a Portable Near-Infrared Device for Detection of Traumatic Intracranial Hematomas	JOURNAL OF NEUROTRAUMA			English	Article						head injury; intracranial hematomas; near-infrared spectroscopy; traumatic brain injury	SPECTROSCOPY	The purpose of this multicenter observational clinical study was to evaluate the performance of a near-infrared (NIR)-based, non-invasive, portable device to screen for traumatic intracranial hematomas. Five trauma centers collected data using the portable NIR device at the time a computed tomography (CT) scan was performed to evaluate a suspected traumatic brain injury (TBI). The CT scans were read by an independent neuroradiologist who was blinded to the NIR measurements. Of 431 patients enrolled, 365 patients were included in the per-protocol population analyzed. Of the 365 patients, 96 were determined by CT scan to have intracranial hemorrhages of various sizes, depths, and anatomical locations. The NIR device demonstrated sensitivity of 88% (95% confidence interval [CI] 74.9,95.0%), and specificity of 90.7% (95% CI 86.4,93.7%), in detecting the 50 intracranial hematomas that were large enough to be clinically important (larger than 3.5mL in volume), and that were less than 2.5 cm from the surface of the brain. For all 96 cases with intracranial hemorrhage, regardless of size and type of hemorrhage, the sensitivity was 68.7% (CI 58.3,77.6%), and specificity was 90.7% (CI 86.4,93.7%). These results confirm the results of previous studies that indicate that a NIR-based portable device can reliably screen for intracranial hematomas that are superficial and of a size likely to be of clinical importance. The NIR device cannot replace CT scanning in the diagnosis of TBI, but the device might be useful to supplement clinical information used to triage TBI patients, and in situations in which CT scanning is not readily available.	[Robertson, Claudia S.; Garza, Homero] Baylor Univ, Dept Neurosurg, Houston, TX 77030 USA; [Zager, Eric L.] Dept Neurosurg, Philadelphia, PA USA; [Maloney-Wilensky, Eileen] Neurosurg Clin Res Div, Philadelphia, PA USA; [Narayan, Raj K.] N Shore Univ Hosp, Dept Neurosurg, Manhasset, NY USA; [Handly, Neal] Drexel Univ, Dept Emergency Med, Coll Med, Philadelphia, PA 19104 USA; [Johnson, Anne] Drexel Univ, Clin Res Grp, Coll Med, Philadelphia, PA 19104 USA; Hahnemann Hosp, Philadelphia, PA USA; [Sharma, Alok] Lokmanya Tilak Municipal Gen Hosp, Dept Neurosurg, Bombay, Maharashtra, India; [Hanley, Daniel F.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Hanley, Daniel F.] Johns Hopkins Univ, Dept Neurosurg & Anesthesia Crit Med, Baltimore, MD 21218 USA; [Koenig, Carolyn H.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Koenig, Carolyn H.] Univ Cincinnati, Coll Med, Mayfield Clin, Cincinnati, OH 45267 USA; [Morgan, Timothy] Johns Hopkins Univ, Div Brain Injury Outcomes, Clin Reading Ctr, Baltimore, MD USA; [Plaum, Justin M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA		Robertson, CS (corresponding author), Baylor Univ, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu		Hanley, Daniel/0000-0002-9536-4258	InfraScan, Inc.	This study was supported by InfraScan, Inc. We thank Meltem Izzetoglu, Ph.D. from Drexel University, who provided statistical analysis for the study.	ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; Cope M, 1991, THESIS U COLL LONDON; FLETCHER RH, 1997, CLIN EPIDEMIOLOGY; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Francis SV, 2005, J CLIN NEUROSCI, V12, P291, DOI 10.1016/j.jocn.2004.06.009; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Kessel B, 2007, INJURY, V38, P1065, DOI 10.1016/j.injury.2007.05.009; Marion DW, 2006, NEUROSURGERY, V58, P655; Robertson C S, 1997, J Biomed Opt, V2, P31, DOI 10.1117/12.261680; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0; [No title captured]	13	58	61	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1597	1604		10.1089/neu.2010.1340			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500006	20568959				2022-02-06	
J	Stuart, RM; Schmidt, M; Kurtz, P; Waziri, A; Helbok, R; Mayer, SA; Lee, K; Badjatia, N; Hirsch, LJ; Connolly, ES; Claassen, J				Stuart, R. Morgan; Schmidt, Michael; Kurtz, Pedro; Waziri, Allen; Helbok, Raimund; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Hirsch, Lawrence J.; Connolly, E. Sander; Claassen, Jan			Intracranial Multimodal Monitoring for Acute Brain Injury: A Single Institution Review of Current Practices	NEUROCRITICAL CARE			English	Article						Intracranial monitoring; Multimodality brain monitoring; Acute brain injury; Microdialysis; Brain oxygen; Neurological intensive care unit; Subarachnoid hemorrhage; Intracerebral hemorrhage; Traumatic brain injury; Stroke; Depth electrode; Neurocritical care; EEG; Nonconvulsive seizures; Intracortical EEG (ICE)	CEREBRAL PERFUSION-PRESSURE; PROVINCIAL TRAUMA CENTER; FRESH-FROZEN PLASMA; WAVE-FORM ANALYSIS; DELIVERY 1 YEAR; HEAD-INJURY; TISSUE OXYGEN; SUBARACHNOID HEMORRHAGE; RESOURCE UTILIZATION; CLINICAL-EXPERIENCE	Critical care management of patients with severe acute brain injury has undergone tremendous advances. Neurosurgeons and neurointensivists have a large armamentarium of invasive monitoring devices available to help detect secondary brain injury and guide therapy. No consensus exists regarding patient specific selection of monitoring devices, the placement of devices in relation to injured brain tissue, or the preferred insertion technique. Here we review our experience in a consecutive series of acutely brain injured patients who underwent multimodality monitoring. Sixty-one patients admitted to the Neurological Intensive Care Unit underwent multimodality intracranial monitoring between January 2005 and October 2008. Patient demographics, hospital length of stay, types of monitoring devices and modalities monitored, insertion techniques, device placement location relative to injury, and complications are reported. Monitored modalities included brain tissue oxygen (PbtO(2)) in 97% (N = 59), microdialysis (MD) in 79% (N = 48), intracranial electroencephalography in 31% (N = 19), brain temperature in 18% (N = 11), and cerebral blood flow in 11% (N = 7). On average, monitoring started within 2 days (0-8) of admission and was continued for 7 days (1-17). The majority of probes (56%; N = 35) were placed into patients with focal brain injuries, while in 43% N = 26 the injury was diffuse. Among those with focal injury, probe placement was categorized as peri-lesional in 46% (N = 16), and within a clot or infarct in 17% (N = 6). The most frequent complication of multimodality brain monitoring was device malfunction or dislodgement (43%; N = 26). Rates of hematoma and infection were 3 and 5%, respectively. Average NICU length of stay was 17 days (3-48) and 26% (N = 16) of patients were dead at discharge. Collaboration among institutions is necessary to establish practice guidelines for the choice and placement of multimodal monitors. Further advancement in device technology is needed to improve insertion techniques, inter-device compatibility, and device durability. Multimodality data needs to be analyzed to determine the preferable device location.	[Schmidt, Michael; Kurtz, Pedro; Helbok, Raimund; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Claassen, Jan] Columbia Univ, Div Crit Care Neurol, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA; [Stuart, R. Morgan; Waziri, Allen; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Connolly, E. Sander; Claassen, Jan] Columbia Univ, Dept Neurol Surg, Coll Phys & Surg, New York, NY 10032 USA; [Hirsch, Lawrence J.; Claassen, Jan] Columbia Univ, Dept Neurol, Coll Phys & Surg, Comprehens Epilepsy Ctr, New York, NY 10032 USA		Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, Dept Neurol, Coll Phys & Surg, 177 Ft Washington Ave,Milstein 8 Ctr Room 300, New York, NY 10032 USA.	jclaassen@neuro.columbia.edu	Claassen, Jan/AAA-5451-2020; Badjatia, Neeraj/AAS-4855-2021; Helbok, Raimund/AAA-8361-2021	Badjatia, Neeraj/0000-0003-1509-9034; Hirsch, Lawrence/0000-0002-6333-832X			[Anonymous], 1994, JAMA, V271, P777; Bardt TF, 1998, ACTA NEUROCHIR, V140, P357, DOI 10.1007/s007010050109; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P551; Birch AA, 2006, NEUROCRIT CARE, V5, P51, DOI 10.1385/NCC:5:1:51; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; CZOSNYKA M, 1992, ACTA NEUROCHIR, V115, P90, DOI 10.1007/BF01406364; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Hlatky R, 2001, SEMIN RESP CRIT CARE, V22, P3, DOI 10.1055/s-2001-13835; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.neu.0000316273.35833.7c, 10.1227/01.NEU.0000017465.78245.6C]; Mack William J, 2003, Neurosurg Focus, V14, pe3; Meixensberger J, 1998, ACT NEUR S, V71, P260; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Radolovich DK, 2009, NEUROCRIT CARE, V10, P274, DOI 10.1007/s12028-009-9190-3; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Simons R, 1999, J TRAUMA, V46, P811, DOI 10.1097/00005373-199905000-00008; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Steiner T, 2001, STROKE, V32, P2500, DOI 10.1161/hs1101.097400; Stewart C, 2008, NEUROSURGERY, V63, P1159, DOI 10.1227/01.NEU.0000333265.19131.7C; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Waziri AE, 2007, EPILEPSIA, V48, P208; Winchell RJ, 1998, J TRAUMA, V45, P104	33	58	59	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2010	12	2					188	198		10.1007/s12028-010-9330-9			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	573IL	WOS:000275905800008	20107926				2022-02-06	
J	Koutures, CG; Gregory, AJM				Koutures, Chris G.; Gregory, Andrew J. M.		Council Sports Med Fitness	Clinical Report-Injuries in Youth Soccer	PEDIATRICS			English	Article						soccer; concussion; knee injury; anterior cruciate ligament tear	CRUCIATE LIGAMENT INJURIES; FOOTBALL SOCCER; HEAD-INJURIES; CONSENSUS STATEMENT; BRAIN-INJURY; RISK-FACTORS; FEMALE; CONCUSSIONS; PLAYERS	Injury rates in youth soccer, known as football outside the United States, are higher than in many other contact/collision sports and have greater relative numbers in younger, preadolescent players. With regard to musculoskeletal injuries, young females tend to suffer more knee injuries, and young males suffer more ankle injuries. Concussions are fairly prevalent in soccer as a result of contact/collision rather than purposeful attempts at heading the ball. Appropriate rule enforcement and emphasis on safe play can reduce the risk of soccer-related injuries. This report serves as a basis for encouraging safe participation in soccer for children and adolescents. Pediatrics 2010; 125:410-414									*AM YOUTH SOCC ORG, AB AYSO; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Bergeron Michael F, 2007, New Dir Youth Dev, P27; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; *CDCP, HEADS CONC HIGH SCH; *CINC CHILDR HOSP, ACL INJ TREATM PREV; Collins CL, 2008, INJURY PREV, V14, P34, DOI 10.1136/ip.2007.017277; Crichlow R, 2006, CLIN J SPORT MED, V16, P352, DOI 10.1097/00042752-200607000-00012; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 2005, CLIN J SPORT MED, V15, P212; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Emery CA, 2006, AM J SPORT MED, V34, P1636, DOI 10.1177/0363546506288018; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Houshian S, 2000, BRIT J SPORT MED, V34, P218, DOI 10.1136/bjsm.34.3.218; Ireland ML, 2002, ORTHOP CLIN N AM, V33, P637, DOI 10.1016/S0030-5898(02)00028-7; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Kakavelakis KN, 2003, SCAND J MED SCI SPOR, V13, P175, DOI 10.1034/j.1600-0838.2003.00294.x; Kirkendall D. T., 2002, Medicine & Science in Sports & Exercise, V34, pS101; Le Gall F, 2008, AM J SPORT MED, V36, P276, DOI 10.1177/0363546507307866; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; *NAT FED HIGH SCH, 2008, HIGH SCH ATHL PART S; *NAT SPORT GOODS A, PART RANK ALPH; PATLAK M, 2002, SOCCER BAD CHILDRENS; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; *SANT MON ORTHP SP, ACL PREV PROJ; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; Sullivan J. A., 2000, CARE YOUNG ATHLETE; *US CONS PROD SAF, 2007, NAT EL INJ SURV SYST; *US CONS PROD SAF, 1995, GUID MOV SOCC GOAL S; US Youth Soccer Association, HIST US SOCC; Vinger PF, 2000, PHYSICIAN SPORTSMED, V28, P49, DOI 10.3810/psm.2000.06.961; Washington RL, 2004, PEDIATRICS, V113, P619; Wong P, 2005, BRIT J SPORT MED, V39, P473, DOI 10.1136/bjsm.2004.015511; Youn J, 2008, MED SCI SPORT EXER, V40, P428, DOI [10.1249/mss.0b013e31815e7263, 10.1249/MSS.0b013e31815e7263]	49	58	58	5	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					410	414		10.1542/peds.2009-3009			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	573VH	WOS:000275942900028	20100755	Bronze			2022-02-06	
J	Rochat, L; Beni, C; Billieux, J; Azouvi, P; Annoni, JM; Van der Linden, M				Rochat, Lucien; Beni, Catia; Billieux, Joel; Azouvi, Philippe; Annoni, Jean-Marie; Van der Linden, Martial			Assessment of impulsivity after moderate to severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						TBI; Impulsivity; Executive functions; UPPS	BEHAVIOR SCALE; DECISION-MAKING; 4-FACTOR MODEL; PERSONALITY; FACETS; PERFORMANCE; ADAPTATION; DEFICITS	The aim of the study was to develop and validate a short questionnaire assessing four dimensions of impulsivity (urgency, lack of premeditation, lack of perseverance, sensation seeking) in patients with traumatic brain injury (TBI). To this end, 82 patients with TBI and their caregivers completed a short questionnaire adapted from the UPPS Impulsive Behavior Scale designed to assess impulsivity changes after TBI. Confirmatory factor analyses (CFAs) performed on the version of the scale completed by the relatives revealed that a hierarchical model holding that lack of premeditation and lack of perseverance are facets of a higher order construct (lack of conscientiousness), with urgency and sensation seeking as separate correlated factors, fit the data best. Urgency, lack of premeditation, and lack of perseverance increased after the TBI, whereas sensation seeking decreased. CFA failed to reveal a satisfactory model in the version of the scale completed by the patients. The psychological processes related to these impulsivity changes and the discrepancy observed between self-report and informant-report are discussed. This short questionnaire opens up interesting prospects for better comprehension and assessment of behavioural symptoms of TBI.	[Rochat, Lucien; Beni, Catia; Billieux, Joel; Van der Linden, Martial] Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, CH-1205 Geneva, Switzerland; [Azouvi, Philippe] Versailles St Quentin Univ, Neurol Reeduc Ctr, Garches, France; [Annoni, Jean-Marie] Univ Hosp Geneva, Neuropsychol Unit, Geneva, Switzerland; [Van der Linden, Martial] Univ Liege, Cognit Psychopathol Unit, B-4000 Liege, Belgium		Rochat, L (corresponding author), Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, 40 Blvd Pont dArve, CH-1205 Geneva, Switzerland.	Lucien.Rochat@unige.ch		Billieux, Joel/0000-0002-7388-6194; Rochat, Lucien/0000-0002-9992-2720			Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Billieux J, 2007, ADDICT BEHAV, V32, P1189, DOI 10.1016/j.addbeh.2006.08.007; Billieux J, 2008, PERS INDIV DIFFER, V44, P1432, DOI 10.1016/j.paid.2007.12.011; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Byrne B.M., 1994, STRUCTURAL EQUATION; Claes L, 2005, PERS INDIV DIFFER, V39, P739, DOI 10.1016/j.paid.2005.02.022; Costa P. T., 1992, REVISED NEO PERSONAL; d'Acremont M, 2005, J YOUTH ADOLESCENCE, V34, P427, DOI 10.1007/s10964-005-7260-1; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Gay P, 2008, ACTA PSYCHOL, V129, P332, DOI 10.1016/j.actpsy.2008.08.010; Greve KW, 2001, BRAIN INJURY, V15, P255; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Lecrubier Y, 1995, EUR PSYCHIAT, V10, P331, DOI 10.1016/0924-9338(96)80333-6; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEVY R, 2005, CEREB CORTEX, V5, P1; Marsh NV, 2006, NEUROPSYCHOL REHABIL, V16, P684, DOI 10.1080/09602010500220290; MAZAUX JM, 2000, TRAITE NEUROPSYCHOLO, V2, P31; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Miller J, 2003, PERS INDIV DIFFER, V34, P1403, DOI 10.1016/S0191-8869(02)00122-8; Muthen L.K., 2017, MPLUS USERS GUIDE, V8th ed.; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Reitan RM, 1985, HALSTEADREITAN NEURO; Rochat L, 2008, ALZ DIS ASSOC DIS, V22, P278, DOI 10.1097/WAD.0b013e318166d692; Rochat L, 2009, J NEUROPSYCHOL, V3, P213, DOI 10.1348/174866408X397656; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23; Schmidt RE, 2008, SWISS J PSYCHOL, V67, P107, DOI 10.1024/1421-0185.67.2.107; Schmidt RE, 2008, BEHAV SLEEP MED, V6, P178, DOI 10.1080/15402000802162570; Smith GT, 2007, ASSESSMENT, V14, P155, DOI 10.1177/1073191106295527; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Van der Linden M, 2006, EUR J PSYCHOL ASSESS, V22, P38, DOI 10.1027/1015-5759.22.1.38; Votruba KL, 2008, J HEAD TRAUMA REHAB, V23, P65, DOI 10.1097/01.HTR.0000314525.93381.69; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Whiteside SP, 2005, EUR J PERSONALITY, V19, P559, DOI 10.1002/per.556; Whiteside SP, 2003, EXP CLIN PSYCHOPHARM, V11, P210, DOI 10.1037/1064-1297.11.3.210; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271; Wood RL, 2001, BRAIN DAM B, P3; Zermatten A, 2005, J NERV MENT DIS, V193, P647, DOI 10.1097/01.nmd.0000180777.41295.65	46	58	60	1	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	5					778	797	PII 924372892	10.1080/09602011.2010.495245			20	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	648YB	WOS:000281730300008	20635306	Green Published			2022-02-06	
J	Claassen, J				Claassen, Jan			How I Treat Patients with EEG Patterns on the Ictal-Interictal Continuum in the Neuro ICU	NEUROCRITICAL CARE			English	Article						Continuous EEG; Ictal-interictal continuum; Intensive care unit; Non-convulsive seizures; Non-convulsive status epilepticus	PARTIAL STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; GENERALIZED STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; DIFFUSION ABNORMALITIES; NONCONVULSIVE SEIZURES; DISCHARGES; ENOLASE	Refractory status epilepticus (RSE) is associated with a high risk of poor outcome and treated by most neurointensivists with continuous intravenous antiepileptic medications (cIV-AEDs). Continuous EEG monitoring has allowed us to unveil a number of epileptiform patterns of less certain significance. These have been labeled ictal to interictal continuum (IIC), many of which are associated with poor outcome. It is unclear to which extent individual patterns are epiphenomena or lead to additional brain injury. The treatment of these patterns is highly controversial and guidelines how to manage them are non existent. In this review of a challenging case, I will discuss a number of approaches to determine the ictal nature of the IIC in an effort to minimize neuronal injury from epileptiform brain activity on the one hand and from the treatment on the other hand. Ultimately it will be most important to replace the dichotomy of ictal versus non-ictal patterns by differentiating between harmful and non-harmful patterns.	[Claassen, Jan] Columbia Univ, Dept Neurol, Div Neurocrit Care, New York, NY 10032 USA; [Claassen, Jan] Columbia Univ, Dept Neurol, Comprehens Epilepsy Ctr, New York, NY 10032 USA		Claassen, J (corresponding author), Columbia Univ, Dept Neurol, Div Neurocrit Care, Milstein Hosp Bldg,177 Ft Washington Ave,Milstein, New York, NY 10032 USA.	jc1439@columbia.edu	Viani, Rafael/V-1196-2018; Claassen, Jan/AAA-5451-2020		National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024156]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This publication was made possible by Grant Number UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at the NCRR Website. Information on Re-engineering the Clinical Research Enterprise can be obtained from the NIH Roadmap website. I would like to thank Stephan A. Mayer, Lawrence J. Hirsch, and J. Michael Schmidt for their support, guidance, and review of this manuscript.	Assal F, 2001, SEIZURE-EUR J EPILEP, V10, P260, DOI 10.1053/seiz.2000.0506; Bozkurt MF, 2002, CLIN ELECTROENCEPHAL, V33, P171, DOI 10.1177/155005940203300407; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DURING MJ, 1993, LANCET, V341, P1607; Engelhorn T, 2007, NEUROSCI LETT, V417, P275, DOI 10.1016/j.neulet.2007.02.072; Engelhorn T, 2005, AM J NEURORADIOL, V26, P1563; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Fushimi M, 2003, ACTA NEUROL SCAND, V108, P55, DOI 10.1034/j.1600-0404.2003.00084.x; Gerber PA, 2008, J CLIN NEUROPHYSIOL, V25, P241, DOI 10.1097/WNP.0b013e318182ed67; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Katramados AM, 2009, EPILEPSIA, V50, P265, DOI 10.1111/j.1528-1167.2008.01736.x; Kimiwada T, 2006, EPILEPSIA, V47, P167, DOI 10.1111/j.1528-1167.2006.00383.x; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Morales-Villagran A, 2008, J NEUROSCI METH, V168, P48, DOI 10.1016/j.jneumeth.2007.09.005; RABINOWICZ AL, 1995, EPILEPSIA, V36, P475, DOI 10.1111/j.1528-1157.1995.tb00489.x; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Szabo K, 2005, BRAIN, V128, P1369, DOI 10.1093/brain/awh454; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WARACH S, 1994, AM J NEURORADIOL, V15, P965; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; WESTMORELAND BF, 1986, ARCH NEUROL-CHICAGO, V43, P494, DOI 10.1001/archneur.1986.00520050066024	36	58	61	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2009	11	3					437	444		10.1007/s12028-009-9295-8			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	521SH	WOS:000271943800023	19851892				2022-02-06	
J	Kilbourne, M; Kuehn, R; Tosun, C; Caridi, J; Keledjian, K; Bochicchio, G; Scalea, T; Gerzanich, V; Simard, JM				Kilbourne, Michael; Kuehn, Reed; Tosun, Cigdem; Caridi, John; Keledjian, Kaspar; Bochicchio, Grant; Scalea, Thomas; Gerzanich, Volodymyr; Simard, J. Marc			Novel Model of Frontal Impact Closed Head Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						activated caspase-3; beta-amyloid precursor protein; diffuse axonal injury; frontal impact; impact acceleration; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; FLUID PERCUSSION INJURY; ACCELERATION; BIOMECHANICS; DEFICITS; PEPTIDE; DAMAGE; MILD	Frontal impact, closed head trauma is a frequent cause of traumatic brain injury (TBI) in motor vehicle and sports accidents. Diffuse axonal injury (DAI) is common in humans and experimental animals, and results from shearing forces that develop within the anisotropic brain. Because the specific anisotropic properties of the brain are axis-dependent, the anatomical site where force is applied as well as the resultant acceleration, be it linear, rotational, or some combination, are important determinants of the resulting pattern of brain injury. Available rodent models of closed head injury do not reproduce the frontal impact commonly encountered in humans. Here we describe a new rat model of closed head injury that is a modification of the impact-acceleration model of Marmarou. In our model (the Maryland model), the impact force is applied to the anterior part of the cranium and produces TBI by causing anterior-posterior plus sagittal rotational acceleration of the brain inside the intact cranium. Skull fractures, prolonged apnea, and mortality were absent. The animals exhibited petechial hemorrhages, DAI marked by a bead-like pattern of beta-amyloid precursor protein (beta-APP) in damaged axons, and widespread upregulation of beta-APP in neurons, with regions affected including the orbitofrontal cortex (coup), corpus callosum, caudate, putamen, thalamus, cerebellum, and brainstem. Activated caspase-3 was prominent in hippocampal neurons and Purkinje cells at the grey-white matter junction of the cerebellum. Neurobehavioral dysfunction, manifesting as reduced spontaneous exploration, lasted more than 1 week. We conclude that the Maryland model produces diffuse injuries that may be relevant to human brain injury.	[Tosun, Cigdem; Caridi, John; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Kilbourne, Michael; Kuehn, Reed] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Keledjian, Kaspar; Bochicchio, Grant; Scalea, Thomas] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Bochicchio, Grant; Scalea, Thomas; Simard, J. Marc] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA		Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020		Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808, NS060801, NS061934]; Christopher and Dana Reeve Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061934, R01NS061808] Funding Source: NIH RePORTER	This work was supported by grants to J.M.S. from the Department of Veterans Affairs (Baltimore, MD), the National Heart, Lung, and Blood Institute (no. HL082517), the National Institute of Neurological Disorders and Stroke (no. NS061808 and NS060801), and the Christopher and Dana Reeve Foundation, and to V. G. from the National Institute of Neurological Disorders and Stroke (no. NS061934).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ellingson Benjamin M., 2005, V41, P86; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; KOLB B, 1985, NEUROBEH TOXICOL TER, V7, P71; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Pierce JES, 1996, J NEUROSCI, V16, P1083; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Xiao-Sheng H, 2004, J CLIN NEUROSCI, V11, P402, DOI 10.1016/j.jocn.2004.01.001	40	58	63	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2233	2243		10.1089/neu.2009.0968			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200011	19929375	Green Published			2022-02-06	
J	Tisdall, MM; Taylor, C; Tachtsidis, I; Leung, TS; Elwell, CE; Smith, M				Tisdall, Martin M.; Taylor, Christopher; Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin			The Effect on Cerebral Tissue Oxygenation Index of Changes in the Concentrations of Inspired Oxygen and End-Tidal Carbon Dioxide in Healthy Adult Volunteers	ANESTHESIA AND ANALGESIA			English	Article							NEAR-INFRARED SPECTROSCOPY; JUGULAR VENOUS OXIMETRY; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; OPTICAL PATHLENGTH; BLOOD-VOLUME; NIRO 300; ARTERIAL; THRESHOLDS; SATURATION	BACKGROUND: A variety of near-infrared spectroscopy devices can be used to make noninvasive measurements of cerebral tissue oxygen saturation (ScO2). The ScO2 measured by the NIRO 300 spectrometer (Hamamatsu Photonics, Japan) is called the cerebral tissue oxygenation index (TOI) and is an assessment of the balance between cerebral oxygen delivery and utilization. We designed this study to investigate the effect of systemic and intracranial physiological changes on TOI. METHODS: Fifteen healthy volunteers were studied during isocapneic hyperoxia and hypoxemia, and normoxic hypercapnea and hypocapnea. Absolute cerebral TOI and changes in oxy- and deoxyhemoglobin concentrations were measured using a a NIRO 300 spectrometer. Changes in arterial oxygen saturation (Sao(2)), ETco(2), heart rate, mean arterial blood pressure (MBP), and middle cerebral artery blood flow velocity (V-mca) were also measured during these physiological challenges. Changes in cerebral blood volume (CBV) were subsequently calculated from changes in total cerebral hemoglobin concentration. RESULTS: Baseline TOI was 67.3% with an interquartile range (IQR) of 65.2%-71.9%. Hypoxemia was associated with a median decrease in TOI of 7.1% (IQR -9.1% to -5.4'%) from baseline (P < 0.0001) and hyperoxia with a median increase of 2.3% (IQR 2.0%-2.5%) (P < 0.0001). Hypocapnea caused a reduction in TOI of 2.1% (IQR -3.3%, to -1.3%) from baseline (P < 0.0001) and hypercapnea an increase of 2.6% (IQR 1.40/-3.7%) (P < 0.0001). Changes in Sao(2) (P < 0.0001), ETco(2) (P < 0.0001), CBV (P = 0.0003), and MBP (P = 0.03) were significant variables affecting TOI. Changes in V-mca (P = 0.7) and heart rate (P = 0.2) were not significant factors. CONCLUSION: TOI is an easy-to-monitor variable that provides real-time, multisite, and noninvasive assessment of the balance between cerebral oxygen delivery and utilization. However, TOI is a complex variable that is affected by Sao(2) and ETco(2), and, to a lesser extent, by MBP and CBV. Clinicians need to be aware of the systemic and cerebral physiological changes that can affect TOI to interpret changes in this variable during clinical monitoring. (Anesth Analg 2009:109:906-13)	[Tisdall, Martin M.; Taylor, Christopher; Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, London WC1N 3BG, England; [Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin] UCL, Dept Med Phys & Bioengn, London, England		Smith, M (corresponding author), Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, Box 30,Queen Sq, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Tachtsidis, Ilias/N-2747-2018; Smith, Martin/B-2616-2009	Tachtsidis, Ilias/0000-0002-8125-0313; Elwell, Clare/0000-0002-7281-7234; Tisdall, Martin/0000-0001-8880-8386	Wellcome TrustWellcome TrustEuropean Commission [075608]; Engineering Physical Science Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [GR/N14248/01]; Hamamatsu Photonics; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR); EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/G005036/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701458] Funding Source: UKRI; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/G005036/1, GR/N14248/01] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish	Supported by the Wellcome Trust (Grant no. 075608) (to MT), the Engineering Physical Science Research Council (Grant no. GR/N14248/01) (to IT), and Hamamatsu Photonics, KK (to TL). This work was undertaken at University College London Hospitals and partially funded by the Department of Health's NIHR Biomedical Research Centres funding scheme. The work was also made possible in part by a donation in memory of Karolyn Margaret Jones.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; An HY, 2002, MAGNET RESON MED, V48, P583, DOI 10.1002/mrm.10257; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; Castellan N. J, 1988, NONPARAMETRIC STAT B; Dash RK, 2004, ANN BIOMED ENG, V32, P1676, DOI 10.1007/s10439-004-7821-6; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; GREENBERG JH, 1978, CIRC RES, V43, P324, DOI 10.1161/01.RES.43.2.324; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 1997, ANESTH ANALG, V85, P817, DOI 10.1097/00000539-199710000-00018; Ito H, 2005, J CEREBR BLOOD F MET, V25, P852, DOI 10.1038/sj.jcbfm.9600076; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Okada E, 2003, APPL OPTICS, V42, P2915, DOI 10.1364/AO.42.002915; Owen-Reece H, 1999, BRIT J ANAESTH, V82, P418, DOI 10.1093/bja/82.3.418; Quaresima V, 2000, J BIOMED OPT, V5, P201, DOI 10.1117/1.429987; Rasmussen P, 2007, J CEREBR BLOOD F MET, V27, P1082, DOI 10.1038/sj.jcbfm.9600416; Schell RM, 2000, ANESTH ANALG, V90, P559, DOI 10.1097/00000539-200003000-00012; Smith M, 2008, NEUROSURG CLIN N AM, V19, P489, DOI 10.1016/j.nec.2008.07.008; Sorensen LC, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2357730; Suzuki S, 1999, P SOC PHOTO-OPT INS, V3597, P582, DOI 10.1117/12.356862; Tachtsidis I, 2008, ADV EXP MED BIOL, V614, P389, DOI 10.1007/978-0-387-74911-2_43; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; WHITESELL R, 1981, ANESTH ANALG, V60, P508; [No title captured]	31	58	59	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2009	109	3					906	913		10.1213/ane.0b013e3181aedcdc			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	488EB	WOS:000269330800035	19690266	Green Accepted			2022-02-06	
J	Sribnick, EA; Del Re, AM; Ray, SK; Woodward, JJ; Banik, NL				Sribnick, Eric A.; Del Re, Angelo M.; Ray, Swapan K.; Woodward, John J.; Banik, Naren L.			Estrogen attenuates glutamate-induced cell death by inhibiting Ca2+ influx through L-type voltage-gated Ca2+ channels	BRAIN RESEARCH			English	Article						Apoptosis; Calpain; Ca2+ influx; Caspase-3; Glutamate; Motoneurons; Nifedipine	SPINAL-CORD-INJURY; NMDA RECEPTOR ACTIVATION; PRIMARY CORTICAL-NEURONS; PROTEIN-KINASE PATHWAY; C6 GLIOMA-CELLS; BRAIN-INJURY; INDUCED APOPTOSIS; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; PLASMA-MEMBRANE	Estrogen-mediated neuroprotection is observed in neurodegenerative disease and neurotrauma models; however, deter-mining a mechanism for these effects has been difficult. We propose that estrogen may limit cell death in the nervous system tissue by inhibiting increases in intracellular free Ca2+. Here, we present data using VSC 4.1 cell line, a ventral spinal motoneuron and neuroblastoma hybrid cell line. Treatment with 1 mM glutamate for 24 h induced apoptosis. When cells were pre-treated with 100 nM 17 beta-estradiol (estrogen) for 1 h and then co-treated with glutamate, apoptotic death was significantly attenuated. Estrogen also prevented glutamate-mediated changes in resting membrane potential and membrane capacitance. Treatment with either 17 alpha-estradiol or cell impermeable estrogen did not mimic the findings seen with estrogen. Glutamate treatment significantly increased both intracellular free Ca2+ and the activities of downstream proteases such as calpain and caspase-3. Estrogen attenuated both the increases in intracellular free Ca2+ and protease activities, In order to determine the pathway responsible for estrogen-mediated inhibition of these increases in intracellular free Ca2+, cells were treated with several Ca2+ entry inhibitors, but only the L-type Ca2+ channel blocker nifedipine demonstrated cytoprotective effects comparable to estrogen. To expand these findings, cells were treated with the L-type Ca2+ channel agonist FPL 64176, which increased both cell death and intracellular free Ca2+ and estrogen inhibited both effects. From these observations, we conclude that estrogen limits glutamate-induced cell death in VSC 4.1 cells through effects on L-type Ca2+ channels, inhibiting Ca2+ influx as well as activation of the pro-apoptotic proteases calpain and caspase-3. (C) 2009 Elsevier B.V. All rights reserved.	[Sribnick, Eric A.; Del Re, Angelo M.; Woodward, John J.; Banik, Naren L.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209 USA		Banik, NL (corresponding author), Med Univ S Carolina, Div Neurol, Dept Neurosci, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020		Medical Scientist Training Program (MSTP) [GM08716]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Spinal Cord Injury Research Fund [SCIRF-0803]; state of South Carolina;  [NS-31622];  [NS-45967];  [NS-57811];  [CA-91460]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS057811, R01NS031622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA009986] Funding Source: NIH RePORTER	This work was supported in part by R01 grants (NS-31622, NS-45967, NS-57811, and CA-91460) and a Medical Scientist Training Program (MSTP) grant (GM08716) from the National Institutes of Health (Bethesda, MD, USA), and also a Spinal Cord Injury Research Fund grant (SCIRF-0803) from the state of South Carolina.	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Ba F, 2004, NEUROCHEM INT, V45, P31, DOI 10.1016/j.neuint.2003.12.013; BARNEA A, 1970, BIOCHEMISTRY-US, V9, P1899, DOI 10.1021/bi00811a006; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bennett MVL, 1996, COLD SPRING HARB SYM, V61, P373; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berman FW, 2000, J NEUROCHEM, V74, P1443, DOI 10.1046/j.1471-4159.2000.0741443.x; Bhatt A, 2002, J CELL SCI, V115, P3415; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; Cano-Abad MF, 2001, J BIOL CHEM, V276, P39695, DOI 10.1074/jbc.M102334200; Chaban VV, 2003, NEUROSCIENCE, V118, P941, DOI 10.1016/S0306-4522(02)00915-6; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Das A, 2008, BRAIN RES, V1227, P207, DOI 10.1016/j.brainres.2008.06.045; Das BP, 2005, J THEOR COMPUT CHEM, V4, P1, DOI 10.1142/S0219633605001441; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; FINIELS F, 1995, J NEUROCHEM, V65, P1027; George J, 2009, NEUROCHEM RES, V34, P66, DOI 10.1007/s11064-008-9659-z; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Karmakar S, 2007, NEUROSCI LETT, V415, P242, DOI 10.1016/j.neulet.2007.01.071; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; Kim YJ, 2000, J NEUROCHEM, V74, P2490, DOI 10.1046/j.1471-4159.2000.0742490.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; LaBella V, 1996, NEUROSCIENCE, V70, P1039, DOI 10.1016/0306-4522(95)00401-7; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee MO, 2002, MOL CELL ENDOCRINOL, V188, P47, DOI 10.1016/S0303-7207(01)00753-5; LEVITAN IB, 1997, NEURON CELL MOL BIOL; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Mitsumoto Y, 1998, BIOCHEM BIOPH RES CO, V248, P660, DOI 10.1006/bbrc.1998.8986; Monroe DG, 2002, MOL ENDOCRINOL, V16, P1322, DOI 10.1210/me.16.6.1322; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morales A, 2003, EUR J NEUROSCI, V18, P2505, DOI 10.1046/j.1460-9568.2003.02997.x; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nakamizo T, 2000, NEUROREPORT, V11, P3493, DOI 10.1097/00001756-200011090-00019; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Sharrow KM, 2002, NEUROSCIENCE, V113, P89, DOI 10.1016/S0306-4522(02)00151-3; Singer CA, 1999, J NEUROSCI, V19, P2455; SMITH RG, 1994, P NATL ACAD SCI USA, V91, P3393, DOI 10.1073/pnas.91.8.3393; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xue BJ, 2003, BRAIN RES, V976, P41, DOI 10.1016/S0006-8993(03)02629-5; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884	79	58	64	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2009	1276						159	170		10.1016/j.brainres.2009.04.022			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	464PD	WOS:000267516700018	19389388	Green Accepted			2022-02-06	
J	Williams, RF; Magnotti, LJ; Croce, MA; Hargraves, BB; Fischer, PE; Schroeppel, TJ; Zarzaur, BL; Muhlbauer, M; Timmons, SD; Fabian, TC				Williams, Regan F.; Magnotti, Louis J.; Croce, Martin A.; Hargraves, Brinson B.; Fischer, Peter E.; Schroeppel, Thomas J.; Zarzaur, Ben L.; Muhlbauer, Michael; Timmons, Shelly D.; Fabian, Timothy C.			Impact of Decompressive Craniectomy on Functional Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Decompressive craniectomy; Severe traumatic brain injury; Uncontrollable intracranial hypertension; Glasgow outcome score extended	SURGICAL DECOMPRESSION; MANAGEMENT; SCALE; ICP	Background. The beneficial effect of decompressive craniectomy (DC) in the treatment of traumatic brain injury (TBI) remains controversial. In many centers, it is used as a salvage procedure for uncontrollable intracranial pressure (ICP). It is our contention that DC represents a viable early option for head trauma patients. The purpose of this study was to evaluate the efficacy of DC on functional outcome after severe TBI in the largest single institutional series reported in the literature. Methods: Patients with severe TBI (Abbreviated Injury Score 4-5) treated with DC for the management of increased ICP during 6-year period were identified from the trauma registry. Functional outcome was measured 1 year to 6 years postinjury using the Glasgow Outcome Score Extended (GOSE) via telephone interview and classified as good (GOSE 5-8) or poor (GOSE 1-4, including death). Outcomes were compared using Wilcoxon rank-sum and chi(2) tests where appropriate. Results. One hundred and seventy-one patients were identified: 137 (80%) men and 34 (20%) women. Overall mortality (all in-hospital) was 32% (head-related = 22%). Of the 117 survivors, follow-up was obtained in all but 6 (95%). Good outcome was achieved in 96 patients (56% overall, 82% of survivors). Those with good outcome were younger (26 years vs. 43 years, p = 0.0028) and experienced a greater change in predecompression to postdecompression ICP (ICP reduced by 23 mm Hg vs. 10 mm Hg, p < 0.0001). Not surprisingly, unchanged ICP (predecompression to postdecompression) was associated with poor outcome (p = 0.0031). There was no difference in immediate predecompression ICP between survivors versus nonsurvivors. However, immediate predecompression Glasgow Coma Score was significantly higher in survivors compared with nonsurvivors (7 vs. 5, p < 0.0001). Conclusions: DC resulted in good functional outcome in >50% of patients with severe TBI. The greatest benefit was observed in younger patients with a demonstrable reduction in ICP after decompression. The prospect of improved functional outcome offered by this procedure in the treatment of severe TBI warrants prospective investigation.	[Williams, Regan F.; Magnotti, Louis J.; Croce, Martin A.; Hargraves, Brinson B.; Fischer, Peter E.; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Muhlbauer, Michael; Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA		Magnotti, LJ (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 910 Madison Ave,Rm 217, Memphis, TN 38163 USA.	lmagnott@utmem.edu	Zarzaur, Ben/S-6572-2019	Schroeppel, Thomas/0000-0001-9164-5004; Zarzaur, Ben/0000-0001-9988-9572			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; *CDC, 2006, MMWR-MORBID MORTAL W, V55, P201; Cooper P R, 1976, Surg Neurol, V5, P25; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; GAAB MR, 1990, ACT NEUR S, V51, P326; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; KOCHER T, 1901, THERAPIE HIRNDRUCKES, P262; Kunze E, 1998, ACT NEUR S, V71, P16; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	26	58	62	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1570	1576		10.1097/TA.0b013e3181a594c4			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	457PN	WOS:000266944500009	19509616				2022-02-06	
J	Warner, KJ; Sharar, SR; Copass, MK; Bulger, EM				Warner, Keir J.; Sharar, Sam R.; Copass, Michael K.; Bulger, Eileen M.			PREHOSPITAL MANAGEMENT OF THE DIFFICULT AIRWAY: A PROSPECTIVE COHORT STUDY	JOURNAL OF EMERGENCY MEDICINE			English	Article						Prehospital; Difficult Airway; Intubation; Surgical Airway; Neuromuscular Blocking Agents	TRAUMATIC BRAIN-INJURY; HOSPITAL ENDOTRACHEAL INTUBATION; EMERGENCY TRACHEAL INTUBATION; NEUROMUSCULAR BLOCKING-AGENTS; EXPERIENCE; IMPACT; GUIDELINES; INTUHATION; SEQUENCE; MODERATE	The role of prehospital endotracheal intubation (ETI) remains controversial, with significant national variability in practice. The purpose of this project was to evaluate ETI management in a system of advanced life support (ALS) providers experienced in ETI and other advanced airway techniques, and describe management and outcomes of patients with a "difficult airway." Data were collected prospectively for all ETIs performed by the fire department over a 4-year period (2001-2005), and included demographics, number of laryngoscopy attempts, airway procedures, complications, and outcomes. Of 80,501 ALS patient contacts, 4091 (5.1%) underwent attempted oral ETI, with a 96.8% success rate in four or fewer attempts. The difficult airway cohort included 130 patients (3.2%), whose airway management consisted of oral ETI after more than four attempts (46%), bag-valve-mask ventilation (33%), cricothyroidotomy (8%), retrograde ETI (5%), and digital ETI (1%). Procedural success rates ranged from 14% (digital ETI) to 91% (cricothyroidotomy). Nine patients (7%) had failed airway management, of whom 5 were found in cardiac arrest. The two most common reasons subjectively reported by ALS providers for airway difficulty were anterior trachea (39%) and small mouth (30%). Overall mortality for the difficult airway cohort was 44%. Prehospital ETI can be performed with a high success rate by experienced ALS providers, but may still require advanced airway techniques in a small subset of patients. Patient anatomy is a primary factor in failed ETI. Among the advanced procedures, cricothyroidotomy had the highest success rate and should not be delayed by other interventions. (C) 2009 Elsevier Inc.	[Warner, Keir J.; Bulger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Sharar, Sam R.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Copass, Michael K.] Univ Washington, Harborview Med Ctr, Emergency Serv, Seattle, WA 98104 USA		Warner, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.				Medic One Foundation, Seattle, Washington	Supported by a grant from The Medic One Foundation, Seattle, Washington.	Bair AE, 2003, J EMERG MED, V24, P151, DOI 10.1016/S0736-4679(02)00715-1; Bair AE, 2002, J EMERG MED, V23, P131, DOI 10.1016/S0736-4679(02)00501-2; Baker CC, 2005, J TRAUMA, V58, P723; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gruen RL, 2006, ANN SURG, V244, P371, DOI 10.1097/01.sla.0000234655.83517.56; Jaeger K, 2000, RESUSCITATION, V43, P147, DOI 10.1016/S0300-9572(99)00124-0; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Mizelle H Leland, 2002, Prehosp Emerg Care, V6, P472, DOI 10.1080/10903120290938184; Mort TC, 2004, J CLIN ANESTH, V16, P508, DOI 10.1016/j.jclinane.2004.01.007; Mort TC, 2004, ANESTH ANALG, V99, P607, DOI 10.1213/01.ANE.0000122825.04923.15; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	21	58	59	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679			J EMERG MED	J. Emerg. Med.	APR	2009	36	3					257	265		10.1016/j.jemermed.2007.10.058			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	430KH	WOS:000264987500008	18439793				2022-02-06	
J	Fitzgerald, M; Bartlett, CA; Evill, L; Rodger, J; Harvey, AR; Dunlop, SA				Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Harvey, Alan R.; Dunlop, Sarah A.			Secondary degeneration of the optic nerve following partial transection: The benefits of lomerizine	EXPERIMENTAL NEUROLOGY			English	Article						Neurotrauma; Secondary injury; Visual System; Retinal ganglion cell; Neuronal death; Glia; Chondroitin sulphate proteoglycans; Oxidative stress	RETINAL GANGLION-CELLS; CALCIUM-CHANNEL BLOCKER; SPINAL-CORD-INJURY; OXIDATIVE STRESS; AXONAL REGENERATION; DEATH; DAMAGE; NEUROPROTECTION; ACTIVATION; MECHANISMS	Secondary degeneration is a form of 'bystander' damage that can affect neural tissue both nearby and remote from an initial injury. Partial optic nerve transection is an excellent model in which to unequivocally differentiate events occurring during secondary degeneration from those resulting from primary CNS injury. We analysed the primary injury site within the optic nerve (ON) and intact areas vulnerable to secondary degeneration. Areas affected by the primary injury showed morphological disruption, loss of beta-III tubulin axonal staining, reduced myelinated axon density, greater proteoglycan expression (phosphacan), increased microglia and macrophage numbers and increased oxidative stress. Similar, but less extreme, changes were seen in areas of the optic nerve undergoing secondary degeneration. The CNS-specific L- and T-type calcium channel blocker lomerizine alleviated some of the changes in areas vulnerable to secondary degeneration. Lomerizine reduced morphological disruption, oxidative stress and phosphacan expression, and limited early increases in macrophage numbers. However, lomerizine failed to prevent progressive de-myelination of ON axons. Within the retina, secondary retinal ganglion cell (RGC) death was significant in areas vulnerable to secondary degeneration. Lomerizine protected RGCs from secondary death at 4 weeks but did not fully restore behavioural function (optokinetic nystagmus). We conclude that blockade of calcium channels is neuroprotective and limits secondary degenerative changes following CNS injury. However such an approach may need to be combined with other treatments to ensure long-term maintenance of full visual function. (C) 2008 Elsevier Inc. All rights reserved.	[Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Dunlop, Sarah A.] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Dunlop, Sarah A.] Univ Western Australia, Western Australian Inst Med Res, Crawley, WA 6009, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia		Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	melfitz1@cyllene.uwa.edu.au	Harvey, Alan R/A-4911-2008; Dunlop, Sarah A/G-9357-2013; Rodger, Jennifer/H-5735-2014; Fitzgerald, Melinda/C-4235-2011	Rodger, Jennifer/0000-0003-3413-4229; Fitzgerald, Melinda/0000-0002-4823-8179; Dunlop, Sarah/0000-0002-1306-3962; , Alan/0000-0002-2590-831X	Neurotrauma Research Program (Western Australia); NHMRCNational Health and Medical Research Council of Australia [254670]; Woodside Australia; University, State and Commonwealth Governments	This work was supported by the Neurotrauma Research Program (Western Australia) and NH&MRC. Prof. Dunlop is a Professorial Fellow (Research) and Senior Research Fellow of the NH&MRC, Australia (Grant ID: 254670). We thank Woodside Australia for supporting our research by naming us as beneficiaries of the Woodside Sustainability Award 2007. We thank Michael Archer, Marissa Penrose, Vince Clark, Daniel Haustead and Sherralee Lukehurst for assistance with myelination analyses and technical procedures. The phosphocan monoclonal antibody developed by Dr. R.U. Margolis and Dr. R.K Margolis, was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. The authors acknowledge the facilities, scientific and technical assistance of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy, Characterization and Analysis, the University of Western Australia, a facility funded by the University, State and Commonwealth Governments.	Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015; AKAIKE N, 1993, BRAIN RES, V619, P263, DOI 10.1016/0006-8993(93)91620-8; Aucoin JS, 2005, NEUROSCIENCE, V132, P73, DOI 10.1016/j.neuroscience.2004.11.047; Blair M, 2005, INVEST OPHTH VIS SCI, V46, P884, DOI 10.1167/iovs.04-0731; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cui Q, 2007, NEUROSCIENCE, V146, P986, DOI 10.1016/j.neuroscience.2007.02.034; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Delgado-Garcia JM, 2000, BRAIN RES BULL, V52, P475, DOI 10.1016/S0361-9230(00)00281-1; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fu QL, 2008, INVEST OPHTH VIS SCI, V49, P975, DOI 10.1167/iovs.07-1199; Gao LM, 2006, DEV BIOL, V290, P277, DOI 10.1016/j.ydbio.2005.11.007; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Hara H, 1999, CLIN EXP PHARMACOL P, V26, P870, DOI 10.1046/j.1440-1681.1999.03154.x; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hashimoto M, 1997, RES COMMUN MOL PATH, V97, P79; Haustead DJ, 2008, J NEUROSCI, V28, P7376, DOI 10.1523/JNEUROSCI.1135-08.2008; HOGIE M, 2008, ECOTOXICOL ENV SAF; HUNIG T, 1989, COLD SPRING HARB SYM, V54, P61; Hwan AY, 2006, BIOCHEM BIOPH RES CO, V348, P560, DOI 10.1016/j.bbrc.2006.07.105; Johnson TV, 2007, INVEST OPHTH VIS SCI, V48, P3441, DOI 10.1167/iovs.06-1351; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kreutz MR, 1999, RESTOR NEUROL NEUROS, V14, P127; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Maher P, 2005, INVEST OPHTH VIS SCI, V46, P749, DOI 10.1167/iovs.04-0883; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Nguyen SM, 2003, ANTIOXID REDOX SIGN, V5, P629, DOI 10.1089/152308603770310293; Nickells RW, 2007, VET OPHTHALMOL, V10, P88, DOI 10.1111/j.1463-5224.2007.00564.x; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003; Petersen MS, 2006, J IMMUNOL METHODS, V309, P173, DOI 10.1016/j.jim.2005.12.002; Prilloff S, 2007, EUR J NEUROSCI, V25, P3339, DOI 10.1111/j.1460-9568.2007.05550.x; Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P681, DOI 10.1167/iovs.06-0553; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; Schwartz M, 2004, BRAIN RES BULL, V62, P467, DOI 10.1016/S0361-9230(03)00076-5; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; Stys PK, 2002, NEUROSCI LETT, V328, P150, DOI 10.1016/S0304-3940(02)00469-X; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Toriu N, 2000, EXP EYE RES, V70, P475, DOI 10.1006/exer.1999.0809; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Walls G. L., 1942, VERTEBRATE EYE ITS A; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Williams A, 2007, BRAIN, V130, P2554, DOI 10.1093/brain/awm202; Winkler T, 2003, ACTA NEUROCHIR SUPPL, V86, P425; Yamada H, 2006, BRAIN RES, V1071, P75, DOI 10.1016/j.brainres.2005.11.072; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yoo YM, 2005, NEUROSCI LETT, V382, P88, DOI 10.1016/j.neulet.2005.02.070	63	58	61	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					219	230		10.1016/j.expneurol.2008.11.026			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	413UK	WOS:000263817800025	19118550				2022-02-06	
J	Whitney, KA; Shepard, PH; Williams, AL; Davis, JJ; Adams, KM				Whitney, Kriscinda A.; Shepard, Polly H.; Williams, Amanda L.; Davis, Jeremy J.; Adams, Kenneth M.			The Medical Symptom Validity Test in the evaluation of Operation Iraqi Freedom/Operation Enduring Freedom soldiers: A preliminary study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neuropsychology; Malingering; Military Veterans; Traumatic brain injury; Test validity; Memory	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; POSTTRAUMATIC-STRESS-DISORDER; EXAGGERATION; PERFORMANCE; MECHANISMS; VETERANS; SEQUELAE	The clinical utility of the Medical Symptom Validity Test (MSVT) for soldiers returning from service in Operation Iraqi Freedom or Operation Enduring Freedom was preliminarily investigated through retrospective chart review. Results showed that 17%, or 4 of 23, Operation Iraqi Freedom/Operation Enduring Freedom patients at a Polytrauma Network Site (Level 2), performed below cut-offs on the MSVT. On "easy" subtests of the MSVT, the group of individuals who failed the MSVT performed significantly worse than the group of individuals who passed. However, there were no significant group differences on the "hard" subtests of the MSVT. When the profiles of individuals who failed the MSVT were examined, none of them met the criteria for the Dementia Profile. These preliminary findings and additional test data supported the conclusion that participants who failed the MSVT were exhibiting diminished symptom validity, suggesting that the specificity of the MSVT was 100%.	[Whitney, Kriscinda A.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; [Whitney, Kriscinda A.; Shepard, Polly H.] Indiana Univ, Sch Med, Indianapolis, IN USA; [Shepard, Polly H.] Profess Psychol Serv, Indianapolis, IN USA; [Williams, Amanda L.] Ball State Univ, Muncie, IN 47306 USA; [Davis, Jeremy J.] Univ Indianapolis, Indianapolis, IN 46227 USA; [Adams, Kenneth M.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA; [Adams, Kenneth M.] Univ Michigan Hlth Syst, Ann Arbor, MI USA		Whitney, KA (corresponding author), Richard L Roudebush Vet Affairs Med Ctr 116P, 1481 W 10th St, Indianapolis, IN 46202 USA.	kamarks@iupui.edu					Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Delis D.C., 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; FRERICHS R, 2006, ARCH CLIN NEUROPSYCH, V21, P551; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; HOWE LLS, 2009, CLIN NEUROPSYCHOL, V23, P1; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Merckelbach H, 2003, ARCH CLIN NEUROPSYCH, V18, P145, DOI 10.1016/S0887-6177(01)00191-3; Miller HA, 2004, INT J OFFENDER THER, V48, P268, DOI 10.1177/0306624X03259167; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; REYNOLDS CR, 1998, CLIN ASSESSMENT MALI, P250; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; ROGERS R, 1992, SIRS STRUCTURED INTE; Schmidt M., 1996, REY AUDITORY VERBAL; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; *TSGLI, 2007, PROC GUID; *VET BEN ADM, 2006, 21001 VET BEN ADM	30	58	58	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2009	24	2					145	152		10.1093/arclin/acp020			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	454TL	WOS:000266705500003	19395348	Bronze			2022-02-06	
J	Chiaretti, A; Barone, G; Riccardi, R; Antonelli, A; Pezzotti, P; Genovese, O; Tortorolo, L; Conti, G				Chiaretti, A.; Barone, G.; Riccardi, R.; Antonelli, A.; Pezzotti, P.; Genovese, O.; Tortorolo, L.; Conti, G.			NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children	NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; NEURON-SPECIFIC ENOLASE; BRAIN-INJURY; CEREBROSPINAL-FLUID; DOUBLECORTIN EXPRESSION; NEUROTROPHIC FACTORS; FACTOR INFUSION; INFANTS; TRANSPLANTATION; PROLIFERATION	Background: Secondary brain damage after traumatic brain injury (TBI) involves neuroinflammatory mechanisms, mainly dependent on the intracerebral production of specific biomarkers, such as cytokines, neurotrophic factors, and neuron-specific enolase (NSE). NSE is associated with neuronal damage, while neurotrophic factors play a neuroprotective role due to their ability to modulate neuronal precursor biosynthesis, such as doublecortin (DCX). However, the relationships between the expression of these factors and the severity and outcome of TBI are not understood. Methods: To determine whether the concentrations of neurotrophic factors (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], glial-derived neurotrophic factor [GDNF]), DCX, and NSE in the CSF of children with TBI correlate with the severity of brain damage and neurologic outcome, we prospectively collected CSF samples from 32 children at 2 and 48 hours after admission for severe TBI and from 32 matched controls. Severity of TBI was evaluated by Glasgow Coma Scale and neurologic outcome by Glasgow Outcome Score. Results: Early NGF, DCX, and NSE concentrations correlated significantly with the severity of head injury, whereas no correlation was found for BDNF and GDNF. Furthermore, NGF and DCX upregulation and lower NSE expression were associated with better neurologic outcomes. No significant association was found between BDNF and GDNF expression and outcome. Conclusions: Nerve growth factor (NGF), doublecortin (DCX), and neuron-specific enolase concentrations in the CSF are useful markers of brain damage following severe traumatic brain injury (TBI). NGF and DCX upregulation correlates also with better neurologic outcome and could be useful to obtain clinical and prognostic information in children with severe TBI. Neurology (R) 2009; 72:609-616	[Chiaretti, A.; Antonelli, A.; Genovese, O.; Tortorolo, L.; Conti, G.] Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, I-00168 Rome, Italy; [Pezzotti, P.] Agcy Publ Hlth Lazio Region, Rome, Italy		Chiaretti, A (corresponding author), Policlin Gemelli, Largo Gemelli 1, I-00168 Rome, Italy.	achiaretti@yahoo.it	Conti, Giorgio/AAB-9546-2022	Conti, Giorgio/0000-0002-8566-9365; GENOVESE, Orazio/0000-0002-1989-1363; RICCARDI, RICCARDO/0000-0001-7515-6622			Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.ne.18.030195.001255; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Chiaretti A, 2008, NEUROL RES, V30, P223, DOI 10.1179/016164107X247948; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Collin T, 2005, EXP NEUROL, V195, P71, DOI 10.1016/j.expneurol.2005.03.017; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Frielingsdorf H, 2007, NEUROBIOL DIS, V26, P47, DOI 10.1016/j.nbd.2006.11.015; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Winner B, 2008, J NEUROPATH EXP NEUR, V67, P105, DOI 10.1097/nen.0b013e3181630cff; Wong V, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e36; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	39	58	70	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 17	2009	72	7					609	616		10.1212/01.wnl.0000342462.51073.06			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	407TB	WOS:000263386100007	19221293				2022-02-06	
J	Ottochian, M; Salim, A; Berry, C; Chan, LS; Wilson, MT; Margulies, DR				Ottochian, Marcus; Salim, Ali; Berry, Cherisse; Chan, Linda S.; Wilson, Matthew T.; Margulies, Daniel R.			Severe traumatic brain injury: is there a gender difference in mortality?	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	18th Annual Meeting of the Society-for-Black-Academic-Surgeons	APR 17-20, 2008	Cleveland, OH	Soc Black Acad Surg		Trauma; Traumatic brain injury; Gender; Outcome; Mortality	ESTROGEN; MALES; PROTECTION; FEMALES; RATS	BACKGROUND: Emerging evidence suggests that male and female nervous systems respond differently to traumatic brain injury (TB1). The objective of this study was to examine outcomes between the sexes after TBI. PATIENTS AND METHODS: A retrospective review of all severe TBI patients admitted between January and December 2005 was performed. Isolated severe TBI was defined as a head abbreviated injury score greater than 3 with an abbreviated injury score of 3 or less for other anatomic regions. The population was stratified into age subgroups (<14 y, 14-44 y, 45-54 y, and >= 55 y), Logistic regression was used to identify independent predictors of mortality. RESULTS: A total of 1,807 TBI patients were admitted. The mortality was significantly higher for women (<43.2% vs 36.2%, P < .01) with an adjusted odds ratio Of 1.4 (95%) confidence interval, 1.1-1.9, P < .05). After stratification, only women age 55 and older had a significant difference in mortality (odds ratio, 1.71; 95% confidence interval, 1.11-2.62, P = .02). CONCLUSIONS: Female sex (particularly those age >= 55 y) is associated independently with higher mortality in isolated severe TBI. This increased mortality Of postmenopausal women after isolated TBI may suggest a hormonal influence and warrants further investigation. (C) 2009 Elsevier Inc. All rights reserved.	[Salim, Ali; Berry, Cherisse; Wilson, Matthew T.; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Ottochian, Marcus; Chan, Linda S.] Los Angeles Cty Univ So Calif, Med Ctr, Div Trauma, Los Angeles, CA USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Amantea D, 2005, PHARMACOL RES, V52, P119, DOI 10.1016/j.phrs.2005.03.002; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10	19	58	58	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	FEB	2009	197	2					155	158		10.1016/j.amjsurg.2008.09.008			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	408SA	WOS:000263454000005	19185108				2022-02-06	
J	Diaz-Arrastia, R; Agostini, MA; Madden, CJ; Van Ness, PC				Diaz-Arrastia, Ramon; Agostini, Mark A.; Madden, Christopher J.; Van Ness, Paul C.			Posttraumatic epilepsy: The endophenotypes of a human model of epileptogenesis	EPILEPSIA			English	Article						Magnetic resonance imaging; Diffusion tensor imaging; Video-EEG monitoring; Neuropathology of epilepsy	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; HEAD-INJURY; RANDOMIZED-TRIAL; SEIZURES; PREVENTION; NEUROPROTECTION; RAT; ANTIEPILEPTOGENESIS; LESSONS	Posttraumatic epilepsy is a common complication of traumatic brain injury (TBI), occurring in up to 15-20% of patients with severe brain trauma. Trauma accounts for approximately 5% of chronic epilepsy in the community. Because it is a common condition, and because of the relatively short latency period between injury and onset of chronic seizures, posttraumatic epilepsy represents a good model to test antiepileptogenic therapies. However, several well-conducted clinical trials have failed to demonstrate antiepileptogenic efficacy for several common anticonvulsants. Posttraumatic epilepsy can arise through a number of mechanisms, which often coexist within a single patient. Penetrating brain injury produces a cicatrix in the cortex and is associated with a risk of posttraumatic epilepsy of approximately 50%, whereas nonpenetrating head injury may produce focal contusions and intracranial hemorrhages, and is associated with a risk of posttraumatic epilepsy of up to 30%. Furthermore, closed head injury often produces diffuse concussive injury, with shearing of axons and selective damage to vulnerable brain regions, such as the hippocampus. The clinical, neurophysiologic, imaging, and neuropathologic features or epileptogenicity differ between these alternate mechanisms. It is likely that better understanding of the subtypes of epilepsy resulting from brain trauma will be required to successfully identify antiepileptogenic therapies.	[Diaz-Arrastia, Ramon; Agostini, Mark A.; Van Ness, Paul C.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Comprehens Epilepsy Ctr, Parkland Mem Hosp, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Comprehens Epilepsy Ctr, Parkland Mem Hosp, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIH-NICDHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; U.S. Dept. of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This work was supported by grants from NIH-NICDH (R01 HD48179, U01 HD42652), and U.S. Dept. of Education Grant (H133 A020526) (to RD-A).	Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; Cohen-Gadol AA, 2006, J NEUROSURG, V104, P513, DOI 10.3171/jns.2006.104.4.513; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; GOTTESMAN II, 1973, BRIT J PSYCHIAT, V122, P15, DOI 10.1192/bjp.122.1.15; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Klitgaard H, 2003, EPILEPTIC DISORD, V5, pS9; KNAKE S, 2006, TREATMENT EPILEPSY P, P1009; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCNAMARA JO, 1989, EPILEPSIA, V30, pS13, DOI 10.1111/j.1528-1157.1989.tb05809.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 1999, EPILEPSY RES, V33, P67, DOI 10.1016/S0920-1211(98)00074-6; Prince D A, 1999, Adv Neurol, V79, P665; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Wang J.Y., 2008, ARCH NEUROL-CHICAGO, V65, P1; WILLMORE LJ, 1990, NEUROLOGY S3, V31, pS67; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7	45	58	61	0	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						14	20		10.1111/j.1528-1167.2008.02006.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	399VN	WOS:000262827500004	19187290	Bronze			2022-02-06	
J	Driver, S; Ede, A				Driver, Simon; Ede, Alison			Impact of physical activity on mood after TBI	BRAIN INJURY			English	Article						physical activity; exercise; rehabilitation; brain injury; aquatics	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; ACUTE REHABILITATION; COPING STRATEGIES; SOCIAL SUPPORT; FOLLOW-UP; ACTIVITY BEHAVIORS; HEAD TRAUMA; EXERCISE; INDIVIDUALS	Primary objective: To examine the effect of a physical activity programme on the mood states of individual's with a traumatic brain injury. Research design: Participants were randomly assigned to an experimental (aquatic physical activity intervention) (n = 8) or control group (n = 8). Methods and procedures: The intervention group completed an 8-week aquatic programme consisting of 24 sessions. The control group completed a vocational rehabilitation class for the same number of weeks and sessions. Participants within the physical activity and control group completed the Profile of Mood States (POMS) pre- and post-programme. The POMS measures six dimensions of mood including tension, depression, anger, vigour, fatigue and confusion. An ANOVA was completed to examine between and within group differences pre- and post-programme. Main outcomes and results: Results for the experimental group indicated significant differences and large effect sizes for tension, depression, anger, vigour, fatigue and confusion. No significant differences were found for the control group across all variables. Conclusions: As research has shown increased disturbances in psychosocial states following a brain injury as well as higher rates of depression, results have important implications for individuals involved in rehabilitation, as physical activity can positively influence mood.	[Driver, Simon] Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, Denton, TX 76203 USA		Driver, S (corresponding author), Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, POB 310769, Denton, TX 76203 USA.	simon.driver@unt.edu		driver, simon/0000-0003-2356-432X			Alderson AL, 2002, J HEAD TRAUMA REHAB, V17, P210, DOI 10.1097/00001199-200206000-00003; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arenth PM, 2006, BRAIN INJURY, V20, P253, DOI 10.1080/02699050500487662; Baker CW, 2003, HEALTH PSYCHOL, V22, P189, DOI 10.1037/0278-6133.22.2.189; BANDURA A, 1977, J PERS SOC PSYCHOL, V35, P125, DOI 10.1037/0022-3514.35.3.125; Bandura A., 1986, SOCIAL FDN THOUGHT A, P544; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bowen A, 1999, BRAIN INJURY, V13, P547; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bullock C. C., 1991, Therapeutic Recreation Journal, V25, P7; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; Callaghan P, 2004, J Psychiatr Ment Health Nurs, V11, P476, DOI 10.1111/j.1365-2850.2004.00751.x; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cohen J., 1988, STAT ANAL BEHAV SCI; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dawes H, 2006, DISABIL REHABIL, V28, P1243, DOI 10.1080/09638280600554595; Deb S, 1999, AM J PSYCHIAT, V156, P374; DiLorenzo TM, 1999, PREV MED, V28, P75, DOI 10.1006/pmed.1998.0385; Driver S, 2006, ADAPT PHYS ACT Q, V23, P148, DOI 10.1123/apaq.23.2.148; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2005, BRAIN INJURY, V19, P1067, DOI 10.1080/02699050500149338; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; DRYOVAGE J, 1992, COGNITIVE REHABILITA, V4, P12; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fazio S M, 1988, Ther Recreation J, V22, P46; Fines L., 1994, J COGNITIVE REHABILI, P10; Finset A, 2000, BRAIN INJURY, V14, P887; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenwood M. C., 1990, ADAPTED PHYS ACTIVIT, V7, P12, DOI DOI 10.1123/APAQ.7.1.12; HORVAT M, 1986, PARAPLEGIA, V24, P115, DOI 10.1038/sc.1986.15; Israelian MK, 2000, REHABIL PSYCHOL, V45, P284, DOI 10.1037/0090-5550.45.3.284; Johnson CC, 2000, J HLTH ED, V31, P2, DOI DOI 10.1080/10556699.2000.10608640; KALPAKJIAN C, 2001, DISS ABSTR INT B, V61, P6709; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lane AM, 2000, J APPL SPORT PSYCHOL, V12, P16, DOI 10.1080/10413200008404211; Lane AM, 2002, PERCEPT MOTOR SKILL, V94, P732, DOI 10.2466/PMS.94.3.732-734; Lane AM, 2001, J SPORT MED PHYS FIT, V41, P539; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; Lox CL, 1999, REHABIL PSYCHOL, V44, P1; LOX CL, 1996, J HEALTH PSYCHOL, V2, P235; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin JJ, 2002, SPORT PSYCHOL, V16, P384, DOI 10.1123/tsp.16.4.384; MCAULEY E, 1993, J BEHAV MED, V16, P103, DOI 10.1007/BF00844757; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; McGrath JC, 2008, CLIN REHABIL, V22, P635, DOI 10.1177/0269215507086432; McNair DM, 1971, PROFILE MOOD STATES; Mutrie N., 1995, European perspectives on exercise and sport psychology., P50; North T C, 1990, Exerc Sport Sci Rev, V18, P379; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PETRUZZELLO SJ, 1991, SPORTS MED, V11, P143, DOI 10.2165/00007256-199111030-00002; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SLOAN S, 2007, BRAIN IMPAIRMENT, V12, P251; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Stern RA, 1997, APHASIOLOGY, V11, P59, DOI 10.1080/02687039708248455; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUMBO NJ, 1990, THERAPEUTIC RECREATI, V24, P64; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor-Piliae RE, 2007, TOP STROKE REHABIL, V14, P9, DOI 10.1310/tsr1404-9; Terry PC, 2000, J APPL SPORT PSYCHOL, V12, P93, DOI 10.1080/10413200008404215; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zoerink D. A., 1991, Therapeutic Recreation Journal, V25, P19; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	91	58	59	2	23	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	3					203	212	PII 908612884	10.1080/02699050802695574			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100003	19205956				2022-02-06	
J	Immonen, RJ; Irina, KIB; Niskanen, JP; Heidi, GC; Pitkanen, A; Grohn, OHJ				Immonen, Riikka J.; Kharatishvili, Irina; Niskanen, Juha-Pekka; Grohn, Heidi; Pitkanen, Asla; Grohn, Olli H. J.			Distinct MRI pattern in lesional and perilesional area after traumatic brain injury in rat-11 month's follow-up	EXPERIMENTAL NEUROLOGY			English	Article							LATERAL FLUID-PERCUSSION; MAGNETIC-RESONANCE SPECTROSCOPY; APOPTOTIC CELL-DEATH; NEURONAL DEGENERATION; CEREBRAL-ISCHEMIA; ROTATING-FRAME; TIME-COURSE; RATS; MODEL; DIFFUSION	To understand the dynamics of progressive brain damage after lateral fluid-percussion induced traumatic brain injury (TBI) in rat, which is the most widely used animal model of closed head TBI in humans, MRI follow-up of 11 months was performed. The evolution Of tissue damage was quantified using MRI contrast parameters T-2, T-1 rho, diffusion (D-av), and tissue atrophy in the focal cortical lesion and adjacent areas: the perifocal and contralateral cortex, and the ipsilateral and contralateral hippocampus. In the primary cortical lesion area, which undergoes remarkable irreversible pathologic changes, MRI alterations start at 3 h post-injury and continue to progress for LIP to 6 months. Ill more mildly affected perifocal and hippocampal regions, the robust alterations in T-2, T-1 rho, and D-av at 3 h to 3 d post-injury normalize within the next 9-23 d, and thereafter, progressively increase for several weeks. The severity of damage in the perifocal and hippocampal areas 23 d post-injury appeared independent of the focal lesion Volume. Magnetic resonance spectroscopy (MRS) performed at 5 and 10 months post-injury detected metabolic alterations in the ipsilateral hippocampus, Suggesting ongoing neurodegeneration and inflammation. Our data show that TBI induced by lateral fluid-percussion injury triggers long-lasting alterations with region-dependent temporal profiles. Importantly, the temporal pattern in MRI parameters during the first 23 d post-injury call indicate the regions that will develop secondary damage. This information is Valuable for targeting and timing interventions ill Studies aiming at alleviating or reversing the molecular and/or cellular cascades Causing the delayed injury. (C) 2008 Elsevier Inc. All rights reserved.	[Immonen, Riikka J.; Niskanen, Juha-Pekka; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Biomed Imaging Unit, Biomed NMR Res Grp,Dept Neurobiol, FIN-70211 Kuopio, Finland; [Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Grohn, Heidi] N Karelia Cent Hosp, Dept Clin Physiol Nucl Med & Neurophysiol, FIN-80120 Joensuu, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland		Grohn, OHJ (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Biomed Imaging Unit, Biomed NMR Res Grp,Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE (Citizens United for Research for Epilepsy); Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural FoundationFinnish IT center for science	This work was Supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, CURE (Citizens United for Research for Epilepsy), the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Maarit Pulkkinen, Mr. Jarmo Hartikainen, Mrs. Merja Lukkari, and Jari Nissinen, Ph.D., for technical assistance, Nick Hayward, M.Sc., for revising the language of the Manuscript, and Ivan Tkac providing the short echo time STEAM pulse sequence.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Berry I, 1986, Acta Radiol Suppl, V369, P338; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Choi CB, 2005, EUR J RADIOL, V55, P96, DOI 10.1016/j.ejrad.2004.10.009; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dube C, 2001, EXP NEUROL, V167, P227, DOI 10.1006/exnr.2000.7561; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Duvvuri U, 2001, RADIOLOGY, V220, P822, DOI 10.1148/radiol.2203001662; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Grohn HI, 2005, MAGN RESON MED, V54, P14, DOI 10.1002/mrm.20536; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Karhunen H, 2005, NEUROCHEM RES, V30, P1529, DOI 10.1007/s11064-005-8831-y; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Makela HI, 2001, BIOCHEM BIOPH RES CO, V289, P813, DOI 10.1006/bbrc.2001.6058; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Michaeli S, 2006, J MAGN RESON, V181, P135, DOI 10.1016/j.jmr.2006.04.002; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RINK A, 1995, AM J PATHOL, V147, P1575; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; SEPPONEN RE, 1985, J COMPUT ASSIST TOMO, V9, P1007, DOI 10.1097/00004728-198511000-00002; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201	53	58	60	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					29	40		10.1016/j.expneurol.2008.09.009			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	394QM	WOS:000262462300004	18929562				2022-02-06	
J	Maassen, GH; Bossema, E; Brand, N				Maassen, Gerard H.; Bossema, Ercolie; Brand, Nico			Reliable change and practice effects: Outcomes of various indices compared	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Reliable change index; Practice effects; Standard error of measurement of the difference; Standard error of prediction; Regression-based index	CLINICALLY SIGNIFICANT CHANGE; SPORT CONCUSSION; PSYCHOTHERAPY; REGRESSION; JACOBSON; ERROR	In this article the outcomes of three indices for the assessment of reliable change (RCIs) are compared: the null hypothesis method of Chelune, Naugle, Luders, Sedlak, and Awad (1993), the regression-based method of McSweeny, Naugle, Chelune, and Luders (1993), and a recently proposed adjustment to the latter procedure (Maassen, 2003). Simulated data demonstrated the importance of using large control samples. The regression-based method proved to be the most lenient in designating individuals as reliably changed, resulting in the most correct and the most incorrect designations. The adjusted procedure resulted in fewer correct designations and the lowest numbers of incorrect designations. Real-world data showed the same patterns.	[Maassen, Gerard H.; Bossema, Ercolie; Brand, Nico] Univ Utrecht, Utrecht, Netherlands		Maassen, GH (corresponding author), POB 80-140, NL-3508 TC Utrecht, Netherlands.	g.h.maassen@uu.nl					Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bossema ER, 2005, J VASC SURG, V41, P775, DOI 10.1016/j.jvs.2004.12.057; BRAND AN, 1992, J AFFECT DISORDERS, V25, P77, DOI 10.1016/0165-0327(92)90095-N; BRAND N, 1990, EUROPEAN PERSPECTIVE, V2, P321; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Hageman WJJM, 1999, BEHAV RES THER, V37, P1169; HAGEMAN WJJM, 1993, BEHAV RES THER, V31, P693, DOI 10.1016/0005-7967(93)90122-B; HSU LM, 1989, BEHAV ASSESS, V11, P459; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; L?ders H., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maassen GH, 2006, BRIT J SPORT MED, V40, P829, DOI 10.1136/bjsm.2005.023713; Maassen GH, 2000, J CLIN EXP NEUROPSYC, V22, P622, DOI 10.1076/1380-3395(200010)22:5;1-9;FT622; Maassen GH, 2000, PSYCHOMETRIKA, V65, P187, DOI 10.1007/BF02294373; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; MAASSEN GH, 2003, NEDERLANDS TIJDSCHRI, V58, P69; McNemar Q, 1962, PSYCHOL STAT; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Wald FD, 1990, NED TIJDSCHR PSYCHOL, V45, P86; Zegers F. E., 1994, ULTIMATE RELIABLE CH	25	58	58	1	17	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					339	352	PII 794906104	10.1080/13803390802169059			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100008	18618359				2022-02-06	
J	Patel, SP; Sullivan, PG; Pandya, JD; Rabchevsky, AG				Patel, Samir P.; Sullivan, Patrick G.; Pandya, Jignesh D.; Rabchevsky, Alexander G.			Differential Effects of the Mitochondrial Uncoupling Agent, 2,4-Dinitrophenol, or the Nitroxide Antioxidant, Tempol, on Synaptic or Nonsynaptic Mitochondria After Spinal Cord Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						electron transport system; excitotoxicity; mitochondrial bioenergetics; mitochondrial membrane potential (Delta Psi); mitochondrial permeability transition; oxidative damage	TRAUMATIC BRAIN-INJURY; PERMEABILITY TRANSITION; THERAPEUTIC TARGET; CALCIUM-UPTAKE; IMPROVES; NEURONS; DEATH; EXCITOTOXICITY; BIOENERGETICS; REDUCTION	We recently documented the progressive nature of mitochondrial dysfunction over 24 hr after contusion spinal cord injury (SCI), but the underlying mechanism has not been elucidated. We investigated the effects of targeting two distinct possible mechanisms of mitochondrial dysfunction by using the mitochondrial uncoupler 2,4-dinitrophenol (2,4-DNP) or the nitroxide antioxidant Tempol after contusion SCI in rats. A novel aspect of this study was that all assessments were made in both synaptosomal (neuronal)- and nonsynaptosomal (glial and neuronal soma)-derived mitochondria 24 hr after injury. Mitochondrial uncouplers target Ca2+ cycling and subsequent reactive oxygen species production in mitochondria after injury. When 2,4-DNP was injected 15 and 30 min after injury, mitochondrial function was preserved in both populations compared with vehicle-treated rats, whereas 1 hr postinjury treatment was ineffective. Conversely, targeting peroxynitrite with Tempol failed to maintain normal bioenergetics in synaptic mitochondria, but was effective in nonsynaptic mitochondria when administered 15 min after injury. When administered at 15 and 30 min after injury, increased hydroxynonenal, 3-NT, and protein carbonyl levels were significantly reduced by 2,4-DNP, whereas Tempol only reduced 3-NT and protein carbonyls after SCI. Despite such antioxidant effects, only 2,4-DNP was effective in preventing mitochondrial dysfunction, indicating that mitochondrial Ca2+ overload may be the key mechanism involved in acute mitochondrial damage after SCI. Collectively, our observations demonstrate the significant role that mitochondrial dysfunction plays in SCI neuropathology. Moreover, they indicate that combinatorial therapeutic approaches targeting different populations of mitochondria holds great potential in fostering neuroprotection after acute SCI. (C) 2008 Wiley-Liss,Inc.	[Patel, Samir P.; Sullivan, Patrick G.; Pandya, Jignesh D.; Rabchevsky, Alexander G.] Univ Kentucky, SCoBIRC, Lexington, KY 40536 USA; [Patel, Samir P.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Sullivan, Patrick G.; Pandya, Jignesh D.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Rabchevsky, AG (corresponding author), Univ Kentucky, SCoBIRC, B471 Biomed & Biol Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	Kentucky Spinal Cord and Head Injury Research Trust [3-11, NS 048191]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER	Kentucky Spinal Cord and Head Injury Research Trust; Contract grant number: 3-11 (to A.G.R.); Contract grant number: NS 048191 (to P.G.S.).	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bambrick LL, 2006, J BIOENERG BIOMEMBR, V38, P43, DOI 10.1007/s10863-006-9004-7; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; CHEN KY, 1985, BIOCHIM BIOPHYS ACTA, V845, P189, DOI 10.1016/0167-4889(85)90176-4; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1993, RES P ARNMD, V71, P81; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Ljubkovic M, 2007, AM J PHYSIOL-CELL PH, V292, pC1583, DOI 10.1152/ajpcell.00221.2006; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tzagoloff, 1967, METHOD ENZYMOL, V10, P245; Ueda A, 2003, MOL CELL BIOCHEM, V244, P119, DOI 10.1023/A:1022477530291; White RJ, 1996, J NEUROSCI, V16, P5688; ZIENGLER D, 1967, METHOD ENZYMOL, V10, P231	37	58	62	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2009	87	1					130	140		10.1002/jnr.21814			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	397QX	WOS:000262678300014	18709657	Green Accepted			2022-02-06	
J	Theriault, M; De Beaumont, L; Gosselin, N; Filipinni, M; Lassonde, M				Theriault, Martin; De Beaumont, Louis; Gosselin, Nadia; Filipinni, Melissa; Lassonde, Maryse			Electrophysiological abnormalities in well functioning multiple concussed athletes	BRAIN INJURY			English	Article						Event-related potentials; concussion; P3a; P3b; athletes	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SPORTS CONCUSSION; LONG-TERM; P300; RECOVERY; P3A; EPIDEMIOLOGY	Objective: The present study was aimed at characterizing the short- and long-term effects of multiple concussions using an electrophysiological approach. Method: Participants for this study were recruited from college football teams. They included athletes who never sustained concussions compared to two groups of asymptomatic multiple concussed athletes, one that sustained their last concussion within the year and the other more than 2 years prior to testing. All participants were submitted to an auditory three-tone Oddball paradigm while event-related potentials (ERP) were recorded. Results: Results from ERP recordings reveal significantly reduced P3a and P3b amplitudes in the recent concussed group in the three-tone task compared to control athletes. In contrast, athletes who sustained their concussions more than 2 years prior to testing had equivalent P3a and P3b amplitude to that of controls. Conclusion: These findings suggest that, despite functioning normally in their daily lives, concussed athletes still show subtle neuronal changes in information processing. Thus, the persistence of sub-clinical abnormalities on ERP components despite normal overt functioning may indicate sub-optimal compensation in multiple concussed athletes and leave them vulnerable to subsequent concussions.	[Lassonde, Maryse] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada		Lassonde, M (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maryse.lassonde@umontreal.ca			Canadian Institutes of Health Research (CIHR: ML)Canadian Institutes of Health Research (CIHR); Reseau Provincial de Recherche en Adaptation Readaptation (REPAR: MT); Fonds de la Recherche en Sante du Quebec (FRSQ: MT) and the CIHR (LDB)Fonds de la Recherche en Sante du Quebec	This work was supported by a Canada Research Chair in Developmental Neuropsychology held by ML, research grants by the Canadian Institutes of Health Research (CIHR: ML), scholarships by the Reseau Provincial de Recherche en Adaptation Readaptation (REPAR: MT), the Fonds de la Recherche en Sante du Quebec (FRSQ: MT) and the CIHR (LDB). We also wish to thank GT, MD for his precious contribution to the recruitment process.	American Clinical Neurophysiology Society, 2006, J Clin Neurophysiol, V23, P107; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARTH J, 1989, J COGNITIVE NEUROREH, V26, P451; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comerchero MD, 1999, CLIN NEUROPHYSIOL, V110, P24, DOI 10.1016/S0168-5597(98)00033-1; Comerchero MD, 1998, COGNITIVE BRAIN RES, V7, P41, DOI 10.1016/S0926-6410(98)00009-3; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Elting JW, 2005, CLIN NEUROPHYSIOL, V116, P2606, DOI 10.1016/j.clinph.2005.07.014; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JOHNSON R, 1978, ELECTROEN CLIN NEURO, V44, P424, DOI 10.1016/0013-4694(78)90027-5; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; Kopp B, 2006, J COGNITIVE NEUROSCI, V18, P949, DOI 10.1162/jocn.2006.18.6.949; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEZAK MD, 1995, NEUROPSYCHYOLOGICAL; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nordby H, 1999, PERCEPT MOTOR SKILL, V88, P819, DOI 10.2466/PMS.88.3.819-830; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	52	58	60	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					899	906	PII 915243219	10.1080/02699050903283189			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300006	20100126				2022-02-06	
J	Foley, N; Marshall, S; Pikul, J; Salter, K; Teasell, R				Foley, Norine; Marshall, Shawn; Pikul, Jill; Salter, Katherine; Teasell, Robert			Hypermetabolism following Moderate to Severe Traumatic Acute Brain Injury: A Systematic Review	JOURNAL OF NEUROTRAUMA			English	Article						energy expenditure; head injury; nutrition; review	SEVERE HEAD-INJURY; MEASURED ENERGY-EXPENDITURE; PARENTERAL-NUTRITION; METABOLIC-RESPONSE; NITROGEN-EXCRETION; OXYGEN-CONSUMPTION; REQUIREMENTS; PATIENT; SEDATION; THERAPY	Elevations of metabolic rate following traumatic brain injury (TBI) have been reported previously, with estimates ranging from 32% to 2009% above normal values. Die aim of this systematic review was to describe the pattern of energy expenditure during the first 30 days following TBI. We searched six databases for trials that measured the energy expenditure at least once during the first 30 days post-injury and compared that value to one that would be predicted in the non-injured state. We identified 24 studies, three of which were randomized controlled trials (RCTs). The sample sizes of the included studies ranged from 6 to 80 (mean, 24.7), and the mean Glasgow Coma Scale (GCS) score of subjects was 4.8. Mean energy expenditure, expressed as a percentage of a predicted value, ranged from 75% to 2009%. The lowest values were reported in patients admitted in brain death. Several factors were found to have modulating effects on energy expenditure. The administration of paralyzing agents, sedatives, or barbiturates reduced metabolic rate by approximately 12-32%. Propranolol and morphine were associated with smaller decreases in energy expenditure. Factors that do not appear to augment the hypermetabolic response included the administration of steroids and method of feeding (enteral vs. parenteral). Based on our results, it was unclear if elevated temperature, the presence of extracranial injury, or the severity of injury further exacerbate hypermetabolism. We conclude that energy expenditure following TBI is highly variable, and the use of standard factors to estimate the energy needs of individual patients are inappropriate and should be discouraged.	[Foley, Norine; Salter, Katherine] Parkwood Hosp, Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, London, ON N6C 5J1, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa Hosp Rehabil Ctr, Ottawa, ON, Canada; [Pikul, Jill] London Hlth Sci Ctr, Trauma & Transplant Program, London, ON, Canada; [Teasell, Robert] Parkwood Hosp, Dept Phys Med & Rehabil, London, ON N6C 5J1, Canada		Foley, N (corresponding author), Parkwood Hosp, Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, Room B-3019B,801 Commissioners Rd E, London, ON N6C 5J1, Canada.	norine.foley@sjhc.london.on.ca			Ontario Neurotrauma Foundation	This project was funded in part by a grant from the Ontario Neurotrauma Foundation.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bitzani M, 1999, INTENS CARE MED, V25, P970, DOI 10.1007/s001340050991; Boothby WM, 1936, AM J PHYSIOL, V116, P468, DOI 10.1152/ajplegacy.1936.116.2.468; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; *BRAIN TRAUMA FDN, 2000, NUTR J NEUROTRAUMA, V17, P539; Brain Trauma Foundation, 2007, NUTR J NEUROTRAUMA, V24, pS77; Bratton S.L., 2007, J NEUROTRAUM, V24, pS, DOI [10.1089/neu.2007.9981, DOI 10.1089/NEU.2007.9981]; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; BURSZTEIN S, 1978, CRIT CARE MED, V6, P162, DOI 10.1097/00003246-197805000-00008; CARLSON GL, 1994, AM J PHYSIOL, V266, pE845, DOI 10.1152/ajpendo.1994.266.6.E845; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Elia M, 1992, World Rev Nutr Diet, V70, P68; ELWYN DH, 1980, CRIT CARE MED, V8, P9, DOI 10.1097/00003246-198001000-00003; Esper DH, 2006, JPEN-PARENTER ENTER, V30, P71, DOI 10.1177/014860710603000271; FORSBERG E, 1994, CLIN NUTR, V13, P291, DOI 10.1016/0261-5614(94)90052-3; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; Harris J.A., 1919, BIOMETRIC STUDY BASA; HEYMSFIELD SB, 1987, AM J CLIN NUTR, V45, P526, DOI 10.1093/ajcn/45.3.526; KOLPEK JH, 1989, JPEN-PARENTER ENTER, V13, P277, DOI 10.1177/0148607189013003277; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; LEWIS WD, 1988, CRIT CARE MED, V16, P117, DOI 10.1097/00003246-198802000-00004; Loan T, 1999, NUTRITION, V15, P809; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; McCall M, 2003, JPEN-PARENTER ENTER, V27, P27, DOI 10.1177/014860710302700127; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; OTT L, 1989, NUTRITION, V5, P75; OTT M, 1994, CRIT CARE MED, V22, P393, DOI 10.1097/00003246-199403000-00007; OWEN OE, 1988, MAYO CLIN PROC, V63, P503, DOI 10.1016/S0025-6196(12)65649-3; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; PEVSNER PH, 1971, JOHNS HOPKINS MED J, V128, P134; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Roberts P R, 1995, New Horiz, V3, P506; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; VERNET O, 1986, AM J PHYSIOL, V250, pE47, DOI 10.1152/ajpendo.1986.250.1.E47; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; Wilson RF, 1998, J HEAD TRAUMA REHAB, V13, P11, DOI 10.1097/00001199-199802000-00005; Yanagawa T, 2002, COCHRANE DB SYST REV; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; YOUNG B, 1992, J NEUROTRAUM, V9, pS375; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	54	58	64	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1415	1431		10.1089/neu.2008.0628			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500003	19118457				2022-02-06	
J	Tokutomi, T; Miyagi, T; Ogawa, T; Ono, J; Kawamata, T; Sakamoto, T; Shigemori, M; Nakamura, N				Tokutomi, Takashi; Miyagi, Tomoya; Ogawa, Takeki; Ono, Jun-ichi; Kawamata, Tatsuro; Sakamoto, Tetsuya; Shigemori, Minoru; Nakamura, Norio			Age-Associated Increases in Poor Outcomes after Traumatic Brain Injury: A Report from the Japan Neurotrauma Data Bank	JOURNAL OF NEUROTRAUMA			English	Article						age; outcome; traumatic brain injury	CLOSED-HEAD INJURY; COMPUTERIZED-TOMOGRAPHY; ADULT PATIENTS; FARE WORSE; MORTALITY; DEATH; COMA; DETERIORATE; PREDICTOR; CYTOKINES	Age is an important factor influencing outcome after severe traumatic brain injury (TBI). In general, the older the victim, the higher the probability of a poor Outcome. To investigate the mechanism underlying the link between age and Outcome, the data for 797 patients enrolled in the Japan Neurotrauma Data Bank (JNTDB), aged 6 years or older, with Glasgow Coma Scale (GCS) scores of 8 or less on admission or deterioration to that level within 48 h of impact were analyzed. Thirty-eight percent of the patients were between the ages of 40 and 69 years, and 24%, of the patients were older than 69 years. Older patients had higher rates of mortality and lower rates of favorable outcome. The frequency of mass lesions which were associated with poorer outcomes significantly increased with age, but regardless of the intracranial lesion type, older patients had poorer outcomes. The GCS score and the occurrence of systemic complications did not differ significantly according to age. Multiple systemic injury was less frequent in older patients. The varied Occurrence of intracranial lesion types according to age is likely caused by the disparity between the young and aged brain in the progression of secondary brain injury. Alteration in the pathophysiological response, which is related to the development of secondary brain injury in the aging brain, probably contributes to more severe and irreversible brain damage in older patients, and is thus associated with poor outcomes.	[Tokutomi, Takashi; Miyagi, Tomoya; Shigemori, Minoru] Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan; [Tokutomi, Takashi; Ogawa, Takeki; Ono, Jun-ichi; Kawamata, Tatsuro; Sakamoto, Tetsuya; Shigemori, Minoru; Nakamura, Norio] Japanese Council Traff Sci, Japan Soc Neurotraumatol, Japan Neurotrauma Data Bank Comm, Tokyo, Japan		Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@med.kurume-u.ac.jp			General Insurance Association of Japan; Mitsui Sumitomo Insurance Welfare FoundationMitsui Sumitomo Insurance Welfare Foundation; Japan Brain Foundation	This work was Supported by a grant from The General Insurance Association of Japan, Mitsui Sumitomo Insurance Welfare Foundation, and the Japan Brain Foundation.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; *DEP EC SOC AFF PO, 2007, WORLD POP PROSP 2006; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; Nijboer JMM, 2007, J TRAUMA, V63, P670, DOI 10.1097/01.ta.0000228890.65522.53; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; Yokota H, 2007, NEUROL MED-CHIR, V47, P383, DOI 10.2176/nmc.47.383	38	58	59	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1407	1414		10.1089/neu.2008.0577			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500002	19086809				2022-02-06	
J	Wasserman, JK; Schlichter, LC				Wasserman, Jason K.; Schlichter, Lyanne C.			White matter injury in young and aged rats after intracerebral hemorrhage	EXPERIMENTAL NEUROLOGY			English	Article						Stroke; Traumatic brain injury; Axonal injury; Demyelination; Microglial activation; Amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; MIDDLE CEREBRAL-ARTERY; DELAYED MINOCYCLINE TREATMENT; TRAUMATIC BRAIN-INJURY; AXONAL-TRANSPORT; DAMAGED AXONS; NEURON DEATH; BETA-APP; STROKE; EDEMA	Experimental studies of intracerebral hemorrhage (ICH) have focused on neuron death, with little or no information on axonal and myelin damage outside the hematoma. Because development of effective therapies will require an understanding of white matter injury, we examined white matter injury and its spatial and temporal relationship with microglial/macrophage activation in a collagenase model of rat striatal ICH. The hematoma and parenchyma surrounding the hematoma were assessed in young and aged animals at 6 h, 1, 3 and 28 days after ICH onset. Demyelination occurred inside and at the edge of the hematoma; regions where we have shown substantial neuron death. In contrast, there was axonal damage without demyelination at the edge of the hematoma, and by 3 days this damage had spread to the surrounding parenchyma, a region where we have shown there is no neuron death. Because the axonal damage preceded infiltration of activated microglia into the white matter tracts (seen at 3 days), our results support the hypothesis that these cells respond to, rather than perpetrate the damage. Importantly, axonal damage was worse in aged animals, which provides a plausible explanation for the poorer functional recovery of older animals after ICH, despite a similar loss of grey matter. Our findings support strategies that target white matter injury to reduce neurological impairment after ICH. (C) 2008 Elsevier Inc. All rights reserved.	[Schlichter, Lyanne C.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Univ Hlth Network, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada		Schlichter, LC (corresponding author), Toronto Western Hosp, 399 Bathurst St,MC 9-415, Toronto, ON M5T 2S8, Canada.	schliclit@uhnres.utoronto.ca		Wasserman, Jason/0000-0003-3821-8956	Heart & Stroke Foundation, OntarioHeart & Stroke Foundation of CanadaHeart & Stroke Foundation of Ontario [T5546, T6279]; Peterborough KM Hunter Foundation; Heart & Stroke Foundation, OntarioHeart & Stroke Foundation of CanadaHeart & Stroke Foundation of Ontario	Excellent technical assistance was provided by Helen Wang. JKW's work would not have been accomplished without support from Talea Coghlin. Supported by operating grants to LCS from the Heart & Stroke Foundation, Ontario Chapter (HSFO; T5546; T6279), and scholarships to JKW from the Peterborough KM Hunter Foundation, and the Heart & Stroke Foundation, Ontario Chapter.	Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Fordyce CB, 2005, J NEUROSCI, V25, P7139, DOI 10.1523/JNEUROSCI.1251-05.2005; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Marik C, 2007, BRAIN, V130, P2800, DOI 10.1093/brain/awm236; Matsuo A, 1997, AM J PATHOL, V150, P1253; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; MORIOKA T, 1993, J COMP NEUROL, V327, P123, DOI 10.1002/cne.903270110; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Qureshi AI, 2003, CRIT CARE MED, V31, P1482, DOI 10.1097/01.CCM.0000063047.63862.99; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Rincon Fred, 2004, Curr Opin Crit Care, V10, P94, DOI 10.1097/00075198-200404000-00003; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; SCHMUED LC, 1990, J HISTOCHEM CYTOCHEM, V38, P717, DOI 10.1177/38.5.1692056; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tepper JM, 2007, PROG BRAIN RES, V160, P3, DOI 10.1016/S0079-6123(06)60001-0; Wagner KR, 2005, CURR NEUROVASC RES, V2, P149, DOI 10.2174/1567202053586785; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4	45	58	67	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2008	214	2					266	275		10.1016/j.expneurol.2008.08.010			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	380RW	WOS:000261483900014	18848934				2022-02-06	
J	Whelan-Goodinson, R; Ponsford, J; Schonberger, M				Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael			ASSOCIATION BETWEEN PSYCHIATRIC STATE AND OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; psychiatric disorders; outcome	MAJOR DEPRESSION; NATURAL-HISTORY; ALCOHOL; DISORDERS; AGE; REHABILITATION; PREDICTION; MODERATE	Objective: This study aimed to explore the relationship between current post-traumatic brain injury psychiatric disorders and psychosocial outcome. Design: A total of 100 participants and 87 significant others were interviewed using the Structured Clinical Interview for DSM-IV Diagnosis. Participants: Participants with mild to very severe traumatic brain injury up to 5.5 years post-injury. Methods: The Sydney Psychosocial Reintegration Scale assessed changes in vocational status, relationship status and independent living status. Results: The vocational domain of the Sydney Psychosocial Reintegration Scale revealed the greatest degree of change. Current depression and/or anxiety contributed significantly more variance to the regression models than did any other variables. Pre-injury psychiatric disorders and substance use disorders were not predictive of any outcome variables. Longer post-traumatic amnesia duration, fewer years of education, male gender and greater time post-injury were predictive of certain outcome domains. There were no significant differences between traumatic brain injury participants' self-report and the reports of their significant others regarding psychiatric symptoms or outcome measures. Conclusion: The presence of current depression and anxiety are strongly related to poor outcome in terms of vocational status, relationship status and independence. The causative direction of these relationships is unclear. Using a 3-domain outcome measure has shed some light on the factors that contribute to different aspects of outcome following traumatic brain injury.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, AU-3800 Clayton, Vic, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, AU-3800 Clayton, Vic, Australia.	jennie.ponsford@med.monash.edu.au					Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; DAWE S, 2002, MONOGRAPH SERIES COM, V48; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIRST MB, 2004, COMPUTER ASSISTED SC; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TURNER GR, 2004, COGNITIVE BEHAV REHA; WHELANGOODINSON R, J HEAD TRAU IN PRESS	38	58	59	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2008	40	10					850	857		10.2340/16501977-0271			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	400EN	WOS:000262850900011	19242623	Green Submitted, gold			2022-02-06	
J	Fish, J; Manly, T; Emslie, H; Evans, JJ; Wilson, BA				Fish, J.; Manly, T.; Emslie, H.; Evans, J. J.; Wilson, B. A.			Compensatory strategies for acquired disorders of memory and planning: differential effects of a paging system for patients with brain injury of traumatic versus cerebrovascular aetiology	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							REHABILITATION; PEOPLE; AID; RECOVERY	Background: Previous studies have demonstrated the effectiveness of paging systems in compensating for everyday memory and planning problems after brain injury, including in individuals with traumatic brain injury (TBI). Methods: Here, in addition to further analyses of the TBI data from a previous randomised control crossover trial, results are reported from a sub-group of 36 participants with brain injury from cerebrovascular accident (CVA). Results: Results indicate that, as with the TBI group, the pager was effective. However, the pattern of results following cessation of treatment differed. At a group level, TBI participants demonstrated maintenance of pagerrelated benefits, whereas CVA participants' performance returned to baseline levels. Comparisons of demographic and neuropsychological characteristics of the groups showed that the CVA group was older, had a shorter interval post-injury, and had poorer executive function than the TBI group. Furthermore, within the TBI group, maintenance was associated with executive functioning, such that executive dysfunction impeded maintenance. This correlation remained after controlling for demographic differences between groups. Conclusions: Together, these findings suggest that executive dysfunction may affect treatment-for example, whether or not temporary use of the pager is sufficient to establish a subsequently self- sustaining routine.	[Wilson, B. A.] Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; [Evans, J. J.] Univ Glasgow, Sect Psychol Med, Glasgow, Lanark, Scotland		Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Hills Rd,Box 58, Cambridge CB2 2QQ, England.	barbara.wilson@mrc-cbu.cam.ac.uk		Fish, Jessica/0000-0002-9337-1489	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105559837] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: Medline		Baddeley A., 1992, SPEED CAPACITY LANGU; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; CERMAK L S, 1975, Cortex, V11, P163; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Everitt B. S., 1996, MAKING SENSE STAT PS; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Intercollegiate Stroke Working Party, 2004, NAT CLIN GUID STROK; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kime SK, 1996, BRAIN INJURY, V10, P17; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; ROBERTSON IH, 1994, TEST EVERDAY ATTENTI; Royal College of Physicians and British Society of Rehabilitation Medicine, 2003, REH FOLL ACQ BRAIN I; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Voinikonis A, 2005, PERS UBIQUIT COMPUT, V9, P284, DOI 10.1007/s00779-004-0332-5; WILSON B, 1987, REHABILITATION MEMOR; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	31	58	58	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2008	79	8					930	935		10.1136/jnnp.2007.125203			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	328KF	WOS:000257796600017	18039889				2022-02-06	
J	Schumann, J; Alexandrovich, GA; Biegon, A; Yaka, R				Schumann, Johanna; Alexandrovich, G. Alexander; Biegon, Anat; Yaka, Rami			Inhibition of NR2B phosphorylation restores alterations in NMDA receptor expression and improves functional recovery following traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; MAPK; NMDA receptor; NR2B; tyrosine phosphorylation	D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; EXCITATORY AMINO-ACIDS; INCREASES TYROSINE PHOSPHORYLATION; TRANSIENT GLOBAL-ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; POSTSYNAPTIC DENSITIES; SYNAPTIC PLASTICITY; RAT-BRAIN	Traumatic brain injury (TBI) triggers a massive glutamate efflux, hyperactivation of N-methyl-D-aspartate receptors (NMDARs) and neuronal cell death. Previously it was demonstrated that, 15 min following experimentally induced closed head injury (CHI), the density of activated NMDARs increases in the hippocampus, and decreases in the cortex at the impact site. Here we show that CHI-induced alterations in activated NMDARs correlate with changes in the expression levels of the major NMDARs subunits. In the hippocampus, the expression of NR1, NR2A, and NR2B subunits as well as the GluR1 subunit of the AMPA receptor (AMPAR) were increased, while in the cortex at the impact site, we found a decrease in the expression of these subunits. We demonstrate that CHI-induced increase in the expression of NMDAR subunits and GluR1 in the hippocampus, but not in the cortex, is associated with an increase in NR2B tyrosine phosphorylation. Furthermore, inhibition of NR2B-phosphorylation by the tyrosine kinase inhibitor PP2 restores the expression of this subunit to its normal levels. Finally, a single injection of PP2, prior to the induction of CHI, resulted in a significant improvement in long-term recovery of motor functions observed in CHI mice. These results provide a new mechanism by which acute trauma contributes to the development of secondary damage and functional deficits in the brain, and suggests a possible role for Src tyrosine kinase inhibitors as preoperative therapy for planned neurosurgical procedures.	[Schumann, Johanna; Alexandrovich, G. Alexander; Yaka, Rami] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Biegon, Anat] Brookhaven Natl Lab, Upton, NY 11973 USA		Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			Israel Science FoundationIsrael Science Foundation [292/05]; Ministry of Health [6029-6]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 050285-01 A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	We thank Prof. Esther Shohami for helpful discussions and critical reading of the manuscript. This research was supported by the Israel Science Foundation (grant no. 292/05 R.Y.), Ministry of Health (grant no. 6029-6 R.Y.), and the National Institutes of Health (grant no. R01 NS 050285-01 A2, to A.B.).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 1996, ACT NEUR S, V67, P6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; Chen SJ, 1996, J NEUROCHEM, V67, P194; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Cheung HH, 2003, J NEUROCHEM, V86, P1441, DOI 10.1046/j.1471-4159.2003.01951.x; Crossthwaite AJ, 2004, J NEUROCHEM, V88, P1127, DOI 10.1046/j.1471-4159.2004.02257.x; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Dickerson J, 2006, NEUROPSYCHOPHARMACOL, V31, P1420, DOI 10.1038/sj.npp.1300878; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Gascon S, 2008, MOL PSYCHIATR, V13, P99, DOI 10.1038/sj.mp.4002017; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goebel SM, 2005, MOL BRAIN RES, V142, P65, DOI 10.1016/j.molbrainres.2005.09.012; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Hallett PJ, 2006, J NEUROSCI, V26, P4690, DOI 10.1523/JNEUROSCI.0792-06.2006; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jadhav V, 2007, J NEUROSURG, V106, P680, DOI 10.3171/jns.2007.106.4.680; Jadhav V, 2007, SURG NEUROL, V67, P15, DOI 10.1016/j.surneu.2006.07.014; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Schilstrom B, 2006, J NEUROSCI, V26, P8549, DOI 10.1523/JNEUROSCI.5179-05.2006; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Takagi N, 1999, J CEREBR BLOOD F MET, V19, P880, DOI 10.1097/00004647-199908000-00007; Takagi N, 1997, J NEUROCHEM, V69, P1060; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yaka R, 2003, ALCOHOL CLIN EXP RES, V27, P1736, DOI 10.1097/01.ALC.0000095924.87729.D8; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	76	58	59	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					945	957		10.1089/neu.2008.0521			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700001	18721106	Green Published			2022-02-06	
J	Stancin, T; Wade, SL; Walz, NC; Yeates, KO; Taylor, HG				Stancin, Terry; Wade, Shari L.; Walz, Nicolay C.; Yeates, Keith O.; Taylor, H. Gerry			Traumatic brain injuries in early childhood: Initial impact on the family	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; family impact; parent coping; early childhood	ASSESSMENT DEVICE; SEVERITY SCALE; SHORT-TERM; CHILDREN; OUTCOMES; RELIABILITY; ADAPTATION; VALIDITY; HEALTH; PREDICTORS	Objective: The purpose of this study was to examine factors that affect parental burden and distress during the first few months following a traumatic brain injury (TBI) in young children. Methods: Participants were consecutively enrolled children ages 3 through 6 years with either a TBI (n = 89; 21 severe, 22 moderate, and 45 complicated mild) or orthopedic injury (OI; n = 119) requiring hospitalization. During the post-acute period, parents provided information regarding the preinjury family environment and current caregiver functioning and injury-related burden. Results: Compared with parents of young children with OI, parents of children with TBI reported greater overall caregiver burden and greater burden related to the injury. Parents of children with severe TBI also reported more stress with spouses and siblings and higher levels of parental depression and global distress relative to the OI comparison group. Parents of 5- to 6-year-old children reported significantly higher levels of both injury-related burden and distress than parents of 3- to 4-year-old children. Parents of children with mild TBI based on the Glasgow Coma Scale (GCS) who also had positive neuroimaging findings reported greater injury-related burden than parents of children with moderate TBI. Parents reported using a variety of coping strategies, with higher levels of denial and disengagement corresponding with greater injury-related burden and distress. Conclusions: Consistent with previous research on family adaptation to TBI in school-age children, chronic life stresses and interpersonal resources accounted for significant variance in measures of acute injury-related burden and parental distress in parents of younger children, although differences were small. TBI severity defined by GCS scores alone may not be sufficient to identify families at risk of increased burden. Findings suggest that services aimed at facilitating family adjustment following TBI in young children may need to consider a broader definition of risk factors when identifying families who would benefit from interventions.	[Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Dept Rehabil, Med Ctr, Cincinnati, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp, Dept Pediat, Med Ctr, Div Pediat Psychol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus Childrens Hosp, Div Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Childrens Res Inst, Columbus, OH USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Div Dev & Behav Pediat & Pediat Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Cleveland, OH 44106 USA		Stancin, T (corresponding author), Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH 44109 USA.	tstancin@metrohealth.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR008084, M01 RR 08084, KL2 RR026315] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729, R01 HD42729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR026315, M01RR008084] Funding Source: NIH RePORTER		ALDWIN CM, 1987, J PERS SOC PSYCHOL, V53, P337, DOI 10.1037/0022-3514.53.2.337; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HOLAHAN CJ, 1987, J ABNORM PSYCHOL, V96, P3, DOI 10.1037/0021-843X.96.1.3; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lazurus RichardS., 1984, STRESS APPRAISAL COP; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MAYER T, 1984, J TRAUMA, V24, P31, DOI 10.1097/00005373-198401000-00004; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1994, LIFE STRESSORS SOCIA; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; WADE SL, 2006, TREATING NEURODEVELO, P170; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Youngblut JM, 2006, J PEDIATR PSYCHOL, V31, P608, DOI 10.1093/jpepsy/jsj066	36	58	59	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0196-206X			J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	AUG	2008	29	4					253	261		10.1097/DBP.0b013e31816b6b0f			9	Behavioral Sciences; Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology; Pediatrics	337CA	WOS:000258411900003	18454041				2022-02-06	
J	Hoffman, AN; Malena, RR; Westergom, BP; Luthra, P; Cheng, JP; Aslam, HA; Zafonte, RD; Kline, AE				Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.			Environmental enrichment-mediated functional improvement after experimental traumatic brain injury is contingent on task-specific neurobehavioral experience	NEUROSCIENCE LETTERS			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; Morris water maze; neurobehavior; traumatic brain injury	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; COGNITIVE DEFICITS; RECOVERY; RATS; HYPOTHERMIA; EXERCISE; PROTECTION; 8-OH-DPAT; SURVIVAL; EFFICACY	Environmental enrichment (EE) is superior to standard (STD) housing in promoting functional recovery after traumatic brain injury (TBI). However, whether the EE-mediated benefits after TBI are dependent on exposure to enrichment during neurobehavioral training has not been elucidated. To address this issue, isoflurane-anesthetized adult male rats received either a cortical impact or sham injury and were then randomly assigned to early EE, delayed EE, continuous EE or no EE (i.e., STD conditions). Continuous EE or no EE was initiated immediately after surgery and continued for the duration of the study. Early EE began directly after surgery, continued for I week, and was then followed by STD living (2 rats per cage) for the remainder of the study, while delayed EE commenced I week after early STD housing. Functional outcome was assessed with established motor and cognitive tests on post-injury days 1-5 and 14-18, respectively. CA(1)/CA(3) neurons were quantified at 3 weeks. CA(3) cell loss was significantly attenuated in the TBI +continuous EE group versus the TBI + no EE group. Beam-walking was facilitated in the TBI groups that received either early or continuous EE versus those receiving delayed or no EE. Cognitive training was enhanced in the TBI groups that received continuous or delayed EE versus the early EE or no EE groups. These data suggest that EE-mediated functional improvement after TBI is contingent on task-specific neurobehavioral experience. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.; Malena, Rebecca R.; Westergom, Brian P.; Luthra, Pallavi; Cheng, Jeffrey P.; Aslam, Haris A.; Zafonte, Ross D.; Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700, R01 HD046700-02, HD046700, R01 HD046700-03, R01 HD069620, R03 HD043851-01, HD043851, R03 HD043851, R03 HD043851-02, R01 HD046700-01A1, R01 HD046700-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER		BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001	22	58	59	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	FEB 6	2008	431	3					226	230		10.1016/j.neulet.2007.11.042			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	263PK	WOS:000253228800008	18162321	Green Accepted			2022-02-06	
J	Ashman, TA; Cantor, JB; Gordon, WA; Spielman, L; Egan, M; Ginsberg, A; Engmann, C; Dijkers, M; Flanagan, S				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Egan, Matthew; Ginsberg, Annika; Engmann, Clara; Dijkers, Marcel; Flanagan, Steven			Objective measurement of fatigue following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive performance; fatigue; mental fatigue; traumatic brain injury	SPATIAL WORKING-MEMORY; CLOSED-HEAD-INJURY; RHEUMATOID-ARTHRITIS; SUSTAINED ATTENTION; MULTIPLE-SCLEROSIS; CANCER-PATIENTS; MENTAL EFFORT; METHYLPHENIDATE; INVENTORY; VIGILANCE	Objectives: To quantify posttraumatic brain injury (post-TBI) mental fatigue objectively by documenting changes in performance on neuropsychological tests as a result of sustained mental effort and to examine the relationship between objectively measured mental fatigue and self-reported situational and day-to-day fatigue. Participants: The study included 202 community-dwelling individuals with mild-severe TBI and 73 noninjured controls. Measures: Measures included Cambridge Neuropsychological Test Automated Battery, Global Fatigue Index, and situational fatigue rating. Method: Subjects were administered a 30-minute computerized neuropsychological test battery 3 times. The second and third administrations of the battery were separated by approximately 2 hours of interviews and administration of self-report measures. Results: The neuropsychological test scores were factor analyzed, yielding 3 subscales: speed, accuracy, and executive function. Situational fatigue and day-to-day fatigue were significantly higher in individual with TBI group than in individuals without TBI and were associated with speed subscale scores. Individuals with TBI evidenced a significant decline in performance on the accuracy subscale score. These declines in performance related to sustained mental effort were not associated with subjective fatigue in the TBI group. While practice effects on the speed and accuracy scores were observed in non-brain-injured individuals, they were not evidenced in individuals with TBI. Conclusions: Findings were largely consistent with previous literature and indicated that while subjective fatigue is associated with poor performance in individuals with TBI, it is not associated with objective decline in performance of mental tasks.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Egan, Matthew; Ginsberg, Annika; Engmann, Clara; Dijkers, Marcel; Flanagan, Steven] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustav Levy Pl,Box 1240, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596; Flanagan, Steven/0000-0001-9005-5897			Aistars J, 1987, Oncol Nurs Forum, V14, P25; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; BELZA BL, 1995, J RHEUMATOL, V22, P639; BELZA BL, 1993, NURS RES, V42, P93; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1008842517972; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kirsh KL, 2001, J PAIN SYMPTOM MANAG, V22, P931, DOI 10.1016/S0885-3924(01)00350-5; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Luria AR, 1963, RESTORATION FUNCTION; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Mehta MA, 2000, J NEUROSCI, V20; MELAMED S, 1985, SCAND J REHABIL MED, P16; MORRIS RG, 1986, COGNITIVE NEUROCHEMI, P21; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Riekkinen M, 1999, NEUROSCIENCE, V92, P975, DOI 10.1016/S0306-4522(99)00070-6; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schwartz A L, 1998, Oncol Nurs Forum, V25, P711; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Schwid SR, 2002, J REHABIL RES DEV, V39, P211; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Mens-Verhulst J, 1997, WOMEN HEALTH, V26, P51; Van Mens-Verhulst J, 1998, SOC SCI MED, V47, P621, DOI 10.1016/S0277-9536(98)00116-6; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	41	58	58	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					33	40		10.1097/01.HTR.0000308719.70288.22			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800007	18219233				2022-02-06	
J	Davis, DP; Hwang, JQ; Dunford, JV				Davis, Daniel P.; Hwang, James Q.; Dunford, James V.			Rate of decline in oxygen saturation at various pulse oximetry values with prehospital rapid sequence intubation	PREHOSPITAL EMERGENCY CARE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-EMS-Physicians	JAN, 2007	Naples, FL	Natl Assoc EMS Phys		rapid sequence intubation; desaturation; hypoxemia; pulse oximetry	CRICOID PRESSURE; HEAD-INJURY; HYPOTENSION; ASPIRATION; INDUCTION; HYPOXIA; PREOXYGENATION; REGURGITATION; DESATURATION; VENTILATION	Background. A high incidence of desaturations has been observed during prehospital rapid sequence intubation (RSI). The rate of decline in oxygen saturation (SpO2) at various pulse oximetry values has not been defined with emergency RSI. Objective. To define the rate of SpO2 decline at various pulse oximetry values and identify a threshold below which active BVM should be performed during prehospital RSI. Methods. Traumatic brain injury (TBI) patients undergoing RSI by prehospital providers were included in this analysis. The time period from the highest to the lowest preintubation SpO2 value was selected for review. The mean rate of SpO2 decline was calculated for each SpO2 value and then used to define a theoretical SpO2 desaturation curve. The rate of desaturation to hypoxemia (SpO2 90%) was defined for intubation attempts initiated at each SpO2 value. Results. A total of 684 SpO2 values from 87 patients were included. Lower SpO2 values were associated with a faster rate of SpO2 decline, with an inflection point occurring at 93%. The rate of desaturation to hypoxemia with intubation attempts initiated with SpO2 <= 93% was much higher than with SpO2 above 93% (100% vs. 6%, p < 0.01). In patients undergoing multiple attempts, SpO2 values with BVM between attempts was consistently higher than the preintubation SpO2 value. Conclusions. The rate of SpO2 decline increases as SpO2 decreases, with an inflection point occurring around 93%. Intubation attempts below this value are almost always associated with subsequent desaturation, suggesting that BVM should be used prior to laryngoscopy in these patients.	[Davis, Daniel P.; Hwang, James Q.; Dunford, James V.] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA		Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Apfel CC, 2005, CURR OPIN ANESTHESIO, V18, P157, DOI 10.1097/01.aco.0000162834.33474.e0; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; BAILLARD C, 2006, AM J RESP CRIT CARE, P1; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034; Benumof JL, 1999, ANESTHESIOLOGY, V91, P603, DOI 10.1097/00000542-199909000-00006; Brimacombe JR, 1997, CAN J ANAESTH, V44, P414, DOI 10.1007/BF03014464; Butler J, 2005, EMERG MED J, V22, P815, DOI 10.1136/emj.2005.030205; Chassard D, 1996, CAN J ANAESTH, V43, P414, DOI 10.1007/BF03011724; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAVIS DP, 2004, UNPUB J TRAUMA; DRUMMOND GB, 1984, BRIT J ANAESTH, V56, P987, DOI 10.1093/bja/56.9.987; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Edmark L, 2003, ANESTHESIOLOGY, V98, P28, DOI 10.1097/00000542-200301000-00008; Engelhardt T, 1999, BRIT J ANAESTH, V83, P453, DOI 10.1093/bja/83.3.453; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; FANNING GL, 1970, ANESTHESIOLOGY, V32, P553, DOI 10.1097/00000542-197006000-00019; Farmery AD, 1996, BRIT J ANAESTH, V76, P284, DOI 10.1093/bja/76.2.284; Garrard A, 2004, ANAESTHESIA, V59, P435, DOI 10.1111/j.1365-2044.2004.03682.x; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Ho-Tai LM, 1998, CAN J ANAESTH, V45, P206, DOI 10.1007/BF03012903; JENSE HG, 1991, ANESTH ANALG, V72, P89; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Levitan RM, 2006, ANN EMERG MED, V47, P548, DOI 10.1016/j.annemergmed.2006.01.013; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RALPH SJ, 1991, ANAESTHESIA, V46, P40, DOI 10.1111/j.1365-2044.1991.tb09314.x; ROBERTS RB, 1974, ANESTH ANALG, V53, P859, DOI 10.1213/00000539-197453060-00010; Safdar Nasia, 2005, Respir Care, V50, P725; Salem MR, 2000, ANESTHESIOLOGY, V92, P1845, DOI 10.1097/00000542-200006000-00054; SELLICK BA, 1961, LANCET, V2, P404; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Smith KJ, 2003, ANESTHESIOLOGY, V99, P60, DOI 10.1097/00000542-200307000-00013; Smith KJ, 2002, CAN J ANAESTH, V49, P503, DOI 10.1007/BF03017931; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Tournadre JP, 1997, ANESTHESIOLOGY, V86, P7, DOI 10.1097/00000542-199701000-00003; VADEBONCOEUR TF, 2004, J EMERG MED; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wenzel V, 2001, RESUSCITATION, V49, P123, DOI 10.1016/S0300-9572(00)00349-X	45	58	58	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care		2008	12	1					46	51		10.1080/10903120701710470			6	Emergency Medicine; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine; Public, Environmental & Occupational Health	251CB	WOS:000252347100008	18189177				2022-02-06	
J	Simpkins, JW; Singh, M				Simpkins, James W.; Singh, Meharvan			More than a decade of estrogen neuroprotection	ALZHEIMERS & DEMENTIA			English	Article; Proceedings Paper	Leon Thal Symposium on the Prevention of Dementia (LTS 07)	DEC 02-04, 2007	Las Vegas, NV	Lou Ruvo Brain Inst		estrogens; estradiol; neuroprotection; Alzheimer's disease; stroke; mitochondria; cell signaling	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; NIGROSTRIATAL DOPAMINERGIC SYSTEM; GLOBAL COGNITIVE FUNCTION; HEALTH INITIATIVE MEMORY; CEREBRAL-BLOOD-FLOW; SPINAL-CORD-INJURY; POSTMENOPAUSAL WOMEN; ISCHEMIC DAMAGE; VENOUS THROMBOEMBOLISM	Considerable evidence has emerged through more than a decade of research supporting the neuroprotective and cognition-preserving effects of estrogens. Such basic research coupled with various epidemiological studies led quickly to the assessment of Premarin for the treatment of mild to moderate Alzheimer's disease (AD), initiated by the Alzheimer's Disease Cooperative Study Group and headed by Dr. Leon Thal. While this and subsequent trials with Premarin (Wyeth Research, Monmouth Junction, New Jersey) and PremPro (Wyeth Research), a conjugated equine estrogen preparation plus medoxyprogresterone acetate, have not supported the use of estrogens in treating advanced AD, considerable inferences have been made from these placebo controlled trials of estrogens. Here, we aimed to put these AD trials of estrogens in perspective by considering the potential mechanisms of these potent neuroprotective estrogens, the role of estrogens in other neurodegenerative conditions, such as cerebral ischemia, and based on our current understanding of estrogen neurobiology, offer insight into the design of future clinical trails of estrogens for neuronal protection. (c) 2008 The Alzheimer's Association. All rights reserved.	[Simpkins, James W.; Singh, Meharvan] Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzgheimers Dis Res, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA		Simpkins, JW (corresponding author), Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzgheimers Dis Res, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	jsimpkin@hsc.unt.edu		Singh, Meharvan/0000-0002-8072-1769	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG22550, AG10485, AG27956] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010485, P01AG022550, P01AG027956] Funding Source: NIH RePORTER		Anderson LI, 2005, NEUROSCIENCE, V130, P369, DOI 10.1016/j.neuroscience.2004.09.033; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; BISHOP J, 1994, MOL CELL NEUROSCI, V5, P303, DOI 10.1006/mcne.1994.1036; Bracamonte MP, 2001, TRENDS ENDOCRIN MET, V12, P204, DOI 10.1016/S1043-2760(01)00406-4; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brinton RD, 2005, ANN NY ACAD SCI, V1052, P57, DOI 10.1196/annals.1347.005; Budziszewska B, 2001, EXP CLIN ENDOCR DIAB, V109, P168, DOI 10.1055/s-2001-14841; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Carswell HVO, 2000, J CEREBR BLOOD F MET, V20, P931, DOI 10.1097/00004647-200006000-00005; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290, DOI 10.1152/ajpheart.2000.278.1.H290; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Disshon KA, 2000, BRAIN RES, V868, P95, DOI 10.1016/S0006-8993(00)02329-5; Dluzen DE, 1996, NEUROTOXICOL TERATOL, V18, P603, DOI 10.1016/0892-0362(96)00086-4; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Gajjar TM, 2003, J NEURAL TRANSM, V110, P1215, DOI 10.1007/s00702-003-0045-3; Galanopoulou AS, 2003, NEUROSCI LETT, V342, P201, DOI 10.1016/S0304-3940(03)00282-9; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 1997, J STEROID BIOCHEM, V63, P229, DOI 10.1016/S0960-0760(97)00124-6; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harman S Mitchell, 2006, Gend Med, V3, P254, DOI 10.1016/S1550-8579(06)80214-7; Haynes LE, 2003, NEUROSCIENCE, V120, P799, DOI 10.1016/S0306-4522(03)00167-2; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Heron P, 2001, METAB BRAIN DIS, V16, P187, DOI 10.1023/A:1012593027961; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Hoibraaten E, 2001, THROMB HAEMOSTASIS, V85, P775; Horstink MWIM, 2003, ADV NEUROL, V91, P107; Horvath KM, 2002, NEUROSCIENCE, V110, P489, DOI 10.1016/S0306-4522(01)00560-7; Jamous MA, 2005, J NEUROSURG, V103, P1046, DOI 10.3171/jns.2005.103.6.1046; Jamous MA, 2005, J NEUROSURG, V103, P1052, DOI 10.3171/jns.2005.103.6.1052; Johnson AB, 2006, J NEUROIMMUNOL, V174, P82, DOI 10.1016/j.jneuroim.2006.01.019; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Jung ME, 2002, ALCOHOL, V26, P83, DOI 10.1016/S0741-8329(01)00199-9; Kalkbrenner KA, 2003, BRAIN RES, V964, P244, DOI 10.1016/S0006-8993(02)04065-9; Koh KK, 2003, INT J CARDIOL, V87, P1; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Liao SL, 2001, NEUROSCI LETT, V297, P159, DOI 10.1016/S0304-3940(00)01704-3; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; Marder K, 1998, NEUROLOGY, V50, P1141, DOI 10.1212/WNL.50.4.1141; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Mickley KR, 2004, NEUROENDOCRINOLOGY, V79, P305, DOI 10.1159/000079710; Mohamed MK, 2000, EUR J ENDOCRINOL, V142, P307, DOI 10.1530/eje.0.1420307; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PEREZ E, 2006, DRUG DEVELOP RES, V68, P1; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Rabbani O, 1997, EXP NEUROL, V146, P179, DOI 10.1006/exnr.1997.6516; Ramirez AD, 2003, NEUROENDOCRINOLOGY, V77, P223, DOI 10.1159/000070277; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Reibel S, 2000, NEUROSCI LETT, V281, P79, DOI 10.1016/S0304-3940(00)00784-9; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2001, ANN NY ACAD SCI, V949, P203; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Sherwin BB, 1997, NEUROLOGY, V48, pS21, DOI 10.1212/WNL.48.5_Suppl_7.21S; Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17; Shi J, 2001, STROKE, V32, P987, DOI 10.1161/01.STR.32.4.987; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Shughrue PJ, 2004, EXP NEUROL, V190, P468, DOI 10.1016/j.expneurol.2004.08.009; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Sierra A, 2003, ENDOCRINE, V21, P43, DOI 10.1385/ENDO:21:1:43; SIMERLY RB, 1991, MOL ENDOCRINOL, V5, P424, DOI 10.1210/mend-5-3-424; Simpkins JW, 2004, J WOMENS HEALTH, V13, P1165, DOI 10.1089/jwh.2004.13.1165; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; SINGH M, 2005, FUTURE ESTROGEN HORM; Sohrabji F, 2006, ENDOCRINE, V29, P191, DOI 10.1385/ENDO:29:2:191; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thakur MK, 2007, NEUROCHEM INT, V50, P314, DOI 10.1016/j.neuint.2006.08.019; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Velisek L, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.43.s.5.3.x; Veliskova J, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb01553.x; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Watanabe Y, 2001, AM J PHYSIOL-HEART C, V281, pH155, DOI 10.1152/ajpheart.2001.281.1.H155; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhao LQ, 2006, J PHARMACOL EXP THER, V319, P1124, DOI 10.1124/jpet.106.109504	97	58	61	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JAN	2008	4	1		1			S131	S136		10.1016/j.jalz.2007.10.009			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	256AI	WOS:000252699700023	18631989				2022-02-06	
J	Himmelseher, S				Himmelseher, Sabine			Hypertonic saline solutions for treatment of intracranial hypertension	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral edema; critical care; hypertonic-hyperoncotic saline solution; hypertonic saline solution; intracranial hypertension; osmolar load	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HYDROXYETHYL STARCH 130/0.4; SMALL-VOLUME RESUSCITATION; ACUTE ISCHEMIC-STROKE; SODIUM-CHLORIDE; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE; CLINICAL-TRIAL; PRESSURE	Purpose of review This review aims to provide an update on recent knowledge gained on hypertonic saline solutions for the treatment of intracranial hypertension. Explanatory approaches to the mechanisms underlying the edema-reducing effects of the solutions are outlined, practical aspects of use are presented, and trials that assessed their clinical utility are highlighted. Recent findings With an established trauma system, hypertonic saline added to conventional fluid resuscitation did not improve long-term outcome in multiple injury with hypotension and brain trauma. In intensive care, hypertonic saline reduced intracranial hypertension after subarachnoid haemorrhage, brain trauma, and a variety of other brain diseases, including cerebral edema in acute liver failure. Summary Hypertonic saline solutions have evolved as an alternative to mannitol or may be used in otherwise refractory intracranial hypertension to treat raised intracranial pressure. With high osmolar loads, the efficacy of the solution is enhanced, but no simple relationship between the saline concentration and the clinical effects of a solution is established. Caution is advised with high osmolar loads because they carry increased risks for potentially deleterious consequences of hypernatremia or may induce osmotic blood-brain barrier opening with possibly harmful extravasation of the hypertonic solution into the brain tissue.	[Himmelseher, Sabine] Klinikum Rechts Der Isar, Dept Anaesthesiol, D-81675 Munich, Germany		Himmelseher, S (corresponding author), Klinikum Rechts Der Isar, Anasthesiol Klin, Ismaningerstr 22, D-81675 Munich, Germany.	s.himmelseher@gmx.de					Abbott R, 2005, BRIT MED J, V331, P829, DOI 10.1136/bmj.331.7520.829; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2004, ACTA ANAESTH SCAND, V48, P1089, DOI 10.1111/j.1399-6576.2004.00497.x; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Boldt J, 2004, CAN J ANAESTH, V51, P500, DOI 10.1007/BF03018316; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Chang Y, 2006, J APPL PHYSIOL, V100, P1445, DOI 10.1152/japplphysiol.00763.2005; Chen CH, 2006, J CEREBR BLOOD F MET, V26, P951, DOI 10.1038/sj.jcbfm.9600248; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Copp J, 2005, AM J PHYSIOL-CELL PH, V288, pC403, DOI 10.1152/ajpcell.00095.2004; Degos V, 2006, ANESTH ANALG, V103, P1229, DOI 10.1213/01.ane.0000237401.22688.22; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; Dieterich HJ, 2006, CRIT CARE MED, V34, P1775, DOI 10.1097/01.CCM.0000218814.77568.BC; Dieterich HJ, 2003, ANESTH ANALG, V96, P1150, DOI 10.1213/01.ANE.0000050771.72895.66; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; Erard AC, 2003, ANN FR ANESTH, V22, P18, DOI 10.1016/S0750-7658(02)00004-7; Farstad M, 2006, ACTA ANAESTH SCAND, V50, P855, DOI 10.1111/j.1399-6576.2006.01064.x; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Haeberle HA, 2006, J CLIN ANESTH, V18, P96, DOI 10.1016/j.jclinane.2005.06.010; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Haynes GR, 2004, ANESTH ANALG, V99, P620, DOI 10.1213/01.ANE.0000130904.08524.4A; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Huang SJ, 2006, SURG NEUROL, V66, pS26, DOI 10.1016/j.surneu.2006.07.007; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Kasuya H, 2003, STROKE, V34, P956, DOI 10.1161/01.STR.0000064321.10700.63; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Larive LL, 2004, NEUROCRIT CARE, V1, P435, DOI 10.1385/NCC:1:4:435; Lescot T, 2005, INTENS CARE MED, V31, P1042, DOI 10.1007/s00134-005-2709-y; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Martin RJ, 2004, J NEUROL NEUROSUR PS, V75, P22, DOI 10.1136/jnnp.2004.045906; Mortimer Diane Schretzman, 2006, J Neurosci Nurs, V38, P142; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Prough DS, 2006, SHOCK, V26, P290, DOI 10.1097/01.shk.0000225405.66693.49; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; Rhoney Denise H, 2006, Nutr Clin Pract, V21, P462, DOI 10.1177/0115426506021005462; Sirtl CJ, 2001, J PHARM THER, V1, P4; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Suarez Jose I, 2004, Cleve Clin J Med, V71 Suppl 1, pS9; Takefuji S, 2007, EXP NEUROL, V204, P88, DOI 10.1016/j.expneurol.2006.09.025; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P507; Thomale UW, 2004, J NEUROTRAUM, V21, P1737; Toung TJK, 2007, CRIT CARE MED, V35, P526, DOI 10.1097/01.CCM.0000253309.44567.A6; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2005, J NEUROSURG ANESTH, V17, P106, DOI 10.1097/01.ana.0000163200.48483.56; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vincent JL, 2007, ANESTH ANALG, V104, P484, DOI 10.1213/01.ane.0000258224.44806.dd; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Watts DD, 2004, PREHOSP EMERG CARE, V8, P1350; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; Wiedermann CJ, 2003, PATHOPHYSIOL HAEMO T, V33, P225, DOI 10.1159/000081513; Woessner R, 2003, PATHOPHYSIOL HAEMO T, V33, P121, DOI 10.1159/000077819; Yildizdas D, 2006, INDIAN PEDIATR, V43, P771	63	58	68	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2007	20	5					414	426		10.1097/ACO.0b013e3282eff9ea			13	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	V42SF	WOS:000209632800004	17873594				2022-02-06	
J	Koedel, U; Merbt, UM; Schmidt, C; Angele, B; Popp, B; Wagner, H; Pfister, HW; Kirschning, CJ				Koedel, Uwe; Merbt, Ulrike Michaela; Schmidt, Caroline; Angele, Barbara; Popp, Bernadette; Wagner, Hermann; Pfister, Hans-Walter; Kirschning, Carsten J.			Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; CLOSED-HEAD INJURY; ISCHEMIA-REPERFUSION INJURY; INNATE IMMUNE-RESPONSE; DENDRITIC CELLS; INTERLEUKIN-1 RECEPTOR; NEUTROPHIL INFILTRATION; SIGNALING PATHWAYS; SCAVENGER RECEPTOR; CEREBRAL-ISCHEMIA	Endogenous molecules released from disrupted cells and extracellular matrix degradation products activate Toll-like receptors (TLRs) and, thus, might contribute to immune activation after tissue injury. Here, we show that aseptic, cold-induced cortical injury triggered an acute immune response that involves increased production of multiple cytokines/chemokines accompanied by neutrophil recruitment to the lesion site. We observed selective reductions in injury-induced cytokine/chemokine expression as well as in neutrophil accumulation in mice lacking the common TLR signaling adaptor MyD88 compared with wild-type mice. Notably, attenuation of the immune response was paralleled by a reduction in lesion size. Neutrophil depletion of wild-type mice and transplantation of MyD88-deficient bone marrow into lethally irradiated wild-type recipients had no substantial impact on injury-induced expression of cytokines/chemokines and on lesion development. In contrast to MyD88 deficiency, double deficiency of TLR2 and TLR4-despite the two receptors being activated by specific endogenous molecules associated to danger and signal through MyD88-altered neither immune response nor extent of tissue lesion size on injury. our data indicate modulation of the neuroinflammatory response and lesion development after aseptic cortical injury through MyD88-dependent but TLR2/4-independent signaling by central nervous system resident non-myeloid cells.	Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany		Koedel, U (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.	uwe.koedel@med.uni-muenchen.de					Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Babcock AA, 2003, J NEUROSCI, V23, P7922; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brentano F, 2005, ARTHRITIS RHEUM-US, V52, P2656, DOI 10.1002/art.21273; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Carter RJ, 1999, J NEUROSCI, V19, P3248; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Franke H, 2006, PFLUG ARCH EUR J PHY, V452, P622, DOI 10.1007/s00424-006-0071-8; Fukumoto N, 2004, J IMMUNOL, V173, P1620, DOI 10.4049/jimmunol.173.3.1620; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Iseki K, 2002, GLIA, V39, P1, DOI 10.1002/glia.10078; Ishii KJ, 2001, J IMMUNOL, V167, P2602, DOI 10.4049/jimmunol.167.5.2602; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnston B, 2003, J IMMUNOL, V171, P2960, DOI 10.4049/jimmunol.171.6.2960; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kielian T, 2004, J NEUROPATH EXP NEUR, V63, P381, DOI 10.1093/jnen/63.4.381; Klein M, 2006, MICROBES INFECT, V8, P974, DOI 10.1016/j.micinf.2005.10.013; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lin M, 2007, J LEUKOCYTE BIOL, V81, P786, DOI 10.1189/jlb.0806502; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Ni HP, 2002, J BIOL CHEM, V277, P12689, DOI 10.1074/jbc.M110729200; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021; Prinz M, 2006, J CLIN INVEST, V116, P456, DOI 10.1172/JCI26078; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Rupprecht TA, 2007, J IMMUNOL, V178, P1861, DOI 10.4049/jimmunol.178.3.1861; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844; Suzuki Y, 2002, BRAIN DEV-JPN, V24, P1; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Wuttge DM, 2004, ARTERIOSCL THROM VAS, V24, P750, DOI 10.1161/01.ATV.0000124102.11472.36; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; YOUN BS, 1995, J IMMUNOL, V155, P2661; Zhao XY, 2003, J IMMUNOL, V171, P2797, DOI 10.4049/jimmunol.171.6.2797	89	58	61	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2007	171	1					200	213		10.2353/ajpath.2007.060821			14	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	185LO	WOS:000247712700021	17591966	Green Published			2022-02-06	
J	Wood, RL; Williams, C				Wood, Rodger Ll.; Williams, Claire			Neuropsychological correlates of organic alexithymia	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; emotional perception; executive function; affective disorder; cognitive function; TAS 20	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FACTORIAL STRUCTURE; FACIAL EXPRESSIONS; COHERENCE ANALYSIS; SOCIAL-PERCEPTION; SPLIT BRAIN; SCALE; EMOTION; RECOGNITION	Deficits in emotional recognition and perception following traumatic brain injury (TBI) have been associated with alexithymia (Henry et al., 2006; Williams et al., 2001). This study examined the prevalence of alexithymia in a TBI population, and its relationship to injury severity, neuropsychological ability and affective disorder. A total of 121 patients completed the Toronto Alexithymia Scale-20 (TAS-20), a measure that addresses 3 distinct characteristics of the alexithymia concept; difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking. Patients also completed a neuropsychological assessment and measures of depression and anxiety. Results confirm a high prevalence of alexithymia after TBI, relative to the general population and an orthopedic control group. There was no relationship between injury severity and the presence of alexithymia. A negative relationship was found between alexithymia and verbal and sequencing abilities, but there was no relationship with executive dysfunction or any other cognitive domain. Moderate correlations were obtained between alexithymia and affective disorder; regression analyses indicated that alexithymia, depression, and anxiety should be considered distinct, but overlapping constructs. The results of this study suggest that increased neuropsychological attention should be directed towards emotional change after head injury and its relationship with cognition and psychosocial outcome.	Univ Coll Swansea, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Wood, RL (corresponding author), Univ Coll Swansea, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 1996, J NEUROSCI, V16, P7678; Baddeley A., 1992, SPEED CAPACITY LANGU; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Borod J., 2000, NEUROPSYCHOLOGY EMOT; Brooks D. N, 1990, REHABILITATION ADULT, P163; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P.W., 1997, HAYLING BRIXTON TEST; Burgess PW, 2004, CLIN NEUROPSYCHOLOGY; HENDRYX MS, 1991, J PERS ASSESS, V56, P227, DOI 10.1207/s15327752jpa5602_4; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HOPPE KD, 1977, PSYCHOTHER PSYCHOSOM, V28, P148, DOI 10.1159/000287057; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Houtveen JH, 1997, J PSYCHOPHYSIOL, V11, P147; Jessimer M, 1997, BRAIN COGNITION, V34, P246, DOI 10.1006/brcg.1997.0900; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kandel E.R., 1991, PRINCIPLES NEURAL SC, V3rd ed.; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; LAMBERTY GJ, 1995, J NEUROPSYCH CLIN N, V7, P320; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Mandal MK, 1999, J NERV MENT DIS, V187, P603, DOI 10.1097/00005053-199910000-00003; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; Mayes L C, 1992, Psychoanal Study Child, V47, P23; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Muller J, 2003, J PSYCHOSOM RES, V55, P561, DOI 10.1016/S0022-3999(03)00033-3; Nelson H.E., 1982, NATL ADULT READING T; PARKER JDA, 1991, COMPR PSYCHIAT, V32, P387, DOI 10.1016/0010-440X(91)90015-5; PARKER RM, 1992, 20 ITEM TORONTO ALEX; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; SCHLOSSER D, 1989, J CLIN EXP NEUROPSYC, V11, P785, DOI 10.1080/01688638908400935; Smith SD, 2004, BRAIN COGNITION, V55, P452, DOI 10.1016/j.bandc.2004.02.064; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1985, PSYCHOTHER PSYCHOSOM, V44, P191, DOI 10.1159/000287912; TENHOUTEN WD, 1987, PSYCHOTHER PSYCHOSOM, V47, P1; TENHOUTEN WD, 1985, PSYCHOTHER PSYCHOSOM, V44, P89, DOI 10.1159/000287898; TULSKY D, 1997, WAIS 2 WMS 3 TECHNIC; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; WOOD RL, IN PRESS J NEUROPSYC; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	54	58	60	1	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2007	13	3					471	479		10.1017/S1355617707070518			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	162WZ	WOS:000246121500012	17445296				2022-02-06	
J	Sigmund, GA; Tong, KA; Nickerson, JP; Wall, CJ; Oyoyo, U; Ashwal, S				Sigmund, Geoffrey A.; Tong, Karen A.; Nickerson, Joshua P.; Wall, Christopher J.; Oyoyo, Udo; Ashwal, Stephen			Multimodality comparison of neuroimaging in pediatric traumatic brain injury	PEDIATRIC NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; MAGNETIC-RESONANCE; INTENSIVE-CARE; FIELD MR; CT; LESIONS; CHILDREN; TOMOGRAPHY; IMAGES	Traumatic brain injury is a common cause of death and disability in children; early neuroimaging has assumed an increasingly important role in evaluating the extent and severity of injury. Several imaging methods were assessed in a study of 40 children with traumatic brain injury: computed tomography (CT), T-2-weighted magnetic resonance imaging (MRI), fluid-attenuated inversion recovery (FLAIR) MRI, and susceptibility-weighted imaging (SWI) MRI to determine which were most valuable in predicting 6-12 month outcomes as classified by the Pediatric Cerebral Performance Category Scale score. Patients were subdivided into three groups: (1) normal, (2) mild disability, and (3) moderate/severe disability/persistent vegetative state. T-2, FLAIR, and SWI showed no significant difference in lesion volume between normal and mild outcome groups, but did indicate significant differences between normal and poor and between mild and poor outcome groups. Computed tomography revealed no significant differences in lesion volume between any groups. The findings suggest that T-2, FLAIR, and SWI MRI sequences provide a more accurate assessment of injury severity and detection of outcome-influencing lesions than does CT in pediatric traumatic brain injury patients. Although CT was inconsistent at lesion detection/outcome prediction, it remains an essential part of the acute traumatic brain injury work-up to assess the need for neurosurgic intervention. (C) 2007 by Elsevier Inc. All rights reserved.	Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Univ Vermont, Fletcher Allen Healthcare, Burlington, VT USA; Univ Saskatchewan, Dept Med Imaging, Saskatoon, SK, Canada		Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Schuman Pavil,Rm B623,11234 Anderson St, Loma Linda, CA 92354 USA.	ktong@ahs.llumc.edu					Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P597; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SMITH AS, 1985, AM J ROENTGENOL, V145, P949, DOI 10.2214/ajr.145.5.949; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsuchiya T, 1996, AM J NEURORADIOL, V17, P1081; Tsurushima H, 1996, NEUROL SURG TOKYO, V24, P891; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	27	58	71	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	APR	2007	36	4					217	226		10.1016/j.pediatrneurol.2007.01.003			10	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	161QV	WOS:000246031400002	17437903				2022-02-06	
J	Rockswold, SB; Rockswold, GL; Defillo, A				Rockswold, Sarah B.; Rockswold, Gaylan L.; Defillo, Archie			Hyperbaric oxygen in traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						cerebral metabolism; hyperbaric oxygen; intracranial pressure; traumatic brain injury	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; MITOCHONDRIAL-FUNCTION; MULTICENTER TRIAL; LACTIC-ACIDOSIS; MOLECULAR-BASIS; 2 ATMOSPHERES	Objectives: This critical literature review examines historical and current investigations on the efficacy and mechanisms of hyperbaric oxygen (HBO) treatment in traumatic brain injury (TBI). Potential safety risks and oxygen toxicity, as well as HBO's future potential, are also discussed. Methods: Directed literature review. Results: Historically, cerebral vasoconstriction and increased oxygen availability were seen as the primary mechanisms of HBO in TBI. HBO now appears to be improving cerebral aerobic metabolism at a cellular level, namely, by enhancing damaged mitochondrial recovery. HBO given at the ideal treatment paradigm, 1.5 ATA for 60 minutes, does not appear to produce oxygen toxicity and is relatively safe. Discussion: The use of HBO in TBI remains controversial. Growing evidence, however, shows that HBO may be a potential treatment for patients with severe brain injury. Further investigations, including a multicenter prospective randomized clinical trial, will be required to definitively define the role of HBO in severe TBI.	Univ Minnesota, Dept Surg, Div Neurosurg, Hennepin Cty Med Ctr,Dept Neurosurg, Minneapolis, MN 55415 USA		Rockswold, GL (corresponding author), Univ Minnesota, Dept Surg, Div Neurosurg, Hennepin Cty Med Ctr,Dept Neurosurg, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@co.hennepin.mn.us					ARTRU F, 1976, EUR NEUROL, V14, P351, DOI 10.1159/000114759; ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bardin H, 1970, QUANTITATIVE METHOD; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bullock MR, 2006, J NEUROSURG, V104, P171; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DEATON PR, 1994, AM J PHYSIOL, V267, pL187, DOI 10.1152/ajplung.1994.267.2.L187; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNN JE, 1966, HYPERBARIC MEDICINE, P447; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARABIN AL, 1990, J APPL PHYSIOL, V69, P328, DOI 10.1152/jappl.1990.69.1.328; Hattori N, 2003, J NUCL MED, V44, P1709; HAYAKAWA T, 1971, J NEUROL NEUROSUR PS, V34, P580, DOI 10.1136/jnnp.34.5.580; HOLBACH KH, 1972, EUR NEUROL, V8, P158, DOI 10.1159/000114570; HOLBACH KH, 1974, ACTA NEUROCHIR, V30, P247, DOI 10.1007/BF01405583; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; HOLBACH KH, 1973, ADV NEUROSURG, V1, P158; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ILLINGWORTH C, 1962, Br Med J, V2, P1271; INGVAR DH, 1965, ACTA NEUROL SCAND, V41, P92, DOI 10.1111/j.1600-0404.1965.tb04282.x; JACOBSON I, 1963, LANCET, V2, P549; JACOBSON I, 1963, J NEUROSURG, V20, P849, DOI 10.3171/jns.1963.20.10.0849; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KLEIN J, 1990, ANESTH ANALG, V70, P195; Krause G. S., 1986, AM HEART J, V16, P1200; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; MILLER JD, 1971, ARCH NEUROL-CHICAGO, V24, P210, DOI 10.1001/archneur.1971.00480330038003; MILLER JD, 1970, J NEUROSURG, V33, P287, DOI 10.3171/jns.1970.33.3.0287; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; MOGAMI H, 1969, J NEUROSURG, V31, P636, DOI 10.3171/jns.1969.31.6.0636; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MOODY RA, 1970, J NEUROSURG, V32, P51, DOI 10.3171/jns.1970.32.1.0051; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muehstedt SG, 2001, SURGERY, V130, P602, DOI 10.1067/msy.2001.117105; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NODA Y, 1983, J NEUROCHEM, V40, P1329, DOI 10.1111/j.1471-4159.1983.tb13574.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; PUGLIA CD, 1984, TOXICOL APPL PHARM, V75, P258, DOI 10.1016/0041-008X(84)90208-4; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROCKSWOLD G L, 1985, HYPERBARIC OXYGEN RE, V6, P161; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; SALTZMAN HA, 1965, MONOGR SURG SCI, V2, P1; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SMITH G, 1961, SURG GYNECOL OBSTET, V113, P13; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; SUKOFF MH, 1967, SURGERY, V62, P40; SUKOFF MH, 1968, J NEUROSURG, V29, P236, DOI 10.3171/jns.1968.29.3.0236; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; Tindall G T, 1965, Surg Forum, V16, P414; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; Weaver L K, 1999, Respir Care Clin N Am, V5, P51; WEAVER LK, 1988, J HYPERBARIC MED, V3, P215; WEAVER LK, 1999, HYPERBARIC MED PRACT, P245; WHALEN RE, 1966, ARCH NEUROL-CHICAGO, V14, P15, DOI 10.1001/archneur.1966.00470070019002; WISPE JR, 1987, CLIN PERINATOL, V14, P651, DOI 10.1016/S0095-5108(18)30755-3; WRIGHT WB, 1972, 272 US NAV EXP DIV U; WULLENWEBER R, 1969, CEREBRAL BLOOD FLOW, P270; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZHOU Z, 2006, IN PRESS J NEUROSURG	95	58	77	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2007	29	2					162	172		10.1179/016164107X181798			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	165JI	WOS:000246301000008	17439701				2022-02-06	
J	Shen, YM; Kou, ZF; Kreipke, CW; Petrov, T; Hu, JN; Haacke, EM				Shen, Yimin; Kou, Zhifeng; Kreipke, Christian W.; Petrov, Theodor; Hu, Jiani; Haacke, E. Mark			In vivo measurement of tissue damage, oxygen saturation changes and blood flow changes after experimental traumatic brain injury in rats using susceptibility weighted imaging	MAGNETIC RESONANCE IMAGING			English	Article						cerebral blood flow; susceptibility weighted imaging; traumatic brain injury; experimental model; blood oxygen saturation	CONTROLLED CORTICAL IMPACT; SPIN-LABELED MRI; PERFUSION; ENDOTHELIN-1; HIPPOCAMPUS; EXPRESSION; MODEL; HYPERVENTILATION; CORTEX	Traumatic brain injury (TBI) is a prevalent disease, and many TBI patients experience disturbed cerebral blood flow (CBF) after injury. Moreover, TBI is difficult to quantify with conventional imaging modalities. In this paper, we utilized susceptibility weighted imaging (SWI) as a means to monitor functional blood oxygenation changes and to quantify CBF changes in animals after trauma. In this study using six rats, brain trauma was induced by a weight drop model and the brain was scanned over four time points: pre trauma, and 4 h, 24 h and 48 h post trauma. Five rats survived and one died after trauma. A blood phase analysis using filtered SWI phase images suggested that three rats recovered after 48 h and two rats deteriorated. SWI also suggested that CBF decreased by up to 26%. The CBF change is in agreement with the results of arterial spin labeling methods conducted in this study and with previously published results. Furthermore, SWI revealed an enlargement of the major venous vasculature in deep brain structures, in accordance with the location of diffuse axonal injury. Compared with the traditional, invasive, clinical monitoring of cerebral vascular damage and reduction in blood flow, this method offers a novel, safe and noninvasive approach to quantify changes in oxygen saturation and CBF and to visualize structural changes in blood vasculature after TBI. (c) 2007 Elsevier Inc. All rights reserved.	Magnet Resonance Imaging Inst Biomed Res, Detroit, MI 48202 USA; Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA; Wayne State Univ, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Haacke, EM (corresponding author), Magnet Resonance Imaging Inst Biomed Res, Detroit, MI 48202 USA.	nmrimaging@aol.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Bouma G J, 1995, New Horiz, V3, P384; *BRAIN TRAUM FDN, 2000, GUID PERH MAN TRAUM; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; CDC, 2003, REP C MILD TRAUM BRA; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; HAACKE EM, 1999, MAGNETIC RESONANCE I, P741; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hyder F, 2001, NMR BIOMED, V14, P413, DOI 10.1002/nbm.733; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McBeth BD, 2005, ACAD EMERG MED, V12, P483, DOI 10.1197/j.aem.2004.11.028; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; Robertson CL, 2000, ACT NEUR S, V76, P187; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; SCHIERHOUT G, 2000, COCHRANE DB SYST REV, V2; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; ZAUNER A, 1997, HEAD INJURY PATHOLOG, P1; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505; 2000, J NEUROTRAUMA, V17, P513; [No title captured]	42	58	73	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	FEB	2007	25	2					219	227		10.1016/j.mri.2006.09.018			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	136YZ	WOS:000244261300010	17275617				2022-02-06	
J	Cothren, CC; Smith, WR; Moore, EE; Morgan, SJ				Cothren, C. Clay; Smith, Wade R.; Moore, Ernest E.; Morgan, Steven J.			Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients	WORLD JOURNAL OF SURGERY			English	Article							INTERMITTENT PNEUMATIC COMPRESSION; VENA-CAVAL FILTERS; HIGH-RISK; MAJOR TRAUMA; PULMONARY-EMBOLISM; CLINICAL-TRIAL; PROPHYLAXIS; ENOXAPARIN; THROMBOSIS; INJURY	Introduction: Venous thromboembolism is a preventable cause of death in the severely injured patient. Low-molecular-Weight heparins (LMWHs) have been recommended as effective, safe prophylactic agents. However, LMWH use remains controversial in patients at risk for bleeding, those with traumatic brain injury, and those undergoing multiple invasive or operative procedures. We hypothesized that a protocol utilizing once-daily LMWH prophylaxis in high-risk trauma patients, regardless of the need for invasive procedures, is feasible, safe, and effective. Methods: From August 1998 to August 2000, all patients admitted to our American College of Surgeons-verified Level I trauma facility following injury were evaluated for deep venous thrombosis (DVT) risk and prospectively followed. Patients at high risk for DVT, including those with stable intracranial injuries, were placed on our institutional protocol and prospectively followed. Patients on the protocol received daily injections of the LMWH, dalteparin; DVT screening was performed with duplex ultrasonography within 48 hours of admission and after 7 to 10 days after injury. Regimen compliance, bleeding complications, DVT rates, and pulmonary embolus (PE) rates were analyzed. Results: During the 2-year study period, 6247 trauma patients were admitted; 743 were considered at high risk for DVT. Most of the patients were men (72%), with a mean age of 38.7 years (range 15-89 years) and a mean injury severity score (ISS) of 19.5. Compliance with the daily regimen was maintained in 74% of patients. DVT was detected in 3.9% and PE in 0.8%. The wound complications rate was 2.7%, and the need for unexplained transfusions was 3%. There were no exacerbations of head injury following dalteparin initiation due to bleeding. There were 16 patient deaths; none was caused by PE or late hemorrhage. Conclusions: Once-daily dosing of prophylactic LMWH dalteparin is feasible, safe, and effective in high-risk trauma patients. Our protocol allows one to "operate through" systemic prophylaxis and ensures timely prophylaxis for brain-injured and multisystem trauma patients.	Univ Colorado, Hlth Sci Ctr, Dept Gen Surg, Trauma Serv,Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA		Cothren, CC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Gen Surg, Trauma Serv,Denver Hlth Med Ctr, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	clay.cothren@dhha.org					Allen TL, 2005, AM J SURG, V189, P656, DOI 10.1016/j.amjsurg.2005.03.003; Cipolle MD, 2002, J TRAUMA, V52, P453, DOI 10.1097/00005373-200203000-00007; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; Deitcher SR, 2000, AM J MANAG CARE, V6, pS1026; FISHER CG, 1995, J ORTHOP TRAUMA, V9, P1, DOI 10.1097/00005131-199502000-00001; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GRANIT V, 2004, WORLD J SURG, V28, P807; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; Hak D J, 2001, Curr Opin Pulm Med, V7, P338, DOI 10.1097/00063198-200109000-00015; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hill AB, 2002, CAN J SURG, V45, P282; Kelsey LJ, 2000, HEMATOL ONCOL CLIN N, V14, P417, DOI 10.1016/S0889-8588(05)70142-8; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Langan EM, 1999, J VASC SURG, V30, P484, DOI 10.1016/S0741-5214(99)70075-3; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; O'Shea SI, 2002, SEMIN HEMATOL, V39, P172, DOI 10.1053/shem.2002.34090; Olson S, 2002, J CLIN NEUROSCI, V9, P256, DOI 10.1054/jocn.2001.0982; Paiement GD, 1997, ORTHOPEDICS, V20, P7; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Pineo G F, 2001, Expert Opin Pharmacother, V2, P1325; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; Schwarcz TH, 2001, J VASC SURG, V34, P447, DOI 10.1067/mva.2001.117146; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; SMITH WR, 2002, THROMBOPROPHYLAXIS E; Tapson VF, 2005, ARCH INTERN MED, V165, P1458, DOI 10.1001/archinte.165.13.1458; Turpie Alexander G G, 2002, Expert Opin Pharmacother, V3, P575, DOI 10.1517/14656566.3.5.575; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Wenzl ME, 2004, CLIN APPL THROMB-HEM, V10, P1, DOI 10.1177/107602960401000101	33	58	60	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JAN	2007	31	1					98	104		10.1007/s00268-006-0304-1			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	124JW	WOS:000243365100017	17180563				2022-02-06	
J	Gill, HS; Campbell, PA; Murray, DW; De Smet, KA				Gill, H. S.; Campbell, P. A.; Murray, D. W.; De Smet, K. A.			Reduction of the potential for thermal damage during hip resurfacing	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							RETRIEVED FEMORAL HEADS; BONE-CEMENT; REPLACEMENT; POLYMETHYLMETHACRYLATE; ARTHROPLASTY; INTERFACE; INJURY	Resurfacing arthroplasty of the hip is being used increasingly as an alternative to total hip replacement, especially for young active patients. There is concern about necrosis of the femoral head after resurfacing which can result in fracture and loosening. Most systems use a cemented femoral component, with the potential for thermal necrosis of the cancellous bone of the reamed femoral head. We used thermal probes to record temperatures close to the cement-bone interface during resurfacing arthroplasty. The maximum temperature recorded at the cement-bone interface in four cases was approximately 68 degrees C which was higher than that reported to kill osteocytes. A modified surgical technique using insertion of a suction cannula into the lesser trochanter, generous pulsed lavage and early reduction of the joint significantly reduced the maximum recorded cancellous bone temperature to approximately 36 degrees C in five cases (p=0.014). We recommend the modified technique since it significantly reduces temperatures at the cement-bone interface.	Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Dept Orthopaed Surg, Oxford OX3 7LD, England; Orthoped Hosp, Univ Coll Los Angeles, J Vernon Luck Res Ctr, Implant Retrieval Lab, Los Angeles, CA 90007 USA; Anca Med Ctr, B-9000 Ghent, Belgium		Gill, HS (corresponding author), Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Dept Orthopaed Surg, Windmill Rd, Oxford OX3 7LD, England.	richie.gill@ndos.ox.ac.uk	Gill, Harinderjit S/A-9808-2011; Murray, David W/D-7117-2011	Gill, Harinderjit S/0000-0002-7740-2062; 			AMSTUTZ HC, 1996, CLIN ORTHOP S, V329, P511; Andersen K H, 1998, Ugeskr Laeger, V160, P4905; AUST JC, 1981, ARCH SURG-CHICAGO, V116, P345; BERMAN AT, 1984, CLIN ORTHOP RELAT R, V186, P284; CAMPBELL P, 2006, IN PRESS CLIN ORTHOP; CHARNLEY J, 1970, Journal of Bone and Joint Surgery British Volume, V52, P340; DIPISA JA, 1976, CLIN ORTHOP RELAT R, P95; Huiskes R, 1980, Acta Orthop Scand Suppl, V185, P1; LEESON MC, 1993, CLIN ORTHOP RELAT R, V295, P239; Little CP, 2005, J BONE JOINT SURG BR, V87B, P320, DOI 10.1302/0301-620X.87B3.15330; McMinn D, 2006, P I MECH ENG H, V220, P239, DOI 10.1243/095441105X68944; MJOBERG B, 1984, ACTA ORTHOP SCAND, V55, P597, DOI 10.3109/17453678408992403; Morberg P, 1993, J Arthroplasty, V8, P617, DOI 10.1016/0883-5403(93)90009-S; Shimmin AJ, 2005, J BONE JOINT SURG BR, V87B, P463, DOI 10.1302/0301-620X.87B4; Stanczyk M, 2004, J BIOMECH, V37, P1803, DOI [10.1016/j.biomech.2004.03.002, 10.1016/j.jbiomech.2004.03.002]; Stelnicki EJ, 1996, J CRANIOFAC SURG, V7, P192, DOI 10.1097/00001665-199605000-00006; WILLERT HG, 1974, J BONE JOINT SURG AM, VA 56, P1368, DOI 10.2106/00004623-197456070-00005; CONSERVE PLUS TOTAL	18	58	61	0	5	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X	2044-5377		J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	JAN 1	2007	89B	1					16	20		10.1302/0301-620X.89B1.18369			5	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	130IJ	WOS:000243793000004	17259409				2022-02-06	
J	O'Bryant, SE; Engel, LR; Kleiner, JS; Vasterling, JJ; Black, FW				O'Bryant, Sid E.; Engel, Lisa R.; Kleiner, Jennifer S.; Vasterling, Jennifer J.; Black, F. William			Test of memory malingering (TOMM) trial 1 as a screening measure for insufficient effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; PERFORMANCE; VALIDATION; RATES; EXAGGERATION; DEPRESSION; CRITERIA	The identification of insufficient effort is critical to neuropsychological evaluation, and several existing instruments assess effort on neuropsychological tasks. Yet instruments designed to detect insufficient effort are underutilized in standard neuropsychological assessments, perhaps in part because they typically require significant administration time and are, therefore, not ideally suited to screening contexts. The Test of Memory Malingering (TOMM) is a commonly administered, well-validated symptom validity test. This study evaluates the utility of TOMM Trial 1 as a relatively brief screening measure of insufficient effort. Results suggest that TOMM Trial 1 demonstrates high diagnostic accuracy and is a viable option for screening insufficient effort. Diagnostic accuracy estimates are presented for a range of base rates. The need for more comprehensive SVT assessment in most clinical and forensic situation is discussed.	New Orleans VA Med Ctr, New Orleans, LA USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA		O'Bryant, SE (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Neuropsychiat & Behav Sci, 3601 4th St STOP 8321, Lubbock, TX 79430 USA.	sid.obryant@ttuhsc.edu		O'Bryant, Sid/0000-0003-0582-5266			Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCaffrey R. J., 2003, PRACTITIONERS GUIDE; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481	29	58	58	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2007	21	3					511	521		10.1080/13854040600611368			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	158HA	WOS:000245781200088	17455034				2022-02-06	
J	Piazza, O; Storti, MP; Cotena, S; Stoppa, F; Perrotta, D; Esposito, G; Pirozzi, N; Tufano, R				Piazza, O.; Storti, M. P.; Cotena, S.; Stoppa, F.; Perrotta, D.; Esposito, G.; Pirozzi, N.; Tufano, R.			S100B is not a reliable prognostic index in paediatric TBI	PEDIATRIC NEUROSURGERY			English	Article						traumatic brain injury, children; S100B; traumatic brain injury, prognosis	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; SERUM S100B; CARDIAC-ARREST; HEAD TRAUMA; PROTEIN; CHILDREN; RELEASE; MARKER; S-100B	Background: As far as paediatric traumatic brain injury is concerned, it is difficult to quantify the extent of the primary insult, to monitor secondary changes and to predict neurological outcomes by means of the currently used diagnostic tools: physical examination, Glasgow Coma Scale (GCS) score and computed tomography. For this reason, several papers focused on the use of biochemical markers (S100B, neuron-specific enolase) to detect and define the severity of brain damage and predict outcome after traumatic head injury or cardiac arrest. Objective: The aim of this paper is measuring the range of S100B serum concentrations in children affected by traumatic brain injury and describing the possible roles of this protein in the reaction to trauma. Methods: Fifteen children aged 1-15 years were included in the study. Traumatic brain injury severity was defined by paediatric GCS score as mild (9 patients), moderate (2 patients) or severe (4 patients). Blood samples for S100B serum measurement were taken at emergency department admission and after 48 h. Results: The serum S100B concentration was higher in the group of severe trauma patients, who scored the lowest on the GCS at admission, and among them, the highest values were reported by the children with concomitant peripheral lesions. Conclusions: The role of S100B in paediatric traumatic brain injury has not been clarified yet, and the interpretation of its increase when the head trauma is associated with other injuries needs the understanding of the physiopathological mechanisms that rule its release in the systemic circulation. The levels of S100B in serum after a brain injury could be related to the mechanical discharge from a destroyed blood-brain barrier, or they could be due to the active expression by the brain, as a part of its involvement in the systemic inflammatory reaction. Early increase of this protein is not a reliable prognostic index of neurological outcome after pediatric traumatic brain injury, since even very elevated values are compatible with a complete neurological recovery. Copyright (C) 2007 S. Karger AG, Basel.	Univ Naples Federico II, IT-80131 Naples, Italy; IRCCS G Pascale, Dept Clin Pathol, Naples, Italy; Bambino Gesu Pediat Hosp, Emergency Dept, Rome, Italy		Cotena, S (corresponding author), Univ Naples Federico II, Via Pansini 5, IT-80131 Naples, Italy.	si_mi@inwind.it	Piazza, Ornella/G-5339-2012; Piazza, Ornella/Q-2716-2019	Piazza, Ornella/0000-0002-0316-5930; Piazza, Ornella/0000-0002-0316-5930			Abdul-Khaliq H, 2003, RESTOR NEUROL NEUROS, V21, P141; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bemana I, 1997, ACT NEUR S, V70, P194; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Cecchetti C, 2003, Minerva Anestesiol, V69, P907; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Guan Wei, 2003, Chin J Traumatol, V6, P218; HUANG W, 2001, CHIN J TRAUMATOL, V41, P161; Ikeda Y, 1997, ACTA NEUROCHIR, V139, P1166, DOI 10.1007/BF01410978; ISPIDA K, 2003, J CARDIOTHOR VASC AN, V17, P4; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KOCHANEK PM, 2002, YB INTENSIVE CARE EM, P688; Koide Masaaki, 2002, Jpn J Thorac Cardiovasc Surg, V50, P280; Li YK, 2000, J NEUROCHEM, V74, P143; Liu L, 2005, J NEUROCHEM, V92, P546, DOI 10.1111/j.1471-4159.2004.02909.x; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Maschmann J, 2000, ACTA PAEDIATR, V89, P553, DOI 10.1080/080352500750027844; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1999, CLIN CHEM, V45, P138; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Ozatik MA, 2002, PERFUSION-UK, V17, P335, DOI 10.1191/0267659102pf597oa; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Piazza O, 2005, Minerva Chir, V60, P477; PIAZZA O, 2006, ACUTE PAIN, V8, P87; Pietrini D, 2004, Minerva Anestesiol, V70, P549; Sahlein DH, 2003, NEUROSURGERY, V53, P1243, DOI 10.1227/01.NEU.0000093493.16850.11; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Snyder-Ramos SA, 2004, ANAESTHESIA, V59, P344, DOI 10.1111/j.1365-2044.2004.03663.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Verdu A, 2001, REV NEUROLOGIA, V32, P714, DOI 10.33588/rn.3208.2000582; Whitelaw A, 2001, ARCH DIS CHILD-FETAL, V84, pF90, DOI 10.1136/fn.84.2.F90; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; YANG Y, 2002, CHIN J TRAUMATOL ENG, V5, P529	43	58	59	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2007	43	4					258	264		10.1159/000103304			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	190PQ	WOS:000248071700002	17627141				2022-02-06	
J	Serino, A; Ciaramelli, E; Di Santantonio, A; Malagu, S; Servadei, F; Ladavas, E				Serino, Andrea; Ciaramelli, Elisa; Di Santantonio, Anna; Malagu, Susanna; Servadei, Franco; Ladavas, Elisabetta			A pilot study for rehabilitation of central executive deficits after traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; working memory; working memory training; central executive system; Glasgow Coma Scale	WORKING-MEMORY; COGNITIVE REHABILITATION; DIVIDED ATTENTION; HEAD-INJURY; IMPAIRMENTS; RECALL	Primary objective: An impairment of the central executive system (CES) of working memory (WM) is a common consequence of traumatic brain injury (TBI), and may also explain deficits in divided attention, long-term memory and executive functions. Here we investigated the efficacy of a rehabilitative program (working memory training: WMT) targeting the CES in improving WM and other cognitive functions dependent on this system. Methods and procedures: Nine TBI patients with severe WM deficits underwent the WMT (experimental training). The WMT was preceded by a general stimulation training (GST, control training). Patients' cognitive performance was evaluated at the admission, after the GST and at the end of the WMT. Main outcomes and results: Whereas the GST had no effect on patients' performance, after the WMT patients improved in all the cognitive functions dependent on the CES, but not in those functions not thought to tap this system. Importantly, a beneficial WMT effect was found on patients' everyday life functioning. Conclusions: The results support the efficacy of the WMT in recovering CES impairments.	Univ Bologna, Dipartimento Psicol, I-40127 Bologna, Italy; Ctr Studi & Ric Neurosci Cognit, Cesena, Italy; Osped Bufalini, Cesena, Italy		Ladavas, E (corresponding author), Univ Bologna, Dipartimento Psicol, Viale Berti Pichat 5, I-40127 Bologna, Italy.	elisabetta.ladavas@unibo.it	CIARAMELLI, ELISA/AAC-6618-2022	CIARAMELLI, ELISA/0000-0002-4797-8060; Servadei, Franco/0000-0002-3595-3464; LADAVAS, ELISABETTA/0000-0001-8930-725X			Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2002, NEUROPSYCHOLOGIA, V40, P1737, DOI 10.1016/S0028-3932(01)00146-4; Baddeley A.D., 1986, WORKING MEMORY; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cappa SF, 2005, EUR J NEUROL, V12, P665; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CIARAMELLI E, 2006, GIORNALE I PSICOLOGI, V3, P607; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; CULBERTSON W, 2001, TOWER LONDON; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Davidson PSR, 2006, J INT NEUROPSYCH SOC, V12, P210, DOI 10.1017/S1355617706060334; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mateer CA, 1990, COGNITIVE REHABILITA, P68; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Robertson I., 1996, GOAL MANAGEMENT TRAI; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spinnler HTG, 1987, ITAL J NEUROL SCI S6, V8, P7; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; TEASDALE G, 1974, LANCET, V2, P81; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; Zoccolotti P., 1994, BATTERIA TEST ESAME	48	58	60	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2007	21	1					11	19		10.1080/02699050601151811			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600002	17364515				2022-02-06	
J	Beffert, U; Farsian, FN; Masiulis, I; Hammer, RE; Yoon, SO; Giehl, KM; Herz, J				Beffert, Uwe; Farsian, Farnas Nematollah; Masiulis, Irene; Hammer, Robert E.; Yoon, Sung Ok; Giehl, Klaus M.; Herz, Joachim			ApoE receptor 2 controls neuronal survival in the adult brain	CURRENT BIOLOGY			English	Article							LIPOPROTEIN RECEPTORS; SYNAPTIC PLASTICITY; INDUCED APOPTOSIS; CORTICAL-NEURONS; PROTEIN-KINASE; MICE LACKING; REELIN; DEATH; DISRUPTION; MODULATION	A central pathogenic feature of neurodegenerative diseases and neurotrauma is the death of neurons. A mechanistic understanding of the factors and conditions that induce the dysfunction and death of neurons is essential for devising effective treatment strategies against neuronal loss after trauma or during aging. Because Apolipoprotein E (ApoE) is a major risk factor for several neurodegenerative diseases, including Alzheimer's disease [1], a direct or indirect role of ApoE receptors in the disease process is likely. Here we have used gene targeting in mice to investigate possible roles of ApoE receptors in the regulation of neuronal survival. We demonstrate that a differentially spliced isoform of an ApoE receptor, ApoE receptor 2 (Apoer2), is essential for protection against neuronal cell loss during normal aging. Furthermore, the same splice form selectively promotes neuronal cell death after injury through mechanisms that may involve serine/threonine kinases of the Jun N-terminal kinase (JNK) family. These findings raise the possibility that ApoE and its receptors cooperatively regulate common mechanisms that are essential to neuronal survival in the adult brain.	Univ Texas, Southwestern Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Cellular & Mol Biochem, Columbus, OH 43210 USA; Univ Freiburg, Zentrum Neurowissenschaft, D-79104 Freiburg, Germany		Giehl, KM (corresponding author), Univ Texas, Southwestern Med Ctr, Dept Mol Genet, 5323 Harry Hines blvd, Dallas, TX 75390 USA.	klausgiehl@web.de; joachim.herz@utsouthwestern.edu	Yoon, Sung Ok/C-5992-2012	Beffert, Uwe/0000-0001-5877-922X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37 HL063762] Funding Source: Medline		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X; Beffert U, 2006, J NEUROSCI, V26, P2041, DOI 10.1523/JNEUROSCI.4566-05.2006; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen Y, 2005, J NEUROSCI, V25, P8209, DOI 10.1523/JNEUROSCI.1951-05.2005; GIEHL K, 1995, EXP BRAIN RES, V103, P344; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; OUDEGA M, 1994, J COMP NEUROL, V347, P115, DOI 10.1002/cne.903470109; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Stockman RH, 2000, RES HUMAN SOCI CONFL, V2, P1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	26	58	62	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	DEC 19	2006	16	24					2446	2452		10.1016/j.cub.2006.10.029			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	119UP	WOS:000243039800028	17174920	Bronze			2022-02-06	
J	Qiu, WS; Shen, H; Zhang, Y; Wang, WM; Liu, WG; Jiang, QZ; Luo, M; Manou, M				Qiu, Wusi; Shen, Hong; Zhang, Ying; Wang, Weimin; Liu, Weiguo; Jiang, Qizhou; Luo, Ming; Manou, Merriem			Noninvasive selective brain cooling by head and neck cooling is protective in severe traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic brain injury; hypothermia; selective brain cooling; intracranial pressure; prognosis	PROMISING TREATMENT MODALITY; THERAPEUTIC HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; CLINICAL-TRIAL; TEMPERATURE; OPPORTUNITIES; PITFALLS; RATS	Therapeutic hypothermia is a promising treatment for patients with severe traumatic brain injury (TBI). We present here the results of a study in which noninvasive selective brain cooling (SBC) was achieved using a head cap and neckband. Ninety patients with severe TBI were divided into a normothermia control group (n = 45) and a SBC group (n = 45), whose brain temperature was maintained at 33-35 degrees C for 3 days using a combination of head and neck cooling. At 24, 48 and 72 h after injury, the mean intracranial pressure (ICP) values of the patients who underwent SBC were lower than those of the normothermia controls (19.14 +/- 2.33, 19.72 +/- 1.73 and 17.29 +/- 2.07 mmHg, versus 23.41 +/- 2.51, 20.97 +/- 1.86, and 20.13 +/- 1.87 mmHg, respectively, P < 0.01). There was a significant difference in the neurological recovery of the two groups at the 6-month follow-up after TBI. Good neurological outcome (Glasgow Outcome Scale score of 4 to 5) rates 6 months after injury were 68.9% for the SBC group, and 46.7% for the control group (P < 0.05). There were no complications resulting in severe sequelae. In conclusion, the noninvasive SBC described here is a safe method of administering therapeutic hypothermia, which can reduce ICP and improve prognosis without severe complications in patients with severe TBI. (c) 2006 Elsevier Ltd. All rights reserved.	Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg,Brain Ctr, Hangzhou 310009, Peoples R China; Hangzhou Normal Coll, Hangzhou Hosp Affiliated 2, Dept Neurosurg, Sch Med, Hangzhou, Peoples R China		Qiu, WS (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg,Brain Ctr, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.	sh-2nd@126.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Azzaroni A, 1999, BRAIN RES, V844, P206, DOI 10.1016/S0006-8993(99)01903-4; Bell Scott E, 2006, Curr Treat Options Neurol, V8, P167, DOI 10.1007/s11940-006-0007-9; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Hagioka S, 2003, CRIT CARE MED, V31, P2502, DOI 10.1097/01.CCM.0000084845.76762.F4; Irmak MK, 2004, MED HYPOTHESES, V63, P974, DOI 10.1016/j.mehy.2004.05.003; Iwata O, 2003, PEDIATR INT, V45, P163, DOI 10.1046/j.1442-200X.2003.01682.x; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tooley JR, 2005, ARCH DIS CHILD-FETAL, V90, P262, DOI 10.1136/adc.2003.044305; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wright JE, 2005, CRIT CARE NURS Q, V28, P150, DOI 10.1097/00002727-200504000-00007	21	58	62	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	DEC	2006	13	10					995	1000		10.1016/j.jocn.2006.02.027			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119TZ	WOS:000243037900004	17113984				2022-02-06	
J	Lau, A; Arundine, M; Sun, HS; Jones, M; Tymianski, M				Lau, Anthony; Arundine, Mark; Sun, Hong-Shuo; Jones, Michael; Tymianski, Michael			Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						peroxynitrite; traumatic brain injury; caspase-3; apoptosis; nitric oxide; reactive oxygen species	FLUID-PERCUSSION MODEL; CYTOCHROME-C RELEASE; SPINAL-CORD-INJURY; NITRIC-OXIDE; CELL-DEATH; NEURONAL APOPTOSIS; TYROSINE-NITRATION; IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; DNA FRAGMENTATION	In traumatic brain injury (TBI), neurons surviving the primary insult may succumb through poorly understood secondary mechanisms. In vitro, cortical neurons exposed to stretch injury exhibited enhanced vulnerability to NMDA, apoptotic-like DNA fragmentation, peroxynitrite (PN)formation, and cytoplasmic cytochrome c accumulation. Surprisingly, caspase-3 activity was undetectable by both immunoblotting and fluorogenic activity assays. Therefore, we hypothesized that PN directly inhibits caspases in these neurons. Consistent with this, stretch injury in cultured neurons elicited tyrosine nitration of procaspase-3, but not caspase-9 or Apaf-1, suggesting a direct interaction of PN with caspase-3. In an ex vivo system, PN inhibited the activity of caspase-3, and this inhibition was reversible with the addition of the sulfhydryl reducing agent dithiothreitol, indicating that PN inhibits caspases by cysteinyl oxidation. Moreover, in cultures, the PN donor 3-morpholinosydnonimine (SIN-1) blocked staurosporine-induced caspase-3 activation and its downstream effects including PARP-1 [poly-(ADP-ribose)polymerase-1] cleavage and phosphotidylserine inversion, suggesting that peroxynitrite can inhibit caspase-3-mediated apoptosis. To examine these mechanisms in vivo, rats were exposed to a lateral fluid percussion injury (FPI). FPI caused increased neuronal protein nitration that colocalized with TUNEL staining, indicating that PN was associated with neurodegeneration. Caspase-3 activity was inhibited in brain lysates harvested after FPI and was restored by adding dithiothreitol. Our data show that caspase-mediated apoptosis is inhibited in neurons subjected to stretch in vitro and to TBI in vivo, mostly because of cysteinyl oxidation of caspase-3 by PN. However, this is insufficient to prevent cell death, indicating that the TBI therapy may, at a minimum, require a combination of both anti-apoptotic and anti-oxidant strategies.	Toronto Western Res Inst, Div Appl & Intervent Res, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Neurosurg, Toronto, ON M5S 1A8, Canada			mike.tymianski@uhn.on.ca		Tymianski, Mike/0000-0002-6311-9565	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048956] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048956] Funding Source: NIH RePORTER		Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Conti AC, 1998, J NEUROSCI, V18, P5663; David JC, 1996, J NEUROSCI, V16, P200; Dawson VL, 2004, J BIOENERG BIOMEMBR, V36, P287, DOI 10.1023/B:JOBB.0000041755.22613.8d; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hill IE, 2000, EXP NEUROL, V162, P73, DOI 10.1006/exnr.2000.7322; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marcum JL, 2005, BIOCHEM BIOPH RES CO, V334, P342, DOI 10.1016/j.bbrc.2005.06.089; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marsan MA, 2000, J SYST ARCHITECT, V46, P105, DOI 10.1016/S1383-7621(98)00064-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; RADI R, 1991, J BIOL CHEM, V266, P4244; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun HS, 2006, J NEUROPHYSIOL, V95, P2590, DOI 10.1152/jn.00970.2005; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Ueta E, 2003, INT J CANCER, V103, P717, DOI 10.1002/ijc.10832; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	78	58	61	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 8	2006	26	45					11540	11553		10.1523/JNEUROSCI.3507-06.2006			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	103NE	WOS:000241892700005	17093075	Green Published, Bronze			2022-02-06	
J	Ardeshiri, A; Kelley, MH; Korner, IP; Hurn, PD; Herson, PS				Ardeshiri, A.; Kelley, M. H.; Korner, I. P.; Hurn, P. D.; Herson, P. S.			Mechanism of progesterone neuroprotection of rat cerebellar Purkinje cells following oxygen-glucose deprivation	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						allopregnanolone; excitotoxicity; GABA(A) receptor; ischemia	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NEURONAL DAMAGE; CARDIAC-ARREST; GRANULE CELLS; IN-VIVO; ISCHEMIA; DEATH; ALLOPREGNANOLONE; CURRENTS	The survival of rat Purkinje cell (PCs) cerebellar cultures was used to test the hypothesis that progesterone is protective against oxygen-glucose deprivation through potentiation of GABA(A) receptor activity. Electrophysiological recordings confirm that PCs develop robust excitatory and inhibitory synapses in culture. Exposure of cultured PCs to increasing concentrations of progesterone during oxygen-glucose deprivation revealed a concentration-dependent protection by progesterone, with significant protection observed at physiological concentrations, as low as 10 nM. The concurrent application of the GABA(A) receptor antagonist picrotoxin (100 mu M) completely abolished the neuroprotection afforded by progesterone, indicating that progesterone is neuroprotective through activation of GABA(A) receptors. Progesterone potentiates GABA(A) receptor activity indirectly through its metabolites, such as allopregnanolone (ALLO). Therefore, ALLO was applied to PC cultures and was observed to produce significant protection at all concentrations tested, from 10 to 1000 nM. Finally, the inhibition of progesterone metabolism with finasteride abolished the protection afforded by progesterone without having any effect on the neuroprotection caused by ALLO. These data indicate that progesterone protects cerebellar PCs at physiological concentrations through a GABA-active metabolite.	Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA		Herson, PS (corresponding author), Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058792, R21NS052591] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS052591-02, R21 NS052591, R01 NS058792-01A1, R01 NS058792, 1 R21 NS052591] Funding Source: Medline		BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; Barakat L, 2002, J PHYSIOL-LONDON, V541, P753, DOI 10.1113/jphysiol.2001.015834; Beaman-Hall CM, 1998, J NEUROCHEM, V71, P1993; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BRASKO J, 1995, BRAIN RES, V699, P133, DOI 10.1016/0006-8993(95)01015-N; BRORSON JR, 1994, J NEUROSCI, V14, P187; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Caesar K, 2003, P NATL ACAD SCI USA, V100, P16000, DOI 10.1073/pnas.2635195100; Celotti F, 1997, BRAIN RES BULL, V44, P365, DOI 10.1016/S0361-9230(97)00216-5; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fonnum F, 2000, TOXICOL LETT, V112, P9, DOI 10.1016/S0378-4274(99)00246-5; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; GRUOL DL, 1983, BRAIN RES, V263, P223, DOI 10.1016/0006-8993(83)90315-3; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HIRANO T, 1986, P NATL ACAD SCI USA, V83, P4957, DOI 10.1073/pnas.83.13.4957; HIRANO T, 1993, J NEUROPHYSIOL, V70, P1316, DOI 10.1152/jn.1993.70.4.1316; HORN M, 1992, ACTA NEUROPATHOL, V85, P79, DOI 10.1007/BF00304636; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LIEB K, 1995, EXP NEUROL, V134, P222, DOI 10.1006/exnr.1995.1052; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LIU M, 2006, IN PRESS J CEREB BLO; LIU M, 2004, PHARM CEREBRAL ISCHE; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; NEQUIN LG, 1979, BIOL REPROD, V20, P659, DOI 10.1095/biolreprod20.3.659; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; SATO M, 1990, ACTA NEUROPATHOL, V80, P527, DOI 10.1007/BF00294614; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Southan AP, 1998, BRIT J PHARMACOL, V125, P1375, DOI 10.1038/sj.bjp.0702218; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Tsutsui K, 2003, CEREBELLUM, V2, P215, DOI 10.1080/14734220310016169; Welsh JP, 2002, ADV NEUROL, V89, P331; Yamashita A, 2006, NEUROSCI RES, V55, P264, DOI 10.1016/j.neures.2006.03.007	53	58	63	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2006	24	9					2567	2574		10.1111/j.1460-9568.2006.05142.x			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	104JA	WOS:000241953500014	17100844	Green Accepted			2022-02-06	
J	Ramic, M; Emerick, AJ; Bollnow, MR; O'Brien, TE; Tsai, SY; Kartje, GL				Ramic, Maya; Emerick, April J.; Bollnow, Melanie R.; O'Brien, Timothy E.; Tsai, Shih-Yen; Kartje, Gwendolyn L.			Axonal plasticity is associated with motor recovery following amphetamine treatment combined with rehabilitation after brain injury in the adult rat	BRAIN RESEARCH			English	Article						neurite outgrowth; sensorimotor cortex; psychostimulant; physical therapy; basilar pons; motor recovery	NEURITE GROWTH-INHIBITORS; MONOCLONAL-ANTIBODY IN-1; USE-DEPENDENT PLASTICITY; FUNCTIONAL RECOVERY; CORTICOFUGAL PLASTICITY; BEHAVIORAL RECOVERY; LOCOMOTOR FUNCTION; PROMOTES RECOVERY; NUCLEUS-ACCUMBENS; CORTICAL-LESIONS	Clinical and laboratory studies have suggested that amphetamine treatment when paired with rehabilitation results in improved recovery of function after stroke or traumatic brain injury. In the present study, we investigated whether new anatomical pathways developed in association with improved motor function after brain damage and amphetamine treatment linked with rehabilitation. Following a unilateral sensorimotor cortex lesion in the adult rat, amphetamine (2 mg/kg) was administered in conjunction with physiotherapy sessions on postoperative days two and five. Physiotherapy was continued twice daily for the first 3 weeks after injury, and then once daily until week six. Performance on skilled forelimb reaching and ladder rung walking was used to assess motor improvement. Our results show that animals with sensorimotor cortical lesions receiving amphetamine treatment linked with rehabilitation had significant improvement in both tasks. Neuroanatomical tracing of efferent pathways from the opposite, non-damaged cortex resulted in the novel finding that amphetamine treatment linked with rehabilitation, significantly increased axonal growth in the deafferented basilar pontine nuclei. These results support the notion that pharmacological interventions paired with rehabilitation can enhance neuronal plasticity and thereby improve functional recovery after CNS injury.	Edward Hines Jr Vet Adm Hosp, Res Serv, Hines, IL 60141 USA; Loyola Univ, Med Ctr, Neurosci Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Cell Biol, Maywood, IL 60153 USA; Loyola Univ, Dept Math & Stat, Ctr Stat Consulting, Chicago, IL 60626 USA		Emerick, AJ (corresponding author), Edward Hines Jr Vet Adm Hosp, Res Serv, 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.	april.emerick@med.va.gov			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS040960] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [40960] Funding Source: Medline; RRD VA [I01 RX000828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS040960] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000828] Funding Source: NIH RePORTER		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; CARR LA, 1969, SCIENCE, V164, P322, DOI 10.1126/science.164.3877.322; CASTRO AJ, 1972, BRAIN RES, V37, P173, DOI 10.1016/0006-8993(72)90665-8; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Cramer SC, 2004, RESTOR NEUROL NEUROS, V22, P231; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Emerick AJ, 2004, BEHAV BRAIN RES, V152, P315, DOI 10.1016/j.bbr.2003.10.010; Emerick AJ, 2003, J NEUROSCI, V23, P4826; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Flores C, 2000, NEUROSCIENCE, V98, P287, DOI 10.1016/S0306-4522(00)00115-9; Foltys H, 2003, CLIN NEUROPHYSIOL, V114, P2404, DOI 10.1016/S1388-2457(03)00263-3; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; HOFFSCHMIDT B, 2001, P 5 COL SOL S JUN 21, P51; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Jones TA, 1999, J NEUROSCI, V19, P10153; Kartje GL, 1999, ANN NEUROL, V45, P778, DOI 10.1002/1531-8249(199906)45:6<778::AID-ANA12>3.0.CO;2-B; KOMITOVA M, 2006, EXP NEUROL; KONRADI C, 1994, J NEUROSCI, V14, P5623; Li YL, 2003, NEUROPSYCHOPHARMACOL, V28, P1082, DOI 10.1038/sj.npp.1300115; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mueller D, 2006, NEUROSCIENCE, V137, P727, DOI 10.1016/j.neuroscience.2005.09.038; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nelles G, 1999, STROKE, V30, P1510, DOI 10.1161/01.STR.30.8.1510; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Park YH, 2002, BRAIN RES, V951, P43, DOI 10.1016/S0006-8993(02)03103-7; Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x; Sawaki L, 2002, NEUROLOGY, V59, P1262, DOI 10.1212/WNL.59.8.1262; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Song YM, 2005, ARCH NEUROL-CHICAGO, V62, P809, DOI 10.1001/archneur.62.5.809; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Tegenthoff M, 2004, ACTA NEUROL SCAND, V109, P330, DOI 10.1046/j.1600-0404.2003.00235.x; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Wenk CA, 1999, J COMP NEUROL, V410, P143, DOI 10.1002/(SICI)1096-9861(19990719)410:1<143::AID-CNE12>3.0.CO;2-#; Whishaw I.Q., 2005, BEHAV LAB RAT HDB TE, P162170; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; [No title captured]	51	58	60	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 21	2006	1111						176	186		10.1016/j.brainres.2006.06.063			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	089TY	WOS:000240905200022	16920088				2022-02-06	
J	Armstead, WM; Nassar, T; Akkawi, S; Smith, DH; Chen, XH; Cines, DB; Higazi, AA				Armstead, William M.; Nassar, Taher; Akkawi, Saed; Smith, Douglas H.; Chen, Xiao-Han; Cines, Douglas B.; Higazi, Abd Al-Roof			Neutralizing the neurotoxic effects of exogenous and endogenous tPA	NATURE NEUROSCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; CENTRAL-NERVOUS-SYSTEM; BRAIN; INHIBITOR; THERAPY; STROKE; INJURY; CEREBROVASODILATION; FIBRINOLYSIS; IMPAIRMENT	The clinical use of tissue-type plasminogen activator (tPA) in the treatment of stroke is profoundly constrained by its serious side effects. We report that the deleterious effects of tPA on cerebral edema and intracranial bleeding are separable from its fibrinolytic activity and can be neutralized. A hexapeptide (EEIIMD) corresponding to amino acids 350-355 of plasminogen activator inhibitor type 1 (PAI-1) abolished the tPA-induced increase in infarct size and intracranial bleeding in both mechanical and embolic models of stroke in rats, and reduced brain edema and neuronal loss after traumatic brain injury in pigs. These experiments suggest mechanisms to reduce the neurotoxic effects of tPA without compromising its fibrinolytic activity, through the use of selective antagonists and new tPA formulations.	Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Univ Penn, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA		Higazi, AA (corresponding author), Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel.	higazi@mail.med.upenn.edu	smith, douglas/A-1321-2007		NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL076206, HL076406, HL06831, HL82545, HL67381] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL067381, P01HL076406, R01HL076206] Funding Source: NIH RePORTER		Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; AKKAWI S, 2006, AM J PHYSIOL-HEART C, DOI DOI 10.1152/A4PHEART.01042.2005; Armstead WM, 2004, J NEUROTRAUM, V21, P1204, DOI 10.1089/neu.2004.21.1204; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Atochin DN, 2004, STROKE, V35, P2177, DOI 10.1161/01.STR.0000137412.35700.0e; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BUCKLEY NM, 1986, COMP BIOCHEM PHYS A, V83, P1, DOI 10.1016/0300-9629(86)90080-0; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; Higazi AAR, 2005, BLOOD, V105, P1021, DOI 10.1182/blood-2004-03-0995; Lapchak PA, 2001, CNS DRUGS, V15, P819, DOI 10.2165/00023210-200115110-00001; LAPCHAK PA, 2002, CURR NEUROL NEUROSCI, V2, P1, DOI DOI 10.1007/s11910-002-0051-0; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nagai N, 2001, BLOOD, V97, P3086, DOI 10.1182/blood.V97.10.3086; Nagai N, 1999, CIRCULATION, V100, P2541, DOI 10.1161/01.CIR.100.25.2541; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; REBICH S, 1995, AM J PHYSIOL-HEART C, V268, pH1071; THOMAS JM, 1971, GROWTH, V35, P259; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; WAGERLE LC, 1986, PEDIATR RES, V20, P131, DOI 10.1203/00006450-198602000-00007; Zhang LT, 1997, J BIOL CHEM, V272, P27053, DOI 10.1074/jbc.272.43.27053; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zivin JA, 1999, NEUROLOGY, V53, P14, DOI 10.1212/WNL.53.1.14	32	58	58	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2006	9	9					1150	1155		10.1038/nn1757			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	078DE	WOS:000240080800016	16936723				2022-02-06	
J	Marx, CE; Shampine, LJ; Khisti, RT; Trost, WT; Bradford, DW; Grobin, AC; Massing, MW; Madison, RD; Butterfield, MI; Lieberman, JA; Morrow, AL				Marx, Christine E.; Shampine, Lawrence J.; Khisti, Rahul T.; Trost, William T.; Bradford, Daniel W.; Grobin, A. Chistina; Massing, Mark W.; Madison, Roger D.; Butterfield, Marian I.; Lieberman, Jeffrey A.; Morrow, A. Leslie			Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						olanzapine; fluoxetine; antipsychotic; neuroactive steroid; pregnenolone; allopregnanolone; deoxycorticosterone; neurosteroid	NEUROACTIVE STEROID ALLOPREGNANOLONE; TRAUMATIC BRAIN-INJURY; OLANZAPINE/FLUOXETINE COMBINATION; MAJOR DEPRESSION; CELL-DEATH; PROGESTERONE; MEMORY; SULFATE; NEUROSTEROIDS; MICE	Olanzapine and fluoxetine elevate the GABAergic neuroactive steroid allopregnanolone to physiologically relevant concentrations in rodent cerebral cortex. It is unknown if these agents also alter pregnenolone or deoxycorticosterone. Since olanzapine and fluoxetine in combination have clinical utility and may demonstrate synergistic effects, we investigated neuroactive steroid alterations following olanzapine, fluoxetine or coadministration. Male rats received IP vehicle, olanzapine, fluoxetine or the combination of both agents in higher-dose (0, 10, 20 or 10/20 mg/kg, respectively) and lower-dose (0, 5, 10 or 5110 mg/kg, respectively) experiments. Pregnenolone and allopregnanolone levels in hippocampus were determined by gas chromatography/mass spectrometry. Peripheral deoxycorticosterone and other steroid levels were determined by radioimmunoassay. Olanzapine, fluoxetine or the combination increased hippocampal pregnenolone and serum deoxycorticosterone in both higher- and lower-dose experiments, and elevated hippocampal allopregnanolone in higher-dose conditions. No synergistic effects on pregnenolone or allopregnanolone were observed following olanzapine and fluoxetine coadministration compared to either compound alone. Pregnenolone and its sulfate enhance learning and memory in rodent models, and therefore pregnenolone elevations may be relevant to cognitive changes in psychotic and affective disorders. Since pregnenolone decreases have been linked to depression, it is possible that olanzapine- and fluoxetine-induced pregnenolone elevations may contribute to the antidepressant actions of these agents. Published by Elsevier Inc.	Duke Univ, Med Ctr, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Mental Hlth Serv, Durham, NC USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA		Marx, CE (corresponding author), Duke Univ, Med Ctr, 508 Fulton St,Line 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 65080] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH065080] Funding Source: NIH RePORTER		Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; CORYA SA, 2006, DEPRESS ANXIETY, P1; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; GEORGE MS, 1994, BIOL PSYCHIAT, V35, P775, DOI 10.1016/0006-3223(94)91139-8; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Keefe RSE, 2004, AM J PSYCHIAT, V161, P985, DOI 10.1176/appi.ajp.161.6.985; Khisti RT, 2005, BRAIN RES, V1049, P104, DOI 10.1016/j.brainres.2005.05.007; Khisti RT, 2000, BRAIN RES, V865, P291, DOI 10.1016/S0006-8993(00)02373-8; Koch S, 2004, NEUROPHARMACOLOGY, V46, P232, DOI 10.1016/j.neuropharm.2003.09.001; Kodamo M, 2004, BIOL PSYCHIAT, V56, P570, DOI 10.1016/j.biopsych.2004.07.008; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; Lewis DA, 2004, ANN NY ACAD SCI, V1021, P64, DOI 10.1196/annals.1308.008; Maragnoli ME, 2004, BIOL PSYCHIAT, V55, P1095, DOI 10.1016/j.biopsych.2004.02.003; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; MORROW AL, 1990, MOL PHARMACOL, V37, P263; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schule C, 2006, MOL PSYCHIATR, V11, P261, DOI 10.1038/sj.mp.4001782; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Seager MA, 2004, BIOL PSYCHIAT, V55, P1103, DOI 10.1016/j.biopsych.2004.02.012; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Sharma T, 2003, PSYCHOPHARMACOLOGY, V169, P398, DOI 10.1007/s00213-003-1506-y; Shelton RC, 2001, AM J PSYCHIAT, V158, P131, DOI 10.1176/appi.ajp.158.1.131; Shelton RC, 2005, J CLIN PSYCHIAT, V66, P1289, DOI 10.4088/JCP.v66n1012; Tohen M, 2003, ARCH GEN PSYCHIAT, V60, P1079, DOI 10.1001/archpsyc.60.11.1079; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P13451, DOI 10.1021/bi026109w; Ugale RR, 2004, NEUROPSYCHOPHARMACOL, V29, P1597, DOI 10.1038/sj.npp.1300460; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N; WIELAND S, 1995, PSYCHOPHARMACOLOGY, V118, P65, DOI 10.1007/BF02245251; Zhang W, 2000, NEUROPSYCHOPHARMACOL, V23, P250, DOI 10.1016/S0893-133X(00)00119-6	46	58	61	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	AUG	2006	84	4					609	617		10.1016/j.pbb.2006.07.032			9	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	101ZI	WOS:000241779800006	16996120				2022-02-06	
J	Milders, M; Ietswaart, M; Crawford, JR; Currie, D				Milders, Maarten; Ietswaart, Magdalena; Crawford, John R.; Currie, David			Impairments in theory of mind shortly after traumatic brain injury and at 1-year follow-up	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; theory of mind; executive function; recovery; follow-up	CLOSED-HEAD INJURY; SOCIAL COGNITION; PSYCHOSOCIAL ADJUSTMENT; FRONTOTEMPORAL DEMENTIA; LANGUAGE IMPAIRMENT; ACQUIRED THEORY; CHILDREN; PERFORMANCE; DISEASE; BELIEF	Most studies into acquired theory of mind (ToM) deficits assessed patients once, long after the onset of brain injury. As a result, the time course of acquired ToM impairments is largely unknown. The present study examined whether ToM impairments following traumatic brain injury (TBI) recover, remain stable, or worsen over time. Because of the alleged association between ToM and social communication, ToM impairments may deteriorate because of changes in patients' social environment following injury, ToM ability and executive functioning were assessed shortly after injury and at I-year follow-up. Compared with the orthopedic control group, the TBI group was impaired on ToM and executive functioning tasks at both assessments. Furthermore, the ToM impairments in the TBI group remained stable over time.	Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland; Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland		Milders, M (corresponding author), Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland.	m.milders@abdn.ac.uk	Crawford, John R/A-4165-2008; Milders, Maarten/C-5560-2008	Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393			BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Burgess P.W., 1997, HAYLING BRIXTON TEST; Carlson SM, 2004, DEV PSYCHOL, V40, P1105, DOI 10.1037/0012-1649.40.6.1105; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; LEEKAM SR, 1991, COGNITION, V40, P203, DOI 10.1016/0010-0277(91)90025-Y; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Miller CA, 2004, INT J LANG COMM DIS, V39, P191, DOI 10.1080/13682820310001616994; OZONOFF S, 1995, J AUTISM DEV DISORD, V25, P415, DOI 10.1007/BF02179376; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; Powell J., 2000, COGNITIVE NEUROPSYCH, V5, P175, DOI [DOI 10.1080/13546800050083520, 10.1080/13546800050083520]; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Samson D, 2004, NAT NEUROSCI, V7, P499, DOI 10.1038/nn1223; Sarfati Y, 2000, PSYCHOPATHOLOGY, V33, P246, DOI 10.1159/000029153; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Snowden JS, 2003, NEUROPSYCHOLOGIA, V41, P688, DOI 10.1016/S0028-3932(02)00221-X; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Surian L, 2001, BRAIN LANG, V78, P224, DOI 10.1006/brln.2001.2465; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Wechsler D., 1998, MANUAL WECHSLER ADUL; Ziatas K, 1998, J CHILD PSYCHOL PSYC, V39, P755, DOI 10.1017/S0021963098002510	43	58	59	0	19	AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2006	20	4					400	408		10.1037/0894-4105.20.4.400			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	066SQ	WOS:000239250800002	16846258				2022-02-06	
J	Worringham, CJ; Wood, JM; Kerr, GK; Silburn, PA				Worringham, CJ; Wood, JM; Kerr, GK; Silburn, PA			Predictors of driving assessment outcome in Parkinson's disease	MOVEMENT DISORDERS			English	Article						vision; psychomotor performance; driving; prediction; risk factors	TRAUMATIC BRAIN-INJURY; CONTRAST SENSITIVITY; PERFORMANCE; OLDER; DRIVERS; ABILITY; PEOPLE; DISCRIMINATION; ACCIDENTS; ATROPHY	This study evaluated selected clinical and functional tests as predictors of driving safety outcomes in Parkinson's disease (PD) patients. A total of 25 PD patients and 21 age-matched controls, all regular drivers, underwent neurological evaluation and assessment of cognitive, visual, and motor function and a standardized, on-road driving assessment. The capacity of the tests to predict pass/fail driving outcomes was determined by selecting a subset with the highest predictive value from each domain and then subjecting these subsets to discriminant function analysis. Accuracy, sensitivity, specificity, and positive and negative predictive values were determined. Three relatively simple tests from the larger battery predicted passes with relatively high sensitivity (PD, 72.7%; controls, 93.8%; both combined, 85.2%); and moderate specificity (PD, 64.3%; controls, 60.0%; both combined. 63.2%). These tests assessed motor performance (Purdue Pegboard test), contrast sensitivity (Pelli-Robson test), and cognitive function (verbal version of Symbol Digit Modalities test). Adding time since diagnosis for the PD group increased sensitivity to 90.9% and specificity to 71.4%. These simple tests confer more objectivity and predictive power to clinical recommendations for driving, they reflect distinct functions that are necessary for safe driving, and they may be especially useful when on-road assessments are not feasible. (C) 2005 Movement Disorder Society.	Queensland Univ Technol, Sch Human Movement Studies, Kelvin Grove, Qld 4059, Australia; Queensland Univ Technol, Sch Optometry, Kelvin Grove, Qld, Australia; Princess Alexandra Hosp, Dept Neurol, Brisbane, Qld 4102, Australia		Worringham, CJ (corresponding author), Queensland Univ Technol, Sch Human Movement Studies, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	c.worringham@qut.edu.au	Silburn, Peter A/A-3614-2011; Kerr, Graham/I-9705-2012	Kerr, Graham/0000-0002-1008-256X; , Joanne/0000-0002-0776-7736			*AUSTR INC, 2003, ASS FITN DRIV COMM P; Beck A., 1996, BECK DEPRESSION INVE; Beck AT, 1990, BECK ANXIETY INVENTO; Borromei A, 1999, FUNCT NEUROL, V14, P227; BULLIMORE MA, 1993, INVEST OPHTH VIS SCI, V34, P3526; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; De Raedt R, 2001, ACCIDENT ANAL PREV, V33, P809, DOI 10.1016/S0001-4575(00)00095-6; DUBINSKY RM, 1991, NEUROLOGY, V41, P517, DOI 10.1212/WNL.41.4.517; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Gallo JJ, 1999, J AM GERIATR SOC, V47, P335, DOI 10.1111/j.1532-5415.1999.tb02998.x; Gimenez-Roldan S, 1998, Neurologia, V13, P13; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Heikkila VM, 1998, J NEUROL NEUROSUR PS, V64, P325, DOI 10.1136/jnnp.64.3.325; Homann CN, 2003, J NEUROL, V250, P1439, DOI 10.1007/s00415-003-0239-5; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; HUNT LA, 1995, OPTOMETRY VISION SCI, V72, P92, DOI 10.1097/00006324-199502000-00008; Lafayette Instruments, 1999, QUICK REF GUID PURD; LINGS S, 1992, ACTA NEUROL SCAND, V86, P33, DOI 10.1111/j.1600-0404.1992.tb08050.x; *MA GEN HOSP, 2001, LONG SHOULD 2 DRIV B; MADELEY P, 1990, J NEUROL NEUROSUR PS, V53, P580, DOI 10.1136/jnnp.53.7.580; Mallon K, 2004, AM J OCCUP THER, V58, P279, DOI 10.5014/ajot.58.3.279; MCCLAY P, 1989, INT DISABILITY STUDI, V11, P50; Meindorfner C, 2005, MOVEMENT DISORD, V20, P832, DOI 10.1002/mds.20412; O'Suilleabhain P, 2001, J NEUROL NEUROSUR PS, V71, P607, DOI 10.1136/jnnp.71.5.607; Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881; PELLI DG, 1988, CLIN VISION SCI, V2, P187; Pieri V, 2000, J NEUROL SCI, V172, P7, DOI 10.1016/S0022-510X(99)00204-X; Radford K, 2004, DISABIL REHABIL, V26, P65, DOI 10.1080/09638280310001629633; Radford KA, 2004, BRAIN INJURY, V18, P775, DOI 10.1080/02699050310001657394; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Shinar D, 1998, HUM FACTORS, V40, P647, DOI 10.1518/001872098779649346; Smiley-Oyen AL, 2003, EXP BRAIN RES, V152, P453, DOI 10.1007/s00221-003-1570-x; Smith A, 1995, SYMBOL DIGIT MODALIT; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; Stutts JC, 1998, ACCIDENT ANAL PREV, V30, P337, DOI 10.1016/S0001-4575(97)00108-5; van Elst LT, 1997, BRAIN, V120, P2219, DOI 10.1093/brain/120.12.2219; Wood JM, 2005, J NEUROL NEUROSUR PS, V76, P176, DOI 10.1136/jnnp.2004.047118; Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664; Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018; Woodward TS, 2002, NEUROPSYCHOLOGIA, V40, P1948, DOI 10.1016/S0028-3932(02)00068-4; Zesiewicz TA, 2002, NEUROLOGY, V59, P1787, DOI 10.1212/01.WNL.0000035636.83680.C6	42	58	61	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0885-3185			MOVEMENT DISORD	Mov. Disord.	FEB	2006	21	2					230	235		10.1002/mds.20709			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	016DW	WOS:000235601900014	16161149	Green Published			2022-02-06	
J	Hong, SB; Koh, Y; Lee, IC; Kim, MJ; Kim, WS; Kim, DS; Kim, WD; Lim, CM				Hong, SB; Koh, Y; Lee, IC; Kim, MJ; Kim, WS; Kim, DS; Kim, WD; Lim, CM			Induced hypothermia as a new approach to lung rest for the acutely injured lung	CRITICAL CARE MEDICINE			English	Article						acute lung injury; lung rest; mechanical ventilation; hypothermia; ventilator-induced lung injury; ventilatory frequency	RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; EXTRACORPOREAL CO2 REMOVAL; TRAUMATIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; MECHANICAL VENTILATION; RNA EXPRESSION; RATS; ENDOTOXIN	Objective: To investigate whether low-frequency ventilation during hypothermia could attenuate lung injury associated with endotoxin and mechanical ventilation. Design: Experimental animal study. Setting. University-affiliated animal laboratory. Subjects. Forty-eight Sprague-Dawley rats. Interventions: Lipopolysaccharide was administered to rats intratracheally to induce acute lung injury. After 1 hr of this treatment, animals were assigned to normothermia-only (NO, rectal temperature 37 degrees C, ventilatory frequency 90/min), normothermia-lung rest (NR, 37 degrees C, 45/min), hypothermia -only (H0, 27 degrees C, 90/min), or hypothermia-lung rest (HR, 27 degrees C, 45/min). After 1 hr of injurious ventilation, the lungs of the rats were removed for bronchoalveolar lavage and histologic examination. Measurements and Main Results: Compared with the normothermia groups (NO, NR), the neutrophil counts (per milliliter) (NO, 7708 +/- 5704; NR, 10,479 +/- 11,152; HO, 1638 +/- 955; HR, 805 +/- 591) and interleukin-1 beta levels (pg/mL) (1180 +/- 439, 1081 +/- 652, 620 +/- 426, 420 +/- 182, respectively) in the bronchoalveolar lavage fluid, the wet-to-dry lung weight ratios (6.0 +/- 0.4, 5.7 +/- 0.4, 5.6 +/- 0.2, 5.2 +/- 0.2, respectively), and histologic acute lung injury scores (8.3 +/- 2.7, 10.4 +/- 3.1, 3.5 +/- 2.1, 3.1 +/- 2.2, respectively) of the hypothermia groups (HO, HR) were lower (all p <.001). Compared with the HO group, the neutrophil counts and protein content (HO, 1367 +/- 490 mu g/mL vs. HR, 831 +/- 369 mu g/mL) in the bronchoalveolar lavage fluid, the serum lactate dehydrogenase levels (units/mL) (9.1 +/- 3.6 vs. 5.3 +/- 1.5), and the wet-to-dry lung weight ratios of the HR group were lower (all p <.05). Conclusions: Reduction of ventilatory frequency in conjunction with hypothermia attenuated many variables of acute lung injury in rats. Use of hypothermia could be exploited as a new approach to lung rest for the ventilatory management of the acutely injured lung.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea		Hong, SB (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea.						Bartlett RH, 2000, JAMA-J AM MED ASSOC, V283, P904, DOI 10.1001/jama.283.7.904; Behnia R, 1996, ANN CLIN LAB SCI, V26, P437; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Boussarsar M, 2002, INTENS CARE MED, V28, P406, DOI 10.1007/s00134-001-1178-1; Broccard AF, 1998, AM J RESP CRIT CARE, V157, P1935, DOI 10.1164/ajrccm.157.6.9612006; Broccard AF, 2001, AM J RESP CRIT CARE, V164, P802, DOI 10.1164/ajrccm.164.5.2007060; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BSHOUTY Z, 1992, AM REV RESPIR DIS, V145, P372, DOI 10.1164/ajrccm/145.2_Pt_1.372; Choudhury S, 2004, AM J PHYSIOL-LUNG C, V287, pL902, DOI 10.1152/ajplung.00187.2004; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HARKNESS JE, 1995, BIOL MED RABBITS ROD, P84; HASHIN Z, 1978, MATER SCI ENG, V34, P147, DOI 10.1016/0025-5416(78)90045-9; HASINOFF I, 1988, J CRIT CARE, V3, P225, DOI 10.1016/0883-9441(88)90106-2; HIDA W, 1984, J APPL PHYSIOL, V57, P262, DOI 10.1152/jappl.1984.57.1.262; Hotchkiss JR, 2000, AM J RESP CRIT CARE, V161, P463, DOI 10.1164/ajrccm.161.2.9811008; HURST JM, 1985, CRIT CARE MED, V13, P771, DOI 10.1097/00003246-198509000-00019; Imai Y, 1999, J APPL PHYSIOL, V87, P510, DOI 10.1152/jappl.1999.87.2.510; Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P399, DOI 10.1164/ajrccm.162.2.9911026; Lim CM, 2004, INTENS CARE MED, V30, P1638, DOI 10.1007/s00134-004-2336-z; Lim CM, 2003, LUNG, V181, P23, DOI 10.1007/s00408-002-0111-x; Lim CM, 2003, INTENS CARE MED, V29, P453, DOI 10.1007/s00134-002-1529-6; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Moonka R, 1996, J TRAUMA, V40, P1026, DOI 10.1097/00005373-199606000-00031; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Moshkovitz Y, 1998, ANN THORAC SURG, V66, P1179, DOI 10.1016/S0003-4975(98)00805-4; Mowlavi A, 2003, PLAST RECONSTR SURG, V111, P242, DOI 10.1097/01.PRS.0000034936.25458.98; Murphy DB, 2000, AM J RESP CRIT CARE, V162, P27, DOI 10.1164/ajrccm.162.1.9908110; Parsey MV, 1998, J IMMUNOL, V160, P1007; Pattin CA, 1996, J BIOMECH, V29, P69, DOI 10.1016/0021-9290(94)00156-1; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rimensberger PC, 1998, CRIT CARE MED, V26, P548, DOI 10.1097/00003246-199803000-00030; RITTENHOUSE EA, 1974, ANN THORAC SURG, V17, P63, DOI 10.1016/S0003-4975(10)65062-X; Schechtman H, 1997, J BIOMECH, V30, P829, DOI 10.1016/S0021-9290(97)00033-X; Suzuki S, 2004, CRIT CARE MED, V32, P144, DOI 10.1097/01.CCM.0000098857.14923.44; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Torbati D, 2000, INTENS CARE MED, V26, P585, DOI 10.1007/s001340051208; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Whalen MJ, 1997, ACT NEUR S, V70, P260; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470	47	58	67	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	2005	33	9					2049	2055		10.1097/01.CCM.0000178186.37167.53			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	042CG	WOS:000237504200022	16148479				2022-02-06	
J	Brewer, BR; Fagan, M; Klatzky, RL; Matsuoka, Y				Brewer, BR; Fagan, M; Klatzky, RL; Matsuoka, Y			Perceptual limits for a robotic rehabilitation environment using visual feedback distortion	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						feedback distortion; kinesthetic perception; perception of effort; rehabilitation robotics	MANUAL DISCRIMINATION; WEIGHT; INFORMATION; MECHANISMS; RESOLUTION; THERAPY; FORCE; SENSE	Imperceptible visual distortion, in the form of a disguised progression of performance goals, may be a helpful addition to rehabilitation after stroke and other brain injuries. This paper describes work that has been done to lay the groundwork for testing this hypothesis. We have constructed and validated an experimental environment that provides controllable visual distortion and allows precise force and position measurements. To estimate the amount of visual distortion that should be imperceptible, we measured the limits for force and distance/position perception in our rehabilitation environment for young and elderly unimpaired subjects and for a single traumatic brain injury (TBI) patient. We found the Just Noticeable Difference (JND) for produced force to be 19.7% (0.296 N) and the JND for movement distance/finger position to be 13.0% (3.99 mm) for young subjects (ages 18-35). For elderly subjects (ages 61-80), the JND for force was measured to be 31.0% (0.619 N) and the JND for distance/position was 16.1% (5.01 mm). JNDs of 46.0% (0.920 N) and 45.0% (14.8 mm) were found for the motor-impaired individual. In addition, a subject's rating of effort was found to be profoundly influenced by visual feedback concerning the force magnitude. Even when this feedback was distorted, it accounted for 99% of the variance of the effort rating. These results indicate that substantial visual distortions should be imperceptible to the subject, and that visual feedback can be used to influence the subject's perceived experience in our robotic environment. This means that we should be able to use imperceptible visual distortion to alter a patient's perception of therapeutic exercise in a robotic environment.	Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA		Klatzky, RL (corresponding author), Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.	klatzky@cmu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020502] Funding Source: Medline		Allin S, 2002, 10TH SYMPOSIUM ON HAPTIC INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS, PROCEEDINGS, P299, DOI 10.1109/HAPTIC.2002.998972; Atkinson JW, 1964, INTRO MOTIVATION; BANDURA A, 1983, J PERS SOC PSYCHOL, V45, P1017, DOI 10.1037/0022-3514.45.5.1017; BANDURA A, 1986, ORGAN BEHAV HUM DEC, V38, P92, DOI 10.1016/0749-5978(86)90028-2; BERLINER JE, 1973, J ACOUST SOC AM, V53, P1270, DOI 10.1121/1.1913465; Boisan R F, 2002, P 1 INT WORKSH VIRT, P77; Brewer B. R., 2003, P 8 INT C REH ROB DA, P258; Brewer BR, 2003, P ANN INT IEEE EMBS, V25, P1613, DOI 10.1109/IEMBS.2003.1279676; BREWER BR, 2004, P INT C ROB AUT ICRA, V2, P2080; BRODIE EE, 1984, PERCEPT PSYCHOPHYS, V36, P477, DOI 10.3758/BF03207502; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P293, DOI 10.3758/BF03208094; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P29, DOI 10.3758/BF03208071; ELLIOTT ES, 1988, J PERS SOC PSYCHOL, V54, P5, DOI 10.1037/0022-3514.54.1.5; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fagan M, 2003, 11TH SYMPOSIUM ON HAPTIC INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS - HAPTICS 2003, PROCEEDINGS, P159, DOI 10.1109/HAPTIC.2003.1191263; Fitzgibbons PJ, 2001, J ACOUST SOC AM, V109, P2955, DOI 10.1121/1.1371760; FLEISHMAN EA, 1984, ERGONOMICS, V27, P947, DOI 10.1080/00140138408963573; Gescheider GA, 1996, SOMATOSENS MOT RES, V13, P73, DOI 10.3109/08990229609028914; HELLER MA, 1983, PERCEPTION, V12, P607, DOI 10.1068/p120607; HOGAN JC, 1980, J APPL PSYCHOL, V65, P672, DOI 10.1037/0021-9010.65.6.672; JARIC S, 1994, EXP BRAIN RES, V100, P353; JONES LA, 1989, PERCEPTION, V18, P681, DOI 10.1068/p180681; JONES LA, 1990, EXP BRAIN RES, V79, P150; LACKNER JR, 1974, PERCEPT MOTOR SKILL, V38, P1251, DOI 10.2466/pms.1974.38.3c.1251; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Lum PS, 2002, ARCH PHYS MED REHAB, V83, P952, DOI 10.1053/apmr.2001.33101; PANG XD, 1991, PERCEPT PSYCHOPHYS, V49, P531, DOI 10.3758/BF03212187; RAJ DV, 1985, BRAIN, V108, P95, DOI 10.1093/brain/108.1.95; Reinkensmeyer DJ, 2000, J REHABIL RES DEV, V37, P653; ROSS HE, 1987, Q J EXP PSYCHOL-A, V39, P77, DOI 10.1080/02724988743000042; Shinomori K, 2001, J OPT SOC AM A, V18, P310, DOI 10.1364/JOSAA.18.000310; SKIDMORE ER, 2003, THESIS U PITTSBURGH; TAN HZ, 1989, J ACOUST SOC AM, V86, P981, DOI 10.1121/1.398733; TAN HZ, 1995, PERCEPT PSYCHOPHYS, V57, P495, DOI 10.3758/BF03213075; TAUB E, 1994, PL S BEHAV, P185; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Williams JG, 2001, PREV MED, V32, P103, DOI 10.1006/pmed.2000.0792	37	58	60	0	9	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	MAR	2005	13	1					1	11		10.1109/TNSRE.2005.843443			11	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Rehabilitation	907VU	WOS:000227747000001	15813400				2022-02-06	
J	Steudel, WI; Cortbus, F; Schwerdtfeger, K				Steudel, WI; Cortbus, F; Schwerdtfeger, K			Epidemiology and prevention of fatal head injuries in Germany - trends and the impact of the reunification	ACTA NEUROCHIRURGICA			English	Article						head injury; epidemiology; incidence rates; mortality rates; age group-specific data	TRAUMATIC BRAIN INJURY; DEATHS; POPULATION; COMMUNITY; MORTALITY; FEATURES; COUNTY	A review of the data published on the epidemiology of traumatic brain injuries (TBI) reveals that the data of almost all studies are drawn from local or regional series. Nationwide data are rarely available, or are extrapolated from regional data. In Germany, there has been a nationwide mortality register with ICD-9-coded diagnoses since 1968. In addition, it has been compulsory since 1994 that all hospitals in Germany provide ICD-9 data on all admissions and discharges. Based on data provided by the Federal Bureau of Statistics (Statistisches Bundesamt) in Wiesbaden, all head injuries between 1972 and 1998 were analyzed according to ICD-9 and after 1998 according to the updated ICD-10. The data of hospitalized cases and fatal cases were correlated with population data to calculate incidences and mortality rates. Age-group specific data were also available and analyzed. Head injuries in Germany accounted in 1998 for 19.59% of all injuries. The incidence is 337/100,000. The incidence rate of serious head injury is 33.5/100,000. Mortality decreased continuously from 27.2/100,000 in 1972 to 9.0/100,000 in 2000. The mortality is highest in the group older than 75 years. 68.4% of persons with head injury die before admission to a hospital. After the reunification in 1989/1990, the number of fatal head injuries showed a temporary increase. The number of patients treated in-hospital remained essentially unchanged (276/564 patients in 1998). The majority of hospitalized patients suffered minor head injury. Conclusion: Analysis of the admission/discharge data of all German hospitals reveals surprising inside views of age group-related incidence and mortality rates of head injuries in this country. Future research should be focused on patients with minor head injuries who account for nearly 200,000 cases of in-hospital treatment.	Neurochirurg Univ Klin, D-66421 Homburg, Germany		Steudel, WI (corresponding author), Neurochirurg Univ Klin, D-66421 Homburg, Germany.	ncwste@uniklinik-saarland.de					ADELOYE A, 1976, INT SURG, V61, P478; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CORTBUS F, 1999, KLINIK FORSCHUNG, V5, P4; CORTBUS F, 2002, NEUROTRAUMA, P69; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; FIELD FG, 1996, EPIDEMIOLOGY HEAD IN; Firsching R, 2001, WORLD J SURG, V25, P1221; GRONWALL D, 1974, LANCET, V2, P605; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KARLSBECK WD, 1981, J NEUROSURG S, V53, P19; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOCH G, 1996, UNFALLURSACHEN BEIM; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; LILLARD PL, 1978, SURG NEUROL, V9, P79; MacKenzie E J, 1989, Md Med J, V38, P725; MacMillan R, 1979, Health Bull (Edinb), V37, P75; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; PHONPRASERT C, 1980, J TRAUMA, V20, P679, DOI 10.1097/00005373-198008000-00008; PLAUT MR, 1976, MIL MED, V141, P244; RAIMONDI A, 1979, J NEUROSURG, V32, P647; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; Servadei F, 2002, J Neurosurg Sci, V46, P111; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Turazzi S, 1975, J Neurosurg Sci, V19, P215; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; [No title captured]; 1983, SCI AM, V249, P20	34	58	59	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2005	147	3					231	242		10.1007/s00701-004-0441-y			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	905YW	WOS:000227608700002	15627922				2022-02-06	
J	Voulgaris, SG; Partheni, M; Kaliora, H; Haftouras, N; Pessach, IS; Polyzoidis, KS				Voulgaris, SG; Partheni, M; Kaliora, H; Haftouras, N; Pessach, IS; Polyzoidis, KS			Early cerebral monitoring using the transcranial Doppler pulsatility index in patients with severe brain trauma	MEDICAL SCIENCE MONITOR			English	Article						traumatic brain injury; transcranial Doppler; pulsatility index; CPP; ICP	BLOOD-FLOW-VELOCITY; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; MANAGEMENT; INJURY	Background: The early posttraumatic period is critical in patients with traurnatic brain injury (TBI) because of the increased risk of secondary ischemic injuries to the injured brain. For these patients, cerebral perfusion pressure (CPP) monitoring is recommended. This, however, requires an invasive device to measure intracranial pressure (ICP). Transcranial Doppler (TCD) ultrasonography is an effective, noninvasive method for the detection of cerebral hemodynamic changes. Use of the dimensionless TCD-pulsatility index (PI) has the advantage of eliminating errors in measurements due to insonation angle variations. Material/Methods: We investigated 37 patients with severe TBI (GCS less than or equal to8 on admission). The TCD parameters included the systolic, diastolic, and mean velocities of the middle cerebral artery (MCV) and the pulsatility index (PI). Mean arterial pressure (MAT), ICP, CPP, and simultaneous arterial and venous blood gases were also measured. Results: We observed a strong correlation between ICP and PI (r=0.82, p<0.0001) for ICP values >20 mmHG. The correlation of CPP to PI were also statistically significant (P<0.0001). The strongest inverse correlation between CPP and PI was obtained (r=0.86, p<0.0001) for CPP values below 70 mmHg. Conclusions: Pulsatility index measurements permit the early identification of patients with low CPP and high risk of cerebral ischemia. In emergency situations it can be used alone when ICP monitoring is contraindicated or not readily available.	Univ Ioannina, Neurosurg Clin, Sch Med, GR-45110 Ioannina, Greece; Univ Patras, Neurosurg Clin, Patras, Greece		Voulgaris, SG (corresponding author), Univ Ioannina, Neurosurg Clin, Sch Med, GR-45110 Ioannina, Greece.						Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOKINIEC R, 2004, MED SCI MONIT S2, V10, P14; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; HASSLER W, 1988, J NEUROSURG, V68, P745; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Lewis SB, 2001, NEUROSURGERY, V49, P1485, DOI 10.1097/00006123-200112000-00044; LINDEGAARD KF, 1992, TRANSCRANIAL DOPPLER, P67; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Murillo-Cabezas F, 2002, NEUROCIRUGIA, V13, P196; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tan H, 2001, Chin J Traumatol, V4, P156; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Ursino M, 1998, J NEUROSURG, V89, P255, DOI 10.3171/jns.1998.89.2.0255	24	58	60	0	1	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	FEB	2005	11	2					CR49	CR52					4	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	897UA	WOS:000227029700008	15668630				2022-02-06	
J	Ramos, AJ; Rubio, MD; Defagot, C; Hischberg, L; Villar, MJ; Brusco, A				Ramos, AJ; Rubio, MD; Defagot, C; Hischberg, L; Villar, MJ; Brusco, A			The 5HT(1A) receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization	BRAIN RESEARCH			English	Article						ischemia; cortical devascularization; 5HT(1A) receptor; 8-OH-DPAT; S100B; astrocyte	BAY X 3702; TRANSIENT FOREBRAIN ISCHEMIA; FIBRILLARY ACIDIC PROTEIN; GLOBAL CEREBRAL-ISCHEMIA; FIBROBLAST-GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; 5-HT1A RECEPTOR; NUCLEUS BASALIS; CHOLINERGIC NEURONS	Serotonin 1A (5HT(1A)) receptor agonists have shown neuroprotective properties in different models of central nervous system injury. Activation of neuronal 5HT(1A) receptors appears to be involved in the neuroprotective effects. It remains to be elucidated if astroglial cells are responsive to the 5HT(1A) neuroprotective effects. The participation of astroglial S100B trophic factor has been proposed since 5HT(1A) activation leads to S100B release and nanomolar concentration level of this molecule showed pro-survival activity in neuronal cultures. Using the cortical devascularization model (CD; unilateral pial disruption), a procedure that results in localized ischemia without producing direct physical damage to brain tissue, we tested the effects of a full 511TIA agonist, 8-OH-DPAT, or the antagonist WAY-100635 on cortical neuronal survival, astroglial cell response and S 10013 expression. Wistar rats were subjected to CD lesion which consisted of a craniotomy followed by physical damage to the underlying pial blood vessels. Two and twenty-four hours after the CD lesion, animals received intraperitoneally 8-OH-DPAT (1 mg/kg), WAY-100635 (1 mg/kg) or vehicle (sterile saline). At 3, 7 or 14 days post-lesion, animals were sacrificed and their brains processed for immunohistochemistry to detect GFAP, vimentin, MAP-2, S100B and nuclear Hoechst staining. S100B level in the brain cortex and serum was quantified by an ELISA assay. Serum S100B was considered an index of S100B release. 8-OH-DPAT treatment reduced neuronal death, dendrite loss, astroglial hypertrophy and hyperplasia. In contrast, WAY-100635 treatment increased these parameters of damage. S100B intracellular immunoreactivity in astrocytes and total S100B level showed long-lasting changes after the CD lesion and subsequent treatments depending on the 5HT(1A) activity. The level of serum S100B was increased in 8-OH-DPAT-treated animals. Increased damage observed in WAY-100635-treated animals supports the hypothesis that the protective 8-OH-DPAT action may be mediated by specific 5HT(1A) receptors. The reduction in astroglial hypertrophy and hyperplasia as well as long-term changes in S100B immunoreactivity and increased S100B release that we observed allows us to hypothesize that astroglial cells may play an important role in 5HT(1A)-mediated neuroprotection. (C) 2004 Elsevier B.V. All rights reserved.	Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencia, RA-1121 Buenos Aires, DF, Argentina; Univ Austral, Fac Ciencias Biomed, Buenos Aires, DF, Argentina; Sangtec Med AB, S-16102 Bromma, Sweden		Ramos, AJ (corresponding author), Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St Room MP038, Montreal, PQ H3A 2B4, Canada.	alberto.ramos@mcgill.ca	Ramos, Alberto Javier/AAR-7796-2020	Ramos, Alberto Javier/0000-0003-4009-6337			Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Ahlemeyer B, 1997, BRAIN RES, V777, P179; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Azmitia EC, 1996, NEUROPSYCHOPHARMACOL, V14, P35, DOI 10.1016/S0893-133X(96)80057-1; AZMITIA EC, 1995, BRAIN RES, V677, P181, DOI 10.1016/0006-8993(95)00051-Q; Azmitia EC, 2001, BRAIN RES BULL, V56, P413, DOI 10.1016/S0361-9230(01)00614-1; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Conner JM, 1998, NEUROSCIENCE, V83, P1003, DOI 10.1016/S0306-4522(97)00449-1; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; Deumens R, 2004, NEUROSCIENCE, V125, P591, DOI 10.1016/j.neuroscience.2004.02.010; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Douglas R. J., 1998, SYNAPTIC ORG BRAIN, P459; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Eriksen JL, 2002, DEV BRAIN RES, V139, P97, DOI 10.1016/S0165-3806(02)00510-2; Eriksen JL, 2001, DEV BRAIN RES, V128, P157, DOI 10.1016/S0165-3806(01)00172-9; Evrard SG, 2003, DEV BRAIN RES, V147, P119, DOI 10.1016/j.devbrainres.2003.09.004; FAGES C, 1994, BRAIN RES, V639, P161, DOI 10.1016/0006-8993(94)91777-9; FIGUEIREDO BC, 1995, MOL BRAIN RES, V33, P1, DOI 10.1016/0169-328X(95)00099-E; FIGUEIREDO BC, 1993, NEUROSCIENCE, V56, P955; Ganat Y, 2002, NEUROSCIENCE, V112, P977, DOI 10.1016/S0306-4522(02)00060-X; Glass JD, 1999, NEUROSCIENCE, V94, P1253, DOI 10.1016/S0306-4522(99)00369-3; HARING JH, 1993, BRAIN RES, V631, P119, DOI 10.1016/0006-8993(93)91195-X; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; HERRERA DG, 1992, NEUROSCIENCE, V49, P781, DOI 10.1016/0306-4522(92)90356-7; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huang J, 1997, NEUROCHEM RES, V22, P1329, DOI 10.1023/A:1022062921438; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Joosten EAJ, 1997, PROG NEUROBIOL, V53, P1, DOI 10.1016/S0301-0082(97)00024-5; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Klisch J, 2003, NEUROSCI LETT, V342, P25, DOI 10.1016/S0304-3940(03)00222-2; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; Kruger H, 1999, NEUROREPORT, V10, P2651; Kukley M, 2001, NEUROSCIENCE, V107, P405, DOI 10.1016/S0306-4522(01)00369-4; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.0.CO;2-8; LIBERINI P, 1994, BRAIN RES, V648, P1, DOI 10.1016/0006-8993(94)91897-X; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSTEP HL, 2002, CURR OPIN INVESTIG D, V3, P924; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Menet V, 2000, GLIA, V31, P267, DOI 10.1002/1098-1136(200009)31:3<267::AID-GLIA80>3.0.CO;2-N; Menet V, 2001, J NEUROSCI, V21, P6147; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Nishi M, 1997, NEUROSCI LETT, V229, P212, DOI 10.1016/S0304-3940(97)00443-6; Nishi M, 1996, SYNAPSE, V23, P1, DOI 10.1002/(SICI)1098-2396(199605)23:1<1::AID-SYN1>3.0.CO;2-E; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Oosterink BJ, 1998, EUR J PHARMACOL, V358, P147, DOI 10.1016/S0014-2999(98)00614-1; Oosterink BJ, 2003, NEUROREPORT, V14, P57, DOI 10.1097/00001756-200301200-00011; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; PIERA MJ, 1995, ARCH INT PHARMACOD T, V329, P347; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; Privat A, 2003, GLIA, V43, P91, DOI 10.1002/glia.10249; Ramos AJ, 2000, BRAIN RES, V883, P1, DOI 10.1016/S0006-8993(00)02862-6; Ramos AJ, 2002, BRAIN RES, V958, P112, DOI 10.1016/S0006-8993(02)03489-3; Ramos AJ, 2002, ANN NY ACAD SCI, V965, P343; RAMOS AJ, 2002, J NEUROCHEM S1, V81, pAP1; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Schiffer D, 1996, J NEUROL SCI, V139, P27, DOI 10.1016/0022-510X(96)00073-1; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Souza TME, 2000, PHYSIOL BEHAV, V71, P29, DOI 10.1016/S0031-9384(00)00299-7; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Tagliaferro P, 1997, MOL CHEM NEUROPATHOL, V32, P195, DOI 10.1007/BF02815176; Tajrine D, 1997, J NEUROSCI RES, V50, P627; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilson CC, 1998, BRAIN RES, V782, P235, DOI 10.1016/S0006-8993(97)01284-5; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zhu Y, 1998, J CEREBR BLOOD F MET, V18, P1032, DOI 10.1097/00004647-199809000-00013	84	58	59	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 31	2004	1030	2					201	220		10.1016/j.brainres.2004.10.019			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	880FW	WOS:000225775400005	15571670				2022-02-06	
J	Gooch, JL; Oberg, WA; Grams, B; Ward, LA; Walker, ML				Gooch, JL; Oberg, WA; Grams, B; Ward, LA; Walker, ML			Care provider assessment of intrathecal baclofen in children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							GROSS MOTOR FUNCTION; CEREBRAL-PALSY; SPASTICITY; INFUSION; ORIGIN; TRIAL	Intrathecal baclofen is used increasingly to manage severe spasticity in children. Before implanting the baclofen pump, care providers typically ask how it will benefit their child. The purpose of this study was to describe the perceptions of care providers about intrathecal baclofen for management of spasticity in 80 individuals (52 males, 28 females). The individuals were younger than 22 years at the time of implantation (mean age 11 years, SD 5 years; range 3 to 21 years). Participants had been implanted with the pump for a minimum of one year at the time of evaluation. The most common diagnoses were quadriplegic and diplegic cerebral palsy and traumatic brain injury. Most participants were at level IV and V on the Gross Motor Function Classification System. After pump implantation most participants had tone reduction on the Ashworth scale of 1 to 1.9 in the lower extremities and 0 to 0.9 in the upper extremities. Lower extremity range of motion was maintained in 43 of 51 individuals (84%) and lost in 8 participants (16%). Complications requiring surgery occurred in 63 of a larger group of 152 patients (incidence per patient-year of follow-up was 0.19). Thirty-one of the 80 children had orthopedic procedures after pump placement. Only one of these was unexpected and none had rapid progression of scoliosis. Most treatment goals were achieved. Goals most commonly chosen (decreased pain, prevention of worsening of deformity, and improved ease of care) were improved in 91%, 91%, and 88% of participants respectively. Ninety-five per cent of care providers agreed that they would have this procedure performed again (81% strongly agreed, 14% slightly agreed). All care providers reported improvement in scores on the Caregiver Questionnaire. This information has been helpful to families considering intrathecal baclofen therapy.	Univ Utah, Hlth Sci Ctr, Primary Childrens Med Ctr, Salt Lake City, UT 84113 USA		Gooch, JL (corresponding author), Univ Utah, Hlth Sci Ctr, Primary Childrens Med Ctr, 100 N Med Dr, Salt Lake City, UT 84113 USA.	pcjgooch@IHC.com					ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Campbell WM, 2002, DEV MED CHILD NEUROL, V44, P660; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; Gooch JL, 2003, PEDIATR NEUROSURG, V39, P1, DOI 10.1159/000070870; HALEY SM, 1991, PHYS MED REHABIL CLI, V2, P698; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Schneider JW, 2001, DEV MED CHILD NEUROL, V43, P601, DOI 10.1017/S0012162201001098	13	58	61	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	AUG	2004	46	8					548	552		10.1017/S001216220400091X			5	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	842EW	WOS:000222987100008	15287246				2022-02-06	
